
<html lang="en"     class="pb-page"  data-request-id="3686491d-4c95-4d54-b379-ac441b9adc39"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c01901;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-4;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Furazans in Medicinal Chemistry" /></meta><meta name="dc.Creator" content="Ross S.  Mancini" /></meta><meta name="dc.Creator" content="Christopher J.  Barden" /></meta><meta name="dc.Creator" content="Donald F.  Weaver" /></meta><meta name="dc.Creator" content="Mark A.  Reed" /></meta><meta name="dc.Description" content="Incorporation of heterocycles into drug molecules can enhance physical properties and biological activity. A variety of heterocyclic groups is available to medicinal chemists, many of which have be..." /></meta><meta name="Description" content="Incorporation of heterocycles into drug molecules can enhance physical properties and biological activity. A variety of heterocyclic groups is available to medicinal chemists, many of which have be..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 11, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01901" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01901" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01901" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01901" /></link>
        
    
    

<title>Furazans in Medicinal Chemistry | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01901" /></meta><meta property="og:title" content="Furazans in Medicinal Chemistry" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0037.jpeg" /></meta><meta property="og:description" content="Incorporation of heterocycles into drug molecules can enhance physical properties and biological activity. A variety of heterocyclic groups is available to medicinal chemists, many of which have been reviewed in detail elsewhere. Oxadiazoles are a class of heterocycle containing one oxygen and two nitrogen atoms, available in three isomeric forms. While the 1,2,4- and 1,3,4-oxadiazoles have seen widespread application in medicinal chemistry, 1,2,5-oxadiazoles (furazans) are less common. This Review provides a summary of the application of furazan-containing molecules in medicinal chemistry and drug development programs from analysis of both patent and academic literature. Emphasis is placed on programs that reached clinical or preclinical stages of development. The examples provided herein describe the pharmacology and biological activity of furazan derivatives with comparative data provided where possible for other heterocyclic groups and pharmacophores commonly used in medicinal chemistry." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01901"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01901">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01901&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01901&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01901&amp;href=/doi/10.1021/acs.jmedchem.0c01901" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1786-1815</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01721" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c02185" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Furazans in Medicinal Chemistry</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Ross S. Mancini</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ross S. Mancini</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Treventis Corporation, Toronto, Ontario M5T 0S8, Canada</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#285a4549464b414641685c5a4d5e4d465c415b064b4745"><span class="__cf_email__" data-cfemail="dba9b6bab5b8b2b5b29bafa9beadbeb5afb2a8f5b8b4b6">[emailÂ protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ross+S.++Mancini">Ross S. Mancini</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Christopher J. Barden</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher J. Barden</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Treventis Corporation, Toronto, Ontario M5T 0S8, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+J.++Barden">Christopher J. Barden</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Donald F. Weaver</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Donald F. Weaver</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Fundamental Neurobiology, Krembil Research Institute, Toronto, Ontario M5T 0S8, Canada</div><div class="loa-info-affiliations-info">Department of Chemistry, University of Toronto, Toronto, Ontario M5S 3H6, Canada</div><div class="loa-info-affiliations-info">Department of Medicine, University of Toronto, Toronto, Ontario M5S 3H2, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Donald+F.++Weaver">Donald F. Weaver</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Mark A. Reed</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark A. Reed</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Treventis Corporation, Toronto, Ontario M5T 0S8, Canada</div><div class="loa-info-affiliations-info">Department of Fundamental Neurobiology, Krembil Research Institute, Toronto, Ontario M5T 0S8, Canada</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#066b7463636246727463706368726f752865696b"><span class="__cf_email__" data-cfemail="0469766161604470766172616a706d772a676b69">[emailÂ protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark+A.++Reed">Mark A. Reed</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0293-2691" title="Orcid link">http://orcid.org/0000-0002-0293-2691</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01901&amp;href=/doi/10.1021%2Facs.jmedchem.0c01901" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1786â1815</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 11, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>3 November 2020</li><li><span class="item_label"><b>Published</b> online</span>11 February 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 February 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01901" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01901</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1786%26pageCount%3D30%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRoss%2BS.%2BMancini%252C%2BChristopher%2BJ.%2BBarden%252C%2BDonald%2BF.%2BWeaver%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D4%26contentID%3Dacs.jmedchem.0c01901%26title%3DFurazans%2Bin%2BMedicinal%2BChemistry%26numPages%3D30%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1815%26publicationDate%3DFebruary%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01901"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3204</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01901" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Furazans in Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ross&quot;,&quot;last_name&quot;:&quot;S. Mancini&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;J. Barden&quot;},{&quot;first_name&quot;:&quot;Donald&quot;,&quot;last_name&quot;:&quot;F. Weaver&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;A. Reed&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;11&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;1786-1815&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01901&quot;},&quot;abstract&quot;:&quot;Incorporation of heterocycles into drug molecules can enhance physical properties and biological activity. A variety of heterocyclic groups is available to medicinal chemists, many of which have been reviewed in detail elsewhere. Oxadiazoles are a class of heterocycle containing one oxygen and two nitrogen atoms, available in three isomeric forms. While the 1,2,4- and 1,3,4-oxadiazoles have seen widespread application in medicinal chemistry, 1,2,5-oxadiazoles (furazans) are less common. This Review provides a summary of the application of furazan-containing molecules in medicinal chemistry and drug development programs from analysis of both patent and academic literature. Emphasis is placed on programs that reached clinical or preclinical stages of development. The examples provided herein describe the pharmacology and biological activity of furazan derivatives with comparative data provided where possible for other heterocyclic groups and pharmacophores commonly used in medicinal chemistry.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01901&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01901" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01901&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01901" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01901&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01901" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01901&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01901&amp;href=/doi/10.1021/acs.jmedchem.0c01901" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01901" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01901" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01901%26sid%3Dliteratum%253Aachs%26pmid%3D33569941%26genre%3Darticle%26aulast%3DMancini%26date%3D2021%26atitle%3DFurazans%2Bin%2BMedicinal%2BChemistry%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D4%26spage%3D1786%26epage%3D1815%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291161" title="Inflammation">Inflammation</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/jmcmar.2021.64.issue-4/20210225/jmcmar.2021.64.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0037.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Incorporation of heterocycles into drug molecules can enhance physical properties and biological activity. A variety of heterocyclic groups is available to medicinal chemists, many of which have been reviewed in detail elsewhere. Oxadiazoles are a class of heterocycle containing one oxygen and two nitrogen atoms, available in three isomeric forms. While the 1,2,4- and 1,3,4-oxadiazoles have seen widespread application in medicinal chemistry, 1,2,5-oxadiazoles (furazans) are less common. This Review provides a summary of the application of furazan-containing molecules in medicinal chemistry and drug development programs from analysis of both patent and academic literature. Emphasis is placed on programs that reached clinical or preclinical stages of development. The examples provided herein describe the pharmacology and biological activity of furazan derivatives with comparative data provided where possible for other heterocyclic groups and pharmacophores commonly used in medicinal chemistry.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86611" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86611" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Heterocycles are ubiquitous in medicinal chemistry and materials science.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Incorporation of heterocyclic groups into molecules can generate binding interactions with a biological target or serve as a linker to generate favorable geometric conformations. The presence of oxygen and nitrogen atoms often polarizes the ring system and has been used to optimize physical properties such as solubility or crystal morphology. Heterocycles are also used as functional group replacements (bioisosteres) for carboxylates, nitriles, esters, carbamates, etc. to optimize drug-likeness of the compounds.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">Oxadiazoles are a class of five-membered heterocycles containing one oxygen and two nitrogen atoms, having interesting biological activity and thermodynamic properties.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7">(4â7)</a> 1,2,4- and 1,3,4-oxadiazoles are used extensively in the development of bioactive molecules, yet incorporation of 1,2,5-oxadiazoles (furazans) is less common;<a onclick="showRef(event, 'ref5 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref7">(5,7)</a> 1,2,3-oxadiazoles are unstable and prone to ring-opening processes. Furazans are unique in that substituents on the ring system are vicinal, having different geometry relative to the 1,2,4- and 1,3,4-isomers; fused-bicyclic ring systems are possible with furazans but not with 1,2,4- or 1,3,4-oxadiazoles. Furazans are also more polarized than other oxadiazoles given the clustered nature of the heteroatoms. These physical properties have been particularly useful in the development of high-energy density materials.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p last">The synthesis and reactivity of furazans and their derivatives has previously been reviewed in detail,<a onclick="showRef(event, 'ref9 ref10 ref11 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12 ref13 ref14">(9â14)</a> but limited information regarding the biological activity of furazans is provided; biological activity of furazan-<i>N</i>-oxides (furoxans) has also been reviewed.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> In this Review, we provide a detailed summary of the application and scope of furazan-containing molecules in medicinal chemistry and drug discovery. Emphasis is placed on research programs that reached clinical or preclinical stages of development. Analysis of both patent and academic literature was performed to illustrate how furazan derivatives identified as hit/lead chemotypes progress through lead optimization and preclinical stages of the drug development process. Examples where the furazans provide an advantage over other heterocyclic systems are highlighted, in addition to examples where the furazan chemotype was abandoned during development. This report provides a comprehensive illustration of the pharmacology and biological activity of furazan derivatives with comparative data provided for other drug-like pharmacophores used in medicinal chemistry.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Physical Properties</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00714" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00714" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">1,2,5-Oxadiazoles have unique physical and electronic properties relative to the 1,2,4- and 1,3,4-isomers.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Differences in lipophilicity,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> basicity,<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16â18)</a> and magnitude of the dipole moment<a onclick="showRef(event, 'ref5 ref12 ref19 ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref5 ref12 ref19 ref20 ref21 ref22 ref23">(5,12,19â23)</a> are observed (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Furazans are highly inductive, comparable to a trifluoromethyl or tetrazolyl group<a onclick="showRef(event, 'ref13 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref13 ref24 ref25">(13,24,25)</a> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The unique properties of furazans can impart interesting pharmacology to drug-like molecules. Examples are provided in the following sections.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Physical and electronic properties of oxadiazole derivatives; the dipole moment of nitrobenzene (<b>10</b>) is provided for comparison. Directionality of molecular dipoles for bisphenyl oxadiazoles is represented by blue arrows. <sup><i>a</i></sup>Value taken from the SDS (CAS# 273-09-6).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Taft induction constants of some electron withdrawing substituents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Furazans as Bioisosteres</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75423" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75423" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Nitrobenzene Bioisostere</h3><div class="NLM_p">Benzofurazans are a known bioisostere for nitro aromatics. Both the furazan and nitro groups exert a high degree of electron-withdrawing character (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), but the absence of formal charges in the furazan may be advantageous when optimizing âdrug-likenessâ (activity, selectivity, stability). Most importantly, the nitro group has been identified as a toxicophore,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and removal or replacement at the earliest stage of compound development is routine practice.</div><div class="NLM_p">Merck employed nitro-to-furazan isosterism to reduce the human ether-Ã -go-go related gene (hERG) toxicity of novel renal outer medullary potassium channel (ROMK) inhibitors<a onclick="showRef(event, 'ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29">(27â29)</a> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, compounds <b>11</b>â<b>18</b>); Novartis used a similar strategy to derisk a nitrobenzene-containing inhibitor (<b>19</b>) of phosphodiesterase type 4D (PDE4D),<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> generating preclinical lead NVP-ABE171 with improved activity/selectivity profile. Nitrobenzene-containing neuroprotective agents<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> identified by Treventis were also amenable to bioisosteric replacement during lead optimization<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Examples of nitro-to-furazan bioisosterism in drug development. AÎ² = amyloid beta.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A balance of electronegativity and sterics may rationalize the observed bioisosterism of benzofurazans for nitro-aromatics. A structureâactivity relationship (SAR) study reported by Ijzermann et al. (GrÃ¼enthal GmbH, University of Leiden) observed that other benzo-fused heterocycles (benzisoxazole, benzisothiazole, benzimidazole, benzothiazole) were less potent than benzofurazan analogues of nitrobenzylthioinosine<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34,35)</a> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Obreque-Balboa et al. investigated the replacement of a 4-nitro group found in selective ABCC1 receptor ligand <b>21</b> with a variety of electron withdrawing groups (EWGs)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>); the benzofurazan (<b>22h</b>) was more potent than other derivatives (nitrile, CF<sub>3</sub>, ester, triflate) and maintained selectivity over ABCB1 and ABCG2 isoforms. However, bioisosterism of the furazan is dependent on the pharmacology of the system, and exceptions to the trends described here have been reported. Nitro groups in the ROMK inhibitors identified by Merck were more tolerant of other functional group replacements.<a onclick="showRef(event, 'ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29">(27â29)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Replacement of a Nitro Group in Selective ABCC1 Receptor Ligand <b>21</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0032.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (ABCC1) (Î¼M)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (ABCB1) (Î¼M)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (ABCG2) (Î¼M)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">4-(NO<sub>2</sub>)-C<sub>6</sub>H<sub>4</sub></td><td class="colsep0 rowsep0" align="left">13.2</td><td class="colsep0 rowsep0" align="left">no effect<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">87.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22a</b></td><td class="colsep0 rowsep0" align="left">4-(CN)-C<sub>6</sub>H<sub>4</sub></td><td class="colsep0 rowsep0" align="left">26.7</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">99.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22b</b></td><td class="colsep0 rowsep0" align="left">3,4-(F)<sub>2</sub>-C<sub>6</sub>H<sub>3</sub></td><td class="colsep0 rowsep0" align="left">38.0</td><td class="colsep0 rowsep0" align="left">58.5</td><td class="colsep0 rowsep0" align="left">66.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22c</b></td><td class="colsep0 rowsep0" align="left">4-(CF<sub>3</sub>)-C<sub>6</sub>H<sub>4</sub></td><td class="colsep0 rowsep0" align="left">19.8</td><td class="colsep0 rowsep0" align="left">31.3</td><td class="colsep0 rowsep0" align="left">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22d</b></td><td class="colsep0 rowsep0" align="left">4-(SCF<sub>3</sub>)-C<sub>6</sub>H<sub>4</sub></td><td class="colsep0 rowsep0" align="left">20.8</td><td class="colsep0 rowsep0" align="left">36.6</td><td class="colsep0 rowsep0" align="left">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22e</b></td><td class="colsep0 rowsep0" align="left">4-(CO<sub>2</sub>CH<sub>3</sub>)-C<sub>6</sub>H<sub>4</sub></td><td class="colsep0 rowsep0" align="left">58.3</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22f</b></td><td class="colsep0 rowsep0" align="left">4-(SO<sub>2</sub>CH<sub>3</sub>)-C<sub>6</sub>H<sub>4</sub></td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">no effect<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">no effect<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22g</b></td><td class="colsep0 rowsep0" align="left">4-(SO<sub>2</sub>CF<sub>3</sub>)-C<sub>6</sub>H<sub>4</sub></td><td class="colsep0 rowsep0" align="left">22.7</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22h</b></td><td class="colsep0 rowsep0" align="left">5-benzofurazan</td><td class="colsep0 rowsep0" align="left">11.3</td><td class="colsep0 rowsep0" align="left">no effect<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">no effect<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">No observed inhibition of transporter activity at concentrations up to 100 Î¼M.</p></div></div></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Heterocycle analogues of nitrobenzylthioinosine. Activity is maintained in furazan derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Carboxylic Acid Bioisostere</h3><div class="NLM_p">Hydroxyfurazan was proposed as a bioisostere of the carboxylic acid group in 2006. A series of papers<a onclick="showRef(event, 'ref37 ref38 ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39 ref40 ref41">(37â41)</a> demonstrates the hydroxyfurazan moiety is highly ionizable, with p<i>K</i><sub>a</sub> values similar to the parent carboxylic acids. The seminal report by Lolli et al. investigated hydroxyfurazan bioisosteres of the neurotransmitter Î³-aminobutyric acid (GABA) as novel biomimetics;<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> bioisosteres of glutamate (Glu) are described in a later report.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, the furazan analogues maintain receptor affinity albeit with decreased potency.<a onclick="showRef(event, 'ref38 ref40'); return false;" href="javascript:void(0);" class="ref ref38 ref40">(38,40)</a> Computational analysis of <b>23</b> suggests an intramolecular hydrogen bond (H-bond) between the ammonium group and the furazan N5 stabilizes the active conformation; this interaction was not observed in the related isoxazole derivative but could be observed to a lesser extent for a 1,2,5-thiadiazole analogue.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The calculated dipole moment of 3-hydroxyfurazan was found to have different magnitude and directionality relative to the model substrate propenonic acid: it was suggested the decreased affinity of <b>23</b> relative to GABA may be due to less âcarboxy-likeâ character of the ionizable group. However, the p<i>K</i><sub>a</sub> of <b>23</b> and GABA is comparable and both exist in the Zwitterionic state at physiological pH.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Bioisosteric replacement of carboxyl groups in neurotransmitters with hydroxyfurazan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A furazan bioisostere of indomethacin (<b>25</b>) enhanced selectivity for aldo-ketoreductase (AKR), an oncology drug target, over cyclooxygenase (COX) with minimal impact on the physical properties and antiproliferative effects (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>); a moderate increase in lipophilicity was observed.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> Nonsteroidal anti-inflammatory drugs (NSAIDs) such as indomethacin are known to have anticancer activity, but their efficacy is limited by adverse gastrointestinal and cardiovascular responses related to effects on COX activity.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Similar observations were reported for a series of dihydroorotate dehydrogenase (DHODH) inhibitors<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>); isosteric replacement of the cyclopentenyl ring in <b>28</b> and <b>29</b>, a key piece of the pharmacophore, having optimal geometry for ion paring of the carboxylate with Arg-136 and occupancy of the biphenyl in a hydrophobic pocket,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> maintained activity against DHODH in furazan analogues <b>26</b> and <b>27</b>. The difference in activity may be due to differences in species origin of the DHODH enzyme (human vs rat) or the conditions of the assay,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> as <i>in vitro</i> activity of the furazan derivatives was comparable to known DHODH inhibitors DuP-785 (brequinar) and A771726 (teriflunomide) in experiments performed by the authors.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Physical Properties and Biological Activity of Indomethacin and Hydroxyfurazan Bioisostere <b>25</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0033.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Solubility was determined in simulated intestinal fluid.</p></div></div><div></div></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Bioisosteric replacement of carboxyl groups in DHODH inhibitors. A771726 (active metabolite of leflunomide) and brequinar are given for comparison. IC<sub>50</sub> values were determined using rat liver DHODH. <sup><i>a</i></sup>IC<sub>50</sub> values were determined using human DHODH. <sup><i>b</i></sup>IC<sub>50</sub> value for human DHODH = 0.435 Î¼M.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Urea Bioisostere</h3><div class="NLM_p">A less established bioisosterism is 4,5-diaminofurazans as âurea equivalents.â This approach was investigated in a series of papers<a onclick="showRef(event, 'ref47 ref48 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref47 ref48 ref49 ref50">(47â50)</a> describing analogues of ranitidine (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Replacement of the pseudourea moiety with the aminofurazan (<b>30</b>) maintained histamine type-2 (H<sub>2</sub>) receptor antagonism, and a series of more potent analogues (e.g., <b>31</b>) was eventually disclosed.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> Limited examples exist in the literature which employ the diaminofurazan as a urea bioisostere; given the recent recall of ranitidine (Zantac)<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> this approach may be worth exploring in future drug discovery programs.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Aminofurazan derivatives of ranitidine as H<sub>2</sub> receptor antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Enhancement of Activity and Pharmacokinetics</h3><div class="NLM_p">Oleanolic acid (OA) is a natural product with a range of biological effects, including some anticancer activity.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> However, OA does not inhibit leukemia cell proliferation. A report by Ng et al. identified the furazan derivative olean-12-eno[2,3-<i>c</i>][1,2,5]oxadiazol-28-oic acid (OEOA), having antileukemic activity <i>in vitro</i><a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). OEOA does not affect the growth of human neonatal keratinocytes, suggesting the antileukemic activity of OEOA is not due to a general cytotoxic effect of the compound in cell culture. Both OA and OEOA are detected in mouse plasma following intraperitoneal (<i>i.p.</i>) administration, but OEOA shows ca. twofold improvement in half-life (<i>t</i><sub>1/2</sub>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Half-Life and Antiproliferative Effects of OA and OEOA against Leukemia Cell Lines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0034.gif" alt="" id="fx3" /></img><div></div></div><div class="NLM_p last">It was shown that OEOA induces cell cycle arrest of leukemia-derived cells (K562) in the G1 phase <i>via</i> reduction of Cyclin D1, Cdk4 and Cdk6 protein expression, preventing transition into S phase and promoting erythroid differentiation and eventual senescence (âdifferentiation therapyâ). Kinase inhibitors such as imatinib display a related mechanism of action (MoA) but operate at the post-translational level, targeting protein activity rather than its expression; resistance to imatinib treatment has been observed in some patients. The complementary MoA of OEOA is noteworthy.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Neurodegenerative and Neurological Disorders</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74572" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74572" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A significant challenge in treating neurological disorders is the requisite exposure of a drug in the brain or nervous system. Penetration of the blood-brain barrier or blood-cerebrospinal fluid barrier is known to be challenging; drug therapies targeting disorders of the central nervous system (CNS) typically require a higher degree of lipophilic character to enable passive diffusion into the brain. Benzofurazans occupy an interesting chemical space, balancing lipophilic character with a high polarization and inductive effect from the oxadiazole moiety (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Examples of benzofurazans disclosed in drug discovery programs focused on CNS disorders are presented here.</div><div class="NLM_p">Patents from Treventis describe benzofurazan derivatives which inhibit the aggregation of pathogenic amyloid beta (AÎ²) and tau proteins, with claims that the compounds are useful to treat neurodegenerative disorders such as Alzheimerâs disease (AD) and other tauopathies<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Inhibition of AÎ² and tau protein fibrillization was demonstrated <i>in vitro</i> (biochemical aggregation assays), and inhibition of AÎ² oligomerization is also disclosed;<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> prefibrillar aggregates are highly neurotoxic and are implicated in AD pathology.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Hit compounds were identified using a proprietary virtual screening platform (CCM; Common Conformational Morphology), which models amyloid aggregation. <i>In silico</i> screening of 10.8 million commercially available compounds against CCM followed by <i>in vitro</i> screening (AÎ² and tau aggregation assays) of top hits identified a series of nitrobenzene derivatives (similar to TRV1140, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) with good activity profiles. A derisking strategy included replacement of the nitro group (a known toxicophore<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a>) with a variety of known bioisosteres;<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> the benzofurazans maintained activity of the parent compounds and showed favorable ADMET profiles. Dose-dependent <i>in vivo</i> target engagement of both AÎ² and tau oligomers has been demonstrated in several transgenic AD model systems.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Inhibition of AÎ² and tau fibrillization and AÎ² oligomerization by benzofurazan-derived neuroprotective agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">TRV1442 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) has also shown proof-of-concept efficacy as a treatment for amyotrophic lateral sclerosis (ALS).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Treatment with TRV1442 restored motor function and decreased neurodegeneration in multiple animal models; growth defects in neuromuscular junctions associated with disease pathology were reduced, preserving synaptic function. It was proposed that TRV1442 engages a target at the presynaptic level central to disease pathology, as efficacy was observed in SOD1, TDP-43, and C9orf72 model systems of ALS.</div><div class="NLM_p">Forum Pharmaceuticals (formerly EnVivo) claimed modulators of Î³-secretase activity as a therapeutic agent for AD.<a onclick="showRef(event, 'ref56 ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref56 ref57 ref58">(56â58)</a> Modulation, rather than inhibition, of Î³-secretase was shown to decrease production of pathogenic AÎ²<sub>1â42</sub> in favor of shorter, âless pathogenicâ AÎ² peptides while avoiding the known side effects associated with Î³-secretase inhibition.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> A benzofurazan derivative (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, compound <b>32</b>) was identified as a lead compound with submicromolar EC<sub>50</sub> values for AÎ²<sub>1â42</sub> reduction <i>in vitro</i>;<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> development of a more potent, nonfurazan derivative (<b>33</b>) produced clinical candidate EVP-0015962<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). Despite promising results in preclinical investigation, the program was discontinued following results from a phase II clinical trial (<a href="http://www.clinicaltrials.gov" class="extLink">clinicaltrials.gov</a>; NCT01661673). A complementary approach was reported by Mitsubishi Pharma, where inhibition of glycogen synthase kinase-3Î² (GSK-3Î²) reduced levels of phospho-tau and the associated neurofibrillary tangles (another disease pathology marker in AD). Lead compounds displayed nanomolar IC<sub>50</sub> values for GSK-3Î² inhibition and produced dose-dependent reductions in the amount of phospho-tau <i>in vitro</i><a onclick="showRef(event, 'ref60 ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref60 ref61 ref62">(60â62)</a> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, compounds <b>34</b>â<b>38</b>). Further development, in partnership with Sanofi-Aventis, identified a novel chemotype<a onclick="showRef(event, 'ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref63 ref64">(63,64)</a> and preclinical candidate SAR502250;<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> clinical trials in AD were not pursued, and the program was discontinued.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Benzofurazan-derived inhibitors of Î³-secretase (Forum Pharmaceuticals) and GSK-3Î² (Mitsubishi Pharma). Advanced leads and clinical candidates are provided for comparison. EC<sub>50</sub> values were determined in HEK 293 cells (EC<sub>50</sub> value for EVP-0015962 was determined in H4 cells).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Isradipine (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>), a dihydropyridine (DHP) calcium channel antagonist used as an antihypertensive agent, was evaluated in clinical trials to treat Parkinsonâs disease (PD).<a onclick="showRef(event, 'ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref66 ref67">(66,67)</a> The relationship between calcium homeostasis and PD pathology is well-established<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> and isradipine is neuroprotective in <i>in vitro</i><a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> and <i>in vivo</i><a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> models. Unfortunately, isradipine failed to slow the clinical progression of early stage PD<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> in humans (STEADY-PD). The maximum tolerated dose of isradipine<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> may be insufficient to elicit a therapeutic response; L-type calcium channels of the substantia nigra, the proposed drug target for PD, are less sensitive to DHP antagonism than L-type calcium channels found in smooth muscle<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> (drug target for hypertension). Isradipine has also been proposed as a treatment for AD,<a onclick="showRef(event, 'ref72 ref73 ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref72 ref73 ref74 ref75">(72â75)</a> but further research is needed to validate these observations, as related DHP calcium channel blockers nilvadipine and nimodipine (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) have shown limited efficacy in clinical trials.<a onclick="showRef(event, 'ref76 ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref76 ref77 ref78">(76â78)</a> Clinical trials exploring the potential of isradipine to mitigate substance abuse and addiction observed no effect on cocaine dependency or cocaine response.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures of DHP calcium channel antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">RespireRx (formerly Cortex) has developed benzofurazanyl amide derivatives as Î±-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulators (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). These âAmpakinesâ are orally bioavailable and enhance excitatory neuronal communication processes.<a onclick="showRef(event, 'ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref80 ref81">(80,81)</a> The benzofurazans are considered low impact (type II) Ampakines, increasing response amplitude of AMPA-mediated synapses.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Glutamatergic neurotransmission is involved in learning and memory,<a onclick="showRef(event, 'ref83 ref84'); return false;" href="javascript:void(0);" class="ref ref83 ref84">(83,84)</a> with reduced or impaired glutamatergic signaling contributing to cognitive dysfunction.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Preclinical investigation has demonstrated that acute administration of Ampakine CX691 (Farampator, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) increased the concentration of acetylcholine and dopamine in the hippocampus and prefrontal cortex (learning/memory),<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> with chronic administration increasing the expression of neurotrophins (neuroplasticity).<a onclick="showRef(event, 'ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref86 ref87">(86,87)</a> The development of Ampakines as cognitive enhancers is an active area of research.<a onclick="showRef(event, 'ref81 ref88'); return false;" href="javascript:void(0);" class="ref ref81 ref88">(81,88)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structures of type II Ampakines from RespireRx.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Significant improvements in the pharmacokinetic (PK) profile of the benzofurazan derivative CX691 over the first generation benzopyrazine CX516 (Ampalex, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) were observed in phase I clinical trials<a onclick="showRef(event, 'ref89 ref90'); return false;" href="javascript:void(0);" class="ref ref89 ref90">(89,90)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Phase II studies were initiated to investigate Ampakines as a therapeutic agent for schizophrenia, but the programs were eventually terminated.<a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(91,92)</a> Research programs in AD,<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> autism,<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> clinical depression,<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> and sleep depravation<a onclick="showRef(event, 'ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref96 ref97">(96,97)</a> have been pursued with variable degrees of success and limited human data reported. However, a phase IIa clinical trial for attention deficit hyperactivity disorder (ADHD)<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> (NCT03375021) demonstrated CX717 (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) produced a beneficial effect on alertness and amelioration of cognitive deficits. The drug was found to be safe and well-tolerated at the therapeutic dose (800 mg) with low incidence of adverse events (reported events include nausea, headache, dizziness). Further clinical investigation is yet to be reported.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. PK Parameters of Ampakine CX516 (Benzopyrazine) and CX691(Benzofurazan) in Healthy Elderly Humans</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">CX516</th><th class="colsep0 rowsep0" align="center">CX691</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">effective dose</td><td class="colsep0 rowsep0" align="left">900 mg</td><td class="colsep0 rowsep0" align="left">500 mg</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>plasma</sub> (1 h)</td><td class="colsep0 rowsep0" align="left">8.3 Î¼M</td><td class="colsep0 rowsep0" align="left">ca. 2.5 Î¼M</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>plasma</sub> (2 h)</td><td class="colsep0 rowsep0" align="left">4.0 Î¼M</td><td class="colsep0 rowsep0" align="left">ca. 2.0 Î¼M</td></tr></tbody></table></div></div><div class="NLM_p">RespireRx has also demonstrated that Ampakine administration can reduce the incidence of lethal apneas during periods of opioid-induced analgesia,<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> apnea of prematurity<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> and substance abuse (alcohol and barbituates).<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Ampakine coadministration could significantly increase the safety window of opioid-induced analgesia in clinical practice;<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> CX717 and CX1739 (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) have completed phase II clinical trials.<a onclick="showRef(event, 'ref103 ref104'); return false;" href="javascript:void(0);" class="ref ref103 ref104">(103,104)</a> In a published report,<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> administration of CX717 (1.5 g) to healthy volunteers effectively reversed alfentanil-induced respiratory depression without affecting the analgesic effects of the opioid. Modulation of AMPA receptors in the pre-BÃ¶tzinger complex (generates respiratory drive<a onclick="showRef(event, 'ref105 ref106'); return false;" href="javascript:void(0);" class="ref ref105 ref106">(105,106)</a>) rescues respiratory rhythms without antagonizing the effect of alfentanil on Î¼-opioid receptors.<a onclick="showRef(event, 'ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref107 ref108">(107,108)</a> Published literature for CX1739 in humans is currently unavailable. Development programs for CX717 and CX1739 have also been initiated for Pompe Disease<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> and spinal cord injury,<a onclick="showRef(event, 'ref110 ref111'); return false;" href="javascript:void(0);" class="ref ref110 ref111">(110,111)</a> along with continued efforts toward use of Ampakines to treat cognitive dysfunction.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Other benzofurazan-derived Ampakines have been disclosed<a onclick="showRef(event, 'ref98 ref112 ref113 ref114'); return false;" href="javascript:void(0);" class="ref ref98 ref112 ref113 ref114">(98,112â114)</a> (e.g., compounds <b>39</b>â<b>43</b>, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) and prodrug approaches are also being investigated.<a onclick="showRef(event, 'ref98 ref115 ref116'); return false;" href="javascript:void(0);" class="ref ref98 ref115 ref116">(98,115,116)</a></div><div class="NLM_p">Merck has reported a class of nonpeptide reversible inhibitors of caspase-3 (casp-3).<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Peptide-based inhibitors are known to be neuroprotective in models of hypoxia-ischemia,<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> but display irreversible pan-caspase inhibition and off-target effects<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> which limit their utility. A significant advance in the development of Merckâs casp-3 inhibitors<a onclick="showRef(event, 'ref120 ref121'); return false;" href="javascript:void(0);" class="ref ref120 ref121">(120,121)</a> was the incorporation of a furazan moiety, where enhanced activity and selectivity was observed relative to other heterocycles (thiadiazole, pyrazole, triazole, 1,2,4- and 1,3,4-oxadiazoles).<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> The furazan is proposed to possess optimal steric and electronic requirements required for casp-3 selectivity; a more polar and conformationally restricted binding pocket is reported for casp-3 relative to other caspases.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> Merckâs casp-3 inhibitors are reported to be 50â1000-fold greater than peptide-based caspase inhibitors <i>in vitro</i><a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. <i>In vitro</i> IC<sub>50</sub> values for M826 and peptide Ac-DEVD-CHO for activated caspases and camptothecin-induced apoptosis (casp-3 dependent) in NT2 cell culture.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Preclinical studies with M826 (rodent model of hypoxia-ischemia) demonstrated near complete inhibition casp-3 activation <i>in vivo</i> with a concomitant decrease in brain lesions and tissue loss.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Further evaluation in rodent model of Huntingtonâs disease<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> demonstrated M826 is moderately neuroprotective; a reduction in lesion volume (39%) and amount of striatum lesioned (33%) is observed. In this model, only a 66% reduction of activated casp-3 is observed despite a striatal concentration of 32.3 Î¼M 1 h postinjection (neuronal cell EC<sub>50</sub> = 0.12 Î¼M) and sufficient concentrations still detected at 6 h postinjection (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Secondary pathways not involving casp-3 are thought to be responsible, at least in part, for the observed neurodegeneration.<a onclick="showRef(event, 'ref123 ref124'); return false;" href="javascript:void(0);" class="ref ref123 ref124">(123,124)</a> The efficacy of altered dose regimens or repeated doses of M826 to increase the neuroprotective effect was not evaluated in this report. Further, M826 is not CNS-penetrant and required intrastriatal (<i>i.str.</i>) injection.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. PK of M826 in the Malonate-Induced Mouse Model of Huntingtonâs Disease</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">value</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose (<i>i.str.</i>)</td><td class="colsep0 rowsep0" align="left">1.5 nmol</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (1 h)</td><td class="colsep0 rowsep0" align="left">32.3 Î¼M</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">conc (6 h)</td><td class="colsep0 rowsep0" align="left">5.1 Î¼M</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">conc (24 h)</td><td class="colsep0 rowsep0" align="left">0.10 Î¼M</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub></td><td class="colsep0 rowsep0" align="left">3 h</td></tr></tbody></table></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Inflammatory Disorders</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26141" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26141" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">(Benzo)furazan inhibitors of the p38 mitogen-activated protein kinase (MAPK) have been claimed as therapeutic agents useful in treating inflammatory disorders. p38 MAPK is an attractive drug target given its involvement in the production of inflammatory mediators, but clinical development of p38 MAPK inhibitors has proven challenging (low efficacy, toxicity). Many p38 MAPK inhibitors target the ATP-binding pocket, a common domain in a variety of kinases, perhaps leading to some of the observed off-target effects.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Second generation inhibitors of p38 MAPK which target allosteric sites have been developed, but upregulation of compensatory signaling cascades involving Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase 1/2 (ERK1/2) has been observed.</div><div class="NLM_p">A benzofurazan chemotype developed by Mendez and coworkers (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) targets a docking grove of p38 MAPK rather than the ATP-binding site, preventing the association of regulator proteins and inhibiting phosphorylation (activation) by upstream kinases. This, in turn, prevents phosphorylation of downstream substrates by p38 MAPK, reducing the inflammatory response.<a onclick="showRef(event, 'ref126 ref127'); return false;" href="javascript:void(0);" class="ref ref126 ref127">(126,127)</a> A compensatory increase in JNK and ERK1/2 activation was not observed. Nitro-substituted benzofurazans are considered a pan-assay interference (PAINS) motif having promiscuous off-target activity,<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> yet FGA-19 is nontoxic in cell cultures (up to 100 Î¼M) and showed minimal activity against a panel screen of related kinases. Preclinical models of inflammatory pain (acute and chronic) have demonstrated efficacy; carrageenan-induced inflammatory response was suppressed <i>in vivo</i> with concomitant resolution of the associated hyperalgesia. A more potent and sustained analgesic effect was produced using FGA-19 relative to known p38 MAPK inhibitor SB239063 (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Analgesic Effect of FGA-19 and SB239063 <i>in Vivo</i></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">dose (nmol)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">relief onset (h)</th><th class="colsep0 rowsep0" align="center">relief duration</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGA-19</td><td class="colsep0 rowsep0" align="left">3.28</td><td class="colsep0 rowsep0" align="left"><0.5</td><td class="colsep0 rowsep0" align="left">>5 days</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGA-19</td><td class="colsep0 rowsep0" align="left">1.64</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">6 h</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SB239063</td><td class="colsep0 rowsep0" align="left">13.6</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">6 h</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Compounds were administered by intrathecal injection 6 days postcarrageenan insult.</p></div></div></div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Furazan-derived inhibitors of p38 MAPK from Mendez et al. and Allinky Biopharma. Inhibition of TNFÎ± secretion determined in THP-1 monocytes; % inhibition (Allinky) was determined at 10 Î¼M concentration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A related class of furazanopyrazine-derived p38 MAPK inhibitors from Allinky Biopharma (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>, compounds <b>45</b>â<b>52</b>) operate <i>via</i> a similar MoA, but also inhibit the functionally related JNK MAPK.<a onclick="showRef(event, 'ref129 ref130'); return false;" href="javascript:void(0);" class="ref ref129 ref130">(129,130)</a> Compound <b>47</b> was also shown to be CNS-penetrant <i>in vivo</i>;<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> activated p38 MAPK in the spinal cord is associated with chronic inflammatory pain. A protective effect was demonstrated in neuronal stem cells on exposure to inflammatory cytokines (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). These preliminary results are encouraging for conditions like rheumatoid arthritis and chronic inflammatory pain, but further development has yet to be reported.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. <i>In Vitro</i> and <i>in Vivo</i> Profile of <b>47</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="4" align="center" char="."><i>in vitro</i></th><th class="rowsep1 colsep0" colspan="2" align="center" char="."><i>in vivo</i><a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose</th><th class="colsep0 rowsep0" align="center" char=".">p38 inhibition (%)</th><th class="colsep0 rowsep0" align="center" char=".">JNK inhibition (%)</th><th class="colsep0 rowsep0" align="center" char=".">reduction of TNFÎ± (%)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">%Â rescue of neurons<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>plasma</sub> (2 h, Î¼M)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>brain</sub> (2 h, Î¼M)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10Â Î¼M</td><td class="colsep0 rowsep0" align="char" char=".">99</td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="char" char=".">74</td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.0Â Î¼M</td><td class="colsep0 rowsep0" align="char" char=".">37</td><td class="colsep0 rowsep0" align="char" char=".">49</td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="char" char=".">33</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10 mg/kg (IV)</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">0.43</td><td class="colsep0 rowsep0" align="char" char=".">0.80</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Measured in THP-1 monocytes.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">Exposure to cytokines.</p></div><div class="footnote" id="t7fn3"><sup><sup>c</sup></sup><p class="last">PK data were measured in mouse. IV = intravenous.</p></div></div></div><div class="NLM_p">Inhibition of PDE4 to treat chronic inflammatory disorders like asthma and chronic obstructive pulmonary disease (COPD) was proposed as an alternative to glucocorticosteroids. Cilomilast (GlaxoSmithKline) completed several phase III clinical trials for COPD,<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> but development was eventually terminated. Roflumilast (ALTANA) is approved for treatment/management of COPD. NVP-ABE171, developed by Novartis, is a benzofurazan-containing PDE4 inhibitor selective for the type-D isoform.<a onclick="showRef(event, 'ref30 ref132'); return false;" href="javascript:void(0);" class="ref ref30 ref132">(30,132)</a> This compound is orally bioavailable when administered as the <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-glucamine salt and produced a significant reduction in inflammatory response in preclinical models of COPD, with efficacy similar to roflumilast<a onclick="showRef(event, 'ref133 ref134'); return false;" href="javascript:void(0);" class="ref ref133 ref134">(133,134)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). However, PDE4 inhibitors are known to have a narrow therapeutic window and reliable dosing is paramount to a safe therapeutic response. The low solubility of NVP-ABE171 prompted further development focused on improving solubility and reproducibility of the PK profile (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>). Clinical lead <b>53</b> was ultimately selected for phase I profiling.<a onclick="showRef(event, 'ref135 ref136'); return false;" href="javascript:void(0);" class="ref ref135 ref136">(135,136)</a></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Comparison of <i>in Vitro</i> Activity for PDE4 Inhibitors Developed by Novartis (NVP-ABE171, <b>53</b>) GlaxoSmithKline (Cilomilast), and ALTANA (Roflumilast)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0035.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">EC<sub>50</sub> values were determined in peripheral blood mononuclear cells stimulated with lipopolysaccharide (LPS).</p></div><div class="footnote" id="t8fn2"><sup><sup>b</sup></sup><p class="last">LPS-induced inflammation (mouse).</p></div><div class="footnote" id="t8fn3"><sup><sup>c</sup></sup><p class="last">Ovalbumin-induced lung inflammation (rat).</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Solubility-Driven Optimization of NVP-ABE171 to Clinical Candidate <b>53</b><a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">NVP-ABE171</th><th class="colsep0 rowsep0" align="center"><b>53</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solubility (pH 6.8)</td><td class="colsep0 rowsep0" align="left">6.2 Î¼M</td><td class="colsep0 rowsep0" align="left">2.6 mM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (Î¼M)</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">4.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (min)</td><td class="colsep0 rowsep0" align="left">210</td><td class="colsep0 rowsep0" align="left">200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (Î¼MÂ·min)</td><td class="colsep0 rowsep0" align="left">523</td><td class="colsep0 rowsep0" align="left">4408</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">52</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">PK parameters were determined in rat.</p></div></div></div><div class="NLM_p">GlaxoSmithKline reported a furazanyl benzimidazole pharmacophore with broad spectrum kinase inhibition activity<a onclick="showRef(event, 'ref137 ref138 ref139'); return false;" href="javascript:void(0);" class="ref ref137 ref138 ref139">(137â139)</a> (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, compound <b>61</b>). SAR and <i>in silico</i> modeling identified key H-bonding interactions between the aminofurazan and the highly conserved hinge region of ATP-binding site;<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> the C3-amino group acts as a H-bond donor with the carbonyl of Asp-132 and the furazan N2 acts as an H-bond acceptor with Ile-134. An intramolecular H-bond between the aminofurazan and imidazole nitrogen was also proposed to rationalize the observed coplanarity of the biaromatic system. An additional H-bonding interaction with Lys-81 was achieved through introduction of a nitrogen atom at the 5-position of the benzimidazole, further increasing potency.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. SAR of benzimidazole-derived kinase inhibitors and activity profile of selective MSK-1 inhibitor SB-747651A.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Replacement of the furazan with amino-substituted isoxazole, pyridine, pyrazine or pyrazole heterocycles led to decreased activity (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, compounds <b>55</b>â<b>58</b>), perhaps due to differences in the p<i>K</i><sub>a</sub> and H-bonding character of the amino group. Removal of the amino group (<b>60</b>) or replacement with other H-bond donors (<b>56</b> vs <b>59</b>) abolished activity. A steric effect was also observed (<b>57</b> vs <b>58</b>) due to proximity of the âgate-keeperâ Leu-131. Small alkyl substituents on the imidazole nitrogen occupy a lipophilic pocket formed by Val-53, Leu-55, Phe-348 and Leu-184, with ethyl and cyclopropyl groups showing favorable activity. Taken together, lead derivative <b>61</b> was identified as the optimal chemotype, showing broad-spectrum kinase inhibition activity (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>).</div><div class="NLM_p last">A lead optimization program identified selective inhibitors of mitogen and stress activated protein kinases 1 (MSK-1);<a onclick="showRef(event, 'ref140 ref141'); return false;" href="javascript:void(0);" class="ref ref140 ref141">(140,141)</a> activation of MSK-1 by ERK and p38 MAPK pathways regulates the production of inflammatory mediators. The derivative SB-747651A (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>) displays an enhanced selectivity profile relative to other MSK-1 inhibitors (H89, Ro 31-8220);<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> addition of a pendant basic amine moiety is proposed to interact with Glu-138 <i>via</i> ion pairing. The corresponding residues in GSK-3 and RSK-1 are Thr and Asp, respectively, which provides selectivity over these related kinases. Cell-based assays confirm that both MSK-1 and MSK-2 are efficiently inhibited by SB-747651A, resulting in decreased levels of downstream phosphorylation events; activation of upstream regulators ERK1/2, p38, and JNK MAPKs was unaffected. <i>In vitro</i> cellular responses (RNA transcription, cytokine production) to SB-747651A are replicated in MSK-1/2 knockout macrophages, providing a useful tool to study the role of MSK in inflammatory processes.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Hypertension</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44002" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44002" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Isradipine (tradenames DynaCirc, Prescal; <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) is a DHP calcium channel antagonist which targets L-type voltage-gated calcium channels found in vascular smooth muscle cells, preventing calcium flux into the cytoplasm. Contraction of smooth muscle is a calcium-dependent process; altering calcium flux in the vasculature produces a vasodilatory effect.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Isradipine is an effective treatment for chronic hypertension (monotherapy or in combination with other antihypertensives such as Î²-blockers) with a favorable hemodynamic profile and low incidence of adverse events.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> The PK and efficacy of isradipine has been reviewed in detail.<a onclick="showRef(event, 'ref143 ref144 ref145'); return false;" href="javascript:void(0);" class="ref ref143 ref144 ref145">(143â145)</a> The improved PK profiles of second-generation DHP calcium channel antagonists (isradipine, nimodipine, nicardipine, etc.) have enabled more favorable dosing regiments; for example, once daily controlled release or twice daily standard formulation oral tablets is standard-of-care for isradipine<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>). Bioavailability of DHP therapeutics is low due to substantial first-pass metabolism; the improved half-life of the second-generation DHPs is noteworthy. Comparative studies between isradipine (benzofurazan) and nifedipine (nitrobenzene) have demonstrated greater efficacy of isradipine for treatment of essential hypertension.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> A large clinical study (MIDAS) concluded that isradipine is more efficacious than hydrochlorothiazide (a diuretic) in reducing the rate of progression of atherosclerosis. Other clinical programs suggest isradipine is effective for treating congestive heart failure<a onclick="showRef(event, 'ref146 ref147'); return false;" href="javascript:void(0);" class="ref ref146 ref147">(146,147)</a> and angina.<a onclick="showRef(event, 'ref148 ref149'); return false;" href="javascript:void(0);" class="ref ref148 ref149">(148,149)</a> Chemical structures of some available DHP antihypertensive agents are given in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>.</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Dose, Half-Life, and Bioavailability of DHP Calcium Channel Antagonists Used in Treating Essential Hypertension</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">standard dose per day (oral)<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nifedipine (first gen.)</td><td class="colsep0 rowsep0" align="left">40â80 mg (<i>bid</i>. or once daily sustained release)</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">isradipine</td><td class="colsep0 rowsep0" align="left">5â10 mg (<i>bid</i>. or once daily sustained release)</td><td class="colsep0 rowsep0" align="char" char=".">8.4</td><td class="colsep0 rowsep0" align="char" char=".">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nimodipine</td><td class="colsep0 rowsep0" align="left">360 mg (60 mg every 4 h)</td><td class="colsep0 rowsep0" align="char" char=".">0.9</td><td class="colsep0 rowsep0" align="char" char=".">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nicardipine</td><td class="colsep0 rowsep0" align="left">20â60 mg (every 8 h or <i>bid</i>. sustained release)</td><td class="colsep0 rowsep0" align="char" char=".">11.5</td><td class="colsep0 rowsep0" align="char" char=".">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nilvadipine</td><td class="colsep0 rowsep0" align="left">8â16 mg (<i>bid</i>. or once daily sustained release)</td><td class="colsep0 rowsep0" align="char" char=".">11.0</td><td class="colsep0 rowsep0" align="char" char=".">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nilvadipine</td><td class="colsep0 rowsep0" align="left">8â16 mg (<i>bid</i>. or once daily sustained release)</td><td class="colsep0 rowsep0" align="char" char=".">11.0</td><td class="colsep0 rowsep0" align="char" char=".">14</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup><sup>a</sup></sup><p class="last"><i>bid</i>. = twice daily.</p></div></div></div><div class="NLM_p">Potassium channel activation is an alternative approach to modulate calcium-dependent muscle contraction. Increased potassium efflux results in hyperpolarisation of cell membrane, reducing calcium flux into the cytoplasm.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Potassium channel activators (PCAs) have been investigated as antihypertensives; most programs were terminated due to a narrow therapeutic window and poor tolerance in most patients. Benzofurazan analogues of the PCA levcromakalim (GlaxoSmithKline) were disclosed in a patent from Nissan Chemical Industries as therapeutic agents to treat hypertension and ischemic heart diseases<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). The derivative NIP-121 was reported to have a more favorable activity profile than levcromakalim<a onclick="showRef(event, 'ref152 ref153'); return false;" href="javascript:void(0);" class="ref ref152 ref153">(152,153)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a></a>). Preclinical investigation demonstrated dose-dependent reductions in systemic blood pressure; tachycardia was observed, but could be prevented by combination with a Î²-blocker.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> A comparative study of NIP-121 and nifedipine (a calcium channel antagonist) produced similar outcomes, but the dose of NIP-121 was 10-fold lower than nifedipine.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Nissan terminated the development of NIP-121 at the preclinical stage.</div><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. Antihypertensive Effect of PCAs NIP-121 and Levcromakalim in Anesthetized Dogs<a class="ref internalNav" href="#t11fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">dose (IV, Î¼g/kg)</th><th class="colsep0 rowsep0" align="center" char=".">mean aortic pressure reduction (%)</th><th class="colsep0 rowsep0" align="center" char=".">coronary blood flow increase (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NIP-121</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">â7.5</td><td class="colsep0 rowsep0" align="char" char=".">34.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">levcromakalim</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td><td class="colsep0 rowsep0" align="char" char=".">â11.2</td><td class="colsep0 rowsep0" align="char" char=".">33.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t11fn1"><div class="footnote" id="t11fn1"><sup><sup>a</sup></sup><p class="last">Calculated from doseâresponse curves. IV = intravenous.</p></div></div></div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Chemical structures of antihypertensive agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Inhibition of Rho-associated coil-forming serine/threonine kinases (ROCKs) is an established treatment strategy for pulmonary hypertension; Rho kinase-mediated calcium sensitization is implicated in vasoconstriction. Up-regulation of ROCK activity results in smooth muscle constriction and is implicated in cardiovascular diseases. A furazanyl benzimidazole pharmacophore identified by GlaxoSmithKline is known to exhibit broad spectrum kinase inhibition.<a onclick="showRef(event, 'ref137 ref138 ref139'); return false;" href="javascript:void(0);" class="ref ref137 ref138 ref139">(137â139)</a> The aminofurazan moiety is essential (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>), forming two key H-bonding interactions in the hinge region of the ATP-binding site.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> Development and SAR of the furazanyl benzimidazole pharmacophore is described above (see <a class="ref internalNav" href="#sec5" aria-label="Inflammatory Disorders">Inflammatory Disorders</a>). Lead optimization revealed that addition of a pendant amide to the benzimidazole moiety enhanced selectivity for ROCK-1, leading to the discovery of orally bioavailable ROCK-1 inhibitors GSK269962A and SB-772077B (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>) having good activity/selectivity profiles.<a onclick="showRef(event, 'ref156 ref157 ref158'); return false;" href="javascript:void(0);" class="ref ref156 ref157 ref158">(156â158)</a> Administration of either GSK269962A or SB-772077B to hypertensive rats produced dose-dependent decreases in blood pressure with higher potency than established ROCK inhibitors Y-27632, SAR407899, and fasudil (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">Table <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a></a>), and only a modest decrease in blood pressure was observed in normotensive animals. Fasudil (Asahi Kasei Pharma) has proven efficacious in the treatment of pulmonary hypertension,<a onclick="showRef(event, 'ref159 ref160'); return false;" href="javascript:void(0);" class="ref ref159 ref160">(159,160)</a> but the clinical efficacy of furazan-derived ROCK inhibitors has not been investigated; SAR407899 (Sanofi-Aventis) was in phase II clinical evaluation for patients with angina, but the trial was terminated due to low recruitment (NCT03236311).</div><div class="NLM_table-wrap" id="tbl12"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 12. Antihypertensive Effects of ROCK Inhibitors <i>in Vitro</i> and <i>in Vivo</i></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="2" align="center"><i>in vitro</i></th><th class="rowsep1 colsep0" colspan="6" align="center"><i>in vivo</i></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="3" align="center">ÎBP (mm/Hg)/Î<i>H</i>R (bpm)<a class="ref internalNav" href="#t12fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> VR (rat aorta)</th><th class="colsep0 rowsep0" align="center">actin stress fiber inhibition (hASM)</th><th class="colsep0 rowsep0" align="center">dose</th><th class="colsep0 rowsep0" align="center">3 h</th><th class="colsep0 rowsep0" align="center">6 h</th><th class="colsep0 rowsep0" align="center">10 h</th><th class="colsep0 rowsep0" align="center">ÎPAP (mm Hg)<a class="ref internalNav" href="#t12fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">ÎSAP (mm Hg)<a class="ref internalNav" href="#t12fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">SB-772077B</td><td class="colsep0 rowsep0" rowspan="2" align="left">39 nM</td><td class="colsep0 rowsep0" rowspan="2" align="left">3 Î¼M</td><td class="colsep0 rowsep0" align="left">1 mg/kg</td><td class="colsep0 rowsep0" align="left">â20/+20</td><td class="colsep0 rowsep0" align="left">â20/â40</td><td class="colsep0 rowsep0" align="left">â5/â25</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1 Î¼mol/kg</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">â13</td><td class="colsep0 rowsep0" align="left">â40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GSK269962A</td><td class="colsep0 rowsep0" align="left">35 nM</td><td class="colsep0 rowsep0" align="left">3 Î¼M</td><td class="colsep0 rowsep0" align="left">1 mg/kg</td><td class="colsep0 rowsep0" align="left">â20/+30</td><td class="colsep0 rowsep0" align="left">â10/+10</td><td class="colsep0 rowsep0" align="left">0/0</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">Y-27632</td><td class="colsep0 rowsep0" rowspan="2" align="left">1.4 Î¼M</td><td class="colsep0 rowsep0" rowspan="2" align="left">30 Î¼M</td><td class="colsep0 rowsep0" align="left">10 mg/kg</td><td class="colsep0 rowsep0" align="left">â25/+75</td><td class="colsep0 rowsep0" align="left">â10/+10</td><td class="colsep0 rowsep0" align="left">â5/0</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1 Î¼mol/kg</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">â10</td><td class="colsep0 rowsep0" align="left">â32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">fasudil</td><td class="colsep0 rowsep0" align="left">1.3 Î¼M<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">3 mg/kg</td><td class="colsep0 rowsep0" align="left">â30/â50</td><td class="colsep0 rowsep0" align="left">â20/â10</td><td class="colsep0 rowsep0" align="left">0/â10</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SAR407899<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a></td><td class="colsep0 rowsep0" align="left">122 nM</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">1 Î¼mol/kg</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">â6</td><td class="colsep0 rowsep0" align="left">â19</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t12fn1"><div class="footnote" id="t12fn1"><sup><sup>a</sup></sup><p class="last">Spontaneously hypertensive rats.</p></div><div class="footnote" id="t12fn2"><sup><sup>b</sup></sup><p class="last">U44619-induced hypertensive rats (acute changes). VR = vasorelaxation. hASM = human primary aortic smooth muscle cells; BP = blood pressure; HR = heart rate; bpm = beats per minute. PAP = pulmonary arterial pressure. SAP = systemic arterial pressure.</p></div></div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Cancer</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50405" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50405" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Microtubule Targeting Agents (BAL101553)</h3><div class="NLM_p">Microtubule targeting agents (MTAs) are potent inducers of apoptosis useful in treating cancer.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> A novel class of MTA discovered by Aponetics<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> demonstrated apoptotic activity in multiple cancer cell lines. The furazan derivative BAL27862 (avanbulin), developed by Basilea Pharmaceuticals, was selected for clinical development<a onclick="showRef(event, 'ref163 ref164'); return false;" href="javascript:void(0);" class="ref ref163 ref164">(163,164)</a> (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>). BAL27862 is a competitive inhibitor of microtubule assembly (IC<sub>50</sub> = 1.4 Î¼M) which targets the colchicine binding site,<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> with potent antiproliferative activity observed in cancer cell lines resistant to established MTA chemotherapeutics.<a onclick="showRef(event, 'ref166 ref167 ref168 ref169'); return false;" href="javascript:void(0);" class="ref ref166 ref167 ref168 ref169">(166â169)</a> Soluble prodrugs of BAL27862 were developed <i>via</i> conjugation with an amino acid residue.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> Lysine derivative BAL101553 (lisavanbulin) was chosen for preclinical validation, and reports describing the MoA and preclinical efficacy have been published.<a onclick="showRef(event, 'ref166 ref171 ref172 ref173'); return false;" href="javascript:void(0);" class="ref ref166 ref171 ref172 ref173">(166,171â173)</a></div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Inhibition of cell proliferation for benzimidazole-derived MTAs. EC<sub>50</sub> (MTS assay) determined in HeLa cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">BAL10553 is currently undergoing phase I/IIa clinical evaluation in patients with advanced solid tumors and glioblastoma/high-grade glioma (NCT01397929, NCT02895360, NCT02490800) by intravenous (IV) and oral administration. Dose-escalation studies identified an effective dose of 30 mg/m<sup>2</sup> (2-h IV infusion) with toxicities observed at doses >45 mg/m<sup>2</sup>.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> Adverse responses include neurological and myocardial injury due to vascular disruption, with severity correlated with increasing <i>C</i><sub>max</sub> values. A 48-h continuous infusion was developed to reduce the <i>C</i><sub>max</sub> and increase the tolerability of the treatment;<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> higher doses (70 mg/m<sup>2</sup>) are tolerated with no apparent vascular toxicity<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">Table <a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">13</a></a>). The relative bioavailability for oral administration of BAL101553 was found to be 80% (ratio of dose-normalized AUC for oral vs IV route). Combination therapy approaches are also under investigation to increase patient response rates: a phase I trial of BAL101553 with combination radiation therapy is being evaluated in glioblastoma patients (NCT03250299); preclinical data suggests the combination of BAL101553 with eribulin<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> or gemcitabine<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> markedly improves the efficacy of treatment.</div><div class="NLM_table-wrap" id="tbl13"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 13. Differences in PK and Vascular Effects for Administration of BAL101553 by Various Methods</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (route)</th><th class="colsep0 rowsep0" align="center">duration of IV infusion (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC (ngÂ·h/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC/<i>C</i><sub>max</sub></th><th class="colsep0 rowsep0" align="center" char=".">Îsystolic BP (mm Hg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">30 mg/m<sup>2</sup> (IV)</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="char" char=".">267</td><td class="colsep0 rowsep0" align="char" char=".">3620</td><td class="colsep0 rowsep0" align="char" char=".">13.6</td><td class="colsep0 rowsep0" align="char" char=".">+10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">45 mg/m<sup>2</sup> (IV)</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="char" char=".">356</td><td class="colsep0 rowsep0" align="char" char=".">4340</td><td class="colsep0 rowsep0" align="char" char=".">12.2</td><td class="colsep0 rowsep0" align="char" char=".">+20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">45 mg/m<sup>2</sup> (IV)</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="center" char=".">77.7</td><td class="colsep0 rowsep0" align="char" char=".">3830</td><td class="colsep0 rowsep0" align="char" char=".">49.3</td><td class="colsep0 rowsep0" align="char" char=".">â5<a class="ref internalNav" href="#t13fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">70 mg/m<sup>2</sup> (IV)</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="char" char=".">144</td><td class="colsep0 rowsep0" align="char" char=".">8580</td><td class="colsep0 rowsep0" align="char" char=".">59.6</td><td class="colsep0 rowsep0" align="char" char=".">+5<a class="ref internalNav" href="#t13fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">16 mg (<i>p</i>.<i>o</i>.)</td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="char" char=".">131</td><td class="colsep0 rowsep0" align="char" char=".">8400</td><td class="colsep0 rowsep0" align="char" char=".">64.1</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">20 mg (<i>p.o</i>.)<a class="ref internalNav" href="#t13fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="char" char=".">134</td><td class="colsep0 rowsep0" align="char" char=".">12â¯180</td><td class="colsep0 rowsep0" align="char" char=".">90.9</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t13fn1"><div class="footnote" id="t13fn1"><sup><sup>a</sup></sup><p class="last">Grade 4 (serious, life-threatening) hyponatremia observed in 2/7 patients.</p></div><div class="footnote" id="t13fn2"><sup><sup>b</sup></sup><p class="last">Change considered not significant. <i>p.o</i>. = <i>per os</i> (oral administration). N/A = not applicable.</p></div></div></div></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> STAT Inhibitors</h3><div class="NLM_p">Signal transducer and activator of transcription 3 (STAT3) is an established drug target in oncology, with considerable interest in small molecule inhibitors. However, there are currently no approved STAT3 inhibitors available on the market.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> Ureido-furazan AVS-0288 was identified as a potent inhibitor of STAT3 activity;<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> SAR studies<a onclick="showRef(event, 'ref182 ref183'); return false;" href="javascript:void(0);" class="ref ref182 ref183">(182,183)</a> identified MD77 as a promising lead compound (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>), having antiproliferative effects against multiple cancer cell types<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">Table <a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">14</a></a>). Computational docking of MD77 to the SH2 domain of STAT3 identified two key H-bonding interactions between the furazan and Arg-609. Replacement of the furazan with other heterocyclic systems (1,3,4-oxadiazole, isoxazole, imidazole, furan) was not tolerated;<a onclick="showRef(event, 'ref185 ref186'); return false;" href="javascript:void(0);" class="ref ref185 ref186">(185,186)</a> highly electronegative systems (furazan) are proposed to enhance the binding interaction. Derivatives of MD77 have also been used as ligands for Pt(II) chloride to generate âdual-actionâ STAT3/DNA replication inhibitors<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>, compound <b>66</b>). Reduction in tumor volume was comparable to cisplatin treatment with no associated weight loss (<a class="ref showTableEvent internalNav" data-ID="tbl15" href="#tbl15">Table <a class="ref showTableEvent internalNav" data-ID="tbl15" href="#tbl15">15</a></a>). A series of furazan-3-carboxylic acids are claimed as inhibitors of STAT5 (also implicated cancer progression) useful in treating acute myeloid leukemia<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a> (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>, compounds <b>67</b>â<b>69</b>). Phosphorylation of STAT5 (but not expression) was reduced <i>in vitro</i>, producing dose-dependent reductions of downstream transcriptional activity. No effect on STAT3 expression or phosphorylation was observed.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Furazan-derived STAT inhibitors. EC<sub>50</sub> values were determined in HCT 116 (colon cancer) cell line for STAT3 inhibitors and BAF3 cells transfected with FLT3-ITD (acute myeloid leukemia) for STAT5 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl14"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 14. Antiproliferative Effect of MD77<a class="ref internalNav" href="#tbl14-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cancer type</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (Î¼M)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">leukemia</td><td class="colsep0 rowsep0" align="left">0.84â2.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nonsmall cell lung carcinoma</td><td class="colsep0 rowsep0" align="left">0.63â3.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">colorectal</td><td class="colsep0 rowsep0" align="left">2.2â3.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CNS-derived</td><td class="colsep0 rowsep0" align="left">1.0â3.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">melanoma</td><td class="colsep0 rowsep0" align="left">0.87â4.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ovarian</td><td class="colsep0 rowsep0" align="left">1.8â4.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">renal</td><td class="colsep0 rowsep0" align="left">1.7â6.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">prostate</td><td class="colsep0 rowsep0" align="left">1.4â3.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">breast</td><td class="colsep0 rowsep0" align="left">2.2â3.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl14-fn1"><div class="footnote" id="tbl14-fn1"><sup><sup>a</sup></sup><p class="last">EC<sub>50</sub> values were determined against >50 tumor cell lines.</p></div></div></div><div class="NLM_table-wrap" id="tbl15"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 15. Inhibition of Tumor Growth <i>in Vivo</i> for <b>66</b> and Cisplatin in Lewis Lung Carcinoma Xenograft Mice</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">dose <i>i.p.</i> (mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">tumor growth inhibition (%)</th><th class="colsep0 rowsep0" align="center" char=".">weight loss (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>66</b></td><td class="colsep0 rowsep0" align="center" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">85</td><td class="colsep0 rowsep0" align="char" char=".">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cisplatin</td><td class="colsep0 rowsep0" align="center" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">88</td><td class="colsep0 rowsep0" align="char" char=".">27</td></tr></tbody></table></div></div></div><div id="sec7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Inhibitors of ProteinâProtein Interactions</h3><div class="NLM_p">Inhibition of proteinâprotein interactions (PPIs) is challenging and was once considered âundruggableâ using small molecules. However, delivery of high molecular weight therapeutics (peptides, biologics) is difficult, whereas small molecules are often permeable. Benzo-fused and pyrazine-fused furazan derivatives have been identified in multiple drug development programs as effective inhibitors of PPIs, with activity comparable to larger biomolecules. Ji and coworkers identified furazanopyrazines which inhibit Î²-catenin/T-cell factor (Tcf) dimerization;<a onclick="showRef(event, 'ref189 ref190'); return false;" href="javascript:void(0);" class="ref ref189 ref190">(189,190)</a> hyperactivation of signaling pathways regulated by Î²-catenin is associated with the progression of various cancers and fibroses. The small molecule inhibitors show similar efficacy <i>in vitro</i> to a series of peptidomimetics<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> developed by the same group (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>, compounds <b>70</b>, <b>71</b>); higher potency is observed in cell-free systems for the peptidomimetics, but activity in cell-based systems is comparable (related to drug permeability). Zhang et al. identified furazanopyrazines which inhibit the dimerization of survivin (signaling protein regulated by Î²-catenin).<a onclick="showRef(event, 'ref192 ref193'); return false;" href="javascript:void(0);" class="ref ref192 ref193">(192,193)</a> Chemotherapeutics which target the transcription and expression of survivin show limited efficacy in clinical trials;<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> regulation of survivin at the protein level is a complementary approach. Inhibition of survivin dimerization and dissociation of preformed survivin dimers was demonstrated in cell-free systems, and lead compound LQZ-7F (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>) showed efficacy <i>in vitro</i> in a variety of cancer cell lines (mRNA expression and protein synthesis are unaffected, supporting a MoA involving inhibition of PPIs).<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> LQZ-7F also reduced tumor volume (ca. 30%) in xenograft mice and was well-tolerated even with repeated dosing.</div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Antiproliferative activity of furazanopyrazine-derived (<b>70</b>, LQZ-7F) or peptidomimetic (<b>71</b>) inhibitors of PPIs in cancer cell lines (SW480, HCT 116 = colon; A549 = lung; HL-60 = acute myeloid leukemia). EC<sub>50</sub> values given in parentheses are for the ethyl ester prodrug of <b>71</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The heterodimerization of cMyc-Max is another PPI implicated in cancer progression (overexpression, deregulation of cMyc).<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> A series of nitrobenzofurazans were developed as selective inhibitors of cMyc-Max dimerization, having no effect on Max-Max homodimerization<a onclick="showRef(event, 'ref196 ref197'); return false;" href="javascript:void(0);" class="ref ref196 ref197">(196,197)</a> (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>). The compound 10074-G4 was shown to inhibit dimerization through binding to cMyc monomers; the nitrobenzofurazan engages Arg-366 and Arg-367, while the biphenyl extends into a hydrophobic domain formed by Phe-375 and Ile-381. The furazan and the nitro group were proposed as key parts of the pharmacophore;<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> replacement of the benzofurazan with a benzene or reduction of the nitro group to an amino group abolished activity. However, replacement of the nitro group with a trifluoroacetamido group showed activity comparable to 10074-G5. Additional SAR of the furazan moiety was not disclosed. <i>In vivo</i> profiling of 10074-G5 showed limited efficacy due to dose-limiting solubility and short half-life.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> Optimization of 10074-G5 identified JY-3-094, with ca. fivefold increased potency in biochemical assays but reduced cytotoxicity due to poor cell permeability; ester prodrugs were shown to enhance permeability and intracellular half-life.<a onclick="showRef(event, 'ref200 ref201'); return false;" href="javascript:void(0);" class="ref ref200 ref201">(200,201)</a> Further development of the benzofurazans is yet to be reported.</div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Antiproliferative activity of nitrobenzofurazan inhibitors of Myc/Max heterodimerization in HL60 (acute myeloid leukemia) and Daudi B. (lymphoma) cancer cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Benzofurazans discovered by Bruick and coworkers (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) disrupt the assembly hypoxia inducible factors (HIFs), a transcription factor that is upregulated in many cancers.<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> Binding of the benzofurazans to the Per-Arnt-Sim (PAS) domain of HIF-2Î± prevents the formation of the active heterodimer complex;<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> heterodimerization of HIF-Î± and HIF-Î² is mediated through the PAS domain. The compounds are metabolically stable in cells (half-life ca. 14 h) and produced dose-dependent reductions in active HIF complex.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> Based on proof-of-principle data the benzofurazans, having more favorable physical properties than second-generation inhibitor <b>76</b> (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>), were licensed to Peloton Therapeutics for further development. SAR programs at Peloton<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> identified a key n â Ï*Ar binding interaction between Tyr-281 and the electron-deficient nitrobenzofurazan; replacement of the furazan and nitro groups with other strong EWGs maintained this interaction. Further optimization identified of a novel class of HIF-2Î± allosteric modulators<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> and clinical candidate PT2977 (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>). PT2977 (MK-6482) is currently in phase III evaluation for advanced renal cell carcinoma (NCT04195750).</div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. <i>In vitro</i> activity and binding affinity of benzofurazan inhibitors of HIF assembly. IC<sub>50</sub> values were determined using AlphaScreen assay (values in parentheses were determined using scintillation proximity assay). <i>K</i><sub>D</sub> values were determined by isothermal calorimetry measurements. Second-generation inhibitor <b>76</b> (Bruick) and clinical candidate PT2977 (Peloton) are provided for comparison.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec7_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Inhibitors of IDO1</h3><div class="NLM_p">Inhibition of indoleamine 2,3-dioxygenase 1 (IDO1) has received tremendous attention as a therapeutic target in immuno-oncology.<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a> The furazan derivative INCB024360 (epacadostat; Incyte Corporation) is a potent and selective IDO1 inhibitor, with over 50 clinical trials initiated or proposed (<a href="http://www.clinicaltrials.gov" class="extLink">clinicaltrials.gov</a>). The furazan-based pharmacophore was identified by high-throughput screening; replacement of the furazan with other heterocycles was not tolerated.<a onclick="showRef(event, 'ref208 ref209 ref210 ref211'); return false;" href="javascript:void(0);" class="ref ref208 ref209 ref210 ref211">(208â211)</a> SAR of the furazan moiety is disclosed in some patents,<a onclick="showRef(event, 'ref212 ref213'); return false;" href="javascript:void(0);" class="ref ref212 ref213">(212,213)</a> but information is limited. Improvements to the oral bioavailability and half-life identified INCB024360 as the clinical candidate (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>). Target engagement studies and preclinical investigation support an immune-mediated response to tumor suppression.<a onclick="showRef(event, 'ref209 ref214'); return false;" href="javascript:void(0);" class="ref ref209 ref214">(209,214)</a></div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. <i>In vitro</i> and preclinical <i>in vivo</i> development of INCB024360 (epacadostat) by Incyte Corp. Tumor reduction (red.) was determined in mouse xenograft models.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Binding of INCB024360 to the heme pocket of the IDO1 active site is mediated by the exocyclic hydroxyamidine oxygen atom; imidazole-based inhibitors such as NLG919 engage the heme <i>via</i> a heterocyclic ring nitrogen. Heme-binding of the hydroxyamidine is further stabilized by a H-bond with Ala-264 and two intramolecular H-bonds with the aniline and amino nitrogen atoms of INCB024360, which stabilize the active conformation. The benzene ring occupies a hydrophobic pocket proximal to the heme, engaging in a sulfur-fluorine bonding interaction with Cys-129. Interactions of the furazan moiety with Phe-163, Leu-234, and Phe-226 were also observed.</div><div class="NLM_p">Dose-escalation studies demonstrated INCB024360 was well-tolerated, reducing plasma kynurenine to âhealthyâ levels by two hours postadministration at doses of >100 mg twice-daily (<i>bid</i>.). Preliminary phase I/II data in small patient populations was encouraging, with combination therapy approaches (INCB024360 + monoclonal antibody treatments) improving overall patient responses.<a onclick="showRef(event, 'ref215 ref216 ref217 ref218 ref219'); return false;" href="javascript:void(0);" class="ref ref215 ref216 ref217 ref218 ref219">(215â219)</a> Clinical trials (ECHO/KEYSTONE trials) were initiated to evaluate the efficacy of IDO1 blockade (INCB024360) in combination with other chemotherapy treatments; most trials were terminated following the results of a phase III trial (ECHO-301) in patients with metastatic melanoma, in which INCB024360 + pembrolizumab provided no advantage to pembrolizumab monotherapy.<a onclick="showRef(event, 'ref220'); return false;" href="javascript:void(0);" class="ref ref220">(220)</a> It has been proposed that selective IDO1 inhibition is insufficient to sustain a therapeutic response, with compensatory pathways involving IDO2 and tryptophan 2,3-dioxygenase (TDO) implicated in disease progression during IDO1 blockade.<a onclick="showRef(event, 'ref221'); return false;" href="javascript:void(0);" class="ref ref221">(221)</a></div><div class="NLM_p">Academic research groups and pharmaceutical companies have developed analogues of INCB024360 (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>) with improved PK properties;<a onclick="showRef(event, 'ref222 ref223 ref224 ref225 ref226 ref227'); return false;" href="javascript:void(0);" class="ref ref222 ref223 ref224 ref225 ref226 ref227">(222â227)</a> dose-limiting toxicities (hyperglycemia) have been reported for INCB024360 which may be overcome by lower dosing/longer half-life. Development of pan-IDO/TDO inhibitors (<b>82</b>) has also been reported.<a onclick="showRef(event, 'ref228'); return false;" href="javascript:void(0);" class="ref ref228">(228)</a> Dual action inhibitors targeting IDO/histone deacetylase (HDAC) activity (<b>83</b>) or IDO/DNA synthesis (<b>84</b>) have been disclosed;<a onclick="showRef(event, 'ref229 ref230'); return false;" href="javascript:void(0);" class="ref ref229 ref230">(229,230)</a> preclinical reports have suggested that a combination of IDO1 inhibition with DNA damaging agents may enhance the efficacy of tumor regression versus chemotherapeutics which target DNA synthesis alone.<a onclick="showRef(event, 'ref221'); return false;" href="javascript:void(0);" class="ref ref221">(221)</a></div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. <i>In vitro</i> and preclinical <i>in vivo</i> development of epacadostat-derived IDO1 inhibitors as chemotherapeutics. Tumor reduction (red.) was determined in mouse xenograft models; values in parentheses are the tumor reduction induced by epacadostat in the given model at the same dose. MLM = mouse liver microsomes; HLM = human liver microsomes; RLM = rat liver microsomes; LLC = Lewis lung carcinoma.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec7_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Kinase Inhibitors</h3><div class="NLM_p">Akt (protein kinase B) is involved in regulating cellular processes such as glucose metabolism, apoptosis, proliferation and migration, making it an attractive target for oncology programs.<a onclick="showRef(event, 'ref231'); return false;" href="javascript:void(0);" class="ref ref231">(231)</a> Researchers at GlaxoSmithKline discovered a furazanyl benzimidazole pharmacophore with broad spectrum kinase inhibition activity;<a onclick="showRef(event, 'ref137 ref138 ref139'); return false;" href="javascript:void(0);" class="ref ref137 ref138 ref139">(137â139)</a> the furazan is an essential piece of the pharmacophore (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>), engaging in two key H-bonding interactions in the hinge region of the ATP-binding site.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> Development and SAR of the furazanyl benzimidazole pharmacophore is described above (see <a class="ref internalNav" href="#sec5" aria-label="Inflammatory Disorders">Inflammatory Disorders</a>). Lead optimization identified GSK690693 (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>) as a potent and selective inhibitor of Akt by exploiting a small pocket in the back cleft of the ATP-binding site (absent in related kinases MSK, ROCK, RSK).<a onclick="showRef(event, 'ref139 ref232'); return false;" href="javascript:void(0);" class="ref ref139 ref232">(139,232)</a> Strong antiproliferative activity was observed in multiple cancer cell lines, with minimal toxicity in noncancerous human fibroblasts. Preclinical characterization demonstrated <i>in vivo</i> efficacy against xenograft models of ovarian, prostate and breast carcinoma (<a class="ref showTableEvent internalNav" data-ID="tbl16" href="#tbl16">Table <a class="ref showTableEvent internalNav" data-ID="tbl16" href="#tbl16">16</a></a>); the drug was well-tolerated in mice, although hyperglycemia was observed during treatment.<a onclick="showRef(event, 'ref232 ref233'); return false;" href="javascript:void(0);" class="ref ref232 ref233">(232,233)</a> GSK690693 is the first Akt inhibitor to be evaluated clinically, with trials involving patients with advanced solid tumors, lymphoma (NCT00493818) and hematologic malignancies (NCT00666081);<a onclick="showRef(event, 'ref234'); return false;" href="javascript:void(0);" class="ref ref234">(234)</a> the program was eventually terminated due to drug-related hyperglycemia and peripheral insulin resistance.</div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Furazan-derived kinase inhibitors investigated as chemotherapeutics.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl16"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 16. <i>In Vivo</i> Antitumor Effect of GSK690693 in Xenograft Mice<a class="ref internalNav" href="#tbl16-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">xenograft (type)</th><th class="colsep0 rowsep0" align="center" char=".">tumor volume decrease (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BT474 (breast)</td><td class="colsep0 rowsep0" align="char" char=".">46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCC-1954 (breast)</td><td class="colsep0 rowsep0" align="char" char=".">65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDA-MB-453 (breast)</td><td class="colsep0 rowsep0" align="char" char=".">27<a class="ref internalNav" href="#t16fn1" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SKOV3 (ovarian)</td><td class="colsep0 rowsep0" align="char" char=".">58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LNCaP (prostate)</td><td class="colsep0 rowsep0" align="char" char=".">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PANC1 (pancreatic)</td><td class="colsep0 rowsep0" align="char" char=".">+5<a class="ref internalNav" href="#t16fn1" aria-label="b">b</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl16-fn1"><div class="footnote" id="tbl16-fn1"><sup><sup>a</sup></sup><p class="last">30 mg/kg <i>i.p.</i> daily, 21 days.</p></div><div class="footnote" id="t16fn1"><sup><sup>b</sup></sup><p class="last">Result is not significant (<i>p</i> > 0.05)</p></div></div></div><div class="NLM_p last">Furazan-derived kinase inhibitors have been disclosed in other oncology programs (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>): an approach involving inhibition of p70S6 (feedback inhibition of Akt signaling pathways) was investigated by Vertex Pharmaceuticals<a onclick="showRef(event, 'ref235 ref236'); return false;" href="javascript:void(0);" class="ref ref235 ref236">(235,236)</a> (<b>85</b>). RSK1 inhibitors were claimed by Banyu Pharmaceutical Co. (a subsidiary of Merck) as antitumor agents<a onclick="showRef(event, 'ref237'); return false;" href="javascript:void(0);" class="ref ref237">(237)</a> (<b>86</b>). Patents from 4SC disclosed a series of furazanopyrazines which inhibit multiple kinases and growth factors involved in cancer cell survival, proliferation, migration and metastasis<a onclick="showRef(event, 'ref238'); return false;" href="javascript:void(0);" class="ref ref238">(238)</a> (<b>87</b>); targeting multiple aspects of tumorigenesis (âmultiplex protein kinase inhibitionâ) could enable broad spectrum anticancer activity. Furazanyl triazoles identified by Pyrkov et al. inhibit phosphofructokinase, having antiproliferative effects against lung, colon and breast cancer cell lines<a onclick="showRef(event, 'ref239'); return false;" href="javascript:void(0);" class="ref ref239">(239)</a> (<b>88</b>). More information regarding the development of these inhibitors or their efficacy as a cancer treatment has not been reported, nor are they listed in company pipelines.</div></div><div id="sec7_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Other Approaches</h3><div class="NLM_p">Upregulation of glutathione transferase (GST) is a known mechanism of chemoresistance in tumor cells; conjugation of drug molecules to glutathione (GSH) simulates efflux of the drug from the tumor environment. Nitrobenzofurazan inhibitors of GSTP1-1 identified by Caccuri and coworkers are effective inducers of apoptosis.<a onclick="showRef(event, 'ref240 ref241'); return false;" href="javascript:void(0);" class="ref ref240 ref241">(240,241)</a> Nitrobenzofurazan is considered a PAINS motif with promiscuous reactivity; related derivative 4-chloro-7-nitrobenzofurazan is commonly employed as a fluorescent probe to study thiol conjugation in biological systems.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> However, GST inhibitor NBDHEX (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>) does not react with free GSH and displays only a weak interaction with the GSTP1-1 enzyme <i>in vitro</i>; inhibition of GST is observed only in the presence of both enzyme and GSH. Fluorometric analysis suggests the formation of a stable sigma complex between GSH and NBDHEX, causing dissociation of the JNK-GST complex and induction of apoptosis.<a onclick="showRef(event, 'ref242'); return false;" href="javascript:void(0);" class="ref ref242">(242)</a></div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. NBDHEX and analogues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">NBDHEX is well-tolerated,<a onclick="showRef(event, 'ref243'); return false;" href="javascript:void(0);" class="ref ref243">(243)</a> with <i>in vitro</i> antiproliferative activity against many cancer cell lines (<a class="ref showTableEvent internalNav" data-ID="tbl17" href="#tbl17">Table <a class="ref showTableEvent internalNav" data-ID="tbl17" href="#tbl17">17</a></a>). However, <i>in vivo</i> efficacy is limited by poor bioavailability and limited selectivity over GSTM2-2 (expressed in noncancer cells).<a onclick="showRef(event, 'ref244'); return false;" href="javascript:void(0);" class="ref ref244">(244)</a> Optimization of the physical properties identified MC3181 (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>), having a more desirable activity/selectivity profile and enhanced solubility<a onclick="showRef(event, 'ref245'); return false;" href="javascript:void(0);" class="ref ref245">(245)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl17" href="#tbl17">Table <a class="ref showTableEvent internalNav" data-ID="tbl17" href="#tbl17">17</a></a>). MC3181 also reduces the invasiveness of melanoma tumors and lowers the incidence of metastasis <i>in vitro</i>.<a onclick="showRef(event, 'ref246'); return false;" href="javascript:void(0);" class="ref ref246">(246)</a> Preclinical evaluation of MC3181 in melanoma xenograft models is encouraging; MC3181 was more efficacious than Temozolomide in treating melanomas resistant to BRAF inhibitors (e.g., vemurafenib).<a onclick="showRef(event, 'ref247 ref248'); return false;" href="javascript:void(0);" class="ref ref247 ref248">(247,248)</a> Further improvements to the metabolic stability and bioavailability (pro-drug approaches) is ongoing.<a onclick="showRef(event, 'ref249 ref250'); return false;" href="javascript:void(0);" class="ref ref249 ref250">(249,250)</a></div><div class="NLM_table-wrap" id="tbl17"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 17. <i>In Vitro</i> and Preclinical <i>in Vivo</i> Activity of NBDHEX and MC3181</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">NBDHEX</th><th class="colsep0 rowsep0" align="center">MC3181</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (GSTP1-1)</td><td class="colsep0 rowsep0" align="left">0.8 Î¼M</td><td class="colsep0 rowsep0" align="left">2.6 Î¼M</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (GSTM2-2)</td><td class="colsep0 rowsep0" align="left"><0.01 Î¼M</td><td class="colsep0 rowsep0" align="left">0.08 Î¼M</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solubility (pH 7.4)<a class="ref internalNav" href="#t17fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">0.10 mM</td><td class="colsep0 rowsep0" align="left">5.0 mM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> (A375)</td><td class="colsep0 rowsep0" align="left">0.37 Î¼M</td><td class="colsep0 rowsep0" align="left">0.77 Î¼M</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> (U-2OS)</td><td class="colsep0 rowsep0" align="left">0.9 Î¼M</td><td class="colsep0 rowsep0" align="left">1.1 Î¼M</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> (MM-B1)</td><td class="colsep0 rowsep0" align="left">1.3 Î¼M</td><td class="colsep0 rowsep0" align="left">1.6 Î¼M</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> (MCF-7)</td><td class="colsep0 rowsep0" align="left">1.6 Î¼M</td><td class="colsep0 rowsep0" align="left">1.5 Î¼M</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> (COLO 205)</td><td class="colsep0 rowsep0" align="left">5.3 Î¼M</td><td class="colsep0 rowsep0" align="left">6.5 Î¼M</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> (HT-29)</td><td class="colsep0 rowsep0" align="left">11.0 Î¼M</td><td class="colsep0 rowsep0" align="left">15.8 Î¼M</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tumor red. (A375)<a class="ref internalNav" href="#t17fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">65%<a class="ref internalNav" href="#t17fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">60%<a class="ref internalNav" href="#t17fn4" aria-label="d">d</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t17fn1"><div class="footnote" id="t17fn1"><sup><sup>a</sup></sup><p class="last">Potassium phosphate buffer solution.</p></div><div class="footnote" id="t17fn2"><sup><sup>b</sup></sup><p class="last">Tumor reduction in melanoma xenograft mouse.</p></div><div class="footnote" id="t17fn3"><sup><sup>c</sup></sup><p class="last">40 mg/kg <i>p.o</i>. once daily for 10 consecutive days; tumor weight reduction.</p></div><div class="footnote" id="t17fn4"><sup><sup>d</sup></sup><p class="last">8.0 mg/kg IV q1Dx5/3; tumor volume reduction.</p></div></div></div><div class="NLM_p">Regulation of p21, a cyclin-dependent kinase inhibitor, has been proposed as an oncology drug target,<a onclick="showRef(event, 'ref251'); return false;" href="javascript:void(0);" class="ref ref251">(251)</a> but this approach is complicated by the complex network of p21-related activity in biological functions.<a onclick="showRef(event, 'ref252'); return false;" href="javascript:void(0);" class="ref ref252">(252)</a> A screening program reported by Baden-Wuerttemberg Stiftung identified furazanopyrazines as potent and selective inhibitors of p21 activity<a onclick="showRef(event, 'ref253'); return false;" href="javascript:void(0);" class="ref ref253">(253)</a> (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>, compound <b>89</b>). Selectivity (greater than twofold) over p53 and its target genes (inhibition of MDM2 <50%) was demonstrated <i>in vitro</i>. Inhibition of p21 activity is proposed to occur at the transcriptional level by preventing the association of p53 to the p21-promoter sequence. Other nonfurazanyl chemotypes with good potency and selectivity were also disclosed (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>, compounds <b>90</b>, <b>91</b>). Furazanopyrazines claimed as antitumor agents by Compass Pharmaceuticals inhibit proliferation of patient-derived sarcoma and ovarian tumor cells<a onclick="showRef(event, 'ref254'); return false;" href="javascript:void(0);" class="ref ref254">(254)</a> (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>, compounds <b>92</b>â<b>94</b>), but a MoA was not disclosed.</div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Furazanopyrazines identified by Baden-Wuerttemberg Stiftung and Compass Pharmaceuticals with potent anticancer activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">Antimicrobials</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41618" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41618" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Antibacterial</h3><div class="NLM_p">The prominence of antibiotic resistance and the estimated global burden of multidrug resistant pathogens<a onclick="showRef(event, 'ref255'); return false;" href="javascript:void(0);" class="ref ref255">(255)</a> has prompted research efforts to identify novel chemotypes. Furazan derivatives are known to exhibit a range of antimicrobial activities, including antibiotic, antifungal, and antipest,<a onclick="showRef(event, 'ref256 ref257 ref258 ref259 ref260'); return false;" href="javascript:void(0);" class="ref ref256 ref257 ref258 ref259 ref260">(256â260)</a> yet evidence of selectivity over eukaryotic cells is seldom provided. A report from Abbot Laboratories identified furazanopyrazines (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>, compound <b>95</b>) as broad-spectrum antibiotics with good selectivity over eukaryotic cell lines;<a onclick="showRef(event, 'ref261'); return false;" href="javascript:void(0);" class="ref ref261">(261)</a> antibiotic activity was observed in <i>H. influenzae</i>, <i>S. aureus</i>, and <i>S. pneumoniae</i> with no observable cytotoxicity in yeast (<i>C. albicans</i>) or human lymphocytes (<a class="ref showTableEvent internalNav" data-ID="tbl18" href="#tbl18">Table <a class="ref showTableEvent internalNav" data-ID="tbl18" href="#tbl18">18</a></a>). Benzofurazan-derived inhibitors of flavodoxin (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>, compounds <b>96</b>, <b>97</b>) are reported to be effective against <i>H. pylori</i> infection <i>in vitro</i> (<a class="ref showTableEvent internalNav" data-ID="tbl18" href="#tbl18">Table <a class="ref showTableEvent internalNav" data-ID="tbl18" href="#tbl18">18</a></a>) and <i>in vivo</i> (<a class="ref showTableEvent internalNav" data-ID="tbl19" href="#tbl19">Table <a class="ref showTableEvent internalNav" data-ID="tbl19" href="#tbl19">19</a></a>). The compounds were well-tolerated in mice with no observable toxicity at the administered doses (histopathological examination). Efficacy in metronidazole-resistant <i>H. pylori</i> strains was also demonstrated.<a onclick="showRef(event, 'ref262 ref263 ref264 ref265'); return false;" href="javascript:void(0);" class="ref ref262 ref263 ref264 ref265">(262â265)</a> Inhibition of iron acquisition pathways <i>via</i> bacterial siderophores has been proposed as a therapeutic strategy to treat multidrug resistant pathogens; furazan-derived inhibitors of BasE (no known human homologues) exhibit antibiotic activity against <i>A. baumannii</i>, of which there are multiple drug resistant forms<a onclick="showRef(event, 'ref266'); return false;" href="javascript:void(0);" class="ref ref266">(266)</a> (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>, compound <b>98</b>). The binding affinity of these compounds for isolated BasE is quite strong,<a onclick="showRef(event, 'ref267'); return false;" href="javascript:void(0);" class="ref ref267">(267)</a> suggesting that live cell (MIC = 0.5 mM) and <i>in vivo</i> potency of these compounds can be enhanced through medicinal chemistry.</div><div class="NLM_table-wrap" id="tbl18"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 18. MIC Values of Furazan Derivatives <b>95</b>â<b>99</b> for Various Pathogenic Bacteria</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center"><i>H.Â influenzae</i></th><th class="colsep0 rowsep0" align="center"><i>S.Â aureus</i></th><th class="colsep0 rowsep0" align="center"><i>S.Â pneumoniae</i></th><th class="colsep0 rowsep0" align="center"><i>H. pylori</i> SS1<a class="ref internalNav" href="#t18fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"><i>H. pylori</i> NCTC 11637<a class="ref internalNav" href="#t18fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>95a</b> (R = F)</td><td class="colsep0 rowsep0" align="left">4.3 Î¼M</td><td class="colsep0 rowsep0" align="left">0.28 mM</td><td class="colsep0 rowsep0" align="left">0.28 mM</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>95b</b> (R = Cl)</td><td class="colsep0 rowsep0" align="left">4.0 Î¼M</td><td class="colsep0 rowsep0" align="left">64 Î¼M</td><td class="colsep0 rowsep0" align="left">0.50 mM</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>95c</b> (R = Br)</td><td class="colsep0 rowsep0" align="left">3.4 Î¼M</td><td class="colsep0 rowsep0" align="left">55 Î¼M</td><td class="colsep0 rowsep0" align="left">0.22 mM</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>95d</b> (R = OPh)</td><td class="colsep0 rowsep0" align="left">26 Î¼M</td><td class="colsep0 rowsep0" align="left">13 Î¼M</td><td class="colsep0 rowsep0" align="left">0.21 mM</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>99</b></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">0.25 mM<a class="ref internalNav" href="#t18fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.25 mM<a class="ref internalNav" href="#t18fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>96</b></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">0.78 Î¼M<a class="ref internalNav" href="#t18fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">1.6 Î¼M<a class="ref internalNav" href="#t18fn6" aria-label="f">f</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>97</b></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">105 Î¼M<a class="ref internalNav" href="#t18fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">53 Î¼M<a class="ref internalNav" href="#t18fn6" aria-label="f">f</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t18fn1"><div class="footnote" id="t18fn1"><sup><sup>a</sup></sup><p class="last">Metronidazole-sensitive strain.</p></div><div class="footnote" id="t18fn2"><sup><sup>b</sup></sup><p class="last">Metronidazole-resistant strain.</p></div><div class="footnote" id="t18fn3"><sup><sup>c</sup></sup><p class="last">MIC of azithromycin under the same assay conditions was 0.20 mM.</p></div><div class="footnote" id="t18fn4"><sup><sup>d</sup></sup><p class="last">MIC of tobramycin under the same assay conditions was 0.05 mM.</p></div><div class="footnote" id="t18fn5"><sup><sup>e</sup></sup><p class="last">MIC of metronidazole under the same assay conditions was 2.9 Î¼M.</p></div><div class="footnote" id="t18fn6"><sup><sup>f</sup></sup><p class="last">MIC of metronidazole under the same assay conditions was 187 Î¼M.</p></div></div></div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Furazan-derived antibacterial compounds with good selectivity over eukaryotic cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl19"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 19. <i>In Vivo</i> Efficacy of <b>96</b> and <b>97</b> in <i>H. pylori</i> (SS1) Infected Mice</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">dose <i>p.o</i>. (mg/kg)<a class="ref internalNav" href="#t19fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">infection cures (%)<a class="ref internalNav" href="#t19fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>96</b></td><td class="colsep0 rowsep0" align="center" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>97</b></td><td class="colsep0 rowsep0" align="center" char=".">200</td><td class="colsep0 rowsep0" align="char" char=".">60</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t19fn1"><div class="footnote" id="t19fn1"><sup><sup>a</sup></sup><p class="last">Administered for 8 consecutive days, first dose 8 days postinfection.</p></div><div class="footnote" id="t19fn2"><sup><sup>b</sup></sup><p class="last">Measured 8 days after final dose.</p></div></div></div><div class="NLM_p">Biofilm formation is associated with the majority of microbial infections and is known to enhance antibiotic resistance and virulence.<a onclick="showRef(event, 'ref268'); return false;" href="javascript:void(0);" class="ref ref268">(268)</a> The biofilm matrix contains a dense array of microbial hydrolases and proteases, which can negatively impact drug stability. Das et al. identified oximinofurazans (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>, compound <b>99</b>) with antibiotic activity against <i>S. aureus</i> and <i>P. aeruginosa</i> which also disrupt the associated biofilm (<a class="ref showTableEvent internalNav" data-ID="tbl20" href="#tbl20">Table <a class="ref showTableEvent internalNav" data-ID="tbl20" href="#tbl20">20</a></a>); antibiotic activity of <b>99</b> against planktonic cell cultures is comparable to azithromycin and tobramycin<a onclick="showRef(event, 'ref269'); return false;" href="javascript:void(0);" class="ref ref269">(269)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl18" href="#tbl18">Table <a class="ref showTableEvent internalNav" data-ID="tbl18" href="#tbl18">18</a></a>). A reduction of bacterial motility and reduced adherence properties of the biofilm matrix are implicated in the observed biofilm attenuation. Secretion of microbial hydrolases was also reduced. Limited hemolysis was observed in red blood cells treated with the furazan derivatives which implies selectivity for the pathogen over host cells.</div><div class="NLM_table-wrap" id="tbl20"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 20. Reduction in Biofilm Formation of <i>S. aureus</i> and <i>S. pneumoniae</i> by Uredofurazan <b>99</b> and Antibiotics Azithromycin (AZM) and Tobramycin (TBM)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">dose (Î¼M)</th><th class="colsep0 rowsep0" align="center" char="."><i>S. aureus</i> (%)</th><th class="colsep0 rowsep0" align="center" char="."><i>S. pneumoniae</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>99</b></td><td class="colsep0 rowsep0" align="center" char=".">63</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="char" char=".">73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AZM<a class="ref internalNav" href="#t20fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center" char=".">7.6</td><td class="colsep0 rowsep0" align="char" char=".">48</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TBM<a class="ref internalNav" href="#t20fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">50</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t20fn1"><div class="footnote" id="t20fn1"><sup><sup>a</sup></sup><p class="last">Included as positive controls; data were obtained under the same assay conditions as uredofurazan <b>99</b>.</p></div></div></div></div><div id="sec8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Antiparasitic</h3><div class="NLM_p">4-Hydroxyfurazan-5-carboxylic acid (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>, compound <b>100</b>) was identified as an effective inhibitor of <i>P. falciparum</i> lactate dehydrogenase (<i>pf</i>LDH), an emerging target for antimalarial drug development.<a onclick="showRef(event, 'ref270'); return false;" href="javascript:void(0);" class="ref ref270">(270)</a> Of note, activity was maintained in a <i>P. falciparum</i> strain (K1) resistant to chloroquine, pyrimethamine, and cycloguanilil (<a class="ref showTableEvent internalNav" data-ID="tbl21" href="#tbl21">Table <a class="ref showTableEvent internalNav" data-ID="tbl21" href="#tbl21">21</a></a>). The furazan engages in a key H-bonding interaction with Ser-245 of <i>pf</i>LDH; this interaction is absent in the human homologue, imparting selectivity for the pathogen over the host. Drugs which target this region of <i>pf</i>LDH may preclude the formation of a viable drug-resistant strain, as mutation of Ser-245 produce severe reductions in the catalytic efficiency of <i>pf</i>LDH. PK studies (<a class="ref showTableEvent internalNav" data-ID="tbl22" href="#tbl22">Table <a class="ref showTableEvent internalNav" data-ID="tbl22" href="#tbl22">22</a></a>) demonstrated rapid absorption and good plasma levels of the drug, but a short half-life. Poor cell penetration is also expected, as <b>100</b> exists as the dianion under physiological conditions. Nonetheless, a moderate reduction in parasitic load was observed <i>in vivo</i> (<a class="ref showTableEvent internalNav" data-ID="tbl22" href="#tbl22">Table <a class="ref showTableEvent internalNav" data-ID="tbl22" href="#tbl22">22</a></a>). Other research programs have disclosed (benzo)furazan derivatives with antiparasitic activity against <i>T. brucei</i><a onclick="showRef(event, 'ref271'); return false;" href="javascript:void(0);" class="ref ref271">(271)</a> and <i>L. donovani</i>,<a onclick="showRef(event, 'ref272'); return false;" href="javascript:void(0);" class="ref ref272">(272)</a> but the (benzo)furazan moiety appears to be interchangeable with other heterocycles and the biological activity is modest.</div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Anti-<i>Plasmodium</i> activity of heterocyclic compounds. <i>pf</i> = <i>P. falciparum</i>. <i>hs</i> = <i>H. sapien</i>. LDH = lactate dehydrogenase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl21"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 21. <i>In Vitro</i> Characterization of <b>100</b>â<b>102</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center"><b>100</b></th><th class="colsep0 rowsep0" align="center"><b>101</b></th><th class="colsep0 rowsep0" align="center"><b>102</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>K</i><sub>i</sub> (<i>pf</i>LDH)</td><td class="colsep0 rowsep0" align="left">210 nM</td><td class="colsep0 rowsep0" align="left">470 nM</td><td class="colsep0 rowsep0" align="left">290 nM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> (<i>pf</i> 3D7)<a class="ref internalNav" href="#t21fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">22.5 Î¼M</td><td class="colsep0 rowsep0" align="left">74.4 Î¼M</td><td class="colsep0 rowsep0" align="left">75.3 Î¼M</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EC<sub>90</sub> (<i>pf</i> 3D7)<a class="ref internalNav" href="#t21fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">75.9 Î¼M</td><td class="colsep0 rowsep0" align="left">>200 Î¼M</td><td class="colsep0 rowsep0" align="left">>170 Î¼M</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> (<i>pf</i> K1)<a class="ref internalNav" href="#t21fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">18.6 Î¼M</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">144 Î¼M</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> (KB)<a class="ref internalNav" href="#t21fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.64 mM</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> (HeLa)<a class="ref internalNav" href="#t21fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">1.3 mM</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t21fn1"><div class="footnote" id="t21fn1"><sup><sup>a</sup></sup><p class="last">Drug-sensitive strain.</p></div><div class="footnote" id="t21fn2"><sup><sup>b</sup></sup><p class="last">Drug-resistant strain.</p></div><div class="footnote" id="t21fn3"><sup><sup>c</sup></sup><p class="last">Mammalian eukaryotic cells. <i>pf</i> = <i>P. falciparum</i>.</p></div></div></div><div class="NLM_table-wrap" id="tbl22"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 22. <i>In Vivo</i> PK and Efficacy <b>100</b> and <b>101</b> as Anti-<i>Plasmodium</i> Therapeutics (Preclinical Model)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="2" align="center" char="."><i>C</i><sub>max</sub> (Î¼M)</th><th class="rowsep1 colsep0" colspan="2" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">Â </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug<a class="ref internalNav" href="#t22fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="."><i>p.o</i>.</th><th class="colsep0 rowsep0" align="center" char="."><i>i.p.</i></th><th class="colsep0 rowsep0" align="center" char="."><i>p.o</i>.</th><th class="colsep0 rowsep0" align="center" char="."><i>i.p.</i></th><th class="colsep0 rowsep0" align="center" char=".">parasite reduction (%)<a class="ref internalNav" href="#t22fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>100</b></td><td class="colsep0 rowsep0" align="char" char=".">138</td><td class="colsep0 rowsep0" align="char" char=".">196</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>101</b></td><td class="colsep0 rowsep0" align="char" char=".">153</td><td class="colsep0 rowsep0" align="char" char=".">158</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">30</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t22fn1"><div class="footnote" id="t22fn1"><sup><sup>a</sup></sup><p class="last">Administered at 100 mg/kg.</p></div><div class="footnote" id="t22fn2"><sup><sup>b</sup></sup><p class="last">10 mg/kg chloroquine results in 100% parasite clearance.</p></div></div></div></div><div id="sec8_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Antiviral</h3><div class="NLM_p">Nitrobenzofurazans which inhibit the viral RNA polymerase complex were disclosed by Pike Pharma as anti-influenza agents<a onclick="showRef(event, 'ref273 ref274'); return false;" href="javascript:void(0);" class="ref ref273 ref274">(273,274)</a> (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>). Viral RNA polymerase is highly conserved across many strains, making it an attractive drug target. The benzofurazan participates in a Ï-stacking interaction with Trp-706 and H-bonding with Gln-408, while the nitro group forms an electrostatic interaction with Lys-643.<a onclick="showRef(event, 'ref275 ref276'); return false;" href="javascript:void(0);" class="ref ref275 ref276">(275,276)</a> Antiviral activity against influenza type A, type B, and respiratory syncytial virus (RSV) was demonstrated <i>in vitro</i>.<a onclick="showRef(event, 'ref273 ref274'); return false;" href="javascript:void(0);" class="ref ref273 ref274">(273,274)</a> The MoA involves benzofurazan-mediated disruption of the PA-PB1 subunit interaction, leading to RNA polymerase inhibition. The anti-influenza activity of benzofurazans was unknown prior to these reports.</div><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0028.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Antiviral activity of nitrobenzofurazans against influenza A (H1N1) and RSV.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45">Other Indications</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80566" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80566" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Mitochondrial uncouplers induce proton leak from the inner membrane space to the mitochondrial matrix independent of the ATP synthase machinery, increasing cellular metabolism. Disorders linked to mitochondrial oxidative stress or metabolism can be treated using mitochondrial uncouplers. For example, 2,4-dinitrophenol (DNP) has been used to treat obesity. Most mitochondrial uncouplers also depolarize the plasma membrane, resulting in off-target cytotoxicity; DNP was removed from the market in 1938 due to a narrow therapeutic window and severe adverse effects. The furazanopyrazine BAM15 was identified as a selective uncoupler of the mitochondrial membrane, having no impact on the plasma membrane.<a onclick="showRef(event, 'ref277'); return false;" href="javascript:void(0);" class="ref ref277">(277)</a> The compound is well-tolerated <i>in vivo</i>, producing therapeutic responses in models of kidney injury,<a onclick="showRef(event, 'ref277'); return false;" href="javascript:void(0);" class="ref ref277">(277)</a> diet-induced obesity,<a onclick="showRef(event, 'ref278'); return false;" href="javascript:void(0);" class="ref ref278">(278)</a> insulin resistance (diabetes)<a onclick="showRef(event, 'ref279'); return false;" href="javascript:void(0);" class="ref ref279">(279)</a> and fatty liver disease.<a onclick="showRef(event, 'ref280'); return false;" href="javascript:void(0);" class="ref ref280">(280)</a> SAR studies determined the furazanopyrazine is essential, providing the requisite balance of lipophilic character and acidity,<a onclick="showRef(event, 'ref281 ref282'); return false;" href="javascript:void(0);" class="ref ref281 ref282">(281,282)</a> and replacement with other heterocycles led to decreased activity<a onclick="showRef(event, 'ref283'); return false;" href="javascript:void(0);" class="ref ref283">(283)</a> (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>). Optimization of the activity, physical properties and PK profile identified hydroxy-substituted furazanopyrazines as efficient mitochondrial uncouplers<a onclick="showRef(event, 'ref284'); return false;" href="javascript:void(0);" class="ref ref284">(284)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl23" href="#tbl23">Table <a class="ref showTableEvent internalNav" data-ID="tbl23" href="#tbl23">23</a></a>). The advanced lead SHS4121705 is currently being investigated by Continuum Biosciences as a treatment for nonalcoholic steatohepatitis.<a onclick="showRef(event, 'ref282'); return false;" href="javascript:void(0);" class="ref ref282">(282)</a></div><figure id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0029.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. SAR of furazanopyrazine-derived mitochondrial uncoupler BAM15. EC<sub>50</sub> values indicate the concentration which stimulates 50% of maximum achievable oxygen consumption rate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl23"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 23. Physical Properties and Biological Activity of BAM15 and Preclinical Lead SHS4121705</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0036.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t23fn1"><div class="footnote" id="t23fn1"><sup><sup>a</sup></sup><p class="last">Measured in phosphate-buffered saline, pH 7.4.</p></div><div class="footnote" id="t23fn2"><sup><sup>b</sup></sup><p class="last">Concentration which stimulates 50% of maximum achievable OCR.</p></div><div class="footnote" id="t23fn3"><sup><sup>c</sup></sup><p class="last">Measured relative to baseline OCR.</p></div><div class="footnote" id="t23fn4"><sup><sup>d</sup></sup><p class="last">Dose of 10 mg/kg (<i>p.o</i>.). OCR = oxygen consumption rate.</p></div></div><div></div></div><div class="NLM_p">A series of P-gp ligands have been disclosed by Colabufo and coworkers as positron emission topography (PET) imaging tools<a onclick="showRef(event, 'ref285'); return false;" href="javascript:void(0);" class="ref ref285">(285)</a> and cotherapeutic agents to mitigate efflux-related drug resistance<a onclick="showRef(event, 'ref286'); return false;" href="javascript:void(0);" class="ref ref286">(286)</a> (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>). The addition of a pendant furazan to the established pharmacophore MC70 significantly enhanced potency and selectivity (MDR1/MRP1); the furazan moiety forms an additional H-bonding interaction with Gln-195.<a onclick="showRef(event, 'ref287'); return false;" href="javascript:void(0);" class="ref ref287">(287)</a> The furazan derivatives could enhance the efficacy of chemotherapeutics: MC70 enhances doxorubicin response in breast cancer cell lines.<a onclick="showRef(event, 'ref286'); return false;" href="javascript:void(0);" class="ref ref286">(286)</a> Development of imaging agents to study P-gp function <i>in vivo</i> has also been proposed. Novo Nordisk identified a class of furazans which are selective inhibitors of GSK-3Î² and were investigated as therapeutic agents to treat diabetes<a onclick="showRef(event, 'ref236 ref288'); return false;" href="javascript:void(0);" class="ref ref236 ref288">(236,288)</a> (<a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>). Stimulation of glycogen synthase activity was observed in tissue cultures (ca. threefold stimulation at 10 Î¼M), suggesting good permeability of the compounds.<a onclick="showRef(event, 'ref289'); return false;" href="javascript:void(0);" class="ref ref289">(289)</a><i>In vivo</i> efficacy and other preclinical data have not been reported.</div><figure id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0030.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Structures and <i>in vitro</i> potency of selective P-gp ligands reported by Colabufo et al. EC<sub>50</sub> values were determined in MDCK-MDR1 cell line.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0031.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Selective inhibitors of GSK-3Î² identified by Novo Nordisk. EC<sub>50</sub> values are provided for <i>in vitro</i> stimulation of glycogen synthase activity in CHO cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47">Outlook</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00587" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00587" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">(Benzo)furazan derivatives show a range of interesting biology, with furazanyl benzimidazoles, furazanopyrazines, and uredo/amido furazans being most prevalent in drug discovery programs. The ability to generate benzo-fused systems provides chemical space unique to that of the 1,2,4- or 1,3,4-oxadiazole isomers; a balance of lipophilic character and polarity is achieved. Nonetheless, the prevalence of furazans in drug discovery programs and drug molecules is considerably low. Furazan derivatives are often identified in high-throughput screening programs, likely due to a range of possible binding interactions (H-bonding, Ï-stacking, and polar or van der Waals interactions), but are seldom carried through development. The identification of benzofurazans (particularly nitrobenzofurazans) as a PAINS motif, having promiscuous reactivity, would explain the low incidence of furazan-containing drugs. Removal of such âred flagsâ are typical first steps of a lead optimization program. However, one must carefully analyze benzofurazan-containing structures that have been described as PAINS.<a onclick="showRef(event, 'ref290'); return false;" href="javascript:void(0);" class="ref ref290">(290)</a> The benzofurazan group is an electron deficient ring system; therefore, the presence of a leaving group <i>ortho</i> to the furazan moiety could permit nucleophilic attachment and potential off-target reactivity within a screening assay. These types of structures, as with any highly electron deficient heterocyclic ring system, should be evaluated carefully. Also, as with nitro-containing compounds, benzofurazans have the potential to be florescent; secondary screening with orthogonal assays should be performed when fluoresce-based assays are employed.</div><div class="NLM_p last">The biology and pharmacology described in this Review demonstrate that selective target engagement can be obtained through standard SAR practices to generate safe and efficacious furazan-derived molecules. Given that furazans are less common in the patent and academic literature, this chemotype may also offer interesting opportunities to explore new chemical space in future drug discovery programs.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01901" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46446" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46446" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ross S. Mancini</span> - <span class="hlFld-Affiliation affiliation">Treventis
Corporation, Toronto, Ontario M5T 0S8, Canada</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c9bba4a8a7aaa0a7a089bdbbacbfaca7bda0bae7aaa6a4"><span class="__cf_email__" data-cfemail="02706f636c616b6c6b4276706774676c766b712c616d6f">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark A. Reed</span> - <span class="hlFld-Affiliation affiliation">Treventis
Corporation, Toronto, Ontario M5T 0S8, Canada</span>;Â 
    <span class="hlFld-Affiliation affiliation">Department
of Fundamental Neurobiology, Krembil Research
Institute, Toronto, Ontario M5T 0S8, Canada</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0293-2691" title="Orcid link">http://orcid.org/0000-0002-0293-2691</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#137e617676775367617665767d677a603d707c7e"><span class="__cf_email__" data-cfemail="1a77687f7f7e5a6e687f6c7f746e736934797577">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher J. Barden</span> - <span class="hlFld-Affiliation affiliation">Treventis
Corporation, Toronto, Ontario M5T 0S8, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Donald F. Weaver</span> - <span class="hlFld-Affiliation affiliation">Department
of Fundamental Neurobiology, Krembil Research
Institute, Toronto, Ontario M5T 0S8, Canada</span>;Â 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Toronto, Toronto, Ontario M5S 3H6, Canada</span>;Â 
    <span class="hlFld-Affiliation affiliation">Department
of Medicine, University of Toronto, Toronto, Ontario M5S 3H2, Canada</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>R.S.M. and M.A.R. designed the search criteria, evaluated the literature, and drafted the initial version of the manuscript. The manuscript was further reviewed and drafted through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li><span class="author-information-subsection-header">Funding</span><p>Funding was provided by Treventis Corp.</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Funding was provided by Treventis Corp. All authors are shareholders of Treventis Corp., a firm with patents pending and issued that incorporate furazan moieties. The authors declare no other competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82137" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82137" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Ross S. Mancini</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=BIO-d7e4394-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ross S. Mancini</b> obtained his B.Sc. at the University of Ottawa, Canada. In 2017, he received his Ph.D. in organic chemistry from the University of Toronto, Canada under the supervision of Prof. Mark Taylor, working in the field of glycochemistry and chemical glycosylation. His postdoctoral research (2017â2019) in the lab of Prof. Donald Weaver (Krembil Research Institute, Toronto, Canada) focused on the design and synthesis of small molecule therapeutics to treat neurodegenerative disorders. He is currently employed by Treventis Corp. as a Senior Scientist in medicinal chemistry, where he continues to research drug therapies for neurodegenerative disorders.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Mark A. Reed</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=BIO-d7e4399-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Mark A. Reed</b> received his B.Sc. at the University of Reading and D.Phil. in synthetic organic chemistry from the University of Sussex, UK. Following postdoctoral training under the supervision of Professor Victor Snieckus (Queens University, Canada), he joined the medicinal chemistry department at ICOS Corporation (Bothell, WA) followed by the Schering Plough Research Institute (Cambridge, MA). In 2008, he cofounded Treventis Corporation and holds the position of CSO. Dr. Reed also holds the position of Staff Scientist at the Krembil Research Institute, University Health Network and is an Assistant Professor within the department of Pharmacology and Toxicology, University of Toronto.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Christopher J. Barden</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=BIO-d7e4404-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Christopher J. Barden</b> received a B.S. in chemistry at James Madison University and a Ph.D. in physical (computational) chemistry at the University of Georgia. He was admitted to the bar of the United States Patent and Trademark office in 2009. A computational chemist and patent agent, he has been involved in drug discovery programs for the past fifteen years, principally in the anti-infective, oncology, and neurodegenerative spaces. He is concurrently Associate Scientist at University Health Networkâs Krembil Research Institute and Chief Executive Officer of Treventis Corporation, a start-up he cofounded that uses <i>in silico</i> drug design approaches against protein misfolding diseases.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Donald F. Weaver</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=BIO-d7e4412-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Donald F. Weaver</b> received his M.D. and Ph.D. (organic chemistry) from Queenâs University, Canada. He also completed training as a clinical neurologist. His research is focused on the design and development of novel agents for the treatment of chronic neurologic diseases with an emphasis on dementia, particularly Alzheimerâs disease. Currently, he is Director of the Krembil Research Institute, University Health Network, University of Toronto, where he is also Professor of Medicine (Neurology) and Chemistry. He is also a practicing neurologist at the Toronto Western Hospital.</p></figure></div><div class="ack" id="ACK-d7e5233-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23610" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23610" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">D.F.W. thanks the Canada Research Charis program for support as a Tier I CRC in Protein Misfolding Diseases.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">A375</td><td class="NLM_def"><p class="first last">human melanoma</p></td></tr><tr><td class="NLM_term">A549</td><td class="NLM_def"><p class="first last">human lung cancer</p></td></tr><tr><td class="NLM_term">ABC</td><td class="NLM_def"><p class="first last">adenosine triphosphate-binding cassette</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimerâs disease</p></td></tr><tr><td class="NLM_term">ADHD</td><td class="NLM_def"><p class="first last">attention deficit hyperactivity disorder</p></td></tr><tr><td class="NLM_term">ADMET</td><td class="NLM_def"><p class="first last">absorption distribution metabolism excretion toxicity</p></td></tr><tr><td class="NLM_term">AKR</td><td class="NLM_def"><p class="first last">aldo-ketoreductase</p></td></tr><tr><td class="NLM_term">Akt</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">ALS</td><td class="NLM_def"><p class="first last">amyotrophic lateral sclerosis</p></td></tr><tr><td class="NLM_term">AMPA</td><td class="NLM_def"><p class="first last">2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">AZM</td><td class="NLM_def"><p class="first last">azithromycin</p></td></tr><tr><td class="NLM_term">AÎ²</td><td class="NLM_def"><p class="first last">amyloid beta</p></td></tr><tr><td class="NLM_term">BAF3</td><td class="NLM_def"><p class="first last">murine interleukin-3 dependent pro-B cell</p></td></tr><tr><td class="NLM_term"><i>bid</i>.</td><td class="NLM_def"><p class="first last">bis in die</p></td></tr><tr><td class="NLM_term">BP</td><td class="NLM_def"><p class="first last">blood pressure</p></td></tr><tr><td class="NLM_term">bpm</td><td class="NLM_def"><p class="first last">beats per minute</p></td></tr><tr><td class="NLM_term">BT474</td><td class="NLM_def"><p class="first last">human breast cancer</p></td></tr><tr><td class="NLM_term">C9orf72</td><td class="NLM_def"><p class="first last">chromosome 9 open reading frame 72</p></td></tr><tr><td class="NLM_term">ca.</td><td class="NLM_def"><p class="first last">circa</p></td></tr><tr><td class="NLM_term">casp</td><td class="NLM_def"><p class="first last">caspase</p></td></tr><tr><td class="NLM_term">Cdk</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase</p></td></tr><tr><td class="NLM_term">CHO</td><td class="NLM_def"><p class="first last">Chinese hamster ovary</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">COLO 205</td><td class="NLM_def"><p class="first last">human colon cancer</p></td></tr><tr><td class="NLM_term">COPD</td><td class="NLM_def"><p class="first last">chronic obstructive pulmonary disease</p></td></tr><tr><td class="NLM_term">COX</td><td class="NLM_def"><p class="first last">cyclooxygenase</p></td></tr><tr><td class="NLM_term">Daudi B.</td><td class="NLM_def"><p class="first last">human lymphoma</p></td></tr><tr><td class="NLM_term">DHODH</td><td class="NLM_def"><p class="first last">dihydroorotate dehydrogenase</p></td></tr><tr><td class="NLM_term">DHP</td><td class="NLM_def"><p class="first last">dihydropyridine</p></td></tr><tr><td class="NLM_term">DNA</td><td class="NLM_def"><p class="first last">DNA</p></td></tr><tr><td class="NLM_term">DNP</td><td class="NLM_def"><p class="first last">2,4-dinitrophenol</p></td></tr><tr><td class="NLM_term">EC<sub>50</sub></td><td class="NLM_def"><p class="first last">effective concentration of 50%</p></td></tr><tr><td class="NLM_term">ECHO/KEYSTONE</td><td class="NLM_def"><p class="first last">epacadostat clinical trials</p></td></tr><tr><td class="NLM_term">EGF</td><td class="NLM_def"><p class="first last">epidermal growth factor</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">EWG</td><td class="NLM_def"><p class="first last">electron withdrawing group</p></td></tr><tr><td class="NLM_term">FLT3-ITD</td><td class="NLM_def"><p class="first last">aggressive form of leukemia</p></td></tr><tr><td class="NLM_term">GABA</td><td class="NLM_def"><p class="first last">Î³-aminobutyric acid</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">GSK</td><td class="NLM_def"><p class="first last">glycogen synthase kinase</p></td></tr><tr><td class="NLM_term">GST</td><td class="NLM_def"><p class="first last">glutathione transferase</p></td></tr><tr><td class="NLM_term">H2</td><td class="NLM_def"><p class="first last">histamine type-2</p></td></tr><tr><td class="NLM_term">H4</td><td class="NLM_def"><p class="first last">human neuroglioma</p></td></tr><tr><td class="NLM_term">hASM</td><td class="NLM_def"><p class="first last">human primary aortic smooth muscle</p></td></tr><tr><td class="NLM_term">H-bonding</td><td class="NLM_def"><p class="first last">hydrogen bonding</p></td></tr><tr><td class="NLM_term">HCC-1954</td><td class="NLM_def"><p class="first last">human breast cancer</p></td></tr><tr><td class="NLM_term">HCT 116</td><td class="NLM_def"><p class="first last">human colon cancer</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term">HEK 293</td><td class="NLM_def"><p class="first last">human embryonic kidney 293</p></td></tr><tr><td class="NLM_term">HEL</td><td class="NLM_def"><p class="first last">human eurethroleukemia</p></td></tr><tr><td class="NLM_term">HeLa</td><td class="NLM_def"><p class="first last">human cervical cancer</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-Ã -go-go related gene</p></td></tr><tr><td class="NLM_term">HIF</td><td class="NLM_def"><p class="first last">hypoxia inducible factor</p></td></tr><tr><td class="NLM_term">HL-60</td><td class="NLM_def"><p class="first last">human leukemia</p></td></tr><tr><td class="NLM_term">HR</td><td class="NLM_def"><p class="first last">heart rate</p></td></tr><tr><td class="NLM_term">HT-29</td><td class="NLM_def"><p class="first last">human colon cancer</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">inhibitory concentration of 50%</p></td></tr><tr><td class="NLM_term"><i>i.p.</i></td><td class="NLM_def"><p class="first last">intraperitoneal</p></td></tr><tr><td class="NLM_term"><i>i.str.</i></td><td class="NLM_def"><p class="first last">intrastriatal</p></td></tr><tr><td class="NLM_term">IDO</td><td class="NLM_def"><p class="first last">indoleamine 2,3-dioxygenase</p></td></tr><tr><td class="NLM_term">IGF</td><td class="NLM_def"><p class="first last">insulin-like growth factor</p></td></tr><tr><td class="NLM_term">IV</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">JNK</td><td class="NLM_def"><p class="first last">Jun N-terminal kinase</p></td></tr><tr><td class="NLM_term">K562</td><td class="NLM_def"><p class="first last">human leukemia</p></td></tr><tr><td class="NLM_term">KA</td><td class="NLM_def"><p class="first last">kannic acid</p></td></tr><tr><td class="NLM_term">KB</td><td class="NLM_def"><p class="first last">mammalian eukaryote</p></td></tr><tr><td class="NLM_term">LLC</td><td class="NLM_def"><p class="first last">Lewis lung carcinoma</p></td></tr><tr><td class="NLM_term">LNCaP</td><td class="NLM_def"><p class="first last">human prostate cancer</p></td></tr><tr><td class="NLM_term">LPS</td><td class="NLM_def"><p class="first last">lipopolysaccharide</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">MCF-7</td><td class="NLM_def"><p class="first last">human breast cancer</p></td></tr><tr><td class="NLM_term">MDA-MB-453</td><td class="NLM_def"><p class="first last">human breast cancer</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">Madin-Darby Canine Kidney</p></td></tr><tr><td class="NLM_term">MDR1</td><td class="NLM_def"><p class="first last">multidrug resistance mutation 1</p></td></tr><tr><td class="NLM_term">MIC</td><td class="NLM_def"><p class="first last">minimum inhibitory concentration</p></td></tr><tr><td class="NLM_term">MIDAS</td><td class="NLM_def"><p class="first last">Multicenter Isradipine Diuretic Atherosclerosis Study</p></td></tr><tr><td class="NLM_term">MLM</td><td class="NLM_def"><p class="first last">mouse liver microsomes</p></td></tr><tr><td class="NLM_term">MM-B1</td><td class="NLM_def"><p class="first last">human mesothelioma</p></td></tr><tr><td class="NLM_term">MoA</td><td class="NLM_def"><p class="first last">mechanism of action</p></td></tr><tr><td class="NLM_term">mRNA</td><td class="NLM_def"><p class="first last">messenger ribonucleic acid</p></td></tr><tr><td class="NLM_term">MRP1</td><td class="NLM_def"><p class="first last">multidrug resistance-associated protein 1</p></td></tr><tr><td class="NLM_term">MSK</td><td class="NLM_def"><p class="first last">mitogen and stress activated protein kinases</p></td></tr><tr><td class="NLM_term">MTA</td><td class="NLM_def"><p class="first last">microtubule targeting agent</p></td></tr><tr><td class="NLM_term">MTS</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2<i>H</i>-tetrazolium</p></td></tr><tr><td class="NLM_term">NMDA</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate</p></td></tr><tr><td class="NLM_term">NSAIDs</td><td class="NLM_def"><p class="first last">nonsteroidal anti-inflammatory drugs</p></td></tr><tr><td class="NLM_term">OA</td><td class="NLM_def"><p class="first last">oleanolic acid</p></td></tr><tr><td class="NLM_term">OCR</td><td class="NLM_def"><p class="first last">oxygen consumption rate</p></td></tr><tr><td class="NLM_term">OEOA</td><td class="NLM_def"><p class="first last">olean-12-eno[2,3-c] [1,2,5]oxadiazol-28-oic acid</p></td></tr><tr><td class="NLM_term"><i>p.o</i>.</td><td class="NLM_def"><p class="first last">per os</p></td></tr><tr><td class="NLM_term">PAINS</td><td class="NLM_def"><p class="first last">pan-assay interference</p></td></tr><tr><td class="NLM_term">PANC1</td><td class="NLM_def"><p class="first last">human pancreatic cancer</p></td></tr><tr><td class="NLM_term">PAP</td><td class="NLM_def"><p class="first last">pulmonary arterial pressure</p></td></tr><tr><td class="NLM_term">PAS</td><td class="NLM_def"><p class="first last">Per-Arnt-Sim</p></td></tr><tr><td class="NLM_term">PCAs</td><td class="NLM_def"><p class="first last">potassium channel activators</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">Parkinsonâs disease</p></td></tr><tr><td class="NLM_term">PDE</td><td class="NLM_def"><p class="first last">phosphodiesterase</p></td></tr><tr><td class="NLM_term">PET</td><td class="NLM_def"><p class="first last">positron emission topography</p></td></tr><tr><td class="NLM_term"><i>pf</i>LDH</td><td class="NLM_def"><p class="first last"><i>Plasmodium falciparum</i> lactate dehydrogenase</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">PLK</td><td class="NLM_def"><p class="first last">polo-like kinase</p></td></tr><tr><td class="NLM_term">PPIs</td><td class="NLM_def"><p class="first last">proteinâprotein interactions</p></td></tr><tr><td class="NLM_term">q1Dx5/3</td><td class="NLM_def"><p class="first last">once-daily dose five times per week over three weeks</p></td></tr><tr><td class="NLM_term">red.</td><td class="NLM_def"><p class="first last">reduction</p></td></tr><tr><td class="NLM_term">RLM</td><td class="NLM_def"><p class="first last">rat liver microsomes</p></td></tr><tr><td class="NLM_term">RNA</td><td class="NLM_def"><p class="first last">ribonucleic acid</p></td></tr><tr><td class="NLM_term">ROCK</td><td class="NLM_def"><p class="first last">Rho-associated coil-forming serine/threonine kinase</p></td></tr><tr><td class="NLM_term">ROMK</td><td class="NLM_def"><p class="first last">renal outer medullary potassium channel</p></td></tr><tr><td class="NLM_term">RSK</td><td class="NLM_def"><p class="first last">respiratory syncytial virus</p></td></tr><tr><td class="NLM_term">SAP</td><td class="NLM_def"><p class="first last">systemic arterial pressure</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structureâactivity relationship</p></td></tr><tr><td class="NLM_term">SKOV3</td><td class="NLM_def"><p class="first last">human ovarian cancer</p></td></tr><tr><td class="NLM_term">SOD1</td><td class="NLM_def"><p class="first last">superoxide dismutase 1</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">STEADY-PD</td><td class="NLM_def"><p class="first last">Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease</p></td></tr><tr><td class="NLM_term">SW480</td><td class="NLM_def"><p class="first last">human colon cancer</p></td></tr><tr><td class="NLM_term">TBM</td><td class="NLM_def"><p class="first last">tobramycin</p></td></tr><tr><td class="NLM_term">Tcf</td><td class="NLM_def"><p class="first last">T-cell factor</p></td></tr><tr><td class="NLM_term">TDO</td><td class="NLM_def"><p class="first last">tryptophan 2,3-dioxygenase</p></td></tr><tr><td class="NLM_term">TDP-43</td><td class="NLM_def"><p class="first last">transactive response DNA binding protein of 43 kDa</p></td></tr><tr><td class="NLM_term">THP-1</td><td class="NLM_def"><p class="first last">human monocyte</p></td></tr><tr><td class="NLM_term">TNF-Î±</td><td class="NLM_def"><p class="first last">tumor necrosis factor alpha</p></td></tr><tr><td class="NLM_term">U-2OS</td><td class="NLM_def"><p class="first last">human osteosarcoma</p></td></tr><tr><td class="NLM_term">VEGF</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor</p></td></tr><tr><td class="NLM_term">VR</td><td class="NLM_def"><p class="first last">vasorelaxation</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i56">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10821" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10821" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 290 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Builla, J.</span>; <span class="NLM_string-name">Vaquero, J. J.</span>; <span class="NLM_string-name">Barluenga, J.</span></span>; Eds.  <i>Modern Heterocyclic Chemistry, Volume 4</i>; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Weinhiem</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2F9783527637737" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+Alvarez-Builla&author=J.+J.+Vaquero&author=J.+Barluenga&title=Modern+Heterocyclic+Chemistry%2C+Volume+4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2F9783527637737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527637737%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez-Builla%26aufirst%3DJ.%26btitle%3DModern%2520Heterocyclic%2520Chemistry%252C%2520Volume%25204%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makhova, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belenâkii, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazieva, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalinger, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konstantinova, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuznetsov, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kravchenko, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krayushkin, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakitin, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starosotnikov, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fershtat, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shevelev, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirinian, V. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarovenko, V. N.</span></span> <span> </span><span class="NLM_article-title">Progress in the chemistry of nitrogen-, oxygen- and sulfur-containing heterocyclic systems</span>. <i>Russ. Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>89</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">55</span>â <span class="NLM_lpage">124</span>, <span class="refDoi">Â DOI: 10.1070/RCR4914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1070%2FRCR4914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjslCgtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2020&pages=55-124&issue=1&author=N.+N.+Makhovaauthor=L.+I.+Belen%E2%80%99kiiauthor=G.+A.+Gazievaauthor=I.+L.+Dalingerauthor=L.+S.+Konstantinovaauthor=V.+V.+Kuznetsovauthor=A.+N.+Kravchenkoauthor=M.+M.+Krayushkinauthor=O.+A.+Rakitinauthor=A.+M.+Starosotnikovauthor=L.+L.+Fershtatauthor=S.+A.+Shevelevauthor=V.+Z.+Shirinianauthor=V.+N.+Yarovenko&title=Progress+in+the+chemistry+of+nitrogen-%2C+oxygen-+and+sulfur-containing+heterocyclic+systems&doi=10.1070%2FRCR4914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in the chemistry of nitrogen-, oxygen- and sulfur-containing heterocyclic systems</span></div><div class="casAuthors">Makhova, Nina N.; Belen'kii, Leonid I.; Gazieva, Galina A.; Dalinger, Igor L.; Konstantinova, Lidia S.; Kuznetsov, Vladimir V.; Kravchenko, Angelina N.; Krayushkin, Mikhail M.; Rakitin, Oleg A.; Starosotnikov, Alexey M.; Fershtat, Leonid L.; Shevelev, Svyatoslav A.; Shirinian, Valerik Z.; Yarovenko, Vladimir N.</div><div class="citationInfo"><span class="NLM_cas:title">Russian Chemical Reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-124</span>CODEN:
                <span class="NLM_cas:coden">RCRVAB</span>;
        ISSN:<span class="NLM_cas:issn">0036-021X</span>.
    
            (<span class="NLM_cas:orgname">IOP Publishing Ltd.</span>)
        </div><div class="casAbstract">The review is devoted to modern trends in the chem. of nitrogen-, oxygen- and sulfur-contg. monocyclic, polynuclear and benzo(hetero)annulated heterocyclic compds.  Methods for the synthesis and chem. reactivity of furazan, furoxan, thiazole, thiadiazole, dithiazole, thiophene, glycoluril, imidazotriazine, diaziridine and other heterocycles are discussed.  Characteristic features of reactions depending on the structure of the starting compds., intermediates and reaction medium (org. solvents, ionic liqs.) and mechanistic aspects of the most interesting transformations are considered.  Data on the biol. activities and prospects for practical applications of the indicated heterocyclic systems are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeWvE6_J7P9rVg90H21EOLACvtfcHk0ljtOB0gySjnyQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjslCgtb8%253D&md5=4209dc4cbd1d7d25c593fbc0d673f701</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1070%2FRCR4914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1070%252FRCR4914%26sid%3Dliteratum%253Aachs%26aulast%3DMakhova%26aufirst%3DN.%2BN.%26aulast%3DBelen%25E2%2580%2599kii%26aufirst%3DL.%2BI.%26aulast%3DGazieva%26aufirst%3DG.%2BA.%26aulast%3DDalinger%26aufirst%3DI.%2BL.%26aulast%3DKonstantinova%26aufirst%3DL.%2BS.%26aulast%3DKuznetsov%26aufirst%3DV.%2BV.%26aulast%3DKravchenko%26aufirst%3DA.%2BN.%26aulast%3DKrayushkin%26aufirst%3DM.%2BM.%26aulast%3DRakitin%26aufirst%3DO.%2BA.%26aulast%3DStarosotnikov%26aufirst%3DA.%2BM.%26aulast%3DFershtat%26aufirst%3DL.%2BL.%26aulast%3DShevelev%26aufirst%3DS.%2BA.%26aulast%3DShirinian%26aufirst%3DV.%2BZ.%26aulast%3DYarovenko%26aufirst%3DV.%2BN.%26atitle%3DProgress%2520in%2520the%2520chemistry%2520of%2520nitrogen-%252C%2520oxygen-%2520and%2520sulfur-containing%2520heterocyclic%2520systems%26jtitle%3DRuss.%2520Chem.%2520Rev.%26date%3D2020%26volume%3D89%26issue%3D1%26spage%3D55%26epage%3D124%26doi%3D10.1070%2FRCR4914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N.</span></span>; Ed.  <i>Bioisosteres In Medicinal Chemistry</i>; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Weinhiem</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2F9783527654307" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=N.+Brown&title=Bioisosteres+In+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2F9783527654307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527654307%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DN.%26btitle%3DBioisosteres%2520In%2520Medicinal%2520Chemistry%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pace, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierro, P.</span></span> <span> </span><span class="NLM_article-title">The new era of 1,2,4-oxadiazoles</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">4337</span>â <span class="NLM_lpage">4348</span>, <span class="refDoi">Â DOI: 10.1039/b908937c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1039%2Fb908937c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=19830279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Gksb7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=4337-4348&issue=21&author=A.+Paceauthor=P.+Pierro&title=The+new+era+of+1%2C2%2C4-oxadiazoles&doi=10.1039%2Fb908937c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The new era of 1,2,4-oxadiazoles</span></div><div class="casAuthors">Pace, Andrea; Pierro, Paola</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4337-4348</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">This review covers the synthesis, the chem. and photochem. reactivity, and the use of 1,2,4-oxadiazoles in materials and as bioactive compds.  Further, the material in this survey includes some historical background, general features, state-of-the-art applications together with a crit. discussion about current limitations and suggestions for future developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS_Jcg58EXy7Vg90H21EOLACvtfcHk0lhifWPFGAlGag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Gksb7E&md5=9314bd3fbc51b2e5bc1a6eafa44646a4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1039%2Fb908937c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb908937c%26sid%3Dliteratum%253Aachs%26aulast%3DPace%26aufirst%3DA.%26aulast%3DPierro%26aufirst%3DP.%26atitle%3DThe%2520new%2520era%2520of%25201%252C2%252C4-oxadiazoles%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2009%26volume%3D7%26issue%3D21%26spage%3D4337%26epage%3D4348%26doi%3D10.1039%2Fb908937c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bostrom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowright, A. T.</span></span> <span> </span><span class="NLM_article-title">Oxadiazoles in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1817</span>â <span class="NLM_lpage">1830</span>, <span class="refDoi">Â DOI: 10.1021/jm2013248</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2013248" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BC383pt1Oisw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1817-1830&issue=5&author=J.+Bostromauthor=A.+Hognerauthor=A.+Llinasauthor=E.+Wellnerauthor=A.+T.+Plowright&title=Oxadiazoles+in+medicinal+chemistry&doi=10.1021%2Fjm2013248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Oxadiazoles in medicinal chemistry</span></div><div class="casAuthors">Bostrom Jonas; Hogner Anders; Llinas Antonio; Wellner Eric; Plowright Alleyn T</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1817-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Oxadiazoles are five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom, and they exist in different regioisomeric forms.  Oxadiazoles are frequently occurring motifs in druglike molecules, and they are often used with the intention of being bioisosteric replacements for ester and amide functionalities.  The current study presents a systematic comparison of 1,2,4- and 1,3,4-oxadiazole matched pairs in the AstraZeneca compound collection.  In virtually all cases, the 1,3,4-oxadiazole isomer shows an order of magnitude lower lipophilicity (log D), as compared to its isomeric partner.  Significant differences are also observed with respect to metabolic stability, hERG inhibition, and aqueous solubility, favoring the 1,3,4-oxadiazole isomers.  The difference in profile between the 1,2,4 and 1,3,4 regioisomers can be rationalized by their intrinsically different charge distributions (e.g., dipole moments).  To facilitate the use of these heteroaromatic rings, novel synthetic routes for ready access of a broad spectrum of 1,3,4-oxadiazoles, under mild conditions, are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSO9RQiG9xFS2Zyxfu64m4ffW6udTcc2ebr71JTh1LnjLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383pt1Oisw%253D%253D&md5=b934995431ced1be297e6f126262f3cb</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fjm2013248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2013248%26sid%3Dliteratum%253Aachs%26aulast%3DBostrom%26aufirst%3DJ.%26aulast%3DHogner%26aufirst%3DA.%26aulast%3DLlinas%26aufirst%3DA.%26aulast%3DWellner%26aufirst%3DE.%26aulast%3DPlowright%26aufirst%3DA.%2BT.%26atitle%3DOxadiazoles%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D5%26spage%3D1817%26epage%3D1830%26doi%3D10.1021%2Fjm2013248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Oliveira, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lira, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa-Filho, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzo, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Athayde-Filho, P. F.</span></span> <span> </span><span class="NLM_article-title">Synthetic approaches and pharmacological activity of 1,3,4-oxadiazoles: a review of the literature from 2000â2012</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">10192</span>â <span class="NLM_lpage">10231</span>, <span class="refDoi">Â DOI: 10.3390/molecules170910192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.3390%2Fmolecules170910192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=22926303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BC38bhslSjsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=10192-10231&issue=9&author=C.+S.+de%0AOliveiraauthor=B.+F.+Liraauthor=J.+M.+Barbosa-Filhoauthor=J.+G.+Lorenzoauthor=P.+F.+de+Athayde-Filho&title=Synthetic+approaches+and+pharmacological+activity+of+1%2C3%2C4-oxadiazoles%3A+a+review+of+the+literature+from+2000%E2%80%932012&doi=10.3390%2Fmolecules170910192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches and pharmacological activity of 1,3,4-oxadiazoles: a review of the literature from 2000-2012</span></div><div class="casAuthors">de Oliveira Cledualdo Soares; Lira Bruno Freitas; Barbosa-Filho Jose Maria; Lorenzo Jorge Goncalo Fernandez; de Athayde-Filho Petronio Filgueiras</div><div class="citationInfo"><span class="NLM_cas:title">Molecules (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">10192-231</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This review provides readers with an overview of the main synthetic methodologies for 1,3,4-oxadiazole derivatives, and of their broad spectrum of pharmacological activities as reported over the past twelve years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTx5iuA9u6HIK-9TkgmBqTqfW6udTcc2eYlbfM72pB0mLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bhslSjsA%253D%253D&md5=4f09fb45888e071f2601ff846fc83d9d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3390%2Fmolecules170910192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules170910192%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BOliveira%26aufirst%3DC.%2BS.%26aulast%3DLira%26aufirst%3DB.%2BF.%26aulast%3DBarbosa-Filho%26aufirst%3DJ.%2BM.%26aulast%3DLorenzo%26aufirst%3DJ.%2BG.%26aulast%3Dde%2BAthayde-Filho%26aufirst%3DP.%2BF.%26atitle%3DSynthetic%2520approaches%2520and%2520pharmacological%2520activity%2520of%25201%252C3%252C4-oxadiazoles%253A%2520a%2520review%2520of%2520the%2520literature%2520from%25202000%25E2%2580%25932012%26jtitle%3DMolecules%26date%3D2012%26volume%3D17%26issue%3D9%26spage%3D10192%26epage%3D10231%26doi%3D10.3390%2Fmolecules170910192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biernacki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciupak, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubinski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demkowicz, S.</span></span> <span> </span><span class="NLM_article-title">Novel 1,2,4-oxadiazole derivatives in drug discovery</span>. <i>Pharmaceuticals</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">111</span>, <span class="refDoi">Â DOI: 10.3390/ph13060111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.3390%2Fph13060111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFyktLzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2020&pages=111&issue=6&author=K.+Biernackiauthor=M.+Daskoauthor=O.+Ciupakauthor=K.+Kubinskiauthor=J.+Rachonauthor=S.+Demkowicz&title=Novel+1%2C2%2C4-oxadiazole+derivatives+in+drug+discovery&doi=10.3390%2Fph13060111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 1,2,4-oxadiazole derivatives in drug discovery</span></div><div class="casAuthors">Biernacki, Karol; Dasko, Mateusz; Ciupak, Olga; Kubinski, Konrad; Rachon, Janusz; Demkowicz, Sebastian</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceuticals</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">111</span>CODEN:
                <span class="NLM_cas:coden">PHARH2</span>;
        ISSN:<span class="NLM_cas:issn">1424-8247</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Five-membered 1,2,4-oxadiazole heterocyclic ring has received considerable attention because of its unique bioisosteric properties and an unusually wide spectrum of biol. activities.  Thus, it is a perfect framework for the novel drug development.  After a century since the 1,2,4-oxadiazole have been discovered, the uncommon potential attracted medicinal chemists' attention, leading to the discovery of a few presently accessible drugs contg. 1,2,4-oxadiazole unit.  It is worth noting that the interest in a 1,2,4-oxadiazoles' biol. application has been doubled in the last fifteen years.  Herein, after a concise historical introduction, we present a comprehensive overview of the recent achievements in the synthesis of 1,2,4-oxadiazole-based compds. and the major advances in their biol. applications in the period of the last five years as well as brief remarks on prospects for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxL_5MioSG4LVg90H21EOLACvtfcHk0lgyf2qMB5WdUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFyktLzN&md5=98d1ab4ede67a8ff5a872e37c1a4f044</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3390%2Fph13060111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph13060111%26sid%3Dliteratum%253Aachs%26aulast%3DBiernacki%26aufirst%3DK.%26aulast%3DDasko%26aufirst%3DM.%26aulast%3DCiupak%26aufirst%3DO.%26aulast%3DKubinski%26aufirst%3DK.%26aulast%3DRachon%26aufirst%3DJ.%26aulast%3DDemkowicz%26aufirst%3DS.%26atitle%3DNovel%25201%252C2%252C4-oxadiazole%2520derivatives%2520in%2520drug%2520discovery%26jtitle%3DPharmaceuticals%26date%3D2020%26volume%3D13%26issue%3D6%26spage%3D111%26doi%3D10.3390%2Fph13060111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fershtat, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makhova, N. N.</span></span> <span> </span><span class="NLM_article-title">1,2,5-Oxadiazole-based high-energy-density materials: Synthesis and performance</span>. <i>ChemPlusChem</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>85</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">13</span>â <span class="NLM_lpage">42</span>, <span class="refDoi">Â DOI: 10.1002/cplu.201900542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fcplu.201900542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFantbbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2020&pages=13-42&issue=1&author=L.+L.+Fershtatauthor=N.+N.+Makhova&title=1%2C2%2C5-Oxadiazole-based+high-energy-density+materials%3A+Synthesis+and+performance&doi=10.1002%2Fcplu.201900542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">1,2,5-Oxadiazole-Based High-Energy-Density Materials: Synthesis and Performance</span></div><div class="casAuthors">Fershtat, Leonid L.; Makhova, Nina N.</div><div class="citationInfo"><span class="NLM_cas:title">ChemPlusChem</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-42</span>CODEN:
                <span class="NLM_cas:coden">CHEMM5</span>;
        ISSN:<span class="NLM_cas:issn">2192-6506</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">This Review covers the synthesis and performance of the most promising 1,2,5-oxadiazole-based high-energy d. materials (HEDMs).  These materials comprise a 1,2,5-oxadiazole subunit as a key structural motif linked to various acyclic explosophoric groups or to nitrogen-rich and nitrogen-oxygen azoles: 1,2,4-triazole, tetrazole, 1,2,4- and 1,3,4-oxadiazoles.  Energetic alliances of two and more 1,2,5-oxadiazole rings linked directly or through heteroatom spacers are also presented.  Particular attention is devoted to the installation of different explosophores: nitro, nitramino, azo, azoxy, dinitromethyl, trinitroethyl moieties and their combination.  Promising environmentally benign energetic materials with high detonation velocity and pressure, and outstanding insensitivity are summarized.  Overall, the presented materials may be considered as next-generation high-performance energetic materials that are superior to commonly used traditional explosives (TNT, PETN, RDX, HMX).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb-4xMS6r2b7Vg90H21EOLACvtfcHk0lgyf2qMB5WdUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFantbbF&md5=b2a1e1115a4b19b7afc947ffcec53b2c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fcplu.201900542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcplu.201900542%26sid%3Dliteratum%253Aachs%26aulast%3DFershtat%26aufirst%3DL.%2BL.%26aulast%3DMakhova%26aufirst%3DN.%2BN.%26atitle%3D1%252C2%252C5-Oxadiazole-based%2520high-energy-density%2520materials%253A%2520Synthesis%2520and%2520performance%26jtitle%3DChemPlusChem%26date%3D2020%26volume%3D85%26issue%3D1%26spage%3D13%26epage%3D42%26doi%3D10.1002%2Fcplu.201900542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fershtat, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makhova, N. N.</span></span> <span> </span><span class="NLM_article-title">Advances in the synthesis of non-annelated polynuclear heterocyclic systems comprising the 1,2,5-oxadiazole ring</span>. <i>Russ. Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>85</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1097</span>â <span class="NLM_lpage">1145</span>, <span class="refDoi">Â DOI: 10.1070/RCR4619</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1070%2FRCR4619" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktl2nt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2016&pages=1097-1145&issue=10&author=L.+L.+Fershtatauthor=N.+N.+Makhova&title=Advances+in+the+synthesis+of+non-annelated+polynuclear+heterocyclic+systems+comprising+the+1%2C2%2C5-oxadiazole+ring&doi=10.1070%2FRCR4619"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the synthesis of non-annelated polynuclear heterocyclic systems comprising the 1,2,5-oxadiazole ring</span></div><div class="casAuthors">Fershtat, Leonid L.; Makhova, Nina N.</div><div class="citationInfo"><span class="NLM_cas:title">Russian Chemical Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1097-1145</span>CODEN:
                <span class="NLM_cas:coden">RCRVAB</span>;
        ISSN:<span class="NLM_cas:issn">0036-021X</span>.
    
            (<span class="NLM_cas:orgname">IOP Publishing Ltd.</span>)
        </div><div class="casAbstract">This review is concerned with recently developed synthetic methods for non-annelated polynuclear heterocyclic systems that incorporate, along with a furazan and(or) furoxan ring, polynitrogen and nitrogen oxygen heterocycles (1,2,4 and 1,3,4 oxadiazole, 1,2,3 and 1,2,4 triazole, tetrazole, pyrazole, sym triazine, 1,2,4,5 tetrazine and so on) linked via C C or C N bonds or heteroat. [N, O, S, N N, N(O) N] bridges.  Methods for prepg. assemblies in which a furazan ring and(or) a furoxan ring are linked to one another by C C bonds or heteroatoms (N, O, S) are surveyed.  Potential applications of the synthesized structures as pharmacol. active and high energy compds. are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTi2mQGeouYbVg90H21EOLACvtfcHk0lg3nfgZBcIRDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktl2nt7Y%253D&md5=b4422f1fb0427b3fcd8321156645cc3c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1070%2FRCR4619&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1070%252FRCR4619%26sid%3Dliteratum%253Aachs%26aulast%3DFershtat%26aufirst%3DL.%2BL.%26aulast%3DMakhova%26aufirst%3DN.%2BN.%26atitle%3DAdvances%2520in%2520the%2520synthesis%2520of%2520non-annelated%2520polynuclear%2520heterocyclic%2520systems%2520comprising%2520the%25201%252C2%252C5-oxadiazole%2520ring%26jtitle%3DRuss.%2520Chem.%2520Rev.%26date%3D2016%26volume%3D85%26issue%3D10%26spage%3D1097%26epage%3D1145%26doi%3D10.1070%2FRCR4619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheremetev, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yudin, I. L.</span></span> <span> </span><span class="NLM_article-title">Advances in the chemistry of furazano[3,4-b]pyrazines and their analogues</span>. <i>Russ. Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">87</span>â <span class="NLM_lpage">100</span>, <span class="refDoi">Â DOI: 10.1070/RC2003v072n01ABEH000776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1070%2FRC2003v072n01ABEH000776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkt1Kku74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2003&pages=87-100&issue=1&author=A.+B.+Sheremetevauthor=I.+L.+Yudin&title=Advances+in+the+chemistry+of+furazano%5B3%2C4-b%5Dpyrazines+and+their+analogues&doi=10.1070%2FRC2003v072n01ABEH000776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the chemistry of furazano[3,4-b]pyrazines and their analogues</span></div><div class="casAuthors">Sheremetev, A. B.; Yudin, I. L.</div><div class="citationInfo"><span class="NLM_cas:title">Russian Chemical Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-100</span>CODEN:
                <span class="NLM_cas:coden">RCRVAB</span>;
        ISSN:<span class="NLM_cas:issn">0036-021X</span>.
    
            (<span class="NLM_cas:orgname">Turpion Ltd.</span>)
        </div><div class="casAbstract">A review.  The published data on the methods for the synthesis of furazans fused to six-membered heterocycles with two heteroatoms in positions 1 and 4, their reactivities and practical applications are considered and systematized.  The bibliog. includes 89 refs.  A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVhO9RA4br67Vg90H21EOLACvtfcHk0lg3nfgZBcIRDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkt1Kku74%253D&md5=fdf884395d1a3e627d546060db0e7892</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1070%2FRC2003v072n01ABEH000776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1070%252FRC2003v072n01ABEH000776%26sid%3Dliteratum%253Aachs%26aulast%3DSheremetev%26aufirst%3DA.%2BB.%26aulast%3DYudin%26aufirst%3DI.%2BL.%26atitle%3DAdvances%2520in%2520the%2520chemistry%2520of%2520furazano%255B3%252C4-b%255Dpyrazines%2520and%2520their%2520analogues%26jtitle%3DRuss.%2520Chem.%2520Rev.%26date%3D2003%26volume%3D72%26issue%3D1%26spage%3D87%26epage%3D100%26doi%3D10.1070%2FRC2003v072n01ABEH000776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paton, R. M.</span></span> <span> </span><span class="NLM_article-title">Product class 7: 1,2,5-Oxadiazoles</span>. <i>Sci. Synth.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">185</span>â <span class="NLM_lpage">218</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitVClsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=185-218&author=R.+M.+Paton&title=Product+class+7%3A+1%2C2%2C5-Oxadiazoles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Product class 7: 1,2,5-oxadiazoles</span></div><div class="casAuthors">Paton, R. M.</div><div class="citationInfo"><span class="NLM_cas:title">Science of Synthesis</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">185-218</span>CODEN:
                <span class="NLM_cas:coden">SSCYJ9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">A review.  Methods for prepg. 1,2,5-oxadiazoles are reviewed including cyclization, ring transformation, and substituent modification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2qcWV4jPrAbVg90H21EOLACvtfcHk0lg3nfgZBcIRDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitVClsL4%253D&md5=5786f83b06040a5affaf3cae85111462</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPaton%26aufirst%3DR.%2BM.%26atitle%3DProduct%2520class%25207%253A%25201%252C2%252C5-Oxadiazoles%26jtitle%3DSci.%2520Synth.%26date%3D2004%26volume%3D13%26spage%3D185%26epage%3D218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paton, R. M.</span></span> <span> </span><span class="NLM_article-title">1,2,5-Oxadiazoles</span>. <span class="NLM_contrib-group"><span class="NLM_string-name">Katritzky, A. R.</span>; <span class="NLM_string-name">Scriven, E. F. V.</span>; <span class="NLM_string-name">Rees, C. W.</span></span>; Eds.;  <i>Comprehensive Heterocyclic Chemistry II</i>; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Amsterdam</span>, <span class="NLM_year">1996</span>, pp  <span class="NLM_fpage">229</span>â <span class="NLM_lpage">265</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2FB978-008096518-5.00083-6" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&pages=229-265&author=R.+M.+Patonauthor=A.+R.+Katritzky&author=E.+F.+V.+Scriven&author=C.+W.+Rees&title=Comprehensive+Heterocyclic+Chemistry+II"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FB978-008096518-5.00083-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-008096518-5.00083-6%26sid%3Dliteratum%253Aachs%26aulast%3DPaton%26aufirst%3DR.%2BM.%26atitle%3D1%252C2%252C5-Oxadiazoles%26aulast%3DKatritzky%26aufirst%3DA.%2BR.%26btitle%3DComprehensive%2520Heterocyclic%2520Chemistry%2520II%26pub%3DElsevier%26date%3D1996%26spage%3D229%26epage%3D265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheremetev, A. B.</span></span> <span> </span><span class="NLM_article-title">The chemistry of furazans fused to six- and seven-membered heterocycles with one heteroatom</span>. <i>Russ. Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">137</span>â <span class="NLM_lpage">148</span>, <span class="refDoi">Â DOI: 10.1070/RC1999v068n02ABEH000449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1070%2FRC1999v068n02ABEH000449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK1MXivVKgsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1999&pages=137-148&issue=2&author=A.+B.+Sheremetev&title=The+chemistry+of+furazans+fused+to+six-+and+seven-membered+heterocycles+with+one+heteroatom&doi=10.1070%2FRC1999v068n02ABEH000449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The chemistry of furazans fused to six- and seven-membered heterocycles with one heteroatom</span></div><div class="casAuthors">Sheremetev, Aleksei B.</div><div class="citationInfo"><span class="NLM_cas:title">Russian Chemical Reviews</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-148</span>CODEN:
                <span class="NLM_cas:coden">RCRVAB</span>;
        ISSN:<span class="NLM_cas:issn">0036-021X</span>.
    
            (<span class="NLM_cas:orgname">Turpion Ltd.</span>)
        </div><div class="casAbstract">The data on the synthesis and properties of furazan derivs. fused with pyridine, pyran, thiopyran, azepine and thiepine rings are surveyed and described systematically.  A review with 85 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6KUKj8yf9zrVg90H21EOLACvtfcHk0lgsPIYMuFr8xw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXivVKgsrw%253D&md5=6ad55d9ce145e665a40f25302684cc08</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1070%2FRC1999v068n02ABEH000449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1070%252FRC1999v068n02ABEH000449%26sid%3Dliteratum%253Aachs%26aulast%3DSheremetev%26aufirst%3DA.%2BB.%26atitle%3DThe%2520chemistry%2520of%2520furazans%2520fused%2520to%2520six-%2520and%2520seven-membered%2520heterocycles%2520with%2520one%2520heteroatom%26jtitle%3DRuss.%2520Chem.%2520Rev.%26date%3D1999%26volume%3D68%26issue%3D2%26spage%3D137%26epage%3D148%26doi%3D10.1070%2FRC1999v068n02ABEH000449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sliwa, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelichowicz, N.</span></span> <span> </span><span class="NLM_article-title">Fused furazans</span>. <i>Collect. Czech. Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">978</span>â <span class="NLM_lpage">996</span>, <span class="refDoi">Â DOI: 10.1135/cccc19920978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1135%2Fcccc19920978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK38Xks12kt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1992&pages=978-996&issue=5&author=W.+Sliwaauthor=A.+Thomasauthor=N.+Zelichowicz&title=Fused+furazans&doi=10.1135%2Fcccc19920978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Fused furazans</span></div><div class="casAuthors">Sliwa, Wanda; Thomas, Antoni; Zelichowicz, Natalia</div><div class="citationInfo"><span class="NLM_cas:title">Collection of Czechoslovak Chemical Communications</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">978-96</span>CODEN:
                <span class="NLM_cas:coden">CCCCAK</span>;
        ISSN:<span class="NLM_cas:issn">0010-0765</span>.
    </div><div class="casAbstract">A review with 90 refs. on the synthesis, chem. reactivity, phys. properties, biol. activity, and applications of fused furazans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNaImwnyZw-LVg90H21EOLACvtfcHk0lgsPIYMuFr8xw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xks12kt74%253D&md5=8051709a5d189e832653eb87071a06cf</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1135%2Fcccc19920978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1135%252Fcccc19920978%26sid%3Dliteratum%253Aachs%26aulast%3DSliwa%26aufirst%3DW.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DZelichowicz%26aufirst%3DN.%26atitle%3DFused%2520furazans%26jtitle%3DCollect.%2520Czech.%2520Chem.%2520Commun.%26date%3D1992%26volume%3D57%26issue%3D5%26spage%3D978%26epage%3D996%26doi%3D10.1135%2Fcccc19920978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cerecetto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcal, W.</span></span> <span> </span><span class="NLM_article-title">Pharmacological properties of furoxans and benzofuroxans: Recent developments</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">57</span>â <span class="NLM_lpage">71</span>, <span class="refDoi">Â DOI: 10.2174/1389557053402864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.2174%2F1389557053402864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=15638792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2MXot1antQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=57-71&issue=1&author=H.+Cerecettoauthor=W.+Porcal&title=Pharmacological+properties+of+furoxans+and+benzofuroxans%3A+Recent+developments&doi=10.2174%2F1389557053402864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological properties of furoxans and benzofuroxans: Recent developments</span></div><div class="casAuthors">Cerecetto, Hugo; Porcal, Williams</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-71</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The chem. of furoxans (1, 2, 5-oxadiazole-2-oxides) and benzofuroxans (benzo[1, 2-c]1, 2, 5-oxadiazole-1-oxides) is very well known.  These systems are widely used in org. chem. as intermediate compds. for the synthesis of numerous heterocycles.  In the other hand, furoxan and benzofuroxan derivs. were extensively studied as bioactive compds.  They possess remarkable biol. activities, such as anti-microbial and anti-parasitic properties, mutagenic, immunosuppressive and anticancer effects, anti-aggregating and vasorelaxant activity, among others.  In some cases, mol. mode of action was proposed.  Recently, the research and development in the medicinal chem. of these systems have produced hybrid compds. in which furoxan or benzofuroxan moieties together with a classical drug moieties are present in a single mol.  So, new anti-ulcer drugs, calcium channel modulators and vasodilator derivs. were described and they are currently in study.  In this presentation recent developments in the medicinal chem. of furoxans will be reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP8DCgcQChJLVg90H21EOLACvtfcHk0lgsPIYMuFr8xw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXot1antQ%253D%253D&md5=18da9801499316246bc2313c9b734241</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F1389557053402864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557053402864%26sid%3Dliteratum%253Aachs%26aulast%3DCerecetto%26aufirst%3DH.%26aulast%3DPorcal%26aufirst%3DW.%26atitle%3DPharmacological%2520properties%2520of%2520furoxans%2520and%2520benzofuroxans%253A%2520Recent%2520developments%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26issue%3D1%26spage%3D57%26epage%3D71%26doi%3D10.2174%2F1389557053402864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tselinskii, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melânikova, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergizov, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frolova, G. M.</span></span> <span> </span><span class="NLM_article-title">Acid-base properties of 1,2,5-oxadiazoles. 1</span>. <i>Chem. Heterocycl. Compd.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">27</span>â <span class="NLM_lpage">29</span>, <span class="refDoi">Â DOI: 10.1007/BF00507084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1007%2FBF00507084" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1981&pages=27-29&issue=1&author=I.+V.+Tselinskiiauthor=S.+F.+Mel%E2%80%99nikovaauthor=S.+N.+Vergizovauthor=G.+M.+Frolova&title=Acid-base+properties+of+1%2C2%2C5-oxadiazoles.+1&doi=10.1007%2FBF00507084"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2FBF00507084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00507084%26sid%3Dliteratum%253Aachs%26aulast%3DTselinskii%26aufirst%3DI.%2BV.%26aulast%3DMel%25E2%2580%2599nikova%26aufirst%3DS.%2BF.%26aulast%3DVergizov%26aufirst%3DS.%2BN.%26aulast%3DFrolova%26aufirst%3DG.%2BM.%26atitle%3DAcid-base%2520properties%2520of%25201%252C2%252C5-oxadiazoles.%25201%26jtitle%3DChem.%2520Heterocycl.%2520Compd.%26date%3D1981%26volume%3D17%26issue%3D1%26spage%3D27%26epage%3D29%26doi%3D10.1007%2FBF00507084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trifonov, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrovskii, V. A.</span></span> <span> </span><span class="NLM_article-title">Basicity of 2-phenyl-5-R-1,3,4-oxadiazoles</span>. <i>Chem. Heterocycl. Compd.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">657</span>â <span class="NLM_lpage">664</span>, <span class="refDoi">Â DOI: 10.1007/s10593-006-0142-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1007%2Fs10593-006-0142-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWgs7nN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=657-664&issue=5&author=R.+E.+Trifonovauthor=V.+A.+Ostrovskii&title=Basicity+of+2-phenyl-5-R-1%2C3%2C4-oxadiazoles&doi=10.1007%2Fs10593-006-0142-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Basicity of 2-phenyl-5-R-1,3,4-oxadiazoles</span></div><div class="casAuthors">Trifonov, R. E.; Ostrovskii, V. A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry of Heterocyclic Compounds (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">657-664</span>CODEN:
                <span class="NLM_cas:coden">CHCCAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-3122</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The authors have studied the basicity of 2-phenyl-5-R-1,3,4-oxadiazoles (R = H, Me, CH2Ph, t-Bu, CH2Cl, CCl3, CF3) in aq. sulfuric acid solns.  These compds. are weak org. bases (pKBH+ is -1.8 to - 5.2).  The values of pKBH+ detd. on the H0 and X acidity function scales agree well with each other.  The substituent at the 5 position has a substantial effect on the basicity of the 1,3,4-oxadiazole ring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMU-ltFGN_wrVg90H21EOLACvtfcHk0lh33B2MnU20tQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWgs7nN&md5=8064a277d877578115542f2a5399cedb</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs10593-006-0142-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10593-006-0142-y%26sid%3Dliteratum%253Aachs%26aulast%3DTrifonov%26aufirst%3DR.%2BE.%26aulast%3DOstrovskii%26aufirst%3DV.%2BA.%26atitle%3DBasicity%2520of%25202-phenyl-5-R-1%252C3%252C4-oxadiazoles%26jtitle%3DChem.%2520Heterocycl.%2520Compd.%26date%3D2006%26volume%3D42%26issue%3D5%26spage%3D657%26epage%3D664%26doi%3D10.1007%2Fs10593-006-0142-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trifonov, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volovodenko, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergizov, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirinbekov, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gindin, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koren, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrovskii, V. A.</span></span> <span> </span><span class="NLM_article-title">Basicity of phenyl- and methyl-substituted 1,2,4-oxadiazoles</span>. <i>Helv. Chim. Acta</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>88</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1790</span>â <span class="NLM_lpage">1797</span>, <span class="refDoi">Â DOI: 10.1002/hlca.200590140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fhlca.200590140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2MXosVamtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2005&pages=1790-1797&issue=7&author=R.+E.+Trifonovauthor=A.+P.+Volovodenkoauthor=S.+N.+Vergizovauthor=N.+I.+Shirinbekovauthor=V.+A.+Gindinauthor=A.+O.+Korenauthor=V.+A.+Ostrovskii&title=Basicity+of+phenyl-+and+methyl-substituted+1%2C2%2C4-oxadiazoles&doi=10.1002%2Fhlca.200590140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Basicity of phenyl- and methyl-substituted 1,2,4-oxadiazoles</span></div><div class="casAuthors">Trifonov, Rostislav E.; Volovodenko, Anna P.; Vergizov, Sergei N.; Shirinbekov, Nabi I.; Gindin, Vladimir A.; Koren, Andrei O.; Ostrovskii, Vladimir A.</div><div class="citationInfo"><span class="NLM_cas:title">Helvetica Chimica Acta</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1790-1797</span>CODEN:
                <span class="NLM_cas:coden">HCACAV</span>;
        ISSN:<span class="NLM_cas:issn">0018-019X</span>.
    
            (<span class="NLM_cas:orgname">Verlag Helvetica Chimica Acta</span>)
        </div><div class="casAbstract">The basicity of a series of 3,5-disubstituted 1,2,4-oxadiazoles in aq. H2SO4 was examd. by means of UV and 1H-NMR spectroscopy.  The exptl. data were analyzed by the modified Yates-McClelland method to yield the following pKBH+ values: 3,5-dimethyl-1,2,4-oxadiazole, -1.66; 3-methyl-5-phenyl-1,2,4-oxadiazole, -2.61; 3-phenyl-5-methyl-1,2,4-oxadiazole, -2.95; 3,5-diphenyl-1,2,4-oxadiazole, -3.55.  A pKBH+ value of ca. -3.7 was estd. for the parent unsubstituted 1,2,4-oxadiazole based on substituents' additivity increments.  Possible protonation sites of the compds. were discussed in terms of both exptl. data and theor. calcns. (HF/6-31G**).  Generally, protonation is most likely to occur at N(4) of the 1,2,4-oxadiazole ring.  However, concurrent formation of both N(4)- and N(2)-protonated species in comparable amts. is possible in the case of 3-phenyl-1,2,4-oxadiazoles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRnPW9PP9FYLVg90H21EOLACvtfcHk0lh33B2MnU20tQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXosVamtLk%253D&md5=5c145375ce4e6d1ce9264074f524cabe</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fhlca.200590140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhlca.200590140%26sid%3Dliteratum%253Aachs%26aulast%3DTrifonov%26aufirst%3DR.%2BE.%26aulast%3DVolovodenko%26aufirst%3DA.%2BP.%26aulast%3DVergizov%26aufirst%3DS.%2BN.%26aulast%3DShirinbekov%26aufirst%3DN.%2BI.%26aulast%3DGindin%26aufirst%3DV.%2BA.%26aulast%3DKoren%26aufirst%3DA.%2BO.%26aulast%3DOstrovskii%26aufirst%3DV.%2BA.%26atitle%3DBasicity%2520of%2520phenyl-%2520and%2520methyl-substituted%25201%252C2%252C4-oxadiazoles%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D2005%26volume%3D88%26issue%3D7%26spage%3D1790%26epage%3D1797%26doi%3D10.1002%2Fhlca.200590140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lutskii, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepel, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shvaika, O. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimisha, G. P.</span></span> <span> </span><span class="NLM_article-title">Dipole moments and the structure of the molecules of some oxadiazole derivatives</span>. <i>Chem. Heterocycl. Compd.</i> <span class="NLM_year" style="font-weight: bold;">1972</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">343</span>â <span class="NLM_lpage">348</span>, <span class="refDoi">Â DOI: 10.1007/BF00471140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1007%2FBF00471140" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1972&pages=343-348&issue=3&author=A.+E.+Lutskiiauthor=A.+V.+Shepelauthor=O.+P.+Shvaikaauthor=G.+P.+Klimisha&title=Dipole+moments+and+the+structure+of+the+molecules+of+some+oxadiazole+derivatives&doi=10.1007%2FBF00471140"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2FBF00471140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00471140%26sid%3Dliteratum%253Aachs%26aulast%3DLutskii%26aufirst%3DA.%2BE.%26aulast%3DShepel%26aufirst%3DA.%2BV.%26aulast%3DShvaika%26aufirst%3DO.%2BP.%26aulast%3DKlimisha%26aufirst%3DG.%2BP.%26atitle%3DDipole%2520moments%2520and%2520the%2520structure%2520of%2520the%2520molecules%2520of%2520some%2520oxadiazole%2520derivatives%26jtitle%3DChem.%2520Heterocycl.%2520Compd.%26date%3D1972%26volume%3D5%26issue%3D3%26spage%3D343%26epage%3D348%26doi%3D10.1007%2FBF00471140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milone, M</span></span> <span> </span><span class="NLM_article-title">The electric moment of some derivatives of the heterocyclic (C2N2O) group</span>. <i>Gazz. Chim. Ital.</i> <span class="NLM_year" style="font-weight: bold;">1935</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">152</span>â <span class="NLM_lpage">158</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaA2MXktF2itQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1935&pages=152-158&author=M+Milone&title=The+electric+moment+of+some+derivatives+of+the+heterocyclic+%28C2N2O%29+group"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The electric moment of some derivatives of the heterocyclic (C2N2O) group</span></div><div class="casAuthors">Milone, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Gazzetta Chimica Italiana</span>
        (<span class="NLM_cas:date">1935</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">152-8</span>CODEN:
                <span class="NLM_cas:coden">GCITA9</span>;
        ISSN:<span class="NLM_cas:issn">0016-5603</span>.
    </div><div class="casAbstract">cf. C. A. 27, 5003; 28, 97.1.  The work is the beginning of a systematic investigation of the mol. elec. moments of heterocyclic compds., and deals with furazans, azoximes and oxadiazoles.  The object was to characterize the different forms of the C2N2O group (already the subject of numerous chem. studies), to study the relations between the nature and arrangement of the substituent groups and the elec. moments, and from this to ascertain the nature of the bonds and the structure of the cyclic group in relation to other pentat. heterocyclic groups.  The expts. show that the elec. moments of furazans are much greater than those of isomeric azoximes, and that the moments of oxadiazoles are slightly smaller than those of isomeric furazans.  The moments of the furazans; studied were 4-4.7 Ã 10-18, of the oxadiazoles 3.3-3.9 Ã 10-18, and of the azoximes 1.4-1.65 Ã 10-18.  From a qual., point of view the results are important in that they offer a certain means of distinguishing between a furazan and its isomeric azoxime, a problem which is impossible by other methods.  A quant. evaluation of the results is more difficult.  Based on the true elec. moment of the nucleus, and on the assumption that in the case of disubstituted isomers (contg. 2 Me groups, 2 Ph groups, or 1 Me and 1 Ph group), furazans have the max. elec. moments and azoximes the min. moments, there is a certain analogy with disubstituted C6H6 derivs.  On the other hand, to explain why an oxadiazole has a smaller moment than does the corresponding furazan, necessitates the assumption that the 2 C and 2 N atoms of the C2N2O group are located at the corners of a rectangle, a hypothesis at variance with the common hypothesis of the geometric form of pentat. cycles.  The great differences in the elec. moments of isomers are to be attributed to differences in the moments of the various forms of the C2N2O cycle.  The following data give the mol. elec. moment Î¼ (Ã 1018) of the various compds., measured by the app. already described (cf. M., C. A. 29, 4738.5); MeC:N.O.N:CMe, 4.008; MeC:N.N:CMe.O, 3.29; MeC:N.O.N:CEt, 4.061; PhC:N.O.N:CH (I), 3.997; p-MeC6H4C:N.O.N:CH (II), 4.176; MeC:N.O.N:CPh, 4.141; PhC:N.O.CMe:N, 1.41; MeC:N.O.CPh:N, 1.63; MeC:N.N:CPh.O, 3.434; PhC:N.O.N:CPh, 4.739; PhC:N.O.CPh:N, 1.563; PhC:N.N:CPh.O, 3.86.  The rather high moments of I and II show that the C2N2O cycle has a fairly large elec. moment, which is in accord with the fact that Ph2 has no moment, whereas mono substituted benzenes have pos. moments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvNP4iK8Oot7Vg90H21EOLACvtfcHk0lh33B2MnU20tQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaA2MXktF2itQ%253D%253D&md5=85255606646385b65976dc7d1c698664</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMilone%26aufirst%3DM%26atitle%3DThe%2520electric%2520moment%2520of%2520some%2520derivatives%2520of%2520the%2520heterocyclic%2520%2528C2N2O%2529%2520group%26jtitle%3DGazz.%2520Chim.%2520Ital.%26date%3D1935%26volume%3D65%26spage%3D152%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vsetecka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruttero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Exner, O.</span></span> <span> </span><span class="NLM_article-title">Dipole moments and electron distribution of furoxans and furazans</span>. <i>J. Mol. Struct.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>324</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">277</span>â <span class="NLM_lpage">282</span>, <span class="refDoi">Â DOI: 10.1016/0022-2860(94)08305-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2F0022-2860%2894%2908305-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK2MXksFGntw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=1994&pages=277-282&issue=3&author=V.+Vseteckaauthor=R.+Frutteroauthor=A.+Gascoauthor=O.+Exner&title=Dipole+moments+and+electron+distribution+of+furoxans+and+furazans&doi=10.1016%2F0022-2860%2894%2908305-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Dipole moments and electron distribution of furoxans and furazans</span></div><div class="casAuthors">Vsetecka, Vaclav; Fruttero, Roberta; Gasco, Alberto; Exner, Otto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Structure</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">277-82</span>CODEN:
                <span class="NLM_cas:coden">JMOSB4</span>;
        ISSN:<span class="NLM_cas:issn">0022-2860</span>.
    </div><div class="casAbstract">Dipole moments of a set of substituted 1,2,5-oxadiazoles (furazans) and 1,2,5-oxadiazole-2-oxides (furoxans) were measured in benzene soln.  The dipole moment in furazan is oriented with the neg. end towards oxygen in agreement with common opinion (but contrary to the literature).  Comparison of the two classes of compds. revealed a strong electron shift in furoxans, from the exocyclic oxygen back into the heterocyclic system, corresponding to a mesomeric moment of approx. 3D.  However, the electron redistribution cannot be described in terms of simple mesomeric structures.  The mol. of furoxan is well characterized as electron-overcrowded, particularly in the vicinity of the nitrogen atom N(2).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBiaZfOTrd-rVg90H21EOLACvtfcHk0lh33B2MnU20tQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXksFGntw%253D%253D&md5=f37c618f59178c2bc0973cafb0187daa</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2F0022-2860%2894%2908305-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0022-2860%252894%252908305-3%26sid%3Dliteratum%253Aachs%26aulast%3DVsetecka%26aufirst%3DV.%26aulast%3DFruttero%26aufirst%3DR.%26aulast%3DGasco%26aufirst%3DA.%26aulast%3DExner%26aufirst%3DO.%26atitle%3DDipole%2520moments%2520and%2520electron%2520distribution%2520of%2520furoxans%2520and%2520furazans%26jtitle%3DJ.%2520Mol.%2520Struct.%26date%3D1994%26volume%3D324%26issue%3D3%26spage%3D277%26epage%3D282%26doi%3D10.1016%2F0022-2860%2894%2908305-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vsetecka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Exner, O.</span></span> <span> </span><span class="NLM_article-title">New interpretation of dipole moments of aliphatic and aromatic nitro compounds</span>. <i>Collect. Czech. Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1140</span>â <span class="NLM_lpage">1149</span>, <span class="refDoi">Â DOI: 10.1135/cccc19741140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1135%2Fcccc19741140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaE2cXks1amtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1974&pages=1140-1149&issue=5&author=V.+Vseteckaauthor=O.+Exner&title=New+interpretation+of+dipole+moments+of+aliphatic+and+aromatic+nitro+compounds&doi=10.1135%2Fcccc19741140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">New interpretation of dipole moments of aliphatic and aromatic nitro compounds</span></div><div class="casAuthors">Vsetecka, V.; Exner, O.</div><div class="citationInfo"><span class="NLM_cas:title">Collection of Czechoslovak Chemical Communications</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1140-9</span>CODEN:
                <span class="NLM_cas:coden">CCCCAK</span>;
        ISSN:<span class="NLM_cas:issn">0010-0765</span>.
    </div><div class="casAbstract">The concept of mesomeric dipole moments is revised both exptl. and theor. on the basis of 13 nitro compds.  While the dipole moments of aliph. nitro compds. increase steadily with the size of the hydrocarbon residue (up to 3.55 D for 1-nitroadamantane), those of 2,4,6-trisubstituted benzenes decrease with the size (polarizability) of the substituent (down to 3.40 D for 2,4,6-triphenylnitrobenzene).  Hence, neither the difference between nitrobenzene and an aliph. deriv., nor between nitrobenzene and 2,4,6-trimethylnitrobenzene can be taken as a quant. measure of the mesomeric interaction between the nitro group and the arom. nucleus.  Simple calcn. of induced dipole moments, however, without using the simplification of the point dipole, agrees with the exptl. results in a semiquant. manner.  The mesomeric effect of the nitro group is very small and is not manifested clearly in the dipole moments values.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_ClmyNs61G7Vg90H21EOLACvtfcHk0liEcQy2wXLjVw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXks1amtbc%253D&md5=ae21cd6789797349690d8caf2021738d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1135%2Fcccc19741140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1135%252Fcccc19741140%26sid%3Dliteratum%253Aachs%26aulast%3DVsetecka%26aufirst%3DV.%26aulast%3DExner%26aufirst%3DO.%26atitle%3DNew%2520interpretation%2520of%2520dipole%2520moments%2520of%2520aliphatic%2520and%2520aromatic%2520nitro%2520compounds%26jtitle%3DCollect.%2520Czech.%2520Chem.%2520Commun.%26date%3D1974%26volume%3D39%26issue%3D5%26spage%3D1140%26epage%3D1149%26doi%3D10.1135%2Fcccc19741140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El-Azhary, A. A.</span></span> <span> </span><span class="NLM_article-title">Vibrational analysis of the spectra of 1,2,5-oxadiazole, 1,2,5-thiadiazole and 1,2,5-selenadiazole</span>. <i>Acta Chem. Scand.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">11</span>â <span class="NLM_lpage">19</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.3891%2Facta.chem.scand.49-0011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK2MXjvVygsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1995&pages=11-19&issue=1&author=A.+A.+El-Azhary&title=Vibrational+analysis+of+the+spectra+of+1%2C2%2C5-oxadiazole%2C+1%2C2%2C5-thiadiazole+and+1%2C2%2C5-selenadiazole"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Vibrational analysis of the spectra of 1,2,5-oxadiazole, 1,2,5-thiadiazole and 1,2,5-selenadiazole</span></div><div class="casAuthors">El-Azhary, Adel Abbas</div><div class="citationInfo"><span class="NLM_cas:title">Acta Chemica Scandinavica</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-19</span>CODEN:
                <span class="NLM_cas:coden">ACHSE7</span>;
        ISSN:<span class="NLM_cas:issn">0904-213X</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">Equil. geometries and harmonic force fields have been calcd. for 1,2,5-oxadiazole, 1,2,5-thiadiazole, and 1,2,5-selenadiazole at the SCF and MP2 levels of theory using the 6-31G** basis set (Binning-Curtiss for the selenium atom).  Scaled quantum-mech. (SOM) force fields have been calcd. for the three mols. and some of their isotopomers using the exptl. frequencies available from the literature.  The IR absorption intensities were calcd. using the computed dipole deriv. tensors.  The assignment of the exptl. to the calcd. frequencies was done first according to symmetry then mainly according to frequency order.  The calcd. vibrational spectra for the studied mols. by the scaled MP2 force fields are only slightly better than those calcd. by the scaled SCF force fields.  A good correlation was found between the scale factors obtained for both mols. and those obtained for 1,3,4-oxadiazole and 1,3,4-thiadiazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlZKrCrDs1wLVg90H21EOLACvtfcHk0liEcQy2wXLjVw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjvVygsr0%253D&md5=a02533e49f809ec31be03956c488c387</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.3891%2Facta.chem.scand.49-0011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3891%252Facta.chem.scand.49-0011%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Azhary%26aufirst%3DA.%2BA.%26atitle%3DVibrational%2520analysis%2520of%2520the%2520spectra%2520of%25201%252C2%252C5-oxadiazole%252C%25201%252C2%252C5-thiadiazole%2520and%25201%252C2%252C5-selenadiazole%26jtitle%3DActa%2520Chem.%2520Scand.%26date%3D1995%26volume%3D49%26issue%3D1%26spage%3D11%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tselinskii, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melânikova, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelenov, M. P.</span></span> <span> </span><span class="NLM_article-title">Acid-base properties of 1,2,5-oxadiazoles. III</span>. <i>Furazanylacetic acids. Zh. Org. Khim.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">766</span>â <span class="NLM_lpage">769</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1996&pages=766-769&issue=5&author=I.+V.+Tselinskiiauthor=S.+F.+Mel%E2%80%99nikovaauthor=M.+P.+Zelenov&title=Acid-base+properties+of+1%2C2%2C5-oxadiazoles.+III"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTselinskii%26aufirst%3DI.%2BV.%26aulast%3DMel%25E2%2580%2599nikova%26aufirst%3DS.%2BF.%26aulast%3DZelenov%26aufirst%3DM.%2BP.%26atitle%3DAcid-base%2520properties%2520of%25201%252C2%252C5-oxadiazoles.%2520III%26jtitle%3DFurazanylacetic%2520acids.%2520Zh.%2520Org.%2520Khim.%26date%3D1996%26volume%3D32%26issue%3D5%26spage%3D766%26epage%3D769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slovetskii, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fainzilâberg, A. A.</span></span> <span> </span><span class="NLM_article-title">Magnitudes of the inductive effects of the nitro and nitrate groups</span>. <i>Bull. Acad. Sci. USSR, Div. Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1966</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1435</span>â <span class="NLM_lpage">1437</span>, <span class="refDoi">Â DOI: 10.1007/BF01151397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1007%2FBF01151397" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1966&pages=1435-1437&issue=8&author=V.+I.+Slovetskiiauthor=A.+A.+Fainzil%E2%80%99berg&title=Magnitudes+of+the+inductive+effects+of+the+nitro+and+nitrate+groups&doi=10.1007%2FBF01151397"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2FBF01151397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01151397%26sid%3Dliteratum%253Aachs%26aulast%3DSlovetskii%26aufirst%3DV.%2BI.%26aulast%3DFainzil%25E2%2580%2599berg%26aufirst%3DA.%2BA.%26atitle%3DMagnitudes%2520of%2520the%2520inductive%2520effects%2520of%2520the%2520nitro%2520and%2520nitrate%2520groups%26jtitle%3DBull.%2520Acad.%2520Sci.%2520USSR%252C%2520Div.%2520Chem.%2520Sci.%26date%3D1966%26volume%3D15%26issue%3D8%26spage%3D1435%26epage%3D1437%26doi%3D10.1007%2FBF01151397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kazius, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursi, R.</span></span> <span> </span><span class="NLM_article-title">Derivation and validation of toxicophores for mutagenicity prediction. J. Med. Chem. 2005, 48 (1), 312â320. (16) Kazius, J.; McGuire, R.; Bursi, R., Derivation and validation of toxicophores for mutagenicity prediction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">312</span>â <span class="NLM_lpage">320</span>, <span class="refDoi">Â DOI: 10.1021/jm040835a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040835a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFSlur%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=312-320&issue=1&author=J.+Kaziusauthor=R.+McGuireauthor=R.+Bursi&title=Derivation+and+validation+of+toxicophores+for+mutagenicity+prediction.+J.+Med.+Chem.+2005%2C+48+%281%29%2C+312%E2%80%93320.+%2816%29+Kazius%2C+J.%3B+McGuire%2C+R.%3B+Bursi%2C+R.%2C+Derivation+and+validation+of+toxicophores+for+mutagenicity+prediction&doi=10.1021%2Fjm040835a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Derivation and validation of toxicophores for mutagenicity prediction</span></div><div class="casAuthors">Kazius, Jeroen; McGuire, Ross; Bursi, Roberta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">312-320</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mutagenicity is one of the numerous adverse properties of a compd. that hampers its potential to become a marketable drug.  Toxic properties can often be related to chem. structure, more specifically, to particular substructures, which are generally identified as toxicophores.  A no. of toxicophores have already been identified in the literature.  This study aims at increasing the current degree of reliability and accuracy of mutagenicity predictions by identifying novel toxicophores from the application of new criteria for toxicophore rule derivation and validation to a considerably sized mutagenicity dataset.  For this purpose, a dataset of 4337 mol. structures with corresponding Ames test data (2401 mutagens and 1936 nonmutagens) was constructed.  An initial substructure-search of this dataset showed that most mutagens were detected by applying only eight general toxicophores.  From these eight, more specific toxicophores were derived and approved by employing chem. and mechanistic knowledge in combination with statistical criteria.  A final set of 29 toxicophores contg. new substructures was assembled that could classify the mutagenicity of the investigated dataset with a total classification error of 18%.  Furthermore, mutagenicity predictions of an independent validation set of 535 compds. were performed with an error percentage of 15%.  Since these error percentages approach the av. interlab. reproducibility error of Ames tests, which is 15%, it was concluded that these toxicophores can be applied to risk assessment processes and can guide the design of chem. libraries for hit and lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgFd408uWltLVg90H21EOLACvtfcHk0liEcQy2wXLjVw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFSlur%252FL&md5=3ef5be2a1583292818d8b8f0e350bdd1</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm040835a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040835a%26sid%3Dliteratum%253Aachs%26aulast%3DKazius%26aufirst%3DJ.%26aulast%3DMcGuire%26aufirst%3DR.%26aulast%3DBursi%26aufirst%3DR.%26atitle%3DDerivation%2520and%2520validation%2520of%2520toxicophores%2520for%2520mutagenicity%2520prediction.%2520J.%2520Med.%2520Chem.%25202005%252C%252048%2520%25281%2529%252C%2520312%25E2%2580%2593320.%2520%252816%2529%2520Kazius%252C%2520J.%253B%2520McGuire%252C%2520R.%253B%2520Bursi%252C%2520R.%252C%2520Derivation%2520and%2520validation%2520of%2520toxicophores%2520for%2520mutagenicity%2520prediction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D1%26spage%3D312%26epage%3D320%26doi%3D10.1021%2Fjm040835a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priest, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swensen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Galicia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felix, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochu, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas-Fowlkes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaczorowski, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran- 1(3H)-one</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">5829</span>â <span class="NLM_lpage">5832</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2013.08.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmcl.2013.08.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=24075732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFaksLzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5829-5832&issue=21&author=H.+Tangauthor=R.+K.+de+Jesusauthor=S.+P.+Walshauthor=Y.+Zhuauthor=Y.+Yanauthor=B.+T.+Priestauthor=A.+M.+Swensenauthor=M.+Alonso-Galiciaauthor=J.+P.+Felixauthor=R.+M.+Brochuauthor=T.+Baileyauthor=B.+Thomas-Fowlkesauthor=X.+Zhouauthor=L.+Y.+Paiauthor=C.+Hamptonauthor=M.+Hernandezauthor=K.+Owensauthor=S.+Royauthor=G.+J.+Kaczorowskiauthor=L.+Yangauthor=M.+L.+Garciaauthor=A.+Pasternak&title=Discovery+of+a+novel+sub-class+of+ROMK+channel+inhibitors+typified+by+5-%282-%284-%282-%284-%281H-Tetrazol-1-yl%29phenyl%29acetyl%29piperazin-1-yl%29ethyl%29isobenzofuran-+1%283H%29-one&doi=10.1016%2Fj.bmcl.2013.08.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one</span></div><div class="casAuthors">Tang, Haifeng; de Jesus, Reynald K.; Walsh, Shawn P.; Zhu, Yuping; Yan, Yan; Priest, Birgit T.; Swensen, Andrew M.; Alonso-Galicia, Magdalena; Felix, John P.; Brochu, Richard M.; Bailey, Timothy; Thomas-Fowlkes, Brande; Zhou, Xiaoyan; Pai, Lee-Yuh; Hampton, Caryn; Hernandez, Melba; Owens, Karen; Roy, Sophie; Kaczorowski, Gregory J.; Yang, Lihu; Garcia, Maria L.; Pasternak, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5829-5832</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A sub-class of distinct small mol. ROMK inhibitors were developed from the original lead 1.  Medicinal chem. endeavors led to novel ROMK inhibitors with good ROMK functional potency and improved hERG selectivity.  Two of the described ROMK inhibitors were characterized for the first in vivo proof-of-concept biol. studies, and results from an acute rat diuresis model confirmed the hypothesis that ROMK inhibitors represent new mechanism diuretic and natriuretic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqMISo9kJhC7Vg90H21EOLACvtfcHk0ljLTqelVwRhug"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFaksLzO&md5=e88d9eedfcdf23725f6fde1301664cd8</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.104%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DH.%26aulast%3Dde%2BJesus%26aufirst%3DR.%2BK.%26aulast%3DWalsh%26aufirst%3DS.%2BP.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DPriest%26aufirst%3DB.%2BT.%26aulast%3DSwensen%26aufirst%3DA.%2BM.%26aulast%3DAlonso-Galicia%26aufirst%3DM.%26aulast%3DFelix%26aufirst%3DJ.%2BP.%26aulast%3DBrochu%26aufirst%3DR.%2BM.%26aulast%3DBailey%26aufirst%3DT.%26aulast%3DThomas-Fowlkes%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DPai%26aufirst%3DL.%2BY.%26aulast%3DHampton%26aufirst%3DC.%26aulast%3DHernandez%26aufirst%3DM.%26aulast%3DOwens%26aufirst%3DK.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DKaczorowski%26aufirst%3DG.%2BJ.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DGarcia%26aufirst%3DM.%2BL.%26aulast%3DPasternak%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520sub-class%2520of%2520ROMK%2520channel%2520inhibitors%2520typified%2520by%25205-%25282-%25284-%25282-%25284-%25281H-Tetrazol-1-yl%2529phenyl%2529acetyl%2529piperazin-1-yl%2529ethyl%2529isobenzofuran-%25201%25283H%2529-one%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D21%26spage%3D5829%26epage%3D5832%26doi%3D10.1016%2Fj.bmcl.2013.08.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahripour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teumelsan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas-Fowlkes, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felix, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priest, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Galicia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaczorowski, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective small molecule ROMK Inhibitors as potential new mechanism diuretics</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">367</span>â <span class="NLM_lpage">372</span>, <span class="refDoi">Â DOI: 10.1021/ml3000066</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml3000066" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1Cju7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=367-372&issue=5&author=H.+Tangauthor=S.+P.+Walshauthor=Y.+Yanauthor=R.+K.+de+Jesusauthor=A.+Shahripourauthor=N.+Teumelsanauthor=Y.+Zhuauthor=S.+Haauthor=K.+A.+Owensauthor=B.+S.+Thomas-Fowlkesauthor=J.+P.+Felixauthor=J.+Liuauthor=M.+Kohlerauthor=B.+T.+Priestauthor=T.+Baileyauthor=R.+Brochuauthor=M.+Alonso-Galiciaauthor=G.+J.+Kaczorowskiauthor=S.+Royauthor=L.+Yangauthor=S.+G.+Millsauthor=M.+L.+Garciaauthor=A.+Pasternak&title=Discovery+of+selective+small+molecule+ROMK+Inhibitors+as+potential+new+mechanism+diuretics&doi=10.1021%2Fml3000066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Selective Small Molecule ROMK Inhibitors as Potential New Mechanism Diuretics</span></div><div class="casAuthors">Tang, Haifeng; Walsh, Shawn P.; Yan, Yan; de Jesus, Reynalda K.; Shahripour, Aurash; Teumelsan, Nardos; Zhu, Yuping; Ha, Sookhee; Owens, Karen A.; Thomas-Fowlkes, Brande S.; Felix, John P.; Liu, Jessica; Kohler, Martin; Priest, Birgit T.; Bailey, Timothy; Brochu, Richard; Alonso-Galicia, Magdalena; Kaczorowski, Gregory J.; Roy, Sophie; Yang, Lihu; Mills, Sander G.; Garcia, Maria L.; Pasternak, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">367-372</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The renal outer medullary potassium channel (ROMK or Kir1.1) is a putative drug target for a novel class of diuretics that could be used for the treatment of hypertension and edematous states such as heart failure.  An internal high-throughput screening campaign identified 1,4-bis(4-nitrophenethyl)piperazine (5) as a potent ROMK inhibitor.  It is worth noting that this compd. was identified as a minor impurity in a screening hit that was responsible for all of the initially obsd. ROMK activity.  Structure-activity studies resulted in analogs with improved rat pharmacokinetic properties and selectivity over the hERG channel, providing tool compds. that can be used for in vivo pharmacol. assessment.  The featured ROMK inhibitors were also selective against other members of the inward rectifier family of potassium channels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7DJkcFtShlrVg90H21EOLACvtfcHk0ljLTqelVwRhug"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1Cju7k%253D&md5=dac591d9e2a0d89637522ab5d50b4cab</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fml3000066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml3000066%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DH.%26aulast%3DWalsh%26aufirst%3DS.%2BP.%26aulast%3DYan%26aufirst%3DY.%26aulast%3Dde%2BJesus%26aufirst%3DR.%2BK.%26aulast%3DShahripour%26aufirst%3DA.%26aulast%3DTeumelsan%26aufirst%3DN.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DHa%26aufirst%3DS.%26aulast%3DOwens%26aufirst%3DK.%2BA.%26aulast%3DThomas-Fowlkes%26aufirst%3DB.%2BS.%26aulast%3DFelix%26aufirst%3DJ.%2BP.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DKohler%26aufirst%3DM.%26aulast%3DPriest%26aufirst%3DB.%2BT.%26aulast%3DBailey%26aufirst%3DT.%26aulast%3DBrochu%26aufirst%3DR.%26aulast%3DAlonso-Galicia%26aufirst%3DM.%26aulast%3DKaczorowski%26aufirst%3DG.%2BJ.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DMills%26aufirst%3DS.%2BG.%26aulast%3DGarcia%26aufirst%3DM.%2BL.%26aulast%3DPasternak%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520selective%2520small%2520molecule%2520ROMK%2520Inhibitors%2520as%2520potential%2520new%2520mechanism%2520diuretics%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26issue%3D5%26spage%3D367%26epage%3D372%26doi%3D10.1021%2Fml3000066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span>; <span class="NLM_string-name">Pasternak, A.</span>; <span class="NLM_string-name">Yang, L.</span>; <span class="NLM_string-name">Walsh, S. P.</span>; <span class="NLM_string-name">Pio, B.</span>; <span class="NLM_string-name">Shahripour, A.</span>; <span class="NLM_string-name">Teumelsan, N.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the Renal Outer Medullary Potassium Channel</span>. <span class="NLM_patent">WO2012058116A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=H.+Tang&author=A.+Pasternak&author=L.+Yang&author=S.+P.+Walsh&author=B.+Pio&author=A.+Shahripour&author=N.+Teumelsan&title=Inhibitors+of+the+Renal+Outer+Medullary+Potassium+Channel"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DH.%26atitle%3DInhibitors%2520of%2520the%2520Renal%2520Outer%2520Medullary%2520Potassium%2520Channel%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hersperger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">233</span>â <span class="NLM_lpage">235</span>, <span class="refDoi">Â DOI: 10.1016/S0960-894X(01)00720-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2FS0960-894X%2801%2900720-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=11755362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsVyl" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=233-235&issue=2&author=R.+Herspergerauthor=J.+Dawsonauthor=T.+Mueller&title=Synthesis+of+4-%288-benzo%5B1%2C2%2C5%5Doxadiazol-5-yl-%5B1%2C7%5Dnaphthyridine-6-yl%29-benzoic+acid%3A+a+potent+and+selective+phosphodiesterase+type+4D+inhibitor&doi=10.1016%2FS0960-894X%2801%2900720-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor</span></div><div class="casAuthors">Hersperger, Rene; Dawson, Janet; Mueller, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">233-235</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The synthesis of a 6,8-disubstituted 1,7-naphthyridine and its characterization as a potent and selective phosphodiesterase type 4D inhibitor (IC50=1.5 nM) are described.  The title compd., i.e., 4-[8-(2,1,3-benzoxadiazol-5-yl)-1,7-naphthyridin-6-yl]benzoic acid and 4-[8-(2,1,3-benzoxadiazol-5-yl)-1,7-naphthyridin-6-yl]benzoic acid salt with 1-deoxy-1-(methylamino)-D-glucitol.  The compd. inhibited TNFÎ±-release from human peripheral blood mononuclear cells and was orally active in a model of adjuvant-induced arthritis in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeK295xqo3SbVg90H21EOLACvtfcHk0ljRK7hR8OCNuw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsVyl&md5=60845922a243dc78753438545726108d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900720-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900720-X%26sid%3Dliteratum%253Aachs%26aulast%3DHersperger%26aufirst%3DR.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DMueller%26aufirst%3DT.%26atitle%3DSynthesis%2520of%25204-%25288-benzo%255B1%252C2%252C5%255Doxadiazol-5-yl-%255B1%252C7%255Dnaphthyridine-6-yl%2529-benzoic%2520acid%253A%2520a%2520potent%2520and%2520selective%2520phosphodiesterase%2520type%25204D%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26issue%3D2%26spage%3D233%26epage%3D235%26doi%3D10.1016%2FS0960-894X%2801%2900720-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. A.</span>; <span class="NLM_string-name">Yadav, A.</span>; <span class="NLM_string-name">Banfield, S. C.</span>; <span class="NLM_string-name">Barden, C. J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Amino Substituted Biaryl Compounds as Anti-Amyloid Agents</span>. <span class="NLM_patent">WO2012119035A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+A.+Reed&author=A.+Yadav&author=S.+C.+Banfield&author=C.+J.+Barden&title=Preparation+of+Amino+Substituted+Biaryl+Compounds+as+Anti-Amyloid+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DReed%26aufirst%3DM.%2BA.%26atitle%3DPreparation%2520of%2520Amino%2520Substituted%2520Biaryl%2520Compounds%2520as%2520Anti-Amyloid%2520Agents%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. A.</span>; <span class="NLM_string-name">Wood, T. K.</span>; <span class="NLM_string-name">Banfield, S. C.</span>; <span class="NLM_string-name">Barden, C. J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Benzo[c][1,2,5]oxadiazoles as Therapeutic Anti-Amyloid Compounds</span>. <span class="NLM_patent">WO2014031873A2</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=M.+A.+Reed&author=T.+K.+Wood&author=S.+C.+Banfield&author=C.+J.+Barden&title=Preparation+of+Benzo%5Bc%5D%5B1%2C2%2C5%5Doxadiazoles+as+Therapeutic+Anti-Amyloid+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DReed%26aufirst%3DM.%2BA.%26atitle%3DPreparation%2520of%2520Benzo%255Bc%255D%255B1%252C2%252C5%255Doxadiazoles%2520as%2520Therapeutic%2520Anti-Amyloid%2520Compounds%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. A.</span>; <span class="NLM_string-name">Wood, T. K.</span>; <span class="NLM_string-name">Banfield, S. C.</span>; <span class="NLM_string-name">Barden, C. J.</span>; <span class="NLM_string-name">Yadav, A.</span>; <span class="NLM_string-name">Lu, E.</span>; <span class="NLM_string-name">Wu, F.</span></span> <span> </span><span class="NLM_article-title">Preparation of Anti-Amyloid Compounds Containing Benzofurazan</span>. <span class="NLM_patent">WO2015131021A2</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=M.+A.+Reed&author=T.+K.+Wood&author=S.+C.+Banfield&author=C.+J.+Barden&author=A.+Yadav&author=E.+Lu&author=F.+Wu&title=Preparation+of+Anti-Amyloid+Compounds+Containing+Benzofurazan"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DReed%26aufirst%3DM.%2BA.%26atitle%3DPreparation%2520of%2520Anti-Amyloid%2520Compounds%2520Containing%2520Benzofurazan%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deghati, P. Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den
Nieuwendijk, A. M. C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dissen-de
Groote, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span> <span> </span><span class="NLM_article-title">Inhibition of nucleoside transport By new analogues of nitrobenzylthioinosine</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">899</span>â <span class="NLM_lpage">908</span>, <span class="refDoi">Â DOI: 10.1016/S0968-0896(02)00544-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2FS0968-0896%2802%2900544-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=12614875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsVCit7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=899-908&issue=6&author=P.+Y.+F.+Deghatiauthor=A.+Borghiniauthor=A.+M.+C.+H.+van+den%0ANieuwendijkauthor=M.+Dissen-de%0AGrooteauthor=A.+P.+Ijzerman&title=Inhibition+of+nucleoside+transport+By+new+analogues+of+nitrobenzylthioinosine&doi=10.1016%2FS0968-0896%2802%2900544-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of nucleoside transport By new analogues of nitrobenzylthioinosine</span></div><div class="casAuthors">Deghati, Paymaneh Y. F.; Borghini, Alice; Van Den Nieuwendijk, Adrianus M. C. H.; Dissen-de Groote, Miriam; IJzerman, Adriaan P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">899-908</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Nitrobenzylthioinosine (NBTI, 1) was systematically modified by attachment of substituents at positions C6 and N9, and also by substitution of N1 with C.  These modifications were chosen to reduce the polarity of the new compds.  Incorporation of the nitro functionality into a benzoxadiazole ring system was considered first.  These new nucleosides showed high affinity (1.5-10 nM) towards the nucleoside transport protein as present on human erythrocyte ghosts.  Next, modification of this benzoxadiazole ring system with C, S and O in different positions produced a no. of less polar nucleosides with affinity in the higher nanomolar range.  Modification of N9 was achieved with different alkyl and alc. substituents.  An Bu substituent proved best, although all variations yielded substantial decreases in affinity.  Replacement of N1 by a carbon atom in combination with a 2-Cl substituent also resulted in a relatively potent NBTI deriv. (47 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQDsRshjYiDLVg90H21EOLACvtfcHk0ljRK7hR8OCNuw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsVCit7g%253D&md5=f1995328390d4f593b8fddfb682bfc44</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2802%2900544-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252802%252900544-8%26sid%3Dliteratum%253Aachs%26aulast%3DDeghati%26aufirst%3DP.%2BY.%2BF.%26aulast%3DBorghini%26aufirst%3DA.%26aulast%3Dvan%2Bden%2BNieuwendijk%26aufirst%3DA.%2BM.%2BC.%2BH.%26aulast%3DDissen-de%2BGroote%26aufirst%3DM.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26atitle%3DInhibition%2520of%2520nucleoside%2520transport%2520By%2520new%2520analogues%2520of%2520nitrobenzylthioinosine%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26issue%3D6%26spage%3D899%26epage%3D908%26doi%3D10.1016%2FS0968-0896%2802%2900544-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puetz, C.</span>; <span class="NLM_string-name">Sundermann, B.</span>; <span class="NLM_string-name">Sundermann, C.</span>; <span class="NLM_string-name">Ijzermann, A. P.</span>; <span class="NLM_string-name">Tromp, R.</span>; <span class="NLM_string-name">Von Frijtag, D. K. J.</span></span> <span> </span><span class="NLM_article-title">Preparation of analogs of nitrobenzylthioinosine for the treatment of pain, epilepsy, and other CNS-related disorders</span>. <span class="NLM_patent">EP1352910A1</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=C.+Puetz&author=B.+Sundermann&author=C.+Sundermann&author=A.+P.+Ijzermann&author=R.+Tromp&author=D.+K.+J.+Von+Frijtag&title=Preparation+of+analogs+of+nitrobenzylthioinosine+for+the+treatment+of+pain%2C+epilepsy%2C+and+other+CNS-related+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPuetz%26aufirst%3DC.%26atitle%3DPreparation%2520of%2520analogs%2520of%2520nitrobenzylthioinosine%2520for%2520the%2520treatment%2520of%2520pain%252C%2520epilepsy%252C%2520and%2520other%2520CNS-related%2520disorders%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obreque-Balboa, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konig, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschauer, A.</span></span> <span> </span><span class="NLM_article-title">Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">124</span>â <span class="NLM_lpage">133</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2015.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.ejmech.2015.12.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=26774038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtl2lsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2016&pages=124-133&author=J.+E.+Obreque-Balboaauthor=Q.+Sunauthor=G.+Bernhardtauthor=B.+Konigauthor=A.+Buschauer&title=Flavonoid+derivatives+as+selective+ABCC1+modulators%3A+Synthesis+and+functional+characterization&doi=10.1016%2Fj.ejmech.2015.12.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization</span></div><div class="casAuthors">Obreque-Balboa, Jose Esteban; Sun, Qiu; Bernhardt, Guenther; Koenig, Burkhard; Buschauer, Armin</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">124-133</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of chromones, bearing substituted amino groups or N-substituted carboxamide moieties in position 2, was synthesized and characterized in cellular assays for modulation of the ABC transporters ABCC1 (MDCKII-MRP1 cells), ABCB1 (Kb-V1 cells) and ABCG2 (MCF-7/Topo cells).  The most potent ABCC1 modulators identified among these flavonoid-type compds. were comparable to the ref. compd. reversan regarding potency, but superior in terms of selectivity concerning ABCB1 and ABCG2 (2-[4-(Benzo[c][1,2,5]oxadiazol-5-ylmethyl)piperazin-1-yl]-5,7-dimethoxy-4H-chromen-4-one: ABCC1, IC50 11.3 Î¼M; inactive at ABCB1 and ABCG2).  This compd. was as effective as reversan in reverting ABCC1-mediated resistance to cytostatics in MDCKII-MRP1 cells and proved to be stable in mouse plasma and cell culture medium.  Modulators, such 2-[4-(Benzo[c][1,2,5]oxadiazol-5-ylmethyl)piperazin-1-yl]-5,7-dimethoxy-4H-chromen-4-one, were of potential value as pharmacol. tools for the investigation of the (patho)physiol. role of ABCC1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNn-hQZ2-o97Vg90H21EOLACvtfcHk0lgqhUrMvrxWdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtl2lsr4%253D&md5=1df454328811e6a9d1f0c50a0da22873</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DObreque-Balboa%26aufirst%3DJ.%2BE.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DBernhardt%26aufirst%3DG.%26aulast%3DKonig%26aufirst%3DB.%26aulast%3DBuschauer%26aufirst%3DA.%26atitle%3DFlavonoid%2520derivatives%2520as%2520selective%2520ABCC1%2520modulators%253A%2520Synthesis%2520and%2520functional%2520characterization%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D109%26spage%3D124%26epage%3D133%26doi%3D10.1016%2Fj.ejmech.2015.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lolli, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnovale, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippione, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahlgren, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zonari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallicchio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boscaro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friemann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolando, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagnati, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adinolfi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliaro-Bosso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boschi, D.</span></span> <span> </span><span class="NLM_article-title">Bioisosteres of Indomethacin as Inhibitors of aldo-keto reductase 1C3</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">437</span>â <span class="NLM_lpage">443</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.8b00484</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00484" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFGqtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=437-443&issue=4&author=M.+L.+Lolliauthor=I.+M.+Carnovaleauthor=A.+C.+Pippioneauthor=W.+Y.+Wahlgrenauthor=D.+Bonanniauthor=E.+Mariniauthor=D.+Zonariauthor=M.+Gallicchioauthor=V.+Boscaroauthor=P.+Goyalauthor=R.+Friemannauthor=B.+Rolandoauthor=R.+Bagnatiauthor=S.+Adinolfiauthor=S.+Oliaro-Bossoauthor=D.+Boschi&title=Bioisosteres+of+Indomethacin+as+Inhibitors+of+aldo-keto+reductase+1C3&doi=10.1021%2Facsmedchemlett.8b00484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3</span></div><div class="casAuthors">Lolli, Marco L.; Carnovale, Irene M.; Pippione, Agnese C.; Wahlgren, Weixiao Y.; Bonanni, Davide; Marini, Elisabetta; Zonari, Daniele; Gallicchio, Margherita; Boscaro, Valentina; Goyal, Parveen; Friemann, Rosmarie; Rolando, Barbara; Bagnati, Renzo; Adinolfi, Salvatore; Oliaro-Bosso, Simonetta; Boschi, Donatella</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">437-443</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aldo-keto reductase 1C3 (AKR1C3) is an attractive target in drug design for its role in resistance to anticancer therapy.  Several nonsteroidal anti-inflammatory drugs such as indomethacin are known to inhibit AKR1C3 in a nonselective manner because of COX-off target effects.  Here we designed two indomethacin analogs by proposing a bioisosteric connection between the indomethacin carboxylic acid function and either hydroxyfurazan or hydroxy triazole rings.  Both compds. were found to target AKR1C3 in a selective manner.  In particular, hydroxyfurazan deriv. is highly selective for AKR1C3 over the 1C2 isoform (up to 90-times more) and inactive on COX enzymes.  High-resoln. crystal structure of its complex with AKR1C3 shed light onto the binding mode of the new inhibitors.  In cell-based assays (on colorectal and prostate cancer cells), the two indomethacin analogs showed higher potency than indomethacin.  Therefore, these two AKR1C3 inhibitors can be used to provide further insight into the role of AKR1C3 in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpcSn7kYi0LrVg90H21EOLACvtfcHk0lgqhUrMvrxWdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFGqtbY%253D&md5=3330d486e9a28b9ebf0eebb14ae7bb04</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00484%26sid%3Dliteratum%253Aachs%26aulast%3DLolli%26aufirst%3DM.%2BL.%26aulast%3DCarnovale%26aufirst%3DI.%2BM.%26aulast%3DPippione%26aufirst%3DA.%2BC.%26aulast%3DWahlgren%26aufirst%3DW.%2BY.%26aulast%3DBonanni%26aufirst%3DD.%26aulast%3DMarini%26aufirst%3DE.%26aulast%3DZonari%26aufirst%3DD.%26aulast%3DGallicchio%26aufirst%3DM.%26aulast%3DBoscaro%26aufirst%3DV.%26aulast%3DGoyal%26aufirst%3DP.%26aulast%3DFriemann%26aufirst%3DR.%26aulast%3DRolando%26aufirst%3DB.%26aulast%3DBagnati%26aufirst%3DR.%26aulast%3DAdinolfi%26aufirst%3DS.%26aulast%3DOliaro-Bosso%26aufirst%3DS.%26aulast%3DBoschi%26aufirst%3DD.%26atitle%3DBioisosteres%2520of%2520Indomethacin%2520as%2520Inhibitors%2520of%2520aldo-keto%2520reductase%25201C3%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D4%26spage%3D437%26epage%3D443%26doi%3D10.1021%2Facsmedchemlett.8b00484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lolli, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickering, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolando, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contreras-Sanz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruttero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, T. N.</span></span> <span> </span><span class="NLM_article-title">4-Hydroxy-1,2,5-oxadiazol-3-yl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and molecular pharmacological characterization at ionotropic glutamate receptors of compounds related to glutamate and its homologues</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4110</span>â <span class="NLM_lpage">4118</span>, <span class="refDoi">Â DOI: 10.1021/jm1001452</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1001452" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVylsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4110-4118&issue=10&author=M.+L.+Lolliauthor=C.+Giordanoauthor=D.+S.+Pickeringauthor=B.+Rolandoauthor=K.+B.+Hansenauthor=A.+Fotiauthor=A.+Contreras-Sanzauthor=A.+Amirauthor=R.+Frutteroauthor=A.+Gascoauthor=B.+Nielsenauthor=T.+N.+Johansen&title=4-Hydroxy-1%2C2%2C5-oxadiazol-3-yl+moiety+as+bioisoster+of+the+carboxy+function.+Synthesis%2C+ionization+constants%2C+and+molecular+pharmacological+characterization+at+ionotropic+glutamate+receptors+of+compounds+related+to+glutamate+and+its+homologues&doi=10.1021%2Fjm1001452"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">4-Hydroxy-1,2,5-oxadiazol-3-yl moiety as bioisostere of the carboxy function. synthesis, ionization constants, and molecular pharmacological characterization at ionotropic glutamate receptors of compounds related to glutamate and its homologues</span></div><div class="casAuthors">Lolli, Marco L.; Giordano, Cecilia; Pickering, Darryl S.; Rolando, Barbara; Hansen, Kasper B.; Foti, Antonio; Contreras-Sanz, Alberto; Amir, Ahmad; Fruttero, Roberta; Gasco, Alberto; Nielsen, Birgitte; Johansen, Tommy N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4110-4118</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to investigate the 4-hydroxy-1,2,5-oxadiazol-3-yl moiety as a carboxylic acid bioisostere at ionotropic glutamate receptors (iGluRs), a series of acidic Î±-aminocarboxylic acids in which the distal carboxy group was replaced by the 4-hydroxy-1,2,5-oxadiazol-3-yl group was synthesized.  Ionization consts. were detd.  All target compds., except the Asp analog I, were resolved using chiral HPLC.  Whereas I showed good affinity exclusively at NMDA receptors, the Glu analog, (+)-II, was an unselective, though potent AMPA receptor preferring agonist (EC50 = 10 Î¼M at iGluR2) showing only low stereoselectivity.  The two higher Glu homologues, (+)-III and (+)-IV, turned out to be weak agonists at iGluR2 as well as weak antagonists at NR1/NR2A, whereas the corresponding (-)-isomers were selective NR1/NR2A antagonists with somewhat higher potency.  The results proved the 4-hydroxy-1,2,5-oxadiazol-3-yl moiety to be a useful bioisoster at all three classes of iGluRs, capable of being integrated into agonists as well as antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGratZ1tCLQqyLVg90H21EOLACvtfcHk0lgqhUrMvrxWdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVylsrc%253D&md5=dd535ad1a6768b1ae4f7b458c92b86eb</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm1001452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1001452%26sid%3Dliteratum%253Aachs%26aulast%3DLolli%26aufirst%3DM.%2BL.%26aulast%3DGiordano%26aufirst%3DC.%26aulast%3DPickering%26aufirst%3DD.%2BS.%26aulast%3DRolando%26aufirst%3DB.%26aulast%3DHansen%26aufirst%3DK.%2BB.%26aulast%3DFoti%26aufirst%3DA.%26aulast%3DContreras-Sanz%26aufirst%3DA.%26aulast%3DAmir%26aufirst%3DA.%26aulast%3DFruttero%26aufirst%3DR.%26aulast%3DGasco%26aufirst%3DA.%26aulast%3DNielsen%26aufirst%3DB.%26aulast%3DJohansen%26aufirst%3DT.%2BN.%26atitle%3D4-Hydroxy-1%252C2%252C5-oxadiazol-3-yl%2520moiety%2520as%2520bioisoster%2520of%2520the%2520carboxy%2520function.%2520Synthesis%252C%2520ionization%2520constants%252C%2520and%2520molecular%2520pharmacological%2520characterization%2520at%2520ionotropic%2520glutamate%2520receptors%2520of%2520compounds%2520related%2520to%2520glutamate%2520and%2520its%2520homologues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D10%26spage%3D4110%26epage%3D4118%26doi%3D10.1021%2Fjm1001452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lolli, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruttero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasco, A.</span></span> <span> </span><span class="NLM_article-title">New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">102</span>â <span class="NLM_lpage">109</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2011.12.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.ejmech.2011.12.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=22245049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFOku7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2012&pages=102-109&author=M.+L.+Lolliauthor=M.+Giorgisauthor=P.+Toscoauthor=A.+Fotiauthor=R.+Frutteroauthor=A.+Gasco&title=New+inhibitors+of+dihydroorotate+dehydrogenase+%28DHODH%29+based+on+the+4-hydroxy-1%2C2%2C5-oxadiazol-3-yl+%28hydroxyfurazanyl%29+scaffold&doi=10.1016%2Fj.ejmech.2011.12.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold</span></div><div class="casAuthors">Lolli, Marco L.; Giorgis, Marta; Tosco, Paolo; Foti, Antonio; Fruttero, Roberta; Gasco, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">102-109</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Based on some structural analogies with leflunomide and brequinar, two well-known inhibitors of dihydroorotate dehydrogenase (DHODH), a new series of products was designed, by joining the substituted biphenyl moiety to the 4-hydroxy-1,2,5-oxadiazol-3-yl scaffold through an amide bridge.  The compds. were studied for their DHODH inhibitory activity on rat liver mitochondrial/microsomal membranes.  The activity was closely dependent on the substitution pattern at the biphenyl system; the most potent products were those bearing two or four fluorine atoms at the Ph adjacent to the oxadiazole ring.  A mol. modeling study suggested that these structures might have a brequinar-like binding mode.  The greater potency of fluorinated analogs may depend partly on enhanced interactions with the hydrophobic ubiquinone channel, and partly on the role of fluorine in stabilizing the putative bioactive conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJwFl25fJzKbVg90H21EOLACvtfcHk0lhNG7GcQH-01Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFOku7k%253D&md5=432980015b448f67cd065aab7762bcf9</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.12.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.12.038%26sid%3Dliteratum%253Aachs%26aulast%3DLolli%26aufirst%3DM.%2BL.%26aulast%3DGiorgis%26aufirst%3DM.%26aulast%3DTosco%26aufirst%3DP.%26aulast%3DFoti%26aufirst%3DA.%26aulast%3DFruttero%26aufirst%3DR.%26aulast%3DGasco%26aufirst%3DA.%26atitle%3DNew%2520inhibitors%2520of%2520dihydroorotate%2520dehydrogenase%2520%2528DHODH%2529%2520based%2520on%2520the%25204-hydroxy-1%252C2%252C5-oxadiazol-3-yl%2520%2528hydroxyfurazanyl%2529%2520scaffold%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D49%26spage%3D102%26epage%3D109%26doi%3D10.1016%2Fj.ejmech.2011.12.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lolli, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolando, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellendorph, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristiansen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruttero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, T. N.</span></span> <span> </span><span class="NLM_article-title">Hydroxy-1,2,5-oxadiazolyl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and pharmacological characterization of Î³-aminobutyric acid (GABA) related compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">4442</span>â <span class="NLM_lpage">4446</span>, <span class="refDoi">Â DOI: 10.1021/jm051288b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm051288b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtVSiur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4442-4446&issue=14&author=M.+L.+Lolliauthor=S.+L.+Hansenauthor=B.+Rolandoauthor=B.+Nielsenauthor=P.+Wellendorphauthor=K.+Madsenauthor=O.+M.+Larsenauthor=U.+Kristiansenauthor=R.+Frutteroauthor=A.+Gascoauthor=T.+N.+Johansen&title=Hydroxy-1%2C2%2C5-oxadiazolyl+moiety+as+bioisoster+of+the+carboxy+function.+Synthesis%2C+ionization+constants%2C+and+pharmacological+characterization+of+%CE%B3-aminobutyric+acid+%28GABA%29+related+compounds&doi=10.1021%2Fjm051288b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Hydroxy-1,2,5-oxadiazolyl Moiety as Bioisostere of the Carboxy Function. Synthesis, Ionization Constants, and Pharmacological Characterization of Î³-Aminobutyric Acid (GABA) Related Compounds</span></div><div class="casAuthors">Lolli, Marco L.; Hansen, Suzanne L.; Rolando, Barbara; Nielsen, Birgitte; Wellendorph, Petrine; Madsen, Karsten; Larsen, Orla Miller; Kristiansen, Uffe; Fruttero, Roberta; Gasco, Alberto; Johansen, Tommy N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4442-4446</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Three 4-substituted 1,2,5-oxadiazol-3-ols contg. aminoalkyl substituents [analogs and homologs of Î³-aminobutyric acid (GABA)] were synthesized to investigate the hydroxy-1,2,5-oxadiazolyl moiety as a bioisostere for a carboxyl group at GABA receptors.  The pKa values of the target compds. were close to those of GABA.  At GABAA receptors of cultured cerebral cortical neurons, weak agonist and partial agonist profiles were identified, demonstrating the 4-hydroxy-1,2,5-oxadiazol-3-yl unit to be a nonclassical carboxyl group bioisostere.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1prWkxn0b97Vg90H21EOLACvtfcHk0lhNG7GcQH-01Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtVSiur8%253D&md5=084e3ba5592c9cad99902f2291928ce7</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm051288b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051288b%26sid%3Dliteratum%253Aachs%26aulast%3DLolli%26aufirst%3DM.%2BL.%26aulast%3DHansen%26aufirst%3DS.%2BL.%26aulast%3DRolando%26aufirst%3DB.%26aulast%3DNielsen%26aufirst%3DB.%26aulast%3DWellendorph%26aufirst%3DP.%26aulast%3DMadsen%26aufirst%3DK.%26aulast%3DLarsen%26aufirst%3DO.%2BM.%26aulast%3DKristiansen%26aufirst%3DU.%26aulast%3DFruttero%26aufirst%3DR.%26aulast%3DGasco%26aufirst%3DA.%26aulast%3DJohansen%26aufirst%3DT.%2BN.%26atitle%3DHydroxy-1%252C2%252C5-oxadiazolyl%2520moiety%2520as%2520bioisoster%2520of%2520the%2520carboxy%2520function.%2520Synthesis%252C%2520ionization%2520constants%252C%2520and%2520pharmacological%2520characterization%2520of%2520%25CE%25B3-aminobutyric%2520acid%2520%2528GABA%2529%2520related%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D14%26spage%3D4442%26epage%3D4446%26doi%3D10.1021%2Fjm051288b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tosco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lolli, M. L.</span></span> <span> </span><span class="NLM_article-title">Hydroxy-1,2,5-oxadiazolyl moiety as bioisoster of the carboxy function. A computational study on gamma-aminobutyric acid (GABA) related compounds</span>. <i>J. Mol. Model.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">279</span>â <span class="NLM_lpage">291</span>, <span class="refDoi">Â DOI: 10.1007/s00894-008-0269-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1007%2Fs00894-008-0269-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=18247067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVKnsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=279-291&issue=4&author=P.+Toscoauthor=M.+L.+Lolli&title=Hydroxy-1%2C2%2C5-oxadiazolyl+moiety+as+bioisoster+of+the+carboxy+function.+A+computational+study+on+gamma-aminobutyric+acid+%28GABA%29+related+compounds&doi=10.1007%2Fs00894-008-0269-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Hydroxy-1,2,5-oxadiazolyl moiety as bioisoster of the carboxy function. A computational study on Î³-aminobutyric acid (GABA) related compounds</span></div><div class="casAuthors">Tosco, Paolo; Lolli, Marco L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">279-291</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Recently, our research group has proposed the hydroxyfurazanyl (4-hydroxy-1,2,5-oxadiazole-3-yl) moiety as a new non-classical isoster of the carboxy function in the design of Î³-aminobutyric acid (GABA) analogs.  Some compds. showed significant activity at the GABAA receptor, representing the only examples of pentat. heterocycles bearing an Ï-aminoalkyl flexible side chain in the position vicinal to the hydroxy group displaying agonist activity at this receptor subtype.  In this work, an ab initio anal. of the structural and electronic features of furazan-3-ol is presented, in order to provide a theor. basis to the claimed bioisosterism with the carboxy function.  An ab initio conformational study with the C-PCM implicit solvent model was carried out to elucidate the reasons of the peculiar behavior of the furazan models.  Alongside, another conformational search through mol. dynamics in explicit solvent was accomplished, in order to validate the first method.  The electronic features of the 4-hydroxy-1,2,5-oxadiazole-3-yl substructure seem to account for a marked stabilizing effect of the putative bioactive conformation at the GABAA receptor subtype.  The 1,2,5-thiadiazole analog, which shares the same conformational preference of its oxygenated counterpart, was identified as a potential candidate for synthesis and pharmacol. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp91AgVEICm4bVg90H21EOLACvtfcHk0lhNG7GcQH-01Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVKnsLY%253D&md5=1e88ae5747c187d648fdf30fcf9a5c3e</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2Fs00894-008-0269-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-008-0269-0%26sid%3Dliteratum%253Aachs%26aulast%3DTosco%26aufirst%3DP.%26aulast%3DLolli%26aufirst%3DM.%2BL.%26atitle%3DHydroxy-1%252C2%252C5-oxadiazolyl%2520moiety%2520as%2520bioisoster%2520of%2520the%2520carboxy%2520function.%2520A%2520computational%2520study%2520on%2520gamma-aminobutyric%2520acid%2520%2528GABA%2529%2520related%2520compounds%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2008%26volume%3D14%26issue%3D4%26spage%3D279%26epage%3D291%26doi%3D10.1007%2Fs00894-008-0269-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Penning, T. M.</span></span> <span> </span><span class="NLM_article-title">Aldo-keto reductase (AKR) 1C3 inhibitors: A patent review</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1329</span>â <span class="NLM_lpage">1340</span>, <span class="refDoi">Â DOI: 10.1080/13543776.2017.1379503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1080%2F13543776.2017.1379503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28895472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFeqtrrJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1329-1340&issue=12&author=T.+M.+Penning&title=Aldo-keto+reductase+%28AKR%29+1C3+inhibitors%3A+A+patent+review&doi=10.1080%2F13543776.2017.1379503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review</span></div><div class="casAuthors">Penning, Trevor M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1329-1340</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : AKR1C3 is a drug target in hormonal and hormonal independent malignancies and acts as a major peripheral 17Î²-hydroxysteroid dehydrogenase to yield the potent androgens testosterone and dihydrotestosterone, and as a prostaglandin (PG) F synthase to produce proliferative ligands for the PG FP receptor.  AKR1C3 inhibitors may have distinct advantages over existing therapeutics for the treatment of castration resistant prostate cancer, breast cancer and acute myeloid leukemia.  This article reviews the patent literature on AKR1C3 inhibitors using SciFinder which identified inhibitors in the following chem. classes: N-phenylsulfonyl-indoles, N-(benzimidazoylylcarbonyl)- N-(indoylylcarbonyl)- and N-(pyridinepyrrolyl)- piperidines, N-benzimidazoles and N-benzindoles, repurposed nonsteroidal antiinflammatory drugs (indole acetic acids, N-phenylanthranilates and aryl propionic acids), isoquinolines, and nitrogen and sulfur substituted estrenes.  The article evaluates inhibitor AKR potency, specificity, efficacy in cell-based and xenograft models and clin. utility.  The advantage of bifunctional compds. that either competitively inhibit AKR1C3 and block its androgen receptor (AR) coactivator function or act as AKR1C3 inhibitors and direct acting AR antagonists are discussed.  A large no. of potent and selective inhibitors of AKR1C3 have been described however, preclin. optimization, is required before their benefit in human disease can be assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6TZPHO5l5PrVg90H21EOLACvtfcHk0liJgvGe6J8wQw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFeqtrrJ&md5=20a6c3d7c1766c2610e8bcf53af346cf</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1379503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1379503%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BM.%26atitle%3DAldo-keto%2520reductase%2520%2528AKR%2529%25201C3%2520inhibitors%253A%2520A%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26issue%3D12%26spage%3D1329%26epage%3D1340%26doi%3D10.1080%2F13543776.2017.1379503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karunasinghe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, L. R.</span></span> <span> </span><span class="NLM_article-title">Influence of Aldo-keto reductase 1C3 in prostate cancerâa mini review</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">603</span>â <span class="NLM_lpage">616</span>, <span class="refDoi">Â DOI: 10.2174/1568009617666170330115722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.2174%2F1568009617666170330115722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28359237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlelsLrJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=603-616&issue=7&author=N.+Karunasingheauthor=J.+Mastersauthor=J.+U.+Flanaganauthor=L.+R.+Ferguson&title=Influence+of+Aldo-keto+reductase+1C3+in+prostate+cancer%E2%80%94a+mini+review&doi=10.2174%2F1568009617666170330115722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of Aldo-keto Reductas1e 1C3 in Prostate Cancer - A Mini Review</span></div><div class="casAuthors">Karunasinghe, Nishi; Masters, Jonathan; Flanagan, Jack U.; Ferguson, Lynnette R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">603-616</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: Aldo-keto reductase 1C3 (AKR1C3) is an important oxidoreductase with multiple substrates, that are involved in producing extra-testicular androgens.  Its activity is influenced by environmental exposures, as well as by genetic variants.  These genetic variants could therefore produce variable testosterone levels and subsequent androgen receptor (AR) activation.  This could lead to differential downstream prodn. of the prostate-specific antigen (PSA).  As PSA level is used for clin. evaluation of the prostate, these variations could impact prostate cancer (PC) diagnosis, as well as PC management outcomes.  This review brings together information with regards to key functions of this enzyme, its relevance in PC, its transcriptional regulation, clin. aspects assocd. with genetics, differential regulation in cancer and cancer progression, and the types of AKR1C3 inhibitors with future therapeutic value. <P></P> Conclusion: Based on these discussions, hypotheses are forwarded for future applicability of this enzyme and its genetic variants in transformational medical practices in PC.  Options for the use of personalised AKR1C3 inhibitor drugs for late stage PC are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptxSVT8QVctLVg90H21EOLACvtfcHk0liJgvGe6J8wQw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlelsLrJ&md5=41f427a8e98369f41512cdbeafbd4756</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2174%2F1568009617666170330115722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009617666170330115722%26sid%3Dliteratum%253Aachs%26aulast%3DKarunasinghe%26aufirst%3DN.%26aulast%3DMasters%26aufirst%3DJ.%26aulast%3DFlanagan%26aufirst%3DJ.%2BU.%26aulast%3DFerguson%26aufirst%3DL.%2BR.%26atitle%3DInfluence%2520of%2520Aldo-keto%2520reductase%25201C3%2520in%2520prostate%2520cancer%25E2%2580%2594a%2520mini%2520review%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2017%26volume%3D17%26issue%3D7%26spage%3D603%26epage%3D616%26doi%3D10.2174%2F1568009617666170330115722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kassab, S. E.</span></span> <span> </span><span class="NLM_article-title">Indomethacin from Anti-Inflammatory to Anticancer Agent</span>. <span class="NLM_contrib-group"><span class="NLM_string-name">Vaskova, J.</span>; <span class="NLM_string-name">Vasko, L.</span></span>; Eds.;  <i>Medicinal Chemistry</i>; <span class="NLM_publisher-name">IntechOpen Ltd.</span>: <span class="NLM_publisher-loc">London</span>, <span class="NLM_year">2019</span>, pp  <span class="NLM_fpage">45</span>â <span class="NLM_lpage">62</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.5772%2Fintechopen.79677" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=45-62&author=S.+E.+Kassabauthor=J.+Vaskova&author=L.+Vasko&title=Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.5772%2Fintechopen.79677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.5772%252Fintechopen.79677%26sid%3Dliteratum%253Aachs%26aulast%3DKassab%26aufirst%3DS.%2BE.%26atitle%3DIndomethacin%2520from%2520Anti-Inflammatory%2520to%2520Anticancer%2520Agent%26aulast%3DVaskova%26aufirst%3DJ.%26btitle%3DMedicinal%2520Chemistry%26pub%3DIntechOpen%2520Ltd%26date%3D2019%26spage%3D45%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leban, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeb, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgartner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel series of DHODH inhibitors by a docking procedure and QSAR refinement</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">55</span>â <span class="NLM_lpage">58</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2003.10.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmcl.2003.10.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=14684297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvVWntrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=55-58&issue=1&author=J.+Lebanauthor=W.+Saebauthor=G.+Garciaauthor=R.+Baumgartnerauthor=B.+Kramer&title=Discovery+of+a+novel+series+of+DHODH+inhibitors+by+a+docking+procedure+and+QSAR+refinement&doi=10.1016%2Fj.bmcl.2003.10.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel series of DHODH inhibitors by a docking procedure and QSAR refinement</span></div><div class="casAuthors">Leban, Johann; Saeb, Wael; Garcia, Gabriel; Baumgartner, Roland; Kramer, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-58</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A novel series of DHODH (dihydroorotate dehydrogenase) inhibitors was developed based on a lead which was obtained by a docking procedure and a medicinal chem. exploration.  The activity of the initial lead was improved by a QSAR method to yield low nanomolar inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqLL9ci_uixbVg90H21EOLACvtfcHk0liJgvGe6J8wQw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvVWntrk%253D&md5=74505a2e92654bf830a9376e4d2fa127</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.10.021%26sid%3Dliteratum%253Aachs%26aulast%3DLeban%26aufirst%3DJ.%26aulast%3DSaeb%26aufirst%3DW.%26aulast%3DGarcia%26aufirst%3DG.%26aulast%3DBaumgartner%26aufirst%3DR.%26aulast%3DKramer%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520series%2520of%2520DHODH%2520inhibitors%2520by%2520a%2520docking%2520procedure%2520and%2520QSAR%2520refinement%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26issue%3D1%26spage%3D55%26epage%3D58%26doi%3D10.1016%2Fj.bmcl.2003.10.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knecht, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loffler, M.</span></span> <span> </span><span class="NLM_article-title">Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1259</span>â <span class="NLM_lpage">1264</span>, <span class="refDoi">Â DOI: 10.1016/S0006-2952(98)00145-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2FS0006-2952%2898%2900145-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=9802339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK1cXnt1OhtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1998&pages=1259-1264&issue=9&author=W.+Knechtauthor=M.+Loffler&title=Species-related+inhibition+of+human+and+rat+dihydroorotate+dehydrogenase+by+immunosuppressive+isoxazol+and+cinchoninic+acid+derivatives&doi=10.1016%2FS0006-2952%2898%2900145-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives</span></div><div class="casAuthors">Knecht, Wolfgang; Loffler, Monika</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1259-1264</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The isoxazol leflunomide (N-(4-trifluoromethylphenyl)-5-methylisoxazol-4-carboxamide) and its active metabolite A77-1726 (N-(4-trifluoromethyl)-phenyl-2-cyano-3-hydroxy-crotonic acidamide) are promising disease-modifying antirheumatic drugs now in clin. trials.  The malononitrilamides MNA279 (2-cyano-3-cyclopropyl-3-oxo-(4-cyanophenyl)propionamide) MNA715 (N-(4-trifluoromethyl)-phenyl-2-cyano-3-hydroxy-hept-2-en-6-in-carboxylic acidamide) and HR325 (1(3-methyl-4-trifluoromethylphenyl-carbamoyl)-2-cyclopropyl-2-oxo-propionitrile) were shown to block rejection after allograft and xenograft transplantation in animals.  Brequinar and other cinchoninic acid derivs. have also been evaluated as immunosuppressive agents.  A77-1726, HR325 and brequinar have been shown to have strong inhibitory effects on mitochondrial dihydroorotate dehydrogenase [E.C. 1.3.99.11], the fourth enzyme of pyrimidine de novo synthesis, with concomitant redn. of pyrimidine nucleotide pools.  Pyrimidine nucleotides are essential for normal immune cell functions.  Because most investigations had been carried out with cells, cell homogenates or mitochondrial fractions, it was the rationale of the present study to differentiate, under standardized conditions, the effect of leflunomide, A77-1726, MNA279, MNA715, HR 325 and brequinar on the recombinant rat and human enzymes, which were purified in our lab.  Whereas leflunomide was a relatively weak inhibitor of the rat (IC50 = 6.3 Î¼M) and human (IC50 = 98 Î¼M) dihydroorotate dehydrogenase, the influence of A77-1726, MNA 279, MNA715 and HR325 was of comparable efficacy for either the rat (range of IC50, 19-53 nM) or the human enzyme (range of IC50, 0.5-2.3 Î¼M).  From the IC50 values, it was deduced that brequinar was a more potent inhibitor of the human dihydroorotate dehydrogenase activity (IC50 = 10 nM) than of the rat enzyme (IC50 = 367 nM).  The rat enzyme was influenced by all isoxazol derivs. to a greater extent (IC50 = 19 nM A77-1726) than the human enzyme (IC50 = 1.1 Î¼M A77-1726).  These results may provide a plausible explanation for the findings of other labs. with cultured cell lines and lymphocytes: in comparison to cells derived from human tissues, rat and other rodent cells were more susceptible to the isoxazol derivs. and less susceptible to brequinar.  Our detailed kinetic investigations of the bisubstrate reaction catalyzed by rat dihydroorotate dehydrogenase revealed a noncompetitive type of inhibition by A77-1726 with respect to the substrate dihydroorotate and the cosubstrates ubiquinone or decylubiquinone.  For brequinar, the inhibition was noncompetitive with respect to the substrate dihydroorotate, whereas with the quinone it was found to follow the "mixed typed" inhibition.  In addn., brequinar acted as a "slow-binding" inhibitor of the human dihydroorotate dehydrogenase, a feature that might be of consequence for the reversibility of the reaction with the target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9xUIPJ-l5JbVg90H21EOLACvtfcHk0lgXjSMr_f7yeA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnt1OhtLs%253D&md5=a653d5605568239d80f9fc1b2b992e84</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2898%2900145-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252898%252900145-2%26sid%3Dliteratum%253Aachs%26aulast%3DKnecht%26aufirst%3DW.%26aulast%3DLoffler%26aufirst%3DM.%26atitle%3DSpecies-related%2520inhibition%2520of%2520human%2520and%2520rat%2520dihydroorotate%2520dehydrogenase%2520by%2520immunosuppressive%2520isoxazol%2520and%2520cinchoninic%2520acid%2520derivatives%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1998%26volume%3D56%26issue%3D9%26spage%3D1259%26epage%3D1264%26doi%3D10.1016%2FS0006-2952%2898%2900145-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orsetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorba, G.</span></span> <span> </span><span class="NLM_article-title">Characterization of an accessory binding area in the histamine H2 receptor</span>. <i>Eur. J. Pharmacol., Mol. Pharmacol. Sect.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>206</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">167</span>â <span class="NLM_lpage">173</span>, <span class="refDoi">Â DOI: 10.1016/S0922-4106(05)80015-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2FS0922-4106%2805%2980015-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK3MXkt1aqsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=206&publication_year=1991&pages=167-173&issue=3&author=M.+Orsettiauthor=G.+Sorba&title=Characterization+of+an+accessory+binding+area+in+the+histamine+H2+receptor&doi=10.1016%2FS0922-4106%2805%2980015-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of an accessory binding area in the histamine H2 receptor</span></div><div class="casAuthors">Orsetti, Marco; Sorba, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology, Molecular Pharmacology Section</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">206</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">167-73</span>CODEN:
                <span class="NLM_cas:coden">EJPPET</span>;
        ISSN:<span class="NLM_cas:issn">0922-4106</span>.
    </div><div class="casAbstract">The histamine H2 receptor-blocking activity of ranitidine and lamitidine analogs was investigated to gain information on the structure of the receptor area adjacent to the site fitted by the polar group.  The introduction of differently shaped alkyl moieties on the polar group is always accompanied by maintenance or by an increase of H2 receptor antagonism with respect to the starting lead compd. (KB on guinea-pig isolated atria ranging 49-1.5 nM).  The results seem to indicate the presence in the histamine H2 receptor of an area of a predominantly hydrophobic nature located at the boundary of the site fitted by the polar group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaM3rx5pdTIbVg90H21EOLACvtfcHk0lgXjSMr_f7yeA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXkt1aqsrY%253D&md5=72e7c4a8a7a69851cb91da1e05fe8ebc</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0922-4106%2805%2980015-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0922-4106%252805%252980015-X%26sid%3Dliteratum%253Aachs%26aulast%3DOrsetti%26aufirst%3DM.%26aulast%3DSorba%26aufirst%3DG.%26atitle%3DCharacterization%2520of%2520an%2520accessory%2520binding%2520area%2520in%2520the%2520histamine%2520H2%2520receptor%26jtitle%3DEur.%2520J.%2520Pharmacol.%252C%2520Mol.%2520Pharmacol.%2520Sect.%26date%3D1991%26volume%3D206%26issue%3D3%26spage%3D167%26epage%3D173%26doi%3D10.1016%2FS0922-4106%2805%2980015-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorba, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruttero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Stilo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsetti, M.</span></span> <span> </span><span class="NLM_article-title">Potential histamine H2-Receptor antagonists: Synthesis and pharmacological activity of derivatives containing acylamino-furazan moieties</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>325</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">151</span>â <span class="NLM_lpage">155</span>, <span class="refDoi">Â DOI: 10.1002/ardp.19923250304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fardp.19923250304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1353669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK38XhvFChsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=325&publication_year=1992&pages=151-155&issue=3&author=G.+Sorbaauthor=R.+Frutteroauthor=A.+Di+Stiloauthor=A.+Gascoauthor=M.+Orsetti&title=Potential+histamine+H2-Receptor+antagonists%3A+Synthesis+and+pharmacological+activity+of+derivatives+containing+acylamino-furazan+moieties&doi=10.1002%2Fardp.19923250304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Potential histamine H2-receptor antagonists:  synthesis and pharmacological activity of derivatives containing (acylamino)furazan moieties</span></div><div class="casAuthors">Sorba, G.; Fruttero, R.; Di Stilo, A.; Gasco, A.; Orsetti, M.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">325</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">151-5</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    </div><div class="casAbstract">Analogs I [R = H, COR1, CH2R1; R1 = Me, Ph, C6H11, (CH2)2Ph; X = CO, CH2] of 3-amino-4[2-[(5-dimethylaminomethyl-2-furyl)methylthio]ethylamino]furazan have been synthesized and investigated for their H2-antagonist properties on the isolated guinea pig right atrium.  The presence of the carbonyl group lowers the activity in respect to the corresponding leads.  The decrease in activity is only by 1-2 orders of magnitude in the 3-acylaminofurazan series vs. inactivity in the 4-acylamino isomers and in the diacylated series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKT7nqN_h_tLVg90H21EOLACvtfcHk0lgXjSMr_f7yeA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhvFChsb4%253D&md5=16890fdb86fdf6ea78bba942e3526595</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1002%2Fardp.19923250304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.19923250304%26sid%3Dliteratum%253Aachs%26aulast%3DSorba%26aufirst%3DG.%26aulast%3DFruttero%26aufirst%3DR.%26aulast%3DDi%2BStilo%26aufirst%3DA.%26aulast%3DGasco%26aufirst%3DA.%26aulast%3DOrsetti%26aufirst%3DM.%26atitle%3DPotential%2520histamine%2520H2-Receptor%2520antagonists%253A%2520Synthesis%2520and%2520pharmacological%2520activity%2520of%2520derivatives%2520containing%2520acylamino-furazan%2520moieties%26jtitle%3DArch.%2520Pharm.%26date%3D1992%26volume%3D325%26issue%3D3%26spage%3D151%26epage%3D155%26doi%3D10.1002%2Fardp.19923250304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorba, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsetti, M.</span></span> <span> </span><span class="NLM_article-title">Potential histamine H2-receptor antagonists: Twin compounds containing diaminofurazan substructure</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>322</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">579</span>â <span class="NLM_lpage">580</span>, <span class="refDoi">Â DOI: 10.1002/ardp.19893220914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fardp.19893220914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=2575370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK3cXjsFOlug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=1989&pages=579-580&issue=9&author=G.+Sorbaauthor=A.+Gascoauthor=M.+Orsetti&title=Potential+histamine+H2-receptor+antagonists%3A+Twin+compounds+containing+diaminofurazan+substructure&doi=10.1002%2Fardp.19893220914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Potential histamine H2-receptor antagonists:  twin compounds containing diaminofurazan substructure</span></div><div class="casAuthors">Sorba, Giovanni; Gasco, Alberto; Orsetti, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">579-80</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    </div><div class="casAbstract">The title compds. I (n = 2, R = R4; n = 3, R = R2) were prepd.  I have antihistaminic activity, but are not competitive antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr50m03gJXunbVg90H21EOLACvtfcHk0lgTrWTK7vgFHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXjsFOlug%253D%253D&md5=a16c420ce4acd51c8ed754b0f6bf1361</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1002%2Fardp.19893220914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.19893220914%26sid%3Dliteratum%253Aachs%26aulast%3DSorba%26aufirst%3DG.%26aulast%3DGasco%26aufirst%3DA.%26aulast%3DOrsetti%26aufirst%3DM.%26atitle%3DPotential%2520histamine%2520H2-receptor%2520antagonists%253A%2520Twin%2520compounds%2520containing%2520diaminofurazan%2520substructure%26jtitle%3DArch.%2520Pharm.%26date%3D1989%26volume%3D322%26issue%3D9%26spage%3D579%26epage%3D580%26doi%3D10.1002%2Fardp.19893220914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorba, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsetti, M.</span></span> <span> </span><span class="NLM_article-title">Potential histamine H2-receptor antagonists: Synthesis and pharmacological activity of derivatives containing 3-alkylamino-4-amino-furazan moieties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">475</span>â <span class="NLM_lpage">478</span>, <span class="refDoi">Â DOI: 10.1016/0223-5234(89)90050-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2F0223-5234%2889%2990050-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK3cXkt1ekur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1989&pages=475-478&issue=5&author=G.+Sorbaauthor=A.+Gascoauthor=M.+Orsetti&title=Potential+histamine+H2-receptor+antagonists%3A+Synthesis+and+pharmacological+activity+of+derivatives+containing+3-alkylamino-4-amino-furazan+moieties&doi=10.1016%2F0223-5234%2889%2990050-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Potential histamine H2-receptor antagonists:  synthesis and pharmacological activity of derivatives containing 3-alkylamino-4-aminofurazan moieties</span></div><div class="casAuthors">Sorba, Giovanni; Gasco, Alberto; Orsetti, Marco</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">475-8</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    </div><div class="casAbstract">A series of furylmethylthioethylaminofurazans I [R = Me, Et, CHMe2, CMe3, Ph, (CH2)2Ph, cyclohexyl] were prepd. and tested for their H2-antagonist activities on guinea pig right atrium.  A no. of differently shaped alkyl substituents on the terminal 3-amino group were favorable for activity.  The most potent compd. was I (R = cyclohexyl).  Most I showed noncompetitive antagonism at histamine H1 and muscarinic receptors at concns. approx. 100 times higher than those producing competitive H2-receptor block.  This finding suggests that there is an accessorial binding area on H2-receptor near the site fitted by the diaminofurazan moiety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-pYI8Rx1dmbVg90H21EOLACvtfcHk0lgTrWTK7vgFHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXkt1ekur8%253D&md5=d87ba493fa1c50663b177e18cfca1eee</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2F0223-5234%2889%2990050-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0223-5234%252889%252990050-0%26sid%3Dliteratum%253Aachs%26aulast%3DSorba%26aufirst%3DG.%26aulast%3DGasco%26aufirst%3DA.%26aulast%3DOrsetti%26aufirst%3DM.%26atitle%3DPotential%2520histamine%2520H2-receptor%2520antagonists%253A%2520Synthesis%2520and%2520pharmacological%2520activity%2520of%2520derivatives%2520containing%25203-alkylamino-4-amino-furazan%2520moieties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D1989%26volume%3D24%26issue%3D5%26spage%3D475%26epage%3D478%26doi%3D10.1016%2F0223-5234%2889%2990050-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">United States Food and Drug Administration</span>. <span> </span><span class="NLM_article-title">FDA Requests Removal of All Ranitidine
Products
(Zantac) From the Market</span>, April 1, 2020. <a href="https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=United+States+Food+and+Drug+Administration.+FDA+Requests+Removal+of+All+Ranitidine%0AProducts%0A%28Zantac%29+From+the+Market%2C+April+1%2C+2020.+https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-requests-removal-all-ranitidine-products-zantac-market."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DFDA%2520Requests%2520Removal%2520of%2520All%2520Ranitidine%250AProducts%250A%2528Zantac%2529%2520From%2520the%2520Market" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shanmugam, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishayee, A.</span></span> <span> </span><span class="NLM_article-title">Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: preclinical and clinical evidence</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>346</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">206</span>â <span class="NLM_lpage">216</span>, <span class="refDoi">Â DOI: 10.1016/j.canlet.2014.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.canlet.2014.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=24486850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjslKjtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2014&pages=206-216&issue=2&author=M.+K.+Shanmugamauthor=X.+Daiauthor=A.+P.+Kumarauthor=B.+K.+Tanauthor=G.+Sethiauthor=A.+Bishayee&title=Oleanolic+acid+and+its+synthetic+derivatives+for+the+prevention+and+therapy+of+cancer%3A+preclinical+and+clinical+evidence&doi=10.1016%2Fj.canlet.2014.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: Preclinical and clinical evidence</span></div><div class="casAuthors">Shanmugam, Muthu K.; Dai, Xiaoyun; Kumar, Alan Prem; Tan, Benny K. H.; Sethi, Gautam; Bishayee, Anupam</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">206-216</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Oleanolic acid (OA, 3Î²-hydroxyolean-12-en-28-oic acid) is a ubiquitous pentacyclic multifunctional triterpenoid, widely found in several dietary and medicinal plants.  Natural and synthetic OA derivs. can modulate multiple signaling pathways including nuclear factor-ÎºB, AKT, signal transducer and activator of transcription 3, mammalian target of rapamycin, caspases, intercellular adhesion mol. 1, vascular endothelial growth factor, and poly (ADP-ribose) polymerase in a variety of tumor cells.  Importantly, synthetic deriv. of OA, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO), and its C-28 Me ester (CDDO-Me) and C28 imidazole (CDDO-Im) have demonstrated potent antiangiogenic and antitumor activities in rodent cancer models.  These agents are presently under evaluation in phase I studies in cancer patients.  This review summarizes the diverse mol. targets of OA and its derivs. and also provides clear evidence on their promising potential in preclin. and clin. situations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6PpXjnkzuRLVg90H21EOLACvtfcHk0lgTrWTK7vgFHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjslKjtLs%253D&md5=defced39e69d9bf7310d7e609fcafb8f</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2014.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2014.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DShanmugam%26aufirst%3DM.%2BK.%26aulast%3DDai%26aufirst%3DX.%26aulast%3DKumar%26aufirst%3DA.%2BP.%26aulast%3DTan%26aufirst%3DB.%2BK.%26aulast%3DSethi%26aufirst%3DG.%26aulast%3DBishayee%26aufirst%3DA.%26atitle%3DOleanolic%2520acid%2520and%2520its%2520synthetic%2520derivatives%2520for%2520the%2520prevention%2520and%2520therapy%2520of%2520cancer%253A%2520preclinical%2520and%2520clinical%2520evidence%26jtitle%3DCancer%2520Lett.%26date%3D2014%26volume%3D346%26issue%3D2%26spage%3D206%26epage%3D216%26doi%3D10.1016%2Fj.canlet.2014.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ng, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, N. Y.</span></span> <span> </span><span class="NLM_article-title">Olean-12-eno[2,3-c] [1,2,5]oxadiazol-28-oic acid (OEOA) induces G1 cell cycle arrest and differentiation in human leukemia cell lines</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">e63580</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0063580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1371%2Fjournal.pone.0063580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=23696836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosFGjsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e63580&issue=5&author=Y.+P.+Ngauthor=Y.+Chenauthor=Y.+Huauthor=F.+C.+Ipauthor=N.+Y.+Ip&title=Olean-12-eno%5B2%2C3-c%5D+%5B1%2C2%2C5%5Doxadiazol-28-oic+acid+%28OEOA%29+induces+G1+cell+cycle+arrest+and+differentiation+in+human+leukemia+cell+lines&doi=10.1371%2Fjournal.pone.0063580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Olean-12-eno[2,3-c] [1,2,5]oxadiazol-28-oic acid (OEOA) induces G1 cell cycle arrest and differentiation in human leukemia cell lines</span></div><div class="casAuthors">Ng, Yu Pong; Chen, Yuewen; Hu, Yueqing; Ip, Fanny C. F.; Ip, Nancy Y.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e63580</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Oleanolic acid (3Î²-hydroxy-olea-12-en-28-oic acid) is a natural pentacyclic triterpenoic acid found in many fruits, herbs and medicinal plants.  In the past decade, increasing evidence has suggested that oleanolic acid exhibits inhibitory activities against different types of cancer including skin cancer and colon cancer, but not leukemia.  We report here that a deriv. of oleanolic acid, olean-12-eno[2,3-c] [1,2,5] oxadiazol-28-oic acid (designated OEOA) effectively blocks the proliferation of human leukemia cells.  OEOA significantly reduces cell proliferation without inducing cell death in three types of leukemia cell lines, including K562, HEL and Jurket.  Moreover, exposure of K562 cells to OEOA results in G1 cell cycle arrest, with a concomitant induction of cyclin-dependent kinase inhibitor p27 and downregulation of cyclins and Cdks that are essential for cell cycle progression.  Interestingly, OEOA also enhances erythroid differentiation in K562 cells through suppressing the expression of Bcr-Abl and phosphorylation of Erk1/2.  These findings identify a novel chem. entity for further development as therapeutics against leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTEIwoVGzOpLVg90H21EOLACvtfcHk0lgbrp-3euo-gQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosFGjsL4%253D&md5=2e4c907176471bf0aadbc6a9ad6c41da</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0063580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0063580%26sid%3Dliteratum%253Aachs%26aulast%3DNg%26aufirst%3DY.%2BP.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DIp%26aufirst%3DF.%2BC.%26aulast%3DIp%26aufirst%3DN.%2BY.%26atitle%3DOlean-12-eno%255B2%252C3-c%255D%2520%255B1%252C2%252C5%255Doxadiazol-28-oic%2520acid%2520%2528OEOA%2529%2520induces%2520G1%2520cell%2520cycle%2520arrest%2520and%2520differentiation%2520in%2520human%2520leukemia%2520cell%2520lines%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26issue%3D5%26spage%3De63580%26doi%3D10.1371%2Fjournal.pone.0063580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ono, K.</span></span> <span> </span><span class="NLM_article-title">Alzheimerâs disease as oligomeropathy</span>. <i>Neurochem. Int.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">57</span>â <span class="NLM_lpage">70</span>, <span class="refDoi">Â DOI: 10.1016/j.neuint.2017.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.neuint.2017.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28821400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKmsrrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2018&pages=57-70&author=K.+Ono&title=Alzheimer%E2%80%99s+disease+as+oligomeropathy&doi=10.1016%2Fj.neuint.2017.08.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's disease as oligomeropathy</span></div><div class="casAuthors">Ono, Kenjiro</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemistry International</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">57-70</span>CODEN:
                <span class="NLM_cas:coden">NEUIDS</span>;
        ISSN:<span class="NLM_cas:issn">0197-0186</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder and is characterized by pathol. aggregates of amyloid Î²-protein (AÎ²) and tau protein.  On the basis of genetic evidence, biochem. data, and animal models, AÎ² has been suggested to be responsible for the pathogenesis of AD (the amyloid hypothesis).  AÎ² mols. tend to aggregate to form oligomers, protofibrils, and mature fibrils.  Although mature fibrils in the final stage have been thought to be the cause of AD pathogenesis, recent studies using synthetic AÎ² peptides, a cell culture model, AÎ² precursor protein transgenic mice models, and human samples, such as cerebrospinal fluids and postmortem brains of AD patients, suggest that pre-fibrillar forms (oligomers of AÎ²) are more deleterious than are extracellular fibril forms.  Based on this recent evidence showing that oligomers have a central role in the pathogenesis of AD, the term "oligomeropathy" could be used to define AD and other protein-misfolding diseases.  In this review, I discuss recent developments in the "oligomer hypothesis" including our research findings regarding the pathogenesis of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd8CTHdB3lfrVg90H21EOLACvtfcHk0lgbrp-3euo-gQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKmsrrF&md5=d690b3f9fc2b18f091dfd82d5e9682fb</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.neuint.2017.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuint.2017.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DOno%26aufirst%3DK.%26atitle%3DAlzheimer%25E2%2580%2599s%2520disease%2520as%2520oligomeropathy%26jtitle%3DNeurochem.%2520Int.%26date%3D2018%26volume%3D119%26spage%3D57%26epage%3D70%26doi%3D10.1016%2Fj.neuint.2017.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bose, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maois, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, G. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robitaille, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drapeau, P.</span></span> <span> </span><span class="NLM_article-title">The novel small molecule TRVA242 stabilizes neuromuscular junction defects in multiple animal models of amyotrophic lateral sclerosis</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1149</span>â <span class="NLM_lpage">1166</span>, <span class="refDoi">Â DOI: 10.1007/s13311-019-00765-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1007%2Fs13311-019-00765-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=31342410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVeqsr3E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=1149-1166&issue=4&author=P.+Boseauthor=E.+Tremblayauthor=C.+Maoisauthor=V.+Narasimhanauthor=G.+A.+B.+Armstrongauthor=M.+Liaoauthor=J.+A.+Parkerauthor=R.+Robitailleauthor=X.+Y.+Wenauthor=C.+Bardenauthor=P.+Drapeau&title=The+novel+small+molecule+TRVA242+stabilizes+neuromuscular+junction+defects+in+multiple+animal+models+of+amyotrophic+lateral+sclerosis&doi=10.1007%2Fs13311-019-00765-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">The Novel Small Molecule TRVA242 Stabilizes Neuromuscular Junction Defects in Multiple Animal Models of Amyotrophic Lateral Sclerosis</span></div><div class="casAuthors">Bose, Poulomee; Tremblay, Elsa; Maois, Claudia; Narasimhan, Vijay; Armstrong, Gary A. B.; Liao, Meijiang; Parker, J. Alex; Robitaille, Richard; Wen, Xiao Yan; Barden, Christopher; Drapeau, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1149-1166</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disorder in which the neuromuscular junction progressively degenerates, leading to movement difficulties, paralysis, and eventually death.  ALS is currently being treated by only two FDA-approved drugs with modest efficacy in slowing disease progression.  Often, the translation of preclin. findings to bedside terminates prematurely as the evaluation of potential therapeutic compds. focuses on a single study or a single animal model.  To circumscribe these issues, we screened 3,765 novel small mol. derivs. of pimozide, a recently identified repurposed neuroleptic for ALS, in Caenorhabditis elegans, confirmed the hits in zebrafish and validated the most active compds. in mouse genetic models.  Out of the 27 small mols. identified from the high-throughput screen in worms, 4 were found to recover locomotor defects in C. elegans and genetic zebrafish models of ALS.  TRVA242 was identified as the most potent compd. as it significantly improved efficiency in rescuing locomotor, motorneuron, and neuromuscular junction synaptic deficits in a C. elegans TDP-43 model and in multiple zebrafish genetic (TDP-43, SOD1, and C9ORF72) models of ALS.  The actions of TRVA242 were also conserved in a mammalian model as it also stabilized neuromuscular junction deficits in a mouse SOD1 model of ALS.  Compds. such as TRVA242 therefore represent new potential therapeutics for the treatment of ALS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCkmo2vCx997Vg90H21EOLACvtfcHk0lgbrp-3euo-gQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVeqsr3E&md5=763dbc5da05832578672ce87b45c755d</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1007%2Fs13311-019-00765-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-019-00765-w%26sid%3Dliteratum%253Aachs%26aulast%3DBose%26aufirst%3DP.%26aulast%3DTremblay%26aufirst%3DE.%26aulast%3DMaois%26aufirst%3DC.%26aulast%3DNarasimhan%26aufirst%3DV.%26aulast%3DArmstrong%26aufirst%3DG.%2BA.%2BB.%26aulast%3DLiao%26aufirst%3DM.%26aulast%3DParker%26aufirst%3DJ.%2BA.%26aulast%3DRobitaille%26aufirst%3DR.%26aulast%3DWen%26aufirst%3DX.%2BY.%26aulast%3DBarden%26aufirst%3DC.%26aulast%3DDrapeau%26aufirst%3DP.%26atitle%3DThe%2520novel%2520small%2520molecule%2520TRVA242%2520stabilizes%2520neuromuscular%2520junction%2520defects%2520in%2520multiple%2520animal%2520models%2520of%2520amyotrophic%2520lateral%2520sclerosis%26jtitle%3DNeurotherapeutics%26date%3D2019%26volume%3D16%26issue%3D4%26spage%3D1149%26epage%3D1166%26doi%3D10.1007%2Fs13311-019-00765-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G.</span>; <span class="NLM_string-name">Chesworth, R.</span></span> <span> </span><span class="NLM_article-title">1,3,4-Trisubstituted Benzenes as Î³-Secretase Inhibitors and their Preparation and Use in the Treatment of Neurodegenerative Diseases</span>. <span class="NLM_patent">WO2009036428A2</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=G.+Shapiro&author=R.+Chesworth&title=1%2C3%2C4-Trisubstituted+Benzenes+as+%CE%B3-Secretase+Inhibitors+and+their+Preparation+and+Use+in+the+Treatment+of+Neurodegenerative+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DG.%26atitle%3D1%252C3%252C4-Trisubstituted%2520Benzenes%2520as%2520%25CE%25B3-Secretase%2520Inhibitors%2520and%2520their%2520Preparation%2520and%2520Use%2520in%2520the%2520Treatment%2520of%2520Neurodegenerative%2520Diseases%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G.</span>; <span class="NLM_string-name">Chesworth, R.</span></span> <span> </span><span class="NLM_article-title">Preparation of Tetrasubstituted Benzenes as Î³-Secretase Modulators for Treating Alzheimerâs Disease</span>. <span class="NLM_patent">WO2009086277A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=G.+Shapiro&author=R.+Chesworth&title=Preparation+of+Tetrasubstituted+Benzenes+as+%CE%B3-Secretase+Modulators+for+Treating+Alzheimer%E2%80%99s+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DG.%26atitle%3DPreparation%2520of%2520Tetrasubstituted%2520Benzenes%2520as%2520%25CE%25B3-Secretase%2520Modulators%2520for%2520Treating%2520Alzheimer%25E2%2580%2599s%2520Disease%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, G.</span>; <span class="NLM_string-name">Blain, J.-F.</span></span> <span> </span><span class="NLM_article-title">Preparation of Tetrasubstituted Benzenes for Treatment of Early Onset Alzheimerâs Disease</span>. <span class="NLM_patent">WO2013106328A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=G.+Koenig&author=J.-F.+Blain&title=Preparation+of+Tetrasubstituted+Benzenes+for+Treatment+of+Early+Onset+Alzheimer%E2%80%99s+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKoenig%26aufirst%3DG.%26atitle%3DPreparation%2520of%2520Tetrasubstituted%2520Benzenes%2520for%2520Treatment%2520of%2520Early%2520Onset%2520Alzheimer%25E2%2580%2599s%2520Disease%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felsenstein, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrdlicka, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albayya, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spaulding, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgdon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blain, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Strooper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulsteke, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scrocchi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zetterberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portelius, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutter-Paier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahlijanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flood, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leventhal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patzke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesworth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, G.</span></span> <span> </span><span class="NLM_article-title">Modulation of Î³-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice</span>. <i>Mol. Neurodegener.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">61</span>, <span class="refDoi">Â DOI: 10.1186/1750-1326-7-61</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1186%2F1750-1326-7-61" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=23249765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFyqt78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=61&issue=1&author=K.+Rogersauthor=K.+M.+Felsensteinauthor=L.+Hrdlickaauthor=Z.+Tuauthor=F.+Albayyaauthor=W.+Leeauthor=S.+Hoppauthor=M.-J.+Millerauthor=D.+Spauldingauthor=Z.+Yangauthor=H.+Hodgdonauthor=S.+Nolanauthor=M.+Wenauthor=D.+Costaauthor=J.-F.+Blainauthor=E.+Freemanauthor=B.+De+Strooperauthor=V.+Vulstekeauthor=L.+Scrocchiauthor=H.+Zetterbergauthor=E.+Porteliusauthor=B.+Hutter-Paierauthor=D.+Havasauthor=M.+Ahlijanianauthor=D.+Floodauthor=L.+Leventhalauthor=G.+Shapiroauthor=H.+Patzkeauthor=R.+Chesworthauthor=G.+Koenig&title=Modulation+of+%CE%B3-secretase+by+EVP-0015962+reduces+amyloid+deposition+and+behavioral+deficits+in+Tg2576+mice&doi=10.1186%2F1750-1326-7-61"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of Î³-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice</span></div><div class="casAuthors">Rogers, Kathryn; Felsenstein, Kevin M.; Hrdlicka, Lori; Tu, Zhiming; Albayya, Faris; Lee, Winnie; Hopp, Sarah; Miller, Mary-Jo; Spaulding, Darcie; Yang, Zhiyong; Hodgdon, Hilliary; Nolan, Scott; Wen, Melody; Costa, Don; Blain, Jean-Francois; Freeman, Emily; De Strooper, Bart; Vulsteke, Veerle; Scrocchi, Louise; Zetterberg, Henrik; Portelius, Erik; Hutter-Paier, Birgit; Havas, Daniel; Ahlijanian, Michael; Flood, Dorothy; Leventhal, Liza; Shapiro, Gideon; Patzke, Holger; Chesworth, Richard; Koenig, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurodegeneration</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">61</span>CODEN:
                <span class="NLM_cas:coden">MNOEAZ</span>;
        ISSN:<span class="NLM_cas:issn">1750-1326</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: A hallmark of Alzheimer's disease is the presence of senile plaques in human brain primarily contg. the amyloid peptides AÎ²42 and AÎ²40.  Many drug discovery efforts have focused on decreasing the prodn. of AÎ²42 through Î³-secretase inhibition.  However, identification of Î³-secretase inhibitors has also uncovered mechanism-based side effects.  One approach to circumvent these side effects has been modulation of Î³-secretase to shift AÎ² prodn. to favor shorter, less amyloidogenic peptides than AÎ²42, without affecting the overall cleavage efficiency of the enzyme.  This approach, frequently called Î³-secretase modulation, appears more promising and has lead to the development of new therapeutic candidates for disease modification in Alzheimer's disease.  Results: Here we describe EVP-0015962, a novel small mol. Î³-secretase modulator.  EVP-0015962 decreased AÎ²42 in H4 cells (IC50 = 67 nM) and increased the shorter AÎ²38 by 1.7 fold at the IC50 for lowering of AÎ²42.  AÎ²Total, as well as other carboxyl-terminal fragments of amyloid precursor protein, were not changed.  EVP-0015962 did not cause the accumulation of other Î³-secretase substrates, such as the Notch and ephrin A4 receptors, whereas a Î³-secretase inhibitor reduced processing of both.  A single oral dose of EVP-0015962 (30 mg/kg) decreased AÎ²42 and did not alter AÎ²Total peptide levels in a dose-dependent manner in Tg2576 mouse brain at an age when overt AÎ² deposition was not present.  In Tg2576 mice, chronic treatment with EVP-0015962 (20 or 60 mg/kg/day in a food formulation) reduced AÎ² aggregates, amyloid plaques, inflammatory markers and cognitive deficits.  Conclusions: EVP-0015962 is orally bioavailable, detected in brain and a potent, selective Î³-secretase modulator in vitro and in vivo.  Chronic treatment with EVP-0015962 was well tolerated in mice and lowered the prodn. of AÎ²42, attenuated memory deficits and reduced AÎ² plaque formation and inflammation in Tg2576 transgenic animals.  In summary, these data suggest that Î³-secretase modulation with EVP-0015962 represents a viable therapeutic alternative for disease modification in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrawar6w5ZKrrVg90H21EOLACvtfcHk0lioLR29GLbS0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFyqt78%253D&md5=cc1497b9c84ac2a5de368c81d99789c6</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1186%2F1750-1326-7-61&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1750-1326-7-61%26sid%3Dliteratum%253Aachs%26aulast%3DRogers%26aufirst%3DK.%26aulast%3DFelsenstein%26aufirst%3DK.%2BM.%26aulast%3DHrdlicka%26aufirst%3DL.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DAlbayya%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DHopp%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DM.-J.%26aulast%3DSpaulding%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DHodgdon%26aufirst%3DH.%26aulast%3DNolan%26aufirst%3DS.%26aulast%3DWen%26aufirst%3DM.%26aulast%3DCosta%26aufirst%3DD.%26aulast%3DBlain%26aufirst%3DJ.-F.%26aulast%3DFreeman%26aufirst%3DE.%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26aulast%3DVulsteke%26aufirst%3DV.%26aulast%3DScrocchi%26aufirst%3DL.%26aulast%3DZetterberg%26aufirst%3DH.%26aulast%3DPortelius%26aufirst%3DE.%26aulast%3DHutter-Paier%26aufirst%3DB.%26aulast%3DHavas%26aufirst%3DD.%26aulast%3DAhlijanian%26aufirst%3DM.%26aulast%3DFlood%26aufirst%3DD.%26aulast%3DLeventhal%26aufirst%3DL.%26aulast%3DShapiro%26aufirst%3DG.%26aulast%3DPatzke%26aufirst%3DH.%26aulast%3DChesworth%26aufirst%3DR.%26aulast%3DKoenig%26aufirst%3DG.%26atitle%3DModulation%2520of%2520%25CE%25B3-secretase%2520by%2520EVP-0015962%2520reduces%2520amyloid%2520deposition%2520and%2520behavioral%2520deficits%2520in%2520Tg2576%2520mice%26jtitle%3DMol.%2520Neurodegener.%26date%3D2012%26volume%3D7%26issue%3D1%26spage%3D61%26doi%3D10.1186%2F1750-1326-7-61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kohara, T.</span>; <span class="NLM_string-name">Fukunaga, K.</span>; <span class="NLM_string-name">Fujimura, M.</span>; <span class="NLM_string-name">Hanano, T.</span>; <span class="NLM_string-name">Okabe, H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Dihydropyrazolopyridines and Pharmaceutical Use Based on Strong and Selective Inhibition of Glycogen Synthase Kinase-3 Beta</span>. <span class="NLM_patent">WO2002062795A2</span>, <span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=T.+Kohara&author=K.+Fukunaga&author=M.+Fujimura&author=T.+Hanano&author=H.+Okabe&title=Preparation+of+Dihydropyrazolopyridines+and+Pharmaceutical+Use+Based+on+Strong+and+Selective+Inhibition+of+Glycogen+Synthase+Kinase-3+Beta"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKohara%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520Dihydropyrazolopyridines%2520and%2520Pharmaceutical%2520Use%2520Based%2520on%2520Strong%2520and%2520Selective%2520Inhibition%2520of%2520Glycogen%2520Synthase%2520Kinase-3%2520Beta%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kohara, T.</span>; <span class="NLM_string-name">Fukunaga, K.</span>; <span class="NLM_string-name">Fujimura, M.</span>; <span class="NLM_string-name">Hanano, T.</span>; <span class="NLM_string-name">Okabe, H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Dihydropyrazolopyridine Derivatives as GSK-3Î² Inhibitors</span>. <span class="NLM_patent">US20040052822A1</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=T.+Kohara&author=K.+Fukunaga&author=M.+Fujimura&author=T.+Hanano&author=H.+Okabe&title=Preparation+of+Dihydropyrazolopyridine+Derivatives+as+GSK-3%CE%B2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKohara%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520Dihydropyrazolopyridine%2520Derivatives%2520as%2520GSK-3%25CE%25B2%2520Inhibitors%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kohara, T.</span>; <span class="NLM_string-name">Fukunaga, K.</span>; <span class="NLM_string-name">Hanano, T.</span></span> <span> </span><span class="NLM_article-title">Preparation of Dihydropyrazolopyridines as Glycogen Synthase Kinase-3Î² (GSK-3Î²) Inhibitors</span>. <span class="NLM_patent">WO2004014910A1</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=T.+Kohara&author=K.+Fukunaga&author=T.+Hanano&title=Preparation+of+Dihydropyrazolopyridines+as+Glycogen+Synthase+Kinase-3%CE%B2+%28GSK-3%CE%B2%29+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKohara%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520Dihydropyrazolopyridines%2520as%2520Glycogen%2520Synthase%2520Kinase-3%25CE%25B2%2520%2528GSK-3%25CE%25B2%2529%2520Inhibitors%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukunaga, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aritomo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamakoshi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamagami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baba, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, M.</span></span> <span> </span><span class="NLM_article-title">2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3beta inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">6933</span>â <span class="NLM_lpage">6937</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2013.09.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmcl.2013.09.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=24176395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1yqt7vL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=6933-6937&issue=24&author=K.+Fukunagaauthor=F.+Ueharaauthor=K.+Aritomoauthor=A.+Shodaauthor=S.+Hikiauthor=M.+Okuyamaauthor=Y.+Usuiauthor=K.+Watanabeauthor=K.+Yamakoshiauthor=T.+Koharaauthor=T.+Hananoauthor=H.+Tanakaauthor=S.+Tsuchiyaauthor=S.+Sunadaauthor=K.+Saitoauthor=J.+Eguchiauthor=S.+Yukiauthor=S.+Asanoauthor=S.+Tanakaauthor=A.+Moriauthor=K.+Yamagamiauthor=H.+Babaauthor=T.+Horikawaauthor=M.+Fujimura&title=2-%282-Phenylmorpholin-4-yl%29pyrimidin-4%283H%29-ones%3B+a+new+class+of+potent%2C+selective+and+orally+active+glycogen+synthase+kinase-3beta+inhibitors&doi=10.1016%2Fj.bmcl.2013.09.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; A new class of potent, selective and orally active glycogen synthase kinase-3Î² inhibitors</span></div><div class="casAuthors">Fukunaga, Kenji; Uehara, Fumiaki; Aritomo, Keiichi; Shoda, Aya; Hiki, Shinsuke; Okuyama, Masahiro; Usui, Yoshihiro; Watanabe, Kazutoshi; Yamakoshi, Koichi; Kohara, Toshiyuki; Hanano, Tokushi; Tanaka, Hiroshi; Tsuchiya, Susumu; Sunada, Shinji; Saito, Ken-Ichi; Eguchi, Jun-ichi; Yuki, Satoshi; Asano, Shoichi; Tanaka, Shinji; Mori, Akiko; Yamagami, Keiji; Baba, Hiroshi; Horikawa, Takashi; Fujimura, Masatake</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6933-6937</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 2-(2-phenylmorpholin-4-yl)pyrimidin-4(3H)-ones was synthesized and examd. for their inhibitory activity against glycogen synthase kinase-3Î² (GSK-3Î²).  We found compds. I (R = 4-F (II), 2,6-di-OMe, 2-F-6-Cl) to possess potent in vitro GSK-3Î² inhibitory activity with good in vitro PK profiles.  Compd. II demonstrated significant decrease of tau phosphorylation after oral administration in mice and excellent PK profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9woxQA77rTbVg90H21EOLACvtfcHk0ljzK-YU9MBPYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1yqt7vL&md5=6c8bc95e0ccb21078aff1837d83e649e</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.09.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.09.020%26sid%3Dliteratum%253Aachs%26aulast%3DFukunaga%26aufirst%3DK.%26aulast%3DUehara%26aufirst%3DF.%26aulast%3DAritomo%26aufirst%3DK.%26aulast%3DShoda%26aufirst%3DA.%26aulast%3DHiki%26aufirst%3DS.%26aulast%3DOkuyama%26aufirst%3DM.%26aulast%3DUsui%26aufirst%3DY.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DYamakoshi%26aufirst%3DK.%26aulast%3DKohara%26aufirst%3DT.%26aulast%3DHanano%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DTsuchiya%26aufirst%3DS.%26aulast%3DSunada%26aufirst%3DS.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DEguchi%26aufirst%3DJ.%26aulast%3DYuki%26aufirst%3DS.%26aulast%3DAsano%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DS.%26aulast%3DMori%26aufirst%3DA.%26aulast%3DYamagami%26aufirst%3DK.%26aulast%3DBaba%26aufirst%3DH.%26aulast%3DHorikawa%26aufirst%3DT.%26aulast%3DFujimura%26aufirst%3DM.%26atitle%3D2-%25282-Phenylmorpholin-4-yl%2529pyrimidin-4%25283H%2529-ones%253B%2520a%2520new%2520class%2520of%2520potent%252C%2520selective%2520and%2520orally%2520active%2520glycogen%2520synthase%2520kinase-3beta%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D24%26spage%3D6933%26epage%3D6937%26doi%3D10.1016%2Fj.bmcl.2013.09.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span>; <span class="NLM_string-name">Uehara, F.</span>; <span class="NLM_string-name">Hiki, S.</span>; <span class="NLM_string-name">Kohara, T.</span>; <span class="NLM_string-name">Fukunaga, K.</span>; <span class="NLM_string-name">Yokoshima, S.</span></span> <span> </span><span class="NLM_article-title">2-Morpholino-4-Pyrimidinones as Tau Protein Kinase 1 Inhibitors, their Preparation, Pharmaceutical Compositions, and Use in Therapy</span>. <span class="NLM_patent">WO2006028290A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=K.+Watanabe&author=F.+Uehara&author=S.+Hiki&author=T.+Kohara&author=K.+Fukunaga&author=S.+Yokoshima&title=2-Morpholino-4-Pyrimidinones+as+Tau+Protein+Kinase+1+Inhibitors%2C+their+Preparation%2C+Pharmaceutical+Compositions%2C+and+Use+in+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DK.%26atitle%3D2-Morpholino-4-Pyrimidinones%2520as%2520Tau%2520Protein%2520Kinase%25201%2520Inhibitors%252C%2520their%2520Preparation%252C%2520Pharmaceutical%2520Compositions%252C%2520and%2520Use%2520in%2520Therapy%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griebel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stemmelin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Grancha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boquet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slowinski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeske, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eguchi, J.</span></span> <span> </span><span class="NLM_article-title">The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimerâs disease in rodents</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">18045</span>, <span class="refDoi">Â DOI: 10.1038/s41598-019-54557-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2Fs41598-019-54557-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=31792284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlWkur7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=18045&issue=1&author=G.+Griebelauthor=J.+Stemmelinauthor=M.+Lopez-Granchaauthor=D.+Boulayauthor=G.+Boquetauthor=F.+Slowinskiauthor=P.+Pichatauthor=S.+Beeskeauthor=S.+Tanakaauthor=A.+Moriauthor=M.+Fujimuraauthor=J.+Eguchi&title=The+selective+GSK3+inhibitor%2C+SAR502250%2C+displays+neuroprotective+activity+and+attenuates+behavioral+impairments+in+models+of+neuropsychiatric+symptoms+of+Alzheimer%E2%80%99s+disease+in+rodents&doi=10.1038%2Fs41598-019-54557-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer's disease in rodents</span></div><div class="casAuthors">Griebel, Guy; Stemmelin, Jeanne; Lopez-Grancha, Mati; Boulay, Denis; Boquet, Gerald; Slowinski, Franck; Pichat, Philippe; Beeske, Sandra; Tanaka, Shinji; Mori, Akiko; Fujimura, Masatake; Eguchi, Junichi</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">18045</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3 (GSK3) has been identified as a promising target for the treatment of Alzheimer's disease (AD), where abnormal activation of this enzyme has been assocd. with hyperphosphorylation of tau proteins.  This study describes the effects of the selective GSK3 inhibitor, SAR502250, in models of neuroprotection and neuropsychiatric symptoms (NPS) assocd. with AD.  In P301L human tau transgenic mice, SAR502250 attenuated tau hyperphosphorylation in the cortex and spinal cord.  SAR502250 prevented the increase in neuronal cell death in rat embryonic hippocampal neurons following application of the neurotoxic peptide, AÎ²25-35.  In behavioral studies, SAR502250 improved the cognitive deficit in aged transgenic APP(SW)/Tau(VLW) mice or in adult mice after infusion of AÎ² 25-35.  It attenuated aggression in the mouse defense test battery and improved depressive-like state of mice in the chronic mild stress procedure after 4 wk of treatment.  Moreover, SAR502250 decreased hyperactivity produced by psychostimulants.  In contrast, the drug failed to modify anxiety-related behaviors or sensorimotor gating deficit.  This profile confirms the neuroprotective effects of GSK3 inhibitors and suggests an addnl. potential in the treatment of some NPS assocd. with AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgVqMhUSJZI7Vg90H21EOLACvtfcHk0ljzK-YU9MBPYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlWkur7E&md5=3573c37862802bb661aa83750529be88</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-54557-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-54557-5%26sid%3Dliteratum%253Aachs%26aulast%3DGriebel%26aufirst%3DG.%26aulast%3DStemmelin%26aufirst%3DJ.%26aulast%3DLopez-Grancha%26aufirst%3DM.%26aulast%3DBoulay%26aufirst%3DD.%26aulast%3DBoquet%26aufirst%3DG.%26aulast%3DSlowinski%26aufirst%3DF.%26aulast%3DPichat%26aufirst%3DP.%26aulast%3DBeeske%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DS.%26aulast%3DMori%26aufirst%3DA.%26aulast%3DFujimura%26aufirst%3DM.%26aulast%3DEguchi%26aufirst%3DJ.%26atitle%3DThe%2520selective%2520GSK3%2520inhibitor%252C%2520SAR502250%252C%2520displays%2520neuroprotective%2520activity%2520and%2520attenuates%2520behavioral%2520impairments%2520in%2520models%2520of%2520neuropsychiatric%2520symptoms%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520in%2520rodents%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26issue%3D1%26spage%3D18045%26doi%3D10.1038%2Fs41598-019-54557-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simuni, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biglan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaglin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surmeier, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardiner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandabur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Factor, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goudreau, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimes, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kompoliti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyasaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nance, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeiffer, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russel, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saint-Hilaire, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuite, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Gerpen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadikoff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasucci, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deppen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duderstadt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ede, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gartner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanco, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecoraro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeiffer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quesada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gables, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reys, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolandelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommerfeld, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strongosky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terashita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siderowf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langbehn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrentino, M.</span></span> <span> </span><span class="NLM_article-title">Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinsonâs disease (STEADY-PD)</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1823</span>â <span class="NLM_lpage">1831</span>, <span class="refDoi">Â DOI: 10.1002/mds.25639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fmds.25639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=24123224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2hur%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2013&pages=1823-1831&issue=13&author=T.+Simuniauthor=K.+Biglanauthor=D.+Oakesauthor=G.+Bakrisauthor=R.+A.+Hauserauthor=J.+A.+Jaglinauthor=A.+Langauthor=J.+D.+Surmeierauthor=N.+Gardinerauthor=C.+Deeleyauthor=M.+Brandaburauthor=D.+Burkeauthor=S.+A.+Factorauthor=H.+H.+Fernandezauthor=J.+L.+Goudreauauthor=D.+A.+Grimesauthor=S.+Jainauthor=K.+Kompolitiauthor=F.+Marshallauthor=J.+Miyasakiauthor=M.+Nanceauthor=S.+Parkinsonauthor=R.+F.+Pfeifferauthor=G.+W.+Rossauthor=D.+S.+Russelauthor=A.+Sahayauthor=M.+H.+Saint-Hilaireauthor=P.+Tuiteauthor=J.+Van+Gerpenauthor=C.+Zadikoffauthor=P.+Beckerauthor=D.+Berryauthor=L.+M.+Blasucciauthor=J.+Conwayauthor=C.+Deeleyauthor=P.+Deppenauthor=K.+Duderstadtauthor=P.+Edeauthor=M.+Gartnerauthor=L.+S.+Ivancoauthor=R.+McMurrayauthor=M.+Pecoraroauthor=B.+Pfeifferauthor=M.+Quesadaauthor=C.+Gablesauthor=L.+Reysauthor=S.+Rolandelliauthor=D.+Russellauthor=J.+Sierenauthor=B.+Sommerfeldauthor=A.+Strongoskyauthor=S.+Terashitaauthor=C.-A.+Thomasauthor=S.+Wesselsauthor=A.+Siderowfauthor=D.+Langbehnauthor=M.+Sorrentino&title=Phase+II+safety%2C+tolerability%2C+and+dose+selection+study+of+isradipine+as+a+potential+disease-modifying+intervention+in+early+Parkinson%E2%80%99s+disease+%28STEADY-PD%29&doi=10.1002%2Fmds.25639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD)</span></div><div class="casAuthors">Simuni, Tanya; Biglan, Kevin; Oakes, David; Bakris, George; Hauser, Robert A.; Jaglin, Jean A.; Lang, Anthony; Surmeier, James D.; Gardiner, Nita; Deeley, Cheryl; Brandabur, Melanie; Burke, Deborah; Factor, Stewart A.; Fernadez, Hubert H.; Gourdreau, John L.; Grimes, David A.; Jain, Samay; Kompoliti, Katie; Marshall, Frederick; Miyasaki, Janis; Nance, Martha; Pfeiffer, Ronald F.; Webster Ross, G.; Russell, David S.; Sahay, Alok; Saint-Hilaire, Marie H.; Sengun, Cenk; Tuite, Paul; Van Gerpen, Jay; Zadikoff, Cindy; Becker, Pam; Berry, Debra; Blasucci, Lucia M.; Conway, Jennifer; Deeley, Cheryl; Deppen, Patricia; Duderstadt, Kathryn; Ede, Patricia; Gartner, Maureen; Ivanco, Larry S.; McMurray, Rebecca; Pecoraro, Mary; Pfeiffer, Brenda; Quesada, Monica; Reys, Liza; Rolandelli, Susan; Russell, Doozie; Sieren, Jeri; Sommerfeld, Barbara; Strongosky, Audrey; Terashita, Stephanie; Thomas, Cathi-Ann; Wessels, Sherry; Williams, Karen</div><div class="citationInfo"><span class="NLM_cas:title">Movement Disorders</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1823-1831</span>CODEN:
                <span class="NLM_cas:coden">MOVDEA</span>;
        ISSN:<span class="NLM_cas:issn">0885-3185</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Isradipine, a dihydropyridine calcium channel antagonist, has been shown to be neuroprotective in animal models of Parkinson's disease (PD).  To establish a dosage of isradipine controlled-release (CR) that is tolerable and demonstrates preliminary efficacy for use in a future pivotal efficacy trial a Phase 2, randomized, double-blind, parallel group trial (Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease [STEADY-PD]) was undertaken in subjects with early PD not requiring dopaminergic therapy (dopamine agonists or levodopa) randomized 1:1:1:1 to 5, 10, or 20 mg of isradipine CR or matching placebo daily.  The primary outcome was tolerability defined as no more than a 30% difference in the proportion of patients completing the study on the originally assigned dosage between an active and placebo group.  If more than one isradipine dosage was tolerable, then a 3-point difference in total Unified Parkinson's Disease Rating Scale (UPDRS) change between baseline and week 52 (or time to sufficient disability to require dopaminergic therapy) was taken as a criterion for selection of the most desirable dosage for future study.  STEADY-PD enrolled 99 subjects.  The tolerability of isradipine was dose dependent: placebo, 25 of 26 patients (96%); 5 mg, 19 of 23 patients (83%); 10 mg 19 of 26 patients (73%); and 20 mg 9 of 24 patients (37%).  There was no difference in change in UPDRS among dosages.  The most common adverse events were peripheral edema (30) and dizziness (24).  Isradipine 10 mg daily was the maximal tolerable dosage in this study of early PD.  A large placebo-controlled trial will be necessary and is planned to assess efficacy of isradipine 10 mg daily to slow progression of PD disability. Â© 2013 International Parkinson and Movement Disorder Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRBVxnSlTTN7Vg90H21EOLACvtfcHk0ljJALczbj4qHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2hur%252FO&md5=20407b7172678da335c8c72b70ad8c04</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1002%2Fmds.25639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.25639%26sid%3Dliteratum%253Aachs%26aulast%3DSimuni%26aufirst%3DT.%26aulast%3DBiglan%26aufirst%3DK.%26aulast%3DOakes%26aufirst%3DD.%26aulast%3DBakris%26aufirst%3DG.%26aulast%3DHauser%26aufirst%3DR.%2BA.%26aulast%3DJaglin%26aufirst%3DJ.%2BA.%26aulast%3DLang%26aufirst%3DA.%26aulast%3DSurmeier%26aufirst%3DJ.%2BD.%26aulast%3DGardiner%26aufirst%3DN.%26aulast%3DDeeley%26aufirst%3DC.%26aulast%3DBrandabur%26aufirst%3DM.%26aulast%3DBurke%26aufirst%3DD.%26aulast%3DFactor%26aufirst%3DS.%2BA.%26aulast%3DFernandez%26aufirst%3DH.%2BH.%26aulast%3DGoudreau%26aufirst%3DJ.%2BL.%26aulast%3DGrimes%26aufirst%3DD.%2BA.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DKompoliti%26aufirst%3DK.%26aulast%3DMarshall%26aufirst%3DF.%26aulast%3DMiyasaki%26aufirst%3DJ.%26aulast%3DNance%26aufirst%3DM.%26aulast%3DParkinson%26aufirst%3DS.%26aulast%3DPfeiffer%26aufirst%3DR.%2BF.%26aulast%3DRoss%26aufirst%3DG.%2BW.%26aulast%3DRussel%26aufirst%3DD.%2BS.%26aulast%3DSahay%26aufirst%3DA.%26aulast%3DSaint-Hilaire%26aufirst%3DM.%2BH.%26aulast%3DTuite%26aufirst%3DP.%26aulast%3DVan%2BGerpen%26aufirst%3DJ.%26aulast%3DZadikoff%26aufirst%3DC.%26aulast%3DBecker%26aufirst%3DP.%26aulast%3DBerry%26aufirst%3DD.%26aulast%3DBlasucci%26aufirst%3DL.%2BM.%26aulast%3DConway%26aufirst%3DJ.%26aulast%3DDeeley%26aufirst%3DC.%26aulast%3DDeppen%26aufirst%3DP.%26aulast%3DDuderstadt%26aufirst%3DK.%26aulast%3DEde%26aufirst%3DP.%26aulast%3DGartner%26aufirst%3DM.%26aulast%3DIvanco%26aufirst%3DL.%2BS.%26aulast%3DMcMurray%26aufirst%3DR.%26aulast%3DPecoraro%26aufirst%3DM.%26aulast%3DPfeiffer%26aufirst%3DB.%26aulast%3DQuesada%26aufirst%3DM.%26aulast%3DGables%26aufirst%3DC.%26aulast%3DReys%26aufirst%3DL.%26aulast%3DRolandelli%26aufirst%3DS.%26aulast%3DRussell%26aufirst%3DD.%26aulast%3DSieren%26aufirst%3DJ.%26aulast%3DSommerfeld%26aufirst%3DB.%26aulast%3DStrongosky%26aufirst%3DA.%26aulast%3DTerashita%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DC.-A.%26aulast%3DWessels%26aufirst%3DS.%26aulast%3DSiderowf%26aufirst%3DA.%26aulast%3DLangbehn%26aufirst%3DD.%26aulast%3DSorrentino%26aufirst%3DM.%26atitle%3DPhase%2520II%2520safety%252C%2520tolerability%252C%2520and%2520dose%2520selection%2520study%2520of%2520isradipine%2520as%2520a%2520potential%2520disease-modifying%2520intervention%2520in%2520early%2520Parkinson%25E2%2580%2599s%2520disease%2520%2528STEADY-PD%2529%26jtitle%3DMov.%2520Disord.%26date%3D2013%26volume%3D28%26issue%3D13%26spage%3D1823%26epage%3D1831%26doi%3D10.1002%2Fmds.25639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simuni, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biglan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galpern, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgeman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lungu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoulson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarolli, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surmeier, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venuto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kompoliti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evatt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litvan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farbman, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racette, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blindauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Water, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marras, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luca, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadikoff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panisset, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shtilbans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanspal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christine, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiess, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guttman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shill, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slevin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goudreau, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saint-Hilaire, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aquino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shprecher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shulman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parashos, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuite, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danisi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestre, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermanowicz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zweig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchowersky, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarna, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasucci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neefus, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecoraro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racioppa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bwala, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichwein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkiteswaran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ephron, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stovall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrogi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ede, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBlanc, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolandelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fierro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chew, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matwichyna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siderowf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, W. B.</span></span> <span> </span><span class="NLM_article-title">Isradipine versus placebo in early Parkinson Disease: A randomized trial</span>. <i>Ann. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>172</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">591</span>â <span class="NLM_lpage">598</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.7326%2FM19-2534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=32227247" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2020&pages=591-598&issue=9&author=T.+Simuniauthor=D.+Oakesauthor=K.+Biglanauthor=W.+R.+Galpernauthor=R.+Hauserauthor=K.+Hodgemanauthor=E.+Kaysonauthor=D.+Kinelauthor=A.+Langauthor=C.+Lunguauthor=S.+Sharmaauthor=I.+Shoulsonauthor=C.+G.+Tarolliauthor=D.+J.+Surmeierauthor=C.+Venutoauthor=R.+Hollowayauthor=K.+Kompolitiauthor=I.+Richardauthor=R.+Schneiderauthor=M.+Evattauthor=V.+Hinsonauthor=A.+Sahayauthor=I.+Litvanauthor=E.+S.+Farbmanauthor=B.+Racetteauthor=K.+Blindauerauthor=K.+Thomasauthor=C.+Waterauthor=C.+Marrasauthor=C.+C.+Lucaauthor=A.+Hungauthor=A.+Deikauthor=D.+Burkeauthor=C.+Zadikoffauthor=M.+Panissetauthor=M.+Rabinauthor=M.+Brodskyauthor=K.+Millsauthor=A.+Shtilbansauthor=E.+Hanspalauthor=C.+W.+Christineauthor=T.+Subramanianauthor=M.+C.+Schiessauthor=R.+Kumarauthor=K.+L.+Chouauthor=B.+Shahauthor=M.+Guttmanauthor=H.+Shillauthor=J.+Slevinauthor=J.+L.+Goudreauauthor=A.+Parkauthor=J.+Bertoniauthor=M.+H.+Saint-Hilaireauthor=N.+Stoverauthor=C.+Aquinoauthor=D.+Shprecherauthor=A.+Ahmedauthor=L.+Shulmanauthor=S.+A.+Parashosauthor=S.+Leeauthor=P.+Tuiteauthor=M.+Langloisauthor=F.+Danisiauthor=P.+Agarwalauthor=T.+Mestreauthor=D.+Russellauthor=D.+Truongauthor=N.+Hermanowiczauthor=R.+Zweigauthor=O.+Suchowerskyauthor=J.+R.+Sarnaauthor=G.+W.+Rossauthor=L.+Blasucciauthor=C.+Zimmermanauthor=S.+Jenkinsauthor=E.+Neefusauthor=M.+Pecoraroauthor=L.+Wheelerauthor=L.+Richardsonauthor=A.+Ratelauthor=J.+Racioppaauthor=G.+Bwalaauthor=S.+Reichweinauthor=C.+Rochaauthor=K.+Williamsauthor=K.+Keithauthor=E.+Carmanauthor=S.+Evansauthor=A.+Daleyauthor=K.+Venkiteswaranauthor=V.+Ephronauthor=K.+Ortizauthor=A.+Stovallauthor=M.+Goddardauthor=R.+Wagnerauthor=K.+Ambrogiauthor=C.+Petersonauthor=C.+A.+Thomasauthor=M.+Cinesauthor=P.+Edeauthor=P.+LeBlancauthor=S.+Rolandelliauthor=B.+Lewisauthor=A.+Fierroauthor=B.+Chewauthor=J.+McGeeauthor=P.+McCannauthor=M.+Matwichynaauthor=A.+Wattsauthor=M.+McDermottauthor=S.+Eberlyauthor=B.+Grecoauthor=S.+Hendersonauthor=J.+Lowellauthor=A.+Siderowfauthor=R.+Chappellauthor=J.+Phillipsauthor=K.+D.+Sethiauthor=W.+B.+White&title=Isradipine+versus+placebo+in+early+Parkinson+Disease%3A+A+randomized+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.7326%2FM19-2534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252FM19-2534%26sid%3Dliteratum%253Aachs%26aulast%3DSimuni%26aufirst%3DT.%26aulast%3DOakes%26aufirst%3DD.%26aulast%3DBiglan%26aufirst%3DK.%26aulast%3DGalpern%26aufirst%3DW.%2BR.%26aulast%3DHauser%26aufirst%3DR.%26aulast%3DHodgeman%26aufirst%3DK.%26aulast%3DKayson%26aufirst%3DE.%26aulast%3DKinel%26aufirst%3DD.%26aulast%3DLang%26aufirst%3DA.%26aulast%3DLungu%26aufirst%3DC.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DShoulson%26aufirst%3DI.%26aulast%3DTarolli%26aufirst%3DC.%2BG.%26aulast%3DSurmeier%26aufirst%3DD.%2BJ.%26aulast%3DVenuto%26aufirst%3DC.%26aulast%3DHolloway%26aufirst%3DR.%26aulast%3DKompoliti%26aufirst%3DK.%26aulast%3DRichard%26aufirst%3DI.%26aulast%3DSchneider%26aufirst%3DR.%26aulast%3DEvatt%26aufirst%3DM.%26aulast%3DHinson%26aufirst%3DV.%26aulast%3DSahay%26aufirst%3DA.%26aulast%3DLitvan%26aufirst%3DI.%26aulast%3DFarbman%26aufirst%3DE.%2BS.%26aulast%3DRacette%26aufirst%3DB.%26aulast%3DBlindauer%26aufirst%3DK.%26aulast%3DThomas%26aufirst%3DK.%26aulast%3DWater%26aufirst%3DC.%26aulast%3DMarras%26aufirst%3DC.%26aulast%3DLuca%26aufirst%3DC.%2BC.%26aulast%3DHung%26aufirst%3DA.%26aulast%3DDeik%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DD.%26aulast%3DZadikoff%26aufirst%3DC.%26aulast%3DPanisset%26aufirst%3DM.%26aulast%3DRabin%26aufirst%3DM.%26aulast%3DBrodsky%26aufirst%3DM.%26aulast%3DMills%26aufirst%3DK.%26aulast%3DShtilbans%26aufirst%3DA.%26aulast%3DHanspal%26aufirst%3DE.%26aulast%3DChristine%26aufirst%3DC.%2BW.%26aulast%3DSubramanian%26aufirst%3DT.%26aulast%3DSchiess%26aufirst%3DM.%2BC.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DChou%26aufirst%3DK.%2BL.%26aulast%3DShah%26aufirst%3DB.%26aulast%3DGuttman%26aufirst%3DM.%26aulast%3DShill%26aufirst%3DH.%26aulast%3DSlevin%26aufirst%3DJ.%26aulast%3DGoudreau%26aufirst%3DJ.%2BL.%26aulast%3DPark%26aufirst%3DA.%26aulast%3DBertoni%26aufirst%3DJ.%26aulast%3DSaint-Hilaire%26aufirst%3DM.%2BH.%26aulast%3DStover%26aufirst%3DN.%26aulast%3DAquino%26aufirst%3DC.%26aulast%3DShprecher%26aufirst%3DD.%26aulast%3DAhmed%26aufirst%3DA.%26aulast%3DShulman%26aufirst%3DL.%26aulast%3DParashos%26aufirst%3DS.%2BA.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DTuite%26aufirst%3DP.%26aulast%3DLanglois%26aufirst%3DM.%26aulast%3DDanisi%26aufirst%3DF.%26aulast%3DAgarwal%26aufirst%3DP.%26aulast%3DMestre%26aufirst%3DT.%26aulast%3DRussell%26aufirst%3DD.%26aulast%3DTruong%26aufirst%3DD.%26aulast%3DHermanowicz%26aufirst%3DN.%26aulast%3DZweig%26aufirst%3DR.%26aulast%3DSuchowersky%26aufirst%3DO.%26aulast%3DSarna%26aufirst%3DJ.%2BR.%26aulast%3DRoss%26aufirst%3DG.%2BW.%26aulast%3DBlasucci%26aufirst%3DL.%26aulast%3DZimmerman%26aufirst%3DC.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DNeefus%26aufirst%3DE.%26aulast%3DPecoraro%26aufirst%3DM.%26aulast%3DWheeler%26aufirst%3DL.%26aulast%3DRichardson%26aufirst%3DL.%26aulast%3DRatel%26aufirst%3DA.%26aulast%3DRacioppa%26aufirst%3DJ.%26aulast%3DBwala%26aufirst%3DG.%26aulast%3DReichwein%26aufirst%3DS.%26aulast%3DRocha%26aufirst%3DC.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DKeith%26aufirst%3DK.%26aulast%3DCarman%26aufirst%3DE.%26aulast%3DEvans%26aufirst%3DS.%26aulast%3DDaley%26aufirst%3DA.%26aulast%3DVenkiteswaran%26aufirst%3DK.%26aulast%3DEphron%26aufirst%3DV.%26aulast%3DOrtiz%26aufirst%3DK.%26aulast%3DStovall%26aufirst%3DA.%26aulast%3DGoddard%26aufirst%3DM.%26aulast%3DWagner%26aufirst%3DR.%26aulast%3DAmbrogi%26aufirst%3DK.%26aulast%3DPeterson%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DC.%2BA.%26aulast%3DCines%26aufirst%3DM.%26aulast%3DEde%26aufirst%3DP.%26aulast%3DLeBlanc%26aufirst%3DP.%26aulast%3DRolandelli%26aufirst%3DS.%26aulast%3DLewis%26aufirst%3DB.%26aulast%3DFierro%26aufirst%3DA.%26aulast%3DChew%26aufirst%3DB.%26aulast%3DMcGee%26aufirst%3DJ.%26aulast%3DMcCann%26aufirst%3DP.%26aulast%3DMatwichyna%26aufirst%3DM.%26aulast%3DWatts%26aufirst%3DA.%26aulast%3DMcDermott%26aufirst%3DM.%26aulast%3DEberly%26aufirst%3DS.%26aulast%3DGreco%26aufirst%3DB.%26aulast%3DHenderson%26aufirst%3DS.%26aulast%3DLowell%26aufirst%3DJ.%26aulast%3DSiderowf%26aufirst%3DA.%26aulast%3DChappell%26aufirst%3DR.%26aulast%3DPhillips%26aufirst%3DJ.%26aulast%3DSethi%26aufirst%3DK.%2BD.%26aulast%3DWhite%26aufirst%3DW.%2BB.%26atitle%3DIsradipine%2520versus%2520placebo%2520in%2520early%2520Parkinson%2520Disease%253A%2520A%2520randomized%2520trial%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2020%26volume%3D172%26issue%3D9%26spage%3D591%26epage%3D598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liss, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Striessnig, J.</span></span> <span> </span><span class="NLM_article-title">The potential of L-type calcium channels as a drug target for neuroprotective therapy in Parkinsonâs disease</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">263</span>â <span class="NLM_lpage">289</span>, <span class="refDoi">Â DOI: 10.1146/annurev-pharmtox-010818-021214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1146%2Fannurev-pharmtox-010818-021214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=30625283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms12rsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2019&pages=263-289&author=B.+Lissauthor=J.+Striessnig&title=The+potential+of+L-type+calcium+channels+as+a+drug+target+for+neuroprotective+therapy+in+Parkinson%E2%80%99s+disease&doi=10.1146%2Fannurev-pharmtox-010818-021214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson's Disease</span></div><div class="casAuthors">Liss, Birgit; Striessnig, Joerg</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">263-289</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  The motor symptoms of Parkinson's disease (PD) mainly arise from degeneration of dopamine neurons within the substantia nigra.  As no disease-modifying PD therapies are available, and side effects limit long-term benefits of current symptomatic therapies, novel treatment approaches are needed.  The ongoing phase III clin. study STEADY-PD is investigating the potential of the dihydropyridine isradipine, an L-type Ca2+ channel (LTCC) blocker, for neuroprotective PD therapy.  Here we review the clin. and preclin. rationale for this trial and discuss potential reasons for the ambiguous outcomes of in vivo animal model studies that address PD-protective dihydropyridine effects.  We summarize current views about the roles of Cav1.2 and Cav1.3 LTCC isoforms for substantia nigra neuron function, and their high vulnerability to degenerative stressors, and for PD pathophysiol.  We discuss different dihydropyridine sensitivities of LTCC isoforms in view of their potential as drug targets for PD neuroprotection, and we conclude by considering how these aspects could guide further drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSckGrrfwLpbVg90H21EOLACvtfcHk0liJ2Rcf1yCf0w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms12rsA%253D%253D&md5=79cccc8c1127bd07acdc944aadc6173a</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010818-021214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010818-021214%26sid%3Dliteratum%253Aachs%26aulast%3DLiss%26aufirst%3DB.%26aulast%3DStriessnig%26aufirst%3DJ.%26atitle%3DThe%2520potential%2520of%2520L-type%2520calcium%2520channels%2520as%2520a%2520drug%2520target%2520for%2520neuroprotective%2520therapy%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2019%26volume%3D59%26spage%3D263%26epage%3D289%26doi%3D10.1146%2Fannurev-pharmtox-010818-021214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilijic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercer, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rick, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tkatch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meredith, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surmeier, D. J.</span></span> <span> </span><span class="NLM_article-title">âRejuvenationâ protects neurons in mouse models of Parkinsonâs disease</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>447</i></span> (<span class="NLM_issue">7148</span>),  <span class="NLM_fpage">1081</span>â <span class="NLM_lpage">1086</span>, <span class="refDoi">Â DOI: 10.1038/nature05865</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2Fnature05865" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=17558391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvFKmurY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=447&publication_year=2007&pages=1081-1086&issue=7148&author=C.+S.+Chanauthor=J.+N.+Guzmanauthor=E.+Ilijicauthor=J.+N.+Mercerauthor=C.+Rickauthor=T.+Tkatchauthor=G.+E.+Meredithauthor=D.+J.+Surmeier&title=%E2%80%99Rejuvenation%E2%80%99+protects+neurons+in+mouse+models+of+Parkinson%E2%80%99s+disease&doi=10.1038%2Fnature05865"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">'Rejuvenation' protects neurons in mouse models of Parkinson's disease</span></div><div class="casAuthors">Chan, C. Savio; Guzman, Jaime N.; Ilijic, Ema; Mercer, Jeff N.; Rick, Caroline; Tkatch, Tatiana; Meredith, Gloria E.; Surmeier, D. James</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">447</span>
        (<span class="NLM_cas:issue">7148</span>),
    <span class="NLM_cas:pages">1081-1086</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Why dopamine-contg. neurons of the brain's substantia nigra pars compacta die in Parkinson's disease was an enduring mystery.  The authors' studies suggest that the unusual reliance of these neurons on L-type Cav1.3 Ca2+ channels to drive their maintained, rhythmic pacemaking renders them vulnerable to stressors thought to contribute to disease progression.  The reliance on these channels increases with age, as juvenile dopamine-contg. neurons in the substantia nigra pars compacta use pacemaking mechanisms common to neurons not affected in Parkinson's disease.  These mechanisms remain latent in adulthood, and blocking Cav1.3 Ca2+ channels in adult neurons induces a reversion to the juvenile form of pacemaking.  Such blocking ('rejuvenation') protects these neurons in both in vitro and in vivo models of Parkinson's disease, pointing to a new strategy that could slow or stop the progression of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4cTWDOImAdLVg90H21EOLACvtfcHk0lh-1o6qMYPslA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvFKmurY%253D&md5=debc60fc9e881232ff843aa2d702f706</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fnature05865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05865%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DC.%2BS.%26aulast%3DGuzman%26aufirst%3DJ.%2BN.%26aulast%3DIlijic%26aufirst%3DE.%26aulast%3DMercer%26aufirst%3DJ.%2BN.%26aulast%3DRick%26aufirst%3DC.%26aulast%3DTkatch%26aufirst%3DT.%26aulast%3DMeredith%26aufirst%3DG.%2BE.%26aulast%3DSurmeier%26aufirst%3DD.%2BJ.%26atitle%3D%25E2%2580%2599Rejuvenation%25E2%2580%2599%2520protects%2520neurons%2520in%2520mouse%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNature%26date%3D2007%26volume%3D447%26issue%3D7148%26spage%3D1081%26epage%3D1086%26doi%3D10.1038%2Fnature05865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ilijic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surmeier, D. J.</span></span> <span> </span><span class="NLM_article-title">The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinsonâs disease</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">364</span>â <span class="NLM_lpage">371</span>, <span class="refDoi">Â DOI: 10.1016/j.nbd.2011.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.nbd.2011.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=21515375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFWhu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2011&pages=364-371&issue=2&author=E.+Ilijicauthor=J.+N.+Guzmanauthor=D.+J.+Surmeier&title=The+L-type+channel+antagonist+isradipine+is+neuroprotective+in+a+mouse+model+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.nbd.2011.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease</span></div><div class="casAuthors">Ilijic, E.; Guzman, J. N.; Surmeier, D. J.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">364-371</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The motor symptoms of Parkinson's disease (PD) are due to the progressive loss of dopamine (DA) neurons in substantia nigra pars compacta (SNc).  Nothing is known to slow the progression of the disease, making the identification of potential neuroprotective agents of great clin. importance.  Previous studies using the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD have shown that antagonism of L-type Ca2+ channels protects SNc DA neurons.  However, this was not true in a 6-hydroxydopamine (6-OHDA) model.  One potential explanation for this discrepancy is that protection in the 6-OHDA model requires greater antagonism of Cav1.3 L-type Ca2+ channels thought to underlie vulnerability and this was not achievable with the low affinity dihydropyridine (DHP) antagonist used.  To test this hypothesis, the DHP with the highest affinity for Cav1.3 L-type channels-isradipine-was systemically administered and then the DA toxin 6-OHDA injected intrastriatally.  Twenty-five days later, neuroprotection and plasma concn. of isradipine were detd.  This anal. revealed that isradipine produced a dose-dependent sparing of DA fibers and cell bodies at concns. achievable in humans, suggesting that isradipine is a potentially viable neuroprotective agent for PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp6wN3kCMb3rVg90H21EOLACvtfcHk0lh-1o6qMYPslA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFWhu70%253D&md5=b96f0cca0dee1a73e6de38b12b329d30</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2011.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2011.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DIlijic%26aufirst%3DE.%26aulast%3DGuzman%26aufirst%3DJ.%2BN.%26aulast%3DSurmeier%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520L-type%2520channel%2520antagonist%2520isradipine%2520is%2520neuroprotective%2520in%2520a%2520mouse%2520model%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2011%26volume%3D43%26issue%3D2%26spage%3D364%26epage%3D371%26doi%3D10.1016%2Fj.nbd.2011.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ortner, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bock, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougalis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharitonova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuluc, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomberger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitterl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciossek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberacher, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Draheim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kloppenburg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liss, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Striessnig, J.</span></span> <span> </span><span class="NLM_article-title">Lower affinity of isradipine for L-type Ca(2+) channels during substantia nigra dopamine neuron-like activity: Implications for neuroprotection in Parkinsonâs disease</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">28</span>),  <span class="NLM_fpage">6761</span>â <span class="NLM_lpage">6777</span>, <span class="refDoi">Â DOI: 10.1523/JNEUROSCI.2946-16.2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1523%2FJNEUROSCI.2946-16.2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28592699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFCht73F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=6761-6777&issue=28&author=N.+J.+Ortnerauthor=G.+Bockauthor=A.+Dougalisauthor=M.+Kharitonovaauthor=J.+Dudaauthor=S.+Hessauthor=P.+Tulucauthor=T.+Pombergerauthor=N.+Stefanovaauthor=F.+Pitterlauthor=T.+Ciossekauthor=H.+Oberacherauthor=H.+J.+Draheimauthor=P.+Kloppenburgauthor=B.+Lissauthor=J.+Striessnig&title=Lower+affinity+of+isradipine+for+L-type+Ca%282%2B%29+channels+during+substantia+nigra+dopamine+neuron-like+activity%3A+Implications+for+neuroprotection+in+Parkinson%E2%80%99s+disease&doi=10.1523%2FJNEUROSCI.2946-16.2017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Lower affinity of isradipine for L-type Ca2+ channels during substantia nigra dopamine neuron-like activity: implications for neuroprotection in Parkinson's disease</span></div><div class="casAuthors">Ortner, Nadine J.; Bock, Gabriella; Dougalis, Antonios; Kharitonova, Maria; Duda, Johanna; Hess, Simon; Tuluc, Petronel; Pomberger, Thomas; Stefanova, Nadia; Pitterl, Florian; Ciossek, Thomas; Oberacher, Herbert; Draheim, Henning J.; Kloppenburg, Peter; Liss, Birgit; Striessnig, Joerg</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">6761-6777</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">1529-2401</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Ca2+-influx through L-type Ca2+-channels (LTCCs) is assocd. with activity-related stressful oscillations of Ca2+ levels within dopaminergic (DA) neurons in the substantia nigra (SN), which may contribute to their selective degeneration in Parkinson's disease (PD).  LTCC blockers were neuroprotective in mouse neurotoxin models of PD, and isradipine is currently undergoing testing in a phase III clin. trial in early PD.  We report no evidence for neuroprotection by in vivo pretreatment with therapeutically relevant isradipine plasma levels, or Cav1.3 LTCC deficiency in 6-OHDA-treated male mice.  To explain this finding, we investigated the pharmacol. properties of human LTCCs during SN DA-like and arterial smooth muscle (aSM)-like activity patterns using whole-cell patch-clamp recordings in HEK293 cells (Cav1.2 Î±1-subunit, long and short Cav1.3 Î±1-subunit splice variants; Î²3/Î±2Î´1).  During SN DA-like pacemaking, only Cav1.3 variants conducted Ca2+ current (ICa) at subthreshold potentials between action potentials.  SN DA-like burst activity increased integrated ICa during (Cav1.2 plus Cav1.3) and after (Cav1.3) the burst.  Isradipine inhibition was splice variant and isoform dependent, with a 5- to 11-fold lower sensitivity to Cav1.3 variants during SN DA-like pacemaking compared with Cav1.2 during aSM-like activity.  Supratherapeutic isradipine concns. reduced the pacemaker precision of adult mouse SN DA neurons but did not affect their somatic Ca2+ oscillations.  Our data predict that Cav1.2 and Cav1.3 splice variants contribute differentially to Ca2+ load in SN DA neurons, with prominent Cav1.3-mediated ICa between action potentials and after bursts.  The failure of therapeutically relevant isradipine levels to protect SN DA neurons can be explained by weaker state-dependent inhibition of SN DA LTCCs compared with aSM Cav1.2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXyYOpdxSgjrVg90H21EOLACvtfcHk0lh-1o6qMYPslA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFCht73F&md5=1f62fb42846e0d6a04a7645bf2b4fd83</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.2946-16.2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.2946-16.2017%26sid%3Dliteratum%253Aachs%26aulast%3DOrtner%26aufirst%3DN.%2BJ.%26aulast%3DBock%26aufirst%3DG.%26aulast%3DDougalis%26aufirst%3DA.%26aulast%3DKharitonova%26aufirst%3DM.%26aulast%3DDuda%26aufirst%3DJ.%26aulast%3DHess%26aufirst%3DS.%26aulast%3DTuluc%26aufirst%3DP.%26aulast%3DPomberger%26aufirst%3DT.%26aulast%3DStefanova%26aufirst%3DN.%26aulast%3DPitterl%26aufirst%3DF.%26aulast%3DCiossek%26aufirst%3DT.%26aulast%3DOberacher%26aufirst%3DH.%26aulast%3DDraheim%26aufirst%3DH.%2BJ.%26aulast%3DKloppenburg%26aufirst%3DP.%26aulast%3DLiss%26aufirst%3DB.%26aulast%3DStriessnig%26aufirst%3DJ.%26atitle%3DLower%2520affinity%2520of%2520isradipine%2520for%2520L-type%2520Ca%25282%252B%2529%2520channels%2520during%2520substantia%2520nigra%2520dopamine%2520neuron-like%2520activity%253A%2520Implications%2520for%2520neuroprotection%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurosci.%26date%3D2017%26volume%3D37%26issue%3D28%26spage%3D6761%26epage%3D6777%26doi%3D10.1523%2FJNEUROSCI.2946-16.2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghanbari-Maman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghasemian-Roudsari, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliakbari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourbadie, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khodagholic, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaerzadehd, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daftari, M.</span></span> <span> </span><span class="NLM_article-title">Calcium channel blockade ameliorates endoplasmic reticulum stress in the hippocampus induced by amyloidopathy in the entorhinal cortex</span>. <i>Iran. J. Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1466</span>â <span class="NLM_lpage">1476</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=32641955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslWju7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=1466-1476&issue=3&author=A.+Ghanbari-Mamanauthor=F.+Ghasemian-Roudsariauthor=S.+Aliakbariauthor=H.+G.+Pourbadieauthor=F.+Khodagholicauthor=F.+Shaerzadehdauthor=M.+Daftari&title=Calcium+channel+blockade+ameliorates+endoplasmic+reticulum+stress+in+the+hippocampus+induced+by+amyloidopathy+in+the+entorhinal+cortex"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium channel blockade ameliorates endoplasmic reticulum stress in the hippocampus induced by amyloidopathy in the entorhinal cortex</span></div><div class="casAuthors">Ghanbari-Maman, Azam; Ghasemian-Roudsari, Forouzan; Aliakbari, Shayan; Pourbadie, Hamid Gholami; Khodagholi, Fariba; Shaerzadeh, Fatemeh; Daftari, Mahtab</div><div class="citationInfo"><span class="NLM_cas:title">Iranian Journal of Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1466-1476</span>CODEN:
                <span class="NLM_cas:coden">IJPRC9</span>;
        ISSN:<span class="NLM_cas:issn">1726-6890</span>.
    
            (<span class="NLM_cas:orgname">Shaheed Beheshti University of Medical Sciences and Health Services, School of Pharmacy</span>)
        </div><div class="casAbstract">Entorhinal cortex (EC) is one of the first cerebral regions affected in Alzheimer's disease (AD).  The pathol. propagates to neighboring cerebral regions through a prion-like mechanism.  In AD, intracellular calcium dyshomeostasis is assocd. with endoplasmic reticulum (ER) stress.  This study was designed to examine hippocampal ER stress following EC amyloidopathy.  AÎ²1-42 was bilaterally microinjected into the EC under stereotaxic surgery.  Rats were daily treated with 30 Î¼g of isradipine, nimodipine, or placebo over one week.  Passive avoidance and novel object recognition (NOR) tasks were performed using shuttle box and NOR test, resp.  GRP78/BiP and CHOP levels were measured in the hippocampal dentate gyrus (DG) by western blot technique.  The glutathione (GSH) level and PDI activity were also assessed in the hippocampus by colorimetric spectrophotometer.  AÎ² treated group developed passive avoidance and novel recognition memory deficit compared to the control group.  However, treatment with calcium channel blockers reversed the impairment.  BiP and CHOP level increased in the hippocampus following amyloidopathy in the EC.  PDI activity and GSH level in the hippocampus decreased in the AÎ² treated group, but calcium channel blockers restored them toward the control level.  In conclusion, memory impairment due to EC amyloidopathy is assocd. with ER stress related bio-mol. changes in the hippocampus, and treatment with L-type calcium channel blockers may prevent the changes and ultimately improve cognitive performance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxgzyBYyrTRrVg90H21EOLACvtfcHk0ljm3aIKajVElA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslWju7g%253D&md5=5047ec0f982da32399f4707ecfd06d54</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGhanbari-Maman%26aufirst%3DA.%26aulast%3DGhasemian-Roudsari%26aufirst%3DF.%26aulast%3DAliakbari%26aufirst%3DS.%26aulast%3DPourbadie%26aufirst%3DH.%2BG.%26aulast%3DKhodagholic%26aufirst%3DF.%26aulast%3DShaerzadehd%26aufirst%3DF.%26aulast%3DDaftari%26aufirst%3DM.%26atitle%3DCalcium%2520channel%2520blockade%2520ameliorates%2520endoplasmic%2520reticulum%2520stress%2520in%2520the%2520hippocampus%2520induced%2520by%2520amyloidopathy%2520in%2520the%2520entorhinal%2520cortex%26jtitle%3DIran.%2520J.%2520Pharm.%2520Res.%26date%3D2019%26volume%3D18%26issue%3D3%26spage%3D1466%26epage%3D1476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pourbadie, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naderi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehranfard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janahmadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khodagholi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motamedi, F.</span></span> <span> </span><span class="NLM_article-title">Preventing effect of L-type calcium channel blockade on electrophysiological alterations in dentate gyrus granule cells induced by entorhinal amyloid pathology</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">e0117555</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0117555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1371%2Fjournal.pone.0117555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=25689857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVyltL7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0117555&issue=2&author=H.+G.+Pourbadieauthor=N.+Naderiauthor=N.+Mehranfardauthor=M.+Janahmadiauthor=F.+Khodagholiauthor=F.+Motamedi&title=Preventing+effect+of+L-type+calcium+channel+blockade+on+electrophysiological+alterations+in+dentate+gyrus+granule+cells+induced+by+entorhinal+amyloid+pathology&doi=10.1371%2Fjournal.pone.0117555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Preventing effect of L-type calcium channel blockade on electrophysiological alterations in dentate gyrus granule cells induced by entorhinal amyloid pathology</span></div><div class="casAuthors">Pourbadie, Hamid Gholami; Naderi, Nima; Mehranfard, Nasrin; Janahmadi, Mahyar; Khodagholi, Fariba; Motamedi, Fereshteh</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e0117555/1-e0117555/19</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The entorhinal cortex (EC) is one of the earliest affected brain regions in Alzheimer's disease (AD).  EC-amyloid pathol. induces synaptic failure in the dentate gyrus (DG) with resultant behavioral impairment, but there is little known about its impact on neuronal properties in the DG.  It is believed that calcium dyshomeostasis plays a pivotal role in the etiol. of AD.  Here, the effect of the EC amyloid pathogenesis on cellular properties of DG granule cells and also possible neuroprotective role of L-type calcium channel blockers (CCBs), nimodipine and isradipine, were investigated.  The amyloid beta (AÎ²) 1-42 was injected bilaterally into the EC of male rats and one week later, electrophysiol. properties of DG granule cells were assessed.  Voltage clamp recording revealed appearance of giant sIPSC in combination with a decrease in sEPSC frequency which was partially reversed by CCBs in granule cells from AÎ² treated rats.  EC amyloid pathogenesis induced a significant redn. of input resistance (Rin) accompanied by a profound decreased excitability in the DG granule cells.  However, daily administration of CCBs, isradipine or nimodipine (i.c.v. for 6 days), almost preserved the normal excitability against AÎ².  In conclusion, lower tendency to fire AP along with reduced Rin suggest that DG granule cells might undergo an alteration in the membrane ion channel activities which finally lead to the behavioral deficits obsd. in animal models and patients with early-stage Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6QRyECfYhkbVg90H21EOLACvtfcHk0ljm3aIKajVElA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVyltL7O&md5=3199e889ac157bc00b9e0efc77301762</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0117555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0117555%26sid%3Dliteratum%253Aachs%26aulast%3DPourbadie%26aufirst%3DH.%2BG.%26aulast%3DNaderi%26aufirst%3DN.%26aulast%3DMehranfard%26aufirst%3DN.%26aulast%3DJanahmadi%26aufirst%3DM.%26aulast%3DKhodagholi%26aufirst%3DF.%26aulast%3DMotamedi%26aufirst%3DF.%26atitle%3DPreventing%2520effect%2520of%2520L-type%2520calcium%2520channel%2520blockade%2520on%2520electrophysiological%2520alterations%2520in%2520dentate%2520gyrus%2520granule%2520cells%2520induced%2520by%2520entorhinal%2520amyloid%2520pathology%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26issue%3D2%26spage%3De0117555%26doi%3D10.1371%2Fjournal.pone.0117555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anekonda, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frahler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadsworth, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woltjer, R. L.</span></span> <span> </span><span class="NLM_article-title">L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimerâs disease</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">62</span>â <span class="NLM_lpage">70</span>, <span class="refDoi">Â DOI: 10.1016/j.nbd.2010.08.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.nbd.2010.08.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=20816785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWqsLbE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=62-70&issue=1&author=T.+S.+Anekondaauthor=J.+F.+Quinnauthor=C.+Harrisauthor=K.+Frahlerauthor=T.+L.+Wadsworthauthor=R.+L.+Woltjer&title=L-type+voltage-gated+calcium+channel+blockade+with+isradipine+as+a+therapeutic+strategy+for+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.nbd.2010.08.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease</span></div><div class="casAuthors">Anekonda, Thimmappa S.; Quinn, Joseph F.; Harris, Christopher; Frahler, Kate; Wadsworth, Teri L.; Woltjer, Randall L.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-70</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">There is strong evidence that intracellular calcium dysregulation plays an important pathol. role in Alzheimer's disease, and specifically that beta amyloid may induce increases in intracellular calcium and lead to neuronal cell dysfunction and death.  Here we investigated the feasibility of modifying Alzheimer's pathol. with the L-type voltage-gated calcium channel blockers verapamil, diltiazem, isradipine and nimodipine.  All four compds. protected MC65 neuroblastoma cells from amyloid beta protein precursor C-terminal fragment (APP CTF)-induced neurotoxicity.  Isradipine was the most potent blocker, preventing APP CTF neurotoxicity at nanomolar concns.  Intracellular beta amyloid expression was assocd. with increased expression of Cav 1.2 calcium channels and increased intracellular calcium influx from the extracellular space.  Despite the cytoprotection afforded by calcium channel blockers, amyloid beta oligomer formation was not suppressed.  The mechanism of cell death in MC65 cells is appeared to be caspase-3 independent.  With the goal of detg. if there is sufficient exptl. support to move forward with animal trials of isradipine, we detd. its bioavailability in the triple transgenic mouse model of AD.  S.c. implantation of carrier-bound isradipine (3 Î¼g/g/day) for 60 days resulted in nanomolar concns. in both the plasma and brain.  Taken together, our in vitro results support the theory that calcium blockers exert protective effects downstream of the effects of beta amyloid.  Isradipine's neuroprotective effect at concns. that are clin. relevant and achievable in vitro and in vivo suggests that this particular calcium blocking agent may have therapeutic value in the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-QaET8NSy7bVg90H21EOLACvtfcHk0ljm3aIKajVElA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWqsLbE&md5=0ddf211422ee5413299c4b393ab80aff</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2010.08.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2010.08.020%26sid%3Dliteratum%253Aachs%26aulast%3DAnekonda%26aufirst%3DT.%2BS.%26aulast%3DQuinn%26aufirst%3DJ.%2BF.%26aulast%3DHarris%26aufirst%3DC.%26aulast%3DFrahler%26aufirst%3DK.%26aulast%3DWadsworth%26aufirst%3DT.%2BL.%26aulast%3DWoltjer%26aufirst%3DR.%2BL.%26atitle%3DL-type%2520voltage-gated%2520calcium%2520channel%2520blockade%2520with%2520isradipine%2520as%2520a%2520therapeutic%2520strategy%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2011%26volume%3D41%26issue%3D1%26spage%3D62%26epage%3D70%26doi%3D10.1016%2Fj.nbd.2010.08.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anekonda, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, J. F.</span></span> <span> </span><span class="NLM_article-title">Calcium channel blocking as a therapeutic strategy for Alzheimerâs disease: The case for isradipine</span>. <i>Biochim. Biophys. Acta, Mol. Basis Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1812</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1584</span>â <span class="NLM_lpage">1590</span>, <span class="refDoi">Â DOI: 10.1016/j.bbadis.2011.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bbadis.2011.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=21925266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2htbnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1812&publication_year=2011&pages=1584-1590&issue=12&author=T.+S.+Anekondaauthor=J.+F.+Quinn&title=Calcium+channel+blocking+as+a+therapeutic+strategy+for+Alzheimer%E2%80%99s+disease%3A+The+case+for+isradipine&doi=10.1016%2Fj.bbadis.2011.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: The case for isradipine</span></div><div class="casAuthors">Anekonda, Thimmappa S.; Quinn, Joseph F.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1812</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1584-1590</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease is the most devastating neurodegenerative disorder in the elderly, yet treatment options are severely limited.  The drug development effort to modify Alzheimer's disease pathol. by intervention at beta amyloid prodn. sites has been largely ineffective or inconclusive.  The greatest challenge has been to identify and define downstream mechanisms reliably predictive of clin. symptoms.  Beta amyloid accumulation leads to dysregulation of intracellular calcium by plasma membrane L-type calcium channels located on neuronal somatodendrites and axons in the hippocampus and cortex.  Paradoxically, L-type calcium channel subtype Cav1.2 also promotes synaptic plasticity and spatial memory.  Increased intracellular calcium modulates amyloid precursor protein processing and affects multiple downstream pathways including increased hyperphosphorylated tau and suppression of autophagy.  Isradipine is a Federal Drug Administration-approved dihydropyridine calcium channel blocker that binds selectively to Cav1.2 in the hippocampus.  Our studies have shown that isradipine in vitro attenuates beta amyloid oligomer toxicity by suppressing calcium influx into cytoplasm and by suppressing Cav1.2 expression.  We have previously shown that administration of isradipine to triple transgenic animal model for Alzheimer's disease was well-tolerated.  Our results further suggest that isradipine became bioavailable, lowered tau burden, and improved autophagy function in the brain.  A better understanding of brain pharmacokinetics of calcium channel blockers will be crit. for designing new expts. with appropriate drug doses in any future clin. trials for Alzheimer's disease.  This review highlights the importance of Cav1.2 channel overexpression, the accumulation of hyperphosphorylated tau and suppression of autophagy in Alzheimer's disease and modulation of this pathway by isradipine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3wk5eKscM47Vg90H21EOLACvtfcHk0ljMcDOkhA2lZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2htbnJ&md5=212aab116d87460754331fa496c7f63f</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.bbadis.2011.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbadis.2011.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DAnekonda%26aufirst%3DT.%2BS.%26aulast%3DQuinn%26aufirst%3DJ.%2BF.%26atitle%3DCalcium%2520channel%2520blocking%2520as%2520a%2520therapeutic%2520strategy%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520The%2520case%2520for%2520isradipine%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D2011%26volume%3D1812%26issue%3D12%26spage%3D1584%26epage%3D1590%26doi%3D10.1016%2Fj.bbadis.2011.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Arrieta, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birks, J.</span></span> <span> </span><span class="NLM_article-title">Nimodipine for primary degenerative, mixed and vascular dementia</span>. <i>Cochrane Database Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>, (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">CD000147</span>, <span class="refDoi">Â DOI: 10.1002/14651858.CD000147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2F14651858.CD000147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=12137606" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&pages=CD000147&issue=3&author=J.+M.+Lopez-Arrietaauthor=J.+Birks&title=Nimodipine+for+primary+degenerative%2C+mixed+and+vascular+dementia&doi=10.1002%2F14651858.CD000147"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD000147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD000147%26sid%3Dliteratum%253Aachs%26aulast%3DLopez-Arrieta%26aufirst%3DJ.%2BM.%26aulast%3DBirks%26aufirst%3DJ.%26atitle%3DNimodipine%2520for%2520primary%2520degenerative%252C%2520mixed%2520and%2520vascular%2520dementia%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2002%26issue%3D3%26spage%3DCD000147%26doi%3D10.1002%2F14651858.CD000147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lawlor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segurado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennelly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rikkert, M. G. M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boerjesson-Hanson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsolaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucca, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molloy, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riepe, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cregg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDwyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breuilh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaynor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheikhi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taekema, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhey, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nobili, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceschi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frisoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanetti, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konsta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasios, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nenopoulou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsolaki-Tagaraki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pakaski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dereeper, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Sayette, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senechal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavenu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devendeville, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calais, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullan, M.</span></span> <span> </span><span class="NLM_article-title">Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">e1002660</span>, <span class="refDoi">Â DOI: 10.1371/journal.pmed.1002660</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1371%2Fjournal.pmed.1002660" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=30248105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSlt7vP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=e1002660&issue=9&author=B.+Lawlorauthor=R.+Seguradoauthor=S.+Kennellyauthor=M.+G.+M.+O.+Rikkertauthor=R.+Howardauthor=F.+Pasquierauthor=A.+Boerjesson-Hansonauthor=M.+Tsolakiauthor=U.+Luccaauthor=D.+W.+Molloyauthor=R.+Coenauthor=M.+W.+Riepeauthor=J.+Kalmanauthor=R.+A.+Kennyauthor=F.+Creggauthor=S.+O%E2%80%99Dwyerauthor=C.+Walshauthor=J.+Adamsauthor=R.+Banziauthor=L.+Breuilhauthor=L.+Dalyauthor=S.+Hendrixauthor=P.+Aisenauthor=S.+Gaynorauthor=A.+Sheikhiauthor=D.+G.+Taekemaauthor=F.+R.+Verheyauthor=R.+Nemniauthor=F.+Nobiliauthor=M.+Franceschiauthor=G.+Frisoniauthor=O.+Zanettiauthor=A.+Konstaauthor=O.+Anastasiosauthor=S.+Nenopoulouauthor=F.+Tsolaki-Tagarakiauthor=M.+Pakaskiauthor=O.+Dereeperauthor=V.+de+la+Sayetteauthor=O.+Senechalauthor=I.+Lavenuauthor=A.+Devendevilleauthor=G.+Calaisauthor=F.+Crawfordauthor=M.+Mullan&title=Nilvadipine+in+mild+to+moderate+Alzheimer+disease%3A+A+randomised+controlled+trial&doi=10.1371%2Fjournal.pmed.1002660"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Nilvadipine in mild to moderate Alzheimer disease: a randomised controlled trial</span></div><div class="casAuthors">Lawlor, Brian; Segurado, Ricardo; Kennelly, Sean; Rikkert, Marcel G. M. Olde; Howard, Robert; Pasquier, Florence; Boerjesson-Hanson, Anne; Tsolaki, Magda; Lucca, Ugo; Molloy, D. William; Coen, Robert; Riepe, Matthias W.; Kalman, Janos; Kenny, Rose Anne; Cregg, Fiona; O'Dwyer, Sarah; Walsh, Cathal; Adams, Jessica; Banzi, Rita; Breuilh, Laetitia; Daly, Leslie; Hendrix, Suzanne; Aisen, Paul; Gaynor, Siobhan; Sheikhi, Ali; Taekema, Diana G.; Verhey, Frans R.; Nemni, Raffaello; Nobili, Flavio; Franceschi, Massimo; Frisoni, Giovanni; Zanetti, Orazio; Konsta, Anastasia; Anastasios, Orologas; Nenopoulou, Styliani; Tsolaki-Tagaraki, Fani; Pakaski, Magdolna; Dereeper, Olivier; de la Sayette, Vincent; Senechal, Olivier; Lavenu, Isabelle; Devendeville, Agnes; Calais, Gauthier; Crawford, Fiona; Mullan, Michael</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e1002660/1-e1002660/20</span>CODEN:
                <span class="NLM_cas:coden">PMLEAC</span>;
        ISSN:<span class="NLM_cas:issn">1549-1277</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background This study reports the findings of the first large-scale Phase III investigator-driven clin. trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine.  Nilvadipine, licensed to treat hypertension, reduces amyloid prodn., increases regional cerebral blood flow, and has demonstrated antiinflammatory and anti-tau activity in preclin. studies, properties that could have diseasemodifying effects for Alzheimer disease.  We aimed to det. if nilvadipine was effective in slowing cognitive decline in subjects with mild to moderate Alzheimer disease.  Methods and findings NILVAD was an 18-mo, randomised, placebo-controlled, double-blind trial that randomised participants between 15 May 2013 and 13 Apr. 2015.  The study was conducted at 23 academic centers in nine European countries.  Of 577 participants screened, 511 were eligible and were randomised (258 to placebo, 253 to nilvadipine).  Participants took a trial treatment capsule once a day after breakfast for 78 wk.  Participants were aged >50 years, meeting National Institute of Neurol. and Communicative Disorders and Stroke/Alzheimer's disease Criteria (NINCDS-ADRDA) for diagnosis of probable Alzheimer disease, with a Standardised Mini-Mental State Examn. (SMMSE) score of â¥12 and <27.  Participants were randomly assigned to 8 mg sustained-release nilvadipine or matched placebo.  The a priori defined primary outcome was progression on the Alzheimer's Disease Assessment Scale Cognitive Subscale-12 (ADAS-Cog 12) in the modified intention-to-treat (mITT) population (n = 498), with the Clin. Dementia Rating Scale sum of boxes (CDR-sb) as a gated co-primary outcome, eligible to be promoted to primary end point conditional on a significant effect on the ADAS-Cog 12.  The anal. set had a mean age of 73 years and was 62% female.  Baseline demog. and Alzheimer disease-specific characteristics were similar between treatment groups, with reported mean of 1.7 years since diagnosis and mean SMMSE of 20.4.  The prespecified primary analyses failed to show any treatment benefit for nilvadipine on the co-primary outcome (p = 0.465).  Decline from baseline in ADASCog 12 on placebo was 0.79 (95% CI, -0.07-1.64) at 13 wk, 6.41 (5.33-7.49) at 52 wk, and 9.63 (8.33-10.93) at 78 wk and on nilvadipine was 0.88 (0.02-1.74) at 13 wk, 5.75 (4.66-6.85) at 52 wk, and 9.41 (8.09-10.73) at 78 wk.  Exploratory analyses of the planned secondary outcomes showed no substantial effects, including on the CDR-sb or the Disability Assessment for Dementia.  Nilvadipine appeared to be safe and well tolerated.  Mortality was similar between groups (3 on nilvadipine, 4 on placebo); higher counts of adverse events (AEs) on nilvadipine (1,129 vs. 1,030), and serious adverse events (SAEs; 146 vs. 101), were obsd.  There were 14 withdrawals because of AEs.  Major limitations of this study were that subjects had established dementia and the likelihood that non-Alzheimer subjects were included because of the lack of biomarker confirmation of the presence of brain amyloid.  Conclusions The results do not suggest benefit of nilvadipine as a treatment in a population spanning mild to moderate Alzheimer disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtE9BqM0V94rVg90H21EOLACvtfcHk0ljMcDOkhA2lZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSlt7vP&md5=466e7508932a7443edcb2757aed12e54</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.1002660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.1002660%26sid%3Dliteratum%253Aachs%26aulast%3DLawlor%26aufirst%3DB.%26aulast%3DSegurado%26aufirst%3DR.%26aulast%3DKennelly%26aufirst%3DS.%26aulast%3DRikkert%26aufirst%3DM.%2BG.%2BM.%2BO.%26aulast%3DHoward%26aufirst%3DR.%26aulast%3DPasquier%26aufirst%3DF.%26aulast%3DBoerjesson-Hanson%26aufirst%3DA.%26aulast%3DTsolaki%26aufirst%3DM.%26aulast%3DLucca%26aufirst%3DU.%26aulast%3DMolloy%26aufirst%3DD.%2BW.%26aulast%3DCoen%26aufirst%3DR.%26aulast%3DRiepe%26aufirst%3DM.%2BW.%26aulast%3DKalman%26aufirst%3DJ.%26aulast%3DKenny%26aufirst%3DR.%2BA.%26aulast%3DCregg%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DS.%26aulast%3DWalsh%26aufirst%3DC.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DBanzi%26aufirst%3DR.%26aulast%3DBreuilh%26aufirst%3DL.%26aulast%3DDaly%26aufirst%3DL.%26aulast%3DHendrix%26aufirst%3DS.%26aulast%3DAisen%26aufirst%3DP.%26aulast%3DGaynor%26aufirst%3DS.%26aulast%3DSheikhi%26aufirst%3DA.%26aulast%3DTaekema%26aufirst%3DD.%2BG.%26aulast%3DVerhey%26aufirst%3DF.%2BR.%26aulast%3DNemni%26aufirst%3DR.%26aulast%3DNobili%26aufirst%3DF.%26aulast%3DFranceschi%26aufirst%3DM.%26aulast%3DFrisoni%26aufirst%3DG.%26aulast%3DZanetti%26aufirst%3DO.%26aulast%3DKonsta%26aufirst%3DA.%26aulast%3DAnastasios%26aufirst%3DO.%26aulast%3DNenopoulou%26aufirst%3DS.%26aulast%3DTsolaki-Tagaraki%26aufirst%3DF.%26aulast%3DPakaski%26aufirst%3DM.%26aulast%3DDereeper%26aufirst%3DO.%26aulast%3Dde%2Bla%2BSayette%26aufirst%3DV.%26aulast%3DSenechal%26aufirst%3DO.%26aulast%3DLavenu%26aufirst%3DI.%26aulast%3DDevendeville%26aufirst%3DA.%26aulast%3DCalais%26aufirst%3DG.%26aulast%3DCrawford%26aufirst%3DF.%26aulast%3DMullan%26aufirst%3DM.%26atitle%3DNilvadipine%2520in%2520mild%2520to%2520moderate%2520Alzheimer%2520disease%253A%2520A%2520randomised%2520controlled%2520trial%26jtitle%3DPLoS%2520Med.%26date%3D2018%26volume%3D15%26issue%3D9%26spage%3De1002660%26doi%3D10.1371%2Fjournal.pmed.1002660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nimmrich, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, A.</span></span> <span> </span><span class="NLM_article-title">Calcium channel blockers and dementia</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>169</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1203</span>â <span class="NLM_lpage">1210</span>, <span class="refDoi">Â DOI: 10.1111/bph.12240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1111%2Fbph.12240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=23638877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVajsLbN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2013&pages=1203-1210&issue=6&author=V.+Nimmrichauthor=A.+Eckert&title=Calcium+channel+blockers+and+dementia&doi=10.1111%2Fbph.12240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium channel blockers and dementia</span></div><div class="casAuthors">Nimmrich, V.; Eckert, A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1203-1210</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Degenerative dementia is mainly caused by Alzheimer's disease and/or cerebrovascular abnormalities.  Disturbance of the intracellular calcium homeostasis is central to the pathophysiol. of neurodegeneration.  In Alzheimer's disease, enhanced calcium load may be brought about by extracellular accumulation of amyloid-Î².  Recent studies suggest that sol. forms facilitate influx through calcium-conducting ion channels in the plasma membrane, leading to excitotoxic neurodegeneration.  Calcium channel blockade attenuates amyloid-Î²-induced neuronal decline in vitro and is neuroprotective in animal models.  Vascular dementia, on the other hand, is caused by cerebral hypoperfusion and may benefit from calcium channel blockade due to relaxation of the cerebral vasculature.  Several calcium channel blockers have been tested in clin. trials of dementia and the outcome is heterogeneous.  Nimodipine as well as nilvadipine prevent cognitive decline in some trials, whereas other calcium channel blockers failed.  In trials with a pos. outcome, BP redn. did not seem to play a role in preventing dementia, indicating a direct protecting effect on neurons.  An optimization of calcium channel blockers for the treatment of dementia may involve an increase of selectivity for presynaptic calcium channels and an improvement of the affinity to the inactivated state.  Novel low mol. wt. compds. suitable for proof-of-concept studies are now available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1LmtHTozWHrVg90H21EOLACvtfcHk0lh-X4kUXlHRaQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVajsLbN&md5=9f5ea618c201fdad2ae66529110c6963</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1111%2Fbph.12240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12240%26sid%3Dliteratum%253Aachs%26aulast%3DNimmrich%26aufirst%3DV.%26aulast%3DEckert%26aufirst%3DA.%26atitle%3DCalcium%2520channel%2520blockers%2520and%2520dementia%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D169%26issue%3D6%26spage%3D1203%26epage%3D1210%26doi%3D10.1111%2Fbph.12240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roache, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ait-Daoud, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauldin, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murff, W. L.</span></span> <span> </span><span class="NLM_article-title">Effects of repeated-dose isradipine on the abuse liability of cocaine</span>. <i>Exp. Clin. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">319</span>â <span class="NLM_lpage">326</span>, <span class="refDoi">Â DOI: 10.1037/1064-1297.13.4.319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1037%2F1064-1297.13.4.319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=16366762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmt1Ghsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=319-326&issue=4&author=J.+D.+Roacheauthor=B.+A.+Johnsonauthor=N.+Ait-Daoudauthor=J.+B.+Mauldinauthor=J.+E.+Thorntonauthor=L.+T.+Wellsauthor=W.+L.+Murff&title=Effects+of+repeated-dose+isradipine+on+the+abuse+liability+of+cocaine&doi=10.1037%2F1064-1297.13.4.319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of repeated-dose isradipine on the abuse liability of cocaine</span></div><div class="casAuthors">Roache, John D.; Johnson, Bankole A.; Ait-Daoud, Nassima; Mauldin, James B.; Thornton, Joe E.; Wells, Lynda T.; Murff, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">319-326</span>CODEN:
                <span class="NLM_cas:coden">ECLPES</span>;
        ISSN:<span class="NLM_cas:issn">1064-1297</span>.
    
            (<span class="NLM_cas:orgname">American Psychological Association</span>)
        </div><div class="casAbstract">Despite preclin. studies suggesting that isradipine may antagonize the abuse liability of cocaine, pretreatment with sustained-release isradipine did not reduce euphoric mood in cocaine-using volunteers.  This double-blind, within-subject, crossover lab. study detd. whether maximal dose-loading with isradipine could antagonize effects of cocaine in 12 cocaine-dependent research volunteers administered i.v. cocaine doses (0, 0.325, and 0.65 mg/kg) on different days after 5 days of treatment with isradipine or placebo.  Isradipine dose was 30 mg sustained release nightly plus 15 mg immediate release 2 h before cocaine infusion.  Cocaine produced dose-related increases in cocaine's subjective effects and a behavioral measure of reinforcement.  Isradipine enhanced, rather than antagonized, subjective effects, indicating that isradipine does not antagonize cocaine's abuse liability in dependent research volunteers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXKyBOId5_6bVg90H21EOLACvtfcHk0lh-X4kUXlHRaQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmt1Ghsw%253D%253D&md5=94a956a086c71524198bf292a927d5ad</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1037%2F1064-1297.13.4.319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1037%252F1064-1297.13.4.319%26sid%3Dliteratum%253Aachs%26aulast%3DRoache%26aufirst%3DJ.%2BD.%26aulast%3DJohnson%26aufirst%3DB.%2BA.%26aulast%3DAit-Daoud%26aufirst%3DN.%26aulast%3DMauldin%26aufirst%3DJ.%2BB.%26aulast%3DThornton%26aufirst%3DJ.%2BE.%26aulast%3DWells%26aufirst%3DL.%2BT.%26aulast%3DMurff%26aufirst%3DW.%2BL.%26atitle%3DEffects%2520of%2520repeated-dose%2520isradipine%2520on%2520the%2520abuse%2520liability%2520of%2520cocaine%26jtitle%3DExp.%2520Clin.%2520Psychopharmacol.%26date%3D2005%26volume%3D13%26issue%3D4%26spage%3D319%26epage%3D326%26doi%3D10.1037%2F1064-1297.13.4.319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacology of ampakine modulators: From AMPA receptors to synapses and behavior</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">583</span>â <span class="NLM_lpage">602</span>, <span class="refDoi">Â DOI: 10.2174/138945007780618490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.2174%2F138945007780618490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=17504103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsVWmurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=583-602&issue=5&author=A.+C.+Araiauthor=M.+Kessler&title=Pharmacology+of+ampakine+modulators%3A+From+AMPA+receptors+to+synapses+and+behavior&doi=10.2174%2F138945007780618490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior</span></div><div class="casAuthors">Arai, A. C.; Kessler, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">583-602</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Ampakines are drugs structurally derived from aniracetam that potentiate currents mediated by AMPA type glutamate receptors.  These drugs slow deactivation and attenuate desensitization of AMPA receptor currents, increase synaptic responses and enhance long-term potentiation.  This review focuses mainly on recent physiol. studies and on evidence for two distinct subfamilies.  Type I compds. like CX546 are very effective in prolonging synaptic responses while type II compds. like CX516 mainly increase response amplitude.  Type I and II drugs do not compete in binding assays and thus presumably act through sep. sites.  Their differences are likely to have consequences also for synaptic plasticity and behavior.  Thus, while all ampakines facilitated long-term potentiation, only CX546 enhanced long-term depression.  Further discussed are studies showing that ampakine effects vary substantially between neurons, with increases in EPSCs being larger in CA1 pyramidal cells than in thalamus and in hippocampal interneurons.  In behavioral tests, ampakines facilitate learning in many paradigms including odor discrimination, spatial mazes, and conditioning, and they improved short-term memory in a non-matching-to-sample task.  Pos. results were also obtained in various psychol. tests with human subjects.  The drugs were effective in correcting behaviors in various animal models of schizophrenia and depression.  Lastly, evidence is discussed that ampakines have few adverse effects at therapeutically relevant concns. and that they protect neurons against neurotoxic insults, in part by mobilizing growth factors like BDNF.  Type II drugs like CX516 in particular appear to be inherently safe since their ability to prolong responses is kinetically limited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoUgfoEMXCALVg90H21EOLACvtfcHk0lh-X4kUXlHRaQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsVWmurk%253D&md5=77ecd4442f0c551eaec7a9d52c218efc</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.2174%2F138945007780618490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945007780618490%26sid%3Dliteratum%253Aachs%26aulast%3DArai%26aufirst%3DA.%2BC.%26aulast%3DKessler%26aufirst%3DM.%26atitle%3DPharmacology%2520of%2520ampakine%2520modulators%253A%2520From%2520AMPA%2520receptors%2520to%2520synapses%2520and%2520behavior%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2007%26volume%3D8%26issue%3D5%26spage%3D583%26epage%3D602%26doi%3D10.2174%2F138945007780618490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, G.</span></span> <span> </span><span class="NLM_article-title">Glutamate-based therapeutic approaches: Ampakines</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">82</span>â <span class="NLM_lpage">88</span>, <span class="refDoi">Â DOI: 10.1016/j.coph.2005.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.coph.2005.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=16361116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVyntg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=82-88&issue=1&author=G.+Lynch&title=Glutamate-based+therapeutic+approaches%3A+Ampakines&doi=10.1016%2Fj.coph.2005.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate-based therapeutic approaches: ampakines</span></div><div class="casAuthors">Lynch, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">82-88</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Ampakines are a structurally diverse family of small mols. that pos. modulate Î±-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors, and thereby enhance fast, excitatory transmission throughout the brain.  Surprisingly, ampakines have discrete effects on brain activity and behavior.  Because their excitatory synaptic targets mediate communication between cortical regions, serve as sites of memory encoding, and regulate the prodn. of growth factors, ampakines have a broad range of potential therapeutic applications.  Several of these possibilities were tested with pos. results in preclin. models; preliminary clin. work was also encouraging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2MuTJBdzIKrVg90H21EOLACvtfcHk0lh0IapnjZL8vQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVyntg%253D%253D&md5=0c7a59d125d380902d33d9b156715800</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2005.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2005.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DG.%26atitle%3DGlutamate-based%2520therapeutic%2520approaches%253A%2520Ampakines%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2006%26volume%3D6%26issue%3D1%26spage%3D82%26epage%3D88%26doi%3D10.1016%2Fj.coph.2005.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, M.</span></span> <span> </span><span class="NLM_article-title">Benzamide-type AMPA receptor modulators form two subfamilies with distinct modes of action</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>303</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1075</span>â <span class="NLM_lpage">1085</span>, <span class="refDoi">Â DOI: 10.1124/jpet.102.040360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1124%2Fjpet.102.040360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=12438530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD38Xptlamtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2002&pages=1075-1085&issue=3&author=A.+C.+Araiauthor=Y.+F.+Xiaauthor=G.+Rogersauthor=G.+Lynchauthor=M.+Kessler&title=Benzamide-type+AMPA+receptor+modulators+form+two+subfamilies+with+distinct+modes+of+action&doi=10.1124%2Fjpet.102.040360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Benzamide-type AMPA receptor modulators form two subfamilies with distinct modes of action</span></div><div class="casAuthors">Arai, Amy C.; Xia, Yan-Fang; Rogers, Gary; Lynch, Gary; Kessler, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1075-1085</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">CX516 (BDP-12) and CX546, two first-generation benzamide-type AMPA receptor modulators, were compared with regard to their influence on AMPA receptor-mediated currents, autaptic responses in cultured hippocampal neurons, hippocampal excitatory postsynaptic currents, synaptic field potentials, and agonist binding.  The two drugs exhibited comparable potencies in most tests but differed in their efficacy and in their relative impact on various response parameters.  CX546 greatly prolonged the duration of synaptic responses, and it slowed 10-fold the deactivation of excised-patch currents following 1-ms pulses of glutamate.  The effects of CX516 on those measures were, by comparison, small; however, the drug was equally or more efficacious than CX546 in increasing the amplitude of synaptic responses.  This double dissocn. suggests that amplitude and duration of synaptic responses are governed by different aspects of receptor kinetics, which are differentially modified by the two drugs.  These effects can be reproduced in receptor simulations if one assumes that CX516 preferentially accelerates channel opening while CX546 slows channel closing.  In binding tests, CX546 caused an approx. 2-fold increase in the affinity for radiolabeled agonists, whereas CX516 was ineffective.  More importantly, even millimolar concns. of CX516 did not influence the dose-response relation for CX546, suggesting the possibility that they bind to different sites.  Taken together, the evidence suggests that benzamide modulators from the Ampakine family form two subgroups with different modes and sites of action.  Of these, CX516-type drugs may have the greater therapeutic utility because of their limited efficacy in prolonging synaptic responses and in attenuating receptor desensitization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfeJ4I3maOf7Vg90H21EOLACvtfcHk0lh0IapnjZL8vQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xptlamtbw%253D&md5=8f49bf660b3269eb267a5b40f67ad720</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.040360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.040360%26sid%3Dliteratum%253Aachs%26aulast%3DArai%26aufirst%3DA.%2BC.%26aulast%3DXia%26aufirst%3DY.%2BF.%26aulast%3DRogers%26aufirst%3DG.%26aulast%3DLynch%26aufirst%3DG.%26aulast%3DKessler%26aufirst%3DM.%26atitle%3DBenzamide-type%2520AMPA%2520receptor%2520modulators%2520form%2520two%2520subfamilies%2520with%2520distinct%2520modes%2520of%2520action%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D303%26issue%3D3%26spage%3D1075%26epage%3D1085%26doi%3D10.1124%2Fjpet.102.040360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bliss, T. V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collingridge, G. L.</span></span> <span> </span><span class="NLM_article-title">A synaptic model of memory: Long-term potentiation in the hippocampus</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>361</i></span> (<span class="NLM_issue">6407</span>),  <span class="NLM_fpage">31</span>â <span class="NLM_lpage">39</span>, <span class="refDoi">Â DOI: 10.1038/361031a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2F361031a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=8421494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK3sXntlOntw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=1993&pages=31-39&issue=6407&author=T.+V.+P.+Blissauthor=G.+L.+Collingridge&title=A+synaptic+model+of+memory%3A+Long-term+potentiation+in+the+hippocampus&doi=10.1038%2F361031a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">A synaptic model of memory:  long-term potentiation in the hippocampus</span></div><div class="casAuthors">Bliss, T. V. P.; Collingridge, G. L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">6407</span>),
    <span class="NLM_cas:pages">31-9</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">A review, with 174 refs., of long-term potentiation (LTP) of synaptic transmission in the hippocampus as the primary exptl. model for investigating the synaptic basis of learning and memory in vertebrates.  Topics discussed were: properties of hippocampal LTP; induction of LTP; and expression of LTP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD1tHZif2aP7Vg90H21EOLACvtfcHk0lh0IapnjZL8vQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXntlOntw%253D%253D&md5=285f5a175da5a77f4f57a3f5236e3e0a</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2F361031a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F361031a0%26sid%3Dliteratum%253Aachs%26aulast%3DBliss%26aufirst%3DT.%2BV.%2BP.%26aulast%3DCollingridge%26aufirst%3DG.%2BL.%26atitle%3DA%2520synaptic%2520model%2520of%2520memory%253A%2520Long-term%2520potentiation%2520in%2520the%2520hippocampus%26jtitle%3DNature%26date%3D1993%26volume%3D361%26issue%3D6407%26spage%3D31%26epage%3D39%26doi%3D10.1038%2F361031a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Zastrow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malenka, R. C.</span></span> <span> </span><span class="NLM_article-title">Role of AMPA receptor endocytosis in synaptic plasticity</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">315</span>â <span class="NLM_lpage">324</span>, <span class="refDoi">Â DOI: 10.1038/35072500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2F35072500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=11331915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjs1Ogtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=315-324&issue=5&author=R.+C.+Carrollauthor=E.+C.+Beattieauthor=M.+Von+Zastrowauthor=R.+C.+Malenka&title=Role+of+AMPA+receptor+endocytosis+in+synaptic+plasticity&doi=10.1038%2F35072500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Role of AMPA receptor endocytosis in synaptic plasticity</span></div><div class="casAuthors">Carroll, Reed C.; Beattie, Eric C.; Von Zastrow, Mark; Malenka, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">315-324</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with 96 refs.  Activity-mediated changes in the strength of synaptic communication are important for the establishment of proper neuronal connections during development and for the experience-dependent modification of neural circuitry that is believed to underlie all forms of behavioral plasticity.  Owing to the wide-ranging significance of synaptic plasticity, considerable efforts have been made to identify the mechanisms by which synaptic changes are triggered and expressed.  New evidence indicates that one important expression mechanism of several long-lasting forms of synaptic plasticity might involve the phys. transport of AMPA-type glutamate receptors in and out of the synaptic membrane.  Here, the authors focus on the rapidly accumulating evidence that AMPA receptors undergo regulated endocytosis, which is important for long-term depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreym3vak6-8rVg90H21EOLACvtfcHk0lh0IapnjZL8vQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjs1Ogtrw%253D&md5=4ad17e0efc53dc820ee5f3a3bf7d700b</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1038%2F35072500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35072500%26sid%3Dliteratum%253Aachs%26aulast%3DCarroll%26aufirst%3DR.%2BC.%26aulast%3DBeattie%26aufirst%3DE.%2BC.%26aulast%3DVon%2BZastrow%26aufirst%3DM.%26aulast%3DMalenka%26aufirst%3DR.%2BC.%26atitle%3DRole%2520of%2520AMPA%2520receptor%2520endocytosis%2520in%2520synaptic%2520plasticity%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2001%26volume%3D2%26issue%3D5%26spage%3D315%26epage%3D324%26doi%3D10.1038%2F35072500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Volk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, S.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huganir, R. L.</span></span> <span> </span><span class="NLM_article-title">Glutamate synapses in human cognitive disorders</span>. <i>Annu. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">127</span>â <span class="NLM_lpage">149</span>, <span class="refDoi">Â DOI: 10.1146/annurev-neuro-071714-033821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1146%2Fannurev-neuro-071714-033821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=25897873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCjurfE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2015&pages=127-149&author=L.+Volkauthor=S.-L.+Chiuauthor=K.+Sharmaauthor=R.+L.+Huganir&title=Glutamate+synapses+in+human+cognitive+disorders&doi=10.1146%2Fannurev-neuro-071714-033821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate Synapses in Human Cognitive Disorders</span></div><div class="casAuthors">Volk, Lenora; Chiu, Shu-Ling; Sharma, Kamal; Huganir, Richard L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127-149</span>CODEN:
                <span class="NLM_cas:coden">ARNSD5</span>;
        ISSN:<span class="NLM_cas:issn">0147-006X</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">Recent evidence supports the idea that abnormal excitatory synapse function is a major cause of human cognitive disease.  Accumulating data from large genetic assocn. studies indicate that alterations in glutamatergic synapse structure and function represent a common underlying pathol. in many symptomatically distinct cognitive disorders.  In this review, we discuss evidence from human genetic studies and data from animal models supporting a role for aberrant glutamatergic synapse function in the etiol. of intellectual disability (ID), autism spectrum disorder (ASD), and schizophrenia (SCZ), neurodevelopmental disorders that comprise a significant proportion of human cognitive disease and exact a substantial financial and social burden.  We focus on the most promising candidate genes affecting glutamatergic synapse function, highlighting the likely disease-relevant functional consequences of each.  The varied manifestations of impaired perceptual processing, executive function, social interaction, communication, and/or intellectual ability in ID, ASD, and SCZ appear to emerge from altered neural microstructure, function, and/or wiring rather than gross changes in neuron no. or morphol.  Here, we review evidence that these disorders may share a common underlying neuropathy: altered excitatory synapse function.  We first present a brief overview of glutamatergic synapses and then explore the genetic and phenotypic evidence for altered glutamate signaling in ID, ASD, and SCZ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowaHGkEoyPJ7Vg90H21EOLACvtfcHk0ljUO-m4LokSMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCjurfE&md5=cc8d0cdea404920debc33a55b7ce3c55</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1146%2Fannurev-neuro-071714-033821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-neuro-071714-033821%26sid%3Dliteratum%253Aachs%26aulast%3DVolk%26aufirst%3DL.%26aulast%3DChiu%26aufirst%3DS.-L.%26aulast%3DSharma%26aufirst%3DK.%26aulast%3DHuganir%26aufirst%3DR.%2BL.%26atitle%3DGlutamate%2520synapses%2520in%2520human%2520cognitive%2520disorders%26jtitle%3DAnnu.%2520Rev.%2520Neurosci.%26date%3D2015%26volume%3D38%26spage%3D127%26epage%3D149%26doi%3D10.1146%2Fannurev-neuro-071714-033821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woolley, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gartlon, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaughnessy, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pemberton, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harries, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southam, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, L. A.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>202</i></span>,  <span class="NLM_fpage">343</span>â <span class="NLM_lpage">354</span>, <span class="refDoi">Â DOI: 10.1007/s00213-008-1325-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1007%2Fs00213-008-1325-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=18795266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1egs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=2009&pages=343-354&author=M.+L.+Woolleyauthor=K.+A.+Watersauthor=J.+E.+Gartlonauthor=L.+P.+Lacroixauthor=C.+Jenningsauthor=F.+Shaughnessyauthor=A.+Ongauthor=D.+J.+Pembertonauthor=M.+H.+Harriesauthor=E.+Southamauthor=D.+N.+Jonesauthor=L.+A.+Dawson&title=Evaluation+of+the+pro-cognitive+effects+of+the+AMPA+receptor+positive+modulator%2C+5-%281-piperidinylcarbonyl%29-2%2C1%2C3-benzoxadiazole+%28CX691%29%2C+in+the+rat&doi=10.1007%2Fs00213-008-1325-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat</span></div><div class="casAuthors">Woolley, M. L.; Waters, K. A.; Gartlon, J. E.; Lacroix, L. P.; Jennings, C.; Shaughnessy, F.; Ong, A.; Pemberton, D. J.; Harries, M. H.; Southam, E.; Jones, D. N. C.; Dawson, L. A.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">343-354</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Pos. allosteric modulators of the glutamatergic Î±-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor do not stimulate AMPA receptors directly but delay deactivation of the receptor and/or slow its desensitization.  This results in increased synaptic responses and enhanced long-term potentiation.  Thus, it has been suggested that such compds. may have utility for the treatment of cognitive impairment.  The objective of the study was to investigate the effect of an AMPA pos. modulator, CX691, (1) in three rodent models of learning and memory, (2) on neurochem. in the dorsal hippocampus and medial prefrontal cortex following acute administration, and (3) on brain-derived neurotrophic factor (BDNF) mRNA expression in the rat hippocampus following acute and sub-chronic administration.  CX691 attenuated a scopolamine-induced impairment of cued fear conditioning following acute administration (0.1 mg/kg p.o.) and a temporally induced deficit in novel object recognition following both acute (0.1 and 1.0 mg/kg p.o.) and sub-chronic (bi-daily for 7 days) administration (0.01, 0.03, 0.1 mg/kg p.o.).  It also improved attentional set-shifting following sub-chronic administration (0.3 mg/kg p.o.).  Acute CX691 (0.1, 0.3 and 1.0 mg/kg, p.o.) increased extracellular levels of acetylcholine in the dorsal hippocampus and medial prefrontal cortex and dopamine in the medial prefrontal cortex.  Sub-chronic administration of CX691 (0.1 mg/kg, p.o.) elevated BDNF mRNA expression in both the whole and CA1 sub-region of the hippocampus (P < 0.05).  Collectively, these data support the pro-cognitive activity reported for AMPA receptor pos. modulators and suggest that these compds. may be of benefit in treating disorders characterized by cognitive deficits such as Alzheimer's disease and schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv76MXCyplH7Vg90H21EOLACvtfcHk0ljUO-m4LokSMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1egs7g%253D&md5=3ee6ea548c203fcf5c6c620501ceb758</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1007%2Fs00213-008-1325-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-008-1325-2%26sid%3Dliteratum%253Aachs%26aulast%3DWoolley%26aufirst%3DM.%2BL.%26aulast%3DWaters%26aufirst%3DK.%2BA.%26aulast%3DGartlon%26aufirst%3DJ.%2BE.%26aulast%3DLacroix%26aufirst%3DL.%2BP.%26aulast%3DJennings%26aufirst%3DC.%26aulast%3DShaughnessy%26aufirst%3DF.%26aulast%3DOng%26aufirst%3DA.%26aulast%3DPemberton%26aufirst%3DD.%2BJ.%26aulast%3DHarries%26aufirst%3DM.%2BH.%26aulast%3DSoutham%26aufirst%3DE.%26aulast%3DJones%26aufirst%3DD.%2BN.%26aulast%3DDawson%26aufirst%3DL.%2BA.%26atitle%3DEvaluation%2520of%2520the%2520pro-cognitive%2520effects%2520of%2520the%2520AMPA%2520receptor%2520positive%2520modulator%252C%25205-%25281-piperidinylcarbonyl%2529-2%252C1%252C3-benzoxadiazole%2520%2528CX691%2529%252C%2520in%2520the%2520rat%26jtitle%3DPsychopharmacology%26date%3D2009%26volume%3D202%26spage%3D343%26epage%3D354%26doi%3D10.1007%2Fs00213-008-1325-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Radin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippa, A. S.</span></span> <span> </span><span class="NLM_article-title">Effects of chronic systemic low-impact ampakine treatment on neurotrophin expression in rat brain</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">540</span>â <span class="NLM_lpage">544</span>, <span class="refDoi">Â DOI: 10.1016/j.biopha.2018.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.biopha.2018.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=29886374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFSmtrbO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2018&pages=540-544&author=D.+P.+Radinauthor=S.+Johnsonauthor=R.+Purcellauthor=A.+S.+Lippa&title=Effects+of+chronic+systemic+low-impact+ampakine+treatment+on+neurotrophin+expression+in+rat+brain&doi=10.1016%2Fj.biopha.2018.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of chronic systemic low-impact ampakine treatment on neurotrophin expression in rat brain</span></div><div class="casAuthors">Radin, Daniel P.; Johnson, Steven; Purcell, Richard; Lippa, Arnold S.</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">540-544</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Neurotrophin dysregulation has been implicated in a large no. of neurodegenerative and neuropsychiatric diseases.  Unfortunately, neurotrophins cannot cross the blood brain barrier thus, novel means of up regulating their expression are greatly needed.  It has been demonstrated previously that neurotrophins are up regulated in response to increases in brain activity.  Therefore, mols. that act as cognitive enhancers may provide a clin. means of up regulating neurotrophin expression.  Ampakines are a class of mols. that act as pos. allosteric modulators of AMPA-type glutamate receptors.  Currently, they are being developed to prevent opioid-induced respiratory depression without sacrificing the analgesic properties of the opioids.  In addn., these mols. increase neuronal activity and have been shown to restore age-related deficits in LTP in aged rats.  In the current study, we examd. whether two different ampakines could increase levels of BDNF and NGF at doses that are active in behavioral measures of cognition.  Results demonstrate that ampakines CX516 and CX691 induce differential increases in neurotrophins across several brain regions.  Notable increases in NGF were obsd. in the dentate gyrus and piriform cortex while notable BDNF increases were obsd. in basolateral and lateral nuclei of the amygdala.  Taken together, our data demonstrates that chronic administration of clin. relevant doses of ampakines have the ability to elevate neurotrophin expression in different brain regions, and may have therapeutic benefit in multiple neurodegenerative and/or neuropsychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTCPDEB26KrbVg90H21EOLACvtfcHk0ljUO-m4LokSMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFSmtrbO&md5=2476357494ccda889262c86401afc2c3</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2018.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2018.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DRadin%26aufirst%3DD.%2BP.%26aulast%3DJohnson%26aufirst%3DS.%26aulast%3DPurcell%26aufirst%3DR.%26aulast%3DLippa%26aufirst%3DA.%2BS.%26atitle%3DEffects%2520of%2520chronic%2520systemic%2520low-impact%2520ampakine%2520treatment%2520on%2520neurotrophin%2520expression%2520in%2520rat%2520brain%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2018%26volume%3D105%26spage%3D540%26epage%3D544%26doi%3D10.1016%2Fj.biopha.2018.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">OâNeill, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleakman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nisenbaum, E. S.</span></span> <span> </span><span class="NLM_article-title">AMPA receptor potentiators for the treatment of CNS disorders</span>. <i>Curr. Drug Targets: CNS Neurol. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">181</span>â <span class="NLM_lpage">194</span>, <span class="refDoi">Â DOI: 10.2174/1568007043337508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.2174%2F1568007043337508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=15180479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltFCgu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=181-194&issue=3&author=M.+J.+O%E2%80%99Neillauthor=D.+Bleakmanauthor=D.+M.+Zimmermanauthor=E.+S.+Nisenbaum&title=AMPA+receptor+potentiators+for+the+treatment+of+CNS+disorders&doi=10.2174%2F1568007043337508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">AMPA receptor potentiators for the treatment of CNS disorders</span></div><div class="casAuthors">O'Neill, Michael J.; Bleakman, David; Zimmerman, Dennis M.; Nisenbaum, Eric S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets: CNS & Neurological Disorders</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-194</span>CODEN:
                <span class="NLM_cas:coden">CDTCCC</span>;
        ISSN:<span class="NLM_cas:issn">1568-007X</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Glutamate Î±-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors mediate most of the excitatory neurotransmission in the mammalian central nervous system and also participate in forms of synaptic plasticity thought to underlie memory and learning, and the formation of neural networks during development.  Mol. cloning techniques have shown that the AMPA receptor family is composed of 4 different subunits named GluR1-4 or GluRA-D (newly termed as GluA1-GluA4) and native AMPA receptors are most likely tetramers generated by the assembly of 1 or more of these subunits, yielding homomeric or heteromeric receptors.  Addnl. complexity among AMPA receptors is conferred by alternative splicing of RNA for each subunit giving rise to flip and flop variants.  Clin. and exptl. data have suggested that pos. modulation of AMPA receptors may be therapeutically effective in the treatment of cognitive deficits.  Several classes of AMPA receptor potentiators were reported, including pyrrolidones (piracetam, aniracetam), benzothiazides (cyclothiazide), benzylpiperidines (CX-516, CX-546), and more recently biarylpropylsulfonamides (LY392098, LY404187 and LY503430).  These mols. enhance cognitive function in rodents, which appears to correlate with increased hippocampal activity.  In addn., clin. studies have suggested that AMPA receptor modulators enhance cognitive function in elderly subjects, as well as patients suffering from neurol. and psychiatric disorders.  Several independent studies have suggested that AMPA receptors can increase BDNF expression by both calcium-dependent and independent pathways.  For example, recent studies have shown that AMPA receptors interact with the protein Tyr kinase, Lyn.  Activation of Lyn can recruit the mitogen-activated protein kinase (MAPK) signalling pathway and increase the expression of BDNF.  Therefore, in addn. to directly enhancing glutamatergic synaptic transmission, AMPA receptor activation can increase the expression of BDNF in vitro and in vivo.  This may account for activity of AMPA receptor potentiators in rodent models predictive of antidepressant activity (forced swim and tail suspension tests).  The increase in neurotrophin expression also may contribute to the functional, neuroprotective, and neurotrophic actions of LY404187 and LY503430 after infusion of 6-OHDA into the substantia nigra.  In conclusion, several potent, selective and systematically active AMPA receptor potentiators were reported.  Data indicate that these mols. modulate glutamatergic transmission, enhance synaptic transmission, long-term potentiation (LTP), and increase neurotrophin expression.  Therefore, these AMPA receptor potentiators offer an exciting new class of drugs with potentials for treating (1) cognitive impairment assocd. with Alzheimer's disease and schizophrenia, (2) depression, (3) slowing the progression and potentially enhancing recovery from Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHYMd0O34_SLVg90H21EOLACvtfcHk0lhxH1eUlL-a5Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltFCgu7g%253D&md5=5d438c3c4cc13fa863608073601cc6a1</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.2174%2F1568007043337508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568007043337508%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DM.%2BJ.%26aulast%3DBleakman%26aufirst%3DD.%26aulast%3DZimmerman%26aufirst%3DD.%2BM.%26aulast%3DNisenbaum%26aufirst%3DE.%2BS.%26atitle%3DAMPA%2520receptor%2520potentiators%2520for%2520the%2520treatment%2520of%2520CNS%2520disorders%26jtitle%3DCurr.%2520Drug%2520Targets%253A%2520CNS%2520Neurol.%2520Disord.%26date%3D2004%26volume%3D3%26issue%3D3%26spage%3D181%26epage%3D194%26doi%3D10.2174%2F1568007043337508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wezenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkes, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruigt, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulstijn, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbe, B. G.</span></span> <span> </span><span class="NLM_article-title">Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1272</span>â <span class="NLM_lpage">1283</span>, <span class="refDoi">Â DOI: 10.1038/sj.npp.1301257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2Fsj.npp.1301257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=17119538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlaqtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=1272-1283&issue=6&author=E.+Wezenbergauthor=R.+J.+Verkesauthor=G.+S.+Ruigtauthor=W.+Hulstijnauthor=B.+G.+Sabbe&title=Acute+effects+of+the+ampakine+farampator+on+memory+and+information+processing+in+healthy+elderly+volunteers&doi=10.1038%2Fsj.npp.1301257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Acute Effects of the Ampakine Farampator on Memory and Information Processing in Healthy Elderly Volunteers</span></div><div class="casAuthors">Wezenberg, Elke; Jan Verkes, Robert; Ruigt, Ge S. F.; Hulstijn, Wouter; Sabbe, Bernard G. C.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1272-1283</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ampakines act as pos. allosteric modulators of AMPA-type glutamate receptors and facilitate hippocampal long-term potentiation (LTP), a mechanism assocd. with memory storage and consolidation.  The present study investigated the acute effects of farampator, 1-(benzofurazan-5-ylcarbonyl) piperidine, on memory and information processes in healthy elderly volunteers.  A double-blind, placebo-controlled, randomized, cross-over study was performed in 16 healthy, elderly volunteers (eight male, eight female; mean age 66.1, SD 4.5 years).  All subjects received farampator (500 mg) and placebo.  Testing took place 1 h after drug intake, which was around Tmax for farampator.  Subjects performed tasks assessing episodic memory (wordlist learning and picture memory), working and short-term memory (N-back, symbol recall) and motor learning (maze task, pursuit rotor).  Information processing was assessed with a tangled lines task, the symbol digit substitution test (SDST) and the continuous trail making test (CTMT).  Farampator (500 mg) unequivocally improved short-term memory but appeared to impair episodic memory.  Furthermore, it tended to decrease the no. of switching errors in the CTMT.  Drug-induced side effects (SEs) included headache, somnolence and nausea.  Subjects with SEs had significantly higher plasma levels of farampator than subjects without SEs.  Addnl. analyses revealed that in the farampator condition the group without SEs showed a significantly superior memory performance relative to the group with SEs.  The pos. results on short-term memory and the favorable trends in the trail making test (CTMT) are interesting in view of the development of ampakines in the treatment of Alzheimer's disease and schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov4kJJWKwAH7Vg90H21EOLACvtfcHk0lhxH1eUlL-a5Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlaqtbc%253D&md5=889f62faa887fb9f5f7b823d7d26c43c</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1301257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1301257%26sid%3Dliteratum%253Aachs%26aulast%3DWezenberg%26aufirst%3DE.%26aulast%3DVerkes%26aufirst%3DR.%2BJ.%26aulast%3DRuigt%26aufirst%3DG.%2BS.%26aulast%3DHulstijn%26aufirst%3DW.%26aulast%3DSabbe%26aufirst%3DB.%2BG.%26atitle%3DAcute%2520effects%2520of%2520the%2520ampakine%2520farampator%2520on%2520memory%2520and%2520information%2520processing%2520in%2520healthy%2520elderly%2520volunteers%26jtitle%3DNeuropsychopharmacology%26date%3D2007%26volume%3D32%26issue%3D6%26spage%3D1272%26epage%3D1283%26doi%3D10.1038%2Fsj.npp.1301257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambros-Ingerson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schehr, R.</span></span> <span> </span><span class="NLM_article-title">Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>145</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">89</span>â <span class="NLM_lpage">92</span>, <span class="refDoi">Â DOI: 10.1006/exnr.1997.6447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1006%2Fexnr.1997.6447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=9184112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK2sXjvVyitb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=1997&pages=89-92&issue=1&author=G.+Lynchauthor=R.+Grangerauthor=J.+Ambros-Ingersonauthor=C.+M.+Davisauthor=M.+Kesslerauthor=R.+Schehr&title=Evidence+that+a+positive+modulator+of+AMPA-type+glutamate+receptors+improves+delayed+recall+in+aged+humans&doi=10.1006%2Fexnr.1997.6447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans</span></div><div class="casAuthors">Lynch, Gary; Granger, Richard; Ambros-Ingerson, Jose; Davis, C. Mike; Kessler, Markus; Schehr, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-92</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Elderly subjects (65-76 yr) were tested for recall of nonsense syllables prior to and after oral administration of 1-(quinoxalin-6-ylcarbonyl)piperidine (CX516), a centrally active drug that enhances currents mediated by AMPA-type glutamate receptors.  A significant and pos. drug effect was found for delayed (5 min) recall at 75 min post-treatment; av. scores for the highest dose group were >2-fold greater than for the placebo group.  The drug had no evident influence on heart rate or self-assessment of several psychol. variables.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5f-3h5SwCTLVg90H21EOLACvtfcHk0lhxH1eUlL-a5Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjvVyitb4%253D&md5=49509daff4308342655279c1ccdb8a06</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1006%2Fexnr.1997.6447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fexnr.1997.6447%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DG.%26aulast%3DGranger%26aufirst%3DR.%26aulast%3DAmbros-Ingerson%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DC.%2BM.%26aulast%3DKessler%26aufirst%3DM.%26aulast%3DSchehr%26aufirst%3DR.%26atitle%3DEvidence%2520that%2520a%2520positive%2520modulator%2520of%2520AMPA-type%2520glutamate%2520receptors%2520improves%2520delayed%2520recall%2520in%2520aged%2520humans%26jtitle%3DExp.%2520Neurol.%26date%3D1997%26volume%3D145%26issue%3D1%26spage%3D89%26epage%3D92%26doi%3D10.1006%2Fexnr.1997.6447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marenco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knable, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClure, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winterer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberger, D. R.</span></span> <span> </span><span class="NLM_article-title">Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: A case series</span>. <i>Schizophr. Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">221</span>â <span class="NLM_lpage">226</span>, <span class="refDoi">Â DOI: 10.1016/S0920-9964(01)00311-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2FS0920-9964%2801%2900311-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=12223253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BD38vmsVCksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2002&pages=221-226&issue=2&author=S.+Marencoauthor=M.+F.+Eganauthor=T.+E.+Goldbergauthor=M.+B.+Knableauthor=R.+K.+McClureauthor=G.+Wintererauthor=D.+R.+Weinberger&title=Preliminary+experience+with+an+ampakine+%28CX516%29+as+a+single+agent+for+the+treatment+of+schizophrenia%3A+A+case+series&doi=10.1016%2FS0920-9964%2801%2900311-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series</span></div><div class="casAuthors">Marenco Stefano; Egan Michael F; Goldberg Terry E; Knable Michael B; McClure Robert K; Winterer Georg; Weinberger Daniel R</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">221-6</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">We used L-(quinoxalin-6-ylcarbonyl)piperidine (CX516) (a modulator of the alpha-amino-3-hydroxy-5-methyl-4-isoxasole propionic acid (AMPA) receptor) as a sole agent in a double blind placebo-controlled design in a small series of patients with schizophrenia who were partially refractory to treatment with traditional neuroleptics.  The study entailed weekly increments in doses of CX516, from 300 mg tid for week 1 up to 900 mg tid on week 4.  Patients were followed with clinical ratings, neuropsychological testing, and were monitored for adverse events.  Four patients received 2 to 4 weeks of CX516, two received placebo and two withdrew during the placebo phase.  Adverse events associated with drug administration were transient and included leukopenia in one patient and elevation in liver enzymes in another.  No clear improvement in psychosis or in cognition was observed over the course of the study.  CX516 at the doses tested did not appear to yield dramatic effects as a sole agent, but inference from this study is limited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTETmXZUoTbJ-RS7coPn-RtfW6udTcc2ebVEm3riLEUdLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vmsVCksg%253D%253D&md5=b0a55439016bc407522ca3251e5923a7</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2FS0920-9964%2801%2900311-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0920-9964%252801%252900311-5%26sid%3Dliteratum%253Aachs%26aulast%3DMarenco%26aufirst%3DS.%26aulast%3DEgan%26aufirst%3DM.%2BF.%26aulast%3DGoldberg%26aufirst%3DT.%2BE.%26aulast%3DKnable%26aufirst%3DM.%2BB.%26aulast%3DMcClure%26aufirst%3DR.%2BK.%26aulast%3DWinterer%26aufirst%3DG.%26aulast%3DWeinberger%26aufirst%3DD.%2BR.%26atitle%3DPreliminary%2520experience%2520with%2520an%2520ampakine%2520%2528CX516%2529%2520as%2520a%2520single%2520agent%2520for%2520the%2520treatment%2520of%2520schizophrenia%253A%2520A%2520case%2520series%26jtitle%3DSchizophr.%2520Res.%26date%3D2002%26volume%3D57%26issue%3D2%26spage%3D221%26epage%3D226%26doi%3D10.1016%2FS0920-9964%2801%2900311-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goff, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamberti, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leon, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manschreck, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freudenreich, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. A.</span></span> <span> </span><span class="NLM_article-title">A Placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">465</span>â <span class="NLM_lpage">472</span>, <span class="refDoi">Â DOI: 10.1038/sj.npp.1301444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2Fsj.npp.1301444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=17487227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFSmsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2008&pages=465-472&issue=3&author=D.+C.+Goffauthor=J.+S.+Lambertiauthor=A.+C.+Leonauthor=M.+F.+Greenauthor=A.+L.+Millerauthor=J.+Patelauthor=T.+Manschreckauthor=O.+Freudenreichauthor=S.+A.+Johnson&title=A+Placebo-controlled+add-on+trial+of+the+Ampakine%2C+CX516%2C+for+cognitive+deficits+in+schizophrenia&doi=10.1038%2Fsj.npp.1301444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">A Placebo-Controlled Add-On Trial of the Ampakine, CX516, for Cognitive Deficits in Schizophrenia</span></div><div class="casAuthors">Goff, Donald C.; Lamberti, J. Steven; Leon, Andrew C.; Green, Michael F.; Miller, Alexander L.; Patel, Jayendra; Manschreck, Theo; Freudenreich, Oliver; Johnson, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">465-472</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">AMPA-receptor-pos. modulators (Ampakines) facilitate learning and memory in animal models and in preliminary trials in human subjects.  CX516 is the first Ampakine to be studied for cognitive enhancement in schizophrenia.  Stable schizophrenia patients treated with clozapine (n = 52), olanzapine (n = 40), or risperidone (n = 13) were randomly assigned to add-on treatment with CX516 900 mg three times daily or placebo for 4 wk.  Subjects were assessed with a cognitive battery at baseline, week 4, and at 4-wk follow-up.  Clin. scales and safety monitoring were also performed.  The primary endpoint was the change from baseline in a composite cognitive score at week 4 for the intent-to-treat sample.  Addnl. analyses examd. change in symptom rating scores and examd. drug effects on patients treated with clozapine sep. from patients treated with either olanzapine or risperidone.  A total of 105 patients were randomized and 95 (90%) completed the 4-wk trial.  Patients treated with CX516 did not differ from placebo in change from baseline on the composite cognitive score, or on any cognitive test at weeks 4 or 8.  The between groups effect size at week 4 for the cognitive composite score was -0.19 for clozapine-treated patients and 0.24 for patients treated with olanzapine or risperidone.  The placebo group improved more on the PANSS total score than the CX516 group; no other clin. rating differed between treatment groups.  CX516 was assocd. with fatigue, insomnia and epigastric discomfort compared to placebo, but was generally well tolerated.  CX516 was not effective for cognition or for symptoms of schizophrenia when added to clozapine, olanzapine, or risperidone.  Neuropsychopharmacol. (2008) 33, 465-472; published online 9 May 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruiyEh-ji1wLVg90H21EOLACvtfcHk0lhu9_zcZ5G01g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFSmsQ%253D%253D&md5=e978a1f588eabebb39fc20505e6a3863</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1301444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1301444%26sid%3Dliteratum%253Aachs%26aulast%3DGoff%26aufirst%3DD.%2BC.%26aulast%3DLamberti%26aufirst%3DJ.%2BS.%26aulast%3DLeon%26aufirst%3DA.%2BC.%26aulast%3DGreen%26aufirst%3DM.%2BF.%26aulast%3DMiller%26aufirst%3DA.%2BL.%26aulast%3DPatel%26aufirst%3DJ.%26aulast%3DManschreck%26aufirst%3DT.%26aulast%3DFreudenreich%26aufirst%3DO.%26aulast%3DJohnson%26aufirst%3DS.%2BA.%26atitle%3DA%2520Placebo-controlled%2520add-on%2520trial%2520of%2520the%2520Ampakine%252C%2520CX516%252C%2520for%2520cognitive%2520deficits%2520in%2520schizophrenia%26jtitle%3DNeuropsychopharmacology%26date%3D2008%26volume%3D33%26issue%3D3%26spage%3D465%26epage%3D472%26doi%3D10.1038%2Fsj.npp.1301444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mozafari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamsizadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fatemi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allahtavakoli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moghadam-Ahmadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaviani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaeidi, A.</span></span> <span> </span><span class="NLM_article-title">CX691, as an AMPA receptor positive modulator, improves the learning and memory in a rat model of Alzheimerâs disease</span>. <i>Iran J. Basic Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">724</span>â <span class="NLM_lpage">730</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=30140412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BB3c3htlGjtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2018&pages=724-730&issue=7&author=N.+Mozafariauthor=A.+Shamsizadehauthor=I.+Fatemiauthor=M.+Allahtavakoliauthor=A.+Moghadam-Ahmadiauthor=E.+Kavianiauthor=A.+Kaeidi&title=CX691%2C+as+an+AMPA+receptor+positive+modulator%2C+improves+the+learning+and+memory+in+a+rat+model+of+Alzheimer%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">CX691, as an AMPA receptor positive modulator, improves the learning and memory in a rat model of Alzheimer's disease</span></div><div class="casAuthors">Mozafari Nazanin; Shamsizadeh Ali; Fatemi Iman; Allahtavakoli Mohammad; Kaviani Elham; Kaeidi Ayat; Shamsizadeh Ali; Fatemi Iman; Allahtavakoli Mohammad; Kaeidi Ayat; Moghadam-Ahmadi Amir</div><div class="citationInfo"><span class="NLM_cas:title">Iranian journal of basic medical sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">724-730</span>
        ISSN:<span class="NLM_cas:issn">2008-3866</span>.
    </div><div class="casAbstract">Objectives:  Growing evidence suggests that dysfunction of the glutamatergic system and Î±-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid (AMPA) receptors are involved in pathology of Alzheimer's disease (AD).  Because AMPA receptors play a key role in plasticity synaptic regulation, positive modulation of these receptors may rescue the cognitive deficits in the AD.  The aim of this study was to explore the effect of CX691, a specific positive allosteric modulator of the AMPA-type glutamate receptors (Ampakine), on spatial learning and memory in a rat model of AD.  Materials and Methods:  For induction of AD, amyloid-beta 1-42 (AÎ²1-42) was microinjected into the hippocampus of male Wistar rats (250-300 g).  The Morris water maze (MWM) test was used to evaluate the effect of CX691 (0.03 and 0.3 mg/kg, twice a day for 10 days, orally) on spatial learning and memory of rats.  In order to evaluate the protein expression of brain-derived neurotrophic factor (BDNF) in hippocampus tissue, ELISA test was used.  Results:  The obtained data showed that treatment with CX691 (0.3 mg/kg) improves the impairment of spatial learning and memory in AD rats.  Also, treatment with CX691 (0.3 mg/kg), increased the BDNF protein level in hippocampus tissue of AD rats compared to non-treated animals.  Conclusion:  The CX691 can improve the BDNF protein expression as well as spatial performance of learning and memory in AD rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRRjz6QXP7AlIIRAdBLKY41fW6udTcc2ebVEm3riLEUdLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3htlGjtw%253D%253D&md5=bdb5cf0309d672a1843637569fc98a0e</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMozafari%26aufirst%3DN.%26aulast%3DShamsizadeh%26aufirst%3DA.%26aulast%3DFatemi%26aufirst%3DI.%26aulast%3DAllahtavakoli%26aufirst%3DM.%26aulast%3DMoghadam-Ahmadi%26aufirst%3DA.%26aulast%3DKaviani%26aufirst%3DE.%26aulast%3DKaeidi%26aufirst%3DA.%26atitle%3DCX691%252C%2520as%2520an%2520AMPA%2520receptor%2520positive%2520modulator%252C%2520improves%2520the%2520learning%2520and%2520memory%2520in%2520a%2520rat%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DIran%2520J.%2520Basic%2520Med.%2520Sci.%26date%3D2018%26volume%3D21%26issue%3D7%26spage%3D724%26epage%3D730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karras, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gastrell, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawley, J. N.</span></span> <span> </span><span class="NLM_article-title">Amplakine enhancement of social interaction in the BTBR mouse model of autism</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">268</span>â <span class="NLM_lpage">282</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2012.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.neuropharm.2012.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=22801296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFeitLjP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=268-282&author=J.+L.+Silvermanauthor=C.+F.+Oliverauthor=M.+N.+Karrasauthor=P.+T.+Gastrellauthor=J.+N.+Crawley&title=Amplakine+enhancement+of+social+interaction+in+the+BTBR+mouse+model+of+autism&doi=10.1016%2Fj.neuropharm.2012.07.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">AMPAKINE enhancement of social interaction in the BTBR mouse model of autism</span></div><div class="casAuthors">Silverman, J. L.; Oliver, C. F.; Karras, M. N.; Gastrell, P. T.; Crawley, J. N.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">268-282</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Autism is a neurodevelopmental disorder in which the first diagnostic symptom is unusual reciprocal social interactions.  Approx. half of the children diagnosed with an autism spectrum disorder also have intellectual impairments.  General cognitive abilities may be fundamental to many aspects of social cognition.  Cognitive enhancers could conceivably be of significant benefit to children and adults with autism.  AMPAKINE compds. are a novel class of pharmacol. agents that act as pos. modulators of AMPA receptors to enhance excitatory glutamatergic neurotransmission.  This class of compds. was reported to improve learning and memory in several rodent and non-human primate tasks, and to normalize respiratory abnormalities in a mouse model of Rett syndrome.  Here we evaluate the actions of AMPA compds. in adult male and female BTBR mice, a well characterized mouse model of autism.  Acute treatment with CX1837 and CX1739 reversed the deficit in sociability in BTBR mice on the most sensitive parameter, time spent sniffing a novel mouse as compared to time spent sniffing a novel object.  The less sensitive parameter, time in the chamber contg. the novel mouse vs. time in the chamber contg. the novel object, was not rescued by CX1837 or CX1739 treatment.  Preliminary data with CX546, in which Î²-cyclodextrin was the vehicle, revealed behavioral effects of the acute i.p. and oral administration of vehicle alone.  To circumvent the artifacts introduced by the vehicle administration, we employed a novel treatment regimen using pellets of peanut butter for drug delivery.  Absence of vehicle treatment effects when CX1837 and CX1739 were given in the peanut butter pellets, to multiple cohorts of BTBR and B6 control mice, confirmed that the pharmacol.-induced improvements in sociability in BTBR were not confounded by the administration procedures.  The highest dose of CX1837 improved the cognitive deficit in novel object recognition in BTBR.  No drug effects were detected on the high levels of repetitive self-grooming in BTBR.  In open field tests, CX1837 and CX1739 did not induce hyperactivity or sedation in either strain.  It is interesting to speculate that the ability of CX1837 and CX1739 to restore aspects of sociability in BTBR mice could utilize synaptic mechanisms regulating social cognition, suggesting a potential pharmacol. target for interventions to treat symptoms of autism.This article is part of a Special Issue entitled 'Cognitive Enhancers'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuitrJNN0_YbVg90H21EOLACvtfcHk0ljbjf4JmZfWBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFeitLjP&md5=7292a90c5fcb610dcb5466192fd00576</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2012.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2012.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DSilverman%26aufirst%3DJ.%2BL.%26aulast%3DOliver%26aufirst%3DC.%2BF.%26aulast%3DKarras%26aufirst%3DM.%2BN.%26aulast%3DGastrell%26aufirst%3DP.%2BT.%26aulast%3DCrawley%26aufirst%3DJ.%2BN.%26atitle%3DAmplakine%2520enhancement%2520of%2520social%2520interaction%2520in%2520the%2520BTBR%2520mouse%2520model%2520of%2520autism%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D64%26spage%3D268%26epage%3D282%26doi%3D10.1016%2Fj.neuropharm.2012.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cecil, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crites, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malatynska, E.</span></span> <span> </span><span class="NLM_article-title">Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>440</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">27</span>â <span class="NLM_lpage">35</span>, <span class="refDoi">Â DOI: 10.1016/S0014-2999(02)01338-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2FS0014-2999%2802%2901338-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=11959085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD38XivVSjurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=440&publication_year=2002&pages=27-35&issue=1&author=R.+J.+Knappauthor=R.+Goldenbergauthor=C.+Shuckauthor=A.+Cecilauthor=J.+Watkinsauthor=C.+Millerauthor=G.+Critesauthor=E.+Malatynska&title=Antidepressant+activity+of+memory-enhancing+drugs+in+the+reduction+of+submissive+behavior+model&doi=10.1016%2FS0014-2999%2802%2901338-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model</span></div><div class="casAuthors">Knapp, Richard J.; Goldenberg, Rachel; Shuck, Caroline; Cecil, Alicia; Watkins, Jeff; Miller, Cortland; Crites, Glenda; Malatynska, Ewa</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">440</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-35</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The present study tests the activity of nootropic drugs in a behavioral test linked to depression.  This test measures the redn. of submissive behavior in a competition test as the relative success of two food-restricted rats to gain access to a feeder.  Nootropic drugs tested include piracetam (2-oxo-1-pyrrolidine acetamide), aniracetam (1-(4-methoxybenzoyl)-2-pyrrolidinone), the Ampakine, Ampalex, 1-(quinoxalin-6-ylcarbonyl)piperidine, and analogs were compared to the antidepressants, fluoxetine ((Â±)-N-methyl-gamma-(4-[trifluoromethyl]phenoxy)-benzenepropanamine) and desipramine (5H-dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N-methyl-, monohydrochloride), while the anxiolytic diazepam (7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one) served as a control.  Drugs were given i.p. for 3 wk.  The antidepressant and nootropic drugs reduced submissive behavior over time.  The effect was dose dependent as measured for fluoxetine and Ampakines.  The redn. of submissive behavior by Ampakines gradually faded after cessation of treatment and had a more rapid onset of activity (during the 1st week of treatment) than fluoxetine (after 2 wk).  The results suggest that Ampakines may have antidepressant activity.  The potential of depression treatment with memory-enhancing drugs is hypothesized and the link between cognition and depression is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMZ5KSxY3nGbVg90H21EOLACvtfcHk0ljbjf4JmZfWBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivVSjurs%253D&md5=b396f30002d318ecfd6132cc13b9b495</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2802%2901338-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252802%252901338-9%26sid%3Dliteratum%253Aachs%26aulast%3DKnapp%26aufirst%3DR.%2BJ.%26aulast%3DGoldenberg%26aufirst%3DR.%26aulast%3DShuck%26aufirst%3DC.%26aulast%3DCecil%26aufirst%3DA.%26aulast%3DWatkins%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DCrites%26aufirst%3DG.%26aulast%3DMalatynska%26aufirst%3DE.%26atitle%3DAntidepressant%2520activity%2520of%2520memory-enhancing%2520drugs%2520in%2520the%2520reduction%2520of%2520submissive%2520behavior%2520model%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D440%26issue%3D1%26spage%3D27%26epage%3D35%26doi%3D10.1016%2FS0014-2999%2802%2901338-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wesensten, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichardt, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balkin, T. J.</span></span> <span> </span><span class="NLM_article-title">Ampakine (CX717) effects on performance and alertness during simulated night shift work</span>. <i>Aviat., Space Environ. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">937</span>â <span class="NLM_lpage">943</span>, <span class="refDoi">Â DOI: 10.3357/ASEM.2055.2007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.3357%2FASEM.2055.2007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=17955941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1ahsrrJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2007&pages=937-943&issue=10&author=N.+J.+Wesenstenauthor=R.+M.+Reichardtauthor=T.+J.+Balkin&title=Ampakine+%28CX717%29+effects+on+performance+and+alertness+during+simulated+night+shift+work&doi=10.3357%2FASEM.2055.2007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Ampakine (CX717) effects on performance and alertness during simulated night shift work</span></div><div class="casAuthors">Wesensten, Nancy J.; Reichardt, Rebecca M.; Balkin, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Aviation, Space and Environmental Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">937-943</span>CODEN:
                <span class="NLM_cas:coden">ASEMCG</span>;
        ISSN:<span class="NLM_cas:issn">0095-6562</span>.
    
            (<span class="NLM_cas:orgname">Aerospace Medical Association</span>)
        </div><div class="casAbstract">Introduction: Round-the-clock operations in both military and civilian sectors have increased the need for alertness- and performance-maintaining strategies.  The potential performance and objective alertness-enhancing effects of CX717 (a novel cognitive enhancer currently being tested in Phase II clin. trials) were evaluated using a simulated night shift work paradigm.  Methods: In this randomized, double-blind, placebo-controlled, parallel groups design, 48 volunteers underwent 4 consecutive nights of simulated shift work.  Each "shift" consisted of the following: at approx. 2145 (just prior to the start of each simulated night shift), volunteers ingested a single oral dose of CX717 200 mg, CX717 400 mg, CX717 1000 mg, or placebo (N = 12 per drug dosage).  Performance, alertness, mood, and symptoms were then assessed from 2300 to 0700, followed by a polysomnog. monitored daytime sleep period from 0800 to 1200.  Results: Performance and alertness significantly degraded across the simulated night shifts (P < 0.05).  None of the dosages of CX717 reversed these effects (P > 0.05).  CX717 exerted some effects on daytime sleep, most notably redn. of slow-wave sleep time (P < 0.05).  CX717 caused very few side effects and none of those were serious or unexpected.  Discussion and Conclusions: At the doses tested, CX717 was not effective for reversing performance and alertness deficits assocd. with night shift work.  Further work evaluating higher doses of CX717 may be warranted, as are studies in which CX717 effects are explored under other conditions (e.g., Alzheimer's dementia, attention deficit disorder).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou_gG1VfAQ-bVg90H21EOLACvtfcHk0ljbjf4JmZfWBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1ahsrrJ&md5=629ac33ba48ae518bbe95d457502ac70</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.3357%2FASEM.2055.2007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3357%252FASEM.2055.2007%26sid%3Dliteratum%253Aachs%26aulast%3DWesensten%26aufirst%3DN.%2BJ.%26aulast%3DReichardt%26aufirst%3DR.%2BM.%26aulast%3DBalkin%26aufirst%3DT.%2BJ.%26atitle%3DAmpakine%2520%2528CX717%2529%2520effects%2520on%2520performance%2520and%2520alertness%2520during%2520simulated%2520night%2520shift%2520work%26jtitle%3DAviat.%252C%2520Space%2520Environ.%2520Med.%26date%3D2007%26volume%3D78%26issue%3D10%26spage%3D937%26epage%3D943%26doi%3D10.3357%2FASEM.2055.2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arbon, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dijk, D. J.</span></span> <span> </span><span class="NLM_article-title">Acute sleep deprivation: the effects of the Ampakine compound CX717 on human cognitive performance, alertness and recovery sleep</span>. <i>J. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1047</span>â <span class="NLM_lpage">1057</span>, <span class="refDoi">Â DOI: 10.1177/0269881111405353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1177%2F0269881111405353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=21940760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1OksrzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=1047-1057&issue=8&author=J.+Boyleauthor=N.+Stanleyauthor=L.+M.+Jamesauthor=N.+Wrightauthor=S.+Johnsenauthor=E.+L.+Arbonauthor=D.+J.+Dijk&title=Acute+sleep+deprivation%3A+the+effects+of+the+Ampakine+compound+CX717+on+human+cognitive+performance%2C+alertness+and+recovery+sleep&doi=10.1177%2F0269881111405353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Acute sleep deprivation: the effects of the AMPAKINE compound CX717 on human cognitive performance, alertness and recovery sleep</span></div><div class="casAuthors">Boyle, Julia; Stanley, Neil; James, Lynette M.; Wright, Nicola; Johnsen, Sigurd; Arbon, Emma L.; Dijk, Derk-Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1047-1057, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">AMPA receptor modulation is a potential novel approach to enhance cognitive performance.  CX717 is a pos. allosteric modulator of the AMPA receptor that has shown efficacy in rodent and primate cognition models.  CX717 (100 mg, 300 mg and 1000 mg) and placebo were studied in 16 healthy male volunteers (18-45 years) in a randomized, crossover study.  Cognitive function, arousal and recovery sleep (by polysomnog.) were assessed during the extended wakefulness protocol.  Placebo condition was assocd. with significant decrements in cognition, particularly at the circadian nadir (between 03:00 and 05:00).  Pre-specified primary and secondary analyses (general linear mixed modeling, GLMM) at each sep. time point did not reveal consistent improvements in performance or objective alertness with any dose of CX717.  Exploratory repeated measures anal., a method used to take into account the influence of individual differences, demonstrated an improvement in attention-based task performance following the 1000 mg dose.  Anal. of the recovery sleep showed that CX717 1000 mg significantly reduced stage 4 and slow-wave sleep (p â¤ 0.05) with evidence of reduced EEG (EEG) slow-wave and spindle activity.  The study suggests that CX717 only at the 1000 mg dose may counteract effects of sleep deprivation on attention-based tasks and that it may interfere with subsequent recovery sleep.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpopQxMfp-QsLVg90H21EOLACvtfcHk0lho7ChrVZijAA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1OksrzN&md5=afa7339c56f04a354f92f64123c7ced2</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1177%2F0269881111405353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881111405353%26sid%3Dliteratum%253Aachs%26aulast%3DBoyle%26aufirst%3DJ.%26aulast%3DStanley%26aufirst%3DN.%26aulast%3DJames%26aufirst%3DL.%2BM.%26aulast%3DWright%26aufirst%3DN.%26aulast%3DJohnsen%26aufirst%3DS.%26aulast%3DArbon%26aufirst%3DE.%2BL.%26aulast%3DDijk%26aufirst%3DD.%2BJ.%26atitle%3DAcute%2520sleep%2520deprivation%253A%2520the%2520effects%2520of%2520the%2520Ampakine%2520compound%2520CX717%2520on%2520human%2520cognitive%2520performance%252C%2520alertness%2520and%2520recovery%2520sleep%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2012%26volume%3D26%26issue%3D8%26spage%3D1047%26epage%3D1057%26doi%3D10.1177%2F0269881111405353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lippa, A. S.</span></span> <span> </span><span class="NLM_article-title">Compositions and Methods for Treating Attention Deficit Disorders</span>. <span class="NLM_patent">WO2018009256A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+S.+Lippa&title=Compositions+and+Methods+for+Treating+Attention+Deficit+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLippa%26aufirst%3DA.%2BS.%26atitle%3DCompositions%2520and%2520Methods%2520for%2520Treating%2520Attention%2520Deficit%2520Disorders%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, J. J.</span></span> <span> </span><span class="NLM_article-title">Ampakine CX717 protects against fentanyl-induced respiratory depression and lethal apnea in rats</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1364</span>â <span class="NLM_lpage">1370</span>, <span class="refDoi">Â DOI: 10.1097/ALN.0b013e31819faa2a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1097%2FALN.0b013e31819faa2a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=19461299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtFKntb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2009&pages=1364-1370&issue=6&author=J.+Renauthor=X.+Dingauthor=G.+D.+Funkauthor=J.+J.+Greer&title=Ampakine+CX717+protects+against+fentanyl-induced+respiratory+depression+and+lethal+apnea+in+rats&doi=10.1097%2FALN.0b013e31819faa2a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Ampakine CX717 Protects against Fentanyl-induced Respiratory Depression and Lethal Apnea in Rats</span></div><div class="casAuthors">Ren, Jun; Ding, Xiuqing; Funk, Gregory D.; Greer, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1364-1370</span>CODEN:
                <span class="NLM_cas:coden">ANESAV</span>;
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The use of fentanyl as a potent analgesic is contradicted by marked respiratory depression among a subpopulation of patients.  The commonly used approach of reversing fentanyl-induced respiratory depression with Î¼-opiate receptor antagonists such as naloxone has the undesirable effect of blocking analgesia.  Here, the authors report a clin. feasible pharmacol. soln. for countering fentanyl-induced respiratory depression via a mechanism that does not interfere with analgesia.  Specifically, to det. if the ampakine CX717, which has been proven metabolically stable and safe for human use, can prevent and rescue from severe fentanyl-induced apnea.  Plethsymog. recordings were performed from young and adult rats.  Varying doses of fentanyl were administered either i.p. or i.v. to induce moderate to life-threatening apneas.  CX717 was administered either before or after fentanyl administration.  In addn., phrenic nerve recordings were performed from in situ working heart brainstem prepns. from juvenile rats.  Preadministration of CX717 markedly attenuated fentanyl-induced respiratory depression.  Postadministration of CX717 rescued animals from a LD of fentanyl.  Significantly, CX717 countered fentanyl-induced depression of respiratory frequency without suppressing analgesia.  The ED of CX717 was in the range deemed safe on the basis of clin. trials examg. its efficacy for cognitive disorders.  In situ, fentanyl-induced depression in respiratory frequency and amplitude was alleviated by CX717.  CX717 is an agent that enhances the safety of using opiate drugs while preserving the analgesic effects.  This advancement could significantly improve pain management in a variety of clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwzvIELlMB77Vg90H21EOLACvtfcHk0lho7ChrVZijAA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtFKntb4%253D&md5=cafc221d0a8efcba90afb1dcf37ce3cf</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1097%2FALN.0b013e31819faa2a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FALN.0b013e31819faa2a%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DFunk%26aufirst%3DG.%2BD.%26aulast%3DGreer%26aufirst%3DJ.%2BJ.%26atitle%3DAmpakine%2520CX717%2520protects%2520against%2520fentanyl-induced%2520respiratory%2520depression%2520and%2520lethal%2520apnea%2520in%2520rats%26jtitle%3DAnesthesiology%26date%3D2009%26volume%3D110%26issue%3D6%26spage%3D1364%26epage%3D1370%26doi%3D10.1097%2FALN.0b013e31819faa2a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, J. J.</span></span> <span> </span><span class="NLM_article-title">Ampakines enhance weak endogenous respiratory drive and alleviate apnea in perinatal rats</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>191</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">704</span>â <span class="NLM_lpage">710</span>, <span class="refDoi">Â DOI: 10.1164/rccm.201410-1898OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1164%2Frccm.201410-1898OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=25594679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmt12qtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2015&pages=704-710&issue=6&author=J.+Renauthor=X.+Dingauthor=J.+J.+Greer&title=Ampakines+enhance+weak+endogenous+respiratory+drive+and+alleviate+apnea+in+perinatal+rats&doi=10.1164%2Frccm.201410-1898OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Ampakines enhance weak endogenous respiratory drive and alleviate apnea in perinatal rats</span></div><div class="casAuthors">Ren, Jun; Ding, Xiuqing; Greer, John J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">704-710</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Apnea of prematurity, which is prevalent among infants born at less than 34 wk gestation, is treated with caffeine, theophylline, or aminophylline.  However, not all newborns respond adequately to, or tolerate, methylxanthine administration, and thus alternative pharmacol. therapies are required.  Objectives: Rodent models are used to test the hypothesis that the ampakine CX1739, a pos. allosteric modulator of amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors, strengthens perinatal respiratory drive and reduces apneas.  We also provide a systematic study of the effects of caffeine for comparison.  Methods: Respiratory neural activity was recorded from brainstem-spinal cord in vitro perinatal rat prepns., and ÌVE was recorded in newborn rat pups using whole-body plethysmog. under normoxic and hypoxic conditions.  Measurements and Main Results: Using in vitro brainstem-spinal cord prepns., we found that CX1739 (10-100 Î¼M) dose-dependently increases the frequency of respiratory activity generated by fetal and newborn rat prepns. under normoxic and hypoxic conditions.  Plethysmog. recordings in vivo from Postnatal Day 0 rats demonstrated that CX1739 (10 mg/kg) increases the frequency and regularity of ventilation, reduces apneas, and protects against hypoxia-induced respiratory depression.  Conclusions: The net effect of ampakine enhancement of respiratory drive in perinatal rodents is a marked increase in ventilation and the regularity of respiratory patterns in perinatal rat prepns.  Importantly, from the perspective of clin. applications, CX1739 readily crosses the blood-brain barrier, is metabolically stable, and has passed through phase I and II clin. trials in adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3P7JmmSj58bVg90H21EOLACvtfcHk0lho7ChrVZijAA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmt12qtL8%253D&md5=ffd6b698fc9ee953cf04684a4d3dee8e</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1164%2Frccm.201410-1898OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201410-1898OC%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DGreer%26aufirst%3DJ.%2BJ.%26atitle%3DAmpakines%2520enhance%2520weak%2520endogenous%2520respiratory%2520drive%2520and%2520alleviate%2520apnea%2520in%2520perinatal%2520rats%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2015%26volume%3D191%26issue%3D6%26spage%3D704%26epage%3D710%26doi%3D10.1164%2Frccm.201410-1898OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, J. J.</span></span> <span> </span><span class="NLM_article-title">Respiratory depression in rats induced by alcohol and barbiturate and rescue by ampakine CX717</span>. <i>J. Appl. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1004</span>â <span class="NLM_lpage">1011</span>, <span class="refDoi">Â DOI: 10.1152/japplphysiol.00752.2012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1152%2Fjapplphysiol.00752.2012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=22837171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVamt7nP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2012&pages=1004-1011&issue=7&author=J.+Renauthor=X.+Dingauthor=J.+J.+Greer&title=Respiratory+depression+in+rats+induced+by+alcohol+and+barbiturate+and+rescue+by+ampakine+CX717&doi=10.1152%2Fjapplphysiol.00752.2012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory depression in rats induced by alcohol and barbiturate and rescue by ampakine CX717</span></div><div class="casAuthors">Ren, Jun; Ding, Xiuqing; Greer, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Physiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1004-1011</span>CODEN:
                <span class="NLM_cas:coden">JAPHEV</span>;
        ISSN:<span class="NLM_cas:issn">8750-7587</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">Barbiturate use in conjunction with alc. can result in severe respiratory depression and overdose deaths.  The mechanisms underlying the additive/synergistic actions were unresolved.  Current management of ethanol-barbiturate-induced apnea is limited to ventilatory and circulatory support coupled with drug elimination.  Based on recent preclin. and clin. studies of opiate-induced respiratory depression, we hypothesized that ampakine compds. may provide a treatment for other types of drug-induced respiratory depression.  The actions of alc., pentobarbital, bicuculline, and the ampakine CX717, alone and in combination, were measured via 1) ventral root recordings from newborn rat brain stem-spinal cord prepns. and 2) plethysmog. recordings from unrestrained newborn and adult rats.  We found that ethanol caused a modest suppression of respiratory drive in vitro (50 mM) and in vivo (2 g/kg i.p.).  Pentobarbital induced an â¼50% redn. in respiratory frequency in vitro (50 Î¼M) and in vivo (28 mg/kg for pups and 56 mg/kg for adult rats i.p.).  However, severe life-threatening apnea was induced by the combination of the agents in vitro and in vivo via activation of GABAA receptors, which was exacerbated by hypoxic (8% O2) conditions.  Administration of the ampakine CX717 alleviated a significant component of the respiratory depression in vitro (50-150 Î¼M) and in vivo (30 mg/kg i.p.).  Bicuculline also alleviated ethanol-/pentobarbital-induced respiratory depression but caused seizure activity, whereas CX717 did not.  These data demonstrated that ethanol and pentobarbital together caused severe respiratory depression, including lethal apnea, via synergistic actions that blunt chemoreceptive responses to hypoxia and hypercapnia and suppress central respiratory rhythmogenesis.  The ampakine CX717 markedly reduced the severity of respiratory depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr1LInI30ml7Vg90H21EOLACvtfcHk0li4xrACvgCAnw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVamt7nP&md5=b65eeeb361348fada54c7354e94b08bd</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1152%2Fjapplphysiol.00752.2012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fjapplphysiol.00752.2012%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DGreer%26aufirst%3DJ.%2BJ.%26atitle%3DRespiratory%2520depression%2520in%2520rats%2520induced%2520by%2520alcohol%2520and%2520barbiturate%2520and%2520rescue%2520by%2520ampakine%2520CX717%26jtitle%3DJ.%2520Appl.%2520Physiol.%26date%3D2012%26volume%3D113%26issue%3D7%26spage%3D1004%26epage%3D1011%26doi%3D10.1152%2Fjapplphysiol.00752.2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirton, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staff, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozol, R. A.</span></span> <span> </span><span class="NLM_article-title">Postoperative day one: A high risk period for respiratory events</span>. <i>Am. J. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>190</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">752</span>â <span class="NLM_lpage">756</span>, <span class="refDoi">Â DOI: 10.1016/j.amjsurg.2005.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.amjsurg.2005.07.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=16226953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BD2MrkvFalug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2005&pages=752-756&issue=5&author=S.+Taylorauthor=O.+C.+Kirtonauthor=I.+Staffauthor=R.+A.+Kozol&title=Postoperative+day+one%3A+A+high+risk+period+for+respiratory+events&doi=10.1016%2Fj.amjsurg.2005.07.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Postoperative day one: a high risk period for respiratory events</span></div><div class="casAuthors">Taylor Shiv; Kirton Orlando C; Staff Ilene; Kozol Robert A</div><div class="citationInfo"><span class="NLM_cas:title">American journal of surgery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">752-6</span>
        ISSN:<span class="NLM_cas:issn">0002-9610</span>.
    </div><div class="casAbstract">BACKGROUND:  In 2001, the Joint Commission on Accreditation of Healthcare Organizations released Pain Management Standards that has led to an increased focus on pain control.  Since then the Institute for Safe Medication Practices has noted that overaggressive pain management has led to increases in oversedation and fatal respiratory depression.  One of our previous studies found that postoperative patients may be reaching dangerously high levels of sedation as a result of pain management.  Our hypothesis is that postoperative patients who have a respiratory event caused by analgesic use are more likely to have that event in the first postoperative day.  METHODS:  We performed a retrospective case-control analysis identifying 62 postoperative patients who had a respiratory event.  A respiratory event was defined as respiratory depression caused by narcotic use in the postoperative period that was reversed by naloxone.  Sixty-two postoperative patients with no such event were chosen randomly and frequency matched based on surgical procedure and diagnosis-related group.  Risk factors for an event were identified.  RESULTS:  Of the cases, 77.4% had a respiratory event in the first 24 hours postoperatively.  Significant risk factors for an event were as follows: 65 years of age or older, having chronic obstructive pulmonary disease, having 1 or more comorbidities, and being placed on hydromorphone.  CONCLUSIONS:  The first 24 hours after surgery represents a high-risk period for a respiratory event as a result of narcotic use.  The realization of this risk can lead to the implementation of standards to increase patient safety in the first postoperative day.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTirF4ghY7zXTAyhZbj3lKdfW6udTcc2eaP_RefOP-4Drntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MrkvFalug%253D%253D&md5=5747e00c25b34baa1359eb0cb46327cc</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.amjsurg.2005.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjsurg.2005.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DKirton%26aufirst%3DO.%2BC.%26aulast%3DStaff%26aufirst%3DI.%26aulast%3DKozol%26aufirst%3DR.%2BA.%26atitle%3DPostoperative%2520day%2520one%253A%2520A%2520high%2520risk%2520period%2520for%2520respiratory%2520events%26jtitle%3DAm.%2520J.%2520Surg.%26date%3D2005%26volume%3D190%26issue%3D5%26spage%3D752%26epage%3D756%26doi%3D10.1016%2Fj.amjsurg.2005.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">RespireRx Pharmaceuticals Inc.</span> <span> </span><span class="NLM_article-title">Ampakines Development Summary</span> <a href="https://www.sec.gov/Archives/edgar/data/849636/000149315217007695/ex99-3.htm" class="extLink">https://www.sec.gov/Archives/edgar/data/849636/000149315217007695/ex99-3.htm</a>. (accessed June 2, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=RespireRx+Pharmaceuticals+Inc.&title=Ampakines+Development+Summary"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DAmpakines%2520Development%2520Summary%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oertel, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felden, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angst, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varney, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotsch, J.</span></span> <span> </span><span class="NLM_article-title">Selective antagonism of opioid-induced ventilatory depression by an ampakine molecule in humans without loss of opioid analgesia</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>87</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">204</span>â <span class="NLM_lpage">211</span>, <span class="refDoi">Â DOI: 10.1038/clpt.2009.194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2Fclpt.2009.194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=19907420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252Flslykug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2010&pages=204-211&issue=2&author=B.+G.+Oertelauthor=L.+Feldenauthor=P.+V.+Tranauthor=M.+H.+Bradshawauthor=M.+S.+Angstauthor=H.+Schmidtauthor=S.+Johnsonauthor=J.+J.+Greerauthor=G.+Geisslingerauthor=M.+A.+Varneyauthor=J.+Lotsch&title=Selective+antagonism+of+opioid-induced+ventilatory+depression+by+an+ampakine+molecule+in+humans+without+loss+of+opioid+analgesia&doi=10.1038%2Fclpt.2009.194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Selective antagonism of opioid-induced ventilatory depression by an ampakine molecule in humans without loss of opioid analgesia</span></div><div class="casAuthors">Oertel B G; Felden L; Tran P V; Bradshaw M H; Angst M S; Schmidt H; Johnson S; Greer J J; Geisslinger G; Varney M A; Lotsch J</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">204-11</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Ventilatory depression is a significant risk associated with the use of opioids.  We assessed whether opioid-induced ventilatory depression can be selectively antagonized by an ampakine without reduction of analgesia.  In 16 healthy men, after a single oral dose of 1,500 mg of the ampakine CX717, a target concentration of 100 ng/ml alfentanil decreased the respiratory frequency by only 2.9 +/- 33.4% as compared with 25.6 +/- 27.9% during placebo coadministration (P < 0.01).Blood oxygenation and the ventilatory response to hypercapnic challenge also showed significantly smaller decreases with CX717 than with placebo.  In contrast, CX717 did not affect alfentanil-induced analgesia in either electrical or heat-based experimental models of pain.  Both ventilatory depression and analgesia were reversed with 1.6 mg of naloxone.  These results support the use of ampakines as selective antidotes in humans to counter opioid-induced ventilatory depression without affecting opioid-mediated analgesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSyb5RcqSgN3DMsgLhIoICsfW6udTcc2eaP_RefOP-4Drntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252Flslykug%253D%253D&md5=547dcb1e4c5c9bd193c673cb5e38b8b9</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2009.194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2009.194%26sid%3Dliteratum%253Aachs%26aulast%3DOertel%26aufirst%3DB.%2BG.%26aulast%3DFelden%26aufirst%3DL.%26aulast%3DTran%26aufirst%3DP.%2BV.%26aulast%3DBradshaw%26aufirst%3DM.%2BH.%26aulast%3DAngst%26aufirst%3DM.%2BS.%26aulast%3DSchmidt%26aufirst%3DH.%26aulast%3DJohnson%26aufirst%3DS.%26aulast%3DGreer%26aufirst%3DJ.%2BJ.%26aulast%3DGeisslinger%26aufirst%3DG.%26aulast%3DVarney%26aufirst%3DM.%2BA.%26aulast%3DLotsch%26aufirst%3DJ.%26atitle%3DSelective%2520antagonism%2520of%2520opioid-induced%2520ventilatory%2520depression%2520by%2520an%2520ampakine%2520molecule%2520in%2520humans%2520without%2520loss%2520of%2520opioid%2520analgesia%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2010%26volume%3D87%26issue%3D2%26spage%3D204%26epage%3D211%26doi%3D10.1038%2Fclpt.2009.194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gray, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rekling, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bocchiaro, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, J. L.</span></span> <span> </span><span class="NLM_article-title">Modulation of respiratory frequency by peptidergic input to rhythmogenic neurons in the preBotzinger complex</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>286</i></span> (<span class="NLM_issue">5444</span>),  <span class="NLM_fpage">1566</span>â <span class="NLM_lpage">1568</span>, <span class="refDoi">Â DOI: 10.1126/science.286.5444.1566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1126%2Fscience.286.5444.1566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10567264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK1MXns1aju70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=1999&pages=1566-1568&issue=5444&author=P.+A.+Grayauthor=J.+C.+Reklingauthor=C.+M.+Bocchiaroauthor=J.+L.+Feldman&title=Modulation+of+respiratory+frequency+by+peptidergic+input+to+rhythmogenic+neurons+in+the+preBotzinger+complex&doi=10.1126%2Fscience.286.5444.1566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of respiratory frequency by peptidergic input to rhythmogenic neurons in the preBotzinger complex</span></div><div class="casAuthors">Gray, Paul A.; Rekling, Jens C.; Bocchiaro, Christopher M.; Feldman, Jack L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">5444</span>),
    <span class="NLM_cas:pages">1566-1568</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Neurokinin-1 receptor (NK1R) and Î¼-opioid receptor (Î¼OR) agonists affected respiratory rhythm when injected directly into the preBotzinger complex (pre-BotC), the hypothesized site for respiratory rhythmogenesis in mammals.  These effects were mediated by actions on pre-BotC rhythmogenic neurons.  The distribution of NK1R+ neurons anatomically defined the pre-BotC.  Type 1 neurons in the pre-BotC, which have rhythmogenic properties, expressed both NK1 Rs and Î¼ORs, whereas type 2 neurons expressed only NK1Rs.  These findings suggest that the pre-BotC is a definable anat. structure with unique physiol. function and that a subpopulation of neurons expressing both NK1Rs and Î¼ORs generate respiratory rhythm and modulate respiratory frequency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8mgm0Cl-YHLVg90H21EOLACvtfcHk0lhsqX8m47BKNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXns1aju70%253D&md5=ff7f54f36adcd882642f7d705cfb3879</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1126%2Fscience.286.5444.1566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.286.5444.1566%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DP.%2BA.%26aulast%3DRekling%26aufirst%3DJ.%2BC.%26aulast%3DBocchiaro%26aufirst%3DC.%2BM.%26aulast%3DFeldman%26aufirst%3DJ.%2BL.%26atitle%3DModulation%2520of%2520respiratory%2520frequency%2520by%2520peptidergic%2520input%2520to%2520rhythmogenic%2520neurons%2520in%2520the%2520preBotzinger%2520complex%26jtitle%3DScience%26date%3D1999%26volume%3D286%26issue%3D5444%26spage%3D1566%26epage%3D1568%26doi%3D10.1126%2Fscience.286.5444.1566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballanyi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, J. L.</span></span> <span> </span><span class="NLM_article-title">Pre-Botzinger complex: A brainstem region that may generate respiratory rhythm in mammals</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>254</i></span> (<span class="NLM_issue">5032</span>),  <span class="NLM_fpage">726</span>â <span class="NLM_lpage">729</span>, <span class="refDoi">Â DOI: 10.1126/science.1683005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1126%2Fscience.1683005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1683005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADyaK38%252FlsVGlsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=1991&pages=726-729&issue=5032&author=J.+C.+Smithauthor=H.+H.+Ellenbergerauthor=K.+Ballanyiauthor=D.+W.+Richterauthor=J.+L.+Feldman&title=Pre-Botzinger+complex%3A+A+brainstem+region+that+may+generate+respiratory+rhythm+in+mammals&doi=10.1126%2Fscience.1683005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Pre-Botzinger complex: a brainstem region that may generate respiratory rhythm in mammals</span></div><div class="casAuthors">Smith J C; Ellenberger H H; Ballanyi K; Richter D W; Feldman J L</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue">5032</span>),
    <span class="NLM_cas:pages">726-9</span>
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The location of neurons generating the rhythm of breathing in mammals is unknown.  By microsection of the neonatal rat brainstem in vitro, a limited region of the ventral medulla (the pre-Botzinger Complex) that contains neurons essential for rhythmogenesis was identified.  Rhythm generation was eliminated by removal of only this region.  Medullary slices containing the pre-Botzinger Complex generated respiratory-related oscillations similar to those generated by the whole brainstem in vitro, and neurons with voltage-dependent pacemaker-like properties were identified in this region.  Thus, the respiratory rhythm in the mammalian neonatal nervous system may result from a population of conditional bursting pacemaker neurons in the pre-Botzinger Complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpovtKeWUfyszK395ZObgVfW6udTcc2eZpEKc-d8DEtrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38%252FlsVGlsA%253D%253D&md5=ffbcb575d47a5bc6ec879466da3f3175</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1126%2Fscience.1683005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1683005%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DJ.%2BC.%26aulast%3DEllenberger%26aufirst%3DH.%2BH.%26aulast%3DBallanyi%26aufirst%3DK.%26aulast%3DRichter%26aufirst%3DD.%2BW.%26aulast%3DFeldman%26aufirst%3DJ.%2BL.%26atitle%3DPre-Botzinger%2520complex%253A%2520A%2520brainstem%2520region%2520that%2520may%2520generate%2520respiratory%2520rhythm%2520in%2520mammals%26jtitle%3DScience%26date%3D1991%26volume%3D254%26issue%3D5032%26spage%3D726%26epage%3D729%26doi%3D10.1126%2Fscience.1683005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greer, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, J. L.</span></span> <span> </span><span class="NLM_article-title">Role of excitatory amino acids in the generation and transmission of respiratory drive in neonatal rat</span>. <i>J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>437</i></span>,  <span class="NLM_fpage">727</span>â <span class="NLM_lpage">749</span>, <span class="refDoi">Â DOI: 10.1113/jphysiol.1991.sp018622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1113%2Fjphysiol.1991.sp018622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1653855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK3MXlt1yjtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=437&publication_year=1991&pages=727-749&author=J.+J.+Greerauthor=J.+C.+Smithauthor=J.+L.+Feldman&title=Role+of+excitatory+amino+acids+in+the+generation+and+transmission+of+respiratory+drive+in+neonatal+rat&doi=10.1113%2Fjphysiol.1991.sp018622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Role of excitatory amino acids in the generation and transmission of respiratory drive in neonatal rat</span></div><div class="casAuthors">Greer, John J.; Smith, Jeffrey C.; Feldman, Jack L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">437</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">727-49</span>CODEN:
                <span class="NLM_cas:coden">JPHYA7</span>;
        ISSN:<span class="NLM_cas:issn">0022-3751</span>.
    </div><div class="casAbstract">Respiratory rhythm generation in the in vitro neonatal rat brain stem-spinal cord is dependent on and modulated by endogenously released excitatory amino acids acting at non-N-methyl-D-aspartate (NMDA) receptors.  The transmission of inspiratory drive to cranial, accessory, phrenic, and intercostal motoneuron pools also depends on activation of non-NMDA receptors.  Activation of NMDA receptors contributes a relatively small component of inspiratory drive transmission to brain stem and spinal motoneuron pools, and is not necessary for rhythmogenesis.  AP-4-sensitive receptors are importantly involved in inspiratory drive transmission to phrenic and intercostal motoneuron pools, but not in rhythmogenesis or drive transmission to cranial and accessory motoneurons.  This indicates a functional heterogeneity of receptor mechanisms mediating transmission of inspiratory drive in spinal and cranial synaptic pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVnblg3cUtxrVg90H21EOLACvtfcHk0lhsqX8m47BKNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlt1yjtbY%253D&md5=af38b9fc0133f6f5d7a906d0832ef13d</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1113%2Fjphysiol.1991.sp018622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1113%252Fjphysiol.1991.sp018622%26sid%3Dliteratum%253Aachs%26aulast%3DGreer%26aufirst%3DJ.%2BJ.%26aulast%3DSmith%26aufirst%3DJ.%2BC.%26aulast%3DFeldman%26aufirst%3DJ.%2BL.%26atitle%3DRole%2520of%2520excitatory%2520amino%2520acids%2520in%2520the%2520generation%2520and%2520transmission%2520of%2520respiratory%2520drive%2520in%2520neonatal%2520rat%26jtitle%3DJ.%2520Physiol.%26date%3D1991%26volume%3D437%26spage%3D727%26epage%3D749%26doi%3D10.1113%2Fjphysiol.1991.sp018622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Funk, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, J. L.</span></span> <span> </span><span class="NLM_article-title">Generation and transmission of respiratory oscillations in medullary slices: Role of excitatory amino acids</span>. <i>J. Neurophysiol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>70</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1497</span>â <span class="NLM_lpage">1515</span>, <span class="refDoi">Â DOI: 10.1152/jn.1993.70.4.1497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1152%2Fjn.1993.70.4.1497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=8283211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK2cXhsFCnt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1993&pages=1497-1515&issue=4&author=G.+D.+Funkauthor=J.+C.+Smithauthor=J.+L.+Feldman&title=Generation+and+transmission+of+respiratory+oscillations+in+medullary+slices%3A+Role+of+excitatory+amino+acids&doi=10.1152%2Fjn.1993.70.4.1497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Generation and transmission of respiratory oscillations in medullary slices: role of excitatory amino acids</span></div><div class="casAuthors">Funk, Gregory D.; Smith, Jeffrey C.; Feldman, Jack L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurophysiology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1497-515</span>CODEN:
                <span class="NLM_cas:coden">JONEA4</span>;
        ISSN:<span class="NLM_cas:issn">0022-3077</span>.
    </div><div class="casAbstract">The involvement of excitatory amino acid (EAA) receptors in the generation of respiratory rhythm and transmission of inspiratory drive to hypoglossal (XII) motoneurons was examd. in an in vitro neonatal rat medullary slice prepn.  Slices generated rhythmic inspiratory activity in XII nerves.  The role of EAAs in rhythm generation was detd. by analyzing perturbations of respiratory network activity after bath application of EAA receptor antagonists or local microinjection of antagonists into the main column of respiratory neurons in the ventrolateral medulla (ventral respiratory group), particularly in the pre-Botzinger complex (pre-BotC).  The involvement of EAAs in drive transmission to XII motoneurons was examd. by recording perturbations in XII nerve discharge or motoneuron synaptic inputs after microinjection of EAA receptor antagonists into either the XII motor nuclei or sites in the ventrolateral medulla contg. interneurons of the drive transmission circuit.  Block of non-N-methyl-D-aspartate (non-NMDA) receptors by bath application of 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) reversibly reduced XII nerve burst frequency and amplitude in a concn.-dependent manner, completely blocking respiratory motor output at concns. >4 Î¼M.  Activation of 2-amino-4-phosphonobutyric acid (AP-4)-sensitive receptors with DL-AP-4 reduced XII nerve burst amplitude by 30% but did not alter burst frequency.  Block of NMDA receptor channels by bath application of MK-801 did not perturb the frequency or amplitude of motor output.  Inhibition of EAA uptake in the slices by bath application of dihydrokainic acid reversibly increased the frequency and amplitude of XII motor discharge.  Block of non-NMDA receptors at multiple sites along the main column of respiratory neurons in the ventrolateral medulla, including the pre-BotC, by unilateral microinjection of CNQX produced a dose-dependent, bilateral redn. in XII nerve burst amplitude without substantial perturbations of the frequency of respiratory oscillations.  Block of non-NMDA receptors within the pre-BotC at sites ventral to amplitude altering sites produced a redn. in frequency and ultimately bilateral block of respiratory network oscillations.  Non-NMDA receptor block within the XII motor nucleus by unilateral microinjection of CNQX produced a dose-dependent redn. in ipsilateral XII nerve discharge amplitude without perturbing the frequency of respiratory oscillations.  Perturbations of contralateral XII nerve burst amplitude were significantly smaller.  NMDA channel block within the XII motor nucleus did not affect inspiratory burst amplitude, whereas activation of AP-4 receptors caused a 30% redn. in amplitude.  Whole-cell recordings of XII motoneuron synaptic currents and potentials indicated XII motoneurons with respiratory-modulated synaptic inputs receive rhythmic inspiratory drive currents of 150 pA (mean) and potentials of 11 mV.  Exogenous application of CNQX reversibly blocked 90-95% of the rhythmic synaptic inputs.  Local application of DL-AP-4 reduced inspiratory-modulated synaptic currents by 21%, whereas MK-801 application did not affect inspiratory drive currents or potentials.  After blocking action potential-dependent synaptic transmission with tetrodotoxin, local application of L-glutamate produced an inward current that was reduced to 5% of control by CNQX but was unaffected by DL-AP-4.  Local application of non-NMDA receptor agonists [quisqualate (Quis), AMPA, and kainate (Kain)] and NMDA receptor agonists caused membrane depolarization or inward current.  The postsynaptic actions of Quis, AMPA, and Kain were potently and competitively blocked by local application of CNQX.  The motoneuron responses to NMDA were irreversibly blocked by MK-801.  The results indicate that: (1) respiratory rhythm generation in the in vitro neonatal rat medullary slice is dependent on endogenously released EAAs acting at non-NMDA receptors within the pre-BotC; (2) mutually excitatory, non-NMDA receptor-mediated synaptic interactions between pre-BotC neuron populations on each side of the medulla contribute to maintenance of respiratory rhythm; (3) XII motoneurons possess NMDA and non-NMDA (AMPA and Kain) receptors; and (4) an EAA-like substance acting primarily at non-NMDA receptors mediates transmission of inspiratory drive to XII motoneurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRxwALxPOpLLVg90H21EOLACvtfcHk0lhsqX8m47BKNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhsFCnt7c%253D&md5=8ca2319fbaf8a1bacf77f2fd993634fe</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1152%2Fjn.1993.70.4.1497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fjn.1993.70.4.1497%26sid%3Dliteratum%253Aachs%26aulast%3DFunk%26aufirst%3DG.%2BD.%26aulast%3DSmith%26aufirst%3DJ.%2BC.%26aulast%3DFeldman%26aufirst%3DJ.%2BL.%26atitle%3DGeneration%2520and%2520transmission%2520of%2520respiratory%2520oscillations%2520in%2520medullary%2520slices%253A%2520Role%2520of%2520excitatory%2520amino%2520acids%26jtitle%3DJ.%2520Neurophysiol.%26date%3D1993%26volume%3D70%26issue%3D4%26spage%3D1497%26epage%3D1515%26doi%3D10.1152%2Fjn.1993.70.4.1497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">ElMallah, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliardini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerreta, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falk, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, D. D.</span></span> <span> </span><span class="NLM_article-title">Stimulation of respiratory motor output and ventilation in a murine model of Pompe disease by Ampakines</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">326</span>â <span class="NLM_lpage">335</span>, <span class="refDoi">Â DOI: 10.1165/rcmb.2014-0374OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1165%2Frcmb.2014-0374OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=25569118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BC2MvktlKktw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2015&pages=326-335&issue=3&author=M.+K.+ElMallahauthor=S.+Pagliardiniauthor=S.+M.+Turnerauthor=A.+J.+Cerretaauthor=D.+J.+Falkauthor=B.+J.+Byrneauthor=J.+J.+Greerauthor=D.+D.+Fuller&title=Stimulation+of+respiratory+motor+output+and+ventilation+in+a+murine+model+of+Pompe+disease+by+Ampakines&doi=10.1165%2Frcmb.2014-0374OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulation of Respiratory Motor Output and Ventilation in a Murine Model of Pompe Disease by Ampakines</span></div><div class="casAuthors">ElMallah Mai K; Pagliardini Silvia; Greer John J; Turner Sara M; Cerreta Anthony J; Fuller David D; Turner Sara M; Cerreta Anthony J; Fuller David D; Falk Darin J; Byrne Barry J; Falk Darin J; Byrne Barry J; Falk Darin J; Byrne Barry J</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory cell and molecular biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">326-35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pompe disease results from a mutation in the acid Î±-glucosidase gene leading to lysosomal glycogen accumulation.  Respiratory insufficiency is common, and the current U.S.  Food and Drug Administration-approved treatment, enzyme replacement, has limited effectiveness.  Ampakines are drugs that enhance Î±-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor responses and can increase respiratory motor drive.  Recent work indicates that respiratory motor drive can be blunted in Pompe disease, and thus pharmacologic stimulation of breathing may be beneficial.  Using a murine Pompe model with the most severe clinical genotype (the Gaa(-/-) mouse), our primary objective was to test the hypothesis that ampakines can stimulate respiratory motor output and increase ventilation.  Our second objective was to confirm that neuropathology was present in Pompe mouse medullary respiratory control neurons.  The impact of ampakine CX717 on breathing was determined via phrenic and hypoglossal nerve recordings in anesthetized mice and whole-body plethysmography in unanesthetized mice.  The medulla was examined using standard histological methods coupled with immunochemical markers of respiratory control neurons.  Ampakine CX717 robustly increased phrenic and hypoglossal inspiratory bursting and reduced respiratory cycle variability in anesthetized Pompe mice, and it increased inspiratory tidal volume in unanesthetized Pompe mice.  CX717 did not significantly alter these variables in wild-type mice.  Medullary respiratory neurons showed extensive histopathology in Pompe mice.  Ampakines stimulate respiratory neuromotor output and ventilation in Pompe mice, and therefore they have potential as an adjunctive therapy in Pompe disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcToKlCOb9njAGxpATR2EQURfW6udTcc2eburCBSvhDVp7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvktlKktw%253D%253D&md5=99ddff6dab43797c07044f3cce047e7e</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2014-0374OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2014-0374OC%26sid%3Dliteratum%253Aachs%26aulast%3DElMallah%26aufirst%3DM.%2BK.%26aulast%3DPagliardini%26aufirst%3DS.%26aulast%3DTurner%26aufirst%3DS.%2BM.%26aulast%3DCerreta%26aufirst%3DA.%2BJ.%26aulast%3DFalk%26aufirst%3DD.%2BJ.%26aulast%3DByrne%26aufirst%3DB.%2BJ.%26aulast%3DGreer%26aufirst%3DJ.%2BJ.%26aulast%3DFuller%26aufirst%3DD.%2BD.%26atitle%3DStimulation%2520of%2520respiratory%2520motor%2520output%2520and%2520ventilation%2520in%2520a%2520murine%2520model%2520of%2520Pompe%2520disease%2520by%2520Ampakines%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2015%26volume%3D53%26issue%3D3%26spage%3D326%26epage%3D335%26doi%3D10.1165%2Frcmb.2014-0374OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Streeter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Rothi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baekey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, D.</span></span> <span> </span><span class="NLM_article-title">Ampakines increase spinal respiratory motor output after cervical spinal cord injury in rats</span>. <i>The FASEB Journal</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1299.4</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=1299.4&author=K.+Streeterauthor=E.+Gonzalez-Rothiauthor=M.+Sandhuauthor=D.+Baekeyauthor=J.+Greerauthor=D.+Fuller&title=Ampakines+increase+spinal+respiratory+motor+output+after+cervical+spinal+cord+injury+in+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStreeter%26aufirst%3DK.%26aulast%3DGonzalez-Rothi%26aufirst%3DE.%26aulast%3DSandhu%26aufirst%3DM.%26aulast%3DBaekey%26aufirst%3DD.%26aulast%3DGreer%26aufirst%3DJ.%26aulast%3DFuller%26aufirst%3DD.%26atitle%3DAmpakines%2520increase%2520spinal%2520respiratory%2520motor%2520output%2520after%2520cervical%2520spinal%2520cord%2520injury%2520in%2520rats%26jtitle%3DThe%2520FASEB%2520Journal%26date%3D2016%26volume%3D30%26spage%3D1299.4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wollman, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streeter, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, D. D.</span></span> <span> </span><span class="NLM_article-title">Ampakine pretreatment enables a single brief hypoxic episode to evoke phrenic motor facilitation</span>. <i>J. Neurophysiol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>123</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">993</span>â <span class="NLM_lpage">1003</span>, <span class="refDoi">Â DOI: 10.1152/jn.00708.2019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1152%2Fjn.00708.2019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=31940229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVOmsr%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2020&pages=993-1003&issue=3&author=L.+B.+Wollmanauthor=K.+A.+Streeterauthor=D.+D.+Fuller&title=Ampakine+pretreatment+enables+a+single+brief+hypoxic+episode+to+evoke+phrenic+motor+facilitation&doi=10.1152%2Fjn.00708.2019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Ampakine pretreatment enables a single brief hypoxic episode to evokephrenic motor facilitation</span></div><div class="casAuthors">Wollman, L. B.; Streeter, K. A.; Fuller, D. D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurophysiology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">993-1003</span>CODEN:
                <span class="NLM_cas:coden">JONEA4</span>;
        ISSN:<span class="NLM_cas:issn">1522-1598</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">Ampakines are a class of drugs that enhance AMPA receptor function.  Ampakines can enhance expression of neuroplasticity, and the phrenic motor system is fundamentally dependent on excitatory glutamatergic currents.  Accordingly, we tested the hypothesis that combining ampakine pretreatment with a single brief hypoxic exposure would result in phrenic motor facilitation lasting well beyond the period of hypoxia.  Phrenic nerve output was recorded in urethane-anesthetized, ventilated, and vagotomized adult Sprague-Dawley rats.  Ampakine CX717 (15 mg/kg iv; n =8) produced a small increase in phrenic inspiratory burst amplitude and frequency, but values quickly returned to predrug baseline.  When CX717 was followed 2 min later by a 5-min exposure to hypoxia (n= 8; PaO2 â¼45 mmHg), a persistent increase in phrenic inspiratory burst amplitude (i.e., phrenic motor facilitation) was obsd. up to 60 min posthypoxia (103 Â± 53% increase from baseline).  In contrast, when hypoxia was preceded by vehicle injection (10% 2-hydroxypropyl--cyclodextrin; n =8), inspiratory phrenic bursting was similar to baseline values at 60 min.  Addnl. expts. with another ampakine (CX1739, 15 mg/kg) produced comparable results.  We conclude that pairing low-dose ampakine treatment with a single brief hypoxic exposure can evoke sustained phrenic motor facilitation.  This targeted approach for enhancing respiratory neuroplasticity may have value in the context of hypoxia-based neurorehabilitation strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHIOOlJtuY-rVg90H21EOLACvtfcHk0lgLfMU-O9x9Iw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVOmsr%252FM&md5=70be230320a29148f3b076043a8c75b6</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1152%2Fjn.00708.2019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fjn.00708.2019%26sid%3Dliteratum%253Aachs%26aulast%3DWollman%26aufirst%3DL.%2BB.%26aulast%3DStreeter%26aufirst%3DK.%2BA.%26aulast%3DFuller%26aufirst%3DD.%2BD.%26atitle%3DAmpakine%2520pretreatment%2520enables%2520a%2520single%2520brief%2520hypoxic%2520episode%2520to%2520evoke%2520phrenic%2520motor%2520facilitation%26jtitle%3DJ.%2520Neurophysiol.%26date%3D2020%26volume%3D123%26issue%3D3%26spage%3D993%26epage%3D1003%26doi%3D10.1152%2Fjn.00708.2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, R.</span>; <span class="NLM_string-name">Street, L.</span></span> <span> </span><span class="NLM_article-title">Bicyclic Amides for Enhancing Glutamatergic Synaptic Responses</span>. <span class="NLM_patent">US8263591B2</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=R.+Mueller&author=L.+Street&title=Bicyclic+Amides+for+Enhancing+Glutamatergic+Synaptic+Responses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMueller%26aufirst%3DR.%26atitle%3DBicyclic%2520Amides%2520for%2520Enhancing%2520Glutamatergic%2520Synaptic%2520Responses%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Street, L.</span>; <span class="NLM_string-name">Mueller, R.</span>; <span class="NLM_string-name">Lee, S.</span></span> <span> </span><span class="NLM_article-title">Di-Substituted Amides for Enhancing Glutamatergic Synaptic Responses</span>. <span class="NLM_patent">US8013003B2</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=L.+Street&author=R.+Mueller&author=S.+Lee&title=Di-Substituted+Amides+for+Enhancing+Glutamatergic+Synaptic+Responses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DStreet%26aufirst%3DL.%26atitle%3DDi-Substituted%2520Amides%2520for%2520Enhancing%2520Glutamatergic%2520Synaptic%2520Responses%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span>; <span class="NLM_string-name">Zhou, X.</span>; <span class="NLM_string-name">Xiao, D.</span>; <span class="NLM_string-name">Zhong, W.</span>; <span class="NLM_string-name">Xiao, J.</span>; <span class="NLM_string-name">Zheng, Z.</span>; <span class="NLM_string-name">Li, X.</span>; <span class="NLM_string-name">Xie, Y.</span>; <span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Preparation of Brain-Targeting Prodrug for AMPA Receptor Synergist</span>. <span class="NLM_patent">WO2017177896A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=S.+Li&author=X.+Zhou&author=D.+Xiao&author=W.+Zhong&author=J.+Xiao&author=Z.+Zheng&author=X.+Li&author=Y.+Xie&author=X.+Wang&title=Preparation+of+Brain-Targeting+Prodrug+for+AMPA+Receptor+Synergist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Brain-Targeting%2520Prodrug%2520for%2520AMPA%2520Receptor%2520Synergist%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, R. B.</span></span> <span> </span><span class="NLM_article-title">A brain-targeted ampakine compound protects against opioid-induced respiratory depression</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>809</i></span>,  <span class="NLM_fpage">122</span>â <span class="NLM_lpage">129</span>, <span class="refDoi">Â DOI: 10.1016/j.ejphar.2017.05.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.ejphar.2017.05.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28502631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvF2jt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=809&publication_year=2017&pages=122-129&author=W.+Daiauthor=D.+Xiaoauthor=X.+Gaoauthor=X.+B.+Zhouauthor=T.+Y.+Fangauthor=Z.+Yongauthor=R.+B.+Su&title=A+brain-targeted+ampakine+compound+protects+against+opioid-induced+respiratory+depression&doi=10.1016%2Fj.ejphar.2017.05.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">A brain-targeted ampakine compound protects against opioid-induced respiratory depression</span></div><div class="casAuthors">Dai, Wei; Xiao, Dian; Gao, Xiang; Zhou, Xin-Bo; Fang, Tong-Yu; Yong, Zheng; Su, Rui-bin</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">809</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">122-129</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The use of opioid drugs for pain relief can induce life-threatening respiratory depression.  Although naloxone effectively counteracts opioid-induced respiratory depression, it diminishes the efficacy of analgesia.  Our studies indicate that ampakines, in particular, a brain-targeted compd. XD-8-17C, are able to reverse respiratory depression without affecting analgesia at relatively low doses.  Mice and rats were s.c. or i.v. injected with the opioid agonist TH-030418 to induce moderate or severe respiratory depression.  XD-8-17C was i.v. administered before or after TH-030418.  The effect of XD-8-17C on opioid-induced respiratory depression was evaluated in terms of the opioid-induced acute death rate, arterial blood gas anal. and pulmonary function tests.  In addn., the hot-plate test was conducted to investigate whether XD-8-17C influenced opioid-induced analgesia.  Pre-treatment with XD-8-17C significantly reduced opioid-induced acute death, and increased the median LD of TH-030418 by 4.7-fold.  Blood gas anal. and pulmonary function tests demonstrated that post-treatment with XD-8-17C alleviated respiratory depression, as indicated by restoration of arterial blood gas (pO2, sO2, cK+) and lung function parameters (respiratory frequency, minute ventilation) to the normal range.  The hot-plate test showed that XD-8-17C had no impact on the antinociceptive efficacy of morphine.  The ability of XD-8-17C to reverse opioid-induced respiratory depression has the potential to increase the safety and convenience of opioid treatment.  These findings contribute to the discovery of novel therapeutic agents that protect against opioid-induced respiratory depression without loss of analgesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTDjQstw7pt7Vg90H21EOLACvtfcHk0ljbEwexGZ2YRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvF2jt7o%253D&md5=7c0cfc66cd88e777029fcc4d6617d004</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2017.05.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2017.05.025%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DW.%26aulast%3DXiao%26aufirst%3DD.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DX.%2BB.%26aulast%3DFang%26aufirst%3DT.%2BY.%26aulast%3DYong%26aufirst%3DZ.%26aulast%3DSu%26aufirst%3DR.%2BB.%26atitle%3DA%2520brain-targeted%2520ampakine%2520compound%2520protects%2520against%2520opioid-induced%2520respiratory%2520depression%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2017%26volume%3D809%26spage%3D122%26epage%3D129%26doi%3D10.1016%2Fj.ejphar.2017.05.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of brain-targeted thiamine disulfide prodrugs of Ampakine compound LCX001</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">488</span>, <span class="refDoi">Â DOI: 10.3390/molecules21040488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.3390%2Fmolecules21040488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=27089316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVCktLfM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=488&issue=4&author=D.+Xiaoauthor=F.+H.+Mengauthor=W.+Daiauthor=Z.+Yongauthor=J.+Q.+Liuauthor=X.+B.+Zhouauthor=S.+Li&title=Design%2C+synthesis+and+biological+evaluation+of+brain-targeted+thiamine+disulfide+prodrugs+of+Ampakine+compound+LCX001&doi=10.3390%2Fmolecules21040488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of brain-targeted thiamine disulfide prodrugs of ampakine compound LCX001</span></div><div class="casAuthors">Xiao, Dian; Meng, Fan-Hua; Dai, Wei; Yong, Zheng; Liu, Jin-Qiu; Zhou, Xin-Bo; Li, Song</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">488/1-488/14</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A series of thiamine disulfide prodrugs I [R = n-Et, Bu, benzyl, etc.,] of ampakine compd. LCX001 II was synthesized and evaluated.  The trials in-vitro showed that prodrugs I [R = n-pentyl, isopentyl, benzyl] possessed a certain stability in plasma and quickly decompd. in brain homogenate by the disulfide reductase.  In-vivo, prodrug I [R = isopentyl] decreased the peripheral distribution of II and significantly increased brain distribution of LCX001 after i.v. administration.  This compd. showed 2.23- and 3.29-fold greater increases in the AUC0-t and MRT0-t of II in brain, resp., than did II itself.  A preliminary pharmacodynamic study indicated that the required molar dose of prodrug I [R = isopentyl] was only one eighth that of II required to achieve the same effect in mice.  These findings provide an important ref. to evaluate the clin. outlook of ampakine compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiyy-3o3qKgbVg90H21EOLACvtfcHk0ljbEwexGZ2YRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVCktLfM&md5=5b0752309a99b2135ab9eca2b668dc6f</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.3390%2Fmolecules21040488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules21040488%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DD.%26aulast%3DMeng%26aufirst%3DF.%2BH.%26aulast%3DDai%26aufirst%3DW.%26aulast%3DYong%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%2BQ.%26aulast%3DZhou%26aufirst%3DX.%2BB.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520brain-targeted%2520thiamine%2520disulfide%2520prodrugs%2520of%2520Ampakine%2520compound%2520LCX001%26jtitle%3DMolecules%26date%3D2016%26volume%3D21%26issue%3D4%26spage%3D488%26doi%3D10.3390%2Fmolecules21040488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span>; <span class="NLM_string-name">Giroux, A.</span>; <span class="NLM_string-name">Zamboni, R.</span>; <span class="NLM_string-name">McKay, D. J.</span>; <span class="NLM_string-name">Bayly, C. I.</span>; <span class="NLM_string-name">Grimm, E. L.</span>; <span class="NLM_string-name">Colucci, J.</span></span> <span> </span><span class="NLM_article-title">Preparation and Effect of Pyrazinones Against Caspase-3</span>. <span class="NLM_patent">WO2001005772A1</span>, <span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=Y.+Han&author=A.+Giroux&author=R.+Zamboni&author=D.+J.+McKay&author=C.+I.+Bayly&author=E.+L.+Grimm&author=J.+Colucci&title=Preparation+and+Effect+of+Pyrazinones+Against+Caspase-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DY.%26atitle%3DPreparation%2520and%2520Effect%2520of%2520Pyrazinones%2520Against%2520Caspase-3%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâCosta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demaro, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gidday, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacquin, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, E. M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtzman, D. M.</span></span> <span> </span><span class="NLM_article-title">Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>101</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1992</span>â <span class="NLM_lpage">1999</span>, <span class="refDoi">Â DOI: 10.1172/JCI2169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1172%2FJCI2169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=9576764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK1cXjt1Srt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=1998&pages=1992-1999&issue=9&author=Y.+Chengauthor=M.+Deshmukhauthor=A.+D%E2%80%99Costaauthor=J.+A.+Demaroauthor=J.+M.+Giddayauthor=A.+Shahauthor=Y.+Sunauthor=M.+F.+Jacquinauthor=E.+M.+Johnsonauthor=D.+M.+Holtzman&title=Caspase+inhibitor+affords+neuroprotection+with+delayed+administration+in+a+rat+model+of+neonatal+hypoxic-ischemic+brain+injury&doi=10.1172%2FJCI2169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury</span></div><div class="casAuthors">Cheng, Yu; Deshmukh, Mohanish; D'costa, Anselm; Demaro, Joseph A.; Gidday, Jeffrey M.; Shah, Aarti; Sun, Yuling; Jacquin, Mark F.; Johnson, Eugene M., Jr.; Holtzman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1992-1999</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Programmed cell death (apoptosis) is a normal process in the developing nervous system.  Recent data suggest that certain features seen in the process of programmed cell death may be favored in the developing vs. the adult brain in response to different brain injuries.  In a well characterized model of neonatal hypoxia-ischemia, we demonstrate marked but delayed cell death in which there is prominent DNA laddering, TUNEL-labeling, and nuclei with condensed chromatin.  Caspase activation, which is required in many cases of apoptotic cell death, also followed a delayed time course after hypoxia-ischemia.  Administration of boc-aspartyl(OMe)-fluoromethylketone, a pan-caspase inhibitor, was significantly neuroprotective when given by intracerebroventricular injection 3 h after cerebral hypoxia-ischemia.  In addn., systemic injections of boc-aspartyl(OMe)-fluoromethylketone also given in a delayed fashion, resulted in significant neuroprotection.  These findings suggest that caspase inhibitors may be able to provide benefit over a prolonged therapeutic window after hypoxic-ischemic events in the developing brain, a major contributor to static encephalopathy and cerebral palsy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHZ6z0PLKBvbVg90H21EOLACvtfcHk0ljbEwexGZ2YRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjt1Srt7g%253D&md5=96b188e98e09bdc762a51046117a64d5</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1172%2FJCI2169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI2169%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DDeshmukh%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Costa%26aufirst%3DA.%26aulast%3DDemaro%26aufirst%3DJ.%2BA.%26aulast%3DGidday%26aufirst%3DJ.%2BM.%26aulast%3DShah%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DJacquin%26aufirst%3DM.%2BF.%26aulast%3DJohnson%26aufirst%3DE.%2BM.%26aulast%3DHoltzman%26aufirst%3DD.%2BM.%26atitle%3DCaspase%2520inhibitor%2520affords%2520neuroprotection%2520with%2520delayed%2520administration%2520in%2520a%2520rat%2520model%2520of%2520neonatal%2520hypoxic-ischemic%2520brain%2520injury%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1998%26volume%3D101%26issue%3D9%26spage%3D1992%26epage%3D1999%26doi%3D10.1172%2FJCI2169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schotte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Declercq, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Huffel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenabeele, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyaert, R.</span></span> <span> </span><span class="NLM_article-title">Non-specific effects of methyl ketone peptide inhibitors of caspases</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>442</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">117</span>â <span class="NLM_lpage">121</span>, <span class="refDoi">Â DOI: 10.1016/S0014-5793(98)01640-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2FS0014-5793%2898%2901640-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=9923616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK1MXhslaiug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=442&publication_year=1999&pages=117-121&issue=1&author=P.+Schotteauthor=W.+Declercqauthor=S.+Van+Huffelauthor=P.+Vandenabeeleauthor=R.+Beyaert&title=Non-specific+effects+of+methyl+ketone+peptide+inhibitors+of+caspases&doi=10.1016%2FS0014-5793%2898%2901640-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Non-specific effects of methyl ketone peptide inhibitors of caspases</span></div><div class="casAuthors">Schotte, Peter; Declercq, Wim; Van Huffel, Sofie; Vandenabeele, Peter; Beyaert, Rudi</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">442</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">117-121</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Caspases are a family of cysteine proteases which play a crucial role in apoptosis and inflammation.  The involvement of caspases in these processes can be demonstrated by their irreversible inhibition with fluoromethyl ketone and chloromethyl ketone derivs. of peptides resembling the cleavage site of known caspase substrates.  These inhibitors irreversibly alkylate the cysteine residue in the active site of caspases.  In this study we show that a biotinylated fluoromethyl ketone peptide inhibitor of caspases (z-VAD.fmk) also efficiently affinity-labeled cathepsin B and cathepsin H.  In addn., the caspase inhibitors z-VAD.fmk, z-DEVD.fmk and Ac-YVAD.cmk also efficiently inhibited cathepsin B activity in vitro and in tissue culture cells at concns. that are generally used to demonstrate the involvement of caspases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0H6FRXOO7-LVg90H21EOLACvtfcHk0lgKziW-NcVpnA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhslaiug%253D%253D&md5=3e0b34a6e18f2f5b8ccb607d24e45c71</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2898%2901640-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252898%252901640-8%26sid%3Dliteratum%253Aachs%26aulast%3DSchotte%26aufirst%3DP.%26aulast%3DDeclercq%26aufirst%3DW.%26aulast%3DVan%2BHuffel%26aufirst%3DS.%26aulast%3DVandenabeele%26aufirst%3DP.%26aulast%3DBeyaert%26aufirst%3DR.%26atitle%3DNon-specific%2520effects%2520of%2520methyl%2520ketone%2520peptide%2520inhibitors%2520of%2520caspases%26jtitle%3DFEBS%2520Lett.%26date%3D1999%26volume%3D442%26issue%3D1%26spage%3D117%26epage%3D121%26doi%3D10.1016%2FS0014-5793%2898%2901640-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giroux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colucci, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayly, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKay, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xanthoudakis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaillancourt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasper, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamboni, R. J.</span></span> <span> </span><span class="NLM_article-title">Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1173</span>â <span class="NLM_lpage">1180</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2004.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmcl.2004.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=15686936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2MXos1CqtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=1173-1180&issue=4&author=Y.+Hanauthor=A.+Girouxauthor=J.+Colucciauthor=C.+I.+Baylyauthor=D.+J.+McKayauthor=S.+Royauthor=S.+Xanthoudakisauthor=J.+Vaillancourtauthor=D.+M.+Rasperauthor=J.+Tamauthor=P.+Tawaauthor=D.+W.+Nicholsonauthor=R.+J.+Zamboni&title=Novel+pyrazinone+mono-amides+as+potent+and+reversible+caspase-3+inhibitors&doi=10.1016%2Fj.bmcl.2004.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors</span></div><div class="casAuthors">Han, Yongxin; Giroux, Andre; Colucci, John; Bayly, Christopher I.; Mckay, Daniel J.; Roy, Sophie; Xanthoudakis, Steve; Vaillancourt, John; Rasper, Dita M.; Tam, John; Tawa, Paul; Nicholson, Donald W.; Zamboni, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1173-1180</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The iterative process for the discovery of a series of pyrazinone mono-amides as potent, selective and reversible non-peptide caspase-3 inhibitors (e.g., M826 and M867) is reported.  The studied compds. were prepd. according to modified literature procedure from ethylaminobutyrate hydrochloride via intermediate acids (e. g., I), which were synthesized using Dess-Martin periodinane oxidn.  Treating of coupled to the resin in the presence of Hunig's base intermediate acids I with 90% TFA in water gave the desired inhibitors (e. g. II).  These compds. were screened directly, without further purifn., against four representative recombinant human caspases, as well as in the NT2 cell against camptothecin induced apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZYH5uODF8jrVg90H21EOLACvtfcHk0lgKziW-NcVpnA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXos1CqtQ%253D%253D&md5=e5fdf716f194d7809e2070a1287f4b0c</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DY.%26aulast%3DGiroux%26aufirst%3DA.%26aulast%3DColucci%26aufirst%3DJ.%26aulast%3DBayly%26aufirst%3DC.%2BI.%26aulast%3DMcKay%26aufirst%3DD.%2BJ.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DXanthoudakis%26aufirst%3DS.%26aulast%3DVaillancourt%26aufirst%3DJ.%26aulast%3DRasper%26aufirst%3DD.%2BM.%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DTawa%26aufirst%3DP.%26aulast%3DNicholson%26aufirst%3DD.%2BW.%26aulast%3DZamboni%26aufirst%3DR.%2BJ.%26atitle%3DNovel%2520pyrazinone%2520mono-amides%2520as%2520potent%2520and%2520reversible%2520caspase-3%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26issue%3D4%26spage%3D1173%26epage%3D1180%26doi%3D10.1016%2Fj.bmcl.2004.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giroux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aspiotis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francoeur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayly, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKay, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xanthoudakis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaillancourt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasper, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornberry, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Calvo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotonda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamboni, R. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel aspartyl ketone dipeptides as potent and selective caspase-3 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">805</span>â <span class="NLM_lpage">808</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2003.10.064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmcl.2003.10.064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=14741294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltFyhtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=805-808&issue=3&author=Y.+Hanauthor=A.+Girouxauthor=E.+L.+Grimmauthor=R.+Aspiotisauthor=S.+Francoeurauthor=C.+I.+Baylyauthor=D.+J.+McKayauthor=S.+Royauthor=S.+Xanthoudakisauthor=J.+P.+Vaillancourtauthor=D.+M.+Rasperauthor=J.+Tamauthor=P.+Tawaauthor=N.+A.+Thornberryauthor=E.+P.+Patersonauthor=M.+Garcia-Calvoauthor=J.+W.+Beckerauthor=J.+Rotondaauthor=D.+W.+Nicholsonauthor=R.+J.+Zamboni&title=Discovery+of+novel+aspartyl+ketone+dipeptides+as+potent+and+selective+caspase-3+inhibitors&doi=10.1016%2Fj.bmcl.2003.10.064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel aspartyl ketone dipeptides as potent and selective caspase-3 inhibitors</span></div><div class="casAuthors">Han, Yongxin; Giroux, Andre; Grimm, Erich L.; Aspiotis, Renee; Francoeur, Sebastien; Bayly, Christopher I.; Mckay, Daniel J.; Roy, Sophie; Xanthoudakis, Steve; Vaillancourt, John P.; Rasper, Dita M.; Tam, John; Tawa, Paul; Thornberry, Nancy A.; Paterson, Erin P.; Garcia-Calvo, Margarita; Becker, Joseph W.; Rotonda, Jennifer; Nicholson, Donald W.; Zamboni, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">805-808</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The discovery of a series of potent, selective and reversible dipeptidyl caspase-3 inhibitors are reported.  The iterative discovery process of using combinatorial chem., parallel synthesis, mol. modeling and structural biol. will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHZyM_TsXjS7Vg90H21EOLACvtfcHk0lhzclk5DLyaPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltFyhtA%253D%253D&md5=7b06451d7a9e419de06bce82cc7a6f03</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.10.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.10.064%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DY.%26aulast%3DGiroux%26aufirst%3DA.%26aulast%3DGrimm%26aufirst%3DE.%2BL.%26aulast%3DAspiotis%26aufirst%3DR.%26aulast%3DFrancoeur%26aufirst%3DS.%26aulast%3DBayly%26aufirst%3DC.%2BI.%26aulast%3DMcKay%26aufirst%3DD.%2BJ.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DXanthoudakis%26aufirst%3DS.%26aulast%3DVaillancourt%26aufirst%3DJ.%2BP.%26aulast%3DRasper%26aufirst%3DD.%2BM.%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DTawa%26aufirst%3DP.%26aulast%3DThornberry%26aufirst%3DN.%2BA.%26aulast%3DPaterson%26aufirst%3DE.%2BP.%26aulast%3DGarcia-Calvo%26aufirst%3DM.%26aulast%3DBecker%26aufirst%3DJ.%2BW.%26aulast%3DRotonda%26aufirst%3DJ.%26aulast%3DNicholson%26aufirst%3DD.%2BW.%26aulast%3DZamboni%26aufirst%3DR.%2BJ.%26atitle%3DDiscovery%2520of%2520novel%2520aspartyl%2520ketone%2520dipeptides%2520as%2520potent%2520and%2520selective%2520caspase-3%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26issue%3D3%26spage%3D805%26epage%3D808%26doi%3D10.1016%2Fj.bmcl.2003.10.064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chereau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodandapani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomaselli, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spada, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. C.</span></span> <span> </span><span class="NLM_article-title">Structural and Functional Analysis of caspase active sites</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">4151</span>â <span class="NLM_lpage">4160</span>, <span class="refDoi">Â DOI: 10.1021/bi020593l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi020593l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit1Sjs78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=4151-4160&issue=14&author=D.+Chereauauthor=L.+Kodandapaniauthor=K.+J.+Tomaselliauthor=A.+P.+Spadaauthor=J.+C.+Wu&title=Structural+and+Functional+Analysis+of+caspase+active+sites&doi=10.1021%2Fbi020593l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Analysis of Caspase Active Sites</span></div><div class="casAuthors">Chereau, David; Kodandapani, Lalitha; Tomaselli, Kevin J.; Spada, Alfred P.; Wu, Joe C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4151-4160</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Amino acid sequences of caspases 1, 3, 7, and 8 were aligned with their published three-dimensional (3D) structures.  The resultant alignment was used as a template to compare the primary structures of caspases 2, 4-6, and 9-11 to build 3D homol. models.  The structural models were subsequently refined and validated using structure-activity relationship data obtained from an array of substrate-like inhibitors.  All caspases were shown to have identical S1 and catalytic dyad architecture but diverse S2-S4 structures.  S2 pockets of these 11 caspases can be briefly categorized into two groups: Csp3, -6, and -7 as one and Csp1, -2, -4, -5, -8, -9, -10, and -11 as the other.  S2 pockets of Csp3, -6, and -7 are smaller than those of the other eight caspases, and are limited to binding small P2 residues such as Ala and Val.  At the S3 site, the presence of a conserved Arg in all caspases suggests that Glu would be a universally preferred P3 residue.  Csp8 and Csp9 have an addnl. Arg in this pocket that can further enhance the binding of a P3 Glu, whereas Csp2 has a Glu adjacent to the conserved Arg.  As such, Csp2 is the only caspase that can accommodate both pos. and neg. charged P3.  At S4, Csp1, -4, -5, and -11 are closely related with respect to their structures and binder preferences; all have a large hydrophobic pocket and prefer large hydrophobic residues such as Trp.  S4 of Csp2, -3, and -7 represents an opposite group with a conformation that is highly specific in binding an Asp.  The S4 structures of Csp6, -8, -9, and -10 appear to be hybrids of the two extremes, and have little specificity for any P4.  Information revealed from this work provides a guide for designing potent caspase inhibitors with desirable specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmsagQoSpZWbVg90H21EOLACvtfcHk0lhzclk5DLyaPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit1Sjs78%253D&md5=519bffc763e623dc123491c749a7df67</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Fbi020593l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi020593l%26sid%3Dliteratum%253Aachs%26aulast%3DChereau%26aufirst%3DD.%26aulast%3DKodandapani%26aufirst%3DL.%26aulast%3DTomaselli%26aufirst%3DK.%2BJ.%26aulast%3DSpada%26aufirst%3DA.%2BP.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26atitle%3DStructural%2520and%2520Functional%2520Analysis%2520of%2520caspase%2520active%2520sites%26jtitle%3DBiochemistry%26date%3D2003%26volume%3D42%26issue%3D14%26spage%3D4151%26epage%3D4160%26doi%3D10.1021%2Fbi020593l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xanthoudakis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaillancourt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colucci, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giroux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamboni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtzman, D. M.</span></span> <span> </span><span class="NLM_article-title">Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic brain injury</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span> (<span class="NLM_issue">33</span>),  <span class="NLM_fpage">30128</span>â <span class="NLM_lpage">30136</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M202931200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1074%2Fjbc.M202931200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=12058036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD38XmsVKhsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=30128-30136&issue=33&author=B.+H.+Hanauthor=D.+Xuauthor=J.+Choiauthor=Y.+Hanauthor=S.+Xanthoudakisauthor=S.+Royauthor=J.+Tamauthor=J.+Vaillancourtauthor=J.+Colucciauthor=R.+Simanauthor=A.+Girouxauthor=G.+S.+Robertsonauthor=R.+Zamboniauthor=D.+W.+Nicholsonauthor=D.+M.+Holtzman&title=Selective%2C+reversible+caspase-3+inhibitor+is+neuroprotective+and+reveals+distinct+pathways+of+cell+death+after+neonatal+hypoxic-ischemic+brain+injury&doi=10.1074%2Fjbc.M202931200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic brain injury</span></div><div class="casAuthors">Han, Byung Hee; Xu, Daigen; Choi, Junjeong; Han, Yongxin; Xanthoudakis, Steven; Roy, Sophie; Tam, John; Vaillancourt, John; Colucci, John; Siman, Robert; Giroux, Andre; Robertson, George S.; Zamboni, Robert; Nicholson, Donald W.; Holtzman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">30128-30136</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Hypoxia-ischemia (H-I) in the developing brain results in brain injury with prominent features of both apoptosis and necrosis.  A peptide-based pan-caspase inhibitor is neuroprotective against neonatal H-I brain injury, suggesting a central role of caspases in brain injury.  Because previously studied peptide-based caspase inhibitors are not potent and are only partially selective, the exact contribution of specific caspases and other proteases to injury after H-I is not clear.  In this study, we explored the neuroprotective effects of a small, reversible caspase-3 inhibitor M826.  M826 selectively and potently inhibited both caspase-3 enzymic activity and apoptosis in cultured cells in vitro.  In a rat model of neonatal H-I, M826 blocked caspase-3 activation and cleavage of its substrates, which begins 6 h and peaks 24 h after H-I.  Although M826 significantly reduced DNA fragmentation and brain tissue loss, it did not prevent calpain activation in the cortex.  This activation, which is assocd. with excitotoxic/necrotic cell injury, occurred within 30 min to 2 h after H-I even in the presence of M826.  Similar to calpain activation, we found evidence of caspase-2 processing within 30 min to 2 h after H-I that was not affected by M826.  Caspase-2 processing appeared to be secondary to calpain-mediated cleavage and was not assocd. with caspase-2 activation.  These data suggest that caspase-3 specifically contributes to delayed cell death and brain injury after neonatal H-I and that calpain activation is assocd. with and likely a marker for the early component of excitotoxic/necrotic brain injury previously demonstrated in this model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAyhcrZDdT8rVg90H21EOLACvtfcHk0lhzclk5DLyaPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmsVKhsLY%253D&md5=4f7d8b7d07e4c22dec66edb46d4c138b</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M202931200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M202931200%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DB.%2BH.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DXanthoudakis%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DVaillancourt%26aufirst%3DJ.%26aulast%3DColucci%26aufirst%3DJ.%26aulast%3DSiman%26aufirst%3DR.%26aulast%3DGiroux%26aufirst%3DA.%26aulast%3DRobertson%26aufirst%3DG.%2BS.%26aulast%3DZamboni%26aufirst%3DR.%26aulast%3DNicholson%26aufirst%3DD.%2BW.%26aulast%3DHoltzman%26aufirst%3DD.%2BM.%26atitle%3DSelective%252C%2520reversible%2520caspase-3%2520inhibitor%2520is%2520neuroprotective%2520and%2520reveals%2520distinct%2520pathways%2520of%2520cell%2520death%2520after%2520neonatal%2520hypoxic-ischemic%2520brain%2520injury%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26issue%3D33%26spage%3D30128%26epage%3D30136%26doi%3D10.1074%2Fjbc.M202931200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toulmond, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bureau, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashdown, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDonnell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colucci, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giroux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pikounis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xanthoudakis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigby, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamboni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fluckiger, J. P.</span></span> <span> </span><span class="NLM_article-title">Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntingtonâs disease</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>141</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">689</span>â <span class="NLM_lpage">697</span>, <span class="refDoi">Â DOI: 10.1038/sj.bjp.0705662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2Fsj.bjp.0705662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=14744804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVCmurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2004&pages=689-697&issue=4&author=S.+Toulmondauthor=K.+Tangauthor=Y.+Bureauauthor=H.+Ashdownauthor=S.+Degenauthor=R.+O%E2%80%99Donnellauthor=J.+Tamauthor=Y.+Hanauthor=J.+Colucciauthor=A.+Girouxauthor=Y.+Zhuauthor=M.+Boucherauthor=B.+Pikounisauthor=S.+Xanthoudakisauthor=S.+Royauthor=M.+Rigbyauthor=R.+Zamboniauthor=G.+S.+Robertsonauthor=G.+Y.+Ngauthor=D.+W.+Nicholsonauthor=J.+P.+Fluckiger&title=Neuroprotective+effects+of+M826%2C+a+reversible+caspase-3+inhibitor%2C+in+the+rat+malonate+model+of+Huntington%E2%80%99s+disease&doi=10.1038%2Fsj.bjp.0705662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease</span></div><div class="casAuthors">Toulmond, Sylvie; Tang, Keith; Bureau, Yves; Ashdown, Helen; Degen, Sarah; O'Donnell, Ruth; Tam, John; Han, Yongxin; Colucci, John; Giroux, Andre; Zhu, Yanxia; Boucher, Mathieu; Pikounis, Bill; Xanthoudakis, Steven; Roy, Sophie; Rigby, Michael; Zamboni, Robert; Robertson, George S.; Ng, Gordon Y. K.; Nicholson, Donald W.; Flueckiger, Jean-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">689-697</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Caspases, key enzymes in the apoptosis pathway, have been detected in the brain of HD patients and in animal models of the disease.  In the present study, we investigated the neuroprotective properties of a new, reversible, caspase-3-specific inhibitor, M826 (3-({(2S)-2-[5-tert-butyl-3-{[(4-methyl-1,2,5-oxadiazol-3-yl)methyl]amino}-2-oxopyrazin-1(2H)-yl]butanoyl}amino)-5-[hexyl(methyl)amino]-4-oxopentanoic acid), in a rat malonate model of HD.  Pharmacokinetic and autoradiog. studies after intrastriatal (iâ) injection of 1.5 nmol of M826 or its tritiated analog [3H]M826 indicated that the compd. diffused within the entire striatum.  The elimination half-life (T1/2) of M826 in the rat striatum was 3h.  Iâ injection of 1.5 nmol of M826 10 min after malonate infusion induced a significant redn. (66%) in the no. of neurons expressing active caspase-3 in the ipsilateral striatum.  Inhibition of active caspase-3 translated into a significant but moderate redn. (39%) of the lesion vol., and of cell death (24%), 24 h after injury.  The efficacy of M826 at inhibiting cell death was comparable to that of the noncompetitive NMDA receptor antagonist MK801.  These data provide in vivo proof-of-concept of the neuroprotective effects of reversible caspase-3 inhibitors in a model of malonate-induced striatal injury in the adult rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNJDXvnaxjCbVg90H21EOLACvtfcHk0lidNbgNKjDm4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVCmurg%253D&md5=004359dca09ef30fe01749f867fd82ee</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0705662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0705662%26sid%3Dliteratum%253Aachs%26aulast%3DToulmond%26aufirst%3DS.%26aulast%3DTang%26aufirst%3DK.%26aulast%3DBureau%26aufirst%3DY.%26aulast%3DAshdown%26aufirst%3DH.%26aulast%3DDegen%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DR.%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DColucci%26aufirst%3DJ.%26aulast%3DGiroux%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DBoucher%26aufirst%3DM.%26aulast%3DPikounis%26aufirst%3DB.%26aulast%3DXanthoudakis%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DRigby%26aufirst%3DM.%26aulast%3DZamboni%26aufirst%3DR.%26aulast%3DRobertson%26aufirst%3DG.%2BS.%26aulast%3DNg%26aufirst%3DG.%2BY.%26aulast%3DNicholson%26aufirst%3DD.%2BW.%26aulast%3DFluckiger%26aufirst%3DJ.%2BP.%26atitle%3DNeuroprotective%2520effects%2520of%2520M826%252C%2520a%2520reversible%2520caspase-3%2520inhibitor%252C%2520in%2520the%2520rat%2520malonate%2520model%2520of%2520Huntington%25E2%2580%2599s%2520disease%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2004%26volume%3D141%26issue%3D4%26spage%3D689%26epage%3D697%26doi%3D10.1038%2Fsj.bjp.0705662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coulthard, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burchill, S. A.</span></span> <span> </span><span class="NLM_article-title">p38MAPK: stress responses from molecular mechanisms to therapeutics</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">369</span>â <span class="NLM_lpage">379</span>, <span class="refDoi">Â DOI: 10.1016/j.molmed.2009.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.molmed.2009.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=19665431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVehur%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=369-379&issue=8&author=L.+R.+Coulthardauthor=D.+E.+Whiteauthor=D.+L.+Jonesauthor=M.+F.+McDermottauthor=S.+A.+Burchill&title=p38MAPK%3A+stress+responses+from+molecular+mechanisms+to+therapeutics&doi=10.1016%2Fj.molmed.2009.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">p38MAPK: stress responses from molecular mechanisms to therapeutics</span></div><div class="casAuthors">Coulthard, Lydia R.; White, Danielle E.; Jones, Dominic L.; McDermott, Michael F.; Burchill, Susan A.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">369-379</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The p38MAPK protein kinases affect a variety of intracellular responses, with well-recognized roles in inflammation, cell-cycle regulation, cell death, development, differentiation, senescence and tumorigenesis.  In this review, we examine the regulatory and effector components of this pathway, focusing on their emerging roles in biol. processes involved in different pathologies.  We summarize how this pathway has been exploited for the development of therapeutics and discuss the potential obstacles of targeting this promiscuous protein kinase pathway for the treatment of different diseases.  Furthermore, we discuss how the p38MAPK pathway might be best exploited for the development of more effective therapeutics with minimal side effects in a range of specific disease settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcV5JqoEjQ3LVg90H21EOLACvtfcHk0lidNbgNKjDm4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVehur%252FM&md5=d1e83011edb2cce40ade0e2792d5e18f</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2009.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2009.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DCoulthard%26aufirst%3DL.%2BR.%26aulast%3DWhite%26aufirst%3DD.%2BE.%26aulast%3DJones%26aufirst%3DD.%2BL.%26aulast%3DMcDermott%26aufirst%3DM.%2BF.%26aulast%3DBurchill%26aufirst%3DS.%2BA.%26atitle%3Dp38MAPK%253A%2520stress%2520responses%2520from%2520molecular%2520mechanisms%2520to%2520therapeutics%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2009%26volume%3D15%26issue%3D8%26spage%3D369%26epage%3D379%26doi%3D10.1016%2Fj.molmed.2009.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mayor Mendez, F.</span>; <span class="NLM_string-name">Murga Montesinos, C.</span>; <span class="NLM_string-name">Campos Muelas, P. M.</span>; <span class="NLM_string-name">Heijnen, J. J.</span>; <span class="NLM_string-name">Kavelaars, A. M. A. A.</span>; <span class="NLM_string-name">Morreale
de Leon, A.</span>; <span class="NLM_string-name">Gil Redondo, R.</span></span> <span> </span><span class="NLM_article-title">Drugs for Inhibiting p38 and Uses Thereof</span>. <span class="NLM_patent">WO2013064714A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=F.+Mayor+Mendez&author=C.+Murga+Montesinos&author=P.+M.+Campos+Muelas&author=J.+J.+Heijnen&author=A.+M.+A.+A.+Kavelaars&author=A.+Morreale%0Ade+Leon&author=R.+Gil+Redondo&title=Drugs+for+Inhibiting+p38+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMayor%2BMendez%26aufirst%3DF.%26atitle%3DDrugs%2520for%2520Inhibiting%2520p38%2520and%2520Uses%2520Thereof%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willemen, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morreale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil-Redondo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agut, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, F. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heijnen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayor, F.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavelaars, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murga, C.</span></span> <span> </span><span class="NLM_article-title">A novel p38 MAPK docking-groove-targeted compound is a potent inhibitor of inflammatory hyperalgesia</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>459</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">427</span>â <span class="NLM_lpage">439</span>, <span class="refDoi">Â DOI: 10.1042/BJ20130172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1042%2FBJ20130172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=24517375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFemt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=459&publication_year=2014&pages=427-439&issue=3&author=H.+L.+Willemenauthor=P.+M.+Camposauthor=E.+Lucasauthor=A.+Morrealeauthor=R.+Gil-Redondoauthor=J.+Agutauthor=F.+V.+Gonzalezauthor=P.+Ramosauthor=C.+Heijnenauthor=F.+Mayorauthor=A.+Kavelaarsauthor=C.+Murga&title=A+novel+p38+MAPK+docking-groove-targeted+compound+is+a+potent+inhibitor+of+inflammatory+hyperalgesia&doi=10.1042%2FBJ20130172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">A novel p38 MAPK docking-groove-targeted compound is a potent inhibitor of inflammatory hyperalgesia</span></div><div class="casAuthors">Willemen, Hanneke L. D. M.; Campos, Pedro M.; Lucas, Elisa; Morreale, Antonio; Gil-Redondo, Ruben; Agut, Juan; Gonzalez, Florenci V.; Ramos, Paula; Heijnen, Cobi; Mayor, Federico; Kavelaars, Annemieke; Murga, Cristina</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">459</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">427-439</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The MAPK (mitogen-activated protein kinase) p38 is an important mediator of inflammation and of inflammatory and neuropathic pain.  We have described recently that docking-groove-dependent interactions are important for p38 MAPK-mediated signal transduction.  Thus virtual screening was performed to identify putative docking-groove-targeted p38 MAPK inhibitors.  Several compds. of the benzo-oxadiazol family were identified with low micromolar inhibitory activity both in a p38 MAPK activity assay, and in THP-1 human monocytes acting as inhibitors of LPS (lipopolysaccharide)-induced TNFÎ± (tumor necrosis factor Î±) secretion.  Positions 2 and 5 in the Ph ring are essential for the described inhibitory activity with a chloride in position 5 and a Me group in position 2 yielding the best results, giving an IC50 value of 1.8 Î¼M (FGA-19 compd.).  Notably, FGA-19 exerted a potent and long-lasting analgesic effect in vivo when tested in a mouse model of inflammatory hyperalgesia.  A single intrathecal injection of FGA-19 completely resolved hyperalgesia, being 10-fold as potent and displaying longer lasting effects than the established p38 MAPK inhibitor SB239063.  FGA-19 also reversed persistent pain in a model of post-inflammatory hyperalgesia in LysM (lysozyme M)-GRK2 (G-protein-coupled-receptor kinase)+/- mice.  These potent in vivo effects suggested p38 MAPK docking-site-targeted inhibitors as a potential novel strategy for the treatment of inflammatory pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSjDuXZVUav7Vg90H21EOLACvtfcHk0lidNbgNKjDm4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFemt74%253D&md5=988817704d7f3e25748b1d43b64fd3ec</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1042%2FBJ20130172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20130172%26sid%3Dliteratum%253Aachs%26aulast%3DWillemen%26aufirst%3DH.%2BL.%26aulast%3DCampos%26aufirst%3DP.%2BM.%26aulast%3DLucas%26aufirst%3DE.%26aulast%3DMorreale%26aufirst%3DA.%26aulast%3DGil-Redondo%26aufirst%3DR.%26aulast%3DAgut%26aufirst%3DJ.%26aulast%3DGonzalez%26aufirst%3DF.%2BV.%26aulast%3DRamos%26aufirst%3DP.%26aulast%3DHeijnen%26aufirst%3DC.%26aulast%3DMayor%26aufirst%3DF.%26aulast%3DKavelaars%26aufirst%3DA.%26aulast%3DMurga%26aufirst%3DC.%26atitle%3DA%2520novel%2520p38%2520MAPK%2520docking-groove-targeted%2520compound%2520is%2520a%2520potent%2520inhibitor%2520of%2520inflammatory%2520hyperalgesia%26jtitle%3DBiochem.%2520J.%26date%3D2014%26volume%3D459%26issue%3D3%26spage%3D427%26epage%3D439%26doi%3D10.1042%2FBJ20130172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. A.</span></span> <span> </span><span class="NLM_article-title">PAINS in the assay: Chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2091</span>â <span class="NLM_lpage">2113</span>, <span class="refDoi">Â DOI: 10.1021/jm5019093</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5019093" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeisbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2091-2113&issue=5&author=J.+L.+Dahlinauthor=J.+W.+M.+Nissinkauthor=J.+M.+Strasserauthor=S.+Francisauthor=L.+Higginsauthor=H.+Zhouauthor=Z.+Zhangauthor=M.+A.+Walters&title=PAINS+in+the+assay%3A+Chemical+mechanisms+of+assay+interference+and+promiscuous+enzymatic+inhibition+observed+during+a+sulfhydryl-scavenging+HTS&doi=10.1021%2Fjm5019093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">PAINS in the Assay: Chemical Mechanisms of Assay Interference and Promiscuous Enzymatic Inhibition Observed during a Sulfhydryl-Scavenging HTS</span></div><div class="casAuthors">Dahlin, Jayme L.; Nissink, J. Willem M.; Strasser, Jessica M.; Francis, Subhashree; Higgins, LeeAnn; Zhou, Hui; Zhang, Zhiguo; Walters, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2091-2113</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Significant resources in early drug discovery are spent unknowingly pursuing artifacts and promiscuous bioactive compds., while understanding the chem. basis for these adverse behaviors often goes unexplored in pursuit of lead compds.  Nearly all the hits from our recent sulfhydryl-scavenging high-throughput screen (HTS) targeting the histone acetyltransferase Rtt109 were such compds.  Herein, we characterize the chem. basis for assay interference and promiscuous enzymic inhibition for several prominent chemotypes identified by this HTS, including some pan-assay interference compds. (PAINS).  Protein mass spectrometry and ALARM NMR confirmed these compds. react covalently with cysteines on multiple proteins.  Unfortunately, compds. contg. these chemotypes have been published as screening actives in reputable journals and even touted as chem. probes or preclin. candidates.  Our detailed characterization and identification of such thiol-reactive chemotypes should accelerate triage of nuisance compds., guide screening library design, and prevent follow-up on undesirable chem. matter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4XTJapoezkrVg90H21EOLACvtfcHk0lgKD0pnWOPSlg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeisbY%253D&md5=3f77702544cea2ec4c8184b60dd38b8a</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Fjm5019093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5019093%26sid%3Dliteratum%253Aachs%26aulast%3DDahlin%26aufirst%3DJ.%2BL.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DStrasser%26aufirst%3DJ.%2BM.%26aulast%3DFrancis%26aufirst%3DS.%26aulast%3DHiggins%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWalters%26aufirst%3DM.%2BA.%26atitle%3DPAINS%2520in%2520the%2520assay%253A%2520Chemical%2520mechanisms%2520of%2520assay%2520interference%2520and%2520promiscuous%2520enzymatic%2520inhibition%2520observed%2520during%2520a%2520sulfhydryl-scavenging%2520HTS%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D5%26spage%3D2091%26epage%3D2113%26doi%3D10.1021%2Fjm5019093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, P.</span>; <span class="NLM_string-name">Carrasco, E.</span>; <span class="NLM_string-name">Campos, P.</span>; <span class="NLM_string-name">Deleyto, P.</span>; <span class="NLM_string-name">Vega, M.</span>; <span class="NLM_string-name">Gomez-Reino, J. J.</span>; <span class="NLM_string-name">Conde, C.</span>; <span class="NLM_string-name">Gualillo, O.</span>; <span class="NLM_string-name">Perez, J. J.</span>; <span class="NLM_string-name">Messeguer, A.</span></span> <span> </span><span class="NLM_article-title">p38 MAPK Inhibitors for the Treatment of Inflammatory Diseases</span>. <span class="NLM_patent">WO2014094816A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=P.+Gomez&author=E.+Carrasco&author=P.+Campos&author=P.+Deleyto&author=M.+Vega&author=J.+J.+Gomez-Reino&author=C.+Conde&author=O.+Gualillo&author=J.+J.+Perez&author=A.+Messeguer&title=p38+MAPK+Inhibitors+for+the+Treatment+of+Inflammatory+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGomez%26aufirst%3DP.%26atitle%3Dp38%2520MAPK%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Inflammatory%2520Diseases%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, P.</span>; <span class="NLM_string-name">Carrasco, E.</span>; <span class="NLM_string-name">Campos, P.</span>; <span class="NLM_string-name">Vega, M.</span>; <span class="NLM_string-name">Gomez-Reino, J. J.</span>; <span class="NLM_string-name">Perez, J. J.</span>; <span class="NLM_string-name">Messeguer, A.</span>; <span class="NLM_string-name">Torres, I.</span></span> <span> </span><span class="NLM_article-title">p38 and JNK MAPK Inhibitors for the Treatment and Prophylaxis of Degenerative Diseases of the Nervous System</span>. <span class="NLM_patent">WO2015193281A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+Gomez&author=E.+Carrasco&author=P.+Campos&author=M.+Vega&author=J.+J.+Gomez-Reino&author=J.+J.+Perez&author=A.+Messeguer&author=I.+Torres&title=p38+and+JNK+MAPK+Inhibitors+for+the+Treatment+and+Prophylaxis+of+Degenerative+Diseases+of+the+Nervous+System"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGomez%26aufirst%3DP.%26atitle%3Dp38%2520and%2520JNK%2520MAPK%2520Inhibitors%2520for%2520the%2520Treatment%2520and%2520Prophylaxis%2520of%2520Degenerative%2520Diseases%2520of%2520the%2520Nervous%2520System%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giembycz, M. A.</span></span> <span> </span><span class="NLM_article-title">An update and appraisal of the cilomilast phase III clinical development programme for chronic obstructive pulmonary disease</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">138</span>â <span class="NLM_lpage">152</span>, <span class="refDoi">Â DOI: 10.1111/j.1365-2125.2006.02640.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1111%2Fj.1365-2125.2006.02640.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=16842388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVersr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=138-152&issue=2&author=M.+A.+Giembycz&title=An+update+and+appraisal+of+the+cilomilast+phase+III+clinical+development+programme+for+chronic+obstructive+pulmonary+disease&doi=10.1111%2Fj.1365-2125.2006.02640.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Giembycz, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">138-152</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Cilomilast (Ariflo, SB 207499) is an orally active, second-generation phosphodiesterase (PDE) 4 inhibitor that is being developed by GlaxoSmithkline for the treatment of chronic obstructive pulmonary disease (COPD).  The results of Phase I and Phase II studies have demonstrated that cilomilast significantly improves lung function and quality of life to a clin. meaningful extent, which has led to a comprehensive Phase III program of research evaluating efficacy, safety and mechanism of action.  However, the results of those Phase III studies are unremarkable and disappointing, raising doubt over the future of cilomilast as a novel therapy for COPD.  This review summarizes data obtained from the Phase III clin. development program, highlights some of the potential concerns both specific to cilomilast and to PDE4 inhibitors in general and assesses the likelihood that cilomilast will reach the market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG3j4h3elSNrVg90H21EOLACvtfcHk0lgKD0pnWOPSlg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVersr8%253D&md5=0d8f4c3833a446ed6a43cc9b355a2c46</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2006.02640.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2006.02640.x%26sid%3Dliteratum%253Aachs%26aulast%3DGiembycz%26aufirst%3DM.%2BA.%26atitle%3DAn%2520update%2520and%2520appraisal%2520of%2520the%2520cilomilast%2520phase%2520III%2520clinical%2520development%2520programme%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2006%26volume%3D62%26issue%3D2%26spage%3D138%26epage%3D152%26doi%3D10.1111%2Fj.1365-2125.2006.02640.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trifilieff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyss, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzoni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersperger, R.</span></span> <span> </span><span class="NLM_article-title">Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with anti-inflammatory activities</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>301</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">241</span>â <span class="NLM_lpage">248</span>, <span class="refDoi">Â DOI: 10.1124/jpet.301.1.241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1124%2Fjpet.301.1.241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=11907180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1KqsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=301&publication_year=2002&pages=241-248&issue=1&author=A.+Trifilieffauthor=D.+Wyssauthor=C.+Walkerauthor=L.+Mazzoniauthor=R.+Hersperger&title=Pharmacological+profile+of+a+novel+phosphodiesterase+4+inhibitor%2C+4-%288-benzo%5B1%2C2%2C5%5Doxadiazol-5-yl-%5B1%2C7%5Dnaphthyridin-6-yl%29benzoic+acid+%28NVP-ABE171%29%2C+a+1%2C7-naphthyridine+derivative%2C+with+anti-inflammatory+activities&doi=10.1124%2Fjpet.301.1.241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with anti-inflammatory activities</span></div><div class="casAuthors">Trifilieff, Alexandre; Wyss, Daniel; Walker, Christoph; Mazzoni, Lazzaro; Hersperger, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">301</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">241-248</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The pharmacol. of a new class of phosphodiesterase 4 (PDE4) inhibitor, 6,8-disubstituted 1,7-naphthyridines, was investigated by using NVP-ABE171 as a representative compd., and its potency was compared with that of the most advanced PDE4 inhibitor currently undergoing clin. trials, Ariflo [cis-4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl-r-1-cyclohexanecarboxylic acid)].  NVP-ABE171 inhibited the activity of PDE 4A, 4B, 4C, and 4D with resp. IC50 values of 602, 34, 1230, and 1.5 nM.  Ariflo was about 40 times less potent.  In human cells, NVP-ABE171 in the nanomolar range inhibited the eosinophil and neutrophil oxidative burst, the release of cytokines by T cells, and tumor necrosis factor-Î± release from monocytes.  Ariflo had a similar inhibition profile but was 7-50-fold less potent.  In BALB/c mice challenged with lipopolysaccharide, NVP-ABE171 inhibited airway neutrophil influx and activation, with an ED50 in the range of 3 mg/kg.  Ariflo was inactive at â¤10 mg/kg.  In ovalbumin-sensitized Brown Norway rats, NVP-ABE171 inhibited lipopolysaccharide-induced airway neutrophil influx and activation (ED50 of 0.2 mg/kg) and ovalbumin-induced airway eosinophil influx and activation (ED50 of 0.1 mg/kg).  Ariflo was about 100-folds less potent in both models.  In the ovalbumin model, NVP-ABE171 had a duration of action of >24 h.  NVP-ABE171 is a novel PDE4 inhibitor that has activity both in vitro on human inflammatory cells and in vivo in animal models of lung inflammation.  This compd. class may have potential for the treatment of airway inflammatory conditions such as asthma and chronic obstructive pulmonary diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq76eMiujQMLVg90H21EOLACvtfcHk0lhuTNKGePHuJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1KqsrY%253D&md5=ac551981b3c2d6d7bc0b9bf7aa7d570e</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1124%2Fjpet.301.1.241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.301.1.241%26sid%3Dliteratum%253Aachs%26aulast%3DTrifilieff%26aufirst%3DA.%26aulast%3DWyss%26aufirst%3DD.%26aulast%3DWalker%26aufirst%3DC.%26aulast%3DMazzoni%26aufirst%3DL.%26aulast%3DHersperger%26aufirst%3DR.%26atitle%3DPharmacological%2520profile%2520of%2520a%2520novel%2520phosphodiesterase%25204%2520inhibitor%252C%25204-%25288-benzo%255B1%252C2%252C5%255Doxadiazol-5-yl-%255B1%252C7%255Dnaphthyridin-6-yl%2529benzoic%2520acid%2520%2528NVP-ABE171%2529%252C%2520a%25201%252C7-naphthyridine%2520derivative%252C%2520with%2520anti-inflammatory%2520activities%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D301%26issue%3D1%26spage%3D241%26epage%3D248%26doi%3D10.1124%2Fjpet.301.1.241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatzelmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morcillo, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lungarella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adnot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanjar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beume, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schudt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenor, H.</span></span> <span> </span><span class="NLM_article-title">The preclinical pharmacology of roflumilastâa selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">235</span>â <span class="NLM_lpage">256</span>, <span class="refDoi">Â DOI: 10.1016/j.pupt.2010.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.pupt.2010.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=20381629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlWqur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=235-256&issue=4&author=A.+Hatzelmannauthor=E.+J.+Morcilloauthor=G.+Lungarellaauthor=S.+Adnotauthor=S.+Sanjarauthor=R.+Beumeauthor=C.+Schudtauthor=H.+Tenor&title=The+preclinical+pharmacology+of+roflumilast%E2%80%94a+selective%2C+oral+phosphodiesterase+4+inhibitor+in+development+for+chronic+obstructive+pulmonary+disease&doi=10.1016%2Fj.pupt.2010.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">The preclinical pharmacology of roflumilast - A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Hatzelmann, Armin; Morcillo, Esteban J.; Lungarella, Giuseppe; Adnot, Serge; Sanjar, Shahin; Beume, Rolf; Schudt, Christian; Tenor, Hermann</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-256</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  After more than two decades of research into phosphodiesterase 4 (PDE4) inhibitors, roflumilast (3-cyclopropylmethoxy-4-difluoromethoxy-N-[3,5-di-chloropyrid-4-yl]-benzamide) may become the first agent in this class to be approved for patient treatment worldwide.  Within the PDE family of 11 known isoenzymes, roflumilast is selective for PDE4, showing balanced selectivity for subtypes A-D, and is of high subnanomolar potency.  The active principle of roflumilast in man is its dichloropyridyl N-oxide metabolite, which has similar potency as a PDE4 inhibitor as the parent compd.  The long half-life and high potency of this metabolite allows for once-daily, oral administration of a single, 500-Î¼g tablet of roflumilast.  The mol. mode of action of roflumilast - PDE4 inhibition and subsequent enhancement of cAMP levels - is well established.  To further understand its functional mode of action in chronic obstructive pulmonary disease (COPD), for which roflumilast is being developed, a series of in vitro and in vivo preclin. studies has been performed.  COPD is a progressive, devastating condition of the lung assocd. with an abnormal inflammatory response to noxious particles and gases, particularly tobacco smoke.  In addn., according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), significant extrapulmonary effects, including comorbidities, may add to the severity of the disease in individual patients, and which may be addressed preferentially by orally administered remedies.  COPD shows an increasing prevalence and mortality, and its treatment remains a high, unmet medical need.  In vivo, roflumilast mitigates key COPD-related disease mechanisms such as tobacco smoke-induced lung inflammation, mucociliary malfunction, lung fibrotic and emphysematous remodelling, oxidative stress, pulmonary vascular remodelling and pulmonary hypertension.  In vitro, roflumilast N-oxide has been demonstrated to affect the functions of many cell types, including neutrophils, monocytes/macrophages, CD4+ and CD8+ T-cells, endothelial cells, epithelial cells, smooth muscle cells and fibroblasts.  These cellular effects are thought to be responsible for the beneficial effects of roflumilast on the disease mechanisms of COPD, which translate into reduced exacerbations and improved lung function.  As a multicomponent disease, COPD requires a broad therapeutic approach that might be achieved by PDE4 inhibition.  However, as a PDE4 inhibitor, roflumilast is not a direct bronchodilator.  In summary, roflumilast may be the first-in-class PDE4 inhibitor for COPD therapy.  In addn. to being a non-steroid, anti-inflammatory drug designed to target pulmonary inflammation, the preclin. pharmacol. described in this review points to a broad functional mode of action of roflumilast that putatively addresses addnl. COPD mechanisms.  This enables roflumilast to offer effective, oral maintenance treatment for COPD, with an acceptable tolerability profile and the potential to favorably affect the extrapulmonary effects of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDAicMKzimBbVg90H21EOLACvtfcHk0lhuTNKGePHuJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlWqur8%253D&md5=ada4424630713054cefe9a6f5c98121b</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2010.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2010.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DHatzelmann%26aufirst%3DA.%26aulast%3DMorcillo%26aufirst%3DE.%2BJ.%26aulast%3DLungarella%26aufirst%3DG.%26aulast%3DAdnot%26aufirst%3DS.%26aulast%3DSanjar%26aufirst%3DS.%26aulast%3DBeume%26aufirst%3DR.%26aulast%3DSchudt%26aufirst%3DC.%26aulast%3DTenor%26aufirst%3DH.%26atitle%3DThe%2520preclinical%2520pharmacology%2520of%2520roflumilast%25E2%2580%2594a%2520selective%252C%2520oral%2520phosphodiesterase%25204%2520inhibitor%2520in%2520development%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2010%26volume%3D23%26issue%3D4%26spage%3D235%26epage%3D256%26doi%3D10.1016%2Fj.pupt.2010.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dastidar, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirumalla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palle, V.</span></span> <span> </span><span class="NLM_article-title">Pharmacology of a novel, orally active PDE4 inhibitor</span>. <i>Pharmacology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>83</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">275</span>â <span class="NLM_lpage">286</span>, <span class="refDoi">Â DOI: 10.1159/000209608</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1159%2F000209608" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=19321962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvFWlsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2009&pages=275-286&issue=5&author=S.+G.+Dastidarauthor=A.+Rayauthor=R.+Shirumallaauthor=D.+Rajagopalauthor=S.+Chaudharyauthor=K.+Nandaauthor=P.+Sharmaauthor=M.+K.+Sethauthor=S.+Balachandranauthor=N.+Guptaauthor=V.+Palle&title=Pharmacology+of+a+novel%2C+orally+active+PDE4+inhibitor&doi=10.1159%2F000209608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of a Novel, Orally Active PDE4 Inhibitor</span></div><div class="casAuthors">Dastidar, Sunanda G.; Ray, Abhijit; Shirumalla, Rajkumar; Rajagopal, Deepa; Chaudhary, Shiwani; Nanda, Kamna; Sharma, Pawan; Seth, Mahesh Kumar; Balachandran, Sarala; Gupta, Nidhi; Palle, Venkata</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">275-286</span>CODEN:
                <span class="NLM_cas:coden">PHMGBN</span>;
        ISSN:<span class="NLM_cas:issn">0031-7012</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: Intracellular cyclic adenosine monophosphate (cAMP) in inflammatory cells and airway smooth muscle is crit. to the modulation of inflammatory response generation.  Phosphodiesterase 4 (PDE4), an enzyme that catalyzes cAMP degrdn., is therefore being actively explored as a mol. target for the treatment of airway inflammation, particularly asthma and chronic obstructive pulmonary disease.  The field has undergone major advances in optimizing generation of compds. with a safe therapeutic margin; however, most PDE4 inhibitors tested so far have unacceptable side effects, particularly nausea and vomiting.  Methods: We evaluated NIS-62949 in a wide range of in vitro and ex vivo cell-based assays to ascertain its anti-inflammatory potential.  The compd. was evaluated in murine models of lipopolysaccharide-induced endotoxemia and pulmonary neutrophilia.  Parameters of airway inflammation, airway hyperreactivity and bronchoconstriction were evaluated in a guinea pig model of antigen-induced allergy.  In order to assess the emetic potential, the compd. was evaluated biochem. for binding to high-affinity rolipram-binding site.  Subsequently, the compd. was tested in a surrogate model for emesis, and the results obtained were correlated directly to tests conducted in a Beagle dog model.  Results: NIS-62949 is a potent, highly selective PDE4 inhibitor.  The compd. demonstrated potent ability to inhibit tumor necrosis factor-Î± release from human peripheral blood mononuclear cells, lymphocyte proliferation and cytokine prodn.  The in vitro profile of NIS-62949 prompted further evaluation of the compd. in vivo and the compd. was found to be comparable to roflumilast in several exptl. models of pulmonary inflammation.  Importantly, NIS-62949 displayed a safer profile compared to roflumilast.  Conclusions: Our results report the development of a promising, novel PDE4 inhibitor, NIS-62949, with a wider therapeutic window as compared to second-generation PDE4 inhibitors such as roflumilast.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQBGkvWYkMMrVg90H21EOLACvtfcHk0lhuTNKGePHuJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvFWlsbg%253D&md5=4fbdb3da007ccf0bee0f8305069f8474</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1159%2F000209608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000209608%26sid%3Dliteratum%253Aachs%26aulast%3DDastidar%26aufirst%3DS.%2BG.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DShirumalla%26aufirst%3DR.%26aulast%3DRajagopal%26aufirst%3DD.%26aulast%3DChaudhary%26aufirst%3DS.%26aulast%3DNanda%26aufirst%3DK.%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DSeth%26aufirst%3DM.%2BK.%26aulast%3DBalachandran%26aufirst%3DS.%26aulast%3DGupta%26aufirst%3DN.%26aulast%3DPalle%26aufirst%3DV.%26atitle%3DPharmacology%2520of%2520a%2520novel%252C%2520orally%2520active%2520PDE4%2520inhibitor%26jtitle%3DPharmacology%26date%3D2009%26volume%3D83%26issue%3D5%26spage%3D275%26epage%3D286%26doi%3D10.1159%2F000209608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Press, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fullerton, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tranter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denholm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberthuer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatto, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keenan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercer, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuffnell, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trifilieff, A.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic acid, an improved PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">6747</span>â <span class="NLM_lpage">6752</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00902</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00902" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlOju7zI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6747-6752&issue=17&author=N.+J.+Pressauthor=R.+J.+Taylorauthor=J.+D.+Fullertonauthor=P.+Tranterauthor=C.+McCarthyauthor=T.+H.+Kellerauthor=N.+Arnoldauthor=D.+Beerauthor=L.+Brownauthor=R.+Cheungauthor=J.+Christieauthor=A.+Denholmauthor=S.+Haberthuerauthor=J.+D.+Hattoauthor=M.+Keenanauthor=M.+K.+Mercerauthor=H.+Oakmanauthor=H.+Sahriauthor=A.+R.+Tuffnellauthor=M.+Tweedauthor=A.+Trifilieff&title=Discovery+and+optimization+of+4-%288-%283-Fluorophenyl%29-1%2C7-naphthyridin-6-yl%29transcyclohexanecarboxylic+acid%2C+an+improved+PDE4+inhibitor+for+the+treatment+of+chronic+obstructive+pulmonary+disease+%28COPD%29&doi=10.1021%2Facs.jmedchem.5b00902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)</span></div><div class="casAuthors">Press, Neil J.; Taylor, Roger J.; Fullerton, Joseph D.; Tranter, Pamela; McCarthy, Clive; Keller, Thomas H.; Arnold, Nicola; Beer, David; Brown, Lyndon; Cheung, Robert; Christie, Julie; Denholm, Alastair; Haberthuer, Sandra; Hatto, Julia D. I.; Keenan, Mark; Mercer, Mark K.; Oakman, Helen; Sahri, Helene; Tuffnell, Andrew R.; Tweed, Morris; Trifilieff, Alexandre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6747-6752</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein the authors describe the optimization of a series of PDE4 inhibitors, with special focus on soly. and pharmacokinetics, to clin. compd. 2, 4-(8-(3-fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic acid.  Although compd. 2 produces emesis in humans when given as a single dose, its exemplary pharmacokinetic properties enabled a novel dosing regime comprising multiple escalating doses and the resultant achievement of high plasma drug levels without assocd. nausea or emesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtmzZuZpBNSLVg90H21EOLACvtfcHk0ljneyVzRlLE4Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlOju7zI&md5=ddc41343095c67022590f0dc12c41bb2</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00902%26sid%3Dliteratum%253Aachs%26aulast%3DPress%26aufirst%3DN.%2BJ.%26aulast%3DTaylor%26aufirst%3DR.%2BJ.%26aulast%3DFullerton%26aufirst%3DJ.%2BD.%26aulast%3DTranter%26aufirst%3DP.%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DArnold%26aufirst%3DN.%26aulast%3DBeer%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DL.%26aulast%3DCheung%26aufirst%3DR.%26aulast%3DChristie%26aufirst%3DJ.%26aulast%3DDenholm%26aufirst%3DA.%26aulast%3DHaberthuer%26aufirst%3DS.%26aulast%3DHatto%26aufirst%3DJ.%2BD.%26aulast%3DKeenan%26aufirst%3DM.%26aulast%3DMercer%26aufirst%3DM.%2BK.%26aulast%3DOakman%26aufirst%3DH.%26aulast%3DSahri%26aufirst%3DH.%26aulast%3DTuffnell%26aufirst%3DA.%2BR.%26aulast%3DTweed%26aufirst%3DM.%26aulast%3DTrifilieff%26aufirst%3DA.%26atitle%3DDiscovery%2520and%2520optimization%2520of%25204-%25288-%25283-Fluorophenyl%2529-1%252C7-naphthyridin-6-yl%2529transcyclohexanecarboxylic%2520acid%252C%2520an%2520improved%2520PDE4%2520inhibitor%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520%2528COPD%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D17%26spage%3D6747%26epage%3D6752%26doi%3D10.1021%2Facs.jmedchem.5b00902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Press, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fullerton, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tranter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denholm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberthuer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatto, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keenan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercer, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuffnell, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyler, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fozard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trifilieff, A.</span></span> <span> </span><span class="NLM_article-title">Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7472</span>â <span class="NLM_lpage">7479</span>, <span class="refDoi">Â DOI: 10.1021/jm300459a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300459a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOrurnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7472-7479&issue=17&author=N.+J.+Pressauthor=R.+J.+Taylorauthor=J.+D.+Fullertonauthor=P.+Tranterauthor=C.+McCarthyauthor=T.+H.+Kellerauthor=N.+Arnoldauthor=D.+Beerauthor=L.+Brownauthor=R.+Cheungauthor=J.+Christieauthor=A.+Denholmauthor=S.+Haberthuerauthor=J.+D.+Hattoauthor=M.+Keenanauthor=M.+K.+Mercerauthor=H.+Oakmanauthor=H.+Sahriauthor=A.+R.+Tuffnellauthor=M.+Tweedauthor=J.+W.+Tylerauthor=T.+Wagnerauthor=J.+R.+Fozardauthor=A.+Trifilieff&title=Solubility-driven+optimization+of+phosphodiesterase-4+inhibitors+leading+to+a+clinical+candidate&doi=10.1021%2Fjm300459a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Solubility-Driven Optimization of Phosphodiesterase-4 Inhibitors Leading to a Clinical Candidate</span></div><div class="casAuthors">Press, Neil J.; Taylor, Roger J.; Fullerton, Joseph D.; Tranter, Pamela; McCarthy, Clive; Keller, Thomas H.; Arnold, Nicola; Beer, David; Brown, Lyndon; Cheung, Robert; Christie, Julie; Denholm, Alastair; Haberthuer, Sandra; Hatto, Julia D. I.; Keenan, Mark; Mercer, Mark K.; Oakman, Helen; Sahri, Helene; Tuffnell, Andrew R.; Tweed, Morris; Tyler, John W.; Wagner, Trixie; Fozard, John R.; Trifilieff, Alexandre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7472-7479</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The soly.-driven optimization of a series of 1,7-naphthyridine phosphodiesterase-4 inhibitors is described.  Directed structural changes resulted in increased aq. soly., enabling superior pharmacokinetic properties with retention of PDE4 inhibition.  A range of potent and orally bioavailable compds. with good in vivo efficacy in animal models of inflammation and reduced emetic potential compared to previously described drugs were synthesized.  Compd. 2d (I) was taken forward as a clin. candidate for the treatment of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL0BzBNQVqnrVg90H21EOLACvtfcHk0ljneyVzRlLE4Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOrurnO&md5=deee9ca074de0b531a130d9a6ce530b2</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Fjm300459a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300459a%26sid%3Dliteratum%253Aachs%26aulast%3DPress%26aufirst%3DN.%2BJ.%26aulast%3DTaylor%26aufirst%3DR.%2BJ.%26aulast%3DFullerton%26aufirst%3DJ.%2BD.%26aulast%3DTranter%26aufirst%3DP.%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DArnold%26aufirst%3DN.%26aulast%3DBeer%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DL.%26aulast%3DCheung%26aufirst%3DR.%26aulast%3DChristie%26aufirst%3DJ.%26aulast%3DDenholm%26aufirst%3DA.%26aulast%3DHaberthuer%26aufirst%3DS.%26aulast%3DHatto%26aufirst%3DJ.%2BD.%26aulast%3DKeenan%26aufirst%3DM.%26aulast%3DMercer%26aufirst%3DM.%2BK.%26aulast%3DOakman%26aufirst%3DH.%26aulast%3DSahri%26aufirst%3DH.%26aulast%3DTuffnell%26aufirst%3DA.%2BR.%26aulast%3DTweed%26aufirst%3DM.%26aulast%3DTyler%26aufirst%3DJ.%2BW.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DFozard%26aufirst%3DJ.%2BR.%26aulast%3DTrifilieff%26aufirst%3DA.%26atitle%3DSolubility-driven%2520optimization%2520of%2520phosphodiesterase-4%2520inhibitors%2520leading%2520to%2520a%2520clinical%2520candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D17%26spage%3D7472%26epage%3D7479%26doi%3D10.1021%2Fjm300459a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alberti, M. J.</span>; <span class="NLM_string-name">Garland, S.</span>; <span class="NLM_string-name">Jung, D. K.</span>; <span class="NLM_string-name">Veal, J. M.</span>; <span class="NLM_string-name">Witherington, J.</span></span> <span> </span><span class="NLM_article-title">Preparation of 2-(4-Amino-3-furazanyl)benzimidazoles as Mitogen-Activated and Rho-Kinase Inhibitors</span>. <span class="NLM_patent">WO2003080125A2</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=M.+J.+Alberti&author=S.+Garland&author=D.+K.+Jung&author=J.+M.+Veal&author=J.+Witherington&title=Preparation+of+2-%284-Amino-3-furazanyl%29benzimidazoles+as+Mitogen-Activated+and+Rho-Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlberti%26aufirst%3DM.%2BJ.%26atitle%3DPreparation%2520of%25202-%25284-Amino-3-furazanyl%2529benzimidazoles%2520as%2520Mitogen-Activated%2520and%2520Rho-Kinase%2520Inhibitors%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, N.</span>; <span class="NLM_string-name">Bamford, M. J.</span>; <span class="NLM_string-name">Garland, S.</span>; <span class="NLM_string-name">Goodman, K. B.</span>; <span class="NLM_string-name">Haifeng, C.</span>; <span class="NLM_string-name">Hilfiker, M. A.</span>; <span class="NLM_string-name">Lee, D.</span>; <span class="NLM_string-name">Panchal, T. A.</span>; <span class="NLM_string-name">Stavenger, R. A.</span>; <span class="NLM_string-name">Wilson, D. M.</span>; <span class="NLM_string-name">Witherington, J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Imidazopyridines as Kinase Inhibitors</span>. <span class="NLM_patent">WO2003080610A1</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=N.+Bailey&author=M.+J.+Bamford&author=S.+Garland&author=K.+B.+Goodman&author=C.+Haifeng&author=M.+A.+Hilfiker&author=D.+Lee&author=T.+A.+Panchal&author=R.+A.+Stavenger&author=D.+M.+Wilson&author=J.+Witherington&title=Preparation+of+Imidazopyridines+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DN.%26atitle%3DPreparation%2520of%2520Imidazopyridines%2520as%2520Kinase%2520Inhibitors%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heerding, D. A.</span>; <span class="NLM_string-name">Clark, T. J.</span>; <span class="NLM_string-name">Drewry, D. H.</span>; <span class="NLM_string-name">Leber, J. D.</span>; <span class="NLM_string-name">Safonov, I.</span>; <span class="NLM_string-name">Yamashita, D. S.</span></span> <span> </span><span class="NLM_article-title">Preparation of 1H-Imidazo[4,5-c]pyridin-2-yl Derivatives as Inhibitors of Akt Activity</span>. <span class="NLM_patent">WO2005011700A1</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=D.+A.+Heerding&author=T.+J.+Clark&author=D.+H.+Drewry&author=J.+D.+Leber&author=I.+Safonov&author=D.+S.+Yamashita&title=Preparation+of+1H-Imidazo%5B4%2C5-c%5Dpyridin-2-yl+Derivatives+as+Inhibitors+of+Akt+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHeerding%26aufirst%3DD.%2BA.%26atitle%3DPreparation%2520of%25201H-Imidazo%255B4%252C5-c%255Dpyridin-2-yl%2520Derivatives%2520as%2520Inhibitors%2520of%2520Akt%2520Activity%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bamford, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberti, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaiba, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harling, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchal, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steadman, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takle, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witherington, J.</span></span> <span> </span><span class="NLM_article-title">(1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: A novel class of potent MSK-1-inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">3402</span>â <span class="NLM_lpage">3406</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2005.05.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmcl.2005.05.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=15950465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsVClsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=3402-3406&issue=14&author=M.+J.+Bamfordauthor=M.+J.+Albertiauthor=N.+Baileyauthor=S.+Daviesauthor=D.+K.+Deanauthor=A.+Gaibaauthor=S.+Garlandauthor=J.+D.+Harlingauthor=D.+K.+Jungauthor=T.+A.+Panchalauthor=C.+A.+Parrauthor=J.+G.+Steadmanauthor=A.+K.+Takleauthor=J.+T.+Townsendauthor=D.+M.+Wilsonauthor=J.+Witherington&title=%281H-imidazo%5B4%2C5-c%5Dpyridin-2-yl%29-1%2C2%2C5-oxadiazol-3-ylamine+derivatives%3A+A+novel+class+of+potent+MSK-1-inhibitors&doi=10.1016%2Fj.bmcl.2005.05.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">(1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: A novel class of potent MSK-1-inhibitors</span></div><div class="casAuthors">Bamford, Mark J.; Alberti, Michael J.; Bailey, Nicholas; Davies, Susannah; Dean, David K.; Gaiba, Alessandra; Garland, Stephen; Harling, John D.; Jung, David K.; Panchal, Terence A.; Parr, Christopher A.; Steadman, Jon G.; Takle, Andrew K.; Townsend, James T.; Wilson, David M.; Witherington, Jason</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3402-3406</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of imidazo[4,5-c]pyridines bearing a 1,2,5-oxadiazol-3-ylamine functionality has been developed.  These are potent inhibitors of mitogen and stress-activated protein kinase-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptkdZkGxrcxrVg90H21EOLACvtfcHk0lhV2XhMSTzY6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsVClsr4%253D&md5=5c12382fec9201f5ead2b12382d6bba9</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.05.021%26sid%3Dliteratum%253Aachs%26aulast%3DBamford%26aufirst%3DM.%2BJ.%26aulast%3DAlberti%26aufirst%3DM.%2BJ.%26aulast%3DBailey%26aufirst%3DN.%26aulast%3DDavies%26aufirst%3DS.%26aulast%3DDean%26aufirst%3DD.%2BK.%26aulast%3DGaiba%26aufirst%3DA.%26aulast%3DGarland%26aufirst%3DS.%26aulast%3DHarling%26aufirst%3DJ.%2BD.%26aulast%3DJung%26aufirst%3DD.%2BK.%26aulast%3DPanchal%26aufirst%3DT.%2BA.%26aulast%3DParr%26aufirst%3DC.%2BA.%26aulast%3DSteadman%26aufirst%3DJ.%2BG.%26aulast%3DTakle%26aufirst%3DA.%2BK.%26aulast%3DTownsend%26aufirst%3DJ.%2BT.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26aulast%3DWitherington%26aufirst%3DJ.%26atitle%3D%25281H-imidazo%255B4%252C5-c%255Dpyridin-2-yl%2529-1%252C2%252C5-oxadiazol-3-ylamine%2520derivatives%253A%2520A%2520novel%2520class%2520of%2520potent%2520MSK-1-inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26issue%3D14%26spage%3D3402%26epage%3D3406%26doi%3D10.1016%2Fj.bmcl.2005.05.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bamford, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchal, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehmi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steadman, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takle, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. M.</span></span> <span> </span><span class="NLM_article-title">(1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: further optimization as highly potent and selective MSK-1-inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">3407</span>â <span class="NLM_lpage">3411</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2005.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmcl.2005.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=15955699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsVClsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=3407-3411&issue=14&author=M.+J.+Bamfordauthor=N.+Baileyauthor=S.+Daviesauthor=D.+K.+Deanauthor=L.+Francisauthor=T.+A.+Panchalauthor=C.+A.+Parrauthor=S.+Sehmiauthor=J.+G.+Steadmanauthor=A.+K.+Takleauthor=J.+T.+Townsendauthor=D.+M.+Wilson&title=%281H-imidazo%5B4%2C5-c%5Dpyridin-2-yl%29-1%2C2%2C5-oxadiazol-3-ylamine+derivatives%3A+further+optimization+as+highly+potent+and+selective+MSK-1-inhibitors&doi=10.1016%2Fj.bmcl.2005.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">(1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Further optimisation as highly potent and selective MSK-1-inhibitors</span></div><div class="casAuthors">Bamford, Mark J.; Bailey, Nicholas; Davies, Susannah; Dean, David K.; Francis, Leann; Panchal, Terence A.; Parr, Christopher A.; Sehmi, Sanjeet; Steadman, Jon G.; Takle, Andrew K.; Townsend, James T.; Wilson, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3407-3411</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The novel imidazo[4,5-c]pyridine 1,2,5-oxadiazol-3-yl template affords an excellent start point for identification of inhibitors of a no. of protein kinases.  Here the authors report on its optimization for mitogen and stress-activated protein kinase-1 (MSK-1) inhibitory activity, and selectivity over other kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeMu-4dj1HPbVg90H21EOLACvtfcHk0lhV2XhMSTzY6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsVClsr8%253D&md5=84f0665b88f747c4c3f0c2d7ee8e0f5d</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DBamford%26aufirst%3DM.%2BJ.%26aulast%3DBailey%26aufirst%3DN.%26aulast%3DDavies%26aufirst%3DS.%26aulast%3DDean%26aufirst%3DD.%2BK.%26aulast%3DFrancis%26aufirst%3DL.%26aulast%3DPanchal%26aufirst%3DT.%2BA.%26aulast%3DParr%26aufirst%3DC.%2BA.%26aulast%3DSehmi%26aufirst%3DS.%26aulast%3DSteadman%26aufirst%3DJ.%2BG.%26aulast%3DTakle%26aufirst%3DA.%2BK.%26aulast%3DTownsend%26aufirst%3DJ.%2BT.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26atitle%3D%25281H-imidazo%255B4%252C5-c%255Dpyridin-2-yl%2529-1%252C2%252C5-oxadiazol-3-ylamine%2520derivatives%253A%2520further%2520optimization%2520as%2520highly%2520potent%2520and%2520selective%2520MSK-1-inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26issue%3D14%26spage%3D3407%26epage%3D3411%26doi%3D10.1016%2Fj.bmcl.2005.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naqvi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darragh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, J. S.</span></span> <span> </span><span class="NLM_article-title">Characterization of the cellular action of the MSK inhibitor SB-747651A</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>441</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">347</span>â <span class="NLM_lpage">357</span>, <span class="refDoi">Â DOI: 10.1042/BJ20110970</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1042%2FBJ20110970" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=21970321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Cgs7fE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=441&publication_year=2012&pages=347-357&issue=1&author=S.+Naqviauthor=A.+Macdonaldauthor=C.+E.+McCoyauthor=J.+Darraghauthor=A.+D.+Reithauthor=J.+S.+Arthur&title=Characterization+of+the+cellular+action+of+the+MSK+inhibitor+SB-747651A&doi=10.1042%2FBJ20110970"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the cellular action of the MSK inhibitor SB-747651A</span></div><div class="casAuthors">Naqvi, Shaista; MacDnald, Andrew; McCoy, Claire E.; Darragh, Joanne; Reith, Alastair D.; Arthur, J. Simon C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">441</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">347-357</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">MSK1 (mitogen- and stress-activated kinase 1) and MSK2 are nuclear protein kinases that regulate transcription downstream of the ERK1/2 (extracellular-signal-regulated kinase 1/2) and p38Î± MAPKs (mitogen-activated protein kinases) via the phosphorylation of CREB (cAMP-response-element-binding protein) and histone H3.  Previous studies on the function of MSKs have used two inhibitors, H89 and Ro 31-8220, both of which have multiple off-target effects.  In the present study, we report the characterization of the in vitro and cellular properties of an improved MSK1 inhibitor, SB-747651A.  In vitro, SB-747651A inhibits MSK1 with an IC50 value of 11 nM.  Screening of an in vitro panel of 117 protein kinases revealed that, at 1 Î¼M, SB-747651A inhibited four other kinases, PRK2 (double-stranded-RNA-dependent protein kinase 2), RSK1 (ribosomal S6 kinase 1), p70S6K (S6K is S6 kinase) (p70RSK) and ROCK-II (Rho-assocd. protein kinase 2), with a similar potency to MSK1.  In cells, SB-747651A fully inhibited MSK activity at 5-10 Î¼M.  SB-747651A was found to inhibit the prodn. of the anti-inflammatory cytokine IL-10 (interleukin-10) in wild-type, but not MSK1/2-knockout, macrophages following LPS (lipopolysaccharide) stimulation.  Both SB-747651A and MSK1/2 knockout resulted in elevated pro-inflammatory cytokine prodn. by macrophages in response to LPS.  Comparison of the effects of SB-747651A, both in vitro and in cells, demonstrated that SB-747651A exhibited improved selectivity over H89 and Ro 31-8220 and therefore represents a useful tool to study MSK function in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvkT4WnkI0bLVg90H21EOLACvtfcHk0lhV2XhMSTzY6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Cgs7fE&md5=a3fa505f314cb7fa8eec761e5c891abb</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1042%2FBJ20110970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20110970%26sid%3Dliteratum%253Aachs%26aulast%3DNaqvi%26aufirst%3DS.%26aulast%3DMacdonald%26aufirst%3DA.%26aulast%3DMcCoy%26aufirst%3DC.%2BE.%26aulast%3DDarragh%26aufirst%3DJ.%26aulast%3DReith%26aufirst%3DA.%2BD.%26aulast%3DArthur%26aufirst%3DJ.%2BS.%26atitle%3DCharacterization%2520of%2520the%2520cellular%2520action%2520of%2520the%2520MSK%2520inhibitor%2520SB-747651A%26jtitle%3DBiochem.%2520J.%26date%3D2012%26volume%3D441%26issue%3D1%26spage%3D347%26epage%3D357%26doi%3D10.1042%2FBJ20110970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brogden, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorkin, E. M.</span></span> <span> </span><span class="NLM_article-title">Isradipine: An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">618</span>â <span class="NLM_lpage">649</span>, <span class="refDoi">Â DOI: 10.2165/00003495-199549040-00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.2165%2F00003495-199549040-00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=7789292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK2MXltFCksbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1995&pages=618-649&issue=4&author=R.+N.+Brogdenauthor=E.+M.+Sorkin&title=Isradipine%3A+An+update+of+its+pharmacodynamic+and+pharmacokinetic+properties+and+therapeutic+efficacy+in+the+treatment+of+mild+to+moderate+hypertension&doi=10.2165%2F00003495-199549040-00009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension</span></div><div class="casAuthors">Brogden, Rex N.; Sorkin, Eugene M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">618-49</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    </div><div class="casAbstract">A review with 212 refs.  Pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension by using isradipine, intraoperative hypertension, drug interactions, atherosclerosis, etc., are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphqI4erc-kpLVg90H21EOLACvtfcHk0liGVLmQ4hDNkQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXltFCksbg%253D&md5=ad8a76380c42bce9f476c9ae8773f6fa</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.2165%2F00003495-199549040-00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-199549040-00009%26sid%3Dliteratum%253Aachs%26aulast%3DBrogden%26aufirst%3DR.%2BN.%26aulast%3DSorkin%26aufirst%3DE.%2BM.%26atitle%3DIsradipine%253A%2520An%2520update%2520of%2520its%2520pharmacodynamic%2520and%2520pharmacokinetic%2520properties%2520and%2520therapeutic%2520efficacy%2520in%2520the%2520treatment%2520of%2520mild%2520to%2520moderate%2520hypertension%26jtitle%3DDrugs%26date%3D1995%26volume%3D49%26issue%3D4%26spage%3D618%26epage%3D649%26doi%3D10.2165%2F00003495-199549040-00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lund-Johansen, P.</span></span> <span> </span><span class="NLM_article-title">Cardiac effects of isradipine in patients with hypertension</span>. <i>Am. J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">294S</span>â <span class="NLM_lpage">299S</span>, <span class="refDoi">Â DOI: 10.1093/ajh/6.7.294S</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1093%2Fajh%2F6.7.294S" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=8398014" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1993&pages=294S-299S&author=P.+Lund-Johansen&title=Cardiac+effects+of+isradipine+in+patients+with+hypertension&doi=10.1093%2Fajh%2F6.7.294S"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1093%2Fajh%2F6.7.294S&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fajh%252F6.7.294S%26sid%3Dliteratum%253Aachs%26aulast%3DLund-Johansen%26aufirst%3DP.%26atitle%3DCardiac%2520effects%2520of%2520isradipine%2520in%2520patients%2520with%2520hypertension%26jtitle%3DAm.%2520J.%2520Hypertens.%26date%3D1993%26volume%3D6%26spage%3D294S%26epage%3D299S%26doi%3D10.1093%2Fajh%2F6.7.294S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirsten, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirsten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heintz, B.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacokinetics of vasodilators. Part I</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">457</span>â <span class="NLM_lpage">482</span>, <span class="refDoi">Â DOI: 10.2165/00003088-199834060-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.2165%2F00003088-199834060-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=9646008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK1cXkt1eisrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1998&pages=457-482&issue=6&author=R.+Kirstenauthor=K.+Nelsonauthor=D.+Kirstenauthor=B.+Heintz&title=Clinical+pharmacokinetics+of+vasodilators.+Part+I&doi=10.2165%2F00003088-199834060-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of vasodilators. Part I</span></div><div class="casAuthors">Kirsten, Roland; Nelson, Karen; Kirsten, Daniel; Heintz, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">457-482</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review with 313 refs.  Understanding the mechanism of action and the pharmacokinetic properties of vasodilatory drugs facilitates optimal use in clin. practice.  It should be kept in mind that a drug belongs to a class but is a distinct entity, sometimes derived from a prototype to achieve a specific effect.  The most common pharmacokinetic drug improvement is the development of a drug with a half-life sufficiently long to allow an adequate once-daily dosage.  Developing a controlled release prepn. can increase the apparent half-life of a drug.  Altering the mol. structure may also increase the half-life of a prototype drug.  Another desirable improvement is increasing the specificity of a drug, which may result in fewer adverse effects, or more efficacy at the target site.  This is esp. important for vasodilatory drugs which may be administered over decades for the treatment of hypertension, which usually does not interfere with subjective well-being.  Compliance is greatly increased with once-daily dosing.  Vasodilatory agents cause relaxation by either a decrease in cytoplasmic calcium, an increase in nitric oxide (NO) or by inhibiting myosin light chain kinase.  They are divided into 9 classes: calcium antagonists, potassium channel openers, ACE inhibitors, angiotensin-II receptor antagonists, Î±-adrenergic and imidazole receptor antagonists, Î²1-adrenergic agonists, phosphodiesterase inhibitors, eicosanoids and NO donors.  Despite chem. differences, the pharmacokinetic properties of calcium antagonists are similar.  Absorption from the gastrointestinal tract is high, with all substances undergoing considerable first-pass metab. by the liver, resulting in low bioavailability and pronounced individual variation in pharmacokinetics.  Renal impairment has little effect on pharmacokinetics since renal elimination of these agents is minimal.  Except for the newer drugs of the dihydropyridine type, amlodipine, felodipine, isradipine, nilvadipine, nisoldipine and nitrendipine, the half-life of calcium antagonists is short.  Maintaining an effective drug concn. for the remainder of these agents requires multiple daily dosing, in some cases even with controlled release formulations.  However, a coat-core prepn. of nifedipine has been developed to allow once-daily administration.  Adverse effects are directly correlated to the potency of the individual calcium antagonist.  Treatment with the potassium channel opener minoxidil is reserved for patients with moderately severe to severe hypertension which is refractory to other treatment.  Diazoxide and hydralazine are chiefly used to treat severe hypertensive emergencies, primary pulmonary and malignant hypertension and in severe preeclampsia.  ACE inhibitors prevent conversion of angiotensin-I to angiotensin-II and are most effective when renin prodn. is increased.  Since ACE is identical to kininase-II, which inactivates the potent endogenous vasodilator bradykinin, ACE inhibition causes a redn. in bradykinin degrdn.  ACE inhibitors exert cardioprotective and cardioreparative effects by preventing and reversing cardiac fibrosis and ventricular hypertrophy in animal models.  The predominant elimination pathway of most ACE inhibitors is via renal excretion.  Therefore, renal impairment is assocd. with reduced elimination and a dosage redn. of 25 to 50% is recommended in patients with moderate to severe renal impairment.  Sepg. angiotensin-II inhibition from bradykinin potentiation has been the goal in developing angiotensin-II receptor antagonists.  The incidence of adverse effects of such an agent, losartan, is comparable to that encountered with placebo treatment, and the troublesome cough assocd. with ACE inhibitors is absent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6SzD63jhmybVg90H21EOLACvtfcHk0liGVLmQ4hDNkQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkt1eisrs%253D&md5=c4444fc03336f0f637e7769172e50d83</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.2165%2F00003088-199834060-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-199834060-00003%26sid%3Dliteratum%253Aachs%26aulast%3DKirsten%26aufirst%3DR.%26aulast%3DNelson%26aufirst%3DK.%26aulast%3DKirsten%26aufirst%3DD.%26aulast%3DHeintz%26aufirst%3DB.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520vasodilators.%2520Part%2520I%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1998%26volume%3D34%26issue%3D6%26spage%3D457%26epage%3D482%26doi%3D10.2165%2F00003088-199834060-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Broudy, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemienczuk, D.</span></span> <span> </span><span class="NLM_article-title">Beneficial effects of the calcium antagonist PN 200â110 in patients with congestive heart failure</span>. <i>J. Cardiovasc. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">190</span>â <span class="NLM_lpage">195</span>, <span class="refDoi">Â DOI: 10.1097/00005344-198708000-00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1097%2F00005344-198708000-00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=2441170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADyaL2s3osFCltA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1987&pages=190-195&issue=2&author=D.+R.+Broudyauthor=B.+H.+Greenbergauthor=D.+Siemienczuk&title=Beneficial+effects+of+the+calcium+antagonist+PN+200%E2%80%93110+in+patients+with+congestive+heart+failure&doi=10.1097%2F00005344-198708000-00009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Beneficial effects of the calcium antagonist PN 200-110 in patients with congestive heart failure</span></div><div class="casAuthors">Broudy D R; Greenberg B H; Siemienczuk D</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cardiovascular pharmacology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">190-5</span>
        ISSN:<span class="NLM_cas:issn">0160-2446</span>.
    </div><div class="casAbstract">We studied the acute hemodynamic effects of PN 200-110, a newly available calcium antagonist, in 12 patients with severe congestive heart failure.  Measurements of cardiac performance were obtained by a right heart catheter before and after administration of 5 and 15 mg of PN.  Peak drug effects occurred 1-2 h following the administration of PN 200-110 and were dose related.  The 15-mg dose reduced mean arterial pressure (MAP) from 90 +/- 11 to 75 +/- 6 mm Hg (mean +/- SD) (p less than 0.001) and decreased systemic vascular resistance (SVR) from 1,740 +/- 500 to 995 +/- 300 dynes X s X cm-5 (p less than 0.01).  Stroke volume index (SVI) increased from 26 +/- 7 to 36 +/- 10 ml/m2 (p less than 0.001), and cardiac index (CI) rose from 2.1 +/- .3 to 2.8 +/- .6 L/m2 (p less than 0.01).  Pulmonary arterial wedge pressure (PAW) changed insignificantly.  Seven patients performed graded supine exercise at identical workloads before and after treatment.  When peak exercise values were compared, the addition of PN 200-110 further reduced SVR from 1,282 +/- 461 to 936 +/- 356 dynes X s X cm-5 (p less than 0.01) and increased CI from 3.3 +/- 1.1 to 4.3 +/- 1.3 L/m2 (p less than 0.01).  Only minor, self-limiting side effects were noticed during acute administration.  Of the seven patients discharged on PN 200-110 and followed for at least 6 months, six reported substantial relief of symptoms.(ABSTRACT TRUNCATED AT 250 WORDS)</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQQh4CXaM4H8HRxY89Cm6SyfW6udTcc2eZxNcUYqrW6rLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2s3osFCltA%253D%253D&md5=139b9fb0cfb753999b73a5becf47d48a</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1097%2F00005344-198708000-00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005344-198708000-00009%26sid%3Dliteratum%253Aachs%26aulast%3DBroudy%26aufirst%3DD.%2BR.%26aulast%3DGreenberg%26aufirst%3DB.%2BH.%26aulast%3DSiemienczuk%26aufirst%3DD.%26atitle%3DBeneficial%2520effects%2520of%2520the%2520calcium%2520antagonist%2520PN%2520200%25E2%2580%2593110%2520in%2520patients%2520with%2520congestive%2520heart%2520failure%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D1987%26volume%3D10%26issue%3D2%26spage%3D190%26epage%3D195%26doi%3D10.1097%2F00005344-198708000-00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemienczuk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broudy, D.</span></span> <span> </span><span class="NLM_article-title">Hemodynamic effects of PN 200â110 (isradipine) in congestive heart failure</span>. <i>Am. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">70B</span>â <span class="NLM_lpage">74B</span>, <span class="refDoi">Â DOI: 10.1016/0002-9149(87)90085-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2F0002-9149%2887%2990085-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=2949588" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1987&pages=70B-74B&issue=3&author=B.+Greenbergauthor=D.+Siemienczukauthor=D.+Broudy&title=Hemodynamic+effects+of+PN+200%E2%80%93110+%28isradipine%29+in+congestive+heart+failure&doi=10.1016%2F0002-9149%2887%2990085-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2F0002-9149%2887%2990085-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0002-9149%252887%252990085-3%26sid%3Dliteratum%253Aachs%26aulast%3DGreenberg%26aufirst%3DB.%26aulast%3DSiemienczuk%26aufirst%3DD.%26aulast%3DBroudy%26aufirst%3DD.%26atitle%3DHemodynamic%2520effects%2520of%2520PN%2520200%25E2%2580%2593110%2520%2528isradipine%2529%2520in%2520congestive%2520heart%2520failure%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D1987%26volume%3D59%26issue%3D3%26spage%3D70B%26epage%3D74B%26doi%3D10.1016%2F0002-9149%2887%2990085-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pool, P. E.</span></span> <span> </span><span class="NLM_article-title">Efficacy of a new calcium antagonist PN 200â110 (isradipine) in angina pectoris</span>. <i>Am. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">123B</span>â <span class="NLM_lpage">129B</span>, <span class="refDoi">Â DOI: 10.1016/0002-9149(87)90091-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2F0002-9149%2887%2990091-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=2949583" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1987&pages=123B-129B&issue=3&author=S.+H.+Taylorauthor=N.+C.+Jacksonauthor=J.+Allenauthor=P.+E.+Pool&title=Efficacy+of+a+new+calcium+antagonist+PN+200%E2%80%93110+%28isradipine%29+in+angina+pectoris&doi=10.1016%2F0002-9149%2887%2990091-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2F0002-9149%2887%2990091-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0002-9149%252887%252990091-9%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%2BH.%26aulast%3DJackson%26aufirst%3DN.%2BC.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DPool%26aufirst%3DP.%2BE.%26atitle%3DEfficacy%2520of%2520a%2520new%2520calcium%2520antagonist%2520PN%2520200%25E2%2580%2593110%2520%2528isradipine%2529%2520in%2520angina%2520pectoris%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D1987%26volume%3D59%26issue%3D3%26spage%3D123B%26epage%3D129B%26doi%3D10.1016%2F0002-9149%2887%2990091-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Handler, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowton, E.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability and efficacy of PN 200â110, a new calcium antagonist in patients with angina and coronary heart disease</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">415</span>â <span class="NLM_lpage">417</span>, <span class="refDoi">Â DOI: 10.1007/BF00549587</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1007%2FBF00549587" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=6240405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADyaL2M7gtFKjsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1984&pages=415-417&issue=4&author=C.+E.+Handlerauthor=E.+Sowton&title=Safety%2C+tolerability+and+efficacy+of+PN+200%E2%80%93110%2C+a+new+calcium+antagonist+in+patients+with+angina+and+coronary+heart+disease&doi=10.1007%2FBF00549587"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability and efficacy of PN 200-110, a new calcium antagonist in patients with angina and coronary heart disease</span></div><div class="casAuthors">Handler C E; Sowton E</div><div class="citationInfo"><span class="NLM_cas:title">European journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">415-7</span>
        ISSN:<span class="NLM_cas:issn">0031-6970</span>.
    </div><div class="casAbstract">The safety, tolerability and efficacy of PN 200-110, a new calcium antagonist with minimal negative inotropic effects, were studied in twelve patients with stable angina pectoris and coronary artery disease.  The study design was single-blind and placebo-controlled and increasing doses of the drug were used on consecutive days to investigate a dose response relationship.  Eleven patients completed the trial.  Response to the drug was evaluated using symptom limited cycle ergometric exercise.  PN 200-110 in all three tested doses of 2.5 mg, 5.0 mg and 10.0 mg significantly increased the resting heart rate (p less than 0.02) and the exercise time to the onset of angina pectoris (p less than 0.02).  Doses above 2.5 mg did not appear to improve the exercise parameters evaluated.  Four patients had side effects probably due to PN 200-110 but these were mild and included dizziness, headache and flushing.  There were no abnormal results from haematological and biochemical screening or from urine testing.  We conclude that PN 220-110 can be given safely to patients with coronary artery disease without producing deleterious effects on blood pressure either at rest or during exercise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTaixT8j7AAv8zK395ZObgVfW6udTcc2eamCsSqmRivRbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2M7gtFKjsA%253D%253D&md5=06b87a1e8c2dd3e8a9652c3e924245e4</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1007%2FBF00549587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00549587%26sid%3Dliteratum%253Aachs%26aulast%3DHandler%26aufirst%3DC.%2BE.%26aulast%3DSowton%26aufirst%3DE.%26atitle%3DSafety%252C%2520tolerability%2520and%2520efficacy%2520of%2520PN%2520200%25E2%2580%2593110%252C%2520a%2520new%2520calcium%2520antagonist%2520in%2520patients%2520with%2520angina%2520and%2520coronary%2520heart%2520disease%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1984%26volume%3D27%26issue%3D4%26spage%3D415%26epage%3D417%26doi%3D10.1007%2FBF00549587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilde, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keef, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hume, J. R.</span></span> <span> </span><span class="NLM_article-title">Electrophysiological mechanisms of minoxidil sulfate-induced vasodilation of rabbit portal vein</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1102</span>â <span class="NLM_lpage">1111</span>, <span class="refDoi">Â DOI: 10.1161/01.RES.65.4.1102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1161%2F01.RES.65.4.1102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=2791221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaL1MXmtVyqsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1989&pages=1102-1111&issue=4&author=N.+Leblancauthor=D.+W.+Wildeauthor=K.+D.+Keefauthor=J.+R.+Hume&title=Electrophysiological+mechanisms+of+minoxidil+sulfate-induced+vasodilation+of+rabbit+portal+vein&doi=10.1161%2F01.RES.65.4.1102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Electrophysiological mechanisms of minoxidil sulfate-induced vasodilation of rabbit portal vein</span></div><div class="casAuthors">Leblanc, Normand; Wilde, Dixon W.; Keef, Kathleen D.; Hume, Joseph R.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1102-11</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    </div><div class="casAbstract">The electrophysiol. and mech. properties of the vasodilator minoxidil sulfate (MNXS) were examd. in isolated smooth muscle cells and strips from rabbit portal vein.  At micromolar concns., MNXS inhibited norepinephrine (0.1-1.0 Î¼M)-induced contractions in isolated muscle strips.  In isolated cells, norepinephrine caused a concn.-dependent depolarization of the resting membrane potential, which was attenuated by MNXS (5 Î¼M); MNXS alone caused a hyperpolarization of the membrane potential.  This hyperpolarization was insensitive to Na+-K+ pump blockade by ouabain, but was inhibited by the K+ channel antagonist, tetraethylammonium (20 mM).  In voltage-clamp expts., a resting (background) conductance assocd. with the resting membrane potential was identified.  This conductance, which is reduced by Ba2+ as well as tetraethylammonium, was increased by MNXS (2 Î¼M).  In addnl. expts., whole-cell L-type Ca2+ currents were inhibited by micromolar concns. of MNXS.  Concns. of MNXS that inhibit norepinephrine-induced contractions promote K+ conductance and inhibit Ca2+ entry through voltage-dependent Ca2+ channels in vascular smooth muscle cells.  These electrophysiol. effects of MNXS may be responsible for the vasorelaxant effects of the drug obsd. in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1_enkU-aM27Vg90H21EOLACvtfcHk0liZdRZMQhjMHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXmtVyqsrs%253D&md5=9e3919922bdc9e333f5f3c767e126f46</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1161%2F01.RES.65.4.1102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.65.4.1102%26sid%3Dliteratum%253Aachs%26aulast%3DLeblanc%26aufirst%3DN.%26aulast%3DWilde%26aufirst%3DD.%2BW.%26aulast%3DKeef%26aufirst%3DK.%2BD.%26aulast%3DHume%26aufirst%3DJ.%2BR.%26atitle%3DElectrophysiological%2520mechanisms%2520of%2520minoxidil%2520sulfate-induced%2520vasodilation%2520of%2520rabbit%2520portal%2520vein%26jtitle%3DCirc.%2520Res.%26date%3D1989%26volume%3D65%26issue%3D4%26spage%3D1102%26epage%3D1111%26doi%3D10.1161%2F01.RES.65.4.1102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oka, M.</span>; <span class="NLM_string-name">Seto, K.</span></span> <span> </span><span class="NLM_article-title">Pulmonary Hypertension Remedy</span>. <span class="NLM_patent">WO9412503A1</span>, <span class="NLM_year">1994</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&author=M.+Oka&author=K.+Seto&title=Pulmonary+Hypertension+Remedy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOka%26aufirst%3DM.%26atitle%3DPulmonary%2520Hypertension%2520Remedy%26date%3D1994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shikada, K.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, S.</span></span> <span> </span><span class="NLM_article-title">Cardiovascular pharmacology of NIP-121, a potassium channel opener</span>. <i>Cardiovasc. Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">86</span>â <span class="NLM_lpage">101</span>, <span class="refDoi">Â DOI: 10.1111/j.1527-3466.1995.tb00215.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1111%2Fj.1527-3466.1995.tb00215.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK2MXotlygurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1995&pages=86-101&issue=1&author=T.+Yamashitaauthor=Y.+Masudaauthor=K.-i.+Shikadaauthor=S.+Tanaka&title=Cardiovascular+pharmacology+of+NIP-121%2C+a+potassium+channel+opener&doi=10.1111%2Fj.1527-3466.1995.tb00215.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular pharmacology of NIP-121, a potassium channel opener</span></div><div class="casAuthors">Yamashita, Toru; Masuda, Yukinori; Shikada, Ken-ichi; Tanaka, Sakuya</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Drug Reviews</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-101</span>CODEN:
                <span class="NLM_cas:coden">CDREEA</span>;
        ISSN:<span class="NLM_cas:issn">0897-5957</span>.
    
            (<span class="NLM_cas:orgname">Neva Press</span>)
        </div><div class="casAbstract">A review with 63 refs. of preclin. cardiovascular pharmacol. of NIP-121.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfQdybnbfoZ7Vg90H21EOLACvtfcHk0ljSd7rBl7awbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXotlygurk%253D&md5=574160b385cf7ea96cd2a783a3b19d66</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3466.1995.tb00215.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3466.1995.tb00215.x%26sid%3Dliteratum%253Aachs%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DMasuda%26aufirst%3DY.%26aulast%3DShikada%26aufirst%3DK.-i.%26aulast%3DTanaka%26aufirst%3DS.%26atitle%3DCardiovascular%2520pharmacology%2520of%2520NIP-121%252C%2520a%2520potassium%2520channel%2520opener%26jtitle%3DCardiovasc.%2520Drug%2520Rev.%26date%3D1995%26volume%3D13%26issue%3D1%26spage%3D86%26epage%3D101%26doi%3D10.1111%2Fj.1527-3466.1995.tb00215.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujikura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, S.</span></span> <span> </span><span class="NLM_article-title">Comparative study of vasodilator effects of the potassium channel openers NIP-121 and levcromakalim in dogs and rats</span>. <i>Jpn. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">145</span>â <span class="NLM_lpage">152</span>, <span class="refDoi">Â DOI: 10.1254/jjp.68.145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1254%2Fjjp.68.145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=7563971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK2MXmsFequrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1995&pages=145-152&issue=2&author=T.+Yamashitaauthor=Y.+Masudaauthor=N.+Kawamuraauthor=N.+Fujikuraauthor=S.+Tanaka&title=Comparative+study+of+vasodilator+effects+of+the+potassium+channel+openers+NIP-121+and+levcromakalim+in+dogs+and+rats&doi=10.1254%2Fjjp.68.145"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative study of vasodilator effects of the potassium channel openers NIP-121 and levcromakalim in dogs and rats</span></div><div class="casAuthors">Yamashita, Toru; Masuda, Yukinori; Kawamura, Norimitsu; Fujikura, Naoki; Tanaka, Sakuya</div><div class="citationInfo"><span class="NLM_cas:title">Japanese Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-52</span>CODEN:
                <span class="NLM_cas:coden">JJPAAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-5198</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">The effects of potassium channel openers NIP-121 ((+)-7,8-dihydro-6,6-dimethyl-7-hydroxy-8-(2-oxo-piperidine-1-yl)-6H-pyrano[2,3-f]benz-2,1,3-oxadiazole) and levcromakalim were examd. in vitro and in vivo.  In isolated canine vascular beds, NIP-121 (3 x 10-9 to 10-7 M) and levcromakalim (3 x 10-8 to 10-6 M) produced a concn.-dependent redn. in the vasoconstrictor responses to U46619.  The effects were antagonized by glibenclamide, an ATP-sensitive potassium channel blocker.  The maximal relaxation was more than 70% of the maximal vasodilation induced by papaverine (10-4 M), except in the basilar artery.  These compds. had very potent effects on the coronary and cranial mesenteric arteries and saphenous vein.  In the coronary perfused rat heart, both compds. (10-7 M) also increased coronary perfusion flow.  The effects were also inhibited by glibenclamide (10-6 M).  In anesthetized dogs, NIP-121 (1 to 10 Î¼g/kg (3.2 to 32 nmol/kg), i.v.) and levcromakalim (3 to 30 Î¼g/kg (10.5 to 105 nmol/kg), i.v.) dose-dependently increased coronary and renal blood flow.  NIP-121 and levcromakalim at higher doses produced the greatest increase in coronary blood flow among the blood vessels examd., in spite of the hypotensive effect.  In conclusion, NIP-121 and levcromakalim were similarly selective vasodilators on the canine isolated coronary and cranial mesenteric arteries and saphenous vein, and they selectively increased coronary blood flow in vivo.  With respect to increasing the coronary blood flow, NIP-121 had a fourfold greater potency than levcromakalim.  This effect might be related to the glibenclamide-sensitive potassium channels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofI9PmFXLI8bVg90H21EOLACvtfcHk0ljSd7rBl7awbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmsFequrc%253D&md5=2083784d2c1fb23009323b59b9f4c8ce</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1254%2Fjjp.68.145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjjp.68.145%26sid%3Dliteratum%253Aachs%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DMasuda%26aufirst%3DY.%26aulast%3DKawamura%26aufirst%3DN.%26aulast%3DFujikura%26aufirst%3DN.%26aulast%3DTanaka%26aufirst%3DS.%26atitle%3DComparative%2520study%2520of%2520vasodilator%2520effects%2520of%2520the%2520potassium%2520channel%2520openers%2520NIP-121%2520and%2520levcromakalim%2520in%2520dogs%2520and%2520rats%26jtitle%3DJpn.%2520J.%2520Pharmacol.%26date%3D1995%26volume%3D68%26issue%3D2%26spage%3D145%26epage%3D152%26doi%3D10.1254%2Fjjp.68.145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shigenobu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, S.</span></span> <span> </span><span class="NLM_article-title">The antihypertensive property of NIP-121, a novel potassium channel opener in rats</span>. <i>J. Cardiovasc. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">190</span>â <span class="NLM_lpage">197</span>, <span class="refDoi">Â DOI: 10.1097/00005344-199108000-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1097%2F00005344-199108000-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1717778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK3MXlsFSjsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1991&pages=190-197&issue=2&author=Y.+Masudaauthor=C.+Arakawaauthor=T.+Yokoyamaauthor=K.+Shigenobuauthor=S.+Tanaka&title=The+antihypertensive+property+of+NIP-121%2C+a+novel+potassium+channel+opener+in+rats&doi=10.1097%2F00005344-199108000-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">The antihypertensive property of NIP-121, a novel potassium channel opener in rats</span></div><div class="casAuthors">Masuda, Y.; Arakawa, C.; Yokoyama, T.; Shigenobu, K.; Tanaka, S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiovascular Pharmacology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">190-7</span>CODEN:
                <span class="NLM_cas:coden">JCPCDT</span>;
        ISSN:<span class="NLM_cas:issn">0160-2446</span>.
    </div><div class="casAbstract">The antihypertensive effects of NIP-121 (I), a novel potassium channel opener, were examd. in comparison with cromakalim and its active enantiomer, lemakalim.  In expts. by direct blood pressure measurements, orally administered NIP-121 dose-relatedly decreased arterial blood pressure in conscious spontaneously hypertensive rats (SHRs), and the ED20 values (the doses to produce 20% decrease of the mean blood pressure) of NIP-121 and cromakalim were 0.010 and 0.11 mg/kg, resp., NIP-121 thus being about ten times more potent than cromakalim.  The duration of the hypotensive effect of NIP-121 was longer than that by cromakalim.  The hypotensive effect of NIP-121 was stronger in SHRs than in normotensive rats.  All three drugs showed tachycardia that was antagonized by a Î²-blocker, propranolol.  I.v. administered NIP-121 also showed a more potent hypotensive action with longer duration than cromakalim in conscious SHRs.  The ED20 values for hypotension by NIP-121, cromakalim, and lemakalim were 0.017, 0.040, and 0.016 mg/kg, resp.  The i.v. hypotensive potency of NIP-121 but not cromakalim was similar to that of p.o. administration.  The repeated treatments with NIP-121 (0.025, 0.05, and 0.1 mg/kg p.o. once a day) for 15 days did not modify the degree of the hypotensive action.  In the anesthetized SHRs, pretreatment with glibenclamide but not other antagonists (atropine, propranolol, diphenhydramine + cimetidine, or indomethacin) suppressed the decrease in blood pressure induced by NIP-121.  In anesthetized and ganglion-blocked rats, NIP-121 (0.003-0.3 mg/kg, i.v.) dose-dependently antagonized the pressor responses to i.v. injection or norepinephrine, angiotensin I, angiotensin II, arginine vasopressin, prostaglandin F2Î±, or Bay K 8644; among these interventions, the pressor response to Bay K 8644 was antagonized most potently.  These results indicate that NIP-121 has a potent and long-lasting antihypertensive effect that may largely be produced by its activity as a potassium channel opener.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIbJNqWKWrJbVg90H21EOLACvtfcHk0ljSd7rBl7awbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlsFSjsbs%253D&md5=984eb7cbfb52efb6570a520f97ce1589</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1097%2F00005344-199108000-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005344-199108000-00003%26sid%3Dliteratum%253Aachs%26aulast%3DMasuda%26aufirst%3DY.%26aulast%3DArakawa%26aufirst%3DC.%26aulast%3DYokoyama%26aufirst%3DT.%26aulast%3DShigenobu%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DS.%26atitle%3DThe%2520antihypertensive%2520property%2520of%2520NIP-121%252C%2520a%2520novel%2520potassium%2520channel%2520opener%2520in%2520rats%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D1991%26volume%3D18%26issue%3D2%26spage%3D190%26epage%3D197%26doi%3D10.1097%2F00005344-199108000-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurtry, I. F.</span></span> <span> </span><span class="NLM_article-title">NIP-121 is more effective than nifedipine in acutely reversing chronic pulmonary hypertension</span>. <i>J. Appl. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1075</span>â <span class="NLM_lpage">1080</span>, <span class="refDoi">Â DOI: 10.1152/jappl.1993.75.3.1075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1152%2Fjappl.1993.75.3.1075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=8226514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK2cXhvValur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1993&pages=1075-1080&issue=3&author=M.+Okaauthor=K.+G.+Morrisauthor=I.+F.+McMurtry&title=NIP-121+is+more+effective+than+nifedipine+in+acutely+reversing+chronic+pulmonary+hypertension&doi=10.1152%2Fjappl.1993.75.3.1075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">NIP-121 is more effective than nifedipine in acutely reversing chronic pulmonary hypertension</span></div><div class="casAuthors">Oka, Masahiko; Morris, Kenneth G.; McMurtry, Ivan F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Physiology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1075-80</span>CODEN:
                <span class="NLM_cas:coden">JAPHEV</span>;
        ISSN:<span class="NLM_cas:issn">8750-7587</span>.
    </div><div class="casAbstract">To det. if NIP-121, a new antihypertensive agent with K+ channel-opening activity, would be an effective vasodilator in pulmonary hypertension, the authors studied its acute hemodynamic effects under normoxic conditions in conscious chronically hypoxic pulmonary hypertensive rats and in control pulmonary normotensive rats.  In contrast to no pulmonary vasodilation by NIP-121 in control rats, the K+ channel activator (10-100 mg/kg i.v.) decreased both mean pulmonary arterial pressure (from 42 Â± 2 to 33 Â± 2 mmHg; P â© 0.05) and total pulmonary resistance (from 278 Â± 30 to 213 Â± 32 mmHg/L/min; Pâ©0.05) in hypertensive rats.  NIP-121 produced similar dose-related decreases in mean systemic arterial pressure and total systemic resistance in both groups of rats.  Both the pulmonary and the systemic vasodilations to NIP-121 were inhibited by pretreatment with the blocker of ATP-sensitive K+ channels, glybenclamide (20 mg/kg), but not with the inhibitor of endothelium-derived relaxing factor synthesis, nitro-L-arginine (10 mg/kg).  The L-type voltage-gated Ca2+ channel blocker, nifedipine (10-1,000 mg/kg i.v.), failed to cause pulmonary vasodilation in normoxic hypertensive rats, although there was dose-related systemic vasodilation.  These results show that in contrast to the Ca2+ channel blocker, nifedipine, the K+ channel activator, NIP-121, is a potent vasodilator of chronic hypoxia-induced pulmonary hypertension in the rat.  The mechanism of its hypotensive action in the hypertensive pulmonary vasculature might be more than simply membrane hyperpolarization and indirect inhibition of the L-type voltage-gated Ca2+ channel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPk-PNN2BGDbVg90H21EOLACvtfcHk0lhXWWDpionY4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhvValur8%253D&md5=a0e1cc239b880476e0befb5ee41f2656</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1152%2Fjappl.1993.75.3.1075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fjappl.1993.75.3.1075%26sid%3Dliteratum%253Aachs%26aulast%3DOka%26aufirst%3DM.%26aulast%3DMorris%26aufirst%3DK.%2BG.%26aulast%3DMcMurtry%26aufirst%3DI.%2BF.%26atitle%3DNIP-121%2520is%2520more%2520effective%2520than%2520nifedipine%2520in%2520acutely%2520reversing%2520chronic%2520pulmonary%2520hypertension%26jtitle%3DJ.%2520Appl.%2520Physiol.%26date%3D1993%26volume%3D75%26issue%3D3%26spage%3D1075%26epage%3D1080%26doi%3D10.1152%2Fjappl.1993.75.3.1075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stavenger, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowdell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franz, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaitanopoulos, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilfiker, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivy, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leber, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, J. P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viet, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolivette, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semus, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dul, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandekar, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behm, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doe, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">2</span>â <span class="NLM_lpage">5</span>, <span class="refDoi">Â DOI: 10.1021/jm060873p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060873p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlansbnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2-5&issue=1&author=R.+A.+Stavengerauthor=H.+Cuiauthor=S.+E.+Dowdellauthor=R.+G.+Franzauthor=D.+E.+Gaitanopoulosauthor=K.+B.+Goodmanauthor=M.+A.+Hilfikerauthor=R.+L.+Ivyauthor=J.+D.+Leberauthor=J.+P.+Marinoauthor=H.-J.+Ohauthor=A.+Q.+Vietauthor=W.+Xuauthor=G.+Yeauthor=D.+Zhangauthor=Y.+Zhaoauthor=L.+J.+Jolivetteauthor=M.+S.+Headauthor=S.+F.+Semusauthor=P.+A.+Elkinsauthor=R.+B.+Kirkpatrickauthor=E.+Dulauthor=S.+S.+Khandekarauthor=T.+Yiauthor=D.+K.+Jungauthor=L.+L.+Wrightauthor=G.+K.+Smithauthor=D.+J.+Behmauthor=C.+P.+Doeauthor=R.+Bentleyauthor=Z.+X.+Chenauthor=E.+Huauthor=D.+Lee&title=Discovery+of+aminofurazan-azabenzimidazoles+as+inhibitors+of+Rho-kinase+with+high+kinase+selectivity+and+antihypertensive+activity&doi=10.1021%2Fjm060873p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Aminofurazan-azabenzimidazoles as Inhibitors of Rho-Kinase with High Kinase Selectivity and Antihypertensive Activity</span></div><div class="casAuthors">Stavenger, Robert A.; Cui, Haifeng; Dowdell, Sarah E.; Franz, Robert G.; Gaitanopoulos, Dimitri E.; Goodman, Krista B.; Hilfiker, Mark A.; Ivy, Robert L.; Leber, Jack D.; Marino, Joseph P., Jr.; Oh, Hye-Ja; Viet, Andrew Q.; Xu, Weiwei; Ye, Guosen; Zhang, Daohua; Zhao, Yongdong; Jolivette, Larry J.; Head, Martha S.; Semus, Simon F.; Elkins, Patricia A.; Kirkpatrick, Robert B.; Dul, Edward; Khandekar, Sanjay S.; Yi, Tracey; Jung, David K.; Wright, Lois L.; Smith, Gary K.; Behm, David J.; Doe, Christopher P.; Bentley, Ross; Chen, Zunxuan X.; Hu, Erding; Lee, Dennis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-5</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery, proposed binding mode, and optimization of a novel class of Rho-kinase inhibitors are presented.  Appropriate substitution on the 6-position of the azabenzimidazole core provided subnanomolar enzyme potency in vitro while dramatically improving selectivity over a panel of other kinases.  Pharmacokinetic data was obtained for the most potent and selective examples and one (6n) has been shown to lower blood pressure in a rat model of hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzfD1mp8bYv7Vg90H21EOLACvtfcHk0lhXWWDpionY4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlansbnE&md5=055d95d44fc906aba4e0bdbf0bc1aac9</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1021%2Fjm060873p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060873p%26sid%3Dliteratum%253Aachs%26aulast%3DStavenger%26aufirst%3DR.%2BA.%26aulast%3DCui%26aufirst%3DH.%26aulast%3DDowdell%26aufirst%3DS.%2BE.%26aulast%3DFranz%26aufirst%3DR.%2BG.%26aulast%3DGaitanopoulos%26aufirst%3DD.%2BE.%26aulast%3DGoodman%26aufirst%3DK.%2BB.%26aulast%3DHilfiker%26aufirst%3DM.%2BA.%26aulast%3DIvy%26aufirst%3DR.%2BL.%26aulast%3DLeber%26aufirst%3DJ.%2BD.%26aulast%3DMarino%26aufirst%3DJ.%2BP.%26aulast%3DOh%26aufirst%3DH.-J.%26aulast%3DViet%26aufirst%3DA.%2BQ.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DYe%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DJolivette%26aufirst%3DL.%2BJ.%26aulast%3DHead%26aufirst%3DM.%2BS.%26aulast%3DSemus%26aufirst%3DS.%2BF.%26aulast%3DElkins%26aufirst%3DP.%2BA.%26aulast%3DKirkpatrick%26aufirst%3DR.%2BB.%26aulast%3DDul%26aufirst%3DE.%26aulast%3DKhandekar%26aufirst%3DS.%2BS.%26aulast%3DYi%26aufirst%3DT.%26aulast%3DJung%26aufirst%3DD.%2BK.%26aulast%3DWright%26aufirst%3DL.%2BL.%26aulast%3DSmith%26aufirst%3DG.%2BK.%26aulast%3DBehm%26aufirst%3DD.%2BJ.%26aulast%3DDoe%26aufirst%3DC.%2BP.%26aulast%3DBentley%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DZ.%2BX.%26aulast%3DHu%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520aminofurazan-azabenzimidazoles%2520as%2520inhibitors%2520of%2520Rho-kinase%2520with%2520high%2520kinase%2520selectivity%2520and%2520antihypertensive%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D1%26spage%3D2%26epage%3D5%26doi%3D10.1021%2Fjm060873p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behm, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafferty, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stavenger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamford, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grygielko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dul, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolivette, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, J. P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willette, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, E.</span></span> <span> </span><span class="NLM_article-title">Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>320</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">89</span>â <span class="NLM_lpage">98</span>, <span class="refDoi">Â DOI: 10.1124/jpet.106.110635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1124%2Fjpet.106.110635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=17018693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsFeqsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2007&pages=89-98&issue=1&author=C.+Doeauthor=R.+Bentleyauthor=D.+J.+Behmauthor=R.+Laffertyauthor=R.+Stavengerauthor=D.+Jungauthor=M.+Bamfordauthor=T.+Panchalauthor=E.+Grygielkoauthor=L.+L.+Wrightauthor=G.+K.+Smithauthor=Z.+Chenauthor=C.+Webbauthor=S.+Khandekarauthor=T.+Yiauthor=R.+Kirkpatrickauthor=E.+Dulauthor=L.+Jolivetteauthor=J.+P.+Marinoauthor=R.+Willetteauthor=D.+Leeauthor=E.+Hu&title=Novel+Rho+kinase+inhibitors+with+anti-inflammatory+and+vasodilatory+activities&doi=10.1124%2Fjpet.106.110635"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities</span></div><div class="casAuthors">Doe, Chris; Bentley, Ross; Behm, David J.; Lafferty, Robert; Stavenger, Robert; Jung, David; Bamford, Mark; Panchal, Terry; Grygielko, Eugene; Wright, Lois L.; Smith, Gary K.; Chen, Zunxuan; Webb, Christine; Khandekar, Sanjay; Yi, Tracey; Kirkpatrick, Robert; Dul, Edward; Jolivette, Larry; Marino, Joseph P., Jr.; Willette, Robert; Lee, Dennis; Hu, Erding</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-98</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Increased Rho kinase (ROCK) activity contributes to smooth muscle contraction and regulates blood pressure homeostasis.  We hypothesized that potent and selective ROCK inhibitors with novel structural motifs would help elucidate the functional role of ROCK and further explore the therapeutic potential of ROCK inhibition for hypertension.  In this article, we characterized two aminofurazan-based inhibitors, GSK269962A [N-(3-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(4-morpholinyl)ethyl]-oxy}benzamide] and SB-7720770-B [4-(7-{[(3S)-3-amino-1-pyrrolidinyl]carbonyl}-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine], as members of a novel class of compds. that potently inhibit ROCK enzymic activity.  GSK269962A and SB-772077-B have IC50 values of 1.6 and 5.6 nM toward recombinant human ROCK1, resp.  GSK269962A also exhibited more than 30-fold selectivity against a panel of serine/threonine kinases.  In lipopolysaccharide-stimulated monocytes, these inhibitors blocked the generation of inflammatory cytokines, such as interleukin-6 and tumor necrosis factor-Î±.  Furthermore, both SB-772077-B and GSK269962A induced vasorelaxation in preconstricted rat aorta with an IC50 of 39 and 35 nM, resp.  Oral administration of either GSK269962A or SB-772077-B produced a profound dose-dependent redn. of systemic blood pressure in spontaneously hypertensive rats.  At doses of 1, 3, and 30 mg/kg, both compds. induced a redn. in blood pressure of approx. 10, 20, and 50 mm Hg.  In addn., administration of SB-772077-B also dramatically lowered blood pressure in DOCA salt-induced hypertensive rats.  SB-772077-B and GSK269962A represent a novel class of ROCK inhibitors that have profound effects in the vasculature and may enable us to further evaluate the potential beneficial effects of ROCK inhibition in animal models of cardiovascular as well as other chronic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOuPjuVLTrwrVg90H21EOLACvtfcHk0lhXWWDpionY4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsFeqsw%253D%253D&md5=ab8ba12bca20241815721e2cc9273774</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.110635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.110635%26sid%3Dliteratum%253Aachs%26aulast%3DDoe%26aufirst%3DC.%26aulast%3DBentley%26aufirst%3DR.%26aulast%3DBehm%26aufirst%3DD.%2BJ.%26aulast%3DLafferty%26aufirst%3DR.%26aulast%3DStavenger%26aufirst%3DR.%26aulast%3DJung%26aufirst%3DD.%26aulast%3DBamford%26aufirst%3DM.%26aulast%3DPanchal%26aufirst%3DT.%26aulast%3DGrygielko%26aufirst%3DE.%26aulast%3DWright%26aufirst%3DL.%2BL.%26aulast%3DSmith%26aufirst%3DG.%2BK.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DWebb%26aufirst%3DC.%26aulast%3DKhandekar%26aufirst%3DS.%26aulast%3DYi%26aufirst%3DT.%26aulast%3DKirkpatrick%26aufirst%3DR.%26aulast%3DDul%26aufirst%3DE.%26aulast%3DJolivette%26aufirst%3DL.%26aulast%3DMarino%26aufirst%3DJ.%2BP.%26aulast%3DWillette%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DE.%26atitle%3DNovel%2520Rho%2520kinase%2520inhibitors%2520with%2520anti-inflammatory%2520and%2520vasodilatory%2520activities%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D320%26issue%3D1%26spage%3D89%26epage%3D98%26doi%3D10.1124%2Fjpet.106.110635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhaliwal, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badejo, A. M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murthy, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadowitz, P. J.</span></span> <span> </span><span class="NLM_article-title">Analysis of pulmonary vasodilator responses to SB-772077-B [4-(7-((3-amino-1-pyrrolidinyl)carbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin-2-yl)-1, 2,5-oxadiazol-3-amine], a novel aminofurazan-based Rho kinase inhibitor</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>330</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">334</span>â <span class="NLM_lpage">341</span>, <span class="refDoi">Â DOI: 10.1124/jpet.109.151449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1124%2Fjpet.109.151449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=19369577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFelurY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2009&pages=334-341&issue=1&author=J.+S.+Dhaliwalauthor=A.+M.+Badejoauthor=D.+B.+Caseyauthor=S.+N.+Murthyauthor=P.+J.+Kadowitz&title=Analysis+of+pulmonary+vasodilator+responses+to+SB-772077-B+%5B4-%287-%28%283-amino-1-pyrrolidinyl%29carbonyl%29-1-ethyl-1H-imidazo%284%2C5-c%29pyridin-2-yl%29-1%2C+2%2C5-oxadiazol-3-amine%5D%2C+a+novel+aminofurazan-based+Rho+kinase+inhibitor&doi=10.1124%2Fjpet.109.151449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of pulmonary vasodilator responses to SB-772077-B [4-(7-((3-amino-1-pyrrolidinyl)carbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin-2-yl)-1,2,5-oxadiazol-3-amine], a novel aminofurazan-based Rho kinase inhibitor</span></div><div class="casAuthors">Dhaliwal, Jasdeep S.; Badejo, Adeleke M., Jr.; Casey, David B.; Murthy, Subramanyam N.; Kadowitz, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">334-341</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The effects of SB-772077-B [4-(7-((3-amino-1-pyrrolidinyl)carbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin-2-yl)-1,2,5-oxadiazol-3-amine], an aminofurazan-based Rho kinase inhibitor, on the pulmonary vascular bed and on monocrotaline-induced pulmonary hypertension were investigated in the rat.  The i.v. injections of SB-772077-B decreased pulmonary and systemic arterial pressures and increased cardiac output.  The decreases in pulmonary arterial pressure were enhanced when pulmonary vascular resistance was increased by U46619 [9,11-dideoxy-11Î±,9Î±-epoxymethanoprostaglandin F2Î±], hypoxia, or NÏ-nitro-L-arginine Me ester.  SB-772077-B was more potent than Y-27632 [trans-4-[(1R)-1-aminoethyl]-N-4-pyridinyl-cyclohexanecarboxamide dihydrochloride] or fasudil [5-(1,4-diazepane-1-sulfonyl)isoquinoline] in decreasing pulmonary and systemic arterial pressures.  The results with SB-772077-B, fasudil, and Y-27632 suggest that Rho kinase is constitutively active and is involved in the regulation of baseline tone and vasoconstrictor responses.  Chronic treatment with SB-772077-B attenuated the increase in pulmonary arterial pressure induced by monocrotaline.  The i.v. injection of SB-772077-B decreased pulmonary and systemic arterial pressures in rats with monocrotaline-induced pulmonary hypertension.  The decreases in pulmonary arterial pressure in response to SB-772077-B in monocrotaline-treated rats were smaller than responses in U46619-infused animals, and the anal. of responses suggests that approx. 60% of the pulmonary hypertensive response is mediated by a Rho kinase-sensitive mechanism.  The observation that Rho kinase inhibitors decrease pulmonary arterial pressure when pulmonary vascular resistance is increased by interventions such as hypoxia, U46619, angiotensin II, nitric-oxide synthase inhibition, and Bay K 8644 [S-(-)-1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-[trifluoromethyl]phenyl) -3-pyridine carboxylic acid Me ester] suggest that the vasodilatation is independent of the mechanisms used to increase intracellular calcium and promote vasoconstriction.  The present results suggest that SB-772077-B would be beneficial in the treatment of pulmonary hypertensive disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3sKZGsLduDLVg90H21EOLACvtfcHk0liwYDc8X0OEMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFelurY%253D&md5=a66fd5a7b6e1469790f2122daed760b7</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.151449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.151449%26sid%3Dliteratum%253Aachs%26aulast%3DDhaliwal%26aufirst%3DJ.%2BS.%26aulast%3DBadejo%26aufirst%3DA.%2BM.%26aulast%3DCasey%26aufirst%3DD.%2BB.%26aulast%3DMurthy%26aufirst%3DS.%2BN.%26aulast%3DKadowitz%26aufirst%3DP.%2BJ.%26atitle%3DAnalysis%2520of%2520pulmonary%2520vasodilator%2520responses%2520to%2520SB-772077-B%2520%255B4-%25287-%2528%25283-amino-1-pyrrolidinyl%2529carbonyl%2529-1-ethyl-1H-imidazo%25284%252C5-c%2529pyridin-2-yl%2529-1%252C%25202%252C5-oxadiazol-3-amine%255D%252C%2520a%2520novel%2520aminofurazan-based%2520Rho%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D330%26issue%3D1%26spage%3D334%26epage%3D341%26doi%3D10.1124%2Fjpet.109.151449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span> <span> </span><span class="NLM_article-title">Effects of fasudil on pulmonary hypertension in clinical practice</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">54</span>â <span class="NLM_lpage">63</span>, <span class="refDoi">Â DOI: 10.1016/j.pupt.2017.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.pupt.2017.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28782712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtl2rur3F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2017&pages=54-63&author=Y.+Zhangauthor=S.+Wu&title=Effects+of+fasudil+on+pulmonary+hypertension+in+clinical+practice&doi=10.1016%2Fj.pupt.2017.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of fasudil on pulmonary hypertension in clinical practice</span></div><div class="casAuthors">Zhang, Yiqing; Wu, Shangjie</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">54-63</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Pulmonary hypertension (PH) is a pathophysiol. disorder that may involve multiple clin. conditions and can complicate the majority of cardiovascular and respiratory diseases.  The presence of PH is assocd. with worse outcomes, but the efficacy of current therapy is still unsatisfactory.  Because Rho-kinase (ROCK) plays an important role in the pathogenesis of PH, the ROCK inhibitor fasudil is expected to contribute to PH treatment.  In animal models of PH, fasudil reduced pulmonary artery pressure (PAP) and improved survival.  Furthermore, the short-term efficacy and safety of fasudil in the treatment of PH are demonstrated in clin. trials.  Both PAP and pulmonary vascular resistance in patients with PH are significantly decreased by i.v. or inhaled fasudil without apparent side effect.  However, no clin. trial has assessed the long-term efficacy of fasudil in the treatment of PH.  Limited data suggest that the mid-term use of fasudil could improve exercise capacity and reduce in-hospital mortality.  We also discuss the combined use of fasudil and other drugs for PH treatment.  However, these combinations have not yet been evaluated in a clin. trial.  According to animal studies, the combination of fasudil with beraprost or sildenafil shows synergistic effects, whereas the combination of fasudil with bosentan has no addnl. ameliorating effects on PH development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBw2u2T8Y2lrVg90H21EOLACvtfcHk0liwYDc8X0OEMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtl2rur3F&md5=8e5174dd5b4649d7f086c41718968aa2</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2017.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2017.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DS.%26atitle%3DEffects%2520of%2520fasudil%2520on%2520pulmonary%2520hypertension%2520in%2520clinical%2520practice%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2017%26volume%3D46%26spage%3D54%26epage%3D63%26doi%3D10.1016%2Fj.pupt.2017.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsubara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizoguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osanai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanabe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimokawa, H.</span></span> <span> </span><span class="NLM_article-title">Double-blind, placebo-controlled clinical trial with a Rho-kinase inhibitor in pulmonary arterial hypertensionâa pilot efficacy trial</span>. <i>Circ. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2619</span>â <span class="NLM_lpage">2625</span>, <span class="refDoi">Â DOI: 10.1253/circj.CJ-13-0443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1253%2Fcircj.CJ-13-0443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=23912836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslSns77I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2013&pages=2619-2625&issue=10&author=Y.+Fukumotoauthor=N.+Yamadaauthor=H.+Matsubaraauthor=M.+Mizoguchiauthor=K.+Uchinoauthor=A.+Yaoauthor=Y.+Kiharaauthor=M.+Kawanoauthor=H.+Watanabeauthor=Y.+Takedaauthor=T.+Adachiauthor=S.+Osanaiauthor=N.+Tanabeauthor=T.+Inoueauthor=A.+Kuboauthor=Y.+Otaauthor=K.+Fukudaauthor=T.+Nakanoauthor=H.+Shimokawa&title=Double-blind%2C+placebo-controlled+clinical+trial+with+a+Rho-kinase+inhibitor+in+pulmonary+arterial+hypertension%E2%80%94a+pilot+efficacy+trial&doi=10.1253%2Fcircj.CJ-13-0443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Double-blind, placebo-controlled clinical trial with a Rho-kinase inhibitor in pulmonary arterial hypertension - a pilot efficacy trial -</span></div><div class="casAuthors">Fukumoto, Yoshihiro; Yamada, Norikazu; Matsubara, Hiromi; Mizoguchi, Minori; Uchino, Kazuaki; Yao, Atsushi; Kihara, Yasuki; Kawano, Mitsuhiro; Watanabe, Hiroshi; Takeda, Yutaka; Adachi, Takeshi; Osanai, Shinobu; Tanabe, Nobuhiro; Inoue, Teruo; Kubo, Akihiro; Ota, Yuri; Fukuda, Koichiro; Nakano, Takeshi; Shimokawa, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2619-2625</span>CODEN:
                <span class="NLM_cas:coden">CJIOBY</span>;
        ISSN:<span class="NLM_cas:issn">1346-9843</span>.
    
            (<span class="NLM_cas:orgname">Japanese Circulation Society</span>)
        </div><div class="casAbstract">Background: We have previously demonstrated that long-term inhibition of Rho-kinase ameliorates pulmonary arterial hypertension (PAH) in animal models.  In the present study, we examd. the clin. effects of mid-term oral treatment with an extended release formulation of AT-877 (fasudil hydrochloride), a specific Rho-kinase inhibitor (AT-877ER) on PAH.  Methods and Results: 23 PAH patients were treated with either placebo (10/2 females/males, 51Â±16 years, idiopathic PAH (IPAH) in 6, PAH assocd. with connective tissue disease (CTD-PAH) in 3, PAH with congenital heart disease (CHD-PAH) in 2, and portal PAH in 1) or AT-877ER (6/5 females/males, 47Â±14 years, IPAH in 2, CTD-PAH in 5, and CHD-PAH in 4); 3 patients were excluded.  We performed a 6-min walk test and right heart catheterization in the remaining 20 patients, before and 3 mo after the treatment (placebo n=11, AT-877ER n=9).  Although there were no significant differences between the 2 groups for the 6-min walk distance, pulmonary hemodynamics tended to be improved in the AT-877ER group, esp. the prevalence of improved cardiac index from baseline, which was significantly higher in the AT-877ER than in the placebo group.  In the AT-877ER group, serum levels of hydroxyfasudil, an active metabolite of AT-877ER tended to correlate with improvements in the cardiac index and mean pulmonary artery pressure.  Conclusions: Mid-term treatment with oral AT-877ER showed addnl. improvement in pulmonary hemodynamics in patients with PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof001r8Pp19rVg90H21EOLACvtfcHk0liwYDc8X0OEMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslSns77I&md5=1f9a29ee6f6b0a9d40c80c883811f109</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1253%2Fcircj.CJ-13-0443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1253%252Fcircj.CJ-13-0443%26sid%3Dliteratum%253Aachs%26aulast%3DFukumoto%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DN.%26aulast%3DMatsubara%26aufirst%3DH.%26aulast%3DMizoguchi%26aufirst%3DM.%26aulast%3DUchino%26aufirst%3DK.%26aulast%3DYao%26aufirst%3DA.%26aulast%3DKihara%26aufirst%3DY.%26aulast%3DKawano%26aufirst%3DM.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DTakeda%26aufirst%3DY.%26aulast%3DAdachi%26aufirst%3DT.%26aulast%3DOsanai%26aufirst%3DS.%26aulast%3DTanabe%26aufirst%3DN.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DA.%26aulast%3DOta%26aufirst%3DY.%26aulast%3DFukuda%26aufirst%3DK.%26aulast%3DNakano%26aufirst%3DT.%26aulast%3DShimokawa%26aufirst%3DH.%26atitle%3DDouble-blind%252C%2520placebo-controlled%2520clinical%2520trial%2520with%2520a%2520Rho-kinase%2520inhibitor%2520in%2520pulmonary%2520arterial%2520hypertension%25E2%2580%2594a%2520pilot%2520efficacy%2520trial%26jtitle%3DCirc.%2520J.%26date%3D2013%26volume%3D77%26issue%3D10%26spage%3D2619%26epage%3D2625%26doi%3D10.1253%2Fcircj.CJ-13-0443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, L.</span></span> <span> </span><span class="NLM_article-title">Microtubules as a target for anticancer drugs</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">253</span>â <span class="NLM_lpage">265</span>, <span class="refDoi">Â DOI: 10.1038/nrc1317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2Fnrc1317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=15057285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=253-265&issue=4&author=M.+A.+Jordanauthor=L.+Wilson&title=Microtubules+as+a+target+for+anticancer+drugs&doi=10.1038%2Fnrc1317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules as a target for anticancer drugs</span></div><div class="casAuthors">Jordan, Mary Ann; Wilson, Leslie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-265</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Highly dynamic mitotic-spindle microtubules are among the most successful targets for anticancer therapy.  Microtubule-targeted drugs, including paclitaxel and Vinca alkaloids, were previously considered to work primarily by increasing or decreasing the cellular microtubule mass.  Although these effects might have a role in their chemotherapeutic actions, we now know that at lower concns., microtubule-targeted drugs can suppress microtubule dynamics without changing microtubule mass; this action leads to mitotic block and apoptosis.  In addn. to the expanding array of chem. diverse antimitotic agents, some microtubule-targeted drugs can act as vascular-targeting agents, rapidly depolymg. microtubules of newly formed vasculature to shut down the blood supply to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRJbrFnzwqjbVg90H21EOLACvtfcHk0ljmda_eh9N15A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D&md5=bbbf212e03ffe6763098fc41f21a8158</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1038%2Fnrc1317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1317%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMicrotubules%2520as%2520a%2520target%2520for%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26issue%3D4%26spage%3D253%26epage%3D265%26doi%3D10.1038%2Fnrc1317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eberle, M.</span>; <span class="NLM_string-name">Bachmann, M.</span>; <span class="NLM_string-name">Strebel, A.</span>; <span class="NLM_string-name">Roy, S.</span>; <span class="NLM_string-name">Srivastava, S.</span>; <span class="NLM_string-name">Saha, G.</span></span> <span> </span><span class="NLM_article-title">Preparation of Furazanobenzimidazoles as Apoptosis Inducers for the Treatment of Neoplastic and Autoimmune Diseases</span>. <span class="NLM_patent">WO2004103994A1</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=M.+Eberle&author=M.+Bachmann&author=A.+Strebel&author=S.+Roy&author=S.+Srivastava&author=G.+Saha&title=Preparation+of+Furazanobenzimidazoles+as+Apoptosis+Inducers+for+the+Treatment+of+Neoplastic+and+Autoimmune+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEberle%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520Furazanobenzimidazoles%2520as%2520Apoptosis%2520Inducers%2520for%2520the%2520Treatment%2520of%2520Neoplastic%2520and%2520Autoimmune%2520Diseases%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eberle, M.</span>; <span class="NLM_string-name">Bachmann, F.</span>; <span class="NLM_string-name">Strebel, A.</span>; <span class="NLM_string-name">Roy, S.</span>; <span class="NLM_string-name">Srivastava, S.</span>; <span class="NLM_string-name">Saha, G.</span></span> <span> </span><span class="NLM_article-title">Preparation of Substituted Benzimidazoles for Inducing Apoptosis</span>. <span class="NLM_patent">US20070066670A1</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=M.+Eberle&author=F.+Bachmann&author=A.+Strebel&author=S.+Roy&author=S.+Srivastava&author=G.+Saha&title=Preparation+of+Substituted+Benzimidazoles+for+Inducing+Apoptosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEberle%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520Substituted%2520Benzimidazoles%2520for%2520Inducing%2520Apoptosis%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eberle, M.</span>; <span class="NLM_string-name">Bachmann, F.</span>; <span class="NLM_string-name">Strebel, A.</span>; <span class="NLM_string-name">Roy, S.</span>; <span class="NLM_string-name">Srivastava, S.</span>; <span class="NLM_string-name">Saha, G.</span></span> <span> </span><span class="NLM_article-title">Preparation of Substituted Benzimidazoles for Inducing Apoptosis</span>. <span class="NLM_patent">WO2005077939A1</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+Eberle&author=F.+Bachmann&author=A.+Strebel&author=S.+Roy&author=S.+Srivastava&author=G.+Saha&title=Preparation+of+Substituted+Benzimidazoles+for+Inducing+Apoptosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEberle%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520Substituted%2520Benzimidazoles%2520for%2520Inducing%2520Apoptosis%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buey, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohlmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinelt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span> <span> </span><span class="NLM_article-title">The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>426</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1848</span>â <span class="NLM_lpage">1860</span>, <span class="refDoi">Â DOI: 10.1016/j.jmb.2014.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.jmb.2014.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=24530796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlSrtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2014&pages=1848-1860&issue=8&author=A.+E.+Protaauthor=F.+Danelauthor=F.+Bachmannauthor=K.+Bargstenauthor=R.+M.+Bueyauthor=J.+Pohlmannauthor=S.+Reineltauthor=H.+Laneauthor=M.+O.+Steinmetz&title=The+novel+microtubule-destabilizing+drug+BAL27862+binds+to+the+colchicine+site+of+tubulin+with+distinct+effects+on+microtubule+organization&doi=10.1016%2Fj.jmb.2014.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">The Novel Microtubule-Destabilizing Drug BAL27862 Binds to the Colchicine Site of Tubulin with Distinct Effects on Microtubule Organization</span></div><div class="casAuthors">Prota, Andrea E.; Danel, Franck; Bachmann, Felix; Bargsten, Katja; Buey, Ruben M.; Pohlmann, Jens; Reinelt, Stefan; Lane, Heidi; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1848-1860</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Microtubule-targeting agents are widely used for the treatment of cancer and as tool compds. to study the microtubule cytoskeleton.  BAL27862 is a novel microtubule-destabilizing drug that is currently undergoing phase I clin. evaluation as the prodrug BAL101553.  The drug is a potent inhibitor of tumor cell growth and shows a promising activity profile in a panel of human cancer models resistant to clin. relevant microtubule-targeting agents.  Here, we evaluated the mol. mechanism of the tubulin-BAL27862 interaction using a combination of cell biol., biochem. and structural biol. methods.  Tubulin-binding assays revealed that BAL27862 potently inhibited tubulin assembly at 37 Â°C with an IC50 of 1.4 Î¼M and bound to unassembled tubulin with a stoichiometry of 1 mol/mol tubulin and a dissocn. const. of 244 Â± 30 nM.  BAL27862 bound to tubulin independently of vinblastine, without the formation of tubulin oligomers.  The kinetics of BAL27862 binding to tubulin were distinct from those of colchicine, with evidence of competition between BAL27862 and colchicine for binding.  Detn. of the tubulin-BAL27862 structure by X-ray crystallog. demonstrated that BAL27862 binds to the same site as colchicine at the intradimer interface.  Comparison of crystal structures of tubulin-BAL27862 and tubulin-colchicine complexes shows that the binding mode of BAL27862 to tubulin is similar to that of colchicine.  However, comparative analyses of the effects of BAL27862 and colchicine on the microtubule mitotic spindle and in tubulin protease-protection expts. suggest different outcomes of tubulin binding.  Taken together, our data define BAL27862 as a potent, colchicine site-binding, microtubule-destabilizing agent with distinct effects on microtubule organization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIsVCA_6rcHLVg90H21EOLACvtfcHk0ljmda_eh9N15A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlSrtrs%253D&md5=147ddbbfe5b90157cb8b2e04e1791668</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2014.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2014.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DDanel%26aufirst%3DF.%26aulast%3DBachmann%26aufirst%3DF.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DBuey%26aufirst%3DR.%2BM.%26aulast%3DPohlmann%26aufirst%3DJ.%26aulast%3DReinelt%26aufirst%3DS.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DThe%2520novel%2520microtubule-destabilizing%2520drug%2520BAL27862%2520binds%2520to%2520the%2520colchicine%2520site%2520of%2520tubulin%2520with%2520distinct%2520effects%2520on%2520microtubule%2520organization%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D426%26issue%3D8%26spage%3D1848%26epage%3D1860%26doi%3D10.1016%2Fj.jmb.2014.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broggini-Tenzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messikommer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nytko, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guckenberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruschy, M.</span></span> <span> </span><span class="NLM_article-title">The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models</span>. <i>Radiother. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>124</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">433</span>â <span class="NLM_lpage">438</span>, <span class="refDoi">Â DOI: 10.1016/j.radonc.2017.07.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.radonc.2017.07.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28797699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1ynsr%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2017&pages=433-438&issue=3&author=A.+Sharmaauthor=A.+Broggini-Tenzerauthor=V.+Vuongauthor=A.+Messikommerauthor=K.+J.+Nytkoauthor=M.+Guckenbergerauthor=F.+Bachmannauthor=H.+A.+Laneauthor=M.+Pruschy&title=The+novel+microtubule+targeting+agent+BAL101553+in+combination+with+radiotherapy+in+treatment-refractory+tumor+models&doi=10.1016%2Fj.radonc.2017.07.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models</span></div><div class="casAuthors">Sharma, Ashish; Broggini-Tenzer, Angela; Vuong, Van; Messikommer, Alessandra; Nytko, Katarzyna J.; Guckenberger, Matthias; Bachmann, Felix; Lane, Heidi A.; Pruschy, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Radiotherapy and Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">433-438</span>CODEN:
                <span class="NLM_cas:coden">RAONDT</span>;
        ISSN:<span class="NLM_cas:issn">0167-8140</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Resistance to microtubule targeting agents (MTA) represents a major drawback in successful cancer therapy with MTAs.  Here we investigated the combined treatment modality of the novel MTA BAL101553 in combination with radiotherapy in paclitaxel and epothilone-resistant tumor models.  Multiple regimens of BAL101553, or its active moiety BAL27862 for in vitro expts., were probed in combination with radiotherapy in P-glycoprotein-overexpressing, human colon adenocarcinoma cells (SW480) and in tubulin-mutated human NSCLC cells (A549EpoB40) and tumors thereof.  BAL27862 reduced the proliferative activity of SW480 and A549EpoB40 tumor cells with similar potency as in A549 wildtype cells.  Combined treatment of BAL27862 with ionizing radiation in vitro resulted in an additive redn. of clonogenicity.  Moreover, treatment of paclitaxel- and epothilone-resistant tumors with fractionated irradn. and different regimens of BAL101553 (a single i.v. bolus vs. oral daily) suppressed tumor growth and resulted in an extended additive tumor growth delay with strong redn. of tumor proliferation and mean tumor vessel d.  BAL101553 is a promising alternative in taxane- and epothilone-refractory tumors as part of a combined treatment modality with ionizing radiation.  Its potent antitumor effect is not only tumor cell-directed but also targets the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok4R4m3sJuT7Vg90H21EOLACvtfcHk0lisNmges34k5w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1ynsr%252FJ&md5=77c6288feb6fb73e419c1905e82c102d</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.radonc.2017.07.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.radonc.2017.07.024%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DBroggini-Tenzer%26aufirst%3DA.%26aulast%3DVuong%26aufirst%3DV.%26aulast%3DMessikommer%26aufirst%3DA.%26aulast%3DNytko%26aufirst%3DK.%2BJ.%26aulast%3DGuckenberger%26aufirst%3DM.%26aulast%3DBachmann%26aufirst%3DF.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DPruschy%26aufirst%3DM.%26atitle%3DThe%2520novel%2520microtubule%2520targeting%2520agent%2520BAL101553%2520in%2520combination%2520with%2520radiotherapy%2520in%2520treatment-refractory%2520tumor%2520models%26jtitle%3DRadiother.%2520Oncol.%26date%3D2017%26volume%3D124%26issue%3D3%26spage%3D433%26epage%3D438%26doi%3D10.1016%2Fj.radonc.2017.07.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duran, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikic, B. I.</span></span> <span> </span><span class="NLM_article-title">Abstract 4412: In vitro activity of the novel tubulin active agent BAL27862 in MDR1(+) and MDR1(â) human breast and ovarian cancer variants selected for resistance to taxanes</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">4412</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM10-4412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1158%2F1538-7445.AM10-4412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=20460507" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=4412&author=G.+E.+Duranauthor=H.+Laneauthor=F.+Bachmannauthor=B.+I.+Sikic&title=Abstract+4412%3A+In+vitro+activity+of+the+novel+tubulin+active+agent+BAL27862+in+MDR1%28%2B%29+and+MDR1%28%E2%88%92%29+human+breast+and+ovarian+cancer+variants+selected+for+resistance+to+taxanes&doi=10.1158%2F1538-7445.AM10-4412"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM10-4412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM10-4412%26sid%3Dliteratum%253Aachs%26aulast%3DDuran%26aufirst%3DG.%2BE.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DBachmann%26aufirst%3DF.%26aulast%3DSikic%26aufirst%3DB.%2BI.%26atitle%3DAbstract%25204412%253A%2520In%2520vitro%2520activity%2520of%2520the%2520novel%2520tubulin%2520active%2520agent%2520BAL27862%2520in%2520MDR1%2528%252B%2529%2520and%2520MDR1%2528%25E2%2588%2592%2529%2520human%2520breast%2520and%2520ovarian%2520cancer%2520variants%2520selected%2520for%2520resistance%2520to%2520taxanes%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D4412%26doi%3D10.1158%2F1538-7445.AM10-4412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esteve, M.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honore, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braguer, D.</span></span> <span> </span><span class="NLM_article-title">Abstract 1977: BAL27862: A unique microtubule-targeted drug that suppresses microtubule dynamics, severs microtubules, and overcomes Bcl-2- and tubulin subtype-related drug resistance</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1977</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM10-1977</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1158%2F1538-7445.AM10-1977" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1977&author=M.-A.+Esteveauthor=S.+Honoreauthor=N.+McKayauthor=F.+Bachmannauthor=H.+Laneauthor=D.+Braguer&title=Abstract+1977%3A+BAL27862%3A+A+unique+microtubule-targeted+drug+that+suppresses+microtubule+dynamics%2C+severs+microtubules%2C+and+overcomes+Bcl-2-+and+tubulin+subtype-related+drug+resistance&doi=10.1158%2F1538-7445.AM10-1977"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM10-1977&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM10-1977%26sid%3Dliteratum%253Aachs%26aulast%3DEsteve%26aufirst%3DM.-A.%26aulast%3DHonore%26aufirst%3DS.%26aulast%3DMcKay%26aufirst%3DN.%26aulast%3DBachmann%26aufirst%3DF.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DBraguer%26aufirst%3DD.%26atitle%3DAbstract%25201977%253A%2520BAL27862%253A%2520A%2520unique%2520microtubule-targeted%2520drug%2520that%2520suppresses%2520microtubule%2520dynamics%252C%2520severs%2520microtubules%252C%2520and%2520overcomes%2520Bcl-2-%2520and%2520tubulin%2520subtype-related%2520drug%2520resistance%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1977%26doi%3D10.1158%2F1538-7445.AM10-1977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duran, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikic, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. A.</span></span> <span> </span><span class="NLM_article-title">Abstract 831: BAL101553 (prodrug of BAL27862): A unique microtubule destabilizer active against drug refractory breast cancers alone and in combination with trastuzumab</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">831</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM2014-831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1158%2F1538-7445.AM2014-831" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=831&author=F.+Bachmannauthor=K.+Burgerauthor=G.+E.+Duranauthor=B.+I.+Sikicauthor=H.+A.+Lane&title=Abstract+831%3A+BAL101553+%28prodrug+of+BAL27862%29%3A+A+unique+microtubule+destabilizer+active+against+drug+refractory+breast+cancers+alone+and+in+combination+with+trastuzumab&doi=10.1158%2F1538-7445.AM2014-831"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2014-831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2014-831%26sid%3Dliteratum%253Aachs%26aulast%3DBachmann%26aufirst%3DF.%26aulast%3DBurger%26aufirst%3DK.%26aulast%3DDuran%26aufirst%3DG.%2BE.%26aulast%3DSikic%26aufirst%3DB.%2BI.%26aulast%3DLane%26aufirst%3DH.%2BA.%26atitle%3DAbstract%2520831%253A%2520BAL101553%2520%2528prodrug%2520of%2520BAL27862%2529%253A%2520A%2520unique%2520microtubule%2520destabilizer%2520active%2520against%2520drug%2520refractory%2520breast%2520cancers%2520alone%2520and%2520in%2520combination%2520with%2520trastuzumab%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D831%26doi%3D10.1158%2F1538-7445.AM2014-831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pohlmann, J.</span>; <span class="NLM_string-name">Bachmann, F.</span></span> <span> </span><span class="NLM_article-title">Furazanylbenzimidazoles as Prodrugs to Treat Neoplastic or Autoimmune Diseases</span>. <span class="NLM_patent">WO2011012577A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+Pohlmann&author=F.+Bachmann&title=Furazanylbenzimidazoles+as+Prodrugs+to+Treat+Neoplastic+or+Autoimmune+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPohlmann%26aufirst%3DJ.%26atitle%3DFurazanylbenzimidazoles%2520as%2520Prodrugs%2520to%2520Treat%2520Neoplastic%2520or%2520Autoimmune%2520Diseases%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorlick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keir, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lock, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carol, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurmasheva, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghton, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. A.</span></span> <span> </span><span class="NLM_article-title">Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program</span>. <i>Pediatr. Blood Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1106</span>â <span class="NLM_lpage">1109</span>, <span class="refDoi">Â DOI: 10.1002/pbc.25329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fpbc.25329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=25407467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXms1Ghs7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=1106-1109&issue=6&author=E.+A.+Kolbauthor=R.+Gorlickauthor=S.+T.+Keirauthor=J.+M.+Marisauthor=M.+H.+Kangauthor=C.+P.+Reynoldsauthor=R.+B.+Lockauthor=H.+Carolauthor=J.+Wuauthor=R.+T.+Kurmashevaauthor=P.+J.+Houghtonauthor=M.+A.+Smith&title=Initial+testing+%28stage+1%29+of+BAL101553%2C+a+novel+tubulin+binding+agent%2C+by+the+pediatric+preclinical+testing+program&doi=10.1002%2Fpbc.25329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program</span></div><div class="casAuthors">Kolb, E. Anders; Gorlick, Richard; Keir, Stephen T.; Maris, John M.; Kang, Min H.; Reynolds, C. Patrick; Lock, Richard B.; Carol, Hernan; Wu, Jianrong; Kurmasheva, Raushan T.; Houghton, Peter J.; Smith, Malcolm A.</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric Blood & Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1106-1109</span>CODEN:
                <span class="NLM_cas:coden">PBCEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1545-5017</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">BAL101553 is a highly water sol. prodrug of BAL27862 that arrests tumor cell proliferation and induces cell death in cancer cells through disruption of the microtubule network.  In vitro BAL27862 demonstrated potent activity, with the median relative IC50 (rIC50) of 13.8 nM (range 5.4-25.2 nM).  The in vitro activity of BAL27862 against the PPTP cell lines is distinctive from that previously described for vincristine.  BAL101553 induced significant differences in EFS distribution compared to control in 16 of 30 (53%) solid tumor xenografts and in two of four (67%) of the evaluable ALL xenografts.  No objective responses were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokrIdslHwMhrVg90H21EOLACvtfcHk0lgnay3S-XHMIw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXms1Ghs7s%253D&md5=a2dece66bed1d4e13650c26608a7a777</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1002%2Fpbc.25329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpbc.25329%26sid%3Dliteratum%253Aachs%26aulast%3DKolb%26aufirst%3DE.%2BA.%26aulast%3DGorlick%26aufirst%3DR.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26aulast%3DKang%26aufirst%3DM.%2BH.%26aulast%3DReynolds%26aufirst%3DC.%2BP.%26aulast%3DLock%26aufirst%3DR.%2BB.%26aulast%3DCarol%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DKurmasheva%26aufirst%3DR.%2BT.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26atitle%3DInitial%2520testing%2520%2528stage%25201%2529%2520of%2520BAL101553%252C%2520a%2520novel%2520tubulin%2520binding%2520agent%252C%2520by%2520the%2520pediatric%2520preclinical%2520testing%2520program%26jtitle%3DPediatr.%2520Blood%2520Cancer%26date%3D2015%26volume%3D62%26issue%3D6%26spage%3D1106%26epage%3D1109%26doi%3D10.1002%2Fpbc.25329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berges, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchoghandjian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serge, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honore, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figarella-Branger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braguer, D.</span></span> <span> </span><span class="NLM_article-title">EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">759</span>â <span class="NLM_lpage">774</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.27374</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.18632%2Foncotarget.27374" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=32165998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BB383ivVehtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=759-774&issue=8&author=R.+Bergesauthor=A.+Tchoghandjianauthor=A.+Sergeauthor=S.+Honoreauthor=D.+Figarella-Brangerauthor=F.+Bachmannauthor=H.+A.+Laneauthor=D.+Braguer&title=EB1-dependent+long+survival+of+glioblastoma-grafted+mice+with+the+oral+tubulin-binder+BAL101553+is+associated+with+inhibition+of+tumor+angiogenesis&doi=10.18632%2Foncotarget.27374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis</span></div><div class="casAuthors">Berges Raphael; Tchoghandjian Aurelie; Honore Stephane; Figarella-Branger Dominique; Braguer Diane; Serge Arnauld; Figarella-Branger Dominique; Braguer Diane; Bachmann Felix; Lane Heidi A</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">759-774</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Glioblastoma (GBM) are aggressive brain tumors with limited treatment options.  Cancer stem-like cells (CSLCs) contribute to GBM invasiveness, representing promising targets.  BAL101553, a prodrug of BAL27862, is a novel small molecule tubulin-binding agent, promoting tumor cell death through spindle assembly checkpoint activation, which is currently in Phase 1/2a in advanced solid tumor patients including GBM.  This study aimed to evaluate long-term daily oral BAL101553 treatment of mice orthotopically grafted with GBM CSLCs (GBM6) according to EB1 expression-level, and to decipher its mechanism of action on GBM stem cells.  Oral treatment with BAL101553 for 100 days provoked a large EB1 expression level-dependent survival benefit, together with a decrease in tumor growth and brain invasion.  Formation of vascular structures by the fluorescent GBM6-GFP-sh0 cells, mimicking endothelial vascular networks, was observed in the brains of control grafted mice.  Following BAL101553 treatment, vessels were no longer detectable, suggesting inhibition of the endothelial trans-differentiation of GBM stem cells.  In vitro, BAL27862 treatment resulted in a switch to the endothelial-like phenotype of GBM6 towards an astrocytic phenotype.  Moreover, the drug inhibited secretion of VEGF, thus preventing normal endothelial cell migration activated by CSLCs.  The decrease in VEGF secretion was confirmed in a human GBM explant following drug treatment.  Altogether, our data first confirm the potential of EB1 expression as a response-predictive biomarker of BAL101553 in GBM we previously published and add new insights in BAL101553 long-term action by counteracting CSLCs mediated tumor angiogenesis.  Our results strongly support BAL101553 clinical studies in GBM patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRiCnNJOXm0MTslzEEsg76ufW6udTcc2eajVzlPHAO5crntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383ivVehtg%253D%253D&md5=6ac3f234687c047e70eaf5a6964a2b5f</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.27374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.27374%26sid%3Dliteratum%253Aachs%26aulast%3DBerges%26aufirst%3DR.%26aulast%3DTchoghandjian%26aufirst%3DA.%26aulast%3DSerge%26aufirst%3DA.%26aulast%3DHonore%26aufirst%3DS.%26aulast%3DFigarella-Branger%26aufirst%3DD.%26aulast%3DBachmann%26aufirst%3DF.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DBraguer%26aufirst%3DD.%26atitle%3DEB1-dependent%2520long%2520survival%2520of%2520glioblastoma-grafted%2520mice%2520with%2520the%2520oral%2520tubulin-binder%2520BAL101553%2520is%2520associated%2520with%2520inhibition%2520of%2520tumor%2520angiogenesis%26jtitle%3DOncotarget%26date%3D2020%26volume%3D11%26issue%3D8%26spage%3D759%26epage%3D774%26doi%3D10.18632%2Foncotarget.27374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berges, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchoghandjian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honore, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteve, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figarella-Branger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braguer, D.</span></span> <span> </span><span class="NLM_article-title">The novel tubulin-binding checkpoint activator BAL101553 inhibits EB1-dependent migration and invasion and promotes differentiation of glioblastoma stem-like cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2740</span>â <span class="NLM_lpage">2749</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-16-0252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1158%2F1535-7163.MCT-16-0252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=27540016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVOqsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2740-2749&issue=11&author=R.+Bergesauthor=A.+Tchoghandjianauthor=S.+Honoreauthor=M.+A.+Esteveauthor=D.+Figarella-Brangerauthor=F.+Bachmannauthor=H.+A.+Laneauthor=D.+Braguer&title=The+novel+tubulin-binding+checkpoint+activator+BAL101553+inhibits+EB1-dependent+migration+and+invasion+and+promotes+differentiation+of+glioblastoma+stem-like+cells&doi=10.1158%2F1535-7163.MCT-16-0252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">The novel tubulin-binding checkpoint activator BAL101553 inhibits EB1-dependent migration and invasion and promotes differentiation of glioblastoma stem-like cells</span></div><div class="casAuthors">Berges, Raphael; Tchoghandjian, Aurelie; Honore, Stephane; Esteve, Marie-Anne; Figarella-Branger, Dominique; Bachmann, Felix; Lane, Heidi A.; Braguer, Diane</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2740-2749</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Glioblastoma patients have limited treatment options.  Cancer stem-like cells (CSLC) contribute to glioblastoma invasiveness and repopulation; hence, they represent promising targets for novel therapies.  BAL101553 is a prodrug of BAL27862, a novel microtubule-destabilizing agent inhibiting tumor cell proliferation through activation of the spindle assembly checkpoint, which is currently in phase I/II clin. development.  Broad anticancer activity has been demonstrated against human cancer models, including tumors refractory to conventional treatments.  We have shown that overexpression of microtubule + end-binding 1-protein (EB1) correlates with glioblastoma progression and poor survival.  Here, we show that BAL27862 inhibits the growth of two glioblastoma CSLCs.  As EB1 is overexpressed in the CSLC line GBM6, which displays a high tumorigenicity and infiltrative pattern of migration in vivo, we investigated drug activity on GBM6 according to EB1 expression.  BAL27862 inhibited migration and colony formation at subcytotoxic concns. in EB1-expressing control cells (GBM6-sh0) but only at cytotoxic concns. in EB1-downregulated (GBM-shE1) cells.  Three administrations of BAL101553 were sufficient to provoke an EB1-dependent survival benefit in tumor-bearing mice.  Patterns of invasion and quantification of tumor cells in brain demonstrated that GBM6-sh0 cells were more invasive than GBM6-shEB1 cells, and that the antiproliferative and anti-invasive effects of BAL101553 were more potent in mice bearing control tumors than in EB1-downregulated tumors.  This was assocd. with inhibition of stem cell properties in the GBM6-sh0 model.  Finally, BAL27862 triggered astrocytic differentiation of GBM6 in an EB1-dependent manner.  These results support the potential of BAL101553 for glioblastoma treatment, with EB1 expression as a predictive biomarker of response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhHhC4OWk7z7Vg90H21EOLACvtfcHk0lhCj-76wsqVOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVOqsLo%253D&md5=46386df75bc8ab36ab2177cd32dc8cf5</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0252%26sid%3Dliteratum%253Aachs%26aulast%3DBerges%26aufirst%3DR.%26aulast%3DTchoghandjian%26aufirst%3DA.%26aulast%3DHonore%26aufirst%3DS.%26aulast%3DEsteve%26aufirst%3DM.%2BA.%26aulast%3DFigarella-Branger%26aufirst%3DD.%26aulast%3DBachmann%26aufirst%3DF.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DBraguer%26aufirst%3DD.%26atitle%3DThe%2520novel%2520tubulin-binding%2520checkpoint%2520activator%2520BAL101553%2520inhibits%2520EB1-dependent%2520migration%2520and%2520invasion%2520and%2520promotes%2520differentiation%2520of%2520glioblastoma%2520stem-like%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26issue%3D11%26spage%3D2740%26epage%3D2749%26doi%3D10.1158%2F1535-7163.MCT-16-0252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, T. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamantis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zubairi, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haris, N. R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greystoke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tunariu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molife, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannah, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt-Hoffmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristeleit, R. S.</span></span> <span> </span><span class="NLM_article-title">Phase 1/2a trial of intravenous BAL101553, a novel tumor checkpoint controller (TCC), in advanced solid tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2525</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2016.34.15_suppl.2525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1200%2FJCO.2016.34.15_suppl.2525" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=2525&author=J.+Lopezauthor=T.+R.+J.+Evansauthor=E.+R.+Plummerauthor=N.+Diamantisauthor=H.+M.+Shawauthor=I.+H.+Zubairiauthor=N.+R.+M.+Harisauthor=J.+MacDonaldauthor=A.+Greystokeauthor=R.+L.+Rouxauthor=N.+Tunariuauthor=L.+R.+Molifeauthor=A.+L.+Hannahauthor=S.+Andersonauthor=H.+A.+Laneauthor=M.+Maurerauthor=A.+Schmitt-Hoffmannauthor=F.+Bachmannauthor=M.+F.+Engelhardtauthor=R.+S.+Kristeleit&title=Phase+1%2F2a+trial+of+intravenous+BAL101553%2C+a+novel+tumor+checkpoint+controller+%28TCC%29%2C+in+advanced+solid+tumors&doi=10.1200%2FJCO.2016.34.15_suppl.2525"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.34.15_suppl.2525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.34.15_suppl.2525%26sid%3Dliteratum%253Aachs%26aulast%3DLopez%26aufirst%3DJ.%26aulast%3DEvans%26aufirst%3DT.%2BR.%2BJ.%26aulast%3DPlummer%26aufirst%3DE.%2BR.%26aulast%3DDiamantis%26aufirst%3DN.%26aulast%3DShaw%26aufirst%3DH.%2BM.%26aulast%3DZubairi%26aufirst%3DI.%2BH.%26aulast%3DHaris%26aufirst%3DN.%2BR.%2BM.%26aulast%3DMacDonald%26aufirst%3DJ.%26aulast%3DGreystoke%26aufirst%3DA.%26aulast%3DRoux%26aufirst%3DR.%2BL.%26aulast%3DTunariu%26aufirst%3DN.%26aulast%3DMolife%26aufirst%3DL.%2BR.%26aulast%3DHannah%26aufirst%3DA.%2BL.%26aulast%3DAnderson%26aufirst%3DS.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DMaurer%26aufirst%3DM.%26aulast%3DSchmitt-Hoffmann%26aufirst%3DA.%26aulast%3DBachmann%26aufirst%3DF.%26aulast%3DEngelhardt%26aufirst%3DM.%2BF.%26aulast%3DKristeleit%26aufirst%3DR.%2BS.%26atitle%3DPhase%25201%252F2a%2520trial%2520of%2520intravenous%2520BAL101553%252C%2520a%2520novel%2520tumor%2520checkpoint%2520controller%2520%2528TCC%2529%252C%2520in%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26spage%3D2525%26doi%3D10.1200%2FJCO.2016.34.15_suppl.2525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, M.</span>; <span class="NLM_string-name">Schmitt-Hoffmann, A.</span>; <span class="NLM_string-name">Larger, P.</span></span> <span> </span><span class="NLM_article-title">Novel Dosage Principle for Drugs Useful for Treating Neoplastic Diseases</span>. <span class="NLM_patent">WO2018210868A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=M.+Engelhardt&author=A.+Schmitt-Hoffmann&author=P.+Larger&title=Novel+Dosage+Principle+for+Drugs+Useful+for+Treating+Neoplastic+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEngelhardt%26aufirst%3DM.%26atitle%3DNovel%2520Dosage%2520Principle%2520for%2520Drugs%2520Useful%2520for%2520Treating%2520Neoplastic%2520Diseases%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joerger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stathis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metaxas, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantiero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mark, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaindl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuedeli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sessa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Moos, R.</span></span> <span> </span><span class="NLM_article-title">A phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1067</span>â <span class="NLM_lpage">1076</span>, <span class="refDoi">Â DOI: 10.1007/s10637-019-00850-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1007%2Fs10637-019-00850-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=31471863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs12is7bE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=1067-1076&author=M.+Joergerauthor=A.+Stathisauthor=Y.+Metaxasauthor=D.+Hessauthor=M.+Mantieroauthor=M.+Markauthor=M.+Voldenauthor=T.+Kaindlauthor=M.+Engelhardtauthor=P.+Largerauthor=H.+Laneauthor=P.+Hafnerauthor=N.+Levyauthor=S.+Stuedeliauthor=C.+Sessaauthor=R.+von+Moos&title=A+phase+1+study+of+BAL101553%2C+a+novel+tumor+checkpoint+controller+targeting+microtubules%2C+administered+as+48-h+infusion+in+adult+patients+with+advanced+solid+tumors&doi=10.1007%2Fs10637-019-00850-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors</span></div><div class="casAuthors">Joerger, Markus; Stathis, Anastasios; Metaxas, Yannis; Hess, Dagmar; Mantiero, Mara; Mark, Michael; Volden, Matthias; Kaindl, Thomas; Engelhardt, Marc; Larger, Patrice; Lane, Heidi; Hafner, Peter; Levy, Nicole; Stuedeli, Silvia; Sessa, Cristiana; von Moos, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1067-1076</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose BAL101553, the prodrug of the microtubule-destabilizer BAL27862, previously showed signs of antitumor activity when administered as a 2-h infusion, but its use was limited by vascular toxicity.  We investigated an alternative dosing strategy aimed at improving the safety profile of BAL101553.  Methods This multicenter, open-label, Phase 1 dose-escalation study used a 3 + 3 design to det. the max. tolerated dose (MTD), dose-limiting toxicities (DLTs), pharmacokinetics, and antitumor activity of BAL101553 administered as a 48-h IV infusion on Days 1, 8, and 15 of a 28-day cycle.  Patients received oral BAL101553 on Days 15-21 of cycle 2 to assess oral bioavailability.  Results BAL101553 was well tolerated at doses up to â¤70 mg/m2.  Three grade 3 DLTs occurred: hypotension (70 mg/m2), hyponatremia and neutropenia (both 90 mg/m2).  The MTD for 48-h IV BAL101553 was 70 mg/m2.  At this dose level, the AUC for BAL27862 was 8580 ng.h/mL and the Cmax was 144 ng/mL.  No apparent dose-related effects on blood pressure were obsd. with 48-h BAL101553 IV infusion.  BAL27862 oral bioavailability was >80%.  Conclusions Continuous 48-h IV BAL101553 infusion achieved higher exposure of the BAL27862 active metabolite than a 2-h infusion at the RP2D and did not cause vascular toxicity.  Clinicaltrials.gov registration: NCT02895360.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphRUL_sO_xQLVg90H21EOLACvtfcHk0lhCj-76wsqVOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs12is7bE&md5=d5452c063a5b91e56ba492163e139b57</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1007%2Fs10637-019-00850-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-019-00850-z%26sid%3Dliteratum%253Aachs%26aulast%3DJoerger%26aufirst%3DM.%26aulast%3DStathis%26aufirst%3DA.%26aulast%3DMetaxas%26aufirst%3DY.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DMantiero%26aufirst%3DM.%26aulast%3DMark%26aufirst%3DM.%26aulast%3DVolden%26aufirst%3DM.%26aulast%3DKaindl%26aufirst%3DT.%26aulast%3DEngelhardt%26aufirst%3DM.%26aulast%3DLarger%26aufirst%3DP.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DHafner%26aufirst%3DP.%26aulast%3DLevy%26aufirst%3DN.%26aulast%3DStuedeli%26aufirst%3DS.%26aulast%3DSessa%26aufirst%3DC.%26aulast%3Dvon%2BMoos%26aufirst%3DR.%26atitle%3DA%2520phase%25201%2520study%2520of%2520BAL101553%252C%2520a%2520novel%2520tumor%2520checkpoint%2520controller%2520targeting%2520microtubules%252C%2520administered%2520as%252048-h%2520infusion%2520in%2520adult%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2020%26volume%3D38%26spage%3D1067%26epage%3D1076%26doi%3D10.1007%2Fs10637-019-00850-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loehn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plettenburg, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivashchenko, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kannt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmeister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadereit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linz, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbert, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janiak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâConnor, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruetten, H.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of SAR407899, a novel Rho-kinase inhibitor</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">676</span>â <span class="NLM_lpage">683</span>, <span class="refDoi">Â DOI: 10.1161/HYPERTENSIONAHA.109.134353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1161%2FHYPERTENSIONAHA.109.134353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=19597037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpslelu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2009&pages=676-683&issue=3&author=M.+Loehnauthor=O.+Plettenburgauthor=Y.+Ivashchenkoauthor=A.+Kanntauthor=A.+Hofmeisterauthor=D.+Kadereitauthor=M.+Schaeferauthor=W.+Linzauthor=M.+Kohlmannauthor=J.-M.+Herbertauthor=P.+Janiakauthor=S.+E.+O%E2%80%99Connorauthor=H.+Ruetten&title=Pharmacological+characterization+of+SAR407899%2C+a+novel+Rho-kinase+inhibitor&doi=10.1161%2FHYPERTENSIONAHA.109.134353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological Characterization of SAR407899, a Novel Rho-Kinase Inhibitor</span></div><div class="casAuthors">Loehn, Matthias; Plettenburg, Oliver; Ivashchenko, Yuri; Kannt, Aimo; Hofmeister, Armin; Kadereit, Dieter; Schaefer, Matthias; Linz, Wolfgang; Kohlmann, Markus; Herbert, Jean-Marc; Janiak, Philip; O'Connor, Stephen E.; Ruetten, Hartmut</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">676-683</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Recent advances in basic and clin. research have identified Rho kinase as an important target potentially implicated in a variety of cardiovascular diseases.  Rho kinase is a downstream mediator of RhoA that leads to stress fiber formation, membrane ruffling, smooth muscle contraction, and cell motility.  Increased Rho-kinase activity is assocd. with vasoconstriction and elevated blood pressure.  We identified a novel inhibitor of Rho kinase (SAR407899) and characterized its effects in biochem., cellular, tissue-based, and in vivo assays.  SAR407899 is an ATP-competitive Rho-kinase inhibitor, equipotent against human and rat-derived Rho-kinase 2 with inhibition const. values of 36 nM and 41 nM, resp.  It is highly selective in panel of 117 receptor and enzyme targets.  SAR407899 is â8-fold more active than fasudil.  In vitro, SAR407899 demonstrated concn.-dependent inhibition of Rho-kinase-mediated phosphorylation of myosin phosphatase, thrombin-induced stress fiber formation, platelet-derived growth factor-induced proliferation, and monocyte chemotactic protein-1-stimulated chemotaxis.  SAR407899 potently (mean IC50 values: 122 to 280 nM) and species-independently relaxed precontracted isolated arteries of different species and different vascular beds.  In vivo, over the dose range 3 to 30 mg/kg PO, SAR407899 lowered blood pressure in a variety of rodent models of arterial hypertension.  The antihypertensive effect of SAR407899 was superior to that of fasudil and Y-27632.  In conclusion, SAR407899 is a novel and potent selective Rho-kinase inhibitor with promising antihypertensive activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHI_7WEKzfELVg90H21EOLACvtfcHk0ljoO03iG-T0aQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpslelu7w%253D&md5=b3a58165590d5cca120a77e12e085325</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.109.134353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.109.134353%26sid%3Dliteratum%253Aachs%26aulast%3DLoehn%26aufirst%3DM.%26aulast%3DPlettenburg%26aufirst%3DO.%26aulast%3DIvashchenko%26aufirst%3DY.%26aulast%3DKannt%26aufirst%3DA.%26aulast%3DHofmeister%26aufirst%3DA.%26aulast%3DKadereit%26aufirst%3DD.%26aulast%3DSchaefer%26aufirst%3DM.%26aulast%3DLinz%26aufirst%3DW.%26aulast%3DKohlmann%26aufirst%3DM.%26aulast%3DHerbert%26aufirst%3DJ.-M.%26aulast%3DJaniak%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DS.%2BE.%26aulast%3DRuetten%26aufirst%3DH.%26atitle%3DPharmacological%2520characterization%2520of%2520SAR407899%252C%2520a%2520novel%2520Rho-kinase%2520inhibitor%26jtitle%3DHypertension%26date%3D2009%26volume%3D54%26issue%3D3%26spage%3D676%26epage%3D683%26doi%3D10.1161%2FHYPERTENSIONAHA.109.134353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, F.</span>; <span class="NLM_string-name">Lane, H.</span>; <span class="NLM_string-name">McSheehy, P.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical Combinations Including Eribulin for Use in the Treatment of Neoplastic Diseases</span>. <span class="NLM_patent">WO2019097073A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=F.+Bachmann&author=H.+Lane&author=P.+McSheehy&title=Pharmaceutical+Combinations+Including+Eribulin+for+Use+in+the+Treatment+of+Neoplastic+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBachmann%26aufirst%3DF.%26atitle%3DPharmaceutical%2520Combinations%2520Including%2520Eribulin%2520for%2520Use%2520in%2520the%2520Treatment%2520of%2520Neoplastic%2520Diseases%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, F.</span>; <span class="NLM_string-name">Lane, H.</span>; <span class="NLM_string-name">McSheehy, P.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical Combinations for Use in the Treatment of Neoplastic Diseases</span>. <span class="NLM_patent">WO2020058405A1</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=F.+Bachmann&author=H.+Lane&author=P.+McSheehy&title=Pharmaceutical+Combinations+for+Use+in+the+Treatment+of+Neoplastic+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBachmann%26aufirst%3DF.%26atitle%3DPharmaceutical%2520Combinations%2520for%2520Use%2520in%2520the%2520Treatment%2520of%2520Neoplastic%2520Diseases%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meneghetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, S.</span></span> <span> </span><span class="NLM_article-title">Signal transducer and activator of transcription protein 3 (STAT3): An update on its direct inhibitors as promising anticancer agents</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">27</span>),  <span class="NLM_fpage">5165</span>â <span class="NLM_lpage">5206</span>, <span class="refDoi">Â DOI: 10.2174/0929867325666180719122729</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.2174%2F0929867325666180719122729" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=30027840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVymt7bI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=5165-5206&issue=27&author=A.+Gelainauthor=M.+Moriauthor=F.+Meneghettiauthor=S.+Villa&title=Signal+transducer+and+activator+of+transcription+protein+3+%28STAT3%29%3A+An+update+on+its+direct+inhibitors+as+promising+anticancer+agents&doi=10.2174%2F0929867325666180719122729"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents</span></div><div class="casAuthors">Gelain, Arianna; Mori, Matteo; Meneghetti, Fiorella; Villa, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">5165-5206</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Background: Since Signal Transducer and Activator of Transcription 3 (STAT3) is a transcription factor which plays an important role in multiple aspects of cancer, including progression and migration, and it is constitutively activated in various human tumors, STAT3 inhibition has emerged as a validated strategy for the treatment of several malignancies.  The aim of this review is to provide an update on the identification of new promising direct inhibitors targeting STAT3 domains, as potential anticancer agents.  Methods: A thorough literature search focused on recently reported STAT3 direct inhibitors was undertaken.  We considered the relevant developments regarding the STAT3 domains, which have been identified as potential drug targets.  Results: In detail, 135 peer-reviewed papers and 7 patents were cited; the inhibitors we took into account targeted the DNA binding domain (compds. were grouped into natural derivs., small mols., peptides, aptamers and oligonucleotides), the SH2 binding domain (natural, semi-synthetic and synthetic compds.) and specific residues, like cysteines (natural, semi-synthetic, synthetic compds. and dual inhibitors) and tyrosine 705.  Conclusion: The huge no. of direct STAT3 inhibitors recently identified demonstrates a strong interest in the investigation of this target, although it represents a challenging task considering that no drug targeting this enzyme is currently available for anticancer therapy.  Notably, many studies on the available inhibitors evidenced that some of them possess a dual mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQTc4wg6lMDbVg90H21EOLACvtfcHk0ljoO03iG-T0aQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVymt7bI&md5=1df39128edf16ad4b697263614ed36e5</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.2174%2F0929867325666180719122729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867325666180719122729%26sid%3Dliteratum%253Aachs%26aulast%3DGelain%26aufirst%3DA.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DMeneghetti%26aufirst%3DF.%26aulast%3DVilla%26aufirst%3DS.%26atitle%3DSignal%2520transducer%2520and%2520activator%2520of%2520transcription%2520protein%25203%2520%2528STAT3%2529%253A%2520An%2520update%2520on%2520its%2520direct%2520inhibitors%2520as%2520promising%2520anticancer%2520agents%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2019%26volume%3D26%26issue%3D27%26spage%3D5165%26epage%3D5206%26doi%3D10.2174%2F0929867325666180719122729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, B. M.</span>; <span class="NLM_string-name">Han, D. C.</span>; <span class="NLM_string-name">Son, K. H.</span>; <span class="NLM_string-name">Shin, D. S.</span>; <span class="NLM_string-name">Lee, J.</span></span> <span> </span><span class="NLM_article-title">Agent for Prevention and Treatment of Cancer Comprising Oxadiazole Urea Compound Obstructing Activity of STAT</span>. <span class="NLM_patent">US200800514442A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=B.+M.+Kwon&author=D.+C.+Han&author=K.+H.+Son&author=D.+S.+Shin&author=J.+Lee&title=Agent+for+Prevention+and+Treatment+of+Cancer+Comprising+Oxadiazole+Urea+Compound+Obstructing+Activity+of+STAT"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKwon%26aufirst%3DB.%2BM.%26atitle%3DAgent%2520for%2520Prevention%2520and%2520Treatment%2520of%2520Cancer%2520Comprising%2520Oxadiazole%2520Urea%2520Compound%2520Obstructing%2520Activity%2520of%2520STAT%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masciocchi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlocco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meneghetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedretti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, B.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legnani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toma, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis, modeling, and crystallographic study of 3,4-disubstituted-1,2,5-oxadiazoles and evaluation of their ability to decrease STAT3 activity</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">156</span>â <span class="NLM_lpage">164</span>, <span class="refDoi">Â DOI: 10.1039/c0md00057d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1039%2Fc0md00057d" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVans7fF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=156-164&issue=2&author=D.-S.+Shinauthor=D.+Masciocchiauthor=A.+Gelainauthor=S.+Villaauthor=D.+Barloccoauthor=F.+Meneghettiauthor=A.+Pedrettiauthor=Y.-M.+Hanauthor=D.+C.+Hanauthor=B.-M.+Kwonauthor=L.+Legnaniauthor=L.+Toma&title=Synthesis%2C+modeling%2C+and+crystallographic+study+of+3%2C4-disubstituted-1%2C2%2C5-oxadiazoles+and+evaluation+of+their+ability+to+decrease+STAT3+activity&doi=10.1039%2Fc0md00057d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, modeling, and crystallographic study of 3,4-disubstituted-1,2,5-oxadiazoles and evaluation of their ability to decrease STAT3 activity</span></div><div class="casAuthors">Shin, Dae-Seop; Masciocchi, Daniela; Gelain, Arianna; Villa, Stefania; Barlocco, Daniela; Meneghetti, Fiorella; Pedretti, Alessandro; Han, Young-Min; Han, Dong-Cho; Kwon, Byoung-Mog; Legnani, Laura; Toma, Lucio</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">156-164</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">STAT3 (Signal Transducer and Activator of Transcription 3) is a transcription factor constitutively activated by aberrant upstream tyrosine kinase activities in a broad spectrum of human solid and blood tumors, thus suggesting that its inhibition could represent an interesting mol. target for cancer therapy.  With the aim to disclose novel scaffolds for compds. active on STAT3 the potential of the 1,2,5-oxadiazole ring was explored and several new compds. substituted at positions 3 and 4 of the heterocycle were synthesized.  When tested in a dual-luciferase assay, using HCT-116 cells, some compds. showed a significant inhibition value towards STAT3, particularly I.  So, to give support to the biol. results, modeling and crystallog. studies of representative terms of the new series were performed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrluNnelBcqurVg90H21EOLACvtfcHk0lhXFeHlkABhhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVans7fF&md5=d1f0b03f0efd84e22c9c0ab5dc3e84f5</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1039%2Fc0md00057d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0md00057d%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DD.-S.%26aulast%3DMasciocchi%26aufirst%3DD.%26aulast%3DGelain%26aufirst%3DA.%26aulast%3DVilla%26aufirst%3DS.%26aulast%3DBarlocco%26aufirst%3DD.%26aulast%3DMeneghetti%26aufirst%3DF.%26aulast%3DPedretti%26aufirst%3DA.%26aulast%3DHan%26aufirst%3DY.-M.%26aulast%3DHan%26aufirst%3DD.%2BC.%26aulast%3DKwon%26aufirst%3DB.-M.%26aulast%3DLegnani%26aufirst%3DL.%26aulast%3DToma%26aufirst%3DL.%26atitle%3DSynthesis%252C%2520modeling%252C%2520and%2520crystallographic%2520study%2520of%25203%252C4-disubstituted-1%252C2%252C5-oxadiazoles%2520and%2520evaluation%2520of%2520their%2520ability%2520to%2520decrease%2520STAT3%2520activity%26jtitle%3DMedChemComm%26date%3D2010%26volume%3D1%26issue%3D2%26spage%3D156%26epage%3D164%26doi%3D10.1039%2Fc0md00057d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masciocchi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meneghetti, F.</span></span> <span> </span><span class="NLM_article-title">The influence of the substitution pattern on the molecular conformation of ureido-1,2,5-oxadiazoles, related to STAT3 inhibitors: Chemical behavior and structural investigation</span>. <i>Chem. Biodiversity</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1240</span>â <span class="NLM_lpage">1253</span>, <span class="refDoi">Â DOI: 10.1002/cbdv.201100339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fcbdv.201100339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=22782873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVagtrnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=1240-1253&issue=7&author=S.+Villaauthor=D.+Masciocchiauthor=A.+Gelainauthor=F.+Meneghetti&title=The+influence+of+the+substitution+pattern+on+the+molecular+conformation+of+ureido-1%2C2%2C5-oxadiazoles%2C+related+to+STAT3+inhibitors%3A+Chemical+behavior+and+structural+investigation&doi=10.1002%2Fcbdv.201100339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">The Influence of the Substitution Pattern on the Molecular Conformation of Ureido-1,2,5-oxadiazoles, Related to STAT3 Inhibitors: Chemical Behavior and Structural Investigation</span></div><div class="casAuthors">Villa, Stefania; Masciocchi, Daniela; Gelain, Arianna; Meneghetti, Fiorella</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biodiversity</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1240-1253</span>CODEN:
                <span class="NLM_cas:coden">CBHIAM</span>;
        ISSN:<span class="NLM_cas:issn">1612-1872</span>.
    
            (<span class="NLM_cas:orgname">Verlag Helvetica Chimica Acta</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is a protein constitutively activated by aberrant upstream tyrosine kinase activities in a broad spectrum of human solid and blood tumors.  Therefore, the availability of drugs affecting STAT3 may have important therapeutic potential for the treatment of cancer.  Pursuing our efforts in exploring the influence of the substitution pattern of the ureido 1,2,5-oxadiazole moiety on the mol. conformation, new compds. substituted at positions 3 and 4 on the furazan ring were synthesized.  The inhibition properties vs. STAT3 of the novel compds. were evaluated in a dual-luciferase assay, using HCT-116 cells, and the results evidenced a moderate activity only for the compds. endowed with a planar arrangement.  Crystallog. studies of the new derivs. were performed in order to evidence the peculiar chem. behavior and to evaluate how structural modulations affected the biol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzOEMfnmvY2rVg90H21EOLACvtfcHk0lhXFeHlkABhhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVagtrnE&md5=2ad6fad4fae37367cce8d74eb98ad1d5</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1002%2Fcbdv.201100339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbdv.201100339%26sid%3Dliteratum%253Aachs%26aulast%3DVilla%26aufirst%3DS.%26aulast%3DMasciocchi%26aufirst%3DD.%26aulast%3DGelain%26aufirst%3DA.%26aulast%3DMeneghetti%26aufirst%3DF.%26atitle%3DThe%2520influence%2520of%2520the%2520substitution%2520pattern%2520on%2520the%2520molecular%2520conformation%2520of%2520ureido-1%252C2%252C5-oxadiazoles%252C%2520related%2520to%2520STAT3%2520inhibitors%253A%2520Chemical%2520behavior%2520and%2520structural%2520investigation%26jtitle%3DChem.%2520Biodiversity%26date%3D2012%26volume%3D9%26issue%3D7%26spage%3D1240%26epage%3D1253%26doi%3D10.1002%2Fcbdv.201100339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masciocchi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meneghetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedretti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlocco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legnani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, B.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, A.</span></span> <span> </span><span class="NLM_article-title">Biological and computational evaluation of an oxadiazole derivative (MD77) as a new lead for direct STAT3 inhibitors</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">592</span>â <span class="NLM_lpage">599</span>, <span class="refDoi">Â DOI: 10.1039/c2md20018j</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1039%2Fc2md20018j" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFart7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=592-599&issue=5&author=D.+Masciocchiauthor=S.+Villaauthor=F.+Meneghettiauthor=A.+Pedrettiauthor=D.+Barloccoauthor=L.+Legnaniauthor=L.+Tomaauthor=B.-M.+Kwonauthor=S.+Nakanoauthor=A.+Asaiauthor=A.+Gelain&title=Biological+and+computational+evaluation+of+an+oxadiazole+derivative+%28MD77%29+as+a+new+lead+for+direct+STAT3+inhibitors&doi=10.1039%2Fc2md20018j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Biological and computational evaluation of an oxadiazole derivative (MD77) as a new lead for direct STAT3 inhibitors</span></div><div class="casAuthors">Masciocchi, Daniela; Villa, Stefania; Meneghetti, Fiorella; Pedretti, Alessandro; Barlocco, Daniela; Legnani, Laura; Toma, Lucio; Kwon, Byoung-Mog; Nakano, Shintaro; Asai, Akira; Gelain, Arianna</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">592-599</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Signal Transducer and Activator of Transcription 3 (STAT3) is a latent cytoplasmic protein overexpressed in various cancer cell lines.  STAT3 participates in oncogenesis by stimulating cell proliferation and preventing apoptosis and it has been proven as a suitable target for anticancer therapy.  In order to identify direct STAT3 inhibitors, we performed a binding assay on several previously synthesized 1,2,5-oxadiazole derivs.  Among them, compd. MD77, N-[4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl]-4-(trifluoromethyl)benzamide, showed a good ability to bind the STAT3-SH2 domain in a dose-dependent manner (IC50 = 17.7 Î¼M).  Computational studies were carried out to investigate its binding mode.  Moreover, compd. MD77 showed a significant anti-proliferative activity vs. several tumor cell lines.  On these bases, compd. MD77 was selected as a lead for the future development of direct STAT3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrESgLmH0AmJbVg90H21EOLACvtfcHk0lhXFeHlkABhhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFart7g%253D&md5=5c41c49a9192d95d2c00653b51ea45d3</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1039%2Fc2md20018j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20018j%26sid%3Dliteratum%253Aachs%26aulast%3DMasciocchi%26aufirst%3DD.%26aulast%3DVilla%26aufirst%3DS.%26aulast%3DMeneghetti%26aufirst%3DF.%26aulast%3DPedretti%26aufirst%3DA.%26aulast%3DBarlocco%26aufirst%3DD.%26aulast%3DLegnani%26aufirst%3DL.%26aulast%3DToma%26aufirst%3DL.%26aulast%3DKwon%26aufirst%3DB.-M.%26aulast%3DNakano%26aufirst%3DS.%26aulast%3DAsai%26aufirst%3DA.%26aulast%3DGelain%26aufirst%3DA.%26atitle%3DBiological%2520and%2520computational%2520evaluation%2520of%2520an%2520oxadiazole%2520derivative%2520%2528MD77%2529%2520as%2520a%2520new%2520lead%2520for%2520direct%2520STAT3%2520inhibitors%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26issue%3D5%26spage%3D592%26epage%3D599%26doi%3D10.1039%2Fc2md20018j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meneghetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masciocchi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlocco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, D.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, B.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legnani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, A.</span></span> <span> </span><span class="NLM_article-title">Ureido-pyridazinone derivatives: Insights into the structural and conformational properties for STAT3 inhibition</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">4907</span>â <span class="NLM_lpage">4912</span>, <span class="refDoi">Â DOI: 10.1002/ejoc.201500599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fejoc.201500599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVyhsL%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=4907-4912&issue=22&author=F.+Meneghettiauthor=S.+Villaauthor=D.+Masciocchiauthor=D.+Barloccoauthor=L.+Tomaauthor=D.-C.+Hanauthor=B.-M.+Kwonauthor=N.+Ogoauthor=A.+Asaiauthor=L.+Legnaniauthor=A.+Gelain&title=Ureido-pyridazinone+derivatives%3A+Insights+into+the+structural+and+conformational+properties+for+STAT3+inhibition&doi=10.1002%2Fejoc.201500599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Ureido-Pyridazinone Derivatives: Insights into the Structural and Conformational Properties for STAT3 Inhibition</span></div><div class="casAuthors">Meneghetti, Fiorella; Villa, Stefania; Masciocchi, Daniela; Barlocco, Daniela; Toma, Lucio; Han, Dong-Cho; Kwon, Byoung-Mog; Ogo, Naohisa; Asai, Akira; Legnani, Laura; Gelain, Arianna</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4907-4912</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Three new ureido-pyridazinone derivs., which are structurally related to the known STAT3 inhibitor AVS-0288, were designed by taking into account the structure-activity relationships detd. for several ureido-oxadiazole derivs. previously studied by our group.  Their synthesis was first attempted through suitable 5-aminopyridazinone intermediates, and the mol. structures of these intermediates were confirmed by means of X-ray diffraction data on 5-amino-6-phenylpyridazin-3(2H)-one.  Amine functionalization was unsuccessful, therefore, an alternative method was devised.  Dual-luciferase and AlphaScreen-based assays were used to test their activity.  The obtained data were rationalized on the basis of a modeling study, which focused our attention on the geometrical preferences of the ureido moiety.  Computational results seem to indicate that both the 1,2,5-oxadiazole ring and the extended ZZ arrangement were essential and probably act in a synergistic way to confer significant activity against STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZXBd5q49qdbVg90H21EOLACvtfcHk0ljdiTUSQXpMvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVyhsL%252FL&md5=b2628519d53faef5077312f5aee851d7</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201500599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201500599%26sid%3Dliteratum%253Aachs%26aulast%3DMeneghetti%26aufirst%3DF.%26aulast%3DVilla%26aufirst%3DS.%26aulast%3DMasciocchi%26aufirst%3DD.%26aulast%3DBarlocco%26aufirst%3DD.%26aulast%3DToma%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DD.-C.%26aulast%3DKwon%26aufirst%3DB.-M.%26aulast%3DOgo%26aufirst%3DN.%26aulast%3DAsai%26aufirst%3DA.%26aulast%3DLegnani%26aufirst%3DL.%26aulast%3DGelain%26aufirst%3DA.%26atitle%3DUreido-pyridazinone%2520derivatives%253A%2520Insights%2520into%2520the%2520structural%2520and%2520conformational%2520properties%2520for%2520STAT3%2520inhibition%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2015%26volume%3D2015%26issue%3D22%26spage%3D4907%26epage%3D4912%26doi%3D10.1002%2Fejoc.201500599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlocco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchiano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappello, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basile, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guccione, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meneghetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, S.</span></span> <span> </span><span class="NLM_article-title">A field-based disparity analysis of new 1,2,5-oxadiazole derivatives endowed with antiproliferative activity</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>90</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">820</span>â <span class="NLM_lpage">839</span>, <span class="refDoi">Â DOI: 10.1111/cbdd.13003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1111%2Fcbdd.13003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28419754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXns1KgsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2017&pages=820-839&issue=5&author=F.+Portaauthor=A.+Gelainauthor=D.+Barloccoauthor=N.+Ferriauthor=S.+Marchianoauthor=V.+Cappelloauthor=L.+Basileauthor=S.+Guccioneauthor=F.+Meneghettiauthor=S.+Villa&title=A+field-based+disparity+analysis+of+new+1%2C2%2C5-oxadiazole+derivatives+endowed+with+antiproliferative+activity&doi=10.1111%2Fcbdd.13003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">A field-based disparity analysis of new 1,2,5-oxadiazole derivatives endowed with antiproliferative activity</span></div><div class="casAuthors">Porta, Federica; Gelain, Arianna; Barlocco, Daniela; Ferri, Nicola; Marchiano, Silvia; Cappello, Valentina; Basile, Livia; Guccione, Salvatore; Meneghetti, Fiorella; Villa, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">820-839</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A series of 1,2,5-oxadiazoles were synthesized as new potential antiproliferative agents.  The in vitro cytotoxic activity evaluation of title compds. through MTT assay revealed that some of them showed significant activity against the HCT-116 cancer cell line.  The field-based disparity anal. provided indications about the electrostatic, hydrophobic, and shape features underlying the cytotoxicity, suggesting that increasing the neg. electrostatic field on the heterocyclic core of the structure has pos. effects on the activity.  The structure-activity relationships (SAR) around a particular compd. can be explained allowing for a structural rationale for the differences in activity.  The SAR provided by this series of compds. can be exploited to carry out further lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk-N4lAAlhc7Vg90H21EOLACvtfcHk0ljdiTUSQXpMvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXns1KgsLo%253D&md5=b01d51dec301220658e4089728799f3f</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.13003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.13003%26sid%3Dliteratum%253Aachs%26aulast%3DPorta%26aufirst%3DF.%26aulast%3DGelain%26aufirst%3DA.%26aulast%3DBarlocco%26aufirst%3DD.%26aulast%3DFerri%26aufirst%3DN.%26aulast%3DMarchiano%26aufirst%3DS.%26aulast%3DCappello%26aufirst%3DV.%26aulast%3DBasile%26aufirst%3DL.%26aulast%3DGuccione%26aufirst%3DS.%26aulast%3DMeneghetti%26aufirst%3DF.%26aulast%3DVilla%26aufirst%3DS.%26atitle%3DA%2520field-based%2520disparity%2520analysis%2520of%2520new%25201%252C2%252C5-oxadiazole%2520derivatives%2520endowed%2520with%2520antiproliferative%2520activity%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2017%26volume%3D90%26issue%3D5%26spage%3D820%26epage%3D839%26doi%3D10.1111%2Fcbdd.13003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facchetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meneghetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlocco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masciocchi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyoshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchiano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimoldi, I.</span></span> <span> </span><span class="NLM_article-title">An in vivo active 1,2,5-oxadiazole Pt(II) complex: A promising anticancer agent endowed with STAT3 inhibitory properties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">196</span>â <span class="NLM_lpage">206</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2017.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.ejmech.2017.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28324784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvVKrsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2017&pages=196-206&author=F.+Portaauthor=G.+Facchettiauthor=N.+Ferriauthor=A.+Gelainauthor=F.+Meneghettiauthor=S.+Villaauthor=D.+Barloccoauthor=D.+Masciocchiauthor=A.+Asaiauthor=N.+Miyoshiauthor=S.+Marchianoauthor=B.+M.+Kwonauthor=Y.+Jinauthor=V.+Gandinauthor=C.+Marzanoauthor=I.+Rimoldi&title=An+in+vivo+active+1%2C2%2C5-oxadiazole+Pt%28II%29+complex%3A+A+promising+anticancer+agent+endowed+with+STAT3+inhibitory+properties&doi=10.1016%2Fj.ejmech.2017.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">An in vivo active 1,2,5-oxadiazole Pt(II) complex: A promising anticancer agent endowed with STAT3 inhibitory properties</span></div><div class="casAuthors">Porta, Federica; Facchetti, Giorgio; Ferri, Nicola; Gelain, Arianna; Meneghetti, Fiorella; Villa, Stefania; Barlocco, Daniela; Masciocchi, Daniela; Asai, Akira; Miyoshi, Nao; Marchiano, Silvia; Kwon, Byoung-Mog; Jin, Yena; Gandin, Valentina; Marzano, Cristina; Rimoldi, Isabella</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">196-206</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">New Pt(II) complexes (Pt-1-3) bearing 1,2,5-oxadiazole ligands (1-3) were synthesized, characterized and evaluated for their ability to disrupt STAT3 dimerization.  Ligand 3Â·HCl showed cytotoxic effects on HCT-116 cells (IC50 = 95.2 Î¼M) and a selective ability to interact with STAT3 (IC50 = 8.2 Î¼M) vs. STAT1 (IC50 > 30 Î¼M).  Its corresponding platinum complex Pt-3 exhibited an increased cytotoxicity (IC50 = 18.4 Î¼M) and a stronger interaction with STAT3 (IC50 = 1.4 Î¼M), leading to inhibition of its signaling pathway.  Pt-3 was also evaluated in cell-based assays for its action on p53 expression and on STAT3 phosphorylation.  In syngeneic murine Lewis lung carcinoma (LLC) implanted in C57BL/6 mice, Pt-3 showed a higher antitumor activity with fewer side effects than cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqivlmoUtNye7Vg90H21EOLACvtfcHk0ljdiTUSQXpMvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvVKrsrg%253D&md5=3069d1f9605d1b0bb046e74b1e1cf1e8</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DPorta%26aufirst%3DF.%26aulast%3DFacchetti%26aufirst%3DG.%26aulast%3DFerri%26aufirst%3DN.%26aulast%3DGelain%26aufirst%3DA.%26aulast%3DMeneghetti%26aufirst%3DF.%26aulast%3DVilla%26aufirst%3DS.%26aulast%3DBarlocco%26aufirst%3DD.%26aulast%3DMasciocchi%26aufirst%3DD.%26aulast%3DAsai%26aufirst%3DA.%26aulast%3DMiyoshi%26aufirst%3DN.%26aulast%3DMarchiano%26aufirst%3DS.%26aulast%3DKwon%26aufirst%3DB.%2BM.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DGandin%26aufirst%3DV.%26aulast%3DMarzano%26aufirst%3DC.%26aulast%3DRimoldi%26aufirst%3DI.%26atitle%3DAn%2520in%2520vivo%2520active%25201%252C2%252C5-oxadiazole%2520Pt%2528II%2529%2520complex%253A%2520A%2520promising%2520anticancer%2520agent%2520endowed%2520with%2520STAT3%2520inhibitory%2520properties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D131%26spage%3D196%26epage%3D206%26doi%3D10.1016%2Fj.ejmech.2017.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rademann, J.</span>; <span class="NLM_string-name">Wong, E. L.</span>; <span class="NLM_string-name">Arkona, C.</span>; <span class="NLM_string-name">Kim, B. G.</span>; <span class="NLM_string-name">Nawrotzky, E.</span></span> <span> </span><span class="NLM_article-title">Preparation of Tetrazolylmethylamino Furazan-3-carboxylic Acid Derivatives for the Treatment of Cancer</span>. <span class="NLM_patent">WO2018065536A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=J.+Rademann&author=E.+L.+Wong&author=C.+Arkona&author=B.+G.+Kim&author=E.+Nawrotzky&title=Preparation+of+Tetrazolylmethylamino+Furazan-3-carboxylic+Acid+Derivatives+for+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRademann%26aufirst%3DJ.%26atitle%3DPreparation%2520of%2520Tetrazolylmethylamino%2520Furazan-3-carboxylic%2520Acid%2520Derivatives%2520for%2520the%2520Treatment%2520of%2520Cancer%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Catrow, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective small-molecule inhibitors for the beta-catenin/T-cell factor protein-protein interaction through the optimization of the acyl hydrazone moiety</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4678</span>â <span class="NLM_lpage">4692</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00223</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00223" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosFakt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4678-4692&issue=11&author=J.+L.+Catrowauthor=Y.+Zhangauthor=M.+Zhangauthor=H.+Ji&title=Discovery+of+selective+small-molecule+inhibitors+for+the+beta-catenin%2FT-cell+factor+protein-protein+interaction+through+the+optimization+of+the+acyl+hydrazone+moiety&doi=10.1021%2Facs.jmedchem.5b00223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Selective Small-Molecule Inhibitors for the Î²-Catenin/T-Cell Factor Protein-Protein Interaction through the Optimization of the Acyl Hydrazone Moiety</span></div><div class="casAuthors">Catrow, J. Leon; Zhang, Yongqiang; Zhang, Min; Ji, Haitao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4678-4692</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acyl hydrazone is an important functional group for the discovery of bioactive small mols.  This functional group is also recognized as a pan assay interference structure.  In this study, a new small-mol. inhibitor for the Î²-catenin/Tcf protein-protein interaction (PPI), ZINC02092166, was identified through AlphaScreen and FP assays.  This compd. contains an acyl hydrazone group and exhibits higher inhibitory activities in cell-based assays than biochem. assays.  Inhibitor optimization resulted in chem. stable derivs. that disrupt the Î²-catenin/Tcf PPI.  The binding mode of new inhibitors was characterized by site-directed mutagenesis and structure-activity relationship studies.  This series of inhibitors with a new scaffold exhibits dual selectivity for Î²-catenin/Tcf over Î²-catenin/cadherin and Î²-catenin/APC PPIs.  One deriv. of this series suppresses canonical Wnt signaling, downregulates the expression of Wnt target genes, and inhibits the growth of cancer cells.  This compd. represents a solid starting point for the development of potent and selective Î²-catenin/Tcf inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqusdU2c6KIQLVg90H21EOLACvtfcHk0liPjuR3oGKzrw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosFakt7o%253D&md5=11aa0209009144341d692c4cf6966790</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00223%26sid%3Dliteratum%253Aachs%26aulast%3DCatrow%26aufirst%3DJ.%2BL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DJi%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520selective%2520small-molecule%2520inhibitors%2520for%2520the%2520beta-catenin%252FT-cell%2520factor%2520protein-protein%2520interaction%2520through%2520the%2520optimization%2520of%2520the%2520acyl%2520hydrazone%2520moiety%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D11%26spage%3D4678%26epage%3D4692%26doi%3D10.1021%2Facs.jmedchem.5b00223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ji, H.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Zhang, M.</span>; <span class="NLM_string-name">Catrow, J. L.</span></span> <span> </span><span class="NLM_article-title">Methods and Compositions of Substituted 5H-[1,2,5]Oxadiazolo[3â²,4â²:5,6]pyraziono[2,3-b]indole Analogs as Inhibitors of Beta-Catenin/T-Cell Factor Protein-Protein Interactions</span>. <span class="NLM_patent">WO2016187050A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=H.+Ji&author=Y.+Zhang&author=M.+Zhang&author=J.+L.+Catrow&title=Methods+and+Compositions+of+Substituted+5H-%5B1%2C2%2C5%5DOxadiazolo%5B3%E2%80%B2%2C4%E2%80%B2%3A5%2C6%5Dpyraziono%5B2%2C3-b%5Dindole+Analogs+as+Inhibitors+of+Beta-Catenin%2FT-Cell+Factor+Protein-Protein+Interactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DH.%26atitle%3DMethods%2520and%2520Compositions%2520of%2520Substituted%25205H-%255B1%252C2%252C5%255DOxadiazolo%255B3%25E2%2580%25B2%252C4%25E2%2580%25B2%253A5%252C6%255Dpyraziono%255B2%252C3-b%255Dindole%2520Analogs%2520as%2520Inhibitors%2520of%2520Beta-Catenin%252FT-Cell%2520Factor%2520Protein-Protein%2520Interactions%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, H.</span></span> <span> </span><span class="NLM_article-title">Optimization of peptidomimetics as selective inhibitors for the beta-catenin/T-cell factor protein-protein interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3617</span>â <span class="NLM_lpage">3635</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b00147</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00147" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXksFentb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3617-3635&issue=7&author=Z.+Wangauthor=M.+Zhangauthor=J.+Wangauthor=H.+Ji&title=Optimization+of+peptidomimetics+as+selective+inhibitors+for+the+beta-catenin%2FT-cell+factor+protein-protein+interaction&doi=10.1021%2Facs.jmedchem.9b00147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Peptidomimetics as Selective Inhibitors for the Î²-Catenin/T-Cell Factor Protein-Protein Interaction</span></div><div class="casAuthors">Wang, Zhen; Zhang, Min; Wang, Jin; Ji, Haitao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3617-3635</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Î²-catenin/T-cell factor (Tcf) protein-protein interaction (PPI) plays a crit. role in the Î²-catenin signaling pathway which is hyperactivated in many cancers and fibroses.  Based on compd. 1, which was designed to target the Tcf4 G13ANDE17 binding site of Î²-catenin, extensive structure-activity relationship studies have been conducted.  As a result, compds. 53 and 57 were found to disrupt the Î²-catenin/Tcf PPI with the Ki values of 0.64 and 0.44 Î¼M, resp., and exhibit good selectivity for Î²-catenin/Tcf over Î²-catenin/E-cadherin and Î²-catenin/adenomatous polyposis coli (APC) PPIs.  The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) cell viability assays revealed that 56, the Et ester of 53, was more potent than 53 in inhibiting viability of most of the Wnt/Î²-catenin hyperactive cancer cells.  Further cell-based studies indicated that 56 disrupted the Î²-catenin/Tcf PPI without affecting the Î²-catenin/E-cadherin and Î²-catenin/APC PPIs, suppressed transactivation of Wnt/Î²-catenin signaling in dose-dependent manners, and inhibited migration and invasiveness of Wnt/Î²-catenin-dependent cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmQ02RIKeK5LVg90H21EOLACvtfcHk0liPjuR3oGKzrw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXksFentb8%253D&md5=8b4a19745fe5ae7561093523b07681a6</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00147%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DH.%26atitle%3DOptimization%2520of%2520peptidomimetics%2520as%2520selective%2520inhibitors%2520for%2520the%2520beta-catenin%252FT-cell%2520factor%2520protein-protein%2520interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D7%26spage%3D3617%26epage%3D3635%26doi%3D10.1021%2Facs.jmedchem.9b00147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peery, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. T.</span></span> <span> </span><span class="NLM_article-title">Effective targeting of the survivin dimerization interface with small-molecule inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">453</span>â <span class="NLM_lpage">462</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-15-1874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1158%2F0008-5472.CAN-15-1874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=26744521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC28Xos1WisA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=453-462&issue=2&author=J.+Qiauthor=Z.+Dongauthor=J.+Liuauthor=R.+C.+Peeryauthor=S.+Zhangauthor=J.+Y.+Liuauthor=J.+T.+Zhang&title=Effective+targeting+of+the+survivin+dimerization+interface+with+small-molecule+inhibitors&doi=10.1158%2F0008-5472.CAN-15-1874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Effective Targeting of the Survivin Dimerization Interface with Small-Molecule Inhibitors</span></div><div class="casAuthors">Qi, Jing; Dong, Zizheng; Liu, Jianguo; Peery, Robert C.; Zhang, Shaobo; Liu, Jing-Yuan; Zhang, Jian-Ting</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">453-462</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Many oncoproteins are considered undruggable because they lack enzymic activities.  In this study, we present a small-mol.-based anticancer agent that acts by inhibiting dimerization of the oncoprotein survivin, thereby promoting its degrdn. along with spontaneous apoptosis in cancer cells.  Through a combination of computational anal. of the dimerization interface and in silico screening, we identified one compd. that induced proteasome-dependent survivin degrdn.  Anal. of a set of structural analogs led us to identify a lead compd. (LQZ-7F), which was effective in blocking the survival of multiple cancer cell lines in a low micromolar concn. range.  LQZ-7F induced proteasome-dependent survivin degrdn., mitotic arrest, and apoptosis, and it blocked the growth of human tumors in mouse xenograft assays.  In addn. to providing preclin. proof of concept for a survivin-targeting anticancer agent, our work offers novel in silico screening strategies to therapeutically target homodimeric oncogenic proteins considered undruggable.  Cancer Res; 76(2); 453-62. Â©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFIaf1nDDoJbVg90H21EOLACvtfcHk0liPjuR3oGKzrw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xos1WisA%253D%253D&md5=b8ca613a6f9c029097942e21dc212025</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-1874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-1874%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DPeery%26aufirst%3DR.%2BC.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DJ.%2BY.%26aulast%3DZhang%26aufirst%3DJ.%2BT.%26atitle%3DEffective%2520targeting%2520of%2520the%2520survivin%2520dimerization%2520interface%2520with%2520small-molecule%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26issue%3D2%26spage%3D453%26epage%3D462%26doi%3D10.1158%2F0008-5472.CAN-15-1874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-T.</span>; <span class="NLM_string-name">Liu, J.-Y.</span></span> <span> </span><span class="NLM_article-title">Survivin-Targeting Anti-Tumor Agents and Uses and Screening Methods Thereof</span>. <span class="NLM_patent">WO2016187046A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.-T.+Zhang&author=J.-Y.+Liu&title=Survivin-Targeting+Anti-Tumor+Agents+and+Uses+and+Screening+Methods+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.-T.%26atitle%3DSurvivin-Targeting%2520Anti-Tumor%2520Agents%2520and%2520Uses%2520and%2520Screening%2520Methods%2520Thereof%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aljahdali, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, X.</span></span> <span> </span><span class="NLM_article-title">Cancer therapeutics using survivin BIRC5 as a target: What can we do after over two decades of study?</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">368</span>, <span class="refDoi">Â DOI: 10.1186/s13046-019-1362-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1186%2Fs13046-019-1362-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=31439015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BB3MrgsF2hsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=368&author=F.+Liauthor=I.+Aljahdaliauthor=X.+Ling&title=Cancer+therapeutics+using+survivin+BIRC5+as+a+target%3A+What+can+we+do+after+over+two+decades+of+study%3F&doi=10.1186%2Fs13046-019-1362-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?</span></div><div class="casAuthors">Li Fengzhi; Aljahdali Ieman; Ling Xiang; Li Fengzhi; Aljahdali Ieman; Ling Xiang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of experimental & clinical cancer research : CR</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">368</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Survivin (also named BIRC5) is a well-known cancer therapeutic target.  Since its discovery more than two decades ago, the use of survivin as a target for cancer therapeutics has remained a central goal of survivin studies in the cancer field.  Many studies have provided intriguing insight into survivin's functional role in cancers, thus providing promise for survivin as a cancer therapeutic target.  Despite this, moving survivin-targeting agents into and through the clinic remains a challenge.  In order to address this challenge, we may need to rethink current strategies in order to develop a new mindset for targeting survivin.  In this Review, we will first summarize the current survivin mechanistic studies, and then review the status of survivin cancer therapeutics, which is classified into five categories: (i) survivin-partner protein interaction inhibitors, (ii) survivin homodimerization inhibitors, (iii) survivin gene transcription inhibitors, (iv) survivin mRNA inhibitors and (v) survivin immunotherapy.  We will then provide our opinions on cancer therapeutics using survivin as a target, with the goal of stimulating discussion that might facilitate translational research for discovering improved strategies and/or more effective anticancer agents that target survivin for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRMtQEKH7hnxdts4TFFB11gfW6udTcc2eYMtP5k7EA7xrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrgsF2hsA%253D%253D&md5=98ff4475bb1640831f1c42b398b4519c</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1186%2Fs13046-019-1362-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-019-1362-1%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%26aulast%3DAljahdali%26aufirst%3DI.%26aulast%3DLing%26aufirst%3DX.%26atitle%3DCancer%2520therapeutics%2520using%2520survivin%2520BIRC5%2520as%2520a%2520target%253A%2520What%2520can%2520we%2520do%2520after%2520over%2520two%2520decades%2520of%2520study%253F%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D38%26spage%3D368%26doi%3D10.1186%2Fs13046-019-1362-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prochownik, E. V.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of the Myc oncoprotein</span>. <i>Biochim. Biophys. Acta, Gene Regul. Mech.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1849</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">525</span>â <span class="NLM_lpage">543</span>, <span class="refDoi">Â DOI: 10.1016/j.bbagrm.2014.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bbagrm.2014.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFGnsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1849&publication_year=2015&pages=525-543&issue=5&author=S.+Fletcherauthor=E.+V.+Prochownik&title=Small-molecule+inhibitors+of+the+Myc+oncoprotein&doi=10.1016%2Fj.bbagrm.2014.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors of the Myc oncoprotein</span></div><div class="casAuthors">Fletcher, Steven; Prochownik, Edward V.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Gene Regulatory Mechanisms</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1849</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">525-543</span>CODEN:
                <span class="NLM_cas:coden">BBAGC6</span>;
        ISSN:<span class="NLM_cas:issn">1874-9399</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The c-Myc (Myc) oncoprotein is among the most attractive of cancer targets given that it is de-regulated in the majority of tumors and that its inhibition profoundly affects their growth and/or survival.  However, its role as a seldom-mutated transcription factor, its lack of enzymic activity for which suitable pharmaceutical inhibitors could be crafted and its expression by normal cells have largely been responsible for its being viewed as "undruggable".  Work over the past several years, however, has begun to reverse this idea by allowing us to view Myc within the larger context of global gene regulatory control.  Thus, Myc and its obligate heterodimeric partner, Max, are integral to the coordinated recruitment and post-translational modification of components of the core transcriptional machinery.  Moreover, Myc over-expression re-programs numerous crit. cellular functions and alters the cell's susceptibility to their inhibition.  This new knowledge has therefore served as a framework upon which to develop new pharmaceutical approaches.  These include the continuing development of small mols. which act directly to inhibit the crit. Myc-Max interaction, those which act indirectly to prevent Myc-directed post-translational modifications necessary to initiate productive transcription and those which inhibit vital pathways upon which the Myc-transformed cell is particularly reliant.  This article is part of a Special Issue entitled: Myc proteins in cell biol. and pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpwveGWUG8ZLVg90H21EOLACvtfcHk0lhmNIZn9NlkkQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFGnsL0%253D&md5=5f6a99316dc48b9f55796e2f7514cef4</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagrm.2014.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagrm.2014.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DProchownik%26aufirst%3DE.%2BV.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520the%2520Myc%2520oncoprotein%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gene%2520Regul.%2520Mech.%26date%3D2015%26volume%3D1849%26issue%3D5%26spage%3D525%26epage%3D543%26doi%3D10.1016%2Fj.bbagrm.2014.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Metallo, S.</span>; <span class="NLM_string-name">Prochownik, E.</span>; <span class="NLM_string-name">Viacava Follis, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of Thiazolidinedione-Benzoxadiazole Conjugates as Inhibitors of c-Myc-Max Interaction for Treatment of Cancer</span>. <span class="NLM_patent">WO2010083404A2</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+Metallo&author=E.+Prochownik&author=A.+Viacava+Follis&title=Preparation+of+Thiazolidinedione-Benzoxadiazole+Conjugates+as+Inhibitors+of+c-Myc-Max+Interaction+for+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMetallo%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Thiazolidinedione-Benzoxadiazole%2520Conjugates%2520as%2520Inhibitors%2520of%2520c-Myc-Max%2520Interaction%2520for%2520Treatment%2520of%2520Cancer%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span> <span> </span><span class="NLM_article-title">Preparation of 10074-G5 Analogs That Are Potent c-Myc Inhibitors With Improved Cell Permeability</span>. <span class="NLM_patent">US20140296307A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=S.+Fletcher&title=Preparation+of+10074-G5+Analogs+That+Are+Potent+c-Myc+Inhibitors+With+Improved+Cell+Permeability"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFletcher%26aufirst%3DS.%26atitle%3DPreparation%2520of%252010074-G5%2520Analogs%2520That%2520Are%2520Potent%2520c-Myc%2520Inhibitors%2520With%2520Improved%2520Cell%2520Permeability%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yap, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharavi, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prochownik, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore identification of c-Myc inhibitor 10074-G5</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">370</span>â <span class="NLM_lpage">374</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2012.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmcl.2012.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=23177256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsleisLrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=370-374&issue=1&author=J.+L.+Yapauthor=H.+Wangauthor=A.+Huauthor=J.+Chauhanauthor=K.+Y.+Jungauthor=R.+B.+Gharaviauthor=E.+V.+Prochownikauthor=S.+Fletcher&title=Pharmacophore+identification+of+c-Myc+inhibitor+10074-G5&doi=10.1016%2Fj.bmcl.2012.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore identification of c-Myc inhibitor 10074-G5</span></div><div class="casAuthors">Yap, Jeremy L.; Wang, Huabo; Hu, Angela; Chauhan, Jay; Jung, Kwan-Young; Gharavi, Robert B.; Prochownik, Edward V.; Fletcher, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">370-374</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A structure-activity relationship (SAR) study of the c-Myc (Myc) inhibitor 10074-G5 (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to det. its pharmacophore.  While the 7-nitrobenzofurazan was found to be crit. for inhibitory activity, the ortho-biphenyl could be replaced with a para-carboxyphenyl group to furnish the new inhibitor JY-3-094 (3q, I).  Around five times as potent as the lead with an IC50 of 33 Î¼M for disruption of the Myc-Max heterodimer, JY-3-094 demonstrated excellent selectivity over Max-Max homodimers, with no apparent effect at 100 Î¼M.  Importantly, the carboxylic acid of JY-3-094 improves the physicochem. properties of the lead compd., which will facilitate the incorporation of addnl. hydrophobicity that might enhance Myc inhibitory activity further still.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZT899nMTVtLVg90H21EOLACvtfcHk0liPOkLnzKR9tQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsleisLrL&md5=1c812da2c5989dc7d6906d50b10446df</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DJ.%2BL.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DA.%26aulast%3DChauhan%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DK.%2BY.%26aulast%3DGharavi%26aufirst%3DR.%2BB.%26aulast%3DProchownik%26aufirst%3DE.%2BV.%26aulast%3DFletcher%26aufirst%3DS.%26atitle%3DPharmacophore%2520identification%2520of%2520c-Myc%2520inhibitor%252010074-G5%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D1%26spage%3D370%26epage%3D374%26doi%3D10.1016%2Fj.bmcl.2012.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parise, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beumer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egorin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazo, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prochownik, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiseman, J. L.</span></span> <span> </span><span class="NLM_article-title">In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>335</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">715</span>â <span class="NLM_lpage">727</span>, <span class="refDoi">Â DOI: 10.1124/jpet.110.170555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1124%2Fjpet.110.170555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=20801893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2010&pages=715-727&issue=3&author=D.+M.+Clausenauthor=J.+Guoauthor=R.+A.+Pariseauthor=J.+H.+Beumerauthor=M.+J.+Egorinauthor=J.+S.+Lazoauthor=E.+V.+Prochownikauthor=J.+L.+Eiseman&title=In+vitro+cytotoxicity+and+in+vivo+efficacy%2C+pharmacokinetics%2C+and+metabolism+of+10074-G5%2C+a+novel+small-molecule+inhibitor+of+c-Myc%2FMax+dimerization&doi=10.1124%2Fjpet.110.170555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization</span></div><div class="casAuthors">Clausen, Dana M.; Guo, Jianxia; Parise, Robert A.; Beumer, Jan H.; Egorin, Merrill J.; Lazo, John S.; Prochownik, Edward V.; Eiseman, Julie L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">715-727</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The c-Myc oncoprotein is overexpressed in many tumors and is essential for maintaining the proliferation of transformed cells.  To function as a transcription factor, c-Myc must dimerize with Max via the basic helix-loop-helix leucine zipper protein (bHLHZIP) domains in each protein.  The small mol. 7-nitro-N-(2-phenylphenyl)-2,1,3-benzoxadiazol-4-amine (10074-G5) binds to and distorts the bHLH-ZIP domain of c-Myc, thereby inhibiting c-Myc/Max heterodimer formation and inhibiting its transcriptional activity.  We report in vitro cytotoxicity and in vivo efficacy, pharmacodynamics, pharmacokinetics, and metab. of 10074-G5 in human xenograft-bearing mice.  In vitro, 10074-G5 inhibited the growth of Daudi Burkitt's lymphoma cells and disrupted c-Myc/Max dimerization.  10074-G5 had no effect on the growth of Daudi xenografts in C.B-17 SCID mice that were treated with 20 mg/kg 10074-G5 i.v. for 5 consecutive days.  Inhibition of c-Myc/Max dimerization in Daudi xenografts was not seen 2 or 24 h after treatment.  Concns. of 10074-G5 in various matrixes were detd. by high-performance liq. chromatog.-UV, and metabolites of 10074-G5 were identified by liq. chromatog./tandem mass spectrometry.  The plasma half-life of 10074-G5 in mice treated with 20 mg/kg i.v. was 37 min, and peak plasma concn. was 58 Î¼M, which was 10-fold higher than peak tumor concn.  The lack of antitumor activity probably was caused by the rapid metab. of 10074-G5 to inactive metabolites, resulting in tumor concns. of 10074-G5 insufficient to inhibit c-Myc/Max dimerization.  Our identification of 10074-G5 metabolites in mice will help design new, more metabolically stable small-mol. inhibitors of c-Myc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6sWVYIO38MrVg90H21EOLACvtfcHk0liPOkLnzKR9tQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrbJ&md5=148af632cc604b34f895573cdfbbd036</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.170555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.170555%26sid%3Dliteratum%253Aachs%26aulast%3DClausen%26aufirst%3DD.%2BM.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DParise%26aufirst%3DR.%2BA.%26aulast%3DBeumer%26aufirst%3DJ.%2BH.%26aulast%3DEgorin%26aufirst%3DM.%2BJ.%26aulast%3DLazo%26aufirst%3DJ.%2BS.%26aulast%3DProchownik%26aufirst%3DE.%2BV.%26aulast%3DEiseman%26aufirst%3DJ.%2BL.%26atitle%3DIn%2520vitro%2520cytotoxicity%2520and%2520in%2520vivo%2520efficacy%252C%2520pharmacokinetics%252C%2520and%2520metabolism%2520of%252010074-G5%252C%2520a%2520novel%2520small-molecule%2520inhibitor%2520of%2520c-Myc%252FMax%2520dimerization%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D335%26issue%3D3%26spage%3D715%26epage%3D727%26doi%3D10.1124%2Fjpet.110.170555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendleton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabato, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cione, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prochownik, E. V.</span></span> <span> </span><span class="NLM_article-title">Disruption of Myc-Max heterodimerization with improved cell-penetrating analogs of the small molecule 10074-G5</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">936</span>â <span class="NLM_lpage">947</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.1108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.18632%2Foncotarget.1108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=23801058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BC3sjlsV2ksA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=936-947&issue=6&author=H.+Wangauthor=J.+Chauhanauthor=A.+Huauthor=K.+Pendletonauthor=J.+L.+Yapauthor=P.+E.+Sabatoauthor=J.+W.+Jonesauthor=M.+Perriauthor=J.+Yuauthor=E.+Cioneauthor=M.+A.+Kaneauthor=S.+Fletcherauthor=E.+V.+Prochownik&title=Disruption+of+Myc-Max+heterodimerization+with+improved+cell-penetrating+analogs+of+the+small+molecule+10074-G5&doi=10.18632%2Foncotarget.1108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of Myc-Max heterodimerization with improved cell-penetrating analogs of the small molecule 10074-G5</span></div><div class="casAuthors">Wang Huabo; Chauhan Jay; Hu Angela; Pendleton Kelsey; Yap Jeremy L; Sabato Philip E; Jones Jace W; Perri Mariarita; Yu Jianshi; Cione Erika; Kane Maureen A; Fletcher Steven; Prochownik Edward V</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">936-47</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The c-Myc (Myc) oncoprotein is a high-value therapeutic target given that it is deregulated in multiple types of cancer.  However, potent small molecule inhibitors of Myc have been difficult to identify, particularly those whose mechanism relies on blocking the association between Myc and its obligate heterodimerization partner, Max.  We have recently reported a structure-activity relationship study of one such small molecule, 10074-G5, and generated an analog, JY-3-094, with significantly improved ability to prevent or disrupt the association between recombinant Myc and Max proteins.  However, JY-3094 penetrates cells poorly.  Here, we show that esterification of a critical para-carboxylic acid function of JY-3-094 by various blocking groups significantly improves cellular uptake although it impairs the ability to disrupt Myc-Max association in vitro.  These pro-drugs are highly concentrated within cells where JY-3-094 is then generated by the action of esterases.  However, the pro-drugs are also variably susceptible to extracellular esterases, which can deplete extracellular reservoirs.  Furthermore, while JY-3-094 is retained by cells for long periods of time, much of it is compartmentalized within the cytoplasm in a form that appears to be less available to interact with Myc.  Our results suggest that persistently high extracellular levels of pro-drug, without excessive susceptibility to extracellular esterases, are critical to establishing and maintaining intracellular levels of JY-3-094 that are sufficient to provide for long-term inhibition of Myc-Max association.  Analogs of JY-3-094 appear to represent promising small molecule Myc inhibitors that warrant further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTUpo3PsQLURaqcneEtCi92fW6udTcc2eZc9sY-6ypmJrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjlsV2ksA%253D%253D&md5=044730ff03610d8981f13a77f0edb10a</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.1108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.1108%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DChauhan%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DA.%26aulast%3DPendleton%26aufirst%3DK.%26aulast%3DYap%26aufirst%3DJ.%2BL.%26aulast%3DSabato%26aufirst%3DP.%2BE.%26aulast%3DJones%26aufirst%3DJ.%2BW.%26aulast%3DPerri%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DCione%26aufirst%3DE.%26aulast%3DKane%26aufirst%3DM.%2BA.%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DProchownik%26aufirst%3DE.%2BV.%26atitle%3DDisruption%2520of%2520Myc-Max%2520heterodimerization%2520with%2520improved%2520cell-penetrating%2520analogs%2520of%2520the%2520small%2520molecule%252010074-G5%26jtitle%3DOncotarget%26date%3D2013%26volume%3D4%26issue%3D6%26spage%3D936%26epage%3D947%26doi%3D10.18632%2Foncotarget.1108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabato, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prochownik, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of methyl 4â²-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1â²-biphenyl]-3-carboxylate, an improved small-molecule inhibitor of c-Myc-max dimerization</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2274</span>â <span class="NLM_lpage">2285</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201402189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fcmdc.201402189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=24976143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVGjsLnP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=2274-2285&issue=10&author=J.+Chauhanauthor=H.+Wangauthor=J.+L.+Yapauthor=P.+E.+Sabatoauthor=A.+Huauthor=E.+V.+Prochownikauthor=S.+Fletcher&title=Discovery+of+methyl+4%E2%80%B2-methyl-5-%287-nitrobenzo%5Bc%5D%5B1%2C2%2C5%5Doxadiazol-4-yl%29-%5B1%2C1%E2%80%B2-biphenyl%5D-3-carboxylate%2C+an+improved+small-molecule+inhibitor+of+c-Myc-max+dimerization&doi=10.1002%2Fcmdc.201402189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Methyl 4'-Methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1'-biphenyl]-3-carboxylate, an Improved Small-Molecule Inhibitor of c-Myc-Max Dimerization</span></div><div class="casAuthors">Chauhan, Jay; Wang, Huabo; Yap, Jeremy L.; Sabato, Philip E.; Hu, Angela; Prochownik, Edward V.; Fletcher, Steven</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2274-2285</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">C-Myc is a basic helix-loop-helix-leucine zipper (bHLH-ZIP) transcription factor that is responsible for the transcription of a wide range of target genes involved in many cancer-related cellular processes.  Over-expression of c-Myc has been obsd. in, and directly contributes to, a variety of human cancers including those of the hematopoietic system, lung, prostate and colon.  To become transcriptionally active, c-Myc must first dimerize with Myc-assocd. factor X (Max) via its own bHLH-ZIP domain.  A proven strategy towards the inhibition of c-Myc oncogenic activity is to interfere with the structural integrity of the c-Myc-Max heterodimer.  The small mol. 10074-G5 is an inhibitor of c-Myc-Max dimerization (IC50=146 Î¼M) that operates by binding and stabilizing c-Myc in its monomeric form.  The authors have identified a congener of 10074-G5, compd. I that is about five times as potent (IC50=34 Î¼M) at inhibiting c-Myc-Max dimerization as the parent compd.  I exhibited an approx. twofold selectivity for c-Myc-Max heterodimers over Max-Max homodimers, suggesting that its mode of action is through binding c-Myc.  I inhibited the proliferation of c-Myc-over-expressing HL60 and Daudi cells with single-digit micromolar IC50 values by causing growth arrest at the G0/G1 phase.  Coimmunopptn. studies indicated that I inhibits c-Myc-Max dimerization in cells, which was further substantiated by the specific silencing of a c-Myc-driven luciferase reporter gene.  Finally, I's intracellular half-life was >17 h.  Collectively, these data demonstrate I to be one of the most potent, cellularly active and stable c-Myc inhibitors reported to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNAXo4mr-8crVg90H21EOLACvtfcHk0lihJBa1BaeMPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVGjsLnP&md5=48a68fdb45bdd898704aca4a2697c7da</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402189%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYap%26aufirst%3DJ.%2BL.%26aulast%3DSabato%26aufirst%3DP.%2BE.%26aulast%3DHu%26aufirst%3DA.%26aulast%3DProchownik%26aufirst%3DE.%2BV.%26aulast%3DFletcher%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520methyl%25204%25E2%2580%25B2-methyl-5-%25287-nitrobenzo%255Bc%255D%255B1%252C2%252C5%255Doxadiazol-4-yl%2529-%255B1%252C1%25E2%2580%25B2-biphenyl%255D-3-carboxylate%252C%2520an%2520improved%2520small-molecule%2520inhibitor%2520of%2520c-Myc-max%2520dimerization%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26issue%3D10%26spage%3D2274%26epage%3D2285%26doi%3D10.1002%2Fcmdc.201402189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruick, R. K.</span>; <span class="NLM_string-name">Caldwell, C. G.</span>; <span class="NLM_string-name">Frantz, D. E.</span>; <span class="NLM_string-name">Gardner, K. H.</span>; <span class="NLM_string-name">MacMillan, J. B.</span>; <span class="NLM_string-name">Scheuermann, T. H.</span>; <span class="NLM_string-name">Tambar, U. K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of HIF-2Î± Heterodimerization With HIF1Î² (ARNT)</span>. <span class="NLM_patent">WO2014078479A2</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=R.+K.+Bruick&author=C.+G.+Caldwell&author=D.+E.+Frantz&author=K.+H.+Gardner&author=J.+B.+MacMillan&author=T.+H.+Scheuermann&author=U.+K.+Tambar&title=Inhibition+of+HIF-2%CE%B1+Heterodimerization+With+HIF1%CE%B2+%28ARNT%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBruick%26aufirst%3DR.%2BK.%26atitle%3DInhibition%2520of%2520HIF-2%25CE%25B1%2520Heterodimerization%2520With%2520HIF1%25CE%25B2%2520%2528ARNT%2529%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayeh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheuermann, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longgood, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Key, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naidoo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melito, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frantz, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruick, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacMillan, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tambar, U. K.</span></span> <span> </span><span class="NLM_article-title">Development of inhibitors of the PAS-B domain of the HIF-2alpha transcription factor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1739</span>â <span class="NLM_lpage">1747</span>, <span class="refDoi">Â DOI: 10.1021/jm301847z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301847z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVCjsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1739-1747&issue=4&author=J.+L.+Rogersauthor=L.+Bayehauthor=T.+H.+Scheuermannauthor=J.+Longgoodauthor=J.+Keyauthor=J.+Naidooauthor=L.+Melitoauthor=C.+Shokriauthor=D.+E.+Frantzauthor=R.+K.+Bruickauthor=K.+H.+Gardnerauthor=J.+B.+MacMillanauthor=U.+K.+Tambar&title=Development+of+inhibitors+of+the+PAS-B+domain+of+the+HIF-2alpha+transcription+factor&doi=10.1021%2Fjm301847z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Inhibitors of the PAS-B Domain of the HIF-2Î± Transcription Factor</span></div><div class="casAuthors">Rogers, Jamie L.; Bayeh, Liela; Scheuermann, Thomas H.; Longgood, Jamie; Key, Jason; Naidoo, Jacinth; Melito, Lisa; Shokri, Cameron; Frantz, Doug E.; Bruick, Richard K.; Gardner, Kevin H.; MacMillan, John B.; Tambar, Uttam K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1739-1747</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hypoxia inducible factors (HIFs) are heterodimeric transcription factors induced in a variety of pathophysiol. settings, including cancer.  The first detailed structure-activity relationship study of small mols. designed to inhibit HIF-2Î±-ARNT heterodimerization by binding an internal cavity of the HIF-2Î± PAS-B domain is described herein.  A series of benzoxadiazole derivs. was synthesized and evaluated for their inhibitory activity.  Through a series of biophys. characterizations of inhibitor-protein interactions [NMR and X-ray crystallog. for compds. I (R = H or Cl)], the structural requirements for artificial inhibitors of the HIF-2Î±-ARNT PAS-B interaction have been established.  These results may serve as a foundation for discovering therapeutic agents that function by a novel mode of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUwOF6FlDBrLVg90H21EOLACvtfcHk0lihJBa1BaeMPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVCjsrs%253D&md5=03a967dcc64865633544f0973c806edc</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1021%2Fjm301847z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301847z%26sid%3Dliteratum%253Aachs%26aulast%3DRogers%26aufirst%3DJ.%2BL.%26aulast%3DBayeh%26aufirst%3DL.%26aulast%3DScheuermann%26aufirst%3DT.%2BH.%26aulast%3DLonggood%26aufirst%3DJ.%26aulast%3DKey%26aufirst%3DJ.%26aulast%3DNaidoo%26aufirst%3DJ.%26aulast%3DMelito%26aufirst%3DL.%26aulast%3DShokri%26aufirst%3DC.%26aulast%3DFrantz%26aufirst%3DD.%2BE.%26aulast%3DBruick%26aufirst%3DR.%2BK.%26aulast%3DGardner%26aufirst%3DK.%2BH.%26aulast%3DMacMillan%26aufirst%3DJ.%2BB.%26aulast%3DTambar%26aufirst%3DU.%2BK.%26atitle%3DDevelopment%2520of%2520inhibitors%2520of%2520the%2520PAS-B%2520domain%2520of%2520the%2520HIF-2alpha%2520transcription%2520factor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D4%26spage%3D1739%26epage%3D1747%26doi%3D10.1021%2Fjm301847z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheuermann, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Key, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naidoo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longgood, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frantz, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tambar, U. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruick, R. K.</span></span> <span> </span><span class="NLM_article-title">Allosteric inhibition of hypoxia inducible factor-2 with small molecules</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">271</span>â <span class="NLM_lpage">276</span>, <span class="refDoi">Â DOI: 10.1038/nchembio.1185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2Fnchembio.1185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=23434853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivFygtLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=271-276&issue=4&author=T.+H.+Scheuermannauthor=Q.+Liauthor=H.+W.+Maauthor=J.+Keyauthor=L.+Zhangauthor=R.+Chenauthor=J.+A.+Garciaauthor=J.+Naidooauthor=J.+Longgoodauthor=D.+E.+Frantzauthor=U.+K.+Tambarauthor=K.+H.+Gardnerauthor=R.+K.+Bruick&title=Allosteric+inhibition+of+hypoxia+inducible+factor-2+with+small+molecules&doi=10.1038%2Fnchembio.1185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibition of hypoxia inducible factor-2 with small molecules</span></div><div class="casAuthors">Scheuermann, Thomas H.; Li, Qiming; Ma, He-Wen; Key, Jason; Zhang, Lei; Chen, Rui; Garcia, Joseph A.; Naidoo, Jacinth; Longgood, Jamie; Frantz, Doug E.; Tambar, Uttam K.; Gardner, Kevin H.; Bruick, Richard K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">271-276</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hypoxia inducible factors (HIFs) are heterodimeric transcription factors induced in many cancers where they frequently promote the expression of protumorigenic pathways.  Though transcription factors are typically considered 'undruggable', the PAS-B domain of the HIF-2Î± subunit contains a large cavity within its hydrophobic core that offers a unique foothold for small-mol. regulation.  Here we identify artificial ligands that bind within this pocket and characterize the resulting structural and functional changes caused by binding.  Notably, these ligands antagonize HIF-2 heterodimerization and DNA-binding activity in vitro and in cultured cells, reducing HIF-2 target gene expression.  Despite the high sequence identity between HIF-2Î± and HIF-1Î±, these ligands are highly selective and do not affect HIF-1 function.  These chem. tools establish the mol. basis for selective regulation of HIF-2, providing potential therapeutic opportunities to intervene in HIF-2-driven tumors, such as renal cell carcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBimby6zSuR7Vg90H21EOLACvtfcHk0lihJBa1BaeMPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivFygtLc%253D&md5=e2e58842b3fe6472248c10012de365fb</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1185%26sid%3Dliteratum%253Aachs%26aulast%3DScheuermann%26aufirst%3DT.%2BH.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DH.%2BW.%26aulast%3DKey%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DGarcia%26aufirst%3DJ.%2BA.%26aulast%3DNaidoo%26aufirst%3DJ.%26aulast%3DLonggood%26aufirst%3DJ.%26aulast%3DFrantz%26aufirst%3DD.%2BE.%26aulast%3DTambar%26aufirst%3DU.%2BK.%26aulast%3DGardner%26aufirst%3DK.%2BH.%26aulast%3DBruick%26aufirst%3DR.%2BK.%26atitle%3DAllosteric%2520inhibition%2520of%2520hypoxia%2520inducible%2520factor-2%2520with%2520small%2520molecules%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26issue%3D4%26spage%3D271%26epage%3D276%26doi%3D10.1038%2Fnchembio.1185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wehn, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grina, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlachter, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czerwinski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goggin, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halfmann, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddie, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olive, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, E. M.</span></span> <span> </span><span class="NLM_article-title">Design and activity of specific hypoxia-inducible factor-2Î± (HIF-2Î±) inhibitors for the treatment of clear cell renal cell carcinoma: Discovery of clinical candidate (S)-3-((2,2-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1<i>H</i>-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">9691</span>â <span class="NLM_lpage">9721</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b01196</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01196" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKqt7%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9691-9721&issue=21&author=P.+M.+Wehnauthor=J.+P.+Rizziauthor=D.+D.+Dixonauthor=J.+A.+Grinaauthor=S.+T.+Schlachterauthor=B.+Wangauthor=R.+Xuauthor=H.+Yangauthor=X.+Duauthor=G.+Hanauthor=K.+Wangauthor=Z.+Caoauthor=T.+Chengauthor=R.+M.+Czerwinskiauthor=B.+S.+Gogginauthor=H.+Huangauthor=M.+M.+Halfmannauthor=M.+A.+Maddieauthor=E.+L.+Mortonauthor=S.+R.+Oliveauthor=H.+Tanauthor=S.+Xieauthor=T.+Wongauthor=J.+A.+Joseyauthor=E.+M.+Wallace&title=Design+and+activity+of+specific+hypoxia-inducible+factor-2%CE%B1+%28HIF-2%CE%B1%29+inhibitors+for+the+treatment+of+clear+cell+renal+cell+carcinoma%3A+Discovery+of+clinical+candidate+%28S%29-3-%28%282%2C2-difluoro-1-hydroxy-7-%28methylsulfonyl%29-2%2C3-dihydro-1H-inden-4-yl%29oxy%29-5-fluorobenzonitrile+%28PT2385%29&doi=10.1021%2Facs.jmedchem.8b01196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Activity of Specific Hypoxia-Inducible Factor-2Î± (HIF-2Î±) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385)</span></div><div class="casAuthors">Wehn, Paul M.; Rizzi, James P.; Dixon, Darryl D.; Grina, Jonas A.; Schlachter, Stephen T.; Wang, Bin; Xu, Rui; Yang, Hanbiao; Du, Xinlin; Han, Guangzhou; Wang, Keshi; Cao, Zhaodan; Cheng, Tzuling; Czerwinski, Robert M.; Goggin, Barry S.; Huang, Heli; Halfmann, Megan M.; Maddie, Melissa A.; Morton, Emily L.; Olive, Sarah R.; Tan, Huiling; Xie, Shanhai; Wong, Tai; Josey, John A.; Wallace, Eli M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9691-9721</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HIF-2Î±, a member of the HIF family of transcription factors, is a key oncogenic driver in cancers such as clear cell renal cell carcinoma (ccRCC).  A signature feature of these cancers is the overaccumulation of HIF-2Î± protein, often by inactivation of the E3 ligase VHL (von Hippel-Lindau).  Herein the authors disclose their structure based drug design (SBDD) approach that culminated in the identification of PT2385, the first HIF-2Î± antagonist to enter clin. trials.  Highlights include the use of a putative n â Ï*Ar interaction to guide early analog design, the conformational restriction of an essential hydroxyl moiety, and the remarkable impact of fluorination near the hydroxyl group.  Evaluation of select compds. from two structural classes in a sequence of PK/PD, efficacy, PK, and metabolite profiling identified I (PT2385, luciferase EC50 = 27 nM) as the clin. candidate.  Finally, a retrospective crystallog. anal. describes the structural perturbations necessary for efficient antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwG1t-5Van7rVg90H21EOLACvtfcHk0liyP9WsuX_i7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKqt7%252FN&md5=fcbb754286f47e1b1df3edb62bd2381e</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01196%26sid%3Dliteratum%253Aachs%26aulast%3DWehn%26aufirst%3DP.%2BM.%26aulast%3DRizzi%26aufirst%3DJ.%2BP.%26aulast%3DDixon%26aufirst%3DD.%2BD.%26aulast%3DGrina%26aufirst%3DJ.%2BA.%26aulast%3DSchlachter%26aufirst%3DS.%2BT.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DHan%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DT.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DGoggin%26aufirst%3DB.%2BS.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DHalfmann%26aufirst%3DM.%2BM.%26aulast%3DMaddie%26aufirst%3DM.%2BA.%26aulast%3DMorton%26aufirst%3DE.%2BL.%26aulast%3DOlive%26aufirst%3DS.%2BR.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DT.%26aulast%3DJosey%26aufirst%3DJ.%2BA.%26aulast%3DWallace%26aufirst%3DE.%2BM.%26atitle%3DDesign%2520and%2520activity%2520of%2520specific%2520hypoxia-inducible%2520factor-2%25CE%25B1%2520%2528HIF-2%25CE%25B1%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520clear%2520cell%2520renal%2520cell%2520carcinoma%253A%2520Discovery%2520of%2520clinical%2520candidate%2520%2528S%2529-3-%2528%25282%252C2-difluoro-1-hydroxy-7-%2528methylsulfonyl%2529-2%252C3-dihydro-1H-inden-4-yl%2529oxy%2529-5-fluorobenzonitrile%2520%2528PT2385%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D21%26spage%3D9691%26epage%3D9721%26doi%3D10.1021%2Facs.jmedchem.8b01196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grina, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlachter, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehn, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czerwinski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ged, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, E. M.</span></span> <span> </span><span class="NLM_article-title">3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzo nitrile (PT2977), a hypoxia-inducible factor 2alpha (HIF-2alpha) inhibitor for the treatment of clear cell renal cell carcinoma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6876</span>â <span class="NLM_lpage">6893</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b00719</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00719" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1ensL%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6876-6893&issue=15&author=R.+Xuauthor=K.+Wangauthor=J.+P.+Rizziauthor=H.+Huangauthor=J.+A.+Grinaauthor=S.+T.+Schlachterauthor=B.+Wangauthor=P.+M.+Wehnauthor=H.+Yangauthor=D.+D.+Dixonauthor=R.+M.+Czerwinskiauthor=X.+Duauthor=E.+L.+Gedauthor=G.+Hanauthor=H.+Tanauthor=T.+Wongauthor=S.+Xieauthor=J.+A.+Joseyauthor=E.+M.+Wallace&title=3-%5B%281S%2C2S%2C3R%29-2%2C3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl%5Doxy-5-fluorobenzo+nitrile+%28PT2977%29%2C+a+hypoxia-inducible+factor+2alpha+%28HIF-2alpha%29+inhibitor+for+the+treatment+of+clear+cell+renal+cell+carcinoma&doi=10.1021%2Facs.jmedchem.9b00719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2Î± (HIF-2Î±) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma</span></div><div class="casAuthors">Xu, Rui; Wang, Keshi; Rizzi, James P.; Huang, Heli; Grina, Jonas A.; Schlachter, Stephen T.; Wang, Bin; Wehn, Paul M.; Yang, Hanbiao; Dixon, Darryl D.; Czerwinski, Robert M.; Du, Xinlin; Ged, Emily L.; Han, Guangzhou; Tan, Huiling; Wong, Tai; Xie, Shanhai; Josey, John A.; Wallace, Eli M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6876-6893</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The hypoxia-inducible factor 2Î± (HIF-2Î±) is a key oncogenic driver in clear cell renal cell carcinoma (ccRCC).  Our first HIF-2Î± inhibitor PT2385 demonstrated promising proof of concept clin. activity in heavily pretreated advanced ccRCC patients.  However, PT2385 was restricted by variable and dose-limited pharmacokinetics resulting from extensive metab. of PT2385 to its glucuronide metabolite.  Herein we describe the discovery of second-generation HIF-2Î± inhibitor PT2977 with increased potency and improved pharmacokinetic profile achieved by redn. of phase 2 metab.  Structural modification by changing the geminal difluoro group in PT2385 to a vicinal difluoro group resulted in enhanced potency, decreased lipophilicity, and significantly improved pharmacokinetic properties.  In a phase 1 dose-escalation study, the clin. pharmacokinetics for PT2977 supports the hypothesis that attenuating the rate of glucuronidation would improve exposure and reduce variability in patients.  Early evidence of clin. activity shows promise for PT2977 in the treatment of ccRCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOUK3HAjMQC7Vg90H21EOLACvtfcHk0liyP9WsuX_i7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1ensL%252FN&md5=ec1f0a964e0fda36f92261c30edf284e</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00719%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DRizzi%26aufirst%3DJ.%2BP.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DGrina%26aufirst%3DJ.%2BA.%26aulast%3DSchlachter%26aufirst%3DS.%2BT.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWehn%26aufirst%3DP.%2BM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DDixon%26aufirst%3DD.%2BD.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DGed%26aufirst%3DE.%2BL.%26aulast%3DHan%26aufirst%3DG.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DS.%26aulast%3DJosey%26aufirst%3DJ.%2BA.%26aulast%3DWallace%26aufirst%3DE.%2BM.%26atitle%3D3-%255B%25281S%252C2S%252C3R%2529-2%252C3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl%255Doxy-5-fluorobenzo%2520nitrile%2520%2528PT2977%2529%252C%2520a%2520hypoxia-inducible%2520factor%25202alpha%2520%2528HIF-2alpha%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520clear%2520cell%2520renal%2520cell%2520carcinoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D15%26spage%3D6876%26epage%3D6893%26doi%3D10.1021%2Facs.jmedchem.9b00719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malachowski, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuHadaway, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of IDO1 inhibitors: From bench to bedside</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">6795</span>â <span class="NLM_lpage">6811</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-17-2285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1158%2F0008-5472.CAN-17-2285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=29247038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOgur3P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=6795-6811&issue=24&author=G.+C.+Prendergastauthor=W.+P.+Malachowskiauthor=J.+B.+DuHadawayauthor=A.+J.+Muller&title=Discovery+of+IDO1+inhibitors%3A+From+bench+to+bedside&doi=10.1158%2F0008-5472.CAN-17-2285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of IDO1 Inhibitors: From Bench to Bedside</span></div><div class="casAuthors">Prendergast, George C.; Malachowski, William P.; Du Hadaway, James B.; Muller, Alexander J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6795-6811</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Small-mol. inhibitors of indoleamine 2,3-dioxygenase-1 (IDO1) are emerging at the vanguard of exptl. agents in oncol.  Here, pioneers of this new drug class provide a bench-to-bedside review on preclin. validation of IDO1 as a cancer therapeutic target and on the discovery and development of a set of mechanistically distinct compds., indoximod, epacadostat, and navoximod, that were first to be evaluated as IDO inhibitors in clin. trials.  As immunometabolic adjuvants to widen therapeutic windows, IDO inhibitors may leverage not only immuno-oncol. modalities but also chemotherapy and radiotherapy as stds. of care in the oncol. clinic.  Cancer Res; 77(24); 6795-811. Â©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogb24W39wzLLVg90H21EOLACvtfcHk0lhG4_Xj1mKW3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOgur3P&md5=78c80872b9a4dd4db6621645196291d9</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-2285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-2285%26sid%3Dliteratum%253Aachs%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26aulast%3DMalachowski%26aufirst%3DW.%2BP.%26aulast%3DDuHadaway%26aufirst%3DJ.%2BB.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26atitle%3DDiscovery%2520of%2520IDO1%2520inhibitors%253A%2520From%2520bench%2520to%2520bedside%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D24%26spage%3D6795%26epage%3D6811%26doi%3D10.1158%2F0008-5472.CAN-17-2285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayland, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bower, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leffet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansbury, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">7364</span>â <span class="NLM_lpage">7367</span>, <span class="refDoi">Â DOI: 10.1021/jm900518f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900518f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVSksb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7364-7367&issue=23&author=E.+W.+Yueauthor=B.+Doutyauthor=B.+Waylandauthor=M.+Bowerauthor=X.+Liuauthor=L.+Leffetauthor=Q.+Wangauthor=K.+J.+Bowmanauthor=M.+J.+Hansburyauthor=C.+Liuauthor=M.+Weiauthor=Y.+Liauthor=R.+Wynnauthor=T.+C.+Burnauthor=H.+K.+Koblishauthor=J.+S.+Fridmanauthor=B.+Metcalfauthor=P.+A.+Scherleauthor=A.+P.+Combs&title=Discovery+of+potent+competitive+inhibitors+of+indoleamine+2%2C3-dioxygenase+with+in+vivo+pharmacodynamic+activity+and+efficacy+in+a+mouse+melanoma+model&doi=10.1021%2Fjm900518f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model</span></div><div class="casAuthors">Yue, Eddy W.; Douty, Brent; Wayland, Brian; Bower, Michael; Liu, Xiangdong; Leffet, Lynn; Wang, Qian; Bowman, Kevin J.; Hansbury, Michael J.; Liu, Changnian; Wei, Min; Li, Yanlong; Wynn, Richard; Burn, Timothy C.; Koblish, Holly K.; Fridman, Jordan S.; Metcalf, Brian; Scherle, Peggy A.; Combs, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7364-7367</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A hydroxyamidine chemotype has been discovered as a key pharmacophore in novel inhibitors of indoleamine 2,3-dioxygenase (IDO).  Optimization led to the identification of (I), which is a potent (HeLa IC50 = 19 nM) competitive inhibitor of IDO.  Testing of I in mice demonstrated pharmacodynamic inhibition of IDO, as measured by decreased kynurenine levels (>50%) in plasma and dose dependent efficacy in mice bearing GM-CSF-secreting B16 melanoma tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZsq88hx0J77Vg90H21EOLACvtfcHk0lhG4_Xj1mKW3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVSksb8%253D&md5=328d92bffb88a86da030c31eff707dc6</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1021%2Fjm900518f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900518f%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DE.%2BW.%26aulast%3DDouty%26aufirst%3DB.%26aulast%3DWayland%26aufirst%3DB.%26aulast%3DBower%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLeffet%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DBowman%26aufirst%3DK.%2BJ.%26aulast%3DHansbury%26aufirst%3DM.%2BJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWynn%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DKoblish%26aufirst%3DH.%2BK.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DDiscovery%2520of%2520potent%2520competitive%2520inhibitors%2520of%2520indoleamine%25202%252C3-dioxygenase%2520with%2520in%2520vivo%2520pharmacodynamic%2520activity%2520and%2520efficacy%2520in%2520a%2520mouse%2520melanoma%2520model%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D23%26spage%3D7364%26epage%3D7367%26doi%3D10.1021%2Fjm900518f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayland, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takvorian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glenn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bower, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leffet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansbury, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span></span> <span> </span><span class="NLM_article-title">INCB24360 (epacadostat), a highly potent and selective indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor for immuno-oncology</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">486</span>â <span class="NLM_lpage">491</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.6b00391</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00391" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Gqsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=486-491&issue=5&author=E.+W.+Yueauthor=R.+Sparksauthor=P.+Polamauthor=D.+Modiauthor=B.+Doutyauthor=B.+Waylandauthor=B.+Glassauthor=A.+Takvorianauthor=J.+Glennauthor=W.+Zhuauthor=M.+Bowerauthor=X.+Liuauthor=L.+Leffetauthor=Q.+Wangauthor=K.+J.+Bowmanauthor=M.+J.+Hansburyauthor=M.+Weiauthor=Y.+Liauthor=R.+Wynnauthor=T.+C.+Burnauthor=H.+K.+Koblishauthor=J.+S.+Fridmanauthor=T.+Emmauthor=P.+A.+Scherleauthor=B.+Metcalfauthor=A.+P.+Combs&title=INCB24360+%28epacadostat%29%2C+a+highly+potent+and+selective+indoleamine-2%2C3-dioxygenase+1+%28IDO1%29+inhibitor+for+immuno-oncology&doi=10.1021%2Facsmedchemlett.6b00391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology</span></div><div class="casAuthors">Yue, Eddy W.; Sparks, Richard; Polam, Padmaja; Modi, Dilip; Douty, Brent; Wayland, Brian; Glass, Brian; Takvorian, Amy; Glenn, Joseph; Zhu, Wenyu; Bower, Michael; Liu, Xiangdong; Leffet, Lynn; Wang, Qian; Bowman, Kevin J.; Hansbury, Michael J.; Wei, Min; Li, Yanlong; Wynn, Richard; Burn, Timothy C.; Koblish, Holly K.; Fridman, Jordan S.; Emm, Tom; Scherle, Peggy A.; Metcalf, Brian; Combs, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">486-491</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A data-centric medicinal chem. approach led to the invention of a potent and selective IDO1 inhibitor 4f, INCB24360 (epacadostat).  The mol. structure of INCB24360 contains several previously unknown or underutilized functional groups in drug substances, including a hydroxyamidine, furazan, bromide and sulfamide.  These moieties taken together in a single structure afford a compd. which falls outside of "drug-like" space.  Nevertheless, the in vitro ADME data is consistent with the good cell permeability and oral bioavailability obsd. in all species (rat, dog, monkey) tested.  The extensive intramol. hydrogen bonding obsd. in the small mol. crystal structure of 4f is believed to significantly contribute to the obsd. permeability and PK.  Epacadostat in combination with anti-PD1 mAb pembrolizumab is currently being studied in a phase 3 clin. trial in patients with unresectable or metastatic melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpm79ArpY1yLVg90H21EOLACvtfcHk0lgEF3NyRdf7RA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Gqsb0%253D&md5=92bebde519334e9e2a776250bb0258ac</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00391%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DE.%2BW.%26aulast%3DSparks%26aufirst%3DR.%26aulast%3DPolam%26aufirst%3DP.%26aulast%3DModi%26aufirst%3DD.%26aulast%3DDouty%26aufirst%3DB.%26aulast%3DWayland%26aufirst%3DB.%26aulast%3DGlass%26aufirst%3DB.%26aulast%3DTakvorian%26aufirst%3DA.%26aulast%3DGlenn%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DBower%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLeffet%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DBowman%26aufirst%3DK.%2BJ.%26aulast%3DHansbury%26aufirst%3DM.%2BJ.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWynn%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DKoblish%26aufirst%3DH.%2BK.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DEmm%26aufirst%3DT.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DINCB24360%2520%2528epacadostat%2529%252C%2520a%2520highly%2520potent%2520and%2520selective%2520indoleamine-2%252C3-dioxygenase%25201%2520%2528IDO1%2529%2520inhibitor%2520for%2520immuno-oncology%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D5%26spage%3D486%26epage%3D491%26doi%3D10.1021%2Facsmedchemlett.6b00391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span>; <span class="NLM_string-name">Yue, E. W.</span></span> <span> </span><span class="NLM_article-title">Preparation of 4-Amino-Nâ²-hydroxy-1,2,5-oxadiazole-3-carboximidamides and Related Compounds as Modulators of Indoleamine 2,3-Dioxygenase for Inhibiting Immunosuppression and Treating Various Disorders</span>. <span class="NLM_patent">WO2006122150A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=A.+P.+Combs&author=E.+W.+Yue&title=Preparation+of+4-Amino-N%E2%80%B2-hydroxy-1%2C2%2C5-oxadiazole-3-carboximidamides+and+Related+Compounds+as+Modulators+of+Indoleamine+2%2C3-Dioxygenase+for+Inhibiting+Immunosuppression+and+Treating+Various+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DPreparation%2520of%25204-Amino-N%25E2%2580%25B2-hydroxy-1%252C2%252C5-oxadiazole-3-carboximidamides%2520and%2520Related%2520Compounds%2520as%2520Modulators%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520for%2520Inhibiting%2520Immunosuppression%2520and%2520Treating%2520Various%2520Disorders%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span>; <span class="NLM_string-name">Yue, E. W.</span>; <span class="NLM_string-name">Sparks, R. B.</span>; <span class="NLM_string-name">Zhu, W.</span>; <span class="NLM_string-name">Zhou, J.</span>; <span class="NLM_string-name">Lin, Q.</span>; <span class="NLM_string-name">Weng, L.</span>; <span class="NLM_string-name">Yue, T.-Y.</span>; <span class="NLM_string-name">Liu, P.</span></span> <span> </span><span class="NLM_article-title">Preparation of 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase</span>. <span class="NLM_patent">WO2010005958A2</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=A.+P.+Combs&author=E.+W.+Yue&author=R.+B.+Sparks&author=W.+Zhu&author=J.+Zhou&author=Q.+Lin&author=L.+Weng&author=T.-Y.+Yue&author=P.+Liu&title=Preparation+of+1%2C2%2C5-Oxadiazoles+as+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DPreparation%2520of%25201%252C2%252C5-Oxadiazoles%2520as%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span>; <span class="NLM_string-name">Yue, E. W.</span></span> <span> </span><span class="NLM_article-title">Preparation of Azole-amidines as Modulators of Indoleamine 2,3-Dioxygenase</span>. <span class="NLM_patent">WO2008036652A2</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=A.+P.+Combs&author=E.+W.+Yue&title=Preparation+of+Azole-amidines+as+Modulators+of+Indoleamine+2%2C3-Dioxygenase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DPreparation%2520of%2520Azole-amidines%2520as%2520Modulators%2520of%2520Indoleamine%25202%252C3-Dioxygenase%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span></span> <span> </span><span class="NLM_article-title">Preparation of Amidinoheterocycles as Modulators of Indoleamine 2,3-Dioxygenases</span>. <span class="NLM_patent">WO2008036643A2</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Combs%2C+A.+P.+Preparation+of+Amidinoheterocycles+as+Modulators+of+Indoleamine+2%2C3-Dioxygenases.+WO2008036643A2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DPreparation%2520of%2520Amidinoheterocycles%2520as%2520Modulators%2520of%2520Indoleamine%25202%252C3-Dioxygenases" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jochems, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernando, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwilas, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donahue, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepone, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenga, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heery, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brechbiel, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madan, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, R.</span></span> <span> </span><span class="NLM_article-title">The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">37762</span>â <span class="NLM_lpage">37772</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.9326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.18632%2Foncotarget.9326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=27192116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FgsVGntw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=37762-37772&issue=25&author=C.+Jochemsauthor=M.+Fantiniauthor=R.+I.+Fernandoauthor=A.+R.+Kwilasauthor=R.+N.+Donahueauthor=L.+M.+Leponeauthor=I.+Grengaauthor=C.+R.+Heeryauthor=J.+W.+Hodgeauthor=J.+Schlomauthor=K.+Y.+Tsangauthor=Y.-S.+Kimauthor=M.+W.+Brechbielauthor=J.+L.+Gulleyauthor=R.+A.+Madanauthor=R.+Newton&title=The+IDO1+selective+inhibitor+epacadostat+enhances+dendritic+cell+immunogenicity+and+lytic+ability+of+tumor+antigen-specific+T+cells&doi=10.18632%2Foncotarget.9326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells</span></div><div class="casAuthors">Jochems Caroline; Fantini Massimo; Fernando Romaine I; Kwilas Anna R; Donahue Renee N; Lepone Lauren M; Grenga Italia; Heery Christopher R; Hodge James W; Schlom Jeffrey; Tsang Kwong Y; Kim Young-Seung; Brechbiel Martin W; Gulley James L; Madan Ravi A; Newton Robert</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">37762-37772</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epacadostat is a novel inhibitor of indoleamine-2,3-dioxygenase-1 (IDO1) that suppresses systemic tryptophan catabolism and is currently being evaluated in ongoing clinical trials.  We investigated the effects of epacadostat on (a) human dendritic cells (DCs) with respect to maturation and ability to activate human tumor antigen-specific cytotoxic T-cell (CTL) lines, and subsequent T-cell lysis of tumor cells, (b) human regulatory T cells (Tregs), and (c) human peripheral blood mononuclear cells (PBMCs) in vitro.  Simultaneous treatment with epacadostat and IFN-Î³ plus lipopolysaccharide (LPS) did not change the phenotype of matured human DCs, and as expected decreased the tryptophan breakdown and kynurenine production.  Peptide-specific T-cell lines stimulated with DCs pulsed with peptide produced significantly more IFN-Î³, TNFÎ±, GM-CSF and IL-8 if the DCs were treated with epacadostat.  These T cells also displayed higher levels of tumor cell lysis on a per cell basis.  Epacadostat also significantly decreased Treg proliferation induced by IDO production from IFN-Î³ plus LPS matured human DCs, although the Treg phenotype did not change.  Multicolor flow cytometry was performed on human PBMCs treated with epacadostat; analysis of 123 discrete immune cell subsets revealed no changes in major immune cell types, an increase in activated CD83+ conventional DCs, and a decrease in immature activated Tim3+ NK cells.  These studies show for the first time several effects of epacadostat on human DCs, and subsequent effects on CTL and Tregs, and provide a rationale as to how epacadostat could potentially increase the efficacy of immunotherapeutics, including cancer vaccines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6d9vu8-NFF4IRAdBLKY41fW6udTcc2eZRdPGWnEqLUrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FgsVGntw%253D%253D&md5=5a4ae654278a48cf45a8a234d4ee8343</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.9326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.9326%26sid%3Dliteratum%253Aachs%26aulast%3DJochems%26aufirst%3DC.%26aulast%3DFantini%26aufirst%3DM.%26aulast%3DFernando%26aufirst%3DR.%2BI.%26aulast%3DKwilas%26aufirst%3DA.%2BR.%26aulast%3DDonahue%26aufirst%3DR.%2BN.%26aulast%3DLepone%26aufirst%3DL.%2BM.%26aulast%3DGrenga%26aufirst%3DI.%26aulast%3DHeery%26aufirst%3DC.%2BR.%26aulast%3DHodge%26aufirst%3DJ.%2BW.%26aulast%3DSchlom%26aufirst%3DJ.%26aulast%3DTsang%26aufirst%3DK.%2BY.%26aulast%3DKim%26aufirst%3DY.-S.%26aulast%3DBrechbiel%26aufirst%3DM.%2BW.%26aulast%3DGulley%26aufirst%3DJ.%2BL.%26aulast%3DMadan%26aufirst%3DR.%2BA.%26aulast%3DNewton%26aufirst%3DR.%26atitle%3DThe%2520IDO1%2520selective%2520inhibitor%2520epacadostat%2520enhances%2520dendritic%2520cell%2520immunogenicity%2520and%2520lytic%2520ability%2520of%2520tumor%2520antigen-specific%2520T%2520cells%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D25%26spage%3D37762%26epage%3D37772%26doi%3D10.18632%2Foncotarget.9326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gibney, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutzky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olszanski, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajewski, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanks, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maleski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J. S.</span></span> <span> </span><span class="NLM_article-title">Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma</span>. <i>J. Immunother. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">80</span>, <span class="refDoi">Â DOI: 10.1186/s40425-019-0562-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1186%2Fs40425-019-0562-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=30894212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BB3cbmsVSmtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=80&issue=1&author=G.+T.+Gibneyauthor=O.+Hamidauthor=J.+Lutzkyauthor=A.+J.+Olszanskiauthor=T.+C.+Mitchellauthor=T.+F.+Gajewskiauthor=B.+Chmielowskiauthor=B.+A.+Hanksauthor=Y.+Zhaoauthor=R.+C.+Newtonauthor=J.+Maleskiauthor=L.+Leopoldauthor=J.+S.+Weber&title=Phase+1%2F2+study+of+epacadostat+in+combination+with+ipilimumab+in+patients+with+unresectable+or+metastatic+melanoma&doi=10.1186%2Fs40425-019-0562-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma</span></div><div class="casAuthors">Gibney Geoffrey T; Weber Jeffrey S; Gibney Geoffrey T; Hamid Omid; Lutzky Jose; Olszanski Anthony J; Mitchell Tara C; Gajewski Thomas F; Chmielowski Bartosz; Hanks Brent A; Zhao Yufan; Newton Robert C; Maleski Janet; Leopold Lance; Weber Jeffrey S</div><div class="citationInfo"><span class="NLM_cas:title">Journal for immunotherapy of cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) enzyme.  We present phase 1 results from a phase 1/2 clinical study of epacadostat in combination with ipilimumab, an anti-cytotoxic T-lymphocyte-associated protein 4 antibody, in advanced melanoma (NCT01604889).  METHODS:  Only the phase 1, open-label portion of the study was conducted, per the sponsor's decision to terminate the study early based on the changing melanoma treatment landscape favoring exploration of programmed cell death protein 1 (PD-1)/PD-ligand 1 inhibitor-based combination strategies.  Such decision was not related to the safety of epacadostat plus ipilimumab.  Patients received oral epacadostat (25, 50, 100, or 300 mg twice daily [BID]; 75 mg daily [50 mg AM, 25 mg PM]; or 50 mg BID intermittent [2 weeks on/1 week off]) plus intravenous ipilimumab 3 mg/kg every 3 weeks.  RESULTS:  Fifty patients received â¥1 dose of epacadostat.  As of January 20, 2017, 2 patients completed treatment and 48 discontinued, primarily because of adverse events (AEs) and disease progression (n = 20 each).  Dose-limiting toxicities occurred in 11 patients (n = 1 each with epacadostat 25 mg BID, 50 mg BID intermittent, 75 mg daily; n = 4 each with epacadostat 50 mg BID, 300 mg BID).  The most common immune-related treatment-emergent AEs included rash (50%), alanine aminotransferase elevation (28%), pruritus (28%), aspartate aminotransferase elevation (24%), and hypothyroidism (10%).  Among immunotherapy-naive patients (n = 39), the objective response rate was 26% by immune-related response criteria and 23% by Response Evaluation Criteria in Solid Tumors version 1.1.  No objective response was seen in the 11 patients who received prior immunotherapy.  Epacadostat exposure was dose proportional, with clinically significant IDO1 inhibition at doses â¥25 mg BID.  CONCLUSIONS:  When combined with ipilimumab, epacadostat â¤50 mg BID demonstrated clinical and pharmacologic activity and was generally well tolerated in patients with advanced melanoma.  TRIAL REGISTRATION:  ClinicalTrials.gov identifier, NCT01604889 .  Registration date, May 9, 2012, retrospectively registered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQpZW4VHEUQl-RS7coPn-RtfW6udTcc2eY90Eu8hneKbrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbmsVSmtg%253D%253D&md5=7bc5d59472fe8fa1865f68769cb6a176</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1186%2Fs40425-019-0562-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40425-019-0562-8%26sid%3Dliteratum%253Aachs%26aulast%3DGibney%26aufirst%3DG.%2BT.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DLutzky%26aufirst%3DJ.%26aulast%3DOlszanski%26aufirst%3DA.%2BJ.%26aulast%3DMitchell%26aufirst%3DT.%2BC.%26aulast%3DGajewski%26aufirst%3DT.%2BF.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DHanks%26aufirst%3DB.%2BA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DMaleski%26aufirst%3DJ.%26aulast%3DLeopold%26aufirst%3DL.%26aulast%3DWeber%26aufirst%3DJ.%2BS.%26atitle%3DPhase%25201%252F2%2520study%2520of%2520epacadostat%2520in%2520combination%2520with%2520ipilimumab%2520in%2520patients%2520with%2520unresectable%2520or%2520metastatic%2520melanoma%26jtitle%3DJ.%2520Immunother.%2520Cancer%26date%3D2019%26volume%3D7%26issue%3D1%26spage%3D80%26doi%3D10.1186%2Fs40425-019-0562-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasser, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olszanski, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luke, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balmanoukian, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maleski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajewski, T. F.</span></span> <span> </span><span class="NLM_article-title">Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">32</span>),  <span class="NLM_fpage">3223</span>â <span class="NLM_lpage">3230</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2018.78.9602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1200%2FJCO.2018.78.9602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=30265610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvFylsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=3223-3230&issue=32&author=T.+C.+Mitchellauthor=O.+Hamidauthor=D.+C.+Smithauthor=T.+M.+Bauerauthor=J.+S.+Wasserauthor=A.+J.+Olszanskiauthor=J.+J.+Lukeauthor=A.+S.+Balmanoukianauthor=E.+V.+Schmidtauthor=Y.+Zhaoauthor=X.+Gongauthor=J.+Maleskiauthor=L.+Leopoldauthor=T.+F.+Gajewski&title=Epacadostat+plus+pembrolizumab+in+patients+with+advanced+solid+tumors%3A+phase+I+results+from+a+multicenter%2C+open-label+phase+I%2FII+trial+%28ECHO-202%2FKEYNOTE-037%29&doi=10.1200%2FJCO.2018.78.9602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037)</span></div><div class="casAuthors">Mitchell, Tara C.; Hamid, Omid; Smith, David C.; Bauer, Todd M.; Wasser, Jeffrey S.; Olszanski, Anthony J.; Luke, Jason J.; Balmanoukian, Ani S.; Schmidt, Emmett V.; Zhao, Yufan; Gong, Xiaohua; Maleski, Janet; Leopold, Lance; Gajewski, Thomas F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">3223-3230</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Tumors may evade immunosurveillance through upregulation of the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme.  Epacadostat is a potent and highly selective IDO1 enzyme inhibitor.  The open-label phase I/II ECHO-202/KEYNOTE-037 trial evaluated epacadostat plus pembrolizumab, a programmed death protein 1 inhibitor, in patients with advanced solid tumors.  Phase I results on max. tolerated dose, safety, tolerability, preliminary antitumor activity, and pharmacokinetics are reported.  Patients and Methods Patients received escalating doses of oral epacadostat (25, 50, 100, or 300 mg) twice per day plus i.v. pembrolizumab 2 mg/kg or 200 mg every 3 wk.  During the safety expansion, patients received epacadostat (50, 100, or 300 mg) twice per day plus pembrolizumab 200 mg every 3 wk.  Results Sixty-two patients were enrolled and received one or more doses of study treatment.  The max. tolerated dose of epacadostat in combination with pembrolizumab was not reached.  Fifty-two patients (84%) experienced treatment-related adverse events (TRAEs), with fatigue (36%), rash (36%), arthralgia (24%), pruritus (23%), and nausea (21%) occurring in â¥ 20%.  Grade 3/4 TRAEs were reported in 24% of patients.  Seven patients (11%) discontinued study treatment because of TRAEs.  No TRAEs led to death.  Epacadostat 100 mg twice per day plus pembrolizumab 200 mg every 3 wk was recommended for phase II evaluation.  Objective responses (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) occurred in 12 (55%) of 22 patients with melanoma and in patients with non-small-cell lung cancer, renal cell carcinoma, endometrial adenocarcinoma, urothelial carcinoma, and squamous cell carcinoma of the head and neck.  The pharmacokinetics of epacadostat and pembrolizumab and antidrug antibody rate were comparable to historical controls for monotherapies.  Conclusion Epacadostat in combination with pembrolizumab generally was well tolerated and had encouraging antitumor activity in multiple advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4WSlpguIRwbVg90H21EOLACvtfcHk0lilzbi_696ERA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvFylsbg%253D&md5=dfdac94152fd0eb096847a60ea44c145</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.78.9602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.78.9602%26sid%3Dliteratum%253Aachs%26aulast%3DMitchell%26aufirst%3DT.%2BC.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DSmith%26aufirst%3DD.%2BC.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DWasser%26aufirst%3DJ.%2BS.%26aulast%3DOlszanski%26aufirst%3DA.%2BJ.%26aulast%3DLuke%26aufirst%3DJ.%2BJ.%26aulast%3DBalmanoukian%26aufirst%3DA.%2BS.%26aulast%3DSchmidt%26aufirst%3DE.%2BV.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DX.%26aulast%3DMaleski%26aufirst%3DJ.%26aulast%3DLeopold%26aufirst%3DL.%26aulast%3DGajewski%26aufirst%3DT.%2BF.%26atitle%3DEpacadostat%2520plus%2520pembrolizumab%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%253A%2520phase%2520I%2520results%2520from%2520a%2520multicenter%252C%2520open-label%2520phase%2520I%252FII%2520trial%2520%2528ECHO-202%252FKEYNOTE-037%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26issue%3D32%26spage%3D3223%26epage%3D3230%26doi%3D10.1200%2FJCO.2018.78.9602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Komrokji, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailloux, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padron, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sallman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancet, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinsley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nardelli, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinilla-Ibarz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epling-Burnette, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">List, A. F.</span></span> <span> </span><span class="NLM_article-title">A phase II study to determine the safety and efficacy of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO) enzyme INCB024360 in patients with myelodysplastic syndromes</span>. <i>Clin. Lymphoma Myeloma Leuk.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">157</span>â <span class="NLM_lpage">161</span>, <span class="refDoi">Â DOI: 10.1016/j.clml.2018.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.clml.2018.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=30713125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BB3cjosVagsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=157-161&issue=3&author=R.+S.+Komrokjiauthor=S.+Weiauthor=A.+W.+Maillouxauthor=L.+Zhangauthor=E.+Padronauthor=D.+Sallmanauthor=J.+E.+Lancetauthor=S.+Tinsleyauthor=L.+A.+Nardelliauthor=J.+Pinilla-Ibarzauthor=P.+K.+Epling-Burnetteauthor=A.+F.+List&title=A+phase+II+study+to+determine+the+safety+and+efficacy+of+the+oral+inhibitor+of+indoleamine+2%2C3-dioxygenase+%28IDO%29+enzyme+INCB024360+in+patients+with+myelodysplastic+syndromes&doi=10.1016%2Fj.clml.2018.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes</span></div><div class="casAuthors">Komrokji Rami S; Wei Sheng; Mailloux Adam W; Zhang Ling; Padron Eric; Sallman David; Lancet Jeffrey E; Tinsley Sara; Nardelli Lisa A; Pinilla-Ibarz Javier; Epling-Burnette Pearlie K; List Alan F</div><div class="citationInfo"><span class="NLM_cas:title">Clinical lymphoma, myeloma & leukemia</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">157-161</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  INCB024360 is an oral inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO), which catalyzes the degradation of tryptophan to kynurenine.  Preclinical data suggest that IDO1 inhibition by INCB024360 will increase T cell proliferation, and decrease T regulatory cells and myeloid derived suppressor cells suppressive activity.  We conducted a phase II study to explore activity and pharmacodynamics of INCB024360 in patients with myelodysplastic syndromes.  PATIENTS AND METHODS:  All patients were treated with INCB024360 600 mg orally twice a day for at least 16 weeks.  Fifteen patients were enrolled.  The median age was 72 years.  The International Prognostic Scoring System risk was low in 27% (n = 4), intermediate-1 in 47% (n = 7), and intermediate-2 in 27% (n = 4).  All patients had prior azacitidine.  RESULTS:  The best response was stable disease in 12 (80%) patients and progressive disease in 3 (20%) patients.  The treatment was relatively well-tolerated.  One patient developed hypothyroidism and adrenal insufficiency (grade 2), and 1 patient had low testosterone level.  The mean IDO expression was 39% at baseline and 26% after treatment (n = 9; P = .4).  The mean burst forming unit-erythroid changed from 72 to 191 colonies/10(6) (n = 5; P = .036), and the mean colony forming unit-granulocye, monocyte from 62 to 180 colonies/10(6) (n = 6; P = .5).  The mean myeloid derived suppressor cell % (CD33Lin-HLA cells) was 29.5% at baseline compared with 27.6% after treatment (n = 9; P = .7).  The mean T-regulatory effector memory cell % changed from 9.6% at screening to 7.4% at end of treatment (n = 14; P = .8).  The mean kynurenine/tryptophan ratio decreased from 45 at baseline to 26 (42% reduction) at cycle 2, day 1 (P < .005).  CONCLUSION:  Future directions may include testing INCB024360 early in the course of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWYB_1Nq9sPL0AGQpJZWpJfW6udTcc2ebwDjiSkAogSLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjosVagsQ%253D%253D&md5=c2cf2712dbd57d75a0ce71fbc7d365fe</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1016%2Fj.clml.2018.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clml.2018.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DKomrokji%26aufirst%3DR.%2BS.%26aulast%3DWei%26aufirst%3DS.%26aulast%3DMailloux%26aufirst%3DA.%2BW.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DPadron%26aufirst%3DE.%26aulast%3DSallman%26aufirst%3DD.%26aulast%3DLancet%26aufirst%3DJ.%2BE.%26aulast%3DTinsley%26aufirst%3DS.%26aulast%3DNardelli%26aufirst%3DL.%2BA.%26aulast%3DPinilla-Ibarz%26aufirst%3DJ.%26aulast%3DEpling-Burnette%26aufirst%3DP.%2BK.%26aulast%3DList%26aufirst%3DA.%2BF.%26atitle%3DA%2520phase%2520II%2520study%2520to%2520determine%2520the%2520safety%2520and%2520efficacy%2520of%2520the%2520oral%2520inhibitor%2520of%2520indoleamine%25202%252C3-dioxygenase%2520%2528IDO%2529%2520enzyme%2520INCB024360%2520in%2520patients%2520with%2520myelodysplastic%2520syndromes%26jtitle%3DClin.%2520Lymphoma%2520Myeloma%2520Leuk.%26date%3D2019%26volume%3D19%26issue%3D3%26spage%3D157%26epage%3D161%26doi%3D10.1016%2Fj.clml.2018.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kristeleit, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirinkin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Khouly, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondarenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodheart, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorbunova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penning, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maleski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schilder, R. J.</span></span> <span> </span><span class="NLM_article-title">A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>146</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">484</span>â <span class="NLM_lpage">490</span>, <span class="refDoi">Â DOI: 10.1016/j.ygyno.2017.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.ygyno.2017.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28698009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFClsLnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2017&pages=484-490&issue=3&author=R.+Kristeleitauthor=I.+Davidenkoauthor=V.+Shirinkinauthor=F.+El-Khoulyauthor=I.+Bondarenkoauthor=M.+J.+Goodheartauthor=V.+Gorbunovaauthor=C.+A.+Penningauthor=J.+G.+Shiauthor=X.+Liuauthor=R.+C.+Newtonauthor=Y.+Zhaoauthor=J.+Maleskiauthor=L.+Leopoldauthor=R.+J.+Schilder&title=A+randomised%2C+open-label%2C+phase+2+study+of+the+IDO1+inhibitor+epacadostat+%28INCB024360%29+versus+tamoxifen+as+therapy+for+biochemically+recurrent+%28CA-125+relapse%29-only+epithelial+ovarian+cancer%2C+primary+peritoneal+carcinoma%2C+or+fallopian+tube+cancer&doi=10.1016%2Fj.ygyno.2017.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer</span></div><div class="casAuthors">Kristeleit, Rebecca; Davidenko, Irina; Shirinkin, Vadim; El-Khouly, Fatima; Bondarenko, Igor; Goodheart, Michael J.; Gorbunova, Vera; Penning, Carol A.; Shi, Jack G.; Liu, Xiangdong; Newton, Robert C.; Zhao, Yufan; Maleski, Janet; Leopold, Lance; Schilder, Russell J.</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">484-490</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase-1 (IDO1) is a key regulator of immune tolerance in ovarian cancer.  This study investigated efficacy and safety of the IDO1 enzyme inhibitor epacadostat vs. tamoxifen in patients with biochem.-only recurrence (CA-125 elevation) following complete remission after first-line chemotherapy for advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.  In this open-label, phase 2 study (NCT01685255), patients were randomised 1:1 to epacadostat 600 mg or tamoxifen 20 mg twice daily for successive 28-day cycles and stratified by time since completion of first-line chemotherapy to first CA-125 elevation (3 to < 12 or â¥ 12 mo).  The primary endpoint was investigator-assessed progression-free survival (PFS; RECIST v1.1).  Secondary endpoints included CA-125 response (Gynecol. Cancer InterGroup criteria), overall survival, safety, and tolerability.  The study was terminated primarily due to slow accrual and lack of evidence of superiority.  Median PFS was 3.75 mo for epacadostat (n = 22) vs. 5.56 mo for tamoxifen (n = 20; HR, 1.34 [95% CI, 0.58-3.14]; P = 0.54).  Of evaluable patients, 1 (5.0%) epacadostat and 3 (15.8%) tamoxifen patients had confirmed CA-125 responses.  The most common treatment-emergent adverse event was fatigue (epacadostat, 36.4%; tamoxifen, 40.0%).  Immune-related adverse events, obsd. with epacadostat only, were primarily rash (18.2%) and pruritus (9.1%).  Epacadostat pharmacokinetics/pharmacodynamics were consistent with its known mechanism of action.  IDO1 expression was obsd. in 94% of archival tumor samples.  This first report of immunotherapy evaluation in biochem.-only relapse ovarian cancer and of IDO1 inhibitor monotherapy in ovarian cancer found no significant difference in efficacy between epacadostat and tamoxifen.  Epacadostat was generally well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRb4SuL159WLVg90H21EOLACvtfcHk0lgNN-ZoEGaYHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFClsLnF&md5=bd3859b2936669042690ce675e90a12d</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2017.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2017.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DKristeleit%26aufirst%3DR.%26aulast%3DDavidenko%26aufirst%3DI.%26aulast%3DShirinkin%26aufirst%3DV.%26aulast%3DEl-Khouly%26aufirst%3DF.%26aulast%3DBondarenko%26aufirst%3DI.%26aulast%3DGoodheart%26aufirst%3DM.%2BJ.%26aulast%3DGorbunova%26aufirst%3DV.%26aulast%3DPenning%26aufirst%3DC.%2BA.%26aulast%3DShi%26aufirst%3DJ.%2BG.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DMaleski%26aufirst%3DJ.%26aulast%3DLeopold%26aufirst%3DL.%26aulast%3DSchilder%26aufirst%3DR.%2BJ.%26atitle%3DA%2520randomised%252C%2520open-label%252C%2520phase%25202%2520study%2520of%2520the%2520IDO1%2520inhibitor%2520epacadostat%2520%2528INCB024360%2529%2520versus%2520tamoxifen%2520as%2520therapy%2520for%2520biochemically%2520recurrent%2520%2528CA-125%2520relapse%2529-only%2520epithelial%2520ovarian%2520cancer%252C%2520primary%2520peritoneal%2520carcinoma%252C%2520or%2520fallopian%2520tube%2520cancer%26jtitle%3DGynecol.%2520Oncol.%26date%3D2017%26volume%3D146%26issue%3D3%26spage%3D484%26epage%3D490%26doi%3D10.1016%2Fj.ygyno.2017.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beatty, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDwyer, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaub, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maleski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajewski, T. F.</span></span> <span> </span><span class="NLM_article-title">First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3269</span>â <span class="NLM_lpage">3276</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-16-2272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1158%2F1078-0432.CCR-16-2272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28053021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSnurfP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=3269-3276&issue=13&author=G.+L.+Beattyauthor=P.+J.+O%E2%80%99Dwyerauthor=J.+Clarkauthor=J.+G.+Shiauthor=K.+J.+Bowmanauthor=P.+A.+Scherleauthor=R.+C.+Newtonauthor=R.+Schaubauthor=J.+Maleskiauthor=L.+Leopoldauthor=T.+F.+Gajewski&title=First-in-human+phase+I+study+of+the+oral+inhibitor+of+indoleamine+2%2C3-dioxygenase-1+epacadostat+%28INCB024360%29+in+patients+with+advanced+solid+malignancies&doi=10.1158%2F1078-0432.CCR-16-2272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies</span></div><div class="casAuthors">Beatty, Gregory L.; O'Dwyer, Peter J.; Clark, Jason; Shi, Jack G.; Bowman, Kevin J.; Scherle, Peggy A.; Newton, Robert C.; Schaub, Richard; Maleski, Janet; Leopold, Lance; Gajewski, Thomas F.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3269-3276</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase-1 (IDO1) catalyzes the degrdn. of tryptophan to N-formyl-kynurenine.  Overexpressed in many solid malignancies, IDO1 can promote tumor escape from host immunosurveillance.  This first-in-human phase I study investigated the max. tolerated dose, safety, pharmacokinetics, pharmacodynamics, and antitumor activity of epacadostat (INCB024360), a potent and selective inhibitor of IDO1.  Fifty-two patients with advanced solid malignancies were treated with epacadostat [50 mg once daily or 50, 100, 300, 400, 500, 600, or 700 mg twice daily (BID)] in a dose-escalation 3 + 3 design and evaluated in 28-day cycles.  Treatment was continued until disease progression or unacceptable toxicity.  One dose-limiting toxicity (DLT) occurred at the dose of 300 mg BID (grade 3, radiation pneumonitis); another DLT occurred at 400 mg BID (grade 3, fatigue).  The most common adverse events in >20% of patients overall were fatigue, nausea, decreased appetite, vomiting, constipation, abdominal pain, diarrhea, dyspnea, back pain, and cough.  Treatment produced significant dose-dependent redns. in plasma kynurenine levels and in the plasma kynurenine/tryptophan ratio at all doses and in all patients.  Near maximal changes were obsd. at doses of â¥100 mg BID with >80% to 90% inhibition of IDO1 achieved throughout the dosing period.  Although no objective responses were detected, stable disease lasting â¥16 wk was obsd. in 7 of 52 patients.  Epacadostat was generally well tolerated, effectively normalized kynurenine levels, and produced maximal inhibition of IDO1 activity at doses of â¥100 mg BID.  Studies investigating epacadostat in combination with other immunomodulatory drugs are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLdL__p3Q7B7Vg90H21EOLACvtfcHk0lgNN-ZoEGaYHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSnurfP&md5=dee4464e680b476ebe0dbad7f5ec8d46</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2272%26sid%3Dliteratum%253Aachs%26aulast%3DBeatty%26aufirst%3DG.%2BL.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DJ.%2BG.%26aulast%3DBowman%26aufirst%3DK.%2BJ.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DSchaub%26aufirst%3DR.%26aulast%3DMaleski%26aufirst%3DJ.%26aulast%3DLeopold%26aufirst%3DL.%26aulast%3DGajewski%26aufirst%3DT.%2BF.%26atitle%3DFirst-in-human%2520phase%2520I%2520study%2520of%2520the%2520oral%2520inhibitor%2520of%2520indoleamine%25202%252C3-dioxygenase-1%2520epacadostat%2520%2528INCB024360%2529%2520in%2520patients%2520with%2520advanced%2520solid%2520malignancies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26issue%3D13%26spage%3D3269%26epage%3D3276%26doi%3D10.1158%2F1078-0432.CCR-16-2272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajewski, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caglevic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlino, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidov, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maleski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diede, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, T. C.</span></span> <span> </span><span class="NLM_article-title">Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1083</span>â <span class="NLM_lpage">1097</span>, <span class="refDoi">Â DOI: 10.1016/S1470-2045(19)30274-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2FS1470-2045%2819%2930274-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=31221619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtF2kurbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1083-1097&issue=8&author=G.+V.+Longauthor=R.+Dummerauthor=O.+Hamidauthor=T.+F.+Gajewskiauthor=C.+Caglevicauthor=S.+Dalleauthor=A.+Aranceauthor=M.+S.+Carlinoauthor=J.-J.+Grobauthor=T.+M.+Kimauthor=L.+Demidovauthor=C.+Robertauthor=J.+Larkinauthor=J.+R.+Andersonauthor=J.+Maleskiauthor=M.+Jonesauthor=S.+J.+Diedeauthor=T.+C.+Mitchell&title=Epacadostat+plus+pembrolizumab+versus+placebo+plus+pembrolizumab+in+patients+with+unresectable+or+metastatic+melanoma+%28ECHO-301%2FKEYNOTE-252%29%3A+a+phase+3%2C+randomised%2C+double-blind+study&doi=10.1016%2FS1470-2045%2819%2930274-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study</span></div><div class="casAuthors">Long, Georgina V.; Dummer, Reinhard; Hamid, Omid; Gajewski, Thomas F.; Caglevic, Christian; Dalle, Stephane; Arance, Ana; Carlino, Matteo S.; Grob, Jean-Jacques; Kim, Tae Min; Demidov, Lev; Robert, Caroline; Larkin, James; Anderson, James R.; Maleski, Janet; Jones, Mark; Diede, Scott J.; Mitchell, Tara C.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1083-1097</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Immunotherapy combination treatments can improve patient outcomes.  Epacadostat, an IDO1 selective inhibitor, and pembrolizumab, a PD-1 inhibitor, showed promising antitumor activity in the phase 1-2 ECHO-202/KEYNOTE-037 study in advanced melanoma.  In this trial, we aimed to compare progression-free survival and overall survival in patients with unresectable stage III or IV melanoma receiving epacadostat plus pembrolizumab vs. placebo plus pembrolizumab.  In this international, randomised, placebo-controlled, double-blind, parallel-group, phase 3 trial, eligible participants were aged 18 years or older, with unresectable stage III or IV melanoma previously untreated with PD-1 or PD-L1 checkpoint inhibitors, an ECOG performance status of 0 or 1, and had a known BRAFV600 mutant status or consented to BRAFV600 mutation testing during screening.  Patients were stratified by PD-L1 expression and BRAFV600 mutation status and randomly assigned (1:1) through a central interactive voice and integrated web response system to receive epacadostat 100 mg orally twice daily plus pembrolizumab 200 mg i.v. every 3 wk or placebo plus pembrolizumab for up to 2 years.  We used block randomisation with a block size of four in each stratum.  Primary endpoints were progression-free survival and overall survival in the intention-to-treat population.  The safety anal. population included randomly assigned patients who received at least one dose of study treatment.  The study was stopped after the second interim anal.; follow-up for safety is ongoing.  This study is registered with ClinicalTrials.gov, no. NCT02752074.  Between June 21, 2016, and Aug 7, 2017, 928 patients were screened and 706 patients were randomly assigned to receive epacadostat plus pembrolizumab (n=354) or placebo plus pembrolizumab (n=352).  Median follow-up was 12Â·4 mo (IQR 10Â·3-14Â·5).  No significant differences were found between the treatment groups for progression-free survival (median 4Â·7 mo, 95% CI 2Â·9-6Â·8, for epacadostat plus pembrolizumab vs 4Â·9 mo, 2Â·9-6Â·8, for placebo plus pembrolizumab; hazard ratio [HR] 1Â·00, 95% CI 0Â·83-1Â·21; one-sided p=0Â·52) or overall survival (median not reached in either group; epacadostat plus pembrolizumab vs placebo plus pembrolizumab: HR 1Â·13, 0Â·86-1Â·49; one-sided p=0Â·81).  The most common grade 3 or worse treatment-related adverse event was lipase increase, which occurred in 14 (4%) of 353 patients receiving epacadostat plus pembrolizumab and 11 (3%) of 352 patients receiving placebo plus pembrolizumab.  Treatment-related serious adverse events were reported in 37 (10%) of 353 patients receiving epacadostat plus pembrolizumab and 32 (9%) of 352 patients receiving placebo plus pembrolizumab.  There were no treatment-related deaths in either treatment group.  Epacadostat 100 mg twice daily plus pembrolizumab did not improve progression-free survival or overall survival compared with placebo plus pembrolizumab in patients with unresectable or metastatic melanoma.  The usefulness of IDO1 inhibition as a strategy to enhance anti-PD-1 therapy activity in cancer remains uncertain.  Incyte Corporation, in collaboration with Merck Sharp & Dohme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8j2WQ35JqjbVg90H21EOLACvtfcHk0lii0nfe8FWG0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtF2kurbM&md5=f1dce1f431d2650fe4f8b8e46677e03d</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2819%2930274-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252819%252930274-8%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DGajewski%26aufirst%3DT.%2BF.%26aulast%3DCaglevic%26aufirst%3DC.%26aulast%3DDalle%26aufirst%3DS.%26aulast%3DArance%26aufirst%3DA.%26aulast%3DCarlino%26aufirst%3DM.%2BS.%26aulast%3DGrob%26aufirst%3DJ.-J.%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DDemidov%26aufirst%3DL.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DJ.%2BR.%26aulast%3DMaleski%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DM.%26aulast%3DDiede%26aufirst%3DS.%2BJ.%26aulast%3DMitchell%26aufirst%3DT.%2BC.%26atitle%3DEpacadostat%2520plus%2520pembrolizumab%2520versus%2520placebo%2520plus%2520pembrolizumab%2520in%2520patients%2520with%2520unresectable%2520or%2520metastatic%2520melanoma%2520%2528ECHO-301%252FKEYNOTE-252%2529%253A%2520a%2520phase%25203%252C%2520randomised%252C%2520double-blind%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2019%26volume%3D20%26issue%3D8%26spage%3D1083%26epage%3D1097%26doi%3D10.1016%2FS1470-2045%2819%2930274-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakharia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span> <span> </span><span class="NLM_article-title">Inhibiting IDO pathways to treat cancer: Lessons from the ECHO-301 trial and beyond</span>. <i>Semin. Immunopathol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">41</span>â <span class="NLM_lpage">48</span>, <span class="refDoi">Â DOI: 10.1007/s00281-018-0702-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1007%2Fs00281-018-0702-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=30203227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1yltrfI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2019&pages=41-48&issue=1&author=A.+J.+Mullerauthor=M.+G.+Manfrediauthor=Y.+Zakhariaauthor=G.+C.+Prendergast&title=Inhibiting+IDO+pathways+to+treat+cancer%3A+Lessons+from+the+ECHO-301+trial+and+beyond&doi=10.1007%2Fs00281-018-0702-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond</span></div><div class="casAuthors">Muller, Alexander J.; Manfredi, Mark G.; Zakharia, Yousef; Prendergast, George C.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunopathology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-48</span>CODEN:
                <span class="NLM_cas:coden">SIEMB7</span>;
        ISSN:<span class="NLM_cas:issn">1863-2297</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  With immunotherapy enjoying a rapid resurgence based on the achievement of durable remissions in some patients with agents that derepress immune function, commonly referred to as "checkpoint inhibitors," enormous attention developed around the IDO1 enzyme as a metabolic mediator of immune escape in cancer.  In particular, outcomes of multiple phase 1/2 trials encouraged the idea that small mol. inhibitors of IDO1 may improve patient responses to anti-PD1 immune checkpoint therapy.  However, recent results from ECHO-301, the first large phase 3 trial to evaluate an IDO1-selective enzyme inhibitor (epacadostat) in combination with an anti-PD1 antibody (pembrolizumab) in advanced melanoma, showed no indication that epacadostat provided an increased benefit.  Here it discuss several caveats assocd. with this failed trial.  First is the uncertainty as to whether the target was adequately inhibited.  In particular, there remains a lack of direct evidence regarding the degree of IDO1 inhibition within the tumor, and previous trial data suggest that sufficient drug exposure may not have been achieved at the dose tested in ECHO-301.  Second, while there is a mechanistic rationale for the combination tested, the preclin. data were not particularly compelling.  More efficacious combinations have been demonstrated with DNA damaging modalities which may therefore be a more attractive alternative.  Third, as a highly selective IDO1 inhibitor, epacadostat was advanced aggressively despite preclin. genetic evidence of tumors bypassing IDO1 blockade.  Indeed, a well-grounded literature starting in 2011 points to targeting strategies that account for both IDO and tryptophan 2,3-dioxygenase as more appealing directions to pursue, including dual inhibitors and inhibitors of nodal downstream effector pathways such as aryl hydrocarbon receptor blockade.  Overall, the clin. readout from a single trial with significant limitations is by no means a definitive test for the field.  While biomarker information yet to be gleaned from ECHO-301 may yet reveal useful information regarding IDO1 pathway drugs, better rationalized compds. and better rationalized trial designs will be important in the future to accurately gage medical impact.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR-55ynvYhvLVg90H21EOLACvtfcHk0lii0nfe8FWG0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1yltrfI&md5=b672f039dcfd843d6c849167846e13a5</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1007%2Fs00281-018-0702-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00281-018-0702-0%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DManfredi%26aufirst%3DM.%2BG.%26aulast%3DZakharia%26aufirst%3DY.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26atitle%3DInhibiting%2520IDO%2520pathways%2520to%2520treat%2520cancer%253A%2520Lessons%2520from%2520the%2520ECHO-301%2520trial%2520and%2520beyond%26jtitle%3DSemin.%2520Immunopathol.%26date%3D2019%26volume%3D41%26issue%3D1%26spage%3D41%26epage%3D48%26doi%3D10.1007%2Fs00281-018-0702-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardolino, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fradera, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knemeyer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurukulasuriya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesburg, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinot, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biju, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciammetta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solban, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of amino-cyclobutarene-derived indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors for cancer immunotherapy</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1530</span>â <span class="NLM_lpage">1536</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.9b00344</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00344" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVSks7rE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1530-1536&issue=11&author=H.+Zhangauthor=K.+Liuauthor=Q.+Puauthor=A.+Achabauthor=M.+J.+Ardolinoauthor=M.+Chengauthor=Y.+Dengauthor=A.+C.+Dotyauthor=H.+Fergusonauthor=X.+Fraderaauthor=I.+Knemeyerauthor=R.+Kurukulasuriyaauthor=Y.+H.+Lamauthor=C.+A.+Lesburgauthor=T.+A.+Martinotauthor=M.+A.+McGowanauthor=J.+R.+Millerauthor=K.+Otteauthor=P.+J.+Bijuauthor=N.+Sciammettaauthor=N.+Solbanauthor=W.+Yuauthor=H.+Zhouauthor=X.+Wangauthor=D.+J.+Bennettauthor=Y.+Han&title=Discovery+of+amino-cyclobutarene-derived+indoleamine-2%2C3-dioxygenase+1+%28IDO1%29+inhibitors+for+cancer+immunotherapy&doi=10.1021%2Facsmedchemlett.9b00344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy</span></div><div class="casAuthors">Zhang, Hongjun; Liu, Kun; Pu, Qinglin; Achab, Abdelghani; Ardolino, Michael J.; Cheng, Mangeng; Deng, Yongqi; Doty, Amy C.; Ferguson, Heidi; Fradera, Xavier; Knemeyer, Ian; Kurukulasuriya, Ravi; Lam, Yu-hong; Lesburg, Charles A.; Martinot, Theodore A.; McGowan, Meredeth A.; Miller, J. Richard; Otte, Karin; Biju, Purakattle J.; Sciammetta, Nunzio; Solban, Nicolas; Yu, Wensheng; Zhou, Hua; Wang, Xiao; Bennett, David Jonathan; Han, Yongxin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1530-1536</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Checkpoint inhibitors have demonstrated unprecedented efficacy and are evolving to become std. of care for certain types of cancers.  However, low overall response rates often hamper the broad utility and potential of these breakthrough therapies.  Combination therapy strategies are currently under intensive investigation in the clinic, including the combination of PD-1/PD-L1 agents with IDO1 inhibitors.  Here, we report the discovery of a class of IDO1 heme-binding inhibitors featuring a unique amino-cyclobutarene motif, which was discovered through SBDD from a known and weakly active inhibitor.  Subsequent optimization efforts focused on improving metabolic stability and were greatly accelerated by utilizing a robust SNAr reaction of a facile nitro-furazan intermediate to quickly explore different polar side chains.  As a culmination of these efforts, compd. 16 was identified and demonstrated a favorable overall profile with superior potency and selectivity.  Extensive studies confirmed the chem. stability and drug-like properties of compd. 16, rendering it a potential drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmACl12NSJBrVg90H21EOLACvtfcHk0ljWrSorzDIUXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVSks7rE&md5=18def13fafda60ed7547810dd97a3c37</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00344%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DPu%26aufirst%3DQ.%26aulast%3DAchab%26aufirst%3DA.%26aulast%3DArdolino%26aufirst%3DM.%2BJ.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DDoty%26aufirst%3DA.%2BC.%26aulast%3DFerguson%26aufirst%3DH.%26aulast%3DFradera%26aufirst%3DX.%26aulast%3DKnemeyer%26aufirst%3DI.%26aulast%3DKurukulasuriya%26aufirst%3DR.%26aulast%3DLam%26aufirst%3DY.%2BH.%26aulast%3DLesburg%26aufirst%3DC.%2BA.%26aulast%3DMartinot%26aufirst%3DT.%2BA.%26aulast%3DMcGowan%26aufirst%3DM.%2BA.%26aulast%3DMiller%26aufirst%3DJ.%2BR.%26aulast%3DOtte%26aufirst%3DK.%26aulast%3DBiju%26aufirst%3DP.%2BJ.%26aulast%3DSciammetta%26aufirst%3DN.%26aulast%3DSolban%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DBennett%26aufirst%3DD.%2BJ.%26aulast%3DHan%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520amino-cyclobutarene-derived%2520indoleamine-2%252C3-dioxygenase%25201%2520%2528IDO1%2529%2520inhibitors%2520for%2520cancer%2520immunotherapy%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D11%26spage%3D1530%26epage%3D1536%26doi%3D10.1021%2Facsmedchemlett.9b00344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span>; <span class="NLM_string-name">Achab, A.</span>; <span class="NLM_string-name">Biju, P.</span>; <span class="NLM_string-name">Deng, Y.</span>; <span class="NLM_string-name">Fradera, X.</span>; <span class="NLM_string-name">Guo, L.</span>; <span class="NLM_string-name">He, S.</span>; <span class="NLM_string-name">Kozlowski, J.</span>; <span class="NLM_string-name">Kurukulasuriya, R.</span>; <span class="NLM_string-name">Liu, K.</span>; <span class="NLM_string-name">McGowan, M. A.</span>; <span class="NLM_string-name">Pu, Q.</span>; <span class="NLM_string-name">Sciammetta, N.</span>; <span class="NLM_string-name">Zhang, H.</span>; <span class="NLM_string-name">Zhao, H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Novel N-Hydroxycarboximidamide Compounds as Indoleamine 2,3-Dioxygenase Inhibitors</span>. <span class="NLM_patent">WO2017106062A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Y.+Han&author=A.+Achab&author=P.+Biju&author=Y.+Deng&author=X.+Fradera&author=L.+Guo&author=S.+He&author=J.+Kozlowski&author=R.+Kurukulasuriya&author=K.+Liu&author=M.+A.+McGowan&author=Q.+Pu&author=N.+Sciammetta&author=H.+Zhang&author=H.+Zhao&title=Preparation+of+Novel+N-Hydroxycarboximidamide+Compounds+as+Indoleamine+2%2C3-Dioxygenase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DY.%26atitle%3DPreparation%2520of%2520Novel%2520N-Hydroxycarboximidamide%2520Compounds%2520as%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span>; <span class="NLM_string-name">Achab, A.</span>; <span class="NLM_string-name">Biju, P.</span>; <span class="NLM_string-name">Cernak, T. A.</span>; <span class="NLM_string-name">Deng, Y.</span>; <span class="NLM_string-name">Fradera, X.</span>; <span class="NLM_string-name">Guo, L.</span>; <span class="NLM_string-name">Han, Y.</span>; <span class="NLM_string-name">He, S.</span>; <span class="NLM_string-name">Kozlowski, J.</span>; <span class="NLM_string-name">Li, D.</span>; <span class="NLM_string-name">Li, G.</span>; <span class="NLM_string-name">Pu, Q.</span>; <span class="NLM_string-name">Shi, Z.-C.</span>; <span class="NLM_string-name">Yu, W.</span>; <span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Novel Substituted Nâ²-Hydroxycarbamimidoyl-1,2,5-oxadiazole Compounds as Indoleamine 2,3-Dioxygenase (IDO) Inhibitors and Their Preparation</span>. <span class="NLM_patent">WO2018044663A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=K.+Liu&author=A.+Achab&author=P.+Biju&author=T.+A.+Cernak&author=Y.+Deng&author=X.+Fradera&author=L.+Guo&author=Y.+Han&author=S.+He&author=J.+Kozlowski&author=D.+Li&author=G.+Li&author=Q.+Pu&author=Z.-C.+Shi&author=W.+Yu&author=H.+Zhang&title=Novel+Substituted+N%E2%80%B2-Hydroxycarbamimidoyl-1%2C2%2C5-oxadiazole+Compounds+as+Indoleamine+2%2C3-Dioxygenase+%28IDO%29+Inhibitors+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%26atitle%3DNovel%2520Substituted%2520N%25E2%2580%25B2-Hydroxycarbamimidoyl-1%252C2%252C5-oxadiazole%2520Compounds%2520as%2520Indoleamine%25202%252C3-Dioxygenase%2520%2528IDO%2529%2520Inhibitors%2520and%2520Their%2520Preparation%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steeneck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderhub, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhaeuser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleymann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of hydroxyamidine based inhibitors of IDO1 for cancer immunotherapy with reduced potential for glucuronidation</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">179</span>â <span class="NLM_lpage">187</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.9b00572</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00572" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1GhsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=179-187&issue=2&author=C.+Steeneckauthor=O.+Kinzelauthor=S.+Anderhubauthor=M.+Hornbergerauthor=S.+Pintoauthor=B.+Morschhaeuserauthor=F.+Braunauthor=G.+Kleymannauthor=T.+Hoffmann&title=Discovery+of+hydroxyamidine+based+inhibitors+of+IDO1+for+cancer+immunotherapy+with+reduced+potential+for+glucuronidation&doi=10.1021%2Facsmedchemlett.9b00572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Hydroxyamidine Based Inhibitors of IDO1 for Cancer Immunotherapy with Reduced Potential for Glucuronidation</span></div><div class="casAuthors">Steeneck, Christoph; Kinzel, Olaf; Anderhub, Simon; Hornberger, Martin; Pinto, Sheena; Morschhaeuser, Barbara; Braun, Floriane; Kleymann, Gerald; Hoffmann, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-187</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Following the impressive success of checkpoint inhibitors in the treatment of cancer, combinations of IDO1 inhibitors with PD-1/PD-L1 antibodies are in clin. development aiming to increase response rates.  Using the hydroxyamidine pharmacophore of the IDO1 inhibitor INCB14943 as a starting point for the design of new inhibitors, the potential shortcomings of extensive hydroxyamidine glucuronidation in humans was addressed.  Compds. were optimized using a stability assay with recombinant UGT1A9 enzyme together with the measurement of glucuronide formation in human hepatocytes.  Optimized analog 24 showed cellular and biochem. IDO1 IC50 values in the low nanomolar range, a suitable in vitro ADME/PK profile, and efficacy in an animal model of cancer.  In a humanized liver mouse model the lead compd. exhibited significantly reduced glucuronidation compared to epacadostat (2).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL0q_mXp0hC7Vg90H21EOLACvtfcHk0ljWrSorzDIUXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1GhsLs%253D&md5=ef40add370d8e26624bda069c834442e</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00572%26sid%3Dliteratum%253Aachs%26aulast%3DSteeneck%26aufirst%3DC.%26aulast%3DKinzel%26aufirst%3DO.%26aulast%3DAnderhub%26aufirst%3DS.%26aulast%3DHornberger%26aufirst%3DM.%26aulast%3DPinto%26aufirst%3DS.%26aulast%3DMorschhaeuser%26aufirst%3DB.%26aulast%3DBraun%26aufirst%3DF.%26aulast%3DKleymann%26aufirst%3DG.%26aulast%3DHoffmann%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520hydroxyamidine%2520based%2520inhibitors%2520of%2520IDO1%2520for%2520cancer%2520immunotherapy%2520with%2520reduced%2520potential%2520for%2520glucuronidation%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26issue%3D2%26spage%3D179%26epage%3D187%26doi%3D10.1021%2Facsmedchemlett.9b00572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steeneck, C.</span>; <span class="NLM_string-name">Kinzel, O.</span>; <span class="NLM_string-name">Anderhub, S.</span>; <span class="NLM_string-name">Hornberger, M.</span>; <span class="NLM_string-name">Kleymann, G.</span>; <span class="NLM_string-name">Hoffmann, T.</span></span> <span> </span><span class="NLM_article-title">Substituted N-Hydroxyamidinoheterocycles as Modulators of Indoleamine 2,3-Dioxygenase and Their Preparation</span>. <span class="NLM_patent">WO2018083241A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=C.+Steeneck&author=O.+Kinzel&author=S.+Anderhub&author=M.+Hornberger&author=G.+Kleymann&author=T.+Hoffmann&title=Substituted+N-Hydroxyamidinoheterocycles+as+Modulators+of+Indoleamine+2%2C3-Dioxygenase+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSteeneck%26aufirst%3DC.%26atitle%3DSubstituted%2520N-Hydroxyamidinoheterocycles%2520as%2520Modulators%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520and%2520Their%2520Preparation%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">112059</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2020.112059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.ejmech.2020.112059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=31981851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslSgtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2020&pages=112059&author=X.+Songauthor=P.+Sunauthor=J.+Wangauthor=W.+Guoauthor=Y.+Wangauthor=L.+H.+Mengauthor=H.+Liu&title=Design%2C+synthesis%2C+and+biological+evaluation+of+1%2C2%2C5-oxadiazole-3-carboximidamide+derivatives+as+novel+indoleamine-2%2C3-dioxygenase+1+inhibitors&doi=10.1016%2Fj.ejmech.2020.112059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors</span></div><div class="casAuthors">Song, Xiaohan; Sun, Pu; Wang, Jiang; Guo, Wei; Wang, Yi; Meng, Ling-hua; Liu, Hong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112059</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of 1,2,5-oxadiazole-3-carboximidamide derivs. I [R = (1-sulfamoylpyrrolidin-3-yl)methyl, (1-methanesulfonylpyrrolidin-3-yl)methyl, [1-(cyclopropanesulfonyl)piperidin-3-yl]methyl, etc] bearing cycle in the side chain were designed, synthesized, and biol. evaluated for their anti-tumor activity.  Most of them exhibited potent activity against hIDO1 in enzymic assays and in HEK293T cells over-expressing hIDO1.  Among them, compd. I [R = [(3R)-1-sulfamoylpyrrolidin-3-yl]methyl, [(3R)-1-sulfamoylpiperidin-3-yl]methyl, [(3S)-1-sulfamoylpiperidin-3-yl]methyl] showed significant inhibitory activity against hIDO1 (IC50 = 108.7, 178.1 and 139.1 nM resp.) and in HEK293T cells expressing hIDO1 (cellular IC50 = 19.88, 68.59 and 57.76 nM resp.).  Moreover, compd. I [R = [(3R)-1-sulfamoylpiperidin-3-yl]methyl] displayed improved PK property with longer half-life (t1/2 = 3.81 h in CD-1 mice) and better oral bioavailability (F = 33.6%) compared with epacadostat.  In addn., compd. I [R = [(3R)-1-sulfamoylpiperidin-3-yl]methyl] showed similar potency to inhibit the growth of CT-26 syngeneic xenograft compared to epacadostat, making it justifiable for further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOVCKyiy04nLVg90H21EOLACvtfcHk0lhKCNXKERHTdA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslSgtrc%253D&md5=eaacdbc7d1498bc8644774d4ae1ff3d0</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112059%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DL.%2BH.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25201%252C2%252C5-oxadiazole-3-carboximidamide%2520derivatives%2520as%2520novel%2520indoleamine-2%252C3-dioxygenase%25201%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D189%26spage%3D112059%26doi%3D10.1016%2Fj.ejmech.2020.112059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vivo antitumor evaluation of an orally active potent phosphonamidate derivative targeting IDO1/IDO2/TDO</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">214</span>â <span class="NLM_lpage">223</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2019.07.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bcp.2019.07.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=31306643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVWlu7jK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2019&pages=214-223&author=X.+Fengauthor=P.+Shenauthor=Y.+Wangauthor=Z.+Liauthor=J.+Bian&title=Synthesis+and+in+vivo+antitumor+evaluation+of+an+orally+active+potent+phosphonamidate+derivative+targeting+IDO1%2FIDO2%2FTDO&doi=10.1016%2Fj.bcp.2019.07.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in vivo antitumor evaluation of an orally active potent phosphonamidate derivative targeting IDO1/IDO2/TDO</span></div><div class="casAuthors">Feng, Xi; Shen, Pei; Wang, Yinuo; Li, Zhiyu; Bian, Jinlei</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">214-223</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting Trp-Kyn pathways has been identified as an attractive approach for the cancer immunotherapies.  In this study, a novel phosphonamidate contg. compd. was designed, synthesized and evaluated for its inhibitory activity against key dioxygenases in Trp-Kyn pathway, including IDO1, IDO2 and TDO.  This compd. showed potent IDO1 inhibitory activity with an IC50 value of 94 nM in an enzymic assay and 12.6 nM in HeLa cells.  In addn., this compd. showed promising IDO2 inhibition and TDO inhibition with IC50 values of 310 nM and 2.6 Î¼M, resp., in enzyme assay.  Based on the promising enzyme inhibitory activity toward IDO/TDO, compd. F04(I) was evaluated of its antitumor effects in two tumor models.  Further evaluation of mechanism demonstrated I with the remarkable capacity of reducing kynurenine level in plasma/TME and restoring anti-tumor immune response.  I could be further developed as a potential immunotherapeutic agent combined with immune checkpoint inhibitors or chemotherapeutic drugs for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruUO0oCjsL5bVg90H21EOLACvtfcHk0lhKCNXKERHTdA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVWlu7jK&md5=465bc2f6148b05c2b00d1dec45f06234</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2019.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2019.07.011%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520in%2520vivo%2520antitumor%2520evaluation%2520of%2520an%2520orally%2520active%2520potent%2520phosphonamidate%2520derivative%2520targeting%2520IDO1%252FIDO2%252FTDO%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2019%26volume%3D168%26spage%3D214%26epage%3D223%26doi%3D10.1016%2Fj.bcp.2019.07.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Improving the potency of cancer immunotherapy by dual targeting of IDO1 and DNA</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">30</span>â <span class="NLM_lpage">36</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201700666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fcmdc.201700666" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=29205945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvF2jsb3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=30-36&issue=1&author=K.+Fangauthor=G.+Dongauthor=H.+Wangauthor=S.+Heauthor=S.+Wuauthor=W.+Wangauthor=C.+Sheng&title=Improving+the+potency+of+cancer+immunotherapy+by+dual+targeting+of+IDO1+and+DNA&doi=10.1002%2Fcmdc.201700666"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA</span></div><div class="casAuthors">Fang, Kun; Dong, Guoqiang; Wang, Hongyu; He, Shipeng; Wu, Shanchao; Wang, Wei; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-36</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Herein we report the first exploration of a dual-targeting drug design strategy to improve the efficacy of small-mol. cancer immunotherapy.  New hybrids of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and DNA alkylating nitrogen mustards that resp. target IDO1 and DNA were rationally designed.  As the first-in-class examples of such mols., they were found to exhibit significantly enhanced anticancer activity in vitro and in vivo with low toxicity.  This proof-of-concept study has established a crit. step toward the development of a novel and effective immunotherapy for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUSxFALgkwHbVg90H21EOLACvtfcHk0lhKCNXKERHTdA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvF2jsb3L&md5=bbef804d59cb318294b791064a5b7909</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700666%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DImproving%2520the%2520potency%2520of%2520cancer%2520immunotherapy%2520by%2520dual%2520targeting%2520of%2520IDO1%2520and%2520DNA%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26issue%3D1%26spage%3D30%26epage%3D36%26doi%3D10.1002%2Fcmdc.201700666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel indoleamine 2,3-dioxygenase 1 (IDO1) and histone deacetylase (HDAC) dual inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">312</span>â <span class="NLM_lpage">317</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.7b00487</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00487" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtVWrurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=312-317&issue=4&author=K.+Fangauthor=G.+Dongauthor=Y.+Liauthor=S.+Heauthor=Y.+Wuauthor=S.+Wuauthor=W.+Wangauthor=C.+Sheng&title=Discovery+of+novel+indoleamine+2%2C3-dioxygenase+1+%28IDO1%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors&doi=10.1021%2Facsmedchemlett.7b00487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors</span></div><div class="casAuthors">Fang, Kun; Dong, Guoqiang; Li, Yu; He, Shipeng; Wu, Ying; Wu, Shanchao; Wang, Wei; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">312-317</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to take advantage of both immunotherapeutic and epigenetic antitumor agents, the first generation of dual indoleamine 2,3-dioxygenase 1 (IDO1) and histone deacetylase (HDAC) inhibitors were designed.  The highly active dual inhibitor 10 showed excellent and balanced activity against both IDO1 (IC50 = 69.0 nM) and HDAC1 (IC50 = 66.5 nM), whose dual targeting mechanisms were validated in cancer cells.  Compd. 10 had good pharmacokinetic profiles as an orally active antitumor agent and significantly reduced the L-kynurenine level in plasma.  In particular, it showed excellent in vivo antitumor efficacy in the murine LLC tumor model with low toxicity.  This proof-of-concept study provided a novel strategy for cancer treatment.  Compd. 10 represents a promising lead compd. for the development of novel antitumor agents and can also be used as a valuable probe to clarify the relationships and mechanisms between cancer immunotherapy and epigenetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEDqXRR2J0zrVg90H21EOLACvtfcHk0lixdPeeUePBwA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtVWrurc%253D&md5=c808b75f03d703dc7e66798759457f4a</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00487%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520novel%2520indoleamine%25202%252C3-dioxygenase%25201%2520%2528IDO1%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D4%26spage%3D312%26epage%3D317%26doi%3D10.1021%2Facsmedchemlett.7b00487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref231"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref231'); return false;" data-citation="" class="refNumLink">231</a></strong><div class="NLM_citation" id="cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reckamp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figlin, R. A.</span></span> <span> </span><span class="NLM_article-title">Akt inhibitors in clinical development for the treatment of cancer</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1355</span>â <span class="NLM_lpage">1366</span>, <span class="refDoi">Â DOI: 10.1517/13543784.2010.520701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1517%2F13543784.2010.520701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=20846000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWmu77K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=1355-1366&issue=11&author=S.+K.+Palauthor=K.+Reckampauthor=H.+Yuauthor=R.+A.+Figlin&title=Akt+inhibitors+in+clinical+development+for+the+treatment+of+cancer&doi=10.1517%2F13543784.2010.520701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Akt inhibitors in clinical development for the treatment of cancer</span></div><div class="casAuthors">Pal, Sumanta Kumar; Reckamp, Karen; Yu, Hua; Figlin, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1355-1366</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: The evolution of targeted therapies is dependent upon identification of cellular moieties that can be pharmacol. modulated.  As one such example, the serine-threonine kinase Akt was identified nearly two decades ago.  Since then, its role in mediating multiple signaling cascades (ultimately leading to cell growth and proliferation) has since been identified.  More recently, several agents have been developed that antagonize Akt - these agents are in various stages of clin. testing.  Areas covered in this review: Herein, we outline development of several promising Akt inhibitors, including perifosine, MK-2206, RX-0201, PBI-05204, GSK2141795 and others.  What the reader will gain: The reader will gain insight into the current pipeline of Akt inhibitors, and the degree to which these agents have been examd. both clin. and preclinically.  Take home message: With an emerging pipeline of agents targeting Akt, it will be crit. to decipher which amongst them holds the greatest promise.  Herein, we explore this drug pipeline and provide strategies for detg. the future clin. application of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWER-qb8DJrbVg90H21EOLACvtfcHk0lixdPeeUePBwA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWmu77K&md5=912f499b18ab4879d7930616ecc66d3e</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1517%2F13543784.2010.520701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2010.520701%26sid%3Dliteratum%253Aachs%26aulast%3DPal%26aufirst%3DS.%2BK.%26aulast%3DReckamp%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DFiglin%26aufirst%3DR.%2BA.%26atitle%3DAkt%2520inhibitors%2520in%2520clinical%2520development%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2010%26volume%3D19%26issue%3D11%26spage%3D1355%26epage%3D1366%26doi%3D10.1517%2F13543784.2010.520701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref232"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref232'); return false;" data-citation="" class="refNumLink">232</a></strong><div class="NLM_citation" id="cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heerding, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leber, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keenan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafrance, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safonov, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takata, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venslavsky, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhry, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaber, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strum, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duckett, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberwein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knick, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansing, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minthorn, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Concha, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of Akt kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">5663</span>â <span class="NLM_lpage">5679</span>, <span class="refDoi">Â DOI: 10.1021/jm8004527</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8004527" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVChs7bE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5663-5679&issue=18&author=D.+A.+Heerdingauthor=N.+Rhodesauthor=J.+D.+Leberauthor=T.+J.+Clarkauthor=R.+M.+Keenanauthor=L.+V.+Lafranceauthor=M.+Liauthor=I.+G.+Safonovauthor=D.+T.+Takataauthor=J.+W.+Venslavskyauthor=D.+S.+Yamashitaauthor=A.+E.+Choudhryauthor=R.+A.+Copelandauthor=Z.+Laiauthor=M.+D.+Schaberauthor=P.+J.+Tumminoauthor=S.+L.+Strumauthor=E.+R.+Woodauthor=D.+R.+Duckettauthor=D.+Eberweinauthor=V.+B.+Knickauthor=T.+J.+Lansingauthor=R.+T.+McConnellauthor=S.+Y.+Zhangauthor=E.+A.+Minthornauthor=N.+O.+Conchaauthor=G.+L.+Warrenauthor=R.+Kumar&title=Identification+of+4-%282-%284-Amino-1%2C2%2C5-oxadiazol-3-yl%29-1-ethyl-7-%7B%5B%283S%29-3-piperidinylmethyl%5Doxy%7D-1H-imidazo%5B4%2C5-c%5Dpyridin-4-yl%29-2-methyl-3-butyn-2-ol+%28GSK690693%29%2C+a+novel+inhibitor+of+Akt+kinase&doi=10.1021%2Fjm8004527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a Novel Inhibitor of AKT Kinase</span></div><div class="casAuthors">Heerding, Dirk A.; Rhodes, Nelson; Leber, Jack D.; Clark, Tammy J.; Keenan, Richard M.; Lafrance, Louis V.; Li, Mei; Safonov, Igor G.; Takata, Dennis T.; Venslavsky, Joseph W.; Yamashita, Dennis S.; Choudhry, Anthony E.; Copeland, Robert A.; Lai, Zhihong; Schaber, Michael D.; Tummino, Peter J.; Strum, Susan L.; Wood, Edgar R.; Duckett, Derek R.; Eberwein, Derek; Knick, Victoria B.; Lansing, Timothy J.; McConnell, Randy T.; Zhang, Shu Yun; Minthorn, Elisabeth A.; Concha, Nestor O.; Warren, Gregory L.; Kumar, Rakesh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5663-5679</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Overexpression of AKT has an antiapoptotic effect in many cell types, and expression of dominant neg. AKT blocks the ability of a variety of growth factors to promote survival.  Therefore, inhibitors of AKT kinase activity might be useful as monotherapy for the treatment of tumors with activated AKT.  Herein, we describe our lead optimization studies culminating in the discovery of compd. 3g (GSK690693, I).  Compd. 3g is a novel ATP competitive, pan-AKT kinase inhibitor with IC50 values of 2, 13, and 9 nM against AKT1, 2, and 3, resp.  An X-ray cocrystal structure was solved with 3g and the kinase domain of AKT2, confirming that 3g bound in the ATP binding pocket.  Compd. 3g potently inhibits intracellular AKT activity as measured by the inhibition of the phosphorylation levels of GSK3Î².  I.p. administration of 3g in immunocompromised mice results in the inhibition of GSK3Î² phosphorylation and tumor growth in human breast carcinoma (BT474) xenografts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIAGkPktggErVg90H21EOLACvtfcHk0lhv3y1G2XHQfQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVChs7bE&md5=c0e6f283a3ee79dffafdd90ec69513bc</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1021%2Fjm8004527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8004527%26sid%3Dliteratum%253Aachs%26aulast%3DHeerding%26aufirst%3DD.%2BA.%26aulast%3DRhodes%26aufirst%3DN.%26aulast%3DLeber%26aufirst%3DJ.%2BD.%26aulast%3DClark%26aufirst%3DT.%2BJ.%26aulast%3DKeenan%26aufirst%3DR.%2BM.%26aulast%3DLafrance%26aufirst%3DL.%2BV.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DSafonov%26aufirst%3DI.%2BG.%26aulast%3DTakata%26aufirst%3DD.%2BT.%26aulast%3DVenslavsky%26aufirst%3DJ.%2BW.%26aulast%3DYamashita%26aufirst%3DD.%2BS.%26aulast%3DChoudhry%26aufirst%3DA.%2BE.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DSchaber%26aufirst%3DM.%2BD.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DStrum%26aufirst%3DS.%2BL.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DDuckett%26aufirst%3DD.%2BR.%26aulast%3DEberwein%26aufirst%3DD.%26aulast%3DKnick%26aufirst%3DV.%2BB.%26aulast%3DLansing%26aufirst%3DT.%2BJ.%26aulast%3DMcConnell%26aufirst%3DR.%2BT.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DMinthorn%26aufirst%3DE.%2BA.%26aulast%3DConcha%26aufirst%3DN.%2BO.%26aulast%3DWarren%26aufirst%3DG.%2BL.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DIdentification%2520of%25204-%25282-%25284-Amino-1%252C2%252C5-oxadiazol-3-yl%2529-1-ethyl-7-%257B%255B%25283S%2529-3-piperidinylmethyl%255Doxy%257D-1H-imidazo%255B4%252C5-c%255Dpyridin-4-yl%2529-2-methyl-3-butyn-2-ol%2520%2528GSK690693%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520Akt%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D18%26spage%3D5663%26epage%3D5679%26doi%3D10.1021%2Fjm8004527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref233"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref233'); return false;" data-citation="" class="refNumLink">233</a></strong><div class="NLM_citation" id="cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerding, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duckett, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberwein, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knick, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansing, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahana, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geske, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleymenova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhry, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leber, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minthorn, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strum, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2366</span>â <span class="NLM_lpage">2374</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-07-5783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1158%2F0008-5472.CAN-07-5783" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=18381444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktV2jsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=2366-2374&issue=7&author=N.+Rhodesauthor=D.+A.+Heerdingauthor=D.+R.+Duckettauthor=D.+J.+Eberweinauthor=V.+B.+Knickauthor=T.+J.+Lansingauthor=R.+T.+McConnellauthor=T.+M.+Gilmerauthor=S.+Y.+Zhangauthor=K.+Robellauthor=J.+A.+Kahanaauthor=R.+S.+Geskeauthor=E.+V.+Kleymenovaauthor=A.+E.+Choudhryauthor=Z.+Laiauthor=J.+D.+Leberauthor=E.+A.+Minthornauthor=S.+L.+Strumauthor=E.+R.+Woodauthor=P.+S.+Huangauthor=R.+A.+Copelandauthor=R.+Kumar&title=Characterization+of+an+Akt+kinase+inhibitor+with+potent+pharmacodynamic+and+antitumor+activity&doi=10.1158%2F0008-5472.CAN-07-5783"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity</span></div><div class="casAuthors">Rhodes, Nelson; Heerding, Dirk A.; Duckett, Derek R.; Eberwein, Derek J.; Knick, Victoria B.; Lansing, Timothy J.; McConnell, Randy T.; Gilmer, Tona M.; Zhang, Shu-Yun; Robell, Kimberly; Kahana, Jason A.; Geske, Robert S.; Kleymenova, Elena V.; Choudhry, Anthony E.; Lai, Zhihong; Leber, Jack D.; Minthorn, Elisabeth A.; Strum, Susan L.; Wood, Edgar R.; Huang, Pearl S.; Copeland, Robert A.; Kumar, Rakesh</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2366-2374</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Akt kinases 1, 2, and 3 are important regulators of cell survival and have been shown to be constitutively active in a variety of human tumors.  GSK690693 is a novel ATP-competitive, low-nanomolar pan-Akt kinase inhibitor.  It is selective for the Akt isoforms vs. the majority of kinases in other families; however, it does inhibit addnl. members of the AGC kinase family.  It causes dose-dependent redns. in the phosphorylation state of multiple proteins downstream of Akt, including GSK3Î², PRAS40, and Forkhead.  GSK690693 inhibited proliferation and induced apoptosis in a subset of tumor cells with potency consistent with intracellular inhibition of Akt kinase activity.  In immune-compromised mice implanted with human BT474 breast carcinoma xenografts, a single i.p. administration of GSK690693 inhibited GSK3Î² phosphorylation in a dose- and time-dependent manner.  After a single dose of GSK690693, >3 Î¼mol/L drug concn. in BT474 tumor xenografts correlated with a sustained decrease in GSK3Î² phosphorylation.  Consistent with the role of Akt in insulin signaling, treatment with GSK690693 resulted in acute and transient increases in blood glucose level.  Daily administration of GSK690693 produced significant antitumor activity in mice bearing established human SKOV-3 ovarian, LNCaP prostate, and BT474 and HCC-1954 breast carcinoma xenografts.  Immunohistochem. anal. of tumor xenografts after repeat dosing with GSK690693 showed redns. in phosphorylated Akt substrates in vivo.  These results support further evaluation of GSK690693 as an anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrIdccCuUbkLVg90H21EOLACvtfcHk0lhv3y1G2XHQfQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktV2jsrg%253D&md5=767976fefa3818022ae86d9903c79dad</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-5783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-5783%26sid%3Dliteratum%253Aachs%26aulast%3DRhodes%26aufirst%3DN.%26aulast%3DHeerding%26aufirst%3DD.%2BA.%26aulast%3DDuckett%26aufirst%3DD.%2BR.%26aulast%3DEberwein%26aufirst%3DD.%2BJ.%26aulast%3DKnick%26aufirst%3DV.%2BB.%26aulast%3DLansing%26aufirst%3DT.%2BJ.%26aulast%3DMcConnell%26aufirst%3DR.%2BT.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DRobell%26aufirst%3DK.%26aulast%3DKahana%26aufirst%3DJ.%2BA.%26aulast%3DGeske%26aufirst%3DR.%2BS.%26aulast%3DKleymenova%26aufirst%3DE.%2BV.%26aulast%3DChoudhry%26aufirst%3DA.%2BE.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DLeber%26aufirst%3DJ.%2BD.%26aulast%3DMinthorn%26aufirst%3DE.%2BA.%26aulast%3DStrum%26aufirst%3DS.%2BL.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DHuang%26aufirst%3DP.%2BS.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DCharacterization%2520of%2520an%2520Akt%2520kinase%2520inhibitor%2520with%2520potent%2520pharmacodynamic%2520and%2520antitumor%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26issue%3D7%26spage%3D2366%26epage%3D2374%26doi%3D10.1158%2F0008-5472.CAN-07-5783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref234"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref234'); return false;" data-citation="" class="refNumLink">234</a></strong><div class="NLM_citation" id="cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurwitz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiorean, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampkin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebowitz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, B.</span></span> <span> </span><span class="NLM_article-title">Akt inhibitor GSK690693: Preliminary results from the first time in human study</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">LB</span>â <span class="NLM_lpage">68</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=LB-68&author=P.+LoRussoauthor=H.+Hurwitzauthor=E.+Chioreanauthor=R.+Jewellauthor=T.+Lampkinauthor=K.+Bachmanauthor=R.+Kumarauthor=P.+Lebowitzauthor=B.+Weber&title=Akt+inhibitor+GSK690693%3A+Preliminary+results+from+the+first+time+in+human+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DHurwitz%26aufirst%3DH.%26aulast%3DChiorean%26aufirst%3DE.%26aulast%3DJewell%26aufirst%3DR.%26aulast%3DLampkin%26aufirst%3DT.%26aulast%3DBachman%26aufirst%3DK.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DLebowitz%26aufirst%3DP.%26aulast%3DWeber%26aufirst%3DB.%26atitle%3DAkt%2520inhibitor%2520GSK690693%253A%2520Preliminary%2520results%2520from%2520the%2520first%2520time%2520in%2520human%2520study%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3DLB%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref235"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref235'); return false;" data-citation="" class="refNumLink">235</a></strong><div class="NLM_citation" id="cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bandarage, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hare, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marhefka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bemis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodems, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charonnet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Come, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span> <span> </span><span class="NLM_article-title">4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Potent and selective p70S6 kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">5191</span>â <span class="NLM_lpage">5194</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2009.07.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmcl.2009.07.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=19632115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVSlsrrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5191-5194&issue=17&author=U.+Bandarageauthor=B.+Hareauthor=J.+Parsonsauthor=L.+Phamauthor=C.+Marhefkaauthor=G.+Bemisauthor=Q.+Tangauthor=C.+S.+Moodyauthor=S.+Rodemsauthor=S.+Shahauthor=C.+Adamsauthor=J.+Bravoauthor=E.+Charonnetauthor=V.+Savicauthor=J.+H.+Comeauthor=J.+Green&title=4-%28Benzimidazol-2-yl%29-1%2C2%2C5-oxadiazol-3-ylamine+derivatives%3A+Potent+and+selective+p70S6+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2009.07.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Potent and selective p70S6 kinase inhibitors</span></div><div class="casAuthors">Bandarage, Upul; Hare, Brian; Parsons, Jonathan; Pham, Ly; Marhefka, Craig; Bemis, Guy; Tang, Qing; Moody, Cameron Stuver; Rodems, Steve; Shah, Sundeep; Adams, Chris; Bravo, Jose; Charonnet, Emmanuelle; Savic, Vladimir; Come, Jon H.; Green, Jeremy</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5191-5194</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The design and synthesis of 4-(benzimidazol-2-yl)-1,2,5-oxadiazol-3-amine derivs. I (R1 = Me, i-Pr, Ph, R2 = H; etc.) as inhibitors of p70S6 kinase was reported.  Structure-based design employing an active site homol. model derived from PKA led to the prepn. of benzimidazole 5-substituted compds. I (R1 = c-Bu, R2 = OH, NH2) as highly potent inhibitors (Ki <1 nM) of p70S6K, with >100-fold selectivity against related kinases PKA, ROCK and GSK3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXcs_rzc0eabVg90H21EOLACvtfcHk0ljm3CQ93omZog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVSlsrrF&md5=93423c5bcbdfc437444c737314d28165</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.07.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.07.022%26sid%3Dliteratum%253Aachs%26aulast%3DBandarage%26aufirst%3DU.%26aulast%3DHare%26aufirst%3DB.%26aulast%3DParsons%26aufirst%3DJ.%26aulast%3DPham%26aufirst%3DL.%26aulast%3DMarhefka%26aufirst%3DC.%26aulast%3DBemis%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DQ.%26aulast%3DMoody%26aufirst%3DC.%2BS.%26aulast%3DRodems%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DAdams%26aufirst%3DC.%26aulast%3DBravo%26aufirst%3DJ.%26aulast%3DCharonnet%26aufirst%3DE.%26aulast%3DSavic%26aufirst%3DV.%26aulast%3DCome%26aufirst%3DJ.%2BH.%26aulast%3DGreen%26aufirst%3DJ.%26atitle%3D4-%2528Benzimidazol-2-yl%2529-1%252C2%252C5-oxadiazol-3-ylamine%2520derivatives%253A%2520Potent%2520and%2520selective%2520p70S6%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D17%26spage%3D5191%26epage%3D5194%26doi%3D10.1016%2Fj.bmcl.2009.07.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref236"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref236'); return false;" data-citation="" class="refNumLink">236</a></strong><div class="NLM_citation" id="cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Come, J. H.</span>; <span class="NLM_string-name">Green, J.</span>; <span class="NLM_string-name">Marhefka, C.</span>; <span class="NLM_string-name">Harbeson, S. L.</span>; <span class="NLM_string-name">Pham, L.</span></span> <span> </span><span class="NLM_article-title">Preparation of Aminofurazan Derivatives as Protein Kinase Inhibitors</span>. <span class="NLM_patent">WO2005019190A2</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=J.+H.+Come&author=J.+Green&author=C.+Marhefka&author=S.+L.+Harbeson&author=L.+Pham&title=Preparation+of+Aminofurazan+Derivatives+as+Protein+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCome%26aufirst%3DJ.%2BH.%26atitle%3DPreparation%2520of%2520Aminofurazan%2520Derivatives%2520as%2520Protein%2520Kinase%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref237"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref237'); return false;" data-citation="" class="refNumLink">237</a></strong><div class="NLM_citation" id="cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asakawa, K.</span>; <span class="NLM_string-name">Hashimoto, M.</span>; <span class="NLM_string-name">Ito, H.</span>; <span class="NLM_string-name">Nakamura, M.</span>; <span class="NLM_string-name">Nonoshita, K.</span>; <span class="NLM_string-name">Okubo, M.</span>; <span class="NLM_string-name">Sato, A.</span>; <span class="NLM_string-name">Takahashi, H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Novel Spiro Indan Derivatives as Protein Kinase RSK1 Inhibitors and Antitumor Agents</span>. <span class="NLM_patent">JP2009173629A</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=K.+Asakawa&author=M.+Hashimoto&author=H.+Ito&author=M.+Nakamura&author=K.+Nonoshita&author=M.+Okubo&author=A.+Sato&author=H.+Takahashi&title=Preparation+of+Novel+Spiro+Indan+Derivatives+as+Protein+Kinase+RSK1+Inhibitors+and+Antitumor+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAsakawa%26aufirst%3DK.%26atitle%3DPreparation%2520of%2520Novel%2520Spiro%2520Indan%2520Derivatives%2520as%2520Protein%2520Kinase%2520RSK1%2520Inhibitors%2520and%2520Antitumor%2520Agents%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref238"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref238'); return false;" data-citation="" class="refNumLink">238</a></strong><div class="NLM_citation" id="cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aulinger-Fuchs, K.</span>; <span class="NLM_string-name">Herz, T.</span>; <span class="NLM_string-name">Krauss, R.</span>; <span class="NLM_string-name">Kubbutat, M.</span>; <span class="NLM_string-name">Lang, M.</span>; <span class="NLM_string-name">Schaechtele, C.</span>; <span class="NLM_string-name">Totzke, F.</span></span> <span> </span><span class="NLM_article-title">Preparation of Oxadiazolopyrazines as Kinase Inhibitors</span>. <span class="NLM_patent">WO2005044270A1</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=K.+Aulinger-Fuchs&author=T.+Herz&author=R.+Krauss&author=M.+Kubbutat&author=M.+Lang&author=C.+Schaechtele&author=F.+Totzke&title=Preparation+of+Oxadiazolopyrazines+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAulinger-Fuchs%26aufirst%3DK.%26atitle%3DPreparation%2520of%2520Oxadiazolopyrazines%2520as%2520Kinase%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref239"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref239'); return false;" data-citation="" class="refNumLink">239</a></strong><div class="NLM_citation" id="cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pyrkov, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevostyanova, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmalhausen, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shkoporov, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinnik, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muronetz, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Severin, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedichev, P. O.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of small-molecule ligands of phosphofructokinase-2 activating or inhibiting glycolysis</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1322</span>â <span class="NLM_lpage">1329</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201300154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fcmdc.201300154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=23813838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVait7zE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1322-1329&issue=8&author=T.+V.+Pyrkovauthor=I.+A.+Sevostyanovaauthor=E.+V.+Schmalhausenauthor=A.+N.+Shkoporovauthor=A.+A.+Vinnikauthor=V.+I.+Muronetzauthor=F.+F.+Severinauthor=P.+O.+Fedichev&title=Structure-based+design+of+small-molecule+ligands+of+phosphofructokinase-2+activating+or+inhibiting+glycolysis&doi=10.1002%2Fcmdc.201300154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Small-Molecule Ligands of Phosphofructokinase-2 Activating or Inhibiting Glycolysis</span></div><div class="casAuthors">Pyrkov, Timothy V.; Sevostyanova, Irina A.; Schmalhausen, Elena V.; Shkoporov, Andrei N.; Vinnik, Andrei A.; Muronetz, Vladimir I.; Severin, Fedor F.; Fedichev, Peter O.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1322-1329</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Glycolysis lies at the basis of metab. and cell energy supply.  The disregulation of glycolysis is involved in such pathol. processes as cancer proliferation, neurodegenerative diseases, and amplification of ischemic damage.  Phosphofructokinase-2 (PFK-2), a bifunctional enzyme and regulator of glycolytic flux, has recently emerged as a promising anticancer target.  Herein, the computer-aided design of a new class of aminofurazan-triazole regulators of PFK-2 is described along with the results of their in vitro evaluation.  The aminofurazan-triazoles differ from other recently described inhibitors of PFK-2 and demonstrate the ability to modulate glycolytic flux in rat muscle lysate, producing a twofold decrease by inhibitors and fourfold increase by activators.  The most potent compds. in the series were shown to inhibit the kinase activity of the hypoxia-inducible form of PFK-2, PFKFB3, as well as proliferation of HeLa, lung adenocarcinoma, colon adenocarcinoma, and breast cancer cells at concns. in the low micromolar range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH3hQmNOqY0LVg90H21EOLACvtfcHk0ljm3CQ93omZog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVait7zE&md5=a78f5f7a035e912e061fef08ad82c8bd</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300154%26sid%3Dliteratum%253Aachs%26aulast%3DPyrkov%26aufirst%3DT.%2BV.%26aulast%3DSevostyanova%26aufirst%3DI.%2BA.%26aulast%3DSchmalhausen%26aufirst%3DE.%2BV.%26aulast%3DShkoporov%26aufirst%3DA.%2BN.%26aulast%3DVinnik%26aufirst%3DA.%2BA.%26aulast%3DMuronetz%26aufirst%3DV.%2BI.%26aulast%3DSeverin%26aufirst%3DF.%2BF.%26aulast%3DFedichev%26aufirst%3DP.%2BO.%26atitle%3DStructure-based%2520design%2520of%2520small-molecule%2520ligands%2520of%2520phosphofructokinase-2%2520activating%2520or%2520inhibiting%2520glycolysis%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26issue%3D8%26spage%3D1322%26epage%3D1329%26doi%3D10.1002%2Fcmdc.201300154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref240"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref240'); return false;" data-citation="" class="refNumLink">240</a></strong><div class="NLM_citation" id="cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sha, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. F.</span></span> <span> </span><span class="NLM_article-title">6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol: A promising new anticancer compound</span>. <i>Biosci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">BSR20171440</span>, <span class="refDoi">Â DOI: 10.1042/BSR20171440</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1042%2FBSR20171440" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=29358310" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=BSR20171440&issue=1&author=H.+H.+Shaauthor=Z.+Wangauthor=S.+C.+Dongauthor=T.+M.+Huauthor=S.+W.+Liuauthor=J.+Y.+Zhangauthor=Y.+Wuauthor=R.+Maauthor=J.+Z.+Wuauthor=D.+Chenauthor=J.+F.+Feng&title=6-%287-Nitro-2%2C1%2C3-benzoxadiazol-4-ylthio%29+hexanol%3A+A+promising+new+anticancer+compound&doi=10.1042%2FBSR20171440"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1042%2FBSR20171440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBSR20171440%26sid%3Dliteratum%253Aachs%26aulast%3DSha%26aufirst%3DH.%2BH.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DDong%26aufirst%3DS.%2BC.%26aulast%3DHu%26aufirst%3DT.%2BM.%26aulast%3DLiu%26aufirst%3DS.%2BW.%26aulast%3DZhang%26aufirst%3DJ.%2BY.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DJ.%2BZ.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DFeng%26aufirst%3DJ.%2BF.%26atitle%3D6-%25287-Nitro-2%252C1%252C3-benzoxadiazol-4-ylthio%2529%2520hexanol%253A%2520A%2520promising%2520new%2520anticancer%2520compound%26jtitle%3DBiosci.%2520Rep.%26date%3D2018%26volume%3D38%26issue%3D1%26spage%3DBSR20171440%26doi%3D10.1042%2FBSR20171440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref241"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref241'); return false;" data-citation="" class="refNumLink">241</a></strong><div class="NLM_citation" id="cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caccuri, A. M.</span>; <span class="NLM_string-name">Ricci, G.</span></span> <span> </span><span class="NLM_article-title">Preparation of 7-Nitro-2,1,3-benzoxadiazole Derivatives for Use in Anticancer Therapy</span>. <span class="NLM_patent">WO2004093874A1</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=A.+M.+Caccuri&author=G.+Ricci&title=Preparation+of+7-Nitro-2%2C1%2C3-benzoxadiazole+Derivatives+for+Use+in+Anticancer+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCaccuri%26aufirst%3DA.%2BM.%26atitle%3DPreparation%2520of%25207-Nitro-2%252C1%252C3-benzoxadiazole%2520Derivatives%2520for%2520Use%2520in%2520Anticancer%2520Therapy%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref242"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref242'); return false;" data-citation="" class="refNumLink">242</a></strong><div class="NLM_citation" id="cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ricci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Maria, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turella, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stella, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filomeni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federici, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccuri, A. M.</span></span> <span> </span><span class="NLM_article-title">7-Nitro-2,1,3-benzoxadiazole derivatives, a new class of suicide inhibitors for glutathione S-transferases. Mechanism of action of potential anticancer drugs</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span> (<span class="NLM_issue">28</span>),  <span class="NLM_fpage">26397</span>â <span class="NLM_lpage">26405</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M503295200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1074%2Fjbc.M503295200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=15888444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvFymtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=26397-26405&issue=28&author=G.+Ricciauthor=F.+De+Mariaauthor=G.+Antoniniauthor=P.+Turellaauthor=A.+Bulloauthor=L.+Stellaauthor=G.+Filomeniauthor=G.+Federiciauthor=A.+M.+Caccuri&title=7-Nitro-2%2C1%2C3-benzoxadiazole+derivatives%2C+a+new+class+of+suicide+inhibitors+for+glutathione+S-transferases.+Mechanism+of+action+of+potential+anticancer+drugs&doi=10.1074%2Fjbc.M503295200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">7-Nitro-2,1,3-benzoxadiazole Derivatives, a New Class of Suicide Inhibitors for Glutathione S-Transferases: mechanism of action of potential anticancer drugs</span></div><div class="casAuthors">Ricci, Giorgio; De Maria, Francesca; Antonini, Giovanni; Turella, Paola; Bullo, Angela; Stella, Lorenzo; Filomeni, Giuseppe; Federici, Giorgio; Caccuri, Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">26397-26405</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Spectroscopic and rapid kinetic expts. were performed to detail the interaction of human glutathione S-transferases GSTA1-1, GSTM2-2, and GSTP1-1 with 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX).  This compd. is a representative mol. of a new class of 7-nitro-2,1,3-benzoxadiazole (NBD) derivs. (non-GSH peptidomimetic compds.) that have been designed both to give strong GST inhibition and to accumulate in tumor cells avoiding the extrusion mechanisms mediated by the multidrug resistance protein pumps.  The authors have recently shown that submicromolar amts. of NBDHEX trigger apoptosis in several human tumor cell lines through the dissocn. of the JNKÂ·GSTP1-1 complex.  Results reported in the present study indicated that NBDHEX behaves like a suicide inhibitor for GSTs.  It bound to the H-site and was conjugated with GSH forming a Ï complex at the C-4 of the benzoxadiazole ring.  This complex was tightly stabilized in the active site of GSTP1-1 and GSTM2-2, whereas in GSTA1-1 the release of the 6-mercapto-1-hexanol from the Ï complex was the favored event.  Docking studies demonstrated the likely localization of the Ï complex in the GST active sites and provide a structural explanation for its strong stabilization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY0uWFsdpScrVg90H21EOLACvtfcHk0lhkCLyq3aQZxA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvFymtbY%253D&md5=a191d7a300478aa7d7fa2f70e2864f1e</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M503295200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M503295200%26sid%3Dliteratum%253Aachs%26aulast%3DRicci%26aufirst%3DG.%26aulast%3DDe%2BMaria%26aufirst%3DF.%26aulast%3DAntonini%26aufirst%3DG.%26aulast%3DTurella%26aufirst%3DP.%26aulast%3DBullo%26aufirst%3DA.%26aulast%3DStella%26aufirst%3DL.%26aulast%3DFilomeni%26aufirst%3DG.%26aulast%3DFederici%26aufirst%3DG.%26aulast%3DCaccuri%26aufirst%3DA.%2BM.%26atitle%3D7-Nitro-2%252C1%252C3-benzoxadiazole%2520derivatives%252C%2520a%2520new%2520class%2520of%2520suicide%2520inhibitors%2520for%2520glutathione%2520S-transferases.%2520Mechanism%2520of%2520action%2520of%2520potential%2520anticancer%2520drugs%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26issue%3D28%26spage%3D26397%26epage%3D26405%26doi%3D10.1074%2Fjbc.M503295200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref243"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref243'); return false;" data-citation="" class="refNumLink">243</a></strong><div class="NLM_citation" id="cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turella, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filomeni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Maria, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghibelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciriolo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianfriglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federici, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccuri, A. M.</span></span> <span> </span><span class="NLM_article-title">Proapoptotic activity of new glutathione S-transferase inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3751</span>â <span class="NLM_lpage">3761</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-04-3903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1158%2F0008-5472.CAN-04-3903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=15867371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslGksr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=3751-3761&issue=9&author=P.+Turellaauthor=C.+Cerellaauthor=G.+Filomeniauthor=A.+Bulloauthor=F.+De+Mariaauthor=L.+Ghibelliauthor=M.+R.+Cirioloauthor=M.+Cianfrigliaauthor=M.+Matteiauthor=G.+Federiciauthor=G.+Ricciauthor=A.+M.+Caccuri&title=Proapoptotic+activity+of+new+glutathione+S-transferase+inhibitors&doi=10.1158%2F0008-5472.CAN-04-3903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit243R"><div class="casContent"><span class="casTitleNuber">243</span><div class="casTitle"><span class="NLM_cas:atitle">Proapoptotic activity of new glutathione S-transferase inhibitors</span></div><div class="casAuthors">Turella, Paola; Cerella, Claudia; Filomeni, Giuseppe; Bullo, Angela; De Maria, Francesca; Ghibelli, Lina; Ciriolo, Maria Rosa; Cianfriglia, Maurizio; Mattei, Maurizio; Federici, Giorgio; Ricci, Giorgio; Caccuri, Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3751-3761</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Selected 7-nitro-2,1,3-benzoxadiazole derivs. have been recently found very efficient inhibitors of glutathione S-transferase (GST) P1-1,5 an enzyme which displays antiapoptotic activity and is also involved in the cellular resistance to anticancer drugs.  These new inhibitors are not tripeptide glutathione-peptidomimetic mols. and display lipophilic properties suitable for crossing the plasma membrane.  In the present work, we show the strong cytotoxic activity of these compds. in the following four different cell lines: K562 (human myeloid leukemia), HepG2 (human hepatic carcinoma), CCRF-CEM (human T-lymphoblastic leukemia), and GLC-4 (human small cell lung carcinoma).  The LC50 values are in the micromolar/submicromolar range and are close to the IC50 values obtained with GSTP1-1, suggesting that the target of these mols. inside the cell is indeed this enzyme.  The cytotoxic mechanism of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol, the most effective GSTP1-1 inhibitor, has been carefully investigated in leukemic CCRF-CEM and K562 cell lines.  Western blot and immunopptn. analyzes have shown that 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol promotes in both cell lines the dissocn. of the GSTP1-1 in a complex with c-jun NH2-terminal kinase (JNK).  This process triggers a reactive oxygen species (ROS)-independent activation of the JNK-mediated pathway that results in a typical process of apoptosis.  Besides this main pathway, in K562 cells, a ROS-mediated apoptosis partially occurs (about 30%) which involves the p38MAPK signal transduction pathway.  The low concn. of this new compd. needed to trigger cytotoxic effects on tumor cells and the low toxicity on mice indicate that the new 7-nitro-2,1,3-benzoxadiazole derivs. are promising anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokV0HclcX2SrVg90H21EOLACvtfcHk0lhkCLyq3aQZxA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslGksr0%253D&md5=15227a889b1865ee73eeb7241725fdbe</span></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-3903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-3903%26sid%3Dliteratum%253Aachs%26aulast%3DTurella%26aufirst%3DP.%26aulast%3DCerella%26aufirst%3DC.%26aulast%3DFilomeni%26aufirst%3DG.%26aulast%3DBullo%26aufirst%3DA.%26aulast%3DDe%2BMaria%26aufirst%3DF.%26aulast%3DGhibelli%26aufirst%3DL.%26aulast%3DCiriolo%26aufirst%3DM.%2BR.%26aulast%3DCianfriglia%26aufirst%3DM.%26aulast%3DMattei%26aufirst%3DM.%26aulast%3DFederici%26aufirst%3DG.%26aulast%3DRicci%26aufirst%3DG.%26aulast%3DCaccuri%26aufirst%3DA.%2BM.%26atitle%3DProapoptotic%2520activity%2520of%2520new%2520glutathione%2520S-transferase%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26issue%3D9%26spage%3D3751%26epage%3D3761%26doi%3D10.1158%2F0008-5472.CAN-04-3903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref244"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref244'); return false;" data-citation="" class="refNumLink">244</a></strong><div class="NLM_citation" id="cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pellizzari Tregno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geroni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapenta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filomeni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federici, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccuri, A. M.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo efficacy of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2606</span>â <span class="NLM_lpage">2617</span>, <span class="refDoi">Â DOI: 10.1016/j.ejca.2009.06.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.ejca.2009.06.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=19665369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVKls7jO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2009&pages=2606-2617&issue=14&author=F.+Pellizzari+Tregnoauthor=A.+Sauauthor=S.+Pezzolaauthor=C.+Geroniauthor=C.+Lapentaauthor=M.+Spadaauthor=G.+Filomeniauthor=E.+Bonannoauthor=G.+Federiciauthor=A.+M.+Caccuri&title=In+vitro+and+in+vivo+efficacy+of+6-%287-nitro-2%2C1%2C3-benzoxadiazol-4-ylthio%29hexanol+%28NBDHEX%29+on+human+melanoma&doi=10.1016%2Fj.ejca.2009.06.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo efficacy of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma</span></div><div class="casAuthors">Pellizzari Tregno, Francesca; Sau, Andrea; Pezzola, Silvia; Geroni, Cristina; Lapenta, Caterina; Spada, Massimo; Filomeni, Giuseppe; Bonanno, Elena; Federici, Giorgio; Caccuri, Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2606-2617</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) is a powerful inhibitor of the glutathione transferase P1-1 (GSTP1-1) and causes the disruption of the complex between GSTP1-1 and c-Jun N-terminal Kinase (JNK).  This induces JNK activation and apoptosis in tumor cells.  In the present work we assess the in vitro and in vivo effectiveness of NBDHEX on two human melanoma cell lines, Me501 and A375.  NBDHEX shows IC50 values in the low micromolar range (IC50 of 1.2 Â± 0.1 Î¼M and 2.0 Â± 0.2 Î¼M for Me501 and A375, resp.) and is over 100 times more cytotoxic to these cell lines than temozolomide.  Apoptosis is obsd. in Me501 cells within 3 h of the addn. of NBDHEX, while in A375 cells the apoptotic event is rather late, and is preceded by a G2/M phase arrest.  In both melanoma cell lines, JNK activity is required for the ability of NBDHEX to trigger apoptosis, confirming that the JNK pathway is an important therapeutic target for this tumor.  NBDHEX is also both effective and well tolerated in in vivo tumor models.  A tumor inhibition of 70% is obsd. in vivo against Me501 human melanoma and a similar result is obtained on A375 model, with 63% of tumor inhibition.  These findings indicate that the activation of the JNK pathway, through a selective GSTP1-1 targeting, could prove to be a promising new strategy for treating melanoma, which responds poorly to conventional therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSP5C-NFxCrbVg90H21EOLACvtfcHk0lhXpeEDhHLseg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVKls7jO&md5=463fe27ac959cf3d29c576461b4d6883</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2009.06.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2009.06.033%26sid%3Dliteratum%253Aachs%26aulast%3DPellizzari%2BTregno%26aufirst%3DF.%26aulast%3DSau%26aufirst%3DA.%26aulast%3DPezzola%26aufirst%3DS.%26aulast%3DGeroni%26aufirst%3DC.%26aulast%3DLapenta%26aufirst%3DC.%26aulast%3DSpada%26aufirst%3DM.%26aulast%3DFilomeni%26aufirst%3DG.%26aulast%3DBonanno%26aufirst%3DE.%26aulast%3DFederici%26aufirst%3DG.%26aulast%3DCaccuri%26aufirst%3DA.%2BM.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520efficacy%2520of%25206-%25287-nitro-2%252C1%252C3-benzoxadiazol-4-ylthio%2529hexanol%2520%2528NBDHEX%2529%2520on%2520human%2520melanoma%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2009%26volume%3D45%26issue%3D14%26spage%3D2606%26epage%3D2617%26doi%3D10.1016%2Fj.ejca.2009.06.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref245"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref245'); return false;" data-citation="" class="refNumLink">245</a></strong><div class="NLM_citation" id="cit245"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rotili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarantino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forgione, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morozzo Della Rocca, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falconi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccuri, A. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure--activity relationship of new cytotoxic agents targeting human glutathione-S-transferases</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">156</span>â <span class="NLM_lpage">171</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2014.10.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.ejmech.2014.10.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=25462236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOjtrzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2015&pages=156-171&author=D.+Rotiliauthor=A.+De+Lucaauthor=D.+Tarantinoauthor=S.+Pezzolaauthor=M.+Forgioneauthor=B.+Morozzo+Della+Roccaauthor=M.+Falconiauthor=A.+Maiauthor=A.+M.+Caccuri&title=Synthesis+and+structure%2D%2Dactivity+relationship+of+new+cytotoxic+agents+targeting+human+glutathione-S-transferases&doi=10.1016%2Fj.ejmech.2014.10.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit245R"><div class="casContent"><span class="casTitleNuber">245</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationship of new cytotoxic agents targeting human glutathione-S-transferases</span></div><div class="casAuthors">Rotili, Dante; De Luca, Anastasia; Tarantino, Domenico; Pezzola, Silvia; Forgione, Mariantonietta; Morozzo della Rocca, Blasco; Falconi, Mattia; Mai, Antonello; Caccuri, Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">156-171</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The 6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)hexan-1-ol (NBDHEX, I), a "suicide inhibitor" of the glutathione-S-transferase GSTP1-1, showed pro-apoptotic properties in tumor cells, but in vivo studies were limited by poor bioavailability and high affinity towards GSTM2-2, expressed in many non-cancerous tissues.  This paper describes the synthesis and biol. characterization of 39 new I analogs, in which the hydroxyhexyl portion at the C4-sulfur atom has been replaced with phenyl-contg. moieties as well as substituted alkyl chains.  Some of the new compds. displayed 10-100 times increased water-soly., and most of them showed higher GSTP1-1 selectivity than I.  The presence of a Ph ring with polar substituents is in general assocd., with some exceptions to low cytotoxicity in osteosarcoma U-2OS cells.  Differently, some alkyl derivs. possess cytotoxicity comparable or higher than I.  Among the novel compds., selected ones, e.g., II, deserve further investigation for their anticancer potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYe3xFsXZO3LVg90H21EOLACvtfcHk0lhXpeEDhHLseg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOjtrzO&md5=cb95f8de3062cfa0632fdb9a8755922d</span></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.10.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.10.033%26sid%3Dliteratum%253Aachs%26aulast%3DRotili%26aufirst%3DD.%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3DTarantino%26aufirst%3DD.%26aulast%3DPezzola%26aufirst%3DS.%26aulast%3DForgione%26aufirst%3DM.%26aulast%3DMorozzo%2BDella%2BRocca%26aufirst%3DB.%26aulast%3DFalconi%26aufirst%3DM.%26aulast%3DMai%26aufirst%3DA.%26aulast%3DCaccuri%26aufirst%3DA.%2BM.%26atitle%3DSynthesis%2520and%2520structure--activity%2520relationship%2520of%2520new%2520cytotoxic%2520agents%2520targeting%2520human%2520glutathione-S-transferases%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D89%26spage%3D156%26epage%3D171%26doi%3D10.1016%2Fj.ejmech.2014.10.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref246"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref246'); return false;" data-citation="" class="refNumLink">246</a></strong><div class="NLM_citation" id="cit246"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luca, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpanese, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapanotti, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viguria, T. M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forgione, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iorio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintieri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimenti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccuri, A. M.</span></span> <span> </span><span class="NLM_article-title">The nitrobenzoxadiazole derivative MC3181 blocks melanoma invasion and metastasis</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">15520</span>â <span class="NLM_lpage">15538</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.14690</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.18632%2Foncotarget.14690" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28107182" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=15520-15538&issue=9&author=A.+D.+Lucaauthor=D.+Carpaneseauthor=M.+C.+Rapanottiauthor=T.+M.+S.+Viguriaauthor=M.+A.+Forgioneauthor=D.+Rotiliauthor=C.+Fulciauthor=E.+Iorioauthor=L.+Quintieriauthor=S.+Chimentiauthor=L.+Bianchiauthor=A.+Rosatoauthor=A.+M.+Caccuri&title=The+nitrobenzoxadiazole+derivative+MC3181+blocks+melanoma+invasion+and+metastasis&doi=10.18632%2Foncotarget.14690"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14690%26sid%3Dliteratum%253Aachs%26aulast%3DLuca%26aufirst%3DA.%2BD.%26aulast%3DCarpanese%26aufirst%3DD.%26aulast%3DRapanotti%26aufirst%3DM.%2BC.%26aulast%3DViguria%26aufirst%3DT.%2BM.%2BS.%26aulast%3DForgione%26aufirst%3DM.%2BA.%26aulast%3DRotili%26aufirst%3DD.%26aulast%3DFulci%26aufirst%3DC.%26aulast%3DIorio%26aufirst%3DE.%26aulast%3DQuintieri%26aufirst%3DL.%26aulast%3DChimenti%26aufirst%3DS.%26aulast%3DBianchi%26aufirst%3DL.%26aulast%3DRosato%26aufirst%3DA.%26aulast%3DCaccuri%26aufirst%3DA.%2BM.%26atitle%3DThe%2520nitrobenzoxadiazole%2520derivative%2520MC3181%2520blocks%2520melanoma%2520invasion%2520and%2520metastasis%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D9%26spage%3D15520%26epage%3D15538%26doi%3D10.18632%2Foncotarget.14690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref247"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref247'); return false;" data-citation="" class="refNumLink">247</a></strong><div class="NLM_citation" id="cit247"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpanese, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenoci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scimeca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geroni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintieri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccuri, A. M.</span></span> <span> </span><span class="NLM_article-title">A novel orally active water-soluble inhibitor of human glutathione transferase exerts a potent and selective antitumor activity against human melanoma xenografts</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">4126</span>â <span class="NLM_lpage">4143</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.2798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.18632%2Foncotarget.2798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=25595904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BC2MvntFOlsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=4126-4143&issue=6&author=A.+De+Lucaauthor=D.+Rotiliauthor=D.+Carpaneseauthor=A.+Lenociauthor=L.+Calderanauthor=M.+Scimecaauthor=A.+Maiauthor=E.+Bonannoauthor=A.+Rosatoauthor=C.+Geroniauthor=L.+Quintieriauthor=A.+M.+Caccuri&title=A+novel+orally+active+water-soluble+inhibitor+of+human+glutathione+transferase+exerts+a+potent+and+selective+antitumor+activity+against+human+melanoma+xenografts&doi=10.18632%2Foncotarget.2798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit247R"><div class="casContent"><span class="casTitleNuber">247</span><div class="casTitle"><span class="NLM_cas:atitle">A novel orally active water-soluble inhibitor of human glutathione transferase exerts a potent and selective antitumor activity against human melanoma xenografts</span></div><div class="casAuthors">De Luca Anastasia; Caccuri Anna Maria; Rotili Dante; Lenoci Alessia; Mai Antonello; Carpanese Debora; Rosato Antonio; Calderan Laura; Quintieri Luigi; Scimeca Manuel; Bonanno Elena; Scimeca Manuel; Bonanno Elena; Mai Antonello; Rosato Antonio; Geroni Cristina; Caccuri Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">4126-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We designed and synthesized two novel nitrobenzoxadiazole (NBD) analogues of the anticancer agent 6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)hexan-1-ol (NBDHEX).  The new compounds, namely MC3165 and MC3181, bear one and two oxygen atoms within the hydroxy-containing alkyl chain at the C4 position of the NBD scaffold, respectively.  This insertion did not alter the chemical reactivity with reduced glutathione, while it conferred a remarkable increase in water solubility.  MC3181 was more selective than NBDHEX towards the target protein, glutathione transferase P1-1, and highly effective in vitro against a panel of human melanoma cell lines, with IC50 in the submicromolar-low micromolar range.  Interestingly, the cellular response to MC3181 was cell-type-specific; the compound triggered a JNK-dependent apoptosis in the BRAF-V600E-mutated A375 cells, while it induced morphological changes together with an increase in melanogenesis in BRAF wild-type SK23-MEL cells.  MC3181 exhibited a remarkable therapeutic activity against BRAF-V600E-mutant xenografts, both after intravenous and oral administration.  Outstandingly, no treatment-related signs of toxicity were observed both in healthy and tumor-bearing mice after single and repeated administrations.  Taken together, these results indicate that MC3181 may represent a potential novel therapeutic opportunity for BRAF-mutated human melanoma, while being safe and water-soluble and thus overcoming all the critical aspects of NBDHEX in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4VH_PZca5wy6Ufuk_1xoTfW6udTcc2ebzLpMNto4vPrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvntFOlsg%253D%253D&md5=ef2d38a6f292e9ceb5ad3f33f7105c07</span></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2798%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3DRotili%26aufirst%3DD.%26aulast%3DCarpanese%26aufirst%3DD.%26aulast%3DLenoci%26aufirst%3DA.%26aulast%3DCalderan%26aufirst%3DL.%26aulast%3DScimeca%26aufirst%3DM.%26aulast%3DMai%26aufirst%3DA.%26aulast%3DBonanno%26aufirst%3DE.%26aulast%3DRosato%26aufirst%3DA.%26aulast%3DGeroni%26aufirst%3DC.%26aulast%3DQuintieri%26aufirst%3DL.%26aulast%3DCaccuri%26aufirst%3DA.%2BM.%26atitle%3DA%2520novel%2520orally%2520active%2520water-soluble%2520inhibitor%2520of%2520human%2520glutathione%2520transferase%2520exerts%2520a%2520potent%2520and%2520selective%2520antitumor%2520activity%2520against%2520human%2520melanoma%2520xenografts%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26issue%3D6%26spage%3D4126%26epage%3D4143%26doi%3D10.18632%2Foncotarget.2798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref248"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref248'); return false;" data-citation="" class="refNumLink">248</a></strong><div class="NLM_citation" id="cit248"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Graziani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artuso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scimeca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atzori, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tentori, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccuri, A. M.</span></span> <span> </span><span class="NLM_article-title">A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>95</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">16</span>â <span class="NLM_lpage">27</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2015.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bcp.2015.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=25795251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFWhsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=16-27&issue=1&author=G.+Grazianiauthor=S.+Artusoauthor=A.+De+Lucaauthor=A.+Muziauthor=D.+Rotiliauthor=M.+Scimecaauthor=M.+G.+Atzoriauthor=C.+Ceciauthor=A.+Maiauthor=C.+Leonettiauthor=L.+Levatiauthor=E.+Bonannoauthor=L.+Tentoriauthor=A.+M.+Caccuri&title=A+new+water+soluble+MAPK+activator+exerts+antitumor+activity+in+melanoma+cells+resistant+to+the+BRAF+inhibitor+vemurafenib&doi=10.1016%2Fj.bcp.2015.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit248R"><div class="casContent"><span class="casTitleNuber">248</span><div class="casTitle"><span class="NLM_cas:atitle">A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib</span></div><div class="casAuthors">Graziani, Grazia; Artuso, Simona; De Luca, Anastasia; Muzi, Alessia; Rotili, Dante; Scimeca, Manuel; Atzori, Maria Grazia; Ceci, Claudia; Mai, Antonello; Leonetti, Carlo; Levati, Lauretta; Bonanno, Elena; Tentori, Lucio; Caccuri, Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-27</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recovery of mitogen activated protein kinase (MAPK) or activation of alternative pathways, such as the PI3K/AKT/mTOR, are involved in acquired resistance to BRAF inhibitors which represent the first-line treatment of BRAF-mutated metastatic melanoma.  We recently demonstrated that 6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)hexan-1-ol (NBDHEX) and its water sol. analog 2-(2-(2-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)ethoxy)ethoxy)ethanol (MC3181) trigger apoptosis in BRAF V600E mutated melanoma cells through activation of the MAPK c-Jun N-terminal kinase (JNK).  Herein, we investigated whether NBDHEX and MC3181 might exert antitumor activity against BRAF V600E mutated human melanoma cells rendered resistant to the BRAF inhibitor vemurafenib.  To this aim we generated a subline of A375 melanoma resistant in vitro and in vivo to vemurafenib (A375-VR8) and characterized by NRAS G13R mutation, high basal levels of CRAF protein and phospho-activation of AKT.  In these cells ERK phosphorylation was not significantly down-modulated by vemurafenib concns. capable of abrogating ERK phosphorylation in sensitive A375 cells.  Both NBDHEX and MC3181 induced marked antiproliferative and apoptotic effects in A375-VR8 cells and, at equitoxic concns., caused a strong phosphorylation of JNK, p38, and of the downstream mediators of apoptosis ATF2 and p53.  Drug treatment further increased ERK phosphorylation, which was required for the cellular response to the NBD derivs., as apoptosis was antagonized by the ERK inhibitor FR180204.  Finally, in vivo administration of MC3181 provoked JNK activation at the tumor site and markedly reduced A375-VR8 growth.  These evidences strongly suggest that the activation of multiple pro-apoptotic MAPK pathways by MC3181 might represent a new strategy for the treatment of melanoma resistant to BRAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphh0RGg9p2brVg90H21EOLACvtfcHk0lhm2A4kVRi5Yw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFWhsLs%253D&md5=4a7784c27fa84b8528ba1006e19aa8d8</span></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2015.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2015.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DGraziani%26aufirst%3DG.%26aulast%3DArtuso%26aufirst%3DS.%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3DMuzi%26aufirst%3DA.%26aulast%3DRotili%26aufirst%3DD.%26aulast%3DScimeca%26aufirst%3DM.%26aulast%3DAtzori%26aufirst%3DM.%2BG.%26aulast%3DCeci%26aufirst%3DC.%26aulast%3DMai%26aufirst%3DA.%26aulast%3DLeonetti%26aufirst%3DC.%26aulast%3DLevati%26aufirst%3DL.%26aulast%3DBonanno%26aufirst%3DE.%26aulast%3DTentori%26aufirst%3DL.%26aulast%3DCaccuri%26aufirst%3DA.%2BM.%26atitle%3DA%2520new%2520water%2520soluble%2520MAPK%2520activator%2520exerts%2520antitumor%2520activity%2520in%2520melanoma%2520cells%2520resistant%2520to%2520the%2520BRAF%2520inhibitor%2520vemurafenib%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2015%26volume%3D95%26issue%3D1%26spage%3D16%26epage%3D27%26doi%3D10.1016%2Fj.bcp.2015.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref249"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref249'); return false;" data-citation="" class="refNumLink">249</a></strong><div class="NLM_citation" id="cit249"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomassi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scimeca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geroni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintieri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccuri, A. M.</span></span> <span> </span><span class="NLM_article-title">Characterization of water-soluble esters of nitrobenzoxadiazole-based GSTP1-1 inhibitors for cancer treatment</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">114060</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2020.114060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bcp.2020.114060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=32473836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFCjsL7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2020&pages=114060&author=V.+Di+Paoloauthor=C.+Fulciauthor=D.+Rotiliauthor=A.+De+Lucaauthor=S.+Tomassiauthor=M.+Serraauthor=M.+Scimecaauthor=C.+Geroniauthor=L.+Quintieriauthor=A.+M.+Caccuri&title=Characterization+of+water-soluble+esters+of+nitrobenzoxadiazole-based+GSTP1-1+inhibitors+for+cancer+treatment&doi=10.1016%2Fj.bcp.2020.114060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit249R"><div class="casContent"><span class="casTitleNuber">249</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of water-soluble esters of nitrobenzoxadiazole-based GSTP1-1 inhibitors for cancer treatment</span></div><div class="casAuthors">Di Paolo, Veronica; Fulci, Chiara; Rotili, Dante; De Luca, Anastasia; Tomassi, Stefano; Serra, Massimo; Scimeca, Manuel; Geroni, Cristina; Quintieri, Luigi; Caccuri, Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">114060</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The 7-nitrobenzo[c][1,2,5]oxadiazole (NBD) deriv. NBDHEX (compd. 1) and its analog MC3181 (compd. 2) have been found to be potent inhibitors of tumor cell growth in vitro and therapeutically active and safe in mice bearing human melanoma xenografts.  To enhance the aq. soly. of these compds., we synthesized the hemisuccinate of 1 (compd. 3) and the phosphate monoesters of 1 and 2 (compd. 4 and 5, resp.).  These novel NBD derivs. displayed a soly. in the conventional phosphate-buffered saline up to 150-fold higher than that of 1, and up to 4-fold higher than that of 2.  Notably, soly. of phosphates 4 and 5 in a potassium phosphate buffer at pH 7.4, was up to 500-fold higher than that of 1, and â¼10-fold higher than that of 2.  Compds. 3-5 retained high cytotoxicity towards cultured human melanoma and osteosarcoma cells and were cleaved in vitro by both human and murine hydrolases, thus releasing the corresponding parent compd. (i.e., 1 or 2).  Interestingly, esters 3-5 displayed high inhibitory activity towards the glutathione transferase (GST) isoform GSTP1-1 and showed a reactivity towards reduced glutathione comparable to that of the resp. parent compd.  Finally, both 4 and 5 were safe and effective when administered i.v. or orally as an aq. soln. to mice xenografted with A375 human melanoma tumors.  Collectively, these results and the previously obsd. synergistic interaction between 1 and 2 and various approved anticancer drugs, suggest the possible utility of phosphates 4 and 5 as single agents and in combination regimens in cancers with unmet medical need, including melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV_rPwBOM8WbVg90H21EOLACvtfcHk0lhm2A4kVRi5Yw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFCjsL7E&md5=f50c23cb3714beffde397ac12a786274</span></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2020.114060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2020.114060%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DV.%26aulast%3DFulci%26aufirst%3DC.%26aulast%3DRotili%26aufirst%3DD.%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3DTomassi%26aufirst%3DS.%26aulast%3DSerra%26aufirst%3DM.%26aulast%3DScimeca%26aufirst%3DM.%26aulast%3DGeroni%26aufirst%3DC.%26aulast%3DQuintieri%26aufirst%3DL.%26aulast%3DCaccuri%26aufirst%3DA.%2BM.%26atitle%3DCharacterization%2520of%2520water-soluble%2520esters%2520of%2520nitrobenzoxadiazole-based%2520GSTP1-1%2520inhibitors%2520for%2520cancer%2520treatment%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2020%26volume%3D178%26spage%3D114060%26doi%3D10.1016%2Fj.bcp.2020.114060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref250"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref250'); return false;" data-citation="" class="refNumLink">250</a></strong><div class="NLM_citation" id="cit250"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciarretta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucidi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morozzo Della Rocca, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintieri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccuri, A. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and characterisation of a new benzamide-containing nitrobenzoxadiazole as a GSTP1-1 inhibitor endowed with high stability to metabolic hydrolysis</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1131</span>â <span class="NLM_lpage">1139</span>, <span class="refDoi">Â DOI: 10.1080/14756366.2019.1617287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1080%2F14756366.2019.1617287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=31169043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFeru7bF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2019&pages=1131-1139&issue=1&author=V.+Di+Paoloauthor=C.+Fulciauthor=D.+Rotiliauthor=F.+Sciarrettaauthor=A.+Lucidiauthor=B.+Morozzo+Della+Roccaauthor=A.+De+Lucaauthor=A.+Rosatoauthor=L.+Quintieriauthor=A.+M.+Caccuri&title=Synthesis+and+characterisation+of+a+new+benzamide-containing+nitrobenzoxadiazole+as+a+GSTP1-1+inhibitor+endowed+with+high+stability+to+metabolic+hydrolysis&doi=10.1080%2F14756366.2019.1617287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and characterisation of a new benzamide-containing nitrobenzoxadiazole as a GSTP1-1 inhibitor endowed with high stability to metabolic hydrolysis</span></div><div class="casAuthors">Di Paolo, Veronica; Fulci, Chiara; Rotili, Dante; Sciarretta, Francesca; Lucidi, Alessia; Morozzo della Rocca, Blasco; De Luca, Anastasia; Rosato, Antonio; Quintieri, Luigi; Caccuri, Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1131-1139</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The antitumor agent 6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)hexan-1-ol (1) is a potent inhibitor of GSTP1-1, a glutathione S-transferase capable of inhibiting apoptosis by binding to JNK1 and TRAF2.  We recently demonstrated that, unlike its parent compd., the benzoyl ester of 1 (compd.3 ) exhibits negligible reactivity towards GSH, and has a different mode of interaction with GSTP1-1.  Unfortunately, 3 is susceptible to rapid metabolic hydrolysis.  In an effort to improve the metabolic stability of 3, its ester group has been replaced by an amide, leading to N-(6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)hexyl)benzamide (4).  Unlike 3, compd.4 was stable to human liver microsomal carboxylesterases, but retained the ability to disrupt the interaction between GSTP1-1 and TRAF2 regardless of GSH levels.  Moreover, 4 exhibited both a higher stability in the presence of GSH and a greater cytotoxicity towards cultured A375 melanoma cells, in comparison with 1 and its analog 2 .  These findings suggest that 4 deserves further preclin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryQcwVkcim0bVg90H21EOLACvtfcHk0lgyTmyWILpNMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFeru7bF&md5=82204ebf3fc0a1c07657a3e0d7d6a41c</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1080%2F14756366.2019.1617287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756366.2019.1617287%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DV.%26aulast%3DFulci%26aufirst%3DC.%26aulast%3DRotili%26aufirst%3DD.%26aulast%3DSciarretta%26aufirst%3DF.%26aulast%3DLucidi%26aufirst%3DA.%26aulast%3DMorozzo%2BDella%2BRocca%26aufirst%3DB.%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3DRosato%26aufirst%3DA.%26aulast%3DQuintieri%26aufirst%3DL.%26aulast%3DCaccuri%26aufirst%3DA.%2BM.%26atitle%3DSynthesis%2520and%2520characterisation%2520of%2520a%2520new%2520benzamide-containing%2520nitrobenzoxadiazole%2520as%2520a%2520GSTP1-1%2520inhibitor%2520endowed%2520with%2520high%2520stability%2520to%2520metabolic%2520hydrolysis%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2019%26volume%3D34%26issue%3D1%26spage%3D1131%26epage%3D1139%26doi%3D10.1080%2F14756366.2019.1617287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref251"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref251'); return false;" data-citation="" class="refNumLink">251</a></strong><div class="NLM_citation" id="cit251"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wettersten, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, R. H.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of p21 as novel therapeutics for chemotherapy-resistant kidney cancer</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">991</span>â <span class="NLM_lpage">994</span>, <span class="refDoi">Â DOI: 10.4155/fmc.13.56</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.4155%2Ffmc.13.56" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=23734682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXos12msLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=991-994&issue=9&author=R.+Liuauthor=H.+I.+Wetterstenauthor=S.-H.+Parkauthor=R.+H.+Weiss&title=Small-molecule+inhibitors+of+p21+as+novel+therapeutics+for+chemotherapy-resistant+kidney+cancer&doi=10.4155%2Ffmc.13.56"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit251R"><div class="casContent"><span class="casTitleNuber">251</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors of p21 as novel therapeutics for chemotherapy-resistant kidney cancer</span></div><div class="casAuthors">Liu, Ruiwu; Wettersten, Hiromi I.; Park, See-Hyoung; Weiss, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">991-994</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  This article presents the use of specific inhibitors of the CDK inhibitor, p21, has tremendous potential as a new paradigm for the treatment of a variety of cancers, as well as a tool in exploring mechanisms of cell cycle arrest and apoptosis.  Small-mol. inhibitors of p21 have distinct advantages including cell permeability,increased stability, ease of manuf. and oral delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoznx3M13qDkbVg90H21EOLACvtfcHk0lgyTmyWILpNMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXos12msLk%253D&md5=03226f0456b4a8f474eceb6614cbc7c9</span></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=10.4155%2Ffmc.13.56&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.13.56%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DWettersten%26aufirst%3DH.%2BI.%26aulast%3DPark%26aufirst%3DS.-H.%26aulast%3DWeiss%26aufirst%3DR.%2BH.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520p21%2520as%2520novel%2520therapeutics%2520for%2520chemotherapy-resistant%2520kidney%2520cancer%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2013%26volume%3D5%26issue%3D9%26spage%3D991%26epage%3D994%26doi%3D10.4155%2Ffmc.13.56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref252"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref252'); return false;" data-citation="" class="refNumLink">252</a></strong><div class="NLM_citation" id="cit252"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abbas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A.</span></span> <span> </span><span class="NLM_article-title">p21 in cancer: intricate networks and multiple activities</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">400</span>â <span class="NLM_lpage">414</span>, <span class="refDoi">Â DOI: 10.1038/nrc2657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2Fnrc2657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=19440234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvFShsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=400-414&issue=6&author=T.+Abbasauthor=A.+Dutta&title=p21+in+cancer%3A+intricate+networks+and+multiple+activities&doi=10.1038%2Fnrc2657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">p21 in cancer: intricate networks and multiple activities</span></div><div class="casAuthors">Abbas, Tarek; Dutta, Anindya</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">400-414</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  One of the main engines that drives cellular transformation is the loss of proper control of the mammalian cell cycle.  The cyclin-dependent kinase inhibitor p21 (also known as p21WAF1/Cip1) promotes cell cycle arrest in response to many stimuli.  It is well positioned to function as both a sensor and an effector of multiple anti-proliferative signals.  This Review focuses on recent advances in our understanding of the regulation of p21 and its biol. functions with emphasis on its p53-independent tumor suppressor activities and paradoxical tumor-promoting activities, and their implications in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ0tFJHIgKlLVg90H21EOLACvtfcHk0lgyTmyWILpNMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvFShsb4%253D&md5=fb31a35ba6d4026baf5bda5ec71a4403</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=10.1038%2Fnrc2657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2657%26sid%3Dliteratum%253Aachs%26aulast%3DAbbas%26aufirst%3DT.%26aulast%3DDutta%26aufirst%3DA.%26atitle%3Dp21%2520in%2520cancer%253A%2520intricate%2520networks%2520and%2520multiple%2520activities%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26issue%3D6%26spage%3D400%26epage%3D414%26doi%3D10.1038%2Fnrc2657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref253"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref253'); return false;" data-citation="" class="refNumLink">253</a></strong><div class="NLM_citation" id="cit253"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guenes, C.</span>; <span class="NLM_string-name">Hoffman, E. M.</span>; <span class="NLM_string-name">Rudolph, K. L.</span></span> <span> </span><span class="NLM_article-title">Screening Methods for Identifying Specific Inhibitors of Protein p21 as Therapeutic Agents for Treating Cancer and Chronic Diseases-Associated Injury</span>. <span class="NLM_patent">WO2014041125A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=C.+Guenes&author=E.+M.+Hoffman&author=K.+L.+Rudolph&title=Screening+Methods+for+Identifying+Specific+Inhibitors+of+Protein+p21+as+Therapeutic+Agents+for+Treating+Cancer+and+Chronic+Diseases-Associated+Injury"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGuenes%26aufirst%3DC.%26atitle%3DScreening%2520Methods%2520for%2520Identifying%2520Specific%2520Inhibitors%2520of%2520Protein%2520p21%2520as%2520Therapeutic%2520Agents%2520for%2520Treating%2520Cancer%2520and%2520Chronic%2520Diseases-Associated%2520Injury%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref254"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref254'); return false;" data-citation="" class="refNumLink">254</a></strong><div class="NLM_citation" id="cit254"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baures, P. W.</span>; <span class="NLM_string-name">James, D. R.</span>; <span class="NLM_string-name">Gless, R. D.</span>; <span class="NLM_string-name">Tran, T.</span>; <span class="NLM_string-name">Verheij, H. J.</span>; <span class="NLM_string-name">Schultz, J. C. C.</span></span> <span> </span><span class="NLM_article-title">Furazano[3,4-b]pyrazines, and Their Preparation, Pharmaceutical Compositions and Use as Antitumor Agents for Treatment of Tumors</span>. <span class="NLM_patent">WO2006044402A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=P.+W.+Baures&author=D.+R.+James&author=R.+D.+Gless&author=T.+Tran&author=H.+J.+Verheij&author=J.+C.+C.+Schultz&title=Furazano%5B3%2C4-b%5Dpyrazines%2C+and+Their+Preparation%2C+Pharmaceutical+Compositions+and+Use+as+Antitumor+Agents+for+Treatment+of+Tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBaures%26aufirst%3DP.%2BW.%26atitle%3DFurazano%255B3%252C4-b%255Dpyrazines%252C%2520and%2520Their%2520Preparation%252C%2520Pharmaceutical%2520Compositions%2520and%2520Use%2520as%2520Antitumor%2520Agents%2520for%2520Treatment%2520of%2520Tumors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref255"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref255'); return false;" data-citation="" class="refNumLink">255</a></strong><div class="NLM_citation" id="cit255"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ventola, C. L.</span></span> <span> </span><span class="NLM_article-title">The antibiotic resistance crisis: part 1: Causes and threats</span>. <i>P. T.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">277</span>â <span class="NLM_lpage">283</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=25859123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BC2MjivVaksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2015&pages=277-283&issue=4&author=C.+L.+Ventola&title=The+antibiotic+resistance+crisis%3A+part+1%3A+Causes+and+threats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit255R"><div class="casContent"><span class="casTitleNuber">255</span><div class="casTitle"><span class="NLM_cas:atitle">The antibiotic resistance crisis: part 1: causes and threats</span></div><div class="casAuthors">Ventola C Lee</div><div class="citationInfo"><span class="NLM_cas:title">P & T : a peer-reviewed journal for formulary management</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">277-83</span>
        ISSN:<span class="NLM_cas:issn">1052-1372</span>.
    </div><div class="casAbstract">Decades after the first patients were treated with antibiotics, bacterial infections have again become a threat because of the rapid emergence of resistant bacteria-a crisis attributed to abuse of these medications and a lack of new drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1SMGX3K8vve98rul4nhSdfW6udTcc2eZ_qvimTF-uSLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjivVaksg%253D%253D&md5=81c1f1c8e3475245b7dd5dad0a279700</span></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVentola%26aufirst%3DC.%2BL.%26atitle%3DThe%2520antibiotic%2520resistance%2520crisis%253A%2520part%25201%253A%2520Causes%2520and%2520threats%26jtitle%3DP.%2520T.%26date%3D2015%26volume%3D40%26issue%3D4%26spage%3D277%26epage%3D283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref256"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref256'); return false;" data-citation="" class="refNumLink">256</a></strong><div class="NLM_citation" id="cit256"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levinson, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evgenâev, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ermolaeva, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efimov, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falyakhov, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garipov, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karimova, R. G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological activity of substituted benzodifurazans</span>. <i>Pharm. Chem. J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">522</span>â <span class="NLM_lpage">525</span>, <span class="refDoi">Â DOI: 10.1023/B:PHAC.0000014855.66913.83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1023%2FB%3APHAC.0000014855.66913.83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpslWjsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2003&pages=522-525&issue=10&author=F.+S.+Levinsonauthor=M.+I.+Evgen%E2%80%99evauthor=E.+A.+Ermolaevaauthor=S.+I.+Efimovauthor=I.+F.+Falyakhovauthor=T.+V.+Garipovauthor=R.+G.+Karimova&title=Synthesis+and+biological+activity+of+substituted+benzodifurazans&doi=10.1023%2FB%3APHAC.0000014855.66913.83"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit256R"><div class="casContent"><span class="casTitleNuber">256</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Activity of Substituted Benzodifurazans</span></div><div class="casAuthors">Levinson, F. S.; Evgen'ev, M. I.; Ermolaeva, E. A.; Efimov, S. I.; Falyakhov, I. F.; Garipov, T. V.; Karimova, R. G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Chemistry Journal (Translation of Khimiko-Farmatsevticheskii Zhurnal)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">522-525</span>CODEN:
                <span class="NLM_cas:coden">PCJOAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-150X</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Consultants Bureau</span>)
        </div><div class="casAbstract">Benzodifurazan derivs., such as I (R = Cl, OMe, n = 1; R = Cl, NH2, NHNHMe, NEt2, 1-piperidinyl, 4-morpholinyl, OMe, n = 0), were prepd. and assayed for antibacterial, fungicidal and acaricidal activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNqKBzYmhzybVg90H21EOLACvtfcHk0lgM4Kl6w4qP2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpslWjsQ%253D%253D&md5=99b41274ba610e0eb9ce60005f9e5945</span></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=10.1023%2FB%3APHAC.0000014855.66913.83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FB%253APHAC.0000014855.66913.83%26sid%3Dliteratum%253Aachs%26aulast%3DLevinson%26aufirst%3DF.%2BS.%26aulast%3DEvgen%25E2%2580%2599ev%26aufirst%3DM.%2BI.%26aulast%3DErmolaeva%26aufirst%3DE.%2BA.%26aulast%3DEfimov%26aufirst%3DS.%2BI.%26aulast%3DFalyakhov%26aufirst%3DI.%2BF.%26aulast%3DGaripov%26aufirst%3DT.%2BV.%26aulast%3DKarimova%26aufirst%3DR.%2BG.%26atitle%3DSynthesis%2520and%2520biological%2520activity%2520of%2520substituted%2520benzodifurazans%26jtitle%3DPharm.%2520Chem.%2520J.%26date%3D2003%26volume%3D37%26issue%3D10%26spage%3D522%26epage%3D525%26doi%3D10.1023%2FB%3APHAC.0000014855.66913.83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref257"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref257'); return false;" data-citation="" class="refNumLink">257</a></strong><div class="NLM_citation" id="cit257"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levinson, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evgenâev, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ermolaeva, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efimov, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garipov, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karimova, R. G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological activity of arylaminosubstituted nitrobenzodifurazans</span>. <i>Pharm. Chem. J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">578</span>â <span class="NLM_lpage">581</span>, <span class="refDoi">Â DOI: 10.1023/B:PHAC.0000016066.53022.f5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1023%2FB%3APHAC.0000016066.53022.f5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2cXht1Clsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2003&pages=578-581&issue=11&author=F.+S.+Levinsonauthor=M.+I.+Evgen%E2%80%99evauthor=E.+A.+Ermolaevaauthor=S.+I.+Efimovauthor=T.+V.+Garipovauthor=R.+G.+Karimova&title=Synthesis+and+biological+activity+of+arylaminosubstituted+nitrobenzodifurazans&doi=10.1023%2FB%3APHAC.0000016066.53022.f5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit257R"><div class="casContent"><span class="casTitleNuber">257</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Activity of Arylaminosubstituted Nitrobenzodifurazans</span></div><div class="casAuthors">Levinson, F. S.; Evgen'ev, M. I.; Ermolaeva, E. A.; Efimov, S. I.; Garipov, T. V.; Karimova, R. G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Chemistry Journal (Translation of Khimiko-Farmatsevticheskii Zhurnal)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">578-581</span>CODEN:
                <span class="NLM_cas:coden">PCJOAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-150X</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Consultants Bureau</span>)
        </div><div class="casAbstract">Aryl amino substituted nitrobenzodifurazans were prepd. via the key nitration of methoxybenzodifurazan.  The antimicrobial activity of the prepd. compds. was also evaluated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYZ50897B_4bVg90H21EOLACvtfcHk0lgM4Kl6w4qP2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXht1Clsr0%253D&md5=4c12bc185e59434ff4134c33146a5b8f</span></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=10.1023%2FB%3APHAC.0000016066.53022.f5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FB%253APHAC.0000016066.53022.f5%26sid%3Dliteratum%253Aachs%26aulast%3DLevinson%26aufirst%3DF.%2BS.%26aulast%3DEvgen%25E2%2580%2599ev%26aufirst%3DM.%2BI.%26aulast%3DErmolaeva%26aufirst%3DE.%2BA.%26aulast%3DEfimov%26aufirst%3DS.%2BI.%26aulast%3DGaripov%26aufirst%3DT.%2BV.%26aulast%3DKarimova%26aufirst%3DR.%2BG.%26atitle%3DSynthesis%2520and%2520biological%2520activity%2520of%2520arylaminosubstituted%2520nitrobenzodifurazans%26jtitle%3DPharm.%2520Chem.%2520J.%26date%3D2003%26volume%3D37%26issue%3D11%26spage%3D578%26epage%3D581%26doi%3D10.1023%2FB%3APHAC.0000016066.53022.f5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref258"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref258'); return false;" data-citation="" class="refNumLink">258</a></strong><div class="NLM_citation" id="cit258"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Babu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raju, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antimicrobial activity of novel 2-(heteryl-carboxamido)-2,3-dihydro-1H-1,2,5-oxadiazolo[3,4-c] [1,3,2]diazaphosphole-2-oxides</span>. <i>ARKIVOC</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2006</i></span>,  <span class="NLM_fpage">189</span>, <span class="refDoi">Â DOI: 10.3998/ark.5550190.0007.f23</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.3998%2Fark.5550190.0007.f23" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2006&publication_year=2007&pages=189&author=Y.+Babuauthor=M.+Kumarauthor=K.+Srinivasuluauthor=C.+Reddyauthor=C.+Raju&title=Synthesis+and+antimicrobial+activity+of+novel+2-%28heteryl-carboxamido%29-2%2C3-dihydro-1H-1%2C2%2C5-oxadiazolo%5B3%2C4-c%5D+%5B1%2C3%2C2%5Ddiazaphosphole-2-oxides&doi=10.3998%2Fark.5550190.0007.f23"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=10.3998%2Fark.5550190.0007.f23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3998%252Fark.5550190.0007.f23%26sid%3Dliteratum%253Aachs%26aulast%3DBabu%26aufirst%3DY.%26aulast%3DKumar%26aufirst%3DM.%26aulast%3DSrinivasulu%26aufirst%3DK.%26aulast%3DReddy%26aufirst%3DC.%26aulast%3DRaju%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520antimicrobial%2520activity%2520of%2520novel%25202-%2528heteryl-carboxamido%2529-2%252C3-dihydro-1H-1%252C2%252C5-oxadiazolo%255B3%252C4-c%255D%2520%255B1%252C3%252C2%255Ddiazaphosphole-2-oxides%26jtitle%3DARKIVOC%26date%3D2007%26volume%3D2006%26spage%3D189%26doi%3D10.3998%2Fark.5550190.0007.f23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref259"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref259'); return false;" data-citation="" class="refNumLink">259</a></strong><div class="NLM_citation" id="cit259"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Babu, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankar, A. U. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siva
Kumar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh Reddy, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis, spectral characterization and antimicrobial activity of 2-(substituted)-2,2-[1,3-dihydro-(3,4â1,2,5-oxadiazolediyl)diaza][5â²,5â²-dimethyl-1â²,3â²-propanediyl)dioxy]phosphoranes</span>. <i>Org. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">15</span>â <span class="NLM_lpage">21</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtF2nsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=15-21&issue=1&author=Y.+H.+Babuauthor=A.+U.+R.+Sankarauthor=B.+Siva%0AKumarauthor=C.+Suresh+Reddy&title=Synthesis%2C+spectral+characterization+and+antimicrobial+activity+of+2-%28substituted%29-2%2C2-%5B1%2C3-dihydro-%283%2C4%E2%80%931%2C2%2C5-oxadiazolediyl%29diaza%5D%5B5%E2%80%B2%2C5%E2%80%B2-dimethyl-1%E2%80%B2%2C3%E2%80%B2-propanediyl%29dioxy%5Dphosphoranes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit259R"><div class="casContent"><span class="casTitleNuber">259</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, spectral characterization and antimicrobial activity of 2-(substituted)-2,2-[1,3-dihydro-(3,4-1,2,5-oxadiazolediyl)diaza][5',5'-dimethyl-1',3'-propanediyl)dioxy]phosphoranes</span></div><div class="casAuthors">Babu, Y. Hari; Sankar, A. Uma Ravi; Siva Kumar, B.; Suresh Reddy, C.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Communications</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-21</span>CODEN:
                <span class="NLM_cas:coden">OCROBQ</span>;
        ISSN:<span class="NLM_cas:issn">1307-6175</span>.
    
            (<span class="NLM_cas:orgname">ACG Publications</span>)
        </div><div class="casAbstract">The cyclic oxadiazolediyl dioxachlorophosphine precursor on subsequent reaction with various alcs. underwent halide displacement to give 2-substituted diaza phospholes.  These phospholes on oxidative addn. with di hydroxy alcs. form corresponding phosphoranes The antimicrobial activities of these compds. were evaluated and they exhibited significant antimicrobial activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonRi6U_K6qvbVg90H21EOLACvtfcHk0lh02TPuzp5coQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtF2nsL4%253D&md5=39b815acc1fbc1c4fce7d47223f56f11</span></div><a href="/servlet/linkout?suffix=cit259&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBabu%26aufirst%3DY.%2BH.%26aulast%3DSankar%26aufirst%3DA.%2BU.%2BR.%26aulast%3DSiva%2BKumar%26aufirst%3DB.%26aulast%3DSuresh%2BReddy%26aufirst%3DC.%26atitle%3DSynthesis%252C%2520spectral%2520characterization%2520and%2520antimicrobial%2520activity%2520of%25202-%2528substituted%2529-2%252C2-%255B1%252C3-dihydro-%25283%252C4%25E2%2580%25931%252C2%252C5-oxadiazolediyl%2529diaza%255D%255B5%25E2%2580%25B2%252C5%25E2%2580%25B2-dimethyl-1%25E2%2580%25B2%252C3%25E2%2580%25B2-propanediyl%2529dioxy%255Dphosphoranes%26jtitle%3DOrg.%2520Commun.%26date%3D2010%26volume%3D3%26issue%3D1%26spage%3D15%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref260"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref260'); return false;" data-citation="" class="refNumLink">260</a></strong><div class="NLM_citation" id="cit260"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galkina, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takhautdinova, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tudrii, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusupova, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falyakhov, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozdeev, O. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shulaeva, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipenskaya, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakhibullina, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krivolapov, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litvinov, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galkin, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherkasov, R. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis, structure, and antibacterial activity of aminobenzofuroxan and aminobenzofurazan</span>. <i>Russ. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">591</span>â <span class="NLM_lpage">597</span>, <span class="refDoi">Â DOI: 10.1134/S1070428013040167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1134%2FS1070428013040167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsFGjtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=591-597&issue=4&author=I.+V.+Galkinaauthor=G.+L.+Takhautdinovaauthor=E.+V.+Tudriiauthor=L.+M.+Yusupovaauthor=I.+F.+Falyakhovauthor=O.+K.+Pozdeevauthor=M.+P.+Shulaevaauthor=L.+V.+Kipenskayaauthor=V.+G.+Sakhibullinaauthor=D.+B.+Krivolapovauthor=I.+A.+Litvinovauthor=V.+I.+Galkinauthor=R.+A.+Cherkasov&title=Synthesis%2C+structure%2C+and+antibacterial+activity+of+aminobenzofuroxan+and+aminobenzofurazan&doi=10.1134%2FS1070428013040167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit260R"><div class="casContent"><span class="casTitleNuber">260</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, structure, and antibacterial activity of aminobenzofuroxan and aminobenzofurazan</span></div><div class="casAuthors">Galkina, I. V.; Takhautdinova, G. L.; Tudrii, E. V.; Yusupova, L. M.; Falyakhov, I. F.; Pozdeev, O. K.; Shulaeva, M. P.; Kipenskaya, L. V.; Sakhibullina, V. G.; Krivolapov, D. B.; Litvinov, I. A.; Galkin, V. I.; Cherkasov, R. A.</div><div class="citationInfo"><span class="NLM_cas:title">Russian Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">591-597</span>CODEN:
                <span class="NLM_cas:coden">RJOCEQ</span>;
        ISSN:<span class="NLM_cas:issn">1070-4280</span>.
    
            (<span class="NLM_cas:orgname">SP MAIK Nauka/Interperiodica</span>)
        </div><div class="casAbstract">The amination of 4,6-dichloro-5,7-dinitrobenzofuroxan and -benzofurazan with dibenzylamine followed the arom. nucleophilic substitution pattern (SNAr) and gave 4,6-bis(dibenzylamino)-5,7-dinitro-2,1,3-benzoxadiazole 1-oxide (I) with elimination of HCl.  Regardless of the reactant ratio, 4,6-dichloro-5,7-dinitrobenzofuroxan was converted into 4,6-bis(dibenzylamino)-5,7-dinitrobenzofuroxan (II), whereas 4,6-dichloro-5,7-dinitrobenzofurazan under analogous conditions gave rise to an unusual bisammonium deriv. which lost a proton from the amino group on C(4) and a benzyl group from the amino group on C(6), affording the corresponding diamine with secondary and tertiary N atoms.  The structure of the isolated compds. was detd. by IR, NMR, elemental anal., and x-ray anal. [I: triclinic, space group P-1, a 9.548(5), b 12.465(7), c 13.608(7) Ã, Î± 79.515(7), Î² 71.609(6), Î³ 79.489(7)Â°, V 1497.5(1) Ã3, Z 2; II: triclinic, space group P-1, a 7.591(1), b 13.463(2), c 13.795(4) Ã, Î± 114.525(3), Î² 99.512(3), Î³ 100.451(2)Â°, V 1214.9(4) Ã3, Z 2].  Their thermal stability was studied by simultaneous thermogravimetry and differential scanning calorimetry.  Addnl., the compds. were screened for antibacterial and antifungal activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowsz97CrGRtrVg90H21EOLACvtfcHk0lh02TPuzp5coQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsFGjtLo%253D&md5=ef956c7c939fc2fbb998e2b4a62f8b7a</span></div><a href="/servlet/linkout?suffix=cit260&amp;dbid=16384&amp;doi=10.1134%2FS1070428013040167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1134%252FS1070428013040167%26sid%3Dliteratum%253Aachs%26aulast%3DGalkina%26aufirst%3DI.%2BV.%26aulast%3DTakhautdinova%26aufirst%3DG.%2BL.%26aulast%3DTudrii%26aufirst%3DE.%2BV.%26aulast%3DYusupova%26aufirst%3DL.%2BM.%26aulast%3DFalyakhov%26aufirst%3DI.%2BF.%26aulast%3DPozdeev%26aufirst%3DO.%2BK.%26aulast%3DShulaeva%26aufirst%3DM.%2BP.%26aulast%3DKipenskaya%26aufirst%3DL.%2BV.%26aulast%3DSakhibullina%26aufirst%3DV.%2BG.%26aulast%3DKrivolapov%26aufirst%3DD.%2BB.%26aulast%3DLitvinov%26aufirst%3DI.%2BA.%26aulast%3DGalkin%26aufirst%3DV.%2BI.%26aulast%3DCherkasov%26aufirst%3DR.%2BA.%26atitle%3DSynthesis%252C%2520structure%252C%2520and%2520antibacterial%2520activity%2520of%2520aminobenzofuroxan%2520and%2520aminobenzofurazan%26jtitle%3DRuss.%2520J.%2520Org.%2520Chem.%26date%3D2013%26volume%3D49%26issue%3D4%26spage%3D591%26epage%3D597%26doi%3D10.1134%2FS1070428013040167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref261"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref261'); return false;" data-citation="" class="refNumLink">261</a></strong><div class="NLM_citation" id="cit261"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beebe, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilius, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merta, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soni, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beutel, B. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and SAR evaluation of oxadiazolopyrazines as selective Haemophilus influenzae antibacterial agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">3133</span>â <span class="NLM_lpage">3136</span>, <span class="refDoi">Â DOI: 10.1016/S0960-894X(03)00727-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2FS0960-894X%2803%2900727-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=12951079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvV2lsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=3133-3136&issue=19&author=X.+Beebeauthor=A.+M.+Niliusauthor=P.+J.+Mertaauthor=N.+B.+Soniauthor=M.+H.+Buiauthor=R.+Wagnerauthor=B.+A.+Beutel&title=Synthesis+and+SAR+evaluation+of+oxadiazolopyrazines+as+selective+Haemophilus+influenzae+antibacterial+agents&doi=10.1016%2FS0960-894X%2803%2900727-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit261R"><div class="casContent"><span class="casTitleNuber">261</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and SAR evaluation of oxadiazolopyrazines as selective Haemophilus influenzae antibacterial agents</span></div><div class="casAuthors">Beebe, Xenia; Nilius, Angela M.; Merta, Philip J.; Soni, Niru B.; Bui, Mai H.; Wagner, Rolf; Beutel, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3133-3136</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The parallel synthesis and antibacterial activity of 5-hydroxy-1,2,5-oxadiazolo[3,4-b]pyrazines, e.g., I, is reported.  The compds. were synthesized by condensing diaminofurazan (II) with Î±-keto acids to give a variety of aryl-substituted analogs.  Halogenated Ph groups at C-6 give rise to the greatest Haemophilus influenzae antibacterial activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXyJKZ9hzxF7Vg90H21EOLACvtfcHk0lh02TPuzp5coQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvV2lsLk%253D&md5=a64b56982c86d0e7a16897346c203a03</span></div><a href="/servlet/linkout?suffix=cit261&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2803%2900727-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252803%252900727-3%26sid%3Dliteratum%253Aachs%26aulast%3DBeebe%26aufirst%3DX.%26aulast%3DNilius%26aufirst%3DA.%2BM.%26aulast%3DMerta%26aufirst%3DP.%2BJ.%26aulast%3DSoni%26aufirst%3DN.%2BB.%26aulast%3DBui%26aufirst%3DM.%2BH.%26aulast%3DWagner%26aufirst%3DR.%26aulast%3DBeutel%26aufirst%3DB.%2BA.%26atitle%3DSynthesis%2520and%2520SAR%2520evaluation%2520of%2520oxadiazolopyrazines%2520as%2520selective%2520Haemophilus%2520influenzae%2520antibacterial%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26issue%3D19%26spage%3D3133%26epage%3D3136%26doi%3D10.1016%2FS0960-894X%2803%2900727-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref262"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref262'); return false;" data-citation="" class="refNumLink">262</a></strong><div class="NLM_citation" id="cit262"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cremades, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VelÃ¡zquez-Campoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MartÃ­nez-JÃºlvez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neira, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©rez-Dorado, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermoso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">JimÃ©nez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancho, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of specific flavodoxin inhibitors as potential therapeutic agents against Helicobacter pylori infection</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">928</span>â <span class="NLM_lpage">938</span>, <span class="refDoi">Â DOI: 10.1021/cb900166q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb900166q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFKgu7rI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=928-938&issue=11&author=N.+Cremadesauthor=A.+Vel%C3%A1zquez-Campoyauthor=M.+Mart%C3%ADnez-J%C3%BAlvezauthor=J.+L.+Neiraauthor=I.+P%C3%A9rez-Doradoauthor=J.+Hermosoauthor=P.+Jim%C3%A9nezauthor=A.+Lanasauthor=P.+S.+Hoffmanauthor=J.+Sancho&title=Discovery+of+specific+flavodoxin+inhibitors+as+potential+therapeutic+agents+against+Helicobacter+pylori+infection&doi=10.1021%2Fcb900166q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit262R"><div class="casContent"><span class="casTitleNuber">262</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Specific Flavodoxin Inhibitors as Potential Therapeutic Agents against Helicobacter pylori Infection</span></div><div class="casAuthors">Cremades, Nunilo; Velazquez-Campoy, Adrian; Martinez-Julvez, Marta; Neira, Jose L.; Perez-Dorado, Inmaculada; Hermoso, Juan; Jimenez, Pilar; Lanas, Angel; Hoffman, Paul S.; Sancho, Javier</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">928-938</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Helicobacter pylori establishes life-long infections in the gastric mucosa of over 1 billion people worldwide.  In many cases, without specific antimicrobial intervention, H. pylori infected individuals will develop type B gastritis, chronic peptic ulcers and, more rarely, gastric neoplasias.  Conventional antimicrobial therapy has been complicated by dramatic increases in resistance to macrolides, metronidazole and fluoroquinolones.  Here, the authors report the development of novel therapeutics that specifically target the unique flavodoxin component of an essential metabolic pathway of H. pylori.  With the use of high-throughput screening methodol., the authors have tested 10,000 chems. and have identified 29 compds. that bind flavodoxin, four of which interrupted in vitro electron transfer to flavodoxin physiol. partners.  Three of these compds. are bactericidal and promisingly selective for H. pylori.  The minimal inhibitory concns. of two of them are 10 times lower than their minimal cytotoxic concns. for HeLa cells.  Importantly, neither of the four inhibitors is toxic for mice after administration of 1-10 mg kg-1 doses twice a day for 5 days.  Enzymic, thermodn. and structural characterization of the inhibitor-flavodoxin complexes suggests these compds. could act by modifying the redox potentials of flavodoxin.  These newly discovered inhibitors represent promising selective leads against the different diseases assocd. to H. pylori infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjDI_jKdwgjbVg90H21EOLACvtfcHk0ljk0RFmDe7EPw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFKgu7rI&md5=dd46db4ba63571b42509b751d53df241</span></div><a href="/servlet/linkout?suffix=cit262&amp;dbid=16384&amp;doi=10.1021%2Fcb900166q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb900166q%26sid%3Dliteratum%253Aachs%26aulast%3DCremades%26aufirst%3DN.%26aulast%3DVel%25C3%25A1zquez-Campoy%26aufirst%3DA.%26aulast%3DMart%25C3%25ADnez-J%25C3%25BAlvez%26aufirst%3DM.%26aulast%3DNeira%26aufirst%3DJ.%2BL.%26aulast%3DP%25C3%25A9rez-Dorado%26aufirst%3DI.%26aulast%3DHermoso%26aufirst%3DJ.%26aulast%3DJim%25C3%25A9nez%26aufirst%3DP.%26aulast%3DLanas%26aufirst%3DA.%26aulast%3DHoffman%26aufirst%3DP.%2BS.%26aulast%3DSancho%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520specific%2520flavodoxin%2520inhibitors%2520as%2520potential%2520therapeutic%2520agents%2520against%2520Helicobacter%2520pylori%2520infection%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2009%26volume%3D4%26issue%3D11%26spage%3D928%26epage%3D938%26doi%3D10.1021%2Fcb900166q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref263"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref263'); return false;" data-citation="" class="refNumLink">263</a></strong><div class="NLM_citation" id="cit263"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galano, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alias, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez-Campoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancho, J.</span></span> <span> </span><span class="NLM_article-title">Improved flavodoxin inhibitors with potential therapeutic effects against Helicobacter pylori infection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6248</span>â <span class="NLM_lpage">6258</span>, <span class="refDoi">Â DOI: 10.1021/jm400786q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400786q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtV2mtrjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6248-6258&issue=15&author=J.+J.+Galanoauthor=M.+Aliasauthor=R.+Perezauthor=A.+Velazquez-Campoyauthor=P.+S.+Hoffmanauthor=J.+Sancho&title=Improved+flavodoxin+inhibitors+with+potential+therapeutic+effects+against+Helicobacter+pylori+infection&doi=10.1021%2Fjm400786q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit263R"><div class="casContent"><span class="casTitleNuber">263</span><div class="casTitle"><span class="NLM_cas:atitle">Improved Flavodoxin Inhibitors with Potential Therapeutic Effects against Helicobacter pylori Infection</span></div><div class="casAuthors">Galano, Juan J.; Alias, Miriam; Perez, Reyes; Velazquez-Campoy, Adrian; Hoffman, Paul S.; Sancho, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6248-6258</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A variety of electron-deficient chromenes and styrenes and nitrobenzooxadiazolyl thioethers and other compds. were tested (and in some cases prepd.) as selective inhibitors of flavodoxin in Helicobacter pylori for potential use in the treatment of gastric ulcer and prevention of stomach cancer with fewer side effects and reduced susceptibilities to drug resistance; their inhibition of flavodoxin and of Helicobacter pylori and their cytotoxicities were detd.  For example, (E)-ArCH:CHNO2 (Ar = 2-F-5-F3CC6H3, 4-Cl-2,6-F2C6H2) inhibited H. pylori with IC50 values of 0.53 Î¼M and therapeutic indexes of 38 and 15, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVtcmy_dYlFLVg90H21EOLACvtfcHk0ljk0RFmDe7EPw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtV2mtrjL&md5=28e1e564ebc186a2da0702973eb8fb64</span></div><a href="/servlet/linkout?suffix=cit263&amp;dbid=16384&amp;doi=10.1021%2Fjm400786q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400786q%26sid%3Dliteratum%253Aachs%26aulast%3DGalano%26aufirst%3DJ.%2BJ.%26aulast%3DAlias%26aufirst%3DM.%26aulast%3DPerez%26aufirst%3DR.%26aulast%3DVelazquez-Campoy%26aufirst%3DA.%26aulast%3DHoffman%26aufirst%3DP.%2BS.%26aulast%3DSancho%26aufirst%3DJ.%26atitle%3DImproved%2520flavodoxin%2520inhibitors%2520with%2520potential%2520therapeutic%2520effects%2520against%2520Helicobacter%2520pylori%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D15%26spage%3D6248%26epage%3D6258%26doi%3D10.1021%2Fjm400786q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref264"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref264'); return false;" data-citation="" class="refNumLink">264</a></strong><div class="NLM_citation" id="cit264"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salillas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alias, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bueno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galano-Frutos, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Reuse, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez-Campoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrodeguas, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sostres, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ainsa, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz-de-Villegas, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touati, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancho, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and efficacy testing of nitroethylene- and 7-nitrobenzoxadiazol-based flavodoxin inhibitors against Helicobacter pylori drug-resistant clinical strains and in Helicobacter pylori-infected mice</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">6102</span>â <span class="NLM_lpage">6115</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b00355</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00355" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFaqs73M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6102-6115&issue=13&author=S.+Salillasauthor=M.+Aliasauthor=V.+Michelauthor=A.+Mahiaauthor=A.+Luciaauthor=L.+Rodriguesauthor=J.+Buenoauthor=J.+J.+Galano-Frutosauthor=H.+De+Reuseauthor=A.+Velazquez-Campoyauthor=J.+A.+Carrodeguasauthor=C.+Sostresauthor=J.+Castilloauthor=J.+A.+Ainsaauthor=M.+D.+Diaz-de-Villegasauthor=A.+Lanasauthor=E.+Touatiauthor=J.+Sancho&title=Design%2C+synthesis%2C+and+efficacy+testing+of+nitroethylene-+and+7-nitrobenzoxadiazol-based+flavodoxin+inhibitors+against+Helicobacter+pylori+drug-resistant+clinical+strains+and+in+Helicobacter+pylori-infected+mice&doi=10.1021%2Facs.jmedchem.9b00355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit264R"><div class="casContent"><span class="casTitleNuber">264</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Efficacy Testing of Nitroethylene- and 7-Nitrobenzoxadiazol-Based Flavodoxin Inhibitors against Helicobacter pylori Drug-Resistant Clinical Strains and in Helicobacter pylori-Infected Mice</span></div><div class="casAuthors">Salillas, Sandra; Alias, Miriam; Michel, Valerie; Mahia, Alejandro; Lucia, Ainhoa; Rodrigues, Liliana; Bueno, Jessica; Galano-Frutos, Juan Jose; De Reuse, Hilde; Velazquez-Campoy, Adrian; Carrodeguas, Jose Alberto; Sostres, Carlos; Castillo, Javier; Ainsa, Jose Antonio; Diaz-de-Villegas, Maria Dolores; Lanas, Angel; Touati, Eliette; Sancho, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6102-6115</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Helicobacter pylori (Hp) infection is the main cause of peptic ulcer and gastric cancer.  Hp eradication rates have fallen due to increasing bacterial resistance to currently used broad-spectrum antimicrobials.  We have designed, synthesized, and tested redox variants of nitroethylene- and 7-nitrobenzoxadiazole-based inhibitors of the essential Hp protein flavodoxin.  Derivs. of the 7-nitrobenzoxadiazole lead, carrying reduced forms of the nitro group and/or oxidized forms of a sulfur atom, display high therapeutic indexes against several ref. Hp strains.  These inhibitors are effective against metronidazole-, clarithromycin-, and rifampicin-resistant Hp clin. isolates.  Their toxicity for mice after oral administration is low, and, when administered individually at single daily doses for 8 days in a mice model of Hp infection, they decrease significantly Hp gastric colonization rates and are able to eradicate the infection in up to 60% of the mice.  These flavodoxin inhibitors constitute a novel family of Hp-specific antimicrobials that may help fight the const. increase of Hp antimicrobial-resistant strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO7BuoCfwxibVg90H21EOLACvtfcHk0ljk0RFmDe7EPw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFaqs73M&md5=7b2ccbffcf8c2dcf2ed24180331e9866</span></div><a href="/servlet/linkout?suffix=cit264&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00355%26sid%3Dliteratum%253Aachs%26aulast%3DSalillas%26aufirst%3DS.%26aulast%3DAlias%26aufirst%3DM.%26aulast%3DMichel%26aufirst%3DV.%26aulast%3DMahia%26aufirst%3DA.%26aulast%3DLucia%26aufirst%3DA.%26aulast%3DRodrigues%26aufirst%3DL.%26aulast%3DBueno%26aufirst%3DJ.%26aulast%3DGalano-Frutos%26aufirst%3DJ.%2BJ.%26aulast%3DDe%2BReuse%26aufirst%3DH.%26aulast%3DVelazquez-Campoy%26aufirst%3DA.%26aulast%3DCarrodeguas%26aufirst%3DJ.%2BA.%26aulast%3DSostres%26aufirst%3DC.%26aulast%3DCastillo%26aufirst%3DJ.%26aulast%3DAinsa%26aufirst%3DJ.%2BA.%26aulast%3DDiaz-de-Villegas%26aufirst%3DM.%2BD.%26aulast%3DLanas%26aufirst%3DA.%26aulast%3DTouati%26aufirst%3DE.%26aulast%3DSancho%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520efficacy%2520testing%2520of%2520nitroethylene-%2520and%25207-nitrobenzoxadiazol-based%2520flavodoxin%2520inhibitors%2520against%2520Helicobacter%2520pylori%2520drug-resistant%2520clinical%2520strains%2520and%2520in%2520Helicobacter%2520pylori-infected%2520mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D13%26spage%3D6102%26epage%3D6115%26doi%3D10.1021%2Facs.jmedchem.9b00355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref265"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref265'); return false;" data-citation="" class="refNumLink">265</a></strong><div class="NLM_citation" id="cit265"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sancho Sanz, J.</span>; <span class="NLM_string-name">Velazquez Campoy, A.</span>; <span class="NLM_string-name">Cremades Casasin, N.</span></span> <span> </span><span class="NLM_article-title">Composition for Treating Infectious Diseases Caused by Helicobacter</span>. <span class="NLM_patent">WO2008107501A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=J.+Sancho+Sanz&author=A.+Velazquez+Campoy&author=N.+Cremades+Casasin&title=Composition+for+Treating+Infectious+Diseases+Caused+by+Helicobacter"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit265&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSancho%2BSanz%26aufirst%3DJ.%26atitle%3DComposition%2520for%2520Treating%2520Infectious%2520Diseases%2520Caused%2520by%2520Helicobacter%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref266"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref266'); return false;" data-citation="" class="refNumLink">266</a></strong><div class="NLM_citation" id="cit266"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christoff, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostoulias, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peleg, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbott, B. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of novel 1,2,5-oxadiazoles and evaluation of action against Acinetobacter baumannii</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">6267</span>â <span class="NLM_lpage">6272</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2017.08.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmc.2017.08.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=29032931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1arsLrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=6267-6272&issue=24&author=R.+M.+Christoffauthor=G.+L.+Murrayauthor=X.+P.+Kostouliasauthor=A.+Y.+Pelegauthor=B.+M.+Abbott&title=Synthesis+of+novel+1%2C2%2C5-oxadiazoles+and+evaluation+of+action+against+Acinetobacter+baumannii&doi=10.1016%2Fj.bmc.2017.08.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit266R"><div class="casContent"><span class="casTitleNuber">266</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of novel 1,2,5-oxadiazoles and evaluation of action against Acinetobacter baumannii</span></div><div class="casAuthors">Christoff, Rebecca M.; Murray, Gerald L.; Kostoulias, Xenia P.; Peleg, Anton Y.; Abbott, Belinda M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6267-6272</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">With multidrug resistant bacteria on the rise, novel antibiotics are becoming highly sought after.  In 2008, eleven compds. were identified by high throughput screening as inhibitors of BasE, a key enzyme of the non-ribosomal peptide synthetase pathway found in Acinetobacter baumannii.  Herein, the authors describe the prepn. of four structurally similar heterocyclic lead compds. from that study, including one 1,2,5-oxadiazole.  A further library of 30 analogs contg. the oxadiazole moiety was then generated.  All compds. were screened against Acinetobacter baumannii and their min. inhibitory concn. data is reported, with (E)-3-(2-hydroxyphenyl)-N-(4-methyl-1,2,5-oxadiazol-3-yl)acrylamide found to have an MIC of 0.5 mM.  This work provides the foundation for further study of 1,2,5-oxadiazoles as novel inhibitors of A. baumannii.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD-LYnmyhuMLVg90H21EOLACvtfcHk0liGBTiiJwdtvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1arsLrI&md5=70a94b4ce073cb4e639bfdd6b77c5be6</span></div><a href="/servlet/linkout?suffix=cit266&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.08.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.08.015%26sid%3Dliteratum%253Aachs%26aulast%3DChristoff%26aufirst%3DR.%2BM.%26aulast%3DMurray%26aufirst%3DG.%2BL.%26aulast%3DKostoulias%26aufirst%3DX.%2BP.%26aulast%3DPeleg%26aufirst%3DA.%2BY.%26aulast%3DAbbott%26aufirst%3DB.%2BM.%26atitle%3DSynthesis%2520of%2520novel%25201%252C2%252C5-oxadiazoles%2520and%2520evaluation%2520of%2520action%2520against%2520Acinetobacter%2520baumannii%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26issue%3D24%26spage%3D6267%26epage%3D6272%26doi%3D10.1016%2Fj.bmc.2017.08.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref267"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref267'); return false;" data-citation="" class="refNumLink">267</a></strong><div class="NLM_citation" id="cit267"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, C. C.</span></span> <span> </span><span class="NLM_article-title">Aryl acid adenylating enzymes involved in siderophore biosynthesis: Fluorescence polarization assay, ligand specificity, and discovery of non-nucleoside inhibitors via high-throughput screening</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">45</span>),  <span class="NLM_fpage">11735</span>â <span class="NLM_lpage">11749</span>, <span class="refDoi">Â DOI: 10.1021/bi801625b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi801625b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kiu77J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=11735-11749&issue=45&author=J.+Neresauthor=D.+J.+Wilsonauthor=L.+Celiaauthor=B.+J.+Beckauthor=C.+C.+Aldrich&title=Aryl+acid+adenylating+enzymes+involved+in+siderophore+biosynthesis%3A+Fluorescence+polarization+assay%2C+ligand+specificity%2C+and+discovery+of+non-nucleoside+inhibitors+via+high-throughput+screening&doi=10.1021%2Fbi801625b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit267R"><div class="casContent"><span class="casTitleNuber">267</span><div class="casTitle"><span class="NLM_cas:atitle">Aryl Acid Adenylating Enzymes Involved in Siderophore Biosynthesis: Fluorescence Polarization Assay, Ligand Specificity, and Discovery of Non-nucleoside Inhibitors via High-Throughput Screening</span></div><div class="casAuthors">Neres, Joao; Wilson, Daniel J.; Celia, Laura; Beck, Brian J.; Aldrich, Courtney C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">11735-11749</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design and synthesis of a fluorescent probe Fl-Sal-AMS 6 based on the tight-binding inhibitor 5'-O-[N-(salicyl)sulfamoyl]adenosine (Sal-AMS) is described for the aryl acid adenylating enzymes (AAAEs) known as MbtA, YbtE, EntE, VibE, DhbE, and BasE involved in siderophore biosynthesis from Mycobacterium tuberculosis, Yersinia pestis, Escherichia coli, Vibrio cholerae, Bacillus subtilis, and Acinetobacter baumannii, resp.  The probe was successfully used to develop a fluorescence polarization assay for these six AAAEs, and equil. dissocn. consts. were detd. in direct binding expts.  Fl-Sal-AMS was effective for AAAEs that utilize salicylic acid or 2,3-dihydroxybenzoic acid as native substrates, with dissocn. consts. ranging from 9-369 nM, but was ineffective for AsbC, the AAAE from Bacillus anthracis, which activates 3,4-dihydroxybenzoic acid.  Competitive binding expts. using a series of ligands including substrates, reaction products, and inhibitors provided the first comparative structure-activity relationships for AAAEs.  The fluorescence polarization assay was then miniaturized to a 384-well plate format, and high-throughput screening was performed at the National Screening Lab. for the Regional Centers of Excellence in Biodefense and Emerging Infectious Diseases (NSRB) against BasE, an AAAE from Acinetobacter baumannii involved in prodn. of the siderophore acinetobactin.  Several small mol. inhibitors with new chemotypes were identified, and compd. 23 contg. a pyrazolo[5,4-a]pyridine scaffold emerged as the most promising ligand with a KD of 78 nM, which was independently confirmed by isothermal calorimetry, and inhibition was also verified in an ATP-[32P]-pyrophosphate exchange steady-state kinetic assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqurhns8FCLb7Vg90H21EOLACvtfcHk0liGBTiiJwdtvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kiu77J&md5=d6682bccddd82d723b9b5bb900b39284</span></div><a href="/servlet/linkout?suffix=cit267&amp;dbid=16384&amp;doi=10.1021%2Fbi801625b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi801625b%26sid%3Dliteratum%253Aachs%26aulast%3DNeres%26aufirst%3DJ.%26aulast%3DWilson%26aufirst%3DD.%2BJ.%26aulast%3DCelia%26aufirst%3DL.%26aulast%3DBeck%26aufirst%3DB.%2BJ.%26aulast%3DAldrich%26aufirst%3DC.%2BC.%26atitle%3DAryl%2520acid%2520adenylating%2520enzymes%2520involved%2520in%2520siderophore%2520biosynthesis%253A%2520Fluorescence%2520polarization%2520assay%252C%2520ligand%2520specificity%252C%2520and%2520discovery%2520of%2520non-nucleoside%2520inhibitors%2520via%2520high-throughput%2520screening%26jtitle%3DBiochemistry%26date%3D2008%26volume%3D47%26issue%3D45%26spage%3D11735%26epage%3D11749%26doi%3D10.1021%2Fbi801625b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref268"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref268'); return false;" data-citation="" class="refNumLink">268</a></strong><div class="NLM_citation" id="cit268"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamiya, S.</span>; <span class="NLM_string-name">Osaki, T.</span>; <span class="NLM_string-name">Yonezawa, H.</span></span> <span> </span><span class="NLM_article-title">Biofilm formation and bacterial pathogenesis</span>.  <i>Antibiotic Therapy: New Developments</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, A.</span>; <span class="NLM_string-name">Hall, J.</span></span>; Eds.; <span class="NLM_publisher-name">Nova Science Publishers, Inc.</span>: <span class="NLM_publisher-loc">Hauppauge</span>, <span class="NLM_year">2013</span>, pp  <span class="NLM_fpage">89</span>â <span class="NLM_lpage">107</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=89-107&author=S.+Kamiya&author=T.+Osaki&author=H.+Yonezawaauthor=A.+Turner&author=J.+Hall&title=Antibiotic+Therapy%3A+New+Developments"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit268&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKamiya%26aufirst%3DS.%26atitle%3DBiofilm%2520formation%2520and%2520bacterial%2520pathogenesis%26btitle%3DAntibiotic%2520Therapy%253A%2520New%2520Developments%26aulast%3DTurner%26aufirst%3DA.%26pub%3DNova%2520Science%2520Publishers%252C%2520Inc%26date%3D2013%26spage%3D89%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref269"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref269'); return false;" data-citation="" class="refNumLink">269</a></strong><div class="NLM_citation" id="cit269"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tribedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manna, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharjee, S.</span></span> <span> </span><span class="NLM_article-title">3-Amino-4-aminoximidofurazan derivatives: Small molecules possessing antimicrobial and antibiofilm activity against Staphylococcus aureus and Pseudomonas aeruginosa</span>. <i>J. Appl. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>120</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">842</span>â <span class="NLM_lpage">859</span>, <span class="refDoi">Â DOI: 10.1111/jam.13063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1111%2Fjam.13063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=26785169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC28XktlGksrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2016&pages=842-859&issue=4&author=M.+C.+Dasauthor=S.+Paulauthor=P.+Guptaauthor=P.+Tribediauthor=S.+Sarkarauthor=D.+Mannaauthor=S.+Bhattacharjee&title=3-Amino-4-aminoximidofurazan+derivatives%3A+Small+molecules+possessing+antimicrobial+and+antibiofilm+activity+against+Staphylococcus+aureus+and+Pseudomonas+aeruginosa&doi=10.1111%2Fjam.13063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit269R"><div class="casContent"><span class="casTitleNuber">269</span><div class="casTitle"><span class="NLM_cas:atitle">3-Amino-4-aminoximidofurazan derivatives: small molecules possessing antimicrobial and antibiofilm activity against Staphylococcus aureus and Pseudomonas aeruginosa</span></div><div class="casAuthors">Das, M. C.; Paul, S.; Gupta, P.; Tribedi, P.; Sarkar, S.; Manna, D.; Bhattacharjee, S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Microbiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">842-859</span>CODEN:
                <span class="NLM_cas:coden">JAMIFK</span>;
        ISSN:<span class="NLM_cas:issn">1364-5072</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The therapeutic treatment of microbial infections involving biofilm becomes quite challenging because of its increasing antibiotic resistance capacities.  Towards this direction, in the present study we have evaluated the antibiofilm property of synthesized 3-amino-4-aminoximidofurazan compds. having polyamine skeleton.  These derivs. were synthesized by incorporating furazan and biguanide moieties.  Different 3-amino-4-aminoximidofurazan derivs. (PI1-4) were synthesized via protic acid catalysis and subsequently characterized by 1H NMR and 13C NMR spectra, recorded at 400 and 100 MHz resp.  We have tested the antimicrobial and antibiofilm activities of these synthetic derivs. (PI1-4) against both Staphylococcus aureus and Pseudomonas aeruginosa.  The compds. so tested were also compared with std. antibiotics namely Tobramycin (Ps. aeruginosa) and Azithromycin (Staph. aureus) which were used as a pos. control in all exptl. sets.  All these compds. (PI1-4) exhibited moderate to significant antimicrobial activities against both micro-organisms wherein compd. PI3 showed max. activity.  Biofilm inhibition of both micro-organisms was then evaluated by crystal violet and safranin staining, estn. of biofilm total protein and microscopy methods using sub-MIC dose of these compds.  Results showed that all compds. executed anti biofilm activity against both Staph. aureus and Ps. aeruginosa wherein compd. PI3 exhibited max. activity.  In relation with microbial biofilm inhibition, we have obsd. redn. in bacterial motility, proteolytic activity and secreted exo-polysaccharide (EPS) from both Staph. aureus and Ps. aeruginosa when they were grown in presence of these compds.  While addressing the issue of toxicity on host, we have obsd. that these mols. exhibited min. level of R.B.C degrdn.  These findings establish the antibacterial and anti biofilm properties of 3-amino-4-aminoximidofurazan derivs. (PI1-4).  Therefore, our current findings demonstrate that 3-amino-4-aminoximidofurazan derivs. (PI1-4) may hold promise to be effective biofilm and microbial inhibitors that may be clin. significant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPPG-vhtzrhLVg90H21EOLACvtfcHk0liGBTiiJwdtvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktlGksrc%253D&md5=1089fd49e2fa8417ec307f7358c739a5</span></div><a href="/servlet/linkout?suffix=cit269&amp;dbid=16384&amp;doi=10.1111%2Fjam.13063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjam.13063%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DM.%2BC.%26aulast%3DPaul%26aufirst%3DS.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DTribedi%26aufirst%3DP.%26aulast%3DSarkar%26aufirst%3DS.%26aulast%3DManna%26aufirst%3DD.%26aulast%3DBhattacharjee%26aufirst%3DS.%26atitle%3D3-Amino-4-aminoximidofurazan%2520derivatives%253A%2520Small%2520molecules%2520possessing%2520antimicrobial%2520and%2520antibiofilm%2520activity%2520against%2520Staphylococcus%2520aureus%2520and%2520Pseudomonas%2520aeruginosa%26jtitle%3DJ.%2520Appl.%2520Microbiol.%26date%3D2016%26volume%3D120%26issue%3D4%26spage%3D842%26epage%3D859%26doi%3D10.1111%2Fjam.13063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref270"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref270'); return false;" data-citation="" class="refNumLink">270</a></strong><div class="NLM_citation" id="cit270"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tranter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sessions, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brady, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendrick, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croft, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barros, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavandera, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ochoa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabarro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez de las Heras, F.</span></span> <span> </span><span class="NLM_article-title">Identification and activity of a series of azole-based compounds with lactate dehydrogenase-directed anti-malarial activity</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span> (<span class="NLM_issue">30</span>),  <span class="NLM_fpage">31429</span>â <span class="NLM_lpage">31439</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M402433200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1074%2Fjbc.M402433200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=15117937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlslOrsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=31429-31439&issue=30&author=A.+Cameronauthor=J.+Readauthor=R.+Tranterauthor=V.+J.+Winterauthor=R.+B.+Sessionsauthor=R.+L.+Bradyauthor=L.+Vivasauthor=A.+Eastonauthor=H.+Kendrickauthor=S.+L.+Croftauthor=D.+Barrosauthor=J.+L.+Lavanderaauthor=J.+J.+Martinauthor=F.+Riscoauthor=S.+Garcia-Ochoaauthor=F.+J.+Gamoauthor=L.+Sanzauthor=L.+Leonauthor=J.+R.+Ruizauthor=R.+Gabarroauthor=A.+Malloauthor=F.+Gomez+de+las+Heras&title=Identification+and+activity+of+a+series+of+azole-based+compounds+with+lactate+dehydrogenase-directed+anti-malarial+activity&doi=10.1074%2Fjbc.M402433200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit270R"><div class="casContent"><span class="casTitleNuber">270</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and activity of a series of azole-based compounds with lactate dehydrogenase-directed anti-malarial activity</span></div><div class="casAuthors">Cameron, Angus; Read, Jon; Tranter, Rebecca; Winter, Victoria J.; Sessions, Richard B.; Brady, R. Leo; Vivas, Livia; Easton, Anna; Kendrick, Howard; Croft, Simon L.; Barros, David; Lavandera, Jose Luis; Martin, Jose Julio; Risco, Felix; Garcia-Ochoa, Silvestre; Gamo, Fracisco Javier; Sanz, Laura; Leon, Luisa; Ruiz, Jose R.; Gabarro, Raquel; Mallo, Araceli; Gomez de las Heras, Federico</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">31429-31439</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Plasmodium falciparum, the causative agent of malaria, relies extensively on glycolysis coupled with homolactic fermn. during its blood-borne stages for energy prodn.  Selective inhibitors of the parasite lactate dehydrogenase (LDH), central to NAD+ regeneration, therefore potentially provide a route to new antimalarial drugs directed against a novel mol. target.  A series of heterocyclic, azole-based compds. are described that preferentially inhibit P. falciparum LDH at sub-micromolar concns., typically at concns. about 100-fold lower than required for human lactate dehydrogenase inhibition.  Crystal structures show these competitive inhibitors form a network of interactions with amino acids within the active site of the enzyme, stacking alongside the nicotinamide ring of the NAD+ cofactor.  These compds. display modest activity against parasitized erythrocytes, including parasite strains with known resistance to existing antimalarials and against Plasmodium berghei in BALB/c mice.  Initial toxicity data suggest the azole derivs. have generally low cytotoxicity, and preliminary pharmaco-kinetic data show favorable bioavailability and circulation times.  These encouraging results suggest that further enhancement of these structures may yield candidates suitable for consideration as new therapeutics for the treatment of malaria.  In combination these studies also provide strong support for the validity of targeting the Plasmodium glycolytic pathway and, in particular, LDH in the search for novel antimalarials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquuWRnYRD7DLVg90H21EOLACvtfcHk0lh32W0AHJJQVg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlslOrsLw%253D&md5=335235a632b3244cab8d5b828d232fa8</span></div><a href="/servlet/linkout?suffix=cit270&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M402433200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M402433200%26sid%3Dliteratum%253Aachs%26aulast%3DCameron%26aufirst%3DA.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DTranter%26aufirst%3DR.%26aulast%3DWinter%26aufirst%3DV.%2BJ.%26aulast%3DSessions%26aufirst%3DR.%2BB.%26aulast%3DBrady%26aufirst%3DR.%2BL.%26aulast%3DVivas%26aufirst%3DL.%26aulast%3DEaston%26aufirst%3DA.%26aulast%3DKendrick%26aufirst%3DH.%26aulast%3DCroft%26aufirst%3DS.%2BL.%26aulast%3DBarros%26aufirst%3DD.%26aulast%3DLavandera%26aufirst%3DJ.%2BL.%26aulast%3DMartin%26aufirst%3DJ.%2BJ.%26aulast%3DRisco%26aufirst%3DF.%26aulast%3DGarcia-Ochoa%26aufirst%3DS.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DSanz%26aufirst%3DL.%26aulast%3DLeon%26aufirst%3DL.%26aulast%3DRuiz%26aufirst%3DJ.%2BR.%26aulast%3DGabarro%26aufirst%3DR.%26aulast%3DMallo%26aufirst%3DA.%26aulast%3DGomez%2Bde%2Blas%2BHeras%26aufirst%3DF.%26atitle%3DIdentification%2520and%2520activity%2520of%2520a%2520series%2520of%2520azole-based%2520compounds%2520with%2520lactate%2520dehydrogenase-directed%2520anti-malarial%2520activity%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26issue%3D30%26spage%3D31429%26epage%3D31439%26doi%3D10.1074%2Fjbc.M402433200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref271"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref271'); return false;" data-citation="" class="refNumLink">271</a></strong><div class="NLM_citation" id="cit271"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Florence, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulloch, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacharova, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T. K.</span></span> <span> </span><span class="NLM_article-title">Development of simplified heterocyclic acetogenin analogues as potent and selective Trypanosoma brucei inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">1503</span>â <span class="NLM_lpage">1506</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201600210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fcmdc.201600210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=27283448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVyjs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1503-1506&issue=14&author=G.+J.+Florenceauthor=A.+L.+Fraserauthor=E.+R.+Gouldauthor=E.+F.+Kingauthor=S.+K.+Menziesauthor=J.+C.+Morrisauthor=M.+I.+Thomsonauthor=L.+B.+Tullochauthor=M.+K.+Zacharovaauthor=T.+K.+Smith&title=Development+of+simplified+heterocyclic+acetogenin+analogues+as+potent+and+selective+Trypanosoma+brucei+inhibitors&doi=10.1002%2Fcmdc.201600210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit271R"><div class="casContent"><span class="casTitleNuber">271</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Simplified Heterocyclic Acetogenin Analogues as Potent and Selective Trypanosoma brucei Inhibitors</span></div><div class="casAuthors">Florence, Gordon J.; Fraser, Andrew L.; Gould, Eoin R.; King, Elizabeth F.; Menzies, Stefanie K.; Morris, Joanne C.; Thomson, Marie I.; Tulloch, Lindsay B.; Zacharova, Marija K.; Smith, Terry K.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1503-1506</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Neglected tropical diseases caused by parasitic infections are an ongoing and increasing concern.  They are a burden to human and animal health, having the most devastating effect on the world's poorest countries.  Building upon our previously reported triazole analogs, in this study we describe the synthesis and biol. testing of other novel heterocyclic acetogenin-inspired derivs., namely 3,5-isoxazoles, furoxans, and furazans.  Several of these compds. maintain low-micromolar levels of inhibition against Trypanosoma brucei, while having no observable inhibitory effect on mammalian cells, leading to the possibility of novel lead compds. for selective treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoctHLE622pVbVg90H21EOLACvtfcHk0lh32W0AHJJQVg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVyjs7g%253D&md5=fcf5866e0376c12dcc956d35867d45d7</span></div><a href="/servlet/linkout?suffix=cit271&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600210%26sid%3Dliteratum%253Aachs%26aulast%3DFlorence%26aufirst%3DG.%2BJ.%26aulast%3DFraser%26aufirst%3DA.%2BL.%26aulast%3DGould%26aufirst%3DE.%2BR.%26aulast%3DKing%26aufirst%3DE.%2BF.%26aulast%3DMenzies%26aufirst%3DS.%2BK.%26aulast%3DMorris%26aufirst%3DJ.%2BC.%26aulast%3DThomson%26aufirst%3DM.%2BI.%26aulast%3DTulloch%26aufirst%3DL.%2BB.%26aulast%3DZacharova%26aufirst%3DM.%2BK.%26aulast%3DSmith%26aufirst%3DT.%2BK.%26atitle%3DDevelopment%2520of%2520simplified%2520heterocyclic%2520acetogenin%2520analogues%2520as%2520potent%2520and%2520selective%2520Trypanosoma%2520brucei%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26issue%3D14%26spage%3D1503%26epage%3D1506%26doi%3D10.1002%2Fcmdc.201600210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref272"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref272'); return false;" data-citation="" class="refNumLink">272</a></strong><div class="NLM_citation" id="cit272"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keurulainen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heiskari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nenonen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasereddin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopelyanskiy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leino, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yli-Kauhaluoma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffe, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiuru, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis of carboxyimidamide-substituted benzo[c][1,2,5]oxadiazoles and their analogs, and evaluation of biological activity against Leishmania donovani</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1673</span>â <span class="NLM_lpage">1678</span>, <span class="refDoi">Â DOI: 10.1039/C5MD00119F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1039%2FC5MD00119F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12mur%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1673-1678&issue=9&author=L.+Keurulainenauthor=M.+Heiskariauthor=S.+Nenonenauthor=A.+Nasereddinauthor=D.+Kopelyanskiyauthor=T.+O.+Leinoauthor=J.+Yli-Kauhaluomaauthor=C.+L.+Jaffeauthor=P.+Kiuru&title=Synthesis+of+carboxyimidamide-substituted+benzo%5Bc%5D%5B1%2C2%2C5%5Doxadiazoles+and+their+analogs%2C+and+evaluation+of+biological+activity+against+Leishmania+donovani&doi=10.1039%2FC5MD00119F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit272R"><div class="casContent"><span class="casTitleNuber">272</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of carboxyimidamide-substituted benzo[c][1,2,5]oxadiazoles and their analogs and evaluation of biological activity against Leishmania donovani</span></div><div class="casAuthors">Keurulainen, Leena; Heiskari, Mikko; Nenonen, Satu; Nasereddin, Abedelmajeed; Kopelyanskiy, Dmitry; Leino, Teppo O.; Yli-Kauhaluoma, Jari; Jaffe, Charles L.; Kiuru, Paula</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1673-1678</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Facile synthesis route to carboxyimidamide-substituted benzoxadiazoles I [R = H, Me, OMe etc.] were developed.  A total of 25 derivs. were synthesized.  They were evaluated for antileishmanial activity by inhibition of Leishmania donovani axenic amastigote growth using a fluorescent viability microplate assay.  The most promising deriv. I [R = 3-Cl] demonstrated an antileishmanial EC50 of 4.0 Î¼M and it also showed activity in infected macrophages (EC50 5.92 Î¼M) without signs of cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryfBNVFAQL2LVg90H21EOLACvtfcHk0lh32W0AHJJQVg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12mur%252FL&md5=f9eba642a1956f7100d498ed067c49a8</span></div><a href="/servlet/linkout?suffix=cit272&amp;dbid=16384&amp;doi=10.1039%2FC5MD00119F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MD00119F%26sid%3Dliteratum%253Aachs%26aulast%3DKeurulainen%26aufirst%3DL.%26aulast%3DHeiskari%26aufirst%3DM.%26aulast%3DNenonen%26aufirst%3DS.%26aulast%3DNasereddin%26aufirst%3DA.%26aulast%3DKopelyanskiy%26aufirst%3DD.%26aulast%3DLeino%26aufirst%3DT.%2BO.%26aulast%3DYli-Kauhaluoma%26aufirst%3DJ.%26aulast%3DJaffe%26aufirst%3DC.%2BL.%26aulast%3DKiuru%26aufirst%3DP.%26atitle%3DSynthesis%2520of%2520carboxyimidamide-substituted%2520benzo%255Bc%255D%255B1%252C2%252C5%255Doxadiazoles%2520and%2520their%2520analogs%252C%2520and%2520evaluation%2520of%2520biological%2520activity%2520against%2520Leishmania%2520donovani%26jtitle%3DMedChemComm%26date%3D2015%26volume%3D6%26issue%3D9%26spage%3D1673%26epage%3D1678%26doi%3D10.1039%2FC5MD00119F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref273"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref273'); return false;" data-citation="" class="refNumLink">273</a></strong><div class="NLM_citation" id="cit273"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, U.</span>; <span class="NLM_string-name">Ranadheera, C.</span></span> <span> </span><span class="NLM_article-title">2,1,3-Benzoxadiazol Derivatives for Inhibition of Influenza A and B Virus and Respiratory Syncytial Virus Replication</span>. <span class="NLM_patent">WO2010128156A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=U.+Kessler&author=C.+Ranadheera&title=2%2C1%2C3-Benzoxadiazol+Derivatives+for+Inhibition+of+Influenza+A+and+B+Virus+and+Respiratory+Syncytial+Virus+Replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit273&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKessler%26aufirst%3DU.%26atitle%3D2%252C1%252C3-Benzoxadiazol%2520Derivatives%2520for%2520Inhibition%2520of%2520Influenza%2520A%2520and%2520B%2520Virus%2520and%2520Respiratory%2520Syncytial%2520Virus%2520Replication%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref274"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref274'); return false;" data-citation="" class="refNumLink">274</a></strong><div class="NLM_citation" id="cit274"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, U.</span>; <span class="NLM_string-name">Ranadheera, C.</span></span> <span> </span><span class="NLM_article-title">2,1,3-Benzoxadiazol Derivatives for the Inhibition of Influenza A and B Virus and Respiratory Syncytial Virus Replication</span>. <span class="NLM_patent">US20120122896A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=U.+Kessler&author=C.+Ranadheera&title=2%2C1%2C3-Benzoxadiazol+Derivatives+for+the+Inhibition+of+Influenza+A+and+B+Virus+and+Respiratory+Syncytial+Virus+Replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit274&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKessler%26aufirst%3DU.%26atitle%3D2%252C1%252C3-Benzoxadiazol%2520Derivatives%2520for%2520the%2520Inhibition%2520of%2520Influenza%2520A%2520and%2520B%2520Virus%2520and%2520Respiratory%2520Syncytial%2520Virus%2520Replication%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref275"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref275'); return false;" data-citation="" class="refNumLink">275</a></strong><div class="NLM_citation" id="cit275"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagnolo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallacara, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurenzana, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deodato, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stergiou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strunze, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tintori, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, M.</span></span> <span> </span><span class="NLM_article-title">The fight against the influenza A virus H1N1: Synthesis, molecular modeling, and biological evaluation of benzofurazan derivatives as viral RNA polymerase inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">129</span>â <span class="NLM_lpage">150</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201300378</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fcmdc.201300378" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=24285596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGgtLbN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=129-150&issue=1&author=M.+Paganoauthor=D.+Castagnoloauthor=M.+Bernardiniauthor=A.+L.+Fallacaraauthor=I.+Laurenzanaauthor=D.+Deodatoauthor=U.+Kesslerauthor=B.+Pilgerauthor=L.+Stergiouauthor=S.+Strunzeauthor=C.+Tintoriauthor=M.+Botta&title=The+fight+against+the+influenza+A+virus+H1N1%3A+Synthesis%2C+molecular+modeling%2C+and+biological+evaluation+of+benzofurazan+derivatives+as+viral+RNA+polymerase+inhibitors&doi=10.1002%2Fcmdc.201300378"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit275R"><div class="casContent"><span class="casTitleNuber">275</span><div class="casTitle"><span class="NLM_cas:atitle">The Fight against the Influenza A Virus H1N1: Synthesis, Molecular Modeling, and Biological Evaluation of Benzofurazan Derivatives as Viral RNA Polymerase Inhibitors</span></div><div class="casAuthors">Pagano, Mafalda; Castagnolo, Daniele; Bernardini, Martina; Fallacara, Anna Lucia; Laurenzana, Ilaria; Deodato, Davide; Kessler, Ulrich; Pilger, Beatrice; Stergiou, Lilli; Strunze, Stephan; Tintori, Cristina; Botta, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">129-150</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The influenza RNA polymerase complex, which consists of the three subunits PA, PB1, and PB2, is a promising target for the development of new antiviral drugs.  A large library of benzofurazan compds. was synthesized and assayed against influenza virus A/WSN/33 (H1N1).  Most of the new derivs. were found to act by inhibiting the viral RNA polymerase complex through disruption of the complex formed between subunits PA and PB1.  Docking studies were also performed to elucidate the binding mode of benzofurazans within the PB1 binding site in PA and to identify amino acids involved in their mechanism of action.  The predicted binding pose is fully consistent with the biol. data and lays the foundation for the rational development of more effective PA-PB1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb5eQEpazuCbVg90H21EOLACvtfcHk0lhn34JuB-VHGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGgtLbN&md5=b998411686f59fc9882ebeee4ea5add7</span></div><a href="/servlet/linkout?suffix=cit275&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300378%26sid%3Dliteratum%253Aachs%26aulast%3DPagano%26aufirst%3DM.%26aulast%3DCastagnolo%26aufirst%3DD.%26aulast%3DBernardini%26aufirst%3DM.%26aulast%3DFallacara%26aufirst%3DA.%2BL.%26aulast%3DLaurenzana%26aufirst%3DI.%26aulast%3DDeodato%26aufirst%3DD.%26aulast%3DKessler%26aufirst%3DU.%26aulast%3DPilger%26aufirst%3DB.%26aulast%3DStergiou%26aufirst%3DL.%26aulast%3DStrunze%26aufirst%3DS.%26aulast%3DTintori%26aufirst%3DC.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DThe%2520fight%2520against%2520the%2520influenza%2520A%2520virus%2520H1N1%253A%2520Synthesis%252C%2520molecular%2520modeling%252C%2520and%2520biological%2520evaluation%2520of%2520benzofurazan%2520derivatives%2520as%2520viral%2520RNA%2520polymerase%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26issue%3D1%26spage%3D129%26epage%3D150%26doi%3D10.1002%2Fcmdc.201300378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref276"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref276'); return false;" data-citation="" class="refNumLink">276</a></strong><div class="NLM_citation" id="cit276"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagnolo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deodato, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranadheera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, M.</span></span> <span> </span><span class="NLM_article-title">Discovery and synthesis of novel benzofurazan derivatives as inhibitors of influenza A virus</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">5575</span>â <span class="NLM_lpage">5577</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2013.08.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmcl.2013.08.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=24012120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSkt7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5575-5577&issue=20&author=U.+Kesslerauthor=D.+Castagnoloauthor=M.+Paganoauthor=D.+Deodatoauthor=M.+Bernardiniauthor=B.+Pilgerauthor=C.+Ranadheeraauthor=M.+Botta&title=Discovery+and+synthesis+of+novel+benzofurazan+derivatives+as+inhibitors+of+influenza+A+virus&doi=10.1016%2Fj.bmcl.2013.08.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit276R"><div class="casContent"><span class="casTitleNuber">276</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and synthesis of novel benzofurazan derivatives as inhibitors of influenza A virus</span></div><div class="casAuthors">Kessler, Ulrich; Castagnolo, Daniele; Pagano, Mafalda; Deodato, Davide; Bernardini, Martina; Pilger, Beatrice; Ranadheera, Charlene; Botta, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5575-5577</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The identification of a novel hit compd. inhibitor (I) of the protein-protein interaction between the influenza RNA-polymerase PA and PB1 subunits has been accomplished by means of high-throughput screening.  A small family of structurally related mols. has been synthesized and biol. evaluated with most of the compds. showing micromolar potency of inhibition against viral replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6J3cLqCNdIrVg90H21EOLACvtfcHk0lhn34JuB-VHGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSkt7rN&md5=52fc0dde69ffc72a0c9e53c7f9630536</span></div><a href="/servlet/linkout?suffix=cit276&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.048%26sid%3Dliteratum%253Aachs%26aulast%3DKessler%26aufirst%3DU.%26aulast%3DCastagnolo%26aufirst%3DD.%26aulast%3DPagano%26aufirst%3DM.%26aulast%3DDeodato%26aufirst%3DD.%26aulast%3DBernardini%26aufirst%3DM.%26aulast%3DPilger%26aufirst%3DB.%26aulast%3DRanadheera%26aufirst%3DC.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DDiscovery%2520and%2520synthesis%2520of%2520novel%2520benzofurazan%2520derivatives%2520as%2520inhibitors%2520of%2520influenza%2520A%2520virus%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D20%26spage%3D5575%26epage%3D5577%26doi%3D10.1016%2Fj.bmcl.2013.08.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref277"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref277'); return false;" data-citation="" class="refNumLink">277</a></strong><div class="NLM_citation" id="cit277"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenwood, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajwa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murrow, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderone, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divakaruni, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomsig, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron
Coleman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Columbus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saucerman, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravichandran, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchiyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okusa, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayliss, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoehn, K. L.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane</span>. <i>Mol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">114</span>â <span class="NLM_lpage">123</span>, <span class="refDoi">Â DOI: 10.1016/j.molmet.2013.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.molmet.2013.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=24634817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOhu7vK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=114-123&issue=2&author=B.+M.+Kenwoodauthor=J.+L.+Weaverauthor=A.+Bajwaauthor=I.+K.+Poonauthor=F.+L.+Byrneauthor=B.+A.+Murrowauthor=J.+A.+Calderoneauthor=L.+Huangauthor=A.+S.+Divakaruniauthor=J.+L.+Tomsigauthor=K.+Okabeauthor=R.+H.+Loauthor=G.+Cameron%0AColemanauthor=L.+Columbusauthor=Z.+Yanauthor=J.+J.+Saucermanauthor=J.+S.+Smithauthor=J.+W.+Holmesauthor=K.+R.+Lynchauthor=K.+S.+Ravichandranauthor=S.+Uchiyamaauthor=W.+L.+Santosauthor=G.+W.+Rogersauthor=M.+D.+Okusaauthor=D.+A.+Baylissauthor=K.+L.+Hoehn&title=Identification+of+a+novel+mitochondrial+uncoupler+that+does+not+depolarize+the+plasma+membrane&doi=10.1016%2Fj.molmet.2013.11.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit277R"><div class="casContent"><span class="casTitleNuber">277</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane</span></div><div class="casAuthors">Kenwood, Brandon M.; Weaver, Janelle L.; Bajwa, Amandeep; Poon, Ivan K.; Byrne, Frances L.; Murrow, Beverley A.; Calderone, Joseph A.; Huang, Liping; Divakaruni, Ajit S.; Tomsig, Jose L.; Okabe, Kohki; Lo, Ryan H.; Cameron Coleman, G.; Columbus, Linda; Yan, Zhen; Saucerman, Jeffrey J.; Smith, Jeffrey S.; Holmes, Jeffrey W.; Lynch, Kevin R.; Ravichandran, Kodi S.; Uchiyama, Seiichi; Santos, Webster L.; Rogers, George W.; Okusa, Mark D.; Bayliss, Douglas A.; Hoehn, Kyle L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Metabolism</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">114-123</span>CODEN:
                <span class="NLM_cas:coden">MMOEAS</span>;
        ISSN:<span class="NLM_cas:issn">2212-8778</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">Dysregulation of oxidative phosphorylation is assocd. with increased mitochondrial reactive oxygen species prodn. and some of the most prevalent human diseases including obesity, cancer, diabetes, neurodegeneration, and heart disease.  Chem. 'mitochondrial uncouplers' are lipophilic weak acids that transport protons into the mitochondrial matrix via a pathway that is independent of ATP synthase, thereby uncoupling nutrient oxidn. from ATP prodn.  Mitochondrial uncouplers also lessen the proton motive force across the mitochondrial inner membrane and thereby increase the rate of mitochondrial respiration while decreasing prodn. of reactive oxygen species.  Thus, mitochondrial uncouplers are valuable chem. tools that enable the measurement of maximal mitochondrial respiration and they have been used therapeutically to decrease mitochondrial reactive oxygen species prodn.  However, the most widely used protonophore uncouplers such as carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) and 2,4-dinitrophenol have off-target activity at other membranes that lead to a range of undesired effects including plasma membrane depolarization, mitochondrial inhibition, and cytotoxicity.  These unwanted properties interfere with the measurement of mitochondrial function and result in a narrow therapeutic index that limits their usefulness in the clinic.  To identify new mitochondrial uncouplers that lack off-target activity at the plasma membrane we screened a small mol. chem. library.  Herein we report the identification and validation of a novel mitochondrial protonophore uncoupler (2-fluorophenyl){6-[(2-fluorophenyl)amino](1,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine, named BAM15, that does not depolarize the plasma membrane.  Compared to FCCP, an uncoupler of equal potency, BAM15 treatment of cultured cells stimulates a higher max. rate of mitochondrial respiration and is less cytotoxic.  Furthermore, BAM15 is bioactive in vivo and dose-dependently protects mice from acute renal ischemic-reperfusion injury.  From a tech. standpoint, BAM15 represents an effective new tool that allows the study of mitochondrial function in the absence of off-target effects that can confound data interpretation.  From a therapeutic perspective, BAM15-mediated protection from ischemia-reperfusion injury and its reduced toxicity will hopefully reignite interest in pharmacol. uncoupling for the treatment of the myriad of diseases that are assocd. with altered mitochondrial function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCXatpkZ9rLrVg90H21EOLACvtfcHk0ljgEwut4ZlAcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOhu7vK&md5=987dce47f833f2cdbba86cb50234b483</span></div><a href="/servlet/linkout?suffix=cit277&amp;dbid=16384&amp;doi=10.1016%2Fj.molmet.2013.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmet.2013.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DKenwood%26aufirst%3DB.%2BM.%26aulast%3DWeaver%26aufirst%3DJ.%2BL.%26aulast%3DBajwa%26aufirst%3DA.%26aulast%3DPoon%26aufirst%3DI.%2BK.%26aulast%3DByrne%26aufirst%3DF.%2BL.%26aulast%3DMurrow%26aufirst%3DB.%2BA.%26aulast%3DCalderone%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DDivakaruni%26aufirst%3DA.%2BS.%26aulast%3DTomsig%26aufirst%3DJ.%2BL.%26aulast%3DOkabe%26aufirst%3DK.%26aulast%3DLo%26aufirst%3DR.%2BH.%26aulast%3DCameron%2BColeman%26aufirst%3DG.%26aulast%3DColumbus%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DZ.%26aulast%3DSaucerman%26aufirst%3DJ.%2BJ.%26aulast%3DSmith%26aufirst%3DJ.%2BS.%26aulast%3DHolmes%26aufirst%3DJ.%2BW.%26aulast%3DLynch%26aufirst%3DK.%2BR.%26aulast%3DRavichandran%26aufirst%3DK.%2BS.%26aulast%3DUchiyama%26aufirst%3DS.%26aulast%3DSantos%26aufirst%3DW.%2BL.%26aulast%3DRogers%26aufirst%3DG.%2BW.%26aulast%3DOkusa%26aufirst%3DM.%2BD.%26aulast%3DBayliss%26aufirst%3DD.%2BA.%26aulast%3DHoehn%26aufirst%3DK.%2BL.%26atitle%3DIdentification%2520of%2520a%2520novel%2520mitochondrial%2520uncoupler%2520that%2520does%2520not%2520depolarize%2520the%2520plasma%2520membrane%26jtitle%3DMol.%2520Metab.%26date%3D2014%26volume%3D3%26issue%3D2%26spage%3D114%26epage%3D123%26doi%3D10.1016%2Fj.molmet.2013.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref278"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref278'); return false;" data-citation="" class="refNumLink">278</a></strong><div class="NLM_citation" id="cit278"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexopoulos, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandon, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salamoun, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beretta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olzomer, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philp, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargett, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sligar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrive, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooney, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoehn, K. L.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">2397</span>, <span class="refDoi">Â DOI: 10.1038/s41467-020-16298-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2Fs41467-020-16298-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=32409697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsFCisrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=2397&issue=1&author=S.+J.+Alexopoulosauthor=S.+Y.+Chenauthor=A.+E.+Brandonauthor=J.+M.+Salamounauthor=F.+L.+Byrneauthor=C.+J.+Garciaauthor=M.+Berettaauthor=E.+M.+Olzomerauthor=D.+P.+Shahauthor=A.+M.+Philpauthor=S.+R.+Hargettauthor=R.+T.+Lawrenceauthor=B.+Leeauthor=J.+Sligarauthor=P.+Carriveauthor=S.+P.+Tuckerauthor=A.+Philpauthor=C.+Lacknerauthor=N.+Turnerauthor=G.+J.+Cooneyauthor=W.+L.+Santosauthor=K.+L.+Hoehn&title=Mitochondrial+uncoupler+BAM15+reverses+diet-induced+obesity+and+insulin+resistance+in+mice&doi=10.1038%2Fs41467-020-16298-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit278R"><div class="casContent"><span class="casTitleNuber">278</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice</span></div><div class="casAuthors">Alexopoulos, Stephanie J.; Chen, Sing-Young; Brandon, Amanda E.; Salamoun, Joseph M.; Byrne, Frances L.; Garcia, Christopher J.; Beretta, Martina; Olzomer, Ellen M.; Shah, Divya P.; Philp, Ashleigh M.; Hargett, Stefan R.; Lawrence, Robert T.; Lee, Brendan; Sligar, James; Carrive, Pascal; Tucker, Simon P.; Philp, Andrew; Lackner, Carolin; Turner, Nigel; Cooney, Gregory J.; Santos, Webster L.; Hoehn, Kyle L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2397</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Obesity is a health problem affecting more than 40% of US adults and 13% of the global population.  Anti-obesity treatments including diet, exercise, surgery and pharmacotherapies have so far failed to reverse obesity incidence.  Herein, we target obesity with a pharmacotherapeutic approach that decreases caloric efficiency by mitochondrial uncoupling.  We show that a recently identified mitochondrial uncoupler BAM15 is orally bioavailable, increases nutrient oxidn., and decreases body fat mass without altering food intake, lean body mass, body temp., or biochem. and haematol. markers of toxicity.  BAM15 decreases hepatic fat, decreases inflammatory lipids, and has strong antioxidant effects.  Hyperinsulinemic-euglycemic clamp studies show that BAM15 improves insulin sensitivity in multiple tissue types.  Collectively, these data demonstrate that pharmacol. mitochondrial uncoupling with BAM15 has powerful anti-obesity and insulin sensitizing effects without compromising lean mass or affecting food intake.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbxHlgDr0Lf7Vg90H21EOLACvtfcHk0ljgEwut4ZlAcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsFCisrs%253D&md5=3b52feb5588349b0255884ec7aee151f</span></div><a href="/servlet/linkout?suffix=cit278&amp;dbid=16384&amp;doi=10.1038%2Fs41467-020-16298-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-020-16298-2%26sid%3Dliteratum%253Aachs%26aulast%3DAlexopoulos%26aufirst%3DS.%2BJ.%26aulast%3DChen%26aufirst%3DS.%2BY.%26aulast%3DBrandon%26aufirst%3DA.%2BE.%26aulast%3DSalamoun%26aufirst%3DJ.%2BM.%26aulast%3DByrne%26aufirst%3DF.%2BL.%26aulast%3DGarcia%26aufirst%3DC.%2BJ.%26aulast%3DBeretta%26aufirst%3DM.%26aulast%3DOlzomer%26aufirst%3DE.%2BM.%26aulast%3DShah%26aufirst%3DD.%2BP.%26aulast%3DPhilp%26aufirst%3DA.%2BM.%26aulast%3DHargett%26aufirst%3DS.%2BR.%26aulast%3DLawrence%26aufirst%3DR.%2BT.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DSligar%26aufirst%3DJ.%26aulast%3DCarrive%26aufirst%3DP.%26aulast%3DTucker%26aufirst%3DS.%2BP.%26aulast%3DPhilp%26aufirst%3DA.%26aulast%3DLackner%26aufirst%3DC.%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DCooney%26aufirst%3DG.%2BJ.%26aulast%3DSantos%26aufirst%3DW.%2BL.%26aulast%3DHoehn%26aufirst%3DK.%2BL.%26atitle%3DMitochondrial%2520uncoupler%2520BAM15%2520reverses%2520diet-induced%2520obesity%2520and%2520insulin%2520resistance%2520in%2520mice%26jtitle%3DNat.%2520Commun.%26date%3D2020%26volume%3D11%26issue%3D1%26spage%3D2397%26doi%3D10.1038%2Fs41467-020-16298-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref279"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref279'); return false;" data-citation="" class="refNumLink">279</a></strong><div class="NLM_citation" id="cit279"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoehn, K.</span>; <span class="NLM_string-name">Kenwood, B.</span></span> <span> </span><span class="NLM_article-title">Compositions and Methods for Regulating Glucose Homeostasis and Insulin Action</span>. <span class="NLM_patent">US20150322081A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=K.+Hoehn&author=B.+Kenwood&title=Compositions+and+Methods+for+Regulating+Glucose+Homeostasis+and+Insulin+Action"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit279&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHoehn%26aufirst%3DK.%26atitle%3DCompositions%2520and%2520Methods%2520for%2520Regulating%2520Glucose%2520Homeostasis%2520and%2520Insulin%2520Action%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref280"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref280'); return false;" data-citation="" class="refNumLink">280</a></strong><div class="NLM_citation" id="cit280"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Childress, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salamoun, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargett, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexopoulos, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santiago-Rivera, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoehn, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, W. L.</span></span> <span> </span><span class="NLM_article-title">[1,2,5]Oxadiazolo[3,4-b]pyrazine-5,6-diamine derivatives as mitochondrial uncouplers for the potential treatment of nonalcoholic steatohepatitis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2511</span>â <span class="NLM_lpage">2526</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b01440</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01440" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitleqtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2511-2526&issue=5&author=E.+S.+Childressauthor=J.+M.+Salamounauthor=S.+R.+Hargettauthor=S.+J.+Alexopoulosauthor=S.+Y.+Chenauthor=D.+P.+Shahauthor=J.+Santiago-Riveraauthor=C.+J.+Garciaauthor=Y.+Daiauthor=S.+P.+Tuckerauthor=K.+L.+Hoehnauthor=W.+L.+Santos&title=%5B1%2C2%2C5%5DOxadiazolo%5B3%2C4-b%5Dpyrazine-5%2C6-diamine+derivatives+as+mitochondrial+uncouplers+for+the+potential+treatment+of+nonalcoholic+steatohepatitis&doi=10.1021%2Facs.jmedchem.9b01440"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit280R"><div class="casContent"><span class="casTitleNuber">280</span><div class="casTitle"><span class="NLM_cas:atitle">[1,2,5]Oxadiazolo[3,4-b]pyrazine-5,6-diamine Derivatives as Mitochondrial Uncouplers for the Potential Treatment of Nonalcoholic Steatohepatitis</span></div><div class="casAuthors">Childress, Elizabeth S.; Salamoun, Joseph M.; Hargett, Stefan R.; Alexopoulos, Stephanie J.; Chen, Sing-Young; Shah, Divya P.; Santiago-Rivera, Jose; Garcia, Christopher J.; Dai, Yumin; Tucker, Simon P.; Hoehn, Kyle L.; Santos, Webster L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2511-2526</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. mitochondrial uncouplers are emerging as a new class of mols. for the treatment of nonalcoholic steatohepatitis.  We utilized BAM15, a potent protonophore that uncouples the mitochondria without depolarizing the plasma membrane, as a lead compd. for structure-activity profiling.  Using oxygen consumption rate as an assay for detg. uncoupling activity, changes on the 5- and 6-position of the oxadiazolopyrazine core were introduced.  Our studies suggest that unsym. aniline derivs. bearing electron withdrawing groups are preferred compared to the sym. counterparts.  In addn., alkyl substituents are not tolerated, and the N-H proton of the aniline ring is responsible for the protonophore activity.  In particular, compd. 10b had an EC50 value of 190 nM in L6 myoblast cells.  In an in vivo model of NASH, 10b decreased liver triglyceride levels and showed improvement in fibrosis, inflammation, and plasma ALT.  Taken together, our studies indicate that mitochondrial uncouplers have potential for the treatment of NASH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbso5j2dO9ZrVg90H21EOLACvtfcHk0lgVtxehUa42vg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitleqtrY%253D&md5=4c94192cdd4908f6f03545f26c8c7be6</span></div><a href="/servlet/linkout?suffix=cit280&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01440%26sid%3Dliteratum%253Aachs%26aulast%3DChildress%26aufirst%3DE.%2BS.%26aulast%3DSalamoun%26aufirst%3DJ.%2BM.%26aulast%3DHargett%26aufirst%3DS.%2BR.%26aulast%3DAlexopoulos%26aufirst%3DS.%2BJ.%26aulast%3DChen%26aufirst%3DS.%2BY.%26aulast%3DShah%26aufirst%3DD.%2BP.%26aulast%3DSantiago-Rivera%26aufirst%3DJ.%26aulast%3DGarcia%26aufirst%3DC.%2BJ.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DTucker%26aufirst%3DS.%2BP.%26aulast%3DHoehn%26aufirst%3DK.%2BL.%26aulast%3DSantos%26aufirst%3DW.%2BL.%26atitle%3D%255B1%252C2%252C5%255DOxadiazolo%255B3%252C4-b%255Dpyrazine-5%252C6-diamine%2520derivatives%2520as%2520mitochondrial%2520uncouplers%2520for%2520the%2520potential%2520treatment%2520of%2520nonalcoholic%2520steatohepatitis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D5%26spage%3D2511%26epage%3D2526%26doi%3D10.1021%2Facs.jmedchem.9b01440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref281"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref281'); return false;" data-citation="" class="refNumLink">281</a></strong><div class="NLM_citation" id="cit281"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenwood, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderone, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taddeo, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoehn, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, W. L.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships of furazano[3,4-b]pyrazines as mitochondrial uncouplers</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">4858</span>â <span class="NLM_lpage">4861</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2015.06.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmcl.2015.06.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=26119501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVyhsrvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4858-4861&issue=21&author=B.+M.+Kenwoodauthor=J.+A.+Calderoneauthor=E.+P.+Taddeoauthor=K.+L.+Hoehnauthor=W.+L.+Santos&title=Structure-activity+relationships+of+furazano%5B3%2C4-b%5Dpyrazines+as+mitochondrial+uncouplers&doi=10.1016%2Fj.bmcl.2015.06.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit281R"><div class="casContent"><span class="casTitleNuber">281</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationships of furazano[3,4-b]pyrazines as mitochondrial uncouplers</span></div><div class="casAuthors">Kenwood, Brandon M.; Calderone, Joseph A.; Taddeo, Evan P.; Hoehn, Kyle L.; Santos, Webster L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4858-4861</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chem. mitochondrial uncouplers are lipophilic weak acids that transport protons into the mitochondrial matrix via a pathway that is independent of ATP synthase, thereby uncoupling nutrient oxidn. from ATP prodn.  These uncouplers have potential for the treatment of diseases such as obesity, Parkinson's disease, and aging.  We have previously identified a novel mitochondrial protonophore, named BAM15, which stimulates mitochondrial respiration across a broad dosing range compared to carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP).  Herein, we report our investigations on the structure-activity relationship profile of BAM15.  Our studies demonstrate the importance of the furazan, pyrazine, and aniline rings as well as pKa in maintaining its effective protonophore activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDO0F_Mr2kGrVg90H21EOLACvtfcHk0lgVtxehUa42vg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVyhsrvE&md5=a2664bbe47bdc166dd015db4f45fcd00</span></div><a href="/servlet/linkout?suffix=cit281&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.06.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.06.040%26sid%3Dliteratum%253Aachs%26aulast%3DKenwood%26aufirst%3DB.%2BM.%26aulast%3DCalderone%26aufirst%3DJ.%2BA.%26aulast%3DTaddeo%26aufirst%3DE.%2BP.%26aulast%3DHoehn%26aufirst%3DK.%2BL.%26aulast%3DSantos%26aufirst%3DW.%2BL.%26atitle%3DStructure-activity%2520relationships%2520of%2520furazano%255B3%252C4-b%255Dpyrazines%2520as%2520mitochondrial%2520uncouplers%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D21%26spage%3D4858%26epage%3D4861%26doi%3D10.1016%2Fj.bmcl.2015.06.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref282"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref282'); return false;" data-citation="" class="refNumLink">282</a></strong><div class="NLM_citation" id="cit282"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salamoun, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargett, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beretta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexopoulos, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olzomer, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoehn, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, W. L.</span></span> <span> </span><span class="NLM_article-title">6-Amino[1,2,5]oxadiazolo[3,4-b]pyrazin-5-ol derivatives as efficacious mitochondrial uncouplers in STAM mouse model of nonalcoholic steatohepatitis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">6203</span>â <span class="NLM_lpage">6224</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c00542</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00542" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptFCltrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=6203-6224&issue=11&author=J.+M.+Salamounauthor=C.+J.+Garciaauthor=S.+R.+Hargettauthor=J.+H.+Murrayauthor=S.+Y.+Chenauthor=M.+Berettaauthor=S.+J.+Alexopoulosauthor=D.+P.+Shahauthor=E.+M.+Olzomerauthor=S.+P.+Tuckerauthor=K.+L.+Hoehnauthor=W.+L.+Santos&title=6-Amino%5B1%2C2%2C5%5Doxadiazolo%5B3%2C4-b%5Dpyrazin-5-ol+derivatives+as+efficacious+mitochondrial+uncouplers+in+STAM+mouse+model+of+nonalcoholic+steatohepatitis&doi=10.1021%2Facs.jmedchem.0c00542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit282R"><div class="casContent"><span class="casTitleNuber">282</span><div class="casTitle"><span class="NLM_cas:atitle">6-Amino[1,2,5]oxadiazolo[3,4-b]pyrazin-5-ol Derivatives as Efficacious Mitochondrial Uncouplers in STAM Mouse Model of Nonalcoholic Steatohepatitis</span></div><div class="casAuthors">Salamoun, Joseph M.; Garcia, Christopher J.; Hargett, Stefan R.; Murray, Jacob H.; Chen, Sing-Young; Beretta, Martina; Alexopoulos, Stephanie J.; Shah, Divya P.; Olzomer, Ellen M.; Tucker, Simon P.; Hoehn, Kyle L.; Santos, Webster L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6203-6224</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. mitochondrial uncouplers have recently garnered great interest for their potential in treating nonalcoholic steatohepatitis (NASH).  In this study, we report the structure-activity relationship profiling of a 6-amino[1,2,5]oxadiazolo[3,4-b]pyrazin-5-ol core, which utilizes the hydroxy moiety as the proton transporter across the mitochondrial inner membrane.  We demonstrate that a wide array of substituents is tolerated with this novel scaffold that increased cellular metabolic rates in vitro using changes in oxygen consumption rate as a readout.  In particular, compd. SHS4121705 (12i) (6-((4-(trifluoromethoxy)phenyl)amino)-[1,2,5]oxadiazolo[3,4-b]pyrazin-5-ol, [2379550-82-8]) displayed an EC50 of 4.3Î¼M in L6 myoblast cells and excellent oral bioavailability and liver exposure in mice.  In the STAM mouse model of NASH, administration of 12i at 25 mg kg-1 day-1 lowered liver triglyceride levels and improved liver markers such as alanine aminotransferase, NAFLD activity score, and fibrosis.  Importantly, no changes in body temp. or food intake were obsd.  As potential treatment of NASH, mitochondrial uncouplers show promise for future development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJTDnUWKTl97Vg90H21EOLACvtfcHk0lgVtxehUa42vg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptFCltrY%253D&md5=b9ab1101f024c4f5ce6f22f80db0df05</span></div><a href="/servlet/linkout?suffix=cit282&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00542%26sid%3Dliteratum%253Aachs%26aulast%3DSalamoun%26aufirst%3DJ.%2BM.%26aulast%3DGarcia%26aufirst%3DC.%2BJ.%26aulast%3DHargett%26aufirst%3DS.%2BR.%26aulast%3DMurray%26aufirst%3DJ.%2BH.%26aulast%3DChen%26aufirst%3DS.%2BY.%26aulast%3DBeretta%26aufirst%3DM.%26aulast%3DAlexopoulos%26aufirst%3DS.%2BJ.%26aulast%3DShah%26aufirst%3DD.%2BP.%26aulast%3DOlzomer%26aufirst%3DE.%2BM.%26aulast%3DTucker%26aufirst%3DS.%2BP.%26aulast%3DHoehn%26aufirst%3DK.%2BL.%26aulast%3DSantos%26aufirst%3DW.%2BL.%26atitle%3D6-Amino%255B1%252C2%252C5%255Doxadiazolo%255B3%252C4-b%255Dpyrazin-5-ol%2520derivatives%2520as%2520efficacious%2520mitochondrial%2520uncouplers%2520in%2520STAM%2520mouse%2520model%2520of%2520nonalcoholic%2520steatohepatitis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D11%26spage%3D6203%26epage%3D6224%26doi%3D10.1021%2Facs.jmedchem.0c00542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref283"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref283'); return false;" data-citation="" class="refNumLink">283</a></strong><div class="NLM_citation" id="cit283"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoehn, K.</span>; <span class="NLM_string-name">Santos, W. L.</span>; <span class="NLM_string-name">Childress, E. S.</span>; <span class="NLM_string-name">Dai, Y.</span>; <span class="NLM_string-name">Murray, J.</span>; <span class="NLM_string-name">Santiago-Rivera, J.</span></span>, <span> </span><span class="NLM_article-title">Compositions and Methods for Preparing and Using Mitochondrial Uncouplers</span>. <span class="NLM_patent">WO2019204813A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=K.+Hoehn&author=W.+L.+Santos&author=E.+S.+Childress&author=Y.+Dai&author=J.+Murray&author=J.+Santiago-Rivera&title=Compositions+and+Methods+for+Preparing+and+Using+Mitochondrial+Uncouplers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit283&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHoehn%26aufirst%3DK.%26atitle%3DCompositions%2520and%2520Methods%2520for%2520Preparing%2520and%2520Using%2520Mitochondrial%2520Uncouplers%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref284"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref284'); return false;" data-citation="" class="refNumLink">284</a></strong><div class="NLM_citation" id="cit284"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, W. L.</span>; <span class="NLM_string-name">Salamoun, J. M.</span>; <span class="NLM_string-name">Garcia, C. J.</span>; <span class="NLM_string-name">Murray, J. H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Oxadiazolopyrazines and Oxadiazolopyridines Useful as Mitochondrial Uncouplers</span>. <span class="NLM_patent">WO2019204813A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=W.+L.+Santos&author=J.+M.+Salamoun&author=C.+J.+Garcia&author=J.+H.+Murray&title=Preparation+of+Oxadiazolopyrazines+and+Oxadiazolopyridines+Useful+as+Mitochondrial+Uncouplers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit284&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DW.%2BL.%26atitle%3DPreparation%2520of%2520Oxadiazolopyrazines%2520and%2520Oxadiazolopyridines%2520Useful%2520as%2520Mitochondrial%2520Uncouplers%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref285"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref285'); return false;" data-citation="" class="refNumLink">285</a></strong><div class="NLM_citation" id="cit285"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savolainen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsinga, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windhorst, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luurtsema, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preclinical evaluation of three novel fluorine-18 labeled radiopharmaceuticals for P-glycoprotein PET imaging at the bloodâbrain barrier</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2265</span>â <span class="NLM_lpage">2275</span>, <span class="refDoi">Â DOI: 10.1021/mp5008103</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp5008103" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref285/cit285&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsVOqu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=2265-2275&issue=7&author=H.+Savolainenauthor=M.+Cantoreauthor=N.+A.+Colabufoauthor=P.+H.+Elsingaauthor=A.+D.+Windhorstauthor=G.+Luurtsema&title=Synthesis+and+preclinical+evaluation+of+three+novel+fluorine-18+labeled+radiopharmaceuticals+for+P-glycoprotein+PET+imaging+at+the+blood%E2%80%93brain+barrier&doi=10.1021%2Fmp5008103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit285R"><div class="casContent"><span class="casTitleNuber">285</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Preclinical Evaluation of Three Novel Fluorine-18 Labeled Radiopharmaceuticals for P-Glycoprotein PET Imaging at the Blood-Brain Barrier</span></div><div class="casAuthors">Savolainen, Heli; Cantore, Mariangela; Colabufo, Nicola A.; Elsinga, Philip H.; Windhorst, Albert D.; Luurtsema, Gert</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2265-2275</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P-Glycoprotein (P-gp), along with other transporter proteins at the blood-brain barrier (BBB), limits the entry of many pharmaceuticals into the brain.  Altered P-gp function has been found in several neurol. diseases.  To study the P-gp function, many positron emission tomog. (PET) radiopharmaceuticals have been developed.  Most P-gp radiopharmaceuticals are labeled with carbon-11, while labeling with fluorine-18 would increase their applicability due to longer half-life.  Here we present the synthesis and in vivo evaluation of three novel fluorine-18 labeled radiopharmaceuticals: 4-((6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-2-(4-fluorophenyl)oxazole (1a), 2-biphenyl-4-yl-2-fluoroethoxy-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline (2), and 5-(1-(2-fluoroethoxy))-[3-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-propyl]-5,6,7,8-tetrahydronaphthalen (3).  Compds. were characterized as P-gp substrates in vitro, and Mdr1a/b(-/-)Bcrp1(-/-) and wild-type mice were used to assess the substrate potential in vivo.  Comparison was made to (R)-[11C]verapamil, which is currently the most frequently used P-gp substrate.  Compd. [18F]3 was performing the best out of the new radiopharmaceuticals; it had 2-fold higher brain uptake in the Mdr1a/b(-/-)Bcrp1(-/-) mice compared to wild-type and was metabolically quite stable.  In the plasma, 69% of the parent compd. was intact after 45 min and 96% in the brain.  Selectivity of [18F]3 to P-gp was tested by comparing the uptake in Mdr1a/b(-/-) mice to uptake in Mdr1a/b(-/-)Bcrp1(-/-) mice, which was statistically not significantly different.  Hence, [18F]3 was found to be selective for P-gp and is a promising new radiopharmaceutical for P-gp PET imaging at the BBB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIwkSldxjfLLVg90H21EOLACvtfcHk0lh9cPM89sr9Mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsVOqu7Y%253D&md5=d51411694ff422a43cc0b59d0fb1c84a</span></div><a href="/servlet/linkout?suffix=cit285&amp;dbid=16384&amp;doi=10.1021%2Fmp5008103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp5008103%26sid%3Dliteratum%253Aachs%26aulast%3DSavolainen%26aufirst%3DH.%26aulast%3DCantore%26aufirst%3DM.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DElsinga%26aufirst%3DP.%2BH.%26aulast%3DWindhorst%26aufirst%3DA.%2BD.%26aulast%3DLuurtsema%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520preclinical%2520evaluation%2520of%2520three%2520novel%2520fluorine-18%2520labeled%2520radiopharmaceuticals%2520for%2520P-glycoprotein%2520PET%2520imaging%2520at%2520the%2520blood%25E2%2580%2593brain%2520barrier%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26issue%3D7%26spage%3D2265%26epage%3D2275%26doi%3D10.1021%2Fmp5008103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref286"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref286'); return false;" data-citation="" class="refNumLink">286</a></strong><div class="NLM_citation" id="cit286"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azzariti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quatrale, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iannelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tommasi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panaro, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paradiso, A.</span></span> <span> </span><span class="NLM_article-title">MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>670</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">74</span>â <span class="NLM_lpage">84</span>, <span class="refDoi">Â DOI: 10.1016/j.ejphar.2011.08.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.ejphar.2011.08.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=21925160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlejurrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=670&publication_year=2011&pages=74-84&issue=1&author=A.+Azzaritiauthor=A.+E.+Quatraleauthor=L.+Porcelliauthor=N.+A.+Colabufoauthor=M.+Cantoreauthor=G.+Cassanoauthor=G.+Gasparreauthor=G.+Iannelliauthor=S.+Tommasiauthor=M.+A.+Panaroauthor=A.+Paradiso&title=MC70+potentiates+doxorubicin+efficacy+in+colon+and+breast+cancer+in+vitro+treatment&doi=10.1016%2Fj.ejphar.2011.08.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit286R"><div class="casContent"><span class="casTitleNuber">286</span><div class="casTitle"><span class="NLM_cas:atitle">MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment</span></div><div class="casAuthors">Azzariti, Amalia; Quatrale, Anna E.; Porcelli, Letizia; Colabufo, Nicola A.; Cantore, Mariangela; Cassano, Giuseppe; Gasparre, Giuseppe; Iannelli, Giuseppina; Tommasi, Stefania; Panaro, Maria A.; Paradiso, Angelo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">670</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-84</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A major limitation of cancer treatment is the ability of cancer cells to develop resistance to chemotherapeutic drugs, by the establishment of multidrug resistance.  Here, we characterize MC70 as ABC transporters inhibitor and anticancer agent, alone or with chemotherapy.  MC70 was analyzed for its interaction with ABCB1, ABCG2, and ABCC1 by specific transport assays.  In breast and colon cancer cell lines, cell growth and apoptosis were measured by MTT assay and DNA laddering Elisa kit, resp.  Cell cycle perturbation and cellular targets modulation were analyzed by Flow-cytometry and Western blotting, resp.  MC70 interacted with ABC transporters.  In breast cancer cells, MC70 slightly inhibited cell proliferation strongly enhancing doxorubicin effectiveness.  By contrast, MC70 was found to inhibit cell growth in colon cancer cells without affecting doxorubicin efficacy and in combination with topoisomerase I inhibitors it could be a promising therapeutic approach.  What is more, it was also obsd. that MC70 induced apoptosis, canceled in favor of necrosis when given in combination with high doses of doxorubicin.  MC70 inhibited cell migration probably through its interaction with sigma-1 receptor.  Modulations of (i) cell cycle, (ii) pAkt and the phosphorylation of the 3 MAPKs were highlighted, while any activity was excluded at transcription level, thus accounting for the phenotypic effects obsd.  MC70 might be considered as a new potential anticancer agent capable to (i) enhance chemotherapy effectiveness and (ii) to play a contributory role in the treatment of chemotherapy resistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD9aQ-wjKQD7Vg90H21EOLACvtfcHk0lh9cPM89sr9Mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlejurrM&md5=9f3bd91a79f76eb3067ff7d243e12376</span></div><a href="/servlet/linkout?suffix=cit286&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2011.08.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2011.08.025%26sid%3Dliteratum%253Aachs%26aulast%3DAzzariti%26aufirst%3DA.%26aulast%3DQuatrale%26aufirst%3DA.%2BE.%26aulast%3DPorcelli%26aufirst%3DL.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DCantore%26aufirst%3DM.%26aulast%3DCassano%26aufirst%3DG.%26aulast%3DGasparre%26aufirst%3DG.%26aulast%3DIannelli%26aufirst%3DG.%26aulast%3DTommasi%26aufirst%3DS.%26aulast%3DPanaro%26aufirst%3DM.%2BA.%26aulast%3DParadiso%26aufirst%3DA.%26atitle%3DMC70%2520potentiates%2520doxorubicin%2520efficacy%2520in%2520colon%2520and%2520breast%2520cancer%2520in%2520vitro%2520treatment%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D670%26issue%3D1%26spage%3D74%26epage%3D84%26doi%3D10.1016%2Fj.ejphar.2011.08.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref287"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref287'); return false;" data-citation="" class="refNumLink">287</a></strong><div class="NLM_citation" id="cit287"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guglielmo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzarato, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chegaev, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruttero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasco, A.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship studies on tetrahydroisoquinoline derivatives: [4â²-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-ol] (MC70) conjugated through flexible alkyl chains with furazan moieties gives rise to potent and selective ligands of P-glycoprotein</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6729</span>â <span class="NLM_lpage">6738</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00252</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00252" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVektrnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6729-6738&issue=14&author=S.+Guglielmoauthor=L.+Lazzaratoauthor=M.+Continoauthor=M.+G.+Perroneauthor=K.+Chegaevauthor=A.+Carrieriauthor=R.+Frutteroauthor=N.+A.+Colabufoauthor=A.+Gasco&title=Structure-activity+relationship+studies+on+tetrahydroisoquinoline+derivatives%3A+%5B4%E2%80%B2-%286%2C7-Dimethoxy-3%2C4-dihydro-1H-isoquinolin-2-ylmethyl%29biphenyl-4-ol%5D+%28MC70%29+conjugated+through+flexible+alkyl+chains+with+furazan+moieties+gives+rise+to+potent+and+selective+ligands+of+P-glycoprotein&doi=10.1021%2Facs.jmedchem.6b00252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit287R"><div class="casContent"><span class="casTitleNuber">287</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship Studies on Tetrahydroisoquinoline Derivatives: [4'-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-ol] (MC70) Conjugated through Flexible Alkyl Chains with Furazan Moieties Gives Rise to Potent and Selective Ligands of P-glycoprotein</span></div><div class="casAuthors">Guglielmo, Stefano; Lazzarato, Loretta; Contino, Marialessandra; Perrone, Maria G.; Chegaev, Konstantin; Carrieri, Antonio; Fruttero, Roberta; Colabufo, Nicola A.; Gasco, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6729-6738</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P-glycoprotein (P-gp) is a well-known membrane transporter expressed in a no. of strategic biol. barriers, where it exerts a protective effect of paramount importance.  Conversely it is one of the main causes of multidrug resistance (MDR), being capable of effluxing many chemotherapeutics.  In a development of previous research, a small library of compds. was created conjugating diversely substituted furazan rings with MC70, a well-known P-gp inhibitor.  These compds. were assessed for their potency against P-gp and another transporter (MRP1), for their apparent permeability (Papp) and for their ability to induce ATPase activity, thus delineating a complete functional profile.  They displayed a substrate mechanism of action and high selectivity toward P-gp, unlike the lead compd.  Data relating to their activity range from low micromolar to sub-nanomolar EC50, the most interesting compds. being 15 (0.97 nM), 19 (1.3 nM), 25 (0.60 nM), and 27 (0.90 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjM7uUfQnShbVg90H21EOLACvtfcHk0ljMgueZVLEVOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVektrnM&md5=b7a170d53c5946cc9b58331bdb607350</span></div><a href="/servlet/linkout?suffix=cit287&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00252%26sid%3Dliteratum%253Aachs%26aulast%3DGuglielmo%26aufirst%3DS.%26aulast%3DLazzarato%26aufirst%3DL.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DPerrone%26aufirst%3DM.%2BG.%26aulast%3DChegaev%26aufirst%3DK.%26aulast%3DCarrieri%26aufirst%3DA.%26aulast%3DFruttero%26aufirst%3DR.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DGasco%26aufirst%3DA.%26atitle%3DStructure-activity%2520relationship%2520studies%2520on%2520tetrahydroisoquinoline%2520derivatives%253A%2520%255B4%25E2%2580%25B2-%25286%252C7-Dimethoxy-3%252C4-dihydro-1H-isoquinolin-2-ylmethyl%2529biphenyl-4-ol%255D%2520%2528MC70%2529%2520conjugated%2520through%2520flexible%2520alkyl%2520chains%2520with%2520furazan%2520moieties%2520gives%2520rise%2520to%2520potent%2520and%2520selective%2520ligands%2520of%2520P-glycoprotein%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D14%26spage%3D6729%26epage%3D6738%26doi%3D10.1021%2Facs.jmedchem.6b00252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref288"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref288'); return false;" data-citation="" class="refNumLink">288</a></strong><div class="NLM_citation" id="cit288"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olesen, P. H.</span>; <span class="NLM_string-name">Kurtzhals, P.</span>; <span class="NLM_string-name">Worsaae, H.</span>; <span class="NLM_string-name">Hansen, B. F.</span>; <span class="NLM_string-name">Sorensen, A. R.</span>; <span class="NLM_string-name">Bowler, A. N.</span></span> <span> </span><span class="NLM_article-title">Preparation of Furazanyltriazole Derivatives as Glycogen Synthase Kinase-3 (GSK-3) Inhibitors</span>. <span class="NLM_patent">WO2002032896A1</span>, <span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=P.+H.+Olesen&author=P.+Kurtzhals&author=H.+Worsaae&author=B.+F.+Hansen&author=A.+R.+Sorensen&author=A.+N.+Bowler&title=Preparation+of+Furazanyltriazole+Derivatives+as+Glycogen+Synthase+Kinase-3+%28GSK-3%29+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit288&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOlesen%26aufirst%3DP.%2BH.%26atitle%3DPreparation%2520of%2520Furazanyltriazole%2520Derivatives%2520as%2520Glycogen%2520Synthase%2520Kinase-3%2520%2528GSK-3%2529%2520Inhibitors%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref289"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref289'); return false;" data-citation="" class="refNumLink">289</a></strong><div class="NLM_citation" id="cit289"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olesen, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urso, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtzhals, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowler, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrbar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, B. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vitro characterization of 1-(4-aminofurazan-3-yl)-5-dialkylaminomethyl-1H-[1,2,3]triazole-4-carboxylic acid derivatives. A new class of selective GSK-3 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">3333</span>â <span class="NLM_lpage">3341</span>, <span class="refDoi">Â DOI: 10.1021/jm021095d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm021095d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksVSjsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=3333-3341&issue=15&author=P.+H.+Olesenauthor=A.+R.+Sorensenauthor=B.+Ursoauthor=P.+Kurtzhalsauthor=A.+N.+Bowlerauthor=U.+Ehrbarauthor=B.+F.+Hansen&title=Synthesis+and+in+vitro+characterization+of+1-%284-aminofurazan-3-yl%29-5-dialkylaminomethyl-1H-%5B1%2C2%2C3%5Dtriazole-4-carboxylic+acid+derivatives.+A+new+class+of+selective+GSK-3+inhibitors&doi=10.1021%2Fjm021095d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit289R"><div class="casContent"><span class="casTitleNuber">289</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in Vitro Characterization of 1-(4-Aminofurazan-3-yl)-5-dialkylaminomethyl-1H-[1,2,3]triazole-4-carboxylic Acid Derivatives. A New Class of Selective GSK-3 Inhibitors</span></div><div class="casAuthors">Olesen, Preben H.; Sorensen, Anders R.; Urso, Birgitte; Kurtzhals, Peter; Bowler, Andrew N.; Ehrbar, Ulrich; Hansen, Bo F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3333-3341</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The title compds. were identified as a novel class of GSK-3 inhibitors with favorable water soly. in a HTS screen.  SAR studies identified bioisosteric structural moieties in this class of compds.  The compds. were tested in a GSK-3 inhibition assay at 100 Î¼M ATP giving IC50's in the range from 0.1 to 10 Î¼M.  The compds. are ATP competitive inhibitors.  They modulate glycogen metab. and stimulate the accumulation of intracellular Î²-catenin in whole cell assays with EC50's in the range from 2 to 18 Î¼M and 4.5-44 Î¼M, resp.  For selected compds., only a 10-fold lower potency was obtained in cellular assays compared to the potency obtained for inhibition of the isolated enzyme, reflecting a good cell permeability of this compd. class.  At 10 Î¼M of test compd. a 3-fold stimulation of the glycogen synthesis in rat soleus muscle was obtained compared to the level of glycogen synthesis obsd. at 0.2 nM insulin.  This stimulation of glycogen synthesis is comparable to the maximal stimulation by insulin itself.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqImSBV8y_St7Vg90H21EOLACvtfcHk0ljMgueZVLEVOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksVSjsbg%253D&md5=a5db0b9969e614021813add91a68a56f</span></div><a href="/servlet/linkout?suffix=cit289&amp;dbid=16384&amp;doi=10.1021%2Fjm021095d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm021095d%26sid%3Dliteratum%253Aachs%26aulast%3DOlesen%26aufirst%3DP.%2BH.%26aulast%3DSorensen%26aufirst%3DA.%2BR.%26aulast%3DUrso%26aufirst%3DB.%26aulast%3DKurtzhals%26aufirst%3DP.%26aulast%3DBowler%26aufirst%3DA.%2BN.%26aulast%3DEhrbar%26aufirst%3DU.%26aulast%3DHansen%26aufirst%3DB.%2BF.%26atitle%3DSynthesis%2520and%2520in%2520vitro%2520characterization%2520of%25201-%25284-aminofurazan-3-yl%2529-5-dialkylaminomethyl-1H-%255B1%252C2%252C3%255Dtriazole-4-carboxylic%2520acid%2520derivatives.%2520A%2520new%2520class%2520of%2520selective%2520GSK-3%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26issue%3D15%26spage%3D3333%26epage%3D3341%26doi%3D10.1021%2Fjm021095d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref290"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref290'); return false;" data-citation="" class="refNumLink">290</a></strong><div class="NLM_citation" id="cit290"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2719</span>â <span class="NLM_lpage">2740</span>, <span class="refDoi">Â DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref290/cit290&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&issue=7&author=J+B.+Baellauthor=G.+A.+Holloway&title=New+substructure+filters+for+removal+of+pan+assay+interference+compounds+%28PAINS%29+from+screening+libraries+and+for+their+exclusion+in+bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit290R"><div class="casContent"><span class="casTitleNuber">290</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0ljMgueZVLEVOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit290&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520substructure%2520filters%2520for%2520removal%2520of%2520pan%2520assay%2520interference%2520compounds%2520%2528PAINS%2529%2520from%2520screening%2520libraries%2520and%2520for%2520their%2520exclusion%2520in%2520bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D7%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230'],'ref231':['cit231'],'ref232':['cit232'],'ref233':['cit233'],'ref234':['cit234'],'ref235':['cit235'],'ref236':['cit236'],'ref237':['cit237'],'ref238':['cit238'],'ref239':['cit239'],'ref240':['cit240'],'ref241':['cit241'],'ref242':['cit242'],'ref243':['cit243'],'ref244':['cit244'],'ref245':['cit245'],'ref246':['cit246'],'ref247':['cit247'],'ref248':['cit248'],'ref249':['cit249'],'ref250':['cit250'],'ref251':['cit251'],'ref252':['cit252'],'ref253':['cit253'],'ref254':['cit254'],'ref255':['cit255'],'ref256':['cit256'],'ref257':['cit257'],'ref258':['cit258'],'ref259':['cit259'],'ref260':['cit260'],'ref261':['cit261'],'ref262':['cit262'],'ref263':['cit263'],'ref264':['cit264'],'ref265':['cit265'],'ref266':['cit266'],'ref267':['cit267'],'ref268':['cit268'],'ref269':['cit269'],'ref270':['cit270'],'ref271':['cit271'],'ref272':['cit272'],'ref273':['cit273'],'ref274':['cit274'],'ref275':['cit275'],'ref276':['cit276'],'ref277':['cit277'],'ref278':['cit278'],'ref279':['cit279'],'ref280':['cit280'],'ref281':['cit281'],'ref282':['cit282'],'ref283':['cit283'],'ref284':['cit284'],'ref285':['cit285'],'ref286':['cit286'],'ref287':['cit287'],'ref288':['cit288'],'ref289':['cit289'],'ref290':['cit290']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0037.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Physical and electronic properties of oxadiazole derivatives; the dipole moment of nitrobenzene (<b>10</b>) is provided for comparison. Directionality of molecular dipoles for bisphenyl oxadiazoles is represented by blue arrows. <sup><i>a</i></sup>Value taken from the SDS (CAS# 273-09-6).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Taft induction constants of some electron withdrawing substituents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Examples of nitro-to-furazan bioisosterism in drug development. AÎ² = amyloid beta.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Heterocycle analogues of nitrobenzylthioinosine. Activity is maintained in furazan derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Bioisosteric replacement of carboxyl groups in neurotransmitters with hydroxyfurazan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Bioisosteric replacement of carboxyl groups in DHODH inhibitors. A771726 (active metabolite of leflunomide) and brequinar are given for comparison. IC<sub>50</sub> values were determined using rat liver DHODH. <sup><i>a</i></sup>IC<sub>50</sub> values were determined using human DHODH. <sup><i>b</i></sup>IC<sub>50</sub> value for human DHODH = 0.435 Î¼M.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Aminofurazan derivatives of ranitidine as H<sub>2</sub> receptor antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Inhibition of AÎ² and tau fibrillization and AÎ² oligomerization by benzofurazan-derived neuroprotective agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Benzofurazan-derived inhibitors of Î³-secretase (Forum Pharmaceuticals) and GSK-3Î² (Mitsubishi Pharma). Advanced leads and clinical candidates are provided for comparison. EC<sub>50</sub> values were determined in HEK 293 cells (EC<sub>50</sub> value for EVP-0015962 was determined in H4 cells).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures of DHP calcium channel antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structures of type II Ampakines from RespireRx.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. <i>In vitro</i> IC<sub>50</sub> values for M826 and peptide Ac-DEVD-CHO for activated caspases and camptothecin-induced apoptosis (casp-3 dependent) in NT2 cell culture.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Furazan-derived inhibitors of p38 MAPK from Mendez et al. and Allinky Biopharma. Inhibition of TNFÎ± secretion determined in THP-1 monocytes; % inhibition (Allinky) was determined at 10 Î¼M concentration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. SAR of benzimidazole-derived kinase inhibitors and activity profile of selective MSK-1 inhibitor SB-747651A.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Chemical structures of antihypertensive agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Inhibition of cell proliferation for benzimidazole-derived MTAs. EC<sub>50</sub> (MTS assay) determined in HeLa cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Furazan-derived STAT inhibitors. EC<sub>50</sub> values were determined in HCT 116 (colon cancer) cell line for STAT3 inhibitors and BAF3 cells transfected with FLT3-ITD (acute myeloid leukemia) for STAT5 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Antiproliferative activity of furazanopyrazine-derived (<b>70</b>, LQZ-7F) or peptidomimetic (<b>71</b>) inhibitors of PPIs in cancer cell lines (SW480, HCT 116 = colon; A549 = lung; HL-60 = acute myeloid leukemia). EC<sub>50</sub> values given in parentheses are for the ethyl ester prodrug of <b>71</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Antiproliferative activity of nitrobenzofurazan inhibitors of Myc/Max heterodimerization in HL60 (acute myeloid leukemia) and Daudi B. (lymphoma) cancer cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. <i>In vitro</i> activity and binding affinity of benzofurazan inhibitors of HIF assembly. IC<sub>50</sub> values were determined using AlphaScreen assay (values in parentheses were determined using scintillation proximity assay). <i>K</i><sub>D</sub> values were determined by isothermal calorimetry measurements. Second-generation inhibitor <b>76</b> (Bruick) and clinical candidate PT2977 (Peloton) are provided for comparison.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. <i>In vitro</i> and preclinical <i>in vivo</i> development of INCB024360 (epacadostat) by Incyte Corp. Tumor reduction (red.) was determined in mouse xenograft models.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. <i>In vitro</i> and preclinical <i>in vivo</i> development of epacadostat-derived IDO1 inhibitors as chemotherapeutics. Tumor reduction (red.) was determined in mouse xenograft models; values in parentheses are the tumor reduction induced by epacadostat in the given model at the same dose. MLM = mouse liver microsomes; HLM = human liver microsomes; RLM = rat liver microsomes; LLC = Lewis lung carcinoma.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Furazan-derived kinase inhibitors investigated as chemotherapeutics.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. NBDHEX and analogues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Furazanopyrazines identified by Baden-Wuerttemberg Stiftung and Compass Pharmaceuticals with potent anticancer activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Furazan-derived antibacterial compounds with good selectivity over eukaryotic cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Anti-<i>Plasmodium</i> activity of heterocyclic compounds. <i>pf</i> = <i>P. falciparum</i>. <i>hs</i> = <i>H. sapien</i>. LDH = lactate dehydrogenase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0028.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Antiviral activity of nitrobenzofurazans against influenza A (H1N1) and RSV.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0029.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. SAR of furazanopyrazine-derived mitochondrial uncoupler BAM15. EC<sub>50</sub> values indicate the concentration which stimulates 50% of maximum achievable oxygen consumption rate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0030.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Structures and <i>in vitro</i> potency of selective P-gp ligands reported by Colabufo et al. EC<sub>50</sub> values were determined in MDCK-MDR1 cell line.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/medium/jm0c01901_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0031.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Selective inhibitors of GSK-3Î² identified by Novo Nordisk. EC<sub>50</sub> values are provided for <i>in vitro</i> stimulation of glycogen synthase activity in CHO cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01901/20210218/images/large/jm0c01901_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01901&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i56">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10135" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10135" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 290 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Builla, J.</span>; <span class="NLM_string-name">Vaquero, J. J.</span>; <span class="NLM_string-name">Barluenga, J.</span></span>; Eds.  <i>Modern Heterocyclic Chemistry, Volume 4</i>; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Weinhiem</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2F9783527637737" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+Alvarez-Builla&author=J.+J.+Vaquero&author=J.+Barluenga&title=Modern+Heterocyclic+Chemistry%2C+Volume+4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2F9783527637737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527637737%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez-Builla%26aufirst%3DJ.%26btitle%3DModern%2520Heterocyclic%2520Chemistry%252C%2520Volume%25204%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makhova, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belenâkii, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazieva, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalinger, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konstantinova, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuznetsov, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kravchenko, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krayushkin, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakitin, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starosotnikov, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fershtat, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shevelev, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirinian, V. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarovenko, V. N.</span></span> <span> </span><span class="NLM_article-title">Progress in the chemistry of nitrogen-, oxygen- and sulfur-containing heterocyclic systems</span>. <i>Russ. Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>89</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">55</span>â <span class="NLM_lpage">124</span>, <span class="refDoi">Â DOI: 10.1070/RCR4914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1070%2FRCR4914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjslCgtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2020&pages=55-124&issue=1&author=N.+N.+Makhovaauthor=L.+I.+Belen%E2%80%99kiiauthor=G.+A.+Gazievaauthor=I.+L.+Dalingerauthor=L.+S.+Konstantinovaauthor=V.+V.+Kuznetsovauthor=A.+N.+Kravchenkoauthor=M.+M.+Krayushkinauthor=O.+A.+Rakitinauthor=A.+M.+Starosotnikovauthor=L.+L.+Fershtatauthor=S.+A.+Shevelevauthor=V.+Z.+Shirinianauthor=V.+N.+Yarovenko&title=Progress+in+the+chemistry+of+nitrogen-%2C+oxygen-+and+sulfur-containing+heterocyclic+systems&doi=10.1070%2FRCR4914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in the chemistry of nitrogen-, oxygen- and sulfur-containing heterocyclic systems</span></div><div class="casAuthors">Makhova, Nina N.; Belen'kii, Leonid I.; Gazieva, Galina A.; Dalinger, Igor L.; Konstantinova, Lidia S.; Kuznetsov, Vladimir V.; Kravchenko, Angelina N.; Krayushkin, Mikhail M.; Rakitin, Oleg A.; Starosotnikov, Alexey M.; Fershtat, Leonid L.; Shevelev, Svyatoslav A.; Shirinian, Valerik Z.; Yarovenko, Vladimir N.</div><div class="citationInfo"><span class="NLM_cas:title">Russian Chemical Reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-124</span>CODEN:
                <span class="NLM_cas:coden">RCRVAB</span>;
        ISSN:<span class="NLM_cas:issn">0036-021X</span>.
    
            (<span class="NLM_cas:orgname">IOP Publishing Ltd.</span>)
        </div><div class="casAbstract">The review is devoted to modern trends in the chem. of nitrogen-, oxygen- and sulfur-contg. monocyclic, polynuclear and benzo(hetero)annulated heterocyclic compds.  Methods for the synthesis and chem. reactivity of furazan, furoxan, thiazole, thiadiazole, dithiazole, thiophene, glycoluril, imidazotriazine, diaziridine and other heterocycles are discussed.  Characteristic features of reactions depending on the structure of the starting compds., intermediates and reaction medium (org. solvents, ionic liqs.) and mechanistic aspects of the most interesting transformations are considered.  Data on the biol. activities and prospects for practical applications of the indicated heterocyclic systems are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeWvE6_J7P9rVg90H21EOLACvtfcHk0libiZolTbBwgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjslCgtb8%253D&md5=4209dc4cbd1d7d25c593fbc0d673f701</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1070%2FRCR4914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1070%252FRCR4914%26sid%3Dliteratum%253Aachs%26aulast%3DMakhova%26aufirst%3DN.%2BN.%26aulast%3DBelen%25E2%2580%2599kii%26aufirst%3DL.%2BI.%26aulast%3DGazieva%26aufirst%3DG.%2BA.%26aulast%3DDalinger%26aufirst%3DI.%2BL.%26aulast%3DKonstantinova%26aufirst%3DL.%2BS.%26aulast%3DKuznetsov%26aufirst%3DV.%2BV.%26aulast%3DKravchenko%26aufirst%3DA.%2BN.%26aulast%3DKrayushkin%26aufirst%3DM.%2BM.%26aulast%3DRakitin%26aufirst%3DO.%2BA.%26aulast%3DStarosotnikov%26aufirst%3DA.%2BM.%26aulast%3DFershtat%26aufirst%3DL.%2BL.%26aulast%3DShevelev%26aufirst%3DS.%2BA.%26aulast%3DShirinian%26aufirst%3DV.%2BZ.%26aulast%3DYarovenko%26aufirst%3DV.%2BN.%26atitle%3DProgress%2520in%2520the%2520chemistry%2520of%2520nitrogen-%252C%2520oxygen-%2520and%2520sulfur-containing%2520heterocyclic%2520systems%26jtitle%3DRuss.%2520Chem.%2520Rev.%26date%3D2020%26volume%3D89%26issue%3D1%26spage%3D55%26epage%3D124%26doi%3D10.1070%2FRCR4914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N.</span></span>; Ed.  <i>Bioisosteres In Medicinal Chemistry</i>; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Weinhiem</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2F9783527654307" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=N.+Brown&title=Bioisosteres+In+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2F9783527654307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527654307%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DN.%26btitle%3DBioisosteres%2520In%2520Medicinal%2520Chemistry%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pace, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierro, P.</span></span> <span> </span><span class="NLM_article-title">The new era of 1,2,4-oxadiazoles</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">4337</span>â <span class="NLM_lpage">4348</span>, <span class="refDoi">Â DOI: 10.1039/b908937c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1039%2Fb908937c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=19830279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Gksb7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=4337-4348&issue=21&author=A.+Paceauthor=P.+Pierro&title=The+new+era+of+1%2C2%2C4-oxadiazoles&doi=10.1039%2Fb908937c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The new era of 1,2,4-oxadiazoles</span></div><div class="casAuthors">Pace, Andrea; Pierro, Paola</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4337-4348</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">This review covers the synthesis, the chem. and photochem. reactivity, and the use of 1,2,4-oxadiazoles in materials and as bioactive compds.  Further, the material in this survey includes some historical background, general features, state-of-the-art applications together with a crit. discussion about current limitations and suggestions for future developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS_Jcg58EXy7Vg90H21EOLACvtfcHk0libiZolTbBwgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Gksb7E&md5=9314bd3fbc51b2e5bc1a6eafa44646a4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1039%2Fb908937c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb908937c%26sid%3Dliteratum%253Aachs%26aulast%3DPace%26aufirst%3DA.%26aulast%3DPierro%26aufirst%3DP.%26atitle%3DThe%2520new%2520era%2520of%25201%252C2%252C4-oxadiazoles%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2009%26volume%3D7%26issue%3D21%26spage%3D4337%26epage%3D4348%26doi%3D10.1039%2Fb908937c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bostrom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowright, A. T.</span></span> <span> </span><span class="NLM_article-title">Oxadiazoles in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1817</span>â <span class="NLM_lpage">1830</span>, <span class="refDoi">Â DOI: 10.1021/jm2013248</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2013248" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BC383pt1Oisw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1817-1830&issue=5&author=J.+Bostromauthor=A.+Hognerauthor=A.+Llinasauthor=E.+Wellnerauthor=A.+T.+Plowright&title=Oxadiazoles+in+medicinal+chemistry&doi=10.1021%2Fjm2013248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Oxadiazoles in medicinal chemistry</span></div><div class="casAuthors">Bostrom Jonas; Hogner Anders; Llinas Antonio; Wellner Eric; Plowright Alleyn T</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1817-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Oxadiazoles are five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom, and they exist in different regioisomeric forms.  Oxadiazoles are frequently occurring motifs in druglike molecules, and they are often used with the intention of being bioisosteric replacements for ester and amide functionalities.  The current study presents a systematic comparison of 1,2,4- and 1,3,4-oxadiazole matched pairs in the AstraZeneca compound collection.  In virtually all cases, the 1,3,4-oxadiazole isomer shows an order of magnitude lower lipophilicity (log D), as compared to its isomeric partner.  Significant differences are also observed with respect to metabolic stability, hERG inhibition, and aqueous solubility, favoring the 1,3,4-oxadiazole isomers.  The difference in profile between the 1,2,4 and 1,3,4 regioisomers can be rationalized by their intrinsically different charge distributions (e.g., dipole moments).  To facilitate the use of these heteroaromatic rings, novel synthetic routes for ready access of a broad spectrum of 1,3,4-oxadiazoles, under mild conditions, are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSO9RQiG9xFS2Zyxfu64m4ffW6udTcc2eaXfAWizikuirntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383pt1Oisw%253D%253D&md5=b934995431ced1be297e6f126262f3cb</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fjm2013248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2013248%26sid%3Dliteratum%253Aachs%26aulast%3DBostrom%26aufirst%3DJ.%26aulast%3DHogner%26aufirst%3DA.%26aulast%3DLlinas%26aufirst%3DA.%26aulast%3DWellner%26aufirst%3DE.%26aulast%3DPlowright%26aufirst%3DA.%2BT.%26atitle%3DOxadiazoles%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D5%26spage%3D1817%26epage%3D1830%26doi%3D10.1021%2Fjm2013248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Oliveira, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lira, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa-Filho, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzo, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Athayde-Filho, P. F.</span></span> <span> </span><span class="NLM_article-title">Synthetic approaches and pharmacological activity of 1,3,4-oxadiazoles: a review of the literature from 2000â2012</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">10192</span>â <span class="NLM_lpage">10231</span>, <span class="refDoi">Â DOI: 10.3390/molecules170910192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.3390%2Fmolecules170910192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=22926303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BC38bhslSjsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=10192-10231&issue=9&author=C.+S.+de%0AOliveiraauthor=B.+F.+Liraauthor=J.+M.+Barbosa-Filhoauthor=J.+G.+Lorenzoauthor=P.+F.+de+Athayde-Filho&title=Synthetic+approaches+and+pharmacological+activity+of+1%2C3%2C4-oxadiazoles%3A+a+review+of+the+literature+from+2000%E2%80%932012&doi=10.3390%2Fmolecules170910192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches and pharmacological activity of 1,3,4-oxadiazoles: a review of the literature from 2000-2012</span></div><div class="casAuthors">de Oliveira Cledualdo Soares; Lira Bruno Freitas; Barbosa-Filho Jose Maria; Lorenzo Jorge Goncalo Fernandez; de Athayde-Filho Petronio Filgueiras</div><div class="citationInfo"><span class="NLM_cas:title">Molecules (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">10192-231</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This review provides readers with an overview of the main synthetic methodologies for 1,3,4-oxadiazole derivatives, and of their broad spectrum of pharmacological activities as reported over the past twelve years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTx5iuA9u6HIK-9TkgmBqTqfW6udTcc2eaXfAWizikuirntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bhslSjsA%253D%253D&md5=4f09fb45888e071f2601ff846fc83d9d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3390%2Fmolecules170910192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules170910192%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BOliveira%26aufirst%3DC.%2BS.%26aulast%3DLira%26aufirst%3DB.%2BF.%26aulast%3DBarbosa-Filho%26aufirst%3DJ.%2BM.%26aulast%3DLorenzo%26aufirst%3DJ.%2BG.%26aulast%3Dde%2BAthayde-Filho%26aufirst%3DP.%2BF.%26atitle%3DSynthetic%2520approaches%2520and%2520pharmacological%2520activity%2520of%25201%252C3%252C4-oxadiazoles%253A%2520a%2520review%2520of%2520the%2520literature%2520from%25202000%25E2%2580%25932012%26jtitle%3DMolecules%26date%3D2012%26volume%3D17%26issue%3D9%26spage%3D10192%26epage%3D10231%26doi%3D10.3390%2Fmolecules170910192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biernacki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciupak, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubinski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demkowicz, S.</span></span> <span> </span><span class="NLM_article-title">Novel 1,2,4-oxadiazole derivatives in drug discovery</span>. <i>Pharmaceuticals</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">111</span>, <span class="refDoi">Â DOI: 10.3390/ph13060111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.3390%2Fph13060111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFyktLzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2020&pages=111&issue=6&author=K.+Biernackiauthor=M.+Daskoauthor=O.+Ciupakauthor=K.+Kubinskiauthor=J.+Rachonauthor=S.+Demkowicz&title=Novel+1%2C2%2C4-oxadiazole+derivatives+in+drug+discovery&doi=10.3390%2Fph13060111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 1,2,4-oxadiazole derivatives in drug discovery</span></div><div class="casAuthors">Biernacki, Karol; Dasko, Mateusz; Ciupak, Olga; Kubinski, Konrad; Rachon, Janusz; Demkowicz, Sebastian</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceuticals</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">111</span>CODEN:
                <span class="NLM_cas:coden">PHARH2</span>;
        ISSN:<span class="NLM_cas:issn">1424-8247</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Five-membered 1,2,4-oxadiazole heterocyclic ring has received considerable attention because of its unique bioisosteric properties and an unusually wide spectrum of biol. activities.  Thus, it is a perfect framework for the novel drug development.  After a century since the 1,2,4-oxadiazole have been discovered, the uncommon potential attracted medicinal chemists' attention, leading to the discovery of a few presently accessible drugs contg. 1,2,4-oxadiazole unit.  It is worth noting that the interest in a 1,2,4-oxadiazoles' biol. application has been doubled in the last fifteen years.  Herein, after a concise historical introduction, we present a comprehensive overview of the recent achievements in the synthesis of 1,2,4-oxadiazole-based compds. and the major advances in their biol. applications in the period of the last five years as well as brief remarks on prospects for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxL_5MioSG4LVg90H21EOLACvtfcHk0lji5smYeH0mTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFyktLzN&md5=98d1ab4ede67a8ff5a872e37c1a4f044</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3390%2Fph13060111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph13060111%26sid%3Dliteratum%253Aachs%26aulast%3DBiernacki%26aufirst%3DK.%26aulast%3DDasko%26aufirst%3DM.%26aulast%3DCiupak%26aufirst%3DO.%26aulast%3DKubinski%26aufirst%3DK.%26aulast%3DRachon%26aufirst%3DJ.%26aulast%3DDemkowicz%26aufirst%3DS.%26atitle%3DNovel%25201%252C2%252C4-oxadiazole%2520derivatives%2520in%2520drug%2520discovery%26jtitle%3DPharmaceuticals%26date%3D2020%26volume%3D13%26issue%3D6%26spage%3D111%26doi%3D10.3390%2Fph13060111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fershtat, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makhova, N. N.</span></span> <span> </span><span class="NLM_article-title">1,2,5-Oxadiazole-based high-energy-density materials: Synthesis and performance</span>. <i>ChemPlusChem</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>85</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">13</span>â <span class="NLM_lpage">42</span>, <span class="refDoi">Â DOI: 10.1002/cplu.201900542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fcplu.201900542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFantbbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2020&pages=13-42&issue=1&author=L.+L.+Fershtatauthor=N.+N.+Makhova&title=1%2C2%2C5-Oxadiazole-based+high-energy-density+materials%3A+Synthesis+and+performance&doi=10.1002%2Fcplu.201900542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">1,2,5-Oxadiazole-Based High-Energy-Density Materials: Synthesis and Performance</span></div><div class="casAuthors">Fershtat, Leonid L.; Makhova, Nina N.</div><div class="citationInfo"><span class="NLM_cas:title">ChemPlusChem</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-42</span>CODEN:
                <span class="NLM_cas:coden">CHEMM5</span>;
        ISSN:<span class="NLM_cas:issn">2192-6506</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">This Review covers the synthesis and performance of the most promising 1,2,5-oxadiazole-based high-energy d. materials (HEDMs).  These materials comprise a 1,2,5-oxadiazole subunit as a key structural motif linked to various acyclic explosophoric groups or to nitrogen-rich and nitrogen-oxygen azoles: 1,2,4-triazole, tetrazole, 1,2,4- and 1,3,4-oxadiazoles.  Energetic alliances of two and more 1,2,5-oxadiazole rings linked directly or through heteroatom spacers are also presented.  Particular attention is devoted to the installation of different explosophores: nitro, nitramino, azo, azoxy, dinitromethyl, trinitroethyl moieties and their combination.  Promising environmentally benign energetic materials with high detonation velocity and pressure, and outstanding insensitivity are summarized.  Overall, the presented materials may be considered as next-generation high-performance energetic materials that are superior to commonly used traditional explosives (TNT, PETN, RDX, HMX).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb-4xMS6r2b7Vg90H21EOLACvtfcHk0lgX3Mn4wlp0ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFantbbF&md5=b2a1e1115a4b19b7afc947ffcec53b2c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fcplu.201900542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcplu.201900542%26sid%3Dliteratum%253Aachs%26aulast%3DFershtat%26aufirst%3DL.%2BL.%26aulast%3DMakhova%26aufirst%3DN.%2BN.%26atitle%3D1%252C2%252C5-Oxadiazole-based%2520high-energy-density%2520materials%253A%2520Synthesis%2520and%2520performance%26jtitle%3DChemPlusChem%26date%3D2020%26volume%3D85%26issue%3D1%26spage%3D13%26epage%3D42%26doi%3D10.1002%2Fcplu.201900542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fershtat, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makhova, N. N.</span></span> <span> </span><span class="NLM_article-title">Advances in the synthesis of non-annelated polynuclear heterocyclic systems comprising the 1,2,5-oxadiazole ring</span>. <i>Russ. Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>85</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1097</span>â <span class="NLM_lpage">1145</span>, <span class="refDoi">Â DOI: 10.1070/RCR4619</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1070%2FRCR4619" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktl2nt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2016&pages=1097-1145&issue=10&author=L.+L.+Fershtatauthor=N.+N.+Makhova&title=Advances+in+the+synthesis+of+non-annelated+polynuclear+heterocyclic+systems+comprising+the+1%2C2%2C5-oxadiazole+ring&doi=10.1070%2FRCR4619"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the synthesis of non-annelated polynuclear heterocyclic systems comprising the 1,2,5-oxadiazole ring</span></div><div class="casAuthors">Fershtat, Leonid L.; Makhova, Nina N.</div><div class="citationInfo"><span class="NLM_cas:title">Russian Chemical Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1097-1145</span>CODEN:
                <span class="NLM_cas:coden">RCRVAB</span>;
        ISSN:<span class="NLM_cas:issn">0036-021X</span>.
    
            (<span class="NLM_cas:orgname">IOP Publishing Ltd.</span>)
        </div><div class="casAbstract">This review is concerned with recently developed synthetic methods for non-annelated polynuclear heterocyclic systems that incorporate, along with a furazan and(or) furoxan ring, polynitrogen and nitrogen oxygen heterocycles (1,2,4 and 1,3,4 oxadiazole, 1,2,3 and 1,2,4 triazole, tetrazole, pyrazole, sym triazine, 1,2,4,5 tetrazine and so on) linked via C C or C N bonds or heteroat. [N, O, S, N N, N(O) N] bridges.  Methods for prepg. assemblies in which a furazan ring and(or) a furoxan ring are linked to one another by C C bonds or heteroatoms (N, O, S) are surveyed.  Potential applications of the synthesized structures as pharmacol. active and high energy compds. are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTi2mQGeouYbVg90H21EOLACvtfcHk0lgX3Mn4wlp0ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktl2nt7Y%253D&md5=b4422f1fb0427b3fcd8321156645cc3c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1070%2FRCR4619&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1070%252FRCR4619%26sid%3Dliteratum%253Aachs%26aulast%3DFershtat%26aufirst%3DL.%2BL.%26aulast%3DMakhova%26aufirst%3DN.%2BN.%26atitle%3DAdvances%2520in%2520the%2520synthesis%2520of%2520non-annelated%2520polynuclear%2520heterocyclic%2520systems%2520comprising%2520the%25201%252C2%252C5-oxadiazole%2520ring%26jtitle%3DRuss.%2520Chem.%2520Rev.%26date%3D2016%26volume%3D85%26issue%3D10%26spage%3D1097%26epage%3D1145%26doi%3D10.1070%2FRCR4619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheremetev, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yudin, I. L.</span></span> <span> </span><span class="NLM_article-title">Advances in the chemistry of furazano[3,4-b]pyrazines and their analogues</span>. <i>Russ. Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">87</span>â <span class="NLM_lpage">100</span>, <span class="refDoi">Â DOI: 10.1070/RC2003v072n01ABEH000776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1070%2FRC2003v072n01ABEH000776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkt1Kku74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2003&pages=87-100&issue=1&author=A.+B.+Sheremetevauthor=I.+L.+Yudin&title=Advances+in+the+chemistry+of+furazano%5B3%2C4-b%5Dpyrazines+and+their+analogues&doi=10.1070%2FRC2003v072n01ABEH000776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the chemistry of furazano[3,4-b]pyrazines and their analogues</span></div><div class="casAuthors">Sheremetev, A. B.; Yudin, I. L.</div><div class="citationInfo"><span class="NLM_cas:title">Russian Chemical Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-100</span>CODEN:
                <span class="NLM_cas:coden">RCRVAB</span>;
        ISSN:<span class="NLM_cas:issn">0036-021X</span>.
    
            (<span class="NLM_cas:orgname">Turpion Ltd.</span>)
        </div><div class="casAbstract">A review.  The published data on the methods for the synthesis of furazans fused to six-membered heterocycles with two heteroatoms in positions 1 and 4, their reactivities and practical applications are considered and systematized.  The bibliog. includes 89 refs.  A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVhO9RA4br67Vg90H21EOLACvtfcHk0lgX3Mn4wlp0ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkt1Kku74%253D&md5=fdf884395d1a3e627d546060db0e7892</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1070%2FRC2003v072n01ABEH000776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1070%252FRC2003v072n01ABEH000776%26sid%3Dliteratum%253Aachs%26aulast%3DSheremetev%26aufirst%3DA.%2BB.%26aulast%3DYudin%26aufirst%3DI.%2BL.%26atitle%3DAdvances%2520in%2520the%2520chemistry%2520of%2520furazano%255B3%252C4-b%255Dpyrazines%2520and%2520their%2520analogues%26jtitle%3DRuss.%2520Chem.%2520Rev.%26date%3D2003%26volume%3D72%26issue%3D1%26spage%3D87%26epage%3D100%26doi%3D10.1070%2FRC2003v072n01ABEH000776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paton, R. M.</span></span> <span> </span><span class="NLM_article-title">Product class 7: 1,2,5-Oxadiazoles</span>. <i>Sci. Synth.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">185</span>â <span class="NLM_lpage">218</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitVClsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=185-218&author=R.+M.+Paton&title=Product+class+7%3A+1%2C2%2C5-Oxadiazoles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Product class 7: 1,2,5-oxadiazoles</span></div><div class="casAuthors">Paton, R. M.</div><div class="citationInfo"><span class="NLM_cas:title">Science of Synthesis</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">185-218</span>CODEN:
                <span class="NLM_cas:coden">SSCYJ9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">A review.  Methods for prepg. 1,2,5-oxadiazoles are reviewed including cyclization, ring transformation, and substituent modification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2qcWV4jPrAbVg90H21EOLACvtfcHk0lgX3Mn4wlp0ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitVClsL4%253D&md5=5786f83b06040a5affaf3cae85111462</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPaton%26aufirst%3DR.%2BM.%26atitle%3DProduct%2520class%25207%253A%25201%252C2%252C5-Oxadiazoles%26jtitle%3DSci.%2520Synth.%26date%3D2004%26volume%3D13%26spage%3D185%26epage%3D218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paton, R. M.</span></span> <span> </span><span class="NLM_article-title">1,2,5-Oxadiazoles</span>. <span class="NLM_contrib-group"><span class="NLM_string-name">Katritzky, A. R.</span>; <span class="NLM_string-name">Scriven, E. F. V.</span>; <span class="NLM_string-name">Rees, C. W.</span></span>; Eds.;  <i>Comprehensive Heterocyclic Chemistry II</i>; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Amsterdam</span>, <span class="NLM_year">1996</span>, pp  <span class="NLM_fpage">229</span>â <span class="NLM_lpage">265</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2FB978-008096518-5.00083-6" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&pages=229-265&author=R.+M.+Patonauthor=A.+R.+Katritzky&author=E.+F.+V.+Scriven&author=C.+W.+Rees&title=Comprehensive+Heterocyclic+Chemistry+II"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FB978-008096518-5.00083-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-008096518-5.00083-6%26sid%3Dliteratum%253Aachs%26aulast%3DPaton%26aufirst%3DR.%2BM.%26atitle%3D1%252C2%252C5-Oxadiazoles%26aulast%3DKatritzky%26aufirst%3DA.%2BR.%26btitle%3DComprehensive%2520Heterocyclic%2520Chemistry%2520II%26pub%3DElsevier%26date%3D1996%26spage%3D229%26epage%3D265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheremetev, A. B.</span></span> <span> </span><span class="NLM_article-title">The chemistry of furazans fused to six- and seven-membered heterocycles with one heteroatom</span>. <i>Russ. Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">137</span>â <span class="NLM_lpage">148</span>, <span class="refDoi">Â DOI: 10.1070/RC1999v068n02ABEH000449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1070%2FRC1999v068n02ABEH000449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK1MXivVKgsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1999&pages=137-148&issue=2&author=A.+B.+Sheremetev&title=The+chemistry+of+furazans+fused+to+six-+and+seven-membered+heterocycles+with+one+heteroatom&doi=10.1070%2FRC1999v068n02ABEH000449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The chemistry of furazans fused to six- and seven-membered heterocycles with one heteroatom</span></div><div class="casAuthors">Sheremetev, Aleksei B.</div><div class="citationInfo"><span class="NLM_cas:title">Russian Chemical Reviews</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-148</span>CODEN:
                <span class="NLM_cas:coden">RCRVAB</span>;
        ISSN:<span class="NLM_cas:issn">0036-021X</span>.
    
            (<span class="NLM_cas:orgname">Turpion Ltd.</span>)
        </div><div class="casAbstract">The data on the synthesis and properties of furazan derivs. fused with pyridine, pyran, thiopyran, azepine and thiepine rings are surveyed and described systematically.  A review with 85 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6KUKj8yf9zrVg90H21EOLACvtfcHk0ljqJldQOAydYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXivVKgsrw%253D&md5=6ad55d9ce145e665a40f25302684cc08</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1070%2FRC1999v068n02ABEH000449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1070%252FRC1999v068n02ABEH000449%26sid%3Dliteratum%253Aachs%26aulast%3DSheremetev%26aufirst%3DA.%2BB.%26atitle%3DThe%2520chemistry%2520of%2520furazans%2520fused%2520to%2520six-%2520and%2520seven-membered%2520heterocycles%2520with%2520one%2520heteroatom%26jtitle%3DRuss.%2520Chem.%2520Rev.%26date%3D1999%26volume%3D68%26issue%3D2%26spage%3D137%26epage%3D148%26doi%3D10.1070%2FRC1999v068n02ABEH000449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sliwa, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelichowicz, N.</span></span> <span> </span><span class="NLM_article-title">Fused furazans</span>. <i>Collect. Czech. Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">978</span>â <span class="NLM_lpage">996</span>, <span class="refDoi">Â DOI: 10.1135/cccc19920978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1135%2Fcccc19920978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK38Xks12kt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1992&pages=978-996&issue=5&author=W.+Sliwaauthor=A.+Thomasauthor=N.+Zelichowicz&title=Fused+furazans&doi=10.1135%2Fcccc19920978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Fused furazans</span></div><div class="casAuthors">Sliwa, Wanda; Thomas, Antoni; Zelichowicz, Natalia</div><div class="citationInfo"><span class="NLM_cas:title">Collection of Czechoslovak Chemical Communications</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">978-96</span>CODEN:
                <span class="NLM_cas:coden">CCCCAK</span>;
        ISSN:<span class="NLM_cas:issn">0010-0765</span>.
    </div><div class="casAbstract">A review with 90 refs. on the synthesis, chem. reactivity, phys. properties, biol. activity, and applications of fused furazans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNaImwnyZw-LVg90H21EOLACvtfcHk0ljqJldQOAydYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xks12kt74%253D&md5=8051709a5d189e832653eb87071a06cf</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1135%2Fcccc19920978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1135%252Fcccc19920978%26sid%3Dliteratum%253Aachs%26aulast%3DSliwa%26aufirst%3DW.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DZelichowicz%26aufirst%3DN.%26atitle%3DFused%2520furazans%26jtitle%3DCollect.%2520Czech.%2520Chem.%2520Commun.%26date%3D1992%26volume%3D57%26issue%3D5%26spage%3D978%26epage%3D996%26doi%3D10.1135%2Fcccc19920978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cerecetto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcal, W.</span></span> <span> </span><span class="NLM_article-title">Pharmacological properties of furoxans and benzofuroxans: Recent developments</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">57</span>â <span class="NLM_lpage">71</span>, <span class="refDoi">Â DOI: 10.2174/1389557053402864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.2174%2F1389557053402864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=15638792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2MXot1antQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=57-71&issue=1&author=H.+Cerecettoauthor=W.+Porcal&title=Pharmacological+properties+of+furoxans+and+benzofuroxans%3A+Recent+developments&doi=10.2174%2F1389557053402864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological properties of furoxans and benzofuroxans: Recent developments</span></div><div class="casAuthors">Cerecetto, Hugo; Porcal, Williams</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-71</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The chem. of furoxans (1, 2, 5-oxadiazole-2-oxides) and benzofuroxans (benzo[1, 2-c]1, 2, 5-oxadiazole-1-oxides) is very well known.  These systems are widely used in org. chem. as intermediate compds. for the synthesis of numerous heterocycles.  In the other hand, furoxan and benzofuroxan derivs. were extensively studied as bioactive compds.  They possess remarkable biol. activities, such as anti-microbial and anti-parasitic properties, mutagenic, immunosuppressive and anticancer effects, anti-aggregating and vasorelaxant activity, among others.  In some cases, mol. mode of action was proposed.  Recently, the research and development in the medicinal chem. of these systems have produced hybrid compds. in which furoxan or benzofuroxan moieties together with a classical drug moieties are present in a single mol.  So, new anti-ulcer drugs, calcium channel modulators and vasodilator derivs. were described and they are currently in study.  In this presentation recent developments in the medicinal chem. of furoxans will be reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP8DCgcQChJLVg90H21EOLACvtfcHk0ljqJldQOAydYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXot1antQ%253D%253D&md5=18da9801499316246bc2313c9b734241</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F1389557053402864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557053402864%26sid%3Dliteratum%253Aachs%26aulast%3DCerecetto%26aufirst%3DH.%26aulast%3DPorcal%26aufirst%3DW.%26atitle%3DPharmacological%2520properties%2520of%2520furoxans%2520and%2520benzofuroxans%253A%2520Recent%2520developments%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26issue%3D1%26spage%3D57%26epage%3D71%26doi%3D10.2174%2F1389557053402864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tselinskii, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melânikova, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergizov, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frolova, G. M.</span></span> <span> </span><span class="NLM_article-title">Acid-base properties of 1,2,5-oxadiazoles. 1</span>. <i>Chem. Heterocycl. Compd.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">27</span>â <span class="NLM_lpage">29</span>, <span class="refDoi">Â DOI: 10.1007/BF00507084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1007%2FBF00507084" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1981&pages=27-29&issue=1&author=I.+V.+Tselinskiiauthor=S.+F.+Mel%E2%80%99nikovaauthor=S.+N.+Vergizovauthor=G.+M.+Frolova&title=Acid-base+properties+of+1%2C2%2C5-oxadiazoles.+1&doi=10.1007%2FBF00507084"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2FBF00507084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00507084%26sid%3Dliteratum%253Aachs%26aulast%3DTselinskii%26aufirst%3DI.%2BV.%26aulast%3DMel%25E2%2580%2599nikova%26aufirst%3DS.%2BF.%26aulast%3DVergizov%26aufirst%3DS.%2BN.%26aulast%3DFrolova%26aufirst%3DG.%2BM.%26atitle%3DAcid-base%2520properties%2520of%25201%252C2%252C5-oxadiazoles.%25201%26jtitle%3DChem.%2520Heterocycl.%2520Compd.%26date%3D1981%26volume%3D17%26issue%3D1%26spage%3D27%26epage%3D29%26doi%3D10.1007%2FBF00507084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trifonov, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrovskii, V. A.</span></span> <span> </span><span class="NLM_article-title">Basicity of 2-phenyl-5-R-1,3,4-oxadiazoles</span>. <i>Chem. Heterocycl. Compd.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">657</span>â <span class="NLM_lpage">664</span>, <span class="refDoi">Â DOI: 10.1007/s10593-006-0142-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1007%2Fs10593-006-0142-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWgs7nN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=657-664&issue=5&author=R.+E.+Trifonovauthor=V.+A.+Ostrovskii&title=Basicity+of+2-phenyl-5-R-1%2C3%2C4-oxadiazoles&doi=10.1007%2Fs10593-006-0142-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Basicity of 2-phenyl-5-R-1,3,4-oxadiazoles</span></div><div class="casAuthors">Trifonov, R. E.; Ostrovskii, V. A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry of Heterocyclic Compounds (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">657-664</span>CODEN:
                <span class="NLM_cas:coden">CHCCAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-3122</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The authors have studied the basicity of 2-phenyl-5-R-1,3,4-oxadiazoles (R = H, Me, CH2Ph, t-Bu, CH2Cl, CCl3, CF3) in aq. sulfuric acid solns.  These compds. are weak org. bases (pKBH+ is -1.8 to - 5.2).  The values of pKBH+ detd. on the H0 and X acidity function scales agree well with each other.  The substituent at the 5 position has a substantial effect on the basicity of the 1,3,4-oxadiazole ring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMU-ltFGN_wrVg90H21EOLACvtfcHk0lhKoda17tRlkA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWgs7nN&md5=8064a277d877578115542f2a5399cedb</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs10593-006-0142-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10593-006-0142-y%26sid%3Dliteratum%253Aachs%26aulast%3DTrifonov%26aufirst%3DR.%2BE.%26aulast%3DOstrovskii%26aufirst%3DV.%2BA.%26atitle%3DBasicity%2520of%25202-phenyl-5-R-1%252C3%252C4-oxadiazoles%26jtitle%3DChem.%2520Heterocycl.%2520Compd.%26date%3D2006%26volume%3D42%26issue%3D5%26spage%3D657%26epage%3D664%26doi%3D10.1007%2Fs10593-006-0142-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trifonov, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volovodenko, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergizov, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirinbekov, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gindin, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koren, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrovskii, V. A.</span></span> <span> </span><span class="NLM_article-title">Basicity of phenyl- and methyl-substituted 1,2,4-oxadiazoles</span>. <i>Helv. Chim. Acta</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>88</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1790</span>â <span class="NLM_lpage">1797</span>, <span class="refDoi">Â DOI: 10.1002/hlca.200590140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fhlca.200590140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2MXosVamtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2005&pages=1790-1797&issue=7&author=R.+E.+Trifonovauthor=A.+P.+Volovodenkoauthor=S.+N.+Vergizovauthor=N.+I.+Shirinbekovauthor=V.+A.+Gindinauthor=A.+O.+Korenauthor=V.+A.+Ostrovskii&title=Basicity+of+phenyl-+and+methyl-substituted+1%2C2%2C4-oxadiazoles&doi=10.1002%2Fhlca.200590140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Basicity of phenyl- and methyl-substituted 1,2,4-oxadiazoles</span></div><div class="casAuthors">Trifonov, Rostislav E.; Volovodenko, Anna P.; Vergizov, Sergei N.; Shirinbekov, Nabi I.; Gindin, Vladimir A.; Koren, Andrei O.; Ostrovskii, Vladimir A.</div><div class="citationInfo"><span class="NLM_cas:title">Helvetica Chimica Acta</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1790-1797</span>CODEN:
                <span class="NLM_cas:coden">HCACAV</span>;
        ISSN:<span class="NLM_cas:issn">0018-019X</span>.
    
            (<span class="NLM_cas:orgname">Verlag Helvetica Chimica Acta</span>)
        </div><div class="casAbstract">The basicity of a series of 3,5-disubstituted 1,2,4-oxadiazoles in aq. H2SO4 was examd. by means of UV and 1H-NMR spectroscopy.  The exptl. data were analyzed by the modified Yates-McClelland method to yield the following pKBH+ values: 3,5-dimethyl-1,2,4-oxadiazole, -1.66; 3-methyl-5-phenyl-1,2,4-oxadiazole, -2.61; 3-phenyl-5-methyl-1,2,4-oxadiazole, -2.95; 3,5-diphenyl-1,2,4-oxadiazole, -3.55.  A pKBH+ value of ca. -3.7 was estd. for the parent unsubstituted 1,2,4-oxadiazole based on substituents' additivity increments.  Possible protonation sites of the compds. were discussed in terms of both exptl. data and theor. calcns. (HF/6-31G**).  Generally, protonation is most likely to occur at N(4) of the 1,2,4-oxadiazole ring.  However, concurrent formation of both N(4)- and N(2)-protonated species in comparable amts. is possible in the case of 3-phenyl-1,2,4-oxadiazoles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRnPW9PP9FYLVg90H21EOLACvtfcHk0lhKoda17tRlkA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXosVamtLk%253D&md5=5c145375ce4e6d1ce9264074f524cabe</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fhlca.200590140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhlca.200590140%26sid%3Dliteratum%253Aachs%26aulast%3DTrifonov%26aufirst%3DR.%2BE.%26aulast%3DVolovodenko%26aufirst%3DA.%2BP.%26aulast%3DVergizov%26aufirst%3DS.%2BN.%26aulast%3DShirinbekov%26aufirst%3DN.%2BI.%26aulast%3DGindin%26aufirst%3DV.%2BA.%26aulast%3DKoren%26aufirst%3DA.%2BO.%26aulast%3DOstrovskii%26aufirst%3DV.%2BA.%26atitle%3DBasicity%2520of%2520phenyl-%2520and%2520methyl-substituted%25201%252C2%252C4-oxadiazoles%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D2005%26volume%3D88%26issue%3D7%26spage%3D1790%26epage%3D1797%26doi%3D10.1002%2Fhlca.200590140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lutskii, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepel, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shvaika, O. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimisha, G. P.</span></span> <span> </span><span class="NLM_article-title">Dipole moments and the structure of the molecules of some oxadiazole derivatives</span>. <i>Chem. Heterocycl. Compd.</i> <span class="NLM_year" style="font-weight: bold;">1972</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">343</span>â <span class="NLM_lpage">348</span>, <span class="refDoi">Â DOI: 10.1007/BF00471140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1007%2FBF00471140" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1972&pages=343-348&issue=3&author=A.+E.+Lutskiiauthor=A.+V.+Shepelauthor=O.+P.+Shvaikaauthor=G.+P.+Klimisha&title=Dipole+moments+and+the+structure+of+the+molecules+of+some+oxadiazole+derivatives&doi=10.1007%2FBF00471140"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2FBF00471140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00471140%26sid%3Dliteratum%253Aachs%26aulast%3DLutskii%26aufirst%3DA.%2BE.%26aulast%3DShepel%26aufirst%3DA.%2BV.%26aulast%3DShvaika%26aufirst%3DO.%2BP.%26aulast%3DKlimisha%26aufirst%3DG.%2BP.%26atitle%3DDipole%2520moments%2520and%2520the%2520structure%2520of%2520the%2520molecules%2520of%2520some%2520oxadiazole%2520derivatives%26jtitle%3DChem.%2520Heterocycl.%2520Compd.%26date%3D1972%26volume%3D5%26issue%3D3%26spage%3D343%26epage%3D348%26doi%3D10.1007%2FBF00471140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milone, M</span></span> <span> </span><span class="NLM_article-title">The electric moment of some derivatives of the heterocyclic (C2N2O) group</span>. <i>Gazz. Chim. Ital.</i> <span class="NLM_year" style="font-weight: bold;">1935</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">152</span>â <span class="NLM_lpage">158</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaA2MXktF2itQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1935&pages=152-158&author=M+Milone&title=The+electric+moment+of+some+derivatives+of+the+heterocyclic+%28C2N2O%29+group"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The electric moment of some derivatives of the heterocyclic (C2N2O) group</span></div><div class="casAuthors">Milone, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Gazzetta Chimica Italiana</span>
        (<span class="NLM_cas:date">1935</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">152-8</span>CODEN:
                <span class="NLM_cas:coden">GCITA9</span>;
        ISSN:<span class="NLM_cas:issn">0016-5603</span>.
    </div><div class="casAbstract">cf. C. A. 27, 5003; 28, 97.1.  The work is the beginning of a systematic investigation of the mol. elec. moments of heterocyclic compds., and deals with furazans, azoximes and oxadiazoles.  The object was to characterize the different forms of the C2N2O group (already the subject of numerous chem. studies), to study the relations between the nature and arrangement of the substituent groups and the elec. moments, and from this to ascertain the nature of the bonds and the structure of the cyclic group in relation to other pentat. heterocyclic groups.  The expts. show that the elec. moments of furazans are much greater than those of isomeric azoximes, and that the moments of oxadiazoles are slightly smaller than those of isomeric furazans.  The moments of the furazans; studied were 4-4.7 Ã 10-18, of the oxadiazoles 3.3-3.9 Ã 10-18, and of the azoximes 1.4-1.65 Ã 10-18.  From a qual., point of view the results are important in that they offer a certain means of distinguishing between a furazan and its isomeric azoxime, a problem which is impossible by other methods.  A quant. evaluation of the results is more difficult.  Based on the true elec. moment of the nucleus, and on the assumption that in the case of disubstituted isomers (contg. 2 Me groups, 2 Ph groups, or 1 Me and 1 Ph group), furazans have the max. elec. moments and azoximes the min. moments, there is a certain analogy with disubstituted C6H6 derivs.  On the other hand, to explain why an oxadiazole has a smaller moment than does the corresponding furazan, necessitates the assumption that the 2 C and 2 N atoms of the C2N2O group are located at the corners of a rectangle, a hypothesis at variance with the common hypothesis of the geometric form of pentat. cycles.  The great differences in the elec. moments of isomers are to be attributed to differences in the moments of the various forms of the C2N2O cycle.  The following data give the mol. elec. moment Î¼ (Ã 1018) of the various compds., measured by the app. already described (cf. M., C. A. 29, 4738.5); MeC:N.O.N:CMe, 4.008; MeC:N.N:CMe.O, 3.29; MeC:N.O.N:CEt, 4.061; PhC:N.O.N:CH (I), 3.997; p-MeC6H4C:N.O.N:CH (II), 4.176; MeC:N.O.N:CPh, 4.141; PhC:N.O.CMe:N, 1.41; MeC:N.O.CPh:N, 1.63; MeC:N.N:CPh.O, 3.434; PhC:N.O.N:CPh, 4.739; PhC:N.O.CPh:N, 1.563; PhC:N.N:CPh.O, 3.86.  The rather high moments of I and II show that the C2N2O cycle has a fairly large elec. moment, which is in accord with the fact that Ph2 has no moment, whereas mono substituted benzenes have pos. moments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvNP4iK8Oot7Vg90H21EOLACvtfcHk0lhKoda17tRlkA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaA2MXktF2itQ%253D%253D&md5=85255606646385b65976dc7d1c698664</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMilone%26aufirst%3DM%26atitle%3DThe%2520electric%2520moment%2520of%2520some%2520derivatives%2520of%2520the%2520heterocyclic%2520%2528C2N2O%2529%2520group%26jtitle%3DGazz.%2520Chim.%2520Ital.%26date%3D1935%26volume%3D65%26spage%3D152%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vsetecka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruttero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Exner, O.</span></span> <span> </span><span class="NLM_article-title">Dipole moments and electron distribution of furoxans and furazans</span>. <i>J. Mol. Struct.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>324</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">277</span>â <span class="NLM_lpage">282</span>, <span class="refDoi">Â DOI: 10.1016/0022-2860(94)08305-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2F0022-2860%2894%2908305-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK2MXksFGntw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=1994&pages=277-282&issue=3&author=V.+Vseteckaauthor=R.+Frutteroauthor=A.+Gascoauthor=O.+Exner&title=Dipole+moments+and+electron+distribution+of+furoxans+and+furazans&doi=10.1016%2F0022-2860%2894%2908305-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Dipole moments and electron distribution of furoxans and furazans</span></div><div class="casAuthors">Vsetecka, Vaclav; Fruttero, Roberta; Gasco, Alberto; Exner, Otto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Structure</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">277-82</span>CODEN:
                <span class="NLM_cas:coden">JMOSB4</span>;
        ISSN:<span class="NLM_cas:issn">0022-2860</span>.
    </div><div class="casAbstract">Dipole moments of a set of substituted 1,2,5-oxadiazoles (furazans) and 1,2,5-oxadiazole-2-oxides (furoxans) were measured in benzene soln.  The dipole moment in furazan is oriented with the neg. end towards oxygen in agreement with common opinion (but contrary to the literature).  Comparison of the two classes of compds. revealed a strong electron shift in furoxans, from the exocyclic oxygen back into the heterocyclic system, corresponding to a mesomeric moment of approx. 3D.  However, the electron redistribution cannot be described in terms of simple mesomeric structures.  The mol. of furoxan is well characterized as electron-overcrowded, particularly in the vicinity of the nitrogen atom N(2).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBiaZfOTrd-rVg90H21EOLACvtfcHk0lgoUW6NNg6-Kg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXksFGntw%253D%253D&md5=f37c618f59178c2bc0973cafb0187daa</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2F0022-2860%2894%2908305-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0022-2860%252894%252908305-3%26sid%3Dliteratum%253Aachs%26aulast%3DVsetecka%26aufirst%3DV.%26aulast%3DFruttero%26aufirst%3DR.%26aulast%3DGasco%26aufirst%3DA.%26aulast%3DExner%26aufirst%3DO.%26atitle%3DDipole%2520moments%2520and%2520electron%2520distribution%2520of%2520furoxans%2520and%2520furazans%26jtitle%3DJ.%2520Mol.%2520Struct.%26date%3D1994%26volume%3D324%26issue%3D3%26spage%3D277%26epage%3D282%26doi%3D10.1016%2F0022-2860%2894%2908305-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vsetecka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Exner, O.</span></span> <span> </span><span class="NLM_article-title">New interpretation of dipole moments of aliphatic and aromatic nitro compounds</span>. <i>Collect. Czech. Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1140</span>â <span class="NLM_lpage">1149</span>, <span class="refDoi">Â DOI: 10.1135/cccc19741140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1135%2Fcccc19741140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaE2cXks1amtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1974&pages=1140-1149&issue=5&author=V.+Vseteckaauthor=O.+Exner&title=New+interpretation+of+dipole+moments+of+aliphatic+and+aromatic+nitro+compounds&doi=10.1135%2Fcccc19741140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">New interpretation of dipole moments of aliphatic and aromatic nitro compounds</span></div><div class="casAuthors">Vsetecka, V.; Exner, O.</div><div class="citationInfo"><span class="NLM_cas:title">Collection of Czechoslovak Chemical Communications</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1140-9</span>CODEN:
                <span class="NLM_cas:coden">CCCCAK</span>;
        ISSN:<span class="NLM_cas:issn">0010-0765</span>.
    </div><div class="casAbstract">The concept of mesomeric dipole moments is revised both exptl. and theor. on the basis of 13 nitro compds.  While the dipole moments of aliph. nitro compds. increase steadily with the size of the hydrocarbon residue (up to 3.55 D for 1-nitroadamantane), those of 2,4,6-trisubstituted benzenes decrease with the size (polarizability) of the substituent (down to 3.40 D for 2,4,6-triphenylnitrobenzene).  Hence, neither the difference between nitrobenzene and an aliph. deriv., nor between nitrobenzene and 2,4,6-trimethylnitrobenzene can be taken as a quant. measure of the mesomeric interaction between the nitro group and the arom. nucleus.  Simple calcn. of induced dipole moments, however, without using the simplification of the point dipole, agrees with the exptl. results in a semiquant. manner.  The mesomeric effect of the nitro group is very small and is not manifested clearly in the dipole moments values.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_ClmyNs61G7Vg90H21EOLACvtfcHk0lgoUW6NNg6-Kg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXks1amtbc%253D&md5=ae21cd6789797349690d8caf2021738d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1135%2Fcccc19741140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1135%252Fcccc19741140%26sid%3Dliteratum%253Aachs%26aulast%3DVsetecka%26aufirst%3DV.%26aulast%3DExner%26aufirst%3DO.%26atitle%3DNew%2520interpretation%2520of%2520dipole%2520moments%2520of%2520aliphatic%2520and%2520aromatic%2520nitro%2520compounds%26jtitle%3DCollect.%2520Czech.%2520Chem.%2520Commun.%26date%3D1974%26volume%3D39%26issue%3D5%26spage%3D1140%26epage%3D1149%26doi%3D10.1135%2Fcccc19741140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El-Azhary, A. A.</span></span> <span> </span><span class="NLM_article-title">Vibrational analysis of the spectra of 1,2,5-oxadiazole, 1,2,5-thiadiazole and 1,2,5-selenadiazole</span>. <i>Acta Chem. Scand.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">11</span>â <span class="NLM_lpage">19</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.3891%2Facta.chem.scand.49-0011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK2MXjvVygsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1995&pages=11-19&issue=1&author=A.+A.+El-Azhary&title=Vibrational+analysis+of+the+spectra+of+1%2C2%2C5-oxadiazole%2C+1%2C2%2C5-thiadiazole+and+1%2C2%2C5-selenadiazole"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Vibrational analysis of the spectra of 1,2,5-oxadiazole, 1,2,5-thiadiazole and 1,2,5-selenadiazole</span></div><div class="casAuthors">El-Azhary, Adel Abbas</div><div class="citationInfo"><span class="NLM_cas:title">Acta Chemica Scandinavica</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-19</span>CODEN:
                <span class="NLM_cas:coden">ACHSE7</span>;
        ISSN:<span class="NLM_cas:issn">0904-213X</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">Equil. geometries and harmonic force fields have been calcd. for 1,2,5-oxadiazole, 1,2,5-thiadiazole, and 1,2,5-selenadiazole at the SCF and MP2 levels of theory using the 6-31G** basis set (Binning-Curtiss for the selenium atom).  Scaled quantum-mech. (SOM) force fields have been calcd. for the three mols. and some of their isotopomers using the exptl. frequencies available from the literature.  The IR absorption intensities were calcd. using the computed dipole deriv. tensors.  The assignment of the exptl. to the calcd. frequencies was done first according to symmetry then mainly according to frequency order.  The calcd. vibrational spectra for the studied mols. by the scaled MP2 force fields are only slightly better than those calcd. by the scaled SCF force fields.  A good correlation was found between the scale factors obtained for both mols. and those obtained for 1,3,4-oxadiazole and 1,3,4-thiadiazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlZKrCrDs1wLVg90H21EOLACvtfcHk0lgoUW6NNg6-Kg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjvVygsr0%253D&md5=a02533e49f809ec31be03956c488c387</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.3891%2Facta.chem.scand.49-0011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3891%252Facta.chem.scand.49-0011%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Azhary%26aufirst%3DA.%2BA.%26atitle%3DVibrational%2520analysis%2520of%2520the%2520spectra%2520of%25201%252C2%252C5-oxadiazole%252C%25201%252C2%252C5-thiadiazole%2520and%25201%252C2%252C5-selenadiazole%26jtitle%3DActa%2520Chem.%2520Scand.%26date%3D1995%26volume%3D49%26issue%3D1%26spage%3D11%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tselinskii, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melânikova, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelenov, M. P.</span></span> <span> </span><span class="NLM_article-title">Acid-base properties of 1,2,5-oxadiazoles. III</span>. <i>Furazanylacetic acids. Zh. Org. Khim.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">766</span>â <span class="NLM_lpage">769</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1996&pages=766-769&issue=5&author=I.+V.+Tselinskiiauthor=S.+F.+Mel%E2%80%99nikovaauthor=M.+P.+Zelenov&title=Acid-base+properties+of+1%2C2%2C5-oxadiazoles.+III"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTselinskii%26aufirst%3DI.%2BV.%26aulast%3DMel%25E2%2580%2599nikova%26aufirst%3DS.%2BF.%26aulast%3DZelenov%26aufirst%3DM.%2BP.%26atitle%3DAcid-base%2520properties%2520of%25201%252C2%252C5-oxadiazoles.%2520III%26jtitle%3DFurazanylacetic%2520acids.%2520Zh.%2520Org.%2520Khim.%26date%3D1996%26volume%3D32%26issue%3D5%26spage%3D766%26epage%3D769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slovetskii, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fainzilâberg, A. A.</span></span> <span> </span><span class="NLM_article-title">Magnitudes of the inductive effects of the nitro and nitrate groups</span>. <i>Bull. Acad. Sci. USSR, Div. Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1966</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1435</span>â <span class="NLM_lpage">1437</span>, <span class="refDoi">Â DOI: 10.1007/BF01151397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1007%2FBF01151397" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1966&pages=1435-1437&issue=8&author=V.+I.+Slovetskiiauthor=A.+A.+Fainzil%E2%80%99berg&title=Magnitudes+of+the+inductive+effects+of+the+nitro+and+nitrate+groups&doi=10.1007%2FBF01151397"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2FBF01151397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01151397%26sid%3Dliteratum%253Aachs%26aulast%3DSlovetskii%26aufirst%3DV.%2BI.%26aulast%3DFainzil%25E2%2580%2599berg%26aufirst%3DA.%2BA.%26atitle%3DMagnitudes%2520of%2520the%2520inductive%2520effects%2520of%2520the%2520nitro%2520and%2520nitrate%2520groups%26jtitle%3DBull.%2520Acad.%2520Sci.%2520USSR%252C%2520Div.%2520Chem.%2520Sci.%26date%3D1966%26volume%3D15%26issue%3D8%26spage%3D1435%26epage%3D1437%26doi%3D10.1007%2FBF01151397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kazius, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursi, R.</span></span> <span> </span><span class="NLM_article-title">Derivation and validation of toxicophores for mutagenicity prediction. J. Med. Chem. 2005, 48 (1), 312â320. (16) Kazius, J.; McGuire, R.; Bursi, R., Derivation and validation of toxicophores for mutagenicity prediction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">312</span>â <span class="NLM_lpage">320</span>, <span class="refDoi">Â DOI: 10.1021/jm040835a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040835a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFSlur%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=312-320&issue=1&author=J.+Kaziusauthor=R.+McGuireauthor=R.+Bursi&title=Derivation+and+validation+of+toxicophores+for+mutagenicity+prediction.+J.+Med.+Chem.+2005%2C+48+%281%29%2C+312%E2%80%93320.+%2816%29+Kazius%2C+J.%3B+McGuire%2C+R.%3B+Bursi%2C+R.%2C+Derivation+and+validation+of+toxicophores+for+mutagenicity+prediction&doi=10.1021%2Fjm040835a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Derivation and validation of toxicophores for mutagenicity prediction</span></div><div class="casAuthors">Kazius, Jeroen; McGuire, Ross; Bursi, Roberta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">312-320</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mutagenicity is one of the numerous adverse properties of a compd. that hampers its potential to become a marketable drug.  Toxic properties can often be related to chem. structure, more specifically, to particular substructures, which are generally identified as toxicophores.  A no. of toxicophores have already been identified in the literature.  This study aims at increasing the current degree of reliability and accuracy of mutagenicity predictions by identifying novel toxicophores from the application of new criteria for toxicophore rule derivation and validation to a considerably sized mutagenicity dataset.  For this purpose, a dataset of 4337 mol. structures with corresponding Ames test data (2401 mutagens and 1936 nonmutagens) was constructed.  An initial substructure-search of this dataset showed that most mutagens were detected by applying only eight general toxicophores.  From these eight, more specific toxicophores were derived and approved by employing chem. and mechanistic knowledge in combination with statistical criteria.  A final set of 29 toxicophores contg. new substructures was assembled that could classify the mutagenicity of the investigated dataset with a total classification error of 18%.  Furthermore, mutagenicity predictions of an independent validation set of 535 compds. were performed with an error percentage of 15%.  Since these error percentages approach the av. interlab. reproducibility error of Ames tests, which is 15%, it was concluded that these toxicophores can be applied to risk assessment processes and can guide the design of chem. libraries for hit and lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgFd408uWltLVg90H21EOLACvtfcHk0li1YDA90X2O6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFSlur%252FL&md5=3ef5be2a1583292818d8b8f0e350bdd1</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm040835a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040835a%26sid%3Dliteratum%253Aachs%26aulast%3DKazius%26aufirst%3DJ.%26aulast%3DMcGuire%26aufirst%3DR.%26aulast%3DBursi%26aufirst%3DR.%26atitle%3DDerivation%2520and%2520validation%2520of%2520toxicophores%2520for%2520mutagenicity%2520prediction.%2520J.%2520Med.%2520Chem.%25202005%252C%252048%2520%25281%2529%252C%2520312%25E2%2580%2593320.%2520%252816%2529%2520Kazius%252C%2520J.%253B%2520McGuire%252C%2520R.%253B%2520Bursi%252C%2520R.%252C%2520Derivation%2520and%2520validation%2520of%2520toxicophores%2520for%2520mutagenicity%2520prediction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D1%26spage%3D312%26epage%3D320%26doi%3D10.1021%2Fjm040835a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priest, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swensen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Galicia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felix, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochu, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas-Fowlkes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaczorowski, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran- 1(3H)-one</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">5829</span>â <span class="NLM_lpage">5832</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2013.08.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmcl.2013.08.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=24075732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFaksLzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5829-5832&issue=21&author=H.+Tangauthor=R.+K.+de+Jesusauthor=S.+P.+Walshauthor=Y.+Zhuauthor=Y.+Yanauthor=B.+T.+Priestauthor=A.+M.+Swensenauthor=M.+Alonso-Galiciaauthor=J.+P.+Felixauthor=R.+M.+Brochuauthor=T.+Baileyauthor=B.+Thomas-Fowlkesauthor=X.+Zhouauthor=L.+Y.+Paiauthor=C.+Hamptonauthor=M.+Hernandezauthor=K.+Owensauthor=S.+Royauthor=G.+J.+Kaczorowskiauthor=L.+Yangauthor=M.+L.+Garciaauthor=A.+Pasternak&title=Discovery+of+a+novel+sub-class+of+ROMK+channel+inhibitors+typified+by+5-%282-%284-%282-%284-%281H-Tetrazol-1-yl%29phenyl%29acetyl%29piperazin-1-yl%29ethyl%29isobenzofuran-+1%283H%29-one&doi=10.1016%2Fj.bmcl.2013.08.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one</span></div><div class="casAuthors">Tang, Haifeng; de Jesus, Reynald K.; Walsh, Shawn P.; Zhu, Yuping; Yan, Yan; Priest, Birgit T.; Swensen, Andrew M.; Alonso-Galicia, Magdalena; Felix, John P.; Brochu, Richard M.; Bailey, Timothy; Thomas-Fowlkes, Brande; Zhou, Xiaoyan; Pai, Lee-Yuh; Hampton, Caryn; Hernandez, Melba; Owens, Karen; Roy, Sophie; Kaczorowski, Gregory J.; Yang, Lihu; Garcia, Maria L.; Pasternak, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5829-5832</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A sub-class of distinct small mol. ROMK inhibitors were developed from the original lead 1.  Medicinal chem. endeavors led to novel ROMK inhibitors with good ROMK functional potency and improved hERG selectivity.  Two of the described ROMK inhibitors were characterized for the first in vivo proof-of-concept biol. studies, and results from an acute rat diuresis model confirmed the hypothesis that ROMK inhibitors represent new mechanism diuretic and natriuretic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqMISo9kJhC7Vg90H21EOLACvtfcHk0li1YDA90X2O6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFaksLzO&md5=e88d9eedfcdf23725f6fde1301664cd8</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.104%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DH.%26aulast%3Dde%2BJesus%26aufirst%3DR.%2BK.%26aulast%3DWalsh%26aufirst%3DS.%2BP.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DPriest%26aufirst%3DB.%2BT.%26aulast%3DSwensen%26aufirst%3DA.%2BM.%26aulast%3DAlonso-Galicia%26aufirst%3DM.%26aulast%3DFelix%26aufirst%3DJ.%2BP.%26aulast%3DBrochu%26aufirst%3DR.%2BM.%26aulast%3DBailey%26aufirst%3DT.%26aulast%3DThomas-Fowlkes%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DPai%26aufirst%3DL.%2BY.%26aulast%3DHampton%26aufirst%3DC.%26aulast%3DHernandez%26aufirst%3DM.%26aulast%3DOwens%26aufirst%3DK.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DKaczorowski%26aufirst%3DG.%2BJ.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DGarcia%26aufirst%3DM.%2BL.%26aulast%3DPasternak%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520sub-class%2520of%2520ROMK%2520channel%2520inhibitors%2520typified%2520by%25205-%25282-%25284-%25282-%25284-%25281H-Tetrazol-1-yl%2529phenyl%2529acetyl%2529piperazin-1-yl%2529ethyl%2529isobenzofuran-%25201%25283H%2529-one%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D21%26spage%3D5829%26epage%3D5832%26doi%3D10.1016%2Fj.bmcl.2013.08.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahripour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teumelsan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas-Fowlkes, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felix, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priest, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Galicia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaczorowski, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective small molecule ROMK Inhibitors as potential new mechanism diuretics</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">367</span>â <span class="NLM_lpage">372</span>, <span class="refDoi">Â DOI: 10.1021/ml3000066</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml3000066" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1Cju7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=367-372&issue=5&author=H.+Tangauthor=S.+P.+Walshauthor=Y.+Yanauthor=R.+K.+de+Jesusauthor=A.+Shahripourauthor=N.+Teumelsanauthor=Y.+Zhuauthor=S.+Haauthor=K.+A.+Owensauthor=B.+S.+Thomas-Fowlkesauthor=J.+P.+Felixauthor=J.+Liuauthor=M.+Kohlerauthor=B.+T.+Priestauthor=T.+Baileyauthor=R.+Brochuauthor=M.+Alonso-Galiciaauthor=G.+J.+Kaczorowskiauthor=S.+Royauthor=L.+Yangauthor=S.+G.+Millsauthor=M.+L.+Garciaauthor=A.+Pasternak&title=Discovery+of+selective+small+molecule+ROMK+Inhibitors+as+potential+new+mechanism+diuretics&doi=10.1021%2Fml3000066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Selective Small Molecule ROMK Inhibitors as Potential New Mechanism Diuretics</span></div><div class="casAuthors">Tang, Haifeng; Walsh, Shawn P.; Yan, Yan; de Jesus, Reynalda K.; Shahripour, Aurash; Teumelsan, Nardos; Zhu, Yuping; Ha, Sookhee; Owens, Karen A.; Thomas-Fowlkes, Brande S.; Felix, John P.; Liu, Jessica; Kohler, Martin; Priest, Birgit T.; Bailey, Timothy; Brochu, Richard; Alonso-Galicia, Magdalena; Kaczorowski, Gregory J.; Roy, Sophie; Yang, Lihu; Mills, Sander G.; Garcia, Maria L.; Pasternak, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">367-372</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The renal outer medullary potassium channel (ROMK or Kir1.1) is a putative drug target for a novel class of diuretics that could be used for the treatment of hypertension and edematous states such as heart failure.  An internal high-throughput screening campaign identified 1,4-bis(4-nitrophenethyl)piperazine (5) as a potent ROMK inhibitor.  It is worth noting that this compd. was identified as a minor impurity in a screening hit that was responsible for all of the initially obsd. ROMK activity.  Structure-activity studies resulted in analogs with improved rat pharmacokinetic properties and selectivity over the hERG channel, providing tool compds. that can be used for in vivo pharmacol. assessment.  The featured ROMK inhibitors were also selective against other members of the inward rectifier family of potassium channels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7DJkcFtShlrVg90H21EOLACvtfcHk0li1YDA90X2O6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1Cju7k%253D&md5=dac591d9e2a0d89637522ab5d50b4cab</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fml3000066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml3000066%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DH.%26aulast%3DWalsh%26aufirst%3DS.%2BP.%26aulast%3DYan%26aufirst%3DY.%26aulast%3Dde%2BJesus%26aufirst%3DR.%2BK.%26aulast%3DShahripour%26aufirst%3DA.%26aulast%3DTeumelsan%26aufirst%3DN.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DHa%26aufirst%3DS.%26aulast%3DOwens%26aufirst%3DK.%2BA.%26aulast%3DThomas-Fowlkes%26aufirst%3DB.%2BS.%26aulast%3DFelix%26aufirst%3DJ.%2BP.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DKohler%26aufirst%3DM.%26aulast%3DPriest%26aufirst%3DB.%2BT.%26aulast%3DBailey%26aufirst%3DT.%26aulast%3DBrochu%26aufirst%3DR.%26aulast%3DAlonso-Galicia%26aufirst%3DM.%26aulast%3DKaczorowski%26aufirst%3DG.%2BJ.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DMills%26aufirst%3DS.%2BG.%26aulast%3DGarcia%26aufirst%3DM.%2BL.%26aulast%3DPasternak%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520selective%2520small%2520molecule%2520ROMK%2520Inhibitors%2520as%2520potential%2520new%2520mechanism%2520diuretics%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26issue%3D5%26spage%3D367%26epage%3D372%26doi%3D10.1021%2Fml3000066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span>; <span class="NLM_string-name">Pasternak, A.</span>; <span class="NLM_string-name">Yang, L.</span>; <span class="NLM_string-name">Walsh, S. P.</span>; <span class="NLM_string-name">Pio, B.</span>; <span class="NLM_string-name">Shahripour, A.</span>; <span class="NLM_string-name">Teumelsan, N.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the Renal Outer Medullary Potassium Channel</span>. <span class="NLM_patent">WO2012058116A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=H.+Tang&author=A.+Pasternak&author=L.+Yang&author=S.+P.+Walsh&author=B.+Pio&author=A.+Shahripour&author=N.+Teumelsan&title=Inhibitors+of+the+Renal+Outer+Medullary+Potassium+Channel"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DH.%26atitle%3DInhibitors%2520of%2520the%2520Renal%2520Outer%2520Medullary%2520Potassium%2520Channel%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hersperger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">233</span>â <span class="NLM_lpage">235</span>, <span class="refDoi">Â DOI: 10.1016/S0960-894X(01)00720-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2FS0960-894X%2801%2900720-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=11755362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsVyl" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=233-235&issue=2&author=R.+Herspergerauthor=J.+Dawsonauthor=T.+Mueller&title=Synthesis+of+4-%288-benzo%5B1%2C2%2C5%5Doxadiazol-5-yl-%5B1%2C7%5Dnaphthyridine-6-yl%29-benzoic+acid%3A+a+potent+and+selective+phosphodiesterase+type+4D+inhibitor&doi=10.1016%2FS0960-894X%2801%2900720-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor</span></div><div class="casAuthors">Hersperger, Rene; Dawson, Janet; Mueller, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">233-235</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The synthesis of a 6,8-disubstituted 1,7-naphthyridine and its characterization as a potent and selective phosphodiesterase type 4D inhibitor (IC50=1.5 nM) are described.  The title compd., i.e., 4-[8-(2,1,3-benzoxadiazol-5-yl)-1,7-naphthyridin-6-yl]benzoic acid and 4-[8-(2,1,3-benzoxadiazol-5-yl)-1,7-naphthyridin-6-yl]benzoic acid salt with 1-deoxy-1-(methylamino)-D-glucitol.  The compd. inhibited TNFÎ±-release from human peripheral blood mononuclear cells and was orally active in a model of adjuvant-induced arthritis in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeK295xqo3SbVg90H21EOLACvtfcHk0lgJKSiKAVsyYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsVyl&md5=60845922a243dc78753438545726108d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900720-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900720-X%26sid%3Dliteratum%253Aachs%26aulast%3DHersperger%26aufirst%3DR.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DMueller%26aufirst%3DT.%26atitle%3DSynthesis%2520of%25204-%25288-benzo%255B1%252C2%252C5%255Doxadiazol-5-yl-%255B1%252C7%255Dnaphthyridine-6-yl%2529-benzoic%2520acid%253A%2520a%2520potent%2520and%2520selective%2520phosphodiesterase%2520type%25204D%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26issue%3D2%26spage%3D233%26epage%3D235%26doi%3D10.1016%2FS0960-894X%2801%2900720-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. A.</span>; <span class="NLM_string-name">Yadav, A.</span>; <span class="NLM_string-name">Banfield, S. C.</span>; <span class="NLM_string-name">Barden, C. J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Amino Substituted Biaryl Compounds as Anti-Amyloid Agents</span>. <span class="NLM_patent">WO2012119035A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+A.+Reed&author=A.+Yadav&author=S.+C.+Banfield&author=C.+J.+Barden&title=Preparation+of+Amino+Substituted+Biaryl+Compounds+as+Anti-Amyloid+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DReed%26aufirst%3DM.%2BA.%26atitle%3DPreparation%2520of%2520Amino%2520Substituted%2520Biaryl%2520Compounds%2520as%2520Anti-Amyloid%2520Agents%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. A.</span>; <span class="NLM_string-name">Wood, T. K.</span>; <span class="NLM_string-name">Banfield, S. C.</span>; <span class="NLM_string-name">Barden, C. J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Benzo[c][1,2,5]oxadiazoles as Therapeutic Anti-Amyloid Compounds</span>. <span class="NLM_patent">WO2014031873A2</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=M.+A.+Reed&author=T.+K.+Wood&author=S.+C.+Banfield&author=C.+J.+Barden&title=Preparation+of+Benzo%5Bc%5D%5B1%2C2%2C5%5Doxadiazoles+as+Therapeutic+Anti-Amyloid+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DReed%26aufirst%3DM.%2BA.%26atitle%3DPreparation%2520of%2520Benzo%255Bc%255D%255B1%252C2%252C5%255Doxadiazoles%2520as%2520Therapeutic%2520Anti-Amyloid%2520Compounds%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. A.</span>; <span class="NLM_string-name">Wood, T. K.</span>; <span class="NLM_string-name">Banfield, S. C.</span>; <span class="NLM_string-name">Barden, C. J.</span>; <span class="NLM_string-name">Yadav, A.</span>; <span class="NLM_string-name">Lu, E.</span>; <span class="NLM_string-name">Wu, F.</span></span> <span> </span><span class="NLM_article-title">Preparation of Anti-Amyloid Compounds Containing Benzofurazan</span>. <span class="NLM_patent">WO2015131021A2</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=M.+A.+Reed&author=T.+K.+Wood&author=S.+C.+Banfield&author=C.+J.+Barden&author=A.+Yadav&author=E.+Lu&author=F.+Wu&title=Preparation+of+Anti-Amyloid+Compounds+Containing+Benzofurazan"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DReed%26aufirst%3DM.%2BA.%26atitle%3DPreparation%2520of%2520Anti-Amyloid%2520Compounds%2520Containing%2520Benzofurazan%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deghati, P. Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den
Nieuwendijk, A. M. C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dissen-de
Groote, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span> <span> </span><span class="NLM_article-title">Inhibition of nucleoside transport By new analogues of nitrobenzylthioinosine</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">899</span>â <span class="NLM_lpage">908</span>, <span class="refDoi">Â DOI: 10.1016/S0968-0896(02)00544-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2FS0968-0896%2802%2900544-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=12614875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsVCit7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=899-908&issue=6&author=P.+Y.+F.+Deghatiauthor=A.+Borghiniauthor=A.+M.+C.+H.+van+den%0ANieuwendijkauthor=M.+Dissen-de%0AGrooteauthor=A.+P.+Ijzerman&title=Inhibition+of+nucleoside+transport+By+new+analogues+of+nitrobenzylthioinosine&doi=10.1016%2FS0968-0896%2802%2900544-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of nucleoside transport By new analogues of nitrobenzylthioinosine</span></div><div class="casAuthors">Deghati, Paymaneh Y. F.; Borghini, Alice; Van Den Nieuwendijk, Adrianus M. C. H.; Dissen-de Groote, Miriam; IJzerman, Adriaan P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">899-908</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Nitrobenzylthioinosine (NBTI, 1) was systematically modified by attachment of substituents at positions C6 and N9, and also by substitution of N1 with C.  These modifications were chosen to reduce the polarity of the new compds.  Incorporation of the nitro functionality into a benzoxadiazole ring system was considered first.  These new nucleosides showed high affinity (1.5-10 nM) towards the nucleoside transport protein as present on human erythrocyte ghosts.  Next, modification of this benzoxadiazole ring system with C, S and O in different positions produced a no. of less polar nucleosides with affinity in the higher nanomolar range.  Modification of N9 was achieved with different alkyl and alc. substituents.  An Bu substituent proved best, although all variations yielded substantial decreases in affinity.  Replacement of N1 by a carbon atom in combination with a 2-Cl substituent also resulted in a relatively potent NBTI deriv. (47 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQDsRshjYiDLVg90H21EOLACvtfcHk0ljIOtx2Q05bog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsVCit7g%253D&md5=f1995328390d4f593b8fddfb682bfc44</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2802%2900544-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252802%252900544-8%26sid%3Dliteratum%253Aachs%26aulast%3DDeghati%26aufirst%3DP.%2BY.%2BF.%26aulast%3DBorghini%26aufirst%3DA.%26aulast%3Dvan%2Bden%2BNieuwendijk%26aufirst%3DA.%2BM.%2BC.%2BH.%26aulast%3DDissen-de%2BGroote%26aufirst%3DM.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26atitle%3DInhibition%2520of%2520nucleoside%2520transport%2520By%2520new%2520analogues%2520of%2520nitrobenzylthioinosine%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26issue%3D6%26spage%3D899%26epage%3D908%26doi%3D10.1016%2FS0968-0896%2802%2900544-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puetz, C.</span>; <span class="NLM_string-name">Sundermann, B.</span>; <span class="NLM_string-name">Sundermann, C.</span>; <span class="NLM_string-name">Ijzermann, A. P.</span>; <span class="NLM_string-name">Tromp, R.</span>; <span class="NLM_string-name">Von Frijtag, D. K. J.</span></span> <span> </span><span class="NLM_article-title">Preparation of analogs of nitrobenzylthioinosine for the treatment of pain, epilepsy, and other CNS-related disorders</span>. <span class="NLM_patent">EP1352910A1</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=C.+Puetz&author=B.+Sundermann&author=C.+Sundermann&author=A.+P.+Ijzermann&author=R.+Tromp&author=D.+K.+J.+Von+Frijtag&title=Preparation+of+analogs+of+nitrobenzylthioinosine+for+the+treatment+of+pain%2C+epilepsy%2C+and+other+CNS-related+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPuetz%26aufirst%3DC.%26atitle%3DPreparation%2520of%2520analogs%2520of%2520nitrobenzylthioinosine%2520for%2520the%2520treatment%2520of%2520pain%252C%2520epilepsy%252C%2520and%2520other%2520CNS-related%2520disorders%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obreque-Balboa, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konig, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschauer, A.</span></span> <span> </span><span class="NLM_article-title">Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">124</span>â <span class="NLM_lpage">133</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2015.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.ejmech.2015.12.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=26774038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtl2lsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2016&pages=124-133&author=J.+E.+Obreque-Balboaauthor=Q.+Sunauthor=G.+Bernhardtauthor=B.+Konigauthor=A.+Buschauer&title=Flavonoid+derivatives+as+selective+ABCC1+modulators%3A+Synthesis+and+functional+characterization&doi=10.1016%2Fj.ejmech.2015.12.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization</span></div><div class="casAuthors">Obreque-Balboa, Jose Esteban; Sun, Qiu; Bernhardt, Guenther; Koenig, Burkhard; Buschauer, Armin</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">124-133</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of chromones, bearing substituted amino groups or N-substituted carboxamide moieties in position 2, was synthesized and characterized in cellular assays for modulation of the ABC transporters ABCC1 (MDCKII-MRP1 cells), ABCB1 (Kb-V1 cells) and ABCG2 (MCF-7/Topo cells).  The most potent ABCC1 modulators identified among these flavonoid-type compds. were comparable to the ref. compd. reversan regarding potency, but superior in terms of selectivity concerning ABCB1 and ABCG2 (2-[4-(Benzo[c][1,2,5]oxadiazol-5-ylmethyl)piperazin-1-yl]-5,7-dimethoxy-4H-chromen-4-one: ABCC1, IC50 11.3 Î¼M; inactive at ABCB1 and ABCG2).  This compd. was as effective as reversan in reverting ABCC1-mediated resistance to cytostatics in MDCKII-MRP1 cells and proved to be stable in mouse plasma and cell culture medium.  Modulators, such 2-[4-(Benzo[c][1,2,5]oxadiazol-5-ylmethyl)piperazin-1-yl]-5,7-dimethoxy-4H-chromen-4-one, were of potential value as pharmacol. tools for the investigation of the (patho)physiol. role of ABCC1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNn-hQZ2-o97Vg90H21EOLACvtfcHk0ljIOtx2Q05bog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtl2lsr4%253D&md5=1df454328811e6a9d1f0c50a0da22873</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DObreque-Balboa%26aufirst%3DJ.%2BE.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DBernhardt%26aufirst%3DG.%26aulast%3DKonig%26aufirst%3DB.%26aulast%3DBuschauer%26aufirst%3DA.%26atitle%3DFlavonoid%2520derivatives%2520as%2520selective%2520ABCC1%2520modulators%253A%2520Synthesis%2520and%2520functional%2520characterization%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D109%26spage%3D124%26epage%3D133%26doi%3D10.1016%2Fj.ejmech.2015.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lolli, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnovale, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippione, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahlgren, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zonari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallicchio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boscaro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friemann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolando, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagnati, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adinolfi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliaro-Bosso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boschi, D.</span></span> <span> </span><span class="NLM_article-title">Bioisosteres of Indomethacin as Inhibitors of aldo-keto reductase 1C3</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">437</span>â <span class="NLM_lpage">443</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.8b00484</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00484" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFGqtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=437-443&issue=4&author=M.+L.+Lolliauthor=I.+M.+Carnovaleauthor=A.+C.+Pippioneauthor=W.+Y.+Wahlgrenauthor=D.+Bonanniauthor=E.+Mariniauthor=D.+Zonariauthor=M.+Gallicchioauthor=V.+Boscaroauthor=P.+Goyalauthor=R.+Friemannauthor=B.+Rolandoauthor=R.+Bagnatiauthor=S.+Adinolfiauthor=S.+Oliaro-Bossoauthor=D.+Boschi&title=Bioisosteres+of+Indomethacin+as+Inhibitors+of+aldo-keto+reductase+1C3&doi=10.1021%2Facsmedchemlett.8b00484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3</span></div><div class="casAuthors">Lolli, Marco L.; Carnovale, Irene M.; Pippione, Agnese C.; Wahlgren, Weixiao Y.; Bonanni, Davide; Marini, Elisabetta; Zonari, Daniele; Gallicchio, Margherita; Boscaro, Valentina; Goyal, Parveen; Friemann, Rosmarie; Rolando, Barbara; Bagnati, Renzo; Adinolfi, Salvatore; Oliaro-Bosso, Simonetta; Boschi, Donatella</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">437-443</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aldo-keto reductase 1C3 (AKR1C3) is an attractive target in drug design for its role in resistance to anticancer therapy.  Several nonsteroidal anti-inflammatory drugs such as indomethacin are known to inhibit AKR1C3 in a nonselective manner because of COX-off target effects.  Here we designed two indomethacin analogs by proposing a bioisosteric connection between the indomethacin carboxylic acid function and either hydroxyfurazan or hydroxy triazole rings.  Both compds. were found to target AKR1C3 in a selective manner.  In particular, hydroxyfurazan deriv. is highly selective for AKR1C3 over the 1C2 isoform (up to 90-times more) and inactive on COX enzymes.  High-resoln. crystal structure of its complex with AKR1C3 shed light onto the binding mode of the new inhibitors.  In cell-based assays (on colorectal and prostate cancer cells), the two indomethacin analogs showed higher potency than indomethacin.  Therefore, these two AKR1C3 inhibitors can be used to provide further insight into the role of AKR1C3 in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpcSn7kYi0LrVg90H21EOLACvtfcHk0ljIOtx2Q05bog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFGqtbY%253D&md5=3330d486e9a28b9ebf0eebb14ae7bb04</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00484%26sid%3Dliteratum%253Aachs%26aulast%3DLolli%26aufirst%3DM.%2BL.%26aulast%3DCarnovale%26aufirst%3DI.%2BM.%26aulast%3DPippione%26aufirst%3DA.%2BC.%26aulast%3DWahlgren%26aufirst%3DW.%2BY.%26aulast%3DBonanni%26aufirst%3DD.%26aulast%3DMarini%26aufirst%3DE.%26aulast%3DZonari%26aufirst%3DD.%26aulast%3DGallicchio%26aufirst%3DM.%26aulast%3DBoscaro%26aufirst%3DV.%26aulast%3DGoyal%26aufirst%3DP.%26aulast%3DFriemann%26aufirst%3DR.%26aulast%3DRolando%26aufirst%3DB.%26aulast%3DBagnati%26aufirst%3DR.%26aulast%3DAdinolfi%26aufirst%3DS.%26aulast%3DOliaro-Bosso%26aufirst%3DS.%26aulast%3DBoschi%26aufirst%3DD.%26atitle%3DBioisosteres%2520of%2520Indomethacin%2520as%2520Inhibitors%2520of%2520aldo-keto%2520reductase%25201C3%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D4%26spage%3D437%26epage%3D443%26doi%3D10.1021%2Facsmedchemlett.8b00484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lolli, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickering, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolando, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contreras-Sanz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruttero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, T. N.</span></span> <span> </span><span class="NLM_article-title">4-Hydroxy-1,2,5-oxadiazol-3-yl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and molecular pharmacological characterization at ionotropic glutamate receptors of compounds related to glutamate and its homologues</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4110</span>â <span class="NLM_lpage">4118</span>, <span class="refDoi">Â DOI: 10.1021/jm1001452</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1001452" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVylsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4110-4118&issue=10&author=M.+L.+Lolliauthor=C.+Giordanoauthor=D.+S.+Pickeringauthor=B.+Rolandoauthor=K.+B.+Hansenauthor=A.+Fotiauthor=A.+Contreras-Sanzauthor=A.+Amirauthor=R.+Frutteroauthor=A.+Gascoauthor=B.+Nielsenauthor=T.+N.+Johansen&title=4-Hydroxy-1%2C2%2C5-oxadiazol-3-yl+moiety+as+bioisoster+of+the+carboxy+function.+Synthesis%2C+ionization+constants%2C+and+molecular+pharmacological+characterization+at+ionotropic+glutamate+receptors+of+compounds+related+to+glutamate+and+its+homologues&doi=10.1021%2Fjm1001452"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">4-Hydroxy-1,2,5-oxadiazol-3-yl moiety as bioisostere of the carboxy function. synthesis, ionization constants, and molecular pharmacological characterization at ionotropic glutamate receptors of compounds related to glutamate and its homologues</span></div><div class="casAuthors">Lolli, Marco L.; Giordano, Cecilia; Pickering, Darryl S.; Rolando, Barbara; Hansen, Kasper B.; Foti, Antonio; Contreras-Sanz, Alberto; Amir, Ahmad; Fruttero, Roberta; Gasco, Alberto; Nielsen, Birgitte; Johansen, Tommy N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4110-4118</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to investigate the 4-hydroxy-1,2,5-oxadiazol-3-yl moiety as a carboxylic acid bioisostere at ionotropic glutamate receptors (iGluRs), a series of acidic Î±-aminocarboxylic acids in which the distal carboxy group was replaced by the 4-hydroxy-1,2,5-oxadiazol-3-yl group was synthesized.  Ionization consts. were detd.  All target compds., except the Asp analog I, were resolved using chiral HPLC.  Whereas I showed good affinity exclusively at NMDA receptors, the Glu analog, (+)-II, was an unselective, though potent AMPA receptor preferring agonist (EC50 = 10 Î¼M at iGluR2) showing only low stereoselectivity.  The two higher Glu homologues, (+)-III and (+)-IV, turned out to be weak agonists at iGluR2 as well as weak antagonists at NR1/NR2A, whereas the corresponding (-)-isomers were selective NR1/NR2A antagonists with somewhat higher potency.  The results proved the 4-hydroxy-1,2,5-oxadiazol-3-yl moiety to be a useful bioisoster at all three classes of iGluRs, capable of being integrated into agonists as well as antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGratZ1tCLQqyLVg90H21EOLACvtfcHk0lhT1phC6VY6_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVylsrc%253D&md5=dd535ad1a6768b1ae4f7b458c92b86eb</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm1001452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1001452%26sid%3Dliteratum%253Aachs%26aulast%3DLolli%26aufirst%3DM.%2BL.%26aulast%3DGiordano%26aufirst%3DC.%26aulast%3DPickering%26aufirst%3DD.%2BS.%26aulast%3DRolando%26aufirst%3DB.%26aulast%3DHansen%26aufirst%3DK.%2BB.%26aulast%3DFoti%26aufirst%3DA.%26aulast%3DContreras-Sanz%26aufirst%3DA.%26aulast%3DAmir%26aufirst%3DA.%26aulast%3DFruttero%26aufirst%3DR.%26aulast%3DGasco%26aufirst%3DA.%26aulast%3DNielsen%26aufirst%3DB.%26aulast%3DJohansen%26aufirst%3DT.%2BN.%26atitle%3D4-Hydroxy-1%252C2%252C5-oxadiazol-3-yl%2520moiety%2520as%2520bioisoster%2520of%2520the%2520carboxy%2520function.%2520Synthesis%252C%2520ionization%2520constants%252C%2520and%2520molecular%2520pharmacological%2520characterization%2520at%2520ionotropic%2520glutamate%2520receptors%2520of%2520compounds%2520related%2520to%2520glutamate%2520and%2520its%2520homologues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D10%26spage%3D4110%26epage%3D4118%26doi%3D10.1021%2Fjm1001452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lolli, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruttero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasco, A.</span></span> <span> </span><span class="NLM_article-title">New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">102</span>â <span class="NLM_lpage">109</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2011.12.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.ejmech.2011.12.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=22245049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFOku7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2012&pages=102-109&author=M.+L.+Lolliauthor=M.+Giorgisauthor=P.+Toscoauthor=A.+Fotiauthor=R.+Frutteroauthor=A.+Gasco&title=New+inhibitors+of+dihydroorotate+dehydrogenase+%28DHODH%29+based+on+the+4-hydroxy-1%2C2%2C5-oxadiazol-3-yl+%28hydroxyfurazanyl%29+scaffold&doi=10.1016%2Fj.ejmech.2011.12.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold</span></div><div class="casAuthors">Lolli, Marco L.; Giorgis, Marta; Tosco, Paolo; Foti, Antonio; Fruttero, Roberta; Gasco, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">102-109</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Based on some structural analogies with leflunomide and brequinar, two well-known inhibitors of dihydroorotate dehydrogenase (DHODH), a new series of products was designed, by joining the substituted biphenyl moiety to the 4-hydroxy-1,2,5-oxadiazol-3-yl scaffold through an amide bridge.  The compds. were studied for their DHODH inhibitory activity on rat liver mitochondrial/microsomal membranes.  The activity was closely dependent on the substitution pattern at the biphenyl system; the most potent products were those bearing two or four fluorine atoms at the Ph adjacent to the oxadiazole ring.  A mol. modeling study suggested that these structures might have a brequinar-like binding mode.  The greater potency of fluorinated analogs may depend partly on enhanced interactions with the hydrophobic ubiquinone channel, and partly on the role of fluorine in stabilizing the putative bioactive conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJwFl25fJzKbVg90H21EOLACvtfcHk0lhT1phC6VY6_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFOku7k%253D&md5=432980015b448f67cd065aab7762bcf9</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.12.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.12.038%26sid%3Dliteratum%253Aachs%26aulast%3DLolli%26aufirst%3DM.%2BL.%26aulast%3DGiorgis%26aufirst%3DM.%26aulast%3DTosco%26aufirst%3DP.%26aulast%3DFoti%26aufirst%3DA.%26aulast%3DFruttero%26aufirst%3DR.%26aulast%3DGasco%26aufirst%3DA.%26atitle%3DNew%2520inhibitors%2520of%2520dihydroorotate%2520dehydrogenase%2520%2528DHODH%2529%2520based%2520on%2520the%25204-hydroxy-1%252C2%252C5-oxadiazol-3-yl%2520%2528hydroxyfurazanyl%2529%2520scaffold%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D49%26spage%3D102%26epage%3D109%26doi%3D10.1016%2Fj.ejmech.2011.12.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lolli, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolando, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellendorph, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristiansen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruttero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, T. N.</span></span> <span> </span><span class="NLM_article-title">Hydroxy-1,2,5-oxadiazolyl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and pharmacological characterization of Î³-aminobutyric acid (GABA) related compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">4442</span>â <span class="NLM_lpage">4446</span>, <span class="refDoi">Â DOI: 10.1021/jm051288b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm051288b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtVSiur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4442-4446&issue=14&author=M.+L.+Lolliauthor=S.+L.+Hansenauthor=B.+Rolandoauthor=B.+Nielsenauthor=P.+Wellendorphauthor=K.+Madsenauthor=O.+M.+Larsenauthor=U.+Kristiansenauthor=R.+Frutteroauthor=A.+Gascoauthor=T.+N.+Johansen&title=Hydroxy-1%2C2%2C5-oxadiazolyl+moiety+as+bioisoster+of+the+carboxy+function.+Synthesis%2C+ionization+constants%2C+and+pharmacological+characterization+of+%CE%B3-aminobutyric+acid+%28GABA%29+related+compounds&doi=10.1021%2Fjm051288b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Hydroxy-1,2,5-oxadiazolyl Moiety as Bioisostere of the Carboxy Function. Synthesis, Ionization Constants, and Pharmacological Characterization of Î³-Aminobutyric Acid (GABA) Related Compounds</span></div><div class="casAuthors">Lolli, Marco L.; Hansen, Suzanne L.; Rolando, Barbara; Nielsen, Birgitte; Wellendorph, Petrine; Madsen, Karsten; Larsen, Orla Miller; Kristiansen, Uffe; Fruttero, Roberta; Gasco, Alberto; Johansen, Tommy N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4442-4446</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Three 4-substituted 1,2,5-oxadiazol-3-ols contg. aminoalkyl substituents [analogs and homologs of Î³-aminobutyric acid (GABA)] were synthesized to investigate the hydroxy-1,2,5-oxadiazolyl moiety as a bioisostere for a carboxyl group at GABA receptors.  The pKa values of the target compds. were close to those of GABA.  At GABAA receptors of cultured cerebral cortical neurons, weak agonist and partial agonist profiles were identified, demonstrating the 4-hydroxy-1,2,5-oxadiazol-3-yl unit to be a nonclassical carboxyl group bioisostere.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1prWkxn0b97Vg90H21EOLACvtfcHk0lhT1phC6VY6_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtVSiur8%253D&md5=084e3ba5592c9cad99902f2291928ce7</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm051288b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051288b%26sid%3Dliteratum%253Aachs%26aulast%3DLolli%26aufirst%3DM.%2BL.%26aulast%3DHansen%26aufirst%3DS.%2BL.%26aulast%3DRolando%26aufirst%3DB.%26aulast%3DNielsen%26aufirst%3DB.%26aulast%3DWellendorph%26aufirst%3DP.%26aulast%3DMadsen%26aufirst%3DK.%26aulast%3DLarsen%26aufirst%3DO.%2BM.%26aulast%3DKristiansen%26aufirst%3DU.%26aulast%3DFruttero%26aufirst%3DR.%26aulast%3DGasco%26aufirst%3DA.%26aulast%3DJohansen%26aufirst%3DT.%2BN.%26atitle%3DHydroxy-1%252C2%252C5-oxadiazolyl%2520moiety%2520as%2520bioisoster%2520of%2520the%2520carboxy%2520function.%2520Synthesis%252C%2520ionization%2520constants%252C%2520and%2520pharmacological%2520characterization%2520of%2520%25CE%25B3-aminobutyric%2520acid%2520%2528GABA%2529%2520related%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D14%26spage%3D4442%26epage%3D4446%26doi%3D10.1021%2Fjm051288b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tosco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lolli, M. L.</span></span> <span> </span><span class="NLM_article-title">Hydroxy-1,2,5-oxadiazolyl moiety as bioisoster of the carboxy function. A computational study on gamma-aminobutyric acid (GABA) related compounds</span>. <i>J. Mol. Model.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">279</span>â <span class="NLM_lpage">291</span>, <span class="refDoi">Â DOI: 10.1007/s00894-008-0269-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1007%2Fs00894-008-0269-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=18247067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVKnsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=279-291&issue=4&author=P.+Toscoauthor=M.+L.+Lolli&title=Hydroxy-1%2C2%2C5-oxadiazolyl+moiety+as+bioisoster+of+the+carboxy+function.+A+computational+study+on+gamma-aminobutyric+acid+%28GABA%29+related+compounds&doi=10.1007%2Fs00894-008-0269-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Hydroxy-1,2,5-oxadiazolyl moiety as bioisoster of the carboxy function. A computational study on Î³-aminobutyric acid (GABA) related compounds</span></div><div class="casAuthors">Tosco, Paolo; Lolli, Marco L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">279-291</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Recently, our research group has proposed the hydroxyfurazanyl (4-hydroxy-1,2,5-oxadiazole-3-yl) moiety as a new non-classical isoster of the carboxy function in the design of Î³-aminobutyric acid (GABA) analogs.  Some compds. showed significant activity at the GABAA receptor, representing the only examples of pentat. heterocycles bearing an Ï-aminoalkyl flexible side chain in the position vicinal to the hydroxy group displaying agonist activity at this receptor subtype.  In this work, an ab initio anal. of the structural and electronic features of furazan-3-ol is presented, in order to provide a theor. basis to the claimed bioisosterism with the carboxy function.  An ab initio conformational study with the C-PCM implicit solvent model was carried out to elucidate the reasons of the peculiar behavior of the furazan models.  Alongside, another conformational search through mol. dynamics in explicit solvent was accomplished, in order to validate the first method.  The electronic features of the 4-hydroxy-1,2,5-oxadiazole-3-yl substructure seem to account for a marked stabilizing effect of the putative bioactive conformation at the GABAA receptor subtype.  The 1,2,5-thiadiazole analog, which shares the same conformational preference of its oxygenated counterpart, was identified as a potential candidate for synthesis and pharmacol. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp91AgVEICm4bVg90H21EOLACvtfcHk0lhLwQHaIjCDoA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVKnsLY%253D&md5=1e88ae5747c187d648fdf30fcf9a5c3e</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2Fs00894-008-0269-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-008-0269-0%26sid%3Dliteratum%253Aachs%26aulast%3DTosco%26aufirst%3DP.%26aulast%3DLolli%26aufirst%3DM.%2BL.%26atitle%3DHydroxy-1%252C2%252C5-oxadiazolyl%2520moiety%2520as%2520bioisoster%2520of%2520the%2520carboxy%2520function.%2520A%2520computational%2520study%2520on%2520gamma-aminobutyric%2520acid%2520%2528GABA%2529%2520related%2520compounds%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2008%26volume%3D14%26issue%3D4%26spage%3D279%26epage%3D291%26doi%3D10.1007%2Fs00894-008-0269-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Penning, T. M.</span></span> <span> </span><span class="NLM_article-title">Aldo-keto reductase (AKR) 1C3 inhibitors: A patent review</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1329</span>â <span class="NLM_lpage">1340</span>, <span class="refDoi">Â DOI: 10.1080/13543776.2017.1379503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1080%2F13543776.2017.1379503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28895472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFeqtrrJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1329-1340&issue=12&author=T.+M.+Penning&title=Aldo-keto+reductase+%28AKR%29+1C3+inhibitors%3A+A+patent+review&doi=10.1080%2F13543776.2017.1379503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review</span></div><div class="casAuthors">Penning, Trevor M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1329-1340</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : AKR1C3 is a drug target in hormonal and hormonal independent malignancies and acts as a major peripheral 17Î²-hydroxysteroid dehydrogenase to yield the potent androgens testosterone and dihydrotestosterone, and as a prostaglandin (PG) F synthase to produce proliferative ligands for the PG FP receptor.  AKR1C3 inhibitors may have distinct advantages over existing therapeutics for the treatment of castration resistant prostate cancer, breast cancer and acute myeloid leukemia.  This article reviews the patent literature on AKR1C3 inhibitors using SciFinder which identified inhibitors in the following chem. classes: N-phenylsulfonyl-indoles, N-(benzimidazoylylcarbonyl)- N-(indoylylcarbonyl)- and N-(pyridinepyrrolyl)- piperidines, N-benzimidazoles and N-benzindoles, repurposed nonsteroidal antiinflammatory drugs (indole acetic acids, N-phenylanthranilates and aryl propionic acids), isoquinolines, and nitrogen and sulfur substituted estrenes.  The article evaluates inhibitor AKR potency, specificity, efficacy in cell-based and xenograft models and clin. utility.  The advantage of bifunctional compds. that either competitively inhibit AKR1C3 and block its androgen receptor (AR) coactivator function or act as AKR1C3 inhibitors and direct acting AR antagonists are discussed.  A large no. of potent and selective inhibitors of AKR1C3 have been described however, preclin. optimization, is required before their benefit in human disease can be assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6TZPHO5l5PrVg90H21EOLACvtfcHk0lhLwQHaIjCDoA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFeqtrrJ&md5=20a6c3d7c1766c2610e8bcf53af346cf</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1379503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1379503%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BM.%26atitle%3DAldo-keto%2520reductase%2520%2528AKR%2529%25201C3%2520inhibitors%253A%2520A%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26issue%3D12%26spage%3D1329%26epage%3D1340%26doi%3D10.1080%2F13543776.2017.1379503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karunasinghe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, L. R.</span></span> <span> </span><span class="NLM_article-title">Influence of Aldo-keto reductase 1C3 in prostate cancerâa mini review</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">603</span>â <span class="NLM_lpage">616</span>, <span class="refDoi">Â DOI: 10.2174/1568009617666170330115722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.2174%2F1568009617666170330115722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28359237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlelsLrJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=603-616&issue=7&author=N.+Karunasingheauthor=J.+Mastersauthor=J.+U.+Flanaganauthor=L.+R.+Ferguson&title=Influence+of+Aldo-keto+reductase+1C3+in+prostate+cancer%E2%80%94a+mini+review&doi=10.2174%2F1568009617666170330115722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of Aldo-keto Reductas1e 1C3 in Prostate Cancer - A Mini Review</span></div><div class="casAuthors">Karunasinghe, Nishi; Masters, Jonathan; Flanagan, Jack U.; Ferguson, Lynnette R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">603-616</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: Aldo-keto reductase 1C3 (AKR1C3) is an important oxidoreductase with multiple substrates, that are involved in producing extra-testicular androgens.  Its activity is influenced by environmental exposures, as well as by genetic variants.  These genetic variants could therefore produce variable testosterone levels and subsequent androgen receptor (AR) activation.  This could lead to differential downstream prodn. of the prostate-specific antigen (PSA).  As PSA level is used for clin. evaluation of the prostate, these variations could impact prostate cancer (PC) diagnosis, as well as PC management outcomes.  This review brings together information with regards to key functions of this enzyme, its relevance in PC, its transcriptional regulation, clin. aspects assocd. with genetics, differential regulation in cancer and cancer progression, and the types of AKR1C3 inhibitors with future therapeutic value. <P></P> Conclusion: Based on these discussions, hypotheses are forwarded for future applicability of this enzyme and its genetic variants in transformational medical practices in PC.  Options for the use of personalised AKR1C3 inhibitor drugs for late stage PC are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptxSVT8QVctLVg90H21EOLACvtfcHk0lhLwQHaIjCDoA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlelsLrJ&md5=41f427a8e98369f41512cdbeafbd4756</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2174%2F1568009617666170330115722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009617666170330115722%26sid%3Dliteratum%253Aachs%26aulast%3DKarunasinghe%26aufirst%3DN.%26aulast%3DMasters%26aufirst%3DJ.%26aulast%3DFlanagan%26aufirst%3DJ.%2BU.%26aulast%3DFerguson%26aufirst%3DL.%2BR.%26atitle%3DInfluence%2520of%2520Aldo-keto%2520reductase%25201C3%2520in%2520prostate%2520cancer%25E2%2580%2594a%2520mini%2520review%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2017%26volume%3D17%26issue%3D7%26spage%3D603%26epage%3D616%26doi%3D10.2174%2F1568009617666170330115722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kassab, S. E.</span></span> <span> </span><span class="NLM_article-title">Indomethacin from Anti-Inflammatory to Anticancer Agent</span>. <span class="NLM_contrib-group"><span class="NLM_string-name">Vaskova, J.</span>; <span class="NLM_string-name">Vasko, L.</span></span>; Eds.;  <i>Medicinal Chemistry</i>; <span class="NLM_publisher-name">IntechOpen Ltd.</span>: <span class="NLM_publisher-loc">London</span>, <span class="NLM_year">2019</span>, pp  <span class="NLM_fpage">45</span>â <span class="NLM_lpage">62</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.5772%2Fintechopen.79677" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=45-62&author=S.+E.+Kassabauthor=J.+Vaskova&author=L.+Vasko&title=Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.5772%2Fintechopen.79677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.5772%252Fintechopen.79677%26sid%3Dliteratum%253Aachs%26aulast%3DKassab%26aufirst%3DS.%2BE.%26atitle%3DIndomethacin%2520from%2520Anti-Inflammatory%2520to%2520Anticancer%2520Agent%26aulast%3DVaskova%26aufirst%3DJ.%26btitle%3DMedicinal%2520Chemistry%26pub%3DIntechOpen%2520Ltd%26date%3D2019%26spage%3D45%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leban, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeb, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgartner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel series of DHODH inhibitors by a docking procedure and QSAR refinement</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">55</span>â <span class="NLM_lpage">58</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2003.10.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmcl.2003.10.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=14684297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvVWntrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=55-58&issue=1&author=J.+Lebanauthor=W.+Saebauthor=G.+Garciaauthor=R.+Baumgartnerauthor=B.+Kramer&title=Discovery+of+a+novel+series+of+DHODH+inhibitors+by+a+docking+procedure+and+QSAR+refinement&doi=10.1016%2Fj.bmcl.2003.10.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel series of DHODH inhibitors by a docking procedure and QSAR refinement</span></div><div class="casAuthors">Leban, Johann; Saeb, Wael; Garcia, Gabriel; Baumgartner, Roland; Kramer, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-58</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A novel series of DHODH (dihydroorotate dehydrogenase) inhibitors was developed based on a lead which was obtained by a docking procedure and a medicinal chem. exploration.  The activity of the initial lead was improved by a QSAR method to yield low nanomolar inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqLL9ci_uixbVg90H21EOLACvtfcHk0li8LDXInFpegA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvVWntrk%253D&md5=74505a2e92654bf830a9376e4d2fa127</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.10.021%26sid%3Dliteratum%253Aachs%26aulast%3DLeban%26aufirst%3DJ.%26aulast%3DSaeb%26aufirst%3DW.%26aulast%3DGarcia%26aufirst%3DG.%26aulast%3DBaumgartner%26aufirst%3DR.%26aulast%3DKramer%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520series%2520of%2520DHODH%2520inhibitors%2520by%2520a%2520docking%2520procedure%2520and%2520QSAR%2520refinement%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26issue%3D1%26spage%3D55%26epage%3D58%26doi%3D10.1016%2Fj.bmcl.2003.10.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knecht, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loffler, M.</span></span> <span> </span><span class="NLM_article-title">Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1259</span>â <span class="NLM_lpage">1264</span>, <span class="refDoi">Â DOI: 10.1016/S0006-2952(98)00145-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2FS0006-2952%2898%2900145-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=9802339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK1cXnt1OhtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1998&pages=1259-1264&issue=9&author=W.+Knechtauthor=M.+Loffler&title=Species-related+inhibition+of+human+and+rat+dihydroorotate+dehydrogenase+by+immunosuppressive+isoxazol+and+cinchoninic+acid+derivatives&doi=10.1016%2FS0006-2952%2898%2900145-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives</span></div><div class="casAuthors">Knecht, Wolfgang; Loffler, Monika</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1259-1264</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The isoxazol leflunomide (N-(4-trifluoromethylphenyl)-5-methylisoxazol-4-carboxamide) and its active metabolite A77-1726 (N-(4-trifluoromethyl)-phenyl-2-cyano-3-hydroxy-crotonic acidamide) are promising disease-modifying antirheumatic drugs now in clin. trials.  The malononitrilamides MNA279 (2-cyano-3-cyclopropyl-3-oxo-(4-cyanophenyl)propionamide) MNA715 (N-(4-trifluoromethyl)-phenyl-2-cyano-3-hydroxy-hept-2-en-6-in-carboxylic acidamide) and HR325 (1(3-methyl-4-trifluoromethylphenyl-carbamoyl)-2-cyclopropyl-2-oxo-propionitrile) were shown to block rejection after allograft and xenograft transplantation in animals.  Brequinar and other cinchoninic acid derivs. have also been evaluated as immunosuppressive agents.  A77-1726, HR325 and brequinar have been shown to have strong inhibitory effects on mitochondrial dihydroorotate dehydrogenase [E.C. 1.3.99.11], the fourth enzyme of pyrimidine de novo synthesis, with concomitant redn. of pyrimidine nucleotide pools.  Pyrimidine nucleotides are essential for normal immune cell functions.  Because most investigations had been carried out with cells, cell homogenates or mitochondrial fractions, it was the rationale of the present study to differentiate, under standardized conditions, the effect of leflunomide, A77-1726, MNA279, MNA715, HR 325 and brequinar on the recombinant rat and human enzymes, which were purified in our lab.  Whereas leflunomide was a relatively weak inhibitor of the rat (IC50 = 6.3 Î¼M) and human (IC50 = 98 Î¼M) dihydroorotate dehydrogenase, the influence of A77-1726, MNA 279, MNA715 and HR325 was of comparable efficacy for either the rat (range of IC50, 19-53 nM) or the human enzyme (range of IC50, 0.5-2.3 Î¼M).  From the IC50 values, it was deduced that brequinar was a more potent inhibitor of the human dihydroorotate dehydrogenase activity (IC50 = 10 nM) than of the rat enzyme (IC50 = 367 nM).  The rat enzyme was influenced by all isoxazol derivs. to a greater extent (IC50 = 19 nM A77-1726) than the human enzyme (IC50 = 1.1 Î¼M A77-1726).  These results may provide a plausible explanation for the findings of other labs. with cultured cell lines and lymphocytes: in comparison to cells derived from human tissues, rat and other rodent cells were more susceptible to the isoxazol derivs. and less susceptible to brequinar.  Our detailed kinetic investigations of the bisubstrate reaction catalyzed by rat dihydroorotate dehydrogenase revealed a noncompetitive type of inhibition by A77-1726 with respect to the substrate dihydroorotate and the cosubstrates ubiquinone or decylubiquinone.  For brequinar, the inhibition was noncompetitive with respect to the substrate dihydroorotate, whereas with the quinone it was found to follow the "mixed typed" inhibition.  In addn., brequinar acted as a "slow-binding" inhibitor of the human dihydroorotate dehydrogenase, a feature that might be of consequence for the reversibility of the reaction with the target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9xUIPJ-l5JbVg90H21EOLACvtfcHk0li8LDXInFpegA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnt1OhtLs%253D&md5=a653d5605568239d80f9fc1b2b992e84</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2898%2900145-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252898%252900145-2%26sid%3Dliteratum%253Aachs%26aulast%3DKnecht%26aufirst%3DW.%26aulast%3DLoffler%26aufirst%3DM.%26atitle%3DSpecies-related%2520inhibition%2520of%2520human%2520and%2520rat%2520dihydroorotate%2520dehydrogenase%2520by%2520immunosuppressive%2520isoxazol%2520and%2520cinchoninic%2520acid%2520derivatives%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1998%26volume%3D56%26issue%3D9%26spage%3D1259%26epage%3D1264%26doi%3D10.1016%2FS0006-2952%2898%2900145-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orsetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorba, G.</span></span> <span> </span><span class="NLM_article-title">Characterization of an accessory binding area in the histamine H2 receptor</span>. <i>Eur. J. Pharmacol., Mol. Pharmacol. Sect.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>206</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">167</span>â <span class="NLM_lpage">173</span>, <span class="refDoi">Â DOI: 10.1016/S0922-4106(05)80015-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2FS0922-4106%2805%2980015-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK3MXkt1aqsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=206&publication_year=1991&pages=167-173&issue=3&author=M.+Orsettiauthor=G.+Sorba&title=Characterization+of+an+accessory+binding+area+in+the+histamine+H2+receptor&doi=10.1016%2FS0922-4106%2805%2980015-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of an accessory binding area in the histamine H2 receptor</span></div><div class="casAuthors">Orsetti, Marco; Sorba, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology, Molecular Pharmacology Section</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">206</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">167-73</span>CODEN:
                <span class="NLM_cas:coden">EJPPET</span>;
        ISSN:<span class="NLM_cas:issn">0922-4106</span>.
    </div><div class="casAbstract">The histamine H2 receptor-blocking activity of ranitidine and lamitidine analogs was investigated to gain information on the structure of the receptor area adjacent to the site fitted by the polar group.  The introduction of differently shaped alkyl moieties on the polar group is always accompanied by maintenance or by an increase of H2 receptor antagonism with respect to the starting lead compd. (KB on guinea-pig isolated atria ranging 49-1.5 nM).  The results seem to indicate the presence in the histamine H2 receptor of an area of a predominantly hydrophobic nature located at the boundary of the site fitted by the polar group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaM3rx5pdTIbVg90H21EOLACvtfcHk0li8LDXInFpegA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXkt1aqsrY%253D&md5=72e7c4a8a7a69851cb91da1e05fe8ebc</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0922-4106%2805%2980015-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0922-4106%252805%252980015-X%26sid%3Dliteratum%253Aachs%26aulast%3DOrsetti%26aufirst%3DM.%26aulast%3DSorba%26aufirst%3DG.%26atitle%3DCharacterization%2520of%2520an%2520accessory%2520binding%2520area%2520in%2520the%2520histamine%2520H2%2520receptor%26jtitle%3DEur.%2520J.%2520Pharmacol.%252C%2520Mol.%2520Pharmacol.%2520Sect.%26date%3D1991%26volume%3D206%26issue%3D3%26spage%3D167%26epage%3D173%26doi%3D10.1016%2FS0922-4106%2805%2980015-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorba, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruttero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Stilo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsetti, M.</span></span> <span> </span><span class="NLM_article-title">Potential histamine H2-Receptor antagonists: Synthesis and pharmacological activity of derivatives containing acylamino-furazan moieties</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>325</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">151</span>â <span class="NLM_lpage">155</span>, <span class="refDoi">Â DOI: 10.1002/ardp.19923250304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fardp.19923250304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1353669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK38XhvFChsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=325&publication_year=1992&pages=151-155&issue=3&author=G.+Sorbaauthor=R.+Frutteroauthor=A.+Di+Stiloauthor=A.+Gascoauthor=M.+Orsetti&title=Potential+histamine+H2-Receptor+antagonists%3A+Synthesis+and+pharmacological+activity+of+derivatives+containing+acylamino-furazan+moieties&doi=10.1002%2Fardp.19923250304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Potential histamine H2-receptor antagonists:  synthesis and pharmacological activity of derivatives containing (acylamino)furazan moieties</span></div><div class="casAuthors">Sorba, G.; Fruttero, R.; Di Stilo, A.; Gasco, A.; Orsetti, M.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">325</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">151-5</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    </div><div class="casAbstract">Analogs I [R = H, COR1, CH2R1; R1 = Me, Ph, C6H11, (CH2)2Ph; X = CO, CH2] of 3-amino-4[2-[(5-dimethylaminomethyl-2-furyl)methylthio]ethylamino]furazan have been synthesized and investigated for their H2-antagonist properties on the isolated guinea pig right atrium.  The presence of the carbonyl group lowers the activity in respect to the corresponding leads.  The decrease in activity is only by 1-2 orders of magnitude in the 3-acylaminofurazan series vs. inactivity in the 4-acylamino isomers and in the diacylated series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKT7nqN_h_tLVg90H21EOLACvtfcHk0lg4edoLeoYKhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhvFChsb4%253D&md5=16890fdb86fdf6ea78bba942e3526595</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1002%2Fardp.19923250304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.19923250304%26sid%3Dliteratum%253Aachs%26aulast%3DSorba%26aufirst%3DG.%26aulast%3DFruttero%26aufirst%3DR.%26aulast%3DDi%2BStilo%26aufirst%3DA.%26aulast%3DGasco%26aufirst%3DA.%26aulast%3DOrsetti%26aufirst%3DM.%26atitle%3DPotential%2520histamine%2520H2-Receptor%2520antagonists%253A%2520Synthesis%2520and%2520pharmacological%2520activity%2520of%2520derivatives%2520containing%2520acylamino-furazan%2520moieties%26jtitle%3DArch.%2520Pharm.%26date%3D1992%26volume%3D325%26issue%3D3%26spage%3D151%26epage%3D155%26doi%3D10.1002%2Fardp.19923250304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorba, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsetti, M.</span></span> <span> </span><span class="NLM_article-title">Potential histamine H2-receptor antagonists: Twin compounds containing diaminofurazan substructure</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>322</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">579</span>â <span class="NLM_lpage">580</span>, <span class="refDoi">Â DOI: 10.1002/ardp.19893220914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fardp.19893220914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=2575370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK3cXjsFOlug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=1989&pages=579-580&issue=9&author=G.+Sorbaauthor=A.+Gascoauthor=M.+Orsetti&title=Potential+histamine+H2-receptor+antagonists%3A+Twin+compounds+containing+diaminofurazan+substructure&doi=10.1002%2Fardp.19893220914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Potential histamine H2-receptor antagonists:  twin compounds containing diaminofurazan substructure</span></div><div class="casAuthors">Sorba, Giovanni; Gasco, Alberto; Orsetti, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">579-80</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    </div><div class="casAbstract">The title compds. I (n = 2, R = R4; n = 3, R = R2) were prepd.  I have antihistaminic activity, but are not competitive antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr50m03gJXunbVg90H21EOLACvtfcHk0lg4edoLeoYKhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXjsFOlug%253D%253D&md5=a16c420ce4acd51c8ed754b0f6bf1361</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1002%2Fardp.19893220914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.19893220914%26sid%3Dliteratum%253Aachs%26aulast%3DSorba%26aufirst%3DG.%26aulast%3DGasco%26aufirst%3DA.%26aulast%3DOrsetti%26aufirst%3DM.%26atitle%3DPotential%2520histamine%2520H2-receptor%2520antagonists%253A%2520Twin%2520compounds%2520containing%2520diaminofurazan%2520substructure%26jtitle%3DArch.%2520Pharm.%26date%3D1989%26volume%3D322%26issue%3D9%26spage%3D579%26epage%3D580%26doi%3D10.1002%2Fardp.19893220914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorba, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsetti, M.</span></span> <span> </span><span class="NLM_article-title">Potential histamine H2-receptor antagonists: Synthesis and pharmacological activity of derivatives containing 3-alkylamino-4-amino-furazan moieties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">475</span>â <span class="NLM_lpage">478</span>, <span class="refDoi">Â DOI: 10.1016/0223-5234(89)90050-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2F0223-5234%2889%2990050-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK3cXkt1ekur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1989&pages=475-478&issue=5&author=G.+Sorbaauthor=A.+Gascoauthor=M.+Orsetti&title=Potential+histamine+H2-receptor+antagonists%3A+Synthesis+and+pharmacological+activity+of+derivatives+containing+3-alkylamino-4-amino-furazan+moieties&doi=10.1016%2F0223-5234%2889%2990050-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Potential histamine H2-receptor antagonists:  synthesis and pharmacological activity of derivatives containing 3-alkylamino-4-aminofurazan moieties</span></div><div class="casAuthors">Sorba, Giovanni; Gasco, Alberto; Orsetti, Marco</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">475-8</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    </div><div class="casAbstract">A series of furylmethylthioethylaminofurazans I [R = Me, Et, CHMe2, CMe3, Ph, (CH2)2Ph, cyclohexyl] were prepd. and tested for their H2-antagonist activities on guinea pig right atrium.  A no. of differently shaped alkyl substituents on the terminal 3-amino group were favorable for activity.  The most potent compd. was I (R = cyclohexyl).  Most I showed noncompetitive antagonism at histamine H1 and muscarinic receptors at concns. approx. 100 times higher than those producing competitive H2-receptor block.  This finding suggests that there is an accessorial binding area on H2-receptor near the site fitted by the diaminofurazan moiety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-pYI8Rx1dmbVg90H21EOLACvtfcHk0lg4edoLeoYKhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXkt1ekur8%253D&md5=d87ba493fa1c50663b177e18cfca1eee</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2F0223-5234%2889%2990050-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0223-5234%252889%252990050-0%26sid%3Dliteratum%253Aachs%26aulast%3DSorba%26aufirst%3DG.%26aulast%3DGasco%26aufirst%3DA.%26aulast%3DOrsetti%26aufirst%3DM.%26atitle%3DPotential%2520histamine%2520H2-receptor%2520antagonists%253A%2520Synthesis%2520and%2520pharmacological%2520activity%2520of%2520derivatives%2520containing%25203-alkylamino-4-amino-furazan%2520moieties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D1989%26volume%3D24%26issue%3D5%26spage%3D475%26epage%3D478%26doi%3D10.1016%2F0223-5234%2889%2990050-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">United States Food and Drug Administration</span>. <span> </span><span class="NLM_article-title">FDA Requests Removal of All Ranitidine
Products
(Zantac) From the Market</span>, April 1, 2020. <a href="https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=United+States+Food+and+Drug+Administration.+FDA+Requests+Removal+of+All+Ranitidine%0AProducts%0A%28Zantac%29+From+the+Market%2C+April+1%2C+2020.+https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-requests-removal-all-ranitidine-products-zantac-market."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DFDA%2520Requests%2520Removal%2520of%2520All%2520Ranitidine%250AProducts%250A%2528Zantac%2529%2520From%2520the%2520Market" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shanmugam, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishayee, A.</span></span> <span> </span><span class="NLM_article-title">Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: preclinical and clinical evidence</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>346</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">206</span>â <span class="NLM_lpage">216</span>, <span class="refDoi">Â DOI: 10.1016/j.canlet.2014.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.canlet.2014.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=24486850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjslKjtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2014&pages=206-216&issue=2&author=M.+K.+Shanmugamauthor=X.+Daiauthor=A.+P.+Kumarauthor=B.+K.+Tanauthor=G.+Sethiauthor=A.+Bishayee&title=Oleanolic+acid+and+its+synthetic+derivatives+for+the+prevention+and+therapy+of+cancer%3A+preclinical+and+clinical+evidence&doi=10.1016%2Fj.canlet.2014.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: Preclinical and clinical evidence</span></div><div class="casAuthors">Shanmugam, Muthu K.; Dai, Xiaoyun; Kumar, Alan Prem; Tan, Benny K. H.; Sethi, Gautam; Bishayee, Anupam</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">206-216</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Oleanolic acid (OA, 3Î²-hydroxyolean-12-en-28-oic acid) is a ubiquitous pentacyclic multifunctional triterpenoid, widely found in several dietary and medicinal plants.  Natural and synthetic OA derivs. can modulate multiple signaling pathways including nuclear factor-ÎºB, AKT, signal transducer and activator of transcription 3, mammalian target of rapamycin, caspases, intercellular adhesion mol. 1, vascular endothelial growth factor, and poly (ADP-ribose) polymerase in a variety of tumor cells.  Importantly, synthetic deriv. of OA, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO), and its C-28 Me ester (CDDO-Me) and C28 imidazole (CDDO-Im) have demonstrated potent antiangiogenic and antitumor activities in rodent cancer models.  These agents are presently under evaluation in phase I studies in cancer patients.  This review summarizes the diverse mol. targets of OA and its derivs. and also provides clear evidence on their promising potential in preclin. and clin. situations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6PpXjnkzuRLVg90H21EOLACvtfcHk0liV5El0-sV4Sw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjslKjtLs%253D&md5=defced39e69d9bf7310d7e609fcafb8f</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2014.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2014.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DShanmugam%26aufirst%3DM.%2BK.%26aulast%3DDai%26aufirst%3DX.%26aulast%3DKumar%26aufirst%3DA.%2BP.%26aulast%3DTan%26aufirst%3DB.%2BK.%26aulast%3DSethi%26aufirst%3DG.%26aulast%3DBishayee%26aufirst%3DA.%26atitle%3DOleanolic%2520acid%2520and%2520its%2520synthetic%2520derivatives%2520for%2520the%2520prevention%2520and%2520therapy%2520of%2520cancer%253A%2520preclinical%2520and%2520clinical%2520evidence%26jtitle%3DCancer%2520Lett.%26date%3D2014%26volume%3D346%26issue%3D2%26spage%3D206%26epage%3D216%26doi%3D10.1016%2Fj.canlet.2014.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ng, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, N. Y.</span></span> <span> </span><span class="NLM_article-title">Olean-12-eno[2,3-c] [1,2,5]oxadiazol-28-oic acid (OEOA) induces G1 cell cycle arrest and differentiation in human leukemia cell lines</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">e63580</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0063580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1371%2Fjournal.pone.0063580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=23696836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosFGjsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e63580&issue=5&author=Y.+P.+Ngauthor=Y.+Chenauthor=Y.+Huauthor=F.+C.+Ipauthor=N.+Y.+Ip&title=Olean-12-eno%5B2%2C3-c%5D+%5B1%2C2%2C5%5Doxadiazol-28-oic+acid+%28OEOA%29+induces+G1+cell+cycle+arrest+and+differentiation+in+human+leukemia+cell+lines&doi=10.1371%2Fjournal.pone.0063580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Olean-12-eno[2,3-c] [1,2,5]oxadiazol-28-oic acid (OEOA) induces G1 cell cycle arrest and differentiation in human leukemia cell lines</span></div><div class="casAuthors">Ng, Yu Pong; Chen, Yuewen; Hu, Yueqing; Ip, Fanny C. F.; Ip, Nancy Y.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e63580</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Oleanolic acid (3Î²-hydroxy-olea-12-en-28-oic acid) is a natural pentacyclic triterpenoic acid found in many fruits, herbs and medicinal plants.  In the past decade, increasing evidence has suggested that oleanolic acid exhibits inhibitory activities against different types of cancer including skin cancer and colon cancer, but not leukemia.  We report here that a deriv. of oleanolic acid, olean-12-eno[2,3-c] [1,2,5] oxadiazol-28-oic acid (designated OEOA) effectively blocks the proliferation of human leukemia cells.  OEOA significantly reduces cell proliferation without inducing cell death in three types of leukemia cell lines, including K562, HEL and Jurket.  Moreover, exposure of K562 cells to OEOA results in G1 cell cycle arrest, with a concomitant induction of cyclin-dependent kinase inhibitor p27 and downregulation of cyclins and Cdks that are essential for cell cycle progression.  Interestingly, OEOA also enhances erythroid differentiation in K562 cells through suppressing the expression of Bcr-Abl and phosphorylation of Erk1/2.  These findings identify a novel chem. entity for further development as therapeutics against leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTEIwoVGzOpLVg90H21EOLACvtfcHk0liV5El0-sV4Sw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosFGjsL4%253D&md5=2e4c907176471bf0aadbc6a9ad6c41da</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0063580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0063580%26sid%3Dliteratum%253Aachs%26aulast%3DNg%26aufirst%3DY.%2BP.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DIp%26aufirst%3DF.%2BC.%26aulast%3DIp%26aufirst%3DN.%2BY.%26atitle%3DOlean-12-eno%255B2%252C3-c%255D%2520%255B1%252C2%252C5%255Doxadiazol-28-oic%2520acid%2520%2528OEOA%2529%2520induces%2520G1%2520cell%2520cycle%2520arrest%2520and%2520differentiation%2520in%2520human%2520leukemia%2520cell%2520lines%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26issue%3D5%26spage%3De63580%26doi%3D10.1371%2Fjournal.pone.0063580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ono, K.</span></span> <span> </span><span class="NLM_article-title">Alzheimerâs disease as oligomeropathy</span>. <i>Neurochem. Int.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">57</span>â <span class="NLM_lpage">70</span>, <span class="refDoi">Â DOI: 10.1016/j.neuint.2017.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.neuint.2017.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28821400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKmsrrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2018&pages=57-70&author=K.+Ono&title=Alzheimer%E2%80%99s+disease+as+oligomeropathy&doi=10.1016%2Fj.neuint.2017.08.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's disease as oligomeropathy</span></div><div class="casAuthors">Ono, Kenjiro</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemistry International</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">57-70</span>CODEN:
                <span class="NLM_cas:coden">NEUIDS</span>;
        ISSN:<span class="NLM_cas:issn">0197-0186</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder and is characterized by pathol. aggregates of amyloid Î²-protein (AÎ²) and tau protein.  On the basis of genetic evidence, biochem. data, and animal models, AÎ² has been suggested to be responsible for the pathogenesis of AD (the amyloid hypothesis).  AÎ² mols. tend to aggregate to form oligomers, protofibrils, and mature fibrils.  Although mature fibrils in the final stage have been thought to be the cause of AD pathogenesis, recent studies using synthetic AÎ² peptides, a cell culture model, AÎ² precursor protein transgenic mice models, and human samples, such as cerebrospinal fluids and postmortem brains of AD patients, suggest that pre-fibrillar forms (oligomers of AÎ²) are more deleterious than are extracellular fibril forms.  Based on this recent evidence showing that oligomers have a central role in the pathogenesis of AD, the term "oligomeropathy" could be used to define AD and other protein-misfolding diseases.  In this review, I discuss recent developments in the "oligomer hypothesis" including our research findings regarding the pathogenesis of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd8CTHdB3lfrVg90H21EOLACvtfcHk0liV5El0-sV4Sw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKmsrrF&md5=d690b3f9fc2b18f091dfd82d5e9682fb</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.neuint.2017.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuint.2017.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DOno%26aufirst%3DK.%26atitle%3DAlzheimer%25E2%2580%2599s%2520disease%2520as%2520oligomeropathy%26jtitle%3DNeurochem.%2520Int.%26date%3D2018%26volume%3D119%26spage%3D57%26epage%3D70%26doi%3D10.1016%2Fj.neuint.2017.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bose, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maois, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, G. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robitaille, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drapeau, P.</span></span> <span> </span><span class="NLM_article-title">The novel small molecule TRVA242 stabilizes neuromuscular junction defects in multiple animal models of amyotrophic lateral sclerosis</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1149</span>â <span class="NLM_lpage">1166</span>, <span class="refDoi">Â DOI: 10.1007/s13311-019-00765-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1007%2Fs13311-019-00765-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=31342410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVeqsr3E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=1149-1166&issue=4&author=P.+Boseauthor=E.+Tremblayauthor=C.+Maoisauthor=V.+Narasimhanauthor=G.+A.+B.+Armstrongauthor=M.+Liaoauthor=J.+A.+Parkerauthor=R.+Robitailleauthor=X.+Y.+Wenauthor=C.+Bardenauthor=P.+Drapeau&title=The+novel+small+molecule+TRVA242+stabilizes+neuromuscular+junction+defects+in+multiple+animal+models+of+amyotrophic+lateral+sclerosis&doi=10.1007%2Fs13311-019-00765-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">The Novel Small Molecule TRVA242 Stabilizes Neuromuscular Junction Defects in Multiple Animal Models of Amyotrophic Lateral Sclerosis</span></div><div class="casAuthors">Bose, Poulomee; Tremblay, Elsa; Maois, Claudia; Narasimhan, Vijay; Armstrong, Gary A. B.; Liao, Meijiang; Parker, J. Alex; Robitaille, Richard; Wen, Xiao Yan; Barden, Christopher; Drapeau, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1149-1166</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disorder in which the neuromuscular junction progressively degenerates, leading to movement difficulties, paralysis, and eventually death.  ALS is currently being treated by only two FDA-approved drugs with modest efficacy in slowing disease progression.  Often, the translation of preclin. findings to bedside terminates prematurely as the evaluation of potential therapeutic compds. focuses on a single study or a single animal model.  To circumscribe these issues, we screened 3,765 novel small mol. derivs. of pimozide, a recently identified repurposed neuroleptic for ALS, in Caenorhabditis elegans, confirmed the hits in zebrafish and validated the most active compds. in mouse genetic models.  Out of the 27 small mols. identified from the high-throughput screen in worms, 4 were found to recover locomotor defects in C. elegans and genetic zebrafish models of ALS.  TRVA242 was identified as the most potent compd. as it significantly improved efficiency in rescuing locomotor, motorneuron, and neuromuscular junction synaptic deficits in a C. elegans TDP-43 model and in multiple zebrafish genetic (TDP-43, SOD1, and C9ORF72) models of ALS.  The actions of TRVA242 were also conserved in a mammalian model as it also stabilized neuromuscular junction deficits in a mouse SOD1 model of ALS.  Compds. such as TRVA242 therefore represent new potential therapeutics for the treatment of ALS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCkmo2vCx997Vg90H21EOLACvtfcHk0ljBuIMYQr_GIw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVeqsr3E&md5=763dbc5da05832578672ce87b45c755d</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1007%2Fs13311-019-00765-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-019-00765-w%26sid%3Dliteratum%253Aachs%26aulast%3DBose%26aufirst%3DP.%26aulast%3DTremblay%26aufirst%3DE.%26aulast%3DMaois%26aufirst%3DC.%26aulast%3DNarasimhan%26aufirst%3DV.%26aulast%3DArmstrong%26aufirst%3DG.%2BA.%2BB.%26aulast%3DLiao%26aufirst%3DM.%26aulast%3DParker%26aufirst%3DJ.%2BA.%26aulast%3DRobitaille%26aufirst%3DR.%26aulast%3DWen%26aufirst%3DX.%2BY.%26aulast%3DBarden%26aufirst%3DC.%26aulast%3DDrapeau%26aufirst%3DP.%26atitle%3DThe%2520novel%2520small%2520molecule%2520TRVA242%2520stabilizes%2520neuromuscular%2520junction%2520defects%2520in%2520multiple%2520animal%2520models%2520of%2520amyotrophic%2520lateral%2520sclerosis%26jtitle%3DNeurotherapeutics%26date%3D2019%26volume%3D16%26issue%3D4%26spage%3D1149%26epage%3D1166%26doi%3D10.1007%2Fs13311-019-00765-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G.</span>; <span class="NLM_string-name">Chesworth, R.</span></span> <span> </span><span class="NLM_article-title">1,3,4-Trisubstituted Benzenes as Î³-Secretase Inhibitors and their Preparation and Use in the Treatment of Neurodegenerative Diseases</span>. <span class="NLM_patent">WO2009036428A2</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=G.+Shapiro&author=R.+Chesworth&title=1%2C3%2C4-Trisubstituted+Benzenes+as+%CE%B3-Secretase+Inhibitors+and+their+Preparation+and+Use+in+the+Treatment+of+Neurodegenerative+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DG.%26atitle%3D1%252C3%252C4-Trisubstituted%2520Benzenes%2520as%2520%25CE%25B3-Secretase%2520Inhibitors%2520and%2520their%2520Preparation%2520and%2520Use%2520in%2520the%2520Treatment%2520of%2520Neurodegenerative%2520Diseases%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G.</span>; <span class="NLM_string-name">Chesworth, R.</span></span> <span> </span><span class="NLM_article-title">Preparation of Tetrasubstituted Benzenes as Î³-Secretase Modulators for Treating Alzheimerâs Disease</span>. <span class="NLM_patent">WO2009086277A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=G.+Shapiro&author=R.+Chesworth&title=Preparation+of+Tetrasubstituted+Benzenes+as+%CE%B3-Secretase+Modulators+for+Treating+Alzheimer%E2%80%99s+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DG.%26atitle%3DPreparation%2520of%2520Tetrasubstituted%2520Benzenes%2520as%2520%25CE%25B3-Secretase%2520Modulators%2520for%2520Treating%2520Alzheimer%25E2%2580%2599s%2520Disease%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, G.</span>; <span class="NLM_string-name">Blain, J.-F.</span></span> <span> </span><span class="NLM_article-title">Preparation of Tetrasubstituted Benzenes for Treatment of Early Onset Alzheimerâs Disease</span>. <span class="NLM_patent">WO2013106328A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=G.+Koenig&author=J.-F.+Blain&title=Preparation+of+Tetrasubstituted+Benzenes+for+Treatment+of+Early+Onset+Alzheimer%E2%80%99s+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKoenig%26aufirst%3DG.%26atitle%3DPreparation%2520of%2520Tetrasubstituted%2520Benzenes%2520for%2520Treatment%2520of%2520Early%2520Onset%2520Alzheimer%25E2%2580%2599s%2520Disease%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felsenstein, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrdlicka, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albayya, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spaulding, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgdon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blain, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Strooper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulsteke, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scrocchi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zetterberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portelius, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutter-Paier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahlijanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flood, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leventhal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patzke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesworth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, G.</span></span> <span> </span><span class="NLM_article-title">Modulation of Î³-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice</span>. <i>Mol. Neurodegener.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">61</span>, <span class="refDoi">Â DOI: 10.1186/1750-1326-7-61</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1186%2F1750-1326-7-61" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=23249765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFyqt78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=61&issue=1&author=K.+Rogersauthor=K.+M.+Felsensteinauthor=L.+Hrdlickaauthor=Z.+Tuauthor=F.+Albayyaauthor=W.+Leeauthor=S.+Hoppauthor=M.-J.+Millerauthor=D.+Spauldingauthor=Z.+Yangauthor=H.+Hodgdonauthor=S.+Nolanauthor=M.+Wenauthor=D.+Costaauthor=J.-F.+Blainauthor=E.+Freemanauthor=B.+De+Strooperauthor=V.+Vulstekeauthor=L.+Scrocchiauthor=H.+Zetterbergauthor=E.+Porteliusauthor=B.+Hutter-Paierauthor=D.+Havasauthor=M.+Ahlijanianauthor=D.+Floodauthor=L.+Leventhalauthor=G.+Shapiroauthor=H.+Patzkeauthor=R.+Chesworthauthor=G.+Koenig&title=Modulation+of+%CE%B3-secretase+by+EVP-0015962+reduces+amyloid+deposition+and+behavioral+deficits+in+Tg2576+mice&doi=10.1186%2F1750-1326-7-61"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of Î³-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice</span></div><div class="casAuthors">Rogers, Kathryn; Felsenstein, Kevin M.; Hrdlicka, Lori; Tu, Zhiming; Albayya, Faris; Lee, Winnie; Hopp, Sarah; Miller, Mary-Jo; Spaulding, Darcie; Yang, Zhiyong; Hodgdon, Hilliary; Nolan, Scott; Wen, Melody; Costa, Don; Blain, Jean-Francois; Freeman, Emily; De Strooper, Bart; Vulsteke, Veerle; Scrocchi, Louise; Zetterberg, Henrik; Portelius, Erik; Hutter-Paier, Birgit; Havas, Daniel; Ahlijanian, Michael; Flood, Dorothy; Leventhal, Liza; Shapiro, Gideon; Patzke, Holger; Chesworth, Richard; Koenig, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurodegeneration</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">61</span>CODEN:
                <span class="NLM_cas:coden">MNOEAZ</span>;
        ISSN:<span class="NLM_cas:issn">1750-1326</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: A hallmark of Alzheimer's disease is the presence of senile plaques in human brain primarily contg. the amyloid peptides AÎ²42 and AÎ²40.  Many drug discovery efforts have focused on decreasing the prodn. of AÎ²42 through Î³-secretase inhibition.  However, identification of Î³-secretase inhibitors has also uncovered mechanism-based side effects.  One approach to circumvent these side effects has been modulation of Î³-secretase to shift AÎ² prodn. to favor shorter, less amyloidogenic peptides than AÎ²42, without affecting the overall cleavage efficiency of the enzyme.  This approach, frequently called Î³-secretase modulation, appears more promising and has lead to the development of new therapeutic candidates for disease modification in Alzheimer's disease.  Results: Here we describe EVP-0015962, a novel small mol. Î³-secretase modulator.  EVP-0015962 decreased AÎ²42 in H4 cells (IC50 = 67 nM) and increased the shorter AÎ²38 by 1.7 fold at the IC50 for lowering of AÎ²42.  AÎ²Total, as well as other carboxyl-terminal fragments of amyloid precursor protein, were not changed.  EVP-0015962 did not cause the accumulation of other Î³-secretase substrates, such as the Notch and ephrin A4 receptors, whereas a Î³-secretase inhibitor reduced processing of both.  A single oral dose of EVP-0015962 (30 mg/kg) decreased AÎ²42 and did not alter AÎ²Total peptide levels in a dose-dependent manner in Tg2576 mouse brain at an age when overt AÎ² deposition was not present.  In Tg2576 mice, chronic treatment with EVP-0015962 (20 or 60 mg/kg/day in a food formulation) reduced AÎ² aggregates, amyloid plaques, inflammatory markers and cognitive deficits.  Conclusions: EVP-0015962 is orally bioavailable, detected in brain and a potent, selective Î³-secretase modulator in vitro and in vivo.  Chronic treatment with EVP-0015962 was well tolerated in mice and lowered the prodn. of AÎ²42, attenuated memory deficits and reduced AÎ² plaque formation and inflammation in Tg2576 transgenic animals.  In summary, these data suggest that Î³-secretase modulation with EVP-0015962 represents a viable therapeutic alternative for disease modification in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrawar6w5ZKrrVg90H21EOLACvtfcHk0ljBuIMYQr_GIw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFyqt78%253D&md5=cc1497b9c84ac2a5de368c81d99789c6</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1186%2F1750-1326-7-61&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1750-1326-7-61%26sid%3Dliteratum%253Aachs%26aulast%3DRogers%26aufirst%3DK.%26aulast%3DFelsenstein%26aufirst%3DK.%2BM.%26aulast%3DHrdlicka%26aufirst%3DL.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DAlbayya%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DHopp%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DM.-J.%26aulast%3DSpaulding%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DHodgdon%26aufirst%3DH.%26aulast%3DNolan%26aufirst%3DS.%26aulast%3DWen%26aufirst%3DM.%26aulast%3DCosta%26aufirst%3DD.%26aulast%3DBlain%26aufirst%3DJ.-F.%26aulast%3DFreeman%26aufirst%3DE.%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26aulast%3DVulsteke%26aufirst%3DV.%26aulast%3DScrocchi%26aufirst%3DL.%26aulast%3DZetterberg%26aufirst%3DH.%26aulast%3DPortelius%26aufirst%3DE.%26aulast%3DHutter-Paier%26aufirst%3DB.%26aulast%3DHavas%26aufirst%3DD.%26aulast%3DAhlijanian%26aufirst%3DM.%26aulast%3DFlood%26aufirst%3DD.%26aulast%3DLeventhal%26aufirst%3DL.%26aulast%3DShapiro%26aufirst%3DG.%26aulast%3DPatzke%26aufirst%3DH.%26aulast%3DChesworth%26aufirst%3DR.%26aulast%3DKoenig%26aufirst%3DG.%26atitle%3DModulation%2520of%2520%25CE%25B3-secretase%2520by%2520EVP-0015962%2520reduces%2520amyloid%2520deposition%2520and%2520behavioral%2520deficits%2520in%2520Tg2576%2520mice%26jtitle%3DMol.%2520Neurodegener.%26date%3D2012%26volume%3D7%26issue%3D1%26spage%3D61%26doi%3D10.1186%2F1750-1326-7-61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kohara, T.</span>; <span class="NLM_string-name">Fukunaga, K.</span>; <span class="NLM_string-name">Fujimura, M.</span>; <span class="NLM_string-name">Hanano, T.</span>; <span class="NLM_string-name">Okabe, H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Dihydropyrazolopyridines and Pharmaceutical Use Based on Strong and Selective Inhibition of Glycogen Synthase Kinase-3 Beta</span>. <span class="NLM_patent">WO2002062795A2</span>, <span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=T.+Kohara&author=K.+Fukunaga&author=M.+Fujimura&author=T.+Hanano&author=H.+Okabe&title=Preparation+of+Dihydropyrazolopyridines+and+Pharmaceutical+Use+Based+on+Strong+and+Selective+Inhibition+of+Glycogen+Synthase+Kinase-3+Beta"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKohara%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520Dihydropyrazolopyridines%2520and%2520Pharmaceutical%2520Use%2520Based%2520on%2520Strong%2520and%2520Selective%2520Inhibition%2520of%2520Glycogen%2520Synthase%2520Kinase-3%2520Beta%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kohara, T.</span>; <span class="NLM_string-name">Fukunaga, K.</span>; <span class="NLM_string-name">Fujimura, M.</span>; <span class="NLM_string-name">Hanano, T.</span>; <span class="NLM_string-name">Okabe, H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Dihydropyrazolopyridine Derivatives as GSK-3Î² Inhibitors</span>. <span class="NLM_patent">US20040052822A1</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=T.+Kohara&author=K.+Fukunaga&author=M.+Fujimura&author=T.+Hanano&author=H.+Okabe&title=Preparation+of+Dihydropyrazolopyridine+Derivatives+as+GSK-3%CE%B2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKohara%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520Dihydropyrazolopyridine%2520Derivatives%2520as%2520GSK-3%25CE%25B2%2520Inhibitors%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kohara, T.</span>; <span class="NLM_string-name">Fukunaga, K.</span>; <span class="NLM_string-name">Hanano, T.</span></span> <span> </span><span class="NLM_article-title">Preparation of Dihydropyrazolopyridines as Glycogen Synthase Kinase-3Î² (GSK-3Î²) Inhibitors</span>. <span class="NLM_patent">WO2004014910A1</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=T.+Kohara&author=K.+Fukunaga&author=T.+Hanano&title=Preparation+of+Dihydropyrazolopyridines+as+Glycogen+Synthase+Kinase-3%CE%B2+%28GSK-3%CE%B2%29+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKohara%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520Dihydropyrazolopyridines%2520as%2520Glycogen%2520Synthase%2520Kinase-3%25CE%25B2%2520%2528GSK-3%25CE%25B2%2529%2520Inhibitors%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukunaga, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aritomo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamakoshi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamagami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baba, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, M.</span></span> <span> </span><span class="NLM_article-title">2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3beta inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">6933</span>â <span class="NLM_lpage">6937</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2013.09.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmcl.2013.09.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=24176395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1yqt7vL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=6933-6937&issue=24&author=K.+Fukunagaauthor=F.+Ueharaauthor=K.+Aritomoauthor=A.+Shodaauthor=S.+Hikiauthor=M.+Okuyamaauthor=Y.+Usuiauthor=K.+Watanabeauthor=K.+Yamakoshiauthor=T.+Koharaauthor=T.+Hananoauthor=H.+Tanakaauthor=S.+Tsuchiyaauthor=S.+Sunadaauthor=K.+Saitoauthor=J.+Eguchiauthor=S.+Yukiauthor=S.+Asanoauthor=S.+Tanakaauthor=A.+Moriauthor=K.+Yamagamiauthor=H.+Babaauthor=T.+Horikawaauthor=M.+Fujimura&title=2-%282-Phenylmorpholin-4-yl%29pyrimidin-4%283H%29-ones%3B+a+new+class+of+potent%2C+selective+and+orally+active+glycogen+synthase+kinase-3beta+inhibitors&doi=10.1016%2Fj.bmcl.2013.09.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; A new class of potent, selective and orally active glycogen synthase kinase-3Î² inhibitors</span></div><div class="casAuthors">Fukunaga, Kenji; Uehara, Fumiaki; Aritomo, Keiichi; Shoda, Aya; Hiki, Shinsuke; Okuyama, Masahiro; Usui, Yoshihiro; Watanabe, Kazutoshi; Yamakoshi, Koichi; Kohara, Toshiyuki; Hanano, Tokushi; Tanaka, Hiroshi; Tsuchiya, Susumu; Sunada, Shinji; Saito, Ken-Ichi; Eguchi, Jun-ichi; Yuki, Satoshi; Asano, Shoichi; Tanaka, Shinji; Mori, Akiko; Yamagami, Keiji; Baba, Hiroshi; Horikawa, Takashi; Fujimura, Masatake</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6933-6937</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 2-(2-phenylmorpholin-4-yl)pyrimidin-4(3H)-ones was synthesized and examd. for their inhibitory activity against glycogen synthase kinase-3Î² (GSK-3Î²).  We found compds. I (R = 4-F (II), 2,6-di-OMe, 2-F-6-Cl) to possess potent in vitro GSK-3Î² inhibitory activity with good in vitro PK profiles.  Compd. II demonstrated significant decrease of tau phosphorylation after oral administration in mice and excellent PK profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9woxQA77rTbVg90H21EOLACvtfcHk0lhjfjCtlkxTig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1yqt7vL&md5=6c8bc95e0ccb21078aff1837d83e649e</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.09.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.09.020%26sid%3Dliteratum%253Aachs%26aulast%3DFukunaga%26aufirst%3DK.%26aulast%3DUehara%26aufirst%3DF.%26aulast%3DAritomo%26aufirst%3DK.%26aulast%3DShoda%26aufirst%3DA.%26aulast%3DHiki%26aufirst%3DS.%26aulast%3DOkuyama%26aufirst%3DM.%26aulast%3DUsui%26aufirst%3DY.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DYamakoshi%26aufirst%3DK.%26aulast%3DKohara%26aufirst%3DT.%26aulast%3DHanano%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DTsuchiya%26aufirst%3DS.%26aulast%3DSunada%26aufirst%3DS.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DEguchi%26aufirst%3DJ.%26aulast%3DYuki%26aufirst%3DS.%26aulast%3DAsano%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DS.%26aulast%3DMori%26aufirst%3DA.%26aulast%3DYamagami%26aufirst%3DK.%26aulast%3DBaba%26aufirst%3DH.%26aulast%3DHorikawa%26aufirst%3DT.%26aulast%3DFujimura%26aufirst%3DM.%26atitle%3D2-%25282-Phenylmorpholin-4-yl%2529pyrimidin-4%25283H%2529-ones%253B%2520a%2520new%2520class%2520of%2520potent%252C%2520selective%2520and%2520orally%2520active%2520glycogen%2520synthase%2520kinase-3beta%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D24%26spage%3D6933%26epage%3D6937%26doi%3D10.1016%2Fj.bmcl.2013.09.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span>; <span class="NLM_string-name">Uehara, F.</span>; <span class="NLM_string-name">Hiki, S.</span>; <span class="NLM_string-name">Kohara, T.</span>; <span class="NLM_string-name">Fukunaga, K.</span>; <span class="NLM_string-name">Yokoshima, S.</span></span> <span> </span><span class="NLM_article-title">2-Morpholino-4-Pyrimidinones as Tau Protein Kinase 1 Inhibitors, their Preparation, Pharmaceutical Compositions, and Use in Therapy</span>. <span class="NLM_patent">WO2006028290A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=K.+Watanabe&author=F.+Uehara&author=S.+Hiki&author=T.+Kohara&author=K.+Fukunaga&author=S.+Yokoshima&title=2-Morpholino-4-Pyrimidinones+as+Tau+Protein+Kinase+1+Inhibitors%2C+their+Preparation%2C+Pharmaceutical+Compositions%2C+and+Use+in+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DK.%26atitle%3D2-Morpholino-4-Pyrimidinones%2520as%2520Tau%2520Protein%2520Kinase%25201%2520Inhibitors%252C%2520their%2520Preparation%252C%2520Pharmaceutical%2520Compositions%252C%2520and%2520Use%2520in%2520Therapy%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griebel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stemmelin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Grancha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boquet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slowinski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeske, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eguchi, J.</span></span> <span> </span><span class="NLM_article-title">The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimerâs disease in rodents</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">18045</span>, <span class="refDoi">Â DOI: 10.1038/s41598-019-54557-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2Fs41598-019-54557-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=31792284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlWkur7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=18045&issue=1&author=G.+Griebelauthor=J.+Stemmelinauthor=M.+Lopez-Granchaauthor=D.+Boulayauthor=G.+Boquetauthor=F.+Slowinskiauthor=P.+Pichatauthor=S.+Beeskeauthor=S.+Tanakaauthor=A.+Moriauthor=M.+Fujimuraauthor=J.+Eguchi&title=The+selective+GSK3+inhibitor%2C+SAR502250%2C+displays+neuroprotective+activity+and+attenuates+behavioral+impairments+in+models+of+neuropsychiatric+symptoms+of+Alzheimer%E2%80%99s+disease+in+rodents&doi=10.1038%2Fs41598-019-54557-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer's disease in rodents</span></div><div class="casAuthors">Griebel, Guy; Stemmelin, Jeanne; Lopez-Grancha, Mati; Boulay, Denis; Boquet, Gerald; Slowinski, Franck; Pichat, Philippe; Beeske, Sandra; Tanaka, Shinji; Mori, Akiko; Fujimura, Masatake; Eguchi, Junichi</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">18045</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3 (GSK3) has been identified as a promising target for the treatment of Alzheimer's disease (AD), where abnormal activation of this enzyme has been assocd. with hyperphosphorylation of tau proteins.  This study describes the effects of the selective GSK3 inhibitor, SAR502250, in models of neuroprotection and neuropsychiatric symptoms (NPS) assocd. with AD.  In P301L human tau transgenic mice, SAR502250 attenuated tau hyperphosphorylation in the cortex and spinal cord.  SAR502250 prevented the increase in neuronal cell death in rat embryonic hippocampal neurons following application of the neurotoxic peptide, AÎ²25-35.  In behavioral studies, SAR502250 improved the cognitive deficit in aged transgenic APP(SW)/Tau(VLW) mice or in adult mice after infusion of AÎ² 25-35.  It attenuated aggression in the mouse defense test battery and improved depressive-like state of mice in the chronic mild stress procedure after 4 wk of treatment.  Moreover, SAR502250 decreased hyperactivity produced by psychostimulants.  In contrast, the drug failed to modify anxiety-related behaviors or sensorimotor gating deficit.  This profile confirms the neuroprotective effects of GSK3 inhibitors and suggests an addnl. potential in the treatment of some NPS assocd. with AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgVqMhUSJZI7Vg90H21EOLACvtfcHk0ljRsn03TomVEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlWkur7E&md5=3573c37862802bb661aa83750529be88</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-54557-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-54557-5%26sid%3Dliteratum%253Aachs%26aulast%3DGriebel%26aufirst%3DG.%26aulast%3DStemmelin%26aufirst%3DJ.%26aulast%3DLopez-Grancha%26aufirst%3DM.%26aulast%3DBoulay%26aufirst%3DD.%26aulast%3DBoquet%26aufirst%3DG.%26aulast%3DSlowinski%26aufirst%3DF.%26aulast%3DPichat%26aufirst%3DP.%26aulast%3DBeeske%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DS.%26aulast%3DMori%26aufirst%3DA.%26aulast%3DFujimura%26aufirst%3DM.%26aulast%3DEguchi%26aufirst%3DJ.%26atitle%3DThe%2520selective%2520GSK3%2520inhibitor%252C%2520SAR502250%252C%2520displays%2520neuroprotective%2520activity%2520and%2520attenuates%2520behavioral%2520impairments%2520in%2520models%2520of%2520neuropsychiatric%2520symptoms%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520in%2520rodents%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26issue%3D1%26spage%3D18045%26doi%3D10.1038%2Fs41598-019-54557-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simuni, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biglan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaglin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surmeier, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardiner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandabur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Factor, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goudreau, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimes, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kompoliti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyasaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nance, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeiffer, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russel, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saint-Hilaire, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuite, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Gerpen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadikoff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasucci, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deppen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duderstadt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ede, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gartner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanco, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecoraro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeiffer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quesada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gables, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reys, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolandelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommerfeld, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strongosky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terashita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siderowf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langbehn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrentino, M.</span></span> <span> </span><span class="NLM_article-title">Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinsonâs disease (STEADY-PD)</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1823</span>â <span class="NLM_lpage">1831</span>, <span class="refDoi">Â DOI: 10.1002/mds.25639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fmds.25639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=24123224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2hur%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2013&pages=1823-1831&issue=13&author=T.+Simuniauthor=K.+Biglanauthor=D.+Oakesauthor=G.+Bakrisauthor=R.+A.+Hauserauthor=J.+A.+Jaglinauthor=A.+Langauthor=J.+D.+Surmeierauthor=N.+Gardinerauthor=C.+Deeleyauthor=M.+Brandaburauthor=D.+Burkeauthor=S.+A.+Factorauthor=H.+H.+Fernandezauthor=J.+L.+Goudreauauthor=D.+A.+Grimesauthor=S.+Jainauthor=K.+Kompolitiauthor=F.+Marshallauthor=J.+Miyasakiauthor=M.+Nanceauthor=S.+Parkinsonauthor=R.+F.+Pfeifferauthor=G.+W.+Rossauthor=D.+S.+Russelauthor=A.+Sahayauthor=M.+H.+Saint-Hilaireauthor=P.+Tuiteauthor=J.+Van+Gerpenauthor=C.+Zadikoffauthor=P.+Beckerauthor=D.+Berryauthor=L.+M.+Blasucciauthor=J.+Conwayauthor=C.+Deeleyauthor=P.+Deppenauthor=K.+Duderstadtauthor=P.+Edeauthor=M.+Gartnerauthor=L.+S.+Ivancoauthor=R.+McMurrayauthor=M.+Pecoraroauthor=B.+Pfeifferauthor=M.+Quesadaauthor=C.+Gablesauthor=L.+Reysauthor=S.+Rolandelliauthor=D.+Russellauthor=J.+Sierenauthor=B.+Sommerfeldauthor=A.+Strongoskyauthor=S.+Terashitaauthor=C.-A.+Thomasauthor=S.+Wesselsauthor=A.+Siderowfauthor=D.+Langbehnauthor=M.+Sorrentino&title=Phase+II+safety%2C+tolerability%2C+and+dose+selection+study+of+isradipine+as+a+potential+disease-modifying+intervention+in+early+Parkinson%E2%80%99s+disease+%28STEADY-PD%29&doi=10.1002%2Fmds.25639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD)</span></div><div class="casAuthors">Simuni, Tanya; Biglan, Kevin; Oakes, David; Bakris, George; Hauser, Robert A.; Jaglin, Jean A.; Lang, Anthony; Surmeier, James D.; Gardiner, Nita; Deeley, Cheryl; Brandabur, Melanie; Burke, Deborah; Factor, Stewart A.; Fernadez, Hubert H.; Gourdreau, John L.; Grimes, David A.; Jain, Samay; Kompoliti, Katie; Marshall, Frederick; Miyasaki, Janis; Nance, Martha; Pfeiffer, Ronald F.; Webster Ross, G.; Russell, David S.; Sahay, Alok; Saint-Hilaire, Marie H.; Sengun, Cenk; Tuite, Paul; Van Gerpen, Jay; Zadikoff, Cindy; Becker, Pam; Berry, Debra; Blasucci, Lucia M.; Conway, Jennifer; Deeley, Cheryl; Deppen, Patricia; Duderstadt, Kathryn; Ede, Patricia; Gartner, Maureen; Ivanco, Larry S.; McMurray, Rebecca; Pecoraro, Mary; Pfeiffer, Brenda; Quesada, Monica; Reys, Liza; Rolandelli, Susan; Russell, Doozie; Sieren, Jeri; Sommerfeld, Barbara; Strongosky, Audrey; Terashita, Stephanie; Thomas, Cathi-Ann; Wessels, Sherry; Williams, Karen</div><div class="citationInfo"><span class="NLM_cas:title">Movement Disorders</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1823-1831</span>CODEN:
                <span class="NLM_cas:coden">MOVDEA</span>;
        ISSN:<span class="NLM_cas:issn">0885-3185</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Isradipine, a dihydropyridine calcium channel antagonist, has been shown to be neuroprotective in animal models of Parkinson's disease (PD).  To establish a dosage of isradipine controlled-release (CR) that is tolerable and demonstrates preliminary efficacy for use in a future pivotal efficacy trial a Phase 2, randomized, double-blind, parallel group trial (Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease [STEADY-PD]) was undertaken in subjects with early PD not requiring dopaminergic therapy (dopamine agonists or levodopa) randomized 1:1:1:1 to 5, 10, or 20 mg of isradipine CR or matching placebo daily.  The primary outcome was tolerability defined as no more than a 30% difference in the proportion of patients completing the study on the originally assigned dosage between an active and placebo group.  If more than one isradipine dosage was tolerable, then a 3-point difference in total Unified Parkinson's Disease Rating Scale (UPDRS) change between baseline and week 52 (or time to sufficient disability to require dopaminergic therapy) was taken as a criterion for selection of the most desirable dosage for future study.  STEADY-PD enrolled 99 subjects.  The tolerability of isradipine was dose dependent: placebo, 25 of 26 patients (96%); 5 mg, 19 of 23 patients (83%); 10 mg 19 of 26 patients (73%); and 20 mg 9 of 24 patients (37%).  There was no difference in change in UPDRS among dosages.  The most common adverse events were peripheral edema (30) and dizziness (24).  Isradipine 10 mg daily was the maximal tolerable dosage in this study of early PD.  A large placebo-controlled trial will be necessary and is planned to assess efficacy of isradipine 10 mg daily to slow progression of PD disability. Â© 2013 International Parkinson and Movement Disorder Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRBVxnSlTTN7Vg90H21EOLACvtfcHk0ljRsn03TomVEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2hur%252FO&md5=20407b7172678da335c8c72b70ad8c04</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1002%2Fmds.25639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.25639%26sid%3Dliteratum%253Aachs%26aulast%3DSimuni%26aufirst%3DT.%26aulast%3DBiglan%26aufirst%3DK.%26aulast%3DOakes%26aufirst%3DD.%26aulast%3DBakris%26aufirst%3DG.%26aulast%3DHauser%26aufirst%3DR.%2BA.%26aulast%3DJaglin%26aufirst%3DJ.%2BA.%26aulast%3DLang%26aufirst%3DA.%26aulast%3DSurmeier%26aufirst%3DJ.%2BD.%26aulast%3DGardiner%26aufirst%3DN.%26aulast%3DDeeley%26aufirst%3DC.%26aulast%3DBrandabur%26aufirst%3DM.%26aulast%3DBurke%26aufirst%3DD.%26aulast%3DFactor%26aufirst%3DS.%2BA.%26aulast%3DFernandez%26aufirst%3DH.%2BH.%26aulast%3DGoudreau%26aufirst%3DJ.%2BL.%26aulast%3DGrimes%26aufirst%3DD.%2BA.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DKompoliti%26aufirst%3DK.%26aulast%3DMarshall%26aufirst%3DF.%26aulast%3DMiyasaki%26aufirst%3DJ.%26aulast%3DNance%26aufirst%3DM.%26aulast%3DParkinson%26aufirst%3DS.%26aulast%3DPfeiffer%26aufirst%3DR.%2BF.%26aulast%3DRoss%26aufirst%3DG.%2BW.%26aulast%3DRussel%26aufirst%3DD.%2BS.%26aulast%3DSahay%26aufirst%3DA.%26aulast%3DSaint-Hilaire%26aufirst%3DM.%2BH.%26aulast%3DTuite%26aufirst%3DP.%26aulast%3DVan%2BGerpen%26aufirst%3DJ.%26aulast%3DZadikoff%26aufirst%3DC.%26aulast%3DBecker%26aufirst%3DP.%26aulast%3DBerry%26aufirst%3DD.%26aulast%3DBlasucci%26aufirst%3DL.%2BM.%26aulast%3DConway%26aufirst%3DJ.%26aulast%3DDeeley%26aufirst%3DC.%26aulast%3DDeppen%26aufirst%3DP.%26aulast%3DDuderstadt%26aufirst%3DK.%26aulast%3DEde%26aufirst%3DP.%26aulast%3DGartner%26aufirst%3DM.%26aulast%3DIvanco%26aufirst%3DL.%2BS.%26aulast%3DMcMurray%26aufirst%3DR.%26aulast%3DPecoraro%26aufirst%3DM.%26aulast%3DPfeiffer%26aufirst%3DB.%26aulast%3DQuesada%26aufirst%3DM.%26aulast%3DGables%26aufirst%3DC.%26aulast%3DReys%26aufirst%3DL.%26aulast%3DRolandelli%26aufirst%3DS.%26aulast%3DRussell%26aufirst%3DD.%26aulast%3DSieren%26aufirst%3DJ.%26aulast%3DSommerfeld%26aufirst%3DB.%26aulast%3DStrongosky%26aufirst%3DA.%26aulast%3DTerashita%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DC.-A.%26aulast%3DWessels%26aufirst%3DS.%26aulast%3DSiderowf%26aufirst%3DA.%26aulast%3DLangbehn%26aufirst%3DD.%26aulast%3DSorrentino%26aufirst%3DM.%26atitle%3DPhase%2520II%2520safety%252C%2520tolerability%252C%2520and%2520dose%2520selection%2520study%2520of%2520isradipine%2520as%2520a%2520potential%2520disease-modifying%2520intervention%2520in%2520early%2520Parkinson%25E2%2580%2599s%2520disease%2520%2528STEADY-PD%2529%26jtitle%3DMov.%2520Disord.%26date%3D2013%26volume%3D28%26issue%3D13%26spage%3D1823%26epage%3D1831%26doi%3D10.1002%2Fmds.25639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simuni, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biglan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galpern, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgeman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lungu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoulson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarolli, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surmeier, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venuto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kompoliti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evatt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litvan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farbman, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racette, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blindauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Water, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marras, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luca, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadikoff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panisset, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shtilbans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanspal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christine, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiess, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guttman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shill, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slevin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goudreau, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saint-Hilaire, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aquino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shprecher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shulman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parashos, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuite, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danisi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestre, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermanowicz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zweig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchowersky, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarna, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasucci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neefus, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecoraro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racioppa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bwala, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichwein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkiteswaran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ephron, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stovall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrogi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ede, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBlanc, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolandelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fierro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chew, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matwichyna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siderowf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, W. B.</span></span> <span> </span><span class="NLM_article-title">Isradipine versus placebo in early Parkinson Disease: A randomized trial</span>. <i>Ann. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>172</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">591</span>â <span class="NLM_lpage">598</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.7326%2FM19-2534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=32227247" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2020&pages=591-598&issue=9&author=T.+Simuniauthor=D.+Oakesauthor=K.+Biglanauthor=W.+R.+Galpernauthor=R.+Hauserauthor=K.+Hodgemanauthor=E.+Kaysonauthor=D.+Kinelauthor=A.+Langauthor=C.+Lunguauthor=S.+Sharmaauthor=I.+Shoulsonauthor=C.+G.+Tarolliauthor=D.+J.+Surmeierauthor=C.+Venutoauthor=R.+Hollowayauthor=K.+Kompolitiauthor=I.+Richardauthor=R.+Schneiderauthor=M.+Evattauthor=V.+Hinsonauthor=A.+Sahayauthor=I.+Litvanauthor=E.+S.+Farbmanauthor=B.+Racetteauthor=K.+Blindauerauthor=K.+Thomasauthor=C.+Waterauthor=C.+Marrasauthor=C.+C.+Lucaauthor=A.+Hungauthor=A.+Deikauthor=D.+Burkeauthor=C.+Zadikoffauthor=M.+Panissetauthor=M.+Rabinauthor=M.+Brodskyauthor=K.+Millsauthor=A.+Shtilbansauthor=E.+Hanspalauthor=C.+W.+Christineauthor=T.+Subramanianauthor=M.+C.+Schiessauthor=R.+Kumarauthor=K.+L.+Chouauthor=B.+Shahauthor=M.+Guttmanauthor=H.+Shillauthor=J.+Slevinauthor=J.+L.+Goudreauauthor=A.+Parkauthor=J.+Bertoniauthor=M.+H.+Saint-Hilaireauthor=N.+Stoverauthor=C.+Aquinoauthor=D.+Shprecherauthor=A.+Ahmedauthor=L.+Shulmanauthor=S.+A.+Parashosauthor=S.+Leeauthor=P.+Tuiteauthor=M.+Langloisauthor=F.+Danisiauthor=P.+Agarwalauthor=T.+Mestreauthor=D.+Russellauthor=D.+Truongauthor=N.+Hermanowiczauthor=R.+Zweigauthor=O.+Suchowerskyauthor=J.+R.+Sarnaauthor=G.+W.+Rossauthor=L.+Blasucciauthor=C.+Zimmermanauthor=S.+Jenkinsauthor=E.+Neefusauthor=M.+Pecoraroauthor=L.+Wheelerauthor=L.+Richardsonauthor=A.+Ratelauthor=J.+Racioppaauthor=G.+Bwalaauthor=S.+Reichweinauthor=C.+Rochaauthor=K.+Williamsauthor=K.+Keithauthor=E.+Carmanauthor=S.+Evansauthor=A.+Daleyauthor=K.+Venkiteswaranauthor=V.+Ephronauthor=K.+Ortizauthor=A.+Stovallauthor=M.+Goddardauthor=R.+Wagnerauthor=K.+Ambrogiauthor=C.+Petersonauthor=C.+A.+Thomasauthor=M.+Cinesauthor=P.+Edeauthor=P.+LeBlancauthor=S.+Rolandelliauthor=B.+Lewisauthor=A.+Fierroauthor=B.+Chewauthor=J.+McGeeauthor=P.+McCannauthor=M.+Matwichynaauthor=A.+Wattsauthor=M.+McDermottauthor=S.+Eberlyauthor=B.+Grecoauthor=S.+Hendersonauthor=J.+Lowellauthor=A.+Siderowfauthor=R.+Chappellauthor=J.+Phillipsauthor=K.+D.+Sethiauthor=W.+B.+White&title=Isradipine+versus+placebo+in+early+Parkinson+Disease%3A+A+randomized+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.7326%2FM19-2534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252FM19-2534%26sid%3Dliteratum%253Aachs%26aulast%3DSimuni%26aufirst%3DT.%26aulast%3DOakes%26aufirst%3DD.%26aulast%3DBiglan%26aufirst%3DK.%26aulast%3DGalpern%26aufirst%3DW.%2BR.%26aulast%3DHauser%26aufirst%3DR.%26aulast%3DHodgeman%26aufirst%3DK.%26aulast%3DKayson%26aufirst%3DE.%26aulast%3DKinel%26aufirst%3DD.%26aulast%3DLang%26aufirst%3DA.%26aulast%3DLungu%26aufirst%3DC.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DShoulson%26aufirst%3DI.%26aulast%3DTarolli%26aufirst%3DC.%2BG.%26aulast%3DSurmeier%26aufirst%3DD.%2BJ.%26aulast%3DVenuto%26aufirst%3DC.%26aulast%3DHolloway%26aufirst%3DR.%26aulast%3DKompoliti%26aufirst%3DK.%26aulast%3DRichard%26aufirst%3DI.%26aulast%3DSchneider%26aufirst%3DR.%26aulast%3DEvatt%26aufirst%3DM.%26aulast%3DHinson%26aufirst%3DV.%26aulast%3DSahay%26aufirst%3DA.%26aulast%3DLitvan%26aufirst%3DI.%26aulast%3DFarbman%26aufirst%3DE.%2BS.%26aulast%3DRacette%26aufirst%3DB.%26aulast%3DBlindauer%26aufirst%3DK.%26aulast%3DThomas%26aufirst%3DK.%26aulast%3DWater%26aufirst%3DC.%26aulast%3DMarras%26aufirst%3DC.%26aulast%3DLuca%26aufirst%3DC.%2BC.%26aulast%3DHung%26aufirst%3DA.%26aulast%3DDeik%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DD.%26aulast%3DZadikoff%26aufirst%3DC.%26aulast%3DPanisset%26aufirst%3DM.%26aulast%3DRabin%26aufirst%3DM.%26aulast%3DBrodsky%26aufirst%3DM.%26aulast%3DMills%26aufirst%3DK.%26aulast%3DShtilbans%26aufirst%3DA.%26aulast%3DHanspal%26aufirst%3DE.%26aulast%3DChristine%26aufirst%3DC.%2BW.%26aulast%3DSubramanian%26aufirst%3DT.%26aulast%3DSchiess%26aufirst%3DM.%2BC.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DChou%26aufirst%3DK.%2BL.%26aulast%3DShah%26aufirst%3DB.%26aulast%3DGuttman%26aufirst%3DM.%26aulast%3DShill%26aufirst%3DH.%26aulast%3DSlevin%26aufirst%3DJ.%26aulast%3DGoudreau%26aufirst%3DJ.%2BL.%26aulast%3DPark%26aufirst%3DA.%26aulast%3DBertoni%26aufirst%3DJ.%26aulast%3DSaint-Hilaire%26aufirst%3DM.%2BH.%26aulast%3DStover%26aufirst%3DN.%26aulast%3DAquino%26aufirst%3DC.%26aulast%3DShprecher%26aufirst%3DD.%26aulast%3DAhmed%26aufirst%3DA.%26aulast%3DShulman%26aufirst%3DL.%26aulast%3DParashos%26aufirst%3DS.%2BA.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DTuite%26aufirst%3DP.%26aulast%3DLanglois%26aufirst%3DM.%26aulast%3DDanisi%26aufirst%3DF.%26aulast%3DAgarwal%26aufirst%3DP.%26aulast%3DMestre%26aufirst%3DT.%26aulast%3DRussell%26aufirst%3DD.%26aulast%3DTruong%26aufirst%3DD.%26aulast%3DHermanowicz%26aufirst%3DN.%26aulast%3DZweig%26aufirst%3DR.%26aulast%3DSuchowersky%26aufirst%3DO.%26aulast%3DSarna%26aufirst%3DJ.%2BR.%26aulast%3DRoss%26aufirst%3DG.%2BW.%26aulast%3DBlasucci%26aufirst%3DL.%26aulast%3DZimmerman%26aufirst%3DC.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DNeefus%26aufirst%3DE.%26aulast%3DPecoraro%26aufirst%3DM.%26aulast%3DWheeler%26aufirst%3DL.%26aulast%3DRichardson%26aufirst%3DL.%26aulast%3DRatel%26aufirst%3DA.%26aulast%3DRacioppa%26aufirst%3DJ.%26aulast%3DBwala%26aufirst%3DG.%26aulast%3DReichwein%26aufirst%3DS.%26aulast%3DRocha%26aufirst%3DC.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DKeith%26aufirst%3DK.%26aulast%3DCarman%26aufirst%3DE.%26aulast%3DEvans%26aufirst%3DS.%26aulast%3DDaley%26aufirst%3DA.%26aulast%3DVenkiteswaran%26aufirst%3DK.%26aulast%3DEphron%26aufirst%3DV.%26aulast%3DOrtiz%26aufirst%3DK.%26aulast%3DStovall%26aufirst%3DA.%26aulast%3DGoddard%26aufirst%3DM.%26aulast%3DWagner%26aufirst%3DR.%26aulast%3DAmbrogi%26aufirst%3DK.%26aulast%3DPeterson%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DC.%2BA.%26aulast%3DCines%26aufirst%3DM.%26aulast%3DEde%26aufirst%3DP.%26aulast%3DLeBlanc%26aufirst%3DP.%26aulast%3DRolandelli%26aufirst%3DS.%26aulast%3DLewis%26aufirst%3DB.%26aulast%3DFierro%26aufirst%3DA.%26aulast%3DChew%26aufirst%3DB.%26aulast%3DMcGee%26aufirst%3DJ.%26aulast%3DMcCann%26aufirst%3DP.%26aulast%3DMatwichyna%26aufirst%3DM.%26aulast%3DWatts%26aufirst%3DA.%26aulast%3DMcDermott%26aufirst%3DM.%26aulast%3DEberly%26aufirst%3DS.%26aulast%3DGreco%26aufirst%3DB.%26aulast%3DHenderson%26aufirst%3DS.%26aulast%3DLowell%26aufirst%3DJ.%26aulast%3DSiderowf%26aufirst%3DA.%26aulast%3DChappell%26aufirst%3DR.%26aulast%3DPhillips%26aufirst%3DJ.%26aulast%3DSethi%26aufirst%3DK.%2BD.%26aulast%3DWhite%26aufirst%3DW.%2BB.%26atitle%3DIsradipine%2520versus%2520placebo%2520in%2520early%2520Parkinson%2520Disease%253A%2520A%2520randomized%2520trial%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2020%26volume%3D172%26issue%3D9%26spage%3D591%26epage%3D598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liss, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Striessnig, J.</span></span> <span> </span><span class="NLM_article-title">The potential of L-type calcium channels as a drug target for neuroprotective therapy in Parkinsonâs disease</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">263</span>â <span class="NLM_lpage">289</span>, <span class="refDoi">Â DOI: 10.1146/annurev-pharmtox-010818-021214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1146%2Fannurev-pharmtox-010818-021214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=30625283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms12rsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2019&pages=263-289&author=B.+Lissauthor=J.+Striessnig&title=The+potential+of+L-type+calcium+channels+as+a+drug+target+for+neuroprotective+therapy+in+Parkinson%E2%80%99s+disease&doi=10.1146%2Fannurev-pharmtox-010818-021214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson's Disease</span></div><div class="casAuthors">Liss, Birgit; Striessnig, Joerg</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">263-289</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  The motor symptoms of Parkinson's disease (PD) mainly arise from degeneration of dopamine neurons within the substantia nigra.  As no disease-modifying PD therapies are available, and side effects limit long-term benefits of current symptomatic therapies, novel treatment approaches are needed.  The ongoing phase III clin. study STEADY-PD is investigating the potential of the dihydropyridine isradipine, an L-type Ca2+ channel (LTCC) blocker, for neuroprotective PD therapy.  Here we review the clin. and preclin. rationale for this trial and discuss potential reasons for the ambiguous outcomes of in vivo animal model studies that address PD-protective dihydropyridine effects.  We summarize current views about the roles of Cav1.2 and Cav1.3 LTCC isoforms for substantia nigra neuron function, and their high vulnerability to degenerative stressors, and for PD pathophysiol.  We discuss different dihydropyridine sensitivities of LTCC isoforms in view of their potential as drug targets for PD neuroprotection, and we conclude by considering how these aspects could guide further drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSckGrrfwLpbVg90H21EOLACvtfcHk0liWs4PCQSQFyQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms12rsA%253D%253D&md5=79cccc8c1127bd07acdc944aadc6173a</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010818-021214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010818-021214%26sid%3Dliteratum%253Aachs%26aulast%3DLiss%26aufirst%3DB.%26aulast%3DStriessnig%26aufirst%3DJ.%26atitle%3DThe%2520potential%2520of%2520L-type%2520calcium%2520channels%2520as%2520a%2520drug%2520target%2520for%2520neuroprotective%2520therapy%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2019%26volume%3D59%26spage%3D263%26epage%3D289%26doi%3D10.1146%2Fannurev-pharmtox-010818-021214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilijic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercer, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rick, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tkatch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meredith, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surmeier, D. J.</span></span> <span> </span><span class="NLM_article-title">âRejuvenationâ protects neurons in mouse models of Parkinsonâs disease</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>447</i></span> (<span class="NLM_issue">7148</span>),  <span class="NLM_fpage">1081</span>â <span class="NLM_lpage">1086</span>, <span class="refDoi">Â DOI: 10.1038/nature05865</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2Fnature05865" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=17558391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvFKmurY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=447&publication_year=2007&pages=1081-1086&issue=7148&author=C.+S.+Chanauthor=J.+N.+Guzmanauthor=E.+Ilijicauthor=J.+N.+Mercerauthor=C.+Rickauthor=T.+Tkatchauthor=G.+E.+Meredithauthor=D.+J.+Surmeier&title=%E2%80%99Rejuvenation%E2%80%99+protects+neurons+in+mouse+models+of+Parkinson%E2%80%99s+disease&doi=10.1038%2Fnature05865"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">'Rejuvenation' protects neurons in mouse models of Parkinson's disease</span></div><div class="casAuthors">Chan, C. Savio; Guzman, Jaime N.; Ilijic, Ema; Mercer, Jeff N.; Rick, Caroline; Tkatch, Tatiana; Meredith, Gloria E.; Surmeier, D. James</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">447</span>
        (<span class="NLM_cas:issue">7148</span>),
    <span class="NLM_cas:pages">1081-1086</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Why dopamine-contg. neurons of the brain's substantia nigra pars compacta die in Parkinson's disease was an enduring mystery.  The authors' studies suggest that the unusual reliance of these neurons on L-type Cav1.3 Ca2+ channels to drive their maintained, rhythmic pacemaking renders them vulnerable to stressors thought to contribute to disease progression.  The reliance on these channels increases with age, as juvenile dopamine-contg. neurons in the substantia nigra pars compacta use pacemaking mechanisms common to neurons not affected in Parkinson's disease.  These mechanisms remain latent in adulthood, and blocking Cav1.3 Ca2+ channels in adult neurons induces a reversion to the juvenile form of pacemaking.  Such blocking ('rejuvenation') protects these neurons in both in vitro and in vivo models of Parkinson's disease, pointing to a new strategy that could slow or stop the progression of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4cTWDOImAdLVg90H21EOLACvtfcHk0lhYO0vFH69LcQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvFKmurY%253D&md5=debc60fc9e881232ff843aa2d702f706</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fnature05865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05865%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DC.%2BS.%26aulast%3DGuzman%26aufirst%3DJ.%2BN.%26aulast%3DIlijic%26aufirst%3DE.%26aulast%3DMercer%26aufirst%3DJ.%2BN.%26aulast%3DRick%26aufirst%3DC.%26aulast%3DTkatch%26aufirst%3DT.%26aulast%3DMeredith%26aufirst%3DG.%2BE.%26aulast%3DSurmeier%26aufirst%3DD.%2BJ.%26atitle%3D%25E2%2580%2599Rejuvenation%25E2%2580%2599%2520protects%2520neurons%2520in%2520mouse%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNature%26date%3D2007%26volume%3D447%26issue%3D7148%26spage%3D1081%26epage%3D1086%26doi%3D10.1038%2Fnature05865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ilijic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surmeier, D. J.</span></span> <span> </span><span class="NLM_article-title">The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinsonâs disease</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">364</span>â <span class="NLM_lpage">371</span>, <span class="refDoi">Â DOI: 10.1016/j.nbd.2011.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.nbd.2011.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=21515375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFWhu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2011&pages=364-371&issue=2&author=E.+Ilijicauthor=J.+N.+Guzmanauthor=D.+J.+Surmeier&title=The+L-type+channel+antagonist+isradipine+is+neuroprotective+in+a+mouse+model+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.nbd.2011.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease</span></div><div class="casAuthors">Ilijic, E.; Guzman, J. N.; Surmeier, D. J.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">364-371</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The motor symptoms of Parkinson's disease (PD) are due to the progressive loss of dopamine (DA) neurons in substantia nigra pars compacta (SNc).  Nothing is known to slow the progression of the disease, making the identification of potential neuroprotective agents of great clin. importance.  Previous studies using the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD have shown that antagonism of L-type Ca2+ channels protects SNc DA neurons.  However, this was not true in a 6-hydroxydopamine (6-OHDA) model.  One potential explanation for this discrepancy is that protection in the 6-OHDA model requires greater antagonism of Cav1.3 L-type Ca2+ channels thought to underlie vulnerability and this was not achievable with the low affinity dihydropyridine (DHP) antagonist used.  To test this hypothesis, the DHP with the highest affinity for Cav1.3 L-type channels-isradipine-was systemically administered and then the DA toxin 6-OHDA injected intrastriatally.  Twenty-five days later, neuroprotection and plasma concn. of isradipine were detd.  This anal. revealed that isradipine produced a dose-dependent sparing of DA fibers and cell bodies at concns. achievable in humans, suggesting that isradipine is a potentially viable neuroprotective agent for PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp6wN3kCMb3rVg90H21EOLACvtfcHk0lhYO0vFH69LcQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFWhu70%253D&md5=b96f0cca0dee1a73e6de38b12b329d30</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2011.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2011.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DIlijic%26aufirst%3DE.%26aulast%3DGuzman%26aufirst%3DJ.%2BN.%26aulast%3DSurmeier%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520L-type%2520channel%2520antagonist%2520isradipine%2520is%2520neuroprotective%2520in%2520a%2520mouse%2520model%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2011%26volume%3D43%26issue%3D2%26spage%3D364%26epage%3D371%26doi%3D10.1016%2Fj.nbd.2011.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ortner, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bock, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougalis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharitonova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuluc, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomberger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitterl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciossek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberacher, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Draheim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kloppenburg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liss, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Striessnig, J.</span></span> <span> </span><span class="NLM_article-title">Lower affinity of isradipine for L-type Ca(2+) channels during substantia nigra dopamine neuron-like activity: Implications for neuroprotection in Parkinsonâs disease</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">28</span>),  <span class="NLM_fpage">6761</span>â <span class="NLM_lpage">6777</span>, <span class="refDoi">Â DOI: 10.1523/JNEUROSCI.2946-16.2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1523%2FJNEUROSCI.2946-16.2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28592699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFCht73F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=6761-6777&issue=28&author=N.+J.+Ortnerauthor=G.+Bockauthor=A.+Dougalisauthor=M.+Kharitonovaauthor=J.+Dudaauthor=S.+Hessauthor=P.+Tulucauthor=T.+Pombergerauthor=N.+Stefanovaauthor=F.+Pitterlauthor=T.+Ciossekauthor=H.+Oberacherauthor=H.+J.+Draheimauthor=P.+Kloppenburgauthor=B.+Lissauthor=J.+Striessnig&title=Lower+affinity+of+isradipine+for+L-type+Ca%282%2B%29+channels+during+substantia+nigra+dopamine+neuron-like+activity%3A+Implications+for+neuroprotection+in+Parkinson%E2%80%99s+disease&doi=10.1523%2FJNEUROSCI.2946-16.2017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Lower affinity of isradipine for L-type Ca2+ channels during substantia nigra dopamine neuron-like activity: implications for neuroprotection in Parkinson's disease</span></div><div class="casAuthors">Ortner, Nadine J.; Bock, Gabriella; Dougalis, Antonios; Kharitonova, Maria; Duda, Johanna; Hess, Simon; Tuluc, Petronel; Pomberger, Thomas; Stefanova, Nadia; Pitterl, Florian; Ciossek, Thomas; Oberacher, Herbert; Draheim, Henning J.; Kloppenburg, Peter; Liss, Birgit; Striessnig, Joerg</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">6761-6777</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">1529-2401</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Ca2+-influx through L-type Ca2+-channels (LTCCs) is assocd. with activity-related stressful oscillations of Ca2+ levels within dopaminergic (DA) neurons in the substantia nigra (SN), which may contribute to their selective degeneration in Parkinson's disease (PD).  LTCC blockers were neuroprotective in mouse neurotoxin models of PD, and isradipine is currently undergoing testing in a phase III clin. trial in early PD.  We report no evidence for neuroprotection by in vivo pretreatment with therapeutically relevant isradipine plasma levels, or Cav1.3 LTCC deficiency in 6-OHDA-treated male mice.  To explain this finding, we investigated the pharmacol. properties of human LTCCs during SN DA-like and arterial smooth muscle (aSM)-like activity patterns using whole-cell patch-clamp recordings in HEK293 cells (Cav1.2 Î±1-subunit, long and short Cav1.3 Î±1-subunit splice variants; Î²3/Î±2Î´1).  During SN DA-like pacemaking, only Cav1.3 variants conducted Ca2+ current (ICa) at subthreshold potentials between action potentials.  SN DA-like burst activity increased integrated ICa during (Cav1.2 plus Cav1.3) and after (Cav1.3) the burst.  Isradipine inhibition was splice variant and isoform dependent, with a 5- to 11-fold lower sensitivity to Cav1.3 variants during SN DA-like pacemaking compared with Cav1.2 during aSM-like activity.  Supratherapeutic isradipine concns. reduced the pacemaker precision of adult mouse SN DA neurons but did not affect their somatic Ca2+ oscillations.  Our data predict that Cav1.2 and Cav1.3 splice variants contribute differentially to Ca2+ load in SN DA neurons, with prominent Cav1.3-mediated ICa between action potentials and after bursts.  The failure of therapeutically relevant isradipine levels to protect SN DA neurons can be explained by weaker state-dependent inhibition of SN DA LTCCs compared with aSM Cav1.2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXyYOpdxSgjrVg90H21EOLACvtfcHk0lhYO0vFH69LcQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFCht73F&md5=1f62fb42846e0d6a04a7645bf2b4fd83</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.2946-16.2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.2946-16.2017%26sid%3Dliteratum%253Aachs%26aulast%3DOrtner%26aufirst%3DN.%2BJ.%26aulast%3DBock%26aufirst%3DG.%26aulast%3DDougalis%26aufirst%3DA.%26aulast%3DKharitonova%26aufirst%3DM.%26aulast%3DDuda%26aufirst%3DJ.%26aulast%3DHess%26aufirst%3DS.%26aulast%3DTuluc%26aufirst%3DP.%26aulast%3DPomberger%26aufirst%3DT.%26aulast%3DStefanova%26aufirst%3DN.%26aulast%3DPitterl%26aufirst%3DF.%26aulast%3DCiossek%26aufirst%3DT.%26aulast%3DOberacher%26aufirst%3DH.%26aulast%3DDraheim%26aufirst%3DH.%2BJ.%26aulast%3DKloppenburg%26aufirst%3DP.%26aulast%3DLiss%26aufirst%3DB.%26aulast%3DStriessnig%26aufirst%3DJ.%26atitle%3DLower%2520affinity%2520of%2520isradipine%2520for%2520L-type%2520Ca%25282%252B%2529%2520channels%2520during%2520substantia%2520nigra%2520dopamine%2520neuron-like%2520activity%253A%2520Implications%2520for%2520neuroprotection%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurosci.%26date%3D2017%26volume%3D37%26issue%3D28%26spage%3D6761%26epage%3D6777%26doi%3D10.1523%2FJNEUROSCI.2946-16.2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghanbari-Maman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghasemian-Roudsari, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliakbari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourbadie, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khodagholic, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaerzadehd, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daftari, M.</span></span> <span> </span><span class="NLM_article-title">Calcium channel blockade ameliorates endoplasmic reticulum stress in the hippocampus induced by amyloidopathy in the entorhinal cortex</span>. <i>Iran. J. Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1466</span>â <span class="NLM_lpage">1476</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=32641955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslWju7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=1466-1476&issue=3&author=A.+Ghanbari-Mamanauthor=F.+Ghasemian-Roudsariauthor=S.+Aliakbariauthor=H.+G.+Pourbadieauthor=F.+Khodagholicauthor=F.+Shaerzadehdauthor=M.+Daftari&title=Calcium+channel+blockade+ameliorates+endoplasmic+reticulum+stress+in+the+hippocampus+induced+by+amyloidopathy+in+the+entorhinal+cortex"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium channel blockade ameliorates endoplasmic reticulum stress in the hippocampus induced by amyloidopathy in the entorhinal cortex</span></div><div class="casAuthors">Ghanbari-Maman, Azam; Ghasemian-Roudsari, Forouzan; Aliakbari, Shayan; Pourbadie, Hamid Gholami; Khodagholi, Fariba; Shaerzadeh, Fatemeh; Daftari, Mahtab</div><div class="citationInfo"><span class="NLM_cas:title">Iranian Journal of Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1466-1476</span>CODEN:
                <span class="NLM_cas:coden">IJPRC9</span>;
        ISSN:<span class="NLM_cas:issn">1726-6890</span>.
    
            (<span class="NLM_cas:orgname">Shaheed Beheshti University of Medical Sciences and Health Services, School of Pharmacy</span>)
        </div><div class="casAbstract">Entorhinal cortex (EC) is one of the first cerebral regions affected in Alzheimer's disease (AD).  The pathol. propagates to neighboring cerebral regions through a prion-like mechanism.  In AD, intracellular calcium dyshomeostasis is assocd. with endoplasmic reticulum (ER) stress.  This study was designed to examine hippocampal ER stress following EC amyloidopathy.  AÎ²1-42 was bilaterally microinjected into the EC under stereotaxic surgery.  Rats were daily treated with 30 Î¼g of isradipine, nimodipine, or placebo over one week.  Passive avoidance and novel object recognition (NOR) tasks were performed using shuttle box and NOR test, resp.  GRP78/BiP and CHOP levels were measured in the hippocampal dentate gyrus (DG) by western blot technique.  The glutathione (GSH) level and PDI activity were also assessed in the hippocampus by colorimetric spectrophotometer.  AÎ² treated group developed passive avoidance and novel recognition memory deficit compared to the control group.  However, treatment with calcium channel blockers reversed the impairment.  BiP and CHOP level increased in the hippocampus following amyloidopathy in the EC.  PDI activity and GSH level in the hippocampus decreased in the AÎ² treated group, but calcium channel blockers restored them toward the control level.  In conclusion, memory impairment due to EC amyloidopathy is assocd. with ER stress related bio-mol. changes in the hippocampus, and treatment with L-type calcium channel blockers may prevent the changes and ultimately improve cognitive performance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxgzyBYyrTRrVg90H21EOLACvtfcHk0lhZMOciwgybrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslWju7g%253D&md5=5047ec0f982da32399f4707ecfd06d54</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGhanbari-Maman%26aufirst%3DA.%26aulast%3DGhasemian-Roudsari%26aufirst%3DF.%26aulast%3DAliakbari%26aufirst%3DS.%26aulast%3DPourbadie%26aufirst%3DH.%2BG.%26aulast%3DKhodagholic%26aufirst%3DF.%26aulast%3DShaerzadehd%26aufirst%3DF.%26aulast%3DDaftari%26aufirst%3DM.%26atitle%3DCalcium%2520channel%2520blockade%2520ameliorates%2520endoplasmic%2520reticulum%2520stress%2520in%2520the%2520hippocampus%2520induced%2520by%2520amyloidopathy%2520in%2520the%2520entorhinal%2520cortex%26jtitle%3DIran.%2520J.%2520Pharm.%2520Res.%26date%3D2019%26volume%3D18%26issue%3D3%26spage%3D1466%26epage%3D1476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pourbadie, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naderi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehranfard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janahmadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khodagholi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motamedi, F.</span></span> <span> </span><span class="NLM_article-title">Preventing effect of L-type calcium channel blockade on electrophysiological alterations in dentate gyrus granule cells induced by entorhinal amyloid pathology</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">e0117555</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0117555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1371%2Fjournal.pone.0117555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=25689857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVyltL7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0117555&issue=2&author=H.+G.+Pourbadieauthor=N.+Naderiauthor=N.+Mehranfardauthor=M.+Janahmadiauthor=F.+Khodagholiauthor=F.+Motamedi&title=Preventing+effect+of+L-type+calcium+channel+blockade+on+electrophysiological+alterations+in+dentate+gyrus+granule+cells+induced+by+entorhinal+amyloid+pathology&doi=10.1371%2Fjournal.pone.0117555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Preventing effect of L-type calcium channel blockade on electrophysiological alterations in dentate gyrus granule cells induced by entorhinal amyloid pathology</span></div><div class="casAuthors">Pourbadie, Hamid Gholami; Naderi, Nima; Mehranfard, Nasrin; Janahmadi, Mahyar; Khodagholi, Fariba; Motamedi, Fereshteh</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e0117555/1-e0117555/19</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The entorhinal cortex (EC) is one of the earliest affected brain regions in Alzheimer's disease (AD).  EC-amyloid pathol. induces synaptic failure in the dentate gyrus (DG) with resultant behavioral impairment, but there is little known about its impact on neuronal properties in the DG.  It is believed that calcium dyshomeostasis plays a pivotal role in the etiol. of AD.  Here, the effect of the EC amyloid pathogenesis on cellular properties of DG granule cells and also possible neuroprotective role of L-type calcium channel blockers (CCBs), nimodipine and isradipine, were investigated.  The amyloid beta (AÎ²) 1-42 was injected bilaterally into the EC of male rats and one week later, electrophysiol. properties of DG granule cells were assessed.  Voltage clamp recording revealed appearance of giant sIPSC in combination with a decrease in sEPSC frequency which was partially reversed by CCBs in granule cells from AÎ² treated rats.  EC amyloid pathogenesis induced a significant redn. of input resistance (Rin) accompanied by a profound decreased excitability in the DG granule cells.  However, daily administration of CCBs, isradipine or nimodipine (i.c.v. for 6 days), almost preserved the normal excitability against AÎ².  In conclusion, lower tendency to fire AP along with reduced Rin suggest that DG granule cells might undergo an alteration in the membrane ion channel activities which finally lead to the behavioral deficits obsd. in animal models and patients with early-stage Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6QRyECfYhkbVg90H21EOLACvtfcHk0lhZMOciwgybrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVyltL7O&md5=3199e889ac157bc00b9e0efc77301762</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0117555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0117555%26sid%3Dliteratum%253Aachs%26aulast%3DPourbadie%26aufirst%3DH.%2BG.%26aulast%3DNaderi%26aufirst%3DN.%26aulast%3DMehranfard%26aufirst%3DN.%26aulast%3DJanahmadi%26aufirst%3DM.%26aulast%3DKhodagholi%26aufirst%3DF.%26aulast%3DMotamedi%26aufirst%3DF.%26atitle%3DPreventing%2520effect%2520of%2520L-type%2520calcium%2520channel%2520blockade%2520on%2520electrophysiological%2520alterations%2520in%2520dentate%2520gyrus%2520granule%2520cells%2520induced%2520by%2520entorhinal%2520amyloid%2520pathology%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26issue%3D2%26spage%3De0117555%26doi%3D10.1371%2Fjournal.pone.0117555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anekonda, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frahler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadsworth, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woltjer, R. L.</span></span> <span> </span><span class="NLM_article-title">L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimerâs disease</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">62</span>â <span class="NLM_lpage">70</span>, <span class="refDoi">Â DOI: 10.1016/j.nbd.2010.08.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.nbd.2010.08.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=20816785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWqsLbE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=62-70&issue=1&author=T.+S.+Anekondaauthor=J.+F.+Quinnauthor=C.+Harrisauthor=K.+Frahlerauthor=T.+L.+Wadsworthauthor=R.+L.+Woltjer&title=L-type+voltage-gated+calcium+channel+blockade+with+isradipine+as+a+therapeutic+strategy+for+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.nbd.2010.08.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease</span></div><div class="casAuthors">Anekonda, Thimmappa S.; Quinn, Joseph F.; Harris, Christopher; Frahler, Kate; Wadsworth, Teri L.; Woltjer, Randall L.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-70</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">There is strong evidence that intracellular calcium dysregulation plays an important pathol. role in Alzheimer's disease, and specifically that beta amyloid may induce increases in intracellular calcium and lead to neuronal cell dysfunction and death.  Here we investigated the feasibility of modifying Alzheimer's pathol. with the L-type voltage-gated calcium channel blockers verapamil, diltiazem, isradipine and nimodipine.  All four compds. protected MC65 neuroblastoma cells from amyloid beta protein precursor C-terminal fragment (APP CTF)-induced neurotoxicity.  Isradipine was the most potent blocker, preventing APP CTF neurotoxicity at nanomolar concns.  Intracellular beta amyloid expression was assocd. with increased expression of Cav 1.2 calcium channels and increased intracellular calcium influx from the extracellular space.  Despite the cytoprotection afforded by calcium channel blockers, amyloid beta oligomer formation was not suppressed.  The mechanism of cell death in MC65 cells is appeared to be caspase-3 independent.  With the goal of detg. if there is sufficient exptl. support to move forward with animal trials of isradipine, we detd. its bioavailability in the triple transgenic mouse model of AD.  S.c. implantation of carrier-bound isradipine (3 Î¼g/g/day) for 60 days resulted in nanomolar concns. in both the plasma and brain.  Taken together, our in vitro results support the theory that calcium blockers exert protective effects downstream of the effects of beta amyloid.  Isradipine's neuroprotective effect at concns. that are clin. relevant and achievable in vitro and in vivo suggests that this particular calcium blocking agent may have therapeutic value in the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-QaET8NSy7bVg90H21EOLACvtfcHk0lhZMOciwgybrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWqsLbE&md5=0ddf211422ee5413299c4b393ab80aff</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2010.08.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2010.08.020%26sid%3Dliteratum%253Aachs%26aulast%3DAnekonda%26aufirst%3DT.%2BS.%26aulast%3DQuinn%26aufirst%3DJ.%2BF.%26aulast%3DHarris%26aufirst%3DC.%26aulast%3DFrahler%26aufirst%3DK.%26aulast%3DWadsworth%26aufirst%3DT.%2BL.%26aulast%3DWoltjer%26aufirst%3DR.%2BL.%26atitle%3DL-type%2520voltage-gated%2520calcium%2520channel%2520blockade%2520with%2520isradipine%2520as%2520a%2520therapeutic%2520strategy%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2011%26volume%3D41%26issue%3D1%26spage%3D62%26epage%3D70%26doi%3D10.1016%2Fj.nbd.2010.08.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anekonda, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, J. F.</span></span> <span> </span><span class="NLM_article-title">Calcium channel blocking as a therapeutic strategy for Alzheimerâs disease: The case for isradipine</span>. <i>Biochim. Biophys. Acta, Mol. Basis Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1812</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1584</span>â <span class="NLM_lpage">1590</span>, <span class="refDoi">Â DOI: 10.1016/j.bbadis.2011.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bbadis.2011.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=21925266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2htbnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1812&publication_year=2011&pages=1584-1590&issue=12&author=T.+S.+Anekondaauthor=J.+F.+Quinn&title=Calcium+channel+blocking+as+a+therapeutic+strategy+for+Alzheimer%E2%80%99s+disease%3A+The+case+for+isradipine&doi=10.1016%2Fj.bbadis.2011.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: The case for isradipine</span></div><div class="casAuthors">Anekonda, Thimmappa S.; Quinn, Joseph F.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1812</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1584-1590</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease is the most devastating neurodegenerative disorder in the elderly, yet treatment options are severely limited.  The drug development effort to modify Alzheimer's disease pathol. by intervention at beta amyloid prodn. sites has been largely ineffective or inconclusive.  The greatest challenge has been to identify and define downstream mechanisms reliably predictive of clin. symptoms.  Beta amyloid accumulation leads to dysregulation of intracellular calcium by plasma membrane L-type calcium channels located on neuronal somatodendrites and axons in the hippocampus and cortex.  Paradoxically, L-type calcium channel subtype Cav1.2 also promotes synaptic plasticity and spatial memory.  Increased intracellular calcium modulates amyloid precursor protein processing and affects multiple downstream pathways including increased hyperphosphorylated tau and suppression of autophagy.  Isradipine is a Federal Drug Administration-approved dihydropyridine calcium channel blocker that binds selectively to Cav1.2 in the hippocampus.  Our studies have shown that isradipine in vitro attenuates beta amyloid oligomer toxicity by suppressing calcium influx into cytoplasm and by suppressing Cav1.2 expression.  We have previously shown that administration of isradipine to triple transgenic animal model for Alzheimer's disease was well-tolerated.  Our results further suggest that isradipine became bioavailable, lowered tau burden, and improved autophagy function in the brain.  A better understanding of brain pharmacokinetics of calcium channel blockers will be crit. for designing new expts. with appropriate drug doses in any future clin. trials for Alzheimer's disease.  This review highlights the importance of Cav1.2 channel overexpression, the accumulation of hyperphosphorylated tau and suppression of autophagy in Alzheimer's disease and modulation of this pathway by isradipine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3wk5eKscM47Vg90H21EOLACvtfcHk0lgvFSdHNHm6eg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2htbnJ&md5=212aab116d87460754331fa496c7f63f</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.bbadis.2011.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbadis.2011.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DAnekonda%26aufirst%3DT.%2BS.%26aulast%3DQuinn%26aufirst%3DJ.%2BF.%26atitle%3DCalcium%2520channel%2520blocking%2520as%2520a%2520therapeutic%2520strategy%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520The%2520case%2520for%2520isradipine%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D2011%26volume%3D1812%26issue%3D12%26spage%3D1584%26epage%3D1590%26doi%3D10.1016%2Fj.bbadis.2011.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Arrieta, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birks, J.</span></span> <span> </span><span class="NLM_article-title">Nimodipine for primary degenerative, mixed and vascular dementia</span>. <i>Cochrane Database Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>, (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">CD000147</span>, <span class="refDoi">Â DOI: 10.1002/14651858.CD000147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2F14651858.CD000147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=12137606" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&pages=CD000147&issue=3&author=J.+M.+Lopez-Arrietaauthor=J.+Birks&title=Nimodipine+for+primary+degenerative%2C+mixed+and+vascular+dementia&doi=10.1002%2F14651858.CD000147"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD000147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD000147%26sid%3Dliteratum%253Aachs%26aulast%3DLopez-Arrieta%26aufirst%3DJ.%2BM.%26aulast%3DBirks%26aufirst%3DJ.%26atitle%3DNimodipine%2520for%2520primary%2520degenerative%252C%2520mixed%2520and%2520vascular%2520dementia%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2002%26issue%3D3%26spage%3DCD000147%26doi%3D10.1002%2F14651858.CD000147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lawlor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segurado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennelly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rikkert, M. G. M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boerjesson-Hanson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsolaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucca, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molloy, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riepe, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cregg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDwyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breuilh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaynor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheikhi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taekema, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhey, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nobili, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceschi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frisoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanetti, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konsta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasios, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nenopoulou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsolaki-Tagaraki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pakaski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dereeper, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Sayette, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senechal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavenu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devendeville, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calais, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullan, M.</span></span> <span> </span><span class="NLM_article-title">Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">e1002660</span>, <span class="refDoi">Â DOI: 10.1371/journal.pmed.1002660</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1371%2Fjournal.pmed.1002660" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=30248105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSlt7vP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=e1002660&issue=9&author=B.+Lawlorauthor=R.+Seguradoauthor=S.+Kennellyauthor=M.+G.+M.+O.+Rikkertauthor=R.+Howardauthor=F.+Pasquierauthor=A.+Boerjesson-Hansonauthor=M.+Tsolakiauthor=U.+Luccaauthor=D.+W.+Molloyauthor=R.+Coenauthor=M.+W.+Riepeauthor=J.+Kalmanauthor=R.+A.+Kennyauthor=F.+Creggauthor=S.+O%E2%80%99Dwyerauthor=C.+Walshauthor=J.+Adamsauthor=R.+Banziauthor=L.+Breuilhauthor=L.+Dalyauthor=S.+Hendrixauthor=P.+Aisenauthor=S.+Gaynorauthor=A.+Sheikhiauthor=D.+G.+Taekemaauthor=F.+R.+Verheyauthor=R.+Nemniauthor=F.+Nobiliauthor=M.+Franceschiauthor=G.+Frisoniauthor=O.+Zanettiauthor=A.+Konstaauthor=O.+Anastasiosauthor=S.+Nenopoulouauthor=F.+Tsolaki-Tagarakiauthor=M.+Pakaskiauthor=O.+Dereeperauthor=V.+de+la+Sayetteauthor=O.+Senechalauthor=I.+Lavenuauthor=A.+Devendevilleauthor=G.+Calaisauthor=F.+Crawfordauthor=M.+Mullan&title=Nilvadipine+in+mild+to+moderate+Alzheimer+disease%3A+A+randomised+controlled+trial&doi=10.1371%2Fjournal.pmed.1002660"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Nilvadipine in mild to moderate Alzheimer disease: a randomised controlled trial</span></div><div class="casAuthors">Lawlor, Brian; Segurado, Ricardo; Kennelly, Sean; Rikkert, Marcel G. M. Olde; Howard, Robert; Pasquier, Florence; Boerjesson-Hanson, Anne; Tsolaki, Magda; Lucca, Ugo; Molloy, D. William; Coen, Robert; Riepe, Matthias W.; Kalman, Janos; Kenny, Rose Anne; Cregg, Fiona; O'Dwyer, Sarah; Walsh, Cathal; Adams, Jessica; Banzi, Rita; Breuilh, Laetitia; Daly, Leslie; Hendrix, Suzanne; Aisen, Paul; Gaynor, Siobhan; Sheikhi, Ali; Taekema, Diana G.; Verhey, Frans R.; Nemni, Raffaello; Nobili, Flavio; Franceschi, Massimo; Frisoni, Giovanni; Zanetti, Orazio; Konsta, Anastasia; Anastasios, Orologas; Nenopoulou, Styliani; Tsolaki-Tagaraki, Fani; Pakaski, Magdolna; Dereeper, Olivier; de la Sayette, Vincent; Senechal, Olivier; Lavenu, Isabelle; Devendeville, Agnes; Calais, Gauthier; Crawford, Fiona; Mullan, Michael</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e1002660/1-e1002660/20</span>CODEN:
                <span class="NLM_cas:coden">PMLEAC</span>;
        ISSN:<span class="NLM_cas:issn">1549-1277</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background This study reports the findings of the first large-scale Phase III investigator-driven clin. trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine.  Nilvadipine, licensed to treat hypertension, reduces amyloid prodn., increases regional cerebral blood flow, and has demonstrated antiinflammatory and anti-tau activity in preclin. studies, properties that could have diseasemodifying effects for Alzheimer disease.  We aimed to det. if nilvadipine was effective in slowing cognitive decline in subjects with mild to moderate Alzheimer disease.  Methods and findings NILVAD was an 18-mo, randomised, placebo-controlled, double-blind trial that randomised participants between 15 May 2013 and 13 Apr. 2015.  The study was conducted at 23 academic centers in nine European countries.  Of 577 participants screened, 511 were eligible and were randomised (258 to placebo, 253 to nilvadipine).  Participants took a trial treatment capsule once a day after breakfast for 78 wk.  Participants were aged >50 years, meeting National Institute of Neurol. and Communicative Disorders and Stroke/Alzheimer's disease Criteria (NINCDS-ADRDA) for diagnosis of probable Alzheimer disease, with a Standardised Mini-Mental State Examn. (SMMSE) score of â¥12 and <27.  Participants were randomly assigned to 8 mg sustained-release nilvadipine or matched placebo.  The a priori defined primary outcome was progression on the Alzheimer's Disease Assessment Scale Cognitive Subscale-12 (ADAS-Cog 12) in the modified intention-to-treat (mITT) population (n = 498), with the Clin. Dementia Rating Scale sum of boxes (CDR-sb) as a gated co-primary outcome, eligible to be promoted to primary end point conditional on a significant effect on the ADAS-Cog 12.  The anal. set had a mean age of 73 years and was 62% female.  Baseline demog. and Alzheimer disease-specific characteristics were similar between treatment groups, with reported mean of 1.7 years since diagnosis and mean SMMSE of 20.4.  The prespecified primary analyses failed to show any treatment benefit for nilvadipine on the co-primary outcome (p = 0.465).  Decline from baseline in ADASCog 12 on placebo was 0.79 (95% CI, -0.07-1.64) at 13 wk, 6.41 (5.33-7.49) at 52 wk, and 9.63 (8.33-10.93) at 78 wk and on nilvadipine was 0.88 (0.02-1.74) at 13 wk, 5.75 (4.66-6.85) at 52 wk, and 9.41 (8.09-10.73) at 78 wk.  Exploratory analyses of the planned secondary outcomes showed no substantial effects, including on the CDR-sb or the Disability Assessment for Dementia.  Nilvadipine appeared to be safe and well tolerated.  Mortality was similar between groups (3 on nilvadipine, 4 on placebo); higher counts of adverse events (AEs) on nilvadipine (1,129 vs. 1,030), and serious adverse events (SAEs; 146 vs. 101), were obsd.  There were 14 withdrawals because of AEs.  Major limitations of this study were that subjects had established dementia and the likelihood that non-Alzheimer subjects were included because of the lack of biomarker confirmation of the presence of brain amyloid.  Conclusions The results do not suggest benefit of nilvadipine as a treatment in a population spanning mild to moderate Alzheimer disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtE9BqM0V94rVg90H21EOLACvtfcHk0lgvFSdHNHm6eg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSlt7vP&md5=466e7508932a7443edcb2757aed12e54</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.1002660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.1002660%26sid%3Dliteratum%253Aachs%26aulast%3DLawlor%26aufirst%3DB.%26aulast%3DSegurado%26aufirst%3DR.%26aulast%3DKennelly%26aufirst%3DS.%26aulast%3DRikkert%26aufirst%3DM.%2BG.%2BM.%2BO.%26aulast%3DHoward%26aufirst%3DR.%26aulast%3DPasquier%26aufirst%3DF.%26aulast%3DBoerjesson-Hanson%26aufirst%3DA.%26aulast%3DTsolaki%26aufirst%3DM.%26aulast%3DLucca%26aufirst%3DU.%26aulast%3DMolloy%26aufirst%3DD.%2BW.%26aulast%3DCoen%26aufirst%3DR.%26aulast%3DRiepe%26aufirst%3DM.%2BW.%26aulast%3DKalman%26aufirst%3DJ.%26aulast%3DKenny%26aufirst%3DR.%2BA.%26aulast%3DCregg%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DS.%26aulast%3DWalsh%26aufirst%3DC.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DBanzi%26aufirst%3DR.%26aulast%3DBreuilh%26aufirst%3DL.%26aulast%3DDaly%26aufirst%3DL.%26aulast%3DHendrix%26aufirst%3DS.%26aulast%3DAisen%26aufirst%3DP.%26aulast%3DGaynor%26aufirst%3DS.%26aulast%3DSheikhi%26aufirst%3DA.%26aulast%3DTaekema%26aufirst%3DD.%2BG.%26aulast%3DVerhey%26aufirst%3DF.%2BR.%26aulast%3DNemni%26aufirst%3DR.%26aulast%3DNobili%26aufirst%3DF.%26aulast%3DFranceschi%26aufirst%3DM.%26aulast%3DFrisoni%26aufirst%3DG.%26aulast%3DZanetti%26aufirst%3DO.%26aulast%3DKonsta%26aufirst%3DA.%26aulast%3DAnastasios%26aufirst%3DO.%26aulast%3DNenopoulou%26aufirst%3DS.%26aulast%3DTsolaki-Tagaraki%26aufirst%3DF.%26aulast%3DPakaski%26aufirst%3DM.%26aulast%3DDereeper%26aufirst%3DO.%26aulast%3Dde%2Bla%2BSayette%26aufirst%3DV.%26aulast%3DSenechal%26aufirst%3DO.%26aulast%3DLavenu%26aufirst%3DI.%26aulast%3DDevendeville%26aufirst%3DA.%26aulast%3DCalais%26aufirst%3DG.%26aulast%3DCrawford%26aufirst%3DF.%26aulast%3DMullan%26aufirst%3DM.%26atitle%3DNilvadipine%2520in%2520mild%2520to%2520moderate%2520Alzheimer%2520disease%253A%2520A%2520randomised%2520controlled%2520trial%26jtitle%3DPLoS%2520Med.%26date%3D2018%26volume%3D15%26issue%3D9%26spage%3De1002660%26doi%3D10.1371%2Fjournal.pmed.1002660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nimmrich, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, A.</span></span> <span> </span><span class="NLM_article-title">Calcium channel blockers and dementia</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>169</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1203</span>â <span class="NLM_lpage">1210</span>, <span class="refDoi">Â DOI: 10.1111/bph.12240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1111%2Fbph.12240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=23638877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVajsLbN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2013&pages=1203-1210&issue=6&author=V.+Nimmrichauthor=A.+Eckert&title=Calcium+channel+blockers+and+dementia&doi=10.1111%2Fbph.12240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium channel blockers and dementia</span></div><div class="casAuthors">Nimmrich, V.; Eckert, A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1203-1210</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Degenerative dementia is mainly caused by Alzheimer's disease and/or cerebrovascular abnormalities.  Disturbance of the intracellular calcium homeostasis is central to the pathophysiol. of neurodegeneration.  In Alzheimer's disease, enhanced calcium load may be brought about by extracellular accumulation of amyloid-Î².  Recent studies suggest that sol. forms facilitate influx through calcium-conducting ion channels in the plasma membrane, leading to excitotoxic neurodegeneration.  Calcium channel blockade attenuates amyloid-Î²-induced neuronal decline in vitro and is neuroprotective in animal models.  Vascular dementia, on the other hand, is caused by cerebral hypoperfusion and may benefit from calcium channel blockade due to relaxation of the cerebral vasculature.  Several calcium channel blockers have been tested in clin. trials of dementia and the outcome is heterogeneous.  Nimodipine as well as nilvadipine prevent cognitive decline in some trials, whereas other calcium channel blockers failed.  In trials with a pos. outcome, BP redn. did not seem to play a role in preventing dementia, indicating a direct protecting effect on neurons.  An optimization of calcium channel blockers for the treatment of dementia may involve an increase of selectivity for presynaptic calcium channels and an improvement of the affinity to the inactivated state.  Novel low mol. wt. compds. suitable for proof-of-concept studies are now available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1LmtHTozWHrVg90H21EOLACvtfcHk0liQKdIJBi4COA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVajsLbN&md5=9f5ea618c201fdad2ae66529110c6963</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1111%2Fbph.12240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12240%26sid%3Dliteratum%253Aachs%26aulast%3DNimmrich%26aufirst%3DV.%26aulast%3DEckert%26aufirst%3DA.%26atitle%3DCalcium%2520channel%2520blockers%2520and%2520dementia%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D169%26issue%3D6%26spage%3D1203%26epage%3D1210%26doi%3D10.1111%2Fbph.12240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roache, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ait-Daoud, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauldin, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murff, W. L.</span></span> <span> </span><span class="NLM_article-title">Effects of repeated-dose isradipine on the abuse liability of cocaine</span>. <i>Exp. Clin. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">319</span>â <span class="NLM_lpage">326</span>, <span class="refDoi">Â DOI: 10.1037/1064-1297.13.4.319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1037%2F1064-1297.13.4.319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=16366762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmt1Ghsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=319-326&issue=4&author=J.+D.+Roacheauthor=B.+A.+Johnsonauthor=N.+Ait-Daoudauthor=J.+B.+Mauldinauthor=J.+E.+Thorntonauthor=L.+T.+Wellsauthor=W.+L.+Murff&title=Effects+of+repeated-dose+isradipine+on+the+abuse+liability+of+cocaine&doi=10.1037%2F1064-1297.13.4.319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of repeated-dose isradipine on the abuse liability of cocaine</span></div><div class="casAuthors">Roache, John D.; Johnson, Bankole A.; Ait-Daoud, Nassima; Mauldin, James B.; Thornton, Joe E.; Wells, Lynda T.; Murff, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">319-326</span>CODEN:
                <span class="NLM_cas:coden">ECLPES</span>;
        ISSN:<span class="NLM_cas:issn">1064-1297</span>.
    
            (<span class="NLM_cas:orgname">American Psychological Association</span>)
        </div><div class="casAbstract">Despite preclin. studies suggesting that isradipine may antagonize the abuse liability of cocaine, pretreatment with sustained-release isradipine did not reduce euphoric mood in cocaine-using volunteers.  This double-blind, within-subject, crossover lab. study detd. whether maximal dose-loading with isradipine could antagonize effects of cocaine in 12 cocaine-dependent research volunteers administered i.v. cocaine doses (0, 0.325, and 0.65 mg/kg) on different days after 5 days of treatment with isradipine or placebo.  Isradipine dose was 30 mg sustained release nightly plus 15 mg immediate release 2 h before cocaine infusion.  Cocaine produced dose-related increases in cocaine's subjective effects and a behavioral measure of reinforcement.  Isradipine enhanced, rather than antagonized, subjective effects, indicating that isradipine does not antagonize cocaine's abuse liability in dependent research volunteers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXKyBOId5_6bVg90H21EOLACvtfcHk0liQKdIJBi4COA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmt1Ghsw%253D%253D&md5=94a956a086c71524198bf292a927d5ad</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1037%2F1064-1297.13.4.319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1037%252F1064-1297.13.4.319%26sid%3Dliteratum%253Aachs%26aulast%3DRoache%26aufirst%3DJ.%2BD.%26aulast%3DJohnson%26aufirst%3DB.%2BA.%26aulast%3DAit-Daoud%26aufirst%3DN.%26aulast%3DMauldin%26aufirst%3DJ.%2BB.%26aulast%3DThornton%26aufirst%3DJ.%2BE.%26aulast%3DWells%26aufirst%3DL.%2BT.%26aulast%3DMurff%26aufirst%3DW.%2BL.%26atitle%3DEffects%2520of%2520repeated-dose%2520isradipine%2520on%2520the%2520abuse%2520liability%2520of%2520cocaine%26jtitle%3DExp.%2520Clin.%2520Psychopharmacol.%26date%3D2005%26volume%3D13%26issue%3D4%26spage%3D319%26epage%3D326%26doi%3D10.1037%2F1064-1297.13.4.319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacology of ampakine modulators: From AMPA receptors to synapses and behavior</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">583</span>â <span class="NLM_lpage">602</span>, <span class="refDoi">Â DOI: 10.2174/138945007780618490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.2174%2F138945007780618490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=17504103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsVWmurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=583-602&issue=5&author=A.+C.+Araiauthor=M.+Kessler&title=Pharmacology+of+ampakine+modulators%3A+From+AMPA+receptors+to+synapses+and+behavior&doi=10.2174%2F138945007780618490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior</span></div><div class="casAuthors">Arai, A. C.; Kessler, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">583-602</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Ampakines are drugs structurally derived from aniracetam that potentiate currents mediated by AMPA type glutamate receptors.  These drugs slow deactivation and attenuate desensitization of AMPA receptor currents, increase synaptic responses and enhance long-term potentiation.  This review focuses mainly on recent physiol. studies and on evidence for two distinct subfamilies.  Type I compds. like CX546 are very effective in prolonging synaptic responses while type II compds. like CX516 mainly increase response amplitude.  Type I and II drugs do not compete in binding assays and thus presumably act through sep. sites.  Their differences are likely to have consequences also for synaptic plasticity and behavior.  Thus, while all ampakines facilitated long-term potentiation, only CX546 enhanced long-term depression.  Further discussed are studies showing that ampakine effects vary substantially between neurons, with increases in EPSCs being larger in CA1 pyramidal cells than in thalamus and in hippocampal interneurons.  In behavioral tests, ampakines facilitate learning in many paradigms including odor discrimination, spatial mazes, and conditioning, and they improved short-term memory in a non-matching-to-sample task.  Pos. results were also obtained in various psychol. tests with human subjects.  The drugs were effective in correcting behaviors in various animal models of schizophrenia and depression.  Lastly, evidence is discussed that ampakines have few adverse effects at therapeutically relevant concns. and that they protect neurons against neurotoxic insults, in part by mobilizing growth factors like BDNF.  Type II drugs like CX516 in particular appear to be inherently safe since their ability to prolong responses is kinetically limited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoUgfoEMXCALVg90H21EOLACvtfcHk0liQKdIJBi4COA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsVWmurk%253D&md5=77ecd4442f0c551eaec7a9d52c218efc</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.2174%2F138945007780618490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945007780618490%26sid%3Dliteratum%253Aachs%26aulast%3DArai%26aufirst%3DA.%2BC.%26aulast%3DKessler%26aufirst%3DM.%26atitle%3DPharmacology%2520of%2520ampakine%2520modulators%253A%2520From%2520AMPA%2520receptors%2520to%2520synapses%2520and%2520behavior%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2007%26volume%3D8%26issue%3D5%26spage%3D583%26epage%3D602%26doi%3D10.2174%2F138945007780618490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, G.</span></span> <span> </span><span class="NLM_article-title">Glutamate-based therapeutic approaches: Ampakines</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">82</span>â <span class="NLM_lpage">88</span>, <span class="refDoi">Â DOI: 10.1016/j.coph.2005.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.coph.2005.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=16361116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVyntg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=82-88&issue=1&author=G.+Lynch&title=Glutamate-based+therapeutic+approaches%3A+Ampakines&doi=10.1016%2Fj.coph.2005.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate-based therapeutic approaches: ampakines</span></div><div class="casAuthors">Lynch, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">82-88</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Ampakines are a structurally diverse family of small mols. that pos. modulate Î±-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors, and thereby enhance fast, excitatory transmission throughout the brain.  Surprisingly, ampakines have discrete effects on brain activity and behavior.  Because their excitatory synaptic targets mediate communication between cortical regions, serve as sites of memory encoding, and regulate the prodn. of growth factors, ampakines have a broad range of potential therapeutic applications.  Several of these possibilities were tested with pos. results in preclin. models; preliminary clin. work was also encouraging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2MuTJBdzIKrVg90H21EOLACvtfcHk0ljC9Z33RaDtLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVyntg%253D%253D&md5=0c7a59d125d380902d33d9b156715800</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2005.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2005.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DG.%26atitle%3DGlutamate-based%2520therapeutic%2520approaches%253A%2520Ampakines%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2006%26volume%3D6%26issue%3D1%26spage%3D82%26epage%3D88%26doi%3D10.1016%2Fj.coph.2005.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, M.</span></span> <span> </span><span class="NLM_article-title">Benzamide-type AMPA receptor modulators form two subfamilies with distinct modes of action</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>303</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1075</span>â <span class="NLM_lpage">1085</span>, <span class="refDoi">Â DOI: 10.1124/jpet.102.040360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1124%2Fjpet.102.040360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=12438530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD38Xptlamtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2002&pages=1075-1085&issue=3&author=A.+C.+Araiauthor=Y.+F.+Xiaauthor=G.+Rogersauthor=G.+Lynchauthor=M.+Kessler&title=Benzamide-type+AMPA+receptor+modulators+form+two+subfamilies+with+distinct+modes+of+action&doi=10.1124%2Fjpet.102.040360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Benzamide-type AMPA receptor modulators form two subfamilies with distinct modes of action</span></div><div class="casAuthors">Arai, Amy C.; Xia, Yan-Fang; Rogers, Gary; Lynch, Gary; Kessler, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1075-1085</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">CX516 (BDP-12) and CX546, two first-generation benzamide-type AMPA receptor modulators, were compared with regard to their influence on AMPA receptor-mediated currents, autaptic responses in cultured hippocampal neurons, hippocampal excitatory postsynaptic currents, synaptic field potentials, and agonist binding.  The two drugs exhibited comparable potencies in most tests but differed in their efficacy and in their relative impact on various response parameters.  CX546 greatly prolonged the duration of synaptic responses, and it slowed 10-fold the deactivation of excised-patch currents following 1-ms pulses of glutamate.  The effects of CX516 on those measures were, by comparison, small; however, the drug was equally or more efficacious than CX546 in increasing the amplitude of synaptic responses.  This double dissocn. suggests that amplitude and duration of synaptic responses are governed by different aspects of receptor kinetics, which are differentially modified by the two drugs.  These effects can be reproduced in receptor simulations if one assumes that CX516 preferentially accelerates channel opening while CX546 slows channel closing.  In binding tests, CX546 caused an approx. 2-fold increase in the affinity for radiolabeled agonists, whereas CX516 was ineffective.  More importantly, even millimolar concns. of CX516 did not influence the dose-response relation for CX546, suggesting the possibility that they bind to different sites.  Taken together, the evidence suggests that benzamide modulators from the Ampakine family form two subgroups with different modes and sites of action.  Of these, CX516-type drugs may have the greater therapeutic utility because of their limited efficacy in prolonging synaptic responses and in attenuating receptor desensitization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfeJ4I3maOf7Vg90H21EOLACvtfcHk0ljC9Z33RaDtLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xptlamtbw%253D&md5=8f49bf660b3269eb267a5b40f67ad720</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.040360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.040360%26sid%3Dliteratum%253Aachs%26aulast%3DArai%26aufirst%3DA.%2BC.%26aulast%3DXia%26aufirst%3DY.%2BF.%26aulast%3DRogers%26aufirst%3DG.%26aulast%3DLynch%26aufirst%3DG.%26aulast%3DKessler%26aufirst%3DM.%26atitle%3DBenzamide-type%2520AMPA%2520receptor%2520modulators%2520form%2520two%2520subfamilies%2520with%2520distinct%2520modes%2520of%2520action%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D303%26issue%3D3%26spage%3D1075%26epage%3D1085%26doi%3D10.1124%2Fjpet.102.040360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bliss, T. V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collingridge, G. L.</span></span> <span> </span><span class="NLM_article-title">A synaptic model of memory: Long-term potentiation in the hippocampus</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>361</i></span> (<span class="NLM_issue">6407</span>),  <span class="NLM_fpage">31</span>â <span class="NLM_lpage">39</span>, <span class="refDoi">Â DOI: 10.1038/361031a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2F361031a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=8421494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK3sXntlOntw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=1993&pages=31-39&issue=6407&author=T.+V.+P.+Blissauthor=G.+L.+Collingridge&title=A+synaptic+model+of+memory%3A+Long-term+potentiation+in+the+hippocampus&doi=10.1038%2F361031a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">A synaptic model of memory:  long-term potentiation in the hippocampus</span></div><div class="casAuthors">Bliss, T. V. P.; Collingridge, G. L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">6407</span>),
    <span class="NLM_cas:pages">31-9</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">A review, with 174 refs., of long-term potentiation (LTP) of synaptic transmission in the hippocampus as the primary exptl. model for investigating the synaptic basis of learning and memory in vertebrates.  Topics discussed were: properties of hippocampal LTP; induction of LTP; and expression of LTP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD1tHZif2aP7Vg90H21EOLACvtfcHk0ljC9Z33RaDtLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXntlOntw%253D%253D&md5=285f5a175da5a77f4f57a3f5236e3e0a</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2F361031a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F361031a0%26sid%3Dliteratum%253Aachs%26aulast%3DBliss%26aufirst%3DT.%2BV.%2BP.%26aulast%3DCollingridge%26aufirst%3DG.%2BL.%26atitle%3DA%2520synaptic%2520model%2520of%2520memory%253A%2520Long-term%2520potentiation%2520in%2520the%2520hippocampus%26jtitle%3DNature%26date%3D1993%26volume%3D361%26issue%3D6407%26spage%3D31%26epage%3D39%26doi%3D10.1038%2F361031a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Zastrow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malenka, R. C.</span></span> <span> </span><span class="NLM_article-title">Role of AMPA receptor endocytosis in synaptic plasticity</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">315</span>â <span class="NLM_lpage">324</span>, <span class="refDoi">Â DOI: 10.1038/35072500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2F35072500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=11331915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjs1Ogtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=315-324&issue=5&author=R.+C.+Carrollauthor=E.+C.+Beattieauthor=M.+Von+Zastrowauthor=R.+C.+Malenka&title=Role+of+AMPA+receptor+endocytosis+in+synaptic+plasticity&doi=10.1038%2F35072500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Role of AMPA receptor endocytosis in synaptic plasticity</span></div><div class="casAuthors">Carroll, Reed C.; Beattie, Eric C.; Von Zastrow, Mark; Malenka, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">315-324</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with 96 refs.  Activity-mediated changes in the strength of synaptic communication are important for the establishment of proper neuronal connections during development and for the experience-dependent modification of neural circuitry that is believed to underlie all forms of behavioral plasticity.  Owing to the wide-ranging significance of synaptic plasticity, considerable efforts have been made to identify the mechanisms by which synaptic changes are triggered and expressed.  New evidence indicates that one important expression mechanism of several long-lasting forms of synaptic plasticity might involve the phys. transport of AMPA-type glutamate receptors in and out of the synaptic membrane.  Here, the authors focus on the rapidly accumulating evidence that AMPA receptors undergo regulated endocytosis, which is important for long-term depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreym3vak6-8rVg90H21EOLACvtfcHk0ljC9Z33RaDtLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjs1Ogtrw%253D&md5=4ad17e0efc53dc820ee5f3a3bf7d700b</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1038%2F35072500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35072500%26sid%3Dliteratum%253Aachs%26aulast%3DCarroll%26aufirst%3DR.%2BC.%26aulast%3DBeattie%26aufirst%3DE.%2BC.%26aulast%3DVon%2BZastrow%26aufirst%3DM.%26aulast%3DMalenka%26aufirst%3DR.%2BC.%26atitle%3DRole%2520of%2520AMPA%2520receptor%2520endocytosis%2520in%2520synaptic%2520plasticity%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2001%26volume%3D2%26issue%3D5%26spage%3D315%26epage%3D324%26doi%3D10.1038%2F35072500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Volk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, S.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huganir, R. L.</span></span> <span> </span><span class="NLM_article-title">Glutamate synapses in human cognitive disorders</span>. <i>Annu. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">127</span>â <span class="NLM_lpage">149</span>, <span class="refDoi">Â DOI: 10.1146/annurev-neuro-071714-033821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1146%2Fannurev-neuro-071714-033821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=25897873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCjurfE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2015&pages=127-149&author=L.+Volkauthor=S.-L.+Chiuauthor=K.+Sharmaauthor=R.+L.+Huganir&title=Glutamate+synapses+in+human+cognitive+disorders&doi=10.1146%2Fannurev-neuro-071714-033821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate Synapses in Human Cognitive Disorders</span></div><div class="casAuthors">Volk, Lenora; Chiu, Shu-Ling; Sharma, Kamal; Huganir, Richard L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127-149</span>CODEN:
                <span class="NLM_cas:coden">ARNSD5</span>;
        ISSN:<span class="NLM_cas:issn">0147-006X</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">Recent evidence supports the idea that abnormal excitatory synapse function is a major cause of human cognitive disease.  Accumulating data from large genetic assocn. studies indicate that alterations in glutamatergic synapse structure and function represent a common underlying pathol. in many symptomatically distinct cognitive disorders.  In this review, we discuss evidence from human genetic studies and data from animal models supporting a role for aberrant glutamatergic synapse function in the etiol. of intellectual disability (ID), autism spectrum disorder (ASD), and schizophrenia (SCZ), neurodevelopmental disorders that comprise a significant proportion of human cognitive disease and exact a substantial financial and social burden.  We focus on the most promising candidate genes affecting glutamatergic synapse function, highlighting the likely disease-relevant functional consequences of each.  The varied manifestations of impaired perceptual processing, executive function, social interaction, communication, and/or intellectual ability in ID, ASD, and SCZ appear to emerge from altered neural microstructure, function, and/or wiring rather than gross changes in neuron no. or morphol.  Here, we review evidence that these disorders may share a common underlying neuropathy: altered excitatory synapse function.  We first present a brief overview of glutamatergic synapses and then explore the genetic and phenotypic evidence for altered glutamate signaling in ID, ASD, and SCZ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowaHGkEoyPJ7Vg90H21EOLACvtfcHk0liqPuIoHtTA4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCjurfE&md5=cc8d0cdea404920debc33a55b7ce3c55</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1146%2Fannurev-neuro-071714-033821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-neuro-071714-033821%26sid%3Dliteratum%253Aachs%26aulast%3DVolk%26aufirst%3DL.%26aulast%3DChiu%26aufirst%3DS.-L.%26aulast%3DSharma%26aufirst%3DK.%26aulast%3DHuganir%26aufirst%3DR.%2BL.%26atitle%3DGlutamate%2520synapses%2520in%2520human%2520cognitive%2520disorders%26jtitle%3DAnnu.%2520Rev.%2520Neurosci.%26date%3D2015%26volume%3D38%26spage%3D127%26epage%3D149%26doi%3D10.1146%2Fannurev-neuro-071714-033821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woolley, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gartlon, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaughnessy, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pemberton, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harries, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southam, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, L. A.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>202</i></span>,  <span class="NLM_fpage">343</span>â <span class="NLM_lpage">354</span>, <span class="refDoi">Â DOI: 10.1007/s00213-008-1325-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1007%2Fs00213-008-1325-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=18795266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1egs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=2009&pages=343-354&author=M.+L.+Woolleyauthor=K.+A.+Watersauthor=J.+E.+Gartlonauthor=L.+P.+Lacroixauthor=C.+Jenningsauthor=F.+Shaughnessyauthor=A.+Ongauthor=D.+J.+Pembertonauthor=M.+H.+Harriesauthor=E.+Southamauthor=D.+N.+Jonesauthor=L.+A.+Dawson&title=Evaluation+of+the+pro-cognitive+effects+of+the+AMPA+receptor+positive+modulator%2C+5-%281-piperidinylcarbonyl%29-2%2C1%2C3-benzoxadiazole+%28CX691%29%2C+in+the+rat&doi=10.1007%2Fs00213-008-1325-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat</span></div><div class="casAuthors">Woolley, M. L.; Waters, K. A.; Gartlon, J. E.; Lacroix, L. P.; Jennings, C.; Shaughnessy, F.; Ong, A.; Pemberton, D. J.; Harries, M. H.; Southam, E.; Jones, D. N. C.; Dawson, L. A.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">343-354</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Pos. allosteric modulators of the glutamatergic Î±-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor do not stimulate AMPA receptors directly but delay deactivation of the receptor and/or slow its desensitization.  This results in increased synaptic responses and enhanced long-term potentiation.  Thus, it has been suggested that such compds. may have utility for the treatment of cognitive impairment.  The objective of the study was to investigate the effect of an AMPA pos. modulator, CX691, (1) in three rodent models of learning and memory, (2) on neurochem. in the dorsal hippocampus and medial prefrontal cortex following acute administration, and (3) on brain-derived neurotrophic factor (BDNF) mRNA expression in the rat hippocampus following acute and sub-chronic administration.  CX691 attenuated a scopolamine-induced impairment of cued fear conditioning following acute administration (0.1 mg/kg p.o.) and a temporally induced deficit in novel object recognition following both acute (0.1 and 1.0 mg/kg p.o.) and sub-chronic (bi-daily for 7 days) administration (0.01, 0.03, 0.1 mg/kg p.o.).  It also improved attentional set-shifting following sub-chronic administration (0.3 mg/kg p.o.).  Acute CX691 (0.1, 0.3 and 1.0 mg/kg, p.o.) increased extracellular levels of acetylcholine in the dorsal hippocampus and medial prefrontal cortex and dopamine in the medial prefrontal cortex.  Sub-chronic administration of CX691 (0.1 mg/kg, p.o.) elevated BDNF mRNA expression in both the whole and CA1 sub-region of the hippocampus (P < 0.05).  Collectively, these data support the pro-cognitive activity reported for AMPA receptor pos. modulators and suggest that these compds. may be of benefit in treating disorders characterized by cognitive deficits such as Alzheimer's disease and schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv76MXCyplH7Vg90H21EOLACvtfcHk0ljjiiHMJrJ10Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1egs7g%253D&md5=3ee6ea548c203fcf5c6c620501ceb758</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1007%2Fs00213-008-1325-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-008-1325-2%26sid%3Dliteratum%253Aachs%26aulast%3DWoolley%26aufirst%3DM.%2BL.%26aulast%3DWaters%26aufirst%3DK.%2BA.%26aulast%3DGartlon%26aufirst%3DJ.%2BE.%26aulast%3DLacroix%26aufirst%3DL.%2BP.%26aulast%3DJennings%26aufirst%3DC.%26aulast%3DShaughnessy%26aufirst%3DF.%26aulast%3DOng%26aufirst%3DA.%26aulast%3DPemberton%26aufirst%3DD.%2BJ.%26aulast%3DHarries%26aufirst%3DM.%2BH.%26aulast%3DSoutham%26aufirst%3DE.%26aulast%3DJones%26aufirst%3DD.%2BN.%26aulast%3DDawson%26aufirst%3DL.%2BA.%26atitle%3DEvaluation%2520of%2520the%2520pro-cognitive%2520effects%2520of%2520the%2520AMPA%2520receptor%2520positive%2520modulator%252C%25205-%25281-piperidinylcarbonyl%2529-2%252C1%252C3-benzoxadiazole%2520%2528CX691%2529%252C%2520in%2520the%2520rat%26jtitle%3DPsychopharmacology%26date%3D2009%26volume%3D202%26spage%3D343%26epage%3D354%26doi%3D10.1007%2Fs00213-008-1325-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Radin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippa, A. S.</span></span> <span> </span><span class="NLM_article-title">Effects of chronic systemic low-impact ampakine treatment on neurotrophin expression in rat brain</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">540</span>â <span class="NLM_lpage">544</span>, <span class="refDoi">Â DOI: 10.1016/j.biopha.2018.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.biopha.2018.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=29886374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFSmtrbO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2018&pages=540-544&author=D.+P.+Radinauthor=S.+Johnsonauthor=R.+Purcellauthor=A.+S.+Lippa&title=Effects+of+chronic+systemic+low-impact+ampakine+treatment+on+neurotrophin+expression+in+rat+brain&doi=10.1016%2Fj.biopha.2018.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of chronic systemic low-impact ampakine treatment on neurotrophin expression in rat brain</span></div><div class="casAuthors">Radin, Daniel P.; Johnson, Steven; Purcell, Richard; Lippa, Arnold S.</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">540-544</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Neurotrophin dysregulation has been implicated in a large no. of neurodegenerative and neuropsychiatric diseases.  Unfortunately, neurotrophins cannot cross the blood brain barrier thus, novel means of up regulating their expression are greatly needed.  It has been demonstrated previously that neurotrophins are up regulated in response to increases in brain activity.  Therefore, mols. that act as cognitive enhancers may provide a clin. means of up regulating neurotrophin expression.  Ampakines are a class of mols. that act as pos. allosteric modulators of AMPA-type glutamate receptors.  Currently, they are being developed to prevent opioid-induced respiratory depression without sacrificing the analgesic properties of the opioids.  In addn., these mols. increase neuronal activity and have been shown to restore age-related deficits in LTP in aged rats.  In the current study, we examd. whether two different ampakines could increase levels of BDNF and NGF at doses that are active in behavioral measures of cognition.  Results demonstrate that ampakines CX516 and CX691 induce differential increases in neurotrophins across several brain regions.  Notable increases in NGF were obsd. in the dentate gyrus and piriform cortex while notable BDNF increases were obsd. in basolateral and lateral nuclei of the amygdala.  Taken together, our data demonstrates that chronic administration of clin. relevant doses of ampakines have the ability to elevate neurotrophin expression in different brain regions, and may have therapeutic benefit in multiple neurodegenerative and/or neuropsychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTCPDEB26KrbVg90H21EOLACvtfcHk0lhtzoKdG4-DDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFSmtrbO&md5=2476357494ccda889262c86401afc2c3</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2018.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2018.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DRadin%26aufirst%3DD.%2BP.%26aulast%3DJohnson%26aufirst%3DS.%26aulast%3DPurcell%26aufirst%3DR.%26aulast%3DLippa%26aufirst%3DA.%2BS.%26atitle%3DEffects%2520of%2520chronic%2520systemic%2520low-impact%2520ampakine%2520treatment%2520on%2520neurotrophin%2520expression%2520in%2520rat%2520brain%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2018%26volume%3D105%26spage%3D540%26epage%3D544%26doi%3D10.1016%2Fj.biopha.2018.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">OâNeill, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleakman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nisenbaum, E. S.</span></span> <span> </span><span class="NLM_article-title">AMPA receptor potentiators for the treatment of CNS disorders</span>. <i>Curr. Drug Targets: CNS Neurol. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">181</span>â <span class="NLM_lpage">194</span>, <span class="refDoi">Â DOI: 10.2174/1568007043337508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.2174%2F1568007043337508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=15180479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltFCgu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=181-194&issue=3&author=M.+J.+O%E2%80%99Neillauthor=D.+Bleakmanauthor=D.+M.+Zimmermanauthor=E.+S.+Nisenbaum&title=AMPA+receptor+potentiators+for+the+treatment+of+CNS+disorders&doi=10.2174%2F1568007043337508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">AMPA receptor potentiators for the treatment of CNS disorders</span></div><div class="casAuthors">O'Neill, Michael J.; Bleakman, David; Zimmerman, Dennis M.; Nisenbaum, Eric S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets: CNS & Neurological Disorders</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-194</span>CODEN:
                <span class="NLM_cas:coden">CDTCCC</span>;
        ISSN:<span class="NLM_cas:issn">1568-007X</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Glutamate Î±-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors mediate most of the excitatory neurotransmission in the mammalian central nervous system and also participate in forms of synaptic plasticity thought to underlie memory and learning, and the formation of neural networks during development.  Mol. cloning techniques have shown that the AMPA receptor family is composed of 4 different subunits named GluR1-4 or GluRA-D (newly termed as GluA1-GluA4) and native AMPA receptors are most likely tetramers generated by the assembly of 1 or more of these subunits, yielding homomeric or heteromeric receptors.  Addnl. complexity among AMPA receptors is conferred by alternative splicing of RNA for each subunit giving rise to flip and flop variants.  Clin. and exptl. data have suggested that pos. modulation of AMPA receptors may be therapeutically effective in the treatment of cognitive deficits.  Several classes of AMPA receptor potentiators were reported, including pyrrolidones (piracetam, aniracetam), benzothiazides (cyclothiazide), benzylpiperidines (CX-516, CX-546), and more recently biarylpropylsulfonamides (LY392098, LY404187 and LY503430).  These mols. enhance cognitive function in rodents, which appears to correlate with increased hippocampal activity.  In addn., clin. studies have suggested that AMPA receptor modulators enhance cognitive function in elderly subjects, as well as patients suffering from neurol. and psychiatric disorders.  Several independent studies have suggested that AMPA receptors can increase BDNF expression by both calcium-dependent and independent pathways.  For example, recent studies have shown that AMPA receptors interact with the protein Tyr kinase, Lyn.  Activation of Lyn can recruit the mitogen-activated protein kinase (MAPK) signalling pathway and increase the expression of BDNF.  Therefore, in addn. to directly enhancing glutamatergic synaptic transmission, AMPA receptor activation can increase the expression of BDNF in vitro and in vivo.  This may account for activity of AMPA receptor potentiators in rodent models predictive of antidepressant activity (forced swim and tail suspension tests).  The increase in neurotrophin expression also may contribute to the functional, neuroprotective, and neurotrophic actions of LY404187 and LY503430 after infusion of 6-OHDA into the substantia nigra.  In conclusion, several potent, selective and systematically active AMPA receptor potentiators were reported.  Data indicate that these mols. modulate glutamatergic transmission, enhance synaptic transmission, long-term potentiation (LTP), and increase neurotrophin expression.  Therefore, these AMPA receptor potentiators offer an exciting new class of drugs with potentials for treating (1) cognitive impairment assocd. with Alzheimer's disease and schizophrenia, (2) depression, (3) slowing the progression and potentially enhancing recovery from Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHYMd0O34_SLVg90H21EOLACvtfcHk0lhtzoKdG4-DDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltFCgu7g%253D&md5=5d438c3c4cc13fa863608073601cc6a1</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.2174%2F1568007043337508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568007043337508%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DM.%2BJ.%26aulast%3DBleakman%26aufirst%3DD.%26aulast%3DZimmerman%26aufirst%3DD.%2BM.%26aulast%3DNisenbaum%26aufirst%3DE.%2BS.%26atitle%3DAMPA%2520receptor%2520potentiators%2520for%2520the%2520treatment%2520of%2520CNS%2520disorders%26jtitle%3DCurr.%2520Drug%2520Targets%253A%2520CNS%2520Neurol.%2520Disord.%26date%3D2004%26volume%3D3%26issue%3D3%26spage%3D181%26epage%3D194%26doi%3D10.2174%2F1568007043337508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wezenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkes, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruigt, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulstijn, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbe, B. G.</span></span> <span> </span><span class="NLM_article-title">Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1272</span>â <span class="NLM_lpage">1283</span>, <span class="refDoi">Â DOI: 10.1038/sj.npp.1301257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2Fsj.npp.1301257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=17119538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlaqtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=1272-1283&issue=6&author=E.+Wezenbergauthor=R.+J.+Verkesauthor=G.+S.+Ruigtauthor=W.+Hulstijnauthor=B.+G.+Sabbe&title=Acute+effects+of+the+ampakine+farampator+on+memory+and+information+processing+in+healthy+elderly+volunteers&doi=10.1038%2Fsj.npp.1301257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Acute Effects of the Ampakine Farampator on Memory and Information Processing in Healthy Elderly Volunteers</span></div><div class="casAuthors">Wezenberg, Elke; Jan Verkes, Robert; Ruigt, Ge S. F.; Hulstijn, Wouter; Sabbe, Bernard G. C.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1272-1283</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ampakines act as pos. allosteric modulators of AMPA-type glutamate receptors and facilitate hippocampal long-term potentiation (LTP), a mechanism assocd. with memory storage and consolidation.  The present study investigated the acute effects of farampator, 1-(benzofurazan-5-ylcarbonyl) piperidine, on memory and information processes in healthy elderly volunteers.  A double-blind, placebo-controlled, randomized, cross-over study was performed in 16 healthy, elderly volunteers (eight male, eight female; mean age 66.1, SD 4.5 years).  All subjects received farampator (500 mg) and placebo.  Testing took place 1 h after drug intake, which was around Tmax for farampator.  Subjects performed tasks assessing episodic memory (wordlist learning and picture memory), working and short-term memory (N-back, symbol recall) and motor learning (maze task, pursuit rotor).  Information processing was assessed with a tangled lines task, the symbol digit substitution test (SDST) and the continuous trail making test (CTMT).  Farampator (500 mg) unequivocally improved short-term memory but appeared to impair episodic memory.  Furthermore, it tended to decrease the no. of switching errors in the CTMT.  Drug-induced side effects (SEs) included headache, somnolence and nausea.  Subjects with SEs had significantly higher plasma levels of farampator than subjects without SEs.  Addnl. analyses revealed that in the farampator condition the group without SEs showed a significantly superior memory performance relative to the group with SEs.  The pos. results on short-term memory and the favorable trends in the trail making test (CTMT) are interesting in view of the development of ampakines in the treatment of Alzheimer's disease and schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov4kJJWKwAH7Vg90H21EOLACvtfcHk0lhtzoKdG4-DDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlaqtbc%253D&md5=889f62faa887fb9f5f7b823d7d26c43c</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1301257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1301257%26sid%3Dliteratum%253Aachs%26aulast%3DWezenberg%26aufirst%3DE.%26aulast%3DVerkes%26aufirst%3DR.%2BJ.%26aulast%3DRuigt%26aufirst%3DG.%2BS.%26aulast%3DHulstijn%26aufirst%3DW.%26aulast%3DSabbe%26aufirst%3DB.%2BG.%26atitle%3DAcute%2520effects%2520of%2520the%2520ampakine%2520farampator%2520on%2520memory%2520and%2520information%2520processing%2520in%2520healthy%2520elderly%2520volunteers%26jtitle%3DNeuropsychopharmacology%26date%3D2007%26volume%3D32%26issue%3D6%26spage%3D1272%26epage%3D1283%26doi%3D10.1038%2Fsj.npp.1301257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambros-Ingerson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schehr, R.</span></span> <span> </span><span class="NLM_article-title">Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>145</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">89</span>â <span class="NLM_lpage">92</span>, <span class="refDoi">Â DOI: 10.1006/exnr.1997.6447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1006%2Fexnr.1997.6447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=9184112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK2sXjvVyitb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=1997&pages=89-92&issue=1&author=G.+Lynchauthor=R.+Grangerauthor=J.+Ambros-Ingersonauthor=C.+M.+Davisauthor=M.+Kesslerauthor=R.+Schehr&title=Evidence+that+a+positive+modulator+of+AMPA-type+glutamate+receptors+improves+delayed+recall+in+aged+humans&doi=10.1006%2Fexnr.1997.6447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans</span></div><div class="casAuthors">Lynch, Gary; Granger, Richard; Ambros-Ingerson, Jose; Davis, C. Mike; Kessler, Markus; Schehr, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-92</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Elderly subjects (65-76 yr) were tested for recall of nonsense syllables prior to and after oral administration of 1-(quinoxalin-6-ylcarbonyl)piperidine (CX516), a centrally active drug that enhances currents mediated by AMPA-type glutamate receptors.  A significant and pos. drug effect was found for delayed (5 min) recall at 75 min post-treatment; av. scores for the highest dose group were >2-fold greater than for the placebo group.  The drug had no evident influence on heart rate or self-assessment of several psychol. variables.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5f-3h5SwCTLVg90H21EOLACvtfcHk0lhR_creU74xSA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjvVyitb4%253D&md5=49509daff4308342655279c1ccdb8a06</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1006%2Fexnr.1997.6447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fexnr.1997.6447%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DG.%26aulast%3DGranger%26aufirst%3DR.%26aulast%3DAmbros-Ingerson%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DC.%2BM.%26aulast%3DKessler%26aufirst%3DM.%26aulast%3DSchehr%26aufirst%3DR.%26atitle%3DEvidence%2520that%2520a%2520positive%2520modulator%2520of%2520AMPA-type%2520glutamate%2520receptors%2520improves%2520delayed%2520recall%2520in%2520aged%2520humans%26jtitle%3DExp.%2520Neurol.%26date%3D1997%26volume%3D145%26issue%3D1%26spage%3D89%26epage%3D92%26doi%3D10.1006%2Fexnr.1997.6447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marenco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knable, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClure, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winterer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberger, D. R.</span></span> <span> </span><span class="NLM_article-title">Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: A case series</span>. <i>Schizophr. Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">221</span>â <span class="NLM_lpage">226</span>, <span class="refDoi">Â DOI: 10.1016/S0920-9964(01)00311-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2FS0920-9964%2801%2900311-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=12223253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BD38vmsVCksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2002&pages=221-226&issue=2&author=S.+Marencoauthor=M.+F.+Eganauthor=T.+E.+Goldbergauthor=M.+B.+Knableauthor=R.+K.+McClureauthor=G.+Wintererauthor=D.+R.+Weinberger&title=Preliminary+experience+with+an+ampakine+%28CX516%29+as+a+single+agent+for+the+treatment+of+schizophrenia%3A+A+case+series&doi=10.1016%2FS0920-9964%2801%2900311-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series</span></div><div class="casAuthors">Marenco Stefano; Egan Michael F; Goldberg Terry E; Knable Michael B; McClure Robert K; Winterer Georg; Weinberger Daniel R</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">221-6</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">We used L-(quinoxalin-6-ylcarbonyl)piperidine (CX516) (a modulator of the alpha-amino-3-hydroxy-5-methyl-4-isoxasole propionic acid (AMPA) receptor) as a sole agent in a double blind placebo-controlled design in a small series of patients with schizophrenia who were partially refractory to treatment with traditional neuroleptics.  The study entailed weekly increments in doses of CX516, from 300 mg tid for week 1 up to 900 mg tid on week 4.  Patients were followed with clinical ratings, neuropsychological testing, and were monitored for adverse events.  Four patients received 2 to 4 weeks of CX516, two received placebo and two withdrew during the placebo phase.  Adverse events associated with drug administration were transient and included leukopenia in one patient and elevation in liver enzymes in another.  No clear improvement in psychosis or in cognition was observed over the course of the study.  CX516 at the doses tested did not appear to yield dramatic effects as a sole agent, but inference from this study is limited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTETmXZUoTbJ-RS7coPn-RtfW6udTcc2ebjnkUMJJl0hbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vmsVCksg%253D%253D&md5=b0a55439016bc407522ca3251e5923a7</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2FS0920-9964%2801%2900311-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0920-9964%252801%252900311-5%26sid%3Dliteratum%253Aachs%26aulast%3DMarenco%26aufirst%3DS.%26aulast%3DEgan%26aufirst%3DM.%2BF.%26aulast%3DGoldberg%26aufirst%3DT.%2BE.%26aulast%3DKnable%26aufirst%3DM.%2BB.%26aulast%3DMcClure%26aufirst%3DR.%2BK.%26aulast%3DWinterer%26aufirst%3DG.%26aulast%3DWeinberger%26aufirst%3DD.%2BR.%26atitle%3DPreliminary%2520experience%2520with%2520an%2520ampakine%2520%2528CX516%2529%2520as%2520a%2520single%2520agent%2520for%2520the%2520treatment%2520of%2520schizophrenia%253A%2520A%2520case%2520series%26jtitle%3DSchizophr.%2520Res.%26date%3D2002%26volume%3D57%26issue%3D2%26spage%3D221%26epage%3D226%26doi%3D10.1016%2FS0920-9964%2801%2900311-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goff, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamberti, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leon, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manschreck, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freudenreich, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. A.</span></span> <span> </span><span class="NLM_article-title">A Placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">465</span>â <span class="NLM_lpage">472</span>, <span class="refDoi">Â DOI: 10.1038/sj.npp.1301444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2Fsj.npp.1301444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=17487227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFSmsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2008&pages=465-472&issue=3&author=D.+C.+Goffauthor=J.+S.+Lambertiauthor=A.+C.+Leonauthor=M.+F.+Greenauthor=A.+L.+Millerauthor=J.+Patelauthor=T.+Manschreckauthor=O.+Freudenreichauthor=S.+A.+Johnson&title=A+Placebo-controlled+add-on+trial+of+the+Ampakine%2C+CX516%2C+for+cognitive+deficits+in+schizophrenia&doi=10.1038%2Fsj.npp.1301444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">A Placebo-Controlled Add-On Trial of the Ampakine, CX516, for Cognitive Deficits in Schizophrenia</span></div><div class="casAuthors">Goff, Donald C.; Lamberti, J. Steven; Leon, Andrew C.; Green, Michael F.; Miller, Alexander L.; Patel, Jayendra; Manschreck, Theo; Freudenreich, Oliver; Johnson, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">465-472</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">AMPA-receptor-pos. modulators (Ampakines) facilitate learning and memory in animal models and in preliminary trials in human subjects.  CX516 is the first Ampakine to be studied for cognitive enhancement in schizophrenia.  Stable schizophrenia patients treated with clozapine (n = 52), olanzapine (n = 40), or risperidone (n = 13) were randomly assigned to add-on treatment with CX516 900 mg three times daily or placebo for 4 wk.  Subjects were assessed with a cognitive battery at baseline, week 4, and at 4-wk follow-up.  Clin. scales and safety monitoring were also performed.  The primary endpoint was the change from baseline in a composite cognitive score at week 4 for the intent-to-treat sample.  Addnl. analyses examd. change in symptom rating scores and examd. drug effects on patients treated with clozapine sep. from patients treated with either olanzapine or risperidone.  A total of 105 patients were randomized and 95 (90%) completed the 4-wk trial.  Patients treated with CX516 did not differ from placebo in change from baseline on the composite cognitive score, or on any cognitive test at weeks 4 or 8.  The between groups effect size at week 4 for the cognitive composite score was -0.19 for clozapine-treated patients and 0.24 for patients treated with olanzapine or risperidone.  The placebo group improved more on the PANSS total score than the CX516 group; no other clin. rating differed between treatment groups.  CX516 was assocd. with fatigue, insomnia and epigastric discomfort compared to placebo, but was generally well tolerated.  CX516 was not effective for cognition or for symptoms of schizophrenia when added to clozapine, olanzapine, or risperidone.  Neuropsychopharmacol. (2008) 33, 465-472; published online 9 May 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruiyEh-ji1wLVg90H21EOLACvtfcHk0lhR_creU74xSA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFSmsQ%253D%253D&md5=e978a1f588eabebb39fc20505e6a3863</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1301444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1301444%26sid%3Dliteratum%253Aachs%26aulast%3DGoff%26aufirst%3DD.%2BC.%26aulast%3DLamberti%26aufirst%3DJ.%2BS.%26aulast%3DLeon%26aufirst%3DA.%2BC.%26aulast%3DGreen%26aufirst%3DM.%2BF.%26aulast%3DMiller%26aufirst%3DA.%2BL.%26aulast%3DPatel%26aufirst%3DJ.%26aulast%3DManschreck%26aufirst%3DT.%26aulast%3DFreudenreich%26aufirst%3DO.%26aulast%3DJohnson%26aufirst%3DS.%2BA.%26atitle%3DA%2520Placebo-controlled%2520add-on%2520trial%2520of%2520the%2520Ampakine%252C%2520CX516%252C%2520for%2520cognitive%2520deficits%2520in%2520schizophrenia%26jtitle%3DNeuropsychopharmacology%26date%3D2008%26volume%3D33%26issue%3D3%26spage%3D465%26epage%3D472%26doi%3D10.1038%2Fsj.npp.1301444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mozafari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamsizadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fatemi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allahtavakoli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moghadam-Ahmadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaviani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaeidi, A.</span></span> <span> </span><span class="NLM_article-title">CX691, as an AMPA receptor positive modulator, improves the learning and memory in a rat model of Alzheimerâs disease</span>. <i>Iran J. Basic Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">724</span>â <span class="NLM_lpage">730</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=30140412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BB3c3htlGjtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2018&pages=724-730&issue=7&author=N.+Mozafariauthor=A.+Shamsizadehauthor=I.+Fatemiauthor=M.+Allahtavakoliauthor=A.+Moghadam-Ahmadiauthor=E.+Kavianiauthor=A.+Kaeidi&title=CX691%2C+as+an+AMPA+receptor+positive+modulator%2C+improves+the+learning+and+memory+in+a+rat+model+of+Alzheimer%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">CX691, as an AMPA receptor positive modulator, improves the learning and memory in a rat model of Alzheimer's disease</span></div><div class="casAuthors">Mozafari Nazanin; Shamsizadeh Ali; Fatemi Iman; Allahtavakoli Mohammad; Kaviani Elham; Kaeidi Ayat; Shamsizadeh Ali; Fatemi Iman; Allahtavakoli Mohammad; Kaeidi Ayat; Moghadam-Ahmadi Amir</div><div class="citationInfo"><span class="NLM_cas:title">Iranian journal of basic medical sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">724-730</span>
        ISSN:<span class="NLM_cas:issn">2008-3866</span>.
    </div><div class="casAbstract">Objectives:  Growing evidence suggests that dysfunction of the glutamatergic system and Î±-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid (AMPA) receptors are involved in pathology of Alzheimer's disease (AD).  Because AMPA receptors play a key role in plasticity synaptic regulation, positive modulation of these receptors may rescue the cognitive deficits in the AD.  The aim of this study was to explore the effect of CX691, a specific positive allosteric modulator of the AMPA-type glutamate receptors (Ampakine), on spatial learning and memory in a rat model of AD.  Materials and Methods:  For induction of AD, amyloid-beta 1-42 (AÎ²1-42) was microinjected into the hippocampus of male Wistar rats (250-300 g).  The Morris water maze (MWM) test was used to evaluate the effect of CX691 (0.03 and 0.3 mg/kg, twice a day for 10 days, orally) on spatial learning and memory of rats.  In order to evaluate the protein expression of brain-derived neurotrophic factor (BDNF) in hippocampus tissue, ELISA test was used.  Results:  The obtained data showed that treatment with CX691 (0.3 mg/kg) improves the impairment of spatial learning and memory in AD rats.  Also, treatment with CX691 (0.3 mg/kg), increased the BDNF protein level in hippocampus tissue of AD rats compared to non-treated animals.  Conclusion:  The CX691 can improve the BDNF protein expression as well as spatial performance of learning and memory in AD rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRRjz6QXP7AlIIRAdBLKY41fW6udTcc2ebjnkUMJJl0hbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3htlGjtw%253D%253D&md5=bdb5cf0309d672a1843637569fc98a0e</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMozafari%26aufirst%3DN.%26aulast%3DShamsizadeh%26aufirst%3DA.%26aulast%3DFatemi%26aufirst%3DI.%26aulast%3DAllahtavakoli%26aufirst%3DM.%26aulast%3DMoghadam-Ahmadi%26aufirst%3DA.%26aulast%3DKaviani%26aufirst%3DE.%26aulast%3DKaeidi%26aufirst%3DA.%26atitle%3DCX691%252C%2520as%2520an%2520AMPA%2520receptor%2520positive%2520modulator%252C%2520improves%2520the%2520learning%2520and%2520memory%2520in%2520a%2520rat%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DIran%2520J.%2520Basic%2520Med.%2520Sci.%26date%3D2018%26volume%3D21%26issue%3D7%26spage%3D724%26epage%3D730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karras, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gastrell, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawley, J. N.</span></span> <span> </span><span class="NLM_article-title">Amplakine enhancement of social interaction in the BTBR mouse model of autism</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">268</span>â <span class="NLM_lpage">282</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2012.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.neuropharm.2012.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=22801296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFeitLjP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=268-282&author=J.+L.+Silvermanauthor=C.+F.+Oliverauthor=M.+N.+Karrasauthor=P.+T.+Gastrellauthor=J.+N.+Crawley&title=Amplakine+enhancement+of+social+interaction+in+the+BTBR+mouse+model+of+autism&doi=10.1016%2Fj.neuropharm.2012.07.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">AMPAKINE enhancement of social interaction in the BTBR mouse model of autism</span></div><div class="casAuthors">Silverman, J. L.; Oliver, C. F.; Karras, M. N.; Gastrell, P. T.; Crawley, J. N.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">268-282</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Autism is a neurodevelopmental disorder in which the first diagnostic symptom is unusual reciprocal social interactions.  Approx. half of the children diagnosed with an autism spectrum disorder also have intellectual impairments.  General cognitive abilities may be fundamental to many aspects of social cognition.  Cognitive enhancers could conceivably be of significant benefit to children and adults with autism.  AMPAKINE compds. are a novel class of pharmacol. agents that act as pos. modulators of AMPA receptors to enhance excitatory glutamatergic neurotransmission.  This class of compds. was reported to improve learning and memory in several rodent and non-human primate tasks, and to normalize respiratory abnormalities in a mouse model of Rett syndrome.  Here we evaluate the actions of AMPA compds. in adult male and female BTBR mice, a well characterized mouse model of autism.  Acute treatment with CX1837 and CX1739 reversed the deficit in sociability in BTBR mice on the most sensitive parameter, time spent sniffing a novel mouse as compared to time spent sniffing a novel object.  The less sensitive parameter, time in the chamber contg. the novel mouse vs. time in the chamber contg. the novel object, was not rescued by CX1837 or CX1739 treatment.  Preliminary data with CX546, in which Î²-cyclodextrin was the vehicle, revealed behavioral effects of the acute i.p. and oral administration of vehicle alone.  To circumvent the artifacts introduced by the vehicle administration, we employed a novel treatment regimen using pellets of peanut butter for drug delivery.  Absence of vehicle treatment effects when CX1837 and CX1739 were given in the peanut butter pellets, to multiple cohorts of BTBR and B6 control mice, confirmed that the pharmacol.-induced improvements in sociability in BTBR were not confounded by the administration procedures.  The highest dose of CX1837 improved the cognitive deficit in novel object recognition in BTBR.  No drug effects were detected on the high levels of repetitive self-grooming in BTBR.  In open field tests, CX1837 and CX1739 did not induce hyperactivity or sedation in either strain.  It is interesting to speculate that the ability of CX1837 and CX1739 to restore aspects of sociability in BTBR mice could utilize synaptic mechanisms regulating social cognition, suggesting a potential pharmacol. target for interventions to treat symptoms of autism.This article is part of a Special Issue entitled 'Cognitive Enhancers'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuitrJNN0_YbVg90H21EOLACvtfcHk0lgAStyeyFveYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFeitLjP&md5=7292a90c5fcb610dcb5466192fd00576</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2012.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2012.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DSilverman%26aufirst%3DJ.%2BL.%26aulast%3DOliver%26aufirst%3DC.%2BF.%26aulast%3DKarras%26aufirst%3DM.%2BN.%26aulast%3DGastrell%26aufirst%3DP.%2BT.%26aulast%3DCrawley%26aufirst%3DJ.%2BN.%26atitle%3DAmplakine%2520enhancement%2520of%2520social%2520interaction%2520in%2520the%2520BTBR%2520mouse%2520model%2520of%2520autism%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D64%26spage%3D268%26epage%3D282%26doi%3D10.1016%2Fj.neuropharm.2012.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cecil, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crites, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malatynska, E.</span></span> <span> </span><span class="NLM_article-title">Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>440</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">27</span>â <span class="NLM_lpage">35</span>, <span class="refDoi">Â DOI: 10.1016/S0014-2999(02)01338-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2FS0014-2999%2802%2901338-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=11959085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD38XivVSjurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=440&publication_year=2002&pages=27-35&issue=1&author=R.+J.+Knappauthor=R.+Goldenbergauthor=C.+Shuckauthor=A.+Cecilauthor=J.+Watkinsauthor=C.+Millerauthor=G.+Critesauthor=E.+Malatynska&title=Antidepressant+activity+of+memory-enhancing+drugs+in+the+reduction+of+submissive+behavior+model&doi=10.1016%2FS0014-2999%2802%2901338-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model</span></div><div class="casAuthors">Knapp, Richard J.; Goldenberg, Rachel; Shuck, Caroline; Cecil, Alicia; Watkins, Jeff; Miller, Cortland; Crites, Glenda; Malatynska, Ewa</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">440</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-35</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The present study tests the activity of nootropic drugs in a behavioral test linked to depression.  This test measures the redn. of submissive behavior in a competition test as the relative success of two food-restricted rats to gain access to a feeder.  Nootropic drugs tested include piracetam (2-oxo-1-pyrrolidine acetamide), aniracetam (1-(4-methoxybenzoyl)-2-pyrrolidinone), the Ampakine, Ampalex, 1-(quinoxalin-6-ylcarbonyl)piperidine, and analogs were compared to the antidepressants, fluoxetine ((Â±)-N-methyl-gamma-(4-[trifluoromethyl]phenoxy)-benzenepropanamine) and desipramine (5H-dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N-methyl-, monohydrochloride), while the anxiolytic diazepam (7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one) served as a control.  Drugs were given i.p. for 3 wk.  The antidepressant and nootropic drugs reduced submissive behavior over time.  The effect was dose dependent as measured for fluoxetine and Ampakines.  The redn. of submissive behavior by Ampakines gradually faded after cessation of treatment and had a more rapid onset of activity (during the 1st week of treatment) than fluoxetine (after 2 wk).  The results suggest that Ampakines may have antidepressant activity.  The potential of depression treatment with memory-enhancing drugs is hypothesized and the link between cognition and depression is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMZ5KSxY3nGbVg90H21EOLACvtfcHk0lgAStyeyFveYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivVSjurs%253D&md5=b396f30002d318ecfd6132cc13b9b495</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2802%2901338-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252802%252901338-9%26sid%3Dliteratum%253Aachs%26aulast%3DKnapp%26aufirst%3DR.%2BJ.%26aulast%3DGoldenberg%26aufirst%3DR.%26aulast%3DShuck%26aufirst%3DC.%26aulast%3DCecil%26aufirst%3DA.%26aulast%3DWatkins%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DCrites%26aufirst%3DG.%26aulast%3DMalatynska%26aufirst%3DE.%26atitle%3DAntidepressant%2520activity%2520of%2520memory-enhancing%2520drugs%2520in%2520the%2520reduction%2520of%2520submissive%2520behavior%2520model%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D440%26issue%3D1%26spage%3D27%26epage%3D35%26doi%3D10.1016%2FS0014-2999%2802%2901338-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wesensten, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichardt, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balkin, T. J.</span></span> <span> </span><span class="NLM_article-title">Ampakine (CX717) effects on performance and alertness during simulated night shift work</span>. <i>Aviat., Space Environ. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">937</span>â <span class="NLM_lpage">943</span>, <span class="refDoi">Â DOI: 10.3357/ASEM.2055.2007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.3357%2FASEM.2055.2007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=17955941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1ahsrrJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2007&pages=937-943&issue=10&author=N.+J.+Wesenstenauthor=R.+M.+Reichardtauthor=T.+J.+Balkin&title=Ampakine+%28CX717%29+effects+on+performance+and+alertness+during+simulated+night+shift+work&doi=10.3357%2FASEM.2055.2007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Ampakine (CX717) effects on performance and alertness during simulated night shift work</span></div><div class="casAuthors">Wesensten, Nancy J.; Reichardt, Rebecca M.; Balkin, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Aviation, Space and Environmental Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">937-943</span>CODEN:
                <span class="NLM_cas:coden">ASEMCG</span>;
        ISSN:<span class="NLM_cas:issn">0095-6562</span>.
    
            (<span class="NLM_cas:orgname">Aerospace Medical Association</span>)
        </div><div class="casAbstract">Introduction: Round-the-clock operations in both military and civilian sectors have increased the need for alertness- and performance-maintaining strategies.  The potential performance and objective alertness-enhancing effects of CX717 (a novel cognitive enhancer currently being tested in Phase II clin. trials) were evaluated using a simulated night shift work paradigm.  Methods: In this randomized, double-blind, placebo-controlled, parallel groups design, 48 volunteers underwent 4 consecutive nights of simulated shift work.  Each "shift" consisted of the following: at approx. 2145 (just prior to the start of each simulated night shift), volunteers ingested a single oral dose of CX717 200 mg, CX717 400 mg, CX717 1000 mg, or placebo (N = 12 per drug dosage).  Performance, alertness, mood, and symptoms were then assessed from 2300 to 0700, followed by a polysomnog. monitored daytime sleep period from 0800 to 1200.  Results: Performance and alertness significantly degraded across the simulated night shifts (P < 0.05).  None of the dosages of CX717 reversed these effects (P > 0.05).  CX717 exerted some effects on daytime sleep, most notably redn. of slow-wave sleep time (P < 0.05).  CX717 caused very few side effects and none of those were serious or unexpected.  Discussion and Conclusions: At the doses tested, CX717 was not effective for reversing performance and alertness deficits assocd. with night shift work.  Further work evaluating higher doses of CX717 may be warranted, as are studies in which CX717 effects are explored under other conditions (e.g., Alzheimer's dementia, attention deficit disorder).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou_gG1VfAQ-bVg90H21EOLACvtfcHk0lgAStyeyFveYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1ahsrrJ&md5=629ac33ba48ae518bbe95d457502ac70</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.3357%2FASEM.2055.2007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3357%252FASEM.2055.2007%26sid%3Dliteratum%253Aachs%26aulast%3DWesensten%26aufirst%3DN.%2BJ.%26aulast%3DReichardt%26aufirst%3DR.%2BM.%26aulast%3DBalkin%26aufirst%3DT.%2BJ.%26atitle%3DAmpakine%2520%2528CX717%2529%2520effects%2520on%2520performance%2520and%2520alertness%2520during%2520simulated%2520night%2520shift%2520work%26jtitle%3DAviat.%252C%2520Space%2520Environ.%2520Med.%26date%3D2007%26volume%3D78%26issue%3D10%26spage%3D937%26epage%3D943%26doi%3D10.3357%2FASEM.2055.2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arbon, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dijk, D. J.</span></span> <span> </span><span class="NLM_article-title">Acute sleep deprivation: the effects of the Ampakine compound CX717 on human cognitive performance, alertness and recovery sleep</span>. <i>J. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1047</span>â <span class="NLM_lpage">1057</span>, <span class="refDoi">Â DOI: 10.1177/0269881111405353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1177%2F0269881111405353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=21940760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1OksrzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=1047-1057&issue=8&author=J.+Boyleauthor=N.+Stanleyauthor=L.+M.+Jamesauthor=N.+Wrightauthor=S.+Johnsenauthor=E.+L.+Arbonauthor=D.+J.+Dijk&title=Acute+sleep+deprivation%3A+the+effects+of+the+Ampakine+compound+CX717+on+human+cognitive+performance%2C+alertness+and+recovery+sleep&doi=10.1177%2F0269881111405353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Acute sleep deprivation: the effects of the AMPAKINE compound CX717 on human cognitive performance, alertness and recovery sleep</span></div><div class="casAuthors">Boyle, Julia; Stanley, Neil; James, Lynette M.; Wright, Nicola; Johnsen, Sigurd; Arbon, Emma L.; Dijk, Derk-Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1047-1057, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">AMPA receptor modulation is a potential novel approach to enhance cognitive performance.  CX717 is a pos. allosteric modulator of the AMPA receptor that has shown efficacy in rodent and primate cognition models.  CX717 (100 mg, 300 mg and 1000 mg) and placebo were studied in 16 healthy male volunteers (18-45 years) in a randomized, crossover study.  Cognitive function, arousal and recovery sleep (by polysomnog.) were assessed during the extended wakefulness protocol.  Placebo condition was assocd. with significant decrements in cognition, particularly at the circadian nadir (between 03:00 and 05:00).  Pre-specified primary and secondary analyses (general linear mixed modeling, GLMM) at each sep. time point did not reveal consistent improvements in performance or objective alertness with any dose of CX717.  Exploratory repeated measures anal., a method used to take into account the influence of individual differences, demonstrated an improvement in attention-based task performance following the 1000 mg dose.  Anal. of the recovery sleep showed that CX717 1000 mg significantly reduced stage 4 and slow-wave sleep (p â¤ 0.05) with evidence of reduced EEG (EEG) slow-wave and spindle activity.  The study suggests that CX717 only at the 1000 mg dose may counteract effects of sleep deprivation on attention-based tasks and that it may interfere with subsequent recovery sleep.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpopQxMfp-QsLVg90H21EOLACvtfcHk0lgBY-To8UcVNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1OksrzN&md5=afa7339c56f04a354f92f64123c7ced2</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1177%2F0269881111405353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881111405353%26sid%3Dliteratum%253Aachs%26aulast%3DBoyle%26aufirst%3DJ.%26aulast%3DStanley%26aufirst%3DN.%26aulast%3DJames%26aufirst%3DL.%2BM.%26aulast%3DWright%26aufirst%3DN.%26aulast%3DJohnsen%26aufirst%3DS.%26aulast%3DArbon%26aufirst%3DE.%2BL.%26aulast%3DDijk%26aufirst%3DD.%2BJ.%26atitle%3DAcute%2520sleep%2520deprivation%253A%2520the%2520effects%2520of%2520the%2520Ampakine%2520compound%2520CX717%2520on%2520human%2520cognitive%2520performance%252C%2520alertness%2520and%2520recovery%2520sleep%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2012%26volume%3D26%26issue%3D8%26spage%3D1047%26epage%3D1057%26doi%3D10.1177%2F0269881111405353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lippa, A. S.</span></span> <span> </span><span class="NLM_article-title">Compositions and Methods for Treating Attention Deficit Disorders</span>. <span class="NLM_patent">WO2018009256A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+S.+Lippa&title=Compositions+and+Methods+for+Treating+Attention+Deficit+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLippa%26aufirst%3DA.%2BS.%26atitle%3DCompositions%2520and%2520Methods%2520for%2520Treating%2520Attention%2520Deficit%2520Disorders%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, J. J.</span></span> <span> </span><span class="NLM_article-title">Ampakine CX717 protects against fentanyl-induced respiratory depression and lethal apnea in rats</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1364</span>â <span class="NLM_lpage">1370</span>, <span class="refDoi">Â DOI: 10.1097/ALN.0b013e31819faa2a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1097%2FALN.0b013e31819faa2a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=19461299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtFKntb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2009&pages=1364-1370&issue=6&author=J.+Renauthor=X.+Dingauthor=G.+D.+Funkauthor=J.+J.+Greer&title=Ampakine+CX717+protects+against+fentanyl-induced+respiratory+depression+and+lethal+apnea+in+rats&doi=10.1097%2FALN.0b013e31819faa2a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Ampakine CX717 Protects against Fentanyl-induced Respiratory Depression and Lethal Apnea in Rats</span></div><div class="casAuthors">Ren, Jun; Ding, Xiuqing; Funk, Gregory D.; Greer, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1364-1370</span>CODEN:
                <span class="NLM_cas:coden">ANESAV</span>;
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The use of fentanyl as a potent analgesic is contradicted by marked respiratory depression among a subpopulation of patients.  The commonly used approach of reversing fentanyl-induced respiratory depression with Î¼-opiate receptor antagonists such as naloxone has the undesirable effect of blocking analgesia.  Here, the authors report a clin. feasible pharmacol. soln. for countering fentanyl-induced respiratory depression via a mechanism that does not interfere with analgesia.  Specifically, to det. if the ampakine CX717, which has been proven metabolically stable and safe for human use, can prevent and rescue from severe fentanyl-induced apnea.  Plethsymog. recordings were performed from young and adult rats.  Varying doses of fentanyl were administered either i.p. or i.v. to induce moderate to life-threatening apneas.  CX717 was administered either before or after fentanyl administration.  In addn., phrenic nerve recordings were performed from in situ working heart brainstem prepns. from juvenile rats.  Preadministration of CX717 markedly attenuated fentanyl-induced respiratory depression.  Postadministration of CX717 rescued animals from a LD of fentanyl.  Significantly, CX717 countered fentanyl-induced depression of respiratory frequency without suppressing analgesia.  The ED of CX717 was in the range deemed safe on the basis of clin. trials examg. its efficacy for cognitive disorders.  In situ, fentanyl-induced depression in respiratory frequency and amplitude was alleviated by CX717.  CX717 is an agent that enhances the safety of using opiate drugs while preserving the analgesic effects.  This advancement could significantly improve pain management in a variety of clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwzvIELlMB77Vg90H21EOLACvtfcHk0lgBY-To8UcVNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtFKntb4%253D&md5=cafc221d0a8efcba90afb1dcf37ce3cf</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1097%2FALN.0b013e31819faa2a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FALN.0b013e31819faa2a%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DFunk%26aufirst%3DG.%2BD.%26aulast%3DGreer%26aufirst%3DJ.%2BJ.%26atitle%3DAmpakine%2520CX717%2520protects%2520against%2520fentanyl-induced%2520respiratory%2520depression%2520and%2520lethal%2520apnea%2520in%2520rats%26jtitle%3DAnesthesiology%26date%3D2009%26volume%3D110%26issue%3D6%26spage%3D1364%26epage%3D1370%26doi%3D10.1097%2FALN.0b013e31819faa2a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, J. J.</span></span> <span> </span><span class="NLM_article-title">Ampakines enhance weak endogenous respiratory drive and alleviate apnea in perinatal rats</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>191</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">704</span>â <span class="NLM_lpage">710</span>, <span class="refDoi">Â DOI: 10.1164/rccm.201410-1898OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1164%2Frccm.201410-1898OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=25594679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmt12qtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2015&pages=704-710&issue=6&author=J.+Renauthor=X.+Dingauthor=J.+J.+Greer&title=Ampakines+enhance+weak+endogenous+respiratory+drive+and+alleviate+apnea+in+perinatal+rats&doi=10.1164%2Frccm.201410-1898OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Ampakines enhance weak endogenous respiratory drive and alleviate apnea in perinatal rats</span></div><div class="casAuthors">Ren, Jun; Ding, Xiuqing; Greer, John J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">704-710</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Apnea of prematurity, which is prevalent among infants born at less than 34 wk gestation, is treated with caffeine, theophylline, or aminophylline.  However, not all newborns respond adequately to, or tolerate, methylxanthine administration, and thus alternative pharmacol. therapies are required.  Objectives: Rodent models are used to test the hypothesis that the ampakine CX1739, a pos. allosteric modulator of amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors, strengthens perinatal respiratory drive and reduces apneas.  We also provide a systematic study of the effects of caffeine for comparison.  Methods: Respiratory neural activity was recorded from brainstem-spinal cord in vitro perinatal rat prepns., and ÌVE was recorded in newborn rat pups using whole-body plethysmog. under normoxic and hypoxic conditions.  Measurements and Main Results: Using in vitro brainstem-spinal cord prepns., we found that CX1739 (10-100 Î¼M) dose-dependently increases the frequency of respiratory activity generated by fetal and newborn rat prepns. under normoxic and hypoxic conditions.  Plethysmog. recordings in vivo from Postnatal Day 0 rats demonstrated that CX1739 (10 mg/kg) increases the frequency and regularity of ventilation, reduces apneas, and protects against hypoxia-induced respiratory depression.  Conclusions: The net effect of ampakine enhancement of respiratory drive in perinatal rodents is a marked increase in ventilation and the regularity of respiratory patterns in perinatal rat prepns.  Importantly, from the perspective of clin. applications, CX1739 readily crosses the blood-brain barrier, is metabolically stable, and has passed through phase I and II clin. trials in adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3P7JmmSj58bVg90H21EOLACvtfcHk0lgBY-To8UcVNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmt12qtL8%253D&md5=ffd6b698fc9ee953cf04684a4d3dee8e</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1164%2Frccm.201410-1898OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201410-1898OC%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DGreer%26aufirst%3DJ.%2BJ.%26atitle%3DAmpakines%2520enhance%2520weak%2520endogenous%2520respiratory%2520drive%2520and%2520alleviate%2520apnea%2520in%2520perinatal%2520rats%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2015%26volume%3D191%26issue%3D6%26spage%3D704%26epage%3D710%26doi%3D10.1164%2Frccm.201410-1898OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, J. J.</span></span> <span> </span><span class="NLM_article-title">Respiratory depression in rats induced by alcohol and barbiturate and rescue by ampakine CX717</span>. <i>J. Appl. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1004</span>â <span class="NLM_lpage">1011</span>, <span class="refDoi">Â DOI: 10.1152/japplphysiol.00752.2012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1152%2Fjapplphysiol.00752.2012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=22837171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVamt7nP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2012&pages=1004-1011&issue=7&author=J.+Renauthor=X.+Dingauthor=J.+J.+Greer&title=Respiratory+depression+in+rats+induced+by+alcohol+and+barbiturate+and+rescue+by+ampakine+CX717&doi=10.1152%2Fjapplphysiol.00752.2012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory depression in rats induced by alcohol and barbiturate and rescue by ampakine CX717</span></div><div class="casAuthors">Ren, Jun; Ding, Xiuqing; Greer, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Physiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1004-1011</span>CODEN:
                <span class="NLM_cas:coden">JAPHEV</span>;
        ISSN:<span class="NLM_cas:issn">8750-7587</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">Barbiturate use in conjunction with alc. can result in severe respiratory depression and overdose deaths.  The mechanisms underlying the additive/synergistic actions were unresolved.  Current management of ethanol-barbiturate-induced apnea is limited to ventilatory and circulatory support coupled with drug elimination.  Based on recent preclin. and clin. studies of opiate-induced respiratory depression, we hypothesized that ampakine compds. may provide a treatment for other types of drug-induced respiratory depression.  The actions of alc., pentobarbital, bicuculline, and the ampakine CX717, alone and in combination, were measured via 1) ventral root recordings from newborn rat brain stem-spinal cord prepns. and 2) plethysmog. recordings from unrestrained newborn and adult rats.  We found that ethanol caused a modest suppression of respiratory drive in vitro (50 mM) and in vivo (2 g/kg i.p.).  Pentobarbital induced an â¼50% redn. in respiratory frequency in vitro (50 Î¼M) and in vivo (28 mg/kg for pups and 56 mg/kg for adult rats i.p.).  However, severe life-threatening apnea was induced by the combination of the agents in vitro and in vivo via activation of GABAA receptors, which was exacerbated by hypoxic (8% O2) conditions.  Administration of the ampakine CX717 alleviated a significant component of the respiratory depression in vitro (50-150 Î¼M) and in vivo (30 mg/kg i.p.).  Bicuculline also alleviated ethanol-/pentobarbital-induced respiratory depression but caused seizure activity, whereas CX717 did not.  These data demonstrated that ethanol and pentobarbital together caused severe respiratory depression, including lethal apnea, via synergistic actions that blunt chemoreceptive responses to hypoxia and hypercapnia and suppress central respiratory rhythmogenesis.  The ampakine CX717 markedly reduced the severity of respiratory depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr1LInI30ml7Vg90H21EOLACvtfcHk0lhCWcdRzYlO7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVamt7nP&md5=b65eeeb361348fada54c7354e94b08bd</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1152%2Fjapplphysiol.00752.2012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fjapplphysiol.00752.2012%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DGreer%26aufirst%3DJ.%2BJ.%26atitle%3DRespiratory%2520depression%2520in%2520rats%2520induced%2520by%2520alcohol%2520and%2520barbiturate%2520and%2520rescue%2520by%2520ampakine%2520CX717%26jtitle%3DJ.%2520Appl.%2520Physiol.%26date%3D2012%26volume%3D113%26issue%3D7%26spage%3D1004%26epage%3D1011%26doi%3D10.1152%2Fjapplphysiol.00752.2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirton, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staff, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozol, R. A.</span></span> <span> </span><span class="NLM_article-title">Postoperative day one: A high risk period for respiratory events</span>. <i>Am. J. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>190</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">752</span>â <span class="NLM_lpage">756</span>, <span class="refDoi">Â DOI: 10.1016/j.amjsurg.2005.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.amjsurg.2005.07.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=16226953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BD2MrkvFalug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2005&pages=752-756&issue=5&author=S.+Taylorauthor=O.+C.+Kirtonauthor=I.+Staffauthor=R.+A.+Kozol&title=Postoperative+day+one%3A+A+high+risk+period+for+respiratory+events&doi=10.1016%2Fj.amjsurg.2005.07.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Postoperative day one: a high risk period for respiratory events</span></div><div class="casAuthors">Taylor Shiv; Kirton Orlando C; Staff Ilene; Kozol Robert A</div><div class="citationInfo"><span class="NLM_cas:title">American journal of surgery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">752-6</span>
        ISSN:<span class="NLM_cas:issn">0002-9610</span>.
    </div><div class="casAbstract">BACKGROUND:  In 2001, the Joint Commission on Accreditation of Healthcare Organizations released Pain Management Standards that has led to an increased focus on pain control.  Since then the Institute for Safe Medication Practices has noted that overaggressive pain management has led to increases in oversedation and fatal respiratory depression.  One of our previous studies found that postoperative patients may be reaching dangerously high levels of sedation as a result of pain management.  Our hypothesis is that postoperative patients who have a respiratory event caused by analgesic use are more likely to have that event in the first postoperative day.  METHODS:  We performed a retrospective case-control analysis identifying 62 postoperative patients who had a respiratory event.  A respiratory event was defined as respiratory depression caused by narcotic use in the postoperative period that was reversed by naloxone.  Sixty-two postoperative patients with no such event were chosen randomly and frequency matched based on surgical procedure and diagnosis-related group.  Risk factors for an event were identified.  RESULTS:  Of the cases, 77.4% had a respiratory event in the first 24 hours postoperatively.  Significant risk factors for an event were as follows: 65 years of age or older, having chronic obstructive pulmonary disease, having 1 or more comorbidities, and being placed on hydromorphone.  CONCLUSIONS:  The first 24 hours after surgery represents a high-risk period for a respiratory event as a result of narcotic use.  The realization of this risk can lead to the implementation of standards to increase patient safety in the first postoperative day.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTirF4ghY7zXTAyhZbj3lKdfW6udTcc2eay3woWby1rxrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MrkvFalug%253D%253D&md5=5747e00c25b34baa1359eb0cb46327cc</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.amjsurg.2005.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjsurg.2005.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DKirton%26aufirst%3DO.%2BC.%26aulast%3DStaff%26aufirst%3DI.%26aulast%3DKozol%26aufirst%3DR.%2BA.%26atitle%3DPostoperative%2520day%2520one%253A%2520A%2520high%2520risk%2520period%2520for%2520respiratory%2520events%26jtitle%3DAm.%2520J.%2520Surg.%26date%3D2005%26volume%3D190%26issue%3D5%26spage%3D752%26epage%3D756%26doi%3D10.1016%2Fj.amjsurg.2005.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">RespireRx Pharmaceuticals Inc.</span> <span> </span><span class="NLM_article-title">Ampakines Development Summary</span> <a href="https://www.sec.gov/Archives/edgar/data/849636/000149315217007695/ex99-3.htm" class="extLink">https://www.sec.gov/Archives/edgar/data/849636/000149315217007695/ex99-3.htm</a>. (accessed June 2, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=RespireRx+Pharmaceuticals+Inc.&title=Ampakines+Development+Summary"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DAmpakines%2520Development%2520Summary%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oertel, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felden, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angst, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varney, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotsch, J.</span></span> <span> </span><span class="NLM_article-title">Selective antagonism of opioid-induced ventilatory depression by an ampakine molecule in humans without loss of opioid analgesia</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>87</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">204</span>â <span class="NLM_lpage">211</span>, <span class="refDoi">Â DOI: 10.1038/clpt.2009.194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2Fclpt.2009.194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=19907420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252Flslykug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2010&pages=204-211&issue=2&author=B.+G.+Oertelauthor=L.+Feldenauthor=P.+V.+Tranauthor=M.+H.+Bradshawauthor=M.+S.+Angstauthor=H.+Schmidtauthor=S.+Johnsonauthor=J.+J.+Greerauthor=G.+Geisslingerauthor=M.+A.+Varneyauthor=J.+Lotsch&title=Selective+antagonism+of+opioid-induced+ventilatory+depression+by+an+ampakine+molecule+in+humans+without+loss+of+opioid+analgesia&doi=10.1038%2Fclpt.2009.194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Selective antagonism of opioid-induced ventilatory depression by an ampakine molecule in humans without loss of opioid analgesia</span></div><div class="casAuthors">Oertel B G; Felden L; Tran P V; Bradshaw M H; Angst M S; Schmidt H; Johnson S; Greer J J; Geisslinger G; Varney M A; Lotsch J</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">204-11</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Ventilatory depression is a significant risk associated with the use of opioids.  We assessed whether opioid-induced ventilatory depression can be selectively antagonized by an ampakine without reduction of analgesia.  In 16 healthy men, after a single oral dose of 1,500 mg of the ampakine CX717, a target concentration of 100 ng/ml alfentanil decreased the respiratory frequency by only 2.9 +/- 33.4% as compared with 25.6 +/- 27.9% during placebo coadministration (P < 0.01).Blood oxygenation and the ventilatory response to hypercapnic challenge also showed significantly smaller decreases with CX717 than with placebo.  In contrast, CX717 did not affect alfentanil-induced analgesia in either electrical or heat-based experimental models of pain.  Both ventilatory depression and analgesia were reversed with 1.6 mg of naloxone.  These results support the use of ampakines as selective antidotes in humans to counter opioid-induced ventilatory depression without affecting opioid-mediated analgesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSyb5RcqSgN3DMsgLhIoICsfW6udTcc2eay3woWby1rxrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252Flslykug%253D%253D&md5=547dcb1e4c5c9bd193c673cb5e38b8b9</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2009.194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2009.194%26sid%3Dliteratum%253Aachs%26aulast%3DOertel%26aufirst%3DB.%2BG.%26aulast%3DFelden%26aufirst%3DL.%26aulast%3DTran%26aufirst%3DP.%2BV.%26aulast%3DBradshaw%26aufirst%3DM.%2BH.%26aulast%3DAngst%26aufirst%3DM.%2BS.%26aulast%3DSchmidt%26aufirst%3DH.%26aulast%3DJohnson%26aufirst%3DS.%26aulast%3DGreer%26aufirst%3DJ.%2BJ.%26aulast%3DGeisslinger%26aufirst%3DG.%26aulast%3DVarney%26aufirst%3DM.%2BA.%26aulast%3DLotsch%26aufirst%3DJ.%26atitle%3DSelective%2520antagonism%2520of%2520opioid-induced%2520ventilatory%2520depression%2520by%2520an%2520ampakine%2520molecule%2520in%2520humans%2520without%2520loss%2520of%2520opioid%2520analgesia%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2010%26volume%3D87%26issue%3D2%26spage%3D204%26epage%3D211%26doi%3D10.1038%2Fclpt.2009.194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gray, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rekling, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bocchiaro, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, J. L.</span></span> <span> </span><span class="NLM_article-title">Modulation of respiratory frequency by peptidergic input to rhythmogenic neurons in the preBotzinger complex</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>286</i></span> (<span class="NLM_issue">5444</span>),  <span class="NLM_fpage">1566</span>â <span class="NLM_lpage">1568</span>, <span class="refDoi">Â DOI: 10.1126/science.286.5444.1566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1126%2Fscience.286.5444.1566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10567264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK1MXns1aju70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=1999&pages=1566-1568&issue=5444&author=P.+A.+Grayauthor=J.+C.+Reklingauthor=C.+M.+Bocchiaroauthor=J.+L.+Feldman&title=Modulation+of+respiratory+frequency+by+peptidergic+input+to+rhythmogenic+neurons+in+the+preBotzinger+complex&doi=10.1126%2Fscience.286.5444.1566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of respiratory frequency by peptidergic input to rhythmogenic neurons in the preBotzinger complex</span></div><div class="casAuthors">Gray, Paul A.; Rekling, Jens C.; Bocchiaro, Christopher M.; Feldman, Jack L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">5444</span>),
    <span class="NLM_cas:pages">1566-1568</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Neurokinin-1 receptor (NK1R) and Î¼-opioid receptor (Î¼OR) agonists affected respiratory rhythm when injected directly into the preBotzinger complex (pre-BotC), the hypothesized site for respiratory rhythmogenesis in mammals.  These effects were mediated by actions on pre-BotC rhythmogenic neurons.  The distribution of NK1R+ neurons anatomically defined the pre-BotC.  Type 1 neurons in the pre-BotC, which have rhythmogenic properties, expressed both NK1 Rs and Î¼ORs, whereas type 2 neurons expressed only NK1Rs.  These findings suggest that the pre-BotC is a definable anat. structure with unique physiol. function and that a subpopulation of neurons expressing both NK1Rs and Î¼ORs generate respiratory rhythm and modulate respiratory frequency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8mgm0Cl-YHLVg90H21EOLACvtfcHk0li51NAoqNxF0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXns1aju70%253D&md5=ff7f54f36adcd882642f7d705cfb3879</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1126%2Fscience.286.5444.1566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.286.5444.1566%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DP.%2BA.%26aulast%3DRekling%26aufirst%3DJ.%2BC.%26aulast%3DBocchiaro%26aufirst%3DC.%2BM.%26aulast%3DFeldman%26aufirst%3DJ.%2BL.%26atitle%3DModulation%2520of%2520respiratory%2520frequency%2520by%2520peptidergic%2520input%2520to%2520rhythmogenic%2520neurons%2520in%2520the%2520preBotzinger%2520complex%26jtitle%3DScience%26date%3D1999%26volume%3D286%26issue%3D5444%26spage%3D1566%26epage%3D1568%26doi%3D10.1126%2Fscience.286.5444.1566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballanyi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, J. L.</span></span> <span> </span><span class="NLM_article-title">Pre-Botzinger complex: A brainstem region that may generate respiratory rhythm in mammals</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>254</i></span> (<span class="NLM_issue">5032</span>),  <span class="NLM_fpage">726</span>â <span class="NLM_lpage">729</span>, <span class="refDoi">Â DOI: 10.1126/science.1683005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1126%2Fscience.1683005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1683005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADyaK38%252FlsVGlsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=1991&pages=726-729&issue=5032&author=J.+C.+Smithauthor=H.+H.+Ellenbergerauthor=K.+Ballanyiauthor=D.+W.+Richterauthor=J.+L.+Feldman&title=Pre-Botzinger+complex%3A+A+brainstem+region+that+may+generate+respiratory+rhythm+in+mammals&doi=10.1126%2Fscience.1683005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Pre-Botzinger complex: a brainstem region that may generate respiratory rhythm in mammals</span></div><div class="casAuthors">Smith J C; Ellenberger H H; Ballanyi K; Richter D W; Feldman J L</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue">5032</span>),
    <span class="NLM_cas:pages">726-9</span>
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The location of neurons generating the rhythm of breathing in mammals is unknown.  By microsection of the neonatal rat brainstem in vitro, a limited region of the ventral medulla (the pre-Botzinger Complex) that contains neurons essential for rhythmogenesis was identified.  Rhythm generation was eliminated by removal of only this region.  Medullary slices containing the pre-Botzinger Complex generated respiratory-related oscillations similar to those generated by the whole brainstem in vitro, and neurons with voltage-dependent pacemaker-like properties were identified in this region.  Thus, the respiratory rhythm in the mammalian neonatal nervous system may result from a population of conditional bursting pacemaker neurons in the pre-Botzinger Complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpovtKeWUfyszK395ZObgVfW6udTcc2eaf-sKd-D_Y5Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38%252FlsVGlsA%253D%253D&md5=ffbcb575d47a5bc6ec879466da3f3175</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1126%2Fscience.1683005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1683005%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DJ.%2BC.%26aulast%3DEllenberger%26aufirst%3DH.%2BH.%26aulast%3DBallanyi%26aufirst%3DK.%26aulast%3DRichter%26aufirst%3DD.%2BW.%26aulast%3DFeldman%26aufirst%3DJ.%2BL.%26atitle%3DPre-Botzinger%2520complex%253A%2520A%2520brainstem%2520region%2520that%2520may%2520generate%2520respiratory%2520rhythm%2520in%2520mammals%26jtitle%3DScience%26date%3D1991%26volume%3D254%26issue%3D5032%26spage%3D726%26epage%3D729%26doi%3D10.1126%2Fscience.1683005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greer, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, J. L.</span></span> <span> </span><span class="NLM_article-title">Role of excitatory amino acids in the generation and transmission of respiratory drive in neonatal rat</span>. <i>J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>437</i></span>,  <span class="NLM_fpage">727</span>â <span class="NLM_lpage">749</span>, <span class="refDoi">Â DOI: 10.1113/jphysiol.1991.sp018622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1113%2Fjphysiol.1991.sp018622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1653855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK3MXlt1yjtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=437&publication_year=1991&pages=727-749&author=J.+J.+Greerauthor=J.+C.+Smithauthor=J.+L.+Feldman&title=Role+of+excitatory+amino+acids+in+the+generation+and+transmission+of+respiratory+drive+in+neonatal+rat&doi=10.1113%2Fjphysiol.1991.sp018622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Role of excitatory amino acids in the generation and transmission of respiratory drive in neonatal rat</span></div><div class="casAuthors">Greer, John J.; Smith, Jeffrey C.; Feldman, Jack L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">437</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">727-49</span>CODEN:
                <span class="NLM_cas:coden">JPHYA7</span>;
        ISSN:<span class="NLM_cas:issn">0022-3751</span>.
    </div><div class="casAbstract">Respiratory rhythm generation in the in vitro neonatal rat brain stem-spinal cord is dependent on and modulated by endogenously released excitatory amino acids acting at non-N-methyl-D-aspartate (NMDA) receptors.  The transmission of inspiratory drive to cranial, accessory, phrenic, and intercostal motoneuron pools also depends on activation of non-NMDA receptors.  Activation of NMDA receptors contributes a relatively small component of inspiratory drive transmission to brain stem and spinal motoneuron pools, and is not necessary for rhythmogenesis.  AP-4-sensitive receptors are importantly involved in inspiratory drive transmission to phrenic and intercostal motoneuron pools, but not in rhythmogenesis or drive transmission to cranial and accessory motoneurons.  This indicates a functional heterogeneity of receptor mechanisms mediating transmission of inspiratory drive in spinal and cranial synaptic pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVnblg3cUtxrVg90H21EOLACvtfcHk0li51NAoqNxF0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlt1yjtbY%253D&md5=af38b9fc0133f6f5d7a906d0832ef13d</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1113%2Fjphysiol.1991.sp018622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1113%252Fjphysiol.1991.sp018622%26sid%3Dliteratum%253Aachs%26aulast%3DGreer%26aufirst%3DJ.%2BJ.%26aulast%3DSmith%26aufirst%3DJ.%2BC.%26aulast%3DFeldman%26aufirst%3DJ.%2BL.%26atitle%3DRole%2520of%2520excitatory%2520amino%2520acids%2520in%2520the%2520generation%2520and%2520transmission%2520of%2520respiratory%2520drive%2520in%2520neonatal%2520rat%26jtitle%3DJ.%2520Physiol.%26date%3D1991%26volume%3D437%26spage%3D727%26epage%3D749%26doi%3D10.1113%2Fjphysiol.1991.sp018622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Funk, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, J. L.</span></span> <span> </span><span class="NLM_article-title">Generation and transmission of respiratory oscillations in medullary slices: Role of excitatory amino acids</span>. <i>J. Neurophysiol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>70</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1497</span>â <span class="NLM_lpage">1515</span>, <span class="refDoi">Â DOI: 10.1152/jn.1993.70.4.1497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1152%2Fjn.1993.70.4.1497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=8283211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK2cXhsFCnt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1993&pages=1497-1515&issue=4&author=G.+D.+Funkauthor=J.+C.+Smithauthor=J.+L.+Feldman&title=Generation+and+transmission+of+respiratory+oscillations+in+medullary+slices%3A+Role+of+excitatory+amino+acids&doi=10.1152%2Fjn.1993.70.4.1497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Generation and transmission of respiratory oscillations in medullary slices: role of excitatory amino acids</span></div><div class="casAuthors">Funk, Gregory D.; Smith, Jeffrey C.; Feldman, Jack L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurophysiology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1497-515</span>CODEN:
                <span class="NLM_cas:coden">JONEA4</span>;
        ISSN:<span class="NLM_cas:issn">0022-3077</span>.
    </div><div class="casAbstract">The involvement of excitatory amino acid (EAA) receptors in the generation of respiratory rhythm and transmission of inspiratory drive to hypoglossal (XII) motoneurons was examd. in an in vitro neonatal rat medullary slice prepn.  Slices generated rhythmic inspiratory activity in XII nerves.  The role of EAAs in rhythm generation was detd. by analyzing perturbations of respiratory network activity after bath application of EAA receptor antagonists or local microinjection of antagonists into the main column of respiratory neurons in the ventrolateral medulla (ventral respiratory group), particularly in the pre-Botzinger complex (pre-BotC).  The involvement of EAAs in drive transmission to XII motoneurons was examd. by recording perturbations in XII nerve discharge or motoneuron synaptic inputs after microinjection of EAA receptor antagonists into either the XII motor nuclei or sites in the ventrolateral medulla contg. interneurons of the drive transmission circuit.  Block of non-N-methyl-D-aspartate (non-NMDA) receptors by bath application of 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) reversibly reduced XII nerve burst frequency and amplitude in a concn.-dependent manner, completely blocking respiratory motor output at concns. >4 Î¼M.  Activation of 2-amino-4-phosphonobutyric acid (AP-4)-sensitive receptors with DL-AP-4 reduced XII nerve burst amplitude by 30% but did not alter burst frequency.  Block of NMDA receptor channels by bath application of MK-801 did not perturb the frequency or amplitude of motor output.  Inhibition of EAA uptake in the slices by bath application of dihydrokainic acid reversibly increased the frequency and amplitude of XII motor discharge.  Block of non-NMDA receptors at multiple sites along the main column of respiratory neurons in the ventrolateral medulla, including the pre-BotC, by unilateral microinjection of CNQX produced a dose-dependent, bilateral redn. in XII nerve burst amplitude without substantial perturbations of the frequency of respiratory oscillations.  Block of non-NMDA receptors within the pre-BotC at sites ventral to amplitude altering sites produced a redn. in frequency and ultimately bilateral block of respiratory network oscillations.  Non-NMDA receptor block within the XII motor nucleus by unilateral microinjection of CNQX produced a dose-dependent redn. in ipsilateral XII nerve discharge amplitude without perturbing the frequency of respiratory oscillations.  Perturbations of contralateral XII nerve burst amplitude were significantly smaller.  NMDA channel block within the XII motor nucleus did not affect inspiratory burst amplitude, whereas activation of AP-4 receptors caused a 30% redn. in amplitude.  Whole-cell recordings of XII motoneuron synaptic currents and potentials indicated XII motoneurons with respiratory-modulated synaptic inputs receive rhythmic inspiratory drive currents of 150 pA (mean) and potentials of 11 mV.  Exogenous application of CNQX reversibly blocked 90-95% of the rhythmic synaptic inputs.  Local application of DL-AP-4 reduced inspiratory-modulated synaptic currents by 21%, whereas MK-801 application did not affect inspiratory drive currents or potentials.  After blocking action potential-dependent synaptic transmission with tetrodotoxin, local application of L-glutamate produced an inward current that was reduced to 5% of control by CNQX but was unaffected by DL-AP-4.  Local application of non-NMDA receptor agonists [quisqualate (Quis), AMPA, and kainate (Kain)] and NMDA receptor agonists caused membrane depolarization or inward current.  The postsynaptic actions of Quis, AMPA, and Kain were potently and competitively blocked by local application of CNQX.  The motoneuron responses to NMDA were irreversibly blocked by MK-801.  The results indicate that: (1) respiratory rhythm generation in the in vitro neonatal rat medullary slice is dependent on endogenously released EAAs acting at non-NMDA receptors within the pre-BotC; (2) mutually excitatory, non-NMDA receptor-mediated synaptic interactions between pre-BotC neuron populations on each side of the medulla contribute to maintenance of respiratory rhythm; (3) XII motoneurons possess NMDA and non-NMDA (AMPA and Kain) receptors; and (4) an EAA-like substance acting primarily at non-NMDA receptors mediates transmission of inspiratory drive to XII motoneurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRxwALxPOpLLVg90H21EOLACvtfcHk0ljPNSk0R8Dgog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhsFCnt7c%253D&md5=8ca2319fbaf8a1bacf77f2fd993634fe</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1152%2Fjn.1993.70.4.1497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fjn.1993.70.4.1497%26sid%3Dliteratum%253Aachs%26aulast%3DFunk%26aufirst%3DG.%2BD.%26aulast%3DSmith%26aufirst%3DJ.%2BC.%26aulast%3DFeldman%26aufirst%3DJ.%2BL.%26atitle%3DGeneration%2520and%2520transmission%2520of%2520respiratory%2520oscillations%2520in%2520medullary%2520slices%253A%2520Role%2520of%2520excitatory%2520amino%2520acids%26jtitle%3DJ.%2520Neurophysiol.%26date%3D1993%26volume%3D70%26issue%3D4%26spage%3D1497%26epage%3D1515%26doi%3D10.1152%2Fjn.1993.70.4.1497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">ElMallah, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliardini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerreta, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falk, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, D. D.</span></span> <span> </span><span class="NLM_article-title">Stimulation of respiratory motor output and ventilation in a murine model of Pompe disease by Ampakines</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">326</span>â <span class="NLM_lpage">335</span>, <span class="refDoi">Â DOI: 10.1165/rcmb.2014-0374OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1165%2Frcmb.2014-0374OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=25569118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BC2MvktlKktw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2015&pages=326-335&issue=3&author=M.+K.+ElMallahauthor=S.+Pagliardiniauthor=S.+M.+Turnerauthor=A.+J.+Cerretaauthor=D.+J.+Falkauthor=B.+J.+Byrneauthor=J.+J.+Greerauthor=D.+D.+Fuller&title=Stimulation+of+respiratory+motor+output+and+ventilation+in+a+murine+model+of+Pompe+disease+by+Ampakines&doi=10.1165%2Frcmb.2014-0374OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulation of Respiratory Motor Output and Ventilation in a Murine Model of Pompe Disease by Ampakines</span></div><div class="casAuthors">ElMallah Mai K; Pagliardini Silvia; Greer John J; Turner Sara M; Cerreta Anthony J; Fuller David D; Turner Sara M; Cerreta Anthony J; Fuller David D; Falk Darin J; Byrne Barry J; Falk Darin J; Byrne Barry J; Falk Darin J; Byrne Barry J</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory cell and molecular biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">326-35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pompe disease results from a mutation in the acid Î±-glucosidase gene leading to lysosomal glycogen accumulation.  Respiratory insufficiency is common, and the current U.S.  Food and Drug Administration-approved treatment, enzyme replacement, has limited effectiveness.  Ampakines are drugs that enhance Î±-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor responses and can increase respiratory motor drive.  Recent work indicates that respiratory motor drive can be blunted in Pompe disease, and thus pharmacologic stimulation of breathing may be beneficial.  Using a murine Pompe model with the most severe clinical genotype (the Gaa(-/-) mouse), our primary objective was to test the hypothesis that ampakines can stimulate respiratory motor output and increase ventilation.  Our second objective was to confirm that neuropathology was present in Pompe mouse medullary respiratory control neurons.  The impact of ampakine CX717 on breathing was determined via phrenic and hypoglossal nerve recordings in anesthetized mice and whole-body plethysmography in unanesthetized mice.  The medulla was examined using standard histological methods coupled with immunochemical markers of respiratory control neurons.  Ampakine CX717 robustly increased phrenic and hypoglossal inspiratory bursting and reduced respiratory cycle variability in anesthetized Pompe mice, and it increased inspiratory tidal volume in unanesthetized Pompe mice.  CX717 did not significantly alter these variables in wild-type mice.  Medullary respiratory neurons showed extensive histopathology in Pompe mice.  Ampakines stimulate respiratory neuromotor output and ventilation in Pompe mice, and therefore they have potential as an adjunctive therapy in Pompe disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcToKlCOb9njAGxpATR2EQURfW6udTcc2eaRIbADK5eVebntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvktlKktw%253D%253D&md5=99ddff6dab43797c07044f3cce047e7e</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2014-0374OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2014-0374OC%26sid%3Dliteratum%253Aachs%26aulast%3DElMallah%26aufirst%3DM.%2BK.%26aulast%3DPagliardini%26aufirst%3DS.%26aulast%3DTurner%26aufirst%3DS.%2BM.%26aulast%3DCerreta%26aufirst%3DA.%2BJ.%26aulast%3DFalk%26aufirst%3DD.%2BJ.%26aulast%3DByrne%26aufirst%3DB.%2BJ.%26aulast%3DGreer%26aufirst%3DJ.%2BJ.%26aulast%3DFuller%26aufirst%3DD.%2BD.%26atitle%3DStimulation%2520of%2520respiratory%2520motor%2520output%2520and%2520ventilation%2520in%2520a%2520murine%2520model%2520of%2520Pompe%2520disease%2520by%2520Ampakines%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2015%26volume%3D53%26issue%3D3%26spage%3D326%26epage%3D335%26doi%3D10.1165%2Frcmb.2014-0374OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Streeter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Rothi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baekey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, D.</span></span> <span> </span><span class="NLM_article-title">Ampakines increase spinal respiratory motor output after cervical spinal cord injury in rats</span>. <i>The FASEB Journal</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1299.4</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=1299.4&author=K.+Streeterauthor=E.+Gonzalez-Rothiauthor=M.+Sandhuauthor=D.+Baekeyauthor=J.+Greerauthor=D.+Fuller&title=Ampakines+increase+spinal+respiratory+motor+output+after+cervical+spinal+cord+injury+in+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStreeter%26aufirst%3DK.%26aulast%3DGonzalez-Rothi%26aufirst%3DE.%26aulast%3DSandhu%26aufirst%3DM.%26aulast%3DBaekey%26aufirst%3DD.%26aulast%3DGreer%26aufirst%3DJ.%26aulast%3DFuller%26aufirst%3DD.%26atitle%3DAmpakines%2520increase%2520spinal%2520respiratory%2520motor%2520output%2520after%2520cervical%2520spinal%2520cord%2520injury%2520in%2520rats%26jtitle%3DThe%2520FASEB%2520Journal%26date%3D2016%26volume%3D30%26spage%3D1299.4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wollman, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streeter, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, D. D.</span></span> <span> </span><span class="NLM_article-title">Ampakine pretreatment enables a single brief hypoxic episode to evoke phrenic motor facilitation</span>. <i>J. Neurophysiol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>123</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">993</span>â <span class="NLM_lpage">1003</span>, <span class="refDoi">Â DOI: 10.1152/jn.00708.2019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1152%2Fjn.00708.2019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=31940229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVOmsr%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2020&pages=993-1003&issue=3&author=L.+B.+Wollmanauthor=K.+A.+Streeterauthor=D.+D.+Fuller&title=Ampakine+pretreatment+enables+a+single+brief+hypoxic+episode+to+evoke+phrenic+motor+facilitation&doi=10.1152%2Fjn.00708.2019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Ampakine pretreatment enables a single brief hypoxic episode to evokephrenic motor facilitation</span></div><div class="casAuthors">Wollman, L. B.; Streeter, K. A.; Fuller, D. D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurophysiology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">993-1003</span>CODEN:
                <span class="NLM_cas:coden">JONEA4</span>;
        ISSN:<span class="NLM_cas:issn">1522-1598</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">Ampakines are a class of drugs that enhance AMPA receptor function.  Ampakines can enhance expression of neuroplasticity, and the phrenic motor system is fundamentally dependent on excitatory glutamatergic currents.  Accordingly, we tested the hypothesis that combining ampakine pretreatment with a single brief hypoxic exposure would result in phrenic motor facilitation lasting well beyond the period of hypoxia.  Phrenic nerve output was recorded in urethane-anesthetized, ventilated, and vagotomized adult Sprague-Dawley rats.  Ampakine CX717 (15 mg/kg iv; n =8) produced a small increase in phrenic inspiratory burst amplitude and frequency, but values quickly returned to predrug baseline.  When CX717 was followed 2 min later by a 5-min exposure to hypoxia (n= 8; PaO2 â¼45 mmHg), a persistent increase in phrenic inspiratory burst amplitude (i.e., phrenic motor facilitation) was obsd. up to 60 min posthypoxia (103 Â± 53% increase from baseline).  In contrast, when hypoxia was preceded by vehicle injection (10% 2-hydroxypropyl--cyclodextrin; n =8), inspiratory phrenic bursting was similar to baseline values at 60 min.  Addnl. expts. with another ampakine (CX1739, 15 mg/kg) produced comparable results.  We conclude that pairing low-dose ampakine treatment with a single brief hypoxic exposure can evoke sustained phrenic motor facilitation.  This targeted approach for enhancing respiratory neuroplasticity may have value in the context of hypoxia-based neurorehabilitation strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHIOOlJtuY-rVg90H21EOLACvtfcHk0ljPNSk0R8Dgog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVOmsr%252FM&md5=70be230320a29148f3b076043a8c75b6</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1152%2Fjn.00708.2019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fjn.00708.2019%26sid%3Dliteratum%253Aachs%26aulast%3DWollman%26aufirst%3DL.%2BB.%26aulast%3DStreeter%26aufirst%3DK.%2BA.%26aulast%3DFuller%26aufirst%3DD.%2BD.%26atitle%3DAmpakine%2520pretreatment%2520enables%2520a%2520single%2520brief%2520hypoxic%2520episode%2520to%2520evoke%2520phrenic%2520motor%2520facilitation%26jtitle%3DJ.%2520Neurophysiol.%26date%3D2020%26volume%3D123%26issue%3D3%26spage%3D993%26epage%3D1003%26doi%3D10.1152%2Fjn.00708.2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, R.</span>; <span class="NLM_string-name">Street, L.</span></span> <span> </span><span class="NLM_article-title">Bicyclic Amides for Enhancing Glutamatergic Synaptic Responses</span>. <span class="NLM_patent">US8263591B2</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=R.+Mueller&author=L.+Street&title=Bicyclic+Amides+for+Enhancing+Glutamatergic+Synaptic+Responses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMueller%26aufirst%3DR.%26atitle%3DBicyclic%2520Amides%2520for%2520Enhancing%2520Glutamatergic%2520Synaptic%2520Responses%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Street, L.</span>; <span class="NLM_string-name">Mueller, R.</span>; <span class="NLM_string-name">Lee, S.</span></span> <span> </span><span class="NLM_article-title">Di-Substituted Amides for Enhancing Glutamatergic Synaptic Responses</span>. <span class="NLM_patent">US8013003B2</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=L.+Street&author=R.+Mueller&author=S.+Lee&title=Di-Substituted+Amides+for+Enhancing+Glutamatergic+Synaptic+Responses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DStreet%26aufirst%3DL.%26atitle%3DDi-Substituted%2520Amides%2520for%2520Enhancing%2520Glutamatergic%2520Synaptic%2520Responses%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span>; <span class="NLM_string-name">Zhou, X.</span>; <span class="NLM_string-name">Xiao, D.</span>; <span class="NLM_string-name">Zhong, W.</span>; <span class="NLM_string-name">Xiao, J.</span>; <span class="NLM_string-name">Zheng, Z.</span>; <span class="NLM_string-name">Li, X.</span>; <span class="NLM_string-name">Xie, Y.</span>; <span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Preparation of Brain-Targeting Prodrug for AMPA Receptor Synergist</span>. <span class="NLM_patent">WO2017177896A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=S.+Li&author=X.+Zhou&author=D.+Xiao&author=W.+Zhong&author=J.+Xiao&author=Z.+Zheng&author=X.+Li&author=Y.+Xie&author=X.+Wang&title=Preparation+of+Brain-Targeting+Prodrug+for+AMPA+Receptor+Synergist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Brain-Targeting%2520Prodrug%2520for%2520AMPA%2520Receptor%2520Synergist%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, R. B.</span></span> <span> </span><span class="NLM_article-title">A brain-targeted ampakine compound protects against opioid-induced respiratory depression</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>809</i></span>,  <span class="NLM_fpage">122</span>â <span class="NLM_lpage">129</span>, <span class="refDoi">Â DOI: 10.1016/j.ejphar.2017.05.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.ejphar.2017.05.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28502631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvF2jt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=809&publication_year=2017&pages=122-129&author=W.+Daiauthor=D.+Xiaoauthor=X.+Gaoauthor=X.+B.+Zhouauthor=T.+Y.+Fangauthor=Z.+Yongauthor=R.+B.+Su&title=A+brain-targeted+ampakine+compound+protects+against+opioid-induced+respiratory+depression&doi=10.1016%2Fj.ejphar.2017.05.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">A brain-targeted ampakine compound protects against opioid-induced respiratory depression</span></div><div class="casAuthors">Dai, Wei; Xiao, Dian; Gao, Xiang; Zhou, Xin-Bo; Fang, Tong-Yu; Yong, Zheng; Su, Rui-bin</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">809</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">122-129</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The use of opioid drugs for pain relief can induce life-threatening respiratory depression.  Although naloxone effectively counteracts opioid-induced respiratory depression, it diminishes the efficacy of analgesia.  Our studies indicate that ampakines, in particular, a brain-targeted compd. XD-8-17C, are able to reverse respiratory depression without affecting analgesia at relatively low doses.  Mice and rats were s.c. or i.v. injected with the opioid agonist TH-030418 to induce moderate or severe respiratory depression.  XD-8-17C was i.v. administered before or after TH-030418.  The effect of XD-8-17C on opioid-induced respiratory depression was evaluated in terms of the opioid-induced acute death rate, arterial blood gas anal. and pulmonary function tests.  In addn., the hot-plate test was conducted to investigate whether XD-8-17C influenced opioid-induced analgesia.  Pre-treatment with XD-8-17C significantly reduced opioid-induced acute death, and increased the median LD of TH-030418 by 4.7-fold.  Blood gas anal. and pulmonary function tests demonstrated that post-treatment with XD-8-17C alleviated respiratory depression, as indicated by restoration of arterial blood gas (pO2, sO2, cK+) and lung function parameters (respiratory frequency, minute ventilation) to the normal range.  The hot-plate test showed that XD-8-17C had no impact on the antinociceptive efficacy of morphine.  The ability of XD-8-17C to reverse opioid-induced respiratory depression has the potential to increase the safety and convenience of opioid treatment.  These findings contribute to the discovery of novel therapeutic agents that protect against opioid-induced respiratory depression without loss of analgesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTDjQstw7pt7Vg90H21EOLACvtfcHk0ljXcZTSdRRgFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvF2jt7o%253D&md5=7c0cfc66cd88e777029fcc4d6617d004</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2017.05.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2017.05.025%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DW.%26aulast%3DXiao%26aufirst%3DD.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DX.%2BB.%26aulast%3DFang%26aufirst%3DT.%2BY.%26aulast%3DYong%26aufirst%3DZ.%26aulast%3DSu%26aufirst%3DR.%2BB.%26atitle%3DA%2520brain-targeted%2520ampakine%2520compound%2520protects%2520against%2520opioid-induced%2520respiratory%2520depression%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2017%26volume%3D809%26spage%3D122%26epage%3D129%26doi%3D10.1016%2Fj.ejphar.2017.05.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of brain-targeted thiamine disulfide prodrugs of Ampakine compound LCX001</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">488</span>, <span class="refDoi">Â DOI: 10.3390/molecules21040488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.3390%2Fmolecules21040488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=27089316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVCktLfM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=488&issue=4&author=D.+Xiaoauthor=F.+H.+Mengauthor=W.+Daiauthor=Z.+Yongauthor=J.+Q.+Liuauthor=X.+B.+Zhouauthor=S.+Li&title=Design%2C+synthesis+and+biological+evaluation+of+brain-targeted+thiamine+disulfide+prodrugs+of+Ampakine+compound+LCX001&doi=10.3390%2Fmolecules21040488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of brain-targeted thiamine disulfide prodrugs of ampakine compound LCX001</span></div><div class="casAuthors">Xiao, Dian; Meng, Fan-Hua; Dai, Wei; Yong, Zheng; Liu, Jin-Qiu; Zhou, Xin-Bo; Li, Song</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">488/1-488/14</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A series of thiamine disulfide prodrugs I [R = n-Et, Bu, benzyl, etc.,] of ampakine compd. LCX001 II was synthesized and evaluated.  The trials in-vitro showed that prodrugs I [R = n-pentyl, isopentyl, benzyl] possessed a certain stability in plasma and quickly decompd. in brain homogenate by the disulfide reductase.  In-vivo, prodrug I [R = isopentyl] decreased the peripheral distribution of II and significantly increased brain distribution of LCX001 after i.v. administration.  This compd. showed 2.23- and 3.29-fold greater increases in the AUC0-t and MRT0-t of II in brain, resp., than did II itself.  A preliminary pharmacodynamic study indicated that the required molar dose of prodrug I [R = isopentyl] was only one eighth that of II required to achieve the same effect in mice.  These findings provide an important ref. to evaluate the clin. outlook of ampakine compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiyy-3o3qKgbVg90H21EOLACvtfcHk0ljXcZTSdRRgFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVCktLfM&md5=5b0752309a99b2135ab9eca2b668dc6f</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.3390%2Fmolecules21040488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules21040488%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DD.%26aulast%3DMeng%26aufirst%3DF.%2BH.%26aulast%3DDai%26aufirst%3DW.%26aulast%3DYong%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%2BQ.%26aulast%3DZhou%26aufirst%3DX.%2BB.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520brain-targeted%2520thiamine%2520disulfide%2520prodrugs%2520of%2520Ampakine%2520compound%2520LCX001%26jtitle%3DMolecules%26date%3D2016%26volume%3D21%26issue%3D4%26spage%3D488%26doi%3D10.3390%2Fmolecules21040488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span>; <span class="NLM_string-name">Giroux, A.</span>; <span class="NLM_string-name">Zamboni, R.</span>; <span class="NLM_string-name">McKay, D. J.</span>; <span class="NLM_string-name">Bayly, C. I.</span>; <span class="NLM_string-name">Grimm, E. L.</span>; <span class="NLM_string-name">Colucci, J.</span></span> <span> </span><span class="NLM_article-title">Preparation and Effect of Pyrazinones Against Caspase-3</span>. <span class="NLM_patent">WO2001005772A1</span>, <span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=Y.+Han&author=A.+Giroux&author=R.+Zamboni&author=D.+J.+McKay&author=C.+I.+Bayly&author=E.+L.+Grimm&author=J.+Colucci&title=Preparation+and+Effect+of+Pyrazinones+Against+Caspase-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DY.%26atitle%3DPreparation%2520and%2520Effect%2520of%2520Pyrazinones%2520Against%2520Caspase-3%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâCosta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demaro, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gidday, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacquin, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, E. M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtzman, D. M.</span></span> <span> </span><span class="NLM_article-title">Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>101</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1992</span>â <span class="NLM_lpage">1999</span>, <span class="refDoi">Â DOI: 10.1172/JCI2169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1172%2FJCI2169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=9576764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK1cXjt1Srt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=1998&pages=1992-1999&issue=9&author=Y.+Chengauthor=M.+Deshmukhauthor=A.+D%E2%80%99Costaauthor=J.+A.+Demaroauthor=J.+M.+Giddayauthor=A.+Shahauthor=Y.+Sunauthor=M.+F.+Jacquinauthor=E.+M.+Johnsonauthor=D.+M.+Holtzman&title=Caspase+inhibitor+affords+neuroprotection+with+delayed+administration+in+a+rat+model+of+neonatal+hypoxic-ischemic+brain+injury&doi=10.1172%2FJCI2169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury</span></div><div class="casAuthors">Cheng, Yu; Deshmukh, Mohanish; D'costa, Anselm; Demaro, Joseph A.; Gidday, Jeffrey M.; Shah, Aarti; Sun, Yuling; Jacquin, Mark F.; Johnson, Eugene M., Jr.; Holtzman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1992-1999</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Programmed cell death (apoptosis) is a normal process in the developing nervous system.  Recent data suggest that certain features seen in the process of programmed cell death may be favored in the developing vs. the adult brain in response to different brain injuries.  In a well characterized model of neonatal hypoxia-ischemia, we demonstrate marked but delayed cell death in which there is prominent DNA laddering, TUNEL-labeling, and nuclei with condensed chromatin.  Caspase activation, which is required in many cases of apoptotic cell death, also followed a delayed time course after hypoxia-ischemia.  Administration of boc-aspartyl(OMe)-fluoromethylketone, a pan-caspase inhibitor, was significantly neuroprotective when given by intracerebroventricular injection 3 h after cerebral hypoxia-ischemia.  In addn., systemic injections of boc-aspartyl(OMe)-fluoromethylketone also given in a delayed fashion, resulted in significant neuroprotection.  These findings suggest that caspase inhibitors may be able to provide benefit over a prolonged therapeutic window after hypoxic-ischemic events in the developing brain, a major contributor to static encephalopathy and cerebral palsy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHZ6z0PLKBvbVg90H21EOLACvtfcHk0lj4H_YZbPWD4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjt1Srt7g%253D&md5=96b188e98e09bdc762a51046117a64d5</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1172%2FJCI2169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI2169%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DDeshmukh%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Costa%26aufirst%3DA.%26aulast%3DDemaro%26aufirst%3DJ.%2BA.%26aulast%3DGidday%26aufirst%3DJ.%2BM.%26aulast%3DShah%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DJacquin%26aufirst%3DM.%2BF.%26aulast%3DJohnson%26aufirst%3DE.%2BM.%26aulast%3DHoltzman%26aufirst%3DD.%2BM.%26atitle%3DCaspase%2520inhibitor%2520affords%2520neuroprotection%2520with%2520delayed%2520administration%2520in%2520a%2520rat%2520model%2520of%2520neonatal%2520hypoxic-ischemic%2520brain%2520injury%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1998%26volume%3D101%26issue%3D9%26spage%3D1992%26epage%3D1999%26doi%3D10.1172%2FJCI2169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schotte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Declercq, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Huffel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenabeele, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyaert, R.</span></span> <span> </span><span class="NLM_article-title">Non-specific effects of methyl ketone peptide inhibitors of caspases</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>442</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">117</span>â <span class="NLM_lpage">121</span>, <span class="refDoi">Â DOI: 10.1016/S0014-5793(98)01640-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2FS0014-5793%2898%2901640-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=9923616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK1MXhslaiug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=442&publication_year=1999&pages=117-121&issue=1&author=P.+Schotteauthor=W.+Declercqauthor=S.+Van+Huffelauthor=P.+Vandenabeeleauthor=R.+Beyaert&title=Non-specific+effects+of+methyl+ketone+peptide+inhibitors+of+caspases&doi=10.1016%2FS0014-5793%2898%2901640-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Non-specific effects of methyl ketone peptide inhibitors of caspases</span></div><div class="casAuthors">Schotte, Peter; Declercq, Wim; Van Huffel, Sofie; Vandenabeele, Peter; Beyaert, Rudi</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">442</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">117-121</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Caspases are a family of cysteine proteases which play a crucial role in apoptosis and inflammation.  The involvement of caspases in these processes can be demonstrated by their irreversible inhibition with fluoromethyl ketone and chloromethyl ketone derivs. of peptides resembling the cleavage site of known caspase substrates.  These inhibitors irreversibly alkylate the cysteine residue in the active site of caspases.  In this study we show that a biotinylated fluoromethyl ketone peptide inhibitor of caspases (z-VAD.fmk) also efficiently affinity-labeled cathepsin B and cathepsin H.  In addn., the caspase inhibitors z-VAD.fmk, z-DEVD.fmk and Ac-YVAD.cmk also efficiently inhibited cathepsin B activity in vitro and in tissue culture cells at concns. that are generally used to demonstrate the involvement of caspases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0H6FRXOO7-LVg90H21EOLACvtfcHk0lj4H_YZbPWD4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhslaiug%253D%253D&md5=3e0b34a6e18f2f5b8ccb607d24e45c71</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2898%2901640-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252898%252901640-8%26sid%3Dliteratum%253Aachs%26aulast%3DSchotte%26aufirst%3DP.%26aulast%3DDeclercq%26aufirst%3DW.%26aulast%3DVan%2BHuffel%26aufirst%3DS.%26aulast%3DVandenabeele%26aufirst%3DP.%26aulast%3DBeyaert%26aufirst%3DR.%26atitle%3DNon-specific%2520effects%2520of%2520methyl%2520ketone%2520peptide%2520inhibitors%2520of%2520caspases%26jtitle%3DFEBS%2520Lett.%26date%3D1999%26volume%3D442%26issue%3D1%26spage%3D117%26epage%3D121%26doi%3D10.1016%2FS0014-5793%2898%2901640-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giroux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colucci, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayly, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKay, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xanthoudakis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaillancourt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasper, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamboni, R. J.</span></span> <span> </span><span class="NLM_article-title">Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1173</span>â <span class="NLM_lpage">1180</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2004.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmcl.2004.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=15686936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2MXos1CqtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=1173-1180&issue=4&author=Y.+Hanauthor=A.+Girouxauthor=J.+Colucciauthor=C.+I.+Baylyauthor=D.+J.+McKayauthor=S.+Royauthor=S.+Xanthoudakisauthor=J.+Vaillancourtauthor=D.+M.+Rasperauthor=J.+Tamauthor=P.+Tawaauthor=D.+W.+Nicholsonauthor=R.+J.+Zamboni&title=Novel+pyrazinone+mono-amides+as+potent+and+reversible+caspase-3+inhibitors&doi=10.1016%2Fj.bmcl.2004.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors</span></div><div class="casAuthors">Han, Yongxin; Giroux, Andre; Colucci, John; Bayly, Christopher I.; Mckay, Daniel J.; Roy, Sophie; Xanthoudakis, Steve; Vaillancourt, John; Rasper, Dita M.; Tam, John; Tawa, Paul; Nicholson, Donald W.; Zamboni, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1173-1180</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The iterative process for the discovery of a series of pyrazinone mono-amides as potent, selective and reversible non-peptide caspase-3 inhibitors (e.g., M826 and M867) is reported.  The studied compds. were prepd. according to modified literature procedure from ethylaminobutyrate hydrochloride via intermediate acids (e. g., I), which were synthesized using Dess-Martin periodinane oxidn.  Treating of coupled to the resin in the presence of Hunig's base intermediate acids I with 90% TFA in water gave the desired inhibitors (e. g. II).  These compds. were screened directly, without further purifn., against four representative recombinant human caspases, as well as in the NT2 cell against camptothecin induced apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZYH5uODF8jrVg90H21EOLACvtfcHk0lj4H_YZbPWD4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXos1CqtQ%253D%253D&md5=e5fdf716f194d7809e2070a1287f4b0c</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DY.%26aulast%3DGiroux%26aufirst%3DA.%26aulast%3DColucci%26aufirst%3DJ.%26aulast%3DBayly%26aufirst%3DC.%2BI.%26aulast%3DMcKay%26aufirst%3DD.%2BJ.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DXanthoudakis%26aufirst%3DS.%26aulast%3DVaillancourt%26aufirst%3DJ.%26aulast%3DRasper%26aufirst%3DD.%2BM.%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DTawa%26aufirst%3DP.%26aulast%3DNicholson%26aufirst%3DD.%2BW.%26aulast%3DZamboni%26aufirst%3DR.%2BJ.%26atitle%3DNovel%2520pyrazinone%2520mono-amides%2520as%2520potent%2520and%2520reversible%2520caspase-3%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26issue%3D4%26spage%3D1173%26epage%3D1180%26doi%3D10.1016%2Fj.bmcl.2004.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giroux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aspiotis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francoeur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayly, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKay, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xanthoudakis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaillancourt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasper, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornberry, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Calvo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotonda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamboni, R. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel aspartyl ketone dipeptides as potent and selective caspase-3 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">805</span>â <span class="NLM_lpage">808</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2003.10.064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmcl.2003.10.064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=14741294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltFyhtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=805-808&issue=3&author=Y.+Hanauthor=A.+Girouxauthor=E.+L.+Grimmauthor=R.+Aspiotisauthor=S.+Francoeurauthor=C.+I.+Baylyauthor=D.+J.+McKayauthor=S.+Royauthor=S.+Xanthoudakisauthor=J.+P.+Vaillancourtauthor=D.+M.+Rasperauthor=J.+Tamauthor=P.+Tawaauthor=N.+A.+Thornberryauthor=E.+P.+Patersonauthor=M.+Garcia-Calvoauthor=J.+W.+Beckerauthor=J.+Rotondaauthor=D.+W.+Nicholsonauthor=R.+J.+Zamboni&title=Discovery+of+novel+aspartyl+ketone+dipeptides+as+potent+and+selective+caspase-3+inhibitors&doi=10.1016%2Fj.bmcl.2003.10.064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel aspartyl ketone dipeptides as potent and selective caspase-3 inhibitors</span></div><div class="casAuthors">Han, Yongxin; Giroux, Andre; Grimm, Erich L.; Aspiotis, Renee; Francoeur, Sebastien; Bayly, Christopher I.; Mckay, Daniel J.; Roy, Sophie; Xanthoudakis, Steve; Vaillancourt, John P.; Rasper, Dita M.; Tam, John; Tawa, Paul; Thornberry, Nancy A.; Paterson, Erin P.; Garcia-Calvo, Margarita; Becker, Joseph W.; Rotonda, Jennifer; Nicholson, Donald W.; Zamboni, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">805-808</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The discovery of a series of potent, selective and reversible dipeptidyl caspase-3 inhibitors are reported.  The iterative discovery process of using combinatorial chem., parallel synthesis, mol. modeling and structural biol. will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHZyM_TsXjS7Vg90H21EOLACvtfcHk0lgbdjzpZmFv2A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltFyhtA%253D%253D&md5=7b06451d7a9e419de06bce82cc7a6f03</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.10.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.10.064%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DY.%26aulast%3DGiroux%26aufirst%3DA.%26aulast%3DGrimm%26aufirst%3DE.%2BL.%26aulast%3DAspiotis%26aufirst%3DR.%26aulast%3DFrancoeur%26aufirst%3DS.%26aulast%3DBayly%26aufirst%3DC.%2BI.%26aulast%3DMcKay%26aufirst%3DD.%2BJ.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DXanthoudakis%26aufirst%3DS.%26aulast%3DVaillancourt%26aufirst%3DJ.%2BP.%26aulast%3DRasper%26aufirst%3DD.%2BM.%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DTawa%26aufirst%3DP.%26aulast%3DThornberry%26aufirst%3DN.%2BA.%26aulast%3DPaterson%26aufirst%3DE.%2BP.%26aulast%3DGarcia-Calvo%26aufirst%3DM.%26aulast%3DBecker%26aufirst%3DJ.%2BW.%26aulast%3DRotonda%26aufirst%3DJ.%26aulast%3DNicholson%26aufirst%3DD.%2BW.%26aulast%3DZamboni%26aufirst%3DR.%2BJ.%26atitle%3DDiscovery%2520of%2520novel%2520aspartyl%2520ketone%2520dipeptides%2520as%2520potent%2520and%2520selective%2520caspase-3%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26issue%3D3%26spage%3D805%26epage%3D808%26doi%3D10.1016%2Fj.bmcl.2003.10.064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chereau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodandapani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomaselli, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spada, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. C.</span></span> <span> </span><span class="NLM_article-title">Structural and Functional Analysis of caspase active sites</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">4151</span>â <span class="NLM_lpage">4160</span>, <span class="refDoi">Â DOI: 10.1021/bi020593l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi020593l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit1Sjs78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=4151-4160&issue=14&author=D.+Chereauauthor=L.+Kodandapaniauthor=K.+J.+Tomaselliauthor=A.+P.+Spadaauthor=J.+C.+Wu&title=Structural+and+Functional+Analysis+of+caspase+active+sites&doi=10.1021%2Fbi020593l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Analysis of Caspase Active Sites</span></div><div class="casAuthors">Chereau, David; Kodandapani, Lalitha; Tomaselli, Kevin J.; Spada, Alfred P.; Wu, Joe C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4151-4160</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Amino acid sequences of caspases 1, 3, 7, and 8 were aligned with their published three-dimensional (3D) structures.  The resultant alignment was used as a template to compare the primary structures of caspases 2, 4-6, and 9-11 to build 3D homol. models.  The structural models were subsequently refined and validated using structure-activity relationship data obtained from an array of substrate-like inhibitors.  All caspases were shown to have identical S1 and catalytic dyad architecture but diverse S2-S4 structures.  S2 pockets of these 11 caspases can be briefly categorized into two groups: Csp3, -6, and -7 as one and Csp1, -2, -4, -5, -8, -9, -10, and -11 as the other.  S2 pockets of Csp3, -6, and -7 are smaller than those of the other eight caspases, and are limited to binding small P2 residues such as Ala and Val.  At the S3 site, the presence of a conserved Arg in all caspases suggests that Glu would be a universally preferred P3 residue.  Csp8 and Csp9 have an addnl. Arg in this pocket that can further enhance the binding of a P3 Glu, whereas Csp2 has a Glu adjacent to the conserved Arg.  As such, Csp2 is the only caspase that can accommodate both pos. and neg. charged P3.  At S4, Csp1, -4, -5, and -11 are closely related with respect to their structures and binder preferences; all have a large hydrophobic pocket and prefer large hydrophobic residues such as Trp.  S4 of Csp2, -3, and -7 represents an opposite group with a conformation that is highly specific in binding an Asp.  The S4 structures of Csp6, -8, -9, and -10 appear to be hybrids of the two extremes, and have little specificity for any P4.  Information revealed from this work provides a guide for designing potent caspase inhibitors with desirable specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmsagQoSpZWbVg90H21EOLACvtfcHk0lgbdjzpZmFv2A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit1Sjs78%253D&md5=519bffc763e623dc123491c749a7df67</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Fbi020593l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi020593l%26sid%3Dliteratum%253Aachs%26aulast%3DChereau%26aufirst%3DD.%26aulast%3DKodandapani%26aufirst%3DL.%26aulast%3DTomaselli%26aufirst%3DK.%2BJ.%26aulast%3DSpada%26aufirst%3DA.%2BP.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26atitle%3DStructural%2520and%2520Functional%2520Analysis%2520of%2520caspase%2520active%2520sites%26jtitle%3DBiochemistry%26date%3D2003%26volume%3D42%26issue%3D14%26spage%3D4151%26epage%3D4160%26doi%3D10.1021%2Fbi020593l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xanthoudakis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaillancourt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colucci, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giroux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamboni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtzman, D. M.</span></span> <span> </span><span class="NLM_article-title">Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic brain injury</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span> (<span class="NLM_issue">33</span>),  <span class="NLM_fpage">30128</span>â <span class="NLM_lpage">30136</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M202931200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1074%2Fjbc.M202931200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=12058036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD38XmsVKhsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=30128-30136&issue=33&author=B.+H.+Hanauthor=D.+Xuauthor=J.+Choiauthor=Y.+Hanauthor=S.+Xanthoudakisauthor=S.+Royauthor=J.+Tamauthor=J.+Vaillancourtauthor=J.+Colucciauthor=R.+Simanauthor=A.+Girouxauthor=G.+S.+Robertsonauthor=R.+Zamboniauthor=D.+W.+Nicholsonauthor=D.+M.+Holtzman&title=Selective%2C+reversible+caspase-3+inhibitor+is+neuroprotective+and+reveals+distinct+pathways+of+cell+death+after+neonatal+hypoxic-ischemic+brain+injury&doi=10.1074%2Fjbc.M202931200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic brain injury</span></div><div class="casAuthors">Han, Byung Hee; Xu, Daigen; Choi, Junjeong; Han, Yongxin; Xanthoudakis, Steven; Roy, Sophie; Tam, John; Vaillancourt, John; Colucci, John; Siman, Robert; Giroux, Andre; Robertson, George S.; Zamboni, Robert; Nicholson, Donald W.; Holtzman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">30128-30136</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Hypoxia-ischemia (H-I) in the developing brain results in brain injury with prominent features of both apoptosis and necrosis.  A peptide-based pan-caspase inhibitor is neuroprotective against neonatal H-I brain injury, suggesting a central role of caspases in brain injury.  Because previously studied peptide-based caspase inhibitors are not potent and are only partially selective, the exact contribution of specific caspases and other proteases to injury after H-I is not clear.  In this study, we explored the neuroprotective effects of a small, reversible caspase-3 inhibitor M826.  M826 selectively and potently inhibited both caspase-3 enzymic activity and apoptosis in cultured cells in vitro.  In a rat model of neonatal H-I, M826 blocked caspase-3 activation and cleavage of its substrates, which begins 6 h and peaks 24 h after H-I.  Although M826 significantly reduced DNA fragmentation and brain tissue loss, it did not prevent calpain activation in the cortex.  This activation, which is assocd. with excitotoxic/necrotic cell injury, occurred within 30 min to 2 h after H-I even in the presence of M826.  Similar to calpain activation, we found evidence of caspase-2 processing within 30 min to 2 h after H-I that was not affected by M826.  Caspase-2 processing appeared to be secondary to calpain-mediated cleavage and was not assocd. with caspase-2 activation.  These data suggest that caspase-3 specifically contributes to delayed cell death and brain injury after neonatal H-I and that calpain activation is assocd. with and likely a marker for the early component of excitotoxic/necrotic brain injury previously demonstrated in this model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAyhcrZDdT8rVg90H21EOLACvtfcHk0lgbdjzpZmFv2A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmsVKhsLY%253D&md5=4f7d8b7d07e4c22dec66edb46d4c138b</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M202931200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M202931200%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DB.%2BH.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DXanthoudakis%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DVaillancourt%26aufirst%3DJ.%26aulast%3DColucci%26aufirst%3DJ.%26aulast%3DSiman%26aufirst%3DR.%26aulast%3DGiroux%26aufirst%3DA.%26aulast%3DRobertson%26aufirst%3DG.%2BS.%26aulast%3DZamboni%26aufirst%3DR.%26aulast%3DNicholson%26aufirst%3DD.%2BW.%26aulast%3DHoltzman%26aufirst%3DD.%2BM.%26atitle%3DSelective%252C%2520reversible%2520caspase-3%2520inhibitor%2520is%2520neuroprotective%2520and%2520reveals%2520distinct%2520pathways%2520of%2520cell%2520death%2520after%2520neonatal%2520hypoxic-ischemic%2520brain%2520injury%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26issue%3D33%26spage%3D30128%26epage%3D30136%26doi%3D10.1074%2Fjbc.M202931200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toulmond, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bureau, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashdown, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDonnell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colucci, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giroux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pikounis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xanthoudakis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigby, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamboni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fluckiger, J. P.</span></span> <span> </span><span class="NLM_article-title">Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntingtonâs disease</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>141</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">689</span>â <span class="NLM_lpage">697</span>, <span class="refDoi">Â DOI: 10.1038/sj.bjp.0705662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2Fsj.bjp.0705662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=14744804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVCmurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2004&pages=689-697&issue=4&author=S.+Toulmondauthor=K.+Tangauthor=Y.+Bureauauthor=H.+Ashdownauthor=S.+Degenauthor=R.+O%E2%80%99Donnellauthor=J.+Tamauthor=Y.+Hanauthor=J.+Colucciauthor=A.+Girouxauthor=Y.+Zhuauthor=M.+Boucherauthor=B.+Pikounisauthor=S.+Xanthoudakisauthor=S.+Royauthor=M.+Rigbyauthor=R.+Zamboniauthor=G.+S.+Robertsonauthor=G.+Y.+Ngauthor=D.+W.+Nicholsonauthor=J.+P.+Fluckiger&title=Neuroprotective+effects+of+M826%2C+a+reversible+caspase-3+inhibitor%2C+in+the+rat+malonate+model+of+Huntington%E2%80%99s+disease&doi=10.1038%2Fsj.bjp.0705662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease</span></div><div class="casAuthors">Toulmond, Sylvie; Tang, Keith; Bureau, Yves; Ashdown, Helen; Degen, Sarah; O'Donnell, Ruth; Tam, John; Han, Yongxin; Colucci, John; Giroux, Andre; Zhu, Yanxia; Boucher, Mathieu; Pikounis, Bill; Xanthoudakis, Steven; Roy, Sophie; Rigby, Michael; Zamboni, Robert; Robertson, George S.; Ng, Gordon Y. K.; Nicholson, Donald W.; Flueckiger, Jean-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">689-697</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Caspases, key enzymes in the apoptosis pathway, have been detected in the brain of HD patients and in animal models of the disease.  In the present study, we investigated the neuroprotective properties of a new, reversible, caspase-3-specific inhibitor, M826 (3-({(2S)-2-[5-tert-butyl-3-{[(4-methyl-1,2,5-oxadiazol-3-yl)methyl]amino}-2-oxopyrazin-1(2H)-yl]butanoyl}amino)-5-[hexyl(methyl)amino]-4-oxopentanoic acid), in a rat malonate model of HD.  Pharmacokinetic and autoradiog. studies after intrastriatal (iâ) injection of 1.5 nmol of M826 or its tritiated analog [3H]M826 indicated that the compd. diffused within the entire striatum.  The elimination half-life (T1/2) of M826 in the rat striatum was 3h.  Iâ injection of 1.5 nmol of M826 10 min after malonate infusion induced a significant redn. (66%) in the no. of neurons expressing active caspase-3 in the ipsilateral striatum.  Inhibition of active caspase-3 translated into a significant but moderate redn. (39%) of the lesion vol., and of cell death (24%), 24 h after injury.  The efficacy of M826 at inhibiting cell death was comparable to that of the noncompetitive NMDA receptor antagonist MK801.  These data provide in vivo proof-of-concept of the neuroprotective effects of reversible caspase-3 inhibitors in a model of malonate-induced striatal injury in the adult rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNJDXvnaxjCbVg90H21EOLACvtfcHk0lgI9mY-DYOLyQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVCmurg%253D&md5=004359dca09ef30fe01749f867fd82ee</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0705662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0705662%26sid%3Dliteratum%253Aachs%26aulast%3DToulmond%26aufirst%3DS.%26aulast%3DTang%26aufirst%3DK.%26aulast%3DBureau%26aufirst%3DY.%26aulast%3DAshdown%26aufirst%3DH.%26aulast%3DDegen%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DR.%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DColucci%26aufirst%3DJ.%26aulast%3DGiroux%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DBoucher%26aufirst%3DM.%26aulast%3DPikounis%26aufirst%3DB.%26aulast%3DXanthoudakis%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DRigby%26aufirst%3DM.%26aulast%3DZamboni%26aufirst%3DR.%26aulast%3DRobertson%26aufirst%3DG.%2BS.%26aulast%3DNg%26aufirst%3DG.%2BY.%26aulast%3DNicholson%26aufirst%3DD.%2BW.%26aulast%3DFluckiger%26aufirst%3DJ.%2BP.%26atitle%3DNeuroprotective%2520effects%2520of%2520M826%252C%2520a%2520reversible%2520caspase-3%2520inhibitor%252C%2520in%2520the%2520rat%2520malonate%2520model%2520of%2520Huntington%25E2%2580%2599s%2520disease%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2004%26volume%3D141%26issue%3D4%26spage%3D689%26epage%3D697%26doi%3D10.1038%2Fsj.bjp.0705662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coulthard, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burchill, S. A.</span></span> <span> </span><span class="NLM_article-title">p38MAPK: stress responses from molecular mechanisms to therapeutics</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">369</span>â <span class="NLM_lpage">379</span>, <span class="refDoi">Â DOI: 10.1016/j.molmed.2009.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.molmed.2009.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=19665431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVehur%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=369-379&issue=8&author=L.+R.+Coulthardauthor=D.+E.+Whiteauthor=D.+L.+Jonesauthor=M.+F.+McDermottauthor=S.+A.+Burchill&title=p38MAPK%3A+stress+responses+from+molecular+mechanisms+to+therapeutics&doi=10.1016%2Fj.molmed.2009.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">p38MAPK: stress responses from molecular mechanisms to therapeutics</span></div><div class="casAuthors">Coulthard, Lydia R.; White, Danielle E.; Jones, Dominic L.; McDermott, Michael F.; Burchill, Susan A.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">369-379</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The p38MAPK protein kinases affect a variety of intracellular responses, with well-recognized roles in inflammation, cell-cycle regulation, cell death, development, differentiation, senescence and tumorigenesis.  In this review, we examine the regulatory and effector components of this pathway, focusing on their emerging roles in biol. processes involved in different pathologies.  We summarize how this pathway has been exploited for the development of therapeutics and discuss the potential obstacles of targeting this promiscuous protein kinase pathway for the treatment of different diseases.  Furthermore, we discuss how the p38MAPK pathway might be best exploited for the development of more effective therapeutics with minimal side effects in a range of specific disease settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcV5JqoEjQ3LVg90H21EOLACvtfcHk0lgI9mY-DYOLyQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVehur%252FM&md5=d1e83011edb2cce40ade0e2792d5e18f</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2009.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2009.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DCoulthard%26aufirst%3DL.%2BR.%26aulast%3DWhite%26aufirst%3DD.%2BE.%26aulast%3DJones%26aufirst%3DD.%2BL.%26aulast%3DMcDermott%26aufirst%3DM.%2BF.%26aulast%3DBurchill%26aufirst%3DS.%2BA.%26atitle%3Dp38MAPK%253A%2520stress%2520responses%2520from%2520molecular%2520mechanisms%2520to%2520therapeutics%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2009%26volume%3D15%26issue%3D8%26spage%3D369%26epage%3D379%26doi%3D10.1016%2Fj.molmed.2009.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mayor Mendez, F.</span>; <span class="NLM_string-name">Murga Montesinos, C.</span>; <span class="NLM_string-name">Campos Muelas, P. M.</span>; <span class="NLM_string-name">Heijnen, J. J.</span>; <span class="NLM_string-name">Kavelaars, A. M. A. A.</span>; <span class="NLM_string-name">Morreale
de Leon, A.</span>; <span class="NLM_string-name">Gil Redondo, R.</span></span> <span> </span><span class="NLM_article-title">Drugs for Inhibiting p38 and Uses Thereof</span>. <span class="NLM_patent">WO2013064714A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=F.+Mayor+Mendez&author=C.+Murga+Montesinos&author=P.+M.+Campos+Muelas&author=J.+J.+Heijnen&author=A.+M.+A.+A.+Kavelaars&author=A.+Morreale%0Ade+Leon&author=R.+Gil+Redondo&title=Drugs+for+Inhibiting+p38+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMayor%2BMendez%26aufirst%3DF.%26atitle%3DDrugs%2520for%2520Inhibiting%2520p38%2520and%2520Uses%2520Thereof%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willemen, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morreale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil-Redondo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agut, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, F. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heijnen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayor, F.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavelaars, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murga, C.</span></span> <span> </span><span class="NLM_article-title">A novel p38 MAPK docking-groove-targeted compound is a potent inhibitor of inflammatory hyperalgesia</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>459</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">427</span>â <span class="NLM_lpage">439</span>, <span class="refDoi">Â DOI: 10.1042/BJ20130172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1042%2FBJ20130172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=24517375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFemt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=459&publication_year=2014&pages=427-439&issue=3&author=H.+L.+Willemenauthor=P.+M.+Camposauthor=E.+Lucasauthor=A.+Morrealeauthor=R.+Gil-Redondoauthor=J.+Agutauthor=F.+V.+Gonzalezauthor=P.+Ramosauthor=C.+Heijnenauthor=F.+Mayorauthor=A.+Kavelaarsauthor=C.+Murga&title=A+novel+p38+MAPK+docking-groove-targeted+compound+is+a+potent+inhibitor+of+inflammatory+hyperalgesia&doi=10.1042%2FBJ20130172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">A novel p38 MAPK docking-groove-targeted compound is a potent inhibitor of inflammatory hyperalgesia</span></div><div class="casAuthors">Willemen, Hanneke L. D. M.; Campos, Pedro M.; Lucas, Elisa; Morreale, Antonio; Gil-Redondo, Ruben; Agut, Juan; Gonzalez, Florenci V.; Ramos, Paula; Heijnen, Cobi; Mayor, Federico; Kavelaars, Annemieke; Murga, Cristina</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">459</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">427-439</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The MAPK (mitogen-activated protein kinase) p38 is an important mediator of inflammation and of inflammatory and neuropathic pain.  We have described recently that docking-groove-dependent interactions are important for p38 MAPK-mediated signal transduction.  Thus virtual screening was performed to identify putative docking-groove-targeted p38 MAPK inhibitors.  Several compds. of the benzo-oxadiazol family were identified with low micromolar inhibitory activity both in a p38 MAPK activity assay, and in THP-1 human monocytes acting as inhibitors of LPS (lipopolysaccharide)-induced TNFÎ± (tumor necrosis factor Î±) secretion.  Positions 2 and 5 in the Ph ring are essential for the described inhibitory activity with a chloride in position 5 and a Me group in position 2 yielding the best results, giving an IC50 value of 1.8 Î¼M (FGA-19 compd.).  Notably, FGA-19 exerted a potent and long-lasting analgesic effect in vivo when tested in a mouse model of inflammatory hyperalgesia.  A single intrathecal injection of FGA-19 completely resolved hyperalgesia, being 10-fold as potent and displaying longer lasting effects than the established p38 MAPK inhibitor SB239063.  FGA-19 also reversed persistent pain in a model of post-inflammatory hyperalgesia in LysM (lysozyme M)-GRK2 (G-protein-coupled-receptor kinase)+/- mice.  These potent in vivo effects suggested p38 MAPK docking-site-targeted inhibitors as a potential novel strategy for the treatment of inflammatory pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSjDuXZVUav7Vg90H21EOLACvtfcHk0liYxGrjTiASSQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFemt74%253D&md5=988817704d7f3e25748b1d43b64fd3ec</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1042%2FBJ20130172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20130172%26sid%3Dliteratum%253Aachs%26aulast%3DWillemen%26aufirst%3DH.%2BL.%26aulast%3DCampos%26aufirst%3DP.%2BM.%26aulast%3DLucas%26aufirst%3DE.%26aulast%3DMorreale%26aufirst%3DA.%26aulast%3DGil-Redondo%26aufirst%3DR.%26aulast%3DAgut%26aufirst%3DJ.%26aulast%3DGonzalez%26aufirst%3DF.%2BV.%26aulast%3DRamos%26aufirst%3DP.%26aulast%3DHeijnen%26aufirst%3DC.%26aulast%3DMayor%26aufirst%3DF.%26aulast%3DKavelaars%26aufirst%3DA.%26aulast%3DMurga%26aufirst%3DC.%26atitle%3DA%2520novel%2520p38%2520MAPK%2520docking-groove-targeted%2520compound%2520is%2520a%2520potent%2520inhibitor%2520of%2520inflammatory%2520hyperalgesia%26jtitle%3DBiochem.%2520J.%26date%3D2014%26volume%3D459%26issue%3D3%26spage%3D427%26epage%3D439%26doi%3D10.1042%2FBJ20130172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. A.</span></span> <span> </span><span class="NLM_article-title">PAINS in the assay: Chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2091</span>â <span class="NLM_lpage">2113</span>, <span class="refDoi">Â DOI: 10.1021/jm5019093</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5019093" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeisbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2091-2113&issue=5&author=J.+L.+Dahlinauthor=J.+W.+M.+Nissinkauthor=J.+M.+Strasserauthor=S.+Francisauthor=L.+Higginsauthor=H.+Zhouauthor=Z.+Zhangauthor=M.+A.+Walters&title=PAINS+in+the+assay%3A+Chemical+mechanisms+of+assay+interference+and+promiscuous+enzymatic+inhibition+observed+during+a+sulfhydryl-scavenging+HTS&doi=10.1021%2Fjm5019093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">PAINS in the Assay: Chemical Mechanisms of Assay Interference and Promiscuous Enzymatic Inhibition Observed during a Sulfhydryl-Scavenging HTS</span></div><div class="casAuthors">Dahlin, Jayme L.; Nissink, J. Willem M.; Strasser, Jessica M.; Francis, Subhashree; Higgins, LeeAnn; Zhou, Hui; Zhang, Zhiguo; Walters, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2091-2113</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Significant resources in early drug discovery are spent unknowingly pursuing artifacts and promiscuous bioactive compds., while understanding the chem. basis for these adverse behaviors often goes unexplored in pursuit of lead compds.  Nearly all the hits from our recent sulfhydryl-scavenging high-throughput screen (HTS) targeting the histone acetyltransferase Rtt109 were such compds.  Herein, we characterize the chem. basis for assay interference and promiscuous enzymic inhibition for several prominent chemotypes identified by this HTS, including some pan-assay interference compds. (PAINS).  Protein mass spectrometry and ALARM NMR confirmed these compds. react covalently with cysteines on multiple proteins.  Unfortunately, compds. contg. these chemotypes have been published as screening actives in reputable journals and even touted as chem. probes or preclin. candidates.  Our detailed characterization and identification of such thiol-reactive chemotypes should accelerate triage of nuisance compds., guide screening library design, and prevent follow-up on undesirable chem. matter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4XTJapoezkrVg90H21EOLACvtfcHk0liYxGrjTiASSQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeisbY%253D&md5=3f77702544cea2ec4c8184b60dd38b8a</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Fjm5019093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5019093%26sid%3Dliteratum%253Aachs%26aulast%3DDahlin%26aufirst%3DJ.%2BL.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DStrasser%26aufirst%3DJ.%2BM.%26aulast%3DFrancis%26aufirst%3DS.%26aulast%3DHiggins%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWalters%26aufirst%3DM.%2BA.%26atitle%3DPAINS%2520in%2520the%2520assay%253A%2520Chemical%2520mechanisms%2520of%2520assay%2520interference%2520and%2520promiscuous%2520enzymatic%2520inhibition%2520observed%2520during%2520a%2520sulfhydryl-scavenging%2520HTS%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D5%26spage%3D2091%26epage%3D2113%26doi%3D10.1021%2Fjm5019093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, P.</span>; <span class="NLM_string-name">Carrasco, E.</span>; <span class="NLM_string-name">Campos, P.</span>; <span class="NLM_string-name">Deleyto, P.</span>; <span class="NLM_string-name">Vega, M.</span>; <span class="NLM_string-name">Gomez-Reino, J. J.</span>; <span class="NLM_string-name">Conde, C.</span>; <span class="NLM_string-name">Gualillo, O.</span>; <span class="NLM_string-name">Perez, J. J.</span>; <span class="NLM_string-name">Messeguer, A.</span></span> <span> </span><span class="NLM_article-title">p38 MAPK Inhibitors for the Treatment of Inflammatory Diseases</span>. <span class="NLM_patent">WO2014094816A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=P.+Gomez&author=E.+Carrasco&author=P.+Campos&author=P.+Deleyto&author=M.+Vega&author=J.+J.+Gomez-Reino&author=C.+Conde&author=O.+Gualillo&author=J.+J.+Perez&author=A.+Messeguer&title=p38+MAPK+Inhibitors+for+the+Treatment+of+Inflammatory+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGomez%26aufirst%3DP.%26atitle%3Dp38%2520MAPK%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Inflammatory%2520Diseases%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, P.</span>; <span class="NLM_string-name">Carrasco, E.</span>; <span class="NLM_string-name">Campos, P.</span>; <span class="NLM_string-name">Vega, M.</span>; <span class="NLM_string-name">Gomez-Reino, J. J.</span>; <span class="NLM_string-name">Perez, J. J.</span>; <span class="NLM_string-name">Messeguer, A.</span>; <span class="NLM_string-name">Torres, I.</span></span> <span> </span><span class="NLM_article-title">p38 and JNK MAPK Inhibitors for the Treatment and Prophylaxis of Degenerative Diseases of the Nervous System</span>. <span class="NLM_patent">WO2015193281A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+Gomez&author=E.+Carrasco&author=P.+Campos&author=M.+Vega&author=J.+J.+Gomez-Reino&author=J.+J.+Perez&author=A.+Messeguer&author=I.+Torres&title=p38+and+JNK+MAPK+Inhibitors+for+the+Treatment+and+Prophylaxis+of+Degenerative+Diseases+of+the+Nervous+System"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGomez%26aufirst%3DP.%26atitle%3Dp38%2520and%2520JNK%2520MAPK%2520Inhibitors%2520for%2520the%2520Treatment%2520and%2520Prophylaxis%2520of%2520Degenerative%2520Diseases%2520of%2520the%2520Nervous%2520System%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giembycz, M. A.</span></span> <span> </span><span class="NLM_article-title">An update and appraisal of the cilomilast phase III clinical development programme for chronic obstructive pulmonary disease</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">138</span>â <span class="NLM_lpage">152</span>, <span class="refDoi">Â DOI: 10.1111/j.1365-2125.2006.02640.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1111%2Fj.1365-2125.2006.02640.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=16842388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVersr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=138-152&issue=2&author=M.+A.+Giembycz&title=An+update+and+appraisal+of+the+cilomilast+phase+III+clinical+development+programme+for+chronic+obstructive+pulmonary+disease&doi=10.1111%2Fj.1365-2125.2006.02640.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Giembycz, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">138-152</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Cilomilast (Ariflo, SB 207499) is an orally active, second-generation phosphodiesterase (PDE) 4 inhibitor that is being developed by GlaxoSmithkline for the treatment of chronic obstructive pulmonary disease (COPD).  The results of Phase I and Phase II studies have demonstrated that cilomilast significantly improves lung function and quality of life to a clin. meaningful extent, which has led to a comprehensive Phase III program of research evaluating efficacy, safety and mechanism of action.  However, the results of those Phase III studies are unremarkable and disappointing, raising doubt over the future of cilomilast as a novel therapy for COPD.  This review summarizes data obtained from the Phase III clin. development program, highlights some of the potential concerns both specific to cilomilast and to PDE4 inhibitors in general and assesses the likelihood that cilomilast will reach the market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG3j4h3elSNrVg90H21EOLACvtfcHk0ljAp6Je7c1Cfg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVersr8%253D&md5=0d8f4c3833a446ed6a43cc9b355a2c46</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2006.02640.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2006.02640.x%26sid%3Dliteratum%253Aachs%26aulast%3DGiembycz%26aufirst%3DM.%2BA.%26atitle%3DAn%2520update%2520and%2520appraisal%2520of%2520the%2520cilomilast%2520phase%2520III%2520clinical%2520development%2520programme%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2006%26volume%3D62%26issue%3D2%26spage%3D138%26epage%3D152%26doi%3D10.1111%2Fj.1365-2125.2006.02640.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trifilieff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyss, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzoni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersperger, R.</span></span> <span> </span><span class="NLM_article-title">Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with anti-inflammatory activities</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>301</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">241</span>â <span class="NLM_lpage">248</span>, <span class="refDoi">Â DOI: 10.1124/jpet.301.1.241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1124%2Fjpet.301.1.241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=11907180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1KqsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=301&publication_year=2002&pages=241-248&issue=1&author=A.+Trifilieffauthor=D.+Wyssauthor=C.+Walkerauthor=L.+Mazzoniauthor=R.+Hersperger&title=Pharmacological+profile+of+a+novel+phosphodiesterase+4+inhibitor%2C+4-%288-benzo%5B1%2C2%2C5%5Doxadiazol-5-yl-%5B1%2C7%5Dnaphthyridin-6-yl%29benzoic+acid+%28NVP-ABE171%29%2C+a+1%2C7-naphthyridine+derivative%2C+with+anti-inflammatory+activities&doi=10.1124%2Fjpet.301.1.241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with anti-inflammatory activities</span></div><div class="casAuthors">Trifilieff, Alexandre; Wyss, Daniel; Walker, Christoph; Mazzoni, Lazzaro; Hersperger, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">301</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">241-248</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The pharmacol. of a new class of phosphodiesterase 4 (PDE4) inhibitor, 6,8-disubstituted 1,7-naphthyridines, was investigated by using NVP-ABE171 as a representative compd., and its potency was compared with that of the most advanced PDE4 inhibitor currently undergoing clin. trials, Ariflo [cis-4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl-r-1-cyclohexanecarboxylic acid)].  NVP-ABE171 inhibited the activity of PDE 4A, 4B, 4C, and 4D with resp. IC50 values of 602, 34, 1230, and 1.5 nM.  Ariflo was about 40 times less potent.  In human cells, NVP-ABE171 in the nanomolar range inhibited the eosinophil and neutrophil oxidative burst, the release of cytokines by T cells, and tumor necrosis factor-Î± release from monocytes.  Ariflo had a similar inhibition profile but was 7-50-fold less potent.  In BALB/c mice challenged with lipopolysaccharide, NVP-ABE171 inhibited airway neutrophil influx and activation, with an ED50 in the range of 3 mg/kg.  Ariflo was inactive at â¤10 mg/kg.  In ovalbumin-sensitized Brown Norway rats, NVP-ABE171 inhibited lipopolysaccharide-induced airway neutrophil influx and activation (ED50 of 0.2 mg/kg) and ovalbumin-induced airway eosinophil influx and activation (ED50 of 0.1 mg/kg).  Ariflo was about 100-folds less potent in both models.  In the ovalbumin model, NVP-ABE171 had a duration of action of >24 h.  NVP-ABE171 is a novel PDE4 inhibitor that has activity both in vitro on human inflammatory cells and in vivo in animal models of lung inflammation.  This compd. class may have potential for the treatment of airway inflammatory conditions such as asthma and chronic obstructive pulmonary diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq76eMiujQMLVg90H21EOLACvtfcHk0lhUEFoUe78fsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1KqsrY%253D&md5=ac551981b3c2d6d7bc0b9bf7aa7d570e</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1124%2Fjpet.301.1.241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.301.1.241%26sid%3Dliteratum%253Aachs%26aulast%3DTrifilieff%26aufirst%3DA.%26aulast%3DWyss%26aufirst%3DD.%26aulast%3DWalker%26aufirst%3DC.%26aulast%3DMazzoni%26aufirst%3DL.%26aulast%3DHersperger%26aufirst%3DR.%26atitle%3DPharmacological%2520profile%2520of%2520a%2520novel%2520phosphodiesterase%25204%2520inhibitor%252C%25204-%25288-benzo%255B1%252C2%252C5%255Doxadiazol-5-yl-%255B1%252C7%255Dnaphthyridin-6-yl%2529benzoic%2520acid%2520%2528NVP-ABE171%2529%252C%2520a%25201%252C7-naphthyridine%2520derivative%252C%2520with%2520anti-inflammatory%2520activities%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D301%26issue%3D1%26spage%3D241%26epage%3D248%26doi%3D10.1124%2Fjpet.301.1.241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatzelmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morcillo, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lungarella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adnot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanjar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beume, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schudt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenor, H.</span></span> <span> </span><span class="NLM_article-title">The preclinical pharmacology of roflumilastâa selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">235</span>â <span class="NLM_lpage">256</span>, <span class="refDoi">Â DOI: 10.1016/j.pupt.2010.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.pupt.2010.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=20381629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlWqur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=235-256&issue=4&author=A.+Hatzelmannauthor=E.+J.+Morcilloauthor=G.+Lungarellaauthor=S.+Adnotauthor=S.+Sanjarauthor=R.+Beumeauthor=C.+Schudtauthor=H.+Tenor&title=The+preclinical+pharmacology+of+roflumilast%E2%80%94a+selective%2C+oral+phosphodiesterase+4+inhibitor+in+development+for+chronic+obstructive+pulmonary+disease&doi=10.1016%2Fj.pupt.2010.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">The preclinical pharmacology of roflumilast - A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Hatzelmann, Armin; Morcillo, Esteban J.; Lungarella, Giuseppe; Adnot, Serge; Sanjar, Shahin; Beume, Rolf; Schudt, Christian; Tenor, Hermann</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-256</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  After more than two decades of research into phosphodiesterase 4 (PDE4) inhibitors, roflumilast (3-cyclopropylmethoxy-4-difluoromethoxy-N-[3,5-di-chloropyrid-4-yl]-benzamide) may become the first agent in this class to be approved for patient treatment worldwide.  Within the PDE family of 11 known isoenzymes, roflumilast is selective for PDE4, showing balanced selectivity for subtypes A-D, and is of high subnanomolar potency.  The active principle of roflumilast in man is its dichloropyridyl N-oxide metabolite, which has similar potency as a PDE4 inhibitor as the parent compd.  The long half-life and high potency of this metabolite allows for once-daily, oral administration of a single, 500-Î¼g tablet of roflumilast.  The mol. mode of action of roflumilast - PDE4 inhibition and subsequent enhancement of cAMP levels - is well established.  To further understand its functional mode of action in chronic obstructive pulmonary disease (COPD), for which roflumilast is being developed, a series of in vitro and in vivo preclin. studies has been performed.  COPD is a progressive, devastating condition of the lung assocd. with an abnormal inflammatory response to noxious particles and gases, particularly tobacco smoke.  In addn., according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), significant extrapulmonary effects, including comorbidities, may add to the severity of the disease in individual patients, and which may be addressed preferentially by orally administered remedies.  COPD shows an increasing prevalence and mortality, and its treatment remains a high, unmet medical need.  In vivo, roflumilast mitigates key COPD-related disease mechanisms such as tobacco smoke-induced lung inflammation, mucociliary malfunction, lung fibrotic and emphysematous remodelling, oxidative stress, pulmonary vascular remodelling and pulmonary hypertension.  In vitro, roflumilast N-oxide has been demonstrated to affect the functions of many cell types, including neutrophils, monocytes/macrophages, CD4+ and CD8+ T-cells, endothelial cells, epithelial cells, smooth muscle cells and fibroblasts.  These cellular effects are thought to be responsible for the beneficial effects of roflumilast on the disease mechanisms of COPD, which translate into reduced exacerbations and improved lung function.  As a multicomponent disease, COPD requires a broad therapeutic approach that might be achieved by PDE4 inhibition.  However, as a PDE4 inhibitor, roflumilast is not a direct bronchodilator.  In summary, roflumilast may be the first-in-class PDE4 inhibitor for COPD therapy.  In addn. to being a non-steroid, anti-inflammatory drug designed to target pulmonary inflammation, the preclin. pharmacol. described in this review points to a broad functional mode of action of roflumilast that putatively addresses addnl. COPD mechanisms.  This enables roflumilast to offer effective, oral maintenance treatment for COPD, with an acceptable tolerability profile and the potential to favorably affect the extrapulmonary effects of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDAicMKzimBbVg90H21EOLACvtfcHk0lhUEFoUe78fsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlWqur8%253D&md5=ada4424630713054cefe9a6f5c98121b</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2010.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2010.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DHatzelmann%26aufirst%3DA.%26aulast%3DMorcillo%26aufirst%3DE.%2BJ.%26aulast%3DLungarella%26aufirst%3DG.%26aulast%3DAdnot%26aufirst%3DS.%26aulast%3DSanjar%26aufirst%3DS.%26aulast%3DBeume%26aufirst%3DR.%26aulast%3DSchudt%26aufirst%3DC.%26aulast%3DTenor%26aufirst%3DH.%26atitle%3DThe%2520preclinical%2520pharmacology%2520of%2520roflumilast%25E2%2580%2594a%2520selective%252C%2520oral%2520phosphodiesterase%25204%2520inhibitor%2520in%2520development%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2010%26volume%3D23%26issue%3D4%26spage%3D235%26epage%3D256%26doi%3D10.1016%2Fj.pupt.2010.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dastidar, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirumalla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palle, V.</span></span> <span> </span><span class="NLM_article-title">Pharmacology of a novel, orally active PDE4 inhibitor</span>. <i>Pharmacology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>83</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">275</span>â <span class="NLM_lpage">286</span>, <span class="refDoi">Â DOI: 10.1159/000209608</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1159%2F000209608" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=19321962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvFWlsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2009&pages=275-286&issue=5&author=S.+G.+Dastidarauthor=A.+Rayauthor=R.+Shirumallaauthor=D.+Rajagopalauthor=S.+Chaudharyauthor=K.+Nandaauthor=P.+Sharmaauthor=M.+K.+Sethauthor=S.+Balachandranauthor=N.+Guptaauthor=V.+Palle&title=Pharmacology+of+a+novel%2C+orally+active+PDE4+inhibitor&doi=10.1159%2F000209608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of a Novel, Orally Active PDE4 Inhibitor</span></div><div class="casAuthors">Dastidar, Sunanda G.; Ray, Abhijit; Shirumalla, Rajkumar; Rajagopal, Deepa; Chaudhary, Shiwani; Nanda, Kamna; Sharma, Pawan; Seth, Mahesh Kumar; Balachandran, Sarala; Gupta, Nidhi; Palle, Venkata</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">275-286</span>CODEN:
                <span class="NLM_cas:coden">PHMGBN</span>;
        ISSN:<span class="NLM_cas:issn">0031-7012</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: Intracellular cyclic adenosine monophosphate (cAMP) in inflammatory cells and airway smooth muscle is crit. to the modulation of inflammatory response generation.  Phosphodiesterase 4 (PDE4), an enzyme that catalyzes cAMP degrdn., is therefore being actively explored as a mol. target for the treatment of airway inflammation, particularly asthma and chronic obstructive pulmonary disease.  The field has undergone major advances in optimizing generation of compds. with a safe therapeutic margin; however, most PDE4 inhibitors tested so far have unacceptable side effects, particularly nausea and vomiting.  Methods: We evaluated NIS-62949 in a wide range of in vitro and ex vivo cell-based assays to ascertain its anti-inflammatory potential.  The compd. was evaluated in murine models of lipopolysaccharide-induced endotoxemia and pulmonary neutrophilia.  Parameters of airway inflammation, airway hyperreactivity and bronchoconstriction were evaluated in a guinea pig model of antigen-induced allergy.  In order to assess the emetic potential, the compd. was evaluated biochem. for binding to high-affinity rolipram-binding site.  Subsequently, the compd. was tested in a surrogate model for emesis, and the results obtained were correlated directly to tests conducted in a Beagle dog model.  Results: NIS-62949 is a potent, highly selective PDE4 inhibitor.  The compd. demonstrated potent ability to inhibit tumor necrosis factor-Î± release from human peripheral blood mononuclear cells, lymphocyte proliferation and cytokine prodn.  The in vitro profile of NIS-62949 prompted further evaluation of the compd. in vivo and the compd. was found to be comparable to roflumilast in several exptl. models of pulmonary inflammation.  Importantly, NIS-62949 displayed a safer profile compared to roflumilast.  Conclusions: Our results report the development of a promising, novel PDE4 inhibitor, NIS-62949, with a wider therapeutic window as compared to second-generation PDE4 inhibitors such as roflumilast.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQBGkvWYkMMrVg90H21EOLACvtfcHk0lhUEFoUe78fsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvFWlsbg%253D&md5=4fbdb3da007ccf0bee0f8305069f8474</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1159%2F000209608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000209608%26sid%3Dliteratum%253Aachs%26aulast%3DDastidar%26aufirst%3DS.%2BG.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DShirumalla%26aufirst%3DR.%26aulast%3DRajagopal%26aufirst%3DD.%26aulast%3DChaudhary%26aufirst%3DS.%26aulast%3DNanda%26aufirst%3DK.%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DSeth%26aufirst%3DM.%2BK.%26aulast%3DBalachandran%26aufirst%3DS.%26aulast%3DGupta%26aufirst%3DN.%26aulast%3DPalle%26aufirst%3DV.%26atitle%3DPharmacology%2520of%2520a%2520novel%252C%2520orally%2520active%2520PDE4%2520inhibitor%26jtitle%3DPharmacology%26date%3D2009%26volume%3D83%26issue%3D5%26spage%3D275%26epage%3D286%26doi%3D10.1159%2F000209608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Press, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fullerton, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tranter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denholm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberthuer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatto, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keenan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercer, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuffnell, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trifilieff, A.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic acid, an improved PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">6747</span>â <span class="NLM_lpage">6752</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00902</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00902" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlOju7zI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6747-6752&issue=17&author=N.+J.+Pressauthor=R.+J.+Taylorauthor=J.+D.+Fullertonauthor=P.+Tranterauthor=C.+McCarthyauthor=T.+H.+Kellerauthor=N.+Arnoldauthor=D.+Beerauthor=L.+Brownauthor=R.+Cheungauthor=J.+Christieauthor=A.+Denholmauthor=S.+Haberthuerauthor=J.+D.+Hattoauthor=M.+Keenanauthor=M.+K.+Mercerauthor=H.+Oakmanauthor=H.+Sahriauthor=A.+R.+Tuffnellauthor=M.+Tweedauthor=A.+Trifilieff&title=Discovery+and+optimization+of+4-%288-%283-Fluorophenyl%29-1%2C7-naphthyridin-6-yl%29transcyclohexanecarboxylic+acid%2C+an+improved+PDE4+inhibitor+for+the+treatment+of+chronic+obstructive+pulmonary+disease+%28COPD%29&doi=10.1021%2Facs.jmedchem.5b00902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)</span></div><div class="casAuthors">Press, Neil J.; Taylor, Roger J.; Fullerton, Joseph D.; Tranter, Pamela; McCarthy, Clive; Keller, Thomas H.; Arnold, Nicola; Beer, David; Brown, Lyndon; Cheung, Robert; Christie, Julie; Denholm, Alastair; Haberthuer, Sandra; Hatto, Julia D. I.; Keenan, Mark; Mercer, Mark K.; Oakman, Helen; Sahri, Helene; Tuffnell, Andrew R.; Tweed, Morris; Trifilieff, Alexandre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6747-6752</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein the authors describe the optimization of a series of PDE4 inhibitors, with special focus on soly. and pharmacokinetics, to clin. compd. 2, 4-(8-(3-fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic acid.  Although compd. 2 produces emesis in humans when given as a single dose, its exemplary pharmacokinetic properties enabled a novel dosing regime comprising multiple escalating doses and the resultant achievement of high plasma drug levels without assocd. nausea or emesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtmzZuZpBNSLVg90H21EOLACvtfcHk0ljyXQfCSEtQfA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlOju7zI&md5=ddc41343095c67022590f0dc12c41bb2</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00902%26sid%3Dliteratum%253Aachs%26aulast%3DPress%26aufirst%3DN.%2BJ.%26aulast%3DTaylor%26aufirst%3DR.%2BJ.%26aulast%3DFullerton%26aufirst%3DJ.%2BD.%26aulast%3DTranter%26aufirst%3DP.%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DArnold%26aufirst%3DN.%26aulast%3DBeer%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DL.%26aulast%3DCheung%26aufirst%3DR.%26aulast%3DChristie%26aufirst%3DJ.%26aulast%3DDenholm%26aufirst%3DA.%26aulast%3DHaberthuer%26aufirst%3DS.%26aulast%3DHatto%26aufirst%3DJ.%2BD.%26aulast%3DKeenan%26aufirst%3DM.%26aulast%3DMercer%26aufirst%3DM.%2BK.%26aulast%3DOakman%26aufirst%3DH.%26aulast%3DSahri%26aufirst%3DH.%26aulast%3DTuffnell%26aufirst%3DA.%2BR.%26aulast%3DTweed%26aufirst%3DM.%26aulast%3DTrifilieff%26aufirst%3DA.%26atitle%3DDiscovery%2520and%2520optimization%2520of%25204-%25288-%25283-Fluorophenyl%2529-1%252C7-naphthyridin-6-yl%2529transcyclohexanecarboxylic%2520acid%252C%2520an%2520improved%2520PDE4%2520inhibitor%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520%2528COPD%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D17%26spage%3D6747%26epage%3D6752%26doi%3D10.1021%2Facs.jmedchem.5b00902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Press, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fullerton, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tranter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denholm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberthuer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatto, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keenan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercer, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuffnell, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyler, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fozard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trifilieff, A.</span></span> <span> </span><span class="NLM_article-title">Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7472</span>â <span class="NLM_lpage">7479</span>, <span class="refDoi">Â DOI: 10.1021/jm300459a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300459a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOrurnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7472-7479&issue=17&author=N.+J.+Pressauthor=R.+J.+Taylorauthor=J.+D.+Fullertonauthor=P.+Tranterauthor=C.+McCarthyauthor=T.+H.+Kellerauthor=N.+Arnoldauthor=D.+Beerauthor=L.+Brownauthor=R.+Cheungauthor=J.+Christieauthor=A.+Denholmauthor=S.+Haberthuerauthor=J.+D.+Hattoauthor=M.+Keenanauthor=M.+K.+Mercerauthor=H.+Oakmanauthor=H.+Sahriauthor=A.+R.+Tuffnellauthor=M.+Tweedauthor=J.+W.+Tylerauthor=T.+Wagnerauthor=J.+R.+Fozardauthor=A.+Trifilieff&title=Solubility-driven+optimization+of+phosphodiesterase-4+inhibitors+leading+to+a+clinical+candidate&doi=10.1021%2Fjm300459a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Solubility-Driven Optimization of Phosphodiesterase-4 Inhibitors Leading to a Clinical Candidate</span></div><div class="casAuthors">Press, Neil J.; Taylor, Roger J.; Fullerton, Joseph D.; Tranter, Pamela; McCarthy, Clive; Keller, Thomas H.; Arnold, Nicola; Beer, David; Brown, Lyndon; Cheung, Robert; Christie, Julie; Denholm, Alastair; Haberthuer, Sandra; Hatto, Julia D. I.; Keenan, Mark; Mercer, Mark K.; Oakman, Helen; Sahri, Helene; Tuffnell, Andrew R.; Tweed, Morris; Tyler, John W.; Wagner, Trixie; Fozard, John R.; Trifilieff, Alexandre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7472-7479</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The soly.-driven optimization of a series of 1,7-naphthyridine phosphodiesterase-4 inhibitors is described.  Directed structural changes resulted in increased aq. soly., enabling superior pharmacokinetic properties with retention of PDE4 inhibition.  A range of potent and orally bioavailable compds. with good in vivo efficacy in animal models of inflammation and reduced emetic potential compared to previously described drugs were synthesized.  Compd. 2d (I) was taken forward as a clin. candidate for the treatment of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL0BzBNQVqnrVg90H21EOLACvtfcHk0ljyXQfCSEtQfA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOrurnO&md5=deee9ca074de0b531a130d9a6ce530b2</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Fjm300459a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300459a%26sid%3Dliteratum%253Aachs%26aulast%3DPress%26aufirst%3DN.%2BJ.%26aulast%3DTaylor%26aufirst%3DR.%2BJ.%26aulast%3DFullerton%26aufirst%3DJ.%2BD.%26aulast%3DTranter%26aufirst%3DP.%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DArnold%26aufirst%3DN.%26aulast%3DBeer%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DL.%26aulast%3DCheung%26aufirst%3DR.%26aulast%3DChristie%26aufirst%3DJ.%26aulast%3DDenholm%26aufirst%3DA.%26aulast%3DHaberthuer%26aufirst%3DS.%26aulast%3DHatto%26aufirst%3DJ.%2BD.%26aulast%3DKeenan%26aufirst%3DM.%26aulast%3DMercer%26aufirst%3DM.%2BK.%26aulast%3DOakman%26aufirst%3DH.%26aulast%3DSahri%26aufirst%3DH.%26aulast%3DTuffnell%26aufirst%3DA.%2BR.%26aulast%3DTweed%26aufirst%3DM.%26aulast%3DTyler%26aufirst%3DJ.%2BW.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DFozard%26aufirst%3DJ.%2BR.%26aulast%3DTrifilieff%26aufirst%3DA.%26atitle%3DSolubility-driven%2520optimization%2520of%2520phosphodiesterase-4%2520inhibitors%2520leading%2520to%2520a%2520clinical%2520candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D17%26spage%3D7472%26epage%3D7479%26doi%3D10.1021%2Fjm300459a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alberti, M. J.</span>; <span class="NLM_string-name">Garland, S.</span>; <span class="NLM_string-name">Jung, D. K.</span>; <span class="NLM_string-name">Veal, J. M.</span>; <span class="NLM_string-name">Witherington, J.</span></span> <span> </span><span class="NLM_article-title">Preparation of 2-(4-Amino-3-furazanyl)benzimidazoles as Mitogen-Activated and Rho-Kinase Inhibitors</span>. <span class="NLM_patent">WO2003080125A2</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=M.+J.+Alberti&author=S.+Garland&author=D.+K.+Jung&author=J.+M.+Veal&author=J.+Witherington&title=Preparation+of+2-%284-Amino-3-furazanyl%29benzimidazoles+as+Mitogen-Activated+and+Rho-Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlberti%26aufirst%3DM.%2BJ.%26atitle%3DPreparation%2520of%25202-%25284-Amino-3-furazanyl%2529benzimidazoles%2520as%2520Mitogen-Activated%2520and%2520Rho-Kinase%2520Inhibitors%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, N.</span>; <span class="NLM_string-name">Bamford, M. J.</span>; <span class="NLM_string-name">Garland, S.</span>; <span class="NLM_string-name">Goodman, K. B.</span>; <span class="NLM_string-name">Haifeng, C.</span>; <span class="NLM_string-name">Hilfiker, M. A.</span>; <span class="NLM_string-name">Lee, D.</span>; <span class="NLM_string-name">Panchal, T. A.</span>; <span class="NLM_string-name">Stavenger, R. A.</span>; <span class="NLM_string-name">Wilson, D. M.</span>; <span class="NLM_string-name">Witherington, J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Imidazopyridines as Kinase Inhibitors</span>. <span class="NLM_patent">WO2003080610A1</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=N.+Bailey&author=M.+J.+Bamford&author=S.+Garland&author=K.+B.+Goodman&author=C.+Haifeng&author=M.+A.+Hilfiker&author=D.+Lee&author=T.+A.+Panchal&author=R.+A.+Stavenger&author=D.+M.+Wilson&author=J.+Witherington&title=Preparation+of+Imidazopyridines+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DN.%26atitle%3DPreparation%2520of%2520Imidazopyridines%2520as%2520Kinase%2520Inhibitors%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heerding, D. A.</span>; <span class="NLM_string-name">Clark, T. J.</span>; <span class="NLM_string-name">Drewry, D. H.</span>; <span class="NLM_string-name">Leber, J. D.</span>; <span class="NLM_string-name">Safonov, I.</span>; <span class="NLM_string-name">Yamashita, D. S.</span></span> <span> </span><span class="NLM_article-title">Preparation of 1H-Imidazo[4,5-c]pyridin-2-yl Derivatives as Inhibitors of Akt Activity</span>. <span class="NLM_patent">WO2005011700A1</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=D.+A.+Heerding&author=T.+J.+Clark&author=D.+H.+Drewry&author=J.+D.+Leber&author=I.+Safonov&author=D.+S.+Yamashita&title=Preparation+of+1H-Imidazo%5B4%2C5-c%5Dpyridin-2-yl+Derivatives+as+Inhibitors+of+Akt+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHeerding%26aufirst%3DD.%2BA.%26atitle%3DPreparation%2520of%25201H-Imidazo%255B4%252C5-c%255Dpyridin-2-yl%2520Derivatives%2520as%2520Inhibitors%2520of%2520Akt%2520Activity%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bamford, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberti, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaiba, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harling, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchal, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steadman, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takle, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witherington, J.</span></span> <span> </span><span class="NLM_article-title">(1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: A novel class of potent MSK-1-inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">3402</span>â <span class="NLM_lpage">3406</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2005.05.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmcl.2005.05.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=15950465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsVClsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=3402-3406&issue=14&author=M.+J.+Bamfordauthor=M.+J.+Albertiauthor=N.+Baileyauthor=S.+Daviesauthor=D.+K.+Deanauthor=A.+Gaibaauthor=S.+Garlandauthor=J.+D.+Harlingauthor=D.+K.+Jungauthor=T.+A.+Panchalauthor=C.+A.+Parrauthor=J.+G.+Steadmanauthor=A.+K.+Takleauthor=J.+T.+Townsendauthor=D.+M.+Wilsonauthor=J.+Witherington&title=%281H-imidazo%5B4%2C5-c%5Dpyridin-2-yl%29-1%2C2%2C5-oxadiazol-3-ylamine+derivatives%3A+A+novel+class+of+potent+MSK-1-inhibitors&doi=10.1016%2Fj.bmcl.2005.05.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">(1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: A novel class of potent MSK-1-inhibitors</span></div><div class="casAuthors">Bamford, Mark J.; Alberti, Michael J.; Bailey, Nicholas; Davies, Susannah; Dean, David K.; Gaiba, Alessandra; Garland, Stephen; Harling, John D.; Jung, David K.; Panchal, Terence A.; Parr, Christopher A.; Steadman, Jon G.; Takle, Andrew K.; Townsend, James T.; Wilson, David M.; Witherington, Jason</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3402-3406</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of imidazo[4,5-c]pyridines bearing a 1,2,5-oxadiazol-3-ylamine functionality has been developed.  These are potent inhibitors of mitogen and stress-activated protein kinase-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptkdZkGxrcxrVg90H21EOLACvtfcHk0lhExCwfxsjRhg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsVClsr4%253D&md5=5c12382fec9201f5ead2b12382d6bba9</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.05.021%26sid%3Dliteratum%253Aachs%26aulast%3DBamford%26aufirst%3DM.%2BJ.%26aulast%3DAlberti%26aufirst%3DM.%2BJ.%26aulast%3DBailey%26aufirst%3DN.%26aulast%3DDavies%26aufirst%3DS.%26aulast%3DDean%26aufirst%3DD.%2BK.%26aulast%3DGaiba%26aufirst%3DA.%26aulast%3DGarland%26aufirst%3DS.%26aulast%3DHarling%26aufirst%3DJ.%2BD.%26aulast%3DJung%26aufirst%3DD.%2BK.%26aulast%3DPanchal%26aufirst%3DT.%2BA.%26aulast%3DParr%26aufirst%3DC.%2BA.%26aulast%3DSteadman%26aufirst%3DJ.%2BG.%26aulast%3DTakle%26aufirst%3DA.%2BK.%26aulast%3DTownsend%26aufirst%3DJ.%2BT.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26aulast%3DWitherington%26aufirst%3DJ.%26atitle%3D%25281H-imidazo%255B4%252C5-c%255Dpyridin-2-yl%2529-1%252C2%252C5-oxadiazol-3-ylamine%2520derivatives%253A%2520A%2520novel%2520class%2520of%2520potent%2520MSK-1-inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26issue%3D14%26spage%3D3402%26epage%3D3406%26doi%3D10.1016%2Fj.bmcl.2005.05.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bamford, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchal, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehmi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steadman, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takle, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. M.</span></span> <span> </span><span class="NLM_article-title">(1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: further optimization as highly potent and selective MSK-1-inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">3407</span>â <span class="NLM_lpage">3411</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2005.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmcl.2005.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=15955699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsVClsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=3407-3411&issue=14&author=M.+J.+Bamfordauthor=N.+Baileyauthor=S.+Daviesauthor=D.+K.+Deanauthor=L.+Francisauthor=T.+A.+Panchalauthor=C.+A.+Parrauthor=S.+Sehmiauthor=J.+G.+Steadmanauthor=A.+K.+Takleauthor=J.+T.+Townsendauthor=D.+M.+Wilson&title=%281H-imidazo%5B4%2C5-c%5Dpyridin-2-yl%29-1%2C2%2C5-oxadiazol-3-ylamine+derivatives%3A+further+optimization+as+highly+potent+and+selective+MSK-1-inhibitors&doi=10.1016%2Fj.bmcl.2005.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">(1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Further optimisation as highly potent and selective MSK-1-inhibitors</span></div><div class="casAuthors">Bamford, Mark J.; Bailey, Nicholas; Davies, Susannah; Dean, David K.; Francis, Leann; Panchal, Terence A.; Parr, Christopher A.; Sehmi, Sanjeet; Steadman, Jon G.; Takle, Andrew K.; Townsend, James T.; Wilson, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3407-3411</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The novel imidazo[4,5-c]pyridine 1,2,5-oxadiazol-3-yl template affords an excellent start point for identification of inhibitors of a no. of protein kinases.  Here the authors report on its optimization for mitogen and stress-activated protein kinase-1 (MSK-1) inhibitory activity, and selectivity over other kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeMu-4dj1HPbVg90H21EOLACvtfcHk0lhExCwfxsjRhg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsVClsr8%253D&md5=84f0665b88f747c4c3f0c2d7ee8e0f5d</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DBamford%26aufirst%3DM.%2BJ.%26aulast%3DBailey%26aufirst%3DN.%26aulast%3DDavies%26aufirst%3DS.%26aulast%3DDean%26aufirst%3DD.%2BK.%26aulast%3DFrancis%26aufirst%3DL.%26aulast%3DPanchal%26aufirst%3DT.%2BA.%26aulast%3DParr%26aufirst%3DC.%2BA.%26aulast%3DSehmi%26aufirst%3DS.%26aulast%3DSteadman%26aufirst%3DJ.%2BG.%26aulast%3DTakle%26aufirst%3DA.%2BK.%26aulast%3DTownsend%26aufirst%3DJ.%2BT.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26atitle%3D%25281H-imidazo%255B4%252C5-c%255Dpyridin-2-yl%2529-1%252C2%252C5-oxadiazol-3-ylamine%2520derivatives%253A%2520further%2520optimization%2520as%2520highly%2520potent%2520and%2520selective%2520MSK-1-inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26issue%3D14%26spage%3D3407%26epage%3D3411%26doi%3D10.1016%2Fj.bmcl.2005.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naqvi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darragh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, J. S.</span></span> <span> </span><span class="NLM_article-title">Characterization of the cellular action of the MSK inhibitor SB-747651A</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>441</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">347</span>â <span class="NLM_lpage">357</span>, <span class="refDoi">Â DOI: 10.1042/BJ20110970</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1042%2FBJ20110970" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=21970321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Cgs7fE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=441&publication_year=2012&pages=347-357&issue=1&author=S.+Naqviauthor=A.+Macdonaldauthor=C.+E.+McCoyauthor=J.+Darraghauthor=A.+D.+Reithauthor=J.+S.+Arthur&title=Characterization+of+the+cellular+action+of+the+MSK+inhibitor+SB-747651A&doi=10.1042%2FBJ20110970"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the cellular action of the MSK inhibitor SB-747651A</span></div><div class="casAuthors">Naqvi, Shaista; MacDnald, Andrew; McCoy, Claire E.; Darragh, Joanne; Reith, Alastair D.; Arthur, J. Simon C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">441</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">347-357</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">MSK1 (mitogen- and stress-activated kinase 1) and MSK2 are nuclear protein kinases that regulate transcription downstream of the ERK1/2 (extracellular-signal-regulated kinase 1/2) and p38Î± MAPKs (mitogen-activated protein kinases) via the phosphorylation of CREB (cAMP-response-element-binding protein) and histone H3.  Previous studies on the function of MSKs have used two inhibitors, H89 and Ro 31-8220, both of which have multiple off-target effects.  In the present study, we report the characterization of the in vitro and cellular properties of an improved MSK1 inhibitor, SB-747651A.  In vitro, SB-747651A inhibits MSK1 with an IC50 value of 11 nM.  Screening of an in vitro panel of 117 protein kinases revealed that, at 1 Î¼M, SB-747651A inhibited four other kinases, PRK2 (double-stranded-RNA-dependent protein kinase 2), RSK1 (ribosomal S6 kinase 1), p70S6K (S6K is S6 kinase) (p70RSK) and ROCK-II (Rho-assocd. protein kinase 2), with a similar potency to MSK1.  In cells, SB-747651A fully inhibited MSK activity at 5-10 Î¼M.  SB-747651A was found to inhibit the prodn. of the anti-inflammatory cytokine IL-10 (interleukin-10) in wild-type, but not MSK1/2-knockout, macrophages following LPS (lipopolysaccharide) stimulation.  Both SB-747651A and MSK1/2 knockout resulted in elevated pro-inflammatory cytokine prodn. by macrophages in response to LPS.  Comparison of the effects of SB-747651A, both in vitro and in cells, demonstrated that SB-747651A exhibited improved selectivity over H89 and Ro 31-8220 and therefore represents a useful tool to study MSK function in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvkT4WnkI0bLVg90H21EOLACvtfcHk0lgKHmEvJV9Hgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Cgs7fE&md5=a3fa505f314cb7fa8eec761e5c891abb</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1042%2FBJ20110970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20110970%26sid%3Dliteratum%253Aachs%26aulast%3DNaqvi%26aufirst%3DS.%26aulast%3DMacdonald%26aufirst%3DA.%26aulast%3DMcCoy%26aufirst%3DC.%2BE.%26aulast%3DDarragh%26aufirst%3DJ.%26aulast%3DReith%26aufirst%3DA.%2BD.%26aulast%3DArthur%26aufirst%3DJ.%2BS.%26atitle%3DCharacterization%2520of%2520the%2520cellular%2520action%2520of%2520the%2520MSK%2520inhibitor%2520SB-747651A%26jtitle%3DBiochem.%2520J.%26date%3D2012%26volume%3D441%26issue%3D1%26spage%3D347%26epage%3D357%26doi%3D10.1042%2FBJ20110970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brogden, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorkin, E. M.</span></span> <span> </span><span class="NLM_article-title">Isradipine: An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">618</span>â <span class="NLM_lpage">649</span>, <span class="refDoi">Â DOI: 10.2165/00003495-199549040-00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.2165%2F00003495-199549040-00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=7789292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK2MXltFCksbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1995&pages=618-649&issue=4&author=R.+N.+Brogdenauthor=E.+M.+Sorkin&title=Isradipine%3A+An+update+of+its+pharmacodynamic+and+pharmacokinetic+properties+and+therapeutic+efficacy+in+the+treatment+of+mild+to+moderate+hypertension&doi=10.2165%2F00003495-199549040-00009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension</span></div><div class="casAuthors">Brogden, Rex N.; Sorkin, Eugene M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">618-49</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    </div><div class="casAbstract">A review with 212 refs.  Pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension by using isradipine, intraoperative hypertension, drug interactions, atherosclerosis, etc., are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphqI4erc-kpLVg90H21EOLACvtfcHk0lgKHmEvJV9Hgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXltFCksbg%253D&md5=ad8a76380c42bce9f476c9ae8773f6fa</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.2165%2F00003495-199549040-00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-199549040-00009%26sid%3Dliteratum%253Aachs%26aulast%3DBrogden%26aufirst%3DR.%2BN.%26aulast%3DSorkin%26aufirst%3DE.%2BM.%26atitle%3DIsradipine%253A%2520An%2520update%2520of%2520its%2520pharmacodynamic%2520and%2520pharmacokinetic%2520properties%2520and%2520therapeutic%2520efficacy%2520in%2520the%2520treatment%2520of%2520mild%2520to%2520moderate%2520hypertension%26jtitle%3DDrugs%26date%3D1995%26volume%3D49%26issue%3D4%26spage%3D618%26epage%3D649%26doi%3D10.2165%2F00003495-199549040-00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lund-Johansen, P.</span></span> <span> </span><span class="NLM_article-title">Cardiac effects of isradipine in patients with hypertension</span>. <i>Am. J. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">294S</span>â <span class="NLM_lpage">299S</span>, <span class="refDoi">Â DOI: 10.1093/ajh/6.7.294S</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1093%2Fajh%2F6.7.294S" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=8398014" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1993&pages=294S-299S&author=P.+Lund-Johansen&title=Cardiac+effects+of+isradipine+in+patients+with+hypertension&doi=10.1093%2Fajh%2F6.7.294S"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1093%2Fajh%2F6.7.294S&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fajh%252F6.7.294S%26sid%3Dliteratum%253Aachs%26aulast%3DLund-Johansen%26aufirst%3DP.%26atitle%3DCardiac%2520effects%2520of%2520isradipine%2520in%2520patients%2520with%2520hypertension%26jtitle%3DAm.%2520J.%2520Hypertens.%26date%3D1993%26volume%3D6%26spage%3D294S%26epage%3D299S%26doi%3D10.1093%2Fajh%2F6.7.294S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirsten, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirsten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heintz, B.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacokinetics of vasodilators. Part I</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">457</span>â <span class="NLM_lpage">482</span>, <span class="refDoi">Â DOI: 10.2165/00003088-199834060-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.2165%2F00003088-199834060-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=9646008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK1cXkt1eisrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1998&pages=457-482&issue=6&author=R.+Kirstenauthor=K.+Nelsonauthor=D.+Kirstenauthor=B.+Heintz&title=Clinical+pharmacokinetics+of+vasodilators.+Part+I&doi=10.2165%2F00003088-199834060-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of vasodilators. Part I</span></div><div class="casAuthors">Kirsten, Roland; Nelson, Karen; Kirsten, Daniel; Heintz, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">457-482</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review with 313 refs.  Understanding the mechanism of action and the pharmacokinetic properties of vasodilatory drugs facilitates optimal use in clin. practice.  It should be kept in mind that a drug belongs to a class but is a distinct entity, sometimes derived from a prototype to achieve a specific effect.  The most common pharmacokinetic drug improvement is the development of a drug with a half-life sufficiently long to allow an adequate once-daily dosage.  Developing a controlled release prepn. can increase the apparent half-life of a drug.  Altering the mol. structure may also increase the half-life of a prototype drug.  Another desirable improvement is increasing the specificity of a drug, which may result in fewer adverse effects, or more efficacy at the target site.  This is esp. important for vasodilatory drugs which may be administered over decades for the treatment of hypertension, which usually does not interfere with subjective well-being.  Compliance is greatly increased with once-daily dosing.  Vasodilatory agents cause relaxation by either a decrease in cytoplasmic calcium, an increase in nitric oxide (NO) or by inhibiting myosin light chain kinase.  They are divided into 9 classes: calcium antagonists, potassium channel openers, ACE inhibitors, angiotensin-II receptor antagonists, Î±-adrenergic and imidazole receptor antagonists, Î²1-adrenergic agonists, phosphodiesterase inhibitors, eicosanoids and NO donors.  Despite chem. differences, the pharmacokinetic properties of calcium antagonists are similar.  Absorption from the gastrointestinal tract is high, with all substances undergoing considerable first-pass metab. by the liver, resulting in low bioavailability and pronounced individual variation in pharmacokinetics.  Renal impairment has little effect on pharmacokinetics since renal elimination of these agents is minimal.  Except for the newer drugs of the dihydropyridine type, amlodipine, felodipine, isradipine, nilvadipine, nisoldipine and nitrendipine, the half-life of calcium antagonists is short.  Maintaining an effective drug concn. for the remainder of these agents requires multiple daily dosing, in some cases even with controlled release formulations.  However, a coat-core prepn. of nifedipine has been developed to allow once-daily administration.  Adverse effects are directly correlated to the potency of the individual calcium antagonist.  Treatment with the potassium channel opener minoxidil is reserved for patients with moderately severe to severe hypertension which is refractory to other treatment.  Diazoxide and hydralazine are chiefly used to treat severe hypertensive emergencies, primary pulmonary and malignant hypertension and in severe preeclampsia.  ACE inhibitors prevent conversion of angiotensin-I to angiotensin-II and are most effective when renin prodn. is increased.  Since ACE is identical to kininase-II, which inactivates the potent endogenous vasodilator bradykinin, ACE inhibition causes a redn. in bradykinin degrdn.  ACE inhibitors exert cardioprotective and cardioreparative effects by preventing and reversing cardiac fibrosis and ventricular hypertrophy in animal models.  The predominant elimination pathway of most ACE inhibitors is via renal excretion.  Therefore, renal impairment is assocd. with reduced elimination and a dosage redn. of 25 to 50% is recommended in patients with moderate to severe renal impairment.  Sepg. angiotensin-II inhibition from bradykinin potentiation has been the goal in developing angiotensin-II receptor antagonists.  The incidence of adverse effects of such an agent, losartan, is comparable to that encountered with placebo treatment, and the troublesome cough assocd. with ACE inhibitors is absent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6SzD63jhmybVg90H21EOLACvtfcHk0lgKHmEvJV9Hgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkt1eisrs%253D&md5=c4444fc03336f0f637e7769172e50d83</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.2165%2F00003088-199834060-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-199834060-00003%26sid%3Dliteratum%253Aachs%26aulast%3DKirsten%26aufirst%3DR.%26aulast%3DNelson%26aufirst%3DK.%26aulast%3DKirsten%26aufirst%3DD.%26aulast%3DHeintz%26aufirst%3DB.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520vasodilators.%2520Part%2520I%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1998%26volume%3D34%26issue%3D6%26spage%3D457%26epage%3D482%26doi%3D10.2165%2F00003088-199834060-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Broudy, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemienczuk, D.</span></span> <span> </span><span class="NLM_article-title">Beneficial effects of the calcium antagonist PN 200â110 in patients with congestive heart failure</span>. <i>J. Cardiovasc. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">190</span>â <span class="NLM_lpage">195</span>, <span class="refDoi">Â DOI: 10.1097/00005344-198708000-00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1097%2F00005344-198708000-00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=2441170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADyaL2s3osFCltA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1987&pages=190-195&issue=2&author=D.+R.+Broudyauthor=B.+H.+Greenbergauthor=D.+Siemienczuk&title=Beneficial+effects+of+the+calcium+antagonist+PN+200%E2%80%93110+in+patients+with+congestive+heart+failure&doi=10.1097%2F00005344-198708000-00009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Beneficial effects of the calcium antagonist PN 200-110 in patients with congestive heart failure</span></div><div class="casAuthors">Broudy D R; Greenberg B H; Siemienczuk D</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cardiovascular pharmacology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">190-5</span>
        ISSN:<span class="NLM_cas:issn">0160-2446</span>.
    </div><div class="casAbstract">We studied the acute hemodynamic effects of PN 200-110, a newly available calcium antagonist, in 12 patients with severe congestive heart failure.  Measurements of cardiac performance were obtained by a right heart catheter before and after administration of 5 and 15 mg of PN.  Peak drug effects occurred 1-2 h following the administration of PN 200-110 and were dose related.  The 15-mg dose reduced mean arterial pressure (MAP) from 90 +/- 11 to 75 +/- 6 mm Hg (mean +/- SD) (p less than 0.001) and decreased systemic vascular resistance (SVR) from 1,740 +/- 500 to 995 +/- 300 dynes X s X cm-5 (p less than 0.01).  Stroke volume index (SVI) increased from 26 +/- 7 to 36 +/- 10 ml/m2 (p less than 0.001), and cardiac index (CI) rose from 2.1 +/- .3 to 2.8 +/- .6 L/m2 (p less than 0.01).  Pulmonary arterial wedge pressure (PAW) changed insignificantly.  Seven patients performed graded supine exercise at identical workloads before and after treatment.  When peak exercise values were compared, the addition of PN 200-110 further reduced SVR from 1,282 +/- 461 to 936 +/- 356 dynes X s X cm-5 (p less than 0.01) and increased CI from 3.3 +/- 1.1 to 4.3 +/- 1.3 L/m2 (p less than 0.01).  Only minor, self-limiting side effects were noticed during acute administration.  Of the seven patients discharged on PN 200-110 and followed for at least 6 months, six reported substantial relief of symptoms.(ABSTRACT TRUNCATED AT 250 WORDS)</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQQh4CXaM4H8HRxY89Cm6SyfW6udTcc2eYXl3asVJI67rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2s3osFCltA%253D%253D&md5=139b9fb0cfb753999b73a5becf47d48a</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1097%2F00005344-198708000-00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005344-198708000-00009%26sid%3Dliteratum%253Aachs%26aulast%3DBroudy%26aufirst%3DD.%2BR.%26aulast%3DGreenberg%26aufirst%3DB.%2BH.%26aulast%3DSiemienczuk%26aufirst%3DD.%26atitle%3DBeneficial%2520effects%2520of%2520the%2520calcium%2520antagonist%2520PN%2520200%25E2%2580%2593110%2520in%2520patients%2520with%2520congestive%2520heart%2520failure%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D1987%26volume%3D10%26issue%3D2%26spage%3D190%26epage%3D195%26doi%3D10.1097%2F00005344-198708000-00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemienczuk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broudy, D.</span></span> <span> </span><span class="NLM_article-title">Hemodynamic effects of PN 200â110 (isradipine) in congestive heart failure</span>. <i>Am. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">70B</span>â <span class="NLM_lpage">74B</span>, <span class="refDoi">Â DOI: 10.1016/0002-9149(87)90085-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2F0002-9149%2887%2990085-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=2949588" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1987&pages=70B-74B&issue=3&author=B.+Greenbergauthor=D.+Siemienczukauthor=D.+Broudy&title=Hemodynamic+effects+of+PN+200%E2%80%93110+%28isradipine%29+in+congestive+heart+failure&doi=10.1016%2F0002-9149%2887%2990085-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2F0002-9149%2887%2990085-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0002-9149%252887%252990085-3%26sid%3Dliteratum%253Aachs%26aulast%3DGreenberg%26aufirst%3DB.%26aulast%3DSiemienczuk%26aufirst%3DD.%26aulast%3DBroudy%26aufirst%3DD.%26atitle%3DHemodynamic%2520effects%2520of%2520PN%2520200%25E2%2580%2593110%2520%2528isradipine%2529%2520in%2520congestive%2520heart%2520failure%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D1987%26volume%3D59%26issue%3D3%26spage%3D70B%26epage%3D74B%26doi%3D10.1016%2F0002-9149%2887%2990085-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pool, P. E.</span></span> <span> </span><span class="NLM_article-title">Efficacy of a new calcium antagonist PN 200â110 (isradipine) in angina pectoris</span>. <i>Am. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">123B</span>â <span class="NLM_lpage">129B</span>, <span class="refDoi">Â DOI: 10.1016/0002-9149(87)90091-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2F0002-9149%2887%2990091-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=2949583" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1987&pages=123B-129B&issue=3&author=S.+H.+Taylorauthor=N.+C.+Jacksonauthor=J.+Allenauthor=P.+E.+Pool&title=Efficacy+of+a+new+calcium+antagonist+PN+200%E2%80%93110+%28isradipine%29+in+angina+pectoris&doi=10.1016%2F0002-9149%2887%2990091-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2F0002-9149%2887%2990091-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0002-9149%252887%252990091-9%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%2BH.%26aulast%3DJackson%26aufirst%3DN.%2BC.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DPool%26aufirst%3DP.%2BE.%26atitle%3DEfficacy%2520of%2520a%2520new%2520calcium%2520antagonist%2520PN%2520200%25E2%2580%2593110%2520%2528isradipine%2529%2520in%2520angina%2520pectoris%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D1987%26volume%3D59%26issue%3D3%26spage%3D123B%26epage%3D129B%26doi%3D10.1016%2F0002-9149%2887%2990091-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Handler, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowton, E.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability and efficacy of PN 200â110, a new calcium antagonist in patients with angina and coronary heart disease</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">415</span>â <span class="NLM_lpage">417</span>, <span class="refDoi">Â DOI: 10.1007/BF00549587</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1007%2FBF00549587" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=6240405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADyaL2M7gtFKjsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1984&pages=415-417&issue=4&author=C.+E.+Handlerauthor=E.+Sowton&title=Safety%2C+tolerability+and+efficacy+of+PN+200%E2%80%93110%2C+a+new+calcium+antagonist+in+patients+with+angina+and+coronary+heart+disease&doi=10.1007%2FBF00549587"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability and efficacy of PN 200-110, a new calcium antagonist in patients with angina and coronary heart disease</span></div><div class="casAuthors">Handler C E; Sowton E</div><div class="citationInfo"><span class="NLM_cas:title">European journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">415-7</span>
        ISSN:<span class="NLM_cas:issn">0031-6970</span>.
    </div><div class="casAbstract">The safety, tolerability and efficacy of PN 200-110, a new calcium antagonist with minimal negative inotropic effects, were studied in twelve patients with stable angina pectoris and coronary artery disease.  The study design was single-blind and placebo-controlled and increasing doses of the drug were used on consecutive days to investigate a dose response relationship.  Eleven patients completed the trial.  Response to the drug was evaluated using symptom limited cycle ergometric exercise.  PN 200-110 in all three tested doses of 2.5 mg, 5.0 mg and 10.0 mg significantly increased the resting heart rate (p less than 0.02) and the exercise time to the onset of angina pectoris (p less than 0.02).  Doses above 2.5 mg did not appear to improve the exercise parameters evaluated.  Four patients had side effects probably due to PN 200-110 but these were mild and included dizziness, headache and flushing.  There were no abnormal results from haematological and biochemical screening or from urine testing.  We conclude that PN 220-110 can be given safely to patients with coronary artery disease without producing deleterious effects on blood pressure either at rest or during exercise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTaixT8j7AAv8zK395ZObgVfW6udTcc2eYXl3asVJI67rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2M7gtFKjsA%253D%253D&md5=06b87a1e8c2dd3e8a9652c3e924245e4</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1007%2FBF00549587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00549587%26sid%3Dliteratum%253Aachs%26aulast%3DHandler%26aufirst%3DC.%2BE.%26aulast%3DSowton%26aufirst%3DE.%26atitle%3DSafety%252C%2520tolerability%2520and%2520efficacy%2520of%2520PN%2520200%25E2%2580%2593110%252C%2520a%2520new%2520calcium%2520antagonist%2520in%2520patients%2520with%2520angina%2520and%2520coronary%2520heart%2520disease%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1984%26volume%3D27%26issue%3D4%26spage%3D415%26epage%3D417%26doi%3D10.1007%2FBF00549587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilde, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keef, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hume, J. R.</span></span> <span> </span><span class="NLM_article-title">Electrophysiological mechanisms of minoxidil sulfate-induced vasodilation of rabbit portal vein</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1102</span>â <span class="NLM_lpage">1111</span>, <span class="refDoi">Â DOI: 10.1161/01.RES.65.4.1102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1161%2F01.RES.65.4.1102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=2791221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaL1MXmtVyqsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1989&pages=1102-1111&issue=4&author=N.+Leblancauthor=D.+W.+Wildeauthor=K.+D.+Keefauthor=J.+R.+Hume&title=Electrophysiological+mechanisms+of+minoxidil+sulfate-induced+vasodilation+of+rabbit+portal+vein&doi=10.1161%2F01.RES.65.4.1102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Electrophysiological mechanisms of minoxidil sulfate-induced vasodilation of rabbit portal vein</span></div><div class="casAuthors">Leblanc, Normand; Wilde, Dixon W.; Keef, Kathleen D.; Hume, Joseph R.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1102-11</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    </div><div class="casAbstract">The electrophysiol. and mech. properties of the vasodilator minoxidil sulfate (MNXS) were examd. in isolated smooth muscle cells and strips from rabbit portal vein.  At micromolar concns., MNXS inhibited norepinephrine (0.1-1.0 Î¼M)-induced contractions in isolated muscle strips.  In isolated cells, norepinephrine caused a concn.-dependent depolarization of the resting membrane potential, which was attenuated by MNXS (5 Î¼M); MNXS alone caused a hyperpolarization of the membrane potential.  This hyperpolarization was insensitive to Na+-K+ pump blockade by ouabain, but was inhibited by the K+ channel antagonist, tetraethylammonium (20 mM).  In voltage-clamp expts., a resting (background) conductance assocd. with the resting membrane potential was identified.  This conductance, which is reduced by Ba2+ as well as tetraethylammonium, was increased by MNXS (2 Î¼M).  In addnl. expts., whole-cell L-type Ca2+ currents were inhibited by micromolar concns. of MNXS.  Concns. of MNXS that inhibit norepinephrine-induced contractions promote K+ conductance and inhibit Ca2+ entry through voltage-dependent Ca2+ channels in vascular smooth muscle cells.  These electrophysiol. effects of MNXS may be responsible for the vasorelaxant effects of the drug obsd. in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1_enkU-aM27Vg90H21EOLACvtfcHk0lijQYUBYM38JA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXmtVyqsrs%253D&md5=9e3919922bdc9e333f5f3c767e126f46</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1161%2F01.RES.65.4.1102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.65.4.1102%26sid%3Dliteratum%253Aachs%26aulast%3DLeblanc%26aufirst%3DN.%26aulast%3DWilde%26aufirst%3DD.%2BW.%26aulast%3DKeef%26aufirst%3DK.%2BD.%26aulast%3DHume%26aufirst%3DJ.%2BR.%26atitle%3DElectrophysiological%2520mechanisms%2520of%2520minoxidil%2520sulfate-induced%2520vasodilation%2520of%2520rabbit%2520portal%2520vein%26jtitle%3DCirc.%2520Res.%26date%3D1989%26volume%3D65%26issue%3D4%26spage%3D1102%26epage%3D1111%26doi%3D10.1161%2F01.RES.65.4.1102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oka, M.</span>; <span class="NLM_string-name">Seto, K.</span></span> <span> </span><span class="NLM_article-title">Pulmonary Hypertension Remedy</span>. <span class="NLM_patent">WO9412503A1</span>, <span class="NLM_year">1994</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&author=M.+Oka&author=K.+Seto&title=Pulmonary+Hypertension+Remedy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOka%26aufirst%3DM.%26atitle%3DPulmonary%2520Hypertension%2520Remedy%26date%3D1994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shikada, K.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, S.</span></span> <span> </span><span class="NLM_article-title">Cardiovascular pharmacology of NIP-121, a potassium channel opener</span>. <i>Cardiovasc. Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">86</span>â <span class="NLM_lpage">101</span>, <span class="refDoi">Â DOI: 10.1111/j.1527-3466.1995.tb00215.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1111%2Fj.1527-3466.1995.tb00215.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK2MXotlygurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1995&pages=86-101&issue=1&author=T.+Yamashitaauthor=Y.+Masudaauthor=K.-i.+Shikadaauthor=S.+Tanaka&title=Cardiovascular+pharmacology+of+NIP-121%2C+a+potassium+channel+opener&doi=10.1111%2Fj.1527-3466.1995.tb00215.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular pharmacology of NIP-121, a potassium channel opener</span></div><div class="casAuthors">Yamashita, Toru; Masuda, Yukinori; Shikada, Ken-ichi; Tanaka, Sakuya</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Drug Reviews</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-101</span>CODEN:
                <span class="NLM_cas:coden">CDREEA</span>;
        ISSN:<span class="NLM_cas:issn">0897-5957</span>.
    
            (<span class="NLM_cas:orgname">Neva Press</span>)
        </div><div class="casAbstract">A review with 63 refs. of preclin. cardiovascular pharmacol. of NIP-121.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfQdybnbfoZ7Vg90H21EOLACvtfcHk0lijQYUBYM38JA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXotlygurk%253D&md5=574160b385cf7ea96cd2a783a3b19d66</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3466.1995.tb00215.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3466.1995.tb00215.x%26sid%3Dliteratum%253Aachs%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DMasuda%26aufirst%3DY.%26aulast%3DShikada%26aufirst%3DK.-i.%26aulast%3DTanaka%26aufirst%3DS.%26atitle%3DCardiovascular%2520pharmacology%2520of%2520NIP-121%252C%2520a%2520potassium%2520channel%2520opener%26jtitle%3DCardiovasc.%2520Drug%2520Rev.%26date%3D1995%26volume%3D13%26issue%3D1%26spage%3D86%26epage%3D101%26doi%3D10.1111%2Fj.1527-3466.1995.tb00215.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujikura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, S.</span></span> <span> </span><span class="NLM_article-title">Comparative study of vasodilator effects of the potassium channel openers NIP-121 and levcromakalim in dogs and rats</span>. <i>Jpn. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">145</span>â <span class="NLM_lpage">152</span>, <span class="refDoi">Â DOI: 10.1254/jjp.68.145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1254%2Fjjp.68.145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=7563971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK2MXmsFequrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1995&pages=145-152&issue=2&author=T.+Yamashitaauthor=Y.+Masudaauthor=N.+Kawamuraauthor=N.+Fujikuraauthor=S.+Tanaka&title=Comparative+study+of+vasodilator+effects+of+the+potassium+channel+openers+NIP-121+and+levcromakalim+in+dogs+and+rats&doi=10.1254%2Fjjp.68.145"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative study of vasodilator effects of the potassium channel openers NIP-121 and levcromakalim in dogs and rats</span></div><div class="casAuthors">Yamashita, Toru; Masuda, Yukinori; Kawamura, Norimitsu; Fujikura, Naoki; Tanaka, Sakuya</div><div class="citationInfo"><span class="NLM_cas:title">Japanese Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-52</span>CODEN:
                <span class="NLM_cas:coden">JJPAAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-5198</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">The effects of potassium channel openers NIP-121 ((+)-7,8-dihydro-6,6-dimethyl-7-hydroxy-8-(2-oxo-piperidine-1-yl)-6H-pyrano[2,3-f]benz-2,1,3-oxadiazole) and levcromakalim were examd. in vitro and in vivo.  In isolated canine vascular beds, NIP-121 (3 x 10-9 to 10-7 M) and levcromakalim (3 x 10-8 to 10-6 M) produced a concn.-dependent redn. in the vasoconstrictor responses to U46619.  The effects were antagonized by glibenclamide, an ATP-sensitive potassium channel blocker.  The maximal relaxation was more than 70% of the maximal vasodilation induced by papaverine (10-4 M), except in the basilar artery.  These compds. had very potent effects on the coronary and cranial mesenteric arteries and saphenous vein.  In the coronary perfused rat heart, both compds. (10-7 M) also increased coronary perfusion flow.  The effects were also inhibited by glibenclamide (10-6 M).  In anesthetized dogs, NIP-121 (1 to 10 Î¼g/kg (3.2 to 32 nmol/kg), i.v.) and levcromakalim (3 to 30 Î¼g/kg (10.5 to 105 nmol/kg), i.v.) dose-dependently increased coronary and renal blood flow.  NIP-121 and levcromakalim at higher doses produced the greatest increase in coronary blood flow among the blood vessels examd., in spite of the hypotensive effect.  In conclusion, NIP-121 and levcromakalim were similarly selective vasodilators on the canine isolated coronary and cranial mesenteric arteries and saphenous vein, and they selectively increased coronary blood flow in vivo.  With respect to increasing the coronary blood flow, NIP-121 had a fourfold greater potency than levcromakalim.  This effect might be related to the glibenclamide-sensitive potassium channels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofI9PmFXLI8bVg90H21EOLACvtfcHk0lijQYUBYM38JA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmsFequrc%253D&md5=2083784d2c1fb23009323b59b9f4c8ce</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1254%2Fjjp.68.145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjjp.68.145%26sid%3Dliteratum%253Aachs%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DMasuda%26aufirst%3DY.%26aulast%3DKawamura%26aufirst%3DN.%26aulast%3DFujikura%26aufirst%3DN.%26aulast%3DTanaka%26aufirst%3DS.%26atitle%3DComparative%2520study%2520of%2520vasodilator%2520effects%2520of%2520the%2520potassium%2520channel%2520openers%2520NIP-121%2520and%2520levcromakalim%2520in%2520dogs%2520and%2520rats%26jtitle%3DJpn.%2520J.%2520Pharmacol.%26date%3D1995%26volume%3D68%26issue%3D2%26spage%3D145%26epage%3D152%26doi%3D10.1254%2Fjjp.68.145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shigenobu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, S.</span></span> <span> </span><span class="NLM_article-title">The antihypertensive property of NIP-121, a novel potassium channel opener in rats</span>. <i>J. Cardiovasc. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">190</span>â <span class="NLM_lpage">197</span>, <span class="refDoi">Â DOI: 10.1097/00005344-199108000-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1097%2F00005344-199108000-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1717778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK3MXlsFSjsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1991&pages=190-197&issue=2&author=Y.+Masudaauthor=C.+Arakawaauthor=T.+Yokoyamaauthor=K.+Shigenobuauthor=S.+Tanaka&title=The+antihypertensive+property+of+NIP-121%2C+a+novel+potassium+channel+opener+in+rats&doi=10.1097%2F00005344-199108000-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">The antihypertensive property of NIP-121, a novel potassium channel opener in rats</span></div><div class="casAuthors">Masuda, Y.; Arakawa, C.; Yokoyama, T.; Shigenobu, K.; Tanaka, S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiovascular Pharmacology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">190-7</span>CODEN:
                <span class="NLM_cas:coden">JCPCDT</span>;
        ISSN:<span class="NLM_cas:issn">0160-2446</span>.
    </div><div class="casAbstract">The antihypertensive effects of NIP-121 (I), a novel potassium channel opener, were examd. in comparison with cromakalim and its active enantiomer, lemakalim.  In expts. by direct blood pressure measurements, orally administered NIP-121 dose-relatedly decreased arterial blood pressure in conscious spontaneously hypertensive rats (SHRs), and the ED20 values (the doses to produce 20% decrease of the mean blood pressure) of NIP-121 and cromakalim were 0.010 and 0.11 mg/kg, resp., NIP-121 thus being about ten times more potent than cromakalim.  The duration of the hypotensive effect of NIP-121 was longer than that by cromakalim.  The hypotensive effect of NIP-121 was stronger in SHRs than in normotensive rats.  All three drugs showed tachycardia that was antagonized by a Î²-blocker, propranolol.  I.v. administered NIP-121 also showed a more potent hypotensive action with longer duration than cromakalim in conscious SHRs.  The ED20 values for hypotension by NIP-121, cromakalim, and lemakalim were 0.017, 0.040, and 0.016 mg/kg, resp.  The i.v. hypotensive potency of NIP-121 but not cromakalim was similar to that of p.o. administration.  The repeated treatments with NIP-121 (0.025, 0.05, and 0.1 mg/kg p.o. once a day) for 15 days did not modify the degree of the hypotensive action.  In the anesthetized SHRs, pretreatment with glibenclamide but not other antagonists (atropine, propranolol, diphenhydramine + cimetidine, or indomethacin) suppressed the decrease in blood pressure induced by NIP-121.  In anesthetized and ganglion-blocked rats, NIP-121 (0.003-0.3 mg/kg, i.v.) dose-dependently antagonized the pressor responses to i.v. injection or norepinephrine, angiotensin I, angiotensin II, arginine vasopressin, prostaglandin F2Î±, or Bay K 8644; among these interventions, the pressor response to Bay K 8644 was antagonized most potently.  These results indicate that NIP-121 has a potent and long-lasting antihypertensive effect that may largely be produced by its activity as a potassium channel opener.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIbJNqWKWrJbVg90H21EOLACvtfcHk0lh5NRiYH8TKCA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlsFSjsbs%253D&md5=984eb7cbfb52efb6570a520f97ce1589</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1097%2F00005344-199108000-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005344-199108000-00003%26sid%3Dliteratum%253Aachs%26aulast%3DMasuda%26aufirst%3DY.%26aulast%3DArakawa%26aufirst%3DC.%26aulast%3DYokoyama%26aufirst%3DT.%26aulast%3DShigenobu%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DS.%26atitle%3DThe%2520antihypertensive%2520property%2520of%2520NIP-121%252C%2520a%2520novel%2520potassium%2520channel%2520opener%2520in%2520rats%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D1991%26volume%3D18%26issue%3D2%26spage%3D190%26epage%3D197%26doi%3D10.1097%2F00005344-199108000-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurtry, I. F.</span></span> <span> </span><span class="NLM_article-title">NIP-121 is more effective than nifedipine in acutely reversing chronic pulmonary hypertension</span>. <i>J. Appl. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1075</span>â <span class="NLM_lpage">1080</span>, <span class="refDoi">Â DOI: 10.1152/jappl.1993.75.3.1075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1152%2Fjappl.1993.75.3.1075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=8226514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADyaK2cXhvValur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1993&pages=1075-1080&issue=3&author=M.+Okaauthor=K.+G.+Morrisauthor=I.+F.+McMurtry&title=NIP-121+is+more+effective+than+nifedipine+in+acutely+reversing+chronic+pulmonary+hypertension&doi=10.1152%2Fjappl.1993.75.3.1075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">NIP-121 is more effective than nifedipine in acutely reversing chronic pulmonary hypertension</span></div><div class="casAuthors">Oka, Masahiko; Morris, Kenneth G.; McMurtry, Ivan F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Physiology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1075-80</span>CODEN:
                <span class="NLM_cas:coden">JAPHEV</span>;
        ISSN:<span class="NLM_cas:issn">8750-7587</span>.
    </div><div class="casAbstract">To det. if NIP-121, a new antihypertensive agent with K+ channel-opening activity, would be an effective vasodilator in pulmonary hypertension, the authors studied its acute hemodynamic effects under normoxic conditions in conscious chronically hypoxic pulmonary hypertensive rats and in control pulmonary normotensive rats.  In contrast to no pulmonary vasodilation by NIP-121 in control rats, the K+ channel activator (10-100 mg/kg i.v.) decreased both mean pulmonary arterial pressure (from 42 Â± 2 to 33 Â± 2 mmHg; P â© 0.05) and total pulmonary resistance (from 278 Â± 30 to 213 Â± 32 mmHg/L/min; Pâ©0.05) in hypertensive rats.  NIP-121 produced similar dose-related decreases in mean systemic arterial pressure and total systemic resistance in both groups of rats.  Both the pulmonary and the systemic vasodilations to NIP-121 were inhibited by pretreatment with the blocker of ATP-sensitive K+ channels, glybenclamide (20 mg/kg), but not with the inhibitor of endothelium-derived relaxing factor synthesis, nitro-L-arginine (10 mg/kg).  The L-type voltage-gated Ca2+ channel blocker, nifedipine (10-1,000 mg/kg i.v.), failed to cause pulmonary vasodilation in normoxic hypertensive rats, although there was dose-related systemic vasodilation.  These results show that in contrast to the Ca2+ channel blocker, nifedipine, the K+ channel activator, NIP-121, is a potent vasodilator of chronic hypoxia-induced pulmonary hypertension in the rat.  The mechanism of its hypotensive action in the hypertensive pulmonary vasculature might be more than simply membrane hyperpolarization and indirect inhibition of the L-type voltage-gated Ca2+ channel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPk-PNN2BGDbVg90H21EOLACvtfcHk0lh5NRiYH8TKCA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhvValur8%253D&md5=a0e1cc239b880476e0befb5ee41f2656</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1152%2Fjappl.1993.75.3.1075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fjappl.1993.75.3.1075%26sid%3Dliteratum%253Aachs%26aulast%3DOka%26aufirst%3DM.%26aulast%3DMorris%26aufirst%3DK.%2BG.%26aulast%3DMcMurtry%26aufirst%3DI.%2BF.%26atitle%3DNIP-121%2520is%2520more%2520effective%2520than%2520nifedipine%2520in%2520acutely%2520reversing%2520chronic%2520pulmonary%2520hypertension%26jtitle%3DJ.%2520Appl.%2520Physiol.%26date%3D1993%26volume%3D75%26issue%3D3%26spage%3D1075%26epage%3D1080%26doi%3D10.1152%2Fjappl.1993.75.3.1075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stavenger, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowdell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franz, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaitanopoulos, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilfiker, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivy, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leber, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, J. P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viet, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolivette, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semus, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dul, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandekar, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behm, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doe, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">2</span>â <span class="NLM_lpage">5</span>, <span class="refDoi">Â DOI: 10.1021/jm060873p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060873p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlansbnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2-5&issue=1&author=R.+A.+Stavengerauthor=H.+Cuiauthor=S.+E.+Dowdellauthor=R.+G.+Franzauthor=D.+E.+Gaitanopoulosauthor=K.+B.+Goodmanauthor=M.+A.+Hilfikerauthor=R.+L.+Ivyauthor=J.+D.+Leberauthor=J.+P.+Marinoauthor=H.-J.+Ohauthor=A.+Q.+Vietauthor=W.+Xuauthor=G.+Yeauthor=D.+Zhangauthor=Y.+Zhaoauthor=L.+J.+Jolivetteauthor=M.+S.+Headauthor=S.+F.+Semusauthor=P.+A.+Elkinsauthor=R.+B.+Kirkpatrickauthor=E.+Dulauthor=S.+S.+Khandekarauthor=T.+Yiauthor=D.+K.+Jungauthor=L.+L.+Wrightauthor=G.+K.+Smithauthor=D.+J.+Behmauthor=C.+P.+Doeauthor=R.+Bentleyauthor=Z.+X.+Chenauthor=E.+Huauthor=D.+Lee&title=Discovery+of+aminofurazan-azabenzimidazoles+as+inhibitors+of+Rho-kinase+with+high+kinase+selectivity+and+antihypertensive+activity&doi=10.1021%2Fjm060873p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Aminofurazan-azabenzimidazoles as Inhibitors of Rho-Kinase with High Kinase Selectivity and Antihypertensive Activity</span></div><div class="casAuthors">Stavenger, Robert A.; Cui, Haifeng; Dowdell, Sarah E.; Franz, Robert G.; Gaitanopoulos, Dimitri E.; Goodman, Krista B.; Hilfiker, Mark A.; Ivy, Robert L.; Leber, Jack D.; Marino, Joseph P., Jr.; Oh, Hye-Ja; Viet, Andrew Q.; Xu, Weiwei; Ye, Guosen; Zhang, Daohua; Zhao, Yongdong; Jolivette, Larry J.; Head, Martha S.; Semus, Simon F.; Elkins, Patricia A.; Kirkpatrick, Robert B.; Dul, Edward; Khandekar, Sanjay S.; Yi, Tracey; Jung, David K.; Wright, Lois L.; Smith, Gary K.; Behm, David J.; Doe, Christopher P.; Bentley, Ross; Chen, Zunxuan X.; Hu, Erding; Lee, Dennis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-5</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery, proposed binding mode, and optimization of a novel class of Rho-kinase inhibitors are presented.  Appropriate substitution on the 6-position of the azabenzimidazole core provided subnanomolar enzyme potency in vitro while dramatically improving selectivity over a panel of other kinases.  Pharmacokinetic data was obtained for the most potent and selective examples and one (6n) has been shown to lower blood pressure in a rat model of hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzfD1mp8bYv7Vg90H21EOLACvtfcHk0lhtceqcuI_Qqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlansbnE&md5=055d95d44fc906aba4e0bdbf0bc1aac9</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1021%2Fjm060873p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060873p%26sid%3Dliteratum%253Aachs%26aulast%3DStavenger%26aufirst%3DR.%2BA.%26aulast%3DCui%26aufirst%3DH.%26aulast%3DDowdell%26aufirst%3DS.%2BE.%26aulast%3DFranz%26aufirst%3DR.%2BG.%26aulast%3DGaitanopoulos%26aufirst%3DD.%2BE.%26aulast%3DGoodman%26aufirst%3DK.%2BB.%26aulast%3DHilfiker%26aufirst%3DM.%2BA.%26aulast%3DIvy%26aufirst%3DR.%2BL.%26aulast%3DLeber%26aufirst%3DJ.%2BD.%26aulast%3DMarino%26aufirst%3DJ.%2BP.%26aulast%3DOh%26aufirst%3DH.-J.%26aulast%3DViet%26aufirst%3DA.%2BQ.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DYe%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DJolivette%26aufirst%3DL.%2BJ.%26aulast%3DHead%26aufirst%3DM.%2BS.%26aulast%3DSemus%26aufirst%3DS.%2BF.%26aulast%3DElkins%26aufirst%3DP.%2BA.%26aulast%3DKirkpatrick%26aufirst%3DR.%2BB.%26aulast%3DDul%26aufirst%3DE.%26aulast%3DKhandekar%26aufirst%3DS.%2BS.%26aulast%3DYi%26aufirst%3DT.%26aulast%3DJung%26aufirst%3DD.%2BK.%26aulast%3DWright%26aufirst%3DL.%2BL.%26aulast%3DSmith%26aufirst%3DG.%2BK.%26aulast%3DBehm%26aufirst%3DD.%2BJ.%26aulast%3DDoe%26aufirst%3DC.%2BP.%26aulast%3DBentley%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DZ.%2BX.%26aulast%3DHu%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520aminofurazan-azabenzimidazoles%2520as%2520inhibitors%2520of%2520Rho-kinase%2520with%2520high%2520kinase%2520selectivity%2520and%2520antihypertensive%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D1%26spage%3D2%26epage%3D5%26doi%3D10.1021%2Fjm060873p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behm, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafferty, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stavenger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamford, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grygielko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dul, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolivette, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, J. P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willette, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, E.</span></span> <span> </span><span class="NLM_article-title">Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>320</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">89</span>â <span class="NLM_lpage">98</span>, <span class="refDoi">Â DOI: 10.1124/jpet.106.110635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1124%2Fjpet.106.110635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=17018693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsFeqsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2007&pages=89-98&issue=1&author=C.+Doeauthor=R.+Bentleyauthor=D.+J.+Behmauthor=R.+Laffertyauthor=R.+Stavengerauthor=D.+Jungauthor=M.+Bamfordauthor=T.+Panchalauthor=E.+Grygielkoauthor=L.+L.+Wrightauthor=G.+K.+Smithauthor=Z.+Chenauthor=C.+Webbauthor=S.+Khandekarauthor=T.+Yiauthor=R.+Kirkpatrickauthor=E.+Dulauthor=L.+Jolivetteauthor=J.+P.+Marinoauthor=R.+Willetteauthor=D.+Leeauthor=E.+Hu&title=Novel+Rho+kinase+inhibitors+with+anti-inflammatory+and+vasodilatory+activities&doi=10.1124%2Fjpet.106.110635"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities</span></div><div class="casAuthors">Doe, Chris; Bentley, Ross; Behm, David J.; Lafferty, Robert; Stavenger, Robert; Jung, David; Bamford, Mark; Panchal, Terry; Grygielko, Eugene; Wright, Lois L.; Smith, Gary K.; Chen, Zunxuan; Webb, Christine; Khandekar, Sanjay; Yi, Tracey; Kirkpatrick, Robert; Dul, Edward; Jolivette, Larry; Marino, Joseph P., Jr.; Willette, Robert; Lee, Dennis; Hu, Erding</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-98</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Increased Rho kinase (ROCK) activity contributes to smooth muscle contraction and regulates blood pressure homeostasis.  We hypothesized that potent and selective ROCK inhibitors with novel structural motifs would help elucidate the functional role of ROCK and further explore the therapeutic potential of ROCK inhibition for hypertension.  In this article, we characterized two aminofurazan-based inhibitors, GSK269962A [N-(3-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(4-morpholinyl)ethyl]-oxy}benzamide] and SB-7720770-B [4-(7-{[(3S)-3-amino-1-pyrrolidinyl]carbonyl}-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine], as members of a novel class of compds. that potently inhibit ROCK enzymic activity.  GSK269962A and SB-772077-B have IC50 values of 1.6 and 5.6 nM toward recombinant human ROCK1, resp.  GSK269962A also exhibited more than 30-fold selectivity against a panel of serine/threonine kinases.  In lipopolysaccharide-stimulated monocytes, these inhibitors blocked the generation of inflammatory cytokines, such as interleukin-6 and tumor necrosis factor-Î±.  Furthermore, both SB-772077-B and GSK269962A induced vasorelaxation in preconstricted rat aorta with an IC50 of 39 and 35 nM, resp.  Oral administration of either GSK269962A or SB-772077-B produced a profound dose-dependent redn. of systemic blood pressure in spontaneously hypertensive rats.  At doses of 1, 3, and 30 mg/kg, both compds. induced a redn. in blood pressure of approx. 10, 20, and 50 mm Hg.  In addn., administration of SB-772077-B also dramatically lowered blood pressure in DOCA salt-induced hypertensive rats.  SB-772077-B and GSK269962A represent a novel class of ROCK inhibitors that have profound effects in the vasculature and may enable us to further evaluate the potential beneficial effects of ROCK inhibition in animal models of cardiovascular as well as other chronic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOuPjuVLTrwrVg90H21EOLACvtfcHk0lhtceqcuI_Qqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsFeqsw%253D%253D&md5=ab8ba12bca20241815721e2cc9273774</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.110635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.110635%26sid%3Dliteratum%253Aachs%26aulast%3DDoe%26aufirst%3DC.%26aulast%3DBentley%26aufirst%3DR.%26aulast%3DBehm%26aufirst%3DD.%2BJ.%26aulast%3DLafferty%26aufirst%3DR.%26aulast%3DStavenger%26aufirst%3DR.%26aulast%3DJung%26aufirst%3DD.%26aulast%3DBamford%26aufirst%3DM.%26aulast%3DPanchal%26aufirst%3DT.%26aulast%3DGrygielko%26aufirst%3DE.%26aulast%3DWright%26aufirst%3DL.%2BL.%26aulast%3DSmith%26aufirst%3DG.%2BK.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DWebb%26aufirst%3DC.%26aulast%3DKhandekar%26aufirst%3DS.%26aulast%3DYi%26aufirst%3DT.%26aulast%3DKirkpatrick%26aufirst%3DR.%26aulast%3DDul%26aufirst%3DE.%26aulast%3DJolivette%26aufirst%3DL.%26aulast%3DMarino%26aufirst%3DJ.%2BP.%26aulast%3DWillette%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DE.%26atitle%3DNovel%2520Rho%2520kinase%2520inhibitors%2520with%2520anti-inflammatory%2520and%2520vasodilatory%2520activities%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D320%26issue%3D1%26spage%3D89%26epage%3D98%26doi%3D10.1124%2Fjpet.106.110635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhaliwal, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badejo, A. M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murthy, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadowitz, P. J.</span></span> <span> </span><span class="NLM_article-title">Analysis of pulmonary vasodilator responses to SB-772077-B [4-(7-((3-amino-1-pyrrolidinyl)carbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin-2-yl)-1, 2,5-oxadiazol-3-amine], a novel aminofurazan-based Rho kinase inhibitor</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>330</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">334</span>â <span class="NLM_lpage">341</span>, <span class="refDoi">Â DOI: 10.1124/jpet.109.151449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1124%2Fjpet.109.151449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=19369577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFelurY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2009&pages=334-341&issue=1&author=J.+S.+Dhaliwalauthor=A.+M.+Badejoauthor=D.+B.+Caseyauthor=S.+N.+Murthyauthor=P.+J.+Kadowitz&title=Analysis+of+pulmonary+vasodilator+responses+to+SB-772077-B+%5B4-%287-%28%283-amino-1-pyrrolidinyl%29carbonyl%29-1-ethyl-1H-imidazo%284%2C5-c%29pyridin-2-yl%29-1%2C+2%2C5-oxadiazol-3-amine%5D%2C+a+novel+aminofurazan-based+Rho+kinase+inhibitor&doi=10.1124%2Fjpet.109.151449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of pulmonary vasodilator responses to SB-772077-B [4-(7-((3-amino-1-pyrrolidinyl)carbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin-2-yl)-1,2,5-oxadiazol-3-amine], a novel aminofurazan-based Rho kinase inhibitor</span></div><div class="casAuthors">Dhaliwal, Jasdeep S.; Badejo, Adeleke M., Jr.; Casey, David B.; Murthy, Subramanyam N.; Kadowitz, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">334-341</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The effects of SB-772077-B [4-(7-((3-amino-1-pyrrolidinyl)carbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin-2-yl)-1,2,5-oxadiazol-3-amine], an aminofurazan-based Rho kinase inhibitor, on the pulmonary vascular bed and on monocrotaline-induced pulmonary hypertension were investigated in the rat.  The i.v. injections of SB-772077-B decreased pulmonary and systemic arterial pressures and increased cardiac output.  The decreases in pulmonary arterial pressure were enhanced when pulmonary vascular resistance was increased by U46619 [9,11-dideoxy-11Î±,9Î±-epoxymethanoprostaglandin F2Î±], hypoxia, or NÏ-nitro-L-arginine Me ester.  SB-772077-B was more potent than Y-27632 [trans-4-[(1R)-1-aminoethyl]-N-4-pyridinyl-cyclohexanecarboxamide dihydrochloride] or fasudil [5-(1,4-diazepane-1-sulfonyl)isoquinoline] in decreasing pulmonary and systemic arterial pressures.  The results with SB-772077-B, fasudil, and Y-27632 suggest that Rho kinase is constitutively active and is involved in the regulation of baseline tone and vasoconstrictor responses.  Chronic treatment with SB-772077-B attenuated the increase in pulmonary arterial pressure induced by monocrotaline.  The i.v. injection of SB-772077-B decreased pulmonary and systemic arterial pressures in rats with monocrotaline-induced pulmonary hypertension.  The decreases in pulmonary arterial pressure in response to SB-772077-B in monocrotaline-treated rats were smaller than responses in U46619-infused animals, and the anal. of responses suggests that approx. 60% of the pulmonary hypertensive response is mediated by a Rho kinase-sensitive mechanism.  The observation that Rho kinase inhibitors decrease pulmonary arterial pressure when pulmonary vascular resistance is increased by interventions such as hypoxia, U46619, angiotensin II, nitric-oxide synthase inhibition, and Bay K 8644 [S-(-)-1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-[trifluoromethyl]phenyl) -3-pyridine carboxylic acid Me ester] suggest that the vasodilatation is independent of the mechanisms used to increase intracellular calcium and promote vasoconstriction.  The present results suggest that SB-772077-B would be beneficial in the treatment of pulmonary hypertensive disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3sKZGsLduDLVg90H21EOLACvtfcHk0lhtceqcuI_Qqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFelurY%253D&md5=a66fd5a7b6e1469790f2122daed760b7</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.151449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.151449%26sid%3Dliteratum%253Aachs%26aulast%3DDhaliwal%26aufirst%3DJ.%2BS.%26aulast%3DBadejo%26aufirst%3DA.%2BM.%26aulast%3DCasey%26aufirst%3DD.%2BB.%26aulast%3DMurthy%26aufirst%3DS.%2BN.%26aulast%3DKadowitz%26aufirst%3DP.%2BJ.%26atitle%3DAnalysis%2520of%2520pulmonary%2520vasodilator%2520responses%2520to%2520SB-772077-B%2520%255B4-%25287-%2528%25283-amino-1-pyrrolidinyl%2529carbonyl%2529-1-ethyl-1H-imidazo%25284%252C5-c%2529pyridin-2-yl%2529-1%252C%25202%252C5-oxadiazol-3-amine%255D%252C%2520a%2520novel%2520aminofurazan-based%2520Rho%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D330%26issue%3D1%26spage%3D334%26epage%3D341%26doi%3D10.1124%2Fjpet.109.151449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span> <span> </span><span class="NLM_article-title">Effects of fasudil on pulmonary hypertension in clinical practice</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">54</span>â <span class="NLM_lpage">63</span>, <span class="refDoi">Â DOI: 10.1016/j.pupt.2017.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.pupt.2017.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28782712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtl2rur3F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2017&pages=54-63&author=Y.+Zhangauthor=S.+Wu&title=Effects+of+fasudil+on+pulmonary+hypertension+in+clinical+practice&doi=10.1016%2Fj.pupt.2017.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of fasudil on pulmonary hypertension in clinical practice</span></div><div class="casAuthors">Zhang, Yiqing; Wu, Shangjie</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">54-63</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Pulmonary hypertension (PH) is a pathophysiol. disorder that may involve multiple clin. conditions and can complicate the majority of cardiovascular and respiratory diseases.  The presence of PH is assocd. with worse outcomes, but the efficacy of current therapy is still unsatisfactory.  Because Rho-kinase (ROCK) plays an important role in the pathogenesis of PH, the ROCK inhibitor fasudil is expected to contribute to PH treatment.  In animal models of PH, fasudil reduced pulmonary artery pressure (PAP) and improved survival.  Furthermore, the short-term efficacy and safety of fasudil in the treatment of PH are demonstrated in clin. trials.  Both PAP and pulmonary vascular resistance in patients with PH are significantly decreased by i.v. or inhaled fasudil without apparent side effect.  However, no clin. trial has assessed the long-term efficacy of fasudil in the treatment of PH.  Limited data suggest that the mid-term use of fasudil could improve exercise capacity and reduce in-hospital mortality.  We also discuss the combined use of fasudil and other drugs for PH treatment.  However, these combinations have not yet been evaluated in a clin. trial.  According to animal studies, the combination of fasudil with beraprost or sildenafil shows synergistic effects, whereas the combination of fasudil with bosentan has no addnl. ameliorating effects on PH development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBw2u2T8Y2lrVg90H21EOLACvtfcHk0ljPHSOJ1ZKJrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtl2rur3F&md5=8e5174dd5b4649d7f086c41718968aa2</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2017.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2017.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DS.%26atitle%3DEffects%2520of%2520fasudil%2520on%2520pulmonary%2520hypertension%2520in%2520clinical%2520practice%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2017%26volume%3D46%26spage%3D54%26epage%3D63%26doi%3D10.1016%2Fj.pupt.2017.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsubara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizoguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osanai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanabe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimokawa, H.</span></span> <span> </span><span class="NLM_article-title">Double-blind, placebo-controlled clinical trial with a Rho-kinase inhibitor in pulmonary arterial hypertensionâa pilot efficacy trial</span>. <i>Circ. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2619</span>â <span class="NLM_lpage">2625</span>, <span class="refDoi">Â DOI: 10.1253/circj.CJ-13-0443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1253%2Fcircj.CJ-13-0443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=23912836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslSns77I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2013&pages=2619-2625&issue=10&author=Y.+Fukumotoauthor=N.+Yamadaauthor=H.+Matsubaraauthor=M.+Mizoguchiauthor=K.+Uchinoauthor=A.+Yaoauthor=Y.+Kiharaauthor=M.+Kawanoauthor=H.+Watanabeauthor=Y.+Takedaauthor=T.+Adachiauthor=S.+Osanaiauthor=N.+Tanabeauthor=T.+Inoueauthor=A.+Kuboauthor=Y.+Otaauthor=K.+Fukudaauthor=T.+Nakanoauthor=H.+Shimokawa&title=Double-blind%2C+placebo-controlled+clinical+trial+with+a+Rho-kinase+inhibitor+in+pulmonary+arterial+hypertension%E2%80%94a+pilot+efficacy+trial&doi=10.1253%2Fcircj.CJ-13-0443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Double-blind, placebo-controlled clinical trial with a Rho-kinase inhibitor in pulmonary arterial hypertension - a pilot efficacy trial -</span></div><div class="casAuthors">Fukumoto, Yoshihiro; Yamada, Norikazu; Matsubara, Hiromi; Mizoguchi, Minori; Uchino, Kazuaki; Yao, Atsushi; Kihara, Yasuki; Kawano, Mitsuhiro; Watanabe, Hiroshi; Takeda, Yutaka; Adachi, Takeshi; Osanai, Shinobu; Tanabe, Nobuhiro; Inoue, Teruo; Kubo, Akihiro; Ota, Yuri; Fukuda, Koichiro; Nakano, Takeshi; Shimokawa, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2619-2625</span>CODEN:
                <span class="NLM_cas:coden">CJIOBY</span>;
        ISSN:<span class="NLM_cas:issn">1346-9843</span>.
    
            (<span class="NLM_cas:orgname">Japanese Circulation Society</span>)
        </div><div class="casAbstract">Background: We have previously demonstrated that long-term inhibition of Rho-kinase ameliorates pulmonary arterial hypertension (PAH) in animal models.  In the present study, we examd. the clin. effects of mid-term oral treatment with an extended release formulation of AT-877 (fasudil hydrochloride), a specific Rho-kinase inhibitor (AT-877ER) on PAH.  Methods and Results: 23 PAH patients were treated with either placebo (10/2 females/males, 51Â±16 years, idiopathic PAH (IPAH) in 6, PAH assocd. with connective tissue disease (CTD-PAH) in 3, PAH with congenital heart disease (CHD-PAH) in 2, and portal PAH in 1) or AT-877ER (6/5 females/males, 47Â±14 years, IPAH in 2, CTD-PAH in 5, and CHD-PAH in 4); 3 patients were excluded.  We performed a 6-min walk test and right heart catheterization in the remaining 20 patients, before and 3 mo after the treatment (placebo n=11, AT-877ER n=9).  Although there were no significant differences between the 2 groups for the 6-min walk distance, pulmonary hemodynamics tended to be improved in the AT-877ER group, esp. the prevalence of improved cardiac index from baseline, which was significantly higher in the AT-877ER than in the placebo group.  In the AT-877ER group, serum levels of hydroxyfasudil, an active metabolite of AT-877ER tended to correlate with improvements in the cardiac index and mean pulmonary artery pressure.  Conclusions: Mid-term treatment with oral AT-877ER showed addnl. improvement in pulmonary hemodynamics in patients with PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof001r8Pp19rVg90H21EOLACvtfcHk0ljPHSOJ1ZKJrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslSns77I&md5=1f9a29ee6f6b0a9d40c80c883811f109</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1253%2Fcircj.CJ-13-0443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1253%252Fcircj.CJ-13-0443%26sid%3Dliteratum%253Aachs%26aulast%3DFukumoto%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DN.%26aulast%3DMatsubara%26aufirst%3DH.%26aulast%3DMizoguchi%26aufirst%3DM.%26aulast%3DUchino%26aufirst%3DK.%26aulast%3DYao%26aufirst%3DA.%26aulast%3DKihara%26aufirst%3DY.%26aulast%3DKawano%26aufirst%3DM.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DTakeda%26aufirst%3DY.%26aulast%3DAdachi%26aufirst%3DT.%26aulast%3DOsanai%26aufirst%3DS.%26aulast%3DTanabe%26aufirst%3DN.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DA.%26aulast%3DOta%26aufirst%3DY.%26aulast%3DFukuda%26aufirst%3DK.%26aulast%3DNakano%26aufirst%3DT.%26aulast%3DShimokawa%26aufirst%3DH.%26atitle%3DDouble-blind%252C%2520placebo-controlled%2520clinical%2520trial%2520with%2520a%2520Rho-kinase%2520inhibitor%2520in%2520pulmonary%2520arterial%2520hypertension%25E2%2580%2594a%2520pilot%2520efficacy%2520trial%26jtitle%3DCirc.%2520J.%26date%3D2013%26volume%3D77%26issue%3D10%26spage%3D2619%26epage%3D2625%26doi%3D10.1253%2Fcircj.CJ-13-0443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, L.</span></span> <span> </span><span class="NLM_article-title">Microtubules as a target for anticancer drugs</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">253</span>â <span class="NLM_lpage">265</span>, <span class="refDoi">Â DOI: 10.1038/nrc1317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2Fnrc1317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=15057285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=253-265&issue=4&author=M.+A.+Jordanauthor=L.+Wilson&title=Microtubules+as+a+target+for+anticancer+drugs&doi=10.1038%2Fnrc1317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules as a target for anticancer drugs</span></div><div class="casAuthors">Jordan, Mary Ann; Wilson, Leslie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-265</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Highly dynamic mitotic-spindle microtubules are among the most successful targets for anticancer therapy.  Microtubule-targeted drugs, including paclitaxel and Vinca alkaloids, were previously considered to work primarily by increasing or decreasing the cellular microtubule mass.  Although these effects might have a role in their chemotherapeutic actions, we now know that at lower concns., microtubule-targeted drugs can suppress microtubule dynamics without changing microtubule mass; this action leads to mitotic block and apoptosis.  In addn. to the expanding array of chem. diverse antimitotic agents, some microtubule-targeted drugs can act as vascular-targeting agents, rapidly depolymg. microtubules of newly formed vasculature to shut down the blood supply to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRJbrFnzwqjbVg90H21EOLACvtfcHk0ljFGsJOcnajrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D&md5=bbbf212e03ffe6763098fc41f21a8158</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1038%2Fnrc1317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1317%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMicrotubules%2520as%2520a%2520target%2520for%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26issue%3D4%26spage%3D253%26epage%3D265%26doi%3D10.1038%2Fnrc1317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eberle, M.</span>; <span class="NLM_string-name">Bachmann, M.</span>; <span class="NLM_string-name">Strebel, A.</span>; <span class="NLM_string-name">Roy, S.</span>; <span class="NLM_string-name">Srivastava, S.</span>; <span class="NLM_string-name">Saha, G.</span></span> <span> </span><span class="NLM_article-title">Preparation of Furazanobenzimidazoles as Apoptosis Inducers for the Treatment of Neoplastic and Autoimmune Diseases</span>. <span class="NLM_patent">WO2004103994A1</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=M.+Eberle&author=M.+Bachmann&author=A.+Strebel&author=S.+Roy&author=S.+Srivastava&author=G.+Saha&title=Preparation+of+Furazanobenzimidazoles+as+Apoptosis+Inducers+for+the+Treatment+of+Neoplastic+and+Autoimmune+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEberle%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520Furazanobenzimidazoles%2520as%2520Apoptosis%2520Inducers%2520for%2520the%2520Treatment%2520of%2520Neoplastic%2520and%2520Autoimmune%2520Diseases%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eberle, M.</span>; <span class="NLM_string-name">Bachmann, F.</span>; <span class="NLM_string-name">Strebel, A.</span>; <span class="NLM_string-name">Roy, S.</span>; <span class="NLM_string-name">Srivastava, S.</span>; <span class="NLM_string-name">Saha, G.</span></span> <span> </span><span class="NLM_article-title">Preparation of Substituted Benzimidazoles for Inducing Apoptosis</span>. <span class="NLM_patent">US20070066670A1</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=M.+Eberle&author=F.+Bachmann&author=A.+Strebel&author=S.+Roy&author=S.+Srivastava&author=G.+Saha&title=Preparation+of+Substituted+Benzimidazoles+for+Inducing+Apoptosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEberle%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520Substituted%2520Benzimidazoles%2520for%2520Inducing%2520Apoptosis%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eberle, M.</span>; <span class="NLM_string-name">Bachmann, F.</span>; <span class="NLM_string-name">Strebel, A.</span>; <span class="NLM_string-name">Roy, S.</span>; <span class="NLM_string-name">Srivastava, S.</span>; <span class="NLM_string-name">Saha, G.</span></span> <span> </span><span class="NLM_article-title">Preparation of Substituted Benzimidazoles for Inducing Apoptosis</span>. <span class="NLM_patent">WO2005077939A1</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+Eberle&author=F.+Bachmann&author=A.+Strebel&author=S.+Roy&author=S.+Srivastava&author=G.+Saha&title=Preparation+of+Substituted+Benzimidazoles+for+Inducing+Apoptosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEberle%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520Substituted%2520Benzimidazoles%2520for%2520Inducing%2520Apoptosis%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buey, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohlmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinelt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span> <span> </span><span class="NLM_article-title">The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>426</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1848</span>â <span class="NLM_lpage">1860</span>, <span class="refDoi">Â DOI: 10.1016/j.jmb.2014.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.jmb.2014.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=24530796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlSrtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2014&pages=1848-1860&issue=8&author=A.+E.+Protaauthor=F.+Danelauthor=F.+Bachmannauthor=K.+Bargstenauthor=R.+M.+Bueyauthor=J.+Pohlmannauthor=S.+Reineltauthor=H.+Laneauthor=M.+O.+Steinmetz&title=The+novel+microtubule-destabilizing+drug+BAL27862+binds+to+the+colchicine+site+of+tubulin+with+distinct+effects+on+microtubule+organization&doi=10.1016%2Fj.jmb.2014.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">The Novel Microtubule-Destabilizing Drug BAL27862 Binds to the Colchicine Site of Tubulin with Distinct Effects on Microtubule Organization</span></div><div class="casAuthors">Prota, Andrea E.; Danel, Franck; Bachmann, Felix; Bargsten, Katja; Buey, Ruben M.; Pohlmann, Jens; Reinelt, Stefan; Lane, Heidi; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1848-1860</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Microtubule-targeting agents are widely used for the treatment of cancer and as tool compds. to study the microtubule cytoskeleton.  BAL27862 is a novel microtubule-destabilizing drug that is currently undergoing phase I clin. evaluation as the prodrug BAL101553.  The drug is a potent inhibitor of tumor cell growth and shows a promising activity profile in a panel of human cancer models resistant to clin. relevant microtubule-targeting agents.  Here, we evaluated the mol. mechanism of the tubulin-BAL27862 interaction using a combination of cell biol., biochem. and structural biol. methods.  Tubulin-binding assays revealed that BAL27862 potently inhibited tubulin assembly at 37 Â°C with an IC50 of 1.4 Î¼M and bound to unassembled tubulin with a stoichiometry of 1 mol/mol tubulin and a dissocn. const. of 244 Â± 30 nM.  BAL27862 bound to tubulin independently of vinblastine, without the formation of tubulin oligomers.  The kinetics of BAL27862 binding to tubulin were distinct from those of colchicine, with evidence of competition between BAL27862 and colchicine for binding.  Detn. of the tubulin-BAL27862 structure by X-ray crystallog. demonstrated that BAL27862 binds to the same site as colchicine at the intradimer interface.  Comparison of crystal structures of tubulin-BAL27862 and tubulin-colchicine complexes shows that the binding mode of BAL27862 to tubulin is similar to that of colchicine.  However, comparative analyses of the effects of BAL27862 and colchicine on the microtubule mitotic spindle and in tubulin protease-protection expts. suggest different outcomes of tubulin binding.  Taken together, our data define BAL27862 as a potent, colchicine site-binding, microtubule-destabilizing agent with distinct effects on microtubule organization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIsVCA_6rcHLVg90H21EOLACvtfcHk0ljFGsJOcnajrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlSrtrs%253D&md5=147ddbbfe5b90157cb8b2e04e1791668</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2014.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2014.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DDanel%26aufirst%3DF.%26aulast%3DBachmann%26aufirst%3DF.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DBuey%26aufirst%3DR.%2BM.%26aulast%3DPohlmann%26aufirst%3DJ.%26aulast%3DReinelt%26aufirst%3DS.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DThe%2520novel%2520microtubule-destabilizing%2520drug%2520BAL27862%2520binds%2520to%2520the%2520colchicine%2520site%2520of%2520tubulin%2520with%2520distinct%2520effects%2520on%2520microtubule%2520organization%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D426%26issue%3D8%26spage%3D1848%26epage%3D1860%26doi%3D10.1016%2Fj.jmb.2014.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broggini-Tenzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messikommer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nytko, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guckenberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruschy, M.</span></span> <span> </span><span class="NLM_article-title">The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models</span>. <i>Radiother. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>124</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">433</span>â <span class="NLM_lpage">438</span>, <span class="refDoi">Â DOI: 10.1016/j.radonc.2017.07.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.radonc.2017.07.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28797699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1ynsr%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2017&pages=433-438&issue=3&author=A.+Sharmaauthor=A.+Broggini-Tenzerauthor=V.+Vuongauthor=A.+Messikommerauthor=K.+J.+Nytkoauthor=M.+Guckenbergerauthor=F.+Bachmannauthor=H.+A.+Laneauthor=M.+Pruschy&title=The+novel+microtubule+targeting+agent+BAL101553+in+combination+with+radiotherapy+in+treatment-refractory+tumor+models&doi=10.1016%2Fj.radonc.2017.07.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models</span></div><div class="casAuthors">Sharma, Ashish; Broggini-Tenzer, Angela; Vuong, Van; Messikommer, Alessandra; Nytko, Katarzyna J.; Guckenberger, Matthias; Bachmann, Felix; Lane, Heidi A.; Pruschy, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Radiotherapy and Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">433-438</span>CODEN:
                <span class="NLM_cas:coden">RAONDT</span>;
        ISSN:<span class="NLM_cas:issn">0167-8140</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Resistance to microtubule targeting agents (MTA) represents a major drawback in successful cancer therapy with MTAs.  Here we investigated the combined treatment modality of the novel MTA BAL101553 in combination with radiotherapy in paclitaxel and epothilone-resistant tumor models.  Multiple regimens of BAL101553, or its active moiety BAL27862 for in vitro expts., were probed in combination with radiotherapy in P-glycoprotein-overexpressing, human colon adenocarcinoma cells (SW480) and in tubulin-mutated human NSCLC cells (A549EpoB40) and tumors thereof.  BAL27862 reduced the proliferative activity of SW480 and A549EpoB40 tumor cells with similar potency as in A549 wildtype cells.  Combined treatment of BAL27862 with ionizing radiation in vitro resulted in an additive redn. of clonogenicity.  Moreover, treatment of paclitaxel- and epothilone-resistant tumors with fractionated irradn. and different regimens of BAL101553 (a single i.v. bolus vs. oral daily) suppressed tumor growth and resulted in an extended additive tumor growth delay with strong redn. of tumor proliferation and mean tumor vessel d.  BAL101553 is a promising alternative in taxane- and epothilone-refractory tumors as part of a combined treatment modality with ionizing radiation.  Its potent antitumor effect is not only tumor cell-directed but also targets the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok4R4m3sJuT7Vg90H21EOLACvtfcHk0liM3JP1DvyWtg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1ynsr%252FJ&md5=77c6288feb6fb73e419c1905e82c102d</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.radonc.2017.07.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.radonc.2017.07.024%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DBroggini-Tenzer%26aufirst%3DA.%26aulast%3DVuong%26aufirst%3DV.%26aulast%3DMessikommer%26aufirst%3DA.%26aulast%3DNytko%26aufirst%3DK.%2BJ.%26aulast%3DGuckenberger%26aufirst%3DM.%26aulast%3DBachmann%26aufirst%3DF.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DPruschy%26aufirst%3DM.%26atitle%3DThe%2520novel%2520microtubule%2520targeting%2520agent%2520BAL101553%2520in%2520combination%2520with%2520radiotherapy%2520in%2520treatment-refractory%2520tumor%2520models%26jtitle%3DRadiother.%2520Oncol.%26date%3D2017%26volume%3D124%26issue%3D3%26spage%3D433%26epage%3D438%26doi%3D10.1016%2Fj.radonc.2017.07.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duran, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikic, B. I.</span></span> <span> </span><span class="NLM_article-title">Abstract 4412: In vitro activity of the novel tubulin active agent BAL27862 in MDR1(+) and MDR1(â) human breast and ovarian cancer variants selected for resistance to taxanes</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">4412</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM10-4412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1158%2F1538-7445.AM10-4412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=20460507" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=4412&author=G.+E.+Duranauthor=H.+Laneauthor=F.+Bachmannauthor=B.+I.+Sikic&title=Abstract+4412%3A+In+vitro+activity+of+the+novel+tubulin+active+agent+BAL27862+in+MDR1%28%2B%29+and+MDR1%28%E2%88%92%29+human+breast+and+ovarian+cancer+variants+selected+for+resistance+to+taxanes&doi=10.1158%2F1538-7445.AM10-4412"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM10-4412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM10-4412%26sid%3Dliteratum%253Aachs%26aulast%3DDuran%26aufirst%3DG.%2BE.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DBachmann%26aufirst%3DF.%26aulast%3DSikic%26aufirst%3DB.%2BI.%26atitle%3DAbstract%25204412%253A%2520In%2520vitro%2520activity%2520of%2520the%2520novel%2520tubulin%2520active%2520agent%2520BAL27862%2520in%2520MDR1%2528%252B%2529%2520and%2520MDR1%2528%25E2%2588%2592%2529%2520human%2520breast%2520and%2520ovarian%2520cancer%2520variants%2520selected%2520for%2520resistance%2520to%2520taxanes%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D4412%26doi%3D10.1158%2F1538-7445.AM10-4412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esteve, M.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honore, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braguer, D.</span></span> <span> </span><span class="NLM_article-title">Abstract 1977: BAL27862: A unique microtubule-targeted drug that suppresses microtubule dynamics, severs microtubules, and overcomes Bcl-2- and tubulin subtype-related drug resistance</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1977</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM10-1977</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1158%2F1538-7445.AM10-1977" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1977&author=M.-A.+Esteveauthor=S.+Honoreauthor=N.+McKayauthor=F.+Bachmannauthor=H.+Laneauthor=D.+Braguer&title=Abstract+1977%3A+BAL27862%3A+A+unique+microtubule-targeted+drug+that+suppresses+microtubule+dynamics%2C+severs+microtubules%2C+and+overcomes+Bcl-2-+and+tubulin+subtype-related+drug+resistance&doi=10.1158%2F1538-7445.AM10-1977"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM10-1977&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM10-1977%26sid%3Dliteratum%253Aachs%26aulast%3DEsteve%26aufirst%3DM.-A.%26aulast%3DHonore%26aufirst%3DS.%26aulast%3DMcKay%26aufirst%3DN.%26aulast%3DBachmann%26aufirst%3DF.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DBraguer%26aufirst%3DD.%26atitle%3DAbstract%25201977%253A%2520BAL27862%253A%2520A%2520unique%2520microtubule-targeted%2520drug%2520that%2520suppresses%2520microtubule%2520dynamics%252C%2520severs%2520microtubules%252C%2520and%2520overcomes%2520Bcl-2-%2520and%2520tubulin%2520subtype-related%2520drug%2520resistance%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1977%26doi%3D10.1158%2F1538-7445.AM10-1977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duran, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikic, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. A.</span></span> <span> </span><span class="NLM_article-title">Abstract 831: BAL101553 (prodrug of BAL27862): A unique microtubule destabilizer active against drug refractory breast cancers alone and in combination with trastuzumab</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">831</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM2014-831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1158%2F1538-7445.AM2014-831" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=831&author=F.+Bachmannauthor=K.+Burgerauthor=G.+E.+Duranauthor=B.+I.+Sikicauthor=H.+A.+Lane&title=Abstract+831%3A+BAL101553+%28prodrug+of+BAL27862%29%3A+A+unique+microtubule+destabilizer+active+against+drug+refractory+breast+cancers+alone+and+in+combination+with+trastuzumab&doi=10.1158%2F1538-7445.AM2014-831"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2014-831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2014-831%26sid%3Dliteratum%253Aachs%26aulast%3DBachmann%26aufirst%3DF.%26aulast%3DBurger%26aufirst%3DK.%26aulast%3DDuran%26aufirst%3DG.%2BE.%26aulast%3DSikic%26aufirst%3DB.%2BI.%26aulast%3DLane%26aufirst%3DH.%2BA.%26atitle%3DAbstract%2520831%253A%2520BAL101553%2520%2528prodrug%2520of%2520BAL27862%2529%253A%2520A%2520unique%2520microtubule%2520destabilizer%2520active%2520against%2520drug%2520refractory%2520breast%2520cancers%2520alone%2520and%2520in%2520combination%2520with%2520trastuzumab%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D831%26doi%3D10.1158%2F1538-7445.AM2014-831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pohlmann, J.</span>; <span class="NLM_string-name">Bachmann, F.</span></span> <span> </span><span class="NLM_article-title">Furazanylbenzimidazoles as Prodrugs to Treat Neoplastic or Autoimmune Diseases</span>. <span class="NLM_patent">WO2011012577A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+Pohlmann&author=F.+Bachmann&title=Furazanylbenzimidazoles+as+Prodrugs+to+Treat+Neoplastic+or+Autoimmune+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPohlmann%26aufirst%3DJ.%26atitle%3DFurazanylbenzimidazoles%2520as%2520Prodrugs%2520to%2520Treat%2520Neoplastic%2520or%2520Autoimmune%2520Diseases%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorlick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keir, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lock, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carol, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurmasheva, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghton, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. A.</span></span> <span> </span><span class="NLM_article-title">Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program</span>. <i>Pediatr. Blood Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1106</span>â <span class="NLM_lpage">1109</span>, <span class="refDoi">Â DOI: 10.1002/pbc.25329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fpbc.25329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=25407467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXms1Ghs7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=1106-1109&issue=6&author=E.+A.+Kolbauthor=R.+Gorlickauthor=S.+T.+Keirauthor=J.+M.+Marisauthor=M.+H.+Kangauthor=C.+P.+Reynoldsauthor=R.+B.+Lockauthor=H.+Carolauthor=J.+Wuauthor=R.+T.+Kurmashevaauthor=P.+J.+Houghtonauthor=M.+A.+Smith&title=Initial+testing+%28stage+1%29+of+BAL101553%2C+a+novel+tubulin+binding+agent%2C+by+the+pediatric+preclinical+testing+program&doi=10.1002%2Fpbc.25329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program</span></div><div class="casAuthors">Kolb, E. Anders; Gorlick, Richard; Keir, Stephen T.; Maris, John M.; Kang, Min H.; Reynolds, C. Patrick; Lock, Richard B.; Carol, Hernan; Wu, Jianrong; Kurmasheva, Raushan T.; Houghton, Peter J.; Smith, Malcolm A.</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric Blood & Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1106-1109</span>CODEN:
                <span class="NLM_cas:coden">PBCEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1545-5017</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">BAL101553 is a highly water sol. prodrug of BAL27862 that arrests tumor cell proliferation and induces cell death in cancer cells through disruption of the microtubule network.  In vitro BAL27862 demonstrated potent activity, with the median relative IC50 (rIC50) of 13.8 nM (range 5.4-25.2 nM).  The in vitro activity of BAL27862 against the PPTP cell lines is distinctive from that previously described for vincristine.  BAL101553 induced significant differences in EFS distribution compared to control in 16 of 30 (53%) solid tumor xenografts and in two of four (67%) of the evaluable ALL xenografts.  No objective responses were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokrIdslHwMhrVg90H21EOLACvtfcHk0liRcJLMfGDZUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXms1Ghs7s%253D&md5=a2dece66bed1d4e13650c26608a7a777</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1002%2Fpbc.25329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpbc.25329%26sid%3Dliteratum%253Aachs%26aulast%3DKolb%26aufirst%3DE.%2BA.%26aulast%3DGorlick%26aufirst%3DR.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26aulast%3DKang%26aufirst%3DM.%2BH.%26aulast%3DReynolds%26aufirst%3DC.%2BP.%26aulast%3DLock%26aufirst%3DR.%2BB.%26aulast%3DCarol%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DKurmasheva%26aufirst%3DR.%2BT.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26atitle%3DInitial%2520testing%2520%2528stage%25201%2529%2520of%2520BAL101553%252C%2520a%2520novel%2520tubulin%2520binding%2520agent%252C%2520by%2520the%2520pediatric%2520preclinical%2520testing%2520program%26jtitle%3DPediatr.%2520Blood%2520Cancer%26date%3D2015%26volume%3D62%26issue%3D6%26spage%3D1106%26epage%3D1109%26doi%3D10.1002%2Fpbc.25329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berges, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchoghandjian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serge, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honore, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figarella-Branger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braguer, D.</span></span> <span> </span><span class="NLM_article-title">EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">759</span>â <span class="NLM_lpage">774</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.27374</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.18632%2Foncotarget.27374" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=32165998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BB383ivVehtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=759-774&issue=8&author=R.+Bergesauthor=A.+Tchoghandjianauthor=A.+Sergeauthor=S.+Honoreauthor=D.+Figarella-Brangerauthor=F.+Bachmannauthor=H.+A.+Laneauthor=D.+Braguer&title=EB1-dependent+long+survival+of+glioblastoma-grafted+mice+with+the+oral+tubulin-binder+BAL101553+is+associated+with+inhibition+of+tumor+angiogenesis&doi=10.18632%2Foncotarget.27374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis</span></div><div class="casAuthors">Berges Raphael; Tchoghandjian Aurelie; Honore Stephane; Figarella-Branger Dominique; Braguer Diane; Serge Arnauld; Figarella-Branger Dominique; Braguer Diane; Bachmann Felix; Lane Heidi A</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">759-774</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Glioblastoma (GBM) are aggressive brain tumors with limited treatment options.  Cancer stem-like cells (CSLCs) contribute to GBM invasiveness, representing promising targets.  BAL101553, a prodrug of BAL27862, is a novel small molecule tubulin-binding agent, promoting tumor cell death through spindle assembly checkpoint activation, which is currently in Phase 1/2a in advanced solid tumor patients including GBM.  This study aimed to evaluate long-term daily oral BAL101553 treatment of mice orthotopically grafted with GBM CSLCs (GBM6) according to EB1 expression-level, and to decipher its mechanism of action on GBM stem cells.  Oral treatment with BAL101553 for 100 days provoked a large EB1 expression level-dependent survival benefit, together with a decrease in tumor growth and brain invasion.  Formation of vascular structures by the fluorescent GBM6-GFP-sh0 cells, mimicking endothelial vascular networks, was observed in the brains of control grafted mice.  Following BAL101553 treatment, vessels were no longer detectable, suggesting inhibition of the endothelial trans-differentiation of GBM stem cells.  In vitro, BAL27862 treatment resulted in a switch to the endothelial-like phenotype of GBM6 towards an astrocytic phenotype.  Moreover, the drug inhibited secretion of VEGF, thus preventing normal endothelial cell migration activated by CSLCs.  The decrease in VEGF secretion was confirmed in a human GBM explant following drug treatment.  Altogether, our data first confirm the potential of EB1 expression as a response-predictive biomarker of BAL101553 in GBM we previously published and add new insights in BAL101553 long-term action by counteracting CSLCs mediated tumor angiogenesis.  Our results strongly support BAL101553 clinical studies in GBM patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRiCnNJOXm0MTslzEEsg76ufW6udTcc2eZAc8nGcK-5trntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383ivVehtg%253D%253D&md5=6ac3f234687c047e70eaf5a6964a2b5f</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.27374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.27374%26sid%3Dliteratum%253Aachs%26aulast%3DBerges%26aufirst%3DR.%26aulast%3DTchoghandjian%26aufirst%3DA.%26aulast%3DSerge%26aufirst%3DA.%26aulast%3DHonore%26aufirst%3DS.%26aulast%3DFigarella-Branger%26aufirst%3DD.%26aulast%3DBachmann%26aufirst%3DF.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DBraguer%26aufirst%3DD.%26atitle%3DEB1-dependent%2520long%2520survival%2520of%2520glioblastoma-grafted%2520mice%2520with%2520the%2520oral%2520tubulin-binder%2520BAL101553%2520is%2520associated%2520with%2520inhibition%2520of%2520tumor%2520angiogenesis%26jtitle%3DOncotarget%26date%3D2020%26volume%3D11%26issue%3D8%26spage%3D759%26epage%3D774%26doi%3D10.18632%2Foncotarget.27374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berges, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchoghandjian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honore, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteve, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figarella-Branger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braguer, D.</span></span> <span> </span><span class="NLM_article-title">The novel tubulin-binding checkpoint activator BAL101553 inhibits EB1-dependent migration and invasion and promotes differentiation of glioblastoma stem-like cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2740</span>â <span class="NLM_lpage">2749</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-16-0252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1158%2F1535-7163.MCT-16-0252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=27540016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVOqsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2740-2749&issue=11&author=R.+Bergesauthor=A.+Tchoghandjianauthor=S.+Honoreauthor=M.+A.+Esteveauthor=D.+Figarella-Brangerauthor=F.+Bachmannauthor=H.+A.+Laneauthor=D.+Braguer&title=The+novel+tubulin-binding+checkpoint+activator+BAL101553+inhibits+EB1-dependent+migration+and+invasion+and+promotes+differentiation+of+glioblastoma+stem-like+cells&doi=10.1158%2F1535-7163.MCT-16-0252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">The novel tubulin-binding checkpoint activator BAL101553 inhibits EB1-dependent migration and invasion and promotes differentiation of glioblastoma stem-like cells</span></div><div class="casAuthors">Berges, Raphael; Tchoghandjian, Aurelie; Honore, Stephane; Esteve, Marie-Anne; Figarella-Branger, Dominique; Bachmann, Felix; Lane, Heidi A.; Braguer, Diane</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2740-2749</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Glioblastoma patients have limited treatment options.  Cancer stem-like cells (CSLC) contribute to glioblastoma invasiveness and repopulation; hence, they represent promising targets for novel therapies.  BAL101553 is a prodrug of BAL27862, a novel microtubule-destabilizing agent inhibiting tumor cell proliferation through activation of the spindle assembly checkpoint, which is currently in phase I/II clin. development.  Broad anticancer activity has been demonstrated against human cancer models, including tumors refractory to conventional treatments.  We have shown that overexpression of microtubule + end-binding 1-protein (EB1) correlates with glioblastoma progression and poor survival.  Here, we show that BAL27862 inhibits the growth of two glioblastoma CSLCs.  As EB1 is overexpressed in the CSLC line GBM6, which displays a high tumorigenicity and infiltrative pattern of migration in vivo, we investigated drug activity on GBM6 according to EB1 expression.  BAL27862 inhibited migration and colony formation at subcytotoxic concns. in EB1-expressing control cells (GBM6-sh0) but only at cytotoxic concns. in EB1-downregulated (GBM-shE1) cells.  Three administrations of BAL101553 were sufficient to provoke an EB1-dependent survival benefit in tumor-bearing mice.  Patterns of invasion and quantification of tumor cells in brain demonstrated that GBM6-sh0 cells were more invasive than GBM6-shEB1 cells, and that the antiproliferative and anti-invasive effects of BAL101553 were more potent in mice bearing control tumors than in EB1-downregulated tumors.  This was assocd. with inhibition of stem cell properties in the GBM6-sh0 model.  Finally, BAL27862 triggered astrocytic differentiation of GBM6 in an EB1-dependent manner.  These results support the potential of BAL101553 for glioblastoma treatment, with EB1 expression as a predictive biomarker of response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhHhC4OWk7z7Vg90H21EOLACvtfcHk0liLzRd8HHkqPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVOqsLo%253D&md5=46386df75bc8ab36ab2177cd32dc8cf5</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0252%26sid%3Dliteratum%253Aachs%26aulast%3DBerges%26aufirst%3DR.%26aulast%3DTchoghandjian%26aufirst%3DA.%26aulast%3DHonore%26aufirst%3DS.%26aulast%3DEsteve%26aufirst%3DM.%2BA.%26aulast%3DFigarella-Branger%26aufirst%3DD.%26aulast%3DBachmann%26aufirst%3DF.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DBraguer%26aufirst%3DD.%26atitle%3DThe%2520novel%2520tubulin-binding%2520checkpoint%2520activator%2520BAL101553%2520inhibits%2520EB1-dependent%2520migration%2520and%2520invasion%2520and%2520promotes%2520differentiation%2520of%2520glioblastoma%2520stem-like%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26issue%3D11%26spage%3D2740%26epage%3D2749%26doi%3D10.1158%2F1535-7163.MCT-16-0252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, T. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamantis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zubairi, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haris, N. R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greystoke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tunariu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molife, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannah, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt-Hoffmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristeleit, R. S.</span></span> <span> </span><span class="NLM_article-title">Phase 1/2a trial of intravenous BAL101553, a novel tumor checkpoint controller (TCC), in advanced solid tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2525</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2016.34.15_suppl.2525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1200%2FJCO.2016.34.15_suppl.2525" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=2525&author=J.+Lopezauthor=T.+R.+J.+Evansauthor=E.+R.+Plummerauthor=N.+Diamantisauthor=H.+M.+Shawauthor=I.+H.+Zubairiauthor=N.+R.+M.+Harisauthor=J.+MacDonaldauthor=A.+Greystokeauthor=R.+L.+Rouxauthor=N.+Tunariuauthor=L.+R.+Molifeauthor=A.+L.+Hannahauthor=S.+Andersonauthor=H.+A.+Laneauthor=M.+Maurerauthor=A.+Schmitt-Hoffmannauthor=F.+Bachmannauthor=M.+F.+Engelhardtauthor=R.+S.+Kristeleit&title=Phase+1%2F2a+trial+of+intravenous+BAL101553%2C+a+novel+tumor+checkpoint+controller+%28TCC%29%2C+in+advanced+solid+tumors&doi=10.1200%2FJCO.2016.34.15_suppl.2525"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.34.15_suppl.2525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.34.15_suppl.2525%26sid%3Dliteratum%253Aachs%26aulast%3DLopez%26aufirst%3DJ.%26aulast%3DEvans%26aufirst%3DT.%2BR.%2BJ.%26aulast%3DPlummer%26aufirst%3DE.%2BR.%26aulast%3DDiamantis%26aufirst%3DN.%26aulast%3DShaw%26aufirst%3DH.%2BM.%26aulast%3DZubairi%26aufirst%3DI.%2BH.%26aulast%3DHaris%26aufirst%3DN.%2BR.%2BM.%26aulast%3DMacDonald%26aufirst%3DJ.%26aulast%3DGreystoke%26aufirst%3DA.%26aulast%3DRoux%26aufirst%3DR.%2BL.%26aulast%3DTunariu%26aufirst%3DN.%26aulast%3DMolife%26aufirst%3DL.%2BR.%26aulast%3DHannah%26aufirst%3DA.%2BL.%26aulast%3DAnderson%26aufirst%3DS.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DMaurer%26aufirst%3DM.%26aulast%3DSchmitt-Hoffmann%26aufirst%3DA.%26aulast%3DBachmann%26aufirst%3DF.%26aulast%3DEngelhardt%26aufirst%3DM.%2BF.%26aulast%3DKristeleit%26aufirst%3DR.%2BS.%26atitle%3DPhase%25201%252F2a%2520trial%2520of%2520intravenous%2520BAL101553%252C%2520a%2520novel%2520tumor%2520checkpoint%2520controller%2520%2528TCC%2529%252C%2520in%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26spage%3D2525%26doi%3D10.1200%2FJCO.2016.34.15_suppl.2525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, M.</span>; <span class="NLM_string-name">Schmitt-Hoffmann, A.</span>; <span class="NLM_string-name">Larger, P.</span></span> <span> </span><span class="NLM_article-title">Novel Dosage Principle for Drugs Useful for Treating Neoplastic Diseases</span>. <span class="NLM_patent">WO2018210868A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=M.+Engelhardt&author=A.+Schmitt-Hoffmann&author=P.+Larger&title=Novel+Dosage+Principle+for+Drugs+Useful+for+Treating+Neoplastic+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEngelhardt%26aufirst%3DM.%26atitle%3DNovel%2520Dosage%2520Principle%2520for%2520Drugs%2520Useful%2520for%2520Treating%2520Neoplastic%2520Diseases%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joerger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stathis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metaxas, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantiero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mark, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaindl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuedeli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sessa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Moos, R.</span></span> <span> </span><span class="NLM_article-title">A phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1067</span>â <span class="NLM_lpage">1076</span>, <span class="refDoi">Â DOI: 10.1007/s10637-019-00850-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1007%2Fs10637-019-00850-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=31471863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs12is7bE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=1067-1076&author=M.+Joergerauthor=A.+Stathisauthor=Y.+Metaxasauthor=D.+Hessauthor=M.+Mantieroauthor=M.+Markauthor=M.+Voldenauthor=T.+Kaindlauthor=M.+Engelhardtauthor=P.+Largerauthor=H.+Laneauthor=P.+Hafnerauthor=N.+Levyauthor=S.+Stuedeliauthor=C.+Sessaauthor=R.+von+Moos&title=A+phase+1+study+of+BAL101553%2C+a+novel+tumor+checkpoint+controller+targeting+microtubules%2C+administered+as+48-h+infusion+in+adult+patients+with+advanced+solid+tumors&doi=10.1007%2Fs10637-019-00850-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors</span></div><div class="casAuthors">Joerger, Markus; Stathis, Anastasios; Metaxas, Yannis; Hess, Dagmar; Mantiero, Mara; Mark, Michael; Volden, Matthias; Kaindl, Thomas; Engelhardt, Marc; Larger, Patrice; Lane, Heidi; Hafner, Peter; Levy, Nicole; Stuedeli, Silvia; Sessa, Cristiana; von Moos, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1067-1076</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose BAL101553, the prodrug of the microtubule-destabilizer BAL27862, previously showed signs of antitumor activity when administered as a 2-h infusion, but its use was limited by vascular toxicity.  We investigated an alternative dosing strategy aimed at improving the safety profile of BAL101553.  Methods This multicenter, open-label, Phase 1 dose-escalation study used a 3 + 3 design to det. the max. tolerated dose (MTD), dose-limiting toxicities (DLTs), pharmacokinetics, and antitumor activity of BAL101553 administered as a 48-h IV infusion on Days 1, 8, and 15 of a 28-day cycle.  Patients received oral BAL101553 on Days 15-21 of cycle 2 to assess oral bioavailability.  Results BAL101553 was well tolerated at doses up to â¤70 mg/m2.  Three grade 3 DLTs occurred: hypotension (70 mg/m2), hyponatremia and neutropenia (both 90 mg/m2).  The MTD for 48-h IV BAL101553 was 70 mg/m2.  At this dose level, the AUC for BAL27862 was 8580 ng.h/mL and the Cmax was 144 ng/mL.  No apparent dose-related effects on blood pressure were obsd. with 48-h BAL101553 IV infusion.  BAL27862 oral bioavailability was >80%.  Conclusions Continuous 48-h IV BAL101553 infusion achieved higher exposure of the BAL27862 active metabolite than a 2-h infusion at the RP2D and did not cause vascular toxicity.  Clinicaltrials.gov registration: NCT02895360.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphRUL_sO_xQLVg90H21EOLACvtfcHk0liLzRd8HHkqPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs12is7bE&md5=d5452c063a5b91e56ba492163e139b57</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1007%2Fs10637-019-00850-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-019-00850-z%26sid%3Dliteratum%253Aachs%26aulast%3DJoerger%26aufirst%3DM.%26aulast%3DStathis%26aufirst%3DA.%26aulast%3DMetaxas%26aufirst%3DY.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DMantiero%26aufirst%3DM.%26aulast%3DMark%26aufirst%3DM.%26aulast%3DVolden%26aufirst%3DM.%26aulast%3DKaindl%26aufirst%3DT.%26aulast%3DEngelhardt%26aufirst%3DM.%26aulast%3DLarger%26aufirst%3DP.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DHafner%26aufirst%3DP.%26aulast%3DLevy%26aufirst%3DN.%26aulast%3DStuedeli%26aufirst%3DS.%26aulast%3DSessa%26aufirst%3DC.%26aulast%3Dvon%2BMoos%26aufirst%3DR.%26atitle%3DA%2520phase%25201%2520study%2520of%2520BAL101553%252C%2520a%2520novel%2520tumor%2520checkpoint%2520controller%2520targeting%2520microtubules%252C%2520administered%2520as%252048-h%2520infusion%2520in%2520adult%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2020%26volume%3D38%26spage%3D1067%26epage%3D1076%26doi%3D10.1007%2Fs10637-019-00850-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loehn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plettenburg, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivashchenko, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kannt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmeister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadereit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linz, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbert, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janiak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâConnor, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruetten, H.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of SAR407899, a novel Rho-kinase inhibitor</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">676</span>â <span class="NLM_lpage">683</span>, <span class="refDoi">Â DOI: 10.1161/HYPERTENSIONAHA.109.134353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1161%2FHYPERTENSIONAHA.109.134353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=19597037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpslelu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2009&pages=676-683&issue=3&author=M.+Loehnauthor=O.+Plettenburgauthor=Y.+Ivashchenkoauthor=A.+Kanntauthor=A.+Hofmeisterauthor=D.+Kadereitauthor=M.+Schaeferauthor=W.+Linzauthor=M.+Kohlmannauthor=J.-M.+Herbertauthor=P.+Janiakauthor=S.+E.+O%E2%80%99Connorauthor=H.+Ruetten&title=Pharmacological+characterization+of+SAR407899%2C+a+novel+Rho-kinase+inhibitor&doi=10.1161%2FHYPERTENSIONAHA.109.134353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological Characterization of SAR407899, a Novel Rho-Kinase Inhibitor</span></div><div class="casAuthors">Loehn, Matthias; Plettenburg, Oliver; Ivashchenko, Yuri; Kannt, Aimo; Hofmeister, Armin; Kadereit, Dieter; Schaefer, Matthias; Linz, Wolfgang; Kohlmann, Markus; Herbert, Jean-Marc; Janiak, Philip; O'Connor, Stephen E.; Ruetten, Hartmut</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">676-683</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Recent advances in basic and clin. research have identified Rho kinase as an important target potentially implicated in a variety of cardiovascular diseases.  Rho kinase is a downstream mediator of RhoA that leads to stress fiber formation, membrane ruffling, smooth muscle contraction, and cell motility.  Increased Rho-kinase activity is assocd. with vasoconstriction and elevated blood pressure.  We identified a novel inhibitor of Rho kinase (SAR407899) and characterized its effects in biochem., cellular, tissue-based, and in vivo assays.  SAR407899 is an ATP-competitive Rho-kinase inhibitor, equipotent against human and rat-derived Rho-kinase 2 with inhibition const. values of 36 nM and 41 nM, resp.  It is highly selective in panel of 117 receptor and enzyme targets.  SAR407899 is â8-fold more active than fasudil.  In vitro, SAR407899 demonstrated concn.-dependent inhibition of Rho-kinase-mediated phosphorylation of myosin phosphatase, thrombin-induced stress fiber formation, platelet-derived growth factor-induced proliferation, and monocyte chemotactic protein-1-stimulated chemotaxis.  SAR407899 potently (mean IC50 values: 122 to 280 nM) and species-independently relaxed precontracted isolated arteries of different species and different vascular beds.  In vivo, over the dose range 3 to 30 mg/kg PO, SAR407899 lowered blood pressure in a variety of rodent models of arterial hypertension.  The antihypertensive effect of SAR407899 was superior to that of fasudil and Y-27632.  In conclusion, SAR407899 is a novel and potent selective Rho-kinase inhibitor with promising antihypertensive activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHI_7WEKzfELVg90H21EOLACvtfcHk0lhJoJaq0M7ZVg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpslelu7w%253D&md5=b3a58165590d5cca120a77e12e085325</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.109.134353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.109.134353%26sid%3Dliteratum%253Aachs%26aulast%3DLoehn%26aufirst%3DM.%26aulast%3DPlettenburg%26aufirst%3DO.%26aulast%3DIvashchenko%26aufirst%3DY.%26aulast%3DKannt%26aufirst%3DA.%26aulast%3DHofmeister%26aufirst%3DA.%26aulast%3DKadereit%26aufirst%3DD.%26aulast%3DSchaefer%26aufirst%3DM.%26aulast%3DLinz%26aufirst%3DW.%26aulast%3DKohlmann%26aufirst%3DM.%26aulast%3DHerbert%26aufirst%3DJ.-M.%26aulast%3DJaniak%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DS.%2BE.%26aulast%3DRuetten%26aufirst%3DH.%26atitle%3DPharmacological%2520characterization%2520of%2520SAR407899%252C%2520a%2520novel%2520Rho-kinase%2520inhibitor%26jtitle%3DHypertension%26date%3D2009%26volume%3D54%26issue%3D3%26spage%3D676%26epage%3D683%26doi%3D10.1161%2FHYPERTENSIONAHA.109.134353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, F.</span>; <span class="NLM_string-name">Lane, H.</span>; <span class="NLM_string-name">McSheehy, P.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical Combinations Including Eribulin for Use in the Treatment of Neoplastic Diseases</span>. <span class="NLM_patent">WO2019097073A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=F.+Bachmann&author=H.+Lane&author=P.+McSheehy&title=Pharmaceutical+Combinations+Including+Eribulin+for+Use+in+the+Treatment+of+Neoplastic+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBachmann%26aufirst%3DF.%26atitle%3DPharmaceutical%2520Combinations%2520Including%2520Eribulin%2520for%2520Use%2520in%2520the%2520Treatment%2520of%2520Neoplastic%2520Diseases%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachmann, F.</span>; <span class="NLM_string-name">Lane, H.</span>; <span class="NLM_string-name">McSheehy, P.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical Combinations for Use in the Treatment of Neoplastic Diseases</span>. <span class="NLM_patent">WO2020058405A1</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=F.+Bachmann&author=H.+Lane&author=P.+McSheehy&title=Pharmaceutical+Combinations+for+Use+in+the+Treatment+of+Neoplastic+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBachmann%26aufirst%3DF.%26atitle%3DPharmaceutical%2520Combinations%2520for%2520Use%2520in%2520the%2520Treatment%2520of%2520Neoplastic%2520Diseases%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meneghetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, S.</span></span> <span> </span><span class="NLM_article-title">Signal transducer and activator of transcription protein 3 (STAT3): An update on its direct inhibitors as promising anticancer agents</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">27</span>),  <span class="NLM_fpage">5165</span>â <span class="NLM_lpage">5206</span>, <span class="refDoi">Â DOI: 10.2174/0929867325666180719122729</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.2174%2F0929867325666180719122729" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=30027840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVymt7bI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=5165-5206&issue=27&author=A.+Gelainauthor=M.+Moriauthor=F.+Meneghettiauthor=S.+Villa&title=Signal+transducer+and+activator+of+transcription+protein+3+%28STAT3%29%3A+An+update+on+its+direct+inhibitors+as+promising+anticancer+agents&doi=10.2174%2F0929867325666180719122729"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents</span></div><div class="casAuthors">Gelain, Arianna; Mori, Matteo; Meneghetti, Fiorella; Villa, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">5165-5206</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Background: Since Signal Transducer and Activator of Transcription 3 (STAT3) is a transcription factor which plays an important role in multiple aspects of cancer, including progression and migration, and it is constitutively activated in various human tumors, STAT3 inhibition has emerged as a validated strategy for the treatment of several malignancies.  The aim of this review is to provide an update on the identification of new promising direct inhibitors targeting STAT3 domains, as potential anticancer agents.  Methods: A thorough literature search focused on recently reported STAT3 direct inhibitors was undertaken.  We considered the relevant developments regarding the STAT3 domains, which have been identified as potential drug targets.  Results: In detail, 135 peer-reviewed papers and 7 patents were cited; the inhibitors we took into account targeted the DNA binding domain (compds. were grouped into natural derivs., small mols., peptides, aptamers and oligonucleotides), the SH2 binding domain (natural, semi-synthetic and synthetic compds.) and specific residues, like cysteines (natural, semi-synthetic, synthetic compds. and dual inhibitors) and tyrosine 705.  Conclusion: The huge no. of direct STAT3 inhibitors recently identified demonstrates a strong interest in the investigation of this target, although it represents a challenging task considering that no drug targeting this enzyme is currently available for anticancer therapy.  Notably, many studies on the available inhibitors evidenced that some of them possess a dual mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQTc4wg6lMDbVg90H21EOLACvtfcHk0lhJoJaq0M7ZVg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVymt7bI&md5=1df39128edf16ad4b697263614ed36e5</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.2174%2F0929867325666180719122729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867325666180719122729%26sid%3Dliteratum%253Aachs%26aulast%3DGelain%26aufirst%3DA.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DMeneghetti%26aufirst%3DF.%26aulast%3DVilla%26aufirst%3DS.%26atitle%3DSignal%2520transducer%2520and%2520activator%2520of%2520transcription%2520protein%25203%2520%2528STAT3%2529%253A%2520An%2520update%2520on%2520its%2520direct%2520inhibitors%2520as%2520promising%2520anticancer%2520agents%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2019%26volume%3D26%26issue%3D27%26spage%3D5165%26epage%3D5206%26doi%3D10.2174%2F0929867325666180719122729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, B. M.</span>; <span class="NLM_string-name">Han, D. C.</span>; <span class="NLM_string-name">Son, K. H.</span>; <span class="NLM_string-name">Shin, D. S.</span>; <span class="NLM_string-name">Lee, J.</span></span> <span> </span><span class="NLM_article-title">Agent for Prevention and Treatment of Cancer Comprising Oxadiazole Urea Compound Obstructing Activity of STAT</span>. <span class="NLM_patent">US200800514442A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=B.+M.+Kwon&author=D.+C.+Han&author=K.+H.+Son&author=D.+S.+Shin&author=J.+Lee&title=Agent+for+Prevention+and+Treatment+of+Cancer+Comprising+Oxadiazole+Urea+Compound+Obstructing+Activity+of+STAT"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKwon%26aufirst%3DB.%2BM.%26atitle%3DAgent%2520for%2520Prevention%2520and%2520Treatment%2520of%2520Cancer%2520Comprising%2520Oxadiazole%2520Urea%2520Compound%2520Obstructing%2520Activity%2520of%2520STAT%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masciocchi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlocco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meneghetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedretti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, B.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legnani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toma, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis, modeling, and crystallographic study of 3,4-disubstituted-1,2,5-oxadiazoles and evaluation of their ability to decrease STAT3 activity</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">156</span>â <span class="NLM_lpage">164</span>, <span class="refDoi">Â DOI: 10.1039/c0md00057d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1039%2Fc0md00057d" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVans7fF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=156-164&issue=2&author=D.-S.+Shinauthor=D.+Masciocchiauthor=A.+Gelainauthor=S.+Villaauthor=D.+Barloccoauthor=F.+Meneghettiauthor=A.+Pedrettiauthor=Y.-M.+Hanauthor=D.+C.+Hanauthor=B.-M.+Kwonauthor=L.+Legnaniauthor=L.+Toma&title=Synthesis%2C+modeling%2C+and+crystallographic+study+of+3%2C4-disubstituted-1%2C2%2C5-oxadiazoles+and+evaluation+of+their+ability+to+decrease+STAT3+activity&doi=10.1039%2Fc0md00057d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, modeling, and crystallographic study of 3,4-disubstituted-1,2,5-oxadiazoles and evaluation of their ability to decrease STAT3 activity</span></div><div class="casAuthors">Shin, Dae-Seop; Masciocchi, Daniela; Gelain, Arianna; Villa, Stefania; Barlocco, Daniela; Meneghetti, Fiorella; Pedretti, Alessandro; Han, Young-Min; Han, Dong-Cho; Kwon, Byoung-Mog; Legnani, Laura; Toma, Lucio</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">156-164</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">STAT3 (Signal Transducer and Activator of Transcription 3) is a transcription factor constitutively activated by aberrant upstream tyrosine kinase activities in a broad spectrum of human solid and blood tumors, thus suggesting that its inhibition could represent an interesting mol. target for cancer therapy.  With the aim to disclose novel scaffolds for compds. active on STAT3 the potential of the 1,2,5-oxadiazole ring was explored and several new compds. substituted at positions 3 and 4 of the heterocycle were synthesized.  When tested in a dual-luciferase assay, using HCT-116 cells, some compds. showed a significant inhibition value towards STAT3, particularly I.  So, to give support to the biol. results, modeling and crystallog. studies of representative terms of the new series were performed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrluNnelBcqurVg90H21EOLACvtfcHk0lh1eFKFSRXZgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVans7fF&md5=d1f0b03f0efd84e22c9c0ab5dc3e84f5</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1039%2Fc0md00057d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0md00057d%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DD.-S.%26aulast%3DMasciocchi%26aufirst%3DD.%26aulast%3DGelain%26aufirst%3DA.%26aulast%3DVilla%26aufirst%3DS.%26aulast%3DBarlocco%26aufirst%3DD.%26aulast%3DMeneghetti%26aufirst%3DF.%26aulast%3DPedretti%26aufirst%3DA.%26aulast%3DHan%26aufirst%3DY.-M.%26aulast%3DHan%26aufirst%3DD.%2BC.%26aulast%3DKwon%26aufirst%3DB.-M.%26aulast%3DLegnani%26aufirst%3DL.%26aulast%3DToma%26aufirst%3DL.%26atitle%3DSynthesis%252C%2520modeling%252C%2520and%2520crystallographic%2520study%2520of%25203%252C4-disubstituted-1%252C2%252C5-oxadiazoles%2520and%2520evaluation%2520of%2520their%2520ability%2520to%2520decrease%2520STAT3%2520activity%26jtitle%3DMedChemComm%26date%3D2010%26volume%3D1%26issue%3D2%26spage%3D156%26epage%3D164%26doi%3D10.1039%2Fc0md00057d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masciocchi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meneghetti, F.</span></span> <span> </span><span class="NLM_article-title">The influence of the substitution pattern on the molecular conformation of ureido-1,2,5-oxadiazoles, related to STAT3 inhibitors: Chemical behavior and structural investigation</span>. <i>Chem. Biodiversity</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1240</span>â <span class="NLM_lpage">1253</span>, <span class="refDoi">Â DOI: 10.1002/cbdv.201100339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fcbdv.201100339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=22782873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVagtrnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=1240-1253&issue=7&author=S.+Villaauthor=D.+Masciocchiauthor=A.+Gelainauthor=F.+Meneghetti&title=The+influence+of+the+substitution+pattern+on+the+molecular+conformation+of+ureido-1%2C2%2C5-oxadiazoles%2C+related+to+STAT3+inhibitors%3A+Chemical+behavior+and+structural+investigation&doi=10.1002%2Fcbdv.201100339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">The Influence of the Substitution Pattern on the Molecular Conformation of Ureido-1,2,5-oxadiazoles, Related to STAT3 Inhibitors: Chemical Behavior and Structural Investigation</span></div><div class="casAuthors">Villa, Stefania; Masciocchi, Daniela; Gelain, Arianna; Meneghetti, Fiorella</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biodiversity</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1240-1253</span>CODEN:
                <span class="NLM_cas:coden">CBHIAM</span>;
        ISSN:<span class="NLM_cas:issn">1612-1872</span>.
    
            (<span class="NLM_cas:orgname">Verlag Helvetica Chimica Acta</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is a protein constitutively activated by aberrant upstream tyrosine kinase activities in a broad spectrum of human solid and blood tumors.  Therefore, the availability of drugs affecting STAT3 may have important therapeutic potential for the treatment of cancer.  Pursuing our efforts in exploring the influence of the substitution pattern of the ureido 1,2,5-oxadiazole moiety on the mol. conformation, new compds. substituted at positions 3 and 4 on the furazan ring were synthesized.  The inhibition properties vs. STAT3 of the novel compds. were evaluated in a dual-luciferase assay, using HCT-116 cells, and the results evidenced a moderate activity only for the compds. endowed with a planar arrangement.  Crystallog. studies of the new derivs. were performed in order to evidence the peculiar chem. behavior and to evaluate how structural modulations affected the biol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzOEMfnmvY2rVg90H21EOLACvtfcHk0lh1eFKFSRXZgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVagtrnE&md5=2ad6fad4fae37367cce8d74eb98ad1d5</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1002%2Fcbdv.201100339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbdv.201100339%26sid%3Dliteratum%253Aachs%26aulast%3DVilla%26aufirst%3DS.%26aulast%3DMasciocchi%26aufirst%3DD.%26aulast%3DGelain%26aufirst%3DA.%26aulast%3DMeneghetti%26aufirst%3DF.%26atitle%3DThe%2520influence%2520of%2520the%2520substitution%2520pattern%2520on%2520the%2520molecular%2520conformation%2520of%2520ureido-1%252C2%252C5-oxadiazoles%252C%2520related%2520to%2520STAT3%2520inhibitors%253A%2520Chemical%2520behavior%2520and%2520structural%2520investigation%26jtitle%3DChem.%2520Biodiversity%26date%3D2012%26volume%3D9%26issue%3D7%26spage%3D1240%26epage%3D1253%26doi%3D10.1002%2Fcbdv.201100339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masciocchi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meneghetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedretti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlocco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legnani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, B.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, A.</span></span> <span> </span><span class="NLM_article-title">Biological and computational evaluation of an oxadiazole derivative (MD77) as a new lead for direct STAT3 inhibitors</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">592</span>â <span class="NLM_lpage">599</span>, <span class="refDoi">Â DOI: 10.1039/c2md20018j</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1039%2Fc2md20018j" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFart7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=592-599&issue=5&author=D.+Masciocchiauthor=S.+Villaauthor=F.+Meneghettiauthor=A.+Pedrettiauthor=D.+Barloccoauthor=L.+Legnaniauthor=L.+Tomaauthor=B.-M.+Kwonauthor=S.+Nakanoauthor=A.+Asaiauthor=A.+Gelain&title=Biological+and+computational+evaluation+of+an+oxadiazole+derivative+%28MD77%29+as+a+new+lead+for+direct+STAT3+inhibitors&doi=10.1039%2Fc2md20018j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Biological and computational evaluation of an oxadiazole derivative (MD77) as a new lead for direct STAT3 inhibitors</span></div><div class="casAuthors">Masciocchi, Daniela; Villa, Stefania; Meneghetti, Fiorella; Pedretti, Alessandro; Barlocco, Daniela; Legnani, Laura; Toma, Lucio; Kwon, Byoung-Mog; Nakano, Shintaro; Asai, Akira; Gelain, Arianna</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">592-599</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Signal Transducer and Activator of Transcription 3 (STAT3) is a latent cytoplasmic protein overexpressed in various cancer cell lines.  STAT3 participates in oncogenesis by stimulating cell proliferation and preventing apoptosis and it has been proven as a suitable target for anticancer therapy.  In order to identify direct STAT3 inhibitors, we performed a binding assay on several previously synthesized 1,2,5-oxadiazole derivs.  Among them, compd. MD77, N-[4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl]-4-(trifluoromethyl)benzamide, showed a good ability to bind the STAT3-SH2 domain in a dose-dependent manner (IC50 = 17.7 Î¼M).  Computational studies were carried out to investigate its binding mode.  Moreover, compd. MD77 showed a significant anti-proliferative activity vs. several tumor cell lines.  On these bases, compd. MD77 was selected as a lead for the future development of direct STAT3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrESgLmH0AmJbVg90H21EOLACvtfcHk0lh1eFKFSRXZgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFart7g%253D&md5=5c41c49a9192d95d2c00653b51ea45d3</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1039%2Fc2md20018j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20018j%26sid%3Dliteratum%253Aachs%26aulast%3DMasciocchi%26aufirst%3DD.%26aulast%3DVilla%26aufirst%3DS.%26aulast%3DMeneghetti%26aufirst%3DF.%26aulast%3DPedretti%26aufirst%3DA.%26aulast%3DBarlocco%26aufirst%3DD.%26aulast%3DLegnani%26aufirst%3DL.%26aulast%3DToma%26aufirst%3DL.%26aulast%3DKwon%26aufirst%3DB.-M.%26aulast%3DNakano%26aufirst%3DS.%26aulast%3DAsai%26aufirst%3DA.%26aulast%3DGelain%26aufirst%3DA.%26atitle%3DBiological%2520and%2520computational%2520evaluation%2520of%2520an%2520oxadiazole%2520derivative%2520%2528MD77%2529%2520as%2520a%2520new%2520lead%2520for%2520direct%2520STAT3%2520inhibitors%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26issue%3D5%26spage%3D592%26epage%3D599%26doi%3D10.1039%2Fc2md20018j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meneghetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masciocchi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlocco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, D.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, B.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legnani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, A.</span></span> <span> </span><span class="NLM_article-title">Ureido-pyridazinone derivatives: Insights into the structural and conformational properties for STAT3 inhibition</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">4907</span>â <span class="NLM_lpage">4912</span>, <span class="refDoi">Â DOI: 10.1002/ejoc.201500599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fejoc.201500599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVyhsL%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=4907-4912&issue=22&author=F.+Meneghettiauthor=S.+Villaauthor=D.+Masciocchiauthor=D.+Barloccoauthor=L.+Tomaauthor=D.-C.+Hanauthor=B.-M.+Kwonauthor=N.+Ogoauthor=A.+Asaiauthor=L.+Legnaniauthor=A.+Gelain&title=Ureido-pyridazinone+derivatives%3A+Insights+into+the+structural+and+conformational+properties+for+STAT3+inhibition&doi=10.1002%2Fejoc.201500599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Ureido-Pyridazinone Derivatives: Insights into the Structural and Conformational Properties for STAT3 Inhibition</span></div><div class="casAuthors">Meneghetti, Fiorella; Villa, Stefania; Masciocchi, Daniela; Barlocco, Daniela; Toma, Lucio; Han, Dong-Cho; Kwon, Byoung-Mog; Ogo, Naohisa; Asai, Akira; Legnani, Laura; Gelain, Arianna</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4907-4912</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Three new ureido-pyridazinone derivs., which are structurally related to the known STAT3 inhibitor AVS-0288, were designed by taking into account the structure-activity relationships detd. for several ureido-oxadiazole derivs. previously studied by our group.  Their synthesis was first attempted through suitable 5-aminopyridazinone intermediates, and the mol. structures of these intermediates were confirmed by means of X-ray diffraction data on 5-amino-6-phenylpyridazin-3(2H)-one.  Amine functionalization was unsuccessful, therefore, an alternative method was devised.  Dual-luciferase and AlphaScreen-based assays were used to test their activity.  The obtained data were rationalized on the basis of a modeling study, which focused our attention on the geometrical preferences of the ureido moiety.  Computational results seem to indicate that both the 1,2,5-oxadiazole ring and the extended ZZ arrangement were essential and probably act in a synergistic way to confer significant activity against STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZXBd5q49qdbVg90H21EOLACvtfcHk0ljKnerg74zs4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVyhsL%252FL&md5=b2628519d53faef5077312f5aee851d7</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201500599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201500599%26sid%3Dliteratum%253Aachs%26aulast%3DMeneghetti%26aufirst%3DF.%26aulast%3DVilla%26aufirst%3DS.%26aulast%3DMasciocchi%26aufirst%3DD.%26aulast%3DBarlocco%26aufirst%3DD.%26aulast%3DToma%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DD.-C.%26aulast%3DKwon%26aufirst%3DB.-M.%26aulast%3DOgo%26aufirst%3DN.%26aulast%3DAsai%26aufirst%3DA.%26aulast%3DLegnani%26aufirst%3DL.%26aulast%3DGelain%26aufirst%3DA.%26atitle%3DUreido-pyridazinone%2520derivatives%253A%2520Insights%2520into%2520the%2520structural%2520and%2520conformational%2520properties%2520for%2520STAT3%2520inhibition%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2015%26volume%3D2015%26issue%3D22%26spage%3D4907%26epage%3D4912%26doi%3D10.1002%2Fejoc.201500599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlocco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchiano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappello, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basile, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guccione, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meneghetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, S.</span></span> <span> </span><span class="NLM_article-title">A field-based disparity analysis of new 1,2,5-oxadiazole derivatives endowed with antiproliferative activity</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>90</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">820</span>â <span class="NLM_lpage">839</span>, <span class="refDoi">Â DOI: 10.1111/cbdd.13003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1111%2Fcbdd.13003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28419754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXns1KgsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2017&pages=820-839&issue=5&author=F.+Portaauthor=A.+Gelainauthor=D.+Barloccoauthor=N.+Ferriauthor=S.+Marchianoauthor=V.+Cappelloauthor=L.+Basileauthor=S.+Guccioneauthor=F.+Meneghettiauthor=S.+Villa&title=A+field-based+disparity+analysis+of+new+1%2C2%2C5-oxadiazole+derivatives+endowed+with+antiproliferative+activity&doi=10.1111%2Fcbdd.13003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">A field-based disparity analysis of new 1,2,5-oxadiazole derivatives endowed with antiproliferative activity</span></div><div class="casAuthors">Porta, Federica; Gelain, Arianna; Barlocco, Daniela; Ferri, Nicola; Marchiano, Silvia; Cappello, Valentina; Basile, Livia; Guccione, Salvatore; Meneghetti, Fiorella; Villa, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">820-839</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A series of 1,2,5-oxadiazoles were synthesized as new potential antiproliferative agents.  The in vitro cytotoxic activity evaluation of title compds. through MTT assay revealed that some of them showed significant activity against the HCT-116 cancer cell line.  The field-based disparity anal. provided indications about the electrostatic, hydrophobic, and shape features underlying the cytotoxicity, suggesting that increasing the neg. electrostatic field on the heterocyclic core of the structure has pos. effects on the activity.  The structure-activity relationships (SAR) around a particular compd. can be explained allowing for a structural rationale for the differences in activity.  The SAR provided by this series of compds. can be exploited to carry out further lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk-N4lAAlhc7Vg90H21EOLACvtfcHk0ljKnerg74zs4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXns1KgsLo%253D&md5=b01d51dec301220658e4089728799f3f</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.13003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.13003%26sid%3Dliteratum%253Aachs%26aulast%3DPorta%26aufirst%3DF.%26aulast%3DGelain%26aufirst%3DA.%26aulast%3DBarlocco%26aufirst%3DD.%26aulast%3DFerri%26aufirst%3DN.%26aulast%3DMarchiano%26aufirst%3DS.%26aulast%3DCappello%26aufirst%3DV.%26aulast%3DBasile%26aufirst%3DL.%26aulast%3DGuccione%26aufirst%3DS.%26aulast%3DMeneghetti%26aufirst%3DF.%26aulast%3DVilla%26aufirst%3DS.%26atitle%3DA%2520field-based%2520disparity%2520analysis%2520of%2520new%25201%252C2%252C5-oxadiazole%2520derivatives%2520endowed%2520with%2520antiproliferative%2520activity%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2017%26volume%3D90%26issue%3D5%26spage%3D820%26epage%3D839%26doi%3D10.1111%2Fcbdd.13003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facchetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meneghetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlocco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masciocchi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyoshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchiano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimoldi, I.</span></span> <span> </span><span class="NLM_article-title">An in vivo active 1,2,5-oxadiazole Pt(II) complex: A promising anticancer agent endowed with STAT3 inhibitory properties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">196</span>â <span class="NLM_lpage">206</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2017.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.ejmech.2017.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28324784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvVKrsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2017&pages=196-206&author=F.+Portaauthor=G.+Facchettiauthor=N.+Ferriauthor=A.+Gelainauthor=F.+Meneghettiauthor=S.+Villaauthor=D.+Barloccoauthor=D.+Masciocchiauthor=A.+Asaiauthor=N.+Miyoshiauthor=S.+Marchianoauthor=B.+M.+Kwonauthor=Y.+Jinauthor=V.+Gandinauthor=C.+Marzanoauthor=I.+Rimoldi&title=An+in+vivo+active+1%2C2%2C5-oxadiazole+Pt%28II%29+complex%3A+A+promising+anticancer+agent+endowed+with+STAT3+inhibitory+properties&doi=10.1016%2Fj.ejmech.2017.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">An in vivo active 1,2,5-oxadiazole Pt(II) complex: A promising anticancer agent endowed with STAT3 inhibitory properties</span></div><div class="casAuthors">Porta, Federica; Facchetti, Giorgio; Ferri, Nicola; Gelain, Arianna; Meneghetti, Fiorella; Villa, Stefania; Barlocco, Daniela; Masciocchi, Daniela; Asai, Akira; Miyoshi, Nao; Marchiano, Silvia; Kwon, Byoung-Mog; Jin, Yena; Gandin, Valentina; Marzano, Cristina; Rimoldi, Isabella</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">196-206</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">New Pt(II) complexes (Pt-1-3) bearing 1,2,5-oxadiazole ligands (1-3) were synthesized, characterized and evaluated for their ability to disrupt STAT3 dimerization.  Ligand 3Â·HCl showed cytotoxic effects on HCT-116 cells (IC50 = 95.2 Î¼M) and a selective ability to interact with STAT3 (IC50 = 8.2 Î¼M) vs. STAT1 (IC50 > 30 Î¼M).  Its corresponding platinum complex Pt-3 exhibited an increased cytotoxicity (IC50 = 18.4 Î¼M) and a stronger interaction with STAT3 (IC50 = 1.4 Î¼M), leading to inhibition of its signaling pathway.  Pt-3 was also evaluated in cell-based assays for its action on p53 expression and on STAT3 phosphorylation.  In syngeneic murine Lewis lung carcinoma (LLC) implanted in C57BL/6 mice, Pt-3 showed a higher antitumor activity with fewer side effects than cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqivlmoUtNye7Vg90H21EOLACvtfcHk0ljKnerg74zs4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvVKrsrg%253D&md5=3069d1f9605d1b0bb046e74b1e1cf1e8</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DPorta%26aufirst%3DF.%26aulast%3DFacchetti%26aufirst%3DG.%26aulast%3DFerri%26aufirst%3DN.%26aulast%3DGelain%26aufirst%3DA.%26aulast%3DMeneghetti%26aufirst%3DF.%26aulast%3DVilla%26aufirst%3DS.%26aulast%3DBarlocco%26aufirst%3DD.%26aulast%3DMasciocchi%26aufirst%3DD.%26aulast%3DAsai%26aufirst%3DA.%26aulast%3DMiyoshi%26aufirst%3DN.%26aulast%3DMarchiano%26aufirst%3DS.%26aulast%3DKwon%26aufirst%3DB.%2BM.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DGandin%26aufirst%3DV.%26aulast%3DMarzano%26aufirst%3DC.%26aulast%3DRimoldi%26aufirst%3DI.%26atitle%3DAn%2520in%2520vivo%2520active%25201%252C2%252C5-oxadiazole%2520Pt%2528II%2529%2520complex%253A%2520A%2520promising%2520anticancer%2520agent%2520endowed%2520with%2520STAT3%2520inhibitory%2520properties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D131%26spage%3D196%26epage%3D206%26doi%3D10.1016%2Fj.ejmech.2017.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rademann, J.</span>; <span class="NLM_string-name">Wong, E. L.</span>; <span class="NLM_string-name">Arkona, C.</span>; <span class="NLM_string-name">Kim, B. G.</span>; <span class="NLM_string-name">Nawrotzky, E.</span></span> <span> </span><span class="NLM_article-title">Preparation of Tetrazolylmethylamino Furazan-3-carboxylic Acid Derivatives for the Treatment of Cancer</span>. <span class="NLM_patent">WO2018065536A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=J.+Rademann&author=E.+L.+Wong&author=C.+Arkona&author=B.+G.+Kim&author=E.+Nawrotzky&title=Preparation+of+Tetrazolylmethylamino+Furazan-3-carboxylic+Acid+Derivatives+for+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRademann%26aufirst%3DJ.%26atitle%3DPreparation%2520of%2520Tetrazolylmethylamino%2520Furazan-3-carboxylic%2520Acid%2520Derivatives%2520for%2520the%2520Treatment%2520of%2520Cancer%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Catrow, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective small-molecule inhibitors for the beta-catenin/T-cell factor protein-protein interaction through the optimization of the acyl hydrazone moiety</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4678</span>â <span class="NLM_lpage">4692</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00223</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00223" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosFakt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4678-4692&issue=11&author=J.+L.+Catrowauthor=Y.+Zhangauthor=M.+Zhangauthor=H.+Ji&title=Discovery+of+selective+small-molecule+inhibitors+for+the+beta-catenin%2FT-cell+factor+protein-protein+interaction+through+the+optimization+of+the+acyl+hydrazone+moiety&doi=10.1021%2Facs.jmedchem.5b00223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Selective Small-Molecule Inhibitors for the Î²-Catenin/T-Cell Factor Protein-Protein Interaction through the Optimization of the Acyl Hydrazone Moiety</span></div><div class="casAuthors">Catrow, J. Leon; Zhang, Yongqiang; Zhang, Min; Ji, Haitao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4678-4692</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acyl hydrazone is an important functional group for the discovery of bioactive small mols.  This functional group is also recognized as a pan assay interference structure.  In this study, a new small-mol. inhibitor for the Î²-catenin/Tcf protein-protein interaction (PPI), ZINC02092166, was identified through AlphaScreen and FP assays.  This compd. contains an acyl hydrazone group and exhibits higher inhibitory activities in cell-based assays than biochem. assays.  Inhibitor optimization resulted in chem. stable derivs. that disrupt the Î²-catenin/Tcf PPI.  The binding mode of new inhibitors was characterized by site-directed mutagenesis and structure-activity relationship studies.  This series of inhibitors with a new scaffold exhibits dual selectivity for Î²-catenin/Tcf over Î²-catenin/cadherin and Î²-catenin/APC PPIs.  One deriv. of this series suppresses canonical Wnt signaling, downregulates the expression of Wnt target genes, and inhibits the growth of cancer cells.  This compd. represents a solid starting point for the development of potent and selective Î²-catenin/Tcf inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqusdU2c6KIQLVg90H21EOLACvtfcHk0lipFpib1akIOw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosFakt7o%253D&md5=11aa0209009144341d692c4cf6966790</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00223%26sid%3Dliteratum%253Aachs%26aulast%3DCatrow%26aufirst%3DJ.%2BL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DJi%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520selective%2520small-molecule%2520inhibitors%2520for%2520the%2520beta-catenin%252FT-cell%2520factor%2520protein-protein%2520interaction%2520through%2520the%2520optimization%2520of%2520the%2520acyl%2520hydrazone%2520moiety%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D11%26spage%3D4678%26epage%3D4692%26doi%3D10.1021%2Facs.jmedchem.5b00223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ji, H.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Zhang, M.</span>; <span class="NLM_string-name">Catrow, J. L.</span></span> <span> </span><span class="NLM_article-title">Methods and Compositions of Substituted 5H-[1,2,5]Oxadiazolo[3â²,4â²:5,6]pyraziono[2,3-b]indole Analogs as Inhibitors of Beta-Catenin/T-Cell Factor Protein-Protein Interactions</span>. <span class="NLM_patent">WO2016187050A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=H.+Ji&author=Y.+Zhang&author=M.+Zhang&author=J.+L.+Catrow&title=Methods+and+Compositions+of+Substituted+5H-%5B1%2C2%2C5%5DOxadiazolo%5B3%E2%80%B2%2C4%E2%80%B2%3A5%2C6%5Dpyraziono%5B2%2C3-b%5Dindole+Analogs+as+Inhibitors+of+Beta-Catenin%2FT-Cell+Factor+Protein-Protein+Interactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DH.%26atitle%3DMethods%2520and%2520Compositions%2520of%2520Substituted%25205H-%255B1%252C2%252C5%255DOxadiazolo%255B3%25E2%2580%25B2%252C4%25E2%2580%25B2%253A5%252C6%255Dpyraziono%255B2%252C3-b%255Dindole%2520Analogs%2520as%2520Inhibitors%2520of%2520Beta-Catenin%252FT-Cell%2520Factor%2520Protein-Protein%2520Interactions%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, H.</span></span> <span> </span><span class="NLM_article-title">Optimization of peptidomimetics as selective inhibitors for the beta-catenin/T-cell factor protein-protein interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3617</span>â <span class="NLM_lpage">3635</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b00147</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00147" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXksFentb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3617-3635&issue=7&author=Z.+Wangauthor=M.+Zhangauthor=J.+Wangauthor=H.+Ji&title=Optimization+of+peptidomimetics+as+selective+inhibitors+for+the+beta-catenin%2FT-cell+factor+protein-protein+interaction&doi=10.1021%2Facs.jmedchem.9b00147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Peptidomimetics as Selective Inhibitors for the Î²-Catenin/T-Cell Factor Protein-Protein Interaction</span></div><div class="casAuthors">Wang, Zhen; Zhang, Min; Wang, Jin; Ji, Haitao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3617-3635</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Î²-catenin/T-cell factor (Tcf) protein-protein interaction (PPI) plays a crit. role in the Î²-catenin signaling pathway which is hyperactivated in many cancers and fibroses.  Based on compd. 1, which was designed to target the Tcf4 G13ANDE17 binding site of Î²-catenin, extensive structure-activity relationship studies have been conducted.  As a result, compds. 53 and 57 were found to disrupt the Î²-catenin/Tcf PPI with the Ki values of 0.64 and 0.44 Î¼M, resp., and exhibit good selectivity for Î²-catenin/Tcf over Î²-catenin/E-cadherin and Î²-catenin/adenomatous polyposis coli (APC) PPIs.  The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) cell viability assays revealed that 56, the Et ester of 53, was more potent than 53 in inhibiting viability of most of the Wnt/Î²-catenin hyperactive cancer cells.  Further cell-based studies indicated that 56 disrupted the Î²-catenin/Tcf PPI without affecting the Î²-catenin/E-cadherin and Î²-catenin/APC PPIs, suppressed transactivation of Wnt/Î²-catenin signaling in dose-dependent manners, and inhibited migration and invasiveness of Wnt/Î²-catenin-dependent cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmQ02RIKeK5LVg90H21EOLACvtfcHk0lipFpib1akIOw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXksFentb8%253D&md5=8b4a19745fe5ae7561093523b07681a6</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00147%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DH.%26atitle%3DOptimization%2520of%2520peptidomimetics%2520as%2520selective%2520inhibitors%2520for%2520the%2520beta-catenin%252FT-cell%2520factor%2520protein-protein%2520interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D7%26spage%3D3617%26epage%3D3635%26doi%3D10.1021%2Facs.jmedchem.9b00147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peery, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. T.</span></span> <span> </span><span class="NLM_article-title">Effective targeting of the survivin dimerization interface with small-molecule inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">453</span>â <span class="NLM_lpage">462</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-15-1874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1158%2F0008-5472.CAN-15-1874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=26744521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC28Xos1WisA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=453-462&issue=2&author=J.+Qiauthor=Z.+Dongauthor=J.+Liuauthor=R.+C.+Peeryauthor=S.+Zhangauthor=J.+Y.+Liuauthor=J.+T.+Zhang&title=Effective+targeting+of+the+survivin+dimerization+interface+with+small-molecule+inhibitors&doi=10.1158%2F0008-5472.CAN-15-1874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Effective Targeting of the Survivin Dimerization Interface with Small-Molecule Inhibitors</span></div><div class="casAuthors">Qi, Jing; Dong, Zizheng; Liu, Jianguo; Peery, Robert C.; Zhang, Shaobo; Liu, Jing-Yuan; Zhang, Jian-Ting</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">453-462</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Many oncoproteins are considered undruggable because they lack enzymic activities.  In this study, we present a small-mol.-based anticancer agent that acts by inhibiting dimerization of the oncoprotein survivin, thereby promoting its degrdn. along with spontaneous apoptosis in cancer cells.  Through a combination of computational anal. of the dimerization interface and in silico screening, we identified one compd. that induced proteasome-dependent survivin degrdn.  Anal. of a set of structural analogs led us to identify a lead compd. (LQZ-7F), which was effective in blocking the survival of multiple cancer cell lines in a low micromolar concn. range.  LQZ-7F induced proteasome-dependent survivin degrdn., mitotic arrest, and apoptosis, and it blocked the growth of human tumors in mouse xenograft assays.  In addn. to providing preclin. proof of concept for a survivin-targeting anticancer agent, our work offers novel in silico screening strategies to therapeutically target homodimeric oncogenic proteins considered undruggable.  Cancer Res; 76(2); 453-62. Â©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFIaf1nDDoJbVg90H21EOLACvtfcHk0lipFpib1akIOw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xos1WisA%253D%253D&md5=b8ca613a6f9c029097942e21dc212025</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-1874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-1874%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DPeery%26aufirst%3DR.%2BC.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DJ.%2BY.%26aulast%3DZhang%26aufirst%3DJ.%2BT.%26atitle%3DEffective%2520targeting%2520of%2520the%2520survivin%2520dimerization%2520interface%2520with%2520small-molecule%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26issue%3D2%26spage%3D453%26epage%3D462%26doi%3D10.1158%2F0008-5472.CAN-15-1874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-T.</span>; <span class="NLM_string-name">Liu, J.-Y.</span></span> <span> </span><span class="NLM_article-title">Survivin-Targeting Anti-Tumor Agents and Uses and Screening Methods Thereof</span>. <span class="NLM_patent">WO2016187046A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.-T.+Zhang&author=J.-Y.+Liu&title=Survivin-Targeting+Anti-Tumor+Agents+and+Uses+and+Screening+Methods+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.-T.%26atitle%3DSurvivin-Targeting%2520Anti-Tumor%2520Agents%2520and%2520Uses%2520and%2520Screening%2520Methods%2520Thereof%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aljahdali, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, X.</span></span> <span> </span><span class="NLM_article-title">Cancer therapeutics using survivin BIRC5 as a target: What can we do after over two decades of study?</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">368</span>, <span class="refDoi">Â DOI: 10.1186/s13046-019-1362-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1186%2Fs13046-019-1362-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=31439015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BB3MrgsF2hsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=368&author=F.+Liauthor=I.+Aljahdaliauthor=X.+Ling&title=Cancer+therapeutics+using+survivin+BIRC5+as+a+target%3A+What+can+we+do+after+over+two+decades+of+study%3F&doi=10.1186%2Fs13046-019-1362-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?</span></div><div class="casAuthors">Li Fengzhi; Aljahdali Ieman; Ling Xiang; Li Fengzhi; Aljahdali Ieman; Ling Xiang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of experimental & clinical cancer research : CR</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">368</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Survivin (also named BIRC5) is a well-known cancer therapeutic target.  Since its discovery more than two decades ago, the use of survivin as a target for cancer therapeutics has remained a central goal of survivin studies in the cancer field.  Many studies have provided intriguing insight into survivin's functional role in cancers, thus providing promise for survivin as a cancer therapeutic target.  Despite this, moving survivin-targeting agents into and through the clinic remains a challenge.  In order to address this challenge, we may need to rethink current strategies in order to develop a new mindset for targeting survivin.  In this Review, we will first summarize the current survivin mechanistic studies, and then review the status of survivin cancer therapeutics, which is classified into five categories: (i) survivin-partner protein interaction inhibitors, (ii) survivin homodimerization inhibitors, (iii) survivin gene transcription inhibitors, (iv) survivin mRNA inhibitors and (v) survivin immunotherapy.  We will then provide our opinions on cancer therapeutics using survivin as a target, with the goal of stimulating discussion that might facilitate translational research for discovering improved strategies and/or more effective anticancer agents that target survivin for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRMtQEKH7hnxdts4TFFB11gfW6udTcc2eYY_o3CdJ3Grrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrgsF2hsA%253D%253D&md5=98ff4475bb1640831f1c42b398b4519c</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1186%2Fs13046-019-1362-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-019-1362-1%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%26aulast%3DAljahdali%26aufirst%3DI.%26aulast%3DLing%26aufirst%3DX.%26atitle%3DCancer%2520therapeutics%2520using%2520survivin%2520BIRC5%2520as%2520a%2520target%253A%2520What%2520can%2520we%2520do%2520after%2520over%2520two%2520decades%2520of%2520study%253F%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D38%26spage%3D368%26doi%3D10.1186%2Fs13046-019-1362-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prochownik, E. V.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of the Myc oncoprotein</span>. <i>Biochim. Biophys. Acta, Gene Regul. Mech.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1849</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">525</span>â <span class="NLM_lpage">543</span>, <span class="refDoi">Â DOI: 10.1016/j.bbagrm.2014.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bbagrm.2014.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFGnsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1849&publication_year=2015&pages=525-543&issue=5&author=S.+Fletcherauthor=E.+V.+Prochownik&title=Small-molecule+inhibitors+of+the+Myc+oncoprotein&doi=10.1016%2Fj.bbagrm.2014.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors of the Myc oncoprotein</span></div><div class="casAuthors">Fletcher, Steven; Prochownik, Edward V.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Gene Regulatory Mechanisms</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1849</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">525-543</span>CODEN:
                <span class="NLM_cas:coden">BBAGC6</span>;
        ISSN:<span class="NLM_cas:issn">1874-9399</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The c-Myc (Myc) oncoprotein is among the most attractive of cancer targets given that it is de-regulated in the majority of tumors and that its inhibition profoundly affects their growth and/or survival.  However, its role as a seldom-mutated transcription factor, its lack of enzymic activity for which suitable pharmaceutical inhibitors could be crafted and its expression by normal cells have largely been responsible for its being viewed as "undruggable".  Work over the past several years, however, has begun to reverse this idea by allowing us to view Myc within the larger context of global gene regulatory control.  Thus, Myc and its obligate heterodimeric partner, Max, are integral to the coordinated recruitment and post-translational modification of components of the core transcriptional machinery.  Moreover, Myc over-expression re-programs numerous crit. cellular functions and alters the cell's susceptibility to their inhibition.  This new knowledge has therefore served as a framework upon which to develop new pharmaceutical approaches.  These include the continuing development of small mols. which act directly to inhibit the crit. Myc-Max interaction, those which act indirectly to prevent Myc-directed post-translational modifications necessary to initiate productive transcription and those which inhibit vital pathways upon which the Myc-transformed cell is particularly reliant.  This article is part of a Special Issue entitled: Myc proteins in cell biol. and pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpwveGWUG8ZLVg90H21EOLACvtfcHk0ljlGVO-jeihBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFGnsL0%253D&md5=5f6a99316dc48b9f55796e2f7514cef4</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagrm.2014.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagrm.2014.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DProchownik%26aufirst%3DE.%2BV.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520the%2520Myc%2520oncoprotein%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gene%2520Regul.%2520Mech.%26date%3D2015%26volume%3D1849%26issue%3D5%26spage%3D525%26epage%3D543%26doi%3D10.1016%2Fj.bbagrm.2014.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Metallo, S.</span>; <span class="NLM_string-name">Prochownik, E.</span>; <span class="NLM_string-name">Viacava Follis, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of Thiazolidinedione-Benzoxadiazole Conjugates as Inhibitors of c-Myc-Max Interaction for Treatment of Cancer</span>. <span class="NLM_patent">WO2010083404A2</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+Metallo&author=E.+Prochownik&author=A.+Viacava+Follis&title=Preparation+of+Thiazolidinedione-Benzoxadiazole+Conjugates+as+Inhibitors+of+c-Myc-Max+Interaction+for+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMetallo%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Thiazolidinedione-Benzoxadiazole%2520Conjugates%2520as%2520Inhibitors%2520of%2520c-Myc-Max%2520Interaction%2520for%2520Treatment%2520of%2520Cancer%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span> <span> </span><span class="NLM_article-title">Preparation of 10074-G5 Analogs That Are Potent c-Myc Inhibitors With Improved Cell Permeability</span>. <span class="NLM_patent">US20140296307A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=S.+Fletcher&title=Preparation+of+10074-G5+Analogs+That+Are+Potent+c-Myc+Inhibitors+With+Improved+Cell+Permeability"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFletcher%26aufirst%3DS.%26atitle%3DPreparation%2520of%252010074-G5%2520Analogs%2520That%2520Are%2520Potent%2520c-Myc%2520Inhibitors%2520With%2520Improved%2520Cell%2520Permeability%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yap, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharavi, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prochownik, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore identification of c-Myc inhibitor 10074-G5</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">370</span>â <span class="NLM_lpage">374</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2012.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmcl.2012.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=23177256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsleisLrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=370-374&issue=1&author=J.+L.+Yapauthor=H.+Wangauthor=A.+Huauthor=J.+Chauhanauthor=K.+Y.+Jungauthor=R.+B.+Gharaviauthor=E.+V.+Prochownikauthor=S.+Fletcher&title=Pharmacophore+identification+of+c-Myc+inhibitor+10074-G5&doi=10.1016%2Fj.bmcl.2012.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore identification of c-Myc inhibitor 10074-G5</span></div><div class="casAuthors">Yap, Jeremy L.; Wang, Huabo; Hu, Angela; Chauhan, Jay; Jung, Kwan-Young; Gharavi, Robert B.; Prochownik, Edward V.; Fletcher, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">370-374</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A structure-activity relationship (SAR) study of the c-Myc (Myc) inhibitor 10074-G5 (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to det. its pharmacophore.  While the 7-nitrobenzofurazan was found to be crit. for inhibitory activity, the ortho-biphenyl could be replaced with a para-carboxyphenyl group to furnish the new inhibitor JY-3-094 (3q, I).  Around five times as potent as the lead with an IC50 of 33 Î¼M for disruption of the Myc-Max heterodimer, JY-3-094 demonstrated excellent selectivity over Max-Max homodimers, with no apparent effect at 100 Î¼M.  Importantly, the carboxylic acid of JY-3-094 improves the physicochem. properties of the lead compd., which will facilitate the incorporation of addnl. hydrophobicity that might enhance Myc inhibitory activity further still.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZT899nMTVtLVg90H21EOLACvtfcHk0ljlGVO-jeihBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsleisLrL&md5=1c812da2c5989dc7d6906d50b10446df</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DJ.%2BL.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DA.%26aulast%3DChauhan%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DK.%2BY.%26aulast%3DGharavi%26aufirst%3DR.%2BB.%26aulast%3DProchownik%26aufirst%3DE.%2BV.%26aulast%3DFletcher%26aufirst%3DS.%26atitle%3DPharmacophore%2520identification%2520of%2520c-Myc%2520inhibitor%252010074-G5%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D1%26spage%3D370%26epage%3D374%26doi%3D10.1016%2Fj.bmcl.2012.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parise, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beumer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egorin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazo, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prochownik, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiseman, J. L.</span></span> <span> </span><span class="NLM_article-title">In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>335</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">715</span>â <span class="NLM_lpage">727</span>, <span class="refDoi">Â DOI: 10.1124/jpet.110.170555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1124%2Fjpet.110.170555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=20801893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2010&pages=715-727&issue=3&author=D.+M.+Clausenauthor=J.+Guoauthor=R.+A.+Pariseauthor=J.+H.+Beumerauthor=M.+J.+Egorinauthor=J.+S.+Lazoauthor=E.+V.+Prochownikauthor=J.+L.+Eiseman&title=In+vitro+cytotoxicity+and+in+vivo+efficacy%2C+pharmacokinetics%2C+and+metabolism+of+10074-G5%2C+a+novel+small-molecule+inhibitor+of+c-Myc%2FMax+dimerization&doi=10.1124%2Fjpet.110.170555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization</span></div><div class="casAuthors">Clausen, Dana M.; Guo, Jianxia; Parise, Robert A.; Beumer, Jan H.; Egorin, Merrill J.; Lazo, John S.; Prochownik, Edward V.; Eiseman, Julie L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">715-727</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The c-Myc oncoprotein is overexpressed in many tumors and is essential for maintaining the proliferation of transformed cells.  To function as a transcription factor, c-Myc must dimerize with Max via the basic helix-loop-helix leucine zipper protein (bHLHZIP) domains in each protein.  The small mol. 7-nitro-N-(2-phenylphenyl)-2,1,3-benzoxadiazol-4-amine (10074-G5) binds to and distorts the bHLH-ZIP domain of c-Myc, thereby inhibiting c-Myc/Max heterodimer formation and inhibiting its transcriptional activity.  We report in vitro cytotoxicity and in vivo efficacy, pharmacodynamics, pharmacokinetics, and metab. of 10074-G5 in human xenograft-bearing mice.  In vitro, 10074-G5 inhibited the growth of Daudi Burkitt's lymphoma cells and disrupted c-Myc/Max dimerization.  10074-G5 had no effect on the growth of Daudi xenografts in C.B-17 SCID mice that were treated with 20 mg/kg 10074-G5 i.v. for 5 consecutive days.  Inhibition of c-Myc/Max dimerization in Daudi xenografts was not seen 2 or 24 h after treatment.  Concns. of 10074-G5 in various matrixes were detd. by high-performance liq. chromatog.-UV, and metabolites of 10074-G5 were identified by liq. chromatog./tandem mass spectrometry.  The plasma half-life of 10074-G5 in mice treated with 20 mg/kg i.v. was 37 min, and peak plasma concn. was 58 Î¼M, which was 10-fold higher than peak tumor concn.  The lack of antitumor activity probably was caused by the rapid metab. of 10074-G5 to inactive metabolites, resulting in tumor concns. of 10074-G5 insufficient to inhibit c-Myc/Max dimerization.  Our identification of 10074-G5 metabolites in mice will help design new, more metabolically stable small-mol. inhibitors of c-Myc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6sWVYIO38MrVg90H21EOLACvtfcHk0lj0QLkKSqe9SQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrbJ&md5=148af632cc604b34f895573cdfbbd036</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.170555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.170555%26sid%3Dliteratum%253Aachs%26aulast%3DClausen%26aufirst%3DD.%2BM.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DParise%26aufirst%3DR.%2BA.%26aulast%3DBeumer%26aufirst%3DJ.%2BH.%26aulast%3DEgorin%26aufirst%3DM.%2BJ.%26aulast%3DLazo%26aufirst%3DJ.%2BS.%26aulast%3DProchownik%26aufirst%3DE.%2BV.%26aulast%3DEiseman%26aufirst%3DJ.%2BL.%26atitle%3DIn%2520vitro%2520cytotoxicity%2520and%2520in%2520vivo%2520efficacy%252C%2520pharmacokinetics%252C%2520and%2520metabolism%2520of%252010074-G5%252C%2520a%2520novel%2520small-molecule%2520inhibitor%2520of%2520c-Myc%252FMax%2520dimerization%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D335%26issue%3D3%26spage%3D715%26epage%3D727%26doi%3D10.1124%2Fjpet.110.170555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendleton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabato, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cione, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prochownik, E. V.</span></span> <span> </span><span class="NLM_article-title">Disruption of Myc-Max heterodimerization with improved cell-penetrating analogs of the small molecule 10074-G5</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">936</span>â <span class="NLM_lpage">947</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.1108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.18632%2Foncotarget.1108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=23801058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BC3sjlsV2ksA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=936-947&issue=6&author=H.+Wangauthor=J.+Chauhanauthor=A.+Huauthor=K.+Pendletonauthor=J.+L.+Yapauthor=P.+E.+Sabatoauthor=J.+W.+Jonesauthor=M.+Perriauthor=J.+Yuauthor=E.+Cioneauthor=M.+A.+Kaneauthor=S.+Fletcherauthor=E.+V.+Prochownik&title=Disruption+of+Myc-Max+heterodimerization+with+improved+cell-penetrating+analogs+of+the+small+molecule+10074-G5&doi=10.18632%2Foncotarget.1108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of Myc-Max heterodimerization with improved cell-penetrating analogs of the small molecule 10074-G5</span></div><div class="casAuthors">Wang Huabo; Chauhan Jay; Hu Angela; Pendleton Kelsey; Yap Jeremy L; Sabato Philip E; Jones Jace W; Perri Mariarita; Yu Jianshi; Cione Erika; Kane Maureen A; Fletcher Steven; Prochownik Edward V</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">936-47</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The c-Myc (Myc) oncoprotein is a high-value therapeutic target given that it is deregulated in multiple types of cancer.  However, potent small molecule inhibitors of Myc have been difficult to identify, particularly those whose mechanism relies on blocking the association between Myc and its obligate heterodimerization partner, Max.  We have recently reported a structure-activity relationship study of one such small molecule, 10074-G5, and generated an analog, JY-3-094, with significantly improved ability to prevent or disrupt the association between recombinant Myc and Max proteins.  However, JY-3094 penetrates cells poorly.  Here, we show that esterification of a critical para-carboxylic acid function of JY-3-094 by various blocking groups significantly improves cellular uptake although it impairs the ability to disrupt Myc-Max association in vitro.  These pro-drugs are highly concentrated within cells where JY-3-094 is then generated by the action of esterases.  However, the pro-drugs are also variably susceptible to extracellular esterases, which can deplete extracellular reservoirs.  Furthermore, while JY-3-094 is retained by cells for long periods of time, much of it is compartmentalized within the cytoplasm in a form that appears to be less available to interact with Myc.  Our results suggest that persistently high extracellular levels of pro-drug, without excessive susceptibility to extracellular esterases, are critical to establishing and maintaining intracellular levels of JY-3-094 that are sufficient to provide for long-term inhibition of Myc-Max association.  Analogs of JY-3-094 appear to represent promising small molecule Myc inhibitors that warrant further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTUpo3PsQLURaqcneEtCi92fW6udTcc2eY8mrRGJAynNbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjlsV2ksA%253D%253D&md5=044730ff03610d8981f13a77f0edb10a</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.1108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.1108%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DChauhan%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DA.%26aulast%3DPendleton%26aufirst%3DK.%26aulast%3DYap%26aufirst%3DJ.%2BL.%26aulast%3DSabato%26aufirst%3DP.%2BE.%26aulast%3DJones%26aufirst%3DJ.%2BW.%26aulast%3DPerri%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DCione%26aufirst%3DE.%26aulast%3DKane%26aufirst%3DM.%2BA.%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DProchownik%26aufirst%3DE.%2BV.%26atitle%3DDisruption%2520of%2520Myc-Max%2520heterodimerization%2520with%2520improved%2520cell-penetrating%2520analogs%2520of%2520the%2520small%2520molecule%252010074-G5%26jtitle%3DOncotarget%26date%3D2013%26volume%3D4%26issue%3D6%26spage%3D936%26epage%3D947%26doi%3D10.18632%2Foncotarget.1108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabato, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prochownik, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of methyl 4â²-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1â²-biphenyl]-3-carboxylate, an improved small-molecule inhibitor of c-Myc-max dimerization</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2274</span>â <span class="NLM_lpage">2285</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201402189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fcmdc.201402189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=24976143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVGjsLnP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=2274-2285&issue=10&author=J.+Chauhanauthor=H.+Wangauthor=J.+L.+Yapauthor=P.+E.+Sabatoauthor=A.+Huauthor=E.+V.+Prochownikauthor=S.+Fletcher&title=Discovery+of+methyl+4%E2%80%B2-methyl-5-%287-nitrobenzo%5Bc%5D%5B1%2C2%2C5%5Doxadiazol-4-yl%29-%5B1%2C1%E2%80%B2-biphenyl%5D-3-carboxylate%2C+an+improved+small-molecule+inhibitor+of+c-Myc-max+dimerization&doi=10.1002%2Fcmdc.201402189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Methyl 4'-Methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1'-biphenyl]-3-carboxylate, an Improved Small-Molecule Inhibitor of c-Myc-Max Dimerization</span></div><div class="casAuthors">Chauhan, Jay; Wang, Huabo; Yap, Jeremy L.; Sabato, Philip E.; Hu, Angela; Prochownik, Edward V.; Fletcher, Steven</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2274-2285</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">C-Myc is a basic helix-loop-helix-leucine zipper (bHLH-ZIP) transcription factor that is responsible for the transcription of a wide range of target genes involved in many cancer-related cellular processes.  Over-expression of c-Myc has been obsd. in, and directly contributes to, a variety of human cancers including those of the hematopoietic system, lung, prostate and colon.  To become transcriptionally active, c-Myc must first dimerize with Myc-assocd. factor X (Max) via its own bHLH-ZIP domain.  A proven strategy towards the inhibition of c-Myc oncogenic activity is to interfere with the structural integrity of the c-Myc-Max heterodimer.  The small mol. 10074-G5 is an inhibitor of c-Myc-Max dimerization (IC50=146 Î¼M) that operates by binding and stabilizing c-Myc in its monomeric form.  The authors have identified a congener of 10074-G5, compd. I that is about five times as potent (IC50=34 Î¼M) at inhibiting c-Myc-Max dimerization as the parent compd.  I exhibited an approx. twofold selectivity for c-Myc-Max heterodimers over Max-Max homodimers, suggesting that its mode of action is through binding c-Myc.  I inhibited the proliferation of c-Myc-over-expressing HL60 and Daudi cells with single-digit micromolar IC50 values by causing growth arrest at the G0/G1 phase.  Coimmunopptn. studies indicated that I inhibits c-Myc-Max dimerization in cells, which was further substantiated by the specific silencing of a c-Myc-driven luciferase reporter gene.  Finally, I's intracellular half-life was >17 h.  Collectively, these data demonstrate I to be one of the most potent, cellularly active and stable c-Myc inhibitors reported to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNAXo4mr-8crVg90H21EOLACvtfcHk0lggSySk-MuViA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVGjsLnP&md5=48a68fdb45bdd898704aca4a2697c7da</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402189%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYap%26aufirst%3DJ.%2BL.%26aulast%3DSabato%26aufirst%3DP.%2BE.%26aulast%3DHu%26aufirst%3DA.%26aulast%3DProchownik%26aufirst%3DE.%2BV.%26aulast%3DFletcher%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520methyl%25204%25E2%2580%25B2-methyl-5-%25287-nitrobenzo%255Bc%255D%255B1%252C2%252C5%255Doxadiazol-4-yl%2529-%255B1%252C1%25E2%2580%25B2-biphenyl%255D-3-carboxylate%252C%2520an%2520improved%2520small-molecule%2520inhibitor%2520of%2520c-Myc-max%2520dimerization%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26issue%3D10%26spage%3D2274%26epage%3D2285%26doi%3D10.1002%2Fcmdc.201402189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruick, R. K.</span>; <span class="NLM_string-name">Caldwell, C. G.</span>; <span class="NLM_string-name">Frantz, D. E.</span>; <span class="NLM_string-name">Gardner, K. H.</span>; <span class="NLM_string-name">MacMillan, J. B.</span>; <span class="NLM_string-name">Scheuermann, T. H.</span>; <span class="NLM_string-name">Tambar, U. K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of HIF-2Î± Heterodimerization With HIF1Î² (ARNT)</span>. <span class="NLM_patent">WO2014078479A2</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=R.+K.+Bruick&author=C.+G.+Caldwell&author=D.+E.+Frantz&author=K.+H.+Gardner&author=J.+B.+MacMillan&author=T.+H.+Scheuermann&author=U.+K.+Tambar&title=Inhibition+of+HIF-2%CE%B1+Heterodimerization+With+HIF1%CE%B2+%28ARNT%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBruick%26aufirst%3DR.%2BK.%26atitle%3DInhibition%2520of%2520HIF-2%25CE%25B1%2520Heterodimerization%2520With%2520HIF1%25CE%25B2%2520%2528ARNT%2529%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayeh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheuermann, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longgood, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Key, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naidoo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melito, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frantz, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruick, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacMillan, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tambar, U. K.</span></span> <span> </span><span class="NLM_article-title">Development of inhibitors of the PAS-B domain of the HIF-2alpha transcription factor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1739</span>â <span class="NLM_lpage">1747</span>, <span class="refDoi">Â DOI: 10.1021/jm301847z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301847z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVCjsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1739-1747&issue=4&author=J.+L.+Rogersauthor=L.+Bayehauthor=T.+H.+Scheuermannauthor=J.+Longgoodauthor=J.+Keyauthor=J.+Naidooauthor=L.+Melitoauthor=C.+Shokriauthor=D.+E.+Frantzauthor=R.+K.+Bruickauthor=K.+H.+Gardnerauthor=J.+B.+MacMillanauthor=U.+K.+Tambar&title=Development+of+inhibitors+of+the+PAS-B+domain+of+the+HIF-2alpha+transcription+factor&doi=10.1021%2Fjm301847z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Inhibitors of the PAS-B Domain of the HIF-2Î± Transcription Factor</span></div><div class="casAuthors">Rogers, Jamie L.; Bayeh, Liela; Scheuermann, Thomas H.; Longgood, Jamie; Key, Jason; Naidoo, Jacinth; Melito, Lisa; Shokri, Cameron; Frantz, Doug E.; Bruick, Richard K.; Gardner, Kevin H.; MacMillan, John B.; Tambar, Uttam K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1739-1747</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hypoxia inducible factors (HIFs) are heterodimeric transcription factors induced in a variety of pathophysiol. settings, including cancer.  The first detailed structure-activity relationship study of small mols. designed to inhibit HIF-2Î±-ARNT heterodimerization by binding an internal cavity of the HIF-2Î± PAS-B domain is described herein.  A series of benzoxadiazole derivs. was synthesized and evaluated for their inhibitory activity.  Through a series of biophys. characterizations of inhibitor-protein interactions [NMR and X-ray crystallog. for compds. I (R = H or Cl)], the structural requirements for artificial inhibitors of the HIF-2Î±-ARNT PAS-B interaction have been established.  These results may serve as a foundation for discovering therapeutic agents that function by a novel mode of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUwOF6FlDBrLVg90H21EOLACvtfcHk0lggSySk-MuViA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVCjsrs%253D&md5=03a967dcc64865633544f0973c806edc</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1021%2Fjm301847z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301847z%26sid%3Dliteratum%253Aachs%26aulast%3DRogers%26aufirst%3DJ.%2BL.%26aulast%3DBayeh%26aufirst%3DL.%26aulast%3DScheuermann%26aufirst%3DT.%2BH.%26aulast%3DLonggood%26aufirst%3DJ.%26aulast%3DKey%26aufirst%3DJ.%26aulast%3DNaidoo%26aufirst%3DJ.%26aulast%3DMelito%26aufirst%3DL.%26aulast%3DShokri%26aufirst%3DC.%26aulast%3DFrantz%26aufirst%3DD.%2BE.%26aulast%3DBruick%26aufirst%3DR.%2BK.%26aulast%3DGardner%26aufirst%3DK.%2BH.%26aulast%3DMacMillan%26aufirst%3DJ.%2BB.%26aulast%3DTambar%26aufirst%3DU.%2BK.%26atitle%3DDevelopment%2520of%2520inhibitors%2520of%2520the%2520PAS-B%2520domain%2520of%2520the%2520HIF-2alpha%2520transcription%2520factor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D4%26spage%3D1739%26epage%3D1747%26doi%3D10.1021%2Fjm301847z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheuermann, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Key, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naidoo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longgood, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frantz, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tambar, U. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruick, R. K.</span></span> <span> </span><span class="NLM_article-title">Allosteric inhibition of hypoxia inducible factor-2 with small molecules</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">271</span>â <span class="NLM_lpage">276</span>, <span class="refDoi">Â DOI: 10.1038/nchembio.1185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2Fnchembio.1185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=23434853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivFygtLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=271-276&issue=4&author=T.+H.+Scheuermannauthor=Q.+Liauthor=H.+W.+Maauthor=J.+Keyauthor=L.+Zhangauthor=R.+Chenauthor=J.+A.+Garciaauthor=J.+Naidooauthor=J.+Longgoodauthor=D.+E.+Frantzauthor=U.+K.+Tambarauthor=K.+H.+Gardnerauthor=R.+K.+Bruick&title=Allosteric+inhibition+of+hypoxia+inducible+factor-2+with+small+molecules&doi=10.1038%2Fnchembio.1185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibition of hypoxia inducible factor-2 with small molecules</span></div><div class="casAuthors">Scheuermann, Thomas H.; Li, Qiming; Ma, He-Wen; Key, Jason; Zhang, Lei; Chen, Rui; Garcia, Joseph A.; Naidoo, Jacinth; Longgood, Jamie; Frantz, Doug E.; Tambar, Uttam K.; Gardner, Kevin H.; Bruick, Richard K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">271-276</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hypoxia inducible factors (HIFs) are heterodimeric transcription factors induced in many cancers where they frequently promote the expression of protumorigenic pathways.  Though transcription factors are typically considered 'undruggable', the PAS-B domain of the HIF-2Î± subunit contains a large cavity within its hydrophobic core that offers a unique foothold for small-mol. regulation.  Here we identify artificial ligands that bind within this pocket and characterize the resulting structural and functional changes caused by binding.  Notably, these ligands antagonize HIF-2 heterodimerization and DNA-binding activity in vitro and in cultured cells, reducing HIF-2 target gene expression.  Despite the high sequence identity between HIF-2Î± and HIF-1Î±, these ligands are highly selective and do not affect HIF-1 function.  These chem. tools establish the mol. basis for selective regulation of HIF-2, providing potential therapeutic opportunities to intervene in HIF-2-driven tumors, such as renal cell carcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBimby6zSuR7Vg90H21EOLACvtfcHk0lggSySk-MuViA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivFygtLc%253D&md5=e2e58842b3fe6472248c10012de365fb</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1185%26sid%3Dliteratum%253Aachs%26aulast%3DScheuermann%26aufirst%3DT.%2BH.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DH.%2BW.%26aulast%3DKey%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DGarcia%26aufirst%3DJ.%2BA.%26aulast%3DNaidoo%26aufirst%3DJ.%26aulast%3DLonggood%26aufirst%3DJ.%26aulast%3DFrantz%26aufirst%3DD.%2BE.%26aulast%3DTambar%26aufirst%3DU.%2BK.%26aulast%3DGardner%26aufirst%3DK.%2BH.%26aulast%3DBruick%26aufirst%3DR.%2BK.%26atitle%3DAllosteric%2520inhibition%2520of%2520hypoxia%2520inducible%2520factor-2%2520with%2520small%2520molecules%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26issue%3D4%26spage%3D271%26epage%3D276%26doi%3D10.1038%2Fnchembio.1185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wehn, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grina, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlachter, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czerwinski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goggin, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halfmann, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddie, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olive, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, E. M.</span></span> <span> </span><span class="NLM_article-title">Design and activity of specific hypoxia-inducible factor-2Î± (HIF-2Î±) inhibitors for the treatment of clear cell renal cell carcinoma: Discovery of clinical candidate (S)-3-((2,2-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1<i>H</i>-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">9691</span>â <span class="NLM_lpage">9721</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b01196</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01196" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKqt7%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9691-9721&issue=21&author=P.+M.+Wehnauthor=J.+P.+Rizziauthor=D.+D.+Dixonauthor=J.+A.+Grinaauthor=S.+T.+Schlachterauthor=B.+Wangauthor=R.+Xuauthor=H.+Yangauthor=X.+Duauthor=G.+Hanauthor=K.+Wangauthor=Z.+Caoauthor=T.+Chengauthor=R.+M.+Czerwinskiauthor=B.+S.+Gogginauthor=H.+Huangauthor=M.+M.+Halfmannauthor=M.+A.+Maddieauthor=E.+L.+Mortonauthor=S.+R.+Oliveauthor=H.+Tanauthor=S.+Xieauthor=T.+Wongauthor=J.+A.+Joseyauthor=E.+M.+Wallace&title=Design+and+activity+of+specific+hypoxia-inducible+factor-2%CE%B1+%28HIF-2%CE%B1%29+inhibitors+for+the+treatment+of+clear+cell+renal+cell+carcinoma%3A+Discovery+of+clinical+candidate+%28S%29-3-%28%282%2C2-difluoro-1-hydroxy-7-%28methylsulfonyl%29-2%2C3-dihydro-1H-inden-4-yl%29oxy%29-5-fluorobenzonitrile+%28PT2385%29&doi=10.1021%2Facs.jmedchem.8b01196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Activity of Specific Hypoxia-Inducible Factor-2Î± (HIF-2Î±) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385)</span></div><div class="casAuthors">Wehn, Paul M.; Rizzi, James P.; Dixon, Darryl D.; Grina, Jonas A.; Schlachter, Stephen T.; Wang, Bin; Xu, Rui; Yang, Hanbiao; Du, Xinlin; Han, Guangzhou; Wang, Keshi; Cao, Zhaodan; Cheng, Tzuling; Czerwinski, Robert M.; Goggin, Barry S.; Huang, Heli; Halfmann, Megan M.; Maddie, Melissa A.; Morton, Emily L.; Olive, Sarah R.; Tan, Huiling; Xie, Shanhai; Wong, Tai; Josey, John A.; Wallace, Eli M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9691-9721</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HIF-2Î±, a member of the HIF family of transcription factors, is a key oncogenic driver in cancers such as clear cell renal cell carcinoma (ccRCC).  A signature feature of these cancers is the overaccumulation of HIF-2Î± protein, often by inactivation of the E3 ligase VHL (von Hippel-Lindau).  Herein the authors disclose their structure based drug design (SBDD) approach that culminated in the identification of PT2385, the first HIF-2Î± antagonist to enter clin. trials.  Highlights include the use of a putative n â Ï*Ar interaction to guide early analog design, the conformational restriction of an essential hydroxyl moiety, and the remarkable impact of fluorination near the hydroxyl group.  Evaluation of select compds. from two structural classes in a sequence of PK/PD, efficacy, PK, and metabolite profiling identified I (PT2385, luciferase EC50 = 27 nM) as the clin. candidate.  Finally, a retrospective crystallog. anal. describes the structural perturbations necessary for efficient antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwG1t-5Van7rVg90H21EOLACvtfcHk0lhcCrXXedGDfQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKqt7%252FN&md5=fcbb754286f47e1b1df3edb62bd2381e</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01196%26sid%3Dliteratum%253Aachs%26aulast%3DWehn%26aufirst%3DP.%2BM.%26aulast%3DRizzi%26aufirst%3DJ.%2BP.%26aulast%3DDixon%26aufirst%3DD.%2BD.%26aulast%3DGrina%26aufirst%3DJ.%2BA.%26aulast%3DSchlachter%26aufirst%3DS.%2BT.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DHan%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DT.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DGoggin%26aufirst%3DB.%2BS.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DHalfmann%26aufirst%3DM.%2BM.%26aulast%3DMaddie%26aufirst%3DM.%2BA.%26aulast%3DMorton%26aufirst%3DE.%2BL.%26aulast%3DOlive%26aufirst%3DS.%2BR.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DT.%26aulast%3DJosey%26aufirst%3DJ.%2BA.%26aulast%3DWallace%26aufirst%3DE.%2BM.%26atitle%3DDesign%2520and%2520activity%2520of%2520specific%2520hypoxia-inducible%2520factor-2%25CE%25B1%2520%2528HIF-2%25CE%25B1%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520clear%2520cell%2520renal%2520cell%2520carcinoma%253A%2520Discovery%2520of%2520clinical%2520candidate%2520%2528S%2529-3-%2528%25282%252C2-difluoro-1-hydroxy-7-%2528methylsulfonyl%2529-2%252C3-dihydro-1H-inden-4-yl%2529oxy%2529-5-fluorobenzonitrile%2520%2528PT2385%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D21%26spage%3D9691%26epage%3D9721%26doi%3D10.1021%2Facs.jmedchem.8b01196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grina, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlachter, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehn, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czerwinski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ged, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, E. M.</span></span> <span> </span><span class="NLM_article-title">3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzo nitrile (PT2977), a hypoxia-inducible factor 2alpha (HIF-2alpha) inhibitor for the treatment of clear cell renal cell carcinoma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6876</span>â <span class="NLM_lpage">6893</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b00719</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00719" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1ensL%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6876-6893&issue=15&author=R.+Xuauthor=K.+Wangauthor=J.+P.+Rizziauthor=H.+Huangauthor=J.+A.+Grinaauthor=S.+T.+Schlachterauthor=B.+Wangauthor=P.+M.+Wehnauthor=H.+Yangauthor=D.+D.+Dixonauthor=R.+M.+Czerwinskiauthor=X.+Duauthor=E.+L.+Gedauthor=G.+Hanauthor=H.+Tanauthor=T.+Wongauthor=S.+Xieauthor=J.+A.+Joseyauthor=E.+M.+Wallace&title=3-%5B%281S%2C2S%2C3R%29-2%2C3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl%5Doxy-5-fluorobenzo+nitrile+%28PT2977%29%2C+a+hypoxia-inducible+factor+2alpha+%28HIF-2alpha%29+inhibitor+for+the+treatment+of+clear+cell+renal+cell+carcinoma&doi=10.1021%2Facs.jmedchem.9b00719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2Î± (HIF-2Î±) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma</span></div><div class="casAuthors">Xu, Rui; Wang, Keshi; Rizzi, James P.; Huang, Heli; Grina, Jonas A.; Schlachter, Stephen T.; Wang, Bin; Wehn, Paul M.; Yang, Hanbiao; Dixon, Darryl D.; Czerwinski, Robert M.; Du, Xinlin; Ged, Emily L.; Han, Guangzhou; Tan, Huiling; Wong, Tai; Xie, Shanhai; Josey, John A.; Wallace, Eli M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6876-6893</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The hypoxia-inducible factor 2Î± (HIF-2Î±) is a key oncogenic driver in clear cell renal cell carcinoma (ccRCC).  Our first HIF-2Î± inhibitor PT2385 demonstrated promising proof of concept clin. activity in heavily pretreated advanced ccRCC patients.  However, PT2385 was restricted by variable and dose-limited pharmacokinetics resulting from extensive metab. of PT2385 to its glucuronide metabolite.  Herein we describe the discovery of second-generation HIF-2Î± inhibitor PT2977 with increased potency and improved pharmacokinetic profile achieved by redn. of phase 2 metab.  Structural modification by changing the geminal difluoro group in PT2385 to a vicinal difluoro group resulted in enhanced potency, decreased lipophilicity, and significantly improved pharmacokinetic properties.  In a phase 1 dose-escalation study, the clin. pharmacokinetics for PT2977 supports the hypothesis that attenuating the rate of glucuronidation would improve exposure and reduce variability in patients.  Early evidence of clin. activity shows promise for PT2977 in the treatment of ccRCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOUK3HAjMQC7Vg90H21EOLACvtfcHk0lhcCrXXedGDfQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1ensL%252FN&md5=ec1f0a964e0fda36f92261c30edf284e</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00719%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DRizzi%26aufirst%3DJ.%2BP.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DGrina%26aufirst%3DJ.%2BA.%26aulast%3DSchlachter%26aufirst%3DS.%2BT.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWehn%26aufirst%3DP.%2BM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DDixon%26aufirst%3DD.%2BD.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DGed%26aufirst%3DE.%2BL.%26aulast%3DHan%26aufirst%3DG.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DS.%26aulast%3DJosey%26aufirst%3DJ.%2BA.%26aulast%3DWallace%26aufirst%3DE.%2BM.%26atitle%3D3-%255B%25281S%252C2S%252C3R%2529-2%252C3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl%255Doxy-5-fluorobenzo%2520nitrile%2520%2528PT2977%2529%252C%2520a%2520hypoxia-inducible%2520factor%25202alpha%2520%2528HIF-2alpha%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520clear%2520cell%2520renal%2520cell%2520carcinoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D15%26spage%3D6876%26epage%3D6893%26doi%3D10.1021%2Facs.jmedchem.9b00719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malachowski, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuHadaway, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of IDO1 inhibitors: From bench to bedside</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">6795</span>â <span class="NLM_lpage">6811</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-17-2285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1158%2F0008-5472.CAN-17-2285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=29247038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOgur3P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=6795-6811&issue=24&author=G.+C.+Prendergastauthor=W.+P.+Malachowskiauthor=J.+B.+DuHadawayauthor=A.+J.+Muller&title=Discovery+of+IDO1+inhibitors%3A+From+bench+to+bedside&doi=10.1158%2F0008-5472.CAN-17-2285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of IDO1 Inhibitors: From Bench to Bedside</span></div><div class="casAuthors">Prendergast, George C.; Malachowski, William P.; Du Hadaway, James B.; Muller, Alexander J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6795-6811</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Small-mol. inhibitors of indoleamine 2,3-dioxygenase-1 (IDO1) are emerging at the vanguard of exptl. agents in oncol.  Here, pioneers of this new drug class provide a bench-to-bedside review on preclin. validation of IDO1 as a cancer therapeutic target and on the discovery and development of a set of mechanistically distinct compds., indoximod, epacadostat, and navoximod, that were first to be evaluated as IDO inhibitors in clin. trials.  As immunometabolic adjuvants to widen therapeutic windows, IDO inhibitors may leverage not only immuno-oncol. modalities but also chemotherapy and radiotherapy as stds. of care in the oncol. clinic.  Cancer Res; 77(24); 6795-811. Â©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogb24W39wzLLVg90H21EOLACvtfcHk0ljvFPWHZ_MBxA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOgur3P&md5=78c80872b9a4dd4db6621645196291d9</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-2285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-2285%26sid%3Dliteratum%253Aachs%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26aulast%3DMalachowski%26aufirst%3DW.%2BP.%26aulast%3DDuHadaway%26aufirst%3DJ.%2BB.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26atitle%3DDiscovery%2520of%2520IDO1%2520inhibitors%253A%2520From%2520bench%2520to%2520bedside%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D24%26spage%3D6795%26epage%3D6811%26doi%3D10.1158%2F0008-5472.CAN-17-2285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayland, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bower, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leffet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansbury, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">7364</span>â <span class="NLM_lpage">7367</span>, <span class="refDoi">Â DOI: 10.1021/jm900518f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900518f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVSksb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7364-7367&issue=23&author=E.+W.+Yueauthor=B.+Doutyauthor=B.+Waylandauthor=M.+Bowerauthor=X.+Liuauthor=L.+Leffetauthor=Q.+Wangauthor=K.+J.+Bowmanauthor=M.+J.+Hansburyauthor=C.+Liuauthor=M.+Weiauthor=Y.+Liauthor=R.+Wynnauthor=T.+C.+Burnauthor=H.+K.+Koblishauthor=J.+S.+Fridmanauthor=B.+Metcalfauthor=P.+A.+Scherleauthor=A.+P.+Combs&title=Discovery+of+potent+competitive+inhibitors+of+indoleamine+2%2C3-dioxygenase+with+in+vivo+pharmacodynamic+activity+and+efficacy+in+a+mouse+melanoma+model&doi=10.1021%2Fjm900518f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model</span></div><div class="casAuthors">Yue, Eddy W.; Douty, Brent; Wayland, Brian; Bower, Michael; Liu, Xiangdong; Leffet, Lynn; Wang, Qian; Bowman, Kevin J.; Hansbury, Michael J.; Liu, Changnian; Wei, Min; Li, Yanlong; Wynn, Richard; Burn, Timothy C.; Koblish, Holly K.; Fridman, Jordan S.; Metcalf, Brian; Scherle, Peggy A.; Combs, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7364-7367</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A hydroxyamidine chemotype has been discovered as a key pharmacophore in novel inhibitors of indoleamine 2,3-dioxygenase (IDO).  Optimization led to the identification of (I), which is a potent (HeLa IC50 = 19 nM) competitive inhibitor of IDO.  Testing of I in mice demonstrated pharmacodynamic inhibition of IDO, as measured by decreased kynurenine levels (>50%) in plasma and dose dependent efficacy in mice bearing GM-CSF-secreting B16 melanoma tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZsq88hx0J77Vg90H21EOLACvtfcHk0ljvFPWHZ_MBxA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVSksb8%253D&md5=328d92bffb88a86da030c31eff707dc6</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1021%2Fjm900518f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900518f%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DE.%2BW.%26aulast%3DDouty%26aufirst%3DB.%26aulast%3DWayland%26aufirst%3DB.%26aulast%3DBower%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLeffet%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DBowman%26aufirst%3DK.%2BJ.%26aulast%3DHansbury%26aufirst%3DM.%2BJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWynn%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DKoblish%26aufirst%3DH.%2BK.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DDiscovery%2520of%2520potent%2520competitive%2520inhibitors%2520of%2520indoleamine%25202%252C3-dioxygenase%2520with%2520in%2520vivo%2520pharmacodynamic%2520activity%2520and%2520efficacy%2520in%2520a%2520mouse%2520melanoma%2520model%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D23%26spage%3D7364%26epage%3D7367%26doi%3D10.1021%2Fjm900518f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayland, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takvorian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glenn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bower, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leffet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansbury, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span></span> <span> </span><span class="NLM_article-title">INCB24360 (epacadostat), a highly potent and selective indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor for immuno-oncology</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">486</span>â <span class="NLM_lpage">491</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.6b00391</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00391" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Gqsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=486-491&issue=5&author=E.+W.+Yueauthor=R.+Sparksauthor=P.+Polamauthor=D.+Modiauthor=B.+Doutyauthor=B.+Waylandauthor=B.+Glassauthor=A.+Takvorianauthor=J.+Glennauthor=W.+Zhuauthor=M.+Bowerauthor=X.+Liuauthor=L.+Leffetauthor=Q.+Wangauthor=K.+J.+Bowmanauthor=M.+J.+Hansburyauthor=M.+Weiauthor=Y.+Liauthor=R.+Wynnauthor=T.+C.+Burnauthor=H.+K.+Koblishauthor=J.+S.+Fridmanauthor=T.+Emmauthor=P.+A.+Scherleauthor=B.+Metcalfauthor=A.+P.+Combs&title=INCB24360+%28epacadostat%29%2C+a+highly+potent+and+selective+indoleamine-2%2C3-dioxygenase+1+%28IDO1%29+inhibitor+for+immuno-oncology&doi=10.1021%2Facsmedchemlett.6b00391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology</span></div><div class="casAuthors">Yue, Eddy W.; Sparks, Richard; Polam, Padmaja; Modi, Dilip; Douty, Brent; Wayland, Brian; Glass, Brian; Takvorian, Amy; Glenn, Joseph; Zhu, Wenyu; Bower, Michael; Liu, Xiangdong; Leffet, Lynn; Wang, Qian; Bowman, Kevin J.; Hansbury, Michael J.; Wei, Min; Li, Yanlong; Wynn, Richard; Burn, Timothy C.; Koblish, Holly K.; Fridman, Jordan S.; Emm, Tom; Scherle, Peggy A.; Metcalf, Brian; Combs, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">486-491</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A data-centric medicinal chem. approach led to the invention of a potent and selective IDO1 inhibitor 4f, INCB24360 (epacadostat).  The mol. structure of INCB24360 contains several previously unknown or underutilized functional groups in drug substances, including a hydroxyamidine, furazan, bromide and sulfamide.  These moieties taken together in a single structure afford a compd. which falls outside of "drug-like" space.  Nevertheless, the in vitro ADME data is consistent with the good cell permeability and oral bioavailability obsd. in all species (rat, dog, monkey) tested.  The extensive intramol. hydrogen bonding obsd. in the small mol. crystal structure of 4f is believed to significantly contribute to the obsd. permeability and PK.  Epacadostat in combination with anti-PD1 mAb pembrolizumab is currently being studied in a phase 3 clin. trial in patients with unresectable or metastatic melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpm79ArpY1yLVg90H21EOLACvtfcHk0ljvFPWHZ_MBxA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Gqsb0%253D&md5=92bebde519334e9e2a776250bb0258ac</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00391%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DE.%2BW.%26aulast%3DSparks%26aufirst%3DR.%26aulast%3DPolam%26aufirst%3DP.%26aulast%3DModi%26aufirst%3DD.%26aulast%3DDouty%26aufirst%3DB.%26aulast%3DWayland%26aufirst%3DB.%26aulast%3DGlass%26aufirst%3DB.%26aulast%3DTakvorian%26aufirst%3DA.%26aulast%3DGlenn%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DBower%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLeffet%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DBowman%26aufirst%3DK.%2BJ.%26aulast%3DHansbury%26aufirst%3DM.%2BJ.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWynn%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DKoblish%26aufirst%3DH.%2BK.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DEmm%26aufirst%3DT.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DINCB24360%2520%2528epacadostat%2529%252C%2520a%2520highly%2520potent%2520and%2520selective%2520indoleamine-2%252C3-dioxygenase%25201%2520%2528IDO1%2529%2520inhibitor%2520for%2520immuno-oncology%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D5%26spage%3D486%26epage%3D491%26doi%3D10.1021%2Facsmedchemlett.6b00391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span>; <span class="NLM_string-name">Yue, E. W.</span></span> <span> </span><span class="NLM_article-title">Preparation of 4-Amino-Nâ²-hydroxy-1,2,5-oxadiazole-3-carboximidamides and Related Compounds as Modulators of Indoleamine 2,3-Dioxygenase for Inhibiting Immunosuppression and Treating Various Disorders</span>. <span class="NLM_patent">WO2006122150A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=A.+P.+Combs&author=E.+W.+Yue&title=Preparation+of+4-Amino-N%E2%80%B2-hydroxy-1%2C2%2C5-oxadiazole-3-carboximidamides+and+Related+Compounds+as+Modulators+of+Indoleamine+2%2C3-Dioxygenase+for+Inhibiting+Immunosuppression+and+Treating+Various+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DPreparation%2520of%25204-Amino-N%25E2%2580%25B2-hydroxy-1%252C2%252C5-oxadiazole-3-carboximidamides%2520and%2520Related%2520Compounds%2520as%2520Modulators%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520for%2520Inhibiting%2520Immunosuppression%2520and%2520Treating%2520Various%2520Disorders%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span>; <span class="NLM_string-name">Yue, E. W.</span>; <span class="NLM_string-name">Sparks, R. B.</span>; <span class="NLM_string-name">Zhu, W.</span>; <span class="NLM_string-name">Zhou, J.</span>; <span class="NLM_string-name">Lin, Q.</span>; <span class="NLM_string-name">Weng, L.</span>; <span class="NLM_string-name">Yue, T.-Y.</span>; <span class="NLM_string-name">Liu, P.</span></span> <span> </span><span class="NLM_article-title">Preparation of 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase</span>. <span class="NLM_patent">WO2010005958A2</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=A.+P.+Combs&author=E.+W.+Yue&author=R.+B.+Sparks&author=W.+Zhu&author=J.+Zhou&author=Q.+Lin&author=L.+Weng&author=T.-Y.+Yue&author=P.+Liu&title=Preparation+of+1%2C2%2C5-Oxadiazoles+as+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DPreparation%2520of%25201%252C2%252C5-Oxadiazoles%2520as%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span>; <span class="NLM_string-name">Yue, E. W.</span></span> <span> </span><span class="NLM_article-title">Preparation of Azole-amidines as Modulators of Indoleamine 2,3-Dioxygenase</span>. <span class="NLM_patent">WO2008036652A2</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=A.+P.+Combs&author=E.+W.+Yue&title=Preparation+of+Azole-amidines+as+Modulators+of+Indoleamine+2%2C3-Dioxygenase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DPreparation%2520of%2520Azole-amidines%2520as%2520Modulators%2520of%2520Indoleamine%25202%252C3-Dioxygenase%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span></span> <span> </span><span class="NLM_article-title">Preparation of Amidinoheterocycles as Modulators of Indoleamine 2,3-Dioxygenases</span>. <span class="NLM_patent">WO2008036643A2</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Combs%2C+A.+P.+Preparation+of+Amidinoheterocycles+as+Modulators+of+Indoleamine+2%2C3-Dioxygenases.+WO2008036643A2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DPreparation%2520of%2520Amidinoheterocycles%2520as%2520Modulators%2520of%2520Indoleamine%25202%252C3-Dioxygenases" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jochems, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernando, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwilas, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donahue, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepone, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenga, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heery, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brechbiel, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madan, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, R.</span></span> <span> </span><span class="NLM_article-title">The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">37762</span>â <span class="NLM_lpage">37772</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.9326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.18632%2Foncotarget.9326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=27192116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FgsVGntw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=37762-37772&issue=25&author=C.+Jochemsauthor=M.+Fantiniauthor=R.+I.+Fernandoauthor=A.+R.+Kwilasauthor=R.+N.+Donahueauthor=L.+M.+Leponeauthor=I.+Grengaauthor=C.+R.+Heeryauthor=J.+W.+Hodgeauthor=J.+Schlomauthor=K.+Y.+Tsangauthor=Y.-S.+Kimauthor=M.+W.+Brechbielauthor=J.+L.+Gulleyauthor=R.+A.+Madanauthor=R.+Newton&title=The+IDO1+selective+inhibitor+epacadostat+enhances+dendritic+cell+immunogenicity+and+lytic+ability+of+tumor+antigen-specific+T+cells&doi=10.18632%2Foncotarget.9326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells</span></div><div class="casAuthors">Jochems Caroline; Fantini Massimo; Fernando Romaine I; Kwilas Anna R; Donahue Renee N; Lepone Lauren M; Grenga Italia; Heery Christopher R; Hodge James W; Schlom Jeffrey; Tsang Kwong Y; Kim Young-Seung; Brechbiel Martin W; Gulley James L; Madan Ravi A; Newton Robert</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">37762-37772</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epacadostat is a novel inhibitor of indoleamine-2,3-dioxygenase-1 (IDO1) that suppresses systemic tryptophan catabolism and is currently being evaluated in ongoing clinical trials.  We investigated the effects of epacadostat on (a) human dendritic cells (DCs) with respect to maturation and ability to activate human tumor antigen-specific cytotoxic T-cell (CTL) lines, and subsequent T-cell lysis of tumor cells, (b) human regulatory T cells (Tregs), and (c) human peripheral blood mononuclear cells (PBMCs) in vitro.  Simultaneous treatment with epacadostat and IFN-Î³ plus lipopolysaccharide (LPS) did not change the phenotype of matured human DCs, and as expected decreased the tryptophan breakdown and kynurenine production.  Peptide-specific T-cell lines stimulated with DCs pulsed with peptide produced significantly more IFN-Î³, TNFÎ±, GM-CSF and IL-8 if the DCs were treated with epacadostat.  These T cells also displayed higher levels of tumor cell lysis on a per cell basis.  Epacadostat also significantly decreased Treg proliferation induced by IDO production from IFN-Î³ plus LPS matured human DCs, although the Treg phenotype did not change.  Multicolor flow cytometry was performed on human PBMCs treated with epacadostat; analysis of 123 discrete immune cell subsets revealed no changes in major immune cell types, an increase in activated CD83+ conventional DCs, and a decrease in immature activated Tim3+ NK cells.  These studies show for the first time several effects of epacadostat on human DCs, and subsequent effects on CTL and Tregs, and provide a rationale as to how epacadostat could potentially increase the efficacy of immunotherapeutics, including cancer vaccines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6d9vu8-NFF4IRAdBLKY41fW6udTcc2eYLtsSMtvWDyrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FgsVGntw%253D%253D&md5=5a4ae654278a48cf45a8a234d4ee8343</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.9326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.9326%26sid%3Dliteratum%253Aachs%26aulast%3DJochems%26aufirst%3DC.%26aulast%3DFantini%26aufirst%3DM.%26aulast%3DFernando%26aufirst%3DR.%2BI.%26aulast%3DKwilas%26aufirst%3DA.%2BR.%26aulast%3DDonahue%26aufirst%3DR.%2BN.%26aulast%3DLepone%26aufirst%3DL.%2BM.%26aulast%3DGrenga%26aufirst%3DI.%26aulast%3DHeery%26aufirst%3DC.%2BR.%26aulast%3DHodge%26aufirst%3DJ.%2BW.%26aulast%3DSchlom%26aufirst%3DJ.%26aulast%3DTsang%26aufirst%3DK.%2BY.%26aulast%3DKim%26aufirst%3DY.-S.%26aulast%3DBrechbiel%26aufirst%3DM.%2BW.%26aulast%3DGulley%26aufirst%3DJ.%2BL.%26aulast%3DMadan%26aufirst%3DR.%2BA.%26aulast%3DNewton%26aufirst%3DR.%26atitle%3DThe%2520IDO1%2520selective%2520inhibitor%2520epacadostat%2520enhances%2520dendritic%2520cell%2520immunogenicity%2520and%2520lytic%2520ability%2520of%2520tumor%2520antigen-specific%2520T%2520cells%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D25%26spage%3D37762%26epage%3D37772%26doi%3D10.18632%2Foncotarget.9326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gibney, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutzky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olszanski, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajewski, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanks, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maleski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J. S.</span></span> <span> </span><span class="NLM_article-title">Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma</span>. <i>J. Immunother. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">80</span>, <span class="refDoi">Â DOI: 10.1186/s40425-019-0562-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1186%2Fs40425-019-0562-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=30894212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BB3cbmsVSmtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=80&issue=1&author=G.+T.+Gibneyauthor=O.+Hamidauthor=J.+Lutzkyauthor=A.+J.+Olszanskiauthor=T.+C.+Mitchellauthor=T.+F.+Gajewskiauthor=B.+Chmielowskiauthor=B.+A.+Hanksauthor=Y.+Zhaoauthor=R.+C.+Newtonauthor=J.+Maleskiauthor=L.+Leopoldauthor=J.+S.+Weber&title=Phase+1%2F2+study+of+epacadostat+in+combination+with+ipilimumab+in+patients+with+unresectable+or+metastatic+melanoma&doi=10.1186%2Fs40425-019-0562-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma</span></div><div class="casAuthors">Gibney Geoffrey T; Weber Jeffrey S; Gibney Geoffrey T; Hamid Omid; Lutzky Jose; Olszanski Anthony J; Mitchell Tara C; Gajewski Thomas F; Chmielowski Bartosz; Hanks Brent A; Zhao Yufan; Newton Robert C; Maleski Janet; Leopold Lance; Weber Jeffrey S</div><div class="citationInfo"><span class="NLM_cas:title">Journal for immunotherapy of cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) enzyme.  We present phase 1 results from a phase 1/2 clinical study of epacadostat in combination with ipilimumab, an anti-cytotoxic T-lymphocyte-associated protein 4 antibody, in advanced melanoma (NCT01604889).  METHODS:  Only the phase 1, open-label portion of the study was conducted, per the sponsor's decision to terminate the study early based on the changing melanoma treatment landscape favoring exploration of programmed cell death protein 1 (PD-1)/PD-ligand 1 inhibitor-based combination strategies.  Such decision was not related to the safety of epacadostat plus ipilimumab.  Patients received oral epacadostat (25, 50, 100, or 300 mg twice daily [BID]; 75 mg daily [50 mg AM, 25 mg PM]; or 50 mg BID intermittent [2 weeks on/1 week off]) plus intravenous ipilimumab 3 mg/kg every 3 weeks.  RESULTS:  Fifty patients received â¥1 dose of epacadostat.  As of January 20, 2017, 2 patients completed treatment and 48 discontinued, primarily because of adverse events (AEs) and disease progression (n = 20 each).  Dose-limiting toxicities occurred in 11 patients (n = 1 each with epacadostat 25 mg BID, 50 mg BID intermittent, 75 mg daily; n = 4 each with epacadostat 50 mg BID, 300 mg BID).  The most common immune-related treatment-emergent AEs included rash (50%), alanine aminotransferase elevation (28%), pruritus (28%), aspartate aminotransferase elevation (24%), and hypothyroidism (10%).  Among immunotherapy-naive patients (n = 39), the objective response rate was 26% by immune-related response criteria and 23% by Response Evaluation Criteria in Solid Tumors version 1.1.  No objective response was seen in the 11 patients who received prior immunotherapy.  Epacadostat exposure was dose proportional, with clinically significant IDO1 inhibition at doses â¥25 mg BID.  CONCLUSIONS:  When combined with ipilimumab, epacadostat â¤50 mg BID demonstrated clinical and pharmacologic activity and was generally well tolerated in patients with advanced melanoma.  TRIAL REGISTRATION:  ClinicalTrials.gov identifier, NCT01604889 .  Registration date, May 9, 2012, retrospectively registered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQpZW4VHEUQl-RS7coPn-RtfW6udTcc2eYLtsSMtvWDyrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbmsVSmtg%253D%253D&md5=7bc5d59472fe8fa1865f68769cb6a176</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1186%2Fs40425-019-0562-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40425-019-0562-8%26sid%3Dliteratum%253Aachs%26aulast%3DGibney%26aufirst%3DG.%2BT.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DLutzky%26aufirst%3DJ.%26aulast%3DOlszanski%26aufirst%3DA.%2BJ.%26aulast%3DMitchell%26aufirst%3DT.%2BC.%26aulast%3DGajewski%26aufirst%3DT.%2BF.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DHanks%26aufirst%3DB.%2BA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DMaleski%26aufirst%3DJ.%26aulast%3DLeopold%26aufirst%3DL.%26aulast%3DWeber%26aufirst%3DJ.%2BS.%26atitle%3DPhase%25201%252F2%2520study%2520of%2520epacadostat%2520in%2520combination%2520with%2520ipilimumab%2520in%2520patients%2520with%2520unresectable%2520or%2520metastatic%2520melanoma%26jtitle%3DJ.%2520Immunother.%2520Cancer%26date%3D2019%26volume%3D7%26issue%3D1%26spage%3D80%26doi%3D10.1186%2Fs40425-019-0562-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasser, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olszanski, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luke, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balmanoukian, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maleski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajewski, T. F.</span></span> <span> </span><span class="NLM_article-title">Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">32</span>),  <span class="NLM_fpage">3223</span>â <span class="NLM_lpage">3230</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2018.78.9602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1200%2FJCO.2018.78.9602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=30265610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvFylsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=3223-3230&issue=32&author=T.+C.+Mitchellauthor=O.+Hamidauthor=D.+C.+Smithauthor=T.+M.+Bauerauthor=J.+S.+Wasserauthor=A.+J.+Olszanskiauthor=J.+J.+Lukeauthor=A.+S.+Balmanoukianauthor=E.+V.+Schmidtauthor=Y.+Zhaoauthor=X.+Gongauthor=J.+Maleskiauthor=L.+Leopoldauthor=T.+F.+Gajewski&title=Epacadostat+plus+pembrolizumab+in+patients+with+advanced+solid+tumors%3A+phase+I+results+from+a+multicenter%2C+open-label+phase+I%2FII+trial+%28ECHO-202%2FKEYNOTE-037%29&doi=10.1200%2FJCO.2018.78.9602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037)</span></div><div class="casAuthors">Mitchell, Tara C.; Hamid, Omid; Smith, David C.; Bauer, Todd M.; Wasser, Jeffrey S.; Olszanski, Anthony J.; Luke, Jason J.; Balmanoukian, Ani S.; Schmidt, Emmett V.; Zhao, Yufan; Gong, Xiaohua; Maleski, Janet; Leopold, Lance; Gajewski, Thomas F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">3223-3230</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Tumors may evade immunosurveillance through upregulation of the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme.  Epacadostat is a potent and highly selective IDO1 enzyme inhibitor.  The open-label phase I/II ECHO-202/KEYNOTE-037 trial evaluated epacadostat plus pembrolizumab, a programmed death protein 1 inhibitor, in patients with advanced solid tumors.  Phase I results on max. tolerated dose, safety, tolerability, preliminary antitumor activity, and pharmacokinetics are reported.  Patients and Methods Patients received escalating doses of oral epacadostat (25, 50, 100, or 300 mg) twice per day plus i.v. pembrolizumab 2 mg/kg or 200 mg every 3 wk.  During the safety expansion, patients received epacadostat (50, 100, or 300 mg) twice per day plus pembrolizumab 200 mg every 3 wk.  Results Sixty-two patients were enrolled and received one or more doses of study treatment.  The max. tolerated dose of epacadostat in combination with pembrolizumab was not reached.  Fifty-two patients (84%) experienced treatment-related adverse events (TRAEs), with fatigue (36%), rash (36%), arthralgia (24%), pruritus (23%), and nausea (21%) occurring in â¥ 20%.  Grade 3/4 TRAEs were reported in 24% of patients.  Seven patients (11%) discontinued study treatment because of TRAEs.  No TRAEs led to death.  Epacadostat 100 mg twice per day plus pembrolizumab 200 mg every 3 wk was recommended for phase II evaluation.  Objective responses (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) occurred in 12 (55%) of 22 patients with melanoma and in patients with non-small-cell lung cancer, renal cell carcinoma, endometrial adenocarcinoma, urothelial carcinoma, and squamous cell carcinoma of the head and neck.  The pharmacokinetics of epacadostat and pembrolizumab and antidrug antibody rate were comparable to historical controls for monotherapies.  Conclusion Epacadostat in combination with pembrolizumab generally was well tolerated and had encouraging antitumor activity in multiple advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4WSlpguIRwbVg90H21EOLACvtfcHk0lh26hz5uNFoPw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvFylsbg%253D&md5=dfdac94152fd0eb096847a60ea44c145</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.78.9602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.78.9602%26sid%3Dliteratum%253Aachs%26aulast%3DMitchell%26aufirst%3DT.%2BC.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DSmith%26aufirst%3DD.%2BC.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DWasser%26aufirst%3DJ.%2BS.%26aulast%3DOlszanski%26aufirst%3DA.%2BJ.%26aulast%3DLuke%26aufirst%3DJ.%2BJ.%26aulast%3DBalmanoukian%26aufirst%3DA.%2BS.%26aulast%3DSchmidt%26aufirst%3DE.%2BV.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DX.%26aulast%3DMaleski%26aufirst%3DJ.%26aulast%3DLeopold%26aufirst%3DL.%26aulast%3DGajewski%26aufirst%3DT.%2BF.%26atitle%3DEpacadostat%2520plus%2520pembrolizumab%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%253A%2520phase%2520I%2520results%2520from%2520a%2520multicenter%252C%2520open-label%2520phase%2520I%252FII%2520trial%2520%2528ECHO-202%252FKEYNOTE-037%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26issue%3D32%26spage%3D3223%26epage%3D3230%26doi%3D10.1200%2FJCO.2018.78.9602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Komrokji, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailloux, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padron, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sallman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancet, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinsley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nardelli, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinilla-Ibarz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epling-Burnette, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">List, A. F.</span></span> <span> </span><span class="NLM_article-title">A phase II study to determine the safety and efficacy of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO) enzyme INCB024360 in patients with myelodysplastic syndromes</span>. <i>Clin. Lymphoma Myeloma Leuk.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">157</span>â <span class="NLM_lpage">161</span>, <span class="refDoi">Â DOI: 10.1016/j.clml.2018.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.clml.2018.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=30713125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BB3cjosVagsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=157-161&issue=3&author=R.+S.+Komrokjiauthor=S.+Weiauthor=A.+W.+Maillouxauthor=L.+Zhangauthor=E.+Padronauthor=D.+Sallmanauthor=J.+E.+Lancetauthor=S.+Tinsleyauthor=L.+A.+Nardelliauthor=J.+Pinilla-Ibarzauthor=P.+K.+Epling-Burnetteauthor=A.+F.+List&title=A+phase+II+study+to+determine+the+safety+and+efficacy+of+the+oral+inhibitor+of+indoleamine+2%2C3-dioxygenase+%28IDO%29+enzyme+INCB024360+in+patients+with+myelodysplastic+syndromes&doi=10.1016%2Fj.clml.2018.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes</span></div><div class="casAuthors">Komrokji Rami S; Wei Sheng; Mailloux Adam W; Zhang Ling; Padron Eric; Sallman David; Lancet Jeffrey E; Tinsley Sara; Nardelli Lisa A; Pinilla-Ibarz Javier; Epling-Burnette Pearlie K; List Alan F</div><div class="citationInfo"><span class="NLM_cas:title">Clinical lymphoma, myeloma & leukemia</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">157-161</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  INCB024360 is an oral inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO), which catalyzes the degradation of tryptophan to kynurenine.  Preclinical data suggest that IDO1 inhibition by INCB024360 will increase T cell proliferation, and decrease T regulatory cells and myeloid derived suppressor cells suppressive activity.  We conducted a phase II study to explore activity and pharmacodynamics of INCB024360 in patients with myelodysplastic syndromes.  PATIENTS AND METHODS:  All patients were treated with INCB024360 600 mg orally twice a day for at least 16 weeks.  Fifteen patients were enrolled.  The median age was 72 years.  The International Prognostic Scoring System risk was low in 27% (n = 4), intermediate-1 in 47% (n = 7), and intermediate-2 in 27% (n = 4).  All patients had prior azacitidine.  RESULTS:  The best response was stable disease in 12 (80%) patients and progressive disease in 3 (20%) patients.  The treatment was relatively well-tolerated.  One patient developed hypothyroidism and adrenal insufficiency (grade 2), and 1 patient had low testosterone level.  The mean IDO expression was 39% at baseline and 26% after treatment (n = 9; P = .4).  The mean burst forming unit-erythroid changed from 72 to 191 colonies/10(6) (n = 5; P = .036), and the mean colony forming unit-granulocye, monocyte from 62 to 180 colonies/10(6) (n = 6; P = .5).  The mean myeloid derived suppressor cell % (CD33Lin-HLA cells) was 29.5% at baseline compared with 27.6% after treatment (n = 9; P = .7).  The mean T-regulatory effector memory cell % changed from 9.6% at screening to 7.4% at end of treatment (n = 14; P = .8).  The mean kynurenine/tryptophan ratio decreased from 45 at baseline to 26 (42% reduction) at cycle 2, day 1 (P < .005).  CONCLUSION:  Future directions may include testing INCB024360 early in the course of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWYB_1Nq9sPL0AGQpJZWpJfW6udTcc2ebCbzFDs6FTMLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjosVagsQ%253D%253D&md5=c2cf2712dbd57d75a0ce71fbc7d365fe</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1016%2Fj.clml.2018.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clml.2018.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DKomrokji%26aufirst%3DR.%2BS.%26aulast%3DWei%26aufirst%3DS.%26aulast%3DMailloux%26aufirst%3DA.%2BW.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DPadron%26aufirst%3DE.%26aulast%3DSallman%26aufirst%3DD.%26aulast%3DLancet%26aufirst%3DJ.%2BE.%26aulast%3DTinsley%26aufirst%3DS.%26aulast%3DNardelli%26aufirst%3DL.%2BA.%26aulast%3DPinilla-Ibarz%26aufirst%3DJ.%26aulast%3DEpling-Burnette%26aufirst%3DP.%2BK.%26aulast%3DList%26aufirst%3DA.%2BF.%26atitle%3DA%2520phase%2520II%2520study%2520to%2520determine%2520the%2520safety%2520and%2520efficacy%2520of%2520the%2520oral%2520inhibitor%2520of%2520indoleamine%25202%252C3-dioxygenase%2520%2528IDO%2529%2520enzyme%2520INCB024360%2520in%2520patients%2520with%2520myelodysplastic%2520syndromes%26jtitle%3DClin.%2520Lymphoma%2520Myeloma%2520Leuk.%26date%3D2019%26volume%3D19%26issue%3D3%26spage%3D157%26epage%3D161%26doi%3D10.1016%2Fj.clml.2018.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kristeleit, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirinkin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Khouly, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondarenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodheart, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorbunova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penning, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maleski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schilder, R. J.</span></span> <span> </span><span class="NLM_article-title">A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>146</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">484</span>â <span class="NLM_lpage">490</span>, <span class="refDoi">Â DOI: 10.1016/j.ygyno.2017.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.ygyno.2017.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28698009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFClsLnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2017&pages=484-490&issue=3&author=R.+Kristeleitauthor=I.+Davidenkoauthor=V.+Shirinkinauthor=F.+El-Khoulyauthor=I.+Bondarenkoauthor=M.+J.+Goodheartauthor=V.+Gorbunovaauthor=C.+A.+Penningauthor=J.+G.+Shiauthor=X.+Liuauthor=R.+C.+Newtonauthor=Y.+Zhaoauthor=J.+Maleskiauthor=L.+Leopoldauthor=R.+J.+Schilder&title=A+randomised%2C+open-label%2C+phase+2+study+of+the+IDO1+inhibitor+epacadostat+%28INCB024360%29+versus+tamoxifen+as+therapy+for+biochemically+recurrent+%28CA-125+relapse%29-only+epithelial+ovarian+cancer%2C+primary+peritoneal+carcinoma%2C+or+fallopian+tube+cancer&doi=10.1016%2Fj.ygyno.2017.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer</span></div><div class="casAuthors">Kristeleit, Rebecca; Davidenko, Irina; Shirinkin, Vadim; El-Khouly, Fatima; Bondarenko, Igor; Goodheart, Michael J.; Gorbunova, Vera; Penning, Carol A.; Shi, Jack G.; Liu, Xiangdong; Newton, Robert C.; Zhao, Yufan; Maleski, Janet; Leopold, Lance; Schilder, Russell J.</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">484-490</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase-1 (IDO1) is a key regulator of immune tolerance in ovarian cancer.  This study investigated efficacy and safety of the IDO1 enzyme inhibitor epacadostat vs. tamoxifen in patients with biochem.-only recurrence (CA-125 elevation) following complete remission after first-line chemotherapy for advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.  In this open-label, phase 2 study (NCT01685255), patients were randomised 1:1 to epacadostat 600 mg or tamoxifen 20 mg twice daily for successive 28-day cycles and stratified by time since completion of first-line chemotherapy to first CA-125 elevation (3 to < 12 or â¥ 12 mo).  The primary endpoint was investigator-assessed progression-free survival (PFS; RECIST v1.1).  Secondary endpoints included CA-125 response (Gynecol. Cancer InterGroup criteria), overall survival, safety, and tolerability.  The study was terminated primarily due to slow accrual and lack of evidence of superiority.  Median PFS was 3.75 mo for epacadostat (n = 22) vs. 5.56 mo for tamoxifen (n = 20; HR, 1.34 [95% CI, 0.58-3.14]; P = 0.54).  Of evaluable patients, 1 (5.0%) epacadostat and 3 (15.8%) tamoxifen patients had confirmed CA-125 responses.  The most common treatment-emergent adverse event was fatigue (epacadostat, 36.4%; tamoxifen, 40.0%).  Immune-related adverse events, obsd. with epacadostat only, were primarily rash (18.2%) and pruritus (9.1%).  Epacadostat pharmacokinetics/pharmacodynamics were consistent with its known mechanism of action.  IDO1 expression was obsd. in 94% of archival tumor samples.  This first report of immunotherapy evaluation in biochem.-only relapse ovarian cancer and of IDO1 inhibitor monotherapy in ovarian cancer found no significant difference in efficacy between epacadostat and tamoxifen.  Epacadostat was generally well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRb4SuL159WLVg90H21EOLACvtfcHk0lj6jyrQnnD1Gw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFClsLnF&md5=bd3859b2936669042690ce675e90a12d</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2017.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2017.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DKristeleit%26aufirst%3DR.%26aulast%3DDavidenko%26aufirst%3DI.%26aulast%3DShirinkin%26aufirst%3DV.%26aulast%3DEl-Khouly%26aufirst%3DF.%26aulast%3DBondarenko%26aufirst%3DI.%26aulast%3DGoodheart%26aufirst%3DM.%2BJ.%26aulast%3DGorbunova%26aufirst%3DV.%26aulast%3DPenning%26aufirst%3DC.%2BA.%26aulast%3DShi%26aufirst%3DJ.%2BG.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DMaleski%26aufirst%3DJ.%26aulast%3DLeopold%26aufirst%3DL.%26aulast%3DSchilder%26aufirst%3DR.%2BJ.%26atitle%3DA%2520randomised%252C%2520open-label%252C%2520phase%25202%2520study%2520of%2520the%2520IDO1%2520inhibitor%2520epacadostat%2520%2528INCB024360%2529%2520versus%2520tamoxifen%2520as%2520therapy%2520for%2520biochemically%2520recurrent%2520%2528CA-125%2520relapse%2529-only%2520epithelial%2520ovarian%2520cancer%252C%2520primary%2520peritoneal%2520carcinoma%252C%2520or%2520fallopian%2520tube%2520cancer%26jtitle%3DGynecol.%2520Oncol.%26date%3D2017%26volume%3D146%26issue%3D3%26spage%3D484%26epage%3D490%26doi%3D10.1016%2Fj.ygyno.2017.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beatty, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDwyer, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaub, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maleski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajewski, T. F.</span></span> <span> </span><span class="NLM_article-title">First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3269</span>â <span class="NLM_lpage">3276</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-16-2272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1158%2F1078-0432.CCR-16-2272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28053021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSnurfP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=3269-3276&issue=13&author=G.+L.+Beattyauthor=P.+J.+O%E2%80%99Dwyerauthor=J.+Clarkauthor=J.+G.+Shiauthor=K.+J.+Bowmanauthor=P.+A.+Scherleauthor=R.+C.+Newtonauthor=R.+Schaubauthor=J.+Maleskiauthor=L.+Leopoldauthor=T.+F.+Gajewski&title=First-in-human+phase+I+study+of+the+oral+inhibitor+of+indoleamine+2%2C3-dioxygenase-1+epacadostat+%28INCB024360%29+in+patients+with+advanced+solid+malignancies&doi=10.1158%2F1078-0432.CCR-16-2272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies</span></div><div class="casAuthors">Beatty, Gregory L.; O'Dwyer, Peter J.; Clark, Jason; Shi, Jack G.; Bowman, Kevin J.; Scherle, Peggy A.; Newton, Robert C.; Schaub, Richard; Maleski, Janet; Leopold, Lance; Gajewski, Thomas F.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3269-3276</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase-1 (IDO1) catalyzes the degrdn. of tryptophan to N-formyl-kynurenine.  Overexpressed in many solid malignancies, IDO1 can promote tumor escape from host immunosurveillance.  This first-in-human phase I study investigated the max. tolerated dose, safety, pharmacokinetics, pharmacodynamics, and antitumor activity of epacadostat (INCB024360), a potent and selective inhibitor of IDO1.  Fifty-two patients with advanced solid malignancies were treated with epacadostat [50 mg once daily or 50, 100, 300, 400, 500, 600, or 700 mg twice daily (BID)] in a dose-escalation 3 + 3 design and evaluated in 28-day cycles.  Treatment was continued until disease progression or unacceptable toxicity.  One dose-limiting toxicity (DLT) occurred at the dose of 300 mg BID (grade 3, radiation pneumonitis); another DLT occurred at 400 mg BID (grade 3, fatigue).  The most common adverse events in >20% of patients overall were fatigue, nausea, decreased appetite, vomiting, constipation, abdominal pain, diarrhea, dyspnea, back pain, and cough.  Treatment produced significant dose-dependent redns. in plasma kynurenine levels and in the plasma kynurenine/tryptophan ratio at all doses and in all patients.  Near maximal changes were obsd. at doses of â¥100 mg BID with >80% to 90% inhibition of IDO1 achieved throughout the dosing period.  Although no objective responses were detected, stable disease lasting â¥16 wk was obsd. in 7 of 52 patients.  Epacadostat was generally well tolerated, effectively normalized kynurenine levels, and produced maximal inhibition of IDO1 activity at doses of â¥100 mg BID.  Studies investigating epacadostat in combination with other immunomodulatory drugs are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLdL__p3Q7B7Vg90H21EOLACvtfcHk0lj6jyrQnnD1Gw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSnurfP&md5=dee4464e680b476ebe0dbad7f5ec8d46</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2272%26sid%3Dliteratum%253Aachs%26aulast%3DBeatty%26aufirst%3DG.%2BL.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DJ.%2BG.%26aulast%3DBowman%26aufirst%3DK.%2BJ.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DSchaub%26aufirst%3DR.%26aulast%3DMaleski%26aufirst%3DJ.%26aulast%3DLeopold%26aufirst%3DL.%26aulast%3DGajewski%26aufirst%3DT.%2BF.%26atitle%3DFirst-in-human%2520phase%2520I%2520study%2520of%2520the%2520oral%2520inhibitor%2520of%2520indoleamine%25202%252C3-dioxygenase-1%2520epacadostat%2520%2528INCB024360%2529%2520in%2520patients%2520with%2520advanced%2520solid%2520malignancies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26issue%3D13%26spage%3D3269%26epage%3D3276%26doi%3D10.1158%2F1078-0432.CCR-16-2272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajewski, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caglevic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlino, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidov, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maleski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diede, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, T. C.</span></span> <span> </span><span class="NLM_article-title">Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1083</span>â <span class="NLM_lpage">1097</span>, <span class="refDoi">Â DOI: 10.1016/S1470-2045(19)30274-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2FS1470-2045%2819%2930274-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=31221619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtF2kurbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1083-1097&issue=8&author=G.+V.+Longauthor=R.+Dummerauthor=O.+Hamidauthor=T.+F.+Gajewskiauthor=C.+Caglevicauthor=S.+Dalleauthor=A.+Aranceauthor=M.+S.+Carlinoauthor=J.-J.+Grobauthor=T.+M.+Kimauthor=L.+Demidovauthor=C.+Robertauthor=J.+Larkinauthor=J.+R.+Andersonauthor=J.+Maleskiauthor=M.+Jonesauthor=S.+J.+Diedeauthor=T.+C.+Mitchell&title=Epacadostat+plus+pembrolizumab+versus+placebo+plus+pembrolizumab+in+patients+with+unresectable+or+metastatic+melanoma+%28ECHO-301%2FKEYNOTE-252%29%3A+a+phase+3%2C+randomised%2C+double-blind+study&doi=10.1016%2FS1470-2045%2819%2930274-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study</span></div><div class="casAuthors">Long, Georgina V.; Dummer, Reinhard; Hamid, Omid; Gajewski, Thomas F.; Caglevic, Christian; Dalle, Stephane; Arance, Ana; Carlino, Matteo S.; Grob, Jean-Jacques; Kim, Tae Min; Demidov, Lev; Robert, Caroline; Larkin, James; Anderson, James R.; Maleski, Janet; Jones, Mark; Diede, Scott J.; Mitchell, Tara C.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1083-1097</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Immunotherapy combination treatments can improve patient outcomes.  Epacadostat, an IDO1 selective inhibitor, and pembrolizumab, a PD-1 inhibitor, showed promising antitumor activity in the phase 1-2 ECHO-202/KEYNOTE-037 study in advanced melanoma.  In this trial, we aimed to compare progression-free survival and overall survival in patients with unresectable stage III or IV melanoma receiving epacadostat plus pembrolizumab vs. placebo plus pembrolizumab.  In this international, randomised, placebo-controlled, double-blind, parallel-group, phase 3 trial, eligible participants were aged 18 years or older, with unresectable stage III or IV melanoma previously untreated with PD-1 or PD-L1 checkpoint inhibitors, an ECOG performance status of 0 or 1, and had a known BRAFV600 mutant status or consented to BRAFV600 mutation testing during screening.  Patients were stratified by PD-L1 expression and BRAFV600 mutation status and randomly assigned (1:1) through a central interactive voice and integrated web response system to receive epacadostat 100 mg orally twice daily plus pembrolizumab 200 mg i.v. every 3 wk or placebo plus pembrolizumab for up to 2 years.  We used block randomisation with a block size of four in each stratum.  Primary endpoints were progression-free survival and overall survival in the intention-to-treat population.  The safety anal. population included randomly assigned patients who received at least one dose of study treatment.  The study was stopped after the second interim anal.; follow-up for safety is ongoing.  This study is registered with ClinicalTrials.gov, no. NCT02752074.  Between June 21, 2016, and Aug 7, 2017, 928 patients were screened and 706 patients were randomly assigned to receive epacadostat plus pembrolizumab (n=354) or placebo plus pembrolizumab (n=352).  Median follow-up was 12Â·4 mo (IQR 10Â·3-14Â·5).  No significant differences were found between the treatment groups for progression-free survival (median 4Â·7 mo, 95% CI 2Â·9-6Â·8, for epacadostat plus pembrolizumab vs 4Â·9 mo, 2Â·9-6Â·8, for placebo plus pembrolizumab; hazard ratio [HR] 1Â·00, 95% CI 0Â·83-1Â·21; one-sided p=0Â·52) or overall survival (median not reached in either group; epacadostat plus pembrolizumab vs placebo plus pembrolizumab: HR 1Â·13, 0Â·86-1Â·49; one-sided p=0Â·81).  The most common grade 3 or worse treatment-related adverse event was lipase increase, which occurred in 14 (4%) of 353 patients receiving epacadostat plus pembrolizumab and 11 (3%) of 352 patients receiving placebo plus pembrolizumab.  Treatment-related serious adverse events were reported in 37 (10%) of 353 patients receiving epacadostat plus pembrolizumab and 32 (9%) of 352 patients receiving placebo plus pembrolizumab.  There were no treatment-related deaths in either treatment group.  Epacadostat 100 mg twice daily plus pembrolizumab did not improve progression-free survival or overall survival compared with placebo plus pembrolizumab in patients with unresectable or metastatic melanoma.  The usefulness of IDO1 inhibition as a strategy to enhance anti-PD-1 therapy activity in cancer remains uncertain.  Incyte Corporation, in collaboration with Merck Sharp & Dohme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8j2WQ35JqjbVg90H21EOLACvtfcHk0lj6jyrQnnD1Gw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtF2kurbM&md5=f1dce1f431d2650fe4f8b8e46677e03d</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2819%2930274-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252819%252930274-8%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DGajewski%26aufirst%3DT.%2BF.%26aulast%3DCaglevic%26aufirst%3DC.%26aulast%3DDalle%26aufirst%3DS.%26aulast%3DArance%26aufirst%3DA.%26aulast%3DCarlino%26aufirst%3DM.%2BS.%26aulast%3DGrob%26aufirst%3DJ.-J.%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DDemidov%26aufirst%3DL.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DJ.%2BR.%26aulast%3DMaleski%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DM.%26aulast%3DDiede%26aufirst%3DS.%2BJ.%26aulast%3DMitchell%26aufirst%3DT.%2BC.%26atitle%3DEpacadostat%2520plus%2520pembrolizumab%2520versus%2520placebo%2520plus%2520pembrolizumab%2520in%2520patients%2520with%2520unresectable%2520or%2520metastatic%2520melanoma%2520%2528ECHO-301%252FKEYNOTE-252%2529%253A%2520a%2520phase%25203%252C%2520randomised%252C%2520double-blind%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2019%26volume%3D20%26issue%3D8%26spage%3D1083%26epage%3D1097%26doi%3D10.1016%2FS1470-2045%2819%2930274-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakharia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span> <span> </span><span class="NLM_article-title">Inhibiting IDO pathways to treat cancer: Lessons from the ECHO-301 trial and beyond</span>. <i>Semin. Immunopathol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">41</span>â <span class="NLM_lpage">48</span>, <span class="refDoi">Â DOI: 10.1007/s00281-018-0702-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1007%2Fs00281-018-0702-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=30203227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1yltrfI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2019&pages=41-48&issue=1&author=A.+J.+Mullerauthor=M.+G.+Manfrediauthor=Y.+Zakhariaauthor=G.+C.+Prendergast&title=Inhibiting+IDO+pathways+to+treat+cancer%3A+Lessons+from+the+ECHO-301+trial+and+beyond&doi=10.1007%2Fs00281-018-0702-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond</span></div><div class="casAuthors">Muller, Alexander J.; Manfredi, Mark G.; Zakharia, Yousef; Prendergast, George C.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunopathology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-48</span>CODEN:
                <span class="NLM_cas:coden">SIEMB7</span>;
        ISSN:<span class="NLM_cas:issn">1863-2297</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  With immunotherapy enjoying a rapid resurgence based on the achievement of durable remissions in some patients with agents that derepress immune function, commonly referred to as "checkpoint inhibitors," enormous attention developed around the IDO1 enzyme as a metabolic mediator of immune escape in cancer.  In particular, outcomes of multiple phase 1/2 trials encouraged the idea that small mol. inhibitors of IDO1 may improve patient responses to anti-PD1 immune checkpoint therapy.  However, recent results from ECHO-301, the first large phase 3 trial to evaluate an IDO1-selective enzyme inhibitor (epacadostat) in combination with an anti-PD1 antibody (pembrolizumab) in advanced melanoma, showed no indication that epacadostat provided an increased benefit.  Here it discuss several caveats assocd. with this failed trial.  First is the uncertainty as to whether the target was adequately inhibited.  In particular, there remains a lack of direct evidence regarding the degree of IDO1 inhibition within the tumor, and previous trial data suggest that sufficient drug exposure may not have been achieved at the dose tested in ECHO-301.  Second, while there is a mechanistic rationale for the combination tested, the preclin. data were not particularly compelling.  More efficacious combinations have been demonstrated with DNA damaging modalities which may therefore be a more attractive alternative.  Third, as a highly selective IDO1 inhibitor, epacadostat was advanced aggressively despite preclin. genetic evidence of tumors bypassing IDO1 blockade.  Indeed, a well-grounded literature starting in 2011 points to targeting strategies that account for both IDO and tryptophan 2,3-dioxygenase as more appealing directions to pursue, including dual inhibitors and inhibitors of nodal downstream effector pathways such as aryl hydrocarbon receptor blockade.  Overall, the clin. readout from a single trial with significant limitations is by no means a definitive test for the field.  While biomarker information yet to be gleaned from ECHO-301 may yet reveal useful information regarding IDO1 pathway drugs, better rationalized compds. and better rationalized trial designs will be important in the future to accurately gage medical impact.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR-55ynvYhvLVg90H21EOLACvtfcHk0lizDb2b5QYuCg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1yltrfI&md5=b672f039dcfd843d6c849167846e13a5</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1007%2Fs00281-018-0702-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00281-018-0702-0%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DManfredi%26aufirst%3DM.%2BG.%26aulast%3DZakharia%26aufirst%3DY.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26atitle%3DInhibiting%2520IDO%2520pathways%2520to%2520treat%2520cancer%253A%2520Lessons%2520from%2520the%2520ECHO-301%2520trial%2520and%2520beyond%26jtitle%3DSemin.%2520Immunopathol.%26date%3D2019%26volume%3D41%26issue%3D1%26spage%3D41%26epage%3D48%26doi%3D10.1007%2Fs00281-018-0702-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardolino, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fradera, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knemeyer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurukulasuriya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesburg, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinot, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biju, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciammetta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solban, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of amino-cyclobutarene-derived indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors for cancer immunotherapy</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1530</span>â <span class="NLM_lpage">1536</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.9b00344</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00344" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVSks7rE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1530-1536&issue=11&author=H.+Zhangauthor=K.+Liuauthor=Q.+Puauthor=A.+Achabauthor=M.+J.+Ardolinoauthor=M.+Chengauthor=Y.+Dengauthor=A.+C.+Dotyauthor=H.+Fergusonauthor=X.+Fraderaauthor=I.+Knemeyerauthor=R.+Kurukulasuriyaauthor=Y.+H.+Lamauthor=C.+A.+Lesburgauthor=T.+A.+Martinotauthor=M.+A.+McGowanauthor=J.+R.+Millerauthor=K.+Otteauthor=P.+J.+Bijuauthor=N.+Sciammettaauthor=N.+Solbanauthor=W.+Yuauthor=H.+Zhouauthor=X.+Wangauthor=D.+J.+Bennettauthor=Y.+Han&title=Discovery+of+amino-cyclobutarene-derived+indoleamine-2%2C3-dioxygenase+1+%28IDO1%29+inhibitors+for+cancer+immunotherapy&doi=10.1021%2Facsmedchemlett.9b00344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy</span></div><div class="casAuthors">Zhang, Hongjun; Liu, Kun; Pu, Qinglin; Achab, Abdelghani; Ardolino, Michael J.; Cheng, Mangeng; Deng, Yongqi; Doty, Amy C.; Ferguson, Heidi; Fradera, Xavier; Knemeyer, Ian; Kurukulasuriya, Ravi; Lam, Yu-hong; Lesburg, Charles A.; Martinot, Theodore A.; McGowan, Meredeth A.; Miller, J. Richard; Otte, Karin; Biju, Purakattle J.; Sciammetta, Nunzio; Solban, Nicolas; Yu, Wensheng; Zhou, Hua; Wang, Xiao; Bennett, David Jonathan; Han, Yongxin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1530-1536</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Checkpoint inhibitors have demonstrated unprecedented efficacy and are evolving to become std. of care for certain types of cancers.  However, low overall response rates often hamper the broad utility and potential of these breakthrough therapies.  Combination therapy strategies are currently under intensive investigation in the clinic, including the combination of PD-1/PD-L1 agents with IDO1 inhibitors.  Here, we report the discovery of a class of IDO1 heme-binding inhibitors featuring a unique amino-cyclobutarene motif, which was discovered through SBDD from a known and weakly active inhibitor.  Subsequent optimization efforts focused on improving metabolic stability and were greatly accelerated by utilizing a robust SNAr reaction of a facile nitro-furazan intermediate to quickly explore different polar side chains.  As a culmination of these efforts, compd. 16 was identified and demonstrated a favorable overall profile with superior potency and selectivity.  Extensive studies confirmed the chem. stability and drug-like properties of compd. 16, rendering it a potential drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmACl12NSJBrVg90H21EOLACvtfcHk0lizDb2b5QYuCg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVSks7rE&md5=18def13fafda60ed7547810dd97a3c37</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00344%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DPu%26aufirst%3DQ.%26aulast%3DAchab%26aufirst%3DA.%26aulast%3DArdolino%26aufirst%3DM.%2BJ.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DDoty%26aufirst%3DA.%2BC.%26aulast%3DFerguson%26aufirst%3DH.%26aulast%3DFradera%26aufirst%3DX.%26aulast%3DKnemeyer%26aufirst%3DI.%26aulast%3DKurukulasuriya%26aufirst%3DR.%26aulast%3DLam%26aufirst%3DY.%2BH.%26aulast%3DLesburg%26aufirst%3DC.%2BA.%26aulast%3DMartinot%26aufirst%3DT.%2BA.%26aulast%3DMcGowan%26aufirst%3DM.%2BA.%26aulast%3DMiller%26aufirst%3DJ.%2BR.%26aulast%3DOtte%26aufirst%3DK.%26aulast%3DBiju%26aufirst%3DP.%2BJ.%26aulast%3DSciammetta%26aufirst%3DN.%26aulast%3DSolban%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DBennett%26aufirst%3DD.%2BJ.%26aulast%3DHan%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520amino-cyclobutarene-derived%2520indoleamine-2%252C3-dioxygenase%25201%2520%2528IDO1%2529%2520inhibitors%2520for%2520cancer%2520immunotherapy%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D11%26spage%3D1530%26epage%3D1536%26doi%3D10.1021%2Facsmedchemlett.9b00344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span>; <span class="NLM_string-name">Achab, A.</span>; <span class="NLM_string-name">Biju, P.</span>; <span class="NLM_string-name">Deng, Y.</span>; <span class="NLM_string-name">Fradera, X.</span>; <span class="NLM_string-name">Guo, L.</span>; <span class="NLM_string-name">He, S.</span>; <span class="NLM_string-name">Kozlowski, J.</span>; <span class="NLM_string-name">Kurukulasuriya, R.</span>; <span class="NLM_string-name">Liu, K.</span>; <span class="NLM_string-name">McGowan, M. A.</span>; <span class="NLM_string-name">Pu, Q.</span>; <span class="NLM_string-name">Sciammetta, N.</span>; <span class="NLM_string-name">Zhang, H.</span>; <span class="NLM_string-name">Zhao, H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Novel N-Hydroxycarboximidamide Compounds as Indoleamine 2,3-Dioxygenase Inhibitors</span>. <span class="NLM_patent">WO2017106062A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Y.+Han&author=A.+Achab&author=P.+Biju&author=Y.+Deng&author=X.+Fradera&author=L.+Guo&author=S.+He&author=J.+Kozlowski&author=R.+Kurukulasuriya&author=K.+Liu&author=M.+A.+McGowan&author=Q.+Pu&author=N.+Sciammetta&author=H.+Zhang&author=H.+Zhao&title=Preparation+of+Novel+N-Hydroxycarboximidamide+Compounds+as+Indoleamine+2%2C3-Dioxygenase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DY.%26atitle%3DPreparation%2520of%2520Novel%2520N-Hydroxycarboximidamide%2520Compounds%2520as%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span>; <span class="NLM_string-name">Achab, A.</span>; <span class="NLM_string-name">Biju, P.</span>; <span class="NLM_string-name">Cernak, T. A.</span>; <span class="NLM_string-name">Deng, Y.</span>; <span class="NLM_string-name">Fradera, X.</span>; <span class="NLM_string-name">Guo, L.</span>; <span class="NLM_string-name">Han, Y.</span>; <span class="NLM_string-name">He, S.</span>; <span class="NLM_string-name">Kozlowski, J.</span>; <span class="NLM_string-name">Li, D.</span>; <span class="NLM_string-name">Li, G.</span>; <span class="NLM_string-name">Pu, Q.</span>; <span class="NLM_string-name">Shi, Z.-C.</span>; <span class="NLM_string-name">Yu, W.</span>; <span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Novel Substituted Nâ²-Hydroxycarbamimidoyl-1,2,5-oxadiazole Compounds as Indoleamine 2,3-Dioxygenase (IDO) Inhibitors and Their Preparation</span>. <span class="NLM_patent">WO2018044663A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=K.+Liu&author=A.+Achab&author=P.+Biju&author=T.+A.+Cernak&author=Y.+Deng&author=X.+Fradera&author=L.+Guo&author=Y.+Han&author=S.+He&author=J.+Kozlowski&author=D.+Li&author=G.+Li&author=Q.+Pu&author=Z.-C.+Shi&author=W.+Yu&author=H.+Zhang&title=Novel+Substituted+N%E2%80%B2-Hydroxycarbamimidoyl-1%2C2%2C5-oxadiazole+Compounds+as+Indoleamine+2%2C3-Dioxygenase+%28IDO%29+Inhibitors+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%26atitle%3DNovel%2520Substituted%2520N%25E2%2580%25B2-Hydroxycarbamimidoyl-1%252C2%252C5-oxadiazole%2520Compounds%2520as%2520Indoleamine%25202%252C3-Dioxygenase%2520%2528IDO%2529%2520Inhibitors%2520and%2520Their%2520Preparation%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steeneck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderhub, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhaeuser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleymann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of hydroxyamidine based inhibitors of IDO1 for cancer immunotherapy with reduced potential for glucuronidation</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">179</span>â <span class="NLM_lpage">187</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.9b00572</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00572" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1GhsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=179-187&issue=2&author=C.+Steeneckauthor=O.+Kinzelauthor=S.+Anderhubauthor=M.+Hornbergerauthor=S.+Pintoauthor=B.+Morschhaeuserauthor=F.+Braunauthor=G.+Kleymannauthor=T.+Hoffmann&title=Discovery+of+hydroxyamidine+based+inhibitors+of+IDO1+for+cancer+immunotherapy+with+reduced+potential+for+glucuronidation&doi=10.1021%2Facsmedchemlett.9b00572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Hydroxyamidine Based Inhibitors of IDO1 for Cancer Immunotherapy with Reduced Potential for Glucuronidation</span></div><div class="casAuthors">Steeneck, Christoph; Kinzel, Olaf; Anderhub, Simon; Hornberger, Martin; Pinto, Sheena; Morschhaeuser, Barbara; Braun, Floriane; Kleymann, Gerald; Hoffmann, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-187</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Following the impressive success of checkpoint inhibitors in the treatment of cancer, combinations of IDO1 inhibitors with PD-1/PD-L1 antibodies are in clin. development aiming to increase response rates.  Using the hydroxyamidine pharmacophore of the IDO1 inhibitor INCB14943 as a starting point for the design of new inhibitors, the potential shortcomings of extensive hydroxyamidine glucuronidation in humans was addressed.  Compds. were optimized using a stability assay with recombinant UGT1A9 enzyme together with the measurement of glucuronide formation in human hepatocytes.  Optimized analog 24 showed cellular and biochem. IDO1 IC50 values in the low nanomolar range, a suitable in vitro ADME/PK profile, and efficacy in an animal model of cancer.  In a humanized liver mouse model the lead compd. exhibited significantly reduced glucuronidation compared to epacadostat (2).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL0q_mXp0hC7Vg90H21EOLACvtfcHk0liOc9yIUisoMg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1GhsLs%253D&md5=ef40add370d8e26624bda069c834442e</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00572%26sid%3Dliteratum%253Aachs%26aulast%3DSteeneck%26aufirst%3DC.%26aulast%3DKinzel%26aufirst%3DO.%26aulast%3DAnderhub%26aufirst%3DS.%26aulast%3DHornberger%26aufirst%3DM.%26aulast%3DPinto%26aufirst%3DS.%26aulast%3DMorschhaeuser%26aufirst%3DB.%26aulast%3DBraun%26aufirst%3DF.%26aulast%3DKleymann%26aufirst%3DG.%26aulast%3DHoffmann%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520hydroxyamidine%2520based%2520inhibitors%2520of%2520IDO1%2520for%2520cancer%2520immunotherapy%2520with%2520reduced%2520potential%2520for%2520glucuronidation%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26issue%3D2%26spage%3D179%26epage%3D187%26doi%3D10.1021%2Facsmedchemlett.9b00572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steeneck, C.</span>; <span class="NLM_string-name">Kinzel, O.</span>; <span class="NLM_string-name">Anderhub, S.</span>; <span class="NLM_string-name">Hornberger, M.</span>; <span class="NLM_string-name">Kleymann, G.</span>; <span class="NLM_string-name">Hoffmann, T.</span></span> <span> </span><span class="NLM_article-title">Substituted N-Hydroxyamidinoheterocycles as Modulators of Indoleamine 2,3-Dioxygenase and Their Preparation</span>. <span class="NLM_patent">WO2018083241A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=C.+Steeneck&author=O.+Kinzel&author=S.+Anderhub&author=M.+Hornberger&author=G.+Kleymann&author=T.+Hoffmann&title=Substituted+N-Hydroxyamidinoheterocycles+as+Modulators+of+Indoleamine+2%2C3-Dioxygenase+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSteeneck%26aufirst%3DC.%26atitle%3DSubstituted%2520N-Hydroxyamidinoheterocycles%2520as%2520Modulators%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520and%2520Their%2520Preparation%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">112059</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2020.112059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.ejmech.2020.112059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=31981851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslSgtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2020&pages=112059&author=X.+Songauthor=P.+Sunauthor=J.+Wangauthor=W.+Guoauthor=Y.+Wangauthor=L.+H.+Mengauthor=H.+Liu&title=Design%2C+synthesis%2C+and+biological+evaluation+of+1%2C2%2C5-oxadiazole-3-carboximidamide+derivatives+as+novel+indoleamine-2%2C3-dioxygenase+1+inhibitors&doi=10.1016%2Fj.ejmech.2020.112059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors</span></div><div class="casAuthors">Song, Xiaohan; Sun, Pu; Wang, Jiang; Guo, Wei; Wang, Yi; Meng, Ling-hua; Liu, Hong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112059</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of 1,2,5-oxadiazole-3-carboximidamide derivs. I [R = (1-sulfamoylpyrrolidin-3-yl)methyl, (1-methanesulfonylpyrrolidin-3-yl)methyl, [1-(cyclopropanesulfonyl)piperidin-3-yl]methyl, etc] bearing cycle in the side chain were designed, synthesized, and biol. evaluated for their anti-tumor activity.  Most of them exhibited potent activity against hIDO1 in enzymic assays and in HEK293T cells over-expressing hIDO1.  Among them, compd. I [R = [(3R)-1-sulfamoylpyrrolidin-3-yl]methyl, [(3R)-1-sulfamoylpiperidin-3-yl]methyl, [(3S)-1-sulfamoylpiperidin-3-yl]methyl] showed significant inhibitory activity against hIDO1 (IC50 = 108.7, 178.1 and 139.1 nM resp.) and in HEK293T cells expressing hIDO1 (cellular IC50 = 19.88, 68.59 and 57.76 nM resp.).  Moreover, compd. I [R = [(3R)-1-sulfamoylpiperidin-3-yl]methyl] displayed improved PK property with longer half-life (t1/2 = 3.81 h in CD-1 mice) and better oral bioavailability (F = 33.6%) compared with epacadostat.  In addn., compd. I [R = [(3R)-1-sulfamoylpiperidin-3-yl]methyl] showed similar potency to inhibit the growth of CT-26 syngeneic xenograft compared to epacadostat, making it justifiable for further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOVCKyiy04nLVg90H21EOLACvtfcHk0liOc9yIUisoMg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslSgtrc%253D&md5=eaacdbc7d1498bc8644774d4ae1ff3d0</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112059%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DL.%2BH.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25201%252C2%252C5-oxadiazole-3-carboximidamide%2520derivatives%2520as%2520novel%2520indoleamine-2%252C3-dioxygenase%25201%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D189%26spage%3D112059%26doi%3D10.1016%2Fj.ejmech.2020.112059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vivo antitumor evaluation of an orally active potent phosphonamidate derivative targeting IDO1/IDO2/TDO</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">214</span>â <span class="NLM_lpage">223</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2019.07.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bcp.2019.07.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=31306643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVWlu7jK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2019&pages=214-223&author=X.+Fengauthor=P.+Shenauthor=Y.+Wangauthor=Z.+Liauthor=J.+Bian&title=Synthesis+and+in+vivo+antitumor+evaluation+of+an+orally+active+potent+phosphonamidate+derivative+targeting+IDO1%2FIDO2%2FTDO&doi=10.1016%2Fj.bcp.2019.07.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in vivo antitumor evaluation of an orally active potent phosphonamidate derivative targeting IDO1/IDO2/TDO</span></div><div class="casAuthors">Feng, Xi; Shen, Pei; Wang, Yinuo; Li, Zhiyu; Bian, Jinlei</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">214-223</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting Trp-Kyn pathways has been identified as an attractive approach for the cancer immunotherapies.  In this study, a novel phosphonamidate contg. compd. was designed, synthesized and evaluated for its inhibitory activity against key dioxygenases in Trp-Kyn pathway, including IDO1, IDO2 and TDO.  This compd. showed potent IDO1 inhibitory activity with an IC50 value of 94 nM in an enzymic assay and 12.6 nM in HeLa cells.  In addn., this compd. showed promising IDO2 inhibition and TDO inhibition with IC50 values of 310 nM and 2.6 Î¼M, resp., in enzyme assay.  Based on the promising enzyme inhibitory activity toward IDO/TDO, compd. F04(I) was evaluated of its antitumor effects in two tumor models.  Further evaluation of mechanism demonstrated I with the remarkable capacity of reducing kynurenine level in plasma/TME and restoring anti-tumor immune response.  I could be further developed as a potential immunotherapeutic agent combined with immune checkpoint inhibitors or chemotherapeutic drugs for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruUO0oCjsL5bVg90H21EOLACvtfcHk0ljreVelh9F-JA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVWlu7jK&md5=465bc2f6148b05c2b00d1dec45f06234</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2019.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2019.07.011%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520in%2520vivo%2520antitumor%2520evaluation%2520of%2520an%2520orally%2520active%2520potent%2520phosphonamidate%2520derivative%2520targeting%2520IDO1%252FIDO2%252FTDO%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2019%26volume%3D168%26spage%3D214%26epage%3D223%26doi%3D10.1016%2Fj.bcp.2019.07.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Improving the potency of cancer immunotherapy by dual targeting of IDO1 and DNA</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">30</span>â <span class="NLM_lpage">36</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201700666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fcmdc.201700666" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=29205945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvF2jsb3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=30-36&issue=1&author=K.+Fangauthor=G.+Dongauthor=H.+Wangauthor=S.+Heauthor=S.+Wuauthor=W.+Wangauthor=C.+Sheng&title=Improving+the+potency+of+cancer+immunotherapy+by+dual+targeting+of+IDO1+and+DNA&doi=10.1002%2Fcmdc.201700666"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA</span></div><div class="casAuthors">Fang, Kun; Dong, Guoqiang; Wang, Hongyu; He, Shipeng; Wu, Shanchao; Wang, Wei; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-36</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Herein we report the first exploration of a dual-targeting drug design strategy to improve the efficacy of small-mol. cancer immunotherapy.  New hybrids of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and DNA alkylating nitrogen mustards that resp. target IDO1 and DNA were rationally designed.  As the first-in-class examples of such mols., they were found to exhibit significantly enhanced anticancer activity in vitro and in vivo with low toxicity.  This proof-of-concept study has established a crit. step toward the development of a novel and effective immunotherapy for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUSxFALgkwHbVg90H21EOLACvtfcHk0ljreVelh9F-JA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvF2jsb3L&md5=bbef804d59cb318294b791064a5b7909</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700666%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DImproving%2520the%2520potency%2520of%2520cancer%2520immunotherapy%2520by%2520dual%2520targeting%2520of%2520IDO1%2520and%2520DNA%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26issue%3D1%26spage%3D30%26epage%3D36%26doi%3D10.1002%2Fcmdc.201700666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel indoleamine 2,3-dioxygenase 1 (IDO1) and histone deacetylase (HDAC) dual inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">312</span>â <span class="NLM_lpage">317</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.7b00487</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00487" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtVWrurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=312-317&issue=4&author=K.+Fangauthor=G.+Dongauthor=Y.+Liauthor=S.+Heauthor=Y.+Wuauthor=S.+Wuauthor=W.+Wangauthor=C.+Sheng&title=Discovery+of+novel+indoleamine+2%2C3-dioxygenase+1+%28IDO1%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors&doi=10.1021%2Facsmedchemlett.7b00487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors</span></div><div class="casAuthors">Fang, Kun; Dong, Guoqiang; Li, Yu; He, Shipeng; Wu, Ying; Wu, Shanchao; Wang, Wei; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">312-317</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to take advantage of both immunotherapeutic and epigenetic antitumor agents, the first generation of dual indoleamine 2,3-dioxygenase 1 (IDO1) and histone deacetylase (HDAC) inhibitors were designed.  The highly active dual inhibitor 10 showed excellent and balanced activity against both IDO1 (IC50 = 69.0 nM) and HDAC1 (IC50 = 66.5 nM), whose dual targeting mechanisms were validated in cancer cells.  Compd. 10 had good pharmacokinetic profiles as an orally active antitumor agent and significantly reduced the L-kynurenine level in plasma.  In particular, it showed excellent in vivo antitumor efficacy in the murine LLC tumor model with low toxicity.  This proof-of-concept study provided a novel strategy for cancer treatment.  Compd. 10 represents a promising lead compd. for the development of novel antitumor agents and can also be used as a valuable probe to clarify the relationships and mechanisms between cancer immunotherapy and epigenetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEDqXRR2J0zrVg90H21EOLACvtfcHk0ljreVelh9F-JA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtVWrurc%253D&md5=c808b75f03d703dc7e66798759457f4a</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00487%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520novel%2520indoleamine%25202%252C3-dioxygenase%25201%2520%2528IDO1%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D4%26spage%3D312%26epage%3D317%26doi%3D10.1021%2Facsmedchemlett.7b00487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref231"><div class="reference"><strong class="refLabel"><a href="#ref231" class="rightTabRefNumLink">231</a></strong><div class="NLM_citation" id="rightTab-cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reckamp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figlin, R. A.</span></span> <span> </span><span class="NLM_article-title">Akt inhibitors in clinical development for the treatment of cancer</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1355</span>â <span class="NLM_lpage">1366</span>, <span class="refDoi">Â DOI: 10.1517/13543784.2010.520701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1517%2F13543784.2010.520701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=20846000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWmu77K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=1355-1366&issue=11&author=S.+K.+Palauthor=K.+Reckampauthor=H.+Yuauthor=R.+A.+Figlin&title=Akt+inhibitors+in+clinical+development+for+the+treatment+of+cancer&doi=10.1517%2F13543784.2010.520701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Akt inhibitors in clinical development for the treatment of cancer</span></div><div class="casAuthors">Pal, Sumanta Kumar; Reckamp, Karen; Yu, Hua; Figlin, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1355-1366</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: The evolution of targeted therapies is dependent upon identification of cellular moieties that can be pharmacol. modulated.  As one such example, the serine-threonine kinase Akt was identified nearly two decades ago.  Since then, its role in mediating multiple signaling cascades (ultimately leading to cell growth and proliferation) has since been identified.  More recently, several agents have been developed that antagonize Akt - these agents are in various stages of clin. testing.  Areas covered in this review: Herein, we outline development of several promising Akt inhibitors, including perifosine, MK-2206, RX-0201, PBI-05204, GSK2141795 and others.  What the reader will gain: The reader will gain insight into the current pipeline of Akt inhibitors, and the degree to which these agents have been examd. both clin. and preclinically.  Take home message: With an emerging pipeline of agents targeting Akt, it will be crit. to decipher which amongst them holds the greatest promise.  Herein, we explore this drug pipeline and provide strategies for detg. the future clin. application of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWER-qb8DJrbVg90H21EOLACvtfcHk0ljreVelh9F-JA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWmu77K&md5=912f499b18ab4879d7930616ecc66d3e</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1517%2F13543784.2010.520701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2010.520701%26sid%3Dliteratum%253Aachs%26aulast%3DPal%26aufirst%3DS.%2BK.%26aulast%3DReckamp%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DFiglin%26aufirst%3DR.%2BA.%26atitle%3DAkt%2520inhibitors%2520in%2520clinical%2520development%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2010%26volume%3D19%26issue%3D11%26spage%3D1355%26epage%3D1366%26doi%3D10.1517%2F13543784.2010.520701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref232"><div class="reference"><strong class="refLabel"><a href="#ref232" class="rightTabRefNumLink">232</a></strong><div class="NLM_citation" id="rightTab-cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heerding, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leber, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keenan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafrance, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safonov, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takata, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venslavsky, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhry, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaber, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strum, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duckett, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberwein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knick, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansing, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minthorn, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Concha, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of Akt kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">5663</span>â <span class="NLM_lpage">5679</span>, <span class="refDoi">Â DOI: 10.1021/jm8004527</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8004527" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVChs7bE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5663-5679&issue=18&author=D.+A.+Heerdingauthor=N.+Rhodesauthor=J.+D.+Leberauthor=T.+J.+Clarkauthor=R.+M.+Keenanauthor=L.+V.+Lafranceauthor=M.+Liauthor=I.+G.+Safonovauthor=D.+T.+Takataauthor=J.+W.+Venslavskyauthor=D.+S.+Yamashitaauthor=A.+E.+Choudhryauthor=R.+A.+Copelandauthor=Z.+Laiauthor=M.+D.+Schaberauthor=P.+J.+Tumminoauthor=S.+L.+Strumauthor=E.+R.+Woodauthor=D.+R.+Duckettauthor=D.+Eberweinauthor=V.+B.+Knickauthor=T.+J.+Lansingauthor=R.+T.+McConnellauthor=S.+Y.+Zhangauthor=E.+A.+Minthornauthor=N.+O.+Conchaauthor=G.+L.+Warrenauthor=R.+Kumar&title=Identification+of+4-%282-%284-Amino-1%2C2%2C5-oxadiazol-3-yl%29-1-ethyl-7-%7B%5B%283S%29-3-piperidinylmethyl%5Doxy%7D-1H-imidazo%5B4%2C5-c%5Dpyridin-4-yl%29-2-methyl-3-butyn-2-ol+%28GSK690693%29%2C+a+novel+inhibitor+of+Akt+kinase&doi=10.1021%2Fjm8004527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a Novel Inhibitor of AKT Kinase</span></div><div class="casAuthors">Heerding, Dirk A.; Rhodes, Nelson; Leber, Jack D.; Clark, Tammy J.; Keenan, Richard M.; Lafrance, Louis V.; Li, Mei; Safonov, Igor G.; Takata, Dennis T.; Venslavsky, Joseph W.; Yamashita, Dennis S.; Choudhry, Anthony E.; Copeland, Robert A.; Lai, Zhihong; Schaber, Michael D.; Tummino, Peter J.; Strum, Susan L.; Wood, Edgar R.; Duckett, Derek R.; Eberwein, Derek; Knick, Victoria B.; Lansing, Timothy J.; McConnell, Randy T.; Zhang, Shu Yun; Minthorn, Elisabeth A.; Concha, Nestor O.; Warren, Gregory L.; Kumar, Rakesh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5663-5679</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Overexpression of AKT has an antiapoptotic effect in many cell types, and expression of dominant neg. AKT blocks the ability of a variety of growth factors to promote survival.  Therefore, inhibitors of AKT kinase activity might be useful as monotherapy for the treatment of tumors with activated AKT.  Herein, we describe our lead optimization studies culminating in the discovery of compd. 3g (GSK690693, I).  Compd. 3g is a novel ATP competitive, pan-AKT kinase inhibitor with IC50 values of 2, 13, and 9 nM against AKT1, 2, and 3, resp.  An X-ray cocrystal structure was solved with 3g and the kinase domain of AKT2, confirming that 3g bound in the ATP binding pocket.  Compd. 3g potently inhibits intracellular AKT activity as measured by the inhibition of the phosphorylation levels of GSK3Î².  I.p. administration of 3g in immunocompromised mice results in the inhibition of GSK3Î² phosphorylation and tumor growth in human breast carcinoma (BT474) xenografts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIAGkPktggErVg90H21EOLACvtfcHk0lg4-s8LqqxPEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVChs7bE&md5=c0e6f283a3ee79dffafdd90ec69513bc</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1021%2Fjm8004527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8004527%26sid%3Dliteratum%253Aachs%26aulast%3DHeerding%26aufirst%3DD.%2BA.%26aulast%3DRhodes%26aufirst%3DN.%26aulast%3DLeber%26aufirst%3DJ.%2BD.%26aulast%3DClark%26aufirst%3DT.%2BJ.%26aulast%3DKeenan%26aufirst%3DR.%2BM.%26aulast%3DLafrance%26aufirst%3DL.%2BV.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DSafonov%26aufirst%3DI.%2BG.%26aulast%3DTakata%26aufirst%3DD.%2BT.%26aulast%3DVenslavsky%26aufirst%3DJ.%2BW.%26aulast%3DYamashita%26aufirst%3DD.%2BS.%26aulast%3DChoudhry%26aufirst%3DA.%2BE.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DSchaber%26aufirst%3DM.%2BD.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DStrum%26aufirst%3DS.%2BL.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DDuckett%26aufirst%3DD.%2BR.%26aulast%3DEberwein%26aufirst%3DD.%26aulast%3DKnick%26aufirst%3DV.%2BB.%26aulast%3DLansing%26aufirst%3DT.%2BJ.%26aulast%3DMcConnell%26aufirst%3DR.%2BT.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DMinthorn%26aufirst%3DE.%2BA.%26aulast%3DConcha%26aufirst%3DN.%2BO.%26aulast%3DWarren%26aufirst%3DG.%2BL.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DIdentification%2520of%25204-%25282-%25284-Amino-1%252C2%252C5-oxadiazol-3-yl%2529-1-ethyl-7-%257B%255B%25283S%2529-3-piperidinylmethyl%255Doxy%257D-1H-imidazo%255B4%252C5-c%255Dpyridin-4-yl%2529-2-methyl-3-butyn-2-ol%2520%2528GSK690693%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520Akt%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D18%26spage%3D5663%26epage%3D5679%26doi%3D10.1021%2Fjm8004527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref233"><div class="reference"><strong class="refLabel"><a href="#ref233" class="rightTabRefNumLink">233</a></strong><div class="NLM_citation" id="rightTab-cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerding, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duckett, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberwein, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knick, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansing, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahana, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geske, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleymenova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhry, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leber, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minthorn, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strum, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2366</span>â <span class="NLM_lpage">2374</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-07-5783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1158%2F0008-5472.CAN-07-5783" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=18381444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktV2jsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=2366-2374&issue=7&author=N.+Rhodesauthor=D.+A.+Heerdingauthor=D.+R.+Duckettauthor=D.+J.+Eberweinauthor=V.+B.+Knickauthor=T.+J.+Lansingauthor=R.+T.+McConnellauthor=T.+M.+Gilmerauthor=S.+Y.+Zhangauthor=K.+Robellauthor=J.+A.+Kahanaauthor=R.+S.+Geskeauthor=E.+V.+Kleymenovaauthor=A.+E.+Choudhryauthor=Z.+Laiauthor=J.+D.+Leberauthor=E.+A.+Minthornauthor=S.+L.+Strumauthor=E.+R.+Woodauthor=P.+S.+Huangauthor=R.+A.+Copelandauthor=R.+Kumar&title=Characterization+of+an+Akt+kinase+inhibitor+with+potent+pharmacodynamic+and+antitumor+activity&doi=10.1158%2F0008-5472.CAN-07-5783"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity</span></div><div class="casAuthors">Rhodes, Nelson; Heerding, Dirk A.; Duckett, Derek R.; Eberwein, Derek J.; Knick, Victoria B.; Lansing, Timothy J.; McConnell, Randy T.; Gilmer, Tona M.; Zhang, Shu-Yun; Robell, Kimberly; Kahana, Jason A.; Geske, Robert S.; Kleymenova, Elena V.; Choudhry, Anthony E.; Lai, Zhihong; Leber, Jack D.; Minthorn, Elisabeth A.; Strum, Susan L.; Wood, Edgar R.; Huang, Pearl S.; Copeland, Robert A.; Kumar, Rakesh</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2366-2374</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Akt kinases 1, 2, and 3 are important regulators of cell survival and have been shown to be constitutively active in a variety of human tumors.  GSK690693 is a novel ATP-competitive, low-nanomolar pan-Akt kinase inhibitor.  It is selective for the Akt isoforms vs. the majority of kinases in other families; however, it does inhibit addnl. members of the AGC kinase family.  It causes dose-dependent redns. in the phosphorylation state of multiple proteins downstream of Akt, including GSK3Î², PRAS40, and Forkhead.  GSK690693 inhibited proliferation and induced apoptosis in a subset of tumor cells with potency consistent with intracellular inhibition of Akt kinase activity.  In immune-compromised mice implanted with human BT474 breast carcinoma xenografts, a single i.p. administration of GSK690693 inhibited GSK3Î² phosphorylation in a dose- and time-dependent manner.  After a single dose of GSK690693, >3 Î¼mol/L drug concn. in BT474 tumor xenografts correlated with a sustained decrease in GSK3Î² phosphorylation.  Consistent with the role of Akt in insulin signaling, treatment with GSK690693 resulted in acute and transient increases in blood glucose level.  Daily administration of GSK690693 produced significant antitumor activity in mice bearing established human SKOV-3 ovarian, LNCaP prostate, and BT474 and HCC-1954 breast carcinoma xenografts.  Immunohistochem. anal. of tumor xenografts after repeat dosing with GSK690693 showed redns. in phosphorylated Akt substrates in vivo.  These results support further evaluation of GSK690693 as an anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrIdccCuUbkLVg90H21EOLACvtfcHk0lg4-s8LqqxPEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktV2jsrg%253D&md5=767976fefa3818022ae86d9903c79dad</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-5783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-5783%26sid%3Dliteratum%253Aachs%26aulast%3DRhodes%26aufirst%3DN.%26aulast%3DHeerding%26aufirst%3DD.%2BA.%26aulast%3DDuckett%26aufirst%3DD.%2BR.%26aulast%3DEberwein%26aufirst%3DD.%2BJ.%26aulast%3DKnick%26aufirst%3DV.%2BB.%26aulast%3DLansing%26aufirst%3DT.%2BJ.%26aulast%3DMcConnell%26aufirst%3DR.%2BT.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DRobell%26aufirst%3DK.%26aulast%3DKahana%26aufirst%3DJ.%2BA.%26aulast%3DGeske%26aufirst%3DR.%2BS.%26aulast%3DKleymenova%26aufirst%3DE.%2BV.%26aulast%3DChoudhry%26aufirst%3DA.%2BE.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DLeber%26aufirst%3DJ.%2BD.%26aulast%3DMinthorn%26aufirst%3DE.%2BA.%26aulast%3DStrum%26aufirst%3DS.%2BL.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DHuang%26aufirst%3DP.%2BS.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DCharacterization%2520of%2520an%2520Akt%2520kinase%2520inhibitor%2520with%2520potent%2520pharmacodynamic%2520and%2520antitumor%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26issue%3D7%26spage%3D2366%26epage%3D2374%26doi%3D10.1158%2F0008-5472.CAN-07-5783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref234"><div class="reference"><strong class="refLabel"><a href="#ref234" class="rightTabRefNumLink">234</a></strong><div class="NLM_citation" id="rightTab-cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurwitz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiorean, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampkin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebowitz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, B.</span></span> <span> </span><span class="NLM_article-title">Akt inhibitor GSK690693: Preliminary results from the first time in human study</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">LB</span>â <span class="NLM_lpage">68</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=LB-68&author=P.+LoRussoauthor=H.+Hurwitzauthor=E.+Chioreanauthor=R.+Jewellauthor=T.+Lampkinauthor=K.+Bachmanauthor=R.+Kumarauthor=P.+Lebowitzauthor=B.+Weber&title=Akt+inhibitor+GSK690693%3A+Preliminary+results+from+the+first+time+in+human+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DHurwitz%26aufirst%3DH.%26aulast%3DChiorean%26aufirst%3DE.%26aulast%3DJewell%26aufirst%3DR.%26aulast%3DLampkin%26aufirst%3DT.%26aulast%3DBachman%26aufirst%3DK.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DLebowitz%26aufirst%3DP.%26aulast%3DWeber%26aufirst%3DB.%26atitle%3DAkt%2520inhibitor%2520GSK690693%253A%2520Preliminary%2520results%2520from%2520the%2520first%2520time%2520in%2520human%2520study%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3DLB%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref235"><div class="reference"><strong class="refLabel"><a href="#ref235" class="rightTabRefNumLink">235</a></strong><div class="NLM_citation" id="rightTab-cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bandarage, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hare, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marhefka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bemis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodems, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charonnet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Come, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span> <span> </span><span class="NLM_article-title">4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Potent and selective p70S6 kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">5191</span>â <span class="NLM_lpage">5194</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2009.07.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmcl.2009.07.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=19632115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVSlsrrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5191-5194&issue=17&author=U.+Bandarageauthor=B.+Hareauthor=J.+Parsonsauthor=L.+Phamauthor=C.+Marhefkaauthor=G.+Bemisauthor=Q.+Tangauthor=C.+S.+Moodyauthor=S.+Rodemsauthor=S.+Shahauthor=C.+Adamsauthor=J.+Bravoauthor=E.+Charonnetauthor=V.+Savicauthor=J.+H.+Comeauthor=J.+Green&title=4-%28Benzimidazol-2-yl%29-1%2C2%2C5-oxadiazol-3-ylamine+derivatives%3A+Potent+and+selective+p70S6+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2009.07.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Potent and selective p70S6 kinase inhibitors</span></div><div class="casAuthors">Bandarage, Upul; Hare, Brian; Parsons, Jonathan; Pham, Ly; Marhefka, Craig; Bemis, Guy; Tang, Qing; Moody, Cameron Stuver; Rodems, Steve; Shah, Sundeep; Adams, Chris; Bravo, Jose; Charonnet, Emmanuelle; Savic, Vladimir; Come, Jon H.; Green, Jeremy</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5191-5194</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The design and synthesis of 4-(benzimidazol-2-yl)-1,2,5-oxadiazol-3-amine derivs. I (R1 = Me, i-Pr, Ph, R2 = H; etc.) as inhibitors of p70S6 kinase was reported.  Structure-based design employing an active site homol. model derived from PKA led to the prepn. of benzimidazole 5-substituted compds. I (R1 = c-Bu, R2 = OH, NH2) as highly potent inhibitors (Ki <1 nM) of p70S6K, with >100-fold selectivity against related kinases PKA, ROCK and GSK3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXcs_rzc0eabVg90H21EOLACvtfcHk0lgTjFz-eeOPOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVSlsrrF&md5=93423c5bcbdfc437444c737314d28165</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.07.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.07.022%26sid%3Dliteratum%253Aachs%26aulast%3DBandarage%26aufirst%3DU.%26aulast%3DHare%26aufirst%3DB.%26aulast%3DParsons%26aufirst%3DJ.%26aulast%3DPham%26aufirst%3DL.%26aulast%3DMarhefka%26aufirst%3DC.%26aulast%3DBemis%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DQ.%26aulast%3DMoody%26aufirst%3DC.%2BS.%26aulast%3DRodems%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DAdams%26aufirst%3DC.%26aulast%3DBravo%26aufirst%3DJ.%26aulast%3DCharonnet%26aufirst%3DE.%26aulast%3DSavic%26aufirst%3DV.%26aulast%3DCome%26aufirst%3DJ.%2BH.%26aulast%3DGreen%26aufirst%3DJ.%26atitle%3D4-%2528Benzimidazol-2-yl%2529-1%252C2%252C5-oxadiazol-3-ylamine%2520derivatives%253A%2520Potent%2520and%2520selective%2520p70S6%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D17%26spage%3D5191%26epage%3D5194%26doi%3D10.1016%2Fj.bmcl.2009.07.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref236"><div class="reference"><strong class="refLabel"><a href="#ref236" class="rightTabRefNumLink">236</a></strong><div class="NLM_citation" id="rightTab-cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Come, J. H.</span>; <span class="NLM_string-name">Green, J.</span>; <span class="NLM_string-name">Marhefka, C.</span>; <span class="NLM_string-name">Harbeson, S. L.</span>; <span class="NLM_string-name">Pham, L.</span></span> <span> </span><span class="NLM_article-title">Preparation of Aminofurazan Derivatives as Protein Kinase Inhibitors</span>. <span class="NLM_patent">WO2005019190A2</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=J.+H.+Come&author=J.+Green&author=C.+Marhefka&author=S.+L.+Harbeson&author=L.+Pham&title=Preparation+of+Aminofurazan+Derivatives+as+Protein+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCome%26aufirst%3DJ.%2BH.%26atitle%3DPreparation%2520of%2520Aminofurazan%2520Derivatives%2520as%2520Protein%2520Kinase%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref237"><div class="reference"><strong class="refLabel"><a href="#ref237" class="rightTabRefNumLink">237</a></strong><div class="NLM_citation" id="rightTab-cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asakawa, K.</span>; <span class="NLM_string-name">Hashimoto, M.</span>; <span class="NLM_string-name">Ito, H.</span>; <span class="NLM_string-name">Nakamura, M.</span>; <span class="NLM_string-name">Nonoshita, K.</span>; <span class="NLM_string-name">Okubo, M.</span>; <span class="NLM_string-name">Sato, A.</span>; <span class="NLM_string-name">Takahashi, H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Novel Spiro Indan Derivatives as Protein Kinase RSK1 Inhibitors and Antitumor Agents</span>. <span class="NLM_patent">JP2009173629A</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=K.+Asakawa&author=M.+Hashimoto&author=H.+Ito&author=M.+Nakamura&author=K.+Nonoshita&author=M.+Okubo&author=A.+Sato&author=H.+Takahashi&title=Preparation+of+Novel+Spiro+Indan+Derivatives+as+Protein+Kinase+RSK1+Inhibitors+and+Antitumor+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAsakawa%26aufirst%3DK.%26atitle%3DPreparation%2520of%2520Novel%2520Spiro%2520Indan%2520Derivatives%2520as%2520Protein%2520Kinase%2520RSK1%2520Inhibitors%2520and%2520Antitumor%2520Agents%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref238"><div class="reference"><strong class="refLabel"><a href="#ref238" class="rightTabRefNumLink">238</a></strong><div class="NLM_citation" id="rightTab-cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aulinger-Fuchs, K.</span>; <span class="NLM_string-name">Herz, T.</span>; <span class="NLM_string-name">Krauss, R.</span>; <span class="NLM_string-name">Kubbutat, M.</span>; <span class="NLM_string-name">Lang, M.</span>; <span class="NLM_string-name">Schaechtele, C.</span>; <span class="NLM_string-name">Totzke, F.</span></span> <span> </span><span class="NLM_article-title">Preparation of Oxadiazolopyrazines as Kinase Inhibitors</span>. <span class="NLM_patent">WO2005044270A1</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=K.+Aulinger-Fuchs&author=T.+Herz&author=R.+Krauss&author=M.+Kubbutat&author=M.+Lang&author=C.+Schaechtele&author=F.+Totzke&title=Preparation+of+Oxadiazolopyrazines+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAulinger-Fuchs%26aufirst%3DK.%26atitle%3DPreparation%2520of%2520Oxadiazolopyrazines%2520as%2520Kinase%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref239"><div class="reference"><strong class="refLabel"><a href="#ref239" class="rightTabRefNumLink">239</a></strong><div class="NLM_citation" id="rightTab-cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pyrkov, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevostyanova, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmalhausen, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shkoporov, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinnik, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muronetz, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Severin, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedichev, P. O.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of small-molecule ligands of phosphofructokinase-2 activating or inhibiting glycolysis</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1322</span>â <span class="NLM_lpage">1329</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201300154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fcmdc.201300154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=23813838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVait7zE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1322-1329&issue=8&author=T.+V.+Pyrkovauthor=I.+A.+Sevostyanovaauthor=E.+V.+Schmalhausenauthor=A.+N.+Shkoporovauthor=A.+A.+Vinnikauthor=V.+I.+Muronetzauthor=F.+F.+Severinauthor=P.+O.+Fedichev&title=Structure-based+design+of+small-molecule+ligands+of+phosphofructokinase-2+activating+or+inhibiting+glycolysis&doi=10.1002%2Fcmdc.201300154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Small-Molecule Ligands of Phosphofructokinase-2 Activating or Inhibiting Glycolysis</span></div><div class="casAuthors">Pyrkov, Timothy V.; Sevostyanova, Irina A.; Schmalhausen, Elena V.; Shkoporov, Andrei N.; Vinnik, Andrei A.; Muronetz, Vladimir I.; Severin, Fedor F.; Fedichev, Peter O.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1322-1329</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Glycolysis lies at the basis of metab. and cell energy supply.  The disregulation of glycolysis is involved in such pathol. processes as cancer proliferation, neurodegenerative diseases, and amplification of ischemic damage.  Phosphofructokinase-2 (PFK-2), a bifunctional enzyme and regulator of glycolytic flux, has recently emerged as a promising anticancer target.  Herein, the computer-aided design of a new class of aminofurazan-triazole regulators of PFK-2 is described along with the results of their in vitro evaluation.  The aminofurazan-triazoles differ from other recently described inhibitors of PFK-2 and demonstrate the ability to modulate glycolytic flux in rat muscle lysate, producing a twofold decrease by inhibitors and fourfold increase by activators.  The most potent compds. in the series were shown to inhibit the kinase activity of the hypoxia-inducible form of PFK-2, PFKFB3, as well as proliferation of HeLa, lung adenocarcinoma, colon adenocarcinoma, and breast cancer cells at concns. in the low micromolar range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH3hQmNOqY0LVg90H21EOLACvtfcHk0lgTjFz-eeOPOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVait7zE&md5=a78f5f7a035e912e061fef08ad82c8bd</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300154%26sid%3Dliteratum%253Aachs%26aulast%3DPyrkov%26aufirst%3DT.%2BV.%26aulast%3DSevostyanova%26aufirst%3DI.%2BA.%26aulast%3DSchmalhausen%26aufirst%3DE.%2BV.%26aulast%3DShkoporov%26aufirst%3DA.%2BN.%26aulast%3DVinnik%26aufirst%3DA.%2BA.%26aulast%3DMuronetz%26aufirst%3DV.%2BI.%26aulast%3DSeverin%26aufirst%3DF.%2BF.%26aulast%3DFedichev%26aufirst%3DP.%2BO.%26atitle%3DStructure-based%2520design%2520of%2520small-molecule%2520ligands%2520of%2520phosphofructokinase-2%2520activating%2520or%2520inhibiting%2520glycolysis%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26issue%3D8%26spage%3D1322%26epage%3D1329%26doi%3D10.1002%2Fcmdc.201300154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref240"><div class="reference"><strong class="refLabel"><a href="#ref240" class="rightTabRefNumLink">240</a></strong><div class="NLM_citation" id="rightTab-cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sha, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. F.</span></span> <span> </span><span class="NLM_article-title">6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol: A promising new anticancer compound</span>. <i>Biosci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">BSR20171440</span>, <span class="refDoi">Â DOI: 10.1042/BSR20171440</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1042%2FBSR20171440" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=29358310" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=BSR20171440&issue=1&author=H.+H.+Shaauthor=Z.+Wangauthor=S.+C.+Dongauthor=T.+M.+Huauthor=S.+W.+Liuauthor=J.+Y.+Zhangauthor=Y.+Wuauthor=R.+Maauthor=J.+Z.+Wuauthor=D.+Chenauthor=J.+F.+Feng&title=6-%287-Nitro-2%2C1%2C3-benzoxadiazol-4-ylthio%29+hexanol%3A+A+promising+new+anticancer+compound&doi=10.1042%2FBSR20171440"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1042%2FBSR20171440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBSR20171440%26sid%3Dliteratum%253Aachs%26aulast%3DSha%26aufirst%3DH.%2BH.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DDong%26aufirst%3DS.%2BC.%26aulast%3DHu%26aufirst%3DT.%2BM.%26aulast%3DLiu%26aufirst%3DS.%2BW.%26aulast%3DZhang%26aufirst%3DJ.%2BY.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DJ.%2BZ.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DFeng%26aufirst%3DJ.%2BF.%26atitle%3D6-%25287-Nitro-2%252C1%252C3-benzoxadiazol-4-ylthio%2529%2520hexanol%253A%2520A%2520promising%2520new%2520anticancer%2520compound%26jtitle%3DBiosci.%2520Rep.%26date%3D2018%26volume%3D38%26issue%3D1%26spage%3DBSR20171440%26doi%3D10.1042%2FBSR20171440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref241"><div class="reference"><strong class="refLabel"><a href="#ref241" class="rightTabRefNumLink">241</a></strong><div class="NLM_citation" id="rightTab-cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caccuri, A. M.</span>; <span class="NLM_string-name">Ricci, G.</span></span> <span> </span><span class="NLM_article-title">Preparation of 7-Nitro-2,1,3-benzoxadiazole Derivatives for Use in Anticancer Therapy</span>. <span class="NLM_patent">WO2004093874A1</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=A.+M.+Caccuri&author=G.+Ricci&title=Preparation+of+7-Nitro-2%2C1%2C3-benzoxadiazole+Derivatives+for+Use+in+Anticancer+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCaccuri%26aufirst%3DA.%2BM.%26atitle%3DPreparation%2520of%25207-Nitro-2%252C1%252C3-benzoxadiazole%2520Derivatives%2520for%2520Use%2520in%2520Anticancer%2520Therapy%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref242"><div class="reference"><strong class="refLabel"><a href="#ref242" class="rightTabRefNumLink">242</a></strong><div class="NLM_citation" id="rightTab-cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ricci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Maria, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turella, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stella, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filomeni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federici, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccuri, A. M.</span></span> <span> </span><span class="NLM_article-title">7-Nitro-2,1,3-benzoxadiazole derivatives, a new class of suicide inhibitors for glutathione S-transferases. Mechanism of action of potential anticancer drugs</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span> (<span class="NLM_issue">28</span>),  <span class="NLM_fpage">26397</span>â <span class="NLM_lpage">26405</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M503295200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1074%2Fjbc.M503295200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=15888444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvFymtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=26397-26405&issue=28&author=G.+Ricciauthor=F.+De+Mariaauthor=G.+Antoniniauthor=P.+Turellaauthor=A.+Bulloauthor=L.+Stellaauthor=G.+Filomeniauthor=G.+Federiciauthor=A.+M.+Caccuri&title=7-Nitro-2%2C1%2C3-benzoxadiazole+derivatives%2C+a+new+class+of+suicide+inhibitors+for+glutathione+S-transferases.+Mechanism+of+action+of+potential+anticancer+drugs&doi=10.1074%2Fjbc.M503295200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">7-Nitro-2,1,3-benzoxadiazole Derivatives, a New Class of Suicide Inhibitors for Glutathione S-Transferases: mechanism of action of potential anticancer drugs</span></div><div class="casAuthors">Ricci, Giorgio; De Maria, Francesca; Antonini, Giovanni; Turella, Paola; Bullo, Angela; Stella, Lorenzo; Filomeni, Giuseppe; Federici, Giorgio; Caccuri, Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">26397-26405</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Spectroscopic and rapid kinetic expts. were performed to detail the interaction of human glutathione S-transferases GSTA1-1, GSTM2-2, and GSTP1-1 with 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX).  This compd. is a representative mol. of a new class of 7-nitro-2,1,3-benzoxadiazole (NBD) derivs. (non-GSH peptidomimetic compds.) that have been designed both to give strong GST inhibition and to accumulate in tumor cells avoiding the extrusion mechanisms mediated by the multidrug resistance protein pumps.  The authors have recently shown that submicromolar amts. of NBDHEX trigger apoptosis in several human tumor cell lines through the dissocn. of the JNKÂ·GSTP1-1 complex.  Results reported in the present study indicated that NBDHEX behaves like a suicide inhibitor for GSTs.  It bound to the H-site and was conjugated with GSH forming a Ï complex at the C-4 of the benzoxadiazole ring.  This complex was tightly stabilized in the active site of GSTP1-1 and GSTM2-2, whereas in GSTA1-1 the release of the 6-mercapto-1-hexanol from the Ï complex was the favored event.  Docking studies demonstrated the likely localization of the Ï complex in the GST active sites and provide a structural explanation for its strong stabilization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY0uWFsdpScrVg90H21EOLACvtfcHk0limmaJFpspGjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvFymtbY%253D&md5=a191d7a300478aa7d7fa2f70e2864f1e</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M503295200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M503295200%26sid%3Dliteratum%253Aachs%26aulast%3DRicci%26aufirst%3DG.%26aulast%3DDe%2BMaria%26aufirst%3DF.%26aulast%3DAntonini%26aufirst%3DG.%26aulast%3DTurella%26aufirst%3DP.%26aulast%3DBullo%26aufirst%3DA.%26aulast%3DStella%26aufirst%3DL.%26aulast%3DFilomeni%26aufirst%3DG.%26aulast%3DFederici%26aufirst%3DG.%26aulast%3DCaccuri%26aufirst%3DA.%2BM.%26atitle%3D7-Nitro-2%252C1%252C3-benzoxadiazole%2520derivatives%252C%2520a%2520new%2520class%2520of%2520suicide%2520inhibitors%2520for%2520glutathione%2520S-transferases.%2520Mechanism%2520of%2520action%2520of%2520potential%2520anticancer%2520drugs%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26issue%3D28%26spage%3D26397%26epage%3D26405%26doi%3D10.1074%2Fjbc.M503295200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref243"><div class="reference"><strong class="refLabel"><a href="#ref243" class="rightTabRefNumLink">243</a></strong><div class="NLM_citation" id="rightTab-cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turella, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filomeni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Maria, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghibelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciriolo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianfriglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federici, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccuri, A. M.</span></span> <span> </span><span class="NLM_article-title">Proapoptotic activity of new glutathione S-transferase inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3751</span>â <span class="NLM_lpage">3761</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-04-3903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1158%2F0008-5472.CAN-04-3903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=15867371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslGksr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=3751-3761&issue=9&author=P.+Turellaauthor=C.+Cerellaauthor=G.+Filomeniauthor=A.+Bulloauthor=F.+De+Mariaauthor=L.+Ghibelliauthor=M.+R.+Cirioloauthor=M.+Cianfrigliaauthor=M.+Matteiauthor=G.+Federiciauthor=G.+Ricciauthor=A.+M.+Caccuri&title=Proapoptotic+activity+of+new+glutathione+S-transferase+inhibitors&doi=10.1158%2F0008-5472.CAN-04-3903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit243R"><div class="casContent"><span class="casTitleNuber">243</span><div class="casTitle"><span class="NLM_cas:atitle">Proapoptotic activity of new glutathione S-transferase inhibitors</span></div><div class="casAuthors">Turella, Paola; Cerella, Claudia; Filomeni, Giuseppe; Bullo, Angela; De Maria, Francesca; Ghibelli, Lina; Ciriolo, Maria Rosa; Cianfriglia, Maurizio; Mattei, Maurizio; Federici, Giorgio; Ricci, Giorgio; Caccuri, Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3751-3761</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Selected 7-nitro-2,1,3-benzoxadiazole derivs. have been recently found very efficient inhibitors of glutathione S-transferase (GST) P1-1,5 an enzyme which displays antiapoptotic activity and is also involved in the cellular resistance to anticancer drugs.  These new inhibitors are not tripeptide glutathione-peptidomimetic mols. and display lipophilic properties suitable for crossing the plasma membrane.  In the present work, we show the strong cytotoxic activity of these compds. in the following four different cell lines: K562 (human myeloid leukemia), HepG2 (human hepatic carcinoma), CCRF-CEM (human T-lymphoblastic leukemia), and GLC-4 (human small cell lung carcinoma).  The LC50 values are in the micromolar/submicromolar range and are close to the IC50 values obtained with GSTP1-1, suggesting that the target of these mols. inside the cell is indeed this enzyme.  The cytotoxic mechanism of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol, the most effective GSTP1-1 inhibitor, has been carefully investigated in leukemic CCRF-CEM and K562 cell lines.  Western blot and immunopptn. analyzes have shown that 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol promotes in both cell lines the dissocn. of the GSTP1-1 in a complex with c-jun NH2-terminal kinase (JNK).  This process triggers a reactive oxygen species (ROS)-independent activation of the JNK-mediated pathway that results in a typical process of apoptosis.  Besides this main pathway, in K562 cells, a ROS-mediated apoptosis partially occurs (about 30%) which involves the p38MAPK signal transduction pathway.  The low concn. of this new compd. needed to trigger cytotoxic effects on tumor cells and the low toxicity on mice indicate that the new 7-nitro-2,1,3-benzoxadiazole derivs. are promising anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokV0HclcX2SrVg90H21EOLACvtfcHk0limmaJFpspGjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslGksr0%253D&md5=15227a889b1865ee73eeb7241725fdbe</span></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-3903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-3903%26sid%3Dliteratum%253Aachs%26aulast%3DTurella%26aufirst%3DP.%26aulast%3DCerella%26aufirst%3DC.%26aulast%3DFilomeni%26aufirst%3DG.%26aulast%3DBullo%26aufirst%3DA.%26aulast%3DDe%2BMaria%26aufirst%3DF.%26aulast%3DGhibelli%26aufirst%3DL.%26aulast%3DCiriolo%26aufirst%3DM.%2BR.%26aulast%3DCianfriglia%26aufirst%3DM.%26aulast%3DMattei%26aufirst%3DM.%26aulast%3DFederici%26aufirst%3DG.%26aulast%3DRicci%26aufirst%3DG.%26aulast%3DCaccuri%26aufirst%3DA.%2BM.%26atitle%3DProapoptotic%2520activity%2520of%2520new%2520glutathione%2520S-transferase%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26issue%3D9%26spage%3D3751%26epage%3D3761%26doi%3D10.1158%2F0008-5472.CAN-04-3903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref244"><div class="reference"><strong class="refLabel"><a href="#ref244" class="rightTabRefNumLink">244</a></strong><div class="NLM_citation" id="rightTab-cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pellizzari Tregno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geroni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapenta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filomeni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federici, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccuri, A. M.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo efficacy of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2606</span>â <span class="NLM_lpage">2617</span>, <span class="refDoi">Â DOI: 10.1016/j.ejca.2009.06.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.ejca.2009.06.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=19665369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVKls7jO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2009&pages=2606-2617&issue=14&author=F.+Pellizzari+Tregnoauthor=A.+Sauauthor=S.+Pezzolaauthor=C.+Geroniauthor=C.+Lapentaauthor=M.+Spadaauthor=G.+Filomeniauthor=E.+Bonannoauthor=G.+Federiciauthor=A.+M.+Caccuri&title=In+vitro+and+in+vivo+efficacy+of+6-%287-nitro-2%2C1%2C3-benzoxadiazol-4-ylthio%29hexanol+%28NBDHEX%29+on+human+melanoma&doi=10.1016%2Fj.ejca.2009.06.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo efficacy of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma</span></div><div class="casAuthors">Pellizzari Tregno, Francesca; Sau, Andrea; Pezzola, Silvia; Geroni, Cristina; Lapenta, Caterina; Spada, Massimo; Filomeni, Giuseppe; Bonanno, Elena; Federici, Giorgio; Caccuri, Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2606-2617</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) is a powerful inhibitor of the glutathione transferase P1-1 (GSTP1-1) and causes the disruption of the complex between GSTP1-1 and c-Jun N-terminal Kinase (JNK).  This induces JNK activation and apoptosis in tumor cells.  In the present work we assess the in vitro and in vivo effectiveness of NBDHEX on two human melanoma cell lines, Me501 and A375.  NBDHEX shows IC50 values in the low micromolar range (IC50 of 1.2 Â± 0.1 Î¼M and 2.0 Â± 0.2 Î¼M for Me501 and A375, resp.) and is over 100 times more cytotoxic to these cell lines than temozolomide.  Apoptosis is obsd. in Me501 cells within 3 h of the addn. of NBDHEX, while in A375 cells the apoptotic event is rather late, and is preceded by a G2/M phase arrest.  In both melanoma cell lines, JNK activity is required for the ability of NBDHEX to trigger apoptosis, confirming that the JNK pathway is an important therapeutic target for this tumor.  NBDHEX is also both effective and well tolerated in in vivo tumor models.  A tumor inhibition of 70% is obsd. in vivo against Me501 human melanoma and a similar result is obtained on A375 model, with 63% of tumor inhibition.  These findings indicate that the activation of the JNK pathway, through a selective GSTP1-1 targeting, could prove to be a promising new strategy for treating melanoma, which responds poorly to conventional therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSP5C-NFxCrbVg90H21EOLACvtfcHk0liFREmWY_2AuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVKls7jO&md5=463fe27ac959cf3d29c576461b4d6883</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2009.06.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2009.06.033%26sid%3Dliteratum%253Aachs%26aulast%3DPellizzari%2BTregno%26aufirst%3DF.%26aulast%3DSau%26aufirst%3DA.%26aulast%3DPezzola%26aufirst%3DS.%26aulast%3DGeroni%26aufirst%3DC.%26aulast%3DLapenta%26aufirst%3DC.%26aulast%3DSpada%26aufirst%3DM.%26aulast%3DFilomeni%26aufirst%3DG.%26aulast%3DBonanno%26aufirst%3DE.%26aulast%3DFederici%26aufirst%3DG.%26aulast%3DCaccuri%26aufirst%3DA.%2BM.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520efficacy%2520of%25206-%25287-nitro-2%252C1%252C3-benzoxadiazol-4-ylthio%2529hexanol%2520%2528NBDHEX%2529%2520on%2520human%2520melanoma%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2009%26volume%3D45%26issue%3D14%26spage%3D2606%26epage%3D2617%26doi%3D10.1016%2Fj.ejca.2009.06.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref245"><div class="reference"><strong class="refLabel"><a href="#ref245" class="rightTabRefNumLink">245</a></strong><div class="NLM_citation" id="rightTab-cit245"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rotili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarantino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forgione, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morozzo Della Rocca, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falconi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccuri, A. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure--activity relationship of new cytotoxic agents targeting human glutathione-S-transferases</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">156</span>â <span class="NLM_lpage">171</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2014.10.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.ejmech.2014.10.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=25462236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOjtrzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2015&pages=156-171&author=D.+Rotiliauthor=A.+De+Lucaauthor=D.+Tarantinoauthor=S.+Pezzolaauthor=M.+Forgioneauthor=B.+Morozzo+Della+Roccaauthor=M.+Falconiauthor=A.+Maiauthor=A.+M.+Caccuri&title=Synthesis+and+structure%2D%2Dactivity+relationship+of+new+cytotoxic+agents+targeting+human+glutathione-S-transferases&doi=10.1016%2Fj.ejmech.2014.10.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit245R"><div class="casContent"><span class="casTitleNuber">245</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationship of new cytotoxic agents targeting human glutathione-S-transferases</span></div><div class="casAuthors">Rotili, Dante; De Luca, Anastasia; Tarantino, Domenico; Pezzola, Silvia; Forgione, Mariantonietta; Morozzo della Rocca, Blasco; Falconi, Mattia; Mai, Antonello; Caccuri, Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">156-171</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The 6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)hexan-1-ol (NBDHEX, I), a "suicide inhibitor" of the glutathione-S-transferase GSTP1-1, showed pro-apoptotic properties in tumor cells, but in vivo studies were limited by poor bioavailability and high affinity towards GSTM2-2, expressed in many non-cancerous tissues.  This paper describes the synthesis and biol. characterization of 39 new I analogs, in which the hydroxyhexyl portion at the C4-sulfur atom has been replaced with phenyl-contg. moieties as well as substituted alkyl chains.  Some of the new compds. displayed 10-100 times increased water-soly., and most of them showed higher GSTP1-1 selectivity than I.  The presence of a Ph ring with polar substituents is in general assocd., with some exceptions to low cytotoxicity in osteosarcoma U-2OS cells.  Differently, some alkyl derivs. possess cytotoxicity comparable or higher than I.  Among the novel compds., selected ones, e.g., II, deserve further investigation for their anticancer potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYe3xFsXZO3LVg90H21EOLACvtfcHk0liFREmWY_2AuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOjtrzO&md5=cb95f8de3062cfa0632fdb9a8755922d</span></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.10.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.10.033%26sid%3Dliteratum%253Aachs%26aulast%3DRotili%26aufirst%3DD.%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3DTarantino%26aufirst%3DD.%26aulast%3DPezzola%26aufirst%3DS.%26aulast%3DForgione%26aufirst%3DM.%26aulast%3DMorozzo%2BDella%2BRocca%26aufirst%3DB.%26aulast%3DFalconi%26aufirst%3DM.%26aulast%3DMai%26aufirst%3DA.%26aulast%3DCaccuri%26aufirst%3DA.%2BM.%26atitle%3DSynthesis%2520and%2520structure--activity%2520relationship%2520of%2520new%2520cytotoxic%2520agents%2520targeting%2520human%2520glutathione-S-transferases%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D89%26spage%3D156%26epage%3D171%26doi%3D10.1016%2Fj.ejmech.2014.10.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref246"><div class="reference"><strong class="refLabel"><a href="#ref246" class="rightTabRefNumLink">246</a></strong><div class="NLM_citation" id="rightTab-cit246"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luca, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpanese, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapanotti, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viguria, T. M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forgione, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iorio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintieri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimenti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccuri, A. M.</span></span> <span> </span><span class="NLM_article-title">The nitrobenzoxadiazole derivative MC3181 blocks melanoma invasion and metastasis</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">15520</span>â <span class="NLM_lpage">15538</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.14690</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.18632%2Foncotarget.14690" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=28107182" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=15520-15538&issue=9&author=A.+D.+Lucaauthor=D.+Carpaneseauthor=M.+C.+Rapanottiauthor=T.+M.+S.+Viguriaauthor=M.+A.+Forgioneauthor=D.+Rotiliauthor=C.+Fulciauthor=E.+Iorioauthor=L.+Quintieriauthor=S.+Chimentiauthor=L.+Bianchiauthor=A.+Rosatoauthor=A.+M.+Caccuri&title=The+nitrobenzoxadiazole+derivative+MC3181+blocks+melanoma+invasion+and+metastasis&doi=10.18632%2Foncotarget.14690"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14690%26sid%3Dliteratum%253Aachs%26aulast%3DLuca%26aufirst%3DA.%2BD.%26aulast%3DCarpanese%26aufirst%3DD.%26aulast%3DRapanotti%26aufirst%3DM.%2BC.%26aulast%3DViguria%26aufirst%3DT.%2BM.%2BS.%26aulast%3DForgione%26aufirst%3DM.%2BA.%26aulast%3DRotili%26aufirst%3DD.%26aulast%3DFulci%26aufirst%3DC.%26aulast%3DIorio%26aufirst%3DE.%26aulast%3DQuintieri%26aufirst%3DL.%26aulast%3DChimenti%26aufirst%3DS.%26aulast%3DBianchi%26aufirst%3DL.%26aulast%3DRosato%26aufirst%3DA.%26aulast%3DCaccuri%26aufirst%3DA.%2BM.%26atitle%3DThe%2520nitrobenzoxadiazole%2520derivative%2520MC3181%2520blocks%2520melanoma%2520invasion%2520and%2520metastasis%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D9%26spage%3D15520%26epage%3D15538%26doi%3D10.18632%2Foncotarget.14690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref247"><div class="reference"><strong class="refLabel"><a href="#ref247" class="rightTabRefNumLink">247</a></strong><div class="NLM_citation" id="rightTab-cit247"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpanese, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenoci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scimeca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geroni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintieri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccuri, A. M.</span></span> <span> </span><span class="NLM_article-title">A novel orally active water-soluble inhibitor of human glutathione transferase exerts a potent and selective antitumor activity against human melanoma xenografts</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">4126</span>â <span class="NLM_lpage">4143</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.2798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.18632%2Foncotarget.2798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=25595904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BC2MvntFOlsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=4126-4143&issue=6&author=A.+De+Lucaauthor=D.+Rotiliauthor=D.+Carpaneseauthor=A.+Lenociauthor=L.+Calderanauthor=M.+Scimecaauthor=A.+Maiauthor=E.+Bonannoauthor=A.+Rosatoauthor=C.+Geroniauthor=L.+Quintieriauthor=A.+M.+Caccuri&title=A+novel+orally+active+water-soluble+inhibitor+of+human+glutathione+transferase+exerts+a+potent+and+selective+antitumor+activity+against+human+melanoma+xenografts&doi=10.18632%2Foncotarget.2798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit247R"><div class="casContent"><span class="casTitleNuber">247</span><div class="casTitle"><span class="NLM_cas:atitle">A novel orally active water-soluble inhibitor of human glutathione transferase exerts a potent and selective antitumor activity against human melanoma xenografts</span></div><div class="casAuthors">De Luca Anastasia; Caccuri Anna Maria; Rotili Dante; Lenoci Alessia; Mai Antonello; Carpanese Debora; Rosato Antonio; Calderan Laura; Quintieri Luigi; Scimeca Manuel; Bonanno Elena; Scimeca Manuel; Bonanno Elena; Mai Antonello; Rosato Antonio; Geroni Cristina; Caccuri Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">4126-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We designed and synthesized two novel nitrobenzoxadiazole (NBD) analogues of the anticancer agent 6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)hexan-1-ol (NBDHEX).  The new compounds, namely MC3165 and MC3181, bear one and two oxygen atoms within the hydroxy-containing alkyl chain at the C4 position of the NBD scaffold, respectively.  This insertion did not alter the chemical reactivity with reduced glutathione, while it conferred a remarkable increase in water solubility.  MC3181 was more selective than NBDHEX towards the target protein, glutathione transferase P1-1, and highly effective in vitro against a panel of human melanoma cell lines, with IC50 in the submicromolar-low micromolar range.  Interestingly, the cellular response to MC3181 was cell-type-specific; the compound triggered a JNK-dependent apoptosis in the BRAF-V600E-mutated A375 cells, while it induced morphological changes together with an increase in melanogenesis in BRAF wild-type SK23-MEL cells.  MC3181 exhibited a remarkable therapeutic activity against BRAF-V600E-mutant xenografts, both after intravenous and oral administration.  Outstandingly, no treatment-related signs of toxicity were observed both in healthy and tumor-bearing mice after single and repeated administrations.  Taken together, these results indicate that MC3181 may represent a potential novel therapeutic opportunity for BRAF-mutated human melanoma, while being safe and water-soluble and thus overcoming all the critical aspects of NBDHEX in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4VH_PZca5wy6Ufuk_1xoTfW6udTcc2eahqCAcdOKWN7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvntFOlsg%253D%253D&md5=ef2d38a6f292e9ceb5ad3f33f7105c07</span></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2798%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3DRotili%26aufirst%3DD.%26aulast%3DCarpanese%26aufirst%3DD.%26aulast%3DLenoci%26aufirst%3DA.%26aulast%3DCalderan%26aufirst%3DL.%26aulast%3DScimeca%26aufirst%3DM.%26aulast%3DMai%26aufirst%3DA.%26aulast%3DBonanno%26aufirst%3DE.%26aulast%3DRosato%26aufirst%3DA.%26aulast%3DGeroni%26aufirst%3DC.%26aulast%3DQuintieri%26aufirst%3DL.%26aulast%3DCaccuri%26aufirst%3DA.%2BM.%26atitle%3DA%2520novel%2520orally%2520active%2520water-soluble%2520inhibitor%2520of%2520human%2520glutathione%2520transferase%2520exerts%2520a%2520potent%2520and%2520selective%2520antitumor%2520activity%2520against%2520human%2520melanoma%2520xenografts%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26issue%3D6%26spage%3D4126%26epage%3D4143%26doi%3D10.18632%2Foncotarget.2798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref248"><div class="reference"><strong class="refLabel"><a href="#ref248" class="rightTabRefNumLink">248</a></strong><div class="NLM_citation" id="rightTab-cit248"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Graziani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artuso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scimeca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atzori, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tentori, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccuri, A. M.</span></span> <span> </span><span class="NLM_article-title">A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>95</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">16</span>â <span class="NLM_lpage">27</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2015.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bcp.2015.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=25795251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFWhsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=16-27&issue=1&author=G.+Grazianiauthor=S.+Artusoauthor=A.+De+Lucaauthor=A.+Muziauthor=D.+Rotiliauthor=M.+Scimecaauthor=M.+G.+Atzoriauthor=C.+Ceciauthor=A.+Maiauthor=C.+Leonettiauthor=L.+Levatiauthor=E.+Bonannoauthor=L.+Tentoriauthor=A.+M.+Caccuri&title=A+new+water+soluble+MAPK+activator+exerts+antitumor+activity+in+melanoma+cells+resistant+to+the+BRAF+inhibitor+vemurafenib&doi=10.1016%2Fj.bcp.2015.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit248R"><div class="casContent"><span class="casTitleNuber">248</span><div class="casTitle"><span class="NLM_cas:atitle">A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib</span></div><div class="casAuthors">Graziani, Grazia; Artuso, Simona; De Luca, Anastasia; Muzi, Alessia; Rotili, Dante; Scimeca, Manuel; Atzori, Maria Grazia; Ceci, Claudia; Mai, Antonello; Leonetti, Carlo; Levati, Lauretta; Bonanno, Elena; Tentori, Lucio; Caccuri, Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-27</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recovery of mitogen activated protein kinase (MAPK) or activation of alternative pathways, such as the PI3K/AKT/mTOR, are involved in acquired resistance to BRAF inhibitors which represent the first-line treatment of BRAF-mutated metastatic melanoma.  We recently demonstrated that 6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)hexan-1-ol (NBDHEX) and its water sol. analog 2-(2-(2-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)ethoxy)ethoxy)ethanol (MC3181) trigger apoptosis in BRAF V600E mutated melanoma cells through activation of the MAPK c-Jun N-terminal kinase (JNK).  Herein, we investigated whether NBDHEX and MC3181 might exert antitumor activity against BRAF V600E mutated human melanoma cells rendered resistant to the BRAF inhibitor vemurafenib.  To this aim we generated a subline of A375 melanoma resistant in vitro and in vivo to vemurafenib (A375-VR8) and characterized by NRAS G13R mutation, high basal levels of CRAF protein and phospho-activation of AKT.  In these cells ERK phosphorylation was not significantly down-modulated by vemurafenib concns. capable of abrogating ERK phosphorylation in sensitive A375 cells.  Both NBDHEX and MC3181 induced marked antiproliferative and apoptotic effects in A375-VR8 cells and, at equitoxic concns., caused a strong phosphorylation of JNK, p38, and of the downstream mediators of apoptosis ATF2 and p53.  Drug treatment further increased ERK phosphorylation, which was required for the cellular response to the NBD derivs., as apoptosis was antagonized by the ERK inhibitor FR180204.  Finally, in vivo administration of MC3181 provoked JNK activation at the tumor site and markedly reduced A375-VR8 growth.  These evidences strongly suggest that the activation of multiple pro-apoptotic MAPK pathways by MC3181 might represent a new strategy for the treatment of melanoma resistant to BRAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphh0RGg9p2brVg90H21EOLACvtfcHk0lhgJ_TeFUR0oA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFWhsLs%253D&md5=4a7784c27fa84b8528ba1006e19aa8d8</span></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2015.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2015.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DGraziani%26aufirst%3DG.%26aulast%3DArtuso%26aufirst%3DS.%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3DMuzi%26aufirst%3DA.%26aulast%3DRotili%26aufirst%3DD.%26aulast%3DScimeca%26aufirst%3DM.%26aulast%3DAtzori%26aufirst%3DM.%2BG.%26aulast%3DCeci%26aufirst%3DC.%26aulast%3DMai%26aufirst%3DA.%26aulast%3DLeonetti%26aufirst%3DC.%26aulast%3DLevati%26aufirst%3DL.%26aulast%3DBonanno%26aufirst%3DE.%26aulast%3DTentori%26aufirst%3DL.%26aulast%3DCaccuri%26aufirst%3DA.%2BM.%26atitle%3DA%2520new%2520water%2520soluble%2520MAPK%2520activator%2520exerts%2520antitumor%2520activity%2520in%2520melanoma%2520cells%2520resistant%2520to%2520the%2520BRAF%2520inhibitor%2520vemurafenib%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2015%26volume%3D95%26issue%3D1%26spage%3D16%26epage%3D27%26doi%3D10.1016%2Fj.bcp.2015.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref249"><div class="reference"><strong class="refLabel"><a href="#ref249" class="rightTabRefNumLink">249</a></strong><div class="NLM_citation" id="rightTab-cit249"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomassi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scimeca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geroni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintieri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccuri, A. M.</span></span> <span> </span><span class="NLM_article-title">Characterization of water-soluble esters of nitrobenzoxadiazole-based GSTP1-1 inhibitors for cancer treatment</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">114060</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2020.114060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bcp.2020.114060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=32473836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFCjsL7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2020&pages=114060&author=V.+Di+Paoloauthor=C.+Fulciauthor=D.+Rotiliauthor=A.+De+Lucaauthor=S.+Tomassiauthor=M.+Serraauthor=M.+Scimecaauthor=C.+Geroniauthor=L.+Quintieriauthor=A.+M.+Caccuri&title=Characterization+of+water-soluble+esters+of+nitrobenzoxadiazole-based+GSTP1-1+inhibitors+for+cancer+treatment&doi=10.1016%2Fj.bcp.2020.114060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit249R"><div class="casContent"><span class="casTitleNuber">249</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of water-soluble esters of nitrobenzoxadiazole-based GSTP1-1 inhibitors for cancer treatment</span></div><div class="casAuthors">Di Paolo, Veronica; Fulci, Chiara; Rotili, Dante; De Luca, Anastasia; Tomassi, Stefano; Serra, Massimo; Scimeca, Manuel; Geroni, Cristina; Quintieri, Luigi; Caccuri, Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">114060</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The 7-nitrobenzo[c][1,2,5]oxadiazole (NBD) deriv. NBDHEX (compd. 1) and its analog MC3181 (compd. 2) have been found to be potent inhibitors of tumor cell growth in vitro and therapeutically active and safe in mice bearing human melanoma xenografts.  To enhance the aq. soly. of these compds., we synthesized the hemisuccinate of 1 (compd. 3) and the phosphate monoesters of 1 and 2 (compd. 4 and 5, resp.).  These novel NBD derivs. displayed a soly. in the conventional phosphate-buffered saline up to 150-fold higher than that of 1, and up to 4-fold higher than that of 2.  Notably, soly. of phosphates 4 and 5 in a potassium phosphate buffer at pH 7.4, was up to 500-fold higher than that of 1, and â¼10-fold higher than that of 2.  Compds. 3-5 retained high cytotoxicity towards cultured human melanoma and osteosarcoma cells and were cleaved in vitro by both human and murine hydrolases, thus releasing the corresponding parent compd. (i.e., 1 or 2).  Interestingly, esters 3-5 displayed high inhibitory activity towards the glutathione transferase (GST) isoform GSTP1-1 and showed a reactivity towards reduced glutathione comparable to that of the resp. parent compd.  Finally, both 4 and 5 were safe and effective when administered i.v. or orally as an aq. soln. to mice xenografted with A375 human melanoma tumors.  Collectively, these results and the previously obsd. synergistic interaction between 1 and 2 and various approved anticancer drugs, suggest the possible utility of phosphates 4 and 5 as single agents and in combination regimens in cancers with unmet medical need, including melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV_rPwBOM8WbVg90H21EOLACvtfcHk0lhgJ_TeFUR0oA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFCjsL7E&md5=f50c23cb3714beffde397ac12a786274</span></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2020.114060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2020.114060%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DV.%26aulast%3DFulci%26aufirst%3DC.%26aulast%3DRotili%26aufirst%3DD.%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3DTomassi%26aufirst%3DS.%26aulast%3DSerra%26aufirst%3DM.%26aulast%3DScimeca%26aufirst%3DM.%26aulast%3DGeroni%26aufirst%3DC.%26aulast%3DQuintieri%26aufirst%3DL.%26aulast%3DCaccuri%26aufirst%3DA.%2BM.%26atitle%3DCharacterization%2520of%2520water-soluble%2520esters%2520of%2520nitrobenzoxadiazole-based%2520GSTP1-1%2520inhibitors%2520for%2520cancer%2520treatment%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2020%26volume%3D178%26spage%3D114060%26doi%3D10.1016%2Fj.bcp.2020.114060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref250"><div class="reference"><strong class="refLabel"><a href="#ref250" class="rightTabRefNumLink">250</a></strong><div class="NLM_citation" id="rightTab-cit250"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciarretta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucidi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morozzo Della Rocca, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintieri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccuri, A. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and characterisation of a new benzamide-containing nitrobenzoxadiazole as a GSTP1-1 inhibitor endowed with high stability to metabolic hydrolysis</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1131</span>â <span class="NLM_lpage">1139</span>, <span class="refDoi">Â DOI: 10.1080/14756366.2019.1617287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1080%2F14756366.2019.1617287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=31169043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFeru7bF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2019&pages=1131-1139&issue=1&author=V.+Di+Paoloauthor=C.+Fulciauthor=D.+Rotiliauthor=F.+Sciarrettaauthor=A.+Lucidiauthor=B.+Morozzo+Della+Roccaauthor=A.+De+Lucaauthor=A.+Rosatoauthor=L.+Quintieriauthor=A.+M.+Caccuri&title=Synthesis+and+characterisation+of+a+new+benzamide-containing+nitrobenzoxadiazole+as+a+GSTP1-1+inhibitor+endowed+with+high+stability+to+metabolic+hydrolysis&doi=10.1080%2F14756366.2019.1617287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and characterisation of a new benzamide-containing nitrobenzoxadiazole as a GSTP1-1 inhibitor endowed with high stability to metabolic hydrolysis</span></div><div class="casAuthors">Di Paolo, Veronica; Fulci, Chiara; Rotili, Dante; Sciarretta, Francesca; Lucidi, Alessia; Morozzo della Rocca, Blasco; De Luca, Anastasia; Rosato, Antonio; Quintieri, Luigi; Caccuri, Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1131-1139</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The antitumor agent 6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)hexan-1-ol (1) is a potent inhibitor of GSTP1-1, a glutathione S-transferase capable of inhibiting apoptosis by binding to JNK1 and TRAF2.  We recently demonstrated that, unlike its parent compd., the benzoyl ester of 1 (compd.3 ) exhibits negligible reactivity towards GSH, and has a different mode of interaction with GSTP1-1.  Unfortunately, 3 is susceptible to rapid metabolic hydrolysis.  In an effort to improve the metabolic stability of 3, its ester group has been replaced by an amide, leading to N-(6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)hexyl)benzamide (4).  Unlike 3, compd.4 was stable to human liver microsomal carboxylesterases, but retained the ability to disrupt the interaction between GSTP1-1 and TRAF2 regardless of GSH levels.  Moreover, 4 exhibited both a higher stability in the presence of GSH and a greater cytotoxicity towards cultured A375 melanoma cells, in comparison with 1 and its analog 2 .  These findings suggest that 4 deserves further preclin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryQcwVkcim0bVg90H21EOLACvtfcHk0ljCMsxpDZgarw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFeru7bF&md5=82204ebf3fc0a1c07657a3e0d7d6a41c</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1080%2F14756366.2019.1617287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756366.2019.1617287%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DV.%26aulast%3DFulci%26aufirst%3DC.%26aulast%3DRotili%26aufirst%3DD.%26aulast%3DSciarretta%26aufirst%3DF.%26aulast%3DLucidi%26aufirst%3DA.%26aulast%3DMorozzo%2BDella%2BRocca%26aufirst%3DB.%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3DRosato%26aufirst%3DA.%26aulast%3DQuintieri%26aufirst%3DL.%26aulast%3DCaccuri%26aufirst%3DA.%2BM.%26atitle%3DSynthesis%2520and%2520characterisation%2520of%2520a%2520new%2520benzamide-containing%2520nitrobenzoxadiazole%2520as%2520a%2520GSTP1-1%2520inhibitor%2520endowed%2520with%2520high%2520stability%2520to%2520metabolic%2520hydrolysis%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2019%26volume%3D34%26issue%3D1%26spage%3D1131%26epage%3D1139%26doi%3D10.1080%2F14756366.2019.1617287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref251"><div class="reference"><strong class="refLabel"><a href="#ref251" class="rightTabRefNumLink">251</a></strong><div class="NLM_citation" id="rightTab-cit251"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wettersten, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, R. H.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of p21 as novel therapeutics for chemotherapy-resistant kidney cancer</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">991</span>â <span class="NLM_lpage">994</span>, <span class="refDoi">Â DOI: 10.4155/fmc.13.56</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.4155%2Ffmc.13.56" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=23734682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXos12msLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=991-994&issue=9&author=R.+Liuauthor=H.+I.+Wetterstenauthor=S.-H.+Parkauthor=R.+H.+Weiss&title=Small-molecule+inhibitors+of+p21+as+novel+therapeutics+for+chemotherapy-resistant+kidney+cancer&doi=10.4155%2Ffmc.13.56"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit251R"><div class="casContent"><span class="casTitleNuber">251</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors of p21 as novel therapeutics for chemotherapy-resistant kidney cancer</span></div><div class="casAuthors">Liu, Ruiwu; Wettersten, Hiromi I.; Park, See-Hyoung; Weiss, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">991-994</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  This article presents the use of specific inhibitors of the CDK inhibitor, p21, has tremendous potential as a new paradigm for the treatment of a variety of cancers, as well as a tool in exploring mechanisms of cell cycle arrest and apoptosis.  Small-mol. inhibitors of p21 have distinct advantages including cell permeability,increased stability, ease of manuf. and oral delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoznx3M13qDkbVg90H21EOLACvtfcHk0ljCMsxpDZgarw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXos12msLk%253D&md5=03226f0456b4a8f474eceb6614cbc7c9</span></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=10.4155%2Ffmc.13.56&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.13.56%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DWettersten%26aufirst%3DH.%2BI.%26aulast%3DPark%26aufirst%3DS.-H.%26aulast%3DWeiss%26aufirst%3DR.%2BH.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520p21%2520as%2520novel%2520therapeutics%2520for%2520chemotherapy-resistant%2520kidney%2520cancer%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2013%26volume%3D5%26issue%3D9%26spage%3D991%26epage%3D994%26doi%3D10.4155%2Ffmc.13.56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref252"><div class="reference"><strong class="refLabel"><a href="#ref252" class="rightTabRefNumLink">252</a></strong><div class="NLM_citation" id="rightTab-cit252"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abbas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A.</span></span> <span> </span><span class="NLM_article-title">p21 in cancer: intricate networks and multiple activities</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">400</span>â <span class="NLM_lpage">414</span>, <span class="refDoi">Â DOI: 10.1038/nrc2657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2Fnrc2657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=19440234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvFShsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=400-414&issue=6&author=T.+Abbasauthor=A.+Dutta&title=p21+in+cancer%3A+intricate+networks+and+multiple+activities&doi=10.1038%2Fnrc2657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">p21 in cancer: intricate networks and multiple activities</span></div><div class="casAuthors">Abbas, Tarek; Dutta, Anindya</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">400-414</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  One of the main engines that drives cellular transformation is the loss of proper control of the mammalian cell cycle.  The cyclin-dependent kinase inhibitor p21 (also known as p21WAF1/Cip1) promotes cell cycle arrest in response to many stimuli.  It is well positioned to function as both a sensor and an effector of multiple anti-proliferative signals.  This Review focuses on recent advances in our understanding of the regulation of p21 and its biol. functions with emphasis on its p53-independent tumor suppressor activities and paradoxical tumor-promoting activities, and their implications in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ0tFJHIgKlLVg90H21EOLACvtfcHk0ljCMsxpDZgarw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvFShsb4%253D&md5=fb31a35ba6d4026baf5bda5ec71a4403</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=10.1038%2Fnrc2657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2657%26sid%3Dliteratum%253Aachs%26aulast%3DAbbas%26aufirst%3DT.%26aulast%3DDutta%26aufirst%3DA.%26atitle%3Dp21%2520in%2520cancer%253A%2520intricate%2520networks%2520and%2520multiple%2520activities%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26issue%3D6%26spage%3D400%26epage%3D414%26doi%3D10.1038%2Fnrc2657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref253"><div class="reference"><strong class="refLabel"><a href="#ref253" class="rightTabRefNumLink">253</a></strong><div class="NLM_citation" id="rightTab-cit253"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guenes, C.</span>; <span class="NLM_string-name">Hoffman, E. M.</span>; <span class="NLM_string-name">Rudolph, K. L.</span></span> <span> </span><span class="NLM_article-title">Screening Methods for Identifying Specific Inhibitors of Protein p21 as Therapeutic Agents for Treating Cancer and Chronic Diseases-Associated Injury</span>. <span class="NLM_patent">WO2014041125A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=C.+Guenes&author=E.+M.+Hoffman&author=K.+L.+Rudolph&title=Screening+Methods+for+Identifying+Specific+Inhibitors+of+Protein+p21+as+Therapeutic+Agents+for+Treating+Cancer+and+Chronic+Diseases-Associated+Injury"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGuenes%26aufirst%3DC.%26atitle%3DScreening%2520Methods%2520for%2520Identifying%2520Specific%2520Inhibitors%2520of%2520Protein%2520p21%2520as%2520Therapeutic%2520Agents%2520for%2520Treating%2520Cancer%2520and%2520Chronic%2520Diseases-Associated%2520Injury%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref254"><div class="reference"><strong class="refLabel"><a href="#ref254" class="rightTabRefNumLink">254</a></strong><div class="NLM_citation" id="rightTab-cit254"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baures, P. W.</span>; <span class="NLM_string-name">James, D. R.</span>; <span class="NLM_string-name">Gless, R. D.</span>; <span class="NLM_string-name">Tran, T.</span>; <span class="NLM_string-name">Verheij, H. J.</span>; <span class="NLM_string-name">Schultz, J. C. C.</span></span> <span> </span><span class="NLM_article-title">Furazano[3,4-b]pyrazines, and Their Preparation, Pharmaceutical Compositions and Use as Antitumor Agents for Treatment of Tumors</span>. <span class="NLM_patent">WO2006044402A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=P.+W.+Baures&author=D.+R.+James&author=R.+D.+Gless&author=T.+Tran&author=H.+J.+Verheij&author=J.+C.+C.+Schultz&title=Furazano%5B3%2C4-b%5Dpyrazines%2C+and+Their+Preparation%2C+Pharmaceutical+Compositions+and+Use+as+Antitumor+Agents+for+Treatment+of+Tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBaures%26aufirst%3DP.%2BW.%26atitle%3DFurazano%255B3%252C4-b%255Dpyrazines%252C%2520and%2520Their%2520Preparation%252C%2520Pharmaceutical%2520Compositions%2520and%2520Use%2520as%2520Antitumor%2520Agents%2520for%2520Treatment%2520of%2520Tumors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref255"><div class="reference"><strong class="refLabel"><a href="#ref255" class="rightTabRefNumLink">255</a></strong><div class="NLM_citation" id="rightTab-cit255"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ventola, C. L.</span></span> <span> </span><span class="NLM_article-title">The antibiotic resistance crisis: part 1: Causes and threats</span>. <i>P. T.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">277</span>â <span class="NLM_lpage">283</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=25859123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A280%3ADC%252BC2MjivVaksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2015&pages=277-283&issue=4&author=C.+L.+Ventola&title=The+antibiotic+resistance+crisis%3A+part+1%3A+Causes+and+threats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit255R"><div class="casContent"><span class="casTitleNuber">255</span><div class="casTitle"><span class="NLM_cas:atitle">The antibiotic resistance crisis: part 1: causes and threats</span></div><div class="casAuthors">Ventola C Lee</div><div class="citationInfo"><span class="NLM_cas:title">P & T : a peer-reviewed journal for formulary management</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">277-83</span>
        ISSN:<span class="NLM_cas:issn">1052-1372</span>.
    </div><div class="casAbstract">Decades after the first patients were treated with antibiotics, bacterial infections have again become a threat because of the rapid emergence of resistant bacteria-a crisis attributed to abuse of these medications and a lack of new drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1SMGX3K8vve98rul4nhSdfW6udTcc2eb3XsoSKEfgLrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjivVaksg%253D%253D&md5=81c1f1c8e3475245b7dd5dad0a279700</span></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVentola%26aufirst%3DC.%2BL.%26atitle%3DThe%2520antibiotic%2520resistance%2520crisis%253A%2520part%25201%253A%2520Causes%2520and%2520threats%26jtitle%3DP.%2520T.%26date%3D2015%26volume%3D40%26issue%3D4%26spage%3D277%26epage%3D283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref256"><div class="reference"><strong class="refLabel"><a href="#ref256" class="rightTabRefNumLink">256</a></strong><div class="NLM_citation" id="rightTab-cit256"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levinson, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evgenâev, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ermolaeva, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efimov, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falyakhov, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garipov, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karimova, R. G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological activity of substituted benzodifurazans</span>. <i>Pharm. Chem. J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">522</span>â <span class="NLM_lpage">525</span>, <span class="refDoi">Â DOI: 10.1023/B:PHAC.0000014855.66913.83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1023%2FB%3APHAC.0000014855.66913.83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpslWjsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2003&pages=522-525&issue=10&author=F.+S.+Levinsonauthor=M.+I.+Evgen%E2%80%99evauthor=E.+A.+Ermolaevaauthor=S.+I.+Efimovauthor=I.+F.+Falyakhovauthor=T.+V.+Garipovauthor=R.+G.+Karimova&title=Synthesis+and+biological+activity+of+substituted+benzodifurazans&doi=10.1023%2FB%3APHAC.0000014855.66913.83"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit256R"><div class="casContent"><span class="casTitleNuber">256</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Activity of Substituted Benzodifurazans</span></div><div class="casAuthors">Levinson, F. S.; Evgen'ev, M. I.; Ermolaeva, E. A.; Efimov, S. I.; Falyakhov, I. F.; Garipov, T. V.; Karimova, R. G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Chemistry Journal (Translation of Khimiko-Farmatsevticheskii Zhurnal)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">522-525</span>CODEN:
                <span class="NLM_cas:coden">PCJOAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-150X</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Consultants Bureau</span>)
        </div><div class="casAbstract">Benzodifurazan derivs., such as I (R = Cl, OMe, n = 1; R = Cl, NH2, NHNHMe, NEt2, 1-piperidinyl, 4-morpholinyl, OMe, n = 0), were prepd. and assayed for antibacterial, fungicidal and acaricidal activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNqKBzYmhzybVg90H21EOLACvtfcHk0lhppg4RSpdAOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpslWjsQ%253D%253D&md5=99b41274ba610e0eb9ce60005f9e5945</span></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=10.1023%2FB%3APHAC.0000014855.66913.83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FB%253APHAC.0000014855.66913.83%26sid%3Dliteratum%253Aachs%26aulast%3DLevinson%26aufirst%3DF.%2BS.%26aulast%3DEvgen%25E2%2580%2599ev%26aufirst%3DM.%2BI.%26aulast%3DErmolaeva%26aufirst%3DE.%2BA.%26aulast%3DEfimov%26aufirst%3DS.%2BI.%26aulast%3DFalyakhov%26aufirst%3DI.%2BF.%26aulast%3DGaripov%26aufirst%3DT.%2BV.%26aulast%3DKarimova%26aufirst%3DR.%2BG.%26atitle%3DSynthesis%2520and%2520biological%2520activity%2520of%2520substituted%2520benzodifurazans%26jtitle%3DPharm.%2520Chem.%2520J.%26date%3D2003%26volume%3D37%26issue%3D10%26spage%3D522%26epage%3D525%26doi%3D10.1023%2FB%3APHAC.0000014855.66913.83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref257"><div class="reference"><strong class="refLabel"><a href="#ref257" class="rightTabRefNumLink">257</a></strong><div class="NLM_citation" id="rightTab-cit257"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levinson, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evgenâev, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ermolaeva, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efimov, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garipov, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karimova, R. G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological activity of arylaminosubstituted nitrobenzodifurazans</span>. <i>Pharm. Chem. J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">578</span>â <span class="NLM_lpage">581</span>, <span class="refDoi">Â DOI: 10.1023/B:PHAC.0000016066.53022.f5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1023%2FB%3APHAC.0000016066.53022.f5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2cXht1Clsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2003&pages=578-581&issue=11&author=F.+S.+Levinsonauthor=M.+I.+Evgen%E2%80%99evauthor=E.+A.+Ermolaevaauthor=S.+I.+Efimovauthor=T.+V.+Garipovauthor=R.+G.+Karimova&title=Synthesis+and+biological+activity+of+arylaminosubstituted+nitrobenzodifurazans&doi=10.1023%2FB%3APHAC.0000016066.53022.f5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit257R"><div class="casContent"><span class="casTitleNuber">257</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Activity of Arylaminosubstituted Nitrobenzodifurazans</span></div><div class="casAuthors">Levinson, F. S.; Evgen'ev, M. I.; Ermolaeva, E. A.; Efimov, S. I.; Garipov, T. V.; Karimova, R. G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Chemistry Journal (Translation of Khimiko-Farmatsevticheskii Zhurnal)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">578-581</span>CODEN:
                <span class="NLM_cas:coden">PCJOAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-150X</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Consultants Bureau</span>)
        </div><div class="casAbstract">Aryl amino substituted nitrobenzodifurazans were prepd. via the key nitration of methoxybenzodifurazan.  The antimicrobial activity of the prepd. compds. was also evaluated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYZ50897B_4bVg90H21EOLACvtfcHk0lhppg4RSpdAOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXht1Clsr0%253D&md5=4c12bc185e59434ff4134c33146a5b8f</span></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=10.1023%2FB%3APHAC.0000016066.53022.f5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FB%253APHAC.0000016066.53022.f5%26sid%3Dliteratum%253Aachs%26aulast%3DLevinson%26aufirst%3DF.%2BS.%26aulast%3DEvgen%25E2%2580%2599ev%26aufirst%3DM.%2BI.%26aulast%3DErmolaeva%26aufirst%3DE.%2BA.%26aulast%3DEfimov%26aufirst%3DS.%2BI.%26aulast%3DGaripov%26aufirst%3DT.%2BV.%26aulast%3DKarimova%26aufirst%3DR.%2BG.%26atitle%3DSynthesis%2520and%2520biological%2520activity%2520of%2520arylaminosubstituted%2520nitrobenzodifurazans%26jtitle%3DPharm.%2520Chem.%2520J.%26date%3D2003%26volume%3D37%26issue%3D11%26spage%3D578%26epage%3D581%26doi%3D10.1023%2FB%3APHAC.0000016066.53022.f5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref258"><div class="reference"><strong class="refLabel"><a href="#ref258" class="rightTabRefNumLink">258</a></strong><div class="NLM_citation" id="rightTab-cit258"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Babu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raju, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antimicrobial activity of novel 2-(heteryl-carboxamido)-2,3-dihydro-1H-1,2,5-oxadiazolo[3,4-c] [1,3,2]diazaphosphole-2-oxides</span>. <i>ARKIVOC</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2006</i></span>,  <span class="NLM_fpage">189</span>, <span class="refDoi">Â DOI: 10.3998/ark.5550190.0007.f23</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.3998%2Fark.5550190.0007.f23" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2006&publication_year=2007&pages=189&author=Y.+Babuauthor=M.+Kumarauthor=K.+Srinivasuluauthor=C.+Reddyauthor=C.+Raju&title=Synthesis+and+antimicrobial+activity+of+novel+2-%28heteryl-carboxamido%29-2%2C3-dihydro-1H-1%2C2%2C5-oxadiazolo%5B3%2C4-c%5D+%5B1%2C3%2C2%5Ddiazaphosphole-2-oxides&doi=10.3998%2Fark.5550190.0007.f23"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=10.3998%2Fark.5550190.0007.f23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3998%252Fark.5550190.0007.f23%26sid%3Dliteratum%253Aachs%26aulast%3DBabu%26aufirst%3DY.%26aulast%3DKumar%26aufirst%3DM.%26aulast%3DSrinivasulu%26aufirst%3DK.%26aulast%3DReddy%26aufirst%3DC.%26aulast%3DRaju%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520antimicrobial%2520activity%2520of%2520novel%25202-%2528heteryl-carboxamido%2529-2%252C3-dihydro-1H-1%252C2%252C5-oxadiazolo%255B3%252C4-c%255D%2520%255B1%252C3%252C2%255Ddiazaphosphole-2-oxides%26jtitle%3DARKIVOC%26date%3D2007%26volume%3D2006%26spage%3D189%26doi%3D10.3998%2Fark.5550190.0007.f23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref259"><div class="reference"><strong class="refLabel"><a href="#ref259" class="rightTabRefNumLink">259</a></strong><div class="NLM_citation" id="rightTab-cit259"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Babu, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankar, A. U. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siva
Kumar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh Reddy, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis, spectral characterization and antimicrobial activity of 2-(substituted)-2,2-[1,3-dihydro-(3,4â1,2,5-oxadiazolediyl)diaza][5â²,5â²-dimethyl-1â²,3â²-propanediyl)dioxy]phosphoranes</span>. <i>Org. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">15</span>â <span class="NLM_lpage">21</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtF2nsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=15-21&issue=1&author=Y.+H.+Babuauthor=A.+U.+R.+Sankarauthor=B.+Siva%0AKumarauthor=C.+Suresh+Reddy&title=Synthesis%2C+spectral+characterization+and+antimicrobial+activity+of+2-%28substituted%29-2%2C2-%5B1%2C3-dihydro-%283%2C4%E2%80%931%2C2%2C5-oxadiazolediyl%29diaza%5D%5B5%E2%80%B2%2C5%E2%80%B2-dimethyl-1%E2%80%B2%2C3%E2%80%B2-propanediyl%29dioxy%5Dphosphoranes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit259R"><div class="casContent"><span class="casTitleNuber">259</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, spectral characterization and antimicrobial activity of 2-(substituted)-2,2-[1,3-dihydro-(3,4-1,2,5-oxadiazolediyl)diaza][5',5'-dimethyl-1',3'-propanediyl)dioxy]phosphoranes</span></div><div class="casAuthors">Babu, Y. Hari; Sankar, A. Uma Ravi; Siva Kumar, B.; Suresh Reddy, C.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Communications</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-21</span>CODEN:
                <span class="NLM_cas:coden">OCROBQ</span>;
        ISSN:<span class="NLM_cas:issn">1307-6175</span>.
    
            (<span class="NLM_cas:orgname">ACG Publications</span>)
        </div><div class="casAbstract">The cyclic oxadiazolediyl dioxachlorophosphine precursor on subsequent reaction with various alcs. underwent halide displacement to give 2-substituted diaza phospholes.  These phospholes on oxidative addn. with di hydroxy alcs. form corresponding phosphoranes The antimicrobial activities of these compds. were evaluated and they exhibited significant antimicrobial activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonRi6U_K6qvbVg90H21EOLACvtfcHk0lgYJUhFA3JUTQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtF2nsL4%253D&md5=39b815acc1fbc1c4fce7d47223f56f11</span></div><a href="/servlet/linkout?suffix=cit259&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBabu%26aufirst%3DY.%2BH.%26aulast%3DSankar%26aufirst%3DA.%2BU.%2BR.%26aulast%3DSiva%2BKumar%26aufirst%3DB.%26aulast%3DSuresh%2BReddy%26aufirst%3DC.%26atitle%3DSynthesis%252C%2520spectral%2520characterization%2520and%2520antimicrobial%2520activity%2520of%25202-%2528substituted%2529-2%252C2-%255B1%252C3-dihydro-%25283%252C4%25E2%2580%25931%252C2%252C5-oxadiazolediyl%2529diaza%255D%255B5%25E2%2580%25B2%252C5%25E2%2580%25B2-dimethyl-1%25E2%2580%25B2%252C3%25E2%2580%25B2-propanediyl%2529dioxy%255Dphosphoranes%26jtitle%3DOrg.%2520Commun.%26date%3D2010%26volume%3D3%26issue%3D1%26spage%3D15%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref260"><div class="reference"><strong class="refLabel"><a href="#ref260" class="rightTabRefNumLink">260</a></strong><div class="NLM_citation" id="rightTab-cit260"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galkina, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takhautdinova, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tudrii, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusupova, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falyakhov, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozdeev, O. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shulaeva, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipenskaya, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakhibullina, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krivolapov, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litvinov, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galkin, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherkasov, R. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis, structure, and antibacterial activity of aminobenzofuroxan and aminobenzofurazan</span>. <i>Russ. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">591</span>â <span class="NLM_lpage">597</span>, <span class="refDoi">Â DOI: 10.1134/S1070428013040167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1134%2FS1070428013040167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsFGjtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=591-597&issue=4&author=I.+V.+Galkinaauthor=G.+L.+Takhautdinovaauthor=E.+V.+Tudriiauthor=L.+M.+Yusupovaauthor=I.+F.+Falyakhovauthor=O.+K.+Pozdeevauthor=M.+P.+Shulaevaauthor=L.+V.+Kipenskayaauthor=V.+G.+Sakhibullinaauthor=D.+B.+Krivolapovauthor=I.+A.+Litvinovauthor=V.+I.+Galkinauthor=R.+A.+Cherkasov&title=Synthesis%2C+structure%2C+and+antibacterial+activity+of+aminobenzofuroxan+and+aminobenzofurazan&doi=10.1134%2FS1070428013040167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit260R"><div class="casContent"><span class="casTitleNuber">260</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, structure, and antibacterial activity of aminobenzofuroxan and aminobenzofurazan</span></div><div class="casAuthors">Galkina, I. V.; Takhautdinova, G. L.; Tudrii, E. V.; Yusupova, L. M.; Falyakhov, I. F.; Pozdeev, O. K.; Shulaeva, M. P.; Kipenskaya, L. V.; Sakhibullina, V. G.; Krivolapov, D. B.; Litvinov, I. A.; Galkin, V. I.; Cherkasov, R. A.</div><div class="citationInfo"><span class="NLM_cas:title">Russian Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">591-597</span>CODEN:
                <span class="NLM_cas:coden">RJOCEQ</span>;
        ISSN:<span class="NLM_cas:issn">1070-4280</span>.
    
            (<span class="NLM_cas:orgname">SP MAIK Nauka/Interperiodica</span>)
        </div><div class="casAbstract">The amination of 4,6-dichloro-5,7-dinitrobenzofuroxan and -benzofurazan with dibenzylamine followed the arom. nucleophilic substitution pattern (SNAr) and gave 4,6-bis(dibenzylamino)-5,7-dinitro-2,1,3-benzoxadiazole 1-oxide (I) with elimination of HCl.  Regardless of the reactant ratio, 4,6-dichloro-5,7-dinitrobenzofuroxan was converted into 4,6-bis(dibenzylamino)-5,7-dinitrobenzofuroxan (II), whereas 4,6-dichloro-5,7-dinitrobenzofurazan under analogous conditions gave rise to an unusual bisammonium deriv. which lost a proton from the amino group on C(4) and a benzyl group from the amino group on C(6), affording the corresponding diamine with secondary and tertiary N atoms.  The structure of the isolated compds. was detd. by IR, NMR, elemental anal., and x-ray anal. [I: triclinic, space group P-1, a 9.548(5), b 12.465(7), c 13.608(7) Ã, Î± 79.515(7), Î² 71.609(6), Î³ 79.489(7)Â°, V 1497.5(1) Ã3, Z 2; II: triclinic, space group P-1, a 7.591(1), b 13.463(2), c 13.795(4) Ã, Î± 114.525(3), Î² 99.512(3), Î³ 100.451(2)Â°, V 1214.9(4) Ã3, Z 2].  Their thermal stability was studied by simultaneous thermogravimetry and differential scanning calorimetry.  Addnl., the compds. were screened for antibacterial and antifungal activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowsz97CrGRtrVg90H21EOLACvtfcHk0lgYJUhFA3JUTQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsFGjtLo%253D&md5=ef956c7c939fc2fbb998e2b4a62f8b7a</span></div><a href="/servlet/linkout?suffix=cit260&amp;dbid=16384&amp;doi=10.1134%2FS1070428013040167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1134%252FS1070428013040167%26sid%3Dliteratum%253Aachs%26aulast%3DGalkina%26aufirst%3DI.%2BV.%26aulast%3DTakhautdinova%26aufirst%3DG.%2BL.%26aulast%3DTudrii%26aufirst%3DE.%2BV.%26aulast%3DYusupova%26aufirst%3DL.%2BM.%26aulast%3DFalyakhov%26aufirst%3DI.%2BF.%26aulast%3DPozdeev%26aufirst%3DO.%2BK.%26aulast%3DShulaeva%26aufirst%3DM.%2BP.%26aulast%3DKipenskaya%26aufirst%3DL.%2BV.%26aulast%3DSakhibullina%26aufirst%3DV.%2BG.%26aulast%3DKrivolapov%26aufirst%3DD.%2BB.%26aulast%3DLitvinov%26aufirst%3DI.%2BA.%26aulast%3DGalkin%26aufirst%3DV.%2BI.%26aulast%3DCherkasov%26aufirst%3DR.%2BA.%26atitle%3DSynthesis%252C%2520structure%252C%2520and%2520antibacterial%2520activity%2520of%2520aminobenzofuroxan%2520and%2520aminobenzofurazan%26jtitle%3DRuss.%2520J.%2520Org.%2520Chem.%26date%3D2013%26volume%3D49%26issue%3D4%26spage%3D591%26epage%3D597%26doi%3D10.1134%2FS1070428013040167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref261"><div class="reference"><strong class="refLabel"><a href="#ref261" class="rightTabRefNumLink">261</a></strong><div class="NLM_citation" id="rightTab-cit261"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beebe, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilius, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merta, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soni, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beutel, B. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and SAR evaluation of oxadiazolopyrazines as selective Haemophilus influenzae antibacterial agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">3133</span>â <span class="NLM_lpage">3136</span>, <span class="refDoi">Â DOI: 10.1016/S0960-894X(03)00727-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2FS0960-894X%2803%2900727-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=12951079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvV2lsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=3133-3136&issue=19&author=X.+Beebeauthor=A.+M.+Niliusauthor=P.+J.+Mertaauthor=N.+B.+Soniauthor=M.+H.+Buiauthor=R.+Wagnerauthor=B.+A.+Beutel&title=Synthesis+and+SAR+evaluation+of+oxadiazolopyrazines+as+selective+Haemophilus+influenzae+antibacterial+agents&doi=10.1016%2FS0960-894X%2803%2900727-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit261R"><div class="casContent"><span class="casTitleNuber">261</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and SAR evaluation of oxadiazolopyrazines as selective Haemophilus influenzae antibacterial agents</span></div><div class="casAuthors">Beebe, Xenia; Nilius, Angela M.; Merta, Philip J.; Soni, Niru B.; Bui, Mai H.; Wagner, Rolf; Beutel, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3133-3136</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The parallel synthesis and antibacterial activity of 5-hydroxy-1,2,5-oxadiazolo[3,4-b]pyrazines, e.g., I, is reported.  The compds. were synthesized by condensing diaminofurazan (II) with Î±-keto acids to give a variety of aryl-substituted analogs.  Halogenated Ph groups at C-6 give rise to the greatest Haemophilus influenzae antibacterial activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXyJKZ9hzxF7Vg90H21EOLACvtfcHk0lgVFmvBpxXi8g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvV2lsLk%253D&md5=a64b56982c86d0e7a16897346c203a03</span></div><a href="/servlet/linkout?suffix=cit261&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2803%2900727-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252803%252900727-3%26sid%3Dliteratum%253Aachs%26aulast%3DBeebe%26aufirst%3DX.%26aulast%3DNilius%26aufirst%3DA.%2BM.%26aulast%3DMerta%26aufirst%3DP.%2BJ.%26aulast%3DSoni%26aufirst%3DN.%2BB.%26aulast%3DBui%26aufirst%3DM.%2BH.%26aulast%3DWagner%26aufirst%3DR.%26aulast%3DBeutel%26aufirst%3DB.%2BA.%26atitle%3DSynthesis%2520and%2520SAR%2520evaluation%2520of%2520oxadiazolopyrazines%2520as%2520selective%2520Haemophilus%2520influenzae%2520antibacterial%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26issue%3D19%26spage%3D3133%26epage%3D3136%26doi%3D10.1016%2FS0960-894X%2803%2900727-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref262"><div class="reference"><strong class="refLabel"><a href="#ref262" class="rightTabRefNumLink">262</a></strong><div class="NLM_citation" id="rightTab-cit262"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cremades, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VelÃ¡zquez-Campoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MartÃ­nez-JÃºlvez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neira, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©rez-Dorado, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermoso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">JimÃ©nez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancho, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of specific flavodoxin inhibitors as potential therapeutic agents against Helicobacter pylori infection</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">928</span>â <span class="NLM_lpage">938</span>, <span class="refDoi">Â DOI: 10.1021/cb900166q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb900166q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFKgu7rI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=928-938&issue=11&author=N.+Cremadesauthor=A.+Vel%C3%A1zquez-Campoyauthor=M.+Mart%C3%ADnez-J%C3%BAlvezauthor=J.+L.+Neiraauthor=I.+P%C3%A9rez-Doradoauthor=J.+Hermosoauthor=P.+Jim%C3%A9nezauthor=A.+Lanasauthor=P.+S.+Hoffmanauthor=J.+Sancho&title=Discovery+of+specific+flavodoxin+inhibitors+as+potential+therapeutic+agents+against+Helicobacter+pylori+infection&doi=10.1021%2Fcb900166q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit262R"><div class="casContent"><span class="casTitleNuber">262</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Specific Flavodoxin Inhibitors as Potential Therapeutic Agents against Helicobacter pylori Infection</span></div><div class="casAuthors">Cremades, Nunilo; Velazquez-Campoy, Adrian; Martinez-Julvez, Marta; Neira, Jose L.; Perez-Dorado, Inmaculada; Hermoso, Juan; Jimenez, Pilar; Lanas, Angel; Hoffman, Paul S.; Sancho, Javier</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">928-938</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Helicobacter pylori establishes life-long infections in the gastric mucosa of over 1 billion people worldwide.  In many cases, without specific antimicrobial intervention, H. pylori infected individuals will develop type B gastritis, chronic peptic ulcers and, more rarely, gastric neoplasias.  Conventional antimicrobial therapy has been complicated by dramatic increases in resistance to macrolides, metronidazole and fluoroquinolones.  Here, the authors report the development of novel therapeutics that specifically target the unique flavodoxin component of an essential metabolic pathway of H. pylori.  With the use of high-throughput screening methodol., the authors have tested 10,000 chems. and have identified 29 compds. that bind flavodoxin, four of which interrupted in vitro electron transfer to flavodoxin physiol. partners.  Three of these compds. are bactericidal and promisingly selective for H. pylori.  The minimal inhibitory concns. of two of them are 10 times lower than their minimal cytotoxic concns. for HeLa cells.  Importantly, neither of the four inhibitors is toxic for mice after administration of 1-10 mg kg-1 doses twice a day for 5 days.  Enzymic, thermodn. and structural characterization of the inhibitor-flavodoxin complexes suggests these compds. could act by modifying the redox potentials of flavodoxin.  These newly discovered inhibitors represent promising selective leads against the different diseases assocd. to H. pylori infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjDI_jKdwgjbVg90H21EOLACvtfcHk0lgVFmvBpxXi8g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFKgu7rI&md5=dd46db4ba63571b42509b751d53df241</span></div><a href="/servlet/linkout?suffix=cit262&amp;dbid=16384&amp;doi=10.1021%2Fcb900166q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb900166q%26sid%3Dliteratum%253Aachs%26aulast%3DCremades%26aufirst%3DN.%26aulast%3DVel%25C3%25A1zquez-Campoy%26aufirst%3DA.%26aulast%3DMart%25C3%25ADnez-J%25C3%25BAlvez%26aufirst%3DM.%26aulast%3DNeira%26aufirst%3DJ.%2BL.%26aulast%3DP%25C3%25A9rez-Dorado%26aufirst%3DI.%26aulast%3DHermoso%26aufirst%3DJ.%26aulast%3DJim%25C3%25A9nez%26aufirst%3DP.%26aulast%3DLanas%26aufirst%3DA.%26aulast%3DHoffman%26aufirst%3DP.%2BS.%26aulast%3DSancho%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520specific%2520flavodoxin%2520inhibitors%2520as%2520potential%2520therapeutic%2520agents%2520against%2520Helicobacter%2520pylori%2520infection%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2009%26volume%3D4%26issue%3D11%26spage%3D928%26epage%3D938%26doi%3D10.1021%2Fcb900166q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref263"><div class="reference"><strong class="refLabel"><a href="#ref263" class="rightTabRefNumLink">263</a></strong><div class="NLM_citation" id="rightTab-cit263"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galano, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alias, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez-Campoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancho, J.</span></span> <span> </span><span class="NLM_article-title">Improved flavodoxin inhibitors with potential therapeutic effects against Helicobacter pylori infection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6248</span>â <span class="NLM_lpage">6258</span>, <span class="refDoi">Â DOI: 10.1021/jm400786q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400786q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtV2mtrjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6248-6258&issue=15&author=J.+J.+Galanoauthor=M.+Aliasauthor=R.+Perezauthor=A.+Velazquez-Campoyauthor=P.+S.+Hoffmanauthor=J.+Sancho&title=Improved+flavodoxin+inhibitors+with+potential+therapeutic+effects+against+Helicobacter+pylori+infection&doi=10.1021%2Fjm400786q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit263R"><div class="casContent"><span class="casTitleNuber">263</span><div class="casTitle"><span class="NLM_cas:atitle">Improved Flavodoxin Inhibitors with Potential Therapeutic Effects against Helicobacter pylori Infection</span></div><div class="casAuthors">Galano, Juan J.; Alias, Miriam; Perez, Reyes; Velazquez-Campoy, Adrian; Hoffman, Paul S.; Sancho, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6248-6258</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A variety of electron-deficient chromenes and styrenes and nitrobenzooxadiazolyl thioethers and other compds. were tested (and in some cases prepd.) as selective inhibitors of flavodoxin in Helicobacter pylori for potential use in the treatment of gastric ulcer and prevention of stomach cancer with fewer side effects and reduced susceptibilities to drug resistance; their inhibition of flavodoxin and of Helicobacter pylori and their cytotoxicities were detd.  For example, (E)-ArCH:CHNO2 (Ar = 2-F-5-F3CC6H3, 4-Cl-2,6-F2C6H2) inhibited H. pylori with IC50 values of 0.53 Î¼M and therapeutic indexes of 38 and 15, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVtcmy_dYlFLVg90H21EOLACvtfcHk0lgVFmvBpxXi8g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtV2mtrjL&md5=28e1e564ebc186a2da0702973eb8fb64</span></div><a href="/servlet/linkout?suffix=cit263&amp;dbid=16384&amp;doi=10.1021%2Fjm400786q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400786q%26sid%3Dliteratum%253Aachs%26aulast%3DGalano%26aufirst%3DJ.%2BJ.%26aulast%3DAlias%26aufirst%3DM.%26aulast%3DPerez%26aufirst%3DR.%26aulast%3DVelazquez-Campoy%26aufirst%3DA.%26aulast%3DHoffman%26aufirst%3DP.%2BS.%26aulast%3DSancho%26aufirst%3DJ.%26atitle%3DImproved%2520flavodoxin%2520inhibitors%2520with%2520potential%2520therapeutic%2520effects%2520against%2520Helicobacter%2520pylori%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D15%26spage%3D6248%26epage%3D6258%26doi%3D10.1021%2Fjm400786q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref264"><div class="reference"><strong class="refLabel"><a href="#ref264" class="rightTabRefNumLink">264</a></strong><div class="NLM_citation" id="rightTab-cit264"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salillas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alias, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bueno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galano-Frutos, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Reuse, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez-Campoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrodeguas, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sostres, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ainsa, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz-de-Villegas, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touati, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancho, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and efficacy testing of nitroethylene- and 7-nitrobenzoxadiazol-based flavodoxin inhibitors against Helicobacter pylori drug-resistant clinical strains and in Helicobacter pylori-infected mice</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">6102</span>â <span class="NLM_lpage">6115</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b00355</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00355" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFaqs73M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6102-6115&issue=13&author=S.+Salillasauthor=M.+Aliasauthor=V.+Michelauthor=A.+Mahiaauthor=A.+Luciaauthor=L.+Rodriguesauthor=J.+Buenoauthor=J.+J.+Galano-Frutosauthor=H.+De+Reuseauthor=A.+Velazquez-Campoyauthor=J.+A.+Carrodeguasauthor=C.+Sostresauthor=J.+Castilloauthor=J.+A.+Ainsaauthor=M.+D.+Diaz-de-Villegasauthor=A.+Lanasauthor=E.+Touatiauthor=J.+Sancho&title=Design%2C+synthesis%2C+and+efficacy+testing+of+nitroethylene-+and+7-nitrobenzoxadiazol-based+flavodoxin+inhibitors+against+Helicobacter+pylori+drug-resistant+clinical+strains+and+in+Helicobacter+pylori-infected+mice&doi=10.1021%2Facs.jmedchem.9b00355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit264R"><div class="casContent"><span class="casTitleNuber">264</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Efficacy Testing of Nitroethylene- and 7-Nitrobenzoxadiazol-Based Flavodoxin Inhibitors against Helicobacter pylori Drug-Resistant Clinical Strains and in Helicobacter pylori-Infected Mice</span></div><div class="casAuthors">Salillas, Sandra; Alias, Miriam; Michel, Valerie; Mahia, Alejandro; Lucia, Ainhoa; Rodrigues, Liliana; Bueno, Jessica; Galano-Frutos, Juan Jose; De Reuse, Hilde; Velazquez-Campoy, Adrian; Carrodeguas, Jose Alberto; Sostres, Carlos; Castillo, Javier; Ainsa, Jose Antonio; Diaz-de-Villegas, Maria Dolores; Lanas, Angel; Touati, Eliette; Sancho, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6102-6115</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Helicobacter pylori (Hp) infection is the main cause of peptic ulcer and gastric cancer.  Hp eradication rates have fallen due to increasing bacterial resistance to currently used broad-spectrum antimicrobials.  We have designed, synthesized, and tested redox variants of nitroethylene- and 7-nitrobenzoxadiazole-based inhibitors of the essential Hp protein flavodoxin.  Derivs. of the 7-nitrobenzoxadiazole lead, carrying reduced forms of the nitro group and/or oxidized forms of a sulfur atom, display high therapeutic indexes against several ref. Hp strains.  These inhibitors are effective against metronidazole-, clarithromycin-, and rifampicin-resistant Hp clin. isolates.  Their toxicity for mice after oral administration is low, and, when administered individually at single daily doses for 8 days in a mice model of Hp infection, they decrease significantly Hp gastric colonization rates and are able to eradicate the infection in up to 60% of the mice.  These flavodoxin inhibitors constitute a novel family of Hp-specific antimicrobials that may help fight the const. increase of Hp antimicrobial-resistant strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO7BuoCfwxibVg90H21EOLACvtfcHk0lhtJ06Fn4_vFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFaqs73M&md5=7b2ccbffcf8c2dcf2ed24180331e9866</span></div><a href="/servlet/linkout?suffix=cit264&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00355%26sid%3Dliteratum%253Aachs%26aulast%3DSalillas%26aufirst%3DS.%26aulast%3DAlias%26aufirst%3DM.%26aulast%3DMichel%26aufirst%3DV.%26aulast%3DMahia%26aufirst%3DA.%26aulast%3DLucia%26aufirst%3DA.%26aulast%3DRodrigues%26aufirst%3DL.%26aulast%3DBueno%26aufirst%3DJ.%26aulast%3DGalano-Frutos%26aufirst%3DJ.%2BJ.%26aulast%3DDe%2BReuse%26aufirst%3DH.%26aulast%3DVelazquez-Campoy%26aufirst%3DA.%26aulast%3DCarrodeguas%26aufirst%3DJ.%2BA.%26aulast%3DSostres%26aufirst%3DC.%26aulast%3DCastillo%26aufirst%3DJ.%26aulast%3DAinsa%26aufirst%3DJ.%2BA.%26aulast%3DDiaz-de-Villegas%26aufirst%3DM.%2BD.%26aulast%3DLanas%26aufirst%3DA.%26aulast%3DTouati%26aufirst%3DE.%26aulast%3DSancho%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520efficacy%2520testing%2520of%2520nitroethylene-%2520and%25207-nitrobenzoxadiazol-based%2520flavodoxin%2520inhibitors%2520against%2520Helicobacter%2520pylori%2520drug-resistant%2520clinical%2520strains%2520and%2520in%2520Helicobacter%2520pylori-infected%2520mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D13%26spage%3D6102%26epage%3D6115%26doi%3D10.1021%2Facs.jmedchem.9b00355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref265"><div class="reference"><strong class="refLabel"><a href="#ref265" class="rightTabRefNumLink">265</a></strong><div class="NLM_citation" id="rightTab-cit265"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sancho Sanz, J.</span>; <span class="NLM_string-name">Velazquez Campoy, A.</span>; <span class="NLM_string-name">Cremades Casasin, N.</span></span> <span> </span><span class="NLM_article-title">Composition for Treating Infectious Diseases Caused by Helicobacter</span>. <span class="NLM_patent">WO2008107501A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=J.+Sancho+Sanz&author=A.+Velazquez+Campoy&author=N.+Cremades+Casasin&title=Composition+for+Treating+Infectious+Diseases+Caused+by+Helicobacter"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit265&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSancho%2BSanz%26aufirst%3DJ.%26atitle%3DComposition%2520for%2520Treating%2520Infectious%2520Diseases%2520Caused%2520by%2520Helicobacter%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref266"><div class="reference"><strong class="refLabel"><a href="#ref266" class="rightTabRefNumLink">266</a></strong><div class="NLM_citation" id="rightTab-cit266"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christoff, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostoulias, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peleg, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbott, B. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of novel 1,2,5-oxadiazoles and evaluation of action against Acinetobacter baumannii</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">6267</span>â <span class="NLM_lpage">6272</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2017.08.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmc.2017.08.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=29032931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1arsLrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=6267-6272&issue=24&author=R.+M.+Christoffauthor=G.+L.+Murrayauthor=X.+P.+Kostouliasauthor=A.+Y.+Pelegauthor=B.+M.+Abbott&title=Synthesis+of+novel+1%2C2%2C5-oxadiazoles+and+evaluation+of+action+against+Acinetobacter+baumannii&doi=10.1016%2Fj.bmc.2017.08.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit266R"><div class="casContent"><span class="casTitleNuber">266</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of novel 1,2,5-oxadiazoles and evaluation of action against Acinetobacter baumannii</span></div><div class="casAuthors">Christoff, Rebecca M.; Murray, Gerald L.; Kostoulias, Xenia P.; Peleg, Anton Y.; Abbott, Belinda M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6267-6272</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">With multidrug resistant bacteria on the rise, novel antibiotics are becoming highly sought after.  In 2008, eleven compds. were identified by high throughput screening as inhibitors of BasE, a key enzyme of the non-ribosomal peptide synthetase pathway found in Acinetobacter baumannii.  Herein, the authors describe the prepn. of four structurally similar heterocyclic lead compds. from that study, including one 1,2,5-oxadiazole.  A further library of 30 analogs contg. the oxadiazole moiety was then generated.  All compds. were screened against Acinetobacter baumannii and their min. inhibitory concn. data is reported, with (E)-3-(2-hydroxyphenyl)-N-(4-methyl-1,2,5-oxadiazol-3-yl)acrylamide found to have an MIC of 0.5 mM.  This work provides the foundation for further study of 1,2,5-oxadiazoles as novel inhibitors of A. baumannii.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD-LYnmyhuMLVg90H21EOLACvtfcHk0lhtJ06Fn4_vFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1arsLrI&md5=70a94b4ce073cb4e639bfdd6b77c5be6</span></div><a href="/servlet/linkout?suffix=cit266&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.08.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.08.015%26sid%3Dliteratum%253Aachs%26aulast%3DChristoff%26aufirst%3DR.%2BM.%26aulast%3DMurray%26aufirst%3DG.%2BL.%26aulast%3DKostoulias%26aufirst%3DX.%2BP.%26aulast%3DPeleg%26aufirst%3DA.%2BY.%26aulast%3DAbbott%26aufirst%3DB.%2BM.%26atitle%3DSynthesis%2520of%2520novel%25201%252C2%252C5-oxadiazoles%2520and%2520evaluation%2520of%2520action%2520against%2520Acinetobacter%2520baumannii%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26issue%3D24%26spage%3D6267%26epage%3D6272%26doi%3D10.1016%2Fj.bmc.2017.08.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref267"><div class="reference"><strong class="refLabel"><a href="#ref267" class="rightTabRefNumLink">267</a></strong><div class="NLM_citation" id="rightTab-cit267"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, C. C.</span></span> <span> </span><span class="NLM_article-title">Aryl acid adenylating enzymes involved in siderophore biosynthesis: Fluorescence polarization assay, ligand specificity, and discovery of non-nucleoside inhibitors via high-throughput screening</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">45</span>),  <span class="NLM_fpage">11735</span>â <span class="NLM_lpage">11749</span>, <span class="refDoi">Â DOI: 10.1021/bi801625b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi801625b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kiu77J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=11735-11749&issue=45&author=J.+Neresauthor=D.+J.+Wilsonauthor=L.+Celiaauthor=B.+J.+Beckauthor=C.+C.+Aldrich&title=Aryl+acid+adenylating+enzymes+involved+in+siderophore+biosynthesis%3A+Fluorescence+polarization+assay%2C+ligand+specificity%2C+and+discovery+of+non-nucleoside+inhibitors+via+high-throughput+screening&doi=10.1021%2Fbi801625b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit267R"><div class="casContent"><span class="casTitleNuber">267</span><div class="casTitle"><span class="NLM_cas:atitle">Aryl Acid Adenylating Enzymes Involved in Siderophore Biosynthesis: Fluorescence Polarization Assay, Ligand Specificity, and Discovery of Non-nucleoside Inhibitors via High-Throughput Screening</span></div><div class="casAuthors">Neres, Joao; Wilson, Daniel J.; Celia, Laura; Beck, Brian J.; Aldrich, Courtney C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">11735-11749</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design and synthesis of a fluorescent probe Fl-Sal-AMS 6 based on the tight-binding inhibitor 5'-O-[N-(salicyl)sulfamoyl]adenosine (Sal-AMS) is described for the aryl acid adenylating enzymes (AAAEs) known as MbtA, YbtE, EntE, VibE, DhbE, and BasE involved in siderophore biosynthesis from Mycobacterium tuberculosis, Yersinia pestis, Escherichia coli, Vibrio cholerae, Bacillus subtilis, and Acinetobacter baumannii, resp.  The probe was successfully used to develop a fluorescence polarization assay for these six AAAEs, and equil. dissocn. consts. were detd. in direct binding expts.  Fl-Sal-AMS was effective for AAAEs that utilize salicylic acid or 2,3-dihydroxybenzoic acid as native substrates, with dissocn. consts. ranging from 9-369 nM, but was ineffective for AsbC, the AAAE from Bacillus anthracis, which activates 3,4-dihydroxybenzoic acid.  Competitive binding expts. using a series of ligands including substrates, reaction products, and inhibitors provided the first comparative structure-activity relationships for AAAEs.  The fluorescence polarization assay was then miniaturized to a 384-well plate format, and high-throughput screening was performed at the National Screening Lab. for the Regional Centers of Excellence in Biodefense and Emerging Infectious Diseases (NSRB) against BasE, an AAAE from Acinetobacter baumannii involved in prodn. of the siderophore acinetobactin.  Several small mol. inhibitors with new chemotypes were identified, and compd. 23 contg. a pyrazolo[5,4-a]pyridine scaffold emerged as the most promising ligand with a KD of 78 nM, which was independently confirmed by isothermal calorimetry, and inhibition was also verified in an ATP-[32P]-pyrophosphate exchange steady-state kinetic assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqurhns8FCLb7Vg90H21EOLACvtfcHk0lhtJ06Fn4_vFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kiu77J&md5=d6682bccddd82d723b9b5bb900b39284</span></div><a href="/servlet/linkout?suffix=cit267&amp;dbid=16384&amp;doi=10.1021%2Fbi801625b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi801625b%26sid%3Dliteratum%253Aachs%26aulast%3DNeres%26aufirst%3DJ.%26aulast%3DWilson%26aufirst%3DD.%2BJ.%26aulast%3DCelia%26aufirst%3DL.%26aulast%3DBeck%26aufirst%3DB.%2BJ.%26aulast%3DAldrich%26aufirst%3DC.%2BC.%26atitle%3DAryl%2520acid%2520adenylating%2520enzymes%2520involved%2520in%2520siderophore%2520biosynthesis%253A%2520Fluorescence%2520polarization%2520assay%252C%2520ligand%2520specificity%252C%2520and%2520discovery%2520of%2520non-nucleoside%2520inhibitors%2520via%2520high-throughput%2520screening%26jtitle%3DBiochemistry%26date%3D2008%26volume%3D47%26issue%3D45%26spage%3D11735%26epage%3D11749%26doi%3D10.1021%2Fbi801625b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref268"><div class="reference"><strong class="refLabel"><a href="#ref268" class="rightTabRefNumLink">268</a></strong><div class="NLM_citation" id="rightTab-cit268"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamiya, S.</span>; <span class="NLM_string-name">Osaki, T.</span>; <span class="NLM_string-name">Yonezawa, H.</span></span> <span> </span><span class="NLM_article-title">Biofilm formation and bacterial pathogenesis</span>.  <i>Antibiotic Therapy: New Developments</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, A.</span>; <span class="NLM_string-name">Hall, J.</span></span>; Eds.; <span class="NLM_publisher-name">Nova Science Publishers, Inc.</span>: <span class="NLM_publisher-loc">Hauppauge</span>, <span class="NLM_year">2013</span>, pp  <span class="NLM_fpage">89</span>â <span class="NLM_lpage">107</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=89-107&author=S.+Kamiya&author=T.+Osaki&author=H.+Yonezawaauthor=A.+Turner&author=J.+Hall&title=Antibiotic+Therapy%3A+New+Developments"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit268&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKamiya%26aufirst%3DS.%26atitle%3DBiofilm%2520formation%2520and%2520bacterial%2520pathogenesis%26btitle%3DAntibiotic%2520Therapy%253A%2520New%2520Developments%26aulast%3DTurner%26aufirst%3DA.%26pub%3DNova%2520Science%2520Publishers%252C%2520Inc%26date%3D2013%26spage%3D89%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref269"><div class="reference"><strong class="refLabel"><a href="#ref269" class="rightTabRefNumLink">269</a></strong><div class="NLM_citation" id="rightTab-cit269"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tribedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manna, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharjee, S.</span></span> <span> </span><span class="NLM_article-title">3-Amino-4-aminoximidofurazan derivatives: Small molecules possessing antimicrobial and antibiofilm activity against Staphylococcus aureus and Pseudomonas aeruginosa</span>. <i>J. Appl. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>120</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">842</span>â <span class="NLM_lpage">859</span>, <span class="refDoi">Â DOI: 10.1111/jam.13063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1111%2Fjam.13063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=26785169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC28XktlGksrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2016&pages=842-859&issue=4&author=M.+C.+Dasauthor=S.+Paulauthor=P.+Guptaauthor=P.+Tribediauthor=S.+Sarkarauthor=D.+Mannaauthor=S.+Bhattacharjee&title=3-Amino-4-aminoximidofurazan+derivatives%3A+Small+molecules+possessing+antimicrobial+and+antibiofilm+activity+against+Staphylococcus+aureus+and+Pseudomonas+aeruginosa&doi=10.1111%2Fjam.13063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit269R"><div class="casContent"><span class="casTitleNuber">269</span><div class="casTitle"><span class="NLM_cas:atitle">3-Amino-4-aminoximidofurazan derivatives: small molecules possessing antimicrobial and antibiofilm activity against Staphylococcus aureus and Pseudomonas aeruginosa</span></div><div class="casAuthors">Das, M. C.; Paul, S.; Gupta, P.; Tribedi, P.; Sarkar, S.; Manna, D.; Bhattacharjee, S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Microbiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">842-859</span>CODEN:
                <span class="NLM_cas:coden">JAMIFK</span>;
        ISSN:<span class="NLM_cas:issn">1364-5072</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The therapeutic treatment of microbial infections involving biofilm becomes quite challenging because of its increasing antibiotic resistance capacities.  Towards this direction, in the present study we have evaluated the antibiofilm property of synthesized 3-amino-4-aminoximidofurazan compds. having polyamine skeleton.  These derivs. were synthesized by incorporating furazan and biguanide moieties.  Different 3-amino-4-aminoximidofurazan derivs. (PI1-4) were synthesized via protic acid catalysis and subsequently characterized by 1H NMR and 13C NMR spectra, recorded at 400 and 100 MHz resp.  We have tested the antimicrobial and antibiofilm activities of these synthetic derivs. (PI1-4) against both Staphylococcus aureus and Pseudomonas aeruginosa.  The compds. so tested were also compared with std. antibiotics namely Tobramycin (Ps. aeruginosa) and Azithromycin (Staph. aureus) which were used as a pos. control in all exptl. sets.  All these compds. (PI1-4) exhibited moderate to significant antimicrobial activities against both micro-organisms wherein compd. PI3 showed max. activity.  Biofilm inhibition of both micro-organisms was then evaluated by crystal violet and safranin staining, estn. of biofilm total protein and microscopy methods using sub-MIC dose of these compds.  Results showed that all compds. executed anti biofilm activity against both Staph. aureus and Ps. aeruginosa wherein compd. PI3 exhibited max. activity.  In relation with microbial biofilm inhibition, we have obsd. redn. in bacterial motility, proteolytic activity and secreted exo-polysaccharide (EPS) from both Staph. aureus and Ps. aeruginosa when they were grown in presence of these compds.  While addressing the issue of toxicity on host, we have obsd. that these mols. exhibited min. level of R.B.C degrdn.  These findings establish the antibacterial and anti biofilm properties of 3-amino-4-aminoximidofurazan derivs. (PI1-4).  Therefore, our current findings demonstrate that 3-amino-4-aminoximidofurazan derivs. (PI1-4) may hold promise to be effective biofilm and microbial inhibitors that may be clin. significant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPPG-vhtzrhLVg90H21EOLACvtfcHk0lhtZuZ2pgQJHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktlGksrc%253D&md5=1089fd49e2fa8417ec307f7358c739a5</span></div><a href="/servlet/linkout?suffix=cit269&amp;dbid=16384&amp;doi=10.1111%2Fjam.13063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjam.13063%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DM.%2BC.%26aulast%3DPaul%26aufirst%3DS.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DTribedi%26aufirst%3DP.%26aulast%3DSarkar%26aufirst%3DS.%26aulast%3DManna%26aufirst%3DD.%26aulast%3DBhattacharjee%26aufirst%3DS.%26atitle%3D3-Amino-4-aminoximidofurazan%2520derivatives%253A%2520Small%2520molecules%2520possessing%2520antimicrobial%2520and%2520antibiofilm%2520activity%2520against%2520Staphylococcus%2520aureus%2520and%2520Pseudomonas%2520aeruginosa%26jtitle%3DJ.%2520Appl.%2520Microbiol.%26date%3D2016%26volume%3D120%26issue%3D4%26spage%3D842%26epage%3D859%26doi%3D10.1111%2Fjam.13063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref270"><div class="reference"><strong class="refLabel"><a href="#ref270" class="rightTabRefNumLink">270</a></strong><div class="NLM_citation" id="rightTab-cit270"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tranter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sessions, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brady, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendrick, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croft, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barros, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavandera, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ochoa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabarro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez de las Heras, F.</span></span> <span> </span><span class="NLM_article-title">Identification and activity of a series of azole-based compounds with lactate dehydrogenase-directed anti-malarial activity</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span> (<span class="NLM_issue">30</span>),  <span class="NLM_fpage">31429</span>â <span class="NLM_lpage">31439</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M402433200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1074%2Fjbc.M402433200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=15117937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlslOrsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=31429-31439&issue=30&author=A.+Cameronauthor=J.+Readauthor=R.+Tranterauthor=V.+J.+Winterauthor=R.+B.+Sessionsauthor=R.+L.+Bradyauthor=L.+Vivasauthor=A.+Eastonauthor=H.+Kendrickauthor=S.+L.+Croftauthor=D.+Barrosauthor=J.+L.+Lavanderaauthor=J.+J.+Martinauthor=F.+Riscoauthor=S.+Garcia-Ochoaauthor=F.+J.+Gamoauthor=L.+Sanzauthor=L.+Leonauthor=J.+R.+Ruizauthor=R.+Gabarroauthor=A.+Malloauthor=F.+Gomez+de+las+Heras&title=Identification+and+activity+of+a+series+of+azole-based+compounds+with+lactate+dehydrogenase-directed+anti-malarial+activity&doi=10.1074%2Fjbc.M402433200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit270R"><div class="casContent"><span class="casTitleNuber">270</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and activity of a series of azole-based compounds with lactate dehydrogenase-directed anti-malarial activity</span></div><div class="casAuthors">Cameron, Angus; Read, Jon; Tranter, Rebecca; Winter, Victoria J.; Sessions, Richard B.; Brady, R. Leo; Vivas, Livia; Easton, Anna; Kendrick, Howard; Croft, Simon L.; Barros, David; Lavandera, Jose Luis; Martin, Jose Julio; Risco, Felix; Garcia-Ochoa, Silvestre; Gamo, Fracisco Javier; Sanz, Laura; Leon, Luisa; Ruiz, Jose R.; Gabarro, Raquel; Mallo, Araceli; Gomez de las Heras, Federico</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">31429-31439</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Plasmodium falciparum, the causative agent of malaria, relies extensively on glycolysis coupled with homolactic fermn. during its blood-borne stages for energy prodn.  Selective inhibitors of the parasite lactate dehydrogenase (LDH), central to NAD+ regeneration, therefore potentially provide a route to new antimalarial drugs directed against a novel mol. target.  A series of heterocyclic, azole-based compds. are described that preferentially inhibit P. falciparum LDH at sub-micromolar concns., typically at concns. about 100-fold lower than required for human lactate dehydrogenase inhibition.  Crystal structures show these competitive inhibitors form a network of interactions with amino acids within the active site of the enzyme, stacking alongside the nicotinamide ring of the NAD+ cofactor.  These compds. display modest activity against parasitized erythrocytes, including parasite strains with known resistance to existing antimalarials and against Plasmodium berghei in BALB/c mice.  Initial toxicity data suggest the azole derivs. have generally low cytotoxicity, and preliminary pharmaco-kinetic data show favorable bioavailability and circulation times.  These encouraging results suggest that further enhancement of these structures may yield candidates suitable for consideration as new therapeutics for the treatment of malaria.  In combination these studies also provide strong support for the validity of targeting the Plasmodium glycolytic pathway and, in particular, LDH in the search for novel antimalarials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquuWRnYRD7DLVg90H21EOLACvtfcHk0lhtZuZ2pgQJHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlslOrsLw%253D&md5=335235a632b3244cab8d5b828d232fa8</span></div><a href="/servlet/linkout?suffix=cit270&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M402433200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M402433200%26sid%3Dliteratum%253Aachs%26aulast%3DCameron%26aufirst%3DA.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DTranter%26aufirst%3DR.%26aulast%3DWinter%26aufirst%3DV.%2BJ.%26aulast%3DSessions%26aufirst%3DR.%2BB.%26aulast%3DBrady%26aufirst%3DR.%2BL.%26aulast%3DVivas%26aufirst%3DL.%26aulast%3DEaston%26aufirst%3DA.%26aulast%3DKendrick%26aufirst%3DH.%26aulast%3DCroft%26aufirst%3DS.%2BL.%26aulast%3DBarros%26aufirst%3DD.%26aulast%3DLavandera%26aufirst%3DJ.%2BL.%26aulast%3DMartin%26aufirst%3DJ.%2BJ.%26aulast%3DRisco%26aufirst%3DF.%26aulast%3DGarcia-Ochoa%26aufirst%3DS.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DSanz%26aufirst%3DL.%26aulast%3DLeon%26aufirst%3DL.%26aulast%3DRuiz%26aufirst%3DJ.%2BR.%26aulast%3DGabarro%26aufirst%3DR.%26aulast%3DMallo%26aufirst%3DA.%26aulast%3DGomez%2Bde%2Blas%2BHeras%26aufirst%3DF.%26atitle%3DIdentification%2520and%2520activity%2520of%2520a%2520series%2520of%2520azole-based%2520compounds%2520with%2520lactate%2520dehydrogenase-directed%2520anti-malarial%2520activity%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26issue%3D30%26spage%3D31429%26epage%3D31439%26doi%3D10.1074%2Fjbc.M402433200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref271"><div class="reference"><strong class="refLabel"><a href="#ref271" class="rightTabRefNumLink">271</a></strong><div class="NLM_citation" id="rightTab-cit271"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Florence, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulloch, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacharova, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T. K.</span></span> <span> </span><span class="NLM_article-title">Development of simplified heterocyclic acetogenin analogues as potent and selective Trypanosoma brucei inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">1503</span>â <span class="NLM_lpage">1506</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201600210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fcmdc.201600210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=27283448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVyjs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1503-1506&issue=14&author=G.+J.+Florenceauthor=A.+L.+Fraserauthor=E.+R.+Gouldauthor=E.+F.+Kingauthor=S.+K.+Menziesauthor=J.+C.+Morrisauthor=M.+I.+Thomsonauthor=L.+B.+Tullochauthor=M.+K.+Zacharovaauthor=T.+K.+Smith&title=Development+of+simplified+heterocyclic+acetogenin+analogues+as+potent+and+selective+Trypanosoma+brucei+inhibitors&doi=10.1002%2Fcmdc.201600210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit271R"><div class="casContent"><span class="casTitleNuber">271</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Simplified Heterocyclic Acetogenin Analogues as Potent and Selective Trypanosoma brucei Inhibitors</span></div><div class="casAuthors">Florence, Gordon J.; Fraser, Andrew L.; Gould, Eoin R.; King, Elizabeth F.; Menzies, Stefanie K.; Morris, Joanne C.; Thomson, Marie I.; Tulloch, Lindsay B.; Zacharova, Marija K.; Smith, Terry K.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1503-1506</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Neglected tropical diseases caused by parasitic infections are an ongoing and increasing concern.  They are a burden to human and animal health, having the most devastating effect on the world's poorest countries.  Building upon our previously reported triazole analogs, in this study we describe the synthesis and biol. testing of other novel heterocyclic acetogenin-inspired derivs., namely 3,5-isoxazoles, furoxans, and furazans.  Several of these compds. maintain low-micromolar levels of inhibition against Trypanosoma brucei, while having no observable inhibitory effect on mammalian cells, leading to the possibility of novel lead compds. for selective treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoctHLE622pVbVg90H21EOLACvtfcHk0lhIEAT6PlIokA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVyjs7g%253D&md5=fcf5866e0376c12dcc956d35867d45d7</span></div><a href="/servlet/linkout?suffix=cit271&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600210%26sid%3Dliteratum%253Aachs%26aulast%3DFlorence%26aufirst%3DG.%2BJ.%26aulast%3DFraser%26aufirst%3DA.%2BL.%26aulast%3DGould%26aufirst%3DE.%2BR.%26aulast%3DKing%26aufirst%3DE.%2BF.%26aulast%3DMenzies%26aufirst%3DS.%2BK.%26aulast%3DMorris%26aufirst%3DJ.%2BC.%26aulast%3DThomson%26aufirst%3DM.%2BI.%26aulast%3DTulloch%26aufirst%3DL.%2BB.%26aulast%3DZacharova%26aufirst%3DM.%2BK.%26aulast%3DSmith%26aufirst%3DT.%2BK.%26atitle%3DDevelopment%2520of%2520simplified%2520heterocyclic%2520acetogenin%2520analogues%2520as%2520potent%2520and%2520selective%2520Trypanosoma%2520brucei%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26issue%3D14%26spage%3D1503%26epage%3D1506%26doi%3D10.1002%2Fcmdc.201600210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref272"><div class="reference"><strong class="refLabel"><a href="#ref272" class="rightTabRefNumLink">272</a></strong><div class="NLM_citation" id="rightTab-cit272"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keurulainen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heiskari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nenonen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasereddin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopelyanskiy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leino, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yli-Kauhaluoma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffe, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiuru, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis of carboxyimidamide-substituted benzo[c][1,2,5]oxadiazoles and their analogs, and evaluation of biological activity against Leishmania donovani</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1673</span>â <span class="NLM_lpage">1678</span>, <span class="refDoi">Â DOI: 10.1039/C5MD00119F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1039%2FC5MD00119F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12mur%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1673-1678&issue=9&author=L.+Keurulainenauthor=M.+Heiskariauthor=S.+Nenonenauthor=A.+Nasereddinauthor=D.+Kopelyanskiyauthor=T.+O.+Leinoauthor=J.+Yli-Kauhaluomaauthor=C.+L.+Jaffeauthor=P.+Kiuru&title=Synthesis+of+carboxyimidamide-substituted+benzo%5Bc%5D%5B1%2C2%2C5%5Doxadiazoles+and+their+analogs%2C+and+evaluation+of+biological+activity+against+Leishmania+donovani&doi=10.1039%2FC5MD00119F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit272R"><div class="casContent"><span class="casTitleNuber">272</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of carboxyimidamide-substituted benzo[c][1,2,5]oxadiazoles and their analogs and evaluation of biological activity against Leishmania donovani</span></div><div class="casAuthors">Keurulainen, Leena; Heiskari, Mikko; Nenonen, Satu; Nasereddin, Abedelmajeed; Kopelyanskiy, Dmitry; Leino, Teppo O.; Yli-Kauhaluoma, Jari; Jaffe, Charles L.; Kiuru, Paula</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1673-1678</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Facile synthesis route to carboxyimidamide-substituted benzoxadiazoles I [R = H, Me, OMe etc.] were developed.  A total of 25 derivs. were synthesized.  They were evaluated for antileishmanial activity by inhibition of Leishmania donovani axenic amastigote growth using a fluorescent viability microplate assay.  The most promising deriv. I [R = 3-Cl] demonstrated an antileishmanial EC50 of 4.0 Î¼M and it also showed activity in infected macrophages (EC50 5.92 Î¼M) without signs of cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryfBNVFAQL2LVg90H21EOLACvtfcHk0lhIEAT6PlIokA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12mur%252FL&md5=f9eba642a1956f7100d498ed067c49a8</span></div><a href="/servlet/linkout?suffix=cit272&amp;dbid=16384&amp;doi=10.1039%2FC5MD00119F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MD00119F%26sid%3Dliteratum%253Aachs%26aulast%3DKeurulainen%26aufirst%3DL.%26aulast%3DHeiskari%26aufirst%3DM.%26aulast%3DNenonen%26aufirst%3DS.%26aulast%3DNasereddin%26aufirst%3DA.%26aulast%3DKopelyanskiy%26aufirst%3DD.%26aulast%3DLeino%26aufirst%3DT.%2BO.%26aulast%3DYli-Kauhaluoma%26aufirst%3DJ.%26aulast%3DJaffe%26aufirst%3DC.%2BL.%26aulast%3DKiuru%26aufirst%3DP.%26atitle%3DSynthesis%2520of%2520carboxyimidamide-substituted%2520benzo%255Bc%255D%255B1%252C2%252C5%255Doxadiazoles%2520and%2520their%2520analogs%252C%2520and%2520evaluation%2520of%2520biological%2520activity%2520against%2520Leishmania%2520donovani%26jtitle%3DMedChemComm%26date%3D2015%26volume%3D6%26issue%3D9%26spage%3D1673%26epage%3D1678%26doi%3D10.1039%2FC5MD00119F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref273"><div class="reference"><strong class="refLabel"><a href="#ref273" class="rightTabRefNumLink">273</a></strong><div class="NLM_citation" id="rightTab-cit273"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, U.</span>; <span class="NLM_string-name">Ranadheera, C.</span></span> <span> </span><span class="NLM_article-title">2,1,3-Benzoxadiazol Derivatives for Inhibition of Influenza A and B Virus and Respiratory Syncytial Virus Replication</span>. <span class="NLM_patent">WO2010128156A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=U.+Kessler&author=C.+Ranadheera&title=2%2C1%2C3-Benzoxadiazol+Derivatives+for+Inhibition+of+Influenza+A+and+B+Virus+and+Respiratory+Syncytial+Virus+Replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit273&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKessler%26aufirst%3DU.%26atitle%3D2%252C1%252C3-Benzoxadiazol%2520Derivatives%2520for%2520Inhibition%2520of%2520Influenza%2520A%2520and%2520B%2520Virus%2520and%2520Respiratory%2520Syncytial%2520Virus%2520Replication%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref274"><div class="reference"><strong class="refLabel"><a href="#ref274" class="rightTabRefNumLink">274</a></strong><div class="NLM_citation" id="rightTab-cit274"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, U.</span>; <span class="NLM_string-name">Ranadheera, C.</span></span> <span> </span><span class="NLM_article-title">2,1,3-Benzoxadiazol Derivatives for the Inhibition of Influenza A and B Virus and Respiratory Syncytial Virus Replication</span>. <span class="NLM_patent">US20120122896A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=U.+Kessler&author=C.+Ranadheera&title=2%2C1%2C3-Benzoxadiazol+Derivatives+for+the+Inhibition+of+Influenza+A+and+B+Virus+and+Respiratory+Syncytial+Virus+Replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit274&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKessler%26aufirst%3DU.%26atitle%3D2%252C1%252C3-Benzoxadiazol%2520Derivatives%2520for%2520the%2520Inhibition%2520of%2520Influenza%2520A%2520and%2520B%2520Virus%2520and%2520Respiratory%2520Syncytial%2520Virus%2520Replication%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref275"><div class="reference"><strong class="refLabel"><a href="#ref275" class="rightTabRefNumLink">275</a></strong><div class="NLM_citation" id="rightTab-cit275"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagnolo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallacara, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurenzana, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deodato, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stergiou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strunze, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tintori, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, M.</span></span> <span> </span><span class="NLM_article-title">The fight against the influenza A virus H1N1: Synthesis, molecular modeling, and biological evaluation of benzofurazan derivatives as viral RNA polymerase inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">129</span>â <span class="NLM_lpage">150</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201300378</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1002%2Fcmdc.201300378" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=24285596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGgtLbN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=129-150&issue=1&author=M.+Paganoauthor=D.+Castagnoloauthor=M.+Bernardiniauthor=A.+L.+Fallacaraauthor=I.+Laurenzanaauthor=D.+Deodatoauthor=U.+Kesslerauthor=B.+Pilgerauthor=L.+Stergiouauthor=S.+Strunzeauthor=C.+Tintoriauthor=M.+Botta&title=The+fight+against+the+influenza+A+virus+H1N1%3A+Synthesis%2C+molecular+modeling%2C+and+biological+evaluation+of+benzofurazan+derivatives+as+viral+RNA+polymerase+inhibitors&doi=10.1002%2Fcmdc.201300378"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit275R"><div class="casContent"><span class="casTitleNuber">275</span><div class="casTitle"><span class="NLM_cas:atitle">The Fight against the Influenza A Virus H1N1: Synthesis, Molecular Modeling, and Biological Evaluation of Benzofurazan Derivatives as Viral RNA Polymerase Inhibitors</span></div><div class="casAuthors">Pagano, Mafalda; Castagnolo, Daniele; Bernardini, Martina; Fallacara, Anna Lucia; Laurenzana, Ilaria; Deodato, Davide; Kessler, Ulrich; Pilger, Beatrice; Stergiou, Lilli; Strunze, Stephan; Tintori, Cristina; Botta, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">129-150</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The influenza RNA polymerase complex, which consists of the three subunits PA, PB1, and PB2, is a promising target for the development of new antiviral drugs.  A large library of benzofurazan compds. was synthesized and assayed against influenza virus A/WSN/33 (H1N1).  Most of the new derivs. were found to act by inhibiting the viral RNA polymerase complex through disruption of the complex formed between subunits PA and PB1.  Docking studies were also performed to elucidate the binding mode of benzofurazans within the PB1 binding site in PA and to identify amino acids involved in their mechanism of action.  The predicted binding pose is fully consistent with the biol. data and lays the foundation for the rational development of more effective PA-PB1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb5eQEpazuCbVg90H21EOLACvtfcHk0lhIEAT6PlIokA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGgtLbN&md5=b998411686f59fc9882ebeee4ea5add7</span></div><a href="/servlet/linkout?suffix=cit275&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300378%26sid%3Dliteratum%253Aachs%26aulast%3DPagano%26aufirst%3DM.%26aulast%3DCastagnolo%26aufirst%3DD.%26aulast%3DBernardini%26aufirst%3DM.%26aulast%3DFallacara%26aufirst%3DA.%2BL.%26aulast%3DLaurenzana%26aufirst%3DI.%26aulast%3DDeodato%26aufirst%3DD.%26aulast%3DKessler%26aufirst%3DU.%26aulast%3DPilger%26aufirst%3DB.%26aulast%3DStergiou%26aufirst%3DL.%26aulast%3DStrunze%26aufirst%3DS.%26aulast%3DTintori%26aufirst%3DC.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DThe%2520fight%2520against%2520the%2520influenza%2520A%2520virus%2520H1N1%253A%2520Synthesis%252C%2520molecular%2520modeling%252C%2520and%2520biological%2520evaluation%2520of%2520benzofurazan%2520derivatives%2520as%2520viral%2520RNA%2520polymerase%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26issue%3D1%26spage%3D129%26epage%3D150%26doi%3D10.1002%2Fcmdc.201300378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref276"><div class="reference"><strong class="refLabel"><a href="#ref276" class="rightTabRefNumLink">276</a></strong><div class="NLM_citation" id="rightTab-cit276"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagnolo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deodato, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranadheera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, M.</span></span> <span> </span><span class="NLM_article-title">Discovery and synthesis of novel benzofurazan derivatives as inhibitors of influenza A virus</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">5575</span>â <span class="NLM_lpage">5577</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2013.08.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmcl.2013.08.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=24012120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSkt7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5575-5577&issue=20&author=U.+Kesslerauthor=D.+Castagnoloauthor=M.+Paganoauthor=D.+Deodatoauthor=M.+Bernardiniauthor=B.+Pilgerauthor=C.+Ranadheeraauthor=M.+Botta&title=Discovery+and+synthesis+of+novel+benzofurazan+derivatives+as+inhibitors+of+influenza+A+virus&doi=10.1016%2Fj.bmcl.2013.08.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit276R"><div class="casContent"><span class="casTitleNuber">276</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and synthesis of novel benzofurazan derivatives as inhibitors of influenza A virus</span></div><div class="casAuthors">Kessler, Ulrich; Castagnolo, Daniele; Pagano, Mafalda; Deodato, Davide; Bernardini, Martina; Pilger, Beatrice; Ranadheera, Charlene; Botta, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5575-5577</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The identification of a novel hit compd. inhibitor (I) of the protein-protein interaction between the influenza RNA-polymerase PA and PB1 subunits has been accomplished by means of high-throughput screening.  A small family of structurally related mols. has been synthesized and biol. evaluated with most of the compds. showing micromolar potency of inhibition against viral replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6J3cLqCNdIrVg90H21EOLACvtfcHk0lixW35KDpddLA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSkt7rN&md5=52fc0dde69ffc72a0c9e53c7f9630536</span></div><a href="/servlet/linkout?suffix=cit276&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.048%26sid%3Dliteratum%253Aachs%26aulast%3DKessler%26aufirst%3DU.%26aulast%3DCastagnolo%26aufirst%3DD.%26aulast%3DPagano%26aufirst%3DM.%26aulast%3DDeodato%26aufirst%3DD.%26aulast%3DBernardini%26aufirst%3DM.%26aulast%3DPilger%26aufirst%3DB.%26aulast%3DRanadheera%26aufirst%3DC.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DDiscovery%2520and%2520synthesis%2520of%2520novel%2520benzofurazan%2520derivatives%2520as%2520inhibitors%2520of%2520influenza%2520A%2520virus%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D20%26spage%3D5575%26epage%3D5577%26doi%3D10.1016%2Fj.bmcl.2013.08.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref277"><div class="reference"><strong class="refLabel"><a href="#ref277" class="rightTabRefNumLink">277</a></strong><div class="NLM_citation" id="rightTab-cit277"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenwood, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajwa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murrow, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderone, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divakaruni, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomsig, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron
Coleman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Columbus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saucerman, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravichandran, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchiyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okusa, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayliss, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoehn, K. L.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane</span>. <i>Mol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">114</span>â <span class="NLM_lpage">123</span>, <span class="refDoi">Â DOI: 10.1016/j.molmet.2013.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.molmet.2013.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=24634817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOhu7vK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=114-123&issue=2&author=B.+M.+Kenwoodauthor=J.+L.+Weaverauthor=A.+Bajwaauthor=I.+K.+Poonauthor=F.+L.+Byrneauthor=B.+A.+Murrowauthor=J.+A.+Calderoneauthor=L.+Huangauthor=A.+S.+Divakaruniauthor=J.+L.+Tomsigauthor=K.+Okabeauthor=R.+H.+Loauthor=G.+Cameron%0AColemanauthor=L.+Columbusauthor=Z.+Yanauthor=J.+J.+Saucermanauthor=J.+S.+Smithauthor=J.+W.+Holmesauthor=K.+R.+Lynchauthor=K.+S.+Ravichandranauthor=S.+Uchiyamaauthor=W.+L.+Santosauthor=G.+W.+Rogersauthor=M.+D.+Okusaauthor=D.+A.+Baylissauthor=K.+L.+Hoehn&title=Identification+of+a+novel+mitochondrial+uncoupler+that+does+not+depolarize+the+plasma+membrane&doi=10.1016%2Fj.molmet.2013.11.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit277R"><div class="casContent"><span class="casTitleNuber">277</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane</span></div><div class="casAuthors">Kenwood, Brandon M.; Weaver, Janelle L.; Bajwa, Amandeep; Poon, Ivan K.; Byrne, Frances L.; Murrow, Beverley A.; Calderone, Joseph A.; Huang, Liping; Divakaruni, Ajit S.; Tomsig, Jose L.; Okabe, Kohki; Lo, Ryan H.; Cameron Coleman, G.; Columbus, Linda; Yan, Zhen; Saucerman, Jeffrey J.; Smith, Jeffrey S.; Holmes, Jeffrey W.; Lynch, Kevin R.; Ravichandran, Kodi S.; Uchiyama, Seiichi; Santos, Webster L.; Rogers, George W.; Okusa, Mark D.; Bayliss, Douglas A.; Hoehn, Kyle L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Metabolism</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">114-123</span>CODEN:
                <span class="NLM_cas:coden">MMOEAS</span>;
        ISSN:<span class="NLM_cas:issn">2212-8778</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">Dysregulation of oxidative phosphorylation is assocd. with increased mitochondrial reactive oxygen species prodn. and some of the most prevalent human diseases including obesity, cancer, diabetes, neurodegeneration, and heart disease.  Chem. 'mitochondrial uncouplers' are lipophilic weak acids that transport protons into the mitochondrial matrix via a pathway that is independent of ATP synthase, thereby uncoupling nutrient oxidn. from ATP prodn.  Mitochondrial uncouplers also lessen the proton motive force across the mitochondrial inner membrane and thereby increase the rate of mitochondrial respiration while decreasing prodn. of reactive oxygen species.  Thus, mitochondrial uncouplers are valuable chem. tools that enable the measurement of maximal mitochondrial respiration and they have been used therapeutically to decrease mitochondrial reactive oxygen species prodn.  However, the most widely used protonophore uncouplers such as carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) and 2,4-dinitrophenol have off-target activity at other membranes that lead to a range of undesired effects including plasma membrane depolarization, mitochondrial inhibition, and cytotoxicity.  These unwanted properties interfere with the measurement of mitochondrial function and result in a narrow therapeutic index that limits their usefulness in the clinic.  To identify new mitochondrial uncouplers that lack off-target activity at the plasma membrane we screened a small mol. chem. library.  Herein we report the identification and validation of a novel mitochondrial protonophore uncoupler (2-fluorophenyl){6-[(2-fluorophenyl)amino](1,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine, named BAM15, that does not depolarize the plasma membrane.  Compared to FCCP, an uncoupler of equal potency, BAM15 treatment of cultured cells stimulates a higher max. rate of mitochondrial respiration and is less cytotoxic.  Furthermore, BAM15 is bioactive in vivo and dose-dependently protects mice from acute renal ischemic-reperfusion injury.  From a tech. standpoint, BAM15 represents an effective new tool that allows the study of mitochondrial function in the absence of off-target effects that can confound data interpretation.  From a therapeutic perspective, BAM15-mediated protection from ischemia-reperfusion injury and its reduced toxicity will hopefully reignite interest in pharmacol. uncoupling for the treatment of the myriad of diseases that are assocd. with altered mitochondrial function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCXatpkZ9rLrVg90H21EOLACvtfcHk0lixW35KDpddLA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOhu7vK&md5=987dce47f833f2cdbba86cb50234b483</span></div><a href="/servlet/linkout?suffix=cit277&amp;dbid=16384&amp;doi=10.1016%2Fj.molmet.2013.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmet.2013.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DKenwood%26aufirst%3DB.%2BM.%26aulast%3DWeaver%26aufirst%3DJ.%2BL.%26aulast%3DBajwa%26aufirst%3DA.%26aulast%3DPoon%26aufirst%3DI.%2BK.%26aulast%3DByrne%26aufirst%3DF.%2BL.%26aulast%3DMurrow%26aufirst%3DB.%2BA.%26aulast%3DCalderone%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DDivakaruni%26aufirst%3DA.%2BS.%26aulast%3DTomsig%26aufirst%3DJ.%2BL.%26aulast%3DOkabe%26aufirst%3DK.%26aulast%3DLo%26aufirst%3DR.%2BH.%26aulast%3DCameron%2BColeman%26aufirst%3DG.%26aulast%3DColumbus%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DZ.%26aulast%3DSaucerman%26aufirst%3DJ.%2BJ.%26aulast%3DSmith%26aufirst%3DJ.%2BS.%26aulast%3DHolmes%26aufirst%3DJ.%2BW.%26aulast%3DLynch%26aufirst%3DK.%2BR.%26aulast%3DRavichandran%26aufirst%3DK.%2BS.%26aulast%3DUchiyama%26aufirst%3DS.%26aulast%3DSantos%26aufirst%3DW.%2BL.%26aulast%3DRogers%26aufirst%3DG.%2BW.%26aulast%3DOkusa%26aufirst%3DM.%2BD.%26aulast%3DBayliss%26aufirst%3DD.%2BA.%26aulast%3DHoehn%26aufirst%3DK.%2BL.%26atitle%3DIdentification%2520of%2520a%2520novel%2520mitochondrial%2520uncoupler%2520that%2520does%2520not%2520depolarize%2520the%2520plasma%2520membrane%26jtitle%3DMol.%2520Metab.%26date%3D2014%26volume%3D3%26issue%3D2%26spage%3D114%26epage%3D123%26doi%3D10.1016%2Fj.molmet.2013.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref278"><div class="reference"><strong class="refLabel"><a href="#ref278" class="rightTabRefNumLink">278</a></strong><div class="NLM_citation" id="rightTab-cit278"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexopoulos, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandon, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salamoun, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beretta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olzomer, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philp, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargett, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sligar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrive, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooney, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoehn, K. L.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">2397</span>, <span class="refDoi">Â DOI: 10.1038/s41467-020-16298-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1038%2Fs41467-020-16298-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=32409697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsFCisrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=2397&issue=1&author=S.+J.+Alexopoulosauthor=S.+Y.+Chenauthor=A.+E.+Brandonauthor=J.+M.+Salamounauthor=F.+L.+Byrneauthor=C.+J.+Garciaauthor=M.+Berettaauthor=E.+M.+Olzomerauthor=D.+P.+Shahauthor=A.+M.+Philpauthor=S.+R.+Hargettauthor=R.+T.+Lawrenceauthor=B.+Leeauthor=J.+Sligarauthor=P.+Carriveauthor=S.+P.+Tuckerauthor=A.+Philpauthor=C.+Lacknerauthor=N.+Turnerauthor=G.+J.+Cooneyauthor=W.+L.+Santosauthor=K.+L.+Hoehn&title=Mitochondrial+uncoupler+BAM15+reverses+diet-induced+obesity+and+insulin+resistance+in+mice&doi=10.1038%2Fs41467-020-16298-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit278R"><div class="casContent"><span class="casTitleNuber">278</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice</span></div><div class="casAuthors">Alexopoulos, Stephanie J.; Chen, Sing-Young; Brandon, Amanda E.; Salamoun, Joseph M.; Byrne, Frances L.; Garcia, Christopher J.; Beretta, Martina; Olzomer, Ellen M.; Shah, Divya P.; Philp, Ashleigh M.; Hargett, Stefan R.; Lawrence, Robert T.; Lee, Brendan; Sligar, James; Carrive, Pascal; Tucker, Simon P.; Philp, Andrew; Lackner, Carolin; Turner, Nigel; Cooney, Gregory J.; Santos, Webster L.; Hoehn, Kyle L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2397</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Obesity is a health problem affecting more than 40% of US adults and 13% of the global population.  Anti-obesity treatments including diet, exercise, surgery and pharmacotherapies have so far failed to reverse obesity incidence.  Herein, we target obesity with a pharmacotherapeutic approach that decreases caloric efficiency by mitochondrial uncoupling.  We show that a recently identified mitochondrial uncoupler BAM15 is orally bioavailable, increases nutrient oxidn., and decreases body fat mass without altering food intake, lean body mass, body temp., or biochem. and haematol. markers of toxicity.  BAM15 decreases hepatic fat, decreases inflammatory lipids, and has strong antioxidant effects.  Hyperinsulinemic-euglycemic clamp studies show that BAM15 improves insulin sensitivity in multiple tissue types.  Collectively, these data demonstrate that pharmacol. mitochondrial uncoupling with BAM15 has powerful anti-obesity and insulin sensitizing effects without compromising lean mass or affecting food intake.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbxHlgDr0Lf7Vg90H21EOLACvtfcHk0lhwqDEYp4N3SA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsFCisrs%253D&md5=3b52feb5588349b0255884ec7aee151f</span></div><a href="/servlet/linkout?suffix=cit278&amp;dbid=16384&amp;doi=10.1038%2Fs41467-020-16298-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-020-16298-2%26sid%3Dliteratum%253Aachs%26aulast%3DAlexopoulos%26aufirst%3DS.%2BJ.%26aulast%3DChen%26aufirst%3DS.%2BY.%26aulast%3DBrandon%26aufirst%3DA.%2BE.%26aulast%3DSalamoun%26aufirst%3DJ.%2BM.%26aulast%3DByrne%26aufirst%3DF.%2BL.%26aulast%3DGarcia%26aufirst%3DC.%2BJ.%26aulast%3DBeretta%26aufirst%3DM.%26aulast%3DOlzomer%26aufirst%3DE.%2BM.%26aulast%3DShah%26aufirst%3DD.%2BP.%26aulast%3DPhilp%26aufirst%3DA.%2BM.%26aulast%3DHargett%26aufirst%3DS.%2BR.%26aulast%3DLawrence%26aufirst%3DR.%2BT.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DSligar%26aufirst%3DJ.%26aulast%3DCarrive%26aufirst%3DP.%26aulast%3DTucker%26aufirst%3DS.%2BP.%26aulast%3DPhilp%26aufirst%3DA.%26aulast%3DLackner%26aufirst%3DC.%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DCooney%26aufirst%3DG.%2BJ.%26aulast%3DSantos%26aufirst%3DW.%2BL.%26aulast%3DHoehn%26aufirst%3DK.%2BL.%26atitle%3DMitochondrial%2520uncoupler%2520BAM15%2520reverses%2520diet-induced%2520obesity%2520and%2520insulin%2520resistance%2520in%2520mice%26jtitle%3DNat.%2520Commun.%26date%3D2020%26volume%3D11%26issue%3D1%26spage%3D2397%26doi%3D10.1038%2Fs41467-020-16298-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref279"><div class="reference"><strong class="refLabel"><a href="#ref279" class="rightTabRefNumLink">279</a></strong><div class="NLM_citation" id="rightTab-cit279"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoehn, K.</span>; <span class="NLM_string-name">Kenwood, B.</span></span> <span> </span><span class="NLM_article-title">Compositions and Methods for Regulating Glucose Homeostasis and Insulin Action</span>. <span class="NLM_patent">US20150322081A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=K.+Hoehn&author=B.+Kenwood&title=Compositions+and+Methods+for+Regulating+Glucose+Homeostasis+and+Insulin+Action"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit279&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHoehn%26aufirst%3DK.%26atitle%3DCompositions%2520and%2520Methods%2520for%2520Regulating%2520Glucose%2520Homeostasis%2520and%2520Insulin%2520Action%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref280"><div class="reference"><strong class="refLabel"><a href="#ref280" class="rightTabRefNumLink">280</a></strong><div class="NLM_citation" id="rightTab-cit280"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Childress, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salamoun, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargett, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexopoulos, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santiago-Rivera, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoehn, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, W. L.</span></span> <span> </span><span class="NLM_article-title">[1,2,5]Oxadiazolo[3,4-b]pyrazine-5,6-diamine derivatives as mitochondrial uncouplers for the potential treatment of nonalcoholic steatohepatitis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2511</span>â <span class="NLM_lpage">2526</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b01440</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01440" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitleqtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2511-2526&issue=5&author=E.+S.+Childressauthor=J.+M.+Salamounauthor=S.+R.+Hargettauthor=S.+J.+Alexopoulosauthor=S.+Y.+Chenauthor=D.+P.+Shahauthor=J.+Santiago-Riveraauthor=C.+J.+Garciaauthor=Y.+Daiauthor=S.+P.+Tuckerauthor=K.+L.+Hoehnauthor=W.+L.+Santos&title=%5B1%2C2%2C5%5DOxadiazolo%5B3%2C4-b%5Dpyrazine-5%2C6-diamine+derivatives+as+mitochondrial+uncouplers+for+the+potential+treatment+of+nonalcoholic+steatohepatitis&doi=10.1021%2Facs.jmedchem.9b01440"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit280R"><div class="casContent"><span class="casTitleNuber">280</span><div class="casTitle"><span class="NLM_cas:atitle">[1,2,5]Oxadiazolo[3,4-b]pyrazine-5,6-diamine Derivatives as Mitochondrial Uncouplers for the Potential Treatment of Nonalcoholic Steatohepatitis</span></div><div class="casAuthors">Childress, Elizabeth S.; Salamoun, Joseph M.; Hargett, Stefan R.; Alexopoulos, Stephanie J.; Chen, Sing-Young; Shah, Divya P.; Santiago-Rivera, Jose; Garcia, Christopher J.; Dai, Yumin; Tucker, Simon P.; Hoehn, Kyle L.; Santos, Webster L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2511-2526</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. mitochondrial uncouplers are emerging as a new class of mols. for the treatment of nonalcoholic steatohepatitis.  We utilized BAM15, a potent protonophore that uncouples the mitochondria without depolarizing the plasma membrane, as a lead compd. for structure-activity profiling.  Using oxygen consumption rate as an assay for detg. uncoupling activity, changes on the 5- and 6-position of the oxadiazolopyrazine core were introduced.  Our studies suggest that unsym. aniline derivs. bearing electron withdrawing groups are preferred compared to the sym. counterparts.  In addn., alkyl substituents are not tolerated, and the N-H proton of the aniline ring is responsible for the protonophore activity.  In particular, compd. 10b had an EC50 value of 190 nM in L6 myoblast cells.  In an in vivo model of NASH, 10b decreased liver triglyceride levels and showed improvement in fibrosis, inflammation, and plasma ALT.  Taken together, our studies indicate that mitochondrial uncouplers have potential for the treatment of NASH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbso5j2dO9ZrVg90H21EOLACvtfcHk0lhwqDEYp4N3SA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitleqtrY%253D&md5=4c94192cdd4908f6f03545f26c8c7be6</span></div><a href="/servlet/linkout?suffix=cit280&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01440%26sid%3Dliteratum%253Aachs%26aulast%3DChildress%26aufirst%3DE.%2BS.%26aulast%3DSalamoun%26aufirst%3DJ.%2BM.%26aulast%3DHargett%26aufirst%3DS.%2BR.%26aulast%3DAlexopoulos%26aufirst%3DS.%2BJ.%26aulast%3DChen%26aufirst%3DS.%2BY.%26aulast%3DShah%26aufirst%3DD.%2BP.%26aulast%3DSantiago-Rivera%26aufirst%3DJ.%26aulast%3DGarcia%26aufirst%3DC.%2BJ.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DTucker%26aufirst%3DS.%2BP.%26aulast%3DHoehn%26aufirst%3DK.%2BL.%26aulast%3DSantos%26aufirst%3DW.%2BL.%26atitle%3D%255B1%252C2%252C5%255DOxadiazolo%255B3%252C4-b%255Dpyrazine-5%252C6-diamine%2520derivatives%2520as%2520mitochondrial%2520uncouplers%2520for%2520the%2520potential%2520treatment%2520of%2520nonalcoholic%2520steatohepatitis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D5%26spage%3D2511%26epage%3D2526%26doi%3D10.1021%2Facs.jmedchem.9b01440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref281"><div class="reference"><strong class="refLabel"><a href="#ref281" class="rightTabRefNumLink">281</a></strong><div class="NLM_citation" id="rightTab-cit281"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenwood, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderone, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taddeo, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoehn, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, W. L.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships of furazano[3,4-b]pyrazines as mitochondrial uncouplers</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">4858</span>â <span class="NLM_lpage">4861</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2015.06.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.bmcl.2015.06.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=26119501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVyhsrvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4858-4861&issue=21&author=B.+M.+Kenwoodauthor=J.+A.+Calderoneauthor=E.+P.+Taddeoauthor=K.+L.+Hoehnauthor=W.+L.+Santos&title=Structure-activity+relationships+of+furazano%5B3%2C4-b%5Dpyrazines+as+mitochondrial+uncouplers&doi=10.1016%2Fj.bmcl.2015.06.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit281R"><div class="casContent"><span class="casTitleNuber">281</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationships of furazano[3,4-b]pyrazines as mitochondrial uncouplers</span></div><div class="casAuthors">Kenwood, Brandon M.; Calderone, Joseph A.; Taddeo, Evan P.; Hoehn, Kyle L.; Santos, Webster L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4858-4861</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chem. mitochondrial uncouplers are lipophilic weak acids that transport protons into the mitochondrial matrix via a pathway that is independent of ATP synthase, thereby uncoupling nutrient oxidn. from ATP prodn.  These uncouplers have potential for the treatment of diseases such as obesity, Parkinson's disease, and aging.  We have previously identified a novel mitochondrial protonophore, named BAM15, which stimulates mitochondrial respiration across a broad dosing range compared to carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP).  Herein, we report our investigations on the structure-activity relationship profile of BAM15.  Our studies demonstrate the importance of the furazan, pyrazine, and aniline rings as well as pKa in maintaining its effective protonophore activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDO0F_Mr2kGrVg90H21EOLACvtfcHk0lhwqDEYp4N3SA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVyhsrvE&md5=a2664bbe47bdc166dd015db4f45fcd00</span></div><a href="/servlet/linkout?suffix=cit281&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.06.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.06.040%26sid%3Dliteratum%253Aachs%26aulast%3DKenwood%26aufirst%3DB.%2BM.%26aulast%3DCalderone%26aufirst%3DJ.%2BA.%26aulast%3DTaddeo%26aufirst%3DE.%2BP.%26aulast%3DHoehn%26aufirst%3DK.%2BL.%26aulast%3DSantos%26aufirst%3DW.%2BL.%26atitle%3DStructure-activity%2520relationships%2520of%2520furazano%255B3%252C4-b%255Dpyrazines%2520as%2520mitochondrial%2520uncouplers%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D21%26spage%3D4858%26epage%3D4861%26doi%3D10.1016%2Fj.bmcl.2015.06.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref282"><div class="reference"><strong class="refLabel"><a href="#ref282" class="rightTabRefNumLink">282</a></strong><div class="NLM_citation" id="rightTab-cit282"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salamoun, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargett, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beretta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexopoulos, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olzomer, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoehn, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, W. L.</span></span> <span> </span><span class="NLM_article-title">6-Amino[1,2,5]oxadiazolo[3,4-b]pyrazin-5-ol derivatives as efficacious mitochondrial uncouplers in STAM mouse model of nonalcoholic steatohepatitis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">6203</span>â <span class="NLM_lpage">6224</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c00542</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00542" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptFCltrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=6203-6224&issue=11&author=J.+M.+Salamounauthor=C.+J.+Garciaauthor=S.+R.+Hargettauthor=J.+H.+Murrayauthor=S.+Y.+Chenauthor=M.+Berettaauthor=S.+J.+Alexopoulosauthor=D.+P.+Shahauthor=E.+M.+Olzomerauthor=S.+P.+Tuckerauthor=K.+L.+Hoehnauthor=W.+L.+Santos&title=6-Amino%5B1%2C2%2C5%5Doxadiazolo%5B3%2C4-b%5Dpyrazin-5-ol+derivatives+as+efficacious+mitochondrial+uncouplers+in+STAM+mouse+model+of+nonalcoholic+steatohepatitis&doi=10.1021%2Facs.jmedchem.0c00542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit282R"><div class="casContent"><span class="casTitleNuber">282</span><div class="casTitle"><span class="NLM_cas:atitle">6-Amino[1,2,5]oxadiazolo[3,4-b]pyrazin-5-ol Derivatives as Efficacious Mitochondrial Uncouplers in STAM Mouse Model of Nonalcoholic Steatohepatitis</span></div><div class="casAuthors">Salamoun, Joseph M.; Garcia, Christopher J.; Hargett, Stefan R.; Murray, Jacob H.; Chen, Sing-Young; Beretta, Martina; Alexopoulos, Stephanie J.; Shah, Divya P.; Olzomer, Ellen M.; Tucker, Simon P.; Hoehn, Kyle L.; Santos, Webster L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6203-6224</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. mitochondrial uncouplers have recently garnered great interest for their potential in treating nonalcoholic steatohepatitis (NASH).  In this study, we report the structure-activity relationship profiling of a 6-amino[1,2,5]oxadiazolo[3,4-b]pyrazin-5-ol core, which utilizes the hydroxy moiety as the proton transporter across the mitochondrial inner membrane.  We demonstrate that a wide array of substituents is tolerated with this novel scaffold that increased cellular metabolic rates in vitro using changes in oxygen consumption rate as a readout.  In particular, compd. SHS4121705 (12i) (6-((4-(trifluoromethoxy)phenyl)amino)-[1,2,5]oxadiazolo[3,4-b]pyrazin-5-ol, [2379550-82-8]) displayed an EC50 of 4.3Î¼M in L6 myoblast cells and excellent oral bioavailability and liver exposure in mice.  In the STAM mouse model of NASH, administration of 12i at 25 mg kg-1 day-1 lowered liver triglyceride levels and improved liver markers such as alanine aminotransferase, NAFLD activity score, and fibrosis.  Importantly, no changes in body temp. or food intake were obsd.  As potential treatment of NASH, mitochondrial uncouplers show promise for future development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJTDnUWKTl97Vg90H21EOLACvtfcHk0lj2Syo1c4zV8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptFCltrY%253D&md5=b9ab1101f024c4f5ce6f22f80db0df05</span></div><a href="/servlet/linkout?suffix=cit282&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00542%26sid%3Dliteratum%253Aachs%26aulast%3DSalamoun%26aufirst%3DJ.%2BM.%26aulast%3DGarcia%26aufirst%3DC.%2BJ.%26aulast%3DHargett%26aufirst%3DS.%2BR.%26aulast%3DMurray%26aufirst%3DJ.%2BH.%26aulast%3DChen%26aufirst%3DS.%2BY.%26aulast%3DBeretta%26aufirst%3DM.%26aulast%3DAlexopoulos%26aufirst%3DS.%2BJ.%26aulast%3DShah%26aufirst%3DD.%2BP.%26aulast%3DOlzomer%26aufirst%3DE.%2BM.%26aulast%3DTucker%26aufirst%3DS.%2BP.%26aulast%3DHoehn%26aufirst%3DK.%2BL.%26aulast%3DSantos%26aufirst%3DW.%2BL.%26atitle%3D6-Amino%255B1%252C2%252C5%255Doxadiazolo%255B3%252C4-b%255Dpyrazin-5-ol%2520derivatives%2520as%2520efficacious%2520mitochondrial%2520uncouplers%2520in%2520STAM%2520mouse%2520model%2520of%2520nonalcoholic%2520steatohepatitis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D11%26spage%3D6203%26epage%3D6224%26doi%3D10.1021%2Facs.jmedchem.0c00542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref283"><div class="reference"><strong class="refLabel"><a href="#ref283" class="rightTabRefNumLink">283</a></strong><div class="NLM_citation" id="rightTab-cit283"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoehn, K.</span>; <span class="NLM_string-name">Santos, W. L.</span>; <span class="NLM_string-name">Childress, E. S.</span>; <span class="NLM_string-name">Dai, Y.</span>; <span class="NLM_string-name">Murray, J.</span>; <span class="NLM_string-name">Santiago-Rivera, J.</span></span>, <span> </span><span class="NLM_article-title">Compositions and Methods for Preparing and Using Mitochondrial Uncouplers</span>. <span class="NLM_patent">WO2019204813A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=K.+Hoehn&author=W.+L.+Santos&author=E.+S.+Childress&author=Y.+Dai&author=J.+Murray&author=J.+Santiago-Rivera&title=Compositions+and+Methods+for+Preparing+and+Using+Mitochondrial+Uncouplers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit283&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHoehn%26aufirst%3DK.%26atitle%3DCompositions%2520and%2520Methods%2520for%2520Preparing%2520and%2520Using%2520Mitochondrial%2520Uncouplers%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref284"><div class="reference"><strong class="refLabel"><a href="#ref284" class="rightTabRefNumLink">284</a></strong><div class="NLM_citation" id="rightTab-cit284"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, W. L.</span>; <span class="NLM_string-name">Salamoun, J. M.</span>; <span class="NLM_string-name">Garcia, C. J.</span>; <span class="NLM_string-name">Murray, J. H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Oxadiazolopyrazines and Oxadiazolopyridines Useful as Mitochondrial Uncouplers</span>. <span class="NLM_patent">WO2019204813A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=W.+L.+Santos&author=J.+M.+Salamoun&author=C.+J.+Garcia&author=J.+H.+Murray&title=Preparation+of+Oxadiazolopyrazines+and+Oxadiazolopyridines+Useful+as+Mitochondrial+Uncouplers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit284&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DW.%2BL.%26atitle%3DPreparation%2520of%2520Oxadiazolopyrazines%2520and%2520Oxadiazolopyridines%2520Useful%2520as%2520Mitochondrial%2520Uncouplers%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref285"><div class="reference"><strong class="refLabel"><a href="#ref285" class="rightTabRefNumLink">285</a></strong><div class="NLM_citation" id="rightTab-cit285"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savolainen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsinga, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windhorst, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luurtsema, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preclinical evaluation of three novel fluorine-18 labeled radiopharmaceuticals for P-glycoprotein PET imaging at the bloodâbrain barrier</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2265</span>â <span class="NLM_lpage">2275</span>, <span class="refDoi">Â DOI: 10.1021/mp5008103</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp5008103" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref285/cit285&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsVOqu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=2265-2275&issue=7&author=H.+Savolainenauthor=M.+Cantoreauthor=N.+A.+Colabufoauthor=P.+H.+Elsingaauthor=A.+D.+Windhorstauthor=G.+Luurtsema&title=Synthesis+and+preclinical+evaluation+of+three+novel+fluorine-18+labeled+radiopharmaceuticals+for+P-glycoprotein+PET+imaging+at+the+blood%E2%80%93brain+barrier&doi=10.1021%2Fmp5008103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit285R"><div class="casContent"><span class="casTitleNuber">285</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Preclinical Evaluation of Three Novel Fluorine-18 Labeled Radiopharmaceuticals for P-Glycoprotein PET Imaging at the Blood-Brain Barrier</span></div><div class="casAuthors">Savolainen, Heli; Cantore, Mariangela; Colabufo, Nicola A.; Elsinga, Philip H.; Windhorst, Albert D.; Luurtsema, Gert</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2265-2275</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P-Glycoprotein (P-gp), along with other transporter proteins at the blood-brain barrier (BBB), limits the entry of many pharmaceuticals into the brain.  Altered P-gp function has been found in several neurol. diseases.  To study the P-gp function, many positron emission tomog. (PET) radiopharmaceuticals have been developed.  Most P-gp radiopharmaceuticals are labeled with carbon-11, while labeling with fluorine-18 would increase their applicability due to longer half-life.  Here we present the synthesis and in vivo evaluation of three novel fluorine-18 labeled radiopharmaceuticals: 4-((6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-2-(4-fluorophenyl)oxazole (1a), 2-biphenyl-4-yl-2-fluoroethoxy-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline (2), and 5-(1-(2-fluoroethoxy))-[3-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-propyl]-5,6,7,8-tetrahydronaphthalen (3).  Compds. were characterized as P-gp substrates in vitro, and Mdr1a/b(-/-)Bcrp1(-/-) and wild-type mice were used to assess the substrate potential in vivo.  Comparison was made to (R)-[11C]verapamil, which is currently the most frequently used P-gp substrate.  Compd. [18F]3 was performing the best out of the new radiopharmaceuticals; it had 2-fold higher brain uptake in the Mdr1a/b(-/-)Bcrp1(-/-) mice compared to wild-type and was metabolically quite stable.  In the plasma, 69% of the parent compd. was intact after 45 min and 96% in the brain.  Selectivity of [18F]3 to P-gp was tested by comparing the uptake in Mdr1a/b(-/-) mice to uptake in Mdr1a/b(-/-)Bcrp1(-/-) mice, which was statistically not significantly different.  Hence, [18F]3 was found to be selective for P-gp and is a promising new radiopharmaceutical for P-gp PET imaging at the BBB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIwkSldxjfLLVg90H21EOLACvtfcHk0lj2Syo1c4zV8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsVOqu7Y%253D&md5=d51411694ff422a43cc0b59d0fb1c84a</span></div><a href="/servlet/linkout?suffix=cit285&amp;dbid=16384&amp;doi=10.1021%2Fmp5008103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp5008103%26sid%3Dliteratum%253Aachs%26aulast%3DSavolainen%26aufirst%3DH.%26aulast%3DCantore%26aufirst%3DM.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DElsinga%26aufirst%3DP.%2BH.%26aulast%3DWindhorst%26aufirst%3DA.%2BD.%26aulast%3DLuurtsema%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520preclinical%2520evaluation%2520of%2520three%2520novel%2520fluorine-18%2520labeled%2520radiopharmaceuticals%2520for%2520P-glycoprotein%2520PET%2520imaging%2520at%2520the%2520blood%25E2%2580%2593brain%2520barrier%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26issue%3D7%26spage%3D2265%26epage%3D2275%26doi%3D10.1021%2Fmp5008103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref286"><div class="reference"><strong class="refLabel"><a href="#ref286" class="rightTabRefNumLink">286</a></strong><div class="NLM_citation" id="rightTab-cit286"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azzariti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quatrale, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iannelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tommasi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panaro, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paradiso, A.</span></span> <span> </span><span class="NLM_article-title">MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>670</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">74</span>â <span class="NLM_lpage">84</span>, <span class="refDoi">Â DOI: 10.1016/j.ejphar.2011.08.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=10.1016%2Fj.ejphar.2011.08.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=21925160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlejurrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=670&publication_year=2011&pages=74-84&issue=1&author=A.+Azzaritiauthor=A.+E.+Quatraleauthor=L.+Porcelliauthor=N.+A.+Colabufoauthor=M.+Cantoreauthor=G.+Cassanoauthor=G.+Gasparreauthor=G.+Iannelliauthor=S.+Tommasiauthor=M.+A.+Panaroauthor=A.+Paradiso&title=MC70+potentiates+doxorubicin+efficacy+in+colon+and+breast+cancer+in+vitro+treatment&doi=10.1016%2Fj.ejphar.2011.08.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit286R"><div class="casContent"><span class="casTitleNuber">286</span><div class="casTitle"><span class="NLM_cas:atitle">MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment</span></div><div class="casAuthors">Azzariti, Amalia; Quatrale, Anna E.; Porcelli, Letizia; Colabufo, Nicola A.; Cantore, Mariangela; Cassano, Giuseppe; Gasparre, Giuseppe; Iannelli, Giuseppina; Tommasi, Stefania; Panaro, Maria A.; Paradiso, Angelo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">670</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-84</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A major limitation of cancer treatment is the ability of cancer cells to develop resistance to chemotherapeutic drugs, by the establishment of multidrug resistance.  Here, we characterize MC70 as ABC transporters inhibitor and anticancer agent, alone or with chemotherapy.  MC70 was analyzed for its interaction with ABCB1, ABCG2, and ABCC1 by specific transport assays.  In breast and colon cancer cell lines, cell growth and apoptosis were measured by MTT assay and DNA laddering Elisa kit, resp.  Cell cycle perturbation and cellular targets modulation were analyzed by Flow-cytometry and Western blotting, resp.  MC70 interacted with ABC transporters.  In breast cancer cells, MC70 slightly inhibited cell proliferation strongly enhancing doxorubicin effectiveness.  By contrast, MC70 was found to inhibit cell growth in colon cancer cells without affecting doxorubicin efficacy and in combination with topoisomerase I inhibitors it could be a promising therapeutic approach.  What is more, it was also obsd. that MC70 induced apoptosis, canceled in favor of necrosis when given in combination with high doses of doxorubicin.  MC70 inhibited cell migration probably through its interaction with sigma-1 receptor.  Modulations of (i) cell cycle, (ii) pAkt and the phosphorylation of the 3 MAPKs were highlighted, while any activity was excluded at transcription level, thus accounting for the phenotypic effects obsd.  MC70 might be considered as a new potential anticancer agent capable to (i) enhance chemotherapy effectiveness and (ii) to play a contributory role in the treatment of chemotherapy resistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD9aQ-wjKQD7Vg90H21EOLACvtfcHk0lg-jMGLE0JREg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlejurrM&md5=9f3bd91a79f76eb3067ff7d243e12376</span></div><a href="/servlet/linkout?suffix=cit286&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2011.08.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2011.08.025%26sid%3Dliteratum%253Aachs%26aulast%3DAzzariti%26aufirst%3DA.%26aulast%3DQuatrale%26aufirst%3DA.%2BE.%26aulast%3DPorcelli%26aufirst%3DL.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DCantore%26aufirst%3DM.%26aulast%3DCassano%26aufirst%3DG.%26aulast%3DGasparre%26aufirst%3DG.%26aulast%3DIannelli%26aufirst%3DG.%26aulast%3DTommasi%26aufirst%3DS.%26aulast%3DPanaro%26aufirst%3DM.%2BA.%26aulast%3DParadiso%26aufirst%3DA.%26atitle%3DMC70%2520potentiates%2520doxorubicin%2520efficacy%2520in%2520colon%2520and%2520breast%2520cancer%2520in%2520vitro%2520treatment%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D670%26issue%3D1%26spage%3D74%26epage%3D84%26doi%3D10.1016%2Fj.ejphar.2011.08.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref287"><div class="reference"><strong class="refLabel"><a href="#ref287" class="rightTabRefNumLink">287</a></strong><div class="NLM_citation" id="rightTab-cit287"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guglielmo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzarato, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chegaev, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruttero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasco, A.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship studies on tetrahydroisoquinoline derivatives: [4â²-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-ol] (MC70) conjugated through flexible alkyl chains with furazan moieties gives rise to potent and selective ligands of P-glycoprotein</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6729</span>â <span class="NLM_lpage">6738</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00252</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00252" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVektrnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6729-6738&issue=14&author=S.+Guglielmoauthor=L.+Lazzaratoauthor=M.+Continoauthor=M.+G.+Perroneauthor=K.+Chegaevauthor=A.+Carrieriauthor=R.+Frutteroauthor=N.+A.+Colabufoauthor=A.+Gasco&title=Structure-activity+relationship+studies+on+tetrahydroisoquinoline+derivatives%3A+%5B4%E2%80%B2-%286%2C7-Dimethoxy-3%2C4-dihydro-1H-isoquinolin-2-ylmethyl%29biphenyl-4-ol%5D+%28MC70%29+conjugated+through+flexible+alkyl+chains+with+furazan+moieties+gives+rise+to+potent+and+selective+ligands+of+P-glycoprotein&doi=10.1021%2Facs.jmedchem.6b00252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit287R"><div class="casContent"><span class="casTitleNuber">287</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship Studies on Tetrahydroisoquinoline Derivatives: [4'-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-ol] (MC70) Conjugated through Flexible Alkyl Chains with Furazan Moieties Gives Rise to Potent and Selective Ligands of P-glycoprotein</span></div><div class="casAuthors">Guglielmo, Stefano; Lazzarato, Loretta; Contino, Marialessandra; Perrone, Maria G.; Chegaev, Konstantin; Carrieri, Antonio; Fruttero, Roberta; Colabufo, Nicola A.; Gasco, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6729-6738</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P-glycoprotein (P-gp) is a well-known membrane transporter expressed in a no. of strategic biol. barriers, where it exerts a protective effect of paramount importance.  Conversely it is one of the main causes of multidrug resistance (MDR), being capable of effluxing many chemotherapeutics.  In a development of previous research, a small library of compds. was created conjugating diversely substituted furazan rings with MC70, a well-known P-gp inhibitor.  These compds. were assessed for their potency against P-gp and another transporter (MRP1), for their apparent permeability (Papp) and for their ability to induce ATPase activity, thus delineating a complete functional profile.  They displayed a substrate mechanism of action and high selectivity toward P-gp, unlike the lead compd.  Data relating to their activity range from low micromolar to sub-nanomolar EC50, the most interesting compds. being 15 (0.97 nM), 19 (1.3 nM), 25 (0.60 nM), and 27 (0.90 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjM7uUfQnShbVg90H21EOLACvtfcHk0lg-jMGLE0JREg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVektrnM&md5=b7a170d53c5946cc9b58331bdb607350</span></div><a href="/servlet/linkout?suffix=cit287&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00252%26sid%3Dliteratum%253Aachs%26aulast%3DGuglielmo%26aufirst%3DS.%26aulast%3DLazzarato%26aufirst%3DL.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DPerrone%26aufirst%3DM.%2BG.%26aulast%3DChegaev%26aufirst%3DK.%26aulast%3DCarrieri%26aufirst%3DA.%26aulast%3DFruttero%26aufirst%3DR.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DGasco%26aufirst%3DA.%26atitle%3DStructure-activity%2520relationship%2520studies%2520on%2520tetrahydroisoquinoline%2520derivatives%253A%2520%255B4%25E2%2580%25B2-%25286%252C7-Dimethoxy-3%252C4-dihydro-1H-isoquinolin-2-ylmethyl%2529biphenyl-4-ol%255D%2520%2528MC70%2529%2520conjugated%2520through%2520flexible%2520alkyl%2520chains%2520with%2520furazan%2520moieties%2520gives%2520rise%2520to%2520potent%2520and%2520selective%2520ligands%2520of%2520P-glycoprotein%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D14%26spage%3D6729%26epage%3D6738%26doi%3D10.1021%2Facs.jmedchem.6b00252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref288"><div class="reference"><strong class="refLabel"><a href="#ref288" class="rightTabRefNumLink">288</a></strong><div class="NLM_citation" id="rightTab-cit288"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olesen, P. H.</span>; <span class="NLM_string-name">Kurtzhals, P.</span>; <span class="NLM_string-name">Worsaae, H.</span>; <span class="NLM_string-name">Hansen, B. F.</span>; <span class="NLM_string-name">Sorensen, A. R.</span>; <span class="NLM_string-name">Bowler, A. N.</span></span> <span> </span><span class="NLM_article-title">Preparation of Furazanyltriazole Derivatives as Glycogen Synthase Kinase-3 (GSK-3) Inhibitors</span>. <span class="NLM_patent">WO2002032896A1</span>, <span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=P.+H.+Olesen&author=P.+Kurtzhals&author=H.+Worsaae&author=B.+F.+Hansen&author=A.+R.+Sorensen&author=A.+N.+Bowler&title=Preparation+of+Furazanyltriazole+Derivatives+as+Glycogen+Synthase+Kinase-3+%28GSK-3%29+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit288&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOlesen%26aufirst%3DP.%2BH.%26atitle%3DPreparation%2520of%2520Furazanyltriazole%2520Derivatives%2520as%2520Glycogen%2520Synthase%2520Kinase-3%2520%2528GSK-3%2529%2520Inhibitors%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref289"><div class="reference"><strong class="refLabel"><a href="#ref289" class="rightTabRefNumLink">289</a></strong><div class="NLM_citation" id="rightTab-cit289"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olesen, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urso, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtzhals, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowler, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrbar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, B. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vitro characterization of 1-(4-aminofurazan-3-yl)-5-dialkylaminomethyl-1H-[1,2,3]triazole-4-carboxylic acid derivatives. A new class of selective GSK-3 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">3333</span>â <span class="NLM_lpage">3341</span>, <span class="refDoi">Â DOI: 10.1021/jm021095d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm021095d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksVSjsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=3333-3341&issue=15&author=P.+H.+Olesenauthor=A.+R.+Sorensenauthor=B.+Ursoauthor=P.+Kurtzhalsauthor=A.+N.+Bowlerauthor=U.+Ehrbarauthor=B.+F.+Hansen&title=Synthesis+and+in+vitro+characterization+of+1-%284-aminofurazan-3-yl%29-5-dialkylaminomethyl-1H-%5B1%2C2%2C3%5Dtriazole-4-carboxylic+acid+derivatives.+A+new+class+of+selective+GSK-3+inhibitors&doi=10.1021%2Fjm021095d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit289R"><div class="casContent"><span class="casTitleNuber">289</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in Vitro Characterization of 1-(4-Aminofurazan-3-yl)-5-dialkylaminomethyl-1H-[1,2,3]triazole-4-carboxylic Acid Derivatives. A New Class of Selective GSK-3 Inhibitors</span></div><div class="casAuthors">Olesen, Preben H.; Sorensen, Anders R.; Urso, Birgitte; Kurtzhals, Peter; Bowler, Andrew N.; Ehrbar, Ulrich; Hansen, Bo F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3333-3341</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The title compds. were identified as a novel class of GSK-3 inhibitors with favorable water soly. in a HTS screen.  SAR studies identified bioisosteric structural moieties in this class of compds.  The compds. were tested in a GSK-3 inhibition assay at 100 Î¼M ATP giving IC50's in the range from 0.1 to 10 Î¼M.  The compds. are ATP competitive inhibitors.  They modulate glycogen metab. and stimulate the accumulation of intracellular Î²-catenin in whole cell assays with EC50's in the range from 2 to 18 Î¼M and 4.5-44 Î¼M, resp.  For selected compds., only a 10-fold lower potency was obtained in cellular assays compared to the potency obtained for inhibition of the isolated enzyme, reflecting a good cell permeability of this compd. class.  At 10 Î¼M of test compd. a 3-fold stimulation of the glycogen synthesis in rat soleus muscle was obtained compared to the level of glycogen synthesis obsd. at 0.2 nM insulin.  This stimulation of glycogen synthesis is comparable to the maximal stimulation by insulin itself.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqImSBV8y_St7Vg90H21EOLACvtfcHk0lhZIReIbHyDVg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksVSjsbg%253D&md5=a5db0b9969e614021813add91a68a56f</span></div><a href="/servlet/linkout?suffix=cit289&amp;dbid=16384&amp;doi=10.1021%2Fjm021095d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm021095d%26sid%3Dliteratum%253Aachs%26aulast%3DOlesen%26aufirst%3DP.%2BH.%26aulast%3DSorensen%26aufirst%3DA.%2BR.%26aulast%3DUrso%26aufirst%3DB.%26aulast%3DKurtzhals%26aufirst%3DP.%26aulast%3DBowler%26aufirst%3DA.%2BN.%26aulast%3DEhrbar%26aufirst%3DU.%26aulast%3DHansen%26aufirst%3DB.%2BF.%26atitle%3DSynthesis%2520and%2520in%2520vitro%2520characterization%2520of%25201-%25284-aminofurazan-3-yl%2529-5-dialkylaminomethyl-1H-%255B1%252C2%252C3%255Dtriazole-4-carboxylic%2520acid%2520derivatives.%2520A%2520new%2520class%2520of%2520selective%2520GSK-3%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26issue%3D15%26spage%3D3333%26epage%3D3341%26doi%3D10.1021%2Fjm021095d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref290"><div class="reference"><strong class="refLabel"><a href="#ref290" class="rightTabRefNumLink">290</a></strong><div class="NLM_citation" id="rightTab-cit290"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2719</span>â <span class="NLM_lpage">2740</span>, <span class="refDoi">Â DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref290/cit290&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&issue=7&author=J+B.+Baellauthor=G.+A.+Holloway&title=New+substructure+filters+for+removal+of+pan+assay+interference+compounds+%28PAINS%29+from+screening+libraries+and+for+their+exclusion+in+bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit290R"><div class="casContent"><span class="casTitleNuber">290</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0lhZIReIbHyDVg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit290&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520substructure%2520filters%2520for%2520removal%2520of%2520pan%2520assay%2520interference%2520compounds%2520%2528PAINS%2529%2520from%2520screening%2520libraries%2520and%2520for%2520their%2520exclusion%2520in%2520bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D7%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01901&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01901%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-4%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01901" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0bebfecd2d1c7","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
